<SEC-DOCUMENT>0001047469-21-000233.txt : 20210201
<SEC-HEADER>0001047469-21-000233.hdr.sgml : 20210201
<ACCEPTANCE-DATETIME>20210201081328
ACCESSION NUMBER:		0001047469-21-000233
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		55
FILED AS OF DATE:		20210201
DATE AS OF CHANGE:		20210201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252210
		FILM NUMBER:		21574430

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>a2242824zf-1a.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg17601_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#fa17601_index_to_the_consolidated_financial_statements">  INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=1><B>As filed with the Securities and Exchange Commission on February&nbsp;1, 2021


 </B></FONT>

</P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>


Registration No.&nbsp;333-252210

 </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>


AMENDMENT NO.1 TO

  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM F-1  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Adagene&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=1>(Exact name of Registrant as specified in Its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Not Applicable<BR>  </B></FONT><FONT SIZE=1>(Translation of Registrant's name into English) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Cayman Islands</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 2834</B></FONT><FONT SIZE=1><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> Not Applicable</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=1><B>4F, Building C14, No.&nbsp;218,<BR>
Xinghu Street, Suzhou Industrial Park<BR>
Suzhou, Jiangsu Province, 215123<BR>
People's Republic of China<BR>
+86-512-8777-3632</B></FONT><FONT SIZE=1><BR>
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Cogency Global Inc.<BR>
122&nbsp;East 42nd&nbsp;Street, 18th&nbsp;Floor<BR>
New York, NY&nbsp;10168<BR>
Phone: (800) 221-0102<BR>
Fax: (800) 944-6607</B></FONT><FONT SIZE=1><BR>
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=7 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>Li He, Esq.<BR>
Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP<BR>
c/o 18th&nbsp;Floor,<BR>
The Hong Kong Club Building<BR>
3A Chater Road, Central<BR>
Hong Kong<BR>
+852 2533-3300<BR>
+852 2533-3306</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> James C. Lin, Esq.<BR>
Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP<BR>
c/o 18th&nbsp;Floor,<BR>
The Hong Kong Club Building<BR>
3A Chater Road, Central<BR>
Hong Kong<BR>
+852 2533-3300<BR>
+852 2533-3306</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Benjamin Su, Esq.<BR>
Daying Zhang, Esq.<BR>
Latham&nbsp;&amp; Watkins&nbsp;LLP<BR>
18th&nbsp;Floor, One Exchange Square<BR>
8 Connaught Place<BR>
Central, Hong Kong<BR>
+852 2912-2500</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Michael E. Sullivan, Esq.<BR>
Latham&nbsp;&amp; Watkins&nbsp;LLP<BR>
12670 High Bluff Drive<BR>
San Diego, CA 92130<BR>
USA<BR>
+1&nbsp;858-523-5400</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to the public:<BR>
As soon as practicable after the effective date of this registration statement.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933. </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>Emerging
growth company&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an emerging growth company that prepares its financial statements in accordance with U.S.&nbsp;GAAP, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>

<div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="65%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of each class of securities<BR>
to be registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed maximum<BR>
aggregate offering<BR>
price<SUP>(1)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
registration fee<SUP>(4)</SUP></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Ordinary shares, par value US$0.0001 per share<SUP>(2)(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>US$125,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>US$13,637.50</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Estimated
solely for the purpose of determining the amount of registration fee in accordance with Rule&nbsp;457(o) under the Securities Act of 1933.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
ordinary shares initially offered and sold outside the United States that may be resold from time to time in the United States either as part of their
distribution or within 40&nbsp;days after the later of the effective date of this registration statement and the date the shares are first bona fide offered to the public, and also includes ordinary
shares that may be purchased by the underwriters pursuant to an over-allotment option. These ordinary shares are not being registered for the purpose of sales outside the United States.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>American
depositary shares issuable upon deposit of the ordinary shares registered hereby will be registered under a separate registration statement on
Form&nbsp;F-6 (Registration No.333-252543). Each American depositary share represents one and one&nbsp;quarter (1.25)&nbsp;ordinary shares.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Previously
paid.

</FONT></DD></DL>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as
amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section&nbsp;8(a), may determine.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="LEFT" >


 </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards
Codification after April&nbsp;5, 2012. </FONT></DD></DL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=411494,FOLIO='blank',FILE='DISK103:[20ZDS1.20ZDS17601]BA17601A.;36',USER='CHE109574',CD='30-JAN-2021;04:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT COLOR="#EF505F" SIZE=2>The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not
permitted.</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT COLOR="#EF505F" SIZE=2><B>Subject to completion<BR>
Preliminary Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>American Depositary Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g705756.jpg" ALT="GRAPHIC" WIDTH="270" HEIGHT="61">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Adagene&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is an initial public offering of American depositary shares, or ADSs, representing ordinary shares of Adagene&nbsp;Inc. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs. Each ADS represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares, par value US$0.0001 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to this offering, there has been no public market for the ADSs. It is currently estimated that the initial public offering price per share will be between US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have applied for listing the ADSs on the Nasdaq Global Market under the symbol "ADAG." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are an "emerging growth company" under applicable U.S. federal securities laws and are eligible for reduced public company reporting requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>


<P style="font-family:times;">


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=3><B>See "Risk Factors" beginning on page&nbsp;20 for factors you should consider before buying the ADSs.</B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the United States Securities and Exchange Commission nor any other regulatory body has approved or disapproved of
these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="63%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Per ADS</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Total</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>See "Underwriting" for additional disclosure regarding compensation payable by us to the underwriters. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have a 30-day option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs from us at the initial public offering price less the underwriting discount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters expect to deliver the ADSs against payment in U.S. dollars in New York, New York on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=5><B>Goldman Sachs (Asia) L.L.C.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:17pt;text-indent:-17pt;"><FONT SIZE=5><B> </B></FONT><FONT SIZE=5><B>Morgan Stanley</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:17pt;text-indent:-17pt;"><FONT SIZE=5><B> </B></FONT><FONT SIZE=5><B>Jefferies</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><BR>
 </FONT><FONT SIZE=4><B>China Renaissance</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=587520,FOLIO='blank',FILE='DISK103:[20ZDS1.20ZDS17601]BC17601A.;29',USER='CHE106795',CD='29-JAN-2021;19:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG17601A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg17601_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG17601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->

<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca17601_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Prospectus Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca17601_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc17601_implications_of_being_an_emerg__imp03121"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Implications of Being an Emerging Growth Company and a Foreign Private Issuer</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc17601_implications_of_being_an_emerg__imp03121"><FONT SIZE=2>12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc17601_conventions_which_apply_to_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conventions Which Apply to this Prospectus</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc17601_conventions_which_apply_to_this_prospectus"><FONT SIZE=2>13</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce17601_the_offering"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Offering</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce17601_the_offering"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cg17601_our_summary_consolidated_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Our Summary Consolidated Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cg17601_our_summary_consolidated_financial_data"><FONT SIZE=2>17</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ci17601_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ci17601_risk_factors"><FONT SIZE=2>20</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cw17601_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cw17601_special_note_regarding_forward-looking_statements"><FONT SIZE=2>99</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cw17601_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cw17601_use_of_proceeds"><FONT SIZE=2>101</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cw17601_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cw17601_dividend_policy"><FONT SIZE=2>102</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cw17601_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cw17601_capitalization"><FONT SIZE=2>103</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cy17601_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cy17601_dilution"><FONT SIZE=2>106</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cy17601_enforceability_of_civil_liabilities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Enforceability of Civil Liabilities</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cy17601_enforceability_of_civil_liabilities"><FONT SIZE=2>108</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cy17601_corporate_history_and_structure"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate History and Structure</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cy17601_corporate_history_and_structure"><FONT SIZE=2>110</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da17601_selected_consolidated_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Consolidated Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da17601_selected_consolidated_financial_data"><FONT SIZE=2>111</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc17601_management_s_discussion_and_an__man03466"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc17601_management_s_discussion_and_an__man03466"><FONT SIZE=2>114</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di17601_business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di17601_business"><FONT SIZE=2>134</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ea17601_regulation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Regulation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ea17601_regulation"><FONT SIZE=2>190</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eg17601_management"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eg17601_management"><FONT SIZE=2>217</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ei17601_principal_shareholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Shareholders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ei17601_principal_shareholders"><FONT SIZE=2>231</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ek17601_related_party_transactions"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Related Party Transactions</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ek17601_related_party_transactions"><FONT SIZE=2>235</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#em17601_description_of_share_capital"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Share Capital</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#em17601_description_of_share_capital"><FONT SIZE=2>237</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eo17601_description_of_american_depositary_shares"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of American Depositary Shares</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eo17601_description_of_american_depositary_shares"><FONT SIZE=2>250</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eo17601_shares_eligible_for_future_sale"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Eligible for Future Sale</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eo17601_shares_eligible_for_future_sale"><FONT SIZE=2>267</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eq17601_taxation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taxation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eq17601_taxation"><FONT SIZE=2>269</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#es17601_underwriting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#es17601_underwriting"><FONT SIZE=2>274</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eu17601_expenses_relating_to_this_offering"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expenses Relating to This Offering</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eu17601_expenses_relating_to_this_offering"><FONT SIZE=2>285</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eu17601_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eu17601_legal_matters"><FONT SIZE=2>286</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eu17601_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eu17601_experts"><FONT SIZE=2>287</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eu17601_where_you_can_find_additional_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find Additional Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eu17601_where_you_can_find_additional_information"><FONT SIZE=2>288</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fa17601_index_to_the_consolidated_financial_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to the Consolidated Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fa17601_index_to_the_consolidated_financial_statements"><FONT SIZE=2>F-1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We are responsible for the information contained in this prospectus. We have not authorized anyone to provide you with different information, and we take no
responsibility for any other information others may give you. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not
permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than its date.</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, the ADSs only in
jurisdictions where offers and sales are permitted. The information contained in this prospectus is current only as of the date of this prospectus, regardless of the time of delivery of this
prospectus or of any sale of the ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not taken any action to permit a public offering of the ADSs outside the United States or to permit the possession or distribution of this prospectus outside the United States.
Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the ADSs and the distribution of the
prospectus outside the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the 25th&nbsp;day after the date of this prospectus), all dealers that buy, sell or trade ADSs, whether or not participating in
this offering, may be required to deliver a prospectus. This is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments
or subscriptions.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=264078,FOLIO='i',FILE='DISK103:[20ZDS1.20ZDS17601]BG17601A.;35',USER='CHE106465',CD='31-JAN-2021;15:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca17601_prospectus_summary"> </A>
<A NAME="toc_ca17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed
information and financial statements and the related notes appearing elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the
risks of investing in the ADSs discussed under "Risk Factors," "Business," and information contained in "Management's Discussion and Analysis of Financial Condition and Results of Operations" before
deciding whether to buy the ADSs. In particular, we call your attention to the risk that we could be delisted from The Nasdaq Global Market pursuant to the Holding Foreign Companies Accountable Act
enacted on December&nbsp;18, 2020 if the Public Company Accounting Oversight Board continues to be unable to inspect our independent registered public accounting firm for three consecutive
years.</I></FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OVERVIEW  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel
antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our
immunotherapy pipeline. These features enable our novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination
immunotherapy development in clinical settings. We have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug
target for differentiated therapeutic antibody development. We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody
product candidates intractable to traditional antibody technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Life is motion</I></FONT><FONT SIZE=2>. The motion of proteins and their dynamic interactions trigger a cascade of complex biological and pharmacological effects.
Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino
acid sequence can adopt multiple structures and functions. Our approach recognizes that a protein's native state is not accurately represented by a single static structure but rather by a variety of
structures in dynamic equilibrium, resulting in a high level of functional diversity, in contrast to the conventional static antibody drug discovery paradigm of "one sequence, one structure and one
function." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have developed our proprietary AI-Powered DPL platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of antibody sequences in
particular, as a new paradigm for antibody drug discovery. Our DPL platform combines artificial intelligence, or AI,
algorithms and ever-increasing big data in antibody sequence, structure, binding epitope and affinity from public and our own proprietary databases to design, construct and screen high-quality
proprietary antibody libraries with well-defined sequence, scaffold and biophysical attributes for antibody drug discovery. Powered by computational physics in combination with AI and big data, our
DPL platform samples a potentially infinite number of dynamic binding interface structures arising from the conformational diversity of a finite number of antibody amino acid sequences, allowing us to
exponentially expand the universe of candidate antibody binding sites far beyond conventional natural or synthetic antibody repertoires. By exploiting conformational diversity, we have designed and
precisely constructed approximately one trillion (10<SUP>12</SUP>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an
antibody) coverage and robust chemistry, manufacturing, and control, or CMC, attributes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe our AI-powered antibody discovery and engineering DPL platform significantly increase R&amp;D productivity for antibody drug discovery, as illustrated by our clinical anti-CD137
and anti-CTLA-4 programs. DPL library screening against CD137 or CTLA-4 antigens has yielded a large number of high affinity primary hits. The abundant discovery hits with diversified binding epitopes
show

</FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=444152,FOLIO='1',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<A NAME="page_ca17601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>


the power of our AI-powered DPL platform not only in creating novel antibodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across different species
of a given antigen with broad species cross-reactivity from human, monkey to mouse, which enables us to study their efficacy and safety in extensive immuno-competent or syngeneic animal models, to
explore their pharmacodynamics and predictive biomarkers in responding vs nonresponding tumor models in vivo, and to understand their deep target biology and novel MOA before testing them in human
clinical trials to look for their clinical signals consistent with their MOA. Our DPL platform empowers us to engage the dynamic epitope of the conformationally dynamic target which might be
challenging using conventional antibody discovery approaches. We believe that the high-affinity and cross-reactive primary hits from our AI-Powered DPL library screening save time and cost from
discovery to early clinical proof of concept. The broad species cross-reactivity of the primary hits also streamlines lead identification and potentially enables high fidelity translation from
preclinical to clinical studies. Furthermore, we believe our AI-powered dynamic precision library expands the diversity at the start of discovery to maximize the chance that suitable leads are found
on the first pass.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Translational
fidelity from preclinical modeling to informed clinical development is one of the top challenges to developing cancer immunotherapies. Most traditionally developed
antibodies do not cross react between their human and murine targets due to their limited species cross-reactivity, making it very difficult to reliably evaluate the same antibody in both the
preclinical and clinical settings. Some of the most contentious issues related to preclinical and clinical studies of CD137 and CTLA-4, the targets of our lead product candidates, immunotherapies are
traceable to the differences between the antibodies used for preclinical and clinical studies. For example, according to Frost&nbsp;&amp; Sullivan, two of the leading clinical anti-CD137 agonist
antibodies bind to different epitopes of CD137 and exhibit dramatic differences in their respective clinical safety and efficacy results, underscoring the importance of finding suitable species
cross-reactive antibodies like those we have utilized for comprehensive preclinical evaluation before entering clinical trials. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that it is essential to model the interactions between tumors and an intact host immune system </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> to evaluate the
therapeutic potential of antibodies in preclinical studies. The flexibility of antibody binding interface is fundamental to the NEObody technology of our DPL Platform and allows us to generate species
cross-reactive antibodies to assess the safety and efficacy potential of mono- and combination therapy candidates in syngeneic animal models before launching clinical trials. We use syngenic mouse
models which are known for their intact </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> immune systems to provide the original proof of concept for cancer immunotherapies by blocking immune
check points with monoclonal antibodies, or mAbs. We believe that the use of species cross-reactive antibodies, rather than surrogate antibodies used in traditional syngeneic animal models, should
facilitate the translational relevance and clinical utility of these well-established preclinical models for determining optimal dose, schedule, sequencing, combination synergy, risk and benefit
features. The results from the assessment of new species cross-reactive antibodies in rigorous preclinical models may allow us to control the scope and cost of clinical trials, enable the
identification of potential clinical biomarkers useful to monitor clinical pharmacological and safety signals, and help preselect patients for precision mono- and combination therapies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
figure below illustrates how our DPL platform integrates our computational algorithm-enabled high-throughput screening and functional antibody evaluation for preclinical candidates
suitable for clinical development as explained above. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=399590,FOLIO='2',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<A NAME="page_ca17601_1_3"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g836147.jpg" ALT="GRAPHIC" WIDTH="654" HEIGHT="364">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
DPL platform is further composed of three proprietary enabling technologies tailored to three key attributes of antibody-based therapeutic modalities: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> NEObody technology is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated
from other synthetic antibody technologies through its innovative designs and precise constructions. NEObody technology enables the generation of antibodies designed with dynamic binding sites that
adapt kinetically to unique epitopes, triggering a novel MOA. The species cross-reactive antibodies generated by NEObody technology not only have the potential to reveal new biological functions of
the targets, but also facilitate preclinical studies using various immune system intact animal models, resulting in high fidelity translation from preclinical to clinical studies. We refer to
antibodies generated by our NEObody technology as NEObodies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> SAFEbody technology is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its
target in healthy tissues. The masking motif is designed to activate, or unmask, the antibody to allow binding in the tumor microenvironment, or TME, where certain activation conditions such as a
protease is upregulated as compared to healthy tissues, allowing the antibody to bind to its target for tumor killing. Our SAFEbody enabled therapeutic candidates are therefore designed to be
activated predominantly in the TME while remaining largely in an inactive state in healthy tissues. Our SAFEbody technology can be applied to mask the binding sites of any antibodies including but not
limited to NEObodies. We refer to such masked antibodies including NEObodies as SAFEbodies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> POWERbody technology, which enables the creation of new versions of bispecific T-cell engagers, or TCEs, with enhanced safety profiles,
antibody-drug conjugates, or ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> SAFEbody technology can be applied to our NEObodies, such as what we did with ADG116 to convert into ADG126. POWERbody is created by applying
the SAFEbody technology to a bispecific TCE in either CD3 or both in CD3 and antigen binding arms to enhance the safety </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=467520,FOLIO='3',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<A NAME="page_ca17601_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>profile.
Our POWERbody technology is designed to improve antitumor activity while maintaining the enhanced safety profile. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>We
believe that comprehensive </FONT><FONT SIZE=2><I>in&nbsp;vivo</I></FONT><FONT SIZE=2> preclinical evaluations are the key to assess the efficacy and safety potential of tailor-made antibody
candidates before progressing them into lengthy and costly clinical trials. NEObody, SAFEbody and POWERbody technologies are all designed to facilitate favorable druggability, manageable CMC
attributes, and reduced immunogenicity. As highlighted by our lead product candidates, such as ADG106, ADG126 and ADG116, our NEObody technology allows us to engineer and select species cross-reactive
NEObodies designed to dynamically adapt to unique and evolutionally conserved epitopes. ADG126 has been further engineered using our SAFEbody technology to address the safety concerns associated with
existing CTLA-4 therapeutics. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
figure below shows how our NEObody, SAFEbody, and POWERbody technologies and DPL platform are inter-connected and utilized for the building of our product pipeline of mono- and
combination immunotherapies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g314883.jpg" ALT="GRAPHIC" WIDTH="274" HEIGHT="277">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=1>Notes: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Antibodies generated by NEObody technology, which are designed with dynamic binding sites that adapt kinetically to unique
epitopes, triggering a novel MOA.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>NEObodies or traditional antibodies are masked in their binding sites by SAFEbody technology as shown by the blocking bar in
the antibody binding sites in the figure, which are designed to be selectively activated in the TME, potentially limiting on-target off-tumor toxicity in normal tissues.  </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Multiple potent modalities, including bispecific T-cell engagers, ADC, and Fc engineering for enhanced ADCC, etc., are masked
in their binding sites by SAFEbody to create a POWERbody.</FONT>

</DD>

</DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
most advanced NEObody product candidate, ADG106, is a fully human ligand-blocking agonistic anti-CD137 mAb currently being evaluated in Phase Ib clinical trials in the United States
and China. ADG106 is designed to target a unique epitope of CD137 that is different from other anti-CD137 antibodies currently under clinical development. Epitope mapping and X-ray structural analysis
of ADG106 with CD137 have shown in preclinical studies that ADG106 is capable of binding to CD137 in a fashion similar to its natural ligand, CD137L. Our first SAFEbody product candidate, ADG126, is a
fully human anti-CTLA-4 masked antibody. It is designed to enhance the safety features by masking the antibody binding site of ADG126, which would be unmasked in the TME, where the activated ADG126
would block CTLA-4 and deplete regulatory T-cells by means of enhanced antibody-dependent cellular cytotoxicity, or ADCC. In preclinical studies, ADG126 was tolerated at doses of up to
200&nbsp;mg/kg in nonhuman primate models. As ADG126&nbsp;is also species cross-reactive in humans, </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=784213,FOLIO='4',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<A NAME="page_ca17601_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>cynomolgus
monkeys and mice, we believe that preclinical studies of ADG126&nbsp;will support the rational design of clinical trials to expedite its development. Our third product candidate, ADG116,
is a fully human anti-CTLA-4 NEObody. Epitope mapping and X-ray structural analysis have shown that in preclinical studies, ADG116 is capable of binding to a novel epitope of CTLA-4 different from
ipilimumab, the only CTLA-4 mAb approved globally. The dynamic interface of ADG116 enabled not only its species cross-reactivity with human, cynomolgus monkey, and mouse CTLA-4 for preclinical
studies, but also its dynamic engagement on a unique epitope of CTLA-4 to trigger a novel MOA, distinct from ipilimumab, by softer ligand blocking and stronger regulatory T-cell depletion via strong
ADCC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
species cross-reactive ADG106, ADG126 and ADG116 have enabled a deep understanding of the interaction between tumor and host immune system </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> in syngeneic animal models. This understanding has been utilized to design and guide the clinical development of rational, mechanism-based mono- and combination therapies
using ADG106, ADG126 and ADG116. Because there is limited clinical safety and efficacy data available for anti-CD137 agonists we have followed our preclinical and mechanistic study for the clinical
development of ADG106. We observed three patients with Grade&nbsp;3 liver enzyme increase; among them, one patient with abnormal liver enzyme baseline showed a Grade&nbsp;3 AST increase. ADG106
showed preliminary clinical antitumor activity in patients who have progressed after several lines of treatment in our completed Phase Ia dose escalation and ongoing Phase Ib dose expansion trials in
the United States and China. It is very encouraging to observe the clinical response in connection with the changes in PD biomarkers due to target engagement in a dose dependent manner. We have also
observed a correlation with a potential predictive biomarker for patient selection in three patients with more than 30% tumor shrinkage across different indications in retrospective analysis in our
ongoing Phase I trials. This predictive biomarker is related to the CD137 pathway. We intend to further explore this predictive biomarker in order to guide our development of precision mono- and
combination immunotherapies based on our preclinical and preliminary clinical data. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Pipeline  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By leveraging our proprietary DPL platform, we have developed a robust pipeline of innovative product candidates in various stages of
development, ranging from research and discovery
to preclinical and clinical development. Our highly differentiated clinical-stage pipeline consists of ADG106, ADG126 and ADG116. We also have a robust preclinical pipeline in various stages of
development. In addition, we have out-licensed the Greater China rights of ADG104, a PD-L1 mAb in Phase Ib and Phase II trials concurrently in China, to our partner, Sanjin and its affiliates. We have
the right to apply for the patents derived from our core and key technologies pertaining to ADG104 in the rest of the world and we retain a majority of the economic benefits derived from ADG104 in the
rest of the world. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=524022,FOLIO='5',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<A NAME="page_ca17601_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following chart provides an overview of the status of each of our programs at clinical or IND-enabling stages, for which we have global rights: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g340646.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="325">
  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG106: Novel agonistic anti-CD137 NEObody candidate  </I></B></FONT></P>


</UL>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG106, is a fully human ligand-blocking, agonistic anti-CD137 immunoglobulin G4, or IgG4, mAb generated using our NEObody technology. ADG106 is
being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. CD137 stimulates the immune system to attack cancer cells and is a key driver for T-cell and natural
killer cell, or NK cell, proliferation. ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like binding and cross-linking by
Fc<FONT FACE="SYMBOL">g</FONT> receptors. The broad species cross-reactivity of ADG106 observed in preclinical studies has enabled us to explore robust translational studies concerning the
biology of CD137 in mouse, rat, nonhuman primate, and human, especially for anti-CD137 as a single agent and in combination therapies in immuno-competent syngeneic tumor models. In preclinical studies
to date, we observed that ADG106 had encouraging antitumor activity and was well tolerated as a monotherapy and in combination with the existing standard-of-care, or SOC, and other immuno-oncology
therapies, which was confirmed in the Phase I clinical trials in cancer patients as a monotherapy. These data indicate that ADG106 has the potential to address the limitations of other existing
anti-CD137 therapies.

 </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the November&nbsp;30, 2020, the Data Cut-off Date, we have completed the Phase&nbsp;Ia dose escalation in each of our Phase&nbsp;I studies of ADG106 in both the United States
and China as a monotherapy in patients with advanced or metastatic solid tumors and/or NHL. We are currently in the Phase&nbsp;Ib dose expansion phase for both trials in the United States and China.
ADG106 was dose escalated up to 10&nbsp;mg/kg and is well tolerated at dose expansion at 3&nbsp;mg/kg, 5&nbsp;mg/kg and at 300mg and 400&nbsp;mg flat doses. A total number of 92 patients have
been dosed. Both clinical trials, namely ADG106-1001 and ADG106-1002, have limited Treatment Emergent Adverse Effects, or TEAEs, liver toxicity or hematologic abnormalities. We observed three patients
with <FONT FACE="SYMBOL">&#179;</FONT>Grade 3 liver enzyme increase; among them, one patient with abnormal liver enzyme baseline showed a Grade 3 AST increase. Two&nbsp;patients developed
hemolytic anemia in ADG106-1002 which were controlled; one of the two patients received prior therapies which were known to cause autoimmune hemolytic anemia. One patient with a solid tumor who
previously failed chemotherapies, radiotherapy, and an anti-PD-L1 related antibody treatment showed a partial response to ADG106 treatment with a 40% tumor size </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=490640,FOLIO='6',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<A NAME="page_ca17601_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>reduction
after two treatment cycles. In addition, two NHL patients showed more than a 30% tumor size reduction after one and two ADG106 treatment cycles, respectively. Furthermore, biomarker studies
showed target engagement with specific PD biomarkers indicative of immune system activation, and clinical response correlated with changes in CD137 target engagement. These data are encouraging given
that the enrolled population was not preselected and was heavily pretreated. We have identified a potential predictive biomarker which correlates with patient response to ADG106 treatment from a
retrospective analysis of the ongoing Phase&nbsp;I clinical trial. Based on this finding, we are in the process of preparing an additional Phase&nbsp;II trial which we expect to initiate in 2021
and for which we intend to stratify and preselect patients using this predictive biomarker to potentially enhance clinical response of
patients to ADG106 treatment. We also plan to pursue potential registrational trials evaluating ADG106 in biomarker enriched patient populations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also evaluated ADG106 in combination with other therapies including chemotherapies, immune modulators, and immuno-oncology therapies in preclinical studies. Data from combination
studies in tumor bearing mice showed that the combination of ADG106 with immune checkpoint inhibitors, including an anti-PD-1/L1 mAb or anti-CTLA-4 mAb, enhanced </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> antitumor activity. We plan to explore the combination of ADG106 with other targeted antibody therapies for the treatment of hematologic malignancies and solid tumors. We
also have identified tumor-specific biomarkers that we believe may correlate with ADG106 antitumor activity in multiple mouse tumor models. These preclinical study findings are consistent with the
interim results from our ongoing Phase&nbsp;Ib clinical trials. Going forward, we are focusing on evaluating combinations of ADG106 with various therapies in clinical trials. We have received NMPA
approval for the ADG106-1008 study in China, which is a Phase Ib/II combination trial of ADG106 with anti-PD-1 in advanced solid tumors and hematological malignancies. We are also in the preparation
for a submission of a Clinical Trial Notification, or CTN, for our ADG106-1003 clinical trial in Australia, which will combine ADG106 with anti-PD-1, anti-VEGF, or anti-CD20 in advanced solid tumors
and hematological malignancies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have observed responses to ADG106 in all three T&nbsp;cell lymphoma patients enrolled in the ADG106-1002 Phase I trial. We are enrolling additional patients in our ADG106-1002 trial
and will conduct an investigator initiated trial in the United Sates to further explore ADG106 as a monotherapy and in combination with other therapies in T&nbsp;cell lymphoma. We expect to submit
an Orphan Drug Designation application to the FDA for ADG106 requesting for expedited regulatory approval for this indication.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG126: Novel anti-CTLA-4 SAFEbody candidate  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our most advanced SAFEbody program, ADG126, is a masked fully-human anti-CTLA-4 mAb engineered to address the safety concerns associated with
existing CTLA-4 therapeutics, while maintaining potency when locally activated in the TME. The FDA approval of ipilimumab validated anti-CTLA-4 for cancer treatment. However, due to its on-target
off-tumor toxicity, the approved indications for ipilimumab are limited, which we believe has caused sales of ipilimumab to trail other immuno-oncology therapies such as anti-PD-1/L1 antibodies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG126
is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target
for the treatment of cancer. In preclinical studies, ADG126 was tolerated at doses of up to 200 mg/kg in nonhuman primate models. We believe the encouraging preclinical tolerability of ADG126 suggests
its potential in combination with other immunotherapies such as an anti-PD-1/PD-L1 antibody or an anti-CD137 antibody, including ADG106. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=10,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=894261,FOLIO='7',FILE='DISK103:[20ZDS1.20ZDS17601]CA17601A.;140',USER='CHE105918',CD=';1-FEB-2021;04:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cc17601_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To better address the unmet clinical need for a safe and potent anti-CTLA-4 antibody for chemotherapy-free mono- and combination immunotherapy, we have submitted
a CTN and received HREC approval for an ADG126 Phase&nbsp;I dose escalation trial in Australia and are expecting to commence patient enrollment by February 2021. We also have received approval from
the FDA to initiate the Phase&nbsp;I clinical trial of ADG126 in the United&nbsp;States in 2021. These two Phase&nbsp;I dose escalation trials will test five&nbsp;doses at 0.1,
<FONT FACE="SYMBOL">&#163;</FONT>0.3, <FONT FACE="SYMBOL">&#163;</FONT>1, <FONT FACE="SYMBOL">&#163;</FONT>3, and
<FONT FACE="SYMBOL">&#163;</FONT>10&nbsp;mg/kg, based on our preclinical primate toxicity study in comparison with ipilimumab. We anticipate that these clinical trials will allow us to
determine the ADG126 effective dose in late 2021. Meanwhile, we are preparing IND submissions to initiate ADG126 clinical trials in China.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG116: Novel anti-CTLA-4 NEObody candidate  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG116 is a fully-human ligand-blocking anti-CTLA-4 mAb generated using our NEObody technology. ADG116 is designed to target a unique conserved
epitope of CTLA-4. In preclinical studies, ADG116 was observed to have softer CTLA-4 ligand blocking and stronger ADCC for depleting regulatory T-cells than ipilimumab. In a head-to-head </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>
efficacy study, ADG116&nbsp;was observed to have at least a five-fold greater anti-tumor activities in comparison with ipilimumab. In
addition, ADG116 was observed to induce antitumor responses concomitant with reduced immunosuppressive regulatory T-cell and enhanced cytotoxic T lymphocyte (CD8<SUP>+</SUP> T-cells) activities in
the TME. We believe that these preclinical results support the further clinical evaluation of ADG116 both as monotherapies and combination therapies for a wide range of tumor types.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of January&nbsp;15, 2021, we have successfully completed dose escalation at the first three doses in our ADG116-1003 clinical trial in Australia, including a dose level at
0.03mg/kg, the dose level used for the first patient who suffered a fatal incident in the ADG116 Phase&nbsp;I trial in the United States. As of January&nbsp;15, 2021, no dose limiting toxicity or
treatment related serious adverse events have been observed in any of the patients treated. There was no treatment induced liver toxicity and all three patients treated at 0.03mg/kg showed normal
liver enzyme level post ADG116 treatment. The Safety Review Committee approved dose escalation for ADG116-1003 clinical trial to 0.1mg/kg. The ADG116-1001 Phase&nbsp;I trial in the United States was
placed on clinical hold on September&nbsp;30, 2019 by the FDA, after we reported to the FDA the death of the only patient dosed in the trial. The FDA removed the clinical hold on December&nbsp;5,
2019 after we submitted an amendment to the study protocol. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Global Partnership and Collaborations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have a successful track record of collaboration and partnerships with global biopharmaceutical companies and academic institutions. So far,
we have established multiple collaboration programs and will continue to seek to continue to seek partnership opportunities where we can leverage our proprietary technology platform to develop novel
antibodies to address unmet
medical needs. Over the past two years, we have established partnerships and collaborations with multiple biopharmaceutical companies. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We entered into a material transfer and collaboration and license agreement with ADC Therapeutics&nbsp;SA, or ADC Therapeutics, under which
ADC Therapeutics intends to use our SAFEbody technology to generate a masked antibody that could be combined with the pyrrolobenzodiazepine cytotoxic payload technology used in ADC Therapeutics' ADCs
for the development of a novel ADC against a solid tumor target. Under the agreement, we could be eligible to receive royalty payments and could have an exclusive option to negotiate a license to
develop and commercialize co-developed assets in certain territories; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We are also collaborating with Guilin Sanjin Pharmaceutical&nbsp;Co.,&nbsp;Ltd., or Sanjin, and its affiliates to develop two different
monoclonal antibodies with the first being ADG104, a </FONT></DD></DL>
</UL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=839942,FOLIO='8',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<A NAME="page_cc17601_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>monospecific
antibody that targets PD-L1 and is in Phase Ib and Phase&nbsp;II clinical trials concurrently in China, and the second being an undisclosed monoclonal antibody, which Sanjin and its
affiliates have recently filed an IND application that has been accepted by the NMPA; </FONT></P>


</UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have recently extended the term of our research collaboration agreement, or the NIH RCA, with the National Heart Lung and Blood Institute,
part of the National Institutes of Health, or NIH, to 2023. We first entered into the NIH RCA in March 2018 to collaborate with Dr.&nbsp;Richard Childs, Chief of the Laboratory of Transplantation
Immunotherapy at NHLBI, who has used antibodies discovered by us to develop a CAR-T cell therapy candidate targeting a human endogenous retrovirus expressed in the majority of clear cell kidney
tumors. The extension of the NIH RCA will allow us to use our proprietary antibody technology to further collaborate with Dr.&nbsp;Richard Childs and his team to develop other antibodies; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We entered into a collaboration and license agreement with Exelixis,&nbsp;Inc., or Exelixis, under which Exelixis will utilize our SAFEbody
technology platform to generate masked versions of mAbs from Exelixis' growing preclinical pipeline for the development of ADCs or other innovative biologics against Exelixis-nominated targets. Under
the agreement, we could be eligible to receive upfront payment as well as milestone and royalty payments on net sales of any potential products developed around each of these targets.


</FONT></DD>

</DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also working with global biopharmaceutical companies to potentially develop additional strategic partnerships. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We had recently worked with Celgene (now Bristol-Myers Squibb) to discover antibodies targeting novel antigens using our proprietary DPL
platform; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Under a material transfer agreement, we are developing SAFEbody drug conjugates against a tumor target selected by Tanabe Research
Laboratories,&nbsp;Inc., or TRL, with potential for negotiating a future license agreement with TRL if our pilot work proves successful; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We recently entered into an evaluation agreement with a global biotechnology company, or the Evaluation Agreement, under which we are
developing bispecific antibodies leveraging our SAFEbody and bispecific technologies against tumor targets provided by the counterparty. The Evaluation Agreement could facilitate the parties' interest
in a further collaboration concerning the development of a new antibody therapeutic; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We had previously collaborated with GlaxoSmithKline (China), or GSK China, where we were engaged to generate high affinity antibodies against
multiple epitopes of multi-transmembrane targets; and we previously worked with Jiangsu Hengrui Medicine Company Limited, or Jiangsu Hengrui, where we were able to discover cross-reactive agonistic
antibody for immuno-oncology. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Team and Investors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were founded in 2011 by Dr.&nbsp;Peter Luo and is led by an experienced management team. Dr.&nbsp;Luo, who previously founded the
biopharmaceutical company Abmaxis which was subsequently acquired by Merck, has a proven track record of more than two decades in antibody discovery and engineering using a multidisciplinary approach
that combines computational and experimental technology based on physical, chemical, and biological sciences. Our management team is composed of industry veterans with extensive experience in
therapeutic antibody research and development and collectively has decades of experience in molecular biology, immunotherapy, immunology, antibody discovery, protein engineering, and clinical
development. Our management team brings a strong history of leadership, innovation, and research and development experience at leading companies, including Merck/Abmaxis, Affomix/Illumina, Amgen,
AnaptysBio, Bristol-Myers Squibb, Celgene, Corixa, Forty Seven Inc., Xencor, Novartis, Pfizer, Prometheus, Quanticel, and Teva Biopharmaceuticals. Our company is further supported by a strong group of
investors that share our commitment to developing </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=838438,FOLIO='9',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<A NAME="page_cc17601_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>next-generation
immuno-oncology therapies for the treatment of cancers. Our investors include leading institutional investors such as F-Prime, Eight Roads, General Atlantic,&nbsp;GP Healthcare
Capital, Sequoia China and Wuxi AppTec. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OUR STRATEGIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are utilizing our proprietary DPL platform to design, construct and develop novel immunotherapies and precision antibodies to address unmet
patient needs globally. Our strategy encompasses the following key elements:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Advance clinical development of our lead product candidates, ADG106, ADG126 and ADG116, as monotherapies and in combination with other
therapies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Develop a deep and broad pipeline of promising antibodies using NEObody<SUP>TM</SUP>, SAFEbody<SUP>TM</SUP> and POWERbody<SUP>TM</SUP>
technologies and advance into preclinical and clinical development. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Leverage our technology to develop our pipeline and strengthen our DPL platform. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Continue to collaborate with leading biopharmaceutical companies and academic institutions to discover and develop novel candidates based upon
our DPL platform. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Maximize value creation by advancing our product candidates to potential commercialization in key markets alone or with strategic partners. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Build global operations for global markets, while leveraging a global supply chain and China cost effectiveness. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


RISK FACTORS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business is subject to a number of risks and uncertainties, including, among others, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have incurred net losses historically and we may continue to incur net losses in the future. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at
all. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product
candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We depend substantially on the success of our product candidates, particularly ADG106, ADG126 and ADG116, which are in clinical development,
and our ability to identify additional product candidates. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize
our product candidates, or experience significant delays in doing so, our business will be materially harmed. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. Even if we
receive regulatory approval for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we
may be subject to penalties if we fail </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=430275,FOLIO='10',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<A NAME="page_cc17601_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>to
comply with regulatory requirements or experience unanticipated problems with our product candidates. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We face intense competition and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective
than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may not be able to enter into additional collaboration agreements beyond our existing strategic partnerships or collaborations with NIH,
Exelixis, ADC Therapeutics and Guilin Sanjin. If we are unable to maintain existing and future strategic partnerships, or if these strategic partnerships are not successful, our business could be
adversely affected. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may be unsuccessful in obtaining or maintaining adequate patent or other intellectual property protection for one or more of our product
candidates, due to the failure to obtain issuance from our owned or licensed patent and trademark applications or to maintain the confidentiality and proprietary nature of our trade secrets, and our
issued patents covering one or more of our product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies and a third party could misappropriate our
trade secrets or independently develop technology that are highly similar to our trade secrets. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have certain shareholders who will have board representation rights after the offering and their individual interests may differ from yours. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> There can be no assurance that we will not be a passive foreign investment company ("PFIC") for U.S. federal income tax purposes for any
taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. federal income tax consequences. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The audit report included in this prospectus is prepared by an auditor that is not inspected by the Public Company Accounting Oversight Board
and, as such, our investors are deprived of the benefits of such inspection. In addition, various legislative and regulatory developments related to U.S.-listed China based companies due to lack of
PCAOB inspection and other developments due to political tensions between the United States and China may have a material adverse impact on our listing and trading in the U.S. and the trading prices
of our ADSs, and we could be delisted if we are unable to meet the PCAOB inspection requirements in time. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We could be delisted if we are unable to meet the PCAOB inspection requirements in time. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The COVID-19 pandemic could adversely impact our business, including our clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also face other challenges, risks and uncertainties that may materially and adversely affect our business, financial condition, results of operations and prospectus. You should
consider the risk discussed in "Risk Factors" and elsewhere in this prospectus before investing in the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate History and Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2011, Adagene&nbsp;Inc. was incorporated under the laws of the Cayman Islands as our offshore holding company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as our intermediary holding
company. In February 2012, Adagene Hong Kong incorporated Adagene (Suzhou) Limited, or Adagene Suzhou, in China, through which we commenced our research and development activities in China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2017, we established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct our research and development activities in the
United States to facilitate the discovery and development of product candidates and expand our global presence, we have further incorporated several subsidiaries overseas, such as Australia, Singapore
and Switzerland. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1034042,FOLIO='11',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<A NAME="page_cc17601_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following diagram illustrates our corporate structure as of the date of this prospectus, including our material subsidiaries: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g178576.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="297">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may refer to "Corporate History and Structure" for more details. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our corporate headquarters is located at 4F, Building C14, No.&nbsp;218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province,
215123, People's Republic of China. Our registered office is located at Vistra (Cayman) Limited, P. O. Box&nbsp;31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman,
KY1&nbsp;-&nbsp;1205 Cayman Islands. Our telephone number is +86-512-8777-3632. Our agent for service of process in the United States is Cogency Global Inc., located at 10E 40th Street, 10th
Floor, New York, NY 10016. Our corporate website is www.adagene.com. The information contained on or that can be accessed through our website is not incorporated by reference into this prospectus, and
you should not consider information on our website to be part of this prospectus.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc17601_implications_of_being_an_emerg__imp03121"> </A>
<A NAME="toc_cc17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY AND A FOREIGN PRIVATE ISSUER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a company with less than US$1.07&nbsp;billion in revenue for the last fiscal year, we qualify as an "emerging growth company" pursuant to
the Jumpstart Our Business Startups Act of 2012
(as amended by the Fixing America's Surface Transportation Act of 2015), or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are
otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or
Section&nbsp;404, in the assessment of the emerging growth company's internal control over financial reporting. The JOBS Act also provides that an emerging growth company does not need to comply
with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. We do not plan to "opt out"
of such exemptions afforded to an emerging growth company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will remain an emerging growth company until the earliest of (i)&nbsp;the last day of our fiscal year during which we have total annual gross revenues of at least
US$1.07&nbsp;billion; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the completion of this offering; (iii)&nbsp;the date on which we have, during the previous
three-year period, issued more than US$1.0&nbsp;billion in non-convertible debt; </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=15,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=916444,FOLIO='12',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<A NAME="page_cc17601_1_13"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>or
(iv)&nbsp;the date on which we are deemed to be a "large accelerated filer" under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of
our ADSs that are held by non-affiliates exceeds US$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter. Once we cease to be an emerging growth company,
we will not be entitled to the exemptions provided in the JOBS Act discussed above. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
consummation of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status.
As a foreign private issuer, we may take advantage of certain provisions in the Nasdaq listing rules that allow us to follow Cayman Islands law for certain corporate governance matters. Even after we
no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under
the Exchange Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for
insiders who profit from trades made in a short period of time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports on
Form&nbsp;10-Q containing unaudited financial and other specified information, or current reports on Form&nbsp;8-K, upon the occurrence of specified significant events; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Regulation Fair Disclosure, or Regulation FD, which regulates selective disclosures of material information by issuers. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc17601_conventions_which_apply_to_this_prospectus"> </A>
<A NAME="toc_cc17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CONVENTIONS WHICH APPLY TO THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we indicate otherwise, all information in this prospectus reflects the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no exercise by the underwriters of their over-allotment option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ordinary shares from us; and </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
where the context otherwise requires and for purposes of this prospectus only:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Adagene Suzhou" refers to Adagene (Suzhou) Limited. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "ADSs" refers to the American depositary shares, each
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Antibody binding interface" or "antibody binding sites" refers to the antibody binding surface spots in contact with its recognition antigen; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "China" or "PRC" refer to the People's Republic of China, excluding, for the purpose of this prospectus only, Taiwan, Hong Kong and Macau; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "conformational diversity" or "dynamic diversity" refers to the existence of more than one conformation or structure due to dynamic fluctuation
of the structures for a given protein sequence, independent of any conformational changes caused by external binding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "epitopes" or "epitope of an antigen" refers to the specific binding spots of an antigen in contact with its antibody binding surface; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Greater China", for the purpose of this prospectus, refers to the People's Republic of China, Hong Kong, Macau and Taiwan; </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=16,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=467965,FOLIO='13',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<A NAME="page_cc17601_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "multi-specificity" refers to a protein exerting a similar function (such as binding) on distinctly different ligands, perhaps while using
different active site residues; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "NEObody" refer to antibody designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOA, using our NEObody
technology; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "POWERbody" refer to antibody that utilizes our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or
antibodies, which are designed to reach beyond the therapeutic potency of traditional monospecific antibodies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "RMB" or "Renminbi" refers to the legal currency of the People's Republic of China; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "SAFEbody" refer to antibody engineered with its binding sites masked, which are designed to be selectively activated in the TME, potentially
limiting on-target off-tumor toxicity in normal tissues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "species cross-reactivity" refers to reactivity of the same protein that recognizes and binds to similar epitopes of a given class of targets
in different species; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "US$," "dollars" or "U.S. dollars" refers to the legal currency of the United States; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "we," "us," "our company," and "our," refer to Adagene&nbsp;Inc., a Cayman Islands company and its subsidiaries. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "NEObodies" refer to antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOAs, using our
NEObody technology; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "ordinary shares" or "shares" prior to the completion of this offering refers to our ordinary shares of par value US$0.0001 per share; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "POWERbodies" refer to antibodies that utilize our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or
antibodies, which are designed to reach beyond the therapeutic potency of traditional monospecific antibodies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "SAFEbodies" refer to antibodies engineered with their binding sites masked, which are designed to be selectively activated in the TME,
potentially limiting on-target off-tumor toxicity in normal tissues. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains information derived from various public sources and certain information from an industry report dated September&nbsp;22, 2020 commissioned by us and prepared
by Frost&nbsp;&amp; Sullivan, a third-party industry research firm, to provide information regarding our industry and market position. Such information involves a number of assumptions and limitations,
and you are cautioned not to give undue weight to these estimates. The industry in which we operate is subject to a high degree of uncertainty and risk due to variety of factors, including those
described in the "Risk Factors" section. These and other factors could cause results to differ materially from those expressed in these publications and reports.

 </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=17,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=907516,FOLIO='14',FILE='DISK103:[20ZDS1.20ZDS17601]CC17601A.;112',USER='CHE105939',CD=';1-FEB-2021;01:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ce17601_1_15"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce17601_the_offering"> </A>
<A NAME="toc_ce17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Offering price</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADSs offered by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs if the underwriters exercise their over-allotment option in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The ADSs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each ADS represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, par value US$0.0001 per
share. The depositary will hold the ordinary shares underlying your ADSs. You will have rights as provided in the deposit agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We do not expect to pay dividends in the foreseeable future. If, however, we declare dividends on our ordinary shares, the
depositary will pay you the cash dividends and other distributions it receives on our ordinary shares, after deducting its fees and expenses in accordance with the terms set forth in the deposit agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You may turn in your ADSs to the depositary in exchange for ordinary shares. The depositary will charge you fees for any
exchange.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment
to the deposit agreement, you agree to be bound by the deposit agreement as amended.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>To better understand the terms of the ADSs, you should carefully read the "Description of American Depositary Shares"
section of this prospectus. You should also read the deposit agreement, which is filed as an exhibit to the registration statement that includes this prospectus.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We will issue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares represented by ADSs in this
offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All options, regardless of grant dates, will entitle holders to the equivalent number of ordinary shares once the vesting
and exercising conditions on such share-based compensation awards are met.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See "Description of Share Capital."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares outstanding immediately after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Immediately upon the completion of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares
will be outstanding (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares if the underwriters exercise their option to purchase additional ADSs in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Over-allotment option</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We have granted to the underwriters an option, which is exercisable within 30&nbsp;days from the date of this prospectus, to
purchase up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs.</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=530949,FOLIO='15',FILE='DISK103:[20ZDS1.20ZDS17601]CE17601A.;19',USER='CHE109169',CD='31-JAN-2021;19:18' -->
<A NAME="page_ce17601_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We expect to receive net proceeds of approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million from this offering,
 after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We plan to use the net proceeds of this offering for (i)&nbsp;approximately 95% for research and development, among which
approximately 26% for ADG106 clinical development, approximately 26% for both ADG126 and ADG116 clinical development, and approximately 43% for our technical and platform development and development of our preclinical candidates, and (ii)
&nbsp;approximately&nbsp;5% for working capital and other general corporate purposes. See "Use of Proceeds."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lockup</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We, [our directors, executive officers and existing shareholders] have agreed with the underwriters, subject to certain
exceptions, not to sell, transfer or dispose of, directly or indirectly, any of ADSs or ordinary shares or securities convertible into or exercisable or exchangeable for ADSs or ordinary shares for a period of [180] days after the date of this
prospectus. See "Shares Eligible for Future Sale" and "Underwriting" for more information.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq trading symbol</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADAG.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment and settlement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The underwriters expect to deliver the ADSs against payment therefor through the facilities of The Depository Trust Company
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depositary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>JPMorgan Chase Bank, N.A.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See "Risk Factors" and other information included in this prospectus for discussions of the risks relating to investing in
the ADSs. You should carefully consider these risks before deciding to invest in the ADSs.</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless specifically indicated otherwise or unless the context otherwise requires, all references to our ordinary shares as of the date of this prospectus exclude a total of 2,262,500
ordinary shares, issued but deemed to be not outstanding as of the date of this prospectus, held by Great Han Fortune LP.


</FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=540542,FOLIO='16',FILE='DISK103:[20ZDS1.20ZDS17601]CE17601A.;19',USER='CHE109169',CD='31-JAN-2021;19:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cg17601_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cg17601_our_summary_consolidated_financial_data"> </A>
<A NAME="toc_cg17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  OUR SUMMARY CONSOLIDATED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2018 and 2019, summary
consolidated balance sheet data as of December&nbsp;31, 2018 and 2019 and summary consolidated cash flow data for the years ended December&nbsp;31, 2018 and 2019 have been derived from our audited
consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United
States of America, or U.S.&nbsp;GAAP. The following summary consolidated statements of comprehensive loss for the nine months ended September&nbsp;30, 2019 and 2020, summary consolidated balance
sheet data as of September&nbsp;30, 2020 and summary consolidated cash flows data for the nine months ended September&nbsp;30, 2019 and 2020 have been derived from our unaudited interim condensed
consolidated financial statements included elsewhere in this prospectus and have been prepared on the same basis as our audited consolidated financial statements and include all adjustments,
consisting only of normal and recurring adjustments, that we consider necessary for a fair statement of our financial position and operating results for the periods presented. Our historical results
are not necessarily indicative of results expected for future periods. You should read this Summary Consolidated Financial Data section together with our consolidated financial statements and the
related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Consolidated Statements of Comprehensive Loss Data  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents our summary consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2018 and
2019 and our selected unaudited interim condensed </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=20,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=862738,FOLIO='17',FILE='DISK103:[20ZDS1.20ZDS17601]CG17601A.;42',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cg17601_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>consolidated
statements of comprehensive loss data for the nine months ended September&nbsp;30, 2019 and 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Nine Months<BR>
Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenue:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Licensing revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Expenses:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,081</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,765</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,438</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,268</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,786</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,170</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,786</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(30,706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>712</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>613</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(138</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>902</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange gain (loss), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss before income tax</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other comprehensive income (loss):</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustments, net of nil tax</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(215</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,367</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,537</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(246</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to ordinary shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Weighted average number of ordinary shares used in per share calculation:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss per ordinary share</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=21,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1007934,FOLIO='18',FILE='DISK103:[20ZDS1.20ZDS17601]CG17601A.;42',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cg17601_1_19"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Consolidated Balance Sheet Data  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents our summary consolidated balance sheet data as of December&nbsp;31, 2018 and 2019 and our selected unaudited
interim consolidated balance sheet data as of September&nbsp;30, 2019 and 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of September&nbsp;30,<BR>
2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in USD thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current assets:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term investments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 51,817</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>103,923</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>86,606</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>86,606</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 54,417</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>105,889</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>89,077</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>89,077</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current liabilities:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts due to related parties</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,674</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals and other current liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,574</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,540</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>717</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,203</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,203</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
10,346</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
7,181</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
10,417</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
10,417</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total liabilities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
10,488</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
8,697</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
13,610</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
13,610</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total mezzanine equity</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 84,955</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>154,201</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>154,387</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total shareholders' equity (deficit)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> (41,027</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>(57,009</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>(78,921</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>75,466</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=1>Note: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1><SUP>(1)</SUP></FONT></DT><DD style="font-family:times;"><FONT SIZE=1>All of the preferred shares will automatically convert into ordinary shares on a one-on-one basis immediately
prior to the completion of this offering. The unaudited pro forma balance sheet information assumes the automatic conversion of all of the outstanding preferred shares into ordinary shares on a
one-to-one basis, as if conversion would have occurred on September&nbsp;30, 2020. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Consolidated Cash Flow Data  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents our summary consolidated cash flow data for the years ended December&nbsp;31, 2018 and 2019 and our selected
unaudited interim consolidated cash flow data for the nine months ended September&nbsp;30, 2019 and 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Nine Months Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in USD thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18,154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(19,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash generated (used in) from investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(29,510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,856</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,942</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,434</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash generated from financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,694</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,097</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate on cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase in cash and cash equivalents</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,322</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,614</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the beginning of year/period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the end of year/period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,673</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,895 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=22,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=970449,FOLIO='19',FILE='DISK103:[20ZDS1.20ZDS17601]CG17601A.;42',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ci17601_1_20"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ci17601_risk_factors"> </A>
<A NAME="toc_ci17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should consider carefully all of the information in this prospectus, including the risks and uncertainties described
below and our consolidated financial statements and related notes, before making an investment in the ADSs. Any of the following risks and uncertainties could have a material adverse effect on our
business, financial condition and results of operations. In particular, as we are a China-based company incorporated in the Cayman Islands, you should pay special attention to subsections headed
"Risks Related to Doing Business in the PRC" below. The market price of the ADSs could decline significantly as a res</I></FONT><FONT SIZE=2>u</FONT><FONT SIZE=2><I>lt of any of these risks and
uncertainties, and you may lose all or part of your investment. When determining whether to invest, you should also refer to the other information contained in this prospectus, including our financial
statements and the related notes thereto. You should also carefully review the cautionary statements referred to under "Special Note Regarding Forward-looking Statements." Our actual results could
differ materially and adversely from those anticipated in this prospectus.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Prospects and Need for Additional Capital  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a limited operating history, which may make it difficult to evaluate our current business and predict
our future performance.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical stage biopharmaceutical company with a limited operating history. Since our inception in 2011, we have focused substantially
all of our efforts and financial resources on the discovery and development of antibody therapeutics for the treatment of cancer. We have no products approved for commercial sale and therefore we have
not generated any revenue from product sales. We have not obtained regulatory approvals for any of our product candidates and there is no assurance that we will obtain approvals in the future. We
expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and
may continue to have an adverse effect on our working capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
operations to date have focused on developing our product candidates, building our intellectual property portfolio, conducting preclinical testing and clinical trials, and raising
capital. These operations provide a limited basis for you to assess our ability to successfully market and commercialize our product candidates. Consequently, predictions about our future success or
viability may not be as accurate as they could be if we had a longer operating history. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving
fields as we seek to shift our focus to late stage development and commercial activities. If we do not address these risks and difficulties successfully, we may not be successful in such a transition. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred net losses historically and we may continue to incur net losses in the near future.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception in 2011, we have devoted our resources to the development of innovative antibodies in the therapeutic area. While we have
generated revenues from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we have had significant operating losses since our inception.
For the years ended December&nbsp;31, 2018 and 2019 and the nine months ended September&nbsp;30, 2020, we incurred net losses of US$15.3&nbsp;million, US$16.4&nbsp;million and
US$29.6&nbsp;million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs. To date, we have financed
our operations principally through private placements. Our product candidates and programs
are in preclinical development or early stage clinical development, and we have not received marketing approval for any of our product candidates. Our product candidates will require substantial
investments and significant marketing efforts before we generate any revenues from product sales, if ever. We </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=554170,FOLIO='20',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>expect
our net losses will increase as more product candidates enter into clinical trial stage. Our ability to generate product revenue and achieve profitability depends on, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completing research and development of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initiating, enrolling patients in and completing clinical trials of product candidates on a timely basis; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining regulatory approvals and marketing authorizations for any product candidates for which we complete clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and maintaining adequate manufacturing capabilities either by ourselves or in connection with third-party manufacturers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> launching and commercializing any product candidates for which we obtain regulatory approvals and marketing authorizations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing a sales, marketing and commercialization team for any future products for which we may obtain regulatory approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seeking to identify additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> addressing any competing technological and market developments; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintaining, protecting and expanding our portfolio of intellectual property rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. Because of the numerous risks and
uncertainties associated with the development, delivery and commercialization of complex innovative antibody therapeutic, we are unable to accurately predict the timing or amount of expenses or when,
or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation
and completion of our clinical trials or the development of any of our product candidates, our expenses could increase and profitability could be further delayed. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce our
operations. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become or remain profitable would decrease the
value of our company and could impair our ability to raise capital, expand our business or continue our operations. Failure to become and remain profitable may adversely affect the market price of the
ADSs and our ability to raise capital and continue operations. A decline in the value of our company could also cause you to lose all or part of your investment. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may need to obtain substantial additional financing to fund our growth and operations, which may not be
available on acceptable terms, if at all.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development of biopharmaceutical product candidates is capital-intensive. We have used substantial funds to advance our discovery programs
and develop our technology and product candidates, and will require significant funds to conduct further research and development, preclinical testing and clinical trials of our product candidates, to
seek regulatory approvals for our product candidates and to manufacture and market products, if any, that are approved for commercial sales. If our product candidates enter and advance through
preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory and manufacturing capabilities. In addition, upon the closing of this offering,
we expect to incur additional costs associated with operating as a public company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=713298,FOLIO='21',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, we have funded our operations primarily through capital contributions from our shareholders via private placements. Our operations have consumed substantial amounts of cash
since inception. As of September&nbsp;30, 2020, we had US$82.9&nbsp;million in cash and cash equivalents. The net cash used in our operating activities was US$14.3&nbsp;million,
US$18.2&nbsp;million and US$20.0&nbsp;million for the years ended December&nbsp;31, 2018 and 2019 and the nine months ended September&nbsp;30, 2020, respectively. Our future funding
requirements and the period for which we expect increasing capital need may be different than what we are planning. Our monthly spending levels vary based on new and ongoing research and development
activities. Because of the numerous risks and uncertainties associated with our product development, we are unable to accurately predict the timing and amount of our operating expenditures, which will
depend largely on:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, timing, progress, costs and results of discovery, preclinical development, laboratory testing and clinical development activities of
our current product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number, scope, progress and results of preclinical and clinical programs we decide to pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and research and
development agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to maintain our current licenses, research and development programs, and to establish new collaboration arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and
defending any intellectual property-related claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost, timing and outcome of regulatory review of any of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our
product candidates for which we receive marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates
and satisfy our obligations as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Any
additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product
candidates, if approved. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future
commercialization efforts. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict
our operations or require us to relinquish rights to our technologies or product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may seek additional funding through a combination of equity and debt financings and collaborations. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, the beneficial ownership interest of existing shareholders and the holders of ADSs will be diluted, and the terms may include
liquidation or other preferences that adversely affect the rights of our existing shareholders and the holders of the ADSs. The incurrence of additional indebtedness or the issuance of certain equity
securities could result in increased fixed payment obligations and could also result in certain additional restrictive covenants, such as incurring additional debt, making capital expenditures, or
declaring dividends. If we raise additional funds through partnerships, collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1028212,FOLIO='22',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>rights
to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have certain shareholders who will have board representation rights after the offering and their
individual interests may differ from yours.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2014, we completed private placements of our Series&nbsp;A-1 and A-2 preferred shares, in which we raised gross proceeds of approximately
US$8.5&nbsp;million. In 2016, we completed a private placement of our Series&nbsp;B preferred shares, in which we raised gross proceeds of approximately US$28.0&nbsp;million. In 2018, we
completed a private placement of our Series&nbsp;C-1 preferred shares, in which we raised gross proceeds of approximately US$50.0&nbsp;million. In 2019, we completed private placements of our
Series&nbsp;C-2 and C-3 preferred shares, in which we raised gross proceeds of approximately
US$69.0&nbsp;million in aggregate. As a result of these private placements, a significant portion of our outstanding equity is currently held by multiple separate institutional investors through
several separate funds and our founders. Collectively, these institutional investors that are our principal shareholders beneficially owned approximately 55.5% of our outstanding voting stock as of
the date of this prospectus on an as-converted basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
institutional investors will continue have a significant level of influence because of their level of ownership, including a greater ability than you and our other shareholders to
influence the election of directors and the potential outcome of other matters submitted to a vote of our shareholders, such as mergers, the sale of substantially all of our assets and other
extraordinary corporate matters. These investors and our founder, Peter Luo, also have certain rights, such as board representation right and registration right that our other shareholders do not
have. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
instance, our post-offering memorandum and articles of association will provide that JSR Limited shall have the right to designate, appoint, remove and replace and reappoint one
director so long it holds at least five percent of the shares outstanding on a fully-diluted basis and an as-converted basis, respectively; as long as Wuxi Pharmatech Healthcare Fund I&nbsp;L.P.,
which is controlled by the ultimate controlling party of our sole supplier, holds at least five percent of the shares outstanding on a fully-diluted basis, it shall have the right to nominate one
independent non-executive director and such one director shall be appointed and agreed by the board; as long as Peter Luo holds or beneficially owns any shares or is employed by us or any of our
subsidiaries, he will serve as one of our directors and the Chairman of the Board of Directors; in addition, during the period commencing upon the effectiveness of our registration statement on
Form&nbsp;F-1, of which this prospectus is a part, and ending on the earlier of (i) the date upon which Peter Luo beneficially owns less than five percent of the shares outstanding on a fully
diluted basis, (ii) the death or legal determination of Peter Luo's incapacity or (iii) the termination of Peter Luo as an executive officer or principal scientific advisor to us or any of our
subsidiaries or for cause (as determined under his related employment or consulting arrangements and subject to all related cure provisions), Peter Luo shall have the right to designate, appoint,
remove and replace and reappoint one additional director; and as long as General Atlantic Singapore AI Pte.&nbsp;Ltd. and its affiliates hold at least five percent of the shares outstanding on a
fully-diluted basis, they shall have the right to designate, appoint, remove and replace and reappoint one director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
interests of these investors could conflict with the interests of our other shareholders, including you, and any future transfer by these investors of their shares of preferred or
ordinary share to other investors who have different business objectives could have a material adverse effect on our business, results of operations, financial condition and the market value of our
ordinary shares or ADSs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=5989,FOLIO='23',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Clinical Development of Our Product Candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to identify or discover new product candidates, and may allocate our limited resources to
pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we will focus our efforts on continued preclinical and clinical developments, regulatory approval process and commercialization with
respect to our existing product candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates.
Research programs to identify new product candidates require substantial technical, financial, and human resources. Our research programs may initially show promise in identifying potential product
candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products
unmarketable or unlikely to obtain marketing approval; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential product candidates may not be effective in treating their targeted diseases. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
we have limited financial and managerial resources, we focus on research programs and product candidates for specific targets. As a result, we may forgo or delay pursuit of
opportunities with
other product candidates that later may be proved to have greater commercial potential or a greater likelihood of success. On the other hand, if we do not prioritize the allocation of our resources
and conduct research programs that cover a broad range of targets or engage clinical programs that are overly expansive, we may be subject to significant risk of loss as a large part of the research
and clinical programs fail. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
there can be no assurance that we will ever be able to develop suitable potential product candidates through internal research programs, which could materially adversely
affect our future growth and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of
product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A key element of our strategy is to leverage our technology platform to expand our pipeline of antibody product candidates and in order to do
so, we will continue to invest in our platform and development capabilities. Although our research and development efforts to date have resulted in a pipeline of product candidates, these product
candidates may not be safe and effective. In addition, although we expect that our platform will allow us to develop a diverse pipeline of novel and differentiated product candidates, we may not prove
to be successful at doing so. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including
as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance.
Even after approval, if we cannot successfully develop or commercialize our products, or if serious adverse events are discovered after commercialization, we will not be able to generate any product
revenue, which would adversely affect business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=98534,FOLIO='24',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our
business and financial condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our product candidates are created with, and dependent upon, our proprietary antibody discovery platforms, such as our proprietary Dynamic
Precision Library platform, which includes our NEObody platform, SAFEbody platform and POWERbody platform. These proprietary
technology platforms are also the basis of our collaborations with certain other partners. To date, no products based on any of these technologies have been approved for commercial sale in any
jurisdiction. Any failures or setbacks with respect to our proprietary technologies, including adverse effects resulting from the use of product candidates derived from these technologies in human
clinical trials and/or the imposition of clinical holds on trials of any product candidates using our proprietary technologies, could have a detrimental impact on our clinical pipeline, as well as our
ability to maintain and enter into new corporate collaborations regarding our technologies or otherwise, which would negatively affect our business and financial conditions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates, for which we intend to seek approval as biologics products, may face competition
sooner than anticipated.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we are successful in achieving a final regulatory approval to commercialize a product candidate ahead of our competitors, our product
candidates may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product
candidates pursuant to the Biologics License Application (BLA) pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar
and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a
biosimilar as "interchangeable" based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12&nbsp;years after
the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are
subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future
commercial prospects for our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be
shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for
interchangeable or generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jurisdictions
in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference
products. For example, the European Union has had an established regulatory pathway for biosimilars since 2005. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
increased likelihood of biosimilar competition has increased the risk of loss of innovators' market exclusivity. Due to this risk, and uncertainties regarding patent protection, if
our clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the
relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory
exclusivity. The loss of market exclusivity </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=815742,FOLIO='25',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>for
a product would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We depend substantially on the success of our product candidates, particularly ADG106, ADG126, ADG116 and
ADG104, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully
identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be
materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business and the ability to generate revenue related to product sales, if ever, will depend on the successful development, regulatory
approval and commercialization of our antibody product candidates for the treatment of patients with cancer, particularly ADG106, ADG126, ADG116 and ADG104, which are still in clinical stage. Other
than ADG106, ADG126, ADG116 and ADG104 which are currently in Phase&nbsp;I development, our current product candidates are in relatively early stages of development. We have invested a significant
portion of our efforts and financial resources in the development of our existing product candidates and all of our product candidates will require significant further development, financial
resources. The success of our product candidates, including ADG106, ADG126, ADG116 and ADG104, will depend on several factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful enrollment in, and completion of, preclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> receipt of regulatory approvals from the FDA, NMPA and other comparable regulatory authorities for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing commercial manufacturing capabilities, either by building facilities ourselves or making arrangements with third-party
manufacturers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> relying on third parties to conduct our clinical trials safely and efficiently; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> protecting our rights in our intellectual property; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ensuring we do not infringe, misappropriate or otherwise violate the patent, trade secret or other intellectual property rights of third
parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> launching commercial sales of our product candidates, if and when approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> competition with other product candidates and drugs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continued acceptable safety profile for our product candidates following final regulatory approval, if and when received. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
to the uncertain, time-consuming and costly clinical development and regulatory approval process, we may not successfully develop any of our product candidates, or we or our partners
may choose to discontinue the development of product candidates for a variety of reasons. Our failure to effectively advance our development programs could have a material adverse effect on our
business, financial condition, results of operations and future growth prospects, and cause the market price of our ADSs to decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=29,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=708032,FOLIO='26',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical trials are expensive, time consuming and difficult to design and implement and may fail to
demonstrate adequate safety and efficacy of our product candidates. The results of our current and previous preclinical studies or clinical trials may not be predictive of future results, and the
results of our current and planned clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities or provide the basis for regulatory approval.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical studies and
extensive clinical trials to demonstrate their safety and efficacy in humans. Clinical testing is expensive and difficult to design and implement. Clinical testing can take many years to complete, and
its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. We will be required to demonstrate with substantial evidence through well-controlled
clinical trials that our product candidates are safe, pure, and potent for use in a diverse patient population before we can seek final regulatory approvals for their commercial sale. Our clinical
trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional and expansive preclinical or clinical testings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot assure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The results are subject to the risk that one or
more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Product candidates in later-stage clinical trials may fail to demonstrate
sufficient safety and efficacy to the satisfaction of the FDA, the NMPA and comparable foreign regulatory authorities, despite having progressed through preclinical studies or initial clinical trials.
Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials or registration clinical trials. For example, a number
of companies in the biopharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining
promising results in earlier clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
failure of a clinical trial to meet its predetermined endpoints may cause us to abandon a pipeline product or an indication and may delay development of any other pipeline products.
Any delay in, or termination of, our clinical trials will delay the submission for regulatory approval and application, and, ultimately, our ability to commercialize any of our pipeline products and
generate revenue. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
principal investigators for our clinical trials may serve and have served as scientific advisors or consultants to us from time to time and receive compensation in connection
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign
regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or
comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be
jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to
the denial of marketing approval of our pipeline products. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may experience delays in our ongoing clinical trials.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be
redesigned, enroll patients on time, or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in or failure to obtain regulatory authorization to commence a trial; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=30,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=517358,FOLIO='27',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in or failure to obtain institutional review board, or IRB, approval at each site; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> difficulty in recruiting clinical trial investigators of appropriate competencies and experience; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in establishing the appropriate dosage levels in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in or failure to recruit and enroll suitable patients to participate in a trial, particularly considering study inclusion and exclusion
criteria and patients' prior lines of therapy and treatment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay
enrollment and reduce the power of a clinical trial to detect statistically significant results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> lower than anticipated retention rates of patients in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to have patients complete a trial or return for post-treatment follow-up; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinical sites deviating from trial protocol or dropping out of a trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays adding new investigators or clinical trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> safety or tolerability concerns could cause us or our collaborators or governmental authorities, as applicable, to suspend or terminate a trial
if it is found that the participants are being exposed to unacceptable health risks, undesirable side effects or other unfavorable characteristics of the product candidate, or if such undesirable
effects or risks are found to be caused by a chemically or mechanistically similar therapeutic or therapeutic candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely
manner, or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in regulatory requirements, policies and guidelines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to comply with the applicable regulatory requirements through the clinical process; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacturing sufficient quantities of a product candidate for use in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the quality or stability of a product candidate falling below acceptable standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the treatment landscape for our target indications that may make our product candidates no longer relevant; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> third-party actions claiming infringement by our product candidates in clinical trials outside the United States and obtaining injunctions
interfering with our progress. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our
planned and ongoing clinical trials. Moreover, while we plan to submit additional investigational new drug applications, or INDs, for other product candidates, we may not be able to file such INDs on
the timeline we expect. For example, we may experience manufacturing delays or other delays with IND-enabling preclinical studies. Moreover, we cannot be sure that submission of an IND will result in
the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design
and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to
new clinical trials we may submit as amendments to existing INDs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=31,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=818455,FOLIO='28',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are required to conduct additional clinical trials or other studies with respect to any of our product candidates beyond those that we initially contemplated, if we are unable to
successfully complete our clinical trials or other studies or if the results of these studies are not positive or are only modestly positive, we may be delayed in obtaining regulatory approval for
that product candidate, we may not be able to obtain regulatory approval at all or we may obtain approval for indications that are not as broad as intended. Our drug development costs will also
increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process. Significant clinical trial delays could allow our
competitors to bring drugs to market before we
do and impair our ability to commercialize our drugs, if and when approved. If any of this occurs, our business will be materially harmed. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trials must be conducted in accordance with the FDA and other applicable regulatory authorities' legal requirements, regulations or guidelines, and are subject to oversight by
these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated
by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, or
other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial or to perform obligations in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a
clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product
candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase
our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also
allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to
commercialize our product candidates and may harm our business and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
clinical trials must be conducted with supplies of our product candidates produced under current good manufacturing practices, or cGMP, requirements and other regulations.
Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited
influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP,
requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study in accordance with GCP or are delayed for a significant time in
the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are
conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of
non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=32,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=789310,FOLIO='29',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ci17601_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we encounter difficulties in enrolling patients in our clinical trials, our clinical development
activities could be delayed or otherwise adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Our clinical trials may be
subject to delays for a variety of reasons, including as a result of enrollment taking longer than anticipated, subject withdrawal or adverse events. These types of developments could cause us to
delay the trial or halt further development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we believe our differentiated product candidates address highly unmet medical needs that will facilitate our patient enrollment, clinical trials may compete with other clinical
trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll
in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for cancer therapies is challenging, as cancer patients
will first receive the applicable standard of care. Many patients who respond positively to the standard of care antibody therapy (and thus do not enroll in clinical trials) are believed to have tumor
types that would have responded well to our product candidates. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved product
candidates. However, these patients may have either compromised immune function from prior administration of chemotherapy or an enhanced immune response from the prior administration of checkpoint
inhibitors. Either of these prior treatment regimens may render our therapies less effective in clinical trials. Additionally, patients who have failed approved therapies will typically have more
advanced cancer and a poorer long-term prognosis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of
our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. We may experience difficulties in patient enrollment in our
clinical trials for a variety of reasons, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> severity of the disease under investigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the size and nature of the patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the patient eligibility criteria defined in the protocol; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the size of the study population required for analysis of the trial's primary endpoints; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> perceived risks and benefits of our pipeline products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our resources to facilitate timely enrollment in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patient referral practices of physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the proximity of patients to trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the design of the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to recruit clinical trial investigators with the appropriate competencies and experience; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain and maintain patients' consent; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the risk that patients enrolled in clinical trials will not complete a clinical trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial
of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and
generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of
our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=33,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=986951,FOLIO='30',FILE='DISK103:[20ZDS1.20ZDS17601]CI17601A.;37',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ck17601_1_31"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time
may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we may publicly disclose preliminary or topline or data from our preclinical studies and clinical trials, which is based on a
preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular
study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data
have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we
previously published. As a result, topline data should be viewed with caution until the final data are available. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that
one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final
data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance
of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. If the
interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval
for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Obtaining Regulatory Approval of Our Drug Candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy,
time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, marketing approval of biologics requires the submission of a BLA to the FDA, and we are not permitted to market any
product candidate in the United States until we obtain approval from the FDA of the BLA for that product candidate. A BLA must be supported by extensive clinical and preclinical data, as well as
extensive information regarding pharmacology, chemistry, manufacturing and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not previously submitted a BLA to the FDA or similar regulatory approval filings to the NMPA or other comparable foreign authorities, for any product candidate, and we cannot be
certain that any of our product candidates will receive regulatory approval. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process, and as a company we have no experience with
the preparation of a BLA submission or any other application for marketing approval. In addition, the FDA has the authority to require a risk evaluation and mitigation strategies, or REMS, plan as
part of
a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers
that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=34,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=453558,FOLIO='31',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>have
undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDA
approval is not guaranteed, and the time required to obtain approval by the FDA, NMPA and other comparable regulatory authorities is unpredictable but typically takes many years
following the commencement of preclinical trials and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, due to external
issues such as pandemics or other public health emergencies, FDA, NMPA and other comparable regulatory authorities may be delayed in their review of product applications. In addition, approval
policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions. We
have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may discover, in-license or acquire and
seek to develop in the future will ever obtain regulatory approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
product candidates could fail to receive regulatory approval from the FDA, NMPA or a comparable regulatory authority for many reasons,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disagreement with the design or implementation of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to demonstrate that a product candidate is safe and effective or safe, pure, and potent for its proposed indication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure of clinical trial results to meet the level of statistical significance required for approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disagreement with our interpretation of data from preclinical trials or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a BLA or other
submission or to obtain regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA, NMPA or comparable regulatory authority's finding of deficiencies related to the manufacturing processes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure of our product candidates to pass current Good Manufacturing Practice, or cGMP, inspections during the regulatory review process or
across the production cycle of our product; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in approval policies or regulations that render our preclinical and clinical data insufficient for approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product
candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of and opinions on our
preclinical and clinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs or conduct additional clinical trials to satisfy the
regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from
clinical trials of our product candidates
are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA, NMPA or a comparable regulatory authority may require more information, including additional preclinical or clinical data, to support approval, which may delay or prevent
approval and our commercialization plans, or we may decide to abandon the development program. If we were to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=35,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1025799,FOLIO='32',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>obtain
approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly
post-marketing clinical trials, may approve a product candidate with a label that is not desirable for the successful commercialization of that product candidate, or may be difficult to meet
manufacturing requirements. In addition, if our product candidate produces undesirable side effects or safety issues, the FDA may require the establishment of Risk Evaluation Mitigation Strategies, or
REMS, or the NMPA or a comparable regulatory authority may require the establishment of a similar strategy, that may, for instance, restrict distribution of our drugs and impose burdensome
implementation requirements on us. Any of the foregoing scenarios could materially harm the commercial prospects of our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns
could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely
manner or at all, which could negatively impact our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, statutory, regulatory, and policy changes, the FDA's ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA's ability
to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and
development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or
modifications to licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for
35&nbsp;days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and
stop critical activities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separately,
in response to the COVID-19 pandemic, on March&nbsp;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on
March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&nbsp;10, 2020, the FDA announced its intention to
resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the
categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside
the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to
prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other
regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or
commercialize such products outside of the United States, which would limit our ability to realize their full market potential.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of
other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does
not mean that regulatory approval will be obtained in any other countries. Approval procedures vary among countries and can involve additional product testing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=36,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=548427,FOLIO='33',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and
validation and additional administrative review periods. Seeking regulatory approvals in various jurisdictions could result in significant delays, difficulties and costs for us and may require
additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction
of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain
regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any
jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in
international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are conducting clinical trials and may in the future conduct additional clinical trials for our product
candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States,
including in Australia, Europe or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In
cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the
application on the basis of foreign data alone unless (i)&nbsp;the data are applicable to the United States population and United States medical practice; (ii)&nbsp;the trials were performed by
clinical investigators of recognized competence and (iii)&nbsp;the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to
be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Otherwise, for studies that are conducted at sites outside of the United&nbsp;States and
not subject to an IND and which are intended to support a marketing application (but which are not intended to serve as the sole basis for marketing approval), the FDA requires the clinical trial to
have been conducted in accordance with good clinical practice, or GCP, requirements and the FDA must be able to validate the data from the clinical trial through an on site inspection if it deems such
inspection necessary. Additionally, the FDA's clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies, such
as NMPA, have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no
assurance that the FDA, NMPA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, NMPA or any
similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and
which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates may cause undesirable adverse events or have other properties that could delay or
prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Undesirable adverse events caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA or other comparable regulatory authority. Results of our trials could reveal a high and
unacceptable severity or prevalence of adverse events. In such an event, our trials could be suspended or terminated and the FDA, NMPA or other comparable regulatory authorities could order us to
cease further development of, or deny approval of, our product </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=37,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=54835,FOLIO='34',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>candidates
for any or all targeted indications. Drug-related adverse events could affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in potential
product liability claims. Moreover, such events may require us to amend our trials, including reducing the dosage in our clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
instance, in September 2019, in our Phase I trial of ADG116 in the United States, we reported to the FDA the death of the only patient dosed in the trial. The FDA subsequently placed
the trial on clinical hold on September&nbsp;30, 2019. The FDA noted that there was insufficient information to assess the risk of drug-induced liver toxicity in patients receiving ADG116 but
requested us to revise the study protocol to mitigate the risk of drug-induced liver toxicity. We submitted to the FDA an amendment to the study protocol, which significantly lowered the starting dose
of ADG116, tightened the inclusion and exclusion criteria to exclude, among others, patients with liver dysfunction, history of alcohol abuse, or poorly controlled diabetes, and stipulated additional
post-dosing monitoring to closely follow treated patients for safety or toxicity signals. The FDA removed the clinical hold on December&nbsp;5, 2019. We have obtained authorization from the
Australian Therapeutic Goods Administration under a CTN to start a Phase I clinical trial of ADG116. We have decided to focus on conducting the Australian clinical trial of ADG116 at a higher starting
dose than currently permitted in the United States, and consequently, we have not re-commenced patient enrollment in the United States. If the data from the Australian clinical trial are favorable, we
may consider using such data for re-submission of an IND application to the NMPA. The NMPA in August 2020 did not approve our application for a clinical trial in China at a higher starting dose than
currently permitted in Australia and requested additional patient safety data prior to considering approving the IND at the proposed starting dose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot provide any assurance that there will not be treatment-related severe adverse events with our product candidates, that the trials for our product candidates will not be
suspended in the future, or that patient recruitment for trials with our product candidates will not be adversely impacted by the ADG116 related adverse events, any of which could materially and
adversely affect our business and prospects. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of
exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. In the event that any of our
product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative
consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may suspend marketing of such products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may withdraw or limit approvals of such products or require us to take an approved product off the market; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and
pharmacies, or issue other communications containing warnings or other safety information about the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we
implement a REMS plan to ensure that the benefits of the product outweigh its risks or to develop a similar strategy as required by a comparable regulatory authority, that may, for instance, restrict
distribution of our drugs and impose burdensome implementation requirements on us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be required to conduct post-market studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be subject to limitations on how we may promote or manufacture the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sales of the product may decrease significantly; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we could be sued and held liable for harm caused to subjects or patients; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=38,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=637317,FOLIO='35',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results
of operations and prospects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
combination therapy involves unique adverse events that could be exacerbated compared to adverse events from monotherapies. These types of adverse events could be caused by our
product candidates and could also cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory
approval by the FDA, NMPA or other comparable regulatory authority. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may seek Orphan Drug Designation for some of our product candidates, and we may be unsuccessful.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as
orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a disease
with a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
if a drug with an Orphan Drug Designation subsequently receives the first FDA approval for the indication for which it has such designation, the drug is entitled to a period
of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication during the period of exclusivity. The applicable period is
seven years in the United States. Orphan Drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we obtain Orphan Drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be
approved for the same condition and the same drugs can be approved for a different condition but used off-label for any orphan indication we may obtain. Even after an orphan drug is approved, the FDA
can subsequently approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major
contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval
process. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use
of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which
could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify
clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA
may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a
determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical
benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=39,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=129767,FOLIO='36',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>accelerated
approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not
itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available
therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the
sponsor's agreement to conduct, in a diligent manner, additional post- approval confirmatory studies to verity and describe the drug's clinical benefit. If such post-approval studies fail to confirm
the drug's clinical benefit, the FDA may withdraw its approval of the drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated
approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited
development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited
development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation
(e.g.,&nbsp;breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or
approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application
or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period
to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive regulatory approvals for our product candidates, we will be subject to ongoing regulatory
obligations and continued regulatory reviews, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience
unanticipated problems with our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage,
import, export, adverse event reporting, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information,
including both federal and state requirements in the United States and requirements of comparable regulatory authorities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturers
and manufacturers' facilities are required to comply with extensive FDA, NMPA and comparable regulatory authority requirements, including, in the United States, ensuring
that quality control and manufacturing procedures conform to current cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess
compliance with cGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must
continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions
of approval, or contain requirements for potentially costly post-marketing testing, including Phase&nbsp;IV clinical trials and surveillance to monitor the safety and efficacy of the product
candidate. The FDA may also </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=40,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=843116,FOLIO='37',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_ck17601_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>require
a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or
additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, NMPA, or a comparable regulatory
authority approves our product candidates, we will have to comply with requirements including, for example, submissions of safety and other post-marketing information and reports, registration, as
well as continued compliance with cGMPs and Good Clinical Practices, or cGCPs, for any clinical trials that we conduct post approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA and NMPA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug reaches
the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or
clinical trials to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the marketing or manufacturing of our drugs, withdrawal of the product from the market, or voluntary or mandatory product
recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, untitled or warning letters, or holds on clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal by the FDA, NMPA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by
us or suspension or revocation of license approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure or detention, or refusal to permit the import or export of our product candidates; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in
accordance with the provisions of the approved label. The FDA, NMPA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a
company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA, NMPA and of other regulatory authorities may change and additional
government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that
may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


All material aspects of the research, development and commercialization of pharmaceutical products are
heavily regulated.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We
intend to focus our activities in the major markets such as the United States and China. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar
regulatory strategies, including regulation of product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory
regimes that make for a more complex and costly regulatory compliance burden for a company like ours that plans to operate in these regions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=41,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=793256,FOLIO='38',FILE='DISK103:[20ZDS1.20ZDS17601]CK17601A.;32',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cm17601_1_39"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The process of obtaining regulatory approvals and compliance with appropriate laws and regulations require substantial time and financial resources. Failure to
comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions.
These sanctions could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or
partial suspension of production or distribution; injunctions; fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to
comply with these regulations could have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future strategic partnerships may be important to us. We will face significant competition in seeking new
strategic partners.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not yet have any capability for manufacturing, sales, marketing or distribution. For some of our product candidates, we may in the future
determine to collaborate with
pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. The competition for strategic partners is intense. Our ability to reach a definitive
agreement for collaboration will depend, among other things, upon our assessment of the strategic partner's resources and expertise, the terms and conditions of the proposed collaboration and the
proposed strategic partner's evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign
regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of
competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge,
and industry and market conditions generally. The strategic partner may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and
whether such collaboration could be more attractive than the one with us for our product candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strategic
partnerships are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future strategic partners. Even if we are successful in entering into collaboration, the terms and conditions of that
collaboration may restrict us from entering into future agreements with other potential collaborators. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to reach agreements with suitable strategic partners on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate,
reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and
undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional
expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into strategic partnerships and do not have sufficient funds or expertise to
undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology
platform and our business may be materially and adversely affected. Any collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for
example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the partner terminates the collaboration. Any such collaboration,
or other strategic transaction, may require us to incur non-recurring or other charges, and increase our near- and long-term expenditures and pose significant integration or implementation challenges
or disrupt our management or business. Accordingly, although there can be no assurance that we will undertake or successfully complete any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=42,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=522318,FOLIO='39',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>transactions
of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial
condition, results of operations, and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and
potential commercialization
of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches the market. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to enter into additional collaboration agreements beyond our existing strategic
partnerships or collaborations with NIH, Exelixis, ADC Therapeutics and Guilin Sanjin. If we are unable to maintain existing and future strategic partnerships or collaborations, or if these strategic
partnerships or collaborations are not successful, our business could be adversely affected.


 </I></B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our existing strategic partnerships, collaborations and any future strategic partnerships we enter into may pose a number of risks, including
the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to enter into critical strategic partnerships or enter into them on favorable terms; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators have significant discretion in determining the effort and resources that they will apply to such a
partnership, and they may not perform their obligations as agreed, expected, or in compliance with applicable legal requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval
or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the partners' strategic focus or available funding, or external factors,
such as an acquisition that diverts resources or creates competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators could independently develop, or develop with third parties, products that compete directly or indirectly
with our product candidates if the strategic partners or collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more
economically attractive than our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product candidates discovered in collaboration with us may be viewed by our strategic partners or collaborators as competitive with their own
product candidates or products, which may cause strategic partners or collaborators to cease to devote resources to the commercialization of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a strategic partner or collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory
approval may not commit sufficient resources to the marketing and distribution of such product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disagreements with strategic partners or collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with
respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information
in such a way as to invite litigation that could </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=43,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=354315,FOLIO='40',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>jeopardize
or invalidate our intellectual property or proprietary information or expose us to potential litigation; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partners or collaborators may claim for a substantial compensation for our failure of development of the product candidates specified
under the relevant out-licensing agreements that solely arose out of problems of our previous R&amp;D basis; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strategic partnerships or collaborations may be terminated for the convenience of the partner or the collaborator and, if terminated, we could
be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any partnerships or collaboration we enter into do not result in the successful development of our product candidates or if one of our partners or collaborator terminates the
agreement with us, our continued development of our product candidates could be delayed and our business may be materially and adversely affected. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need to grow our organization, and we may experience difficulties in managing this growth, which
could disrupt our operations.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2020, we had 198 full-time employees. As our development and commercialization plans and strategies develop, and as we
transition into operating as a public company, we expect to expand our employee base for managerial, operational, financial and other resources. As our product candidates enter and advance through
preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In
the future, we expect to enter into additional relationships with collaborators or partners, suppliers and other organizations and establish a sales and marketing team in preparation for
commercialization activities. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and
procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and
controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.


</FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Disruptions in the financial markets and economic conditions could affect our ability to raise capital.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global economies could suffer dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well as
a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations
of others. In the past, governments have taken unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the
financial markets. If these actions are not successful, the return of adverse economic conditions may cause a significant impact on our ability to raise capital, if needed, on a timely basis and on
acceptable terms or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, there is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some
of the world's leading economies, including the United States and China. There have been concerns over unrest and terrorist threats in the Middle East, Europe and Africa and over the conflicts
involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian countries, which may result in or intensify potential conflicts in relation to
territorial </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=44,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=332028,FOLIO='41',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>disputes
or the trade related disputes between the United States and China. In addition, the U.K. held a referendum on June&nbsp;23, 2016 on its membership in the EU, in which voters approved an
exit from the EU, commonly referred to as "Brexit"; the U.K. formally left the EU on January&nbsp;31, 2020. The U.K. is currently in a transition period which is expected to continue through
December&nbsp;31, 2020, when agreements surrounding trade and other aspects of the U.K.'s future relationship with the EU will need to be finalized. Brexit could adversely affect European and
worldwide economic and market conditions and could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be
contained or resolved, and what effects they may have on the global political and economic conditions in the long term. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we face allegations of non-compliance with laws and encounter sanctions, our reputation, revenues and
liquidity may suffer, and our product candidates and approved products, if any, could be subject to restrictions or withdrawal from the market.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response,
and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to obtain approvals commercialize and generate
revenues from our drugs. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we
are unable to generate revenues from our product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our reputation is important to our success. Negative publicity may adversely affect our reputation and
business prospects.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any negative publicity concerning us, our affiliates or any entity that shares the "Adagene" name, even if untrue, could adversely affect our
reputation and business prospects. There can be no assurance that negative publicity about us or any of our affiliates or any entity that shares the "Adagene" name would not damage our brand image or
have a material adverse effect on our business, results of operations and financial condition. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Potential future acquisitions or strategic collaborations may increase our capital requirements, dilute our
shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual
property rights, technologies or businesses. Any potential acquisition or strategic collaboration may entail numerous risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increased operating expenses and cash requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the assumption of additional indebtedness or contingent liabilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new
personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the diversion of our management's attention from our existing product programs and initiatives in pursuing such a strategic merger or
acquisition; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
products or product candidates and regulatory approvals; and/or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=45,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=594496,FOLIO='42',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or
even to offset the associated acquisition and maintenance costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could
result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to
technology or products that may be important to the development of our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business operations and current or future relationships with healthcare professionals, principal
investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims,
physician payment transparency and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners, or vendors violate these laws, we could
face substantial penalties.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business operations and current or future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and
relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, without
limitation:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. federal civil and criminal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce
or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole
or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in
order to have committed a violation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. federal false claims laws, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary
penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government,
claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from
knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and
services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other
things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material
fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person
or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=46,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=132048,FOLIO='43',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm
consumers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the United States Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices,
biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children's Health Insurance Program to report annually to the government information related to certain payments
and other transfers of value to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate
family members. Effective January&nbsp;1, 2022, the U.S. federal physician transparency reporting requirements will extend to include transfers of value made during the previous year to certain
non-physician providers such as physician assistants and nurse practitioners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices,
including but not limited to, research, distribution, sales; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents
from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international
organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state
laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government,
or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require the registration of pharmaceutical sales
representatives; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and
items of value provided to healthcare professionals and entities. For detailed discussion on material applicable PRC regulation, see "Regulation&#151;PRC Regulation" </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is
possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and
abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant
penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other
countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against
any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our
business may be impaired. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=47,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=444626,FOLIO='44',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently enacted and future legislation in the United States and other countries may affect the prices we may
obtain for our product candidates and increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and many other countries, rising healthcare costs have been a concern for governments, patients and the health insurance
sector, which resulted a number of changes to laws and regulations, and may result in further legislative and regulatory action regarding the healthcare and health insurance systems that could affect
our ability to profitably sell any product candidates for which we obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted in the United States in
March 2010 with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare, and includes measures to change health care delivery, increase the number of
individuals with insurance, ensure access to certain basic health care services, and contain the rising cost of care. Since its enactment, there have been numerous judicial, administrative, executive,
and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are
currently facing legal and constitutional challenges in the Fifth Circuit Court of Appeals and the United States Supreme Court. Additionally, the current administration has issued various Executive
Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare
providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It
is unclear whether the ACA will be overturned, repealed, replaced, or further amended. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, other federal health reform measures have been proposed and adopted in the United States. For example, as a result of the Budget Control Act of 2011, providers are subject
to Medicare payment reductions of 2% per fiscal year through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2020, unless additional
Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to
recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare
providers will be subject to certain incentives or penalties based on new program quality standards. Payment adjustments for the Medicare quality payment program began in 2019. At this time, it is
unclear how the introduction of the quality payment program will impact overall physician reimbursement under the Medicare program. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
January 2017, there has been legislation considered in Congress to restrict the pricing of drug products to a governmental negotiated rate or to other similar rates that would
reduce the costs to government, commercial payers and individuals. In July 2020, President Trump signed four Executive Orders directing the Department of Health and Human Services and other agencies
to take specific actions to reduce prescription drug prices. The first order directs federally qualified health centers to pass along significant discounts on insulin and epinephrine from drug
companies to low-income individuals. The second order would allow the important of prescription drugs from Canada into the United States where the prices are deemed to be lower. The third order would
eliminate safe harbor protections under the federal Anti-Kickback Statute that currently covers rebates paid by manufacturers to Medicare Part&nbsp;D plans and Medicaid managed care organizations,
either directly or through </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=48,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=734606,FOLIO='45',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>pharmacy
benefit managers under contract with such plans or organizations, so long as such actions are not projected to increase federal spending, Medicare beneficiary premiums or patients' total
out-of-pocket cases. The fourth order will reduce the payment for Medicare part&nbsp;B drugs to be paid at the same rate as other developed nations, thereby reducing the reimbursement. All of these
Executive Orders require rulemaking prior to implementation and could be stalled by Congress or the next election. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
combination of healthcare cost containment measures, increased health insurance costs, reduction of the number of people with health insurance coverage, as well as future legislation
and regulations focused on reducing healthcare costs by reducing the cost of or reimbursement and access to pharmaceutical products, may limit or delay our ability to generate revenue, attain
profitability, or commercialize our pipeline products, if approved. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face intense competitions and rapid technological changes, as well as the possibility that our competitors
may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our ability to successfully commercialize our product candidates and our financial
condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are
currently aware of various existing therapies and development candidates that may compete with ADG106, ADG126, ADG116 and ADG104 for the potential treatment of similar targets, such as urelumab and
utomilumab targeting CD137 and ipilimumab targeting CTLA-4. While we are developing ADG126 and ADG116, both targeting CTLA-4, we intend to focus on and prioritize ADG126 as it is generated by our
SAFEbody technology designed to enhance its safety profile. We have competitors in the United States, China and internationally, including major multinational pharmaceutical companies, specialty
pharmaceutical companies, and biotechnology companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development, marketing
and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a
result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial
applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products
that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than
we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates
against competitors. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have no experience in launching and marketing product candidates. We may not be able to effectively build
and manage our sales network, or benefit from third-party collaborators' sales network.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no manufacturing, sales, marketing or commercial product distribution capabilities and have no experience in marketing drugs.
We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other
biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable or decide not to establish internal sales, marketing and commercial distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative
arrangements regarding the sales and marketing of our product candidates, if approved. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements,
or, if we are </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=49,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=743626,FOLIO='46',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>able
to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over
the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We will also face competition in
our search for third parties to assist us with the sales and marketing efforts of our product candidates, if approved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurance that we will be able to develop in-house sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to
successfully commercialize any product candidate, if approved, and as a result, we may not be able to generate product sales revenue. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we are able to commercialize any approved product candidates, coverage and reimbursement may be
limited or unavailable in certain market segments for our product candidates, and we may be subject to unfavorable pricing regulations, which could harm our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country.
Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some
non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a
drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact our revenues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
primary trend in the global healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount
of reimbursement for particular medications. Our ability to commercialize any drugs successfully also will depend in part on the extent to which coverage and reimbursement for these drugs and related
treatments will be available on adequate terms, or at all, from government health administration authorities, private health insurers and other organizations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, no uniform policy of coverage and reimbursement for biopharmaceutical products exists among third-party payors. As a result, obtaining coverage and reimbursement
approval of a drug from a government or other third-party payor is a time-consuming and costly process that could require
us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our drugs on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement
will be obtained. Even if we obtain coverage for a given drug, the resulting reimbursement rates might not be adequate for us to achieve or sustain profitability or may require co-payments that
patients find unacceptably high. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for
medical products. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of our genetically modified drugs.
Patients are unlikely to use our drugs and any approved product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of the drug. Because
some of our product candidates have a higher cost of goods than conventional therapies, may require long-term follow up evaluations, and will likely be administered under the supervision of a
physician, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
may be significant delays in obtaining reimbursement for approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or other
comparable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=50,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=636350,FOLIO='47',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>regulatory
authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may
vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into
existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of
laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates
from both government-funded and private payors for our drugs and any new product candidates that we develop could have a material adverse effect on our business, our operating results, and our overall
financial condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
China, the Ministry of Human Resources and Social Security of China or provincial or local human resources and social security authorities, together with other government authorities,
review the inclusion or removal of drugs from China's National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List,
or the NRDL, or provincial or local medical insurance catalogues for the National Medical Insurance Program regularly, and the tier under which a drug will be classified, both of which affect the
amounts
reimbursable to program participants for their purchases of those drugs. There can be no assurance that our drugs and any approved product candidates will be included in the NRDL or provincial
reimbursements lists. Products included in the NRDL have been typically generic and essential drugs. Innovative drugs similar to our product candidates have historically been more limited on their
inclusion in the NRDL due to the affordability of the government's Basic Medical Insurance, although this has been changing in recent years. According to currently effective PRC laws and regulations,
the prices of approved drugs are determined by market competition. The government regulate prices mainly by establishing a consolidated procurement mechanism, revising the NRDL and strengthening
regulation of medical and pricing practices. We cannot predict the extent to which our business may be affected by potential future legislative or regulatory developments. Changes in pricing
regulation could restrict the amount that we are able to charge for our future approved drugs, which would adversely affect our revenue, profitability and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to seek approval to market our product candidates in the United States, China and in other jurisdictions. In some non-U.S. countries, the pricing of drugs and biologics is
subject to governmental control, which can take considerable time even after obtaining regulatory approval. Market acceptance and sales of our drugs will depend significantly on the availability of
adequate coverage and reimbursement from third-party payors for drugs and may be affected by existing and future health care reform measures. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As we engage in collaboration worldwide, we may be exposed to specific risks of conducting our business and
operations in international markets.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company with global footprints. We are currently building our clinical and technology infrastructures to support our
future global operations and prepare to serve global markets. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets,
or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=51,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=558620,FOLIO='48',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
international business relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and
distribution efforts may increase our expenses or divert our management's attention from the acquisition or development of product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in a specific country's or region's political and cultural climate or economic condition; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> differing regulatory requirements for drug approvals and marketing internationally; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> difficulty of effective enforcement of contractual provisions in local jurisdictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potentially reduced protection for intellectual property rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential third-party patent rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unexpected changes in tariffs, trade barriers and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> economic weakness, including inflation or political instability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with tax, employment, immigration and labor laws for employees traveling abroad; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the effects of applicable tax structures and potentially adverse tax consequences; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to doing
business in another country; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> workforce uncertainty and labor unrest and failure to comply with the applicable laws and regulations in relation to management of the
employment of foreigners within the PRC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to
import goods from an international market with low or lower prices rather than buying them locally; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and regulations and the Foreign
Corrupt Practices Act of the United States, and other applicable rules and regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters, including earthquakes,
volcanoes, typhoons, floods, hurricanes and fires. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Building our commercialization capabilities will require significant investment of time and money. There
would be no assurance that we will successfully set up our commercialization capabilities in any of the proposed jurisdictions or at all, or that we will successfully commercialize any of our product
candidates in the future.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently in the early stages of building and expanding our commercial capabilities to allow us to market our own products, if approved,
in the future. We will need to set up full commercialization capabilities in the jurisdictions, including China and the United States, which would require substantial investment of time and money and
will divert significant management focus and resources. We also face competition with multinational and local pharmaceutical and biotechnology companies with established commercialization capabilities
in terms of marketing and attracting talents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=52,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=458767,FOLIO='49',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Therefore,
there can be no assurance that our efforts to set up commercialization capabilities will be successful in any of the proposed jurisdictions or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if ADG106 or one of our other proprietary product candidates obtains regulatory approval, we may determine that commercializing such product candidate ourselves would not be the
most effective way to create value for our shareholders or holders of ADSs. In addition, if we choose to commercialize any of our product candidates, our marketing efforts may be unsuccessful as a
result of unfavorable pricing or reimbursement limitations, delays, competition or other factors. Failure to successfully market one or more of our approved products, or delays in our
commercialization efforts, may diminish the commercial prospects for such products and may result in financial losses or damage to our reputation, each of which may have a negative impact on the
market price of our ADSs and our financial condition, results of operations and future growth prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may continue to pursue collaborations or licensing arrangements, joint ventures, strategic alliances,
partnerships or other strategic investment or arrangements, which may fail to produce anticipated benefits and adversely affect our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may continue to pursue opportunities for collaboration, out-license, joint ventures, acquisitions of products, assets or technology,
strategic alliances, or partnerships that we believe would advance our development. We may consider pursuing growth through the acquisition of technology, assets or other businesses that may enable us
to enhance our technologies and capabilities. Proposing, negotiating and implementing these opportunities may be a lengthy and complex process. Other companies, including those with substantially
greater financial, marketing, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not be able to identify, secure, or complete any such
transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have limited experience with respect to these business development activities. Management and integration of a licensing arrangement, collaboration, joint venture or other strategic
arrangement may disrupt our current operations, decrease our profitability, result in significant expenses, or divert management resources that otherwise would be available for our existing business.
We may not realize the anticipated benefits of any such transaction or arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
partners, collaborators, or other parties to such transactions or arrangements may fail to fully perform their obligations or meet our expectations or cooperate with us
satisfactorily for various reasons and subject us to potential risks, including the followings:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> partners, collaborators, or other parties have significant discretion in determining the efforts and resources that they will apply to a
transaction or arrangement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> partners, collaborators, or other parties could independently develop, or develop with third parties, services and products that compete
directly or indirectly with our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> partners, collaborators, or other parties may stop, delay or discontinue clinical trials as well as repeat clinical trials or conduct new
clinical trials by using our intellectual property or proprietary information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> partners, collaborators, or other parties may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to
potential liabilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disputes may arise between us and partners, collaborators, or other parties that cause the delay or termination of the research, development or
commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management's attention and resources; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=53,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=957292,FOLIO='50',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> partners, collaborators, or other parties may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable services and products; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> partners, collaborators, or other parties may own or co-own intellectual properties covering our product candidates that results from our
collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual properties. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
such transactions or arrangements may also require actions, consents, approval, waiver, participation or involvement of various degrees from third parties, such as regulators,
government authorities, creditors, licensors or licensees, related individuals, suppliers, distributors, shareholders or other stakeholders or interested parties. There is no assurance that such third
parties will be
cooperative as we desire, or at all, in which case we may be unable to carry out the relevant transactions or arrangements. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to support, conduct and monitor our preclinical studies and clinical trials.
Therefore, we may not be able to directly control the timing, process, expense and quality of our clinical trials and we cannot assure these third parties can duly perform their obligations as agreed
and expected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to
conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies
and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the
applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and
CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical
development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable
GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with
GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat or suspend
clinical trials, which would delay the regulatory approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our
product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard,
it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers may require us to disclose
our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective
agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit
of our creditors or if we are liquidated. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=54,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=869846,FOLIO='51',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If
CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is
compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to
obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our
costs could increase and our ability to generate revenues could be delayed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a
result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on
additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or
that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently rely on a third-party manufacturer to produce our product candidates. Any failure by the
third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical
trials, obtain and maintain regulatory approvals or commercialize approved products, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently rely on a third-party manufacturer and expect to continue to rely for some time on third parties to manufacture our product
candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards, and may do so for the commercial manufacture of some of our product candidates,
if approved. To date, we have obtained bulk drug substance for ADG106, ADG126 and ADG116 from a single-source third-party contract manufacturer. Any reduction or halt in supply of the drug substance
from such contract manufacturer could severely constrain our ability to develop our product candidates until a replacement contract manufacturer is found and qualified. If we are unable to arrange for
and maintain such third-party manufacturing sources that are capable of meeting regulatory standards, or fail to do so on commercially reasonable terms, we may not be able to successfully produce
sufficient supply of product candidate or we may be delayed in doing so. If we were to experience an unexpected loss of supply of our product candidates, for any reason, whether as a result of
manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical
trials. Such failure or substantial delay or loss of
supply could materially harm our business. We are continuously evaluating multiple vendors both in China and abroad to ensure that we have a continuous supply of products for global trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may have little to no control regarding the occurrence of third-party manufacturer incidents. Any failure by our third-party manufacturer to comply with good manufacturing practices,
or GMPs, or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, would lead to a delay in, or failure to seek
or obtain, regulatory approval of any of our product candidates. Furthermore, any change in manufacturer of our product candidates or approved products, if any, would require new regulatory approvals,
which could delay completion of clinical trials or disrupt commercial supply of approved products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize
any product candidates that receive marketing approval on a timely and competitive basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=55,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=346871,FOLIO='52',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<A NAME="page_cm17601_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer, we may have difficulty
transferring such skills or technology to another third party and a feasible alternative many not exist. These factors would increase our reliance on such manufacturer or require us to obtain a
license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that
the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new
manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our current research collaborators or scientific advisors and employees terminate their relationships with
us or develop relationships with our competitors, our ability to discover antibodies and to conduct research and development could be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The responsibility of overseeing research and development of our product candidates is concentrated among a number of key research collaborators
and/or scientific advisors. There can be no assurance that there will not be a detrimental impact on us if one or more of these key research collaborators and/or scientific advisors were to cease
relationship or employment with us, potentially as a result of lateral recruitment by existing or new competitors. As a result, this may adversely affect our ability to conduct research and
development on antibody product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
our ability to continue to conduct and expand operations depends on our ability to attract and retain a large and growing number of personnel. The ability to meet our
expertise needs, including the ability to find qualified personnel to fill positions that become vacant at our research and development department or to collaborate with us in research and development
efforts, while controlling our costs, is generally subject to numerous external factors, including the availability of a sufficient number of qualified persons in the biopharmaceutical industry, the
unemployment levels within those markets, prevailing wage rates, changing demographics, health and other insurance costs and adoption of new or revised employment and labor laws and regulations. If we
are unable to locate, to attract or to retain qualified personnel, the quality of services and products provided to customers may decrease and our financial performance may be adversely affected. In
addition, if costs of labor or related costs to maintain relationships with research collaborators increase for other reasons or if new or revised labor laws, rules or regulations or healthcare laws
are adopted or implemented that further increase labor costs, our business, financial condition and results of operations could be materially adversely affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to attract and retain key senior management members or research and development personnel.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our future success depends upon the continuing services of members of our senior management team and key research and development personnel and
consultants. In particular, Peter Luo, our Chief Executive Officer, Fangyong (Felix) Du, our Chief Technology Officer, Hua Gong, our Chief Operating Officer and Head of Clinical Development and
Precision Medicine, JC Xu, our Chief Scientific Officer, Qinghai Zhao, our Chief Manufacturing Officer and Yu (Albert) Ren, our Chief Strategy and Corporate Development Officer are crucial to our
research and development and operations. Although we typically require our key personnel to enter into non-compete and confidentiality agreements with us, we cannot prevent them from joining our
competitors after the non-compete period. The loss of their services could adversely impact our ability to achieve our business objectives. If one or more of our senior management or key clinical and
scientific personnel are unable or unwilling to continue in their present positions or joins a competitor or forms&nbsp;a competing company, we may not be able to replace them in a timely manner or
at all, which will have a material and adverse effect on our business, financial condition and results of operations. We do not maintain "key person" insurance for any of our executives or other
employees.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=56,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1005565,FOLIO='53',FILE='DISK103:[20ZDS1.20ZDS17601]CM17601A.;42',USER='CHE106212',CD='30-JAN-2021;18:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_co17601_1_54"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the continued growth of our business depends on our ability to hire additional qualified personnel with expertise in molecular biology, chemistry,
biological information processing, computational biology, software, engineering, sales, marketing, and technical support. We compete for qualified management and scientific personnel with other life
science and technology companies, universities, and research institutions in China and overseas. Competition for these individuals is intense, and the turnover rate can be high. Failure to attract and
retain management and scientific and engineering personnel could prevent us from pursuing collaborations or developing our product candidates or technologies. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face risks related to health epidemics, severe weather conditions and other outbreaks.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;China has in the past experienced significant natural disasters, including earthquakes, extreme weather conditions, as well as health scares
related to epidemic diseases, and any similar event could materially impact our business in the future. If a disaster or other disruption were to occur in the future that affects the regions where we
operate our business, our operations could be
materially and adversely affected due to loss of personnel and damage to property. Even if we are not directly affected, such a disaster or disruption could affect the operations or financial
conditions of our customers, which could harm our results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our business could be affected by public health epidemics and pandemics, such as the outbreak of avian influenza, severe acute respiratory syndrome, or SARS, Zika virus,
Ebola virus or other diseases. In late December 2019, a strain of SARS-CoV-2, which causes the COVID-19 disease, was reported to have surfaced in Wuhan, China. On January&nbsp;30, 2020, the World
Health Organization reportedly declared this COVID-19 outbreak a health emergency of international concern. On February&nbsp;28, 2020, the World Health Organization reportedly increased the
assessment of the risk of spread and the risk of impact of COVID-19 to very high at global level. In March 2020, the World Health Organization declared the COVID-19 a pandemic. As COVID-19 has evolved
into a worldwide health crisis, it has resulted in adverse effects in the global economy and financial markets, such as significant declines in the global stock markets. If the COVID-19 outbreak is
not effectively controlled globally, our business and results of operations could be adversely affected to the extent the COVID-19 outbreak harms the Chinese or world economy generally. The extent to
which the COVID-19 outbreak impacts our financial condition and results of operations for the full year of 2020 cannot be reasonably estimated at this time and will depend on future developments that
currently cannot be predicted, including the development of a COVID-19 vaccine and the actions taken to contain the COVID-19 outbreak, among others. Any future outbreak of public health epidemics may
restrict economic activities in affected regions, disrupt our business operations and adversely affect our results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The COVID-19 pandemic could adversely impact our business, including our clinical trials.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The spread of the COVID-19 coronavirus in many countries continues to adversely impact global economic activity and has contributed to
significant volatility and negative pressure in financial markets and supply chains. The pandemic has had, and could have a significantly greater, material adverse effect on the global economy. The
pandemic has resulted, and may continue to result for an extended period, in significant disruption of global financial markets, which may reduce our ability to access capital in the future, which
could negatively affect our liquidity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
COVID-19 pandemic has adversely affected the clinical development of our product candidates. Our clinical development program timelines could continue to be negatively affected by
COVID-19, which could materially and adversely affect our business, financial condition, and results of operations. Further, due to "shelter in place" orders and other public health guidance measures,
we may be required to implement a work-from-home policy for all staff members excluding those necessary to maintain minimum basic operations. In such an instance, our increased reliance on personnel </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=57,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=258225,FOLIO='54',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>working
from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities
that require our personnel to be in our laboratories may be delayed. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
COVID-19 pandemic may impact our workforce, supply chains or distribution networks or otherwise impact our ability to restock our medical device and supply inventories and depending
upon the severity of the COVID-19 pandemic's continued spread in the United States and other countries, we may experience disruptions that could severely impact our business and clinical trials,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitation of company operations, including work from home policies and office closures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> one or more key officers and/or employees could contract COVID-19 or otherwise be adversely affected by the virus; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays or difficulties in receiving deliveries of critical experimental materials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays or difficulties in enrolling patients in our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays or difficulties in clinical site initiation or expansion, including difficulties in recruiting clinical site investigators and clinical
site staff; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health
conditions or being forced to quarantine; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at
contract research organizations, or CROs, and vendors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial
sites and hospital staff supporting the conduct of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by
federal or state governments, employers and others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are
conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee
resources or forced furlough of government or contractor personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal of the FDA or other regulatory authorities to accept data from clinical trials in affected geographies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations in employee resources that would otherwise be focused on our business, including the conduct of our clinical trials, such as
because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact our business and clinical trials will depend on
future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and
social distancing in China, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain
and treat the disease. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=58,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=499879,FOLIO='55',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have limited insurance coverage, and any claims beyond our insurance coverage may result in us incurring
substantial costs and a diversion of resources.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our assessment of our operational
needs and industry practice. We also maintain liability insurance covering our clinical trials. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances,
such as business interruption insurance or key-man insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any
uninsured risks may result in substantial costs and the diversion of resources, which could adversely affect our results of operations and financial condition. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have adopted a share incentive plan and will continue to grant share-based awards in the future, which may
increase expenses associated with share-based compensation. Exercise of the awards granted will increase the number of our outstanding ordinary shares, which may adversely affect the market price of
our ADSs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We adopted the Second Amended and Restated Share Incentive Plan in December 2019 and the 2021 Performance Incentive Plan in January 2021, which
we refer to as the 2019 Plan and the 2021 Plan, respectively, in this prospectus, to enhance our ability to attract and retain exceptionally qualified individuals and to encourage them to acquire a
proprietary interest in the growth and performance of us. Upon the effectiveness of our registration statement on Form&nbsp;F-1, we will terminate the authority to grant additional awards under the
2019 Plan and all future awards will be granted under the 2021 Plan. Therefore, the effective maximum number of shares issuable under the 2019 Plan will be 10,728,501. A total of 2,994,000 of our
ordinary shares is authorized for issuance with respect to awards granted under the 2021 Plan. As of the date of this prospectus, the aggregate number of our ordinary shares underlying our outstanding
awards under the 2019 Plan is 3,601,522. We have not granted any awards under the 2021 Plan. See "Management&#151;Share Incentive Plan." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe the granting of share-based awards is of significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based
compensation to employees in the future. As a result, our expenses associated with share-based compensation may increase, which may have an adverse effect on our results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees, third-party suppliers, consultants and commercial partners may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements, and insider trading.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of fraud or other misconduct by our employees, third-party suppliers, consultants and commercial partners. Misconduct
by these parties could include intentional failures to comply with the regulations of the NMPA and overseas regulators that have jurisdictions over us, comply with healthcare fraud and abuse laws and
regulations in China and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare
industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of
information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our
employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective
in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.
If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could
result in the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=59,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=737343,FOLIO='56',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>individual
imprisonment, disgorgement of profits, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law and curtailment or restructuring of our operations, which could have a significant impact on our
business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in
defending ourselves against any of these claims or investigations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to liability lawsuits arising from our clinical trials.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against
us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance
policies also contain various exclusions, and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a
settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot
successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials. Even a successful defense would require
significant financial and management resources. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regardless
of the merits or eventual outcome, liability claims may result in significant negative consequences to our business and prospects, including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> decreased demand for our product candidates or any resulting products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> damage to our reputation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of other clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs to defend the related litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a diversion of our management's time and resources; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial monetary awards to trial participants or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> inability to commercialize our product candidates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a decline in the market price of our ADSs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to changing law and regulations regarding regulatory matters, corporate governance and public
disclosure that have increased both our costs and the risk of noncompliance.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to rules and regulations by various governing bodies, including, for example, the FDA, the NMPA, the SEC, which is charged with
the protection of investors and the
oversight of companies whose securities are publicly traded, and the various regulatory authorities in China, the United States, the EU, the Cayman Islands, and to new and evolving regulatory measures
under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a
diversion of management time and attention from revenue-generating activities to compliance activities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This
evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and
comply with these regulations and any subsequent changes, we may be subject to penalties and our business may be harmed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=60,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=839813,FOLIO='57',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and Chinese anti-corruption
laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to anti-bribery laws in China that generally prohibit companies and their intermediaries from making payments to government
officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, although currently our primary operating business is in China, we are subject to the
Foreign Corrupt Practices Act, or the FCPA. The FCPA generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We are also subject
to the anti-bribery laws of other jurisdictions, particularly China. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures
and controls to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we, due to either our own deliberate or inadvertent acts
or those of others, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which
could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any failure to comply with applicable regulations and industry standards or obtain various licenses and
permits could harm our reputation, business, results of operations and prospects.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A number of governmental agencies or industry regulatory bodies in China, the United States and other applicable jurisdictions impose strict
rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs' failure to comply with such regulations could result in
the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business,
reputation, prospects for future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the
Association for Assessment and Accreditation of Laboratory Animal Care, it could revoke any such accreditation and the accuracy of our animal research data could be questioned. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we or our third-party research collaborators or other contractors or consultants fail to comply with
environmental, fire protection, drainage or health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the
success of our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and third parties, such as our CROs, are subject to numerous environmental, fire protection, drainage or health and safety laws and
regulations, including but not limited to those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes discharge of stationary
pollution sources. The cost of compliance with health and safety regulations is substantial. Our business activities involve the controlled use of hazardous materials. Our research and development
activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization
efforts, research and development efforts and business operations. We cannot guarantee that the safety procedures utilized by our partners and by third-party manufacturers and suppliers with whom we
may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we could be held
liable for any resulting damages, and such liability could exceed our resources. In addition, we may be required to incur substantial costs to comply with current or future environmental, health and
safety laws and regulations which are complex, change frequently and have tended to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=61,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=950447,FOLIO='58',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>become
more stringent. We do not currently carry biological or hazardous waste insurance coverage. In the event of an accident or environmental discharge, we may be held liable for any consequential
damage and any resulting claims for damages, which may exceed our financial resources and may materially adversely affect our business, financial condition, results of operations and future growth
prospects, and the value of our ADSs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Security breaches, loss of data, and other disruptions could compromise sensitive information related to our
business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of our business, we collect and store preclinical trial data and clinical trial data which could be sensitive, including
research and development information, health-related information, personally identifiable information, intellectual property, and proprietary business information owned or controlled by ourselves or
other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based application systems. We utilize external security and infrastructure vendors
to manage parts of our data centers. We also communicate sensitive data with third parties. We face a number of risks relative to protecting this critical information, including material system
failure or security breach, loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit, and modify our controls
over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data and third-party collaborators who share with us sensitive data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite
the implementation of security measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to
attacks by hackers or viruses or breached due to employee error, malfeasance, or other malicious or inadvertent disruptions that could result in unauthorized access to, use or disclosure of,
corruption of, or loss of sensitive, and/ or proprietary data, including health-related and other personal information, and could subject us to significant liabilities and regulatory and enforcement
actions, and reputational damage. The COVID-19 pandemic is generally increasing the attack surface available to criminals, as more companies and individuals work online and work remotely, and as such,
the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam
emails as well as social engineering attempts from "hackers" hoping to use the COVID-19 pandemic to their advantage. In addition, while we have implemented security measures to prevent unauthorized
access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss, or dissemination could
also result in delays of our product development and regulatory approval efforts as well as damage our reputation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in any regulatory approval or clearance efforts and significantly increase
our costs to recover or reproduce the data, and subsequently commercialize the product. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer
an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of health-related or other personal information, we may have to notify consumers, partners,
collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our
business and reputation. Likewise, we rely on our third-party research institution collaborators and other third parties to conduct clinical trials, and similar events relating to their computer
systems could also have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
insurance policies may not be adequate to compensate us for the potential losses arising from such disruptions, failure, or security breach. In addition, such insurance may not be
available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=62,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=586633,FOLIO='59',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>made
against us and defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to comply with existing or future laws and regulations related to privacy or data security could lead
to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with
such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information worldwide is
rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented and are considering a number
of legislative and regulatory proposals concerning personal data protection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China's Cyber Security Law,
which became effective in June 2017, created China's first national-level data protection for "network operators," which may include all organizations in China that provide services over the internet
or another information network. Numerous regulations, guidelines and other measures are expected to be adopted under the umbrella of the Cyber Security Law. Drafts of some of these measures have now
been published, including (i)&nbsp;the draft rules on cross-border data transfers of personal information and important data published by the China Cyberspace Administration in 2017, and draft rules
on measures for security assessment for cross-border transfer of personal information published by China Cyberspace Administration in 2019, which may, upon enactment, require security review before
transferring human health-related data out of China, and (ii)&nbsp;the Draft Data Security Law promulgated by the Standing Committee of PRC National People's Congress in 2020, which outlines the
main system framework of data security protection. In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State
Council promulgated Regulations on the Administration of Human Genetic Resources (effective in July 2019), which require approval from or filings with the Science and Technology Administration
Department of the State Council where human genetic resources, or HGR, are involved in any international collaborative project and additional approval for any export or cross-border transfer of the
HGR samples or human genetic resource information. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in
confiscation of HGR samples and human genetic resource information and administrative fines or in worst cases, criminal penalties. In addition, the interpretation and application of data and personal
information protection laws in China and elsewhere are often uncertain and in flux. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, we and our partners may be subject to state and federal laws and regulations that govern data privacy, protection and security. Numerous laws and regulations,
including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal
information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security
requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and regulations implemented
thereunder (collectively, "HIPAA"). Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health
information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
when HIPAA does not apply, according to the Federal Trade Commission, or the FTC, violating consumers' privacy rights or failing to take appropriate steps to keep consumers'
personal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=63,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=776067,FOLIO='60',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>information
secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act. The FTC expects a company's data security
measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve
security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, certain state and non-U.S. laws, such as the European Union General Data Protection Regulation, or the GDPR, govern the privacy and security of health information and other
personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with
these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted legislation, the California
Consumer Privacy Act, or CCPA, which went into effect January&nbsp;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights
to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches,
thereby potentially increasing risks associated with a data breach. In Europe, the GDPR went into effect in May 2018 and introduces strict requirements for processing the personal data of individuals
within the EU, and the European Economic Area, or the EEA. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States
and other jurisdictions that the European Commission does not recognize as having "adequate" data protection laws, and recent legal developments in Europe have created complexity and compliance
uncertainty regarding certain transfers of personal data from the EEA. For example, on July&nbsp;16, 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-US Privacy
Shield Framework, or Privacy Shield, under which personal data could be transferred from the EU and the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover,
it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature. Companies that must comply with the GDPR face increased compliance obligations
and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &euro;20&nbsp;million or 4% of the annual global
revenues of the noncompliant company, whichever is greater. Additionally, following Brexit, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law,
the latter regime having the ability to separately fine up to the greater of &pound;17.5&nbsp;million or 4% of global turnover. The relationship between the U.K. and the EU in relation to
certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all
measures required by regulators or courts in their interpretation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under global data protection, privacy and security laws will be
sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental entities,
individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of
certain personal information, require us to change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition,
our current and future relationships with customers, vendors, pharmaceutical partners and other third parties could be negatively affected by any proceedings or actions against us or current or future
data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=64,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=422728,FOLIO='61',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>affecting
personal information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our
business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Business disruptions could seriously harm our future revenue, increase our costs and expenses, and have
adverse effect on our financial condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations and third parties with which we have collaborations could be subjected to earthquakes, power shortages, telecommunications
failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are
predominantly self-insured. In addition, we partially rely on our CROs for conducting research and development, and they may be affected by government shutdowns or withdrawn funding. The occurrence of
any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we maintain incident management and disaster response plans, in the event of a major disruption caused by a natural disaster or man-made problem, such as power disruptions,
computer viruses, data security breaches or terrorism, we may be unable to continue our operations and may endure system interruptions, reputational harm, delays in our development activities, lengthy
interruptions in service, breaches of data security and loss of critical data, any of which could adversely affect our business, results of operations and financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately
or timely report our results of operations or prevent fraud, and investors' confidence and the market price of our ADSs may be materially and adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, we were a private company with limited accounting personnel and other resources with which to address our internal
controls and procedures. Our management has not completed an assessment of the effectiveness of our internal control over financial reporting, and our independent registered public accounting firm has
not conducted an audit of our internal control over financial reporting. In the course of auditing our consolidated financial statements as of December&nbsp;31, 2019 and for the year ended
December&nbsp;31, 2019, we and our independent registered public accounting firm identified two material weaknesses in our internal control over financial reporting and other control deficiencies as
of December&nbsp;31, 2019. A "material weakness" is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified
relate to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S.&nbsp;GAAP and SEC
reporting and compliance requirements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our lack of sufficient documented financial closing policies and procedures, specifically those related to period end expenses cut-off and
accruals. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have taken measures and plan to continue to take measures to remedy the material weaknesses. For details, please refer to "Management's Discussion and Analysis of Financial Condition
and Results of Operations&#151;Internal Control over Financial Reporting." The implementation of these measures may not fully address the material weaknesses in our internal control over
financial reporting, and we cannot conclude that they have been fully remedied. Our failure to correct these material weaknesses or our failure to discover and address any other material weaknesses
could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=65,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=941666,FOLIO='62',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_63"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the completion of this offering, we will become a public company in the United States subject to the Sarbanes-Oxley Act of 2002. Section&nbsp;404 of the Sarbanes-Oxley Act of
2002, or Section&nbsp;404, will require that we include a report from management on our internal control over financial reporting in our annual report on Form&nbsp;20-F beginning with our annual
report for the fiscal year ending December&nbsp;31, 2021. In addition, once we cease to be an "emerging growth company" as such term is defined in the JOBS Act, our independent registered public
accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not
effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own
independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it
interprets the relevant requirements differently from us. In addition, after we become a public company, our reporting obligations may place a significant strain on our management, operational and
financial resources and systems for the
foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section&nbsp;404, we may identify weaknesses and deficiencies in
our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or
amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section&nbsp;404. Generally
speaking, if we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations,
which would likely cause investors to lose confidence in our reported financial information. This could, in turn, limit our access to capital markets, harm our results of operations and lead to a
decline in the trading price of our ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to
potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Intellectual Property  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


It is difficult and costly to protect our proprietary rights and technology, and we may not be able to
protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success will depend, in part, on our ability to obtain, maintain and defend patent and other intellectual property protection
(including trademarks and trade secrets) with respect to our product candidates. We cannot be certain that patents will be issued or granted with respect to our patent applications that are currently
pending, or that issued or granted patents will not later be found to be invalid and/or unenforceable, be interpreted in a manner that does not adequately protect our product candidates, or otherwise
provide us with any competitive advantage. Additionally, the patent applications in respect of patents licensed under our in-license arrangements may not be issued or granted, and as a result, we may
not be able to have adequate protection with respect to such patents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent position of biotechnology and pharmaceutical companies is generally uncertain because it involves complex legal and factual considerations. Patent applications we have filed
may not be granted or issued as valid enforceable patents. Moreover, some of our patents and patent applications may in the future be, co-owned with third parties. If we are unable to obtain an
exclusive license to any such
third-party co-owned interest in such patents or patent applications, such co-owners may be able to license or transfer their rights to other third parties, including our competitors, and our
competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and
such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=66,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1047365,FOLIO='63',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>cooperation
may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. As
such, we do not know the degree of future protection that we will have on our product candidates and technology, if any, and a failure to obtain adequate intellectual property protection with respect
to our product candidates could have a material adverse impact on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Composition-of-matter
patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products,
as such patents provide protection without regard to any method of use. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor
from making and marketing a product that is identical to our products for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their
product for our targeted indications, physicians may prescribe these products "off-label." Although off-label prescriptions may infringe or contribute to the infringement of method-of use patents, the
practice is common and such infringement is difficult to prevent or prosecute. We endeavor to seek composition-of-matter patent protection for all of our product candidates. Where appropriate, we also
seek method-of-use patents and patents protecting other aspects of our product candidates, including processes for discovery and manufacturing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or
otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a
non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices
in the PRC and abroad. For example, we may become involved in opposition, interference, derivation, inter partes review or other similar proceedings challenging our patent rights, and the outcome of
any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or in-licensed patents being narrowed, invalidated or held unenforceable, which could limit our
ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and
products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise
provide us with a competitive advantage. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite
the measures we can take to increase our likelihood of obtaining patent and other intellectual property protections with respect to our product candidates, there can be no
assurance that the existence, validity, enforceability, or scope of our intellectual property rights will not be challenged by a third party, or that we can obtain sufficient scope of claim in those
patents to prevent a third party from competing against our product candidates. For example, in an infringement proceeding, a court may hold that patent rights or other intellectual property rights
owned by us are invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the ground that our patent rights or other intellectual property rights do not
cover the technology in question. An adverse result in any litigation proceedings could put our patent, as well as any patents that may issue in the future from our pending patent applications, at
risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there
is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent
is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=67,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=320375,FOLIO='64',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>several
statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of
the patent withheld relevant information from the National Intellectual Property Administration of China, or NIPA, or the applicable foreign counterpart, or made a misleading statement, during
prosecution. Although we believe that we have conducted our patent prosecution in accordance with all applicable duty of candor and in good faith, the outcome following legal assertions of invalidity
and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the
patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on our product candidates. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit
our ability to enforce such claims against the defendant and others. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
parties may also raise similar claims before administrative bodies in the PRC or abroad, even outside the context of litigation. Such mechanisms include ex parte re-examination,
inter partes review, post-grant review, derivation and equivalent proceedings, such as opposition proceedings. Such legal proceedings could result in revocation or amendment to our patents in such a
way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability can be unpredictable. With respect to the validity of our
patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal
assertion of invalidity and/or unenforceability, we may lose part or all of the patent protection on our product candidates. Any loss
of patent protection could have a material adverse impact on one or more of our product candidates and our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable,
processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect
us from innovations that a competitor develops independently of our proprietary know-how. If a competitor independently develops a technology that we protect as a trade secret and files&nbsp;a
patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not
available on commercially viable terms, then we may not be able to launch our product. Although we require our employees to assign their inventions to us, and require our employees, consultants,
advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other
confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and
techniques. Furthermore, the laws of different countries do not protect proprietary rights to the same extent or in the same manner as the laws of the PRC. We may encounter significant problems in
protecting and defending our intellectual property both in the PRC and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not
be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable
efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=68,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=247965,FOLIO='65',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
unintentionally or willfully disclose our information to competitors or use such information to compete with us. Moreover, our competitors may independently develop equivalent knowledge, methods
and know-how. If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be adversely
affected and this would have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries do not favor
the enforcement or protection of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us
to stop the
infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in certain countries could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at
risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be
commercially meaningful. We and our contractors and partners operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct or indirect
intrusion by private parties or international actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect or enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the
patent laws or interpretation of the patent laws in various countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of
issued patents. For example, patent reform legislation in the United States includes provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient
and cost-effective avenues for competitors to challenge the validity of patents via post-grant proceedings. The Leahy-Smith Act and any continuing changes in patent laws and regulations in various
patent jurisdictions could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our or our collaboration
partners' patent applications and the enforcement or defense of our or our collaboration partners' issued patents, all of which could harm our business, results of operations, financial condition and
prospects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain due to changes in law and courts'
interpretation of the law. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or
weakening the rights of patent owners in certain situations. Other courts in the United States, for example, have heightened the bar for broadly claiming antibodies. This combination of events has
created uncertainty with respect to the validity and enforceability of patents, once obtained. Additionally, there are periodic proposals for changes to the patent laws of China, United States and
other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the relevant law-making bodies in other countries, the laws and
regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=69,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=980282,FOLIO='66',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_co17601_1_67"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similarly
in China, intellectual property laws are constantly evolving, with efforts being made to improve intellectual property protection in China. For example, a Draft Amendment to
the PRC Patent Law was released in January 2019 and updated in July 2020, which proposes introduction of patent term extensions to eligible innovative drug patents. If adopted, the terms of our
Chinese patents may be eligible for extension and allow us to extend patent protection of our products, and the terms of the patents owned by third parties may also be extended, which may in turn
affect our ability to commercialize our products candidates, if and when approved, without facing infringement risks. The length of any such patent term extension is uncertain. If we are required to
delay commercialization for an extended period of time, technological advances may develop and new competitor products may be launched, which may render our product non-competitive. We also cannot
guarantee that other changes to Chinese intellectual property laws would not have a negative impact on our intellectual property protection. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in obtaining or maintaining necessary rights for our development pipeline through
acquisitions and licensing deals.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth
of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to acquire or in-license any compositions, methods
of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more
established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a
competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be
unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our
investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to
abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects for growth. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These
institutions may provide us with an option to negotiate a license to any of the institution's rights in technology resulting from the collaboration. Regardless of such option, we may be unable to
negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution
may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual
property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensing
of intellectual property involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a
license agreement, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope of rights granted under the license agreement and other interpretation-related issues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
licensing agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our right to sublicense patents and other rights to third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our
product candidates, and what activities satisfy those diligence obligations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=70,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=752551,FOLIO='67',FILE='DISK103:[20ZDS1.20ZDS17601]CO17601A.;33',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cq17601_1_68"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our right to transfer or assign the license; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our
partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to
successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may
limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor's express consent
in order for an assignment or transfer to take place. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which
could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our
product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patent rights or misappropriate or otherwise violate our intellectual property rights. To counter infringement or
unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we
assert against perceived infringers could provoke these parties to assert counterclaims against us, alleging that we infringed their patents. In addition, in a patent infringement proceeding, there is
a risk that a court will decide that our asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the others from using the invention at issue.
There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent's claims narrowly or decide that we do not have the right to stop the others from using
the invention at issue on the grounds that our patents do not cover the alleged infringing activity or product. An adverse outcome in a litigation or proceeding involving our patents could limit our
ability to assert our patents against those parties and other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any
of these occurrences could adversely affect our competitive business position, business prospects, and financial condition. Similarly, if we assert trademark infringement claims, a court may determine
that our asserted marks are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could
ultimately be forced to cease use of our trademarks. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
any litigation involving our intellectual property, the award of monetary damages we receive may not be commercially valuable or even sufficient to cover our cost of bringing such
action. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material
adverse effect on the price of our ADSs. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last
for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=71,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=493709,FOLIO='68',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our commercial success depends significantly on our ability to operate without infringing upon,
misappropriating or otherwise violating the intellectual property rights of third parties.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The life sciences industry is subject to rapid technological change and substantial litigation regarding patent and other intellectual property
rights. Our potential competitors in both the PRC and abroad, may have substantially greater resources than us and are likely to make substantial investments in patent portfolios and competing
technologies, and may apply for or obtain patents that could prevent, limit or otherwise interfere with our ability to make, use and sell our products. Numerous third-party patents exist in fields
relating to our products and technologies, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our products and technologies. Moreover,
because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that will cover our products
and technologies if they issue as patents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patents
could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could
block us from using our technology. Our failure to obtain or maintain a license from third parties to any technology that we require may materially harm our business, financial condition and results
of operations. Furthermore, we would be exposed to a threat of litigation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-party
intellectual property right holders may also actively bring infringement or other intellectual property-related claims against us, even if we have received patent protection
for our technologies, products, and services. Regardless of the merit of third parties claims against us for infringement, misappropriation or violations of their intellectual property rights, such
third parties may seek and obtain injunctive or other equitable relief, which could effectively block our ability to perform clinical trials or develop, manufacture or sell our products. Further, if a
patent infringement suit were brought against us, we could be forced to temporarily or permanently stop or delay our development or regulatory approval process or other activities that are the subject
of such suit. Defense of these claims, even if such claims are resolved in our favor, could cause us to incur substantial expenses and be a substantial diversion of our employee resources even if we
are ultimately successful. Any adverse ruling or perception of an adverse ruling in defending ourselves could have a material adverse impact on our cash position and stock price. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have
sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more
effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have
a material adverse effect on the price of our ADSs. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.
The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining patent protection depend on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent authorities, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The NIPA, and various foreign governmental patent agencies including the USPTO, JPO, and EPO require compliance with a number of procedural,
documentary, fee payment and other provisions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=72,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=83636,FOLIO='69',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>during
the patent application and prosecution process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid
to the NIPA and various other governmental patent agencies outside of China in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such
third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own. Noncompliance events that could result in
abandonment or lapse of a patent or patent application include failure to respond to official communications within prescribed time limits, non-payment of fees and failure to properly legalize and
submit formal documents. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which
noncompliance can result in abandonment or lapse of a patent or patent application, resulting in loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to
enter the market earlier than would otherwise have been the case, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and
prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not enter into invention assignment and confidentiality agreements with all of our employees and third
parties and such agreements may not prevent ownership disputes or unauthorized disclosure of trade secrets and other proprietary information.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely in part upon unpatented or unpatentable trade secrets, know-how and continuing technological innovation to develop and maintain our
competitive position, which we seek to protect, in part, by entering into agreements, including confidentiality agreements and non-disclosure agreements, with parties that have a need for access to
them, such as certain of our employees, consultants, academic institutions, corporate partners and, other third-party service providers. Nevertheless, there can be no guarantee that an employee or a
third party will not make an unauthorized use or disclosure of our proprietary confidential information. This might happen intentionally or inadvertently. It is possible that a competitor will gain
access to such information and make use of such information, and that our competitive position will be compromised, in spite of any legal action we might take against persons making such unauthorized
disclosures. In addition, to the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or
resulting know-how and inventions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade
secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors or business partners might intentionally
or inadvertently disclose our trade secret information to competitors or our trade secrets may otherwise be misappropriated. Enforcing a claim that a third party illegally obtained and is using any of
our trade secrets is expensive and time consuming, and the outcome is unpredictable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
sometimes engage individuals or research institutions to conduct research relevant to our business. The ability of these individuals or research institutions to publish or otherwise
publicly disclose data and other information generated during the course of their research is subject to certain contractual limitations. These contractual provisions may be insufficient or inadequate
to protect our confidential information. If we do not apply for patent protection prior to such publication, or if we cannot otherwise maintain the confidentiality of our proprietary technology and
other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized, which could adversely affect our business, financial
condition and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also seek to enter agreements with our employees and consultants that obligate them to assign any inventions created during their work for us to us. However, we may not obtain these
agreements in all circumstances and the assignment of intellectual property under such agreements may not be self-executing. And it is possible that technology relevant to our business will be
independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these
agreements, we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=73,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=773163,FOLIO='70',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
not have adequate remedies for any such breach or violation, and we could lose our trade secrets and inventions through such breaches or violations. Any of the foregoing could have a material and
adverse effect on our business, financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of
their former employers.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of our employees and consultants were previously employed at universities or other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that
we or our employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee's former employer. Litigation may be necessary to
defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and our specific personnel. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims challenging the inventorship of our patents and other intellectual property.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other
intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in
developing our product candidates. Also, former employees may become employed by competitors who develop similar technology, and could assist the competitor in designing around our patents. While it
is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be
unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may
be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is
important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual property rights do not necessarily protect us from all potential threats to our competitive
advantages.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may be able to independently develop similar or alternative technologies or designs that are similar to our product candidates but that
are not covered by the claims of the patents that we own or have exclusively licensed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or may in the
future exclusively license, which could result in the patent applications not issuing or being invalidated after issuing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we might not have been the first to file patent applications covering certain of our inventions, which could result in the patent applications
not issuing or being invalidated after issuing; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=74,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=366847,FOLIO='71',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
property rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that our pending patent applications will not lead to issued patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or
unenforceable, as a result of legal challenges by our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
learned from such activities to develop competitive services and products for commercialization in our major markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may fail to develop additional proprietary technologies that are patentable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the patents of others may have an adverse effect on our business, for example by preventing us from commercializing one or more of our product
candidates for one or more indications. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of the aforementioned threats to our competitive advantage could have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent terms may not be sufficient to effectively protect our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In most countries in which we plan to file applications for patents, the term of an issued patent is generally 20&nbsp;years from the earliest
claimed filing date of the priority application to which a non-provisional patent application in the applicable country claims priority. Although various extensions may be available in various
countries, the life of a patent and the protection it affords are limited. Even if patents covering our product candidates are obtained, we may be open to competition from other companies once our
patent rights expire. Accordingly, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire
before or shortly after such candidates are commercialized. Excluding any patent term adjustment and patent term extension, our currently issued patents are expected to expire from 2033 to 2034. As a
result, our patent portfolio may not provide us with sufficient rights over a sufficient length of time to exclude others from commercializing products similar or identical to ours. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Uncertainty of the length of patent term extensions and data and market exclusivities for our pharmaceutical
products could increase the risk of generic competition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the Federal Food, Drug, and Cosmetic Act, as amended by the law generally referred to as the "Hatch-Waxman Amendments,"
provides the opportunity for patent-term restoration of up to five years to reflect patent term lost during certain portions of product development and the FDA regulatory review process. The
Hatch-Waxman Amendments also have a process for patent linkage, pursuant to which FDA will stay approval of certain follow-on applications during the pendency of litigation between the follow-on
applicant and the patent holder or licensee, generally for a period of 30&nbsp;months. Finally, the Hatch-Waxman Amendments provide for statutory exclusivities that can prevent submission or
approval of certain follow-on marketing applications. For example, federal law provides a five-year period of exclusivity within the United States to the first applicant to obtain approval of a new
chemical entity (as defined) and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical
investigations to obtain approval for the modification. Similarly, the Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where FDA designates the
product candidate as an orphan drug and the drug is approved for the designated orphan indication. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=75,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=696179,FOLIO='72',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>These
provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after FDA grants marketing approval for the innovative product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
China, however, there is no currently effective law or regulation providing patent term extension, patent linkage, or data exclusivity (referred to as regulatory data protection).
Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for integrating patent linkage and data exclusivity into the Chinese
regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, the NMPA has issued several
draft implementing regulations in this regard for public comment but no regulations have been formally issued. These factors result in weaker protection for us against generic competition in China
than could be available to us in the United States until the relevant implementing regulations for extension, patent linkage, or data exclusivity are put into effect officially in China. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. We may also
encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the jurisdictions of the registration of our intellectual properties. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own
products. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions. The legal systems of many other countries do not
favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents in such countries. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our
patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect and enforce our trademarks.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently hold issued trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or
third-party objection, which could prevent the registration or maintenance of the same. If we are unsuccessful in obtaining trademark protection for our primary brands, we may be required to change
our brand names, which could materially adversely affect our business. Moreover, as our products mature, our reliance on our trademarks to differentiate us from our competitors will increase, and as a
result, if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, or engaging in conduct
that constitutes unfair competition, defamation or other violation of our rights, our business could be materially adversely affected. Over the long term, if we are unable to establish name
recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third
parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and
tradenames by our licensees may jeopardize our rights in or diminish </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=76,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=315913,FOLIO='73',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or
other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Doing Business in the PRC  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Uncertainties with respect to the PRC legal system and changes in laws and regulations in China could
adversely affect us.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations in China are governed by the PRC laws and regulations. The PRC legal system is a civil law system based on written statutes.
Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. In addition, any new PRC laws or changes in PRC laws and
regulations related to, among other things, foreign investment and manufacturing in China could have a material adverse effect on our business and our ability to operate our business in China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. Any administrative and court proceedings in China may be protracted,
resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing
statutory provisions and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy, than in more developed
legal systems. These uncertainties may impede our ability to enforce contracts in China and could materially and adversely affect our business and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, or at all, and may have retroactive
effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime after the violation. Such unpredictability towards our contractual, property and procedural
rights could adversely affect our business, and impede our ability to continue our operations and proceed with our future business plans. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be restricted from transferring our scientific data abroad.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the
Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China
must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in
part, by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic
journal. Currently, as the term "state secret" is not clearly defined, there is no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our
preclinical studies or clinical trials conducted within China) abroad, or to our foreign partners in China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of product candidates may be hindered, which may materially and adversely
affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the
requirements under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=77,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=90569,FOLIO='74',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent litigation and negative publicity surrounding China-based companies listed in the United States may
result in increased regulatory scrutiny of us and negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations,
financial condition, cash flows and prospects.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the United States have
negatively impacted stock prices for these companies. Various equity-based research organizations have published reports on China-based companies after examining their corporate governance practices,
related party transactions, sales practices and financial statements, and these reports have led to special investigations and listing suspensions on U.S. national exchanges. Any similar scrutiny of
us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading
price, and increased directors and officers insurance premiums and could have an adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in U.S. and international trade policies, particularly with regard to China, may adversely impact our
business and operating results.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade
policies, including imposing several rounds of tariffs affecting certain products manufactured in China. In March 2018, U.S. President Donald J. Trump announced the imposition of tariffs on steel and
aluminum entering the United States and in June 2018 announced further tariffs targeting goods imported from China. Recently both China and the United States have each imposed tariffs indicating the
potential for further trade barriers. It is unknown whether and to what extent new tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or
our industry. While we have not started commercialization of product candidates, any unfavorable government policies on international trade,
such as capital controls or tariffs, may affect the demand for our drug products, the competitive position of our drug products, the hiring of scientists and other research and development personnel,
and import or export of raw materials in relation to drug development, or prevent us from selling our drug products in certain countries. If any new tariffs, legislation and/or regulations are
implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could
have an adverse effect on our business, financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may be subject to PRC income tax on dividends from us or on any gain realized on the transfer of our
ADSs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Enterprise Income Tax Law of the PRC, or the EIT Law, and its implementation rules, PRC withholding tax at the rate of 10% is
generally applicable to dividends from PRC sources paid to investors that are resident enterprises outside of China and that do not have an establishment or place of business in China, or that have an
establishment or place of business in China but the relevant income is not effectively connected with the establishment or place of business. Any gain realized on the transfer of shares by such
investors is subject to 10% PRC income tax if this gain is regarded as income derived from sources within China. Under the PRC Individual Income Tax Law and its implementation rules, dividends from
sources within China paid to foreign individual investors who are not PRC residents are generally subject to a PRC withholding tax at a rate of 20% and gains from PRC sources realized by these
investors on the transfer of shares are generally subject to 20% PRC income tax. Any such PRC tax liability may be reduced by the provisions of an applicable tax treaty. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
substantially all of our business operations are in China, it is unclear whether the dividends we pay with respect to our shares or ADSs, or the gains realized from the transfer
of our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=78,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=593277,FOLIO='75',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cq17601_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>shares
or ADSs, would be treated as income derived from sources within China and as a result be subject to PRC income tax if we are considered a PRC resident enterprise. If PRC income tax is imposed
on gains realized through the transfer of our ADSs or on dividends paid to our non-resident investors, the value of your investment in our ADSs may be adversely affected. Furthermore, our shareholders
whose jurisdictions of residence have tax treaties or arrangements with China may not qualify for benefits under these tax treaties or arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, pursuant to the Double Tax Avoidance Arrangement between Hong Kong and China, or the Double Tax Avoidance Treaty, and the Notice on Certain Issues with Respect to the
Enforcement of Dividend Provisions in Tax Treaties, or the Notice on Tax Treaties, issued on February&nbsp;20, 2009 by the
State Administration of Taxation, or the SAT, if a Hong Kong resident enterprise owns more than 25% of the equity interest of a PRC company at all times during the twelve-month period immediately
prior to obtaining a dividend from such company, the 10% withholding tax on such dividend is reduced to 5%, provided that certain other conditions and requirements under the Double Tax Avoidance
Treaty and other applicable PRC laws are satisfied at the discretion of the relevant PRC tax authority. However, based on the Notice on Tax Treaties, if the relevant PRC tax authorities determine, in
their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, the PRC tax authorities may adjust the preferential tax
treatment. Based on the Notice on Issues concerning Beneficial Owner in Tax Treaties, or Circular 9, issued on February&nbsp;3, 2018 by the SAT and effective on April&nbsp;1, 2018, when
determining the applicant's status as a "beneficial owner" for purpose of tax treatments in connection with dividends, interests or royalties in the tax treaties, several factors will be taken into
account, and it will be analyzed according to the actual circumstances of the specific cases. If our Hong Kong subsidiary is determined by PRC government authorities as receiving benefits from reduced
income tax rates due to a structure or arrangement that is primarily tax-driven, the dividends paid by our PRC subsidiary to our Hong Kong subsidiary will be taxed at a higher rate, which will have an
adverse effect on our financial and operational conditions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The biopharmaceutical industry in China is highly regulated and such regulations are subject to changes which
may affect approval and commercialization of our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Part of our research and development operations are in China, which we believe confers clinical, commercial and regulatory advantages. The
biopharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new
product candidates. See "Regulation" for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory
framework in China regarding the biopharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may
result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our product candidates in China and reduce the current benefits we
believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the biopharmaceutical industry and any failure by
us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business
activities fines, warnings, administrative or criminal penalties in China. We believe our strategy and approach are aligned with the PRC government's regulatory policies, but we cannot ensure that our
strategy and approach will continue to be aligned. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=79,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1029809,FOLIO='76',FILE='DISK103:[20ZDS1.20ZDS17601]CQ17601A.;22',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cs17601_1_77"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted
Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;15, 2019, the PRC National People's Congress approved the Foreign Investment Law, which came into effect on January&nbsp;1,
2020 and replaces the trio of existing laws regulating foreign investment in the PRC, namely, the Sino-Foreign Equity Joint Venture Enterprise Law, the Sino-Foreign Cooperative Joint Venture
Enterprise Law and the Wholly Foreign-Invested Enterprise Law, together with their implementation rules and ancillary regulations and become the legal foundation for foreign investment in the PRC.
Meanwhile, the </FONT><FONT SIZE=2><I>Implementation Regulation of the Foreign Investment Law and the Measures for Reporting of Information on Foreign Investment</I></FONT><FONT SIZE=2> came into
effect as of January&nbsp;1, 2020, which clarified and elaborated the relevant provisions of the </FONT><FONT SIZE=2><I>Foreign Investment Law</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Foreign Investment Law sets out the basic regulatory framework for foreign investments and proposes to implement a system of pre-entry national treatment with a negative list for
foreign investments, pursuant to which (i)&nbsp;foreign entities and individuals are prohibited from investing in the areas that are not open to foreign investments, (ii)&nbsp;foreign investments
in the restricted industries must satisfy certain requirements under the law, and (iii)&nbsp;foreign investments in business sectors outside of the negative list will be treated equally with
domestic investments. The Foreign Investment Law also sets forth necessary mechanisms to facilitate, protect and manage foreign investments and proposes to establish a foreign investment information
reporting system, through which foreign investors or foreign-invested enterprises are required to submit initial report, report of changes, report of deregistration and annual report relating to their
investments to the Ministry of Commerce, or MOFCOM, or its local branches. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may experience difficulties in effecting service of legal process, enforcing foreign judgments or
bringing actions in China against us or our management named in the prospectus based on foreign laws.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a company incorporated under the laws of the Cayman Islands, we conduct most of our operations in China, and substantially all of our
assets are located in China. As a result, it may be difficult for our shareholders to effect service of process upon us or those persons inside China. In addition, China does not have treaties
providing for the reciprocal recognition and enforcement of judgments of courts with the Cayman Islands and many other countries and regions. Therefore, recognition and enforcement in China of
judgments of a court in any of these non-PRC jurisdictions in relation to any matter not subject to a binding arbitration provision may be difficult or impossible. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder
claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue as a matter of law or practicality in
China. For example, in China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to
foreign entities. Although the local authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement
cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the United States have not been efficient in the absence of mutual and practical
cooperation mechanism. According to Article&nbsp;177 of the PRC Securities Law which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigation or
evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators and relevant authorities, no organization or individual may
provide the documents and materials relating to securities business activities to overseas parties. See also "&#151;Risks Related to the ADSs and this Offering&#151;You may face
difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law" for risks associated with
investing in us as a Cayman Islands company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=80,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1041960,FOLIO='77',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_78"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business may be negatively affected by the potential obligations to make additional social insurance and
housing fund contributions.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are required by PRC labor laws and regulations, such as the Social Insurance Law, Administrative Regulations on the Housing Provident Fund
and other related rules, to pay various statutory employee benefits, including pensions insurance, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and
housing fund, to designated government agencies for the benefit of our employees. The relevant government agencies may examine whether an employer has made adequate and timely payments of the
requisite statutory employee benefits, and employers who fail to make adequate and timely payments may be subject to supplemental contributions, late payment fees, fines compulsory enforcement and/or
other penalties. If the relevant PRC authorities determine that we shall make supplemental social insurance and housing fund contributions or that we are subject to fines and legal sanctions in
relation to our failure to make social insurance and housing fund contributions in full for our employees, our business, financial condition and results of operations may be adversely affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The lease agreements of our leased properties have not been registered with the relevant PRC government
authorities as required by PRC law, which may expose us to potential fines.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under PRC law, lease agreements of commodity housing tenancy are required to be registered with the local construction (real estate)
departments. Although failure to do so does not in itself invalidate the leases, the parties of the lease agreements may be exposed to potential fines if they fail to rectify such non-compliance
within the prescribed time frame after receiving notice from the relevant PRC government authorities. The penalty ranges from RMB1,000 to RMB10,000 for each unregistered lease, at the discretion of
the relevant authority. As of the date of this Prospectus, the lease agreements for our leased properties in China have not been registered with the relevant PRC government authorities. As of the date
of this prospectus, we are not aware of any regulatory or governmental actions, claims or investigations being contemplated or any challenges by third parties to our use of our leased properties that
the lease agreements of which have not been registered with the government authorities. However, we cannot assure you that the government authorities will not impose fines on us due to our failure to
register any of our lease agreements, which may negatively impact our financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any failure to comply with PRC regulations regarding the registration requirements for employee stock
incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating
in Stock Incentive Plan of Overseas Publicly Listed Company, replacing earlier rules promulgated in 2007. Pursuant to these rules, PRC citizens and non-PRC citizens who reside in China for a
continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through
a domestic qualified agent, which could be the PRC subsidiary of such overseas-listed company, and complete certain other procedures. In addition, an overseas-entrusted institution must be retained to
handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or who
reside in the PRC for a continuous period of not less than one year and who have been granted options will be subject to these regulations when our company becomes an overseas-listed company upon
completion of this offering. Failure to complete the SAFE registrations may subject them to fines and legal sanctions, there may be additional restrictions on the ability of them to exercise their
stock options or remit proceeds gained from the sale of their stock into </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=81,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=376680,FOLIO='78',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_79"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
PRC. We also face regulatory uncertainties that could restrict our ability to adopt incentive plans for our directors, executive officers and employees under PRC law. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could
result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside of the PRC with a "de facto management
body" within the PRC is considered a "resident enterprise" and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term "de facto
management body" as the body that exercises full and substantial control over and overall management of the business, productions, personnel, accounts and properties of an enterprise. In 2009, SAT
issued a circular, known as SAT Circular 82, which provides certain specific criteria for determining whether the "de facto management body" of a PRC-controlled enterprise that is incorporated
offshore is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners,
the criteria set forth in the circular may reflect the SAT's general position on how the "de facto management body" test should be
applied in determining the tax resident status of all offshore enterprises. According to SAT Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group
will be regarded as a PRC tax resident by virtue of having its "de facto management body" in China and will be subject to PRC enterprise income tax on its global income only if all of the following
conditions are met: (i)&nbsp;the primary location of the day-to-day operational management and the places where they perform their duties are in the PRC; (ii)&nbsp;decisions relating to the
enterprise's financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC; (iii)&nbsp;the enterprise's primary assets, accounting books and
records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv)&nbsp;at least 50% of voting board members or senior executives habitually reside in the
PRC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that we are not a PRC resident enterprise for PRC tax purposes. See "Taxation&#151;People's Republic of China Taxation." However, the tax resident status of an
enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term "de facto management body." If the PRC tax authorities
determine that we or any of our non-PRC subsidiaries are a PRC resident enterprise for enterprise income tax purposes, we may be required to withhold a 10% withholding tax from dividends we pay to our
shareholders that are non-resident enterprises, including the holders of the ADSs. In addition, non-resident enterprise shareholders (including ADS holders) may be subject to PRC tax on gains realized
on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC. Furthermore, if we are deemed a PRC resident enterprise, dividends payable to our
non-PRC individual shareholders (including ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% (which, in the
case of dividends, may be withheld at source by us). Any PRC tax liability may be reduced under applicable tax treaties. However, it is unclear whether in practice our non-PRC shareholders would be
able to obtain the benefits of any tax treaties between their countries of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns
on your investment in the ADSs or our ordinary shares. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by
their non-PRC holding companies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident Enterprises, or SAT
Circular 698, issued by the SAT in 2009 with retroactive effect from January&nbsp;1, 2008, where a non-resident enterprise transfers the equity interests of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=82,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=351300,FOLIO='79',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_80"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>a
PRC resident enterprise indirectly by disposition of the equity interests of an overseas holding company, or an Indirect Transfer, and such overseas holding company is located in a tax jurisdiction
that: (i)&nbsp;has an effective tax rate less than 12.5% or (ii)&nbsp;does not tax foreign income of its residents, the non-resident enterprise, being the transferor, shall report to the competent
tax authority of the PRC resident enterprise this Indirect Transfer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;3, 2015, the SAT issued the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer
by Non-Resident Enterprises, or SAT Bulletin 7. SAT Bulletin 7 supersedes the rules with respect to the Indirect Transfer under SAT Circular 698. SAT Bulletin 7 has introduced a new tax regime that is
significantly different from the previous one under SAT Circular 698. SAT Bulletin 7 extends the PRC's tax jurisdiction to not only Indirect Transfers set forth under SAT Circular 698 but also
transactions involving a transfer of other taxable assets through an offshore transfer of a foreign intermediate holding company. In addition, SAT Bulletin 7 provides clearer criteria than SAT
Circular 698 for assessment of reasonable commercial purposes and has introduced safe harbors for internal group restructurings and the purchase and sale of equity through a public securities market.
SAT Bulletin 7 also brings challenges to both foreign transferor and transferee (or another person who is obligated to pay for the transfer) of taxable assets. Where a non-resident enterprise
transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an Indirect Transfer, the non-resident enterprise, being the transferor, or the
transferee, or the PRC entity that directly owns the taxable assets, may report such Indirect Transfer to the relevant tax authority. Using a "substance over form" principle, the PRC tax authority may
disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding or deferring PRC tax. As a result, gains
derived from such Indirect Transfer may be subject to PRC enterprise income tax, and the transferee or another person who is obligated to pay for the transfer is obligated to withhold the applicable
taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under PRC tax laws if the
transferee fails to withhold the taxes and the transferor fails to pay the taxes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Matters Concerning Withholding of Income Tax of Non-resident Enterprises at Source,
or SAT Bulletin 37, which, among others, repealed the SAT Circular 698 on December&nbsp;1, 2017. SAT Bulletin 37 further details and clarifies the tax withholding methods in respect of income of
non-resident enterprises under SAT Circular 698. And certain rules stipulated in SAT Bulletin 7 are replaced by SAT Bulletin 37. Where the non-resident enterprise fails to declare the tax payable
pursuant to Article&nbsp;39 of the PRC Enterprise Income Tax Law, the tax authority may order it to pay the tax due within required time limits, and the non-resident enterprise shall declare and pay
the tax payable within such time limits specified by the tax authority; however, if the non-resident enterprise voluntarily declares and pays the tax payable before the tax authority orders it to do
so within required time limits, it shall be deemed that such enterprise has paid the tax in time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face uncertainties as to the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring, sale of
the shares in our offshore subsidiaries and investments. Our company may be subject to filing obligations or taxed if our company is a transferor in such transactions, and may be subject to
withholding obligations if our company is a transferee in such transactions, under SAT Bulletin 7 and SAT Bulletin 37. For transfer of shares in our company by investors who are non-PRC resident
enterprises, our PRC subsidiary may be requested to assist in the filing under SAT Bulletin 7 and SAT Bulletin 37. As a result, we may be required to expend valuable resources to comply with SAT
Bulletin 7 and SAT Bulletin 37 or to request the relevant transferors from whom we purchase taxable assets to comply with these circulars, or to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=83,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=843430,FOLIO='80',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_81"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>establish
that our company should not be taxed under these circulars, which may have a material adverse effect on our financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our preferential tax treatments are revoked, become unavailable or if the calculation of our tax liability
is challenged by the PRC tax authorities, we may be required to pay tax, interest and penalties in excess of our tax provisions, and our results of operations could be materially and adversely
affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Chinese government has provided various tax incentives to our subsidiaries in China. These incentives include reduced enterprise income tax
rates. For example, under the Enterprise Income Tax Law and its implementation rules, the statutory enterprise income tax rate is 25%. However, the income tax of an enterprise that has been determined
to be a technologically advanced service enterprise can be reduced to a preferential rate of 15%. Any increase in the enterprise income tax rate applicable to our PRC subsidiary, or any
discontinuation or retroactive or future reduction of any of the preferential tax treatments currently enjoyed by our PRC subsidiary, could adversely affect our business, financial condition and
results of operations. In addition, in the ordinary course of our business, we are subject to complex income tax and other tax regulations and significant judgment is required in the determination of
a provision for income taxes. Although we believe our tax provisions are reasonable, if the PRC tax authorities successfully challenge our position and we are required to pay tax, interest and
penalties in excess of our tax provisions, our financial condition and results of operations would be materially and adversely affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Among other things, the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six
PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and
complex. Such regulation requires, among other things, the MOFCOM be notified in advance or its approval be obtained in certain situations, such as any change-of-control transaction in which a foreign
investor acquires control of a PRC domestic enterprise of Undertakings, issued by the State Council in 2008 and amended in 2018, were triggered. Moreover, the Anti-Monopoly Law promulgated by the
Standing Committee of the PRC National People's Congress, or NPC, which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover
thresholds must be cleared by the MOFCOM before they can be completed. In addition, PRC national security review rules which became effective in September 2011 require acquisitions by foreign
investors of PRC companies engaged in military-related or certain other industries that are crucial to national security be subject to security review before consummation of any such acquisition. We
may pursue potential strategic acquisitions that are complementary to our business and operations. Complying with the requirements of these regulations to complete such transactions could be
time-consuming, and any required approval processes, including obtaining approval or clearance from the MOFCOM, may delay or inhibit our ability to complete such transactions, which could affect our
ability to expand our business or maintain our market share. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The approval of the China Securities Regulatory Commission may be required in connection with this offering,
and, if required, we cannot predict whether we will be able to obtain such approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The M&amp;A Rules requires an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies and
controlled by PRC companies or individuals to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle's securities on an overseas stock exchange. However, the
application of the M&amp;A Rules remains unclear. If CSRC approval is required, it is uncertain whether it would be possible for us to obtain the approval, and any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=84,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=918446,FOLIO='81',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_82"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>failure
to obtain or delay in obtaining CSRC approval for this offering would subject us to sanctions imposed by the CSRC and other PRC regulatory agencies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
PRC legal counsel has advised us based on their understanding of the current PRC laws, rules and regulations that the CSRC's approval may not be required for the listing and trading
of the ADSs on the Nasdaq Global Market in the context of this offering, given that: (i)&nbsp;the CSRC currently has not issued any definitive rule or interpretation concerning whether offering such
as this offering contemplated by our Company are subject to the M&amp;A Rules; and (ii)&nbsp;our PRC subsidiary was incorporated as wholly foreign-owned enterprises by means of direct investment rather
than by merger or acquisition of equity interest or assets of a PRC domestic company owned by PRC companies or individuals as defined under the M&amp;A Rules that are our beneficial owners. However, there
is uncertainty as to how the M&amp;A Rules will be interpreted or implemented and we cannot assure you that relevant PRC governmental authorities, including CSRC, would reach the same conclusion as our
PRC Legal Counsel. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries'
ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents' Offshore Investment
and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as
foreign individuals that are deemed as PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore
investment activities. SAFE Circular 37 is applicable to our shareholders who are PRC residents and may be applicable to any offshore acquisitions that we make in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
SAFE Circular 37, PRC residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose vehicles, or
SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is a direct or indirect shareholder of an SPV, is required to update its filed
registration with the local branch of SAFE with respect to that SPV, to reflect any material change, including, among other things, any major change of a PRC resident shareholder, name or term of
operation of the SPVs, or any increase or reduction of the SPVs' registered capital, share transfer or swap, merger or division. Moreover, any subsidiary of such SPV in China is required to urge the
PRC resident shareholders to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration or to update the previously filed
registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may
also be prohibited from making additional capital contributions into its subsidiary in China. On February&nbsp;13, 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign
Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June&nbsp;1, 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound
foreign direct investments and outbound overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE or its branches. The qualified
banks will directly examine the applications and accept registrations under the supervision of SAFE. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our existing shareholders, each of whom owns our ordinary shares, including but not limited to as a result of exercising share options, are PRC residents under SAFE Circular 37.
However, we cannot provide any assurance that these PRC residents comply with our request to make or obtain any applicable registrations or change registration or comply with all of the requirements
under SAFE Circular 37 or other related rules. Furthermore, we may not be informed of the identities of all the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=85,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=961289,FOLIO='82',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>PRC
residents holding direct or indirect interest in our company. The failure or inability of our PRC resident shareholders to comply with the registration procedures set forth in these regulations
may subject us to fines and legal sanctions, restrict our cross-border investment activities, limit the ability of our wholly foreign-owned subsidiary in China to distribute dividends and the proceeds
from any reduction in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into the subsidiary. Moreover, failure to comply with the various
foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and
our ability to distribute profits to you could be materially and adversely affected. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
as these foreign exchange regulations are still relatively new and their interpretation and implementation has been constantly evolving, it is unclear how these regulations,
and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant government authorities. For example, we may be subject to a
more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our
financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, we cannot assure you that we or the owners of such company, as the case may be, will be able
to obtain the necessary approvals or complete the necessary filings and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy
and could adversely affect our business and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be materially adversely affected if our shareholders and beneficial owners who are PRC entities fail
to comply with the relevant PRC overseas investment regulations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;26, 2017, the NDRC promulgated the Administrative Measures on Overseas Investments, or NDRC Order No.&nbsp;11, which took
effect as of March&nbsp;1, 2018. According to NDRC Order No.&nbsp;11, non-sensitive overseas investment projects are subject to record-filing requirements with the local branch of the NDRC. On
September&nbsp;6, 2014, MOFCOM promulgated the </FONT><FONT SIZE=2><I>Administrative Measures on Overseas Investments</I></FONT><FONT SIZE=2>, which took effect as of October&nbsp;6, 2014.
According to this regulation, overseas investments of PRC enterprises that involve non-sensitive countries and regions
and non-sensitive industries are subject to record-filing requirements with a local MOFCOM branch. According to the </FONT><FONT SIZE=2><I>Circular of the State Administration of Foreign Exchange on
Issuing the Regulations on Foreign Exchange Administration of the Overseas Direct Investment of Domestic Institutions</I></FONT><FONT SIZE=2>, which was promulgated by SAFE on July&nbsp;13, 2009 and
took effect on August&nbsp;1, 2009, PRC enterprises must register for overseas direct investment with a local SAFE branch. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not be fully informed of the identities of all our shareholders or beneficial owners who are PRC entities, and we cannot provide any assurance that all of our shareholders and
beneficial owners who are PRC entities has or will comply with our request to complete the overseas direct investment procedures under the aforementioned regulations or other related rules in a timely
manner, or at all. If they fail to complete the filings or registrations required by the overseas direct investment regulations, the relevant authorities may order them to suspend or cease the
implementation of such investment impose warnings and sanctions and make corrections within a specified time, or limit our ability to distribute dividends and proceeds to our PRC subsidiary, which may
adversely affect our business, financial condition and results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=86,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=359958,FOLIO='83',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_84"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and
governmental control of currency conversion may delay or prevent us from using the proceeds of this offering to make loans or additional capital contributions to our PRC subsidiary, which could
materially and adversely affect our liquidity and our ability to fund and expand our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an offshore holding company conducting our operations in China through our PRC subsidiary. We also hold certain intellectual properties
and outsource certain research and development activities related to these intellectual properties to our subsidiaries. We may in the future make loans or provide guarantee to our PRC subsidiary
subject to the approval or registration from governmental authorities and limitation of amount, or we may make additional capital contributions to our wholly foreign-owned subsidiary in China. Any
loans to our wholly foreign-owned subsidiary in China, which are treated as foreign-invested enterprises under PRC law, are subject to foreign exchange loan registrations. In addition, a
foreign-invested enterprise, or FIE, shall use its capital pursuant to the principle of authenticity and self-use within its business scope. The capital of an FIE shall not be used for the following
purposes: (i)&nbsp;directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii)&nbsp;directly or indirectly
used for investment in securities or investments other than banks' principal-secured products unless otherwise provided by relevant laws and regulations; (iii)&nbsp;the granting of loans to
non-affiliated enterprises, except where it is expressly permitted in the business license; and (iv)&nbsp;paying the expenses related to the purchase of real estate that is not for self-use (except
for the foreign-invested real estate enterprises). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able
to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans by us to our PRC subsidiary or with respect
to future capital contributions by us to our PRC subsidiary. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds from this offering and to capitalize or
otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and
financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material and adverse effect on our ability to conduct our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Cayman Islands holding company and we rely principally on dividends and other distributions on equity from our PRC subsidiary for our
cash requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders for services of any debt we may incur. If our PRC subsidiary incurs debt on its own
behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiary, which is a
wholly foreign-owned enterprise, may pay dividends only out of its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly
foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund
reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits
based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
portion of our revenue was generated by our PRC subsidiary in Renminbi, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may
limit the ability of our PRC subsidiary to use its Renminbi revenues to pay dividends to us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=87,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=904328,FOLIO='84',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_85"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by SAFE for cross-border transactions falling
under both the current account and the capital account. Any limitation on the ability of our PRC subsidiary to pay dividends or make other kinds of payments to us could materially and adversely limit
our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to
non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the
non-PRC-resident enterprises are incorporated. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fluctuations in exchange rates could have a material adverse effect on our results of operations and the
value of your investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in
political and economic conditions in China and by China's foreign exchange policies. On July&nbsp;21, 2005, the PRC government changed its policy of pegging the value of the Renminbi to the U.S.
dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the
Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. Since October&nbsp;1,
2016, Renminbi has joined the International Monetary Fund's basket of currencies that make up the Special Drawing Right, or SDR, along with the U.S. dollar, the Euro, the Japanese yen and the British
pound. In the fourth quarter of 2016, the Renminbi has depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. With the development of the foreign
exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system, and we
cannot assure you that the Renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S.
government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant
revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from this
offering into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if
we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or the ADSs or for other business purposes, appreciation of the U.S. dollar
against the Renminbi would have a negative effect on the U.S. dollar amount available to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Very
limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to
reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we
may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert Renminbi
into foreign currency. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=88,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=930832,FOLIO='85',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_86"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Governmental control of currency conversion may limit our ability to utilize our cash balance effectively and
affect the value of your investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of
currency out of China. In the years ended December&nbsp;31, 2018 and 2019 and nine months ended September&nbsp;30, 2020, we received a portion of our revenues in Renminbi. Under our current
corporate structure, our Cayman Islands holding company primarily relies on previous rounds of private financing to fund any cash and financing requirements we may have. Under existing PRC foreign
exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign
currencies without prior approval of SAFE by complying with applicable laws and regulations, as well as certain procedural requirements. Specifically, under the existing exchange restrictions, without
prior approval of SAFE, cash generated from the operations of our PRC subsidiary may be used to pay dividends to our company. However, approval from or registration with appropriate government
authorities is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a
result, we need to obtain SAFE approval to use the cash generated from the operations of our PRC subsidiary to pay off their respective debt in a currency other than Renminbi owed to entities outside
China, or to make other capital expenditure payments outside China in a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current account
transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends
in foreign currencies to our shareholders, including holders of the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The audit report included in this prospectus is prepared by an auditor that is not inspected by the Public
Company Accounting Oversight Board and, as such, our investors are deprived of the benefits of such inspection. In addition, various legislative and regulatory developments related to U.S.-listed
China based companies due to lack of PCAOB inspection and other developments due to political tensions between the United States and China may have a material adverse impact on our listing and trading
in the U.S. and the trading prices of our ADSs, and we could be delisted if we are unable to meet the PCAOB inspection requirements in time.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our auditor, the independent registered public accounting firm that issued the audit reports included elsewhere in this prospectus filed with
the U.S. Securities and Exchange Commission, or SEC, as an auditor of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board
(United States), or PCAOB, is
subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with applicable professional standards. Our auditor is located in, and organized
under the laws of, the PRC, which is a jurisdiction where the PCAOB has been unable to conduct inspections without the approval of the Chinese authorities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
May&nbsp;24, 2013, the PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the China Securities Regulatory Commission, or CSRC and
the PRC Ministry of Finance, which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to investigations undertaken by the PCAOB, the
CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively. The PCAOB continues to be in discussions with the CSRC and the PRC Ministry of Finance to permit joint inspections
in the PRC of audit firms that are registered with the PCAOB and audit Chinese companies that trade on U.S. exchanges. On December&nbsp;7, 2018, the SEC and the PCAOB issued a joint statement
highlighting continued challenges faced by the U.S. regulators in their oversight of financial statement audits of U.S.-listed companies with significant operations in China. On April&nbsp;21, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=89,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=194326,FOLIO='86',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_87"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2020,
the Chairman of the SEC, the Chairman of the PCAOB and certain other SEC divisional heads jointly issued a public statement highlighting the significant disclosure, financial reporting and other
risks associated with emerging market investments, including the PCAOB's continued inability to inspect audit work papers in China. The 2018 joint statement and the 2020 public statement reflect a
heightened regulatory interest in this issue. In response to the U.S. President Trump's Memorandum on Protecting United States Investors from Significant Risks from Chinese Companies, on
August&nbsp;6, 2020, the U.S. President's Working Group on Financial Markets, or the PWG, released a report where it recommends that the SEC take steps to enhanced listing requirements on companies
from certain jurisdictions, such as China, that do not provide the PCAOB with sufficient access to audit working papers. The proposed enhanced listing standards require, as a condition to initial and
continued exchange listing, unrestricted PCAOB access to work papers of the principal audit firm for the audit of the listed company. Companies that are unable to satisfy this standard as a result of
governmental restrictions may satisfy this standard by providing a co-audit from an audit firm with comparable resources and experience where the PCAOB determines it has sufficient access to audit
work papers and practices to conduct an appropriate inspection of the co-audit firm. The proposed new listing standards provide for a transition period until January&nbsp;1, 2022 for currently
listed companies. After this transition period, if currently listed companies were unable to meet the enhanced listing standards, then they would become subject to securities exchange rules and
processes that could lead to possible de-listing if not cured. The measures in the PWG report are presumably subject to the standard SEC rulemaking process before becoming effective. On
August&nbsp;10, 2020, the SEC announced that SEC Chairman Jay Clayton had directed the SEC staff to prepare proposals in response to the PWG report, and that the SEC was soliciting public comments
and information with respect to these proposals. The PCAOB's inspections of other firms outside China have identified deficiencies in those firms' audit procedures and quality control procedures,
which may be addressed as part of the inspection process to improve future audit quality. However, it remains unclear what additional actions the SEC and the stock exchanges will take in response to
the PWG report. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
lack of PCAOB inspections in China prevents the PCAOB from fully evaluating audits and quality control procedures of our independent registered public accounting firm. As a result,
we and investors in our ADSs are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the
effectiveness of our independent registered public accounting firm's audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections,
which could cause investors and potential investors in our ADSs to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law, in particular China's, in June
2019, a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress, which if passed, would require the SEC to maintain a list of issuers for which PCAOB is not able to inspect
or investigate an auditor report issued by a foreign public accounting firm. The proposed Ensuring Quality Information and Transparency for Abroad-Based Listings on our Exchanges (EQUITABLE) Act
prescribes increased disclosure requirements for these issuers and, beginning in 2025, the delisting from U.S. national securities exchanges such as the NYSE of issuers included on the SEC's list for
three consecutive years. On May&nbsp;20, 2020, the U.S. Senate passed S. 945, the Holding Foreign Companies Accountable Act, or the Kennedy Bill. On July&nbsp;21, 2020, the U.S. House of
Representatives approved its version of the National Defense Authorization Act for Fiscal Year 2021, which contains provisions comparable to the Kennedy Bill. As part of a continued regulatory focus
in the United States on access to audit and other information currently protected by national law, in particular China's, U.S. President Donald&nbsp;J. Trump signed into law on December&nbsp;18,
2020 the Holding Foreign Companies Accountable Act, which will require the SEC to propose rules within 90 days after its enactment to prohibit securities of any registrant from being listed on any of
the U.S. securities exchanges or traded "over the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=90,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=527653,FOLIO='87',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_88"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>counter"
if the auditor of the registrant's financial statements is not subject to PCAOB inspection for three consecutive years after the law becomes effective. Enactment of this legislation or other
efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for affected issuers, including us, and the market price of the ADSs could be adversely affected, and
we could be delisted if we are unable to cure the situation to meet the PCAOB inspection requirement in time. It is unclear if and when any of such proposed legislations will be enacted. See
"&#151;We could be delisted if we are unable to meet the PCAOB inspection requirements in time." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We could be delisted if we are unable to meet the PCAOB inspection requirements in time.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;18, 2020, the Holding Foreign Companies Accountable Act was enacted. In essence, the act requires the SEC to prohibit
securities of any foreign companies from being listed on U.S. securities exchanges or traded "over-the-counter" if a company retains a foreign accounting firm that cannot be inspected by the PCAOB for
three consecutive years, beginning in 2021. Our independent registered public accounting firm is located in and organized under the laws of the PRC, a jurisdiction where the PCAOB is currently unable
to conduct inspections without the approval of the Chinese authorities, and therefore our auditors are not currently inspected by the PCAOB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enactment of the Holding Foreign Companies Accountable Act and any additional rulemaking efforts to increase U.S. regulatory access to audit information in China could cause investor
uncertainty for affected SEC registrants, including us, and the market price of our ADSs could be materially adversely affected. Additionally, whether the PCAOB will be able to conduct inspections of
our auditors in the next three years, or at all, is subject to substantial uncertainty and depends on a number of factors out of our control. If we are unable to meet the PCAOB inspection requirement
in time, we could be delisted from the Nasdaq Global Market and our ADSs will not be permitted for trading "over-the-counter" either. Such a delisting would substantially impair your ability to sell
or purchase our ADSs when you wish to do so, and the risk and uncertainty associated with delisting would have a negative impact on the price of our ADSs. Also, such a delisting would significantly
affect our ability to raise capital on terms acceptable to us, or at all, which would have a material adverse impact on our business, financial condition and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Proceedings instituted by the SEC against certain PRC-based accounting firms, including the affiliate of our
independent registered public accounting firm, or any related adverse regulatory development in the PRC, could result in our financial statements being determined to not be in compliance with the
requirements of the Exchange Act.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2012, the SEC instituted administrative proceedings against the Big Four PRC-based accounting firms, including our independent
registered public accounting firm, alleging that these firms had violated U.S. securities laws and the SEC's rules and regulations thereunder by failing to provide to the SEC the firms' audit work
papers with respect to certain PRC-based companies that are publicly traded in the United States. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
January&nbsp;22, 2014, the administrative law judge presiding over the matter rendered an initial decision that each of the firms had violated the SEC's rules of practice by failing
to produce audit papers and other documents to the SEC. The initial decision censured each of the firms and barred them from practicing before the SEC for a period of six months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;6, 2015, the four China-based accounting firms each agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to
practice before the SEC and audit U.S.-listed companies. The settlement required the firms to follow detailed procedures and to seek to provide the SEC with access to Chinese firms' audit documents
via the CSRC. Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=91,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=74767,FOLIO='88',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<A NAME="page_cs17601_1_89"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>dismissed
with prejudice four years after entry of the settlement. The four-year mark occurred on February&nbsp;6, 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we cannot predict if the SEC will further challenge the four China-based accounting firms' compliance with U.S. law in connection with U.S. regulatory requests for audit work
papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions, if the accounting firms are subject to additional remedial measures, our ability to file
our financial statements in compliance with SEC requirements could be impacted. A determination that we have not timely filed financial statements in compliance with SEC requirements could ultimately
lead to the delisting of our ordinary shares or ADSs or the termination of the registration of our ordinary shares or ADSs under the Exchange Act, or both, which would substantially reduce or
effectively terminate the trading of our ordinary shares or ADSs in the United States. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to the ADSs and This Offering  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may be subject to limitations on transfer of your ADSs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time
when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the
books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any
provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An active trading market for our ordinary shares or the ADSs may not develop and the trading price for the
ADSs may fluctuate significantly.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied to list the ADSs on the Nasdaq Global Market. We have no current intention to seek a listing for our ordinary shares on any
stock exchange. Prior to the completion of this offering, there has been no public market for the ADSs or our ordinary shares, and we cannot assure you that a liquid public market for the ADSs will
develop. If an active public market for the ADSs does not develop following the completion of this offering, the market price and liquidity of the ADSs may be materially and adversely affected. The
initial public offering price for the ADSs will be determined by negotiation between us and the underwriters based upon several factors, and we can provide no assurance that the trading price of the
ADSs after this offering will not decline below the initial public offering price. As a result, investors in our securities may experience a significant decrease in the value of their ADSs. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The trading price of the ADSs is likely to be volatile, which could result in substantial losses to
investors.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading price of the ADSs is likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of
broad market and industry factors, including the performance and fluctuation of the market prices of other companies with business operations located mainly in China that have listed their securities
in the United States. In addition to market and industry factors, the price and trading volume for the ADSs may be highly volatile for factors specific to our own operations, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> variations in our net revenues, earnings and cash flow; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcements of new investments, acquisitions, strategic partnerships, or joint ventures by us or our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcements of new products and services and expansions by us or our competitors; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=92,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=281406,FOLIO='89',FILE='DISK103:[20ZDS1.20ZDS17601]CS17601A.;38',USER='CHE105540',CD='29-JAN-2021;21:28' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cu17601_1_90"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in financial estimates by securities analysts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fluctuations in operating metrics; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure on our part to realize monetization opportunities as expected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in revenues generated from our significant business partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions or departures of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> release of lock-up or other transfer restrictions on our outstanding equity securities or sales of additional equity securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> detrimental negative publicity about us, our management, our competitors or our industry; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory developments affecting us or our industry; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential litigation or regulatory investigations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors may result in large and sudden changes in the trading volume and price of the ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their
securities. If we were involved in a class action suit, it could divert a significant amount of our management's attention and other resources from our business and operations and require us to incur
significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise
capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and
results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain
reduced reporting requirements.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company," as defined in the JOBS Act, and we may take advantage of certain exemptions from requirements applicable to
other public companies that are not emerging growth companies including, most significantly, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002 for so long as we remain an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to
certain information they may deem important. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts cease to publish research or reports about our business, or if they
adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for the ADSs will be influenced by research or reports that industry or securities analysts publish about our business. If
one or more analysts who cover us downgrade the ADSs, the market price for the ADSs would likely decline. If one or more of these analysts cease to cover us or fail to regularly publish reports on us,
we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for the ADSs to decline. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the
ADSs could adversely affect their market price.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of substantial amounts of the ADSs in the public market after the completion of this offering, or the perception that these sales could
occur, could adversely affect the market price of the ADSs and could materially impair our ability to raise capital through equity offerings in the future. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=93,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=476886,FOLIO='90',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_91"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ADSs
sold in this offering will be freely tradable without restriction or further registration under the Securities Act, and shares held by our existing shareholders may also be sold in the public
market in the future subject to the restrictions in Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act and the applicable lock-up agreements. There will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs (equivalent
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares) outstanding immediately after this offering,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs (equivalent to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary
shares) if the underwriters exercise their
over-allotment option in full. [In connection with this offering, we, our directors and executive officers and our existing shareholders have agreed not to sell any ordinary shares or ADSs
for 180&nbsp;days after the date of this prospectus without the prior written consent of the underwriters, subject to certain exceptions. However, the underwriters may release these securities from
these restrictions at any time, subject to applicable regulations of the Financial Industry Regulatory Authority,&nbsp;Inc.] We cannot predict what effect, if any, market sales of
securities held by our significant shareholders or any other shareholder or the availability of these securities for future sale will have on the market price of the ADSs. See "Underwriting" and
"Shares Eligible for Future Sale" for a more detailed description of the restrictions on selling these securities after this offering. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our memorandum and articles of association contain anti-takeover provisions that could have a material
adverse effect on the rights of holders of our ordinary shares and the ADSs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will adopt amended and restated memorandum and articles of association that will become effective immediately prior to the completion of this
offering. Our new memorandum and articles of association contain provisions to limit the ability of others to acquire control of our company or cause us to engage in change-of-control transactions.
These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to
obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more
series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend
rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, including ordinary
shares represented by ADSs. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our
board of directors decides to issue preferred shares, the price of the ADSs may fall and the voting and other rights of the holders of our ordinary shares and the ADSs may be materially and adversely
affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have not determined a specific use for a portion of the net proceeds from this offering, and we may use
these proceeds in ways with which you may not agree, and such use may not produce income or increase the ADS price.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not determined a specific use for a portion of the net proceeds of this offering, and our management will have considerable discretion
in deciding how to apply these proceeds. You will not have the opportunity to assess whether the proceeds are being used appropriately before you make your investment decision. You must rely on the
judgment of our management regarding the application of the net proceeds of this offering. We cannot assure you that the net proceeds will be used in a manner that would improve our results of
operations or increase the ADS price, nor that these net proceeds will be placed only in investments that generate income or appreciate in value. Currently, we do not have any plans, commitments or
understandings to acquire complementary business, assets and technologies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=94,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=615064,FOLIO='91',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_92"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of
such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior
consent of the ADS holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us. Amendments may reflect, among other things,
operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship with the depositary. In the event that the terms of an amendment are
disadvantageous to ADS holders, ADS holders will only receive 30&nbsp;days' advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement.
Furthermore, we may decide to terminate the ADS facility at any time for any reason. For example, terminations may occur when we decide to list our shares on a non-U.S. securities exchange and
determine not to continue to sponsor an ADS facility or when we become the subject of a takeover or a going-private transaction. If the ADS facility will terminate, ADS holders will receive at least
90&nbsp;days' prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is disadvantageous to ADS holders or
terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but will have no right to any
compensation whatsoever. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement,
which could result in less favorable outcomes to the plaintiff(s) in any such action.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders
waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S.
federal securities laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in
accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities
laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the
laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit
agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the
right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before
entering into the deposit agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including
claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and
discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial
court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the
plaintiff(s) in any such action. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nevertheless,
if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=95,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=98490,FOLIO='92',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_93"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any
substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be
able to exercise your right to direct the voting of the underlying ordinary shares represented by your ADSs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of ADSs do not have the same rights as our registered shareholders. As a holder of ADSs, you will not have any direct right to attend
general meetings of our shareholders or to cast any votes at such meetings. You will only be able to exercise the voting rights attached to the ordinary shares underlying your ADSs indirectly by
giving voting instructions to the depositary in accordance with the provisions of the deposit agreement. Where any matter is to be put to a vote at a general meeting, then upon receipt of your voting
instructions, the depositary will try, as far as is practicable, to vote the underlying ordinary shares represented by your ADSs in accordance with your instructions. You will not be able to directly
exercise your right to vote with respect to the underlying ordinary shares unless you cancel and withdraw the shares and become the registered holder of such shares prior to the record date for the
general meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
a general meeting is convened, you may not receive sufficient advance notice of the meeting to withdraw the ordinary shares represented by your ADSs and become the registered holder
of such shares to allow you to attend the general meeting and to vote directly with respect to any specific matter or resolution to be considered and voted upon at the general meeting. In addition,
under our post-offering memorandum and articles of association that will become effective immediately prior to completion of this offering, for the purposes of determining those shareholders who are
entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or
the setting of such a record date may prevent you from withdrawing the underlying ordinary shares represented by your ADSs and from becoming the registered holder of such shares prior to the record
date, so that you would not be able to attend the general meeting or to vote directly. Where any matter is to be put to a vote at a general meeting, upon our instruction the depositary will notify you
of the upcoming vote and will arrange to deliver our voting materials to you. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to
vote the underlying ordinary shares represented by your ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that
you may not be able to exercise your right to direct how the underlying ordinary shares represented by your ADSs are voted and you may have no legal remedy if the underlying ordinary shares
represented by your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders' meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the deposit agreement, if you do not vote, the depositary may give us a discretionary proxy to vote the ordinary shares underlying the ADSs at shareholders' meetings if we have
timely provided the depositary with notice of meeting and related voting materials and (i)&nbsp;we have instructed the depositary that we wish a discretionary proxy to be given, (ii)&nbsp;we have
informed the depositary that there is no substantial opposition as to a matter to be voted on at the meeting, and (iii)&nbsp;a matter to be voted on at the meeting would not have a material adverse
impact on shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effect of this discretionary proxy is that you cannot prevent the underlying ordinary shares represented by the ADSs from being voted, except under the circumstances described above.
This may make it more difficult for ADS holders to influence the management of the company. Holders of ordinary shares are not subject to this discretionary proxy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=96,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=432651,FOLIO='93',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_94"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because the initial public offering price is substantially higher than the pro forma net tangible book value
per share, you will experience immediate and substantial dilution.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you purchase the ADSs in this offering, you will pay more for each ADS than the corresponding amount paid by existing shareholders for their
ordinary shares. As a result, you will experience immediate and substantial dilution of approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming that no outstanding options to acquire ordinary shares
are
exercised. This number represents the difference between the assumed initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, being the mid-point of the estimated range of the initial
offering
price shown on the front cover of this prospectus, and our pro forma net tangible book value per ADS as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, after giving effect to this offering. You may experience further
dilution to the extent that our ordinary shares are issued upon exercise of any share options. See "Dilution" for a more complete description of how the value of your investment in ADSs will be
diluted upon completion of this offering. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we do not expect to pay dividends in the foreseeable future after this offering, you must rely on
price appreciation of the ADSs for return on your investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently intend to retain most, if not all, of our available funds and any future earnings after this offering to fund the development and
growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in the ADSs as a source for any future
dividend income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has complete discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to
the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands
company may pay a dividend out of either profit or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as
they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our
future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiary, our financial condition, contractual
restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in the ADSs will likely depend entirely upon any future price appreciation of the
ADSs. There is no guarantee that the ADSs will appreciate in value after this offering or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in
the ADSs and you may even lose your entire investment in the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may not receive dividends or other distributions on our ordinary shares and you may not receive any value
for them, if it is illegal or impractical to make them available to you.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other
deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a
holder of ADSs if it consists of securities that require registration under the Securities Act of 1933 but that are not properly registered or distributed under an applicable exemption from
registration. The depositary may also determine that it is not feasible to distribute certain property through the mail. Additionally, the value of certain distributions may be less than the cost of
mailing them. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other
securities received through such distributions. We also have no obligation to take any other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=97,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=404200,FOLIO='94',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_95"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>action
to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value
for them if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may experience dilution of your holdings due to the inability to participate in rights offerings.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, from time to time, distribute rights to our shareholders, including rights to acquire securities. Under the deposit agreement, the
depositary will not distribute rights to holders of ADSs unless the distribution and sale of rights and the securities to which these rights relate are either exempt from registration under the
Securities Act with respect to all holders of ADSs, or are registered under the provisions of the Securities Act. The depositary may, but is not required to, attempt to sell these undistributed rights
to third parties, and may allow the rights to lapse. We may be unable to establish an exemption from registration under the Securities Act, and we are under no obligation to file&nbsp;a registration
statement with respect to these rights or underlying securities or to endeavor to have a registration statement declared effective. Accordingly, holders of ADSs may be unable to participate in our
rights offerings and may experience dilution of their holdings as a result. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur increased costs as a result of being a public company, particularly after we cease to qualify
as an "emerging growth company."  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon completion of this offering, we will become a public company and expect to incur significant legal, accounting and other expenses that we
did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the Securities and Exchange Commission, or the SEC, and the Nasdaq Global Market,
impose various requirements on the corporate governance practices of public companies. As a company with less than US$1.07&nbsp;billion in revenues for our last fiscal year, we qualify as an
"emerging growth company" pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to
public companies. These provisions include exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, in the assessment of
the emerging growth company's internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private
companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect these rules and regulations to increase our legal and financial compliance costs and to make some corporate activities more time-consuming and costly. After we are no longer an
"emerging growth company," we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002 and the other rules and regulations of the SEC. For example, as a result of becoming a public company, we will need to increase the number of independent directors and adopt policies
regarding internal controls and disclosure controls and procedures. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and
officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur
additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers.
We are currently evaluating and monitoring
developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the number of additional costs we may incur or the timing of such costs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=98,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=111456,FOLIO='95',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_96"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may face difficulties in protecting your interests, and your ability to protect your rights through U.S.
courts may be limited, because we are incorporated under Cayman Islands law.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our
memorandum and articles of association, the Companies Act (as amended) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against our directors,
actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of
the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive
authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as
they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States.
Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have the
standing to initiate a shareholder derivative action in a federal court of the United States.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholders
of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of lists of shareholders of
these companies. Our directors have discretion under our articles of association that will become effective immediately prior to completion of this offering to determine whether or not, and under what
conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the
information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of all of the above, our public shareholders may have more difficulties in protecting their interests in the face of actions taken by management, members of our board of
directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States. For a discussion of significant differences between the provisions of the
Companies Act of the Cayman Islands and the laws applicable to companies incorporated in the United States and their shareholders, see "Description of Share Capital&#151;Differences in
Corporate Law."

 </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Certain judgments obtained against us by our shareholders may not be enforceable.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Cayman Islands company and substantially all of our assets are located outside of the United States. Our current operations are
primarily conducted in China. In addition, some of our current directors and officers are nationals and residents of countries other than the United States. Substantially all of the assets of these
persons are located outside the United States. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that
you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and
of China may render you unable to enforce a judgment against our assets or the assets of our directors and officers. For more information regarding the relevant laws of the Cayman Islands and China,
see "Enforceability of Civil Liabilities." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=99,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=153213,FOLIO='96',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_97"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As a company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in
relation to corporate governance matters that differ significantly from the Nasdaq listing standards; these practices may afford less protection to shareholders than they would enjoy if we complied
fully with the Nasdaq listing standards.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a Cayman Islands company listed on the Nasdaq Global Market, we are subject to the Nasdaq listing standards. However, Nasdaq rules permit a
foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman Islands, which is our home country, may differ
significantly from the Nasdaq listing standards. We may elect to rely on home country practice to be exempted from the corporate governance requirements. As a result, our shareholders may be afforded
less protection than they would otherwise enjoy under the Nasdaq listing standards applicable to U.S. domestic issuers. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are
exempt from certain provisions applicable to U.S. domestic public companies.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules and
regulations in the United States that are applicable to U.S. domestic issuers, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form&nbsp;10-Q or current reports on
Form&nbsp;8-K; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under
the Exchange Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for
insiders who profit from trades made in a short period of time; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the selective disclosure rules by issuers of material nonpublic information under Regulation&nbsp;FD. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will be required to file an annual report on Form&nbsp;20-F within four months of the end of each fiscal year. In addition, we intend to publish our results on a quarterly basis as
press releases, distributed pursuant to the rules and regulations of the Nasdaq Global Market. Press releases relating to financial results and material events will also be furnished to the SEC on
Form&nbsp;6-K. However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic
issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There can be no assurance that we will not be a passive foreign investment company, or PFIC, for U.S. federal
income tax purposes for any taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. federal income tax consequences.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, a non-U.S. corporation will be a PFIC for any taxable year in which (i)&nbsp;75% or more of its gross income consists of passive
income, or the income test, or (ii)&nbsp;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production
of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the ordinary shares of another
corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income
generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash
is a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=100,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=664880,FOLIO='97',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cu17601_1_98"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>passive
asset for PFIC purposes. Goodwill is an active asset under the PFIC rules to the extent attributable to activities that produce active income. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for the
current or any future taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. We cannot give any assurance as to whether we will be a PFIC
for the current or any future taxable year because (i)&nbsp;the value of our goodwill may be determined by reference to the market price of our ADSs, which may be volatile given the nature and early
stage of our business, (ii)&nbsp;we expect to hold a significant amount of cash, and (iii)&nbsp;a company's PFIC status is an annual determination that can be made only after the end of each
taxable year. In addition, prior to commercialization of our product candidates, we could be a PFIC for any taxable year in which our interest and other investment income constitutes 75% or more of
our total gross income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we were a PFIC for any taxable year during which a U.S. investor owns our ADSs or ordinary shares, certain adverse U.S. federal income tax consequences could apply to such U.S.
investor. See "Taxation&#151;Material U.S. Federal Income Tax Consequences&#151;Passive Foreign Investment Company Rules." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=101,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=260741,FOLIO='98',FILE='DISK103:[20ZDS1.20ZDS17601]CU17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cw17601_1_99"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cw17601_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_cw17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical
facts are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other
similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements
about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our goals and growth strategies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our future business development, results of operations and financial condition; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our discovery programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to utilize our proprietary Dynamic Precision Library platform, or DPL, to design, construct and develop next-generation antibodies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to advance product candidates into, and successfully complete, clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing or likelihood of regulatory filings and approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the commercializing of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if
approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> future strategic arrangements and/or collaborations and the potential benefits of such arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our anticipated use of our existing resources and the proceeds from this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional
capital; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the implementation of our business model, strategic plans for our business and product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope of protection we are able to establish and maintain for intellectual property rights, such as our proprietary DPL, which includes
NEObody platform, SAFEbody platform and POWERbody platform, product candidates and discovery programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our potential to enter into new collaborations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=102,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=405524,FOLIO='99',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cw17601_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the pricing, coverage and reimbursement of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments relating to our competitors and our industry, including competing product candidates and therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> relevant government policies and regulations relating to our business and industry; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> general economic and business condition in the markets we have businesses; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assumptions underlying or related to any of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read thoroughly this prospectus and the documents that we refer to in this prospectus with the understanding that our actual future results may be materially different from
and worse than what we expect. Other sections of this prospectus include additional factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving
environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all
factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify
all of our forward-looking statements by these cautionary statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should not rely upon forward-looking statements as predictions of future events. We undertake no obligation to update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=103,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=102394,FOLIO='100',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cw17601_1_101"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cw17601_use_of_proceeds"> </A>
<A NAME="toc_cw17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that we will receive net proceeds from this offering of approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional ADSs in full, after deducting underwriting discounts and commissions and the estimated offering
expenses
payable by us. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to use the net proceeds from this offering for the following purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately 95% for research and development;  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately 26% to fund&nbsp;ADG106, covering both Phase&nbsp;I trial and advancement to Phase&nbsp;II trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately 26% to fund both ADG126 and ADG116, covering Phase&nbsp;I trial and advancement to Phase&nbsp;II trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately 43% for our technical and platform development and development of our preclinical candidates; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately 5% for working capital and other general corporate purposes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net proceeds from this offering, together with our cash and cash equivalents, will not be sufficient for us to fund any of our product candidates through regulatory approval, our
preclinical development pipeline through Phase I clinical trials, or any product candidates resulting from our discovery pipeline into clinical trials. As a result, we will need to raise additional
capital to complete the development and commercialization of our products candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in this prospectus. In utilizing the proceeds from
this offering, we are permitted under PRC laws and regulations to provide funding to our PRC subsidiaries only through loans or capital contributions, and only if we satisfy the applicable government
registration and approval requirements. We cannot assure you that we will be able to meet these requirements on a timely basis, if at all. See "Risk Factors&#151;Risks Related to Doing Business
in China&#151;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using
the proceeds of this offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our
business." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=104,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=531055,FOLIO='101',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cw17601_1_102"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cw17601_dividend_policy"> </A>
<A NAME="toc_cw17601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our shares or
the ADSs representing our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are a holding company incorporated in the Cayman Islands. In the future, we may rely on dividends from our subsidiaries, including our PRC subsidiary, for our cash requirements,
including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiary to pay dividends to us. See "PRC Regulation&#151;Regulations on Foreign
Exchange and Dividend Distribution." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to the
provisions of our post-offering articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Under Cayman Islands
law, a Cayman Islands company may pay a dividend out of either profit or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being
unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future
operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. If we pay any
dividends on our ordinary shares, we will pay those dividends which are payable in respect of the ordinary shares underlying the ADSs to the depositary, as the registered holder of such ordinary
shares, and the depositary then will pay such amounts to the ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit
agreement, including the fees and expenses payable thereunder. See "Description of American Depositary Shares." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=105,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=46684,FOLIO='102',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cw17601_1_103"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cw17601_capitalization"> </A>
<A NAME="toc_cw17601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our capitalization as of September&nbsp;30, 2020:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma basis to reflect the automatic conversion of all of our outstanding preferred shares into 27,249,824 ordinary shares immediately
prior to the completion of this offering; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma as adjusted basis to reflect (i)&nbsp;the conversion of all of our issued and outstanding preferred shares into 27,249,824
ordinary shares upon completion of this offering, (ii)&nbsp;the recognition of share-based compensation expense of US$0.2&nbsp;million associated with share options for which the service condition
was satisfied as of September&nbsp;30, 2020 and the performance condition will be satisfied upon the completion of this offering, which has been reflected as an increase to additional paid-in
capital and accumulated deficit and (iii)&nbsp;the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of ADSs by us in this offering
at an assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS being the mid-point of the estimated range of the initial offering price shown on the front cover of this prospectus, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us (assuming the underwriters do not exercise their option to purchase additional ADSs).

 </FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=106,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=667545,FOLIO='103',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cw17601_1_104"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and the information under "Management's
Discussion and Analysis of Financial Condition and Results of Operations." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of September&nbsp;30, 2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma<BR>
as adjusted<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Current portion of long-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>943</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>943</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term borrowings, less current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Mezzanine equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,473,957 shares authorized, issued and outstanding on an
actual basis; and nil outstanding on a pro-forma and pro forma as adjusted basis as of June&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A-2 convertible redeemable preferred shares (par value of US$0.0001 per share; 2,370,414 shares authorized, issued and outstanding on an
actual basis; and nil outstanding on a pro-forma and pro forma as adjusted basis as of June&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible redeemable preferred shares (par value of US$0.0001 per share; 7,494,537 shares authorized, issued and outstanding on an actual
basis; and nil outstanding on a pro-forma and pro forma as adjusted basis as of June&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,597,354 shares authorized, issued and outstanding on an
actual basis; and nil outstanding on a pro-forma and pro forma as adjusted basis as of June&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,913</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C-2 convertible redeemable preferred shares (par value of US$0.0001 per share; 1,861,121 shares authorized, issued and outstanding on an
actual basis; and nil outstanding on a pro-forma and pro forma as adjusted basis as of June&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C-3 convertible redeemable preferred shares (par value of US$0.0001 per share; 4,452,441 shares authorized, issued and outstanding on an
actual basis; and nil outstanding on a pro-forma and pro forma as adjusted basis as of June&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total mezzanine equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154,387</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Shareholders' equity (deficit)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares (par value of US$0.0001 per share; 500,000,000 shares authorized; 16,466,897 shares issued and outstanding as of and September&nbsp;30,
2020;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Subscriptions receivable from shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,975</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,975</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>170,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(92,887</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(92,887</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total shareholders' equity (deficit)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(78,921</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75,466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total mezzanine equity and shareholders' equity (deficit)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75,466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75,466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total capitalization</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79,545</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79,545</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=1>Notes: </FONT></P>



<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
pro forma as adjusted information does not include the impact of: (i)&nbsp;the modification and exercise of 2,375,000 share options on November&nbsp;9, 2020
and (ii)&nbsp;the surrender of 491,119 ordinary shares on January&nbsp;16, 2021.

</FONT></DD></DL>


 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=107,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=480644,FOLIO='104',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_cw17601_1_105"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
pro forma as adjusted information discussed above is illustrative only. Our additional paid-in capital and total shareholders' equity (deficit) following the
completion of this offering are subject to adjustment based on the actual initial public offering price and other terms of this offering determined at pricing. Assuming the number of ADSs offered by
us as set forth on the cover page of this prospectus remains the same, and after deduction of underwriting discounts and commissions and the estimated offering expenses payable by us, a US$1.00 change
in the assumed initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS would, in the case of an increase, increase and, in the case of a decrease, decrease each of additional paid-in capital
and
total shareholders' equity (deficit) by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </FONT>

</DD></DL>


 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=108,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=133789,FOLIO='105',FILE='DISK103:[20ZDS1.20ZDS17601]CW17601A.;64',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cy17601_1_106"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cy17601_dilution"> </A>
<A NAME="toc_cy17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our ADSs, your interest will be diluted to the extent of the difference between the initial public offering price per ADS and
our net tangible book value per ADS after this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the book value per
ordinary share attributable to the existing shareholders for our presently outstanding ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net tangible book value as of September&nbsp;30, 2020 was approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. Net tangible book value represents
the amount of our total consolidated
tangible assets, less the amount of our total consolidated liabilities and mezzanine equity. Dilution is determined by subtracting pro forma as adjusted net tangible book value per ordinary share from
the public offering price per ordinary share.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without taking into account any other changes in such net tangible book value after September&nbsp;30, 2020, other than to give effect to (i)&nbsp;the conversion of all of our
preferred shares into ordinary shares on a one-to-one basis, which will occur automatically immediately prior to the completion of this offering, (ii)&nbsp;the recognition of share-based
compensation expense of US$0.2 million associated with share options for which the service condition was satisfied as of September&nbsp;30, 2020 and the performance condition will be satisfied upon
the completion of this offering, which has been reflected as an increase to additional paid-in capital and accumulated deficit and (iii)&nbsp;our issuance and sale of ADSs offered in this offering
at an initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, after deduction of the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as
adjusted net tangible book value as of September&nbsp;30, 2020 would have been approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS, to existing shareholders and an immediate dilution in net tangible book value of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, to purchasers of ADSs in this offering.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table illustrates the dilution on a per ordinary share basis at the initial public offering price per ordinary share is US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and all ADSs are exchanged for
ordinary shares: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per ADS </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assumed initial public offering price per ordinary share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per ordinary share after giving effect to the automatic conversion of all of our outstanding preferred
shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per ordinary share to give effect to the automatic conversion of all of our outstanding preferred shares
and this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amount of dilution in pro forma net tangible book value per share to new investors in the offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pro forma information discussed above is illustrative only. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes, on a pro forma as adjusted basis as of September&nbsp;30, 2020, the differences between the existing shareholders and the new investors with respect to
the number of ordinary shares (in the form of ADSs or ordinary shares) purchased from us in this offering, the total consideration paid and the average price per ordinary share paid and per ADS at the
initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS before deducting estimated underwriting discounts and commissions and estimated offering expenses. The total number of ordinary shares
does
not include </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=109,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1007755,FOLIO='106',FILE='DISK103:[20ZDS1.20ZDS17601]CY17601A.;37',USER='CHE105542',CD='31-JAN-2021;23:44' -->
<A NAME="page_cy17601_1_107"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ordinary
shares underlying the ADSs issuable upon the exercise of the over-allotment option granted to the underwriters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total Consideration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary Shares<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount (in<BR>
thousands of<BR>
US$) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average Price<BR>
Per Ordinary<BR>
Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average Price<BR>
Per ADS </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing shareholders</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A US$1.00 increase (decrease) in the assumed public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS (the mid-point of the estimated initial public
offering price range shown on the front
cover page of this prospectus) would increase (decrease) our pro forma as adjusted net tangible book value after giving effect to the offering by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million , the pro forma as
adjusted
net tangible book value per ordinary share and per ADS after giving effect to this offering by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS and the dilution in pro forma as
adjusted net tangible book value per ordinary share and per ADS to new investors in this offering by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming no change to the
number of ADS offered by us as set forth on the front cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The discussion and tables above also assume no exercise of any awards outstanding as of the date of this prospectus. As of the date of this prospectus, the aggregate number of our
ordinary shares underlying our outstanding awards under the 2019 Plan is 3,601,522, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. We have not granted any
awards under the 2021 Plan. To the extent that any outstanding share options are exercised, or new awards are issued under our equity incentive plans, or we issue additional equity or convertible debt
securities in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic
considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities,
the issuance of these securities could result in further dilution to our shareholders and/or holders of ADSs.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=110,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=607328,FOLIO='107',FILE='DISK103:[20ZDS1.20ZDS17601]CY17601A.;37',USER='CHE105542',CD='31-JAN-2021;23:44' -->
<A NAME="page_cy17601_1_108"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cy17601_enforceability_of_civil_liabilities"> </A>
<A NAME="toc_cy17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  ENFORCEABILITY OF CIVIL LIABILITIES    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cayman Islands  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability. We enjoy the following
benefits:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> political and economic stability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an effective judicial system; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a favorable tax system; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the absence of exchange control or currency restrictions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability of professional and support services. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;However,
certain disadvantages accompany incorporation in the Cayman Islands. These disadvantages include, but are not limited to, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Cayman Islands has a less developed body of securities laws as compared to the United States and these securities laws provide
significantly less protection to investors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Cayman Islands companies may not have standing to sue before the federal courts of the United States. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
constitutional documents do not contain provisions requiring that disputes, including those arising under the securities laws of the United States, between us, our officers,
directors and shareholders, be arbitrated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Substantially
all of our operations are conducted in China, and a significant portion of our assets are located in China. A majority of our directors and executive officers are nationals
or residents of jurisdictions other than the United States and a substantial portion of their assets are located outside the United States. As a result, it may be difficult for a shareholder to effect
service of process within the United States upon these persons, or to enforce against us or them judgments obtained in United States courts, including judgments predicated upon the civil liability
provisions of the securities laws of the United States or any state in the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have appointed Cogency Global&nbsp;Inc., located at 10E&nbsp;40th Street, 10th&nbsp;Floor, New York, New York&nbsp;10016, as our agent upon whom process may be served in any
action brought against us under the securities laws of the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Walkers
(Hong Kong), our counsel as to Cayman Islands law, and Tian Yuan Law Firm, our counsel as to PRC law, have advised us, respectively, that there is uncertainty as to whether the
courts of the Cayman Islands and China, respectively, would:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability
provisions of the securities laws of the United States or any state in the United States; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws
of the United States or any state in the United States. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have been advised by our Cayman Islands legal counsel, Walkers (Hong Kong), that the courts of the Cayman Islands are unlikely (i)&nbsp;to recognize or enforce against us judgments
of courts of the United States predicated upon the civil liability provisions of the securities laws of the United States or any State; and (ii)&nbsp;in original actions brought in the Cayman
Islands, to impose liabilities against us predicated upon the civil liability provisions of the securities laws of the United States or any State, so </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=111,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=970036,FOLIO='108',FILE='DISK103:[20ZDS1.20ZDS17601]CY17601A.;37',USER='CHE105542',CD='31-JAN-2021;23:44' -->
<A NAME="page_cy17601_1_109"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>far
as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United
States, the courts of the Cayman Islands, will, at common law, recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits of the
underlying dispute, based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain
conditions are met. For such a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine
or penalty nor inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and be of a kind the enforcement of which is,
contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands court may stay
enforcement proceedings if concurrent proceedings are being brought elsewhere. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PRC  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have been advised by Tian Yuan Law Firm, our PRC legal counsel, that there is uncertainty as to whether the courts of the PRC would enforce
judgments of United States courts or Cayman courts obtained against us or these persons predicated upon the civil liability provisions of the U.S. federal and state securities laws. Tian Yuan Law Firm
has further advised us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in
accordance with the requirements of the PRC Civil Procedures Law and other applicable laws and regulations based either on treaties between China and the country where the judgment is made or on
principles of reciprocity between jurisdictions. China does not have any treaties or other form of reciprocity with the United States or the Cayman Islands that provide for the reciprocal recognition
and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors and officers if they
decide that the judgment violates the basic principles of PRC law or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce
a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign shareholders may originate actions based on PRC law against a company in the
PRC, if they can establish sufficient nexus to the PRC for a PRC court to have jurisdiction, and meet other procedural requirements. However, it would be difficult for foreign shareholders to
establish sufficient nexus to the PRC by virtue only of holding the ADSs or ordinary shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=112,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=313350,FOLIO='109',FILE='DISK103:[20ZDS1.20ZDS17601]CY17601A.;37',USER='CHE105542',CD='31-JAN-2021;23:44' -->
<A NAME="page_cy17601_1_110"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cy17601_corporate_history_and_structure"> </A>
<A NAME="toc_cy17601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE HISTORY AND STRUCTURE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate History  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2011, Adagene&nbsp;Inc. was incorporated under the laws of the Cayman Islands as our offshore holding company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as our intermediary holding
company. In February 2012, Adagene Hong Kong incorporated Adagene (Suzhou) Limited, or Adagene Suzhou, in China, through which we commenced our research and development activities in China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2017, we established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct our research and development activities in the
United States to facilitate the discovery and development of product candidates and expand our global presence, we have further incorporated several subsidiaries overseas, such as Australia, Singapore
and Switzerland. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are a holding company and do not directly own any substantive business operations in the PRC. We currently focus our business operations within the PRC through Adagene Suzhou. We
(Adagene Inc.), however, hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. See "Risk
Factors&#151;Risks Related to Doing Business in the PRC." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following diagram illustrates our corporate structure as of the date of this prospectus, including our material subsidiaries: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g178576.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="297">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=113,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=932427,FOLIO='110',FILE='DISK103:[20ZDS1.20ZDS17601]CY17601A.;37',USER='CHE105542',CD='31-JAN-2021;23:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da17601_1_111"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17601_selected_consolidated_financial_data"> </A>
<A NAME="toc_da17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED CONSOLIDATED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following selected consolidated statements of operations data for the years ended December&nbsp;31, 2018 and 2019, summary consolidated
balance sheet data as of December&nbsp;31, 2018 and 2019 and summary consolidated cash flow data for the years ended December&nbsp;31, 2018 and 2019 have been derived from our audited consolidated
financial statements included elsewhere in this prospectus. Our consolidated financial statements are prepared in accordance with U.S.&nbsp;GAAP. The following selected consolidated statements of
comprehensive loss for the nine months ended September&nbsp;30, 2019 and 2020, selected consolidated balance sheet data as of September&nbsp;30, 2020 and selected consolidated cash flows data for
the nine months ended September&nbsp;30, 2019 and 2020 have been derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus and have been
prepared on the same basis as our audited consolidated financial statements and include all adjustments, consisting only of normal and recurring adjustments, that we consider necessary for a fair
statement of our financial position and operating results for the periods presented. Our historical results are not necessarily indicative of results expected for future periods. You should read this
Selected Consolidated Financial Data section together with our
consolidated financial statements and the related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selected Consolidated Statements of Comprehensive Loss Data  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents our selected consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2018 and
2019 and our selected unaudited interim condensed </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=114,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=350426,FOLIO='111',FILE='DISK103:[20ZDS1.20ZDS17601]DA17601A.;42',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_da17601_1_112"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>consolidated
statements of comprehensive loss data for the nine months ended September&nbsp;30, 2019 and 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the<BR>
Nine Months<BR>
Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenue:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Licensing revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Expenses:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,081</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,765</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,438</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,268</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,786</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,170</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,786</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(30,706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>712</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>613</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(138</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>902</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange gain (loss), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss before income tax</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other comprehensive income (loss):</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustments, net of nil tax</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(215</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,367</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,537</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(246</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to ordinary shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Weighted average number of ordinary shares used in per share calculation:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss per ordinary share</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=115,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=912321,FOLIO='112',FILE='DISK103:[20ZDS1.20ZDS17601]DA17601A.;42',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_da17601_1_113"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selected Consolidated Balance Sheet Data  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents our selected consolidated balance sheet data as of December&nbsp;31, 2018 and 2019 and our selected unaudited
interim condensed consolidated balance sheet data as of September&nbsp;30, 2020: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30,<BR>
2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in USD thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current assets:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>92,533</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>82,895</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 51,817</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>103,923</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>86,606</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 54,417</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>105,889</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>89,077</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current liabilities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts due to related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,674</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,896</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,574</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,789</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,331</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current liabilities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B><BR>
10,346</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B><BR>
7,181</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B><BR>
10,417</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total liabilities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B><BR>
10,488</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B><BR>
8,697</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B><BR>
13,610</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total mezzanine equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 84,955</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>154,201</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>154,387</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Shareholders' deficit:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares (par value of US$0.0001 per share; 500,000,000 and 500,000,000 shares authorized; 15,159,136, 15,193,136 and 16,466,897 shares issued and
outstanding as of December 31, 2018 and 2019 and September&nbsp;30, 2020, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Subscriptions receivable from shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,975</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,790</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(411</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(345</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,826</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(63,258</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(92,887</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total shareholders' deficit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> (41,027</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(57,009</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(78,921</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selected Consolidated Cash Flow Data  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents our selected consolidated cash flow data for the years ended December&nbsp;31, 2018 and 2019 and our selected
unaudited interim condensed consolidated cash flow data the nine months ended September&nbsp;30, 2019 and 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Nine Months<BR>
Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in USD thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18,154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(19,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash generated (used in) from investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(29,510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,856</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,942</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,434</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash generated from financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,694</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,097</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate on cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase in cash and cash equivalents</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,322</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,614</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the beginning of year/period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the end of year/period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,673</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,895 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=116,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=629748,FOLIO='113',FILE='DISK103:[20ZDS1.20ZDS17601]DA17601A.;42',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc17601_1_114"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc17601_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_dc17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>  AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations in
conjunction with the section entitled "Selected Consolidated Financial Data" and our consolidated financial statements and the related notes included elsewhere in this prospectus. This discussion
contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements
as a result of various factors, including those set forth under "Risk Factors" and elsewhere in this prospectus.</I></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel
antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity. These features enable our
novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. We
have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody
development. Our platform is designed to enable the rapid development of precision immunotherapy candidates, through the identification of predictive biomarkers for patient stratification and
preselection. We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional
antibody technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have developed our proprietary Dynamic Precision Library, or DPL, platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of
antibody sequences in particular, as a new paradigm for antibody drug discovery. Our DPL platform samples a potentially infinite number of dynamic binding interface structures arising from the
conformational diversity of a finite number of antibody amino acid sequences, allowing us to exponentially expand the universe of candidate antibody binding sites far beyond conventional natural or
synthetic antibody repertoires. By exploiting conformational diversity through the combination of our proprietary computational algorithms and artificial intelligence, we have designed and precisely
constructed approximately one trillion (10<SUP>12</SUP>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an antibody)
coverage and robust chemistry, manufacturing, and control, or CMC, attributes. Our DPL platform is designed to enable high fidelity translation from preclinical to clinical studies by identifying
antibodies well suited for broad species cross-reactivity against the transiently accessible epitopes of challenging targets. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
leveraging our proprietary DPL platform, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to
preclinical and clinical development. Our highly differentiated clinical-stage pipeline consists of ADG106, ADG126 and ADG116. We also have a robust preclinical pipeline in various stages of
development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
our inception in 2011, our operations have focused on organizing and staffing our company, conducting preclinical studies and clinical trials, business planning, establishing our
intellectual property portfolio and raising capital. We do not have any product candidates approved for sale and have not generated any revenue from product sales. We have financed operations mainly
through the private placements of our preferred shares. From November 2014 to December 2019, we raised an aggregate of US$155.5&nbsp;million of gross proceeds from issuance of our preferred shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
inception, we have incurred significant operating losses. Our net losses were US$15.3&nbsp;million and US$16.4&nbsp;million for the years ended December&nbsp;31, 2018 and
2019, respectively. For the nine months ended September&nbsp;30, 2020, our net loss was US$29.6&nbsp;million. As of September&nbsp;30, 2020, we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=117,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=110212,FOLIO='114',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dc17601_1_115"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>had
accumulated deficit of US$92.9&nbsp;million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase
significantly in connection with our ongoing activities, as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue advancement of and investment in our proprietary DPL platform; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advance the development of ADG106, ADG126, ADG116 and other preclinical drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue our ongoing and planned research and development of other lead product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discover and develop additional antibody product candidates and further expand our preclinical and clinical product pipeline; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain, expand and protect our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expand our collaborations with contract manufacturing organizations and contract research organizations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek regulatory approvals for any product candidates that successfully complete clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish sales and marketing teams and distribution network to commercialize any product candidate for which we may obtain regulatory
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attract, hire and retain additional clinical, scientific, management and administrative personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expand our operations globally; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> incur additional costs associated with operating as a public company upon the completion of this offering. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
in January&nbsp;2020, the emergence and wide spread of COVID-19&nbsp;has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in
the United&nbsp;States and China and elsewhere. Substantially all of our operating and workforce are based in the United&nbsp;States and China. Consequently, the COVID-19&nbsp;outbreak could
potentially delay patient's access to hospital and the progress of our clinical trials, including patient enrollment, which may adversely affect our business operations, financial condition and
operating results for 2020. The extent of the impact of the COVID-19&nbsp;pandemic on our business, operations and regulatory and commercialization timelines will depend on certain developments,
including the duration and spread of the outbreak and its impact on clinical trials, regulatory authorities and our key scientific and management personnel as well as its impact on our partners,
laboratory sites, and other third parties with whom we collaborate. See "Risk Factors&#151;Risks relating to obtaining regulatory approval of our drug candidates&#151;The
COVID-19&nbsp;pandemic could adversely impact our business, including our clinical trials." We will continue to actively monitor the rapidly evolving situation related to COVID-19
and may take further actions that alter our business operations, including those that may be required by government authorities, or that we determine are in the best interests of our employees,
partners and shareholders. At this point, the extent to which the COVID-19&nbsp;pandemic may impact our business, operations and regulatory and commercialization timelines remains uncertain. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Key Components of Results of Operations  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensing revenue.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our licensing revenue is currently comprised of royalties, milestone payments, license fees and reimbursement
income. Our
licensing and collaboration revenue for the years ended December&nbsp;31, 2018 and 2019 and the nine months ended September&nbsp;30, 2020 was primarily derived from granting licenses to use and
otherwise exploit certain of our intellectual properties. To date, we have not generated any revenue from the sale of products and do not expect to generate any revenue from product sales in the near
future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=118,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=756908,FOLIO='115',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dc17601_1_116"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and Development Expenses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our research and development expenses consist principally of (1)&nbsp;payroll and other related
costs of
personnel engaged in research and development activities, (2)&nbsp;costs related to pre-clinical testing of our technologies under development and clinical trials such as payments to contract
research organizations, or CRO, and contract manufacturing organization, or CMO, investigators and clinical trial sites that conduct the clinical studies; (3)&nbsp;costs to develop the product
candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, (4)&nbsp;other research and development expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the years ended December&nbsp;31, 2018 and 2019 and the nine months ended September&nbsp;30, 2019 and 2020, our research and development expenses were US$16.1&nbsp;million,
US$16.2&nbsp;million, US$11.5&nbsp;million and US$23.6&nbsp;million, respectively. The increase is primarily due to increased share-based compensation and expansion of staff and an increase in
contract manufacturing costs in light of the progression of the programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
research and development expenses may vary substantially from period to period according to the status of our research and development activities. The timing of expenses is impacted
by the commencement of clinical trials and enrollment of patients in clinical trials. Research and development expenses are expected to increase as we advance the clinical development of ADG106,
ADG126 and ADG116, and further advance the research and development of our other product candidates. The successful development of our product candidates is uncertain. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes our research and development expenses for our clinical-stage product candidates, preclinical product candidates and research pipeline for the years ended
December&nbsp;31, 2018 and 2019 and the nine months ended September&nbsp;30, 2019 and 2020, respectively. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Year<BR>
Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Nine<BR>
Months Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADG106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,145</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,742</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,609</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,528</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADG126</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,326</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,315</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADG116</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,329</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preclinical product candidates, research pipeline and others</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>16,081</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>16,212</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>11,518</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>23,568</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which
material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty
of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of manufacturing clinical supplies, and establishing commercial supplies, of any product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and characteristics of product candidates that we pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost, timing and outcomes of regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost and timing of establishing sales, marketing and distribution capabilities; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=119,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=500287,FOLIO='116',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dc17601_1_117"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms and timing of any collaboration, licensing or other arrangements that we may establish, including any required milestone and royalty
payments thereunder. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in the outcome of any of these variables with respect to the development of our product candidates or any other current or future product candidates could mean a significant
change in the costs and timing associated with the development of such product candidate. For example, if we are required to conduct additional clinical trials or other testing of any of our product
candidates beyond those that are contemplated or if we experience significant delays in enrollment in any clinical trials, we could incur significant additional costs and the clinical development
timeline for our product candidates may be delayed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative expenses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our administrative expenses consist primarily of wages, salaries and benefits for personnel other than
research and
development staff. We expect our administrative expenses to increase in absolute amount in the foreseeable future as we incur additional costs as a result of operating as a public company and as we
advance our product candidates through clinical development, which will also increase our general and administrative expenses. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest income  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income consists primarily of interest income derived from our term deposit. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income primarily includes government subsidies that Adagene Suzhou received from local government in the PRC. The receipt of such
government subsidies is not dependent on our performance of any obligations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Taxation  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cayman Islands  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, we are not subject to income, corporation or capital
gains tax in the Cayman Islands. In addition, our payment of dividends, if any, is not subject to withholding tax in the Cayman Islands. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our subsidiaries in Hong Kong, including Adagene (Hong Kong) Limited, our wholly-owned subsidiary, are subject to Hong Kong profits tax on their
activities conducted in Hong Kong at a uniform tax rate of 16.5%. Under Hong Kong tax law, our subsidiary in Hong Kong is exempted from income tax on their foreign-derived income and there is no
withholding tax in Hong Kong on remittance of dividends. No provision for Hong Kong profits tax was made as we had no estimated assessable profit that was subject to Hong Kong profits tax during
fiscal years 2019 or 2020. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PRC  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our subsidiaries in China are companies incorporated under PRC law and, as such, are subject to PRC enterprise income tax on their taxable
income in accordance with the relevant PRC income tax laws. Pursuant to the PRC Enterprise Income Tax Law, or EIT Law, which became effective on January&nbsp;1, 2008, a uniform 25% enterprise income
tax rate is generally applicable to both foreign-invested enterprises and domestic enterprises, except where a special preferential rate applies. In accordance with the implementation rules of EIT
Law, a qualified Technology Advanced Service Enterprises, or TASE, is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required
supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=120,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=574166,FOLIO='117',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dc17601_1_118"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
TASE certificate every year. Adagene Suzhou was first recognized as a qualified TASE in March 2015 and renewed in December 2018. Adagene Suzhou can enjoy the preferential tax rate of 15% from 2015
to 2021. In addition, the research and development expenses of Adagene Suzhou are subject to a 75% super-deduction for the income tax. The enterprise income tax is calculated based on the entity's
global income as determined under PRC tax laws and accounting standards. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are subject to VAT at a rate of 3%, 6%, or 13% on the services we provide and related surcharges. We are also subject to surcharges on VAT payments in accordance with PRC law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a Cayman Islands holding company, we may receive dividends from Adagene Suzhou. The PRC EIT Law and its implementing rules provide that dividends paid by a PRC entity to a nonresident
enterprise for income tax purposes is subject to PRC withholding tax at a rate of 10%, subject to reduction by an applicable tax treaty with China. Pursuant to the Arrangement between Mainland China
and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, the withholding tax rate in respect to the payment of dividends by a PRC enterprise to a
Hong Kong enterprise may be reduced to 5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least 25% of the PRC enterprise. Pursuant to the Notice of the State Administration
of Taxation on the Issues concerning the Application of the Dividend Clauses of Tax Agreements, or SAT Circular 81, a Hong Kong resident enterprise must meet the following conditions, among others, in
order to apply the reduced withholding tax rate: (i)&nbsp;it must be a company; (ii)&nbsp;it must directly own the required percentage of equity interests and voting rights in the PRC resident
enterprise; and (iii)&nbsp;it must have directly owned such required percentage in the PRC resident enterprise throughout the 12&nbsp;months prior to receiving the dividends. In August 2015, the
State Administration of Taxation promulgated the Administrative Measures for Nonresident Taxpayers to Enjoy Treatment under Tax Treaties, or SAT Circular 35, which became effective on
January&nbsp;1, 2020, 2015. SAT Circular 35 provides that nonresident enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced withholding
tax. Instead, nonresident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria to enjoy the tax treaty benefits are met, directly apply the
reduced withholding tax rate, and file necessary forms and supporting documents when performing tax filings, which will be subject to post-tax filing examinations by the relevant tax authorities.
Accordingly, Adagene (Hong Kong) Limited may be able to benefit from the 5% withholding tax rate for the dividends it receives from its PRC subsidiaries, if it satisfies the conditions prescribed
under SAT Circular 81 and other relevant tax rules and regulations. However, according to SAT Circular 81 and SAT Circular 35, if the relevant tax authorities consider the transactions or arrangements
we have are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable withholding tax in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a "resident enterprise" under the PRC EIT Law, it would be subject to
enterprise income tax on its worldwide income at a rate of 25%. See "Risk Factors&#151;Risks Related to Doing Business in China&#151;If we are classified as a PRC resident enterprise for
PRC
income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our consolidated results of operations for the periods presented. This information should be read together with
our consolidated financial statements and related notes </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=121,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=80065,FOLIO='118',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dc17601_1_119"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>included
elsewhere in this prospectus. The operating results in any period are not necessarily indicative of the results that may be expected for any future period. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Nine Months<BR>
Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenue:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Licensing revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Expenses:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,081</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,765</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,438</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,268</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total operating expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,786</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,170</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,786</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(30,706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>712</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>613</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(138</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>902</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange gain (loss), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss before income tax</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other comprehensive income (loss):</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustments, net of nil tax</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(215</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,367</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,537</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(246</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to ordinary shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Weighted average number of ordinary shares used in per share calculation:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss per ordinary share</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nine Months Ended September&nbsp;30, 2020 Compared to Nine Months Ended September&nbsp;30, 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Licensing revenue  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our licensing revenue increased from nil for the nine months ended September&nbsp;30, 2019 to US$0.3&nbsp;million for the nine months ended
September&nbsp;30, 2020. Our licensing revenue generated in the nine months ended September&nbsp;30, 2020 are a payment from Celgene (now Bristol-Myers Squibb), in connection with providing
certain sequences related to antibody discovery services to Celgene. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=122,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=23633,FOLIO='119',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dc17601_1_120"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the Nine Months Ended<BR>
September&nbsp;30 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except percentages)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Research and development expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll and other related costs of personnel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,349</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs related to clinical trials</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,869</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs related to preclinical testing</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs to develop the product candidates</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,173</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,414</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,054</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 11,518</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>100.0</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>%</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>23,568</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>100.0</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>%</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
research and development expenses increased by 104.6% from US$11.5&nbsp;million for the nine months ended September&nbsp;30, 2019 to US$23.6&nbsp;million for the nine months
ended September&nbsp;30, 2020, primarily attributable to (i)&nbsp;an increase of US$6.5&nbsp;million in payroll and other related costs of personnel primarily due to increased share-based
compensation and expansion of staff and (ii)&nbsp;an increase of US$4.6&nbsp;million in costs related to preclinical testing and clinical trials primarily due to increased contract manufacturing
costs in light of the progression of the programs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administrative expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our administrative expenses increased by 228.4% from US$2.3&nbsp;million for the nine months ended September&nbsp;30, 2019 to
US$7.4&nbsp;million for the nine months ended September&nbsp;30, 2020, primarily attributable to (i) an increase of US$1.5&nbsp;million in employee compensations due to an increase in average
payroll and an increase in the number of employees and (ii)&nbsp;an increase of US$2.9&nbsp;million in the share-based compensation expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Loss from operations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the foregoing, our loss from operations increased by 122.7% from approximately US$13.8&nbsp;million in the nine months ended
September&nbsp;30, 2019 to approximately US$30.7&nbsp;million in the nine months ended September&nbsp;30, 2020. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest income  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our interest income was US$0.6&nbsp;million for the nine months ended September&nbsp;30, 2020, as compared to US$0.7&nbsp;million for the
nine months ended September&nbsp;30, 2019, representing a decrease of US$0.1&nbsp;million. This decrease was primarily attributable to a decrease of cash balance and amount of short-term
investments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our other income increased from US$0.2&nbsp;million for the nine months ended September&nbsp;30, 2019 to US$0.7&nbsp;million for the nine
months ended September&nbsp;30, 2020, primarily attributable to (i)&nbsp;an increase in government subsidies received by Adagene Suzhou to support our ongoing operations in Jiangsu Province during
the nine months ended September&nbsp;30, 2020 and (ii)&nbsp;an
exclusivity payment from ADC Therapeutics pursuant to our collaboration arrangement with ADC Therapeutics, which is not related to our major operation activities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=123,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=115989,FOLIO='120',FILE='DISK103:[20ZDS1.20ZDS17601]DC17601A.;71',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de17601_1_121"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign exchange loss, net  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net foreign exchange loss decreased by 13.8% from US$67.7&nbsp;thousand for the nine months ended September&nbsp;30, 2019 to
US$77.0&nbsp;thousand for the nine months ended September&nbsp;30, 2020. This loss of foreign exchange was primarily attributable to the weakening of Renminbi against U.S. dollars which negatively
impacted our Renminbi denominated portfolio held by Adagene Suzhou. This improvement was primarily due to the positive effect of the fluctuation of Reminbi against U.S.&nbsp;dollars. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in fair value of warrant liabilities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recorded a gain from change in the fair value of warrant liabilities of US$1.2&nbsp;million for the nine months ended September&nbsp;30,
2019 and of nil for the nine months ended September&nbsp;30, 2020. The change was primarily because the warrants to subscribe Series&nbsp;C-2 Preferred Shares expired on April&nbsp;1, 2019. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net loss attributable to Adagene&nbsp;Inc.'s shareholders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the foregoing, our net loss for the period increased by 150.7% from US$11.8&nbsp;million for the nine months ended
September&nbsp;30, 2019 to US$29.6&nbsp;million for the nine months ended September&nbsp;30, 2020. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Year Ended December&nbsp;31, 2019 Compared to Year Ended December&nbsp;31, 2018  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Licensing revenue  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our licensing revenue decreased by 68.2% from US$1.5&nbsp;million in 2018 to US$0.5&nbsp;million in 2019. For the year ended
December&nbsp;31, 2018, we received a payment of US$1.5&nbsp;million from Guilin Sanjin Group&nbsp;Co.,&nbsp;Ltd., or Sanjin, pursuant to our out-licensing arrangement. The relevant rights
under the license were granted to Sanjin in 2018. For the year ended December&nbsp;31, 2019, we recognized a US$0.5&nbsp;million service fee received from Celgene in connection with providing
certain sequences related to antibody discovery services. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>
<!-- -->
US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except percentages)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Research and development expenses</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll and other related costs of personnel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,039</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,880</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs related to clinical trials</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,361</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs related to preclinical testing</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,726</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs to develop the product candidates</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,790</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,599</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,255</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,081</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=124,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=119568,FOLIO='121',FILE='DISK103:[20ZDS1.20ZDS17601]DE17601A.;51',USER='CHE105540',CD='29-JAN-2021;21:51' -->
<A NAME="page_de17601_1_122"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
research and development expenses remained relatively stable and increased by 0.8% from US$16.1&nbsp;million in 2018 to US$16.2&nbsp;million in 2019, which was mainly
attributable to an increase of clinical costs associated with the Phase&nbsp;I clinical trial of ADG106 and ADG116, partially offset by a decrease of contract manufacturing costs, due to ADG106's
advance from preclinical development stage into clinical trial stage. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administrative expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our administrative expenses increased by 24.3% from US$2.8&nbsp;million in 2018 to US$3.4&nbsp;million in 2019. The increase was primarily
due to the increase in the employee compensation due to a rise in average payroll and an increase in the number of employees. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Loss from operations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the foregoing, our loss from operations increased by 10.6% from approximately US$17.3&nbsp;million in 2018 to approximately
US$19.2&nbsp;million in 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest income  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our interest income was US$0.9&nbsp;million in 2019, as compared to US$0.7&nbsp;million in 2018, representing an increase of
US$0.2&nbsp;million. This increase was primarily attributable to the increase of the balance of fixed deposits. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our other income was US$0.7&nbsp;million in 2019, as compared to US$0.9&nbsp;million in 2018, representing a decrease of
US$0.2&nbsp;million. This decrease was primarily due to the decrease in government subsidies during the year of 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign exchange gain, net  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net foreign exchange gain increased by 72.2% from US$12.7&nbsp;thousand to US$21.9&nbsp;thousand, primarily attributable to further
appreciation of Renminbi against U.S. dollars in 2019 following 2018. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in fair value of warrant liabilities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recorded a gain from change in the fair value of warrant liabilities of US$0.5&nbsp;million and US$1.2&nbsp;million in 2018 and 2019,
respectively. The change in the fair value of warrant liabilities was primarily attributable to the change in fair value of warrants due to the passage of time as approaching to the expiration date of
the warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss attributable to Adagene&nbsp;Inc.'s shareholders  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the foregoing, our net loss increased by 7.6% from US$15.3&nbsp;million in 2018 to US$16.4&nbsp;million in 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since the inception, we have incurred net losses and negative cash flow from our operations. We do not expect to generate any revenue from
product sales unless and until we obtain regulatory approval and subsequently commercialize one of our current or future drug candidates. We expect to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=125,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=218902,FOLIO='122',FILE='DISK103:[20ZDS1.20ZDS17601]DE17601A.;51',USER='CHE105540',CD='29-JAN-2021;21:51' -->
<A NAME="page_de17601_1_123"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>incur
additional operating losses in the near future and our operating expenses will increase as we continue to expand our research and development capabilities, invest in preclinical tests and
clinical trials and increase our efforts in obtaining regulatory approvals. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant
commercialization expenses for product sales, marketing and manufacturing. Moreover, following the completion of this offering, we expect to incur additional costs associated with operating as a
public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor
relations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, we have financed our operations principally through proceeds from the issuance and sale of preferred shares in private placement transactions. For more information of our
equity financing, see "Description of Share Capital&#151;History of Securities Issuances." As of September&nbsp;30, 2020, we had US$82.9&nbsp;million in cash and cash equivalents. Our cash
and cash equivalents consist primarily of bank deposits and highly liquid investments, which have original maturities of three months or less when purchased. In February 2019, we entered into a
three-year bank facility agreement with Shanghai Pudong Development Bank, pursuant to which we are entitled to borrow up to RMB7.5&nbsp;million at a fixed annual interest rate of 5.46%, and as of
September&nbsp;30, 2020, the outstanding balance due under such facility was RMB5.9&nbsp;million. In June 2019, we entered into another three-year bank facility agreement with the same bank,
pursuant to which we are entitled to borrow up to RMB6.0&nbsp;million at a fixed annual interest rate of 5.23%, and as of September&nbsp;30, 2020, the outstanding balance due under such facility
was RMB5.4&nbsp;million. In addition, in June 2020, we borrowed a loan with amount of RMB10.0 million from Agricultural Bank of China Limited for a term of one year and at the interest rate of 4.20%
per annum. In September 2020, we borrowed a one-year term loan with amount of RMB5.0&nbsp;million from Bank of Ningbo&nbsp;Co., Ltd. at the interest rate of 4.20% per annum. In September 2020, we
also entered into a three-year bank facility agreement with Shanghai Pudong Development Bank, pursuant to which we are entitled to borrow up to RMB16.5&nbsp;million at a fixed annual interest rate
of 4.27%, as of September&nbsp;30, 2020, the outstanding balance due under such facility was RMB16.5&nbsp;million. In November 2020, we entered into two one-year term loans with amount of RMB5.0
million each from China Merchant Bank&nbsp;Co., Ltd. at the interest rate of 4.10% per annum, as of the date of this prospectus, the outstanding balance due under such facilities was RMB10.0
million.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to finance our future working capital requirements and capital expenditures primarily from funds raised from financing activities, including the net proceeds we will receive
from this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our current operating plan, we believe that our current cash and cash equivalents and proceeds from this offering will be sufficient to meet our current and anticipated working
capital requirements and capital expenditures for at least the next 12&nbsp;months. In that time, we expect that our expenses will increase substantially as we fund new and ongoing research and
development activities and working capital needs. The assumptions on which our estimates are based may prove to be wrong, and we may use our available capital resources sooner than we currently
expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital
outlays and operating expenditures necessary to complete the development and commercialization of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
utilizing the proceeds that we expect to receive from this offering, we may make capital contributions to our subsidiaries in PRC, the United States, Australia, Hong&nbsp;Kong,
Singapore and Switzerland, acquire or establish new subsidiaries, or give loans to our subsidiaries. However, uses of the proceeds by our PRC subsidiary are subject to PRC regulations. See "Risk
Factors&#151;Risks Relating to Doing Business in China&#151;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of
currency conversion may delay or prevent us </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=126,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=615812,FOLIO='123',FILE='DISK103:[20ZDS1.20ZDS17601]DE17601A.;51',USER='CHE105540',CD='29-JAN-2021;21:51' -->
<A NAME="page_de17601_1_124"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>from
using the proceeds of this offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and
expand our business." and "Use of Proceeds." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
operations are primarily based in China. A significant portion of our transactions are settled in Renminbi and our financial statements are presented in U.S. dollars. Under existing
PRC foreign exchange regulations, Renminbi may be converted into foreign currencies for current account items, including profit distributions, interest payments and trade- and service-related foreign
exchange transactions, without prior SAFE approval as long as certain routine procedural requirements are fulfilled. Our PRC subsidiary is allowed to pay dividends in foreign currencies to us without
prior SAFE approval by following certain routine procedural requirements. However, approval from or registration with competent government authorities is required where the Renminbi is to be converted
into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its discretion restrict access to
foreign currencies for current account transactions in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents our selected consolidated cash flow data for the years ended December&nbsp;31, 2018 and 2019 and the nine months ended September&nbsp;30, 2019 and 2020. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the<BR>
Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the<BR>
Nine Months<BR>
Ended<BR>
September 30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18,154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(19,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash (used in) generated from investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(29,510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,856</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,942</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,434</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash generated from financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,694</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,097</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate on cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,322</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,614</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at the beginning of year/period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the end of year/period</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,673</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,895 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating activities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities was US$20.0&nbsp;million in the nine months ended September&nbsp;30, 2020. The difference between our
net loss of US$29.6&nbsp;million and the net cash used in operating activities was mainly due to (i)&nbsp;an increase in prepayments and other current assets of US$1.8&nbsp;million due to our
prepaid service fees to our vendor, and (ii)&nbsp;a decrease in contract liabilities of US$0.1&nbsp;million, partially offset by (i)&nbsp;an increase in share-based compensation of
US$8.0&nbsp;million, (ii)&nbsp;an increase in accounts payable of US$0.5&nbsp;million (iii)&nbsp;a decrease in accounts receivable of US$0.5&nbsp;million and (iv)&nbsp;an increase in
accruals and other current liabilities of US$0.2&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was US$18.2&nbsp;million in 2019. The difference between our net loss of US$16.4&nbsp;million and the net cash used in operating activities was
mainly due to (i)&nbsp;a decrease in amount due to related parties of US$1.8&nbsp;million due to our payment of services fees to Wuxi Biologics, (ii)&nbsp;an increase in amount due from related
parties of US$0.7&nbsp;million, and (iii)&nbsp;change in fair value of warrant liabilities of US$1.2&nbsp;million, partially offset by depreciation and amortization of US$0.8&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was US$14.3&nbsp;million in 2018. The difference between our net loss of US$15.3&nbsp;million and the net cash used in operating activities was
mainly due to (i)&nbsp;an increase in prepayments and other current assets of US$1.3&nbsp;million, (ii)&nbsp;a decrease in accruals and other current liabilities of US$0.9&nbsp;million, and
(iii)&nbsp;a decrease in fair value of warrant liabilities of US$0.5&nbsp;million, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=127,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=671894,FOLIO='124',FILE='DISK103:[20ZDS1.20ZDS17601]DE17601A.;51',USER='CHE105540',CD='29-JAN-2021;21:51' -->
<A NAME="page_de17601_1_125"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>partially
offset by (i)&nbsp;an increase in amount due to related parties of US$2.1&nbsp;million, (ii)&nbsp;an increase in accounts payable of US$0.4&nbsp;million, and (ii)&nbsp;depreciation
and amortization of US$0.9&nbsp;million. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investing activities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash generated from investing activities was US$7.4&nbsp;million in the nine months ended September&nbsp;30, 2020, which was primarily
attributable to (i)&nbsp;withdrawal of short-term investments of US$8.0&nbsp;million and (ii)&nbsp;proceeds from disposal of property, equipment and software of US$0.01&nbsp;million, partially
offset by purchase of property, equipment and software of US$0.6&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash generated from investing activities was US$24.9&nbsp;million in 2019, which was primarily attributable to withdrawal of short-term investments of US$44.0&nbsp;million,
partially offset by placement of short-term investments of US$19.0&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in investing activities was US$29.5&nbsp;million in 2018, which was primarily attributable to placement of short-term investments of US$58.0&nbsp;million, partially
offset by withdrawal of short-term investments of US$29.0&nbsp;million. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financing activities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash generated from financing activities was US$3.1&nbsp;million in the nine months ended September&nbsp;30, 2020, which was mainly
attributable to proceeds from borrowings of US$4.5&nbsp;million, partially offset by repayment of borrowings of US$0.9&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash generated from financing activities was US$69.7&nbsp;million in 2019, which was mainly attributable to proceeds from issuance of convertible redeemable preferred shares and
warrants of US$69.0&nbsp;million, partially offset by repayment of borrowings of US$2.4&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash generated from financing activities was US$51.1&nbsp;million in 2018, which was mainly attributable to proceeds from issuance of convertible redeemable preferred shares and
warrants of US$50.0&nbsp;million, partially offset by repayment of borrowings of US$1.4&nbsp;million. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Capital Expenditures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our capital expenditures are incurred primarily in connection with research and development equipment. Our capital expenditures were
US$0.5&nbsp;million, US$0.2&nbsp;million and US$0.6&nbsp;million, respectively, in 2018, 2019 and the nine months ended September&nbsp;30, 2020. We intend to fund our future capital
expenditures with our existing cash balance and proceeds from this offering. We will continue to make capital expenditures to meet the expected growth of our business. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Commitments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our commitments as of December&nbsp;31, 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payments Due by Years Ending </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>1&nbsp;- 3&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3&nbsp;- 5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term and long-term borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,555</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,039</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Leases<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>257</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>174</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total commitments</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 2,812</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>1,213</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>1,599</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#151;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Operating
leases relate to certain office buildings under non-cancellable operating lease agreements. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=128,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=902266,FOLIO='125',FILE='DISK103:[20ZDS1.20ZDS17601]DE17601A.;51',USER='CHE105540',CD='29-JAN-2021;21:51' -->
<A NAME="page_de17601_1_126"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holding Company Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene&nbsp;Inc. is a holding company with no material operations of its own. Adagene&nbsp;Inc. holds certain intellectual properties and
outsources certain research and development activities related to these intellectual properties to its subsidiaries. We conduct our operations primarily through our subsidiaries. As a result, our
ability to pay dividends depends upon dividends paid by our subsidiaries. If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing
their debt may restrict their ability to pay dividends to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our subsidiary in China is permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with the Accounting Standards for
Business Enterprise as promulgated by the Ministry of Finance of the PRC, or PRC GAAP. Pursuant to the law applicable to China's foreign investment enterprise, our subsidiaries that are foreign
investment enterprises in the PRC have to make appropriation from their after-tax profit, as determined under PRC GAAP, to reserve funds including (i)&nbsp;general reserve fund,
(ii)&nbsp;enterprise expansion fund and (iii)&nbsp;staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in
accordance with PRC GAAP. Appropriation is not required if the reserve fund has reached 50% of the registered capital of our subsidiary. Appropriation to the other two reserve funds are at our
subsidiary's discretion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an offshore holding company, we are permitted under PRC laws and regulations to provide funding from the proceeds of our offshore fund raising activities to our PRC subsidiaries only
through loans or capital contributions, and to our consolidated affiliated entity only through loans, in each case subject to the satisfaction of the applicable government registration and approval
requirements. See "Risk Factors&#151;Risks Related to Doing Business in China&#151;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and
governmental control of currency conversion may delay or prevent us from using the proceeds of this offering to make loans or additional capital contributions to our PRC subsidiary, which could
materially and adversely affect our liquidity and our ability to fund and expand our business." As a result, there is uncertainty with respect to our ability to provide prompt financial support to our
PRC subsidiaries when needed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Commitments and Arrangements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not
entered into any derivative contracts that are indexed to our shares and classified as shareholder's equity or that are not reflected in our consolidated financial statements. Furthermore, we do not
have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk
support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or
product development services with us. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical Accounting Policies, Judgments and Estimates  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of presentation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S.&nbsp;GAAP. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principles of Consolidation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our consolidated financial statements include the financial statements of Adagene Inc. and its subsidiaries. All significant intercompany
balances and transactions have been eliminated upon consolidation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=129,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=342763,FOLIO='126',FILE='DISK103:[20ZDS1.20ZDS17601]DE17601A.;51',USER='CHE105540',CD='29-JAN-2021;21:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg17601_1_127"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of estimates  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting
periods. Significant estimates and assumptions reflected in our consolidated financial statements include, but are not limited to, the useful lives and impairment of long-lived assets, tax valuation
allowance, share-based compensation expenses and the fair value of warrant liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be
reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign currency translation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The functional currency of Adagene&nbsp;Inc., Adagene (Hong Kong) Limited and Adagene Incorporated is the U.S. dollar, or US$. The functional
currency of our PRC subsidiary is Renminbi, or RMB. The functional currency of our Australia subsidiary is Australian dollar, or AU$. The determination of the respective functional currency is based
on the criteria stated in Accounting Standard Codification, or ASC, 830, Foreign Currency Matters. We use US$ as our reporting currency. The financial statements of our PRC subsidiary and Australia
subsidiaries are translated from the functional currency to the reporting currency. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transactions
denominated in foreign currencies are re-measured into the functional currency at the exchange rates quoted by the People's Bank of China, or the PBOC, prevailing on the
transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in
terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements
of comprehensive loss. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets
and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and
losses are translated using the average rate for the year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in
the consolidated statements of comprehensive loss. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue recognition  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At contract inception of collaboration and out-licensing arrangement, we analyze the arrangements to assess whether they are within the scope of
ASC 808, </FONT><FONT SIZE=2><I>Collaborative Arrangements</I></FONT><FONT SIZE=2> or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are
both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC
808 that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied
consistently. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the criteria of </FONT><FONT SIZE=2><I>Accounting Standard Codification,</I></FONT><FONT SIZE=2> or ASC, 606, </FONT><FONT SIZE=2><I>Revenue from Contracts with
Customers</I></FONT><FONT SIZE=2> (Topic 606), or ASC 606, we recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the
consideration to which the entity expects to receive in exchange for those goods or services. We adopted ASC&nbsp;606 for all periods presented. To determine revenue recognition for arrangements
that an entity determines are within the scope of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=130,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=747748,FOLIO='127',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dg17601_1_128"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ASC&nbsp;606,
the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract;
(iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and
(v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect substantially
all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. We review the contract to determine which performance are distinct and represent a
promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. We recognize as revenue the amount of the transaction price that is allocated to
each performance obligation as and when that performance obligation is satisfied. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licenses of Intellectual Property</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;Upfront non-refundable payments for licensing our intellectual property are evaluated to determine
if the license
is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from non-refundable, up-front fees allocated to the
license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Milestone Payments</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;At the inception of each arrangement that includes development, commercialization, and regulatory milestone
payments, we evaluate
whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be
included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which
we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such
development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would
affect revenues and earnings in the period of adjustment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the
license is deemed
to be the predominant item to which the royalties relate, we recognize revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or
all of the royalty has been allocated has been satisfied (or partially satisfied). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, no milestone payments or royalty payments were received. Substantially all of our revenue has been derived from its out-licensing agreements with respect to licensed products
such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract assets and contract liabilities</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;When a customer pays consideration before we transfer products or services, we record our
obligation as a
contract liability; when we satisfy our performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, we recognize our
rights to consideration as a contract asset. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair value measurements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We apply ASC 820, </FONT><FONT SIZE=2><I>Fair Value Measurements and Disclosures</I></FONT><FONT SIZE=2>. ASC 820 defines fair value,
establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=131,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=943059,FOLIO='128',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dg17601_1_129"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>establishes
a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&#151;Observable
inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&#151;Includes
other inputs that are directly or indirectly observable in the marketplace. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&#151;Unobservable
inputs which are supported by little or no market activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC
820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&nbsp;market approach; (2)&nbsp;income approach; and (3)&nbsp;cost approach. The
market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to
convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the
amount that would currently be required to replace an asset. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
carrying amounts of cash and cash equivalent, short-term investments, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to
related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term
borrowings approximate their fair values since they bear interest rates which approximate market interest rates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
measured our warrant liabilities at fair value on a recurring basis. As our warrants are not traded in an active market with readily observable prices, we use significant unobservable
inputs to measure the fair value of warrant liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair
value measurement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents a reconciliation of all financial instruments measured at fair value on a recurring basis using Level&nbsp;3 unobservable inputs: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Warrant<BR>
liabilities </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial recognition during the year ended December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,741,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value change</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(534,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,207,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value change</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,207,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
did not transfer any assets or liabilities in or out of Level&nbsp;3 during the year ended December&nbsp;31, 2018 and 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&nbsp;31, 2018 and 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elements of research and development expenses primarily include (1)&nbsp;payroll and other related costs of personnel engaged in research and
development activities, (2)&nbsp;costs related to pre-clinical testing of our technologies under development and clinical trials such as payments to contract research organizations, or CRO, and
contract manufacturing organizations, or CMO, investigators and clinical trial sites that conduct the clinical studies; (3)&nbsp;costs to develop the product candidates, including raw materials and
supplies, product testing, depreciation and amortization, and facility related expenses, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=132,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=945455,FOLIO='129',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dg17601_1_130"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>(4)&nbsp;other
research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and
have no alternative future uses. As of December&nbsp;31, 2019, we have several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable,
with notice, at our option. We did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December&nbsp;31, 2019 as we did not have any plan to cancel the existing CRO
or CMO contracts. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We follow the liability method of accounting for income taxes in accordance with ASC 740, </FONT><FONT SIZE=2><I>Income
Taxes</I></FONT><FONT SIZE=2>, or ASC 740. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and
liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. We record a valuation allowance to offset deferred tax assets if based on the
weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized
in tax expense in the period that includes the enactment date of the change in tax rate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
evaluate our uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the
consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
recognize in the consolidated financial statements the benefit of a tax position which is "more likely than not" to be sustained under examination based solely on the technical merits
of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the
largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is our policy to recognize interest and penalties related to unrecognized tax
benefits, if any, as a component of income tax expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have incurred net accumulated operating losses for income tax purposes since our inception. We believe that it is more likely than not that these net accumulated operating losses will
not be utilized in the future. Therefore, we have provided full valuation allowances for the deferred tax assets as of
December&nbsp;31, 2018 and 2019. There was no income tax expense for the years ended December&nbsp;31, 2018 and 2019, as our subsidiaries did not have any taxable profits. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share-based compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We grant restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with
ASC 718, Compensation&#151;Stock Compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based
compensation awards are measured at the grant date fair value of the awards and recognized as expenses a)&nbsp;immediately at the grant date if no vesting conditions are
required; or b)&nbsp;for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c)&nbsp;for share-based awards granted with service
conditions and performance conditions, using the graded vesting method over the vesting period if and when the company concludes that it is probable that the performance conditions will be achieved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the
excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, we recognize
incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of the incremental compensation expense and the remaining unrecognized </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=133,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=363788,FOLIO='130',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dg17601_1_131"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compensation
expense for the original awards over the remaining requisite service period after modification. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the
input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, we have made reference to
historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would
decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is
based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. The
estimated fair value of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party appraiser. Our management is ultimately responsible for
the determination of the estimated fair value of its ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions used to estimate the fair value of the share options granted are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months<BR>
ended September&nbsp;30 </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year ended<BR>
December&nbsp;31, 2019 </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.78%-2.73%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.73%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.71%-0.83%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility range</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67.5%-71.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72.3%-73.1%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise multiple</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2-2.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2-2.8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual life</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10&nbsp;years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any
difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the
effective interest method. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Internal Control Over Financial Reporting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal
control over financial reporting. In connection with the audit of our consolidated financial statements as of and for the three fiscal years ended December&nbsp;31, 2018 and 2019, our independent
registered public accounting firm identified two material weaknesses in our internal control over financial reporting as at December&nbsp;31, 2019. As defined in standards established by the PCAOB,
a "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the
annual or interim financial statements will not be prevented or detected on a timely basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
two material weaknesses that have been identified related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S.&nbsp;GAAP and SEC
reporting and compliance requirements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our lack of sufficient documented financial closing policies and procedures, specifically those related to period end expenses cut-off and
accruals. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=134,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=942474,FOLIO='131',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dg17601_1_132"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
material weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
remediate our identified material weakness, we are in the process of adopting several measures to improve our internal control over financial reporting, including (i)&nbsp;hiring
more qualified accounting personnel, with relevant U.S.&nbsp;GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function and setting up a financial and system
control framework; (ii)&nbsp;implementing
regular and continuous U.S.&nbsp;GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel; and (iii)&nbsp;preparing comprehensive accounting
policies, manuals and closing procedures to improve the quality and accuracy of our period-end financial closing process. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that we will incur significant costs in the implementation of such measures. However, we cannot assure you that all these measures will be sufficient to remediate our material
weakness in time, or at all. See "Risk factors&#151;Risks Relating to Our Operations&#151;If we fail to implement and maintain an effective system of internal controls, we may be unable
to accurately or timely report our results of operations or prevent fraud, and investor confidence and the market price of our ADSs may be materially and adversely affected." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a company with less than US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an "emerging growth company" pursuant to the JOBS Act. An emerging growth company
may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation
requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, in the assessment of the emerging growth company's internal control over financial reporting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quantitative and Qualitative Disclosure about Market Risk  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest rate risk  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing
bank deposits. We have not used any derivative financial instruments to manage our interest risk exposure. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed,
nor do we anticipate being exposed, to material risks due to changes in interest rates. However, our future interest income may be lower than expected due to changes in market interest rates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign exchange risk  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global business enterprise with part of our operations based in the PRC. A part of our transactions were settled in Renminbi, and our
financial statements are presented in U.S. dollars. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to
hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in the ADSs will be affected by the exchange rate between
U.S. dollar and Renminbi because a portion of value of our business is effectively denominated in Renminbi, while the ADSs representing our ordinary shares will be traded in U.S. dollars. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
value of the Renminbi against the U.S. dollar and other currencies is affected by changes in China's political and economic conditions and by China's foreign exchange policies, among
other things. In July 2005, the PRC government changed its decades-old policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S.
dollar over the following three years. Between July 2008 and June 2010, this appreciation subsided and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since
June 2010, the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=135,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=96450,FOLIO='132',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_dg17601_1_133"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Renminbi
has fluctuated against the U.S. dollar, at times significantly and unpredictably. While appreciating approximately by 7% against the U.S. dollar in 2017, the Renminbi in 2018 depreciated
approximately by 5% against the U.S. dollar. Since October&nbsp;1, 2016, the US$ has joined the International Monetary Fund (IMF)'s basket of currencies that make up the Special Drawing Right (SDR),
along with the U.S. dollar, the Euro, the Japanese yen and the British pound. With the development of the foreign exchange market and progress towards interest rate liberalization and Renminbi
internationalization, the PRC government may in the future announce further changes to the exchange rate system and there is no guarantee that the RMB will not appreciate or depreciate significantly
in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in
the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that we need to convert U.S. dollars into Renminbi for our operations, appreciation of Renminbi against the U.S. dollar would reduce the Renminbi amount we receive from the
conversion. Conversely, if we decide to convert Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs, servicing our outstanding debt, or for other
business purposes, appreciation of the U.S. dollar against the Renminbi would reduce the U.S. dollar amounts available to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate that we will receive net proceeds of approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million from this offering, after deducting underwriting discounts and commissions and the
estimated offering expenses payable by us, based on the assumed initial offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the midpoint of the estimated initial public offering price range set forth
on the
front cover of this prospectus. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Inflation risk  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, inflation in China has not materially impacted our results of operations. According to the National Bureau of Statistics of
China, the year-over-year percent changes in the consumer price index for December 2018 and 2019 were increases of 1.9% and 4.5%, respectively. Although we have not in the past been materially
affected by inflation since our inception, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently Issued Accounting Pronouncements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For detailed discussion on recent accounting pronouncements, see Note&nbsp;2 to our Consolidated Financial Statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=136,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=747969,FOLIO='133',FILE='DISK103:[20ZDS1.20ZDS17601]DG17601A.;48',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di17601_1_134"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di17601_business"> </A>
<A NAME="toc_di17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OVERVIEW  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel
antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our
immunotherapy pipeline. These features enable our novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination
immunotherapy development in clinical settings. We have
pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development.
We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody
technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Life is motion</I></FONT><FONT SIZE=2>. The motion of proteins and their dynamic interactions trigger a cascade of complex biological and pharmacological effects.
Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino
acid sequence can adopt multiple structures and functions. Our approach recognizes that a protein's native state is not accurately represented by a single static structure but rather by a variety of
structures in dynamic equilibrium, resulting in a high level of functional diversity, in contrast to the conventional static antibody drug discovery paradigm of "one sequence, one structure and one
function." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have developed our proprietary AI-Powered DPL platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of antibody sequences in
particular, as a new paradigm for antibody drug discovery. Our DPL platform combines artificial intelligence, or AI, algorithms and ever-increasing big data in antibody sequence, structure, binding
epitope and affinity from public and our own proprietary databases to design, construct and screen high-quality proprietary antibody libraries with well-defined sequence, scaffold and biophysical
attributes for antibody drug discovery. Powered by computational physics in combination with AI and big data, our DPL platform samples a potentially infinite number of dynamic binding interface
structures arising from the conformational diversity of a finite number of antibody amino acid sequences, allowing us to exponentially expand the universe of candidate antibody binding sites far
beyond conventional natural or synthetic antibody repertoires. By exploiting conformational diversity, we have designed and precisely constructed approximately one trillion (10<SUP>12</SUP>)
antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an antibody) coverage and robust chemistry, manufacturing, and control, or CMC,
attributes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe our AI-powered antibody discovery and engineering DPL platform significantly increase R&amp;D productivity for antibody drug discovery, as illustrated by our clinical anti-CD137
and anti-CTLA-4 programs. DPL library screening against CD137 or CTLA-4 antigens has yielded a large number of high affinity primary hits. The abundant discovery hits with diversified binding epitopes
show the power of our AI-powered DPL platform not only in creating novel antibodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across different
species of a given antigen with broad species cross-reactivity from human, monkey to mouse, which enables us to study their efficacy and safety in extensive immuno-competent or syngeneic animal
models, to explore their pharmacodynamics and predictive biomarkers in responding vs nonresponding tumor models in vivo, and to understand their deep target biology and novel MOA before testing them
in human clinical trials to look for their clinical signals consistent with their MOA. Our DPL platform empowers us to engage the dynamic epitope of the conformationally dynamic target which might be
challenging using conventional antibody discovery approaches. We believe that the high-affinity and cross-reactive primary hits from our AI-Powered DPL library screening save time and cost from
discovery to early clinical

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=137,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=761998,FOLIO='134',FILE='DISK103:[20ZDS1.20ZDS17601]DI17601A.;118',USER='CHE105918',CD=';1-FEB-2021;05:01' -->
<A NAME="page_di17601_1_135"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


proof of concept. The broad species cross-reactivity of the primary hits also streamlines lead identification and potentially enables high fidelity translation from preclinical to clinical studies.
Furthermore, we believe our AI-powered dynamic precision library expands the diversity at the start of discovery to maximize the chance that suitable leads are found on the first pass.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Translational
fidelity from preclinical modeling to informed clinical development is one of the top challenges to developing cancer immunotherapies. Most traditionally developed
antibodies do not cross react between their human and murine targets due to their limited species cross-reactivity, making it very difficult to reliably evaluate the same antibody in both the
preclinical and clinical settings. Some of the most contentious issues related to preclinical and clinical studies of CD137 and CTLA-4, the targets of our lead product candidates, immunotherapies are
traceable to the differences between the antibodies used for preclinical and clinical studies. For example, according to Frost&nbsp;&amp; Sullivan, two of the leading clinical anti-CD137 agonist
antibodies bind to different epitopesc and exhibit dramatic differences in their respective clinical safety and efficacy results, underscoring the importance of finding suitable species cross-reactive
antibodies like those we have utilized for comprehensive preclinical evaluation before entering clinical trials. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that it is essential to model the interactions between tumors and an intact host immune system </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> to evaluate the
therapeutic potential of antibodies in preclinical studies. The flexibility of antibody binding interface is fundamental to the NEObody technology of our DPL Platform and allows us to generate species
cross-reactive antibodies to assess the safety and efficacy potential of mono- and combination therapy candidates in syngeneic animal models before launching clinical trials. We use syngenic animal
models which are known for their intact </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> immune systems to provide the original proof of concept for cancer immunotherapies by blocking immune
check points with monoclonal antibodies, or mAbs. We believe that the use of species cross-reactive antibodies, rather than surrogate antibodies used in traditional syngeneic mouse models, should
facilitate the translational relevance and clinical utility of these well-established preclinical models for determining optimal dose, schedule, sequencing, combination synergy, risk and benefit
features. The results from the assessment of new species cross-reactive antibodies in rigorous preclinical models may allow us to control the scope and cost of clinical trials, enable the
identification of potential clinical biomarkers useful to monitor clinical pharmacological and safety signals, and help preselect patients for precision mono- and combination therapies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
figure below illustrates how our DPL platform integrates our computational algorithm-enabled high-throughput screening and functional antibody evaluation for preclinical candidates
suitable for clinical development as explained above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=138,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=490177,FOLIO='135',FILE='DISK103:[20ZDS1.20ZDS17601]DI17601A.;118',USER='CHE105918',CD=';1-FEB-2021;05:01' -->
<A NAME="page_di17601_1_136"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<BR>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g762069.jpg" ALT="GRAPHIC" WIDTH="660" HEIGHT="367">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
DPL platform is further composed of three proprietary enabling technologies tailored to three key attributes of antibody-based therapeutic modalities: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> NEObody technology is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated
from other synthetic antibody technologies through its innovative designs and precise constructions. NEObody technology enables the generation of antibodies designed with dynamic binding sites that
adapt kinetically to unique epitopes, triggering a novel MOA. The species cross-reactive antibodies generated by NEObody technology not only have the potential to reveal new biological functions of
the targets, but also facilitate preclinical studies using various immune system intact animal models, resulting in high fidelity translation from preclinical to clinical studies. We refer to
antibodies generated by our NEObody technology as NEObodies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> SAFEbody technology is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its
target in healthy tissues. The masking motif is designed to activate, or unmask, the antibody to allow binding in the tumor microenvironment, or TME, where certain activation conditions such as a
protease is upregulated as compared to healthy tissues, allowing the antibody to bind to its target for tumor killing. Our SAFEbody enabled therapeutic candidates are therefore designed to be
activated predominantly in the TME while remaining largely in an inactive state in healthy tissues. Our SAFEbody technology can be applied to mask the binding sites of any antibodies including but not
limited to NEObodies. We refer to such masked antibodies including NEObodies as SAFEbodies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> POWERbody technology, which enables the creation of new versions of bispecific T-cell engagers, or TCEs, with enhanced safety profiles,
antibody-drug conjugates, or ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> SAFEbody technology can be applied to our NEObodies, such as what we did with ADG116 to convert into ADG126. POWERbody is created by applying
the SAFEbody technology to a bispecific TCE in either CD3 or both in CD3 and antigen binding arms to enhance the safety profile. Our POWERbody technology is designed to improve antitumor activity
while maintaining the enhanced safety profile. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=139,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=746302,FOLIO='136',FILE='DISK103:[20ZDS1.20ZDS17601]DI17601A.;118',USER='CHE105918',CD=';1-FEB-2021;05:01' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk17601_1_137"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We believe that comprehensive </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> preclinical evaluations are the key to assess the efficacy and safety potential of
tailor-made antibody candidates before progressing them into lengthy and costly clinical trials. NEObody, SAFEbody and POWERbody technologies are all designed to facilitate favorable druggability,
manageable CMC attributes, and reduced immunogenicity. As highlighted by our lead product candidates, such as ADG106, ADG126 and ADG116, our NEObody technology allows us to engineer and select species
cross-reactive NEObodies designed to dynamically adapt to unique and evolutionally conserved epitopes. ADG126 has been further engineered using our SAFEbody technology to address the safety concerns
associated with existing CTLA-4 therapeutics. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
figure below shows how our NEObody, SAFEbody, and POWERbody technologies on the one hand and DPL platform on the other hand are inter-connected and utilized for the building of our
product pipeline of mono- and combination immunotherapies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g609923.jpg" ALT="GRAPHIC" WIDTH="328" HEIGHT="333">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=1>Notes: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Antibodies generated by NEObody technology, which are designed with dynamic binding sites that adapt kinetically to unique
epitopes, triggering a novel MOA.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>NEObodies or traditional antibodies are masked in their binding sites by SAFEbody technology as shown by the blocking bar in
the antibody binding sites in the figure, which are designed to be selectively activated in the TME, potentially limiting on-target off-tumor toxicity in normal tissues.  </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Multiple potent modalities, including bispecific T-cell engagers, ADC, and Fc engineering for enhanced ADCC, etc., are masked
in their binding sites by SAFEbody to create a POWERbody.</FONT>

</DD>

</DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
most advanced NEObody product candidate, ADG106, is a fully human ligand-blocking agonistic anti-CD137 mAb currently being evaluated in Phase Ib clinical trials in the United States
and China. ADG106 is designed to target a unique epitope of CD137 that is different from other anti-CD137 antibodies currently under clinical development. Epitope mapping and X-ray structural analysis
of ADG106 with CD137 have shown in preclinical studies that ADG106 is capable of binding to CD137 in a fashion similar to its natural ligand, CD137L. Our first SAFEbody product candidate, ADG126, is a
fully human anti-CTLA-4 masked antibody designed to address the safety concerns associated with existing CTLA-4 therapeutics. It is designed to enhance the safety features by masking the antibody
binding site of ADG126, which would be unmasked in the TME, where the activated ADG126 would block CTLA-4 and deplete regulatory T-cells by means of enhanced antibody- </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=140,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=597282,FOLIO='137',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_138"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>dependent
cellular cytotoxicity, or ADCC. In preclinical studies, ADG126 was tolerated at doses of up to 200&nbsp;mg/kg in nonhuman primate models. As ADG126&nbsp;is also species cross-reactive in
humans, cynomolgus monkeys and mice, we believe that preclinical studies of ADG126&nbsp;will support the rational design of clinical trials to expedite its development. Our third product candidate,
ADG116, is a fully human anti-CTLA-4 NEObody. Epitope mapping and X-ray structural analysis have shown that in preclinical studies, ADG116 is capable of binding to a novel epitope of CTLA-4 different
from ipilimumab, the only CTLA-4 mAb approved globally. The dynamic interface of ADG116 enabled not only its species cross-reactivity with human, cynomolgus monkey, and mouse CTLA-4 for preclinical
studies, but also its dynamic engagement on a unique epitope of CTLA-4 to trigger a novel MOA distinct from ipilimumab by softer ligand blocking and stronger regulatory T-cell depletion via strong
ADCC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
species cross-reactive ADG106, ADG126 and ADG116 have enabled a deep understanding of the interaction between tumor and host immune system </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> in syngeneic animal models. This understanding has been utilized to design and guide the clinical development of rational, mechanism-based mono- and combination therapies
using ADG106, ADG126 and ADG116. Because there is limited clinical safety and efficacy data available for anti-CD137 agonists, we have followed our preclinical and mechanistic study for the clinical
development of ADG106. We observed three patients with Grade&nbsp;3 liver enzyme increase; among them, one patient with abnormal liver enzyme baseline showed a Grade&nbsp;3 AST increase. ADG106
showed preliminary clinical antitumor activity in patients who have progressed after several lines of treatment in our completed Phase Ia dose escalation and ongoing Phase Ib dose expansion trials in
the United States and China. It is very encouraging to observe the clinical response in connection with the changes in PD biomarkers due to target engagement in a dose dependent manner. We have also
observed a correlation with a potential predictive biomarker for patient selection in three patients with more than 30% tumor shrinkage across different indications in retrospective analysis in our
ongoing Phase I trials. This predictive biomarker is related to the CD137 pathway. We intend to further explore this predictive biomarker in order to guide our development of precision mono- and
combination immunotherapies based on our preclinical and preliminary clinical data. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Pipeline  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By leveraging our proprietary DPL platform, we have developed a robust pipeline of innovative product candidates in various stages of
development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated clinical-stage pipeline consists of ADG106, ADG126 and ADG116. We also have a robust
preclinical pipeline in various stages of development. In addition, we have out-licensed the Greater China rights of ADG104, a PD-L1 mAb
under clinical development, to our partner, Sanjin. We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 in the rest of the world and we retain a
majority of the economic benefits derived from ADG104 in the rest of the world. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=141,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=428387,FOLIO='138',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_139"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following chart provides an overview of the status of each of our clinical-stage and IND-enabling study stage programs at clinical or IND-enabling stages, for which we have global
rights. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g340646.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="325">
  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG106: Novel agonistic anti-CD137 NEObody candidate  </I></B></FONT></P>


</UL>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG106, is a fully human ligand-blocking, agonistic anti-CD137 immunoglobulin G4, or IgG4, mAb generated using our NEObody technology. ADG106 is
being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. CD137 stimulates the immune system to attack cancer cells and is a key driver for T-cell and natural
killer cell, or NK cell, proliferation. ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like binding and cross-linking by
Fc<FONT FACE="SYMBOL">g</FONT> receptors. The broad species cross-reactivity of ADG106 observed in preclinical studies has enabled us to explore robust translational studies concerning the
biology of CD137 in mouse, rat, nonhuman primate, and human, especially for anti-CD137 as a single agent and in combination therapies in immuno-competent syngeneic tumor models. In preclinical studies
to date, we observed that ADG106 had encouraging antitumor activity and was well tolerated as a monotherapy and in combination with the existing standard-of-care, or SOC, and other immuno-oncology
therapies, which was confirmed in the Phase&nbsp;I clinical trials in cancer patients as a monotherapy. These data indicate that ADG106 has the potential to address the limitations of other existing
anti-CD137 therapies.

 </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the November&nbsp;30, 2020, the Data Cut-off Date, we have completed the Phase&nbsp;Ia dose escalation in each of our Phase&nbsp;I studies of ADG106 in both the
United&nbsp;States and China as a monotherapy in patients with advanced or metastatic solid tumors and/or NHL. We are currently in the Phase&nbsp;Ib dose expansion phase for both trials in the
United States and China. ADG106 was dose escalated up to 10&nbsp;mg/kg and is well tolerated at dose expansion at 3&nbsp;mg/kg, 5 mg/kg and at 300mg and 400 mg flat doses. A total number of 92
patients have been dosed. Both clinical trials, namely ADG106-1001 and ADG106-1002, have limited Treatment Emergent Adverse Effects, or TEAEs, liver toxicity or hematologic abnormalities. We observed
three&nbsp;patients with <FONT FACE="SYMBOL">&#179;</FONT>Grade&nbsp;3 liver enzyme increase; among them, one patient with abnormal liver enzyme baseline showed a Grade&nbsp;3 AST
increase. Two patients developed hemolytic anemia in ADG106-1002 which were controlled; one of the two patients received prior therapies which were known to cause autoimmune hemolytic anemia. One
patient with a solid tumor who previously failed chemotherapies, radiotherapy, and an anti-PD-L1 related antibody treatment showed a partial response to ADG106 treatment with a 40% tumor size
reduction after two </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=142,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=393752,FOLIO='139',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_140"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>treatment
cycles. In addition, two NHL patients showed more than a 30% tumor size reduction after one and two ADG106 treatment cycles, respectively. Furthermore, biomarker studies showed target
engagement with specific PD biomarkers indicative of immune system activation, and clinical response correlated with changes in CD137 target engagement. These data are encouraging given that the
enrolled population was not preselected and was heavily pretreated. We have identified a potential predictive biomarker which correlates with patient response to ADG106 treatment from a retrospective
analysis of the ongoing Phase&nbsp;I clinical trial. Based on this finding, we are in the process of preparing an additional Phase&nbsp;II trial which we expect to initiate in 2021 and for which
we intend to stratify and preselect patients using this predictive biomarker to potentially enhance clinical response of patients to ADG106 treatment. We also plan to pursue potential registrational
trials evaluating ADG106 in biomarker enriched patient populations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also evaluated ADG106 in combination with other therapies including chemotherapies, immune modulators, and immuno-oncology therapies in preclinical studies. Data from combination
studies in tumor bearing mice showed that the combination of ADG106 with immune checkpoint inhibitors, including an anti-PD-1/L1 mAb or anti-CTLA-4 mAb, enhanced </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> antitumor activity. We plan to explore the combination of ADG106 with other targeted antibody therapies for the treatment of hematologic malignancies and solid tumors. We
also have identified tumor-specific biomarkers that we believe may correlate with ADG106 antitumor activity in multiple mouse tumor models. These preclinical study findings are consistent with the
interim results from our ongoing Phase Ib clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Going
forward, we are focusing on evaluating combinations of ADG106 with various therapies in clinical trials. We have received NMPA approval for the ADG106-1008 study in China, which is
a Phase&nbsp;Ib/II combination trial of ADG106 with anti-PD-1 in advanced solid tumors and hematological malignancies. We are also in the preparation for a submission of a Clinical Trial
Notification, or CTN,
for our ADG106-1003 clinical trial in Australia, which will combine ADG106 with anti-PD-1, and other therapies in advanced solid tumors and hematological malignancies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have observed responses to ADG106 in all three T cell lymphoma patients enrolled in the ADG106-1002 Phase I trial. We are enrolling additional patients in our ADG106-1002 trial and
will conduct an investigator initiated trial in the United&nbsp;Sates to further explore ADG106 as a monotherapy and in combination with other therapies in T cell lymphoma. We expect to submit an
Orphan Drug Designation application to the FDA for ADG106 requesting for an expedited regulatory pathway for this indication.

</FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG126: Novel anti-CTLA-4 SAFEbody candidate  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our most advanced SAFEbody program, ADG126, is a masked fully-human anti-CTLA-4 mAb engineered to address the safety concerns associated with
existing CTLA-4 therapeutics, while maintaining potency when locally activated in the TME. The FDA approval of ipilimumab validated anti-CTLA-4 for cancer treatment. However, due to its on-target
off-tumor toxicity, the approved indications for ipilimumab are limited, which we believe has caused sales of ipilimumab to trail other immuno-oncology therapies such as anti-PD-1/L1 antibodies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG126
is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target
for the treatment of cancer. In preclinical studies, ADG126 was tolerated at doses of up to 200 mg/kg in nonhuman primate models. We believe the encouraging preclinical tolerability of ADG126 suggests
its potential in combination with other immunotherapies such as an anti-PD-1/PD-L1 antibody or an anti-CD137 antibody, including ADG106. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To better address the unmet clinical need for a safe and potent anti-CTLA-4 antibody for chemotherapy-free mono- and combination immunotherapy, we have submitted a CTN and received

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=143,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=339375,FOLIO='140',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_141"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


HREC approval for an ADG126 Phase&nbsp;I dose escalation trial in Australia and are expecting to commence patient enrollment by February 2021. We also have received approval from the FDA to initiate
the Phase&nbsp;I clinical trial of ADG126 in the United States in 2021. These two Phase I dose escalation trials will test five doses at 0.1,
<FONT FACE="SYMBOL">&#163;</FONT>0.3, <FONT FACE="SYMBOL">&#163;</FONT>1, <FONT FACE="SYMBOL">&#163;</FONT>3, and <FONT FACE="SYMBOL">&#163;</FONT>10 mg/kg,
based on our preclinical primate toxicity study in comparison with ipilimumab. We anticipate that these clinical trials will allow us to determine the ADG126 effective dose in late 2021. Meanwhile, we
are preparing IND submissions to initiate ADG126 clinical trials in China.

 </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG116: Novel anti-CTLA-4 NEObody candidate  </I></B></FONT></P>


</UL>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG116 is a fully-human ligand-blocking anti-CTLA-4 mAb generated using our NEObody technology. ADG116 is designed to target a unique conserved
epitope of CTLA-4. In preclinical studies, ADG116 was observed to have softer CTLA-4 ligand blocking and stronger ADCC for depleting regulatory T-cells than ipilimumab. In a head-to-head </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>
efficacy study, ADG116 was observed to have a five-fold greater anti-tumor activities in comparison with ipilimumab. In addition, ADG116 was
observed to induce antitumor responses concomitant with reduced immunosuppressive regulatory T-cell and enhanced cytotoxic T lymphocyte (CD8<SUP>+</SUP> T-cells) activities in the TME. We believe
that these preclinical results support the further clinical evaluation of ADG116 both as monotherapy and combination therapy for a wide range of tumor types.

 </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of January&nbsp;15, 2021, we have successfully completed dose escalation at the first&nbsp;three&nbsp;doses in ADG116-1003 clinical trial in Australia, including dose level at
0.03mg/kg, the dose level used for the first patient who suffered a fatal incident in the ADG116 Phase&nbsp;I trial in the United States. As of January&nbsp;15, 2021, no dose limiting toxicity or
treatment related serious adverse events have been observed in any of the patients treated. There was no treatment induced liver toxicity and all three patients treated at 0.03mg/kg showed normal
liver enzyme level post ADG116 treatment. The Safety Review Committee approved dose escalation for ADG116-1003 clinical trial to 0.1mg/kg. The ADG116-1001 Phase&nbsp;I trial in the United States was
placed on clinical hold on September&nbsp;30, 2019 by the FDA, after we reported to the FDA the death of the only patient dosed in the trial. The FDA removed the clinical hold on December&nbsp;5,
2019 after we submitted an amendment to the study protocol. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Global Partnerships and Collaborations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have a successful track record of collaborations and partnerships with global biopharmaceutical companies and academic institutions. So far,
we have established multiple collaboration programs and will continue to seek partnership opportunities where we can leverage our proprietary technology platform to develop novel antibodies to address
unmet medical needs. Over the
past two years, we have established partnerships and collaborations with multiple biopharmaceutical companies. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We entered into a material transfer and collaboration and license agreement with ADC Therapeutics&nbsp;SA, or ADC Therapeutics, under which
ADC Therapeutics intends to use our SAFEbody technology to generate a masked antibody that could be combined with the pyrrolobenzodiazepine cytotoxic payload technology used in ADC Therapeutics' ADCs
for the development of a novel ADC against a solid tumor target. Under the agreement, we could be eligible to receive royalty payments and could have an exclusive option to negotiate a license to
develop and commercialize co-developed assets in certain territories; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We are also collaborating with Guilin Sanjin Pharmaceutical&nbsp;Co.,&nbsp;Ltd., or Sanjin, and its affiliates to develop two different
monoclonal antibodies with the first being ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase&nbsp;II clinical trials concurrently in China, and the second being an
undisclosed monoclonal antibody, which Sanjin and its affiliates have recently filed an IND application that has been accepted by the NMPA; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=144,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=68239,FOLIO='141',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_142"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have recently extended the term of our research collaboration agreement, or the NIH RCA, with the National Heart Lung and Blood Institute,
part of the National Institutes of Health, or NIH, to 2023. We first entered into the NIH RCA in March 2018 to collaborate with Dr.&nbsp;Richard Childs, Chief of the Laboratory of Transplantation
Immunotherapy at NHLBI, who has used antibodies discovered by us to develop a CAR-T cell therapy candidate targeting a human endogenous retrovirus expressed in the majority of clear cell kidney
tumors. The extension of the NIH RCA will allow us to use our proprietary antibody technology to further collaborate with Dr.&nbsp;Richard Childs and his team to develop other antibodies; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We entered into a collaboration and license agreement with Exelixis,&nbsp;Inc., or Exelixis, under which Exelixis will utilize our SAFEbody
technology platform to generate masked versions of mAbs from Exelixis' growing preclinical pipeline for the development of ADCs or other innovative biologics against Exelixis-nominated targets. Under
the agreement, we could be eligible to receive upfront payment as well as milestone and royalty payments on net sales of any potential products developed around each of these targets.

 </FONT></DD>

</DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also working with global biopharmaceutical companies to potentially develop additional strategic partnerships.</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We had recently worked with Celgene (now Bristol-Myers Squibb) to discover antibodies targeting novel antigens using our proprietary DPL
platform; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Under a material transfer agreement, we are developing SAFEbody drug conjugates against a tumor target selected by Tanabe Research
Laboratories,&nbsp;Inc., or TRL, with potential for negotiating a future license agreement with TRL if our pilot work proves successful; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We recently entered into an evaluation agreement with a global biotechnology company, or the Evaluation Agreement, under which we are
developing bispecific antibodies leveraging our SAFEbody and bispecific technologies against tumor targets provided by the counterparty. The Evaluation Agreement could facilitate the parties' interest
in a further collaboration concerning the development of a new antibody therapeutic; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We had previously collaborated with GlaxoSmithKline (China), or GSK China, where we were engaged to generate high affinity antibodies against
multiple epitopes of multi-transmembrane targets; and we previously worked with Jiangsu Hengrui Medicine Company Limited, or Jiangsu Hengrui, where we were able to discover cross-reactive agonistic
antibody for immuno-oncology. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Team and Investors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were founded in 2011 by Dr.&nbsp;Peter Luo and is led by an experienced management team. Dr.&nbsp;Luo, who previously founded the
biopharmaceutical company Abmaxis which was subsequently acquired by Merck, has a proven track record of more than two decades in antibody discovery and engineering using a multidisciplinary approach
that combines computational and experimental technology based on physical, chemical, and biological sciences. Our management team is composed of industry veterans with extensive experience in
therapeutic antibody research and development and collectively has decades of experience in molecular biology, immunotherapy, immunology, antibody discovery, protein engineering, and clinical
development. Our management team brings a strong history of leadership, innovation, and research and development experience at leading companies, including Merck/Abmaxis, Affomix/Illumina, Amgen,
AnaptysBio, Bristol-Myers Squibb, Celgene, Corixa, Forty&nbsp;Seven Inc., Xencor, Novartis, Pfizer, Prometheus, Quanticel, and Teva Biopharmaceuticals. Our company is further supported by a strong
group of investors that share our commitment to developing next-generation immuno-oncology therapies for the treatment of cancers. Our investors include leading institutional investors such as
F-Prime, Eight Roads, General Atlantic,&nbsp;GP Healthcare Capital, Sequoia China and Wuxi AppTec. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=145,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=59823,FOLIO='142',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_143"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OUR STRATEGIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are utilizing our proprietary DPL platform to design, construct and develop novel immunotherapies and precision antibodies to address unmet
patient needs globally. Our strategy encompasses the following key elements:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Advance clinical development of our lead product candidates, ADG106, ADG126 and ADG116, as monotherapies and in
combination with other therapies.</I></B></FONT><FONT SIZE=2> We have completed the Phase&nbsp;Ia dose escalation of our ADG106 Phase Ia clinical trials in both the United States and China and are
expanding our clinical trials in Phase Ib to patients in sensitive tumor types based on clinical and preclinical observations. We have also secured regulatory approval for combination studies in China
and are in process of preparing for biomarker-driven Phase&nbsp;II global trials. We have obtained authorization from the Australian Therapeutic Goods Administration under a CTN for ADG126, our
second-generation CTLA-4 antibody that is designed to activate in the TME, for a Phase&nbsp;I trial in Australia and expect to commence patient enrollment by February 2021. We also have received
approval from the FDA to initiate the Phase I clinical trial of ADG126 in the United States in 2021. We expect both trials to support our global development for our SAFEbody ADG126. In addition, we
obtained authorization from the Australian Therapeutic Goods Administration under a CTN to start a Phase&nbsp;I trial of ADG116 in July 2020. Five patients at three different dose levels were
subsequently dosed. We intend to use clinical data collected from the Australia trial to facilitate effective clinical development in the United States. We intend to continue to explore the use of our
product candidates as monotherapies by focusing on different tumor types and as combination therapies by conducting combination studies with various immuno-oncology agents, such as an anti-PD-1/L1
mAb. We are planning to expand the cohorts in our clinical trials with patients with responsive cancer types or biomarker enriched patients to seek expedited development in the United States and
China. We plan to further assess the combination of ADG106 and an anti-PD-1/L1 mAb, or anti-CTLA-4 mAb for the treatment of solid tumors and hematologic malignancies in a clinical setting. We intend
to build a CTLA-4&nbsp;franchise by exploring the use of our product candidates as tolerable and potent monotherapies and in combination therapies with other cancer therapies, such as chemotherapy,
targeted small molecule drugs, multiple-tyrosine kinase inhibitor drugs and other immune checkpoint inhibitors. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Develop a deep and broad pipeline of promising antibodies using NEObody<SUP>TM</SUP>, SAFEbody<SUP>TM</SUP> and
POWERbody<SUP>TM</SUP> technologies and advance into preclinical and clinical development.</I></B></FONT><FONT SIZE=2> We plan to continue to leverage our proprietary DPL platform to generate and
select a broad clinical pipeline of novel and potentially differentiated product candidates with the goal of submitting more than ten INDs or equivalent applications in the next three to five years.
We are also planning to conduct a basket trial to explore the synergistic effects of our product candidates in combination with other therapeutic agents, such as PD-1 or PD-L1 antibodies, to expand
the market opportunity of our pipeline. We intend to prioritize product candidates based on a range of factors, including strength of preclinical data, potential for development as both a monotherapy
and in combination with other therapies, clinical benefit, efficiency of clinical development paths and commercial market opportunities. In particular, we plan to leverage our differentiated NEObody,
SAFEbody and POWERbody technologies to build a rich pipeline of product candidates with improved product profiles (e.g., enhanced safety and/or efficacy and/or dosing convenience such as less frequent
subcutaneous injections) over existing therapies or targeting novel MOA.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Leverage our technology to develop our pipeline and strengthen our DPL
platform.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We intend to exploit the conformational diversity of antibody discovery through the combination of our proprietary computational
biology algorithms and artificial intelligence to design and discover leading oncology immunotherapies with differentiated product profiles. Leveraging our </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=146,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=950126,FOLIO='143',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_144"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>technology
together with our expertise in immuno-oncology and targeted therapy, we plan to build a rich pipeline of immuno-oncology antibody candidates directed against both clinically validated as
well as potentially novel targets designed to overcome safety or efficacy deficiencies in the current standard-of-care. For example, we are advancing multiple NEObody and SAFEbody programs with
potential unique MOA, which we intend to develop as monotherapies and/or as combination therapies. We intend to also devote resources to further strengthen our DPL platform, including enrichment of
our DPL and masking peptide libraries and optimization of our computational biology algorithms. Through leveraging our enabling DPL technologies for high fidelity translational studies, we aim to
accelerate the discovery and development of a deep, broad and differentiated pipeline of antibody-based therapeutic candidates in precision immuno-oncology. </FONT></P>

</UL>
</UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Continue to collaborate with leading biopharmaceutical companies and academic institutions to discover and develop
novel candidates based upon our DPL platform.</I></B></FONT><FONT SIZE=2> Collaboration is a key part of our growth strategy and we have established multiple collaboration programs in validating our
platforms. We intend to continue to seek collaboration and partnership opportunities where we can leverage our proprietary technology platform to develop novel antibodies to address unmet medical
needs. We also plan to explore our antibody programs in combination trials, and will opportunistically evaluate strategic collaborations or other partnerships to further these potential future
clinical trials. Given the species cross-reactive design of our antibodies, we are able to take advantage of highly predictive animal models where we believe there is a potential for strong additive
or synergistic behavior into the clinical setting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Maximize value creation by advancing our product candidates to potential commercialization in key markets alone or with
strategic partners.</I></B></FONT><FONT SIZE=2> We have retained exclusive worldwide rights to all of our product candidates other than ADG104, for which we out-licensed the Greater China rights to our
partner Sanjin, and intend to pursue clinical development programs with the goal of obtaining regulatory approvals in the United States, China and major international markets. We intend to directly
commercialize our product candidates, if approved, but may opportunistically enter into strategic collaborations or other partnerships with leading biopharmaceutical companies to accelerate our
development timelines and maximize the global commercial potential of our product candidates. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Build global operations for global markets, while leveraging a global supply chain and China cost
effectiveness.</I></B></FONT><FONT SIZE=2> We are a clinical stage biopharmaceutical company with global footprints. We have established subsidiaries in the United States, China, Hong Kong, Australia,
Singapore and Switzerland to conduct and/or support preclinical studies and clinical trials and are seeking patent protection in a number of jurisdictions worldwide. In particular, our presence in
mainland China enables us to access a large pool of target patients and creates the potential to progress our product candidates through clinical development in an efficient and cost-effective manner.
We employ a global clinical development strategy and leverage our global supply chain to comply with the requirements applicable to clinical trials globally in accordance with the requirements of the
FDA, the European Medicines Agency, or EMA, the Japanese Pharmaceuticals and Medical Devices Agency, or PMDA, and other comparable regulatory authorities. We are currently building our clinical and
technology infrastructures to support our future global operations and prepare to serve global markets.

 </FONT></DD></DL>
</UL>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ANTIBODIES FOR THE TREATMENT OF CANCER  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer treatment has traditionally included chemotherapy, radiation, surgery or a combination of these approaches. Small molecule target therapy
can be effective in certain types of cancer, but they can also cause toxicities that may have life-threatening consequences, lower quality of life or untimely termination of treatment. Furthermore,
these small molecule agents offer limited efficacy in many types </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=147,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=611748,FOLIO='144',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<A NAME="page_dk17601_1_145"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
cancer. Over the last 20&nbsp;years, a new paradigm of cancer research and treatment has emerged that involves targeted therapies, including mAbs. Monoclonal antibodies are proteins derived from
living organisms that bind to targets, called antigens, on tumor cells to inhibit tumor growth. As a product
class, immunotherapeutic mAbs have transformed oncology treatment and represent some of the most effective and top selling immunotherapies currently approved by the FDA and available on the market.
The success of conventional immunotherapeutic mAbs has been hindered by limited efficacy and by safety and tolerability concerns. Administration of these mAbs may cause systemic side effects, as well
as localized, organ-specific damage. Much of this toxicity is a direct consequence of the fact that healthy tissues express some of the same antigens that conventional immunotherapeutic mAbs target on
cancerous cells. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;More
recently, immuno-oncology has emerged as a promising new field of cancer therapy that aims to enhance antitumor immune responses by, for example, overcoming mechanisms that cancer
cells have developed to evade the immune system. Some cancer cells overly express proteins, called immune checkpoints, which apply brakes to the immune system, and enable the tumor cells to evade
destruction. Immune checkpoint inhibitors nivolumab, pembrolizumab and ipilimumab&#151;antibodies targeting these immune inhibitory proteins&#151;release these brakes to allow the immune
system to destroy tumor cells. These drugs have shown promising efficacy and are currently being explored for multiple solid and hematological cancer indications. Although these drugs have
demonstrated promising results, only a minority of patients receive durable benefit from treatment with these mAbs alone. Most recently, combination regimens of immunotherapy agents have demonstrated
signs of improved efficacy in larger numbers of patients. However, many of these combinations have significant toxicity and tolerability issues, due in part to the activation of the immune system in
both healthy and cancerous environments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the past decade, new modalities of highly potent mAb-based therapies have emerged. ADCs represent one such modality. These agents are comprised of two functional units chemically
fused or conjugated to each other: a cytotoxic drug payload and a mAb. ADCs combine the targeting abilities of the antibody with the cancer-killing ability of cytotoxic drugs, leading to better
specificity in targeting tumor cells compared to traditional chemotherapy. Bispecific antibodies, another class of second-generation biologics, have the ability to simultaneously bind a cancer cell
and a T-cell, leading to the destruction of the cancerous cell by the T-cell. This ability improves the potency of bispecific antibodies compared to first-generation immunotherapeutic mAbs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
all of these potent new therapies have shown promise, none addresses a key limitation of antibody-based therapeutics&#151;expression of targets in healthy tissue, which
leads to off-tumor toxicity and limits clinical use. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OUR PIPELINE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By leveraging our proprietary DPL platform, we have developed a robust pipeline of innovative product candidates in various stages of
development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated pipeline consists of our lead clinical-stage candidates, ADG106, ADG126 and ADG116.
We also have a robust preclinical pipeline in
various stages of development. In addition, we have out-licensed the Greater China rights of ADG104, a PD-L1 mAb in Phase Ib and Phase II trials concurrently in China to our partner Sanjin. We have
the right to apply for the patents derived from our core and key technologies pertaining to ADG104 in the rest of the world and we retain a majority of the economic benefits derived from ADG104 in the
rest of the world. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=148,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1036154,FOLIO='145',FILE='DISK103:[20ZDS1.20ZDS17601]DK17601A.;187',USER='CHE105939',CD=';1-FEB-2021;01:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dm17601_1_146"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG106: Novel Agonistic Anti-CD137 NEObody Candidate  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead product candidate, ADG106, is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb designed to target a unique conserved epitope of CD137. As of the
Data Cut-off Date, we have completed the Phase&nbsp;Ia dose escalation in each of our Phase&nbsp;I studies of ADG106 as a monotherapy in patients with advanced or metastatic solid tumors and/or
NHL in both the United States and China. ADG106 was well-tolerated in the completed Phase&nbsp;Ia dose escalation of the Phase&nbsp;I
clinical trials. Early efficacy signals were also observed with tumor size reduction, significant target modulations and increased T-cell and NK proliferation, consistent with MOA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Mechanism of Action</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CD137
is a member of the tumor necrosis factor, or TNF, receptor superfamily. As illustrated in the figure below, the binding of an antibody to this receptor induces a
co-stimulatory signal on activated enhanced cytotoxic T lymphocyte, or CD8<SUP>+</SUP> T-cells, and natural killer, or NK cells, resulting in proliferation, and increased pro-inflammatory cytokine
secretion and cytolytic function. CD137 co-stimulation is a clinically validated pathway for T-cell activation and its antitumor response is highlighted by the approval of a CD137-targeting CAR-T
therapy by the FDA. Because most tumors are killed by cytotoxic T-cells in an antigen specific manner, we believe agents that mediate CD8<SUP>+</SUP> T-cell activation can impart strong cytolytic
activity. Therefore, we believe that CD137 agonists are promising candidates with potential to enhance and mediate long lasting antitumor immunity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG106 is designed to bind to activated human CD4<SUP>+</SUP> and CD8<SUP>+</SUP> T-cells with low nanomolar affinity and block CD137 ligand binding in a concentration-dependent
manner to disable its reverse signaling. As shown in the figure below, ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like
binding and cross-linking by Fc<FONT FACE="SYMBOL">g</FONT> receptors. ADG106 has not been observed to bind to unstimulated na&iuml;ve T-cells, which have no detectable level of
CD137 expression. ADG106 is also designed to bind to activated NK cells to boost their cytotoxic and ADCC functions.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g706861.jpg" ALT="GRAPHIC" WIDTH="649" HEIGHT="256">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=1,SEQ=149,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=13359,FOLIO='146',FILE='DISK103:[20ZDS1.20ZDS17601]DM17601A.;138',USER='CHE105939',CD=';1-FEB-2021;01:50' -->
<A NAME="page_dm17601_1_147"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g879587.jpg" ALT="GRAPHIC" WIDTH="612" HEIGHT="382">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1>Notes: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=1>"APC" refers to antigen-presenting cells; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=1>"DC" refers to dendritic cells. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The MOA of ADG106 in tumor TME is illustrated below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g498056.jpg" ALT="GRAPHIC" WIDTH="561" HEIGHT="321">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1>Notes: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=1>"DC" refers to denritic cells; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=1>"Treg" refers to regulatory T-cell. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=150,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=469784,FOLIO='147',FILE='DISK103:[20ZDS1.20ZDS17601]DM17601A.;138',USER='CHE105939',CD=';1-FEB-2021;01:50' -->
<A NAME="page_dm17601_1_148"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Market Opportunity and Competition</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CD137
is an inducible costimulatory receptor expressed on activated T-cells in the TME. Agonistic mAbs targeting CD137 have been developed to harness CD137 signaling
for cancer
immunotherapy. An anti-CD137 agonist would possess the potential to target a wide spectrum of cancer types both as a monotherapy and in combination with various other therapies, especially in the
chemotherapy-free setting, including anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies, three proven immune checkpoint inhibitors. Although we believe there is compelling evidence that supports the
therapeutic potential of a CD137 agonist, there are currently no marketed CD137 agonist drugs. According to Frost&nbsp;&amp; Sullivan, there are two advanced CD137 agonist antibodies in clinical
development. However, clinical development of one of these antibodies has been hampered by inflammatory liver toxicity, despite initial signs of efficacy. The other CD137 antibody under clinical
development has demonstrated better safety features, but is a less potent CD137 agonist. One of the key challenges of CD137 agonist clinical development is CD137 agonist specific toxicity. Previous
clinical trials have shown CD137 antibodies cause immune anomalies, notably polyclonal activation of CD8+ T-cells and secretion of inflammatory cytokines, which affect the function of the liver,
spleen, and bone marrow. We believe that it is therefore critical to develop therapeutic candidates that are designed to maximize potency of CD137 agonism while minimizing CD137 agonist specific
toxicity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Frost &amp; Sullivan Report, the global CD137 monoclonal antibody market will emerge in 2023 and is estimated to reach US$0.6 billion and US$7.2 billion in 2024 and 2035
respectively, with a CAGR of 25.4% from 2024 to 2035. The China CD137 monoclonal antibody market is estimated to emerge in 2028 and is expected to grow to US$1.3 billion in 2035. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm17601_global_and_china_cd137_antibody_market,_2019-2035e"> </A>
<A NAME="toc_dm17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Global and China CD137 Antibody Market, 2019-2035E    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g872988.jpg" ALT="GRAPHIC" WIDTH="679" HEIGHT="244">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=1>Source: Frost &amp; Sullivan Report </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary of Clinical Trial Data</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overview:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have completed Phase&nbsp;Ia dose escalation and are conducting cohort expansion in each of our two Phase&nbsp;I
trials of ADG106 as
a monotherapy in patients with advanced or metastatic solid tumors and/or NHL in the United States, or the ADG106-1001 clinical trial, and in China, or the ADG106-1002 clinical trial. As of the Data
Cut-off Date, ADG106 was dose escalated up to 10 mg/kg and had been observed to be well-tolerated at dose expansion at 3 mg/kg, 5 mg/kg and at 300&nbsp;mg and 400&nbsp;mg flat doses for a total
number of 92&nbsp;patients dosed. Liver enzyme elevation of&nbsp;<FONT FACE="SYMBOL">&#179;</FONT> Grade&nbsp;3 was reported in three patients, with one determined to be not treatment
related. We also observed tumor shrinkage in some patients. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=151,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=800143,FOLIO='148',FILE='DISK103:[20ZDS1.20ZDS17601]DM17601A.;138',USER='CHE105939',CD=';1-FEB-2021;01:50' -->
<A NAME="page_dm17601_1_149"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trial Design:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Phase&nbsp;I clinical trials were designed to evaluate the safety and tolerability of ADG106, as well as its
pharmacokinetics, or
PK, immunogenicity, and preliminary clinical response. There were two parts to the dose escalation study: the accelerated titration phase at 0.03, 0.1, and 0.3&nbsp;mg/kg and a conventional "3+3"
dose escalation phase at 1, 3, 5 and 10&nbsp;mg/kg. ADG106 was administered once every three weeks by intravenous infusion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dose-expansion
cohorts started at dose levels that were observed to be well-tolerated in the dose escalation phase and showed evidence of clinical and biological activities. Patients
with advanced or metastatic solid tumors or NHL, who were refractory or relapsed after exhausting almost all available therapies, were enrolled for a maximum of 24 months unless they withdrew earlier
due to disease progression, intolerable toxicity, or withdrawal of consent. The protocol allowed for up to 52 patients in ADG106-1001 and 124 patients in ADG106-1002 to be enrolled in the accelerated
titration, dose escalation, and dose expansion phases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary objective of the Phase&nbsp;I clinical trials, including both the dose escalation phase and dose expansion phase, is to assess safety and tolerability at increasing dose
levels of ADG106 as a monotherapy in patients with advanced or metastatic solid tumors and/or NHL. The secondary
objectives of the Phase&nbsp;I clinical trial are to characterize the PK profile of ADG106 and to evaluate the immunogenicity of ADG106 and potential antitumor activity of ADG106. An exploratory
objective of such Phase&nbsp;I clinical trial is to identify potential biomarkers of patients who respond to treatment with ADG106. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
endpoints of ADG106 Phase&nbsp;I trial are: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Primary endpoint:  </I></B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dose-limiting toxicities, or DLT, in the first 2 cycles. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Secondary endpoints:  </I></B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Safety endpoints include AEs, clinical laboratory results, vital signs, physical examination findings, and ECG results. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Objective response rate, or ORR, duration of response, or DOR, time to progression, or TTP, disease control rate, or DCR, progression-free
survival, or PFS, and overall survival, or OS, as assessed by Response Evaluation Criteria in Solid Tumors, or RECIST, version 1.1, and/or immune-related RECIST, or irRECIST, for solid tumors, and the
Lugano Classification for NHL/ Hodgkin's lymphoma. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> PK endpoints include peak serum concentration, or Cmax, serum concentration at the end of a dosing interval, or Ctrough, time to reach Cmax, or
Tmax, area under the curve from time zero to the last timepoint, or AUC<SUB>0-last</SUB>, AUC from time zero to infinity, or AUC<SUB>0-inf</SUB>, AUC during a dosing interval, or AUCtau, clearance,
or CL, and volume of distribution at steady state, or Vdss, as data permit. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Anti-drug antibody, or ADA, levels for ADG106. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Status:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As of Data Cut-off Date, the Phase&nbsp;Ia dose escalation portion of the ADG106-1001 Phase&nbsp;I clinical trial in the
United&nbsp;States and the ADG106-1002 Phase&nbsp;I clinical trial in China had been completed and the Phase&nbsp;Ib/II dose expansion phase for both trials was ongoing. We plan to complete the
Phase&nbsp;I trials and initiate biomarker-driven global Phase&nbsp;II trials in 2021. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the Data Cut-off Date, 92&nbsp;patients were enrolled, among whom 35&nbsp;patients were enrolled and treated in the ADG106-1001 clinical trial and 57&nbsp;patients were
enrolled and treated in the ADG106-1002 clinical trial. Thirty-eight patients were enrolled in the dose escalation phase and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=152,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=936734,FOLIO='149',FILE='DISK103:[20ZDS1.20ZDS17601]DM17601A.;138',USER='CHE105939',CD=';1-FEB-2021;01:50' -->
<A NAME="page_dm17601_1_150"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>54&nbsp;patients
were enrolled in the dose expansion phase. Patients in the expansion cohort of both trials were still on the study treatment. The patient demographics and baseline parameters are
listed below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="239pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="177pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Patient Demographics

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>ADG106-1001 (n=35) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>ADG106-1002 (n=57) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Age</B></FONT><FONT SIZE=2> (Years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median (Max, Min)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61(82, 25)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50(72, 21)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Sex</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Female</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Male</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Race</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>African American</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chinese</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Caucasian</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Eastern Cooperative Oncology Group ("ECOG") Performance Status</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Number of Prior Systemic Regimens</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median (Min, Max)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5 (0, 14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3 (0, 10)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cancer Types</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Colorectal Cancer (n=7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Nasopharyngeal Cancer (n=14)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal Cell Carcinoma(n=4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-small Cell Lung Cancer (n=13)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Follicular Lymphoma (n=3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Hodgkin's lymphoma n=10)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Head and Neck Squamous Cell Carcinoma (n=3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Adenoid Cystic Cancer (n=5)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Esophageal Carcinoma (n=2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cervical Cancer (n=4)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Anal Cancer (n=2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Others (n=11)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Other (n=14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety Assessment:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As of the Data Cut-off Date, 35&nbsp;patients and 57&nbsp;patients were enrolled in the two Phase I trials in
the United
States and China, respectively. ADG106 is generally well tolerated at 3mg/kg and 5mg/kg with dose escalation up to 10mg/kg. We observed limited TEAEs, liver toxicity or hematologic abnormalities in
both trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Data Cut-off Date, 35&nbsp;patients enrolled in the ADG106-1001 clinical trial in United&nbsp;States had safety assessments. 24 of 35 (69%)&nbsp;patients discontinued
ADG106 treatment (19&nbsp;patients discontinued due to progression disease, 3&nbsp;patients discontinued due to adverse events). Two&nbsp;DLTs were observed, including a Grade 2 hypoglossal
nerve disorder at 5 mg/kg and a Grade 3 adrenal insufficiency at 10mg/kg cohorts. Across all dose cohorts, liver function tests showed two patients with &gt;Grade&nbsp;3 AST increase, including one
patient who had abnormal baseline liver enzyme exhibited Grade&nbsp;3 AST increase. Hematologic tests showed two patients with Grade&nbsp;3 hemoglobin decreases, and five patients had Grade 3
lymphocyte decreases.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the Data Cut-off Date, 57 patients enrolled in the ADG106-1002 clinical trial in China had safety assessments. 45 of 57 (68.9%)&nbsp;patients discontinued ADG106 treatment
(31&nbsp;patients discontinued due to progression disease, 7&nbsp;patients discontinued due to adverse events, 5 due to withdrawal of consent and 2 due to clinical deterioration). One DLT (Grade 4
neutrophil count decreased, 10mg/kg) was observed in one patient with mantle cell lymphoma. Across all dose cohorts of 57 patients, only one patient showed Grade 3 AST and ALT liver enzyme increases.
Two patients dosed at 5mg/kg or 10mg/kg experienced Grade&nbsp;3 and 4 hemolytic anemia, respectively. Both patients were treated and subsequently recovered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Efficacy Assessment:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As of the Data Cut-off Date, 71 of 92&nbsp;patients enrolled in both trials received post-treatment
scans and were
evaluated for preliminary efficacy assessment. The responses observed in these patients included one partial response, 39&nbsp;stable disease, and 31&nbsp;progressive disease. The disease control
rate was 56% (40 of 71&nbsp;patients). Three patients enrolled in ADG106-1002 clinical trial achieved greater than 30% tumor shrinkage. One patient with a solid tumor had a partial response </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=153,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=37965,FOLIO='150',FILE='DISK103:[20ZDS1.20ZDS17601]DM17601A.;138',USER='CHE105939',CD=';1-FEB-2021;01:50' -->
<A NAME="page_dm17601_1_151"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>with
an approximately 40% tumor size reduction in the target lesions and two NHL patients showed tumor shrinkage of 32% and 33% at the end of the Cycle&nbsp;two. A third ADG106-1002 NHL patient
showed a tumor size reduction of 17% and a patient with esophageal carcinoma enrolled in ADG106-1001 achieved 18% tumor shrinkage. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Data Cut-off Date, of the 71 patients who received post-treatment scans, 23 were enrolled in ADG106-1001 clinical trial. The observed responses were 12 stable disease and 11
progressive disease and a disease control rate of 52% (12 of 23&nbsp;patients). Tumor shrinkage and a decrease in standard uptake value scores on PET CT images were observed in three patients,
including one patient with stage&nbsp;IV follicular lymphoma who was refractory to multiple prior therapies including rituximab, another patient with endometrial carcinoma, and a third patient with
esophageal carcinoma.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the Data Cut-off Date, of the 71 patients who received post-treatment scans, 48 were enrolled in ADG106-1002 clinical trial. The observed responses were one&nbsp;partial
response, 27 stable disease, and 20 progressive disease with a disease control rate of 58% (28 of 48 patients). One patient with nasopharyngeal carcinoma demonstrated partial response with an
approximately 40% tumor size reduction in the target lesion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
three patients with T cell lymphoma enrolled in ADG106-1002 responded to ADG106 treatment and showed tumor size reductions of 32%, 33%, and 17%. Given its unmet medical needs, we are
exploring Orphan Drug Designation with the FDA. In addition, we are collaborating with principal
investigators who specialize in T cell lymphoma to conduct both investigator-initiated trials and an Adagene-sponsored trial to further validate the anti-tumor activities of ADG106 in this indication.
We believe these efforts may lead to expedited regulatory approval of ADG106 for T cell lymphoma. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
conclusion, we observed a disease control rate of 56% among 92&nbsp;patients including one&nbsp;patient with refractory nasopharyngeal carcinoma who had failed four prior
therapies including anti-PD-L1 and four other patients with deep responses that exhibited 33%, 32%, 18%, and 17% tumor size reductions. Six&nbsp;patients remained on ADG106 treatment for over
six&nbsp;months including one&nbsp;patient who received 3&nbsp;mg/kg ADG106 treatment for over one year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case
1: Patient A with NHL, who relapsed after multiple chemotherapies and stem cell transplantation achieved 33% tumor size reduction after one dose of ADG106 at 3&nbsp;mg/kg. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g321006.jpg" ALT="GRAPHIC" WIDTH="397" HEIGHT="369">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=154,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=133066,FOLIO='151',FILE='DISK103:[20ZDS1.20ZDS17601]DM17601A.;138',USER='CHE105939',CD=';1-FEB-2021;01:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_do17601_1_152"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case 2: Patient B with solid tumor (stage&nbsp;IV), who relapsed after multiple lines of treatment (chemotherapies, radiotherapy, target therapy, and immune
checkpoint inhibition therapy), showed 40% tumor size reduction after two doses of ADG106 at 5&nbsp;mg/kg. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g299228.jpg" ALT="GRAPHIC" WIDTH="393" HEIGHT="411">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacodynamic Biomarker Measure of CD137 Target Modulation:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;As shown below, we have observed stimulation of T-cell
proliferation and expansion in
one patient treated with ADG106, evidenced by an increase in percentage of Ki-67 protein (an indicator of proliferative activity). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g62211.jpg" ALT="GRAPHIC" WIDTH="286" HEIGHT="244">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
illustrated below, we have also observed increased proliferation of NK&nbsp;cells in patients treated with ADG106 after the first cycle of treatment. Dose dependent stimulations of
the identified immune cell subpopulation following ADG106 treatment at doses of 0.1, 0.5, and 1.5&nbsp;mg/kg (see figure below on the right) were observed. No significant difference was observed
from <FONT FACE="SYMBOL">&#163;</FONT>1.5 to 10&nbsp;mg/kg, suggesting that the drug may have saturated CD137 receptors on the target cells at the doses
<FONT FACE="SYMBOL">&#179;</FONT>1.5&nbsp;mg/kg. This is the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=155,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=861096,FOLIO='152',FILE='DISK103:[20ZDS1.20ZDS17601]DO17601A.;101',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_do17601_1_153"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>first
report of an anti-CD137 antibody drug showing stimulation of NK&nbsp;cell proliferation in human. This finding also clarifies the MOA of ADG106, suggesting involvement of diverse immune cells
in ADG106 mediated anti-tumor activities in human. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g816723.jpg" ALT="GRAPHIC" WIDTH="439" HEIGHT="207">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ADG106 Phase&nbsp;I clinical trials enrolled cancer patients without regard to cancer types. As shown in the figure below on the left, the effect of ADG106 on soluble&nbsp;CD137
was not tumor type specific, but rather a universal event observed for most of the patients. As seen in the figures below, we observed dose-dependent increases in the biomarker level in patient serum
after ADG106 treatment and correlation of the change of the soluble&nbsp;CD137 with patient response. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g514725.jpg" ALT="GRAPHIC" WIDTH="495" HEIGHT="252">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identification of a Potential Predictive Biomarker for ADG106 Treatment Response:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have identified a potential predictive
biomarker that correlated
with patient treatment responses based on a retrospective analysis of pretreatment biopsy specimens from 28 patients with clinical outcome data as shown in the diagram below on the right panel. As of
the Data Cut-off Date, three patients who achieved greater than 30% tumor shrinkage after ADG106 treatment were found to be biomarker positive. One Phase Ia patient who was treated with a low dose of
ADG106 was biomarker positive and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=156,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=535310,FOLIO='153',FILE='DISK103:[20ZDS1.20ZDS17601]DO17601A.;101',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_do17601_1_154"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>showed
stable disease, as shown in the waterfall plot below on the left panel. Twenty-four&nbsp;biomarker negative patients did not show significant response as measured by tumor size reduction in
CT images. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g515401.jpg" ALT="GRAPHIC" WIDTH="315" HEIGHT="168">
 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g465293.jpg" ALT="GRAPHIC" WIDTH="315" HEIGHT="202">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have developed a high sensitivity multiplex IHC assay to measure the expression of the predictive biomarker. We measured expression of the predictive biomarker in 746 tumor
microarray, or TMA, samples from patients with 14&nbsp;different tumor types and identified biomarker positive expression of up to 42% in various types of solid tumors and hematological
malignancies.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will stratify and preselect patients using this biomarker in the upcoming Phase&nbsp;II clinical trials in 2021. In the early stage of the Phase&nbsp;II clinical trials, biomarker
positive and negative patients will be identified using our multiplex IHC clinical trial assay in order to prospectively validate the predictive biomarker. After an interim analysis, we intend to
collaborate with a diagnostic partner to identify patients for clinical trial enrollment using an analytically validated investigational diagnostic assay in the next stage of the Phase&nbsp;II
clinical trials. This tumor biomarker test may be developed as companion diagnostic to facilitate AD106 registration according to FDA requirements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary of Preclinical Studies and Results</U> </FONT></P>

<P style="font-family:times;">


<FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overview:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;ADG106 was evaluated extensively in both </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT
SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> preclinical studies. ADG106 was observed in </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies to enhance activation of, and cytokine release by, primed
T-cells alone or in combination with other immunomodulatory agents. ADG106 was also observed to have antitumor activities </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> as a monotherapy in a
dose dependent manner in multiple tumor models. When combined with a variety of cancer therapeutics, ADG106 exhibited antitumor activity </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> in
animal models, including in immunotherapy resistant models. Our mechanistic analyses suggest that ADG106 promotes an antitumor response by stimulating infiltration and expansion of CD4<SUP>+</SUP>
and CD8<SUP>+</SUP> T-cells in tumors. ADG106 was well tolerated in animals, with a no-observed-adverse-effect-level, or NOAEL, <FONT FACE="SYMBOL">&#179;</FONT> 100 mg/kg/dose and
<FONT FACE="SYMBOL">&#179;</FONT> 200 mg/kg/dose in rats and cynomolgus monkeys, respectively. These findings support our belief that the ADG106-boosted immune response could offer an
effective alternative solution for cancer immunotherapy as a monotherapy and in combination with other therapies, especially for PD-1/PD-L1 resistant patient populations.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical Pharmacology:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies showed that ADG106 bound with high
affinity and
specificity to a unique epitope of CD137 that blocks the CD137L ligand binding with subsequent enhancement and proliferation of T-cells and pro-inflammatory
interferon-<FONT FACE="SYMBOL">g</FONT> responses. Interferon-<FONT FACE="SYMBOL">g</FONT> is a master checkpoint regulator for many cytokines that targets a common component of
many heterodimeric cytokine receptors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG106 was species cross-reactive against human, mouse, and cynomolgus monkey CD137 and was active as a monotherapy in multiple preclinical tumor models. As shown below (left figure), in
an H22 liver cancer syngeneic mouse model, ADG106 was observed to have </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> antitumor activities as

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=157,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=705321,FOLIO='154',FILE='DISK103:[20ZDS1.20ZDS17601]DO17601A.;101',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_do17601_1_155"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


a monotherapy in a dose dependent manner. As shown below (right figure), tumors treated with ADG106 showed increased CD4<SUP>+</SUP> and CD8<SUP>+</SUP> infiltration compared to an isotype
control.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g809625.jpg" ALT="GRAPHIC" WIDTH="661" HEIGHT="274">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As illustrated in the figure below, ADG106 also showed a durable antitumor response in a CT26 colon cancer syngeneic mouse model. ADG106 treatment induced a complete response, or CR, in
six out of eight mice. These CR mice received reinnoculation of CT26 tumor cells, or rechallenge, and remained tumor-free without additional ADG106 treatment, indicating development of antitumor
memory response elicited by ADG106. Tumors treated with ADG106 showed increased CD4<SUP>+</SUP> and CD8<SUP>+</SUP> infiltration compared to an isotype control, similar to the H22 liver cancer
model (data not shown). These data are consistent with the mechanism of ADG106 as a CD137 agonist in stimulating T-cell proliferation, activation, and infiltration into the TME to induce an antitumor
effect.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g900185.jpg" ALT="GRAPHIC" WIDTH="558" HEIGHT="315">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient stratification:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Understanding which patient populations may preferentially benefit from ADG106 treatment is important in
designing clinical
trials. Our preclinical studies have identified a biomarker that is associated with </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> sensitivity of tumor models to ADG106 treatment. We
determined biomarker level in ten syngeneic mouse tumor models and tested ADG106 </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> in these ten models. In the seven models that were biomarker
positive, four models were sensitive to ADG106 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=158,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=652221,FOLIO='155',FILE='DISK103:[20ZDS1.20ZDS17601]DO17601A.;101',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_do17601_1_156"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>treatment
while three were resistant or less sensitive to ADG106. The three biomarker negative models were resistant to ADG106 treatment. Additionally, the three resistant or less sensitive biomarker
positive models showed synergistic effect to ADG106 treatments in combination with anti-CTLA-4 or anti-PD-L1. As illustrated in the figures below, among two T-cell lymphoma models, the biomarker
positive model was observed to be sensitive to ADG106 treatment (see figure below on the left) and the biomarker negative model was observed to be resistant to ADG106 treatment (see figure below on
the right). This biomarker provides a potential mechanism for stratifying patients that may benefit from ADG106 treatment in future clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g662876.jpg" ALT="GRAPHIC" WIDTH="672" HEIGHT="252">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to monotherapy antitumor activities, we observed that ADG106 had antitumor activities in combination with other therapies in preclinical studies. As shown below, ADG106
produced a synergistic effect with an anti-PD-1/L1 therapy, and SOC, in </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> tumor models, including models that are resistant to current PD-1/PD-L1
and SOC therapies.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g408902.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="265">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=159,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=385914,FOLIO='156',FILE='DISK103:[20ZDS1.20ZDS17601]DO17601A.;101',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dq17601_1_157"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g133668.jpg" ALT="GRAPHIC" WIDTH="504" HEIGHT="292">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In a syngeneic tumor that is biomarker (mentioned above) positive, although ADG106 did not show anti-tumor activity in this model, combination of ADG106 with
atezolizumab (Tecentriq), an approved anti-PD-L1 antibody that blocks PD-1/PD-L1 interaction, showed enhanced antitumor response compared to the corresponding monotherapies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g336902.jpg" ALT="GRAPHIC" WIDTH="354" HEIGHT="283">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
demonstrated below, ADG106 was also observed to show antitumor activities when combined with our CTLA-4 antibody ADG116 in a mouse tumor model that is biomarker (mentioned above) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=160,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=123560,FOLIO='157',FILE='DISK103:[20ZDS1.20ZDS17601]DQ17601A.;99',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_dq17601_1_158"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>positive,
while ADG106 alone did not show antitumor activities. We believe that this data provides a strong rationale for combining our pipeline programs including ADG106 with ADG116. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g766726.jpg" ALT="GRAPHIC" WIDTH="354" HEIGHT="325">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Clinical Development Plan</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed the Phase&nbsp;Ia dose escalation portion of each of our Phase&nbsp;I clinical trials and are conducting a Phase&nbsp;Ib cohort expansion phase
using the selected doses in several indications. Our ADG106 Phase&nbsp;Ia clinical trials are designed to evaluate the safety, tolerability, and PK of repeat ascending doses of ADG106 in advanced or
metastatic solid tumors and NHL. The secondary objective of these trials is to characterize the PK profile of ADG106, to evaluate and potentially identify a maximum tolerated dose or optimal dose of
ADG106, assess relevant biomarkers, and evaluate preliminary signs of antitumor activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ongoing Phase Ib clinical trials are designed to evaluate the preliminary signs of antitumor activity. Based on Phase Ib data, we expect to choose the indications to be further
explored in our future trials, for which plan to stratify and preselect patients based on their biomarker status to improve the
response rate of ADG106. As a part of our strategies to ensure success of ADG106 clinical development, we may also explore niche indications for expedited approval. We may consider testing different
dosages, different dosing schedules as well as ADG106 as a monotherapy or in combination with other immunotherapies in different disease subgroups and/or different disease stages. There are also
investigator-initiated trials of ADG106, sponsored in Singapore by investigators, targeting various indications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are evaluating combinations of ADG106 with various therapies in clinical trials. We have received NMPA approval for the ADG106-1008 study in China which is a Phase Ib/II combination
trial of ADG106 with anti-PD-1 in advanced solid tumors and hematological malignancies. We are also in the preparation for a submission of a CTN for ADG106-1003 study in Australia which is to combine
ADG106 with anti-PD-1, anti-VEGF, and anti-CD20 antibodies in advanced solid tumors and hematological malignancies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=161,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=114594,FOLIO='158',FILE='DISK103:[20ZDS1.20ZDS17601]DQ17601A.;99',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_dq17601_1_159"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG126: Novel Anti-CTLA-4 SAFEbody Candidate  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
most advanced SAFEbody program, ADG126, is a fully human anti-CTLA-4 mAb generated using our SAFEbody technology designed to address the safety concerns with
associated existing CTLA-4 therapeutics, while maintaining efficacy in the TME. Our proprietary SAFEbody technology is designed to enable ADG126 to be activated only in tumor tissues rather than
healthy tissues. In preclinical studies, we observed that ADG126 had an enhanced therapeutic window and improved safety features. Furthermore, in PD studies of ADG126, it was observed that while the
CTLA-4 binding affinity was masked in an intact ADG126 antibody, once the masking peptide was cleaved off of ADG126, its high binding affinity to CTLA-4 was restored. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Mechanism of Action</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG126
is a fully human anti-CTLA-4 mAb. The masking moiety in ADG126 functions to block the interaction between ADG126 and its target CTLA-4 protein. Once ADG126
enters the TME, proteases overexpressed in the TME cleave off the masking moiety, and the antibody is then activated, binding to CTLA-4 and inhibiting its function. ADG126 is locally activated
specifically in the TME, rather than systemically, to stimulate antitumor immune response. The following diagram illustrates the activation process of ADG126 in tumor tissue. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g895358.jpg" ALT="GRAPHIC" WIDTH="621" HEIGHT="222">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that activated ADG126 potentiates T-cell immune response by blocking the inhibitory effect of CTLA-4. ADG126/ADG116 is designed to target CTLA-4 conserved epitope with species
cross-reactivity for translational fidelity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g593559.jpg" ALT="GRAPHIC" WIDTH="253" HEIGHT="217">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=162,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=880622,FOLIO='159',FILE='DISK103:[20ZDS1.20ZDS17601]DQ17601A.;99',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_dq17601_1_160"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
ADG126 has been observed in preclinical animal studies to mediate effector functions to eliminate CTLA-4 expressing cells, particularly regulatory T-cells, primarily through
ADCC. These actions of ADG126 could lead to enhanced activation and proliferation of tumor infiltrating T-effector cells and reduced T-regulatory cell function, which may contribute to a general
increase in T-cell responsiveness, including an enhanced antitumor immune response. The below diagram illustrates the MOA of activated ADG126. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g348093.jpg" ALT="GRAPHIC" WIDTH="648" HEIGHT="385">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=1>Notes:  </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>"ADCP" refers to antibody-dependent cell-mediated phagocytosis;  </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>"MHC" refers to major histocompatibility complex;  </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>"TCR" refers to T-cell receptor; </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Market Opportunity and Competition</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to Frost&nbsp;&amp; Sullivan, as of December&nbsp;31, 2020, ipilimumab is the only marketed CTLA-4 drug targeting cancer and it has been approved for six
indications including monotherapy and combination therapies approved by the FDA. While ipilimumab is the only marketed CTLA-4 antibody drug, there are over ten CTLA-4 antibodies in clinical
development globally, according to Frost&nbsp;&amp; Sullivan. There are currently no marketed CTLA-4 antibody drugs in China, but at least seven CTLA-4 antibodies in clinical development, according to
Frost&nbsp;&amp; Sullivan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
global total CTLA-4 inhibitors market reached US$1.5 billion in 2019 and is estimated to reach US$3.8 billion and US$11.9 billion in 2024 and 2035, respectively, representing a CAGR
of 11.0% from 2024 to 2035, according to the Frost &amp; Sullivan Report. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=163,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=182822,FOLIO='160',FILE='DISK103:[20ZDS1.20ZDS17601]DQ17601A.;99',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_dq17601_1_161"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dq17601_breakdown_of_global_ctla-4_inh__bre02052"> </A>
<A NAME="toc_dq17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Breakdown of Global CTLA-4 Inhibitors Market By Category, 2015-2035E    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g779657.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="243">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=1>Source: Frost &amp; Sullivan Report </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primary limitation of CTLA-4 antibodies is toxicity. We believe that the continued expansion of indications, and the launch of innovative novel
CTLA-4 antibodies with potential for improved safety and better efficacy may increase the market for CTLA-4 antibodies significantly. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary of Preclinical Studies</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical Pharmacology</I></B></FONT><FONT SIZE=2><B>:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We observed in PD studies that ADG126, in its intact SAFEbody form, bound
weakly to CTLA-4.
However, once the proteases cleaved off the masking peptide, ADG126 was activated and bound at a high affinity to human, cynomolgus monkey and mouse CTLA-4, as shown in the figures below. Activated
ADG126 was observed to lead to the release of CD80/CD86 ligands from CTLA-4 sequestration, and stimulation of CD28 signaling to boost T-cell activity. It also targets </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=164,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=993808,FOLIO='161',FILE='DISK103:[20ZDS1.20ZDS17601]DQ17601A.;99',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_dq17601_1_162"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>regulatory
T-cells for depletion within the TME by means of ADCC, to mediate antitumor T-cell immunity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g964339.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="412">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
evaluated the </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> antitumor efficacy of ADG126 in syngeneic mouse tumor models. As shown in the figures below, in these studies,
ADG126 was observed to inhibit tumor growth in different mouse tumor models as a monotherapy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g189723.jpg" ALT="GRAPHIC" WIDTH="589" HEIGHT="264">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=165,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=346158,FOLIO='162',FILE='DISK103:[20ZDS1.20ZDS17601]DQ17601A.;99',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ds17601_1_163"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As shown in the figure below, ADG126 synergized with an anti-PD-1 antibody to elicit a stronger anti-tumor response than ADG126 or the anti-PD-1 antibody alone in
a Lewis lung cancer syngeneic mouse model. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g397522.jpg" ALT="GRAPHIC" WIDTH="516" HEIGHT="232">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG126
treatment was observed to specifically deplete regulatory T-cells in the tumor, but not in peripheral tissues. The following figures illustrate the reduction of CTLA-4 expression
in infiltrating lymphocytes, or TILs (see figure below on the left) and regulatory T-cell depletion (see figure below on the right) by ADG126 in CT26 tumor model. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g601073.jpg" ALT="GRAPHIC" WIDTH="646" HEIGHT="243">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical Toxicology:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We performed preclinical toxicology studies designed to assess the toxicity features of ADG126. We
selected cynomolgus
monkeys and mice as toxicology species for animal toxicity evaluation. No abnormal findings attributable to ADG126 were observed. We utilized a nonobese diabetic mouse model to determine percentage of
survival with AD126 treatment. All mice survived after six treatments of ADG126 at 50 mg/kg. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
a four-week GLP repeat-dose toxicology studies, intravenous infusion of ADG126 to cynomolgus monkeys at 5, 30, or 200 mg/kg/dose once weekly for five doses followed by a 28-day
recovery period was well-tolerated. Adverse, but reversible, microscopic findings of minimal to moderate mixed perivascular infiltrates were observed at 200 mg/kg in both sexes in the kidney, liver,
pancreas, epididymis, skin, and were observed in the ovaries in females, and the connective tissue associated with the mesenteric lymph node and thyroid gland. The NOAEL was considered to be 30
mg/kg/dose and the highest non-severely toxic dose was considered to be 200 mg/kg/dose. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=166,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=615541,FOLIO='163',FILE='DISK103:[20ZDS1.20ZDS17601]DS17601A.;124',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ds17601_1_164"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Clinical Development Plan</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Australian Therapeutic Goods Administration authorized us to initiate a Phase&nbsp;I trial of ADG126-1001 in Australia. The first site of ADG126-1001 has been
approved by the Australian authorities, investigational products have been released, and the site is ready to start patient screening. In addition, three potential patients have been identified for
enrollment in the ADG126-1001 trial and we expect to commence patient enrollment by February. We also have received approval from the FDA to initiate the Phase I clinical trial of ADG126 in the United
States in 2021. These two Phase I dose escalation trials will test five doses at 0.1, 0.3, 1, 3, and 10 mg/kg, based on our preclinical primate toxicity study in comparison with ipilimumab. We
anticipate that these clinical trials will allow us to determine the ADG126 effective dose in late 2021. Meanwhile, we are preparing IND submissions to initiate ADG126 clinical trials in China. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADG116: Novel Anti-CTLA-4 NEObody Candidate  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG116
is a fully human anti-CTLA-4 antibody generated using our NEObody technology, designed to enhance the efficacy and to address toxicity concerns associated with
existing CTLA-4 therapeutics. In our preclinical studies, ADG116 was observed to potentiate CD28 signaling and T-cell immune responses (cytokine production) in the presence of primary stimulatory
signaling. Furthermore, ADG116 reduced immunosuppressive regulatory T-cell activity and enhanced CD8<SUP>+</SUP> T-cells activity in the TME to induce antitumor responses. We believe these
preclinical results support the further clinical evaluation of ADG116 both as a monotherapy and in combination with other therapies for a wide range of tumor types. In July 2020, we obtained
authorization from the Australian Therapeutic Goods Administration under a CTN to start a Phase I clinical trial of ADG116. As of January&nbsp;15, 2021, we have successfully completed dose
escalation at the first three doses in our ADG116-1003 clinical trial in Australia, including a dose level at 0.03mg/kg, which was the dose level used for the first patient who suffered a fatal
incident in the ADG116 Phase&nbsp;I trial in the United States. As of January&nbsp;15, 2021, no dose limiting toxicity or treatment related serious adverse events have been observed in any of the
patients treated. There was no treatment induced liver toxicity and all three patients treated at 0.03mg/kg showed normal liver enzyme level post ADG116 treatment. The ADG116-1001 Phase&nbsp;I trial
in the United States was placed on clinical hold on September&nbsp;30, 2019 by the FDA, after we reported to the FDA the death of the only patient dosed in the trial. The FDA removed the clinical
hold on December&nbsp;5, 2019 after we submitted an amendment to the study protocol. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Mechanism of Action</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG116
is designed to target a unique conserved epitope of CTLA-4. In preclinical studies, ADG116 was observed to have softer CTLA-4 ligand blocking and stronger ADCC
for regulatory T-cell depletion than ipilimumab. Based on the PD results observed in our preclinical studies, we believe that ADG116 has the potential to specifically bind to human CTLA-4, or hCTLA-4,
without binding to other CD28 family receptors, which could potentially block the CTLA-4/CD80 and CTLA-4/CD86 ligand interactions. We believe that ADG116 potentiates CD28 signaling and T-cell immune
response in the presence of a primary stimulatory signaling. Moreover, ADG116 has been observed in preclinical animal studies to mediate effector functions to eliminate CTLA-4 expressing cells,
particularly regulatory T-cells, primarily through ADCC by NK cells. These actions of ADG116 could lead to enhanced activation and proliferation of tumor infiltrating T-effector cells and reduced
T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including an enhanced antitumor immune response. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=167,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=559597,FOLIO='164',FILE='DISK103:[20ZDS1.20ZDS17601]DS17601A.;124',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ds17601_1_165"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Clinical Trial Design</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summarizes the Australia clinical trial design of ADG116. During the accelerated titration phase, one patient per dose level will be treated. If the
patient experiences a DLT or two Grade 2 or above drug-related toxicity, as agreed upon by the investigator and sponsor, the dose level will be expanded according to a "3+3" dose escalation design.
During the traditional "3+3" dose escalation phase, from the dosage level at 0.03mg/kg onwards, dose escalation will follow a traditional "3+3" design with three or six patients treated at each dosage
level, depending on the incidence of DLTs. Initially, three patients will be enrolled into the dosage level with the sentinel patient treated at least 24&nbsp;hours before the subsequent patients.
Duration of treatment is expected to continue up to two years, if the investigator considers that continued treatment could benefit the patient, or until disease progression and/or unacceptable
toxicity, or withdrawal of informed consent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary objectives of the dose escalation stage of the planned clinical trial will be to assess DLT and recommended Phase&nbsp;II dose, or RP2D. The safety profile of ADG116 will
also be assessed in terms of severity, seriousness, and frequency of AEs, laboratory results, vital signs, physical examinations, and ECGs of patients enrolled in the study. The secondary objectives
of the planned clinical trial are to (i)&nbsp;assess plasma PK parameters; (ii)&nbsp;evaluate anti-drug antibodies, or ADAs, in patients' blood before, during and after treatment with ADG116;
(iii)&nbsp;evaluate objective response in accordance with RECIST v1.1 and/or iRECIST; and (iv)&nbsp;evaluate preliminary evidence of antitumor activity of ADG116, as characterized by ORR, DCR,
duration of response, or DOR, duration of stable disease, PFS, and OS. The exploratory objective is to identify PD biomarkers for ADG116, including but not limited to cytokines, plasma proteins,
immune cells, and tissue biomarkers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
endpoints of ADG116 Phase&nbsp;I trial are: </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Primary endpoints:  </I></B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> DLT and RP2D. The safety profile of ADG116 will be assessed in terms of severity, seriousness, and frequency of adverse events, laboratory
results, vital signs, physical examinations, and ECGs enrolled in the study. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Secondary endpoints:  </I></B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Plasma PK parameters including but not limited to: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AUC<SUB>0-inf</SUB> </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AUC from time zero to last measurable concentration  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AUC from time zero to 21&nbsp;days post-dose  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Maximum (peak) plasma concentration  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Time to maximum (peak) plasma concentration  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Trough plasma concentration  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Apparent half-life  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Apparent total body clearance  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Apparent volume of distribution </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mean residence time </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Incidence of ADAs. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Objective response in accordance with RECIST v1.1 and/or iRECIST. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=168,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=206201,FOLIO='165',FILE='DISK103:[20ZDS1.20ZDS17601]DS17601A.;124',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ds17601_1_166"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Preliminary evidence of antitumor activity as characterized by ORR, DCR, DOR, duration of stable disease, PFS, and OS. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Summary of Preclinical Studies and Results</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
extensively evaluated ADG116 in both </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> preclinical
studies. Our </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> efficacy studies were conducted in mice, and safety evaluations were conducted in both cynomolgus monkeys and rats. ADG116 was
observed to show robust </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> anti-tumor activity in multiple syngeneic mouse tumor models. Ipilimumab was included as a benchmark and was compared
with ADG116 in a series of our preclinical studies. In these preclinical studies, we observed that ADG116 had a potential advantage over ipilimumab in potentiating T-cell activation. While ADG116 has
softer CTLA-4 ligand blocking, it was observed to have superior ability in eliminating CTLA-4 positive regulatory T-cells via ADCC in tumors resulting in enhanced antitumor responses. ADG116 was well
tolerated in rats and cynomolgus monkeys at doses up to 30 mg/kg in GLP-compliant four-week repeat-dose toxicology studies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical Pharmacology:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We evaluated ADG116 as a monotherapy </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> in an H22
liver cancer
syngeneic mouse model. As shown in the figure below, ADG116 was observed to induce an encouraging antitumor response at low doses in a dose-dependent manner (see figure below on the left).
Additionally, ADG116 was observed to inhibit tumor growth of large tumors in the same model (see figure below on the right). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g37138.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="247">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g841036.jpg" ALT="GRAPHIC" WIDTH="256" HEIGHT="219">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
illustrated in the below figure, in a liver cancer tumor rechallenge study, ADG116 was observed to induce significant antitumor response. Fifty-nine days after the initial tumor
inoculation and more than 30&nbsp;days after the last ADG116 treatment, mice were then rechallenged with the same tumor. We observed that mice that responded to the initial ADG116 treatment remained
tumor-free even without additional ADG116 treatment while na&iuml;ve mice developed tumors, indicating the development of antitumor memory response elicited by ADG116. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=169,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=837454,FOLIO='166',FILE='DISK103:[20ZDS1.20ZDS17601]DS17601A.;124',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_du17601_1_167"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g728775.jpg" ALT="GRAPHIC" WIDTH="618" HEIGHT="324">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since ADG116 was observed to exhibit strong ADCC activity </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2>, we evaluated the ability of ADG116 to deplete
regulatory T-cells </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> in a CT26 mouse colon cancer syngeneic model. ADG116 treatment was observed to specifically deplete regulatory T-cells in the
tumor, but not in peripheral blood mononuclear cells, or PBMCs, or lymph nodes. The following figure shows significant regulatory T-cell depletion (left figure) and inhibition of CTLA-4 expression
(right figure) in tumors by ADG116. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g767377.jpg" ALT="GRAPHIC" WIDTH="591" HEIGHT="235">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
a series of preclinical studies, we compared the effect of ADG116 to ipilimumab. We believe that these studies suggest that ADG116 has a unique MOA compared to ipilimumab and has a
potential advantage over ipilimumab in eliciting antitumor responses. These preclinical trial results support the further clinical evaluation of ADG116 as a monotherapy and in combination with other
therapies for a wide range of tumor types. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the CTLA-4 blockade bioassay illustrated in the figure below on the left, ADG116 was observed to exhibit weaker blocking than ipilimumab of CTLA-4's ability to inhibit CD80- and
CD86-induced IL-2 production. This result supports our belief that ADG116 can function as a CTLA-4 checkpoint inhibitor with weaker activity than ipilimumab, which may result in less systemic
autoimmune side effects on normal tissues. On the other hand, ADG116 was observed to exhibit notably stronger ADCC activity than ipilimumab in the </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> assay shown in the figure below on the right. Since CTLA-4 is expressed on regulatory T-cells, we believe that ADG116 offers a potential advantage over ipilimumab </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=170,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=894572,FOLIO='167',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_du17601_1_168"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>in
depleting regulatory T-cells by means of ADCC. We subsequently investigated this </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> in a syngeneic mouse tumor model. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g506507.jpg" ALT="GRAPHIC" WIDTH="639" HEIGHT="240">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
compare ADG116's </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> antitumor activity to ipilimumab, we utilized a subcutaneous MC38 mouse syngeneic colon cancer model in
hCTLA-4, knock-in, or KI, C57BL/6 mice. We selected the hCTLA-4 KI mice as ipilimumab does not cross-react with mouse CTLA-4. As shown in the figure below, ADG116 was observed in this study to exhibit
stronger antitumor activity than ipilimumab (ADG116 at 0.2 mg/kg induced equivalent antitumor response as 1 mg/kg of ipilimumab). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g721330.jpg" ALT="GRAPHIC" WIDTH="475" HEIGHT="405">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
shown in the figure below, we measured tumor infiltrating regulatory T-cells in the subcutaneous hCTLA-4 KI MC38 mouse colon cancer model after ADG116 or ipilimumab treatment. Among
the TILs, the percentage of regulatory T-cells was observed to be significantly reduced after ADG116 treatment while the regulatory T-cell reduction after ipilimumab treatment was not significant.
Notably, we observed that regulatory T-cell depletion by ADG116 occurred only in the TME, and not in PBMCs or the spleen. We </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=171,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=430927,FOLIO='168',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_du17601_1_169"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>believe
that these results provide a mechanistic rationale for the enhanced </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> antitumor activity of ADG116 compared to ipilimumab. ADG116 may
reduce the immunosuppressive regulatory T-cell activity specifically in the TME to enhance antitumor immune responses. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g103210.jpg" ALT="GRAPHIC" WIDTH="408" HEIGHT="330">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
illustrated below, in addition to evaluating the efficacy of ADG116 as a monotherapy, we also evaluated ADG116 in combination therapies. ADG116 was observed to have an antitumor
effect with an anti-PD-1 treatment in a Lewis lung cancer syngeneic mouse model. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g154314.jpg" ALT="GRAPHIC" WIDTH="555" HEIGHT="250">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=172,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=620843,FOLIO='169',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_du17601_1_170"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also examined the effects of ADG116 in combination with our CD137 agonistic antibody, ADG106, in a B16F10 melanoma syngeneic mouse model. As shown below, we observed that the
combination of ADG116 with ADG106 enhanced the antitumor activity compared with ADG116 or ADG106 alone. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g252679.jpg" ALT="GRAPHIC" WIDTH="471" HEIGHT="363">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical Toxicology:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We performed preclinical toxicology studies in cynomolgus monkeys and rats to evaluate the toxicity of
ADG116. There were no
abnormal findings in the single-dose toxicology studies. We observed that ADG116 was well tolerated in both cynomolgus monkeys and rats at up to 200 mg/kg. In a GLP-compliant, four-week repeat-dose
toxicology study, ADG116 was tolerated at doses up to 30 mg/kg/dose (five doses per week). In this study, ADG116 related hematology parameter changes, serum chemistry changes, mononuclear infiltration
of predominantly lymphocytes with fewer macrophages into the parenchyma of numerous organs were the primary test article-related effects evaluated. These changes were reversible at
<FONT FACE="SYMBOL">&#163;</FONT> 30 mg/kg/dose, and consistent with the biological role of CTLA-4 in regulating and maintaining peripheral immune tolerance. The NOAEL was considered to be
30 mg/kg/dose in both rats and cynomolgus monkeys. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Development Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of January&nbsp;15, 2021, we have successfully completed the three dose escalation at 0.003 mg/kg, 0.01mg/kg and 0.03mg/kg in the Phase I
clinical trial of ADG116 in Australia. 0.03mg/kg was the dose that we had initiated a Phase I trial of ADG116 in the United States. We intend to use clinical data collected from the Australia trial to
facilitate clinical development in the
United States. We also have a Phase&nbsp;I clinical trial open in the United States for ADG116 as a monotherapy in patients with advanced/metastatic solid tumors; however, we are not currently
enrolling patients in this clinical trial. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


DEEP, BROAD, DIFFERENTIATED PRECLINICAL DISCOVERY PIPELINE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to our three clinical-stage product candidates, ADG106, ADG126 and ADG116, we are building a deep, broad and differentiated
preclinical pipeline. Utilizing our DPL platform and three platform technologies NEObody, SAFEbody, and POWERbody, we have built a portfolio of programs that are at various stages of the drug
discovery and development process. We have the ability to build multiple generations of drugs against the same targets, e.g.,&nbsp;CD137 and CTLA-4, representing the depth of our preclinical
pipeline, as shown in the illustration below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=4,SEQ=173,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=432541,FOLIO='170',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_du17601_1_171"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g432762.jpg" ALT="GRAPHIC" WIDTH="519" HEIGHT="156">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have also built a preclinical and discovery pipeline against multiple validated and novel targets, representing the breadth of our preclinical and discovery pipeline. Our SAFEbody
programs include multiple SAFE NEObodies, such as SAFE CD47 NEObody, as well as a number of undisclosed SAFEbodies. The class of anti-CD47 therapies has attracted significant interests from leading
biopharmaceutical companies given its significant potential. Our POWERbody programs include an immuno-oncology antagonist program, an immuno-oncology agonist program, multiple SAFE antibody drug
conjugate, or ADC, programs and multiple SAFE bispecific T-cell engager programs, which include CD20xCD3 SAFE bispecific antibody, or bsAb, and HER2xCD3 SAFE bsAb.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is an example of our POWERbody preclinical discovery program, which is tumor-associated antigen, or TAA, and CD3 bispecific T-cell engager program. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


SAFEbody TAAxCD3 BsAb T-cell Engager Program  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bispecific T-cell engager antibodies have been explored as a means to recruit cytolytic T-cells to kill tumor cells. This is based on the
simultaneous recognition of an antigen on tumor cells and binding to the CD3 epsilon chain, or CD3<FONT FACE="SYMBOL">e</FONT>, within the T-cell receptor complex on T-cells that bridges
malignant tumor cells directly to CD3<SUP>+</SUP> T-cells. Blinatumomab, or Blincyto, the first bispecific T-cell engager reactive with the B-cell antigen CD19, was approved by the FDA in 2014 for
the treatment of neoplasms. While early studies showed promising clinical efficacy, bispecific T-cell engagers were also hampered by severe dose-limiting toxicities primarily manifesting as cytokine
release syndrome which resulted in a prohibitively narrow therapeutic window. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
our DPL platform, we have developed a deep pipeline of bispecific T-cell engager antibodies for both liquid and solid tumors. To address the safety issues of current CD3 T-cell
engager antibodies, we leveraged our proprietary SAFEbody technology to develop differentiated bispecific T-cell engagers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
TAAxCD3 SAFE-bsAbs comprise anti-human TAA and CD3 SAFEbodies and are intended for the treatment of TAA<SUP>+</SUP> malignancies. Our TAAxCD3 SAFE-bsAb in their activated forms
have been observed to stimulate T-cell activation and TAA<SUP>+</SUP> tumor cell killing. We did not observe our TAAxCD3 SAFE-bsAbs to have visible cytokine release syndrome and other adverse
events in exploratory toxicity studies in cynomolgus monkeys. Our TAAxCD3 SAFE-bsAbs highlight a potential new approach in tumor immunotherapy and provide a rationale for safe and effective treatment
of TAA<SUP>+</SUP> tumors. Based on our preclinical studies, we are moving forward with generating stable cell lines and CMC development of our two TAAxCD3 SAFE-bsAb programs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Studies  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To evaluate the functional activity of parental and SAFE-bsAbs, we tested our bsAbs in multiple cell-based assays. As shown below, the TAAxCD3
parental-bsAb significantly stimulated CD3 signaling in a Jurkat cell-based NFAT reporter assay. Furthermore, the TAAxCD3 parental-bsAb was observed to significantly increase
IFN<FONT FACE="SYMBOL">g</FONT> secretion from CD8<SUP>+</SUP> T-cells and induce TAA overexpressing tumor cell </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=174,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=97293,FOLIO='171',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_du17601_1_172"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>death
by activating CD8<SUP>+</SUP> T-cells in the T-cell-dependent cellular cytotoxicity assay. These results suggest that our CD3 bsAb potentially stimulated T-cells to kill tumor cells.
Consistent with our expectation, the masked SAFE-bsAb was observed to have lower activity in these functional assays. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g177295.jpg" ALT="GRAPHIC" WIDTH="553" HEIGHT="417">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Exploratory Toxicity Study in Cynomolgus Monkeys</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
current efforts in developing therapeutic CD3-based T-cell engagers are impeded by severe dose-limiting toxicities, primarily manifesting as non-specific cytokine
release syndrome, we evaluated the safety results while developing CD3 bsAbs with our SAFEbody technology. Particularly, we evaluated the cytokine and immune-associated events, for TAAxCD3 bsAbs in
cynomolgus monkeys. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cynomolgus
monkeys were dosed intravenously with our TAAxCD3 parental- or SAFE-bsAbs. We observed significant IL-6 release with the parental-bsAb; while we did not observe SAFE-bsAb
induced
IL-6 release at any of the three-dose levels during the testing period, which indicates a noticeable improvement in safety results by SAFEbody masking. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g819917.jpg" ALT="GRAPHIC" WIDTH="640" HEIGHT="129">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=175,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1004958,FOLIO='172',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_du17601_1_173"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g270592.jpg" ALT="GRAPHIC" WIDTH="433" HEIGHT="300">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
cynomolgus monkey treated with the parental-bsAb died approximately 12&nbsp;hours after first dosing at 0.2 mg/kg, likely due to acute cytokine release syndrome, which is
consistent with severe dose-limiting toxicities observed in other bispecific T-cell engager antibodies. Moreover, total T-cells were nearly undetectable at three hours following the initial
parental-bsAb treatment at 0.2 mg/kg. The SAFE-bsAb treated cynomolgus monkey also exhibited reduction of total T-cell counts, but to a lesser degree, and absolute lymphocyte counts rebounded at
24&nbsp;hours after each dosing of SAFE-bsAb. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g595141.jpg" ALT="GRAPHIC" WIDTH="396" HEIGHT="307">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=176,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=960660,FOLIO='173',FILE='DISK103:[20ZDS1.20ZDS17601]DU17601A.;107',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dw17601_1_174"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OUR PLATFORM  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Overview</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
proprietary DPL platform is built upon our insights into precise and dynamic antibody-antigen interaction. As such, our DPL platform has been designed to enable the
discovery of antibodies with better developability properties. By addressing the challenges in traditional antibody design and engineering, we believe that our DPL platform will enable us to improve
the efficacy and safety profile of antibody therapeutics. Our DPL platform is empowered by our computational
platform, artificial intelligence and three innovative technologies: NEObody, SAFEbody, and POWERbody. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AI-Powered Antibody Discovery  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that efficient drug discovery requires significant commitment to resolve three key challenges: 1)&nbsp;the selection of targets
with preclinical and/or clinical validation; 2)&nbsp;the availability of abundant hits at discovery stage for the identification of Pre-Clinical Candidates, or PCC, that usually takes a highly
iterative process from target-to-hits, lead identification and lead optimization; and 3)&nbsp;deep understanding of target biology and MOA from detailed molecular, cellular, </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> preclinical and
human disease models. To address these challenges and to improve antibody R&amp;D productivity, we have designed and built our
AI-powered DPL platform to provide sufficient discovery capacity, capable of generating abundant high quality hits against targets, and then selecting the right leads for extensive preclinical testing
in order to understand their MOAs, their efficacy and safety potential before going for clinical proof of concept testing. Our current focus on oncology portfolio is to establish early clinical proof
of concept, preferably in Phase&nbsp;I trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that it is critical to pair the right PCC with the specific epitope of a chosen target. The affinity and precise orientation by which the specific epitope of a given target is
engaged by the PCC can have a profound impact on the pharmacology and toxicity of drug candidate. Therefore, we believe precision design and engineering of antibody-based drugs make a fundamental
difference on the success of a drug discovery program. As demonstrated by extensive preclinical data of our ADG106, ADG126 and ADG116 programs and early clinical data of our ADG106 program, targeting
the conserved epitope of CD137 by ADG106 and that of CTLA-4 by ADG126/ADG116, respectively, across humans, monkeys and mice can give rise to novel biological and pharmacological activities. The broad
species cross-reactivity of these NEObody drug candidates above can facilitate seamless translational studies from different immune-competent syngeneic tumor models to monkeys, and then subsequent
clinical trials in humans. The novel MOA and biology concerning CD137 and CTLA-4 targets include their regulation in peripheral and tumor microenvironments, the involvement of different immune cells
upon target engagement such as NK cells by anti-CD137 ADG106 agonist and T-regulatory cells by anti-CTLA-4 specific antibodies ADG116 and ADG126. We believe these examples provide strong support for
our proposal to search for "The Right PCC" that is paired with the specific epitope of a given target in order to unlock the biology of such target and its pathway and to facilitate a deep
understanding of its MOA in triggering a cascade of biological and pharmacological events leading to disease control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to search for "The Right PCC", our proprietary DPL platform uses a deep learning approach to explore the conformational diversity of antibody binding sites. Our DPL platform
combines AI algorithms and ever-increasing big data in antibody sequence, structure, and binding epitope and affinity from public and our own proprietary databases to design, construct and screen
high-quality proprietary antibody libraries with well-defined sequence, scaffold and biophysical attributes for antibody drug discovery. Our computational engine combines software, AI and
visualization tools to mine, organize, compute, and interactively explore these immense multidimensional big data sets. We
iteratively inform wetlab experimentation with </FONT><FONT SIZE=2><I>in silico</I></FONT><FONT SIZE=2> computation, and vice versa. By exploiting conformational diversity through the combination of
our proprietary computational algorithms with AI, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=177,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=536215,FOLIO='174',FILE='DISK103:[20ZDS1.20ZDS17601]DW17601A.;60',USER='CHE105939',CD=';1-FEB-2021;01:27' -->
<A NAME="page_dw17601_1_175"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>we
have designed and precisely constructed approximately one trillion (10<SUP>12</SUP>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are
recognized by an antibody) coverage and robust CMC attributes. The antibodies discovered can be further engineered into NEObody, SAFEbody and POWERbody antibodies depending on the targeted product
profile of a given therapeutic target. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ADG106, ADG126 and ADG116 clinical programs illustrate how our AI-powered DPL platform has improved our R&amp;D productivity. Our DPL library is a large physical phage library
(~10<SUP>12</SUP>) that contain our AI-powered synthetic designer antibodies with flexible antibody binding interface. The combination of binding interface flexibility with the variation of amino
acid sequences in the antigen binding interface exponentially increases the conformational diversity of our AI-powered DPL libraries, far beyond conventional natural or synthetic antibody libraries.
Our AI-Powered DPL library screening against CD137 or CTLA4 antigens have yielded a large number of high affinity primary hits. For example, our anti-CD137 agonist antibody ADG106 was identified from
60 high affinity primary hits with a wide range of epitope diversity in terms of their species cross-reactivity, which compared favorably with the number and epitope diversity of high affinity
anti-CD137 antibody hits reported by our global peers on their publicly filed documents. Our anti-CTLA-4 antibody ADG116 was identified from 74 high affinity primary hits with a wide range of epitope
diversity in terms of their species cross-reactivities: 19 clones are human, monkey, canine and mouse cross-reactive; 12 clones are human and monkey cross reactive but weak mouse cross-reactive; 32
clones are human and monkey cross-reactive; 11 clones only recognize human CTLA-4. The abundant discovery hits with diversified binding epitopes for varying degree of species cross-reactivity show the
power of our AI-powered DPL platform not only in creating novel ADG106 and ADG116 NEObodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across
different species of a given antigen for both CD137 and CTLA-4 to enable translational studies from immune-competent animal tumor models to human patients due to their broad species
cross-reactivities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the high affinity and species cross-reactive primary hits from our DPL library screening saves time and cost from primary hits to straight PCC. The broad species
cross-reactivity of the primary hits also streamlines lead identification through simple syngeneic tumor models for safety and efficacy testing. The robust CMC attributes of our DPL library are
designed to also eliminate the requirement to optimize antibody sequences before starting CMC process for IND enabling and formulation studies. Furthermore, we believe our AI-powered dynamic precision
library of approximately one trillion (10<SUP>12</SUP>) antibody sequences expands the diversity at the start of discovery to maximize the chance that suitable leads are found on the first pass. In
conclusion, we believe our AI-powered antibody discovery and engineering DPL platform significantly increases R&amp;D productivity for antibody drug discovery. It has enabled us to generate highly
differentiated PCC molecules that we believe can target the conserved epitope across different species for novel MOAs and also facilitate seamless translational studies from animals to human via their
broad species cross-reactivity.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Briefly,
our AI-powered antibody discovery engine includes six steps: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>First
principle of antibody folding and dynamics. We fold the antibody primary amino acid sequence into three-dimensional structures based on machine learning or
homology modeling in combination with the Molecular Dynamic Simulation in the presence and absence of dynamic interaction with their antigen targets.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>AI-powered
deep learning of antibody sequence and structure and binding epitopes. AI algorithm and machine learning have been widely used to map protein sequence and
structure variation and connectivity. Deep learning has been used to map the antibody and antigen epitope in order to learn the landscape of the epitope space and their correlation with antibody
binding interface. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=178,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=651494,FOLIO='175',FILE='DISK103:[20ZDS1.20ZDS17601]DW17601A.;60',USER='CHE105939',CD=';1-FEB-2021;01:27' -->
<A NAME="page_dw17601_1_176"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Antibody
design that combines the conformational diversity with primary amino acid sequence variation. We have designed antibody libraries that contain dynamic
binding units and their combination in the context of different CDRs and framework scaffold to capture their conformational diversity of antibody binding interface in combination with variation in
primary amino acid sequences far beyond conventional natural or synthetic antibody libraries.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Synthetic
dynamic precision library by AI-powered computational design. The amino acid sequence library is converted into synthetic DNAs that can be assembled and
constructed for phage and yeast library screening.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Directed
evolution by phage and yeast libraries. The synthetic phage and yeast libraries can be screened semi-automatically for more than 100 antigens to yield high
affinity primary hits.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>PCC
identification by targeting conserved epitope with broad species cross-reactivity to unlock the deep biology of target and its MOA upon target engagement by the
PCC. PCC is designed and selected to target the conserved epitope of a given target across different species. Traditionally, affinity of primary hits from synthetic antibody libraries have to be
improved before subjecting them to extensive in vitro and in vivo assays for lead identification and optimization through an iterative process between functional assays and antibody engineering. Our
DPL platform can yield high affinity primary hits, which can then become product candidate leads subject to functional characterization without intensive iterative lead optimization process. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following diagram illustrates how AI algorithms and big data empower rapid antibody discovery with improved productivity: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g239698.jpg" ALT="GRAPHIC" WIDTH="640" HEIGHT="328">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>NEObody</U><SUP>TM</SUP> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEObody
technology is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic
antibody technologies through its innovative designs and precise constructions. Our designs are based on critical insights gained from extensive studies of antibody structural variability made
possible by our proprietary in-house developed computational tools. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=179,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=957689,FOLIO='176',FILE='DISK103:[20ZDS1.20ZDS17601]DW17601A.;60',USER='CHE105939',CD=';1-FEB-2021;01:27' -->
<A NAME="page_dw17601_1_177"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Innovative antibody library design:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We believe that diversity of an antibody library should be defined at the quaternary structural
level, instead of
the traditional primary amino acid sequence level. Comparison of structural and sequence diversity revealed that variability as assessed by structural alignments was generally lower than the
variability observed with sequence alignments. Based on our deep understanding of chemical principles governing antibody folding and extensive analysis of a vast
number of antibody structural variability, through novel statistical tools developed in-house, we have redefined the antibody hyper-variable regions, or HVRs, that are critical for antigen
recognition. These HVRs, as defined based on structural variability, are distinct from but complementary with complementarity-determining regions that are traditionally defined based on amino acid
sequence variability. In addition, we have defined and designed dynamic motifs which adopt multiple conformations and incorporated them into our DPL antibody library design to enable the coverage of a
wide range of structural diversity with a limited number of amino acid sequences. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Broad epitope coverage, particularly of evolutionarily conserved epitopes:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;NEObody technology enables us to discover antibodies
targeting numerous
epitopes against a broad range of antigens. In particular, we focus on the antibodies targeting the conserved epitopes of divergent antigens. These species cross-reactive antibodies not only have the
potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical
to clinical studies. Our NEObody technology has been evaluated in preclinical studies with numerous antigens, including some difficult antigens such as membrane or oligomeric proteins. The success
criteria in our preclinical assays include high affinity of primary hits with diverse antibody sequences, broad epitope coverage, as well as favorable CMC development properties. For example, ADG106
was discovered using our NEObody technology to target a conserved epitope of CD137 that mostly overlaps with its ligand binding site, which we believe enables ADG106 to activate CD137 in its natural
ligand-like fashion, with complete blocking of CD137L, which may differentiate it from two other investigational leading CD137 agonistic antibodies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enhanced developability profiles:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;NEObody technology is designed to preemptively eliminate the chemically unstable sites, or
combinations of
"problematic" sites that may pose risk for downstream manufacturing processes. This precision design strategy coupled with precision oligonucleotides and library construction have resulted in our
high-quality antibody discovery libraries. The primary hits from these libraries generally lack severe "problematic" and spurious amino acid sites, and therefore, may offer promising characteristics
for further development. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>SAFEbody</U><SUP>TM</SUP> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAFEbody
is our proprietary differentiated precision antibody masking technology designed to enable an antibody to bind its target specifically only after conditional
activation of the antibody in target tissues. By engineering our antibody therapeutic candidates to selectively activate in the TME, our SAFEbody technology is designed to improve safety and
tolerability of antibody therapeutics while simultaneously maintaining clinical activity. Through this technology, we believe we can provide a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=180,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=201557,FOLIO='177',FILE='DISK103:[20ZDS1.20ZDS17601]DW17601A.;60',USER='CHE105939',CD=';1-FEB-2021;01:27' -->
<A NAME="page_dw17601_1_178"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>solution
to on-target off-tumor toxicity, one of the long-lasting challenges with many approved antibody therapeutics. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g895358.jpg" ALT="GRAPHIC" WIDTH="621" HEIGHT="222">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activation in the TME:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;SAFEbody technology is designed to mask an antibody binding interface with a masking motif, which then prevents
an antibody
from binding to its target in healthy tissues. The masking motif is designed to activate or unmask the antibody binding in the TME where certain activation conditions such as a protease is upregulated
as compared to healthy tissues, allowing the antibody to bind to and attack the tumor. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while
remaining largely in an inactive state in healthy tissues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Innovative masking moiety library design:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Leveraging computational biology, we have designed multiple masking libraries with structured
scaffolds and
balanced chemistry of amino acids with favorable attributes for masking, easier manufacturing processes, and lower immunogenicity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Precision masking without self-inhibition:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;To differentiate from other masking technologies, our antibody masking moieties have been
designed and
discovered in the right context in an effort to provide greater expression and specificity with no self-inhibition upon activation. We employ sophisticated screening processes for rapid discovery of
highly masked SAFEbody product candidates subject to systematic tuning of the masking efficiency to match the target biology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Improved pharmacology and safety features:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We believe our SAFEbody technology has the potential to also reduce the dose-limiting
toxicities observed
in combination therapies and thus potentially enable
new combinations with other cancer therapies that were previously difficult to use. Our SAFEbody technology may also provide favorable for PK and PD profiles for antibodies and ADCs to reduce the drug
clearance from circulation in healthy tissues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
SAFEbody technology has been applied to multiple target antibodies that have been either discovered with NEObody technology or supplied by our partners. Our ADG126 was discovered by
combining SAFEbody technology with its parental antibody discovered through our NEObody technology. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>POWERbody</U><SUP>TM</SUP> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In recent years, multiple modalities have been developed to enhance the potency of traditional antibody drugs. These include Fc engineering for enhanced ADCC or
cross-linking efficiency, ADCs and TCEs. Some of them, such as TCEs, can be so potent that only micrograms of the active ingredient are needed for a single dose, in contrast to regular antibody where
hundreds of milligrams or even grams are required for a single dose. NEObodies can be converted into SAFEbodies which can be further reformatted into SAFEbody ADCs, bispecific TCEs, and Fc engineered
antibodies. We refer to these to as POWERbodies to indicate their potentially enhanced potency and safety profile.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=181,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=764550,FOLIO='178',FILE='DISK103:[20ZDS1.20ZDS17601]DW17601A.;60',USER='CHE105939',CD=';1-FEB-2021;01:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dy17601_1_179"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe SAFEbodies can be applied to these modalities. Since an unmasked ADC, TCE, or Fc engineered antibody can be so potent, there is the risk that it will
cause severe toxicity due to damage to healthy tissues or fast lysis of tumor cells, resulting in a narrow therapeutic window, as is frequently observed with some ADC drugs or TCEs that have been FDA
approved or are in clinical development. We believe our POWERbodies enabled by our SAFEbody technology with ADC, TCE, etc., due to their inactivity in circulation and specific local activation in TME,
could significantly reduce toxicity and at the same time retain efficacy.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POWERbody
technology aims to boost the efficacy of antibody candidates with safety profiles enhanced by our SAFEbody technology. We believe our POWERbody technology will unleash the full
power of antibody-based therapeutics to kill cancer cells with enhanced safety, achieving full potential in antibody based therapies such as bispecific TCEs and ADCs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


COLLABORATIONS WITH BIOPHARMACEUTICAL COMPANIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We enter into collaborations with biotechnology and pharmaceutical companies to advance the development and commercialization of our technology
platforms and product candidates. We seek collaborations that will allow us to retain significant future participation in product sales through royalties paid on net sales. For example, we have
entered into agreements with ADC Therapeutics to develop antibody drug conjugates against tumor targets using our SAFEbody technology. In addition, we have also out-licensed the Greater China rights
to an anti-PD-L1 antibody and second antibody candidate to Dragon Boat Pharmaceuticals and its affiliates. Our collaborations empower our growth in many ways, including generating cash flow and
revenues that partially offset expenditures on our internal research and development programs, expanding our knowledge base regarding antibody technology across multiple targets and antibodies
provided by our partners, and providing us with future pipeline opportunities through opt-in licensing rights to new product candidates created using our technology. Below are the highlights of
collaborations we formed with our business partners: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exelixis Collaboration and License Agreement

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2021, we entered into a collaboration and license agreement (the "Exelixis Agreement") with Exelixis,&nbsp;Inc., pursuant to which
we agreed to generate masked antibodies with our SAFEbody technology against an initial target and a second target to be selected by Exelixis. Pursuant to the Exelixis Agreement, we granted Exelixis
an exclusive, worldwide, sublicensable license to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by us
with respect to both targets.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to certain exclusivity provisions limiting our right to research, develop, make, and commercialize any other antibodies directed to the selected targets during the term of
the Exelixis Agreement, subject to exceptions for antibodies with sequence identities that differ by a specified amount. Exelixis is subject to certain exclusivity provisions limiting its rights to
research, develop, make, and commercialize any other masked antibodies directed to the selected targets during the term of the Exelixis Agreement, subject to exceptions for antibodies with sequence
identities that differ by a specified amount or use different masking technology.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are required to use commercially reasonable efforts to generate masked antibodies in accordance the program plan for each target at our cost. Exelixis is required to use commercially
reasonable efforts to further develop, obtain regulatory approval and commercialize a product for each target.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Exelixis Agreement, we are entitled to receive an $11,000,000 upfront payment. In addition, we could be eligible to receive, on a target-by-target basis, up to $27,500,000 in
development milestone payments and up to $100,000,000 in regulatory milestone payments upon the achievement of specified development and regulatory milestones, respectively, and up to $262,500,000 in
sales milestone

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=182,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=555247,FOLIO='179',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_180"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


payments upon the achievement of specified commercial milestones. In the aggregate, we could be eligible to receive up to $55,000,000 in development milestone payments, $200,000,000 in regulatory
milestone payments, and up to $525,000,000 in sales milestone payments for both targets under the Exelixis Agreement. In addition, we are entitled to receive mid-single-digit percentage net
sales-based royalties on products developed under the Exelixis Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until
the latest of (i)&nbsp;the tenth anniversary of the first commercial sale of such product in such country, (ii)&nbsp;the expiration of the last-to-expire of certain specified patents that cover
such product's composition of matter or method of use as sold in such country or (iii)&nbsp;the expiration of regulatory or data exclusivity for such product in such country.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Exelixis Agreement will expire upon the termination of all royalty obligations. Exelixis will own the inventions relating to the compounds arising in connection with the Exelixis
Agreement and we will own the inventions relating to our platform. Exelixis may terminate the Exelixis Agreement without cause, in its entirety or on a target-by-target basis, upon a specified notice
period, and may terminate for safety reasons on a target-by-target basis immediately upon notice. Either party has the right to terminate the Exelixis Agreement for cause upon the other party's
uncured material breach or insolvency, provided that, upon our material uncured breach, Exelixis may elect to instead continue the Exelixis Agreement, and any subsequent milestones or royalty amounts
payable to us after such time will be reduced by a specified percentage. Upon termination of the Exelixis Agreement for any reason, the license granted to Exelixis will terminate.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADC Therapeutics Agreements  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2019, we entered into a material transfer and collaboration agreement (the "ADCT Collaboration Agreement") and a license agreement (the
"ADCT License Agreement") with ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of targeted ADCs.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ADCT Collaboration Agreement</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the ADCT Collaboration Agreement, we agreed to generate masked antibodies with our SAFEbody technology that could be combined with the
pyrrolobenzodiazepine-based cytotoxic payload used in ADC Therapeutics' ADCs to create novel ADCs. ADC Therapeutics entered into the ADCT Collaboration Agreement with us to evaluate the use of our
SAFEbody technology with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license our
SAFEbody&#153; technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of September&nbsp;15, 2020. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Both
parties are required to use commercially reasonable efforts to perform certain development obligations under the ADCT Collaboration Agreement. Additionally, we are subject to
exclusivity obligations to ADC Therapeutics under the ADCT Collaboration Agreement with respect to (i)&nbsp;the targets for which ADC Therapeutics has a license or an option to license and
(ii)&nbsp;the use or licensing of our intellectual property that is necessary or useful to the development plan under the ADCT Collaboration Agreement or that would preclude us from granting to ADC
Therapeutics the licenses under the ADCT License Agreement. ADC Therapeutics owns intellectual property that are specific to the SAFEbodies that we develop under the ADCT Collaboration Agreement with
respect to the two elected targets, and we will own all intellectual property developed under the ADCT Collaboration Agreement that relates generally to our SAFEbody platform. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the ADCT Collaboration Agreement, we are eligible to receive up to US$1,600,000 in consideration for our exclusivity obligations, upon achievement of certain development milestones
and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=183,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=167142,FOLIO='180',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_181"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>upon
ADC Therapeutics' election to proceed with development for the two elected targets. As of the date of this prospectus, we have received US$437,500 in aggregate payments under the ADCT
Collaboration Agreement. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days'
prior written notice to us. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party's uncured material breach of the agreement
or the other party's insolvency-related events. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ADCT License Agreement</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the exercise of the options contained in the ADCT Collaboration Agreement, we have granted ADC Therapeutics, with respect to each elected target, an
exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody
drug conjugates that comprise masked antibodies generated by us under these programs. Subject to certain conditions, including the exercise by ADC Therapeutics of its first option to license our
SAFEbody&#153; technology, ADC Therapeutics will grant us the option to negotiate a license to develop, manufacture and commercialize ADCs containing our SAFEbody&#153; technology in
Greater China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, we could be eligible to receive up to US$166,090,000 in aggregate milestone
payments, in addition to mid-single-digit percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be
payable on a country-by-country and product-by-product basis, until the earlier of (i)&nbsp;the tenth anniversary of the first commercial sale of such product or (ii)&nbsp;the expiration of the
last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement
shall become fully paid up, perpetual and irrevocable. In addition to the contingent milestone and royalty payments, if ADC Therapeutics exercises both of its options granted under the ADCT
Collaboration Agreement, we are also entitled to a mid-six-figure dollar amount annual maintenance fee. ADC Therapeutics has not yet exercised the options contained in the ADCT Collaboration Agreement
as of the date of this prospectus. Therefore, we have not received any payment under the ADCT License Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADC
Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&nbsp;for any
reason or no reason upon thirty days' written notice to us, or (ii)&nbsp;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party
has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party's uncured material breach or insolvency. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sanjin Collaboration/ Out-Licensing Agreements  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>2018 Collaboration Agreements</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2018, we entered into (i)&nbsp;a collaboration agreement (the "Sanjin Greater China Agreement") that covers Greater China with Guilin Sanjin
Pharmaceutical&nbsp;Co.,&nbsp;Ltd. ("Sanjin") and certain of its subsidiaries (collectively, "Sanjin Parties") and (ii)&nbsp;a collaboration agreement (the "Sanjin ROW Agreement", together with
the Sanjin Greater China Agreement, the "2018 Sanjin Agreements") that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, we transferred the
Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the "PD-L1 Project"), including patent rights, patent application rights and
technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties' </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=184,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=572879,FOLIO='181',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_182"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>rights
under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. We also
granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights
and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer
fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay us (i)&nbsp;within the validity period of the patent of PD-L1 molecule, single-digit percentage of net sales of
the products that use the licensed antibody after such products enter the market and (ii)&nbsp;a low to mid-low double-digit percentage of the profits resulting from any transfer of the license to
any third parties depending on the timing of the transfer relative to the development stage of the product. We also received a low-seven figure dollar upfront fee upon the effectiveness of the
agreement from Sanjin Parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Sanjin ROW Agreement, we granted Sanjin a royalty-free license to use all intellectual property relating to (i)&nbsp;the collaboration under the agreement that we
controlled before we entered into the agreement or acquired independently of the agreement and (ii)&nbsp;improvements thereto for the purposes of exploiting its rights and performing its obligations
under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual
property generated from cooperation between us and Sanjin's affiliates in connection with the collaboration will be jointly owned. We have the right to apply for the patents derived from our core and
key technologies pertaining to the PD-L1 molecule in the rest of the world and we retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any
patent transfer fee, licensing fee and gains realized under such transfer. In case we intend to transfer to a third party our share of economic interests in any country outside of Greater China, we
must notify Sanjin and Sanjin will receive a right of first refusal if it pays us a deposit equal to a low double-digit percentage of the consideration that we expect to receive from such third party.
If Sanjin waives the right of first refusal, we can proceed
with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Sanjin. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2018 Sanjin Agreements, we agreed not to (i)&nbsp;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&nbsp;grant any rights associated
with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent us from (i)&nbsp;developing or granting
any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and probody against PD-L1 target and (ii)&nbsp;continuing to
provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies
outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party's ability to comply with its respective obligations under the agreements is
negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement
automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to us all the intellectual property transferred by us to the Sanjin
Parties as well as documents and data provided by us under the 2018 Sanjin Agreements. The 2018 Sanjin Agreements are governed by PRC law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>2019 Collaboration Agreements</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2019, we entered into (i)&nbsp;a collaboration agreement that covers Greater China (the "Dragon Boat Greater China Agreement") and (ii)&nbsp;a collaboration
agreement that covers the regions other than Greater China (the "Dragon Boat ROW Agreement," together with the Dragon Boat Greater China Agreement, the "2019 Dragon Boat Agreements"), with Dragon Boat
Biopharmaceutical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=185,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=864691,FOLIO='182',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_183"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>(Shanghai)
Limited. ("Dragon Boat"), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, we will transfer the Chinese intellectual property directly related to a certain
monospecific antibody molecule (the "Specified Molecule") that binds to a specified target (the "Specified Project"), including the patent rights, patent application rights and technologies based on
the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat's rights under the agreement, including but not
limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. We also granted Dragon Boat a royalty-free license to use
our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the
agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China,
including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay us (i)&nbsp;RMB6,000,000 (equivalent to approximately US$0.9&nbsp;million)
milestone payments and (ii)&nbsp;a single-digit percentage of net sales of the products that within the validity period of the patent of the Specified Molecule use the licensed antibody after such
products enter the market. Dragon Boat also paid us a mid-six figure dollar upfront fee upon the signing of the agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Dragon Boat ROW Agreement, we granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&nbsp;the collaboration under the agreement
that we controlled before we entered into the agreement or acquired independently of the agreement and (ii)&nbsp;improvements thereto for the purposes of exploiting its rights and performing its
obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any
intellectual property generated from cooperation between us and Dragon Boat in connection with the collaboration will be jointly owned. We have the right to apply for the patents derived from our core
and key technologies pertaining to the Specified Molecule in the rest of the world and we retain a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not
limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case we intend to transfer to a third party our share of economic interests in any country outside of
Greater China, we must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays us a deposit equal to a low double-digit percentage of the consideration that we expect to
receive from such third party. If Dragon Boat waives the right of first refusal, we can proceed with the transfer, provided that the final transaction price with the third party is not lower than the
amount of the offering price that was included in our notice to Dragon Boat. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2019 Dragon Boat Agreements, we agreed not to (i)&nbsp;independently develop any monospecific antibodies that bind to the specified target or (ii)&nbsp;grant any rights
associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent us from (i)&nbsp;developing
or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and probody against the specific target and
(ii)&nbsp;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct
combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party's ability to comply with its obligations under the
agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each
agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to us all the intellectual property transferred by us to
Dragon Boat as well as documents and data provided by us under the 2019 Dragon Boat Agreements. The 2019 Dragon Boat Agreements are governed by PRC law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=186,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=130090,FOLIO='183',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_184"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this prospectus, we have received approximately US$1.5&nbsp;million and US$0.6&nbsp;million in aggregate payments under the 2018 Sanjin Agreements and the 2019
Dragon Boat Agreements, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


INTELLECTUAL PROPERTY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protection of our intellectual property is fundamental to the long-term success of our business. Specifically, our success is dependent on our
ability to obtain and maintain protection for our technology and the know-how related to our business, defend and enforce our intellectual property rights, and operate our business without infringing,
misappropriating, or otherwise violating valid and enforceable intellectual property rights of others. Our patent strategy is focused on seeking coverage for our core technologies and products, such
as the DPL platform, ADG106, ADG126, and ADG116. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product
candidates, and continuing innovation to develop, strengthen, and maintain our proprietary position in our technology, platforms and product candidates. We expect to rely on data exclusivity, market
exclusivity, patent term adjustment and patent term extensions when available. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of January&nbsp;15, 2021, we own two issued patents and nine pending patent applications in China and we also own two issued patents and seven pending applications in Europe filed
with the European Patent Office, thirteen pending patent applications in the United States and 67 pending patent applications in other jurisdictions. Our patents and patent applications cover our key
technologies and products, including the DPL platform, ADG106, ADG126, and ADG116. Excluding any patent term adjustment and patent term extension, our currently issued patents are expected to expire
from 2033 to 2034. If any patents issue from our pending patent applications, excluding any patent term adjustments and patent term extension, such patents will be expected to expire from 2033 to
2041. The following table summarizes material pending patent applications in the United States, China, Europe and under Patent Cooperation Treaty, or PCT, covering our product candidates, including
ADG106, ADG126, ADG116 and ADG104. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Product Candidates

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title of Patent<BR>
Application </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Type of<BR>
Patent<BR>
Applications<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Jurisdiction </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ADG106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Anti-CD137 molecules and uses thereof</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Composition of matter/ method of use/ method of making</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>United States of America China and European Patent Office</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Combination therapy comprising anti-CD137 antibodies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>method of treatment/ method of use</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>United States of America</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> ADG126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Anti-CTLA4 antibodies and methods of making and using the same</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Composition of matter/ method of use/ method of making</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>United States of America, China and European Patent Office</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> ADG116</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Anti-CTLA4 antibodies and methods of making and using the same</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Composition of matter/ method of use/ method of making</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>United States of America, China and European Patent Office</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> ADG104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Anti-PD-L1 antibodies and use thereof</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Composition of matter/ method of use/ method of making</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>United States of America and European Patent Office</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>You
should read the Risk Factors included elsewhere in this prospectus for important information about risks posed by the loss of patent protection, in particular
the risks described under "Risk Factors&#151;Risks Related to Our Intellectual Property". </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=187,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=448739,FOLIO='184',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_185"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes material issued patents in Europe and China covering our proprietary technologies. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="23%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Application No.

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title of Patent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Type of Patent<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Jurisdiction </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>13877452.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>An Integrated System for Library Construction, Affinity Binder Screening and Expression Thereof</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Method</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>European Patent Office</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> 201380074656.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>An Integrated System for Library Construction, Affinity Binder Screening and Expression Thereof</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Method</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>China</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> 14908246.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Methods and Systems for Autoinduction of Protein Expression</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Method</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>European Patent Office</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> 201410789857.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Filter Vector System And Its Applications</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Method</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>China</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>You
should read the Risk Factors included elsewhere in this prospectus for important information about risks posed by the loss of patent protection, in particular
the risks described under "Risk Factors&#151;Risks Related to Our Intellectual Property". </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
continually assess and refine our intellectual property strategy as we develop new platform technologies and product candidates. To that end, we are prepared to file additional patent
applications relating to the new technologies that we develop if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities. In
addition to filing and prosecuting patent applications in China and the United States, we may elect to file counterpart patent applications in additional countries and regions where we believe such
foreign filing is likely to be beneficial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
with other biopharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our platform technologies and product candidates
will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned pending patent applications, and any patent applications that we may in the
future file or license from third parties may not result in the issuance of patents. In addition, the term of individual issued patents depends upon the legal term for patents in the countries in
which they are obtained. In most countries in which we have filed or intend to file in the future, including the United States, the patent term is 20&nbsp;years from the earliest filing date of a
nonprovisional patent application. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the
applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. The life of a patent, and the protection it
affords, is therefore limited and once the patent life of our issued patents has expired, we may face competition, including from other competing technologies. As a result, our patent portfolio may
not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
seek to ensure that investments made into the development of our technology are protected by relying on a combination of patents, trademarks, copyrights, trade secrets and contractual
rights, including license agreements. In addition to our patent portfolio described above, as of January&nbsp;15, 2021, our PRC subsidiary owns 25 registered trademarks relating to various aspects
of our operations, and two registered domain names in China. To protect our rights, we seek to enter into confidentiality </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=188,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=223254,FOLIO='185',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_186"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>agreements,
nondisclosure agreements and employee disclosure and invention assignment agreements with our employees, contractors and other third parties who may have or need access to our confidential
information. We have also employed internal policies, encryptions and data security measures to protect our proprietary rights. However, there can be no assurance that our efforts will be successful.
If our employees, contractors or other third parties violate these agreements or otherwise infringe upon, misappropriate or otherwise violate our intellectual property rights, we may seek to enforce
our rights against such parties. In addition, from time to time, third parties may initiate litigation against us alleging infringement, misappropriation or other violation of their proprietary rights
or declaring their noninfringement of our intellectual property rights. An adverse result in any such proceeding could enjoin the commercialization of our technology platform and product candidates,
result in significant damages, and have a material adverse effect on our business. Even if we are
successful in any such litigation, we may be required to incur significant costs and dedicate significant personnel time in defending such litigation. For more information on these and other risks
related to intellectual property, see "Risk Factors&#151;Risks Related to Our Intellectual Property". </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MANUFACTURING AND SUPPLY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently operate a cGMP-compliant manufacturing facility. We currently outsource the GMP manufacturing and quality control testing
and cGMP quality assurance release of clinical trial material to WuXi Biologics. We have entered into a framework agreement with Wuxi Biologics, under which it provides services to us on a
project-by-project basis. We are also working with other qualified manufacturers to provide diversified manufacturing and supply services. We also monitor the manufacturing activities of clinical
trial material to ensure the compliance with local and international cGMP and applicable regulations. We have assembled a seasoned internal team with rich experience to drive and monitor the
manufacturing process. Currently, Wuxi Biologics obtains raw materials and supplies for manufacturing activities from multiple suppliers who we believe have sufficient capacity to meet our demands. We
expect to continue our relationships with WuXi Biologics but are continuously evaluating multiple vendors globally to ensure continuous supply of products for global clinical trials. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


COMPETITION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries are highly competitive and characterized by continuing technological advancement, significant
competition and an emphasis on intellectual property. While we believe that our management's research, development and commercialization experience provide us with competitive advantages, we face
potential competition from many different sources, including global biopharmaceutical companies, major multinational pharmaceutical companies, established biotechnology companies, specialty
pharmaceutical companies, universities, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish
collaborative arrangements for the research, development, manufacturing and commercialization of cancer immunotherapies. Any product candidates that we successfully develop and commercialize will
compete with new immunotherapies and other drug products that may become available in the future. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer and more effective, have fewer or less severe side effects or are more convenient than any products that we may develop. Our competitors also may obtain FDA or other regulatory
approval for their products more rapidly than we do. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
compete in the segments of the pharmaceutical, biotechnology and other related markets that develop cancer treatments. There are many other companies that have commercialized and/or
are
developing immuno-oncology treatments for cancer, including large pharmaceutical and biotechnology companies. Many of our competitors have significantly greater financial, technical and human
resources than we have, and mergers and acquisitions in the biopharmaceutical industry may result in even more </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>186</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=189,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=310116,FOLIO='186',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_187"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. Our commercial opportunities could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer
or less costly than our current or future product candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead product candidate, ADG106, is an investigational fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb that is designed to target a unique conserved epitope of CD137. While
potentially unique for this type of product candidate, we expect our primary competition to be with other clinical-stage CD137 agonist product candidates. According to Frost&nbsp;&amp; Sullivan, there
are no marketed CD137 agonist drugs. The two leading molecules in clinical trials are utomilumab (PF-05082566) from Pfizer and urelumab (BMS-663513) from BMS. The following chart reflects CD137
agonist mAb programs in the global pipeline: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g315135.jpg" ALT="GRAPHIC" WIDTH="421" HEIGHT="396">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADG126
and ADG116 are investigational, fully human anti-CTLA-4 mAbs generated through our NEObody and SAFEbody technologies, respectively. We expect our primary competition to be within
the CTLA-4 antibody market, especially with ipilimumab. According to Frost&nbsp;&amp; Sullivan, as of July&nbsp;31, 2020, Yervoy (ipilimumab) from BMS is the only market CTLA-4 drug targeting cancer
with six indications including monotherapy and combination therapies approved by FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2020, BMS submitted a biologics license application, or BLA, with the FDA for Opdivo in combination with Yervoy for the first-line treatment of patients with metastatic or
recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. In April 2020, the FDA approved Opdivo plus Yervoy, administered concomitantly with a limited course of chemotherapy, for the first-line
treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
Yervoy is the only marketed CTLA-4 antibody drug, there are over ten CTLA-4 antibody monotherapies and combination therapies in clinical development globally, according to
Frost&nbsp;&amp; Sullivan. Among the pipeline candidates, tremelimumab by AstraZeneca, as part of a combination </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>187</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=190,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1006027,FOLIO='187',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_188"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>therapy
with durvalumab, is undergoing Phase&nbsp;III clinical trial for six different indications. Four other drug candidates are undergoing Phase&nbsp;II clinical trial, according to
Frost&nbsp;&amp; Sullivan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no marketed CTLA-4 antibody drugs in China, but at least seven CTLA-4 antibodies pipelines are in clinical development, according to the Frost&nbsp;&amp; Sullivan Report. For
example, BMS has submitted a new drug application for ipilimumab; tremelimumab by AstraZeneca has entered Phase&nbsp;III clinical trials for indications including NSCLC, small cell lung cancer and
melanoma. Major limitations of CTLA-4 mAbs include toxicity. According to the Frost&nbsp;&amp; Sullivan Report, nivolumab and ipilimumab combination therapy has shown relatively higher toxicity in
clinical studies even at lower dosages, which was observed from the published clinical data. We believe that the continued expansion of indications, and the launch of innovative novel CTLA-4
antibodies with potential for higher safety and better efficacy may increase the market for CTLA-4 antibodies significantly. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


EMPLOYEES  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had a total of 198 employees as of December&nbsp;31, 2020. The following table sets forth the numbers of our employees categorized by
function as of December&nbsp;31, 2020. We also engage consultants and part-time staff as and when appropriate.

</FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Function

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number<BR>
of<BR>
Employees </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Research and Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computational Biology and Informatics</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Technology Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Drug Discovery</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clinical Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General Administration</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HR</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IT</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administration</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business Development and Marketing</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
success depends on our ability to attract, motivate, train and retain qualified personnel. We believe we offer our employees competitive compensation packages and an environment that
encourages self-development. We regularly recruit new talents through campus events and colleague referral to
build and develop our own talent pool. Through employee succession planning, we help employees understand their career path within Adagene, motivate them to remain in the organization and to achieve
their personal career goals. Other initiatives for talent retention include executive coaching, employee surveys or engagement, training and development, compensation and rewards. As a result of these
efforts, we have generally been able to attract and retain qualified personnel and maintain a stable core management team. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
required by regulations in China, we participate in various employee social security plans that are organized by municipal and provincial governments, including pension insurance,
unemployment insurance, maternity insurance, work-related injury insurance, medical insurance and housing funds. We are required under PRC law to make contributions to employee benefit plans at
specified percentages of the salaries, bonuses and certain allowances of our employees, up to a maximum amount specified by the local government from time to time. We have granted, and plan to
continue to grant, share-based incentive awards to our employees in the future to incentivize their contributions to our growth and development. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>188</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=191,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=305861,FOLIO='188',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<A NAME="page_dy17601_1_189"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that we maintain a good working relationship with our employees, and we have not experienced any material labor disputes. None of our employees is subject to a collective
bargaining agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FACILITIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our headquarter is based in Suzhou, China, where we have our main administrative and laboratory offices, which are approximately 2,946 square
meters in size. The expiration dates of the lease agreements for this facility range from March&nbsp;31, 2021 to October&nbsp;7, 2023. We also have a 2,673&nbsp;square feet facility in San
Diego, California for laboratory, research and development functions, the lease for which expires on August&nbsp;31, 2023. We believe our current facilities are sufficient to meet our near-term
needs and we do not expect difficulties in renewing lease agreements for our facilities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


INSURANCE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We provide social security insurance including pension insurance, unemployment insurance, work-related injury insurance and medical insurance
for our employees. We maintain property insurance, general liability insurance, products/completed operations insurance, auto and international auto liability insurance, workers compensation
insurance, international workers compensation insurance, accident and health insurance and director and officer liabilities insurance. We consider our insurance coverage sufficient and in line with
market practice for our business operations in the industry. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


LEGAL PROCEEDINGS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are
not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations,
financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>189</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=192,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=820315,FOLIO='189',FILE='DISK103:[20ZDS1.20ZDS17601]DY17601A.;113',USER='CHE105939',CD=';1-FEB-2021;01:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ea17601_1_190"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ea17601_regulation"> </A>
<A NAME="toc_ea17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REGULATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Regulation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other
things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising,
promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party
contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct
studies or seek approval or licensure of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the FDA regulates biologic products under the Federal Food, Drug and Cosmetic Act, its implementing regulations and other laws, including, in the case of biologics,
the Public Health Service Act. Our product candidates are subject to regulation by the FDA as biologics. Biologics require the submission of a BLA and licensure, which constitutes approval, by the FDA
before being marketed in the United States. None of our product candidates has been approved by the FDA for marketing in the United States, and we currently have no BLAs pending. Failure to comply
with applicable FDA or other requirements at any time during product development, clinical testing, the approval process or after approval may result in administrative or judicial sanctions. These
sanctions could include the FDA's refusal to approve pending applications, suspension or revocation of approved applications, warning letters, product recalls, product seizures, total or partial
suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completion of preclinical laboratory tests and animal studies performed in accordance with the FDA's GLP regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant
changes are made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials to establish the safety and effectiveness of the proposed biologic product
candidate for its intended indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparation of and submission to the FDA of a BLA when adequate data are obtained from pivotal clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a determination by the FDA within 60&nbsp;days of its receipt of a BLA to accept the application for review; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of an FDA Advisory Committee review, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced
to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product's continued safety, purity and potency, and of selected clinical
investigation sites to assess compliance with Good Clinical Practices, or GCP regulations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>190</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=193,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=685037,FOLIO='190',FILE='DISK103:[20ZDS1.20ZDS17601]EA17601A.;28',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ea17601_1_191"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical and Clinical Development  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND application to the FDA. An IND
application is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND application is on the general investigational plan and
the protocol(s) for clinical trials. The IND application also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic
characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become
effective before human clinical trials may begin. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns
or questions about the proposed clinical trial. If the IND sponsor is not able to address FDA's concerns satisfactorily within the 30-day time frame, the IND may be placed on clinical hold. The IND
sponsor and the FDA must resolve any outstanding concerns or questions before the IND is cleared by the FDA and the clinical trial can begin. Submission of an IND therefore may or may not result in
FDA authorization to begin a clinical trial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the
requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the
objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Generally, a separate submission to the existing IND must be made for each
successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must
review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the
IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to
meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB,
which provides recommendation on whether or not a study should move forward at designated check points based on access to certain data from the study. The DSMB may recommend halting of the clinical
trial if it determines that there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing
clinical trials and clinical trial results to public registries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Phase&nbsp;I&#151;The investigational product is initially introduced into healthy human subjects or patients with the target disease
or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with
increasing doses, and, if possible, to gain early evidence on effectiveness. For investigational products developed for oncology indications, the Phase&nbsp;I trials are normally conducted in
patients with serious or life-threatening diseases without other treatment alternatives. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Phase&nbsp;II&#151;The investigational product is administered to a limited patient population with a specified disease or condition
to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&nbsp;II clinical trials may be conducted to
obtain information prior to beginning larger and more expensive Phase&nbsp;III clinical trials. For certain indications in patients with serious or life-threatening </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>191</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=194,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=581994,FOLIO='191',FILE='DISK103:[20ZDS1.20ZDS17601]EA17601A.;28',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ea17601_1_192"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>diseases
and with no available therapies, it may be possible to obtain BLA approval based on data from Phase&nbsp;II trials if a positive benefit risk profile is demonstrated. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Phase&nbsp;III&#151;The investigational product is administered to an expanded patient population to further evaluate dosage, to
provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended
to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These
so-called Phase&nbsp;4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information
about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The
manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things,
must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected
and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BLA Submission and Review  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, preclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant
data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product's
chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA unless a waiver or exemption
applies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
an original BLA has been submitted, FDA has 60&nbsp;days to determine whether the application can be filed. If FDA determines that an application to be deficient, on its face, in
a way that precludes a complete review, FDA may not accept the application for review and may issue a refuse-to-file letter to the sponsor. If FDA determines the application is filable, the FDA's goal
is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application
for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine,
among other things, whether a product is safe, pure and potent and the facilities in which it is manufactured, processed, packed, or held meets standards designed to assure the product's continued
safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility
or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure
compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will
request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>192</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=195,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1009444,FOLIO='192',FILE='DISK103:[20ZDS1.20ZDS17601]EA17601A.;28',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ea17601_1_193"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the commercial product and/or its drug substance will be produced, the FDA may issue an approval
letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will
describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may
issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA
may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of
a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be
marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to
manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on,
among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and
post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&nbsp;4 post-market studies and surveillance to
further assess and monitor the product's safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expedited Development and Review Programs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to
expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or
life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and
the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once a BLA
is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, in which case the FDA may consider for review sections of the BLA on a
rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and
determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product
can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA
interaction and guidance beginning as early as Phase&nbsp;I and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>193</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=196,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=904552,FOLIO='193',FILE='DISK103:[20ZDS1.20ZDS17601]EA17601A.;28',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ea17601_1_194"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for
other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the
potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular
entities, priority review designation means the FDA's goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination
that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or
mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and
the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well- controlled post-marketing clinical
trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval
pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, FDA established a new regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st&nbsp;Century Cures Act, which was signed into law
in December 2016. The RMAT designation program is intended to fulfill the 21st&nbsp;Century Cures Act requirement that FDA facilitate an efficient development program for, and expedite review of,
any drug that meets the following criteria: (1)&nbsp;it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any
combination product using such therapies or products, with limited exceptions; (2)&nbsp;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and
(3)&nbsp;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like fast track and breakthrough therapy designation,
RMAT designation provides potential benefits that include more
frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible
for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites,
including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of
clinical evidence, clinical trials, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through
post-approval monitoring of all patients treated with the therapy prior to approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fast
track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the
development or approval process. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a
disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the
cost of developing and making available a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation
must be requested before submitting a BLA. After the FDA </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>194</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=197,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=414504,FOLIO='194',FILE='DISK103:[20ZDS1.20ZDS17601]EA17601A.;28',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ea17601_1_195"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>grants
orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage
in, or shorten the duration of, the regulatory review or approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug
exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except
in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or
biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other
benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition,
exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantities of the product to meet the needs of patients with the rare disease or condition. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA,
including, among other things, requirements relating to record keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the
product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee
requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their
establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain
procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may
require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party
manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and
other aspects of regulatory compliance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions
or other restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>195</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=198,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1015730,FOLIO='195',FILE='DISK103:[20ZDS1.20ZDS17601]EA17601A.;28',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ec17601_1_196"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, warning letters or holds on post-approval clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product
approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure or detention, or refusal of the FDA to permit the import or export of products; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that
are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may
prescribe legally available products for uses that are not described in the product's labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across
medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their
choice of treatments. The FDA does, however, restrict manufacturer's communications on the subject of off-label use of their products. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biosimilars and Reference Product Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed
into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are
biosimilar to or interchangeable with an FDA-approved reference biological product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be
shown through analytical studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product be biosimilar to the reference product and the product must demonstrate
that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered to a patient more than once, the biologic and the
reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference
biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles
to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In
addition, the FDA may not approve a biosimilar product until 12&nbsp;years from the date on which the reference product was
first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA containing that applicant's own
preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the competing product. The BPCIA also created certain exclusivity periods
for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed "interchangeable" by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>196</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=199,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=371911,FOLIO='196',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_197"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period.
Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA
is subject to significant uncertainty. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Healthcare Laws and Compliance Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the
states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made
under any federal healthcare program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among
other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or
fraudulent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes which
prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and which, as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009, or HITECH, also imposes certain requirements on HIPAA covered entities and their business associates relating to the privacy, security and
transmission of individually identifiable health information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for
which payment is available under Medicare, Medicaid or the Children's Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments
or other transfers of value made to physicians, as defined by such law, certain other health care providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests
held by physicians and their immediate family members; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> United States state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant
ways, and may not have the same effect, thus complicating compliance efforts, including laws governing the privacy and security of personal data, such as the GDPR, which imposes obligations and
restrictions on the collection and use of personal data relating to individuals located in the EU and EEA (including with regard to health data). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to significant penalties, including, without
limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or
jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>197</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=200,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=964288,FOLIO='197',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_198"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Coverage and Reimbursement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain
regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payers, such as federal, state, and foreign government healthcare
programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payers. Decisions regarding the extent of coverage and amount of
reimbursement to be provided are made on a plan-by-plan basis. As there is no uniform policy of coverage and reimbursement for drug products among third-party payers in the United States, coverage and
reimbursement policies for drug products can differ significantly from payer to payer. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage
and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that
coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payers will decide with respect to coverage and reimbursement
for our drug products. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often
associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician
utilization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and
reimbursement and requirements for substitution of generic products. Third-party payers are increasingly challenging the prices charged for medical products and services, examining the medical
necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in
third-party reimbursement for any product or a decision by a third-party payer not to cover a product could reduce physician usage and patient demand for the product. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Reform  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives,
including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased
governmental control of drug pricing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly
affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing
enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected, and annual fees based on pharmaceutical companies' share of sales to federal healthcare programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>198</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=201,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=737682,FOLIO='198',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_199"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA, and we expect there will be additional challenges and
amendments to the ACA in the future. For example, the 2020 federal spending package permanently eliminates, effective January&nbsp;1, 2020, the ACA-mandated "Cadillac" tax on high-cost
employer-sponsored health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminates the health insurer tax. In addition, the Tax Act was enacted, which, among other
things, removes penalties for not complying with ACA's individual mandate to carry health insurance. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled
that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well.
Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th&nbsp;Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case
back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&nbsp;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari
to review this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal or replace the ACA will impact the ACA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced
payments to several types of Medicare providers, which will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2020, unless
additional Congressional action is taken. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has
resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the federal level, the Trump administration's budget proposal for fiscal year 2021 includes a US$135&nbsp;billion allowance to support legislative proposals seeking to reduce drug
prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Further, the Trump administration released a
"Blueprint," or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of
certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out- of-pocket costs of drug products paid by consumers. The Department of
Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, the Centers for Medicare&nbsp;&amp;
Medicaid Services, or CMS, issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part&nbsp;B drugs beginning January&nbsp;1, 2020. This final rule codified CMS's
policy change that was effective January&nbsp;1, 2019. Most recently, in July 2020, President Trump also signed a number of executive orders that attempt to implement several of the Administration's
proposals. While some of measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative
and/or administrative measures to control drug costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and
in additional downward pressure on the price that we receive for any approved product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>199</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=202,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=3167,FOLIO='199',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_200"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PRC Regulation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to a variety of PRC laws, rules and regulations affecting many aspects of our business. This section sets out a summary of the
major relevant laws, regulations, rules and policies which may have material impact on our business and operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Company Establishment and Foreign Investment  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The establishment, operation and management of corporate entities in China are governed by the Company Law of PRC, or the PRC Company Law, which
was promulgated by the Standing Committee of the National People's Congress, or the NPC, in December 1993 and further amended in December 1999, August 2004, October 2005, December 2013 and October
2018, respectively. According to the PRC Company Law, companies are generally classified into two categories: limited liability companies and companies limited by shares. The PRC Company Law also
applies to foreign-invested limited liability companies. According to the PRC Company Law, where laws on foreign investment have other stipulations, such stipulations shall prevail. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment
activities in the PRC by foreign investors are governed by the Guiding Foreign Investment Direction, which was promulgated by the State Council in February 2002 and came into
effect in April 2002, and the Special Administrative Measures for the Access of Foreign Investment (Negative List), or the Negative List, which was promulgated by the Ministry of Commerce of the PRC,
or the MOFCOM, and the National Development and Reform Commission, or the NDRC, in June 2020 and came into effect in July 2020. The Negative List sets out the restrictive measures in a unified manner,
such as the requirements on shareholding percentages and management, for the access of foreign investments, and the industries that are prohibited from receiving foreign investment. The Negative List
covers 12 industries, and any field not falling under the Negative List shall be administered under the principle of equal treatment to domestic and foreign investment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign
Investment Law of the PRC, or the Foreign Investment Law, was promulgated by the NPC in March 2019 and came into effect in January 2020. When the Foreign Investment Law came into
effect, the Law on Wholly Foreign-owned Enterprises of the PRC, the Law on Sino-foreign Equity Joint Ventures of the PRC and the Law on Sino-foreign Cooperative Joint Ventures of the PRC were repealed
simultaneously. The investment activities of foreign natural persons, enterprises or other organizations (collectively, the "foreign investors") directly or indirectly within the territory of China
shall comply with and be governed by the Foreign Investment Law. Such activities include: 1)&nbsp;establishing by foreign investors of foreign-invested enterprises in China alone or jointly with
other investors; 2)&nbsp;acquiring by foreign investors of shares, equity, property shares, or other similar interests of Chinese domestic enterprises; 3)&nbsp;investing by foreign investors in
new projects in China alone or jointly with other investors; and 4)&nbsp;other forms of investment prescribed by laws, administrative regulations or the State Council. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2019, the State Council promulgated the Regulations on Implementing the Foreign Investment Law of the PRC, which came into effect in January 2020. When the Regulations on
Implementing the Foreign Investment Law of the PRC came into effect, the Regulation on Implementing the Sino-Foreign Equity Joint Venture Enterprise Law of the PRC, Provisional Regulations on the
Duration of Sino-Foreign Equity Joint Venture Enterprise, the Regulations on Implementing the Wholly Foreign-Invested Enterprise Law of the PRC and the Regulations on Implementing the Sino-Foreign
Cooperative Joint Venture Enterprise Law of the PRC were repealed simultaneously. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2019, the MOFCOM and the State Administration for Market Regulation, or the SAMR promulgated the Measures on Reporting of Foreign Investment Information, which came into
effect in January 2020. When the Measures on Reporting of Foreign Investment Information came into effect, the Interim Measures for the Administration of Filing for Establishment and Changes in
Foreign </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>200</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=203,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=939731,FOLIO='200',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_201"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Investment
Enterprises were repealed simultaneously. Since January&nbsp;1, 2020, for foreign investors carrying out investment activities directly or indirectly in China, the foreign investors or
foreign-invested enterprises shall submit investment information to the relevant commerce administrative authorities according to the Measure on Reporting of Foreign Investment Information. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulation on Pharmaceutical Product Development, Approval and Registration  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Drug Regulatory Regime  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Drug Administration Law of the PRC, or the Drug Administration Law, was promulgated by the Standing Committee of the NPC, in September 1984.
The two latest amendments to the Drug Administration Law were the amendment promulgated in April 2015 and in August 2019. The Regulations for the Implementation of the Drug Administration Law was
promulgated by the State Council in August 2002, and was last amended in March 2019. The Drug Administration Law and the Regulations for the Implementation of the Drug Administration Law have jointly
established the legal framework for the administration of pharmaceutical products in China, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to
entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products. It regulates and provides for a framework for the
administration of pharmaceutical manufacturers, pharmaceutical trading companies and medicinal preparations of medical institutions, and the development, research, manufacturing, distribution,
packaging, pricing and advertisements of pharmaceutical products. The Regulations for the Implementation of the Drug Administration Law, at the same time, provide the detailed implementation
regulations for the Drug Administration Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, the drug regulatory system entered a new and significant period of reform. The General Office of the State Council and the General Committee of China Communist Party jointly
issued Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, or the Innovation Opinions. The expedited programs, the
record-filing system, the prioritized review mechanism, the acceptance of foreign clinical data under the Innovation Opinions and other recent reforms encourage drug manufacturers to seek marketing
approval in China first for the development of drugs in highly prioritized therapeutic areas, such as oncology or rare diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
implement the regulatory reform introduced by Innovation Opinions, the Standing Committee of the NPC, the National Medical Products Administration, or the NMPA, a newly formed
government authority as well as other authorities, are currently responsible for revising the laws, regulations and rules governing the pharmaceutical products and the industry. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2019, the Standing Committee of the NPC promulgated the new Drug Administration Law, or the 2019 Amendment, which came into effect in December 2019. The 2019 Amendment contains
many of the major reform initiatives implemented by the Chinese government since 2015, including but not limited to the Marketing Authorization Holder, or the MAH, system, conditional approvals of
drugs, traceability system of drugs, and the cancellation of relevant certification according to the Good Manufacturing Practice, or the GMP, and the Good Supply Practice, or the GSP. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory Authorities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmaceutical products in China are monitored and supervised on a national scale by the NMPA. The local provincial medical products
administrative authorities are responsible for supervision and administration of drugs within their respective administrative regions. The NMPA was newly formed under the SAMR. The NMPA's predecessor,
the State Drug Administration, or the SDA, was replaced by the State Food and Drug Administration, or the SFDA, which was later reorganized into the China </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>201</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=204,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=888104,FOLIO='201',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_202"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Food
and Drug Administration, or the CFDA, as part of the institutional reforms implemented by the State Council. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary responsibilities of the NMPA include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring and supervising the administration of pharmaceutical products, medical appliances and equipment as well as cosmetics in the PRC; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> formulating administrative rules and policies concerning the supervision and administration of pharmaceutical, medical devices, and cosmetics
industry; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluating, registering and approving new drugs, generic drugs, imported drugs and traditional Chinese medicine; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approving and issuing permits for the manufacture and export/import of pharmaceutical products, medical appliances and equipment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approving the establishment of enterprises to be engaged in the manufacture and distribution of pharmaceutical products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> examining and evaluating the safety of pharmaceutical products, medical devices, and cosmetics; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> managing significant accidents involving pharmaceutical products, medical devices and cosmetics. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2013, the Ministry of Health, or the MOH, and the National Population and Family Planning Commission were integrated into the National Health and Family Planning Commission of the
PRC, or the NHFPC. In March 2018, the First Session of the Thirteenth NPC approved the State Council Institutional Reform Proposal, according to which, NHFPC and certain other governmental authorities
were consolidated into the National Health Commission, or the NHC. The responsibilities of the NHC include coordinating the formulation of national drug policies, the national essential medicine
system and the National Essential Medicines List and drafting the administrative rules for the procurement, distribution and use of national essential medicines. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Decision of the CFDA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs, which was promulgated by the CFDA in March 2017 and
came into effect in May 2017, the Investigational New Drug Application, or the IND, approval should be issued by the Center for Drug Evaluation, or the CDE, on behalf of the CFDA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Clinical Trials and Registration of Drugs  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administrative Measures for Drug Registration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2007, the SFDA promulgated the amended version of the Administrative Measures for Drug Registration, or the Registration Measures, which
became effective in October 2007. The Registration Measures mainly cover: (1)&nbsp;definitions of drug registration applications and regulatory responsibilities of drug administration;
(2)&nbsp;general requirements for drug registration, including application for registration of new drugs, generic drugs, imported drugs and supplemental application, as well as application for
re-registration; (3)&nbsp;clinical trials; (4)&nbsp;application, examination and approval of new drugs, generic drugs and imported drugs; (5)&nbsp;supplemental applications and re-registrations
of drugs; (6)&nbsp;inspections; (7)&nbsp;registration standards and specifications; (8)&nbsp;time limit; (9)&nbsp;re-examination; and (10)&nbsp;liabilities and other supplementary
provisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Registration Measures, drug registration applications are divided into three different types, namely Domestic New Drug Application, Domestic Generic Drug Application and
Imported Drug Application. Drugs which fall into one of three general types are divided according to the drug's working mechanism, namely whether the drug is classified as a chemical medicine, a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>202</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=205,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=557620,FOLIO='202',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_203"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>biological
product, a traditional Chinese medicine or a natural medicine. New Drug Application, or NDA, refers to an application for registration of a drug that has not yet been marketed for sale in
China. In addition, the registration of drugs that change the dosage form of the marketed drugs, change the route of administration and increase the new indications shall be reported in accordance
with the application procedures for new drugs. Under the Registration Measures, a Category&nbsp;1 drug refers to a new drug that has never been marketed in any country, and such drug is eligible for
special review or fast track approval by the NMPA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2020, the SAMR released the amended Administrative Measures for Drug Registration, or the Amended Registration Measures, which came into effect in July 2020. The Amended
Registration Measures provide detailed procedural and substantive requirements for the key regulatory concepts established by the Drug Administration Law, and confirms a number of reform actions that
have been taken in the past years, including but not limited to: (i)&nbsp;the full implementation of the MAH system and implied approval of the commencement of clinical trial; (ii)&nbsp;the
implementation of associated review of drugs, excipients and packaging materials; and (iii)&nbsp;the introduction of four procedures for expedited registration of drugs, which are procedures for
ground-breaking therapeutic drugs, procedures for conditional approval, procedures for prioritized reviews and approval, and procedures for special examination and approval. Detailed implementation
rules for drug classification and requirements for corresponding application materials will be promulgated by the NMPA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2016, the CFDA issued the Reform Plan for Registration Category of Chemical Medicine, which outlined the reclassifications of drug applications under the Registration Measures.
According to the Reform Plan for Registration Category of Chemical Medicine, Category&nbsp;1 drugs refer to innovative new drugs that have not been marketed anywhere in the world. Improved new drugs
that are not marketed anywhere in the world fall into Category&nbsp;2 drugs. Generic drugs, that have equivalent quality and efficacy to the originator's drugs and have been marketed abroad but not
yet in China, can be classified as Category&nbsp;3 drugs. Generic drugs, that have equivalent quality and efficacy to the originator's drugs and have been marketed in China, fall into
Category&nbsp;4 drugs. Category&nbsp;5 drugs are drugs which have already been marketed abroad, but are not yet approved in China. Category&nbsp;1 drugs and Category&nbsp;5 drugs can be
registered through the Domestic New Drug Application and the Imported Drug Application Procedures under the Registration Measures, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SFDA promulgated the Administrative Provisions on Special Examination and Approval of Registration of New Drugs in January 2009, according to which, the SFDA conducts special
examination and approval for new drug registration applications when: (1)&nbsp;the effective constituent of drug extracted from plants, animals, minerals, etc., as well as the preparations thereof
have never been marketed in China, and the material medicines and the preparations thereof are newly discovered; (2)&nbsp;the chemical raw material medicines as well as the preparations thereof and
the biological product have not been approved for marketing at home and abroad; (3)&nbsp;the new drugs have obvious clinical treatment advantages for such diseases as AIDS, malignant tumors and
orphan diseases, etc. or (4)&nbsp;the new drugs treat diseases currently with no effective methods of treatment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the clinical trial application stage if the
product candidate falls within items&nbsp;(1) or (2). The provisions provide that for product candidates that fall within items&nbsp;(3) or (4), the application for special examination and
approval cannot be made until filing for production. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accelerated Approval for Clinical Trial and Registration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Innovation Opinions established a framework for reforming the evaluation and approval system for drugs, medical devices and equipment. The
Innovation Opinions enhanced the standard of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>203</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=206,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=994115,FOLIO='203',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_204"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>approval
for drug registration and accelerated the evaluation and approval process for innovative drugs as well as drug clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
CFDA released the Circular Concerning Several Policies on Drug Registration Review and Approval in November 2015, which further clarified the measures and policies for simplifying
and accelerating the approval process of clinical trials, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a one-time umbrella approval procedure allowing the overall approval of all phases of a new drug's clinical trials, replacing the current
phase-by-phase application and approval procedure; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fast track drug registration or clinical trial approval pathway for the following applications: (1)&nbsp;registration of innovative new
drugs for treating HIV, cancer, serious infectious diseases and orphan diseases, etc.; (2)&nbsp;registration of pediatric drugs; (3)&nbsp;registration of geriatric drugs and drugs treating
PRC-prevalent diseases in elders; (4)&nbsp;registration of drugs listed in national major science and technology projects or national key research and development plan; (5)&nbsp;registration of
clinical urgently needed drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (6)&nbsp;registration of foreign innovative drugs to be
manufactured locally in China; (7)&nbsp;concurrent applications for new drug clinical trials which are already approved in the United States or EU or concurrent drug registration applications for
drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities' onsite inspections in the United States or EU and are manufactured using
the same production line in China; and (8)&nbsp;clinical trial applications for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for
drugs with urgent clinical need and patent expiry within one year. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
NMPA released the Circular on Adjusting Evaluation and Approval procedures for Clinical Trials for Drugs in July 2018, according to which, within 60&nbsp;days after the acceptance
of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any
negative or questioning opinion from the CDE. Such approval process has been further enacted into the 2019 Amendment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trial Exemptions and Acceptance of Foreign Data  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data in July 2018, as one of the implementing rules
for the Innovation Opinions, which provides that overseas clinical data can be submitted for the drug registration applications in China. Such applications can be in the form of waivers to China-based
clinical trials, bridging trials and direct NDAs. According to the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data, sponsors may use the data of foreign clinical trials to
support drug registration in China, provided that sponsors must ensure the authenticity, completeness, accuracy and traceability of foreign clinical trial data and such data must be obtained
consistent with the relevant requirements under the Good Clinical Trial Practice of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for
Human Use, or the ICH. Sponsors must also comply with other relevant sections of the Registration Measures when applying for drug registrations in China using foreign clinical trial data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
NMPA now officially permits, and its predecessor agencies have permitted on a case-by-case basis in the past, drugs approved outside of China to be approved in China on a conditional
basis without pre-approval clinical trials being conducted in China. Specifically, the NMPA and the NHC released the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New
Drugs in October 2018, permitting drugs that have been approved within the last ten years in the United States, the EU
or Japan and that prevent or treat orphan diseases, or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China, or for which the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>204</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=207,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=950764,FOLIO='204',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ec17601_1_205"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>foreign-approved
drug would have clear clinical advantages. Applicants will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been
marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Trial Process and Good Clinical Practices  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Registration Measures, a clinical trial consists of Phases&nbsp;I, II, III and IV. Phase&nbsp;I refers to the initial
clinical pharmacology and safety evaluation studies in humans. Phase&nbsp;II refers to the preliminary evaluation of a product candidate's therapeutic effectiveness and safety for particular
indications in patients, to provide evidence and support for the design of Phase&nbsp;III clinical trials and to settle the administrative dose regimen. Phase&nbsp;III refers clinical trials
undertaken to confirm the therapeutic effectiveness and safety on patients with target indications, to evaluate the overall benefit-risk relationships of the drug, and ultimately to provide sufficient
evidence for the review of drug registration application. Phase&nbsp;IV refers to a new drug's post-marketing study to assess therapeutic effectiveness and adverse reactions when the drug is widely
used, to evaluate the overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
improve the quality of clinical trials, the SFDA promulgated the Good Clinical Trial Practice for Drugs in August 2003, or the GCP Rules, which was replaced by the revised Good
Clinical Trial Practice for Drugs, the Revised GCP Rules, promulgated by the NMPA and the NHC in April 2020 and coming into effect in July 2020. According to the Administration of Quality of Drug
Clinical Practice, clinical trial means systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or
absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug. The Revised GCP
Rules provide comprehensive and substantive requirements on the design and conduct of clinical trials in China. In particular, the Revised GCP Rules enhance the protection for study subjects and
tighten the control over bio-samples collected under clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Revised GCP Rules also set out the qualifications and requirements for the investigators and centers participating in clinical trial, who must: (i)&nbsp;have professional
certification at a clinical trial
center, professional knowledge, training experience and capability of clinical trial, and be able to provide the latest resume and relevant qualification documents per request; (ii)&nbsp;be familiar
with the trial protocol, investigator's brochure and relevant information of the trial drug provided by the applicant; (iii)&nbsp;be familiar with and comply with the Revised GCP Rules and relevant
laws and regulations relating to clinical trials; (iv)&nbsp;keep a copy of the authorization form on work allocation signed by investigators; (v)&nbsp;accept supervision and inspection organized
by the applicant and inspection by the drug regulatory authorities; and (vi)&nbsp;in the case of investigators and clinical trial centers authorizing other individual or institution to undertake
certain responsibilities and functions relating to clinical trial, they shall ensure such individual or institution are qualified and establish complete procedures to ensure the responsibilities and
functions are fully performed and generate reliable data. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communication with the CDE  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Circular on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, where the application for clinical
trial of new investigational drug has been approved, upon the completion of Phases&nbsp;I and II clinical trials and prior to Phase&nbsp;III clinical trial, the applicant shall submit the
application for Communication Session to the CDE to discuss the key technical questions including the design of Phase&nbsp;III clinical trial protocol. Within 60&nbsp;days after the acceptance of
and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any
negative or questioning opinion from the CDE. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>205</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=208,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=562573,FOLIO='205',FILE='DISK103:[20ZDS1.20ZDS17601]EC17601A.;31',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ee17601_1_206"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The NMPA promulgated the Administrative Measures for Communication on the Research, Development and Technical Evaluation of Drugs in September 2018, according to
which, during the research and development periods and in the registration applications of, among others, the innovative new drugs, the applicants may propose to conduct communication meetings with
the CDE. The communication meetings can be classified into three types. Type&nbsp;I meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the
research and development of breakthrough therapeutic drugs. Type&nbsp;II meetings are held during the key research and development periods of drugs, mainly including meetings before the IND
application, meetings upon the completion of Phase&nbsp;II trials and before the commencement of Phase&nbsp;III trials, meetings before submitting a marketing application for a new drug, and
meetings for risk evaluation and control. Type&nbsp;III meetings refer to meetings not classified as Type&nbsp;I or Type&nbsp;II. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Drug Clinical Trial Registration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Registration Measures, upon obtaining the approval of its IND applications and before conducting a clinical trial, an applicant
shall file&nbsp;a registration form with the SFDA containing various details, including the clinical trial protocol, the name of the principal researcher of the leading institution, the names of
participating institutions and researchers, an approval letter from the ethics committee, and a sample of the informed consent form, with a copy sent to the competent provincial administration
departments where the trial institutions will be located. The CFDA released the Announcement on Drug Clinical Trial Information Platform in September 2013, according to which, instead of the
aforementioned registration field with the CFDA, all clinical trials approved by the CFDA and conducted in China shall complete a clinical trial registration and publish trial information through the
Drug Clinical Trial Information Platform. The applicant shall complete the trial pre-registration within one month after obtaining the approval of the clinical trial approval in order to obtain the
trial's unique registration number and complete registration of certain follow-up information before the first subject's enrollment in the trial. If the registration is not completed within one year
after the approval of the IND applications, the applicant shall submit an explanation, and if the first submission is not completed within three years, the approval of the IND applications shall
automatically expire. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Drug Application  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Registration Measures, drug registration applications include domestic NDA, domestic generic drug application and imported drug
application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases&nbsp;I, II and III clinical trials have been completed, the
applicant may apply to the SFDA for approval of the NDA. The SFDA then determines whether to approve the application according to the comprehensive evaluation opinion provided by the CDE. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pilot Plan for the MAH System  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Innovation Opinions provide a pilot plan for the MAH system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the authorization of the Standing Committee of the NPC, the General Office of the State Council issued the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in May
2016, which provides a detailed pilot plan for the MAH system in 10 Chinese provinces. Under the MAH system, domestic drug research and development institutions and individuals in the pilot regions
are eligible to be holders of drug registrations without having to become drug manufacturers. The marketing authorization holders may engage contract manufacturers for manufacturing, provided that the
contract manufacturers are licensed and located within the pilot regions. Drugs that qualify for the MAH system are: (1)&nbsp;new drugs (including but not limited to drugs under category&nbsp;I to
category&nbsp;IV of chemical drugs, and targeted preparation, sustained release preparation, controlled release preparation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>206</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=209,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1021039,FOLIO='206',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_207"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>under
category&nbsp;V of chemical drugs, biological products approved as category&nbsp;I and VII drugs and biosimilars under the Registration Measures) approved after the implementation of the MAH
system; (2)&nbsp;generic drugs approved as category&nbsp;III or IV drugs under the Reform Plan for Registration Category of Chemical Medicine; (3)&nbsp;previously approved generics that have
passed equivalence assessments against original drugs; and (4)&nbsp;previously approved drugs whose licenses were held by drug manufacturers originally located within the pilot regions, but which
have moved out of the pilot regions due to corporate mergers or other reasons. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
CFDA promulgated the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System in August 2017. It clarified the legal
liability of the MAH, who is responsible for managing the whole manufacturing and marketing chain and the whole life cycle of drugs and legally liable for preclinical drug study, clinical trials,
manufacturing, marketing, distribution and adverse drug reaction monitoring. According to the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization
Holder System, the MAH shall submit a report of drug manufacturing, marketing, prescription, techniques, pharmacovigilance, quality control measures and other situations to the CFDA within 20 working
days after the end of each year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Pilot Plan for the Drug Marketing Authorization Holder Mechanism, the pilot plan was originally set for a three-year period and was scheduled to expire in November 2018.
The Standing Committee of the NPC promulgated the Decision of Extending the Pilot Period of Authorizing the State Council to Carry Out the Pilot Plan for the Drug Marketing Authorization Holder
Mechanism in Certain Places in October 2018, which extended the term of the MAH system to November&nbsp;4, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the 2019 Amendment, which came into effect on December&nbsp;1, 2019, the MAH system will be applicable throughout the country and the legal representative and the key
person-in-charge of a drug MAH shall be fully responsible for the quality of drugs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


International Multi-Center Clinical Trials  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The International Multi-Center Clinical Trial Guidelines (Trial), or the Multi-Center Clinical Trial Guidelines, which was promulgated by the
CFDA in January 2015 and came into effect in March 2015, provided guidance on the implementation of Multi-Regional Clinical Trials, or the MRCT, in China. According to the Multi-Center Clinical Trial
Guidelines, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to
implement the international multi-center clinical trials in the PRC, the applicants shall comply with relevant laws and regulations, such as the Drug Administration Law, the Implementing Regulations
of the Drug Administration Law and the Registration Measures, execute the GCP Rules, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations
of the countries involved in the international multi-center clinical trials. Where the applicants plan to use the data derived from the international multi-center clinical trials for approval of a
drug registration in the PRC, it shall involve at least two countries, including China, and shall satisfy the requirements for clinical trials set forth in the Multi-Center Clinical Trial Guidelines,
Registration Measures and other related laws and regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2020, the NMPA and the NHC promulgated the Revised GCP Rules, which came into effect in July 2020. The Revised GCP Rules summarize the requirements for initiating an MRCT, that
is, before initiating an MRCT: (i)&nbsp;the applicant shall ensure that all the centers participating in the clinical trial comply with the trial protocol; (ii)&nbsp;the applicant shall provide
each center with the same trial protocol, and each center shall comply with the same unified evaluation criterion for clinical trial and laboratory data and the same guidance for case report form;
(iii)&nbsp;each center shall use the same case report form to record the data of each human subject obtained during the trial; (iv)&nbsp;before </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>207</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=210,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=372450,FOLIO='207',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_208"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>initiating
a clinical trial, a written document is required to specify the responsibilities of the investigators of each center; and (v)&nbsp;the applicant shall ensure the communication among the
investigators of each center. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data
derived from international multi-center clinical trials can be used for the new drug applications with the NMPA. When using international multi-center clinical trial data to support
new drug applications in China, applicants shall submit the completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in accordance with the
content and format requirements under the International Conference on Harmonization-Common Technical Document; subgroup research results summary and comparative analysis shall also be conducted
concurrently. Leveraging the clinical trial data derived from international multi-center clinical trials
conducted by our partners, we may avoid unnecessarily repetitive clinical trials and thus further accelerate the NDA process in China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
CFDA released the Decision on Adjusting Items concerning the Administration of Imported Drug Registration in October 2017, which includes the following key
points:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If the International Multicenter Clinical Trial, or the IMCCT, of a drug is conducted in China, Phase&nbsp;I clinical trial of the drug is
allowed simultaneously. The IMCCT drug does not need to be approved or to enter into either a Phase&nbsp;II or III clinical trial in a foreign country, except for preventive biological products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If the IMCCT is conducted in China, the application for drug marketing authorization can be submitted directly after the completion of the
IMCCT. The Registration Measures and relevant laws and regulations shall be complied with for registration application; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to applications for clinical trial and marketing of the imported innovative chemical drugs and therapeutic biological products,
the marketing authorization in the country or region where the foreign drug manufacturer is located will not be required; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to drug applications that have been accepted before the release of this Decision, if relevant requirements are met, importation
permission can be granted if such applications request exemption of clinical trials for the imported drugs based on the data generated from the IMCCT. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Approval of Human Genetic Resources  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Interim Administrative Measures on Human Genetic Resources, promulgated by the Ministry of Science and Technology and the MOH in June 1998,
aimed at protecting and fairly utilizing human genetic resources in the PRC. The Ministry of Science and Technology promulgated the Service Guide for Administrative Licensing Items concerning
Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC in July 2015, according to which, the sampling, collection or
research activities of human genetic resources by a foreign-invested sponsor fall within the scope of international cooperation, and the cooperating Chinese organization shall apply for approval of
the China Human Genetic Resources Management Office through an online system. The Ministry of Science and Technology further promulgated the Circular on Optimizing the Administrative Examination and
Approval of Human Genetic Resources in October 2017 and October 2020, which became effective in December 2017 and October 2020, respectively and simplified the approval of sampling and collecting
human genetic resources for listing a drug in the PRC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Regulations of the PRC on the Administration of Human Genetic Resources, which was promulgated by the State Council in May 2019 and came into effect in July 2019, further stipulates
that, in order to obtain marketing authorization for relevant drugs and medical devices in China, no approval is required in international clinical trial cooperation using China's human genetic
resources at </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>208</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=211,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=740067,FOLIO='208',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_209"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>clinical
institutions without export of human genetic resource materials. However, the type, quantity and usage of the human genetic resource to be used shall be filed with the administrative
department of science and technology under the State Council before clinical trials. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Drug Manufacturing and Distribution  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Drug Manufacturing  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Drug Administration Law and the Implementing Regulations of the Drug Administration Law, a drug manufacturing enterprise is
required to obtain a drug manufacturing license from the relevant provincial drug administration authority of the PRC. The grant of such license is subject to an inspection of the manufacturing
facilities, and an inspection to determine whether the sanitary condition, quality assurance systems, management structure and equipment meet the required standards. According to the Implementing
Regulations of the Drug Administration Law and the Measures on the Supervision and Administration of the Manufacture of Drugs, which was promulgated in August 2004, amended in November 2017 and
January 2020 and came into effect in July 2020, the drug manufacturing license is valid for five years and shall be renewed at least six months prior to its expiration date upon a re-examination by
the relevant authority. In addition, the name, legal representative, registered address and type of the enterprise specified in the drug manufacturing certificate shall be identical to that set forth
in the business license as approved and issued by the industrial and commercial administrative department. To the extent the MAH does not manufacture the drug internally but through a contract
manufacturing organization, the MAH shall apply for drug manufacturing license with the provincial counterpart of the NMPA, subject itself to inspections and other regulatory oversight by the agency. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Good Manufacturing Practice for Drugs was promulgated in March 1988 and was amended in December 1992 and June 1999 and January 2011. The latest amendment was in June 2020 and will
come into effect in October 2020. The Good Manufacturing Practice for Drugs comprises a set of detailed standard guidelines governing the manufacture of drugs, which include institution and staff
qualifications, production premises and facilities, equipment, hygiene conditions, production management, quality controls, product operation, raw material management, maintenance of sales records,
management of customer complaints and adverse event reports. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Drug Distribution  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Drug Administration Law, its implementing regulations and the Measures for the Supervision and Administration of Circulation of
Pharmaceuticals, which was promulgated by the SFDA in December 2006 and came into effect in May 2007, pharmaceutical enterprises shall be responsible for the quality of the pharmaceuticals that they
manufacture, operate, use, purchase, sell, transport, or store. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Measures for the Administration of Pharmaceutical Operation Certificate, which was promulgated in February 2004 and amended in November 2017 by the CFDA, a Medicine
Operation Certificate is valid for five years. Each holder of the Medicine Operation Certificate must apply for an
extension of its permit six months prior to expiration. The establishment of a wholesale pharmaceutical distribution company requires the approval of provincial medicine administrative authorities.
Upon approval, the authority will grant a Medicine Operation Certificate in respect of the wholesale pharmaceutical product distribution company. The establishment of a retail pharmacy store requires
the approval of the local medicine administrative authorities at or above the county level. Upon approval, the authority will grant a Medicine Operation Certificate in respect of the retail pharmacy
store. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>209</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=212,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=220658,FOLIO='209',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_210"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other PRC Government Regulations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Intellectual Property Rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In terms of international conventions, China has entered into (including but not limited to) the Agreement on Trade-Related Aspects of
Intellectual Property Rights, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the International Registration of Marks and the Patent Cooperation Treaty. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Patent Law of the PRC, which was promulgated by the Standing Committee of the NPC in March 1984, amended in September 1992,
August 2000 and December 2008, and came into effect in October 2009, and the Implementation Rules of the Patent Law of the PRC, which was promulgated by the State Council in June 2001 and amended in
December 2002 and January 2010, there are three types of patents in the PRC: invention patents, utility model patents and design patents. The protection period is 20&nbsp;years for an invention
patent and 10&nbsp;years for a utility model patent and a design patent, commencing from their respective application dates. Any individual or entity that utilizes a patent or conducts any other
activities that infringe a patent without prior authorization of
the patent holder shall pay compensation to the patent holder and is subject to a fine imposed by relevant administrative authorities and, if constituting a crime, shall be held criminally liable in
accordance with the law. According to the Patent Law of the PRC, any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in
China is required to report to the NIPA for confidentiality examination. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trade Secrets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the PRC Anti-Unfair Competition Law, which was promulgated by the Standing Committee of the NPC in September 1993 and amended in
November 2017 and April 2019, respectively, the term "trade secrets" refers to technical and business information that is unknown to the public, has utility, may create business interests or profits
for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others' trade
secrets by: (1)&nbsp;obtaining the trade secrets from the legal owners or holders by any unfair methods such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means;
(2)&nbsp;disclosing, using or permitting others to use the trade secrets obtained illegally under item&nbsp;(1) above; (3)&nbsp;disclosing, using or permitting others to use the trade secrets,
in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence; or (4)&nbsp;instigating, inducing or assisting others to
violate a confidentiality obligation or to violate a rights holder's requirements on keeping confidentiality of trade secrets, disclosing, using or permitting others to use the trade secrets of the
rights holder. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to
have committed a misappropriation of the others' trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may
stop any illegal activities and fine infringing parties. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trademarks  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC in August 1982, and amended in February 1993, October
2001, August 2013 and April 2019, respectively, the period of validity for a registered trademark is ten years, commencing on the date of registration. The registrant shall go through the formalities
for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the registrant fails to do so, a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>210</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=213,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=693613,FOLIO='210',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_211"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>grace
period of six months may be granted. The validity period for each renewal of registration is ten years, commencing on the day immediately after the expiry of the preceding period of validity for
the trademark. In the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior
that infringes the exclusive right under a registered trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and
decided according to the law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Domain Names  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Domain names are protected under the Administrative Measures on the Internet Domain Names, which was promulgated by the Ministry of Industry and
Information Technology in August 2017, and the Implementing Rules on Registration of National Top-level Domain Names, which was promulgated by China Internet Network Information Center in and came
into effect in June 2019. The Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are
handled through domain name service agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Product Liability  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the strict new drug approval process, certain PRC laws have been promulgated to protect the rights of consumers and to strengthen
the control of medical products in the PRC. Under current PRC laws, manufacturers and vendors of defective products in the PRC may incur liability for loss and injury caused by such products.
According to the General Principles of the Civil Law of the PRC promulgated in April 1986 and amended in August 2009 and General Rules of the Civil Law of the People's Republic of China promulgated in
March 2017 and took effect in October 2017 (collectively, the "PRC Civil Law"), the manufacturer or vendor of a defective product which causes property damage or physical injury to any person may be
subject to civil liability for such damage or injury. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 1993, the Product Quality Law of the PRC, or the Product Quality Law, was promulgated to supplement the PRC Civil Law, aiming to protect the legitimate rights and interests
of the end-users
and consumers and to strengthen the supervision and control of the quality of products. The Product Quality Law was last revised in December 2018. According to the revised Product Quality Law,
manufacturers who produce defective products may be subject to civil or criminal liability and have their business licenses revoked. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Law of the PRC on the Protection of the Rights and Interests of Consumers was promulgated in October 1993 and amended in October 2013 to protect consumer rights when they purchase or
use goods and services. According to which, all business operators must comply with this law when they manufacture or sell goods and/or provide services to customers. Under the latest amendment, all
business operators shall protect the customers' privacy and keep any consumer information they obtain during the business operation strictly confidential. In addition, in extreme situations,
pharmaceutical product manufacturers and operators may be subject to criminal liability if their goods or services lead to the death or injuries of customers or other third parties. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Tort  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Tort Law of the PRC promulgated by the Standing Committee of the NPC in December 2009, if damages to other persons are caused
by defective products due to the fault of third parties, such as the parties providing transportation or warehousing, the producers and the sellers of the products have the right to recover their
respective losses from such third parties. If defective </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>211</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=214,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=426640,FOLIO='211',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_212"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>products
are identified after they have been put into circulation, the producers or the sellers shall take remedial measures such as issuance of a warning, recall of products, etc., in a timely
manner. The producers or the sellers shall be liable under tort if they fail to take remedial measures in a timely manner or have not made efforts to take remedial measures, thus causing damages. If
the products are produced or sold with known defects, causing deaths or severe adverse health issues, the infringed party has the right to claim punitive damages in addition to compensatory damages. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Environment Protection  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Environmental Protection Law of the PRC promulgated by the Standing Committee of the NPC, in December 1989, amended in April
2014 and effective in January 2015, any entity which discharges or will discharge pollutants during its course of operations or other activities must implement effective environmental protection
safeguards and procedures to control and properly treat waste gas, waste water, waste residue, dust, malodorous gases, radioactive substances, noise vibrations, electromagnetic radiation and other
hazards produced during such activities. According to the provisions of the Environmental Protection Law, in addition to other relevant laws and regulations of the PRC, the Ministry of Environmental
Protection and its local counterparts take charge of administering and supervising said environmental protection matters. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Environmental Protection Law, the environmental impact statement on any construction project must assess the pollution that the project is likely to produce and its
impact on the environment, and stipulate preventive and curative measures; the statement shall be submitted to competent administrative department of environmental protection for approval.
Installations for the prevention and control of pollution in construction projects must be designed, built and commissioned together with the principal part of the project. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Law of the People's Republic of China on Environment Impact Assessment, which was promulgated in October 2002 and most recently amended in December 2018, the State
implements a classification-based management on the environmental impact assessment of construction projects according to the impact of the construction projects on the environment. Construction units
shall prepare an Environmental Impact Report or an Environmental Impact Statement, or fill out the Environmental Impact Registration Form. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Regulations on Urban Drainage and Sewage Disposal, which was promulgated in October 2013 and came into effect in January 2014, and the Measures for the Administration of
Permits for the Discharge of Urban Sewage into the Drainage Network, which was promulgated in January 2015 and came into effect in March 2015, drainage entities covered by urban drainage facilities
shall discharge sewage into urban drainage facilities in accordance with the relevant provisions of the state. Where a drainage entity needs to discharge sewage into urban drainage facilities, it
shall apply for a drainage license in accordance with the provisions of these Measures. The drainage entity that has not obtained the drainage license shall not discharge sewage into urban drainage
facilities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Fire Protection  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fire Prevention Law of the PRC, or the Fire Prevention Law, was adopted in April 1998 and last amended in April 2019. The Fire Prevention
Law provides that fire control design and construction of a construction project shall comply with the State's fire control technical standards. Developers, designers, builders and project supervisors
shall be responsible for the quality of the fire control design and construction of the construction project pursuant to the law. Development project fire safety design examinations and acceptance
systems shall be implemented for development projects which are required to have fire safety design in accordance with the national fire protection technical standards. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Eight Measures for the Public Security Fire Department to Deepen Reform and Serve Economic and Social Development promulgated by the Ministry of Public Security of the
PRC in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>212</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=215,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=243595,FOLIO='212',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_213"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>August
2015, the fire protection design and completion acceptance fire protection record of construction projects with an investment of less than RMB300,000 or a building area of less than
300&nbsp;square meters (or below the limit set by the housing and urban construction department of the provincial people's government) was no longer required. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Foreign Exchange and Dividend Distribution  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Exchange Control  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the PRC Regulation for the Foreign Exchange promulgated by the State Council in January 1996, which was amended in January 1997 and
August 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment promulgated by the People's Bank of China in June 1996, foreign exchanges required for
distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing distribution of profits or
payment of dividends. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Circular of the State Administration of Foreign Exchange, or the SAFE, on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment and its
appendix promulgated in November 2012 and amended in May 2015, October 2018 and December 2019 by the SAFE, (1)&nbsp;the opening of and payment into foreign exchange accounts under direct investment
accounts are no longer subject to approval by the SAFE; (2)&nbsp;reinvestment with legal income of foreign investors in China is no longer subject to approval by SAFE; (3)&nbsp;the procedures for
capital verification and confirmation that foreign-funded enterprises need to go through are simplified; (4)&nbsp;purchase and external payment of foreign exchange under direct investment accounts
are no longer subject to approval by SAFE; (5)&nbsp;domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6)&nbsp;the administration
over the conversion of foreign exchange capital of foreign-invested enterprises is improved. Later, the SAFE promulgated the Circular on Further Simplifying and Improving Foreign Exchange
Administration Policies in Respect of Direct Investment in February 2015, which was further amended in December 2019 and prescribed that the bank instead of the SAFE can directly handle the foreign
exchange registration and approval under foreign direct investment while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment
through the bank. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which were promulgated by the SAFE in May 2013 and amended in October 2018
and December 2019, regulate and clarify the administration over foreign exchange administration in foreign direct investments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises promulgated by the SAFE in Mach 2015 and
amended in December 2019, and the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects promulgated by the SAFE in June 2016, the settlement of
foreign exchange by foreign invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used
for their own operational purposes within the business scope of the foreign invested enterprises and follow the principles of authenticity. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividend Distribution  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SAFE promulgated the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control in January
2017, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including the following: (1)&nbsp;under the
principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>213</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=216,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=206536,FOLIO='213',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_214"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>statements;
and (2)&nbsp;domestic entities shall hold income to account for previous years' losses before remitting the profits. Moreover, domestic entities shall make detailed explanations of
sources of capital and utilization arrangements, and provide board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Exchange Registration of Offshore Investment by PRC Residents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SAFE promulgated the SAFE Circular 37 in July 2014. The SAFE Circular 37 requires PRC residents (including PRC institutions and individuals)
to register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or the SPV, directly established or indirectly
controlled by PRC residents for offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC
residents are also required to amend their registrations with the SAFE when there is a change to the basic information of the SPV, such as changes of a PRC resident individual shareholder, the name or
operating period of the SPV, or when there is a significant change to the SPV, such as changes of the PRC individual resident's increase or decrease of its capital contribution in the SPV, or any
share transfer or exchange, merger, division of the SPV. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which was promulgated in February 2015 and effective in June
2015 and further amended in December 2019, provides that PRC residents may register with qualified banks instead of the SAFE in connection with their establishment or control of an offshore entity
established
for the purpose of overseas direct investment. The SAFE and its branches shall implement indirect supervision over foreign exchange registration of direct investment via the banks. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Failure
to comply with the registration procedures set forth in the SAFE Circular 37 may result in restrictions on the foreign exchange activities of the relevant onshore company,
including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange capital, and may also
subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Labor  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Labor Law and Labor Contract Law  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the PRC Labor Law, which was promulgated by the Standing Committee of the NPC in July 1994 and amended in August 2009 and December
2018, respectively, the PRC Labor Contract Law, which was promulgated by the Standing Committee of the NPC in June 2007 and amended in December 2012 and came into effect July 2013, and the
Implementing Regulations of the Employment Contracts Law of the PRC, which was promulgated by the State Council in September 2008, labor contracts in written form shall be executed to establish labor
relationships between employers and employees. In addition, wages cannot be lower than the local minimum wage. The employers must establish a system for labor safety and sanitation, strictly abide by
State rules and standards, provide education regarding labor safety and sanitation to its employees, provide employees with labor safety and sanitation conditions and necessary protection materials in
compliance with State rules, and carry out regular health examinations for employees engaged in work involving occupational hazards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Social Insurance and Housing Provident Funds  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Social Insurance Law of PRC, which was promulgated by the Standing Committee of the NPC in October 2010 and came into effect in
July 2011, and further
amended in December 2018, and the Interim Regulations on the Collection and Payment of Social Security Funds, which was promulgated by the State Council in January 1999 and amended in March 2019, and
the Regulations on the Administration of Housing Provident Funds, which was promulgated by the State </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>214</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=217,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=871900,FOLIO='214',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_215"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Council
in April 1999 and amended in March 2002 and March 2019, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic
pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to contribute may be fined
and ordered to make good the deficit within a stipulated time limit. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations on Taxation  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Enterprise Income Tax  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Enterprise Income Tax Law promulgated by the NPC in March 2007 and amended in February 2017 and December 2018, and the
Implementation Rules of the Enterprise Income Tax Law of the PRC promulgated by the State Council in December 2007 and amended in April 2019, other than a few exceptions, the income tax rate for both
domestic enterprises and foreign-invested enterprises is 25%. Enterprises are classified as either "resident enterprises" or "non-resident enterprises". Besides enterprises established within the PRC,
enterprises established outside China whose "de facto management bodies" are located in China are considered "resident enterprises" and subject to the uniform 25% enterprise income tax rate for their
global income. A non-resident enterprise refers to an entity established under foreign law whose "de facto management bodies" are not within the PRC but which have an establishment or place of
business in the PRC, or which do not have an establishment or place of business in the PRC but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends
declared to non-PRC resident enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business but the relevant income is not
effectively connected with the establishment or place of business, to the extent such dividends are derived from sources within the PRC. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Notice on Promoting the Implementation of Corporate Income Tax Policies for Advanced Technology Service Enterprises Nationwide, or the Notice, since January 2017, an
enterprise which is recognized as an "Advanced Technology Service Enterprises" under the Notice enjoys a reduced enterprise income tax rate of 15%. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Arrangement Between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with
Respect to Taxes on Income, or the Double Tax Avoidance Arrangement, which was promulgated and came into effect in August 2006, and other applicable PRC laws, if a Hong Kong resident enterprise is
determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax
on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5%. However, based on the Circular on Certain Issues with Respect to the Enforcement of
Dividend Provisions in Tax Treaties which was promulgated by the State Administration of Taxation, the STA, in February 2009, if the relevant PRC tax authorities determine, in their discretion, that a
company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. Based on the
Announcement on Certain Issues with Respect to the "Beneficial Owner" in Tax Treaties, which was promulgated by the STA in February 2018 and came into effect in April 2018, if an applicant's business
activities do not constitute substantive business activities, it could result in the negative determination of the applicant's status as a "beneficial owner", and consequently, the applicant could be
precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>215</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=218,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=867472,FOLIO='215',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ee17601_1_216"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Value Added Tax  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the Provisional Regulations of the PRC on Value-Added Tax, effective in January 1994 and further amended in November 2008, February
2016, and November 2017, and its implementation rules effected in January 1994 and amended in December 2008 and October 2011, except stipulated otherwise, taxpayers who sell goods, labor services or
tangible personal property leasing services or import goods shall be subject to a 17% tax rate; taxpayers who sell transport services, postal services, basic telecommunications services, construction
services, or real property leasing services, sell real property, transfer the land use right shall be subject to an 11% tax rate, and taxpayers who sell services or intangible assets shall be subject
to a 6% tax rate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Circular of the Ministry of Finance and the State Administration of Taxation on Adjusting Value-added Tax Rates adopted in April 2018, as of May 2018, where a taxpayer
engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 17% and 11% rates are adjusted to 16% and 10%. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Announcement on Relevant Policies for Deepening Value-Added Tax Reform, effective in April 2019, the 16% VAT tax rate, which applies to the sales or imported goods of a
VAT general taxpayer, will be lowered to 13%; and the 10% VAT tax rate will be lowered to 9%. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the Measures for the Exemption of Value-Added Tax from Cross-Border Taxable Activities in the Collection of Value-Added Tax in Lieu of Business Tax (for Trial
Implementation) revised in June 2018, if domestic enterprises provide cross-border taxable activities such as professional technical services, technology transfer, software services, the
above-mentioned cross-border taxable activities are exempt from VAT. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>216</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=219,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=232250,FOLIO='216',FILE='DISK103:[20ZDS1.20ZDS17601]EE17601A.;32',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_eg17601_1_217"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eg17601_management"> </A>
<A NAME="toc_eg17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers, Key Employees and Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding our directors and executive officers as of the date of this prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="187pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Executive Officers

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position/Title </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2> Peter (Peizhi) Luo, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Co-Founder, Chief Executive Officer and Chairman of the Board</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Fangyong (Felix) Du, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Technology Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Hua Gong, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Operating Officer&nbsp;&amp; Head of Clinical Development and Precision Medicine</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>JC Xu, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Qinghai Zhao, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Manufacturing Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Man Kin (Raymond) Tam, M.B.A., B. Eng.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Financial Officer and Director Nominee<SUP>#</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Yu (Albert) Ren, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Strategy and Corporate Development Officer</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="187pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Key Employees

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position/Title </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Yan Li, M.B.A.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, Bioinformatics and Information Technology</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Xiaohong (Kristine) She</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, Head of Clinical Operations</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Guizhong Liu, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Head of Biology and Pharmacology</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Alexander Goergen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Head of Business Development</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Yuren (Ron) Wang, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Head of Portfolio Management</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="187pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Non-Employee Directors

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position/Title </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Daniel Auerbach, M.B.A.*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Chong Xu, Ph.D.*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Yu Miao</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Yunxia Yang*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Lefei Sun</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Andy (Yiu Leung) Cheung</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Independent Director Nominee<SUP>#</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Min Li</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Independent Director Nominee<SUP>#</SUP></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Each
of Mr.&nbsp;Daniel Auerbach, Mr.&nbsp;Chong Xu and Yunxia Yang will resign from our board of directors immediately prior to the SEC's declaration of
effectiveness of our registration statement on Form&nbsp;F-1, of which this prospectus is a part.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1><SUP>#</SUP></FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Each
of Mr. Man Kin (Raymond) Tam, Mr. Andy (Yiu Leung) Cheung and Mr. Min Li has accepted appointment as a director, which will be immediately
effective upon the declaration of effectiveness of our registration statement on Form&nbsp;F-1 by the SEC, of which this prospectus is a part. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I>Peter (Peizhi) Luo, Ph.D.</I></B></FONT><FONT SIZE=2> is our Co-Founder and has served as our Chief Executive Officer since
November 2011 and Chairman of the Board of the Directors since February 2018. Dr.&nbsp;Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor
(Nasdaq: XNCR) from July 1998 to August 2000. In September 2000, Dr.&nbsp;Luo founded Abmaxis&nbsp;Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May
2006, Dr. Luo led the acquisition of Abmaxis&nbsp;Inc. by Merck&nbsp;&amp;&nbsp;Co. (NYSE: MRK), after which Dr.&nbsp;Luo served as a director of Biologics Technology at Merck, and Chief
Technology Officer of Abmaxis, the subsidiary of Merck&nbsp;&amp;&nbsp;Co. Throughout his career, Dr.&nbsp;Luo also led the business development efforts in connection with collaborations and
strategic partnerships with multiple global partners. Dr.&nbsp;Luo received his </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>217</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=220,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=535727,FOLIO='217',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_218"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>bachelor's
degree in applied chemistry in technical physics from Peking University in 1986, master's degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of
Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr.&nbsp;Luo also completed his postdoctoral research in protein folding at Stanford University in 1998.
Dr.&nbsp;Luo's spouse is Xiaohong (Kristine) She who is our Senior Vice President, Head of Clinical Operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Fangyong (Felix) Du, Ph.D.</I></B></FONT><FONT SIZE=2> joined us as Vice Precedent of Technology Development in January 2012 and has served as our Chief Technology
Officer since May 2019. Dr.&nbsp;Du has over 20&nbsp;years of experience in biological research and discovery industry, and has published numerous peer-reviewed articles in world-renowned
scientific journals such as Nature and Science. Dr.&nbsp;Du worked at Affomix from October 2009 to July 2010 and Illumina (Nasdaq: ILMN) from July 2010 to January 2012, and then joined the Company
in January 2012 as the Vice President of Technology Development. Dr.&nbsp;Du received his bachelor's degree and master's degree in physiology and biophysics in 1991 and 1994, respectively, from
Peking University, and his Ph.D. degree in biology from the California Institute of Technology in 2001. Dr.&nbsp;Du also completed his postdoctoral research from Yale University in 2007. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Hua Gong, M.D., Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Chief Operating Officer and Head of Clinical Development and Precision Medicine since July 2020.
Dr.&nbsp;Gong served as the principal scientist of Pfizer (NYSE: PFE) from January 1999 to March 2009. From April 2009 to October 2011, she served as the associate director of Prometheus
Diagnostics&nbsp;&amp; Therapeutics. From November 2011 to January 2013, Dr.&nbsp;Gong
served as an executive director of Premier Research. From January 2013 to June 2020, she served as the senior director and head of genomics biomarker of Novartis. Dr.&nbsp;Gong received her
M.D.&nbsp;degree from An Hui Medical University in 1989, master's degree in biostatistics from Sun Yat-Sen University of Medical Sciences in 1992 and Ph.D. degree in cancer biology from Wayne State
University in 1999. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>JC Xu, M.D., Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Chief Scientific Officer since August 2020. Dr.&nbsp;Xu has more than 20&nbsp;years of experience
in oncology drug discovery and development, and more than four years of experience in business development, strategy, and operations in the biopharmaceutical industry in the United States. Prior to
joining Adagene, Dr.&nbsp;Xu was head of R&amp;ED China Strategy at Celgene now BMS from 2017 to 2020. Prior to that, Dr.&nbsp;Xu was Director of Strategy&nbsp;&amp; Operations at Celgene Quanticel
Research and Director of Biology at Quanticel Pharmaceuticals from 2012 to 2017. Prior to Quanticel, Dr.&nbsp;Xu worked in leadership roles at a number of biopharmaceutical companies, including
Pfizer, Amgen, and Corixa. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Xu
received her M.D. degree from Beijing Medical University (now Peking University Health Science Center) in 1987 and her Ph.D. degree in Immunology from University of Alabama
at Birmingham in 1993. She completed her post-doctoral training at DNAX Research Institute (now Merck Palo Alto) in 1996. She is an inventor of more than 120 issued and pending patents and has
published more than 50 articles in peer-reviewed journals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Qinghai Zhao, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Chief Manufacturing Officer since October 2020. Dr.&nbsp;Zhao has more than 25&nbsp;years of
experience in protein therapeutics development and defining product development strategy from early stage IND through commercial filing. Prior to joining Adagene, Dr.&nbsp;Zhao was Vice President of
Technical Development and Manufacturing at Forty Seven&nbsp;Inc. (NASDAQ:FTSV) from 2017 to October&nbsp;2020. Prior to that, Dr.&nbsp;Zhao was vice president of CMC/Manufacturing at AnaptysBio
(NASDAQ:ANAB) from 2016 to 2017. Prior to AnaptysBio, Dr.&nbsp;Zhao worked as an Executive Director and the Head of CMC at NGM&nbsp;Biopharmaceuticals from 2014 to 2016. Dr.&nbsp;Zhao also held
various positions at Human Genome Sciences,&nbsp;Inc., Cogenesys and Teva Biopharmaceuticals USA from 2001 to 2014. Dr.&nbsp;Zhao received his bachelor's degree from Shanghai Chemical Engineering
Institute (now East China University of Sciences and Technology) in 1982, master's degree from Shanghai Medical University (now merged with Fudan University) in 1986 and Ph.D. degree from University
of Uppsala in 1998. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>218</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=221,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=756537,FOLIO='218',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_219"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Man Kin (Raymond) Tam</I></B></FONT><FONT SIZE=2> has served as our Chief Financial Officer since September 2019 and will serve as our director immediately upon the
effectiveness of our registration statement on Form&nbsp;F-1, of which this prospectus is a part. Mr.&nbsp;Tam has over 20&nbsp;years of management experience in finance and banking across the
Asia-Pacific region. Mr.&nbsp;Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr.&nbsp;Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer
of Resourcehouse Limited from April 2010 to October 2015. From October 2015 to August 2019, Mr.&nbsp;Tam
consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited (HKEx: 8158), Beijing Gas Blue Sky Holdings Limited (HKEx: 6828), and AgenTus
Therapeutics,&nbsp;Inc. Mr.&nbsp;Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants.
He is also a CFA and FRM charter-holder. He received his bachelor's degree in civil&nbsp;&amp; resources engineering from the University of Auckland in 1997, master's degree in practising accounting
from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005. </FONT></P>

<P style="font-family:times;">


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=2><B><I>Yu (Albert) Ren</I></B></FONT><FONT SIZE=2><B>, Ph.D.</B></FONT><FONT SIZE=2> has served as our Chief Strategy and Corporate Development Officer since January 2021.
Prior to joining us, Dr.&nbsp;Ren held various positions at Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. (NYSE: MRK). He had previously worked at Portfolio Management&nbsp;&amp; Global Clinical Development
Finance responsible for financial / strategic planning on KEYTRUDA&reg; development and facilitation of KEYTRUDA&reg; clinical trials prioritization. He also worked at Merck Corporate
Strategy Office on enterprise strategy and at Merck Corporate Business Development on a variety of business development transactions. Before returning to Merck, Dr.&nbsp;Ren served as a principal
consultant at Quintiles/IQVIA Consulting from 2009 to 2010. Dr.&nbsp;Ren gained extensive consulting experience at McKinsey&nbsp;&amp; Company from 2007 to 2009. Dr.&nbsp;Ren started his
professional career at Merck Research Lab working on Pharmaceutical Research&nbsp;&amp; Development from discovery to early clinical development from 2001 to 2006. Dr.&nbsp;Ren received his Ph.D. in
Chemistry from University of Minnesota in 2001, and bachelor's degree in Chemistry from Peking University in 1996.

</FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Key Employees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Yan Li, M.B.A.</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President of Bioinformatics and Information Technology since November 2011. Ms.&nbsp;Li has
over 25&nbsp;years of experience in software development, with about 20&nbsp;years focusing on the development of informatics software tools for antibody library design and analysis. Ms.&nbsp;Li
served as the senior software engineer and applications scientist at Abmaxis from November 2001 to May 2006. Following the acquisition of Abmaxis by Merck&nbsp;&amp; Co, Ms.&nbsp;Li worked at
Merck&nbsp;&amp; Co from May 2006 to December 2010. She received the Merck Award for Excellence in "Innovative Technologies" with the team and a Special Award for her contribution. Ms.&nbsp;Li
received her bachelor's degree in information science from East China University of Science and Technology in 1995 and a Master of Business Administration degree in 2010 from Santa Clara University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Xiaohong (Kristine) She</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President, Head of Clinical Operations since November 2011. Ms.&nbsp;She has over
20&nbsp;years of laboratory and laboratory management experience in the renowned laboratories in the United States and has completed multiple projects in molecular biology and immunology at the labs
of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran's Hospital, and cloning and functional screening of cDNA libraries at
Caltech. Her work has been published in Nature, Science,
Biotechnology, among many other notable publications. Ms.&nbsp;She received her bachelor's degree in microbiology from Wuhan University in 1986 and master's degree in biochemistry and microbiology
from the Institute of Microbiology of the Chinese Academy of Sciences in 1989. Ms.&nbsp;She's spouse is Peter (Peizhi) Luo, Ph.D., our Co-Founder, Chief Executive Officer and Chairman of the Board. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Guizhong Liu, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Head of Biology and Pharmacology since October 2015. Dr.&nbsp;Liu has over 15&nbsp;years of
experience in drug discovery and development, both in small molecule </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>219</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=222,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=662690,FOLIO='219',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_220"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>kinase
inhibitors and large molecule antibodies in oncology and immunology field. He has published over 40 peer-reviewed papers in high-profile journals involving key signalling pathways and targets
in cancer biology. From July 2007 to August 2011, Dr.&nbsp;Liu served as an assistant professor of the department of oncological science at Mount Sinai School of Medicine. Prior to joining us,
Dr.&nbsp;Liu served as head of molecular cancer biology in CrownBio from October 2011 to September 2015. Dr.&nbsp;Liu received his bachelor's degree in biology in 1992 and master's degree in cell
biology in 1995 from Beijing Normal University and Ph.D. degree in cell biology from Peking Union Medical College in 1998. He also completed his postdoctoral training in cancer biology at Mount Sinai
School of Medicine in 2004. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Alexander Goergen</I></B></FONT><FONT SIZE=2> has served as our Head of Business Development since October 2017 when he joined the Company. Mr.&nbsp;Goergen has
worked in various roles at the Covance, TRC and International AIDS Vaccine Initiative from October 2008 to October 2012. Prior to joining us, Alexander worked in business development for Catalent
Pharma Solutions Biologics Division since October 2012. Mr.&nbsp;Goergen completed many licensing, manufacturing, and cell line development programs both domestically and internationally during his
previous employment. Mr.&nbsp;Goergen received his bachelor's degree in Chemistry from Lafayette College in 2008 and master's degree in Biotechnology from the University of Wisconsin-Madison in
2011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Yuren (Ron) Wang, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Head of Portfolio Management since September 2019. Dr.&nbsp;Wang served as the senior director
of business development in Reaction Biology Corporation from March 2013 to December 2018. Prior to joining us, he served as the vice president of R&amp;D research for Jemincare Therapeutics (USA),
responsible for the scientific evaluation of projects, in-licensing and portfolio management from December 2018 to August 2019. Dr.&nbsp;Wang received his bachelor's degree in plant science from
Shandong Agricultural University in 1982, master's degree in biochemistry from the Graduate School of Chinese Academy of Agricultural Sciences in 1986 and Ph.D. degree in cell and molecular biology
from the University of Pennsylvania in 1996. He also completed his postdoctoral training in molecular pharmacology at the University of Pennsylvania in 1999. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I>Daniel Auerbach</I></B></FONT><FONT SIZE=2> has served as our director since July 2013. He joined Fidelity in 1994 and has
been serving as the senior managing partner of Eight Roads, a proprietary investment arm backed by Fidelity. Mr.&nbsp;Auerbach held key board roles with a multitude of companies, including the
former director of Alibaba Group, Wuxi Pharmatech during 2005 to 2007, Innovent (HKEx: 1801) during 2011 to 2018, Hua Medicine (HKEx: 2552) during 2010 to 2018 and others. Mr.&nbsp;Auerbach received
his bachelor's degree in Economics and Foreign Languages from Dartmouth College in 1980 and Master of Business Administration degree from The Harvard Business School in 1987. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Chong Xu, Ph.D. </I></B></FONT><FONT SIZE=2>has served as our director since May 2020. Dr.&nbsp;Xu joined F-Prime Capital in 2015 and is currently serving as its
principal. Prior to joining F-Prime Capital, Dr.&nbsp;Xu worked at McKinsey&nbsp;&amp; Company's Boston office as a consulting professional from September 2014 to October 2015. Dr.&nbsp;Xu also
worked at Massif Partners from April 2011 to May 2012 as an investment professional. From December 2009 to April 2011, Dr.&nbsp;Xu served as an investment professional at Affirmed Healthcare.
Dr.&nbsp;Xu received his bachelor's degree in biology from Zhejiang University in 2001, a Ph.D. degree in cell biology from University of Virginia in 2009, and an MBA degree from Darden School of
Business in 2014. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Yu Miao</I></B></FONT><FONT SIZE=2> has served as our director since May 2020. He also serves as the executive director of GP&nbsp;Healthcare
Capital&nbsp;Co.,&nbsp;Ltd, mainly responsible for equity investment focusing on healthcare industry. Prior to joining&nbsp;GP Healthcare Capital in April 2015, Mr.&nbsp;Yu worked at Eli
Lilly&nbsp;&amp;&nbsp;Co. focusing on quality assurance from July 2011 to June 2012 and Oriza Seed Fund Management&nbsp;Co.,&nbsp;Ltd., focusing on equity investment from July 2014 to April 2015.
Mr.&nbsp;Miao received </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>220</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=223,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=161490,FOLIO='220',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_221"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>his
bachelor's degree in pharmacy from China Pharmaceutical University in 2011, and master's degree in pharmaceutical science from Northeastern University in 2014. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Yunxia Yang</I></B></FONT><FONT SIZE=2> has served as our director since June 2019. She has also served as a managing director of Sequoia Capital China since May 2015
where she focuses on healthcare investment. Ms.&nbsp;Yang has also served as a director of Burning Rock Biotech&nbsp;Ltd since January 2017. Before starting in venture capital, Ms.&nbsp;Yang
worked as a product manager at GE Healthcare from June 2006 to July 2007 and a business development manager at Johnson&nbsp;&amp; Johnson from July 2009 to April 2011. She then worked at Legend Capital,
where she led investment in areas covering gene diagnostics, medical devices and healthcare service, as a member of the healthcare team from April 2011 to May 2015. Ms.&nbsp;Yang received her
master's degree in clinical science from Huazhong Technology University in 1997 and Master of Business Administration degree from Duke University in 2009. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Lefei Sun</I></B></FONT><FONT SIZE=2> has served as our director since December 2019. Mr&nbsp;Sun has been a non-executive director of Hong Kong Asia Medical
Holding Limited, a leading hospital management group in Asia with hospital assets such as Wuhan Asia Heart Hospital, from November 2018. He is also a non-executive director of various biotech
companies such as Ocumension Therapeutics (HKEx:&nbsp;1477) and CANbridge Pharmaceuticals&nbsp;Inc. Mr.&nbsp;Sun has served as head of China healthcare at General Atlantic since May 2018, and
has been a managing director since January 2020, in charge of private equity investment and portfolio management in healthcare and life sciences sectors. From December 2014 to April 2018,
Mr.&nbsp;Sun was a founding partner and a member of investment committee of Beijing HuaTai Ruihe Investment Fund Management Company (LLP), also known as Huatai Healthcare Investment Fund. Prior to
joining General Atlantic, Mr.&nbsp;Sun served as various investment roles at Hony Capital, Credit Suisse, OrbiMed, Orchid Asia, and as a management consultant at McKinsey&nbsp;&amp; Company, all in
the healthcare sector. Mr.&nbsp;Sun obtained his master's degree in neurosciences from Johns Hopkins University School of Medicine in 2006, and his bachelor's degree in mathematics and physics from
Tsinghua University in 2002. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Andy (Yiu Leung) Cheung</I></B></FONT><FONT SIZE=2> will serve as our independent director immediately upon the effectiveness of our registration statement on
Form&nbsp;F-1, of which this prospectus is a part. Mr.&nbsp;Cheung has many years of auditing and accounting professional experience. Mr.&nbsp;Cheung was deputy area managing partner of
Ernst&nbsp;&amp; Young ("EY") in Asia Pacific overseeing the business operations, finance, information technology and risk management functions from July 2018 to June 2020. Mr.&nbsp;Cheung was the
assurance leader for EY in Greater China from July 2013 to June 2018. Mr.&nbsp;Cheung has served as an independent non-executive director of JW (Cayman) Therapeutics&nbsp;Co. Ltd (HKEX:2126) since
October 2020. Mr.&nbsp;Cheung received his bachelor's degree in accounting and finance from the University of Lancaster in the United Kingdom in June 1982. He obtained a master's degree in
accounting and finance from London School of Economics in the United Kingdom in August 1983. Mr.&nbsp;Cheung is a member of Hong Kong Institute of Certified Public Accountants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Min Li</I></B></FONT><FONT SIZE=2> will serve as our independent director immediately upon the effectiveness of our registration statement on Form F-1, of which this
prospectus is a part. Dr. Min Li is the founder, CEO and director of SciNeuro Pharmaceuticals, a biotechnology company headquartered in Shanghai focused on developing innovative therapeutics for CNS
diseases. Dr. Li was formerly Senior Vice President, Global Head of Neuroscience R&amp;D at GSK from 2013 to 2019. During his employment with GSK, he also served as General Manager of GSK R&amp;D China, the
highest-ranking officer at the country level. Before moving into industry, Dr. Li had served as a tenured Professor of Neuroscience at Johns Hopkins University School of Medicine for over 20 years.
Dr. Li served on scientific advisory boards, non-profit and corporate boards that include multinational corporations (Corning, Pfizer and Merck), disease foundations (RYR-foundation, AHA) and biotech
companies (Xencor, Affymax, Datavant, Icagen, and Coda Biotechnologies). He is also an Adjunct Professor of Neuroscience at Johns Hopkins School of Medicine. Dr. Li received his B.S. degree in
biochemistry from Wuhan University in 1984 and his Ph.D. in molecular immunology from Johns Hopkins University in 1990. As </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>221</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=224,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=640370,FOLIO='221',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_222"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>a
Helen Hay Whitney Fellow, he performed postdoctoral research at University of California San Francisco. With a Sloan Award, in 1994 he returned to Johns Hopkins to join the faculty as an Esther A &amp;
Joseph Klingenstein Neuroscience Fellow. Dr. Li has published more than 120 scientific articles and holds patents in biotechnologies. His research and scholarship were recognized internationally with
awards including being a fellow of American Association for Advancement of Science and an established fellow of American Heart Association. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements and Indemnification Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into employment agreements with each of our executive officers. Each of our executive officers is employed for a period of
twelve months, which will be renewed automatically and extended automatically for a period of twelve months unless the executive or us gives prior written notice. We may terminate an executive
officer's employment for cause at any time without advance notice in certain events. We may terminate an executive officer's employment by giving a prior written notice or by paying certain
compensation. An executive officer may terminate his or her employment at any time by giving a prior written notice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
executive officer has agreed to hold, unless expressly consented to by us, at all times during and after the termination of his or her employment agreement, in strict confidence and
not to use, any of our confidential information or the confidential information of our customers and suppliers. In addition, each executive officer has agreed to be bound by certain non-competition
and non-solicitation restrictions during the term of his or her employment and for a maximum of two years following the last date of employment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to enter into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers
against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors will consist of six directors, including two independent directors, namely Andy (Yiu Leung) Cheung and Min Li, upon the
SEC's declaration of effectiveness of our registration statement on Form&nbsp;F-1 to which this prospectus forms&nbsp;a part. A director is not required to hold any shares in our company to
qualify to serve as a director. The Corporate Governance Rules of the Nasdaq generally require that a majority of an issuer's board of directors must consist of independent directors. However, the
Corporate Governance Rules of the Nasdaq permit foreign private issuers like us to follow "home country practice" in certain corporate governance matters. We rely on this "home country practice"
exception and do not have a majority of independent directors serving on our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with our company is required to declare the nature of his or her interest at a
meeting of our directors. A general notice given to the directors by any director to the effect that he or she is a member, shareholder, director, partner, officer or employee of any specified company
or firm and is to be regarded as interested in any contract or transaction with that company or firm shall be deemed a sufficient declaration of interest for the purposes of voting on a resolution in
respect to a contract or transaction in which he/she has an interest, and after such general notice it shall not be necessary to give special notice relating to any particular transaction. A director
may vote in respect of any contract or proposed contract or arrangement notwithstanding that he/she may be interested therein and if he/she does so, his/her vote shall be counted and he/she may be
counted in the quorum at any meeting of the directors at which any such contract or proposed contract or arrangement is considered, subject to any separate requirement for Audit Committee approval
under applicable law or the Listing Rules of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>222</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=225,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=774097,FOLIO='222',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_223"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
Nasdaq. Our board of directors may exercise all of the powers of our company to borrow money, to mortgage or charge its undertaking, property and uncalled capital, or any part thereof, and to
issue debentures, debenture stock or other securities whenever money is borrowed or as security for any debt, liability or obligation of our company or of any third party. None of our directors has a
service contract with us that provides for benefits upon termination of service as a director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the completion of this offering, we intend to establish an audit committee, a compensation committee and a nominating and corporate
governance committee under our board of directors. We intend to adopt a charter for each of the three committees prior to the completion of this offering. Each committee's members and functions are
described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit Committee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our audit committee will consist of Andy (Yiu Leung) Cheung and Min Li, and is chaired by Andy (Yiu Leung)
Cheung. We have
determined that Andy (Yiu Leung) Cheung and Min Li satisfy the requirements of Rule&nbsp;5605(a)(2) of the Listing Rules of the Nasdaq and meet the independence standards under Rule&nbsp;10A-3
under the Securities Exchange Act of 1934, as amended. We have determined that Andy (Yiu Leung) Cheung qualifies as an "audit committee financial expert." The audit committee oversees our accounting
and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and recommending to our board for approval, the appointment, re-appointment or removal of the independent auditor, after considering
its annual performance evaluation of the independent auditor; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approving the remuneration and terms of engagement of the independent auditor and pre-approving all auditing and non-auditing services
permitted to be performed by our independent auditors at least annually; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining a written report from our independent auditor describing matters relating to its independence and quality control procedures; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing with the independent registered public accounting firm any audit problems or difficulties and management's response; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing with our independent auditor, among other things, the audits of the financial statements, including whether any material information
should be disclosed, issues regarding accounting and auditing principles and practices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving all proposed related party transactions, as defined in Item&nbsp;404 of Regulation&nbsp;S-K under the Securities
Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and recommending the financial statements for inclusion within our quarterly earnings releases and to our board for inclusion in our
annual reports; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing the annual audited financial statements with management and the independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any special steps taken to monitor
and control major financial risk exposures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at least annually, reviewing and reassessing the adequacy of the committee charter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approving annual audit plans, and undertaking an annual performance evaluation of the internal audit function; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing and overseeing procedures for the handling of complaints and whistleblowing; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>223</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=226,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=921144,FOLIO='223',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_224"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting separately and periodically with management and the independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to
ensure proper compliance; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reporting regularly to the board. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee will consist of Peter Luo, Andy (Yiu Leung) Cheung and Min Li and is chaired
by Peter Luo We have
determined that Andy (Yiu Leung) Cheung and Min Li satisfy the "independence" requirements of Rule&nbsp;5605(a)(2) of the Listing Rules of the Nasdaq. The compensation committee assists the board in
reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our Chief Executive Officer may not be present at any
committee meeting during which their compensation is deliberated upon. The compensation committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the development and implementation of compensation programs in consultation with our management; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at least annually, reviewing and approving, or recommending to the board for its approval, the compensation for our executive officers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at least annually, reviewing and recommending to the board for determination with respect to the compensation of our non-executive directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at least annually, reviewing periodically and approving any incentive compensation or equity plans, programs or other similar arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing executive officer and director indemnification and insurance matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our regulatory compliance with respect to compensation matters, including our policies on restrictions on compensation plans and
loans to directors and executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at least annually, reviewing and reassessing the adequacy of the committee charter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> selecting compensation consultant, legal counsel or other adviser only after taking into consideration all factors relevant to that person's
independence from management; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reporting regularly to the board. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nominating and Corporate Governance Committee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee will consist of Peter Luo, Andy
(Yiu Leung) Cheung
and Min Li, and is chaired by Peter Luo. We have determined that Andy (Yiu Leung) Cheung and Min Li satisfy the "independence" requirements of Rule&nbsp;5605(a)(2) of the Listing Rules of the
Nasdaq. The nominating and corporate governance committee assists the board in selecting individuals qualified to become our directors and in determining the composition of the board and its
committees. The nominating and corporate governance committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending nominees to the board for election or re-election to the board, or for appointment to fill any vacancy on the board; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing annually with the board the current composition of the board with regards to characteristics such as independence, knowledge, skills,
experience, expertise, diversity and availability of service to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and recommending to our board such policies and procedures with respect to nomination or appointment of members of our board and
chairs and members of its committees or other corporate governance matters as may be required pursuant to any SEC or Nasdaq rules, or otherwise considered desirable and appropriate; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>224</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=227,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=614771,FOLIO='224',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_225"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> selecting and recommending to the board the names of directors to serve as members of the audit committee and the compensation committee, as
well as of the nominating and corporate governance committee itself; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at least annually, reviewing and reassessing the adequacy of the committee charter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and reviewing at least annually the corporate governance principles adopted by the board and advising the board with respect to
significant developments in the law and practice of corporate governance and our compliance with such laws and practices; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluating the performance and effectiveness of the board as a whole. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Duties and Functions of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly and a duty to
act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors also owe to our company a duty to exercise
the skill they actually possess and such care and diligence that a reasonable prudent person would exercise in comparable circumstances. It was previously considered that a director need not exhibit
in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an
objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure
compliance with our memorandum and articles of association, as amended and restated from time to time. Our company has the right to seek damages if a duty owed by our directors is breached. In limited
exceptional circumstances, a shareholder may have the right to seek damages in our name if a duty owed by our directors is breached. The functions and powers of our board of directors include, among
others, (i)&nbsp;convening shareholders' annual general meetings and reporting its work to shareholders at such meetings, (ii)&nbsp;declaring dividends, (iii)&nbsp;appointing officers and
determining their terms of offices and responsibilities, (iv) exercising the borrowing powers of our company, and (v)&nbsp;approving the transfer of shares of our company, including the registering
of such shares in our share register. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms of Directors and Officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our officers are elected by and serve at the discretion of the board of directors. Other than Andy (Yiu Leung) Cheung, Min Li and Man Kin
(Raymond) Tam, each director is not subject to a term of office and holds office until such time as his successor takes office or until the earlier of his death, resignation or removal from office
pursuant to the applicable provisions of our memorandum and articles of association. The initial term of our independent director nominees, namely Andy (Yiu Leung) Cheung and Min Li, is two-year from
the effectiveness of the appointment. The initial term of our non-independent director nominee, Man Kin (Raymond) Tam, is one-year from the effectiveness of the appointment. The initial term for each
of Andy (Yiu Leung) Cheung, Min Li and Man Kin (Raymond) Tam is subject to re-appointment by the board of directors and affirmative vote of Chairman of the board of directors. A director will be
removed from office automatically if, among other things, the director (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his creditors; (ii)&nbsp;dies or is found by our
company to be of unsound mind; (iii)&nbsp;resigns by notice in writing to our company; (iv)&nbsp;without special leave of absence from our board of directors, is absent from three consecutive
meetings of the board and the board resolves that his office be vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provisions
of our post-offering amended and restated memorandum and articles of association. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>225</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=228,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=109240,FOLIO='225',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_226"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interested Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A director may, subject to any separate requirement for audit and risk committee approval under applicable law or applicable Nasdaq listing
rules, vote in respect of any contract or transaction in which he or she is interested, provided that the nature of the interest of any directors in such contract or transaction is disclosed by him or
her at or prior to its consideration and any vote in that matter. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation of Directors and Executive Officers  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the fiscal year ended December&nbsp;31, 2020, we paid an aggregate of US$2.6&nbsp;million in cash to our executive officers, and we paid
US$54,000 cash compensation to our then non-executive director, Mr.&nbsp;Tom Beck, for the fiscal year ended December&nbsp;31, 2020. We did not pay any cash compensation to other non-executive
directors. For the fiscal year ended December&nbsp;31, 2020, we did not set aside or accrue expenses related to pension, retirement or other similar benefits to our executive officers and directors.
Our PRC subsidiary is required by law to make contributions equal to certain percentages of each employee's salary for his or her pension insurance, medical insurance, unemployment insurance and other
statutory benefits and a housing provident fund. For share incentive grants to our directors and executive officers, see "&#151;Share Incentive Plan."


</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Incentive Plan  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adagene&nbsp;Inc. Second Amended and Restated Share Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2015, we adopted Adagene&nbsp;Inc. Share Incentive Plan, or the 2015 Plan, which was later superseded and replaced by
Adagene&nbsp;Inc. Amended and Restated Share Incentive Plan, or the 2017 Plan, in September 2017. In December 2019, we adopted the Second Amended and Restated Share Incentive Plan, or the 2019 Plan,
to supersede and replace the 2017 Plan. The terms of the 2015 Plan, the 2017 Plan and the 2019 Plan are substantially the same other than the maximum aggregate number of shares we may issue under the
respective plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of the 2019 Plan is to attract, motivate, retain and reward certain officers, employees, directors and other eligible persons and to further link the interests of award
recipients with those of our shareholders generally. The 2019 Plan provides for the issuance of up to an aggregate of 11,391,131 of our ordinary shares. Upon the effectiveness of our registration
statement on Form F-1, we will terminate the authority to grant additional awards under the 2019 Plan and all future awards will be granted under the 2021 Plan. Therefore, the effective maximum number
of shares issuable under the 2019 Plan will be 10,728,501. As of the date of this prospectus, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan is
3,601,522, excluding awards that were
forfeited, cancelled or exercised after the relevant grant dates. The term of the awards will expire not more than ten years after the date of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following paragraphs summarize the principal terms of the 2019 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Types of Awards.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan permits the awards of options, share appreciation rights, ordinary shares or restricted shares.
</FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Administration.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan shall be administrated by our board of directors or one or more committees appointed by the
board of directors or
another committee (within its delegated authority), the Plan Administrator. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promissory Notes.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The promissory notes with respect to the 2019 Plan, or the 2019 Promissory Notes are full recourse, repayable
within a period of
time determined by the Plan Administrator, which should not exceed five years (subject to certain early repayment events), and bear interest at the interest rate determined by the Plan Administrator
but not less than the interest rate necessary to avoid the imputation of interest under United States Internal Revenue Code of 1986, as amended or other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>226</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=229,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=243997,FOLIO='226',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_227"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>applicable
tax law. Certain plan participants previously purchased our shares with such promissory notes. The current amount outstanding under these notes (which is also the largest aggregate amount
outstanding since the first issuance of the promissory notes) was US$1.8&nbsp;million immediately. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayment of the Promissory Notes.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The terms, repayment provisions, and collateral release provisions of the note and the pledge
securing the note
shall conform with all applicable rules and regulations, including those of the Federal Reserve Board of the United States and any applicable law, as then in effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrators may decide that an award under the 2019 Plan be granted to any employee, officer or
director of the Company or
its affiliates, or that it be granted to any consultant or adviser who provides services to the Company or its affiliates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Award Agreements.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each award under the 2019 Plan shall be evidenced by an award agreement in the form approved by the plan
administrators. The terms
of the award agreements will be determined by the plan administrators and consistent with the terms of the 2019 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions of Award.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrators shall determine the participants, types of awards, numbers of shares to be covered
by awards, terms and
conditions of each award, including, but not limited to, the price and number of securities to be offered or awarded, the installments (if applicable) in which such awards will become exercisable or
will vest, performance targets (if applicable), the events of termination or reversion of such awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Restrictions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;With a few exceptions, no right of interest of a participant in any award may be subject in any manner to
sale, transfer,
anticipation, alienation, assignment, pledge, encumbrance or charge. This restriction does not apply to (i)&nbsp;transfers to our company, (ii)&nbsp;transfers by gift or domestic relations order
to one or more family members, (iii)&nbsp;the designation of a beneficiary to receive benefits if a participant dies or transfers by will, (iv)&nbsp;permitted transfers or exercises on behalf of a
participant by the participant's duly authorized legal representative if the participant has suffered a disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction or Clawback of Awards.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The awards granted under the 2019 Plan are subject to the terms of our recoupment, clawback or
similar policy as it
may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of awards or any ordinary shares or
other cash or property received with respect to the awards (including any value received from a disposition of the shares acquired upon payment of the Awards). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment and Termination of the 2019 Plan.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The board of directors may, at any time, terminate or, from time to time, amend,
modify or suspend the
2019 Plan, in whole or in part. No awards may be granted during any period that the board of directors suspends the 2019 Plan. To the extent then
required by applicable law or listing agency, any amendment to the 2019 Plan may be subject to shareholder approval. Unless earlier terminated by the board of directors, the 2019 Plan will terminate
at the close of business on the day before the 10<SUP>th</SUP>&nbsp;anniversary of the date the board of directors approved the 2019 Plan. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adagene Inc. 2021 Performance Incentive Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2021, our board of directors adopted, and our shareholders approved, the 2021 Performance Incentive Plan, or the 2021 Plan, to
provide an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The terms of the 2021 Plan are summarized below.
Employees, officers, directors and consultants that provide services to us or one of our subsidiaries may be selected to receive awards under the 2021 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>227</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=230,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=763381,FOLIO='227',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_228"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors or a committee appointed by the board administers the 2021 Plan. The plan administrator has broad authority to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> select participants and determine the types of awards that they are to receive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determine the number of shares that are to be subject to awards and the terms and conditions of awards, including the price (if any) to be paid
for the shares or the award and establish the vesting conditions (if applicable) of such shares or awards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cancel, modify or waive our rights with respect to, or modify, discontinue, suspend or terminate any or all outstanding awards, subject to any
required consents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> construe and interpret the terms of the 2021 Plan and any agreements relating to the plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> accelerate or extend the vesting or exercisability or extend the term of any or all outstanding awards subject to any required consent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to the other provisions of the 2021 Plan, make certain adjustments to one or more outstanding awards (including a repricing of the
exercise or base price of any outstanding option or share appreciation right without shareholder approval) and authorize the termination, conversion, substitution or succession of awards; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> allow the purchase price of an award or our ordinary shares to be paid in the form of cash, check or electronic funds transfer, by the delivery
of previously-owned ordinary shares or by a reduction of the number of shares deliverable pursuant to the award, by services rendered by the recipient of the award, by notice and third party payment
or cashless exercise on such terms as the plan administrator may authorize or any other form permitted by law. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
total of 2,994,000 of our ordinary shares is authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first
trading day in January of each year (commencing with 2022) by an amount equal to (1)&nbsp;5% of the total number of our outstanding ordinary shares on December&nbsp;31 of the prior year, or
(2)&nbsp;such lesser number as determined by our board of directors. Any shares subject to awards granted under the 2021 Plan or our Second Amended and Restated Share Incentive Plan that are not
paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax
withholding obligations, will become available for new award grants under the 2021 Plan. As of the date of this prospectus, no awards have been granted under the 2021 Plan, and the full number of
shares authorized under the 2021 Plan is available for award purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards
under the 2021 Plan may be in the form of incentive or nonqualified stock options, share appreciation rights, share bonuses, restricted shares, share units, restricted share units
and other forms of awards including cash awards. Awards under the plan generally will not be transferable other than by will or the laws of descent and distribution, except that the plan administrator
may authorize certain transfers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options
and share appreciation rights may not be granted under the 2021 Plan at exercise prices below the fair market value of the underlying ordinary shares on the date of grant, except
that the plan administrator may grant such awards with exercise prices below the fair market value of the underlying shares to service-providers who are not subject to U.S. taxes. The maximum term of
options and share appreciation rights granted under the plan is ten years. Incentive stock options granted to any 10% owner of our ordinary shares must have an exercise price that is at least 110% of
the fair market value of our ordinary shares on the grant date and a maximum term of five years. These and other awards may also be issued solely or in part for services. Awards are generally paid in
cash or our ordinary shares. The plan administrator may provide for the deferred payment of awards and may determine the terms applicable to deferrals. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>228</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=231,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=251623,FOLIO='228',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_229"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
is customary in incentive plans of this nature, the number and type of shares available under the 2021 Plan and any outstanding awards, as well as the exercise or purchase prices of
awards, will be subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, share splits, share dividends or other similar events that change the number or
kind of shares outstanding, and extraordinary dividends or distributions of property to the shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
and subject to limited exceptions set forth in the 2021 Plan, if we dissolve or undergo certain corporate transactions such as a merger, business combination or other
reorganization, or a sale of all or substantially all of our assets, all awards then-outstanding under the 2021 Plan will become fully vested or paid, as applicable, and will terminate or be
terminated in such circumstances, unless the plan administrator provides for the assumption, substitution or other continuation of the award. The plan administrator also has the discretion to
establish other change in control provisions with respect to awards granted under the 2021 Plan. For example, the administrator could provide for the acceleration of vesting or payment of an award in
connection with a corporate event that is not described above and provide that any such acceleration shall be automatic upon the occurrence of any such event. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors may amend or terminate the 2021 Plan at any time, but no such action will affect any outstanding award in any manner materially adverse to a participant without
the consent of the participant. Plan amendments will be submitted to shareholders for their approval as required by applicable law or deemed necessary or advisable by the board. The 2021 Plan is not
exclusive; our board of directors and compensation committee may grant shares and performance incentives or other compensation, in shares or cash, under other plans or authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
plan will terminate on January&nbsp;16, 2031. However, the plan administrator will retain its authority until all outstanding awards are exercised or terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes, as of the date of this prospectus, the number of ordinary shares under outstanding awards that we granted to our directors and executive officers under
the 2019 Plan, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>229</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=232,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=496000,FOLIO='229',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eg17601_1_230"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>which
replaced the 2015 Plan, excluding awards that were exercised, forfeited or canceled after the relevant grant dates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="108pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="108pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary<BR>
Shares<BR>
Underlying Equity<BR>
Awards<BR>
Granted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise<BR>
Price<BR>
(US$/Share) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of Grant </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of<BR>
Expiration </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Executive Officers</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter (Peizhi) Luo, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>287,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$13.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 16, 2021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 16, 2031</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fangyong (Felix) Du, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$13.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 16, 2021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 16, 2031</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hua Gong, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$2.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>August 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>August 2030</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>JC Xu, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$2.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>August 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>August 2030</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Qinghai Zhao, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$2.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>October 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>October 2030</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Man Kin (Raymond) Tam, M.B.A., B. Eng.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$1.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>August 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>August 2030</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$1.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>March 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>March 2030</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Yu (Albert) Ren, Ph.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-Employee Directors</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Daniel Auerbach, M.B.A.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chong Xu, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Yu Miao</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Yunxia Yang, M.B.A.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lefei Sun</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andy (Yiu Leung) Cheung (independent director nominee)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Min Li (independent director nominee)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All directors and executive officers as a group</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,112,986</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Various dates from March 2020 to January 2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Various dates from March 2030 to January 2031</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=1>Note:
</FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
shares held by each of these directors and executive officers represent less than 1% of our total outstanding shares. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this prospectus, our award holders other than our directors and executive officers as a group held outstanding awards to purchase 1,488,536 ordinary shares. For
discussions of our accounting policies and estimates for awards granted pursuant to the 2019 Plan, see "Management's Discussion and Analysis of Financial Condition and Results of
Operations&#151;Critical Accounting Policies, Judgments and Estimates&#151;Share-based compensation." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>230</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=233,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=936812,FOLIO='230',FILE='DISK103:[20ZDS1.20ZDS17601]EG17601A.;84',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ei17601_1_231"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ei17601_principal_shareholders"> </A>
<A NAME="toc_ei17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL SHAREHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information concerning the beneficial ownership of our ordinary shares as of the date of this prospectus,
assuming conversion of all of our outstanding series&nbsp;A-1 preferred shares, series&nbsp;A-2 preferred shares, series&nbsp;B preferred shares, series&nbsp;C-1 preferred shares,
series&nbsp;C-2 preferred shares and series&nbsp;C-3 preferred shares into ordinary shares, on a one-to-one basis by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and executive officers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person known to us to beneficially own more than 5% of our ordinary shares. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
calculations in the table below are based on 43,532,275 ordinary shares on an as-converted basis outstanding as of the date of this prospectus and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary
shares
outstanding immediately after the completion of this offering, including (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares to be sold by us in this offering in the form of ADSs,
and (ii)&nbsp;27,249,824
ordinary shares converted from our outstanding preferred shares, assuming that the underwriters do not exercise their option to purchase additional ADSs and excluding the 2,262,500 ordinary shares,
issued but deemed to be not outstanding as of the date of this prospectus, held by Great Han Fortune&nbsp;LP. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership
of that person, we have included shares that the person has the right to acquire within 60&nbsp;days, including through the exercise of any option, warrant, or other right or the conversion of any
other security. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>231</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=234,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=517387,FOLIO='231',FILE='DISK103:[20ZDS1.20ZDS17601]EI17601A.;64',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ei17601_1_232"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>These
shares, however, are not included in the computation of the percentage ownership of any other person. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary Shares<BR>
Beneficially<BR>
Owned Prior to<BR>
this Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary Shares Beneficially<BR>
Owned After this Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>%** </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of total<BR>
ordinary shares on<BR>
an as-converted<BR>
basis*** </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
aggregate voting<BR>
power**** </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Executive Officers:<SUP>&#134;</SUP></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter (Peizhi) Luo<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,449,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fangyong (Felix) Du<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,052,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hua Gong</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>JC Xu</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Qinghai Zhao</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Man Kin (Raymond) Tam</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Yu (Albert) Ren</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Daniel Auerbach</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chong Xu</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Yunxia Yang</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Yu Miao</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lefei Sun</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andy (Yiu Leung) Cheung (independent director nominee)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Min Li (independent director nominee)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All directors and executive officers as a group</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 10,449,636</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>23.5</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Principal Shareholders:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo act-in-concert group<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,449,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>JSR Limited<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,353,242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Asia Ventures II&nbsp;L.P.<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,826,037</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>F-Prime Capital Partners Healthcare Fund III&nbsp;LP<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,826,037</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wuxi Pharmatech Healthcare Fund&nbsp;I&nbsp;L.P.<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,706,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General Atlantic Singapore AI Pte.&nbsp;Ltd.<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,452,441</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=1>Notes:
</FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Less
than 1% of our total outstanding shares on an as-converted basis.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>For
each person and group included in this table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by
the sum of (i)&nbsp;43,532,275 being the number of ordinary shares on an as-converted basis as of the date of this prospectus and (ii)&nbsp;the number of ordinary shares underlying share options
held by such person or group that are exercisable within 60&nbsp;days after the completion of this offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>***</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>For
each person and group included in this table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by
the sum of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, being the number of ordinary shares on an as-converted basis outstanding immediately after this offering, (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, being the number of
ordinary shares to be sold by us in this offering in the form of ADSs, and (iii)&nbsp;the number of ordinary shares underlying share options held by such person or group that are exercisable within
60&nbsp;days after this offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>****</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>For
each person and group included in this column, percentage of voting power is calculated by dividing the voting power beneficially owned by such person or group
by the voting power of all of our ordinary shares as a single class. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>232</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=235,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=210720,FOLIO='232',FILE='DISK103:[20ZDS1.20ZDS17601]EI17601A.;64',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ei17601_1_233"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
business address of our directors and executive officers, except for Fangyong (Felix) Du, Man Kin (Raymond) Tam, Daniel Auerbach, Chong Xu, Yunxia
Yang, Yu Miao and Lefei Sun, is Center 2150, 315 Montgomery Street, 9th&nbsp;Floor, San Francisco CA 94104, United States of America. The business address of Fangyong (Felix) Du and Man Kin
(Raymond) Tam is 4F, Building C14, No.&nbsp;218, Xinghu Street, Suzhou Industrial Park, China 215123; the business address of Daniel Auerbach is Suite&nbsp;2201, Level&nbsp;22, Pacific Place
Two, 88 Queensway, Admiralty, Hong Kong, the business address of Chong Xu is One Main Street, 13th&nbsp;Floor, Cambridge, MA 02142; the business address of Yunxia Yang is Room&nbsp;3606, China
Central Place Tower 3, 77 Jianguo Road, Beijing 100025, PRC, the business address of Yu Miao is Unit 4901, One Lujiazui, No.68, Yin Cheng(C)&nbsp;Rd., Shanghai 200120, PRC; and the business address
of Lefei Sun is Suite&nbsp;5704-5706, 57F, Two IFC, 8 Finance Street, Central, Hong Kong; the business address of Andy (Yiu&nbsp;Leung) Cheung is Queen's Terrace, Tower&nbsp;1 51/F
Unit&nbsp;D, 1&nbsp;Queen Street, Sheungwan, Hong Kong.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
10,449,636 ordinary shares on an as-converted basis held by Peter Luo act-in-concert group, as set forth in note&nbsp;(3) below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
(i)&nbsp;810,944 ordinary shares held by Ping Ren, who is the spouse of Fangyong (Felix) Du, (ii)&nbsp;228,744 ordinary shares held by Great Han
Fortune LP for the benefit of Dr.&nbsp;Du that are vested or will be vested within 60&nbsp;days after this offering, and (iii)&nbsp;12,500 ordinary shares held by Great Han Fortune&nbsp;LP.
Great Han Fortune&nbsp;LP is controlled by Peter Luo and is formed to hold ordinary shares in connection with the share awards issued under the 2019 Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
(i)&nbsp;7,187,314 ordinary shares held by HAN 2020 GRAT, for which Peter Luo is a Trustee, (ii)&nbsp;596,174 ordinary shares issuable immediately
prior to the completion of this offering upon the conversion of 596,174 Series&nbsp;A-1 preferred shares held by HAN 2020 GRAT, for which Peter Luo is a Trustee, (iii)&nbsp;287,415 ordinary shares
underlying 287,415 share options granted to Peter Luo that are vested or will be vested within 60&nbsp;days after this offering, (iv)&nbsp;83,333 ordinary shares held by Great Han
Fortune&nbsp;LP for the benefit of Peter Luo and (v)&nbsp;83,333 ordinary shares held by Great Han Fortune&nbsp;LP for the benefit of Peter Luo that are vested or will be vested within
60&nbsp;days after this offering; (vi)&nbsp;45,980 ordinary shares underlying 45,980 share options granted to Xiaohong She that are vested or will be vested within 60&nbsp;days after this
offering, (vii)&nbsp;10,417 ordinary shares held by Great Han Fortune&nbsp;LP for the benefit of Xiaohong She, and (viii)&nbsp;59,667 ordinary shares held by Great Han Fortune&nbsp;LP for the
benefit of Xiaohong She that are vested or will be vested within 60&nbsp;days after this offering; (ix)&nbsp;1,052,188 ordinary shares and share options beneficially owned by Fangyong (Felix) Du,
as set forth in note&nbsp;(2) above; (x)&nbsp;total of 827,407 ordinary shares held by Raymond Tam and several key employees of the Company, and (xi)&nbsp;total of 216,408 share options granted
to Raymond Tam, Hua Gong, JC Xu and several key employees that are vested or will be vested within 60&nbsp;days after this offering. On December&nbsp;14, 2020, Peter Luo, Fangyong (Felix) Du, Ping
Ren, Hua Gong, JC Xu, Qinghai Zhao, Man Kin (Raymond) Tam, Xiaohong (Kristine) She, Yan Li, Guizhong Liu and Alexander Goergen entered into a concert party agreement, pursuant to which the parties
agree to (i)&nbsp;always be acting in concert in respect of their respective direct or indirect voting rights at our shareholders' general meetings, (ii)&nbsp;recognize the controlling position of
Peter Luo; and (iii)&nbsp;act in concert in accordance with Peter Luo's opinions in respect of the daily operations and management and the major decision-making of us.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
5,353,242 ordinary shares issuable upon the conversion of 5,353,242 Series&nbsp;B preferred shares held by JSR Limited, a British Virgin Islands
company. JSR Limited is controlled by&nbsp;GP Healthcare Capital&nbsp;Co.,&nbsp;Ltd. The registered address of JSR Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town,
Tortola, VG1110, British Virgin Islands.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
(i)&nbsp;2,000,000 ordinary shares and (ii)&nbsp;2,826,037 ordinary shares issuable upon the conversion of 1,589,796 Series&nbsp;A-1 preferred
shares, 790,138 Series&nbsp;A-2 preferred shares and 446,103 Series&nbsp;B preferred shares held by Asia Ventures II&nbsp;L.P., a limited partnership incorporated in the Bermuda. The general
partner of Asia Ventures II&nbsp;L.P. is Asia Partners II&nbsp;L.P., a Bermuda exempt limited partnership. The general partner of Asia Partners II&nbsp;L.P. is Eight Roads&nbsp;GP, who is
ultimately controlled by Eight Roads Holdings Limited. The registered address of Asia Ventures II&nbsp;L.P. is Pembroke Hall, 42 Crow Lane, Pembroke, Bermuda HM 19.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
(i)&nbsp;2,000,000 ordinary shares and (ii)&nbsp;2,826,037 ordinary shares issuable upon the conversion of 1,589,796 Series&nbsp;A-1 preferred
shares, 790,138 Series&nbsp;A-2 preferred shares and 446,103 Series&nbsp;B preferred shares held by F-Prime Capital Partners Healthcare Fund III&nbsp;LP. F-Prime Capital Partners Healthcare
Advisors Fund III&nbsp;LP is the general partner of F-Prime Capital Partners Healthcare Fund III&nbsp;LP. F-Prime Capital Partners Healthcare Advisors Fund III&nbsp;LP is solely managed by
Impresa Management&nbsp;LLC, its general partner and investment manager. Each of the entities listed above expressly disclaims beneficial ownership of the securities listed above except to the
extent of any pecuniary interest therein. The address of these entities is 245 Summer Street, Boston, MA 02210.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
(i)&nbsp;1,880,909 ordinary shares and (ii)&nbsp;2,826,037 ordinary shares issuable upon the conversion of 1,589,796 Series&nbsp;A-1 preferred
shares, 790,138 Series&nbsp;A-2 preferred shares and 446,103 Series&nbsp;B preferred shares held by Wuxi Pharmatech Healthcare Fund I&nbsp;L.P., a limited partnership incorporated in the Cayman
Islands. WuXi Pharmatech Healthcare Fund I&nbsp;L.P. is an indirect wholly owned subsidiary of WuXi AppTec&nbsp;Co.,&nbsp;Ltd (SSE: 603259; SEHK: 2359). WuXi AppTec&nbsp;Co.,&nbsp;Ltd. is a
listed company on the Shanghai Stock Exchange and the Main Board of the Hong Kong Stock </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>233</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=236,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=312319,FOLIO='233',FILE='DISK103:[20ZDS1.20ZDS17601]EI17601A.;64',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ei17601_1_234"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=1>Exchange.
The registered address of WuXi Pharmatech Healthcare Fund I&nbsp;L.P. is P.O.&nbsp;Box&nbsp;309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
4,452,441 ordinary shares issuable upon the conversion of 4,452,441 Series&nbsp;C-3 preferred shares held by General Atlantic Singapore AI
Pte.&nbsp;Ltd., a company incorporated under the laws of Singapore. General Atlantic Singapore AI Pte.&nbsp;Ltd. is wholly-owned by General Atlantic Singapore Fund Pte.&nbsp;Ltd., which is
controlled by General Atlantic Singapore Interholdco&nbsp;Ltd. The registered address of General Atlantic Singapore AI Pte.&nbsp;Ltd. is 80 Robinson Road, #02-00 Singapore&nbsp;068898. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this prospectus, 35.9% of our outstanding ordinary shares or outstanding preferred shares are held by record holders in the United States. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. See "Description of Share Capital&#151;History of Securities
Issuances" for a description of issuances of our ordinary shares and preferred shares that have resulted in significant changes in ownership held by our major shareholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>234</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=237,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=694871,FOLIO='234',FILE='DISK103:[20ZDS1.20ZDS17601]EI17601A.;64',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ek17601_1_235"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ek17601_related_party_transactions"> </A>
<A NAME="toc_ek17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of transactions since January&nbsp;1, 2017 to which we have been a participant in which any of our then directors,
executive officers or holders of more than 5% of any class of our voting securities at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect
material interest. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements and Indemnification Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Management&#151;Employment Agreements and Indemnification Agreements." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Private Placements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Description of Share Capital&#151;History of Securities Issuances." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Incentives  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Management&#151;Share Incentive Plan." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Related Party Transactions  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions with Peter Luo  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, we received a subsidy of US$84.6&nbsp;thousand from the local government for attracting highly skilled personnel on behalf of
Peter Luo, our Chairman, CEO and ordinary and preferred shareholder. We settled this transaction with Peter Luo in May 2020. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions with WuXi AppTec Group  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We received research and development services from WuXi AppTec Group, the parent company of one of our principal shareholders. The amounts for
the purchase of the services were US$1.0&nbsp;million and US$2.1&nbsp;million in 2018 and 2019, respectively. As of December&nbsp;31, 2018 and 2019, the amounts due to WuXi AppTec Group were
US$0.2&nbsp;million and US$0.4&nbsp;million, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amounts for the purchase of the services were US$1.3&nbsp;million and US$2.3&nbsp;million in the nine months ended September&nbsp;30, 2019 and 2020, respectively. As of
September&nbsp;30, 2020, the amount due to WuXi AppTec Group was US$354.3&nbsp;thousand. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions with WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd. or WuXi Biologics  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We received research and development services, including provision of manufacturing and quality control testing services, from WuXi Biologics,
an entity controlled by the ultimate controlling party of one of our principal shareholders. The amounts for the purchase of the services were US$6.5&nbsp;million and US$3.6&nbsp;million in 2018
and 2019, respectively. As of December&nbsp;31, 2018 and 2019, the amounts due to WuXi Biologics were US$3.4&nbsp;million and US$1.4&nbsp;million, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amounts for the purchase of the services were US$2.8&nbsp;million and US$5.1&nbsp;million in the nine months ended September&nbsp;30, 2019 and 2020, respectively. As of
September&nbsp;30, 2020, the amount due to WuXi Biologics was US$2.0&nbsp;million. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director and Executive Officers  </I></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercise of Share Options  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October and November 2017, Dr.&nbsp;Peter (Peizhi) Luo, Xiaohong (Kristine) She and Dr.&nbsp;Fangyong (Felix) Du exercised their
respective vested share options under the 2015 Plan. The payment for exercise of such share options is repaid in installments with nil interest. The aggregate </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>235</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=238,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=755569,FOLIO='235',FILE='DISK103:[20ZDS1.20ZDS17601]EK17601A.;44',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_ek17601_1_236"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>exercise
price for Dr.&nbsp;Luo, Ms.&nbsp;She and Dr.&nbsp;Du was US$365.0&nbsp;thousand, US$67.4&nbsp;thousand and US$173.4&nbsp;thousand, respectively. Each of Dr.&nbsp;Luo,
Ms.&nbsp;She and Dr.&nbsp;Du has settled the payments for their respective exercise of such share options. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Promissory Notes  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the material terms of the promissory notes issued in connection with the share purchase plans between us and our
directors and executive officers: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director or Executive Officer

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Latest Amount<BR>
Previously<BR>
Outstanding </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter (Peizhi) Luo</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$4.2&nbsp;million</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Xiaohong (Kristine) She*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$0.6&nbsp;million</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fangyong (Felix) Du</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$1.5&nbsp;million</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=1>Note: </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>Xiaohong (Kristine) She is the spouse of Dr.&nbsp;Peter (Peizhi) Luo </FONT></P>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
promissory notes were made pursuant to our 2019 Plan. All amounts outstanding under the promissory notes have been settled. For further information, see "Management&#151;Share
Incentive Plan&#151;Adagene&nbsp;Inc. Second Amended and Restated Share Incentive Plans&#151;Repayment of the Promissory Notes." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>236</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=239,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=572247,FOLIO='236',FILE='DISK103:[20ZDS1.20ZDS17601]EK17601A.;44',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_em17601_1_237"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="em17601_description_of_share_capital"> </A>
<A NAME="toc_em17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF SHARE CAPITAL    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Cayman Islands exempted company and our affairs are governed by our memorandum and articles of association, as amended and restated
from time to time, and Companies Act (as amended) of the Cayman Islands, which we refer to as the "Companies Act" below, and the common law of the Cayman Islands.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date hereof, our authorized share capital consists of US$50,000 divided into 500,000,000 shares with a par value of US$0.0001, including: (i)&nbsp;472,750,176 ordinary shares
of par value US$0.0001 each, (ii)&nbsp;7,844,371 series&nbsp;A preferred shares of par value US$0.0001 each (the "Series&nbsp;A Preferred Shares"), which are further divided into 5,473,957
series&nbsp;A-1 preferred shares of par value of US$0.0001 each (the "Series&nbsp;A-1 Preferred Shares"), 2,370,414 series&nbsp;A-2 preferred shares of par value of US$0.0001 each (the
"Series&nbsp;A-2 Preferred Shares"), (iii)&nbsp;7,494,537 series&nbsp;B preferred shares of par value US$0.0001 each (the "Series&nbsp;B Preferred Shares"), and (iv)&nbsp;11,910,916
authorized series&nbsp;C preferred shares with par value of US$0.0001 each (the "Series&nbsp;C Preferred Shares"), which are further divided
into 5,597,354 series&nbsp;C-1 preferred shares with par value of US$0.0001 each (the "Series&nbsp;C-1 Preferred Shares"), 1,861,121 series&nbsp;C-2 preferred shares with par value of US$0.0001
each (the "Series&nbsp;C-2 Preferred Shares") and 4,452,441 series&nbsp;C-3 preferred shares with par value of US$0.0001 each (the "Series&nbsp;C-3 Preferred Shares"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this prospectus, there are 16,282,451 ordinary shares, excluding 2,262,500 ordinary shares, issued but deemed to be not outstanding as of the date of this prospectus,
held by Great Han Fortune LP, 5,473,957 Series&nbsp;A-1 Preferred Shares, 2,370,414 Series&nbsp;A-2 Preferred Shares, 7,494,537 Series&nbsp;B Preferred Shares, 5,597,354 Series&nbsp;C-1
Preferred Shares, 1,861,121 Series&nbsp;C-2 Preferred Shares and 4,452,441 Series&nbsp;C-3 Preferred Shares issued and outstanding. All of our issued and outstanding shares are fully paid.
Immediately prior to the completion of this offering, all of our issued and outstanding preferred shares will be converted into ordinary shares on a one-for-one basis ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to adopt an amended and restated memorandum and articles of association, which will become effective and replace the current sixth amended and restated memorandum and articles of
association in its entirety immediately prior to completion of this offering. Our authorized share capital immediately prior to completion of the offering will be US$80,000 divided into 800,000,000
shares comprising (i) 640,000,000 ordinary shares of a par value of US$0.0001 each, and (ii) 160,000,000 shares of a par value of US$0.0001 each of such class or classes (however designated) as our
board of directors may determine in accordance with our amended and restated memorandum and articles of association. We will
issue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares represented by ADSs in this offering,
assuming the underwriters do not exercise their over-allotment option. All awards under the 2019 Plan, regardless of grant dates, will entitle holders to an equivalent number of ordinary shares once
the vesting and exercising conditions are met. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following are summaries of material provisions of our post-offering amended and restated memorandum and articles of association and the Companies Act insofar as they relate to the
material terms of our ordinary shares that we expect will become effective immediately prior to the completion of this offering.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ordinary shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Immediately prior to the completion of this offering, our authorized share capital is US$80,000 divided into 800,000,000
shares comprising
(i)&nbsp;640,000,000 ordinary shares of a par value of US$0.0001 each, and (ii)&nbsp;160,000,000 shares of a par value of US$0.0001 each of such class or classes (however
designated) as our board of directors may determine in accordance with our amended and restated memorandum and articles of association. Holders of ordinary shares will have the same rights. All of our
issued and outstanding ordinary shares are fully paid and non-assessable. Certificates </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>237</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=240,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=108404,FOLIO='237',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_238"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>representing
the ordinary shares are issued in registered form. We may not issue share to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold, transfer and vote their
ordinary shares. </FONT></P>

<P style="font-family:times;">


<FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors subject
to our
post-offering memorandum and articles of association and the Companies Act. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare
a dividend, but no dividend may exceed the amount recommended by our directors. Our post-offering memorandum and articles of association provide that dividends may be declared and paid out of our
profits, realized or unrealized, or from any reserve set aside from profits which our board of directors determine is no longer needed. Dividends may also be declared and paid out of the share premium
account or any other fund or account which can be authorized for this purpose in accordance with the Companies Act. No dividend may be declared and paid unless our directors determine that,
immediately after the payment, we will be able to pay our debts as they become due in the ordinary course of business and we have funds lawfully available for such purpose.

</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting Rights.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In respect of all matters subject to a shareholders' vote, holder of an each Ordinary Share is entitled to one
vote for each Ordinary
Share registered in his or her name on our register of members. Voting at any meeting of shareholders is by way of a poll unless a show of hands is permitted. A poll may be demanded by the chairman of
such meeting or any one shareholder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum required for a meeting of shareholders consists of two or more shareholders holding not less than one-half of the votes attaching to the issued and outstanding shares entitled
to vote at general meetings present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative. As a Cayman Islands exempted company, we are not
obliged by the Companies Act to call shareholders' annual general meetings. Our post-offering memorandum and articles of association provide that we may (but are not obliged to) in each year hold a
general meeting as our annual general meeting in which case we will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place as may be
determined by our board of directors. We, however, will hold an annual shareholders' meeting during each fiscal year, as required by the Listing Rules of the Nasdaq Global Market. Each general
meeting, other than an
annual general meeting, shall be an extraordinary general meeting. Shareholders' annual general meetings and any other general meetings of our shareholders may be called by a majority of our board of
directors or our chairman or upon a requisition of shareholders holding at the date of deposit of the requisition not less than one-third of the votes attaching to the issued and outstanding shares
entitled to vote at general meetings, in which case the directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our post-offering
memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such
shareholders. Advance notice of at least seven (7)&nbsp;days is required for the convening of our annual general meeting and other general meetings in accordance with our post-offering memorandum
and articles of association.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast by those
shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution also requires the affirmative vote of no less than two-thirds of the votes
attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting. A special resolution will be required for important matters
such as a change of name or making changes to our post-offering memorandum and articles of association. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer of Ordinary Shares.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the restrictions in our post-offering memorandum and articles of association as set out
below, any of our
shareholders may transfer all or any of his or her </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>238</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=241,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=276914,FOLIO='238',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_239"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ordinary
shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors may, in its absolute discretion, decline to register any transfer of any Ordinary Share. Our board of directors may also decline to register any transfer of any
Ordinary Share unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other
evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the instrument of transfer is in respect of only one class of shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the instrument of transfer is properly stamped, if required; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a transfer to joint holders, the number of joint holders to whom the Ordinary Share is to be transferred does not exceed four; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the shares are free from any lien in favor of us; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid
to us in respect thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our directors refuse to register a transfer, they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the
transferee notice of such refusal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration of transfers may, after compliance with any notice requirement of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of
directors may from time to time determine, </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the registration of transfers shall
not be suspended nor the register closed for more than 30&nbsp;days in any year as our board may determine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On a return of capital on winding up or otherwise (other than on conversion, redemption or
purchase of ordinary shares), if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding
up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares
in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up
capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them. Any distribution of assets or capital to a holder of
ordinary shares will be the same in any liquidation event. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calls on Ordinary Shares and Forfeiture of Ordinary Shares.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may from time to time make calls upon
shareholders for any amounts
unpaid on their ordinary shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The ordinary shares that have been called upon and remain unpaid
are subject to forfeiture. </FONT></P>

<P style="font-family:times;">


<FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redemption, Repurchase and Surrender of Ordinary Shares.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may issue shares on terms that such shares are subject to redemption,
at our option or at
the option of the holders thereof, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by an ordinary resolution of our shareholders.
Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by an ordinary resolution of our shareholders, or
are otherwise authorized by our post-offering memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company's profits or out
of the proceeds of a fresh issue of shares

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>239</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=242,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=904571,FOLIO='239',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_240"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the Company can, immediately following such payment, pay
its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)&nbsp;unless it is fully paid up, (b)&nbsp;if
such redemption or repurchase would result in there being no shares outstanding, or (c)&nbsp;if the company has commenced liquidation. In addition, our company may accept the surrender of any fully
paid share for no consideration.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Variations of Rights of Shares.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If at any time our share capital is divided into different classes or series of shares, the
rights attached to any
class or series of shares (unless otherwise provided by the terms of
issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of holders of not less than a majority of the issued shares of
that class or series or with the sanction of a special resolution at a separate meeting of the holders of the shares of the class or series. The rights conferred upon the holders of the shares of any
class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking </FONT> <FONT SIZE=2><I>pari passu</I></FONT><FONT SIZE=2> with
such existing class of shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inspection of Books and Records.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of our ordinary shares have no general right under Cayman Islands law to inspect or
obtain copies of our
list of shareholders or our corporate records. However, we will provide our shareholders with annual audited financial statements. See "Where You Can Find Additional Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Additional Shares.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our post-offering memorandum and articles of association authorizes our board of directors to
issue additional
ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
post-offering memorandum and articles of association also authorizes our board of directors to establish from time to time one or more series of preferred shares and to determine,
with respect to any series of preferred shares, the terms and rights of that series, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dividend rights, dividend rates, conversion rights, voting rights; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rights and terms of redemption and liquidation preferences. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors may issue preferred shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of
holders of ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Takeover Provisions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some provisions of our post-offering memorandum and articles of association may discourage, delay or
prevent a change of
control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one or more series and to
designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes in Capital.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may from time to time by ordinary resolution:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>240</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=243,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=305671,FOLIO='240',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_241"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sub-divide our existing shares, or any of them into shares of a smaller amount; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the
amount of our share capital by the amount of the shares so canceled. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by
law.

 </FONT></P>

<P style="font-family:times;">


<FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exempted Company.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes
between ordinary
resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted
company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> does not have to file an annual return of its shareholders with the Registrar of Companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> is not required to open its register of members for inspection; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> does not have to hold an annual general meeting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may issue shares with no par value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30&nbsp;years in the first
instance); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may register as a limited duration company; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may register as a segregated portfolio company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Limited
liability" means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder's shares of the company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Register of Members  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Companies Act, we must keep a register of members and there should be entered therein:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the names and addresses of our members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as
paid, on the shares of each member; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date on which the name of any person was entered on the register as a member; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date on which any person ceased to be a member. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Companies Act, the register of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a presumption of fact
on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as a matter of the Companies Act to have legal title to the shares as set against its
name in the register of members. Upon completion of this offering, we will perform the procedure necessary to immediately update the register of members to record and give effect to the issuance of
shares by us to the Depositary (or its nominee) as the depositary. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal
title to the shares set against their name.


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>241</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=244,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1018801,FOLIO='241',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_242"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the name of any person is incorrectly entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any
person having ceased to be a member of our company, the person or member aggrieved (or any member of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order
that the register be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Differences in Corporate Law  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Companies Act is derived, to a large extent, from the older Companies Acts of England, but does not follow many recent English law statutory
enactments. In addition, the Companies Act differs from laws applicable to United States corporations and their shareholders. Set
forth below is a summary of the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the State of Delaware.


</FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mergers and Similar Arrangements.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Companies Act permits mergers and consolidations between Cayman Islands companies and between
Cayman Islands
companies and non-Cayman Islands companies. For these purposes, (a)&nbsp;"merger" means the merging of two or more constituent companies and the vesting of their undertaking, property and
liabilities in one of such companies as the surviving company, and (b)&nbsp;a "consolidation" means the combination of two or more constituent companies into a consolidated company and the vesting
of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a
written plan of merger or consolidation, which must then be authorized by (a)&nbsp;a special resolution of the shareholders of each constituent company, and (b)&nbsp;such other authorization, if
any, as may be specified in such constituent company's articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together
with a declaration as to the solvency of the consolidated or surviving company, a declaration as to the assets and liabilities of each constituent company and an undertaking that a copy of the
certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman
Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman subsidiary if a copy of
the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose, a company is a "parent" of a subsidiary if it holds issued
shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his shares
(which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that
the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other
rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction and amalgamation of
companies by way of schemes of arrangement, </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that the arrangement is approved by a majority in number of

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>242</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=245,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=97049,FOLIO='242',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_243"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent three- fourths in value of each such class of shareholders or creditors, as the
case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be
sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be
expected to approve the arrangement if it determines that:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the statutory provisions as to the required majority vote have been met; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of
the minority to promote interests adverse to those of the class; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.

 </FONT></DD>

</DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the "squeeze out" of a dissenting minority shareholder upon a tender offer. When a tender
offer is made and accepted by holders of 90.0% of the shares affected within four months, the offeror may, within a two-month period commencing on the expiration of such four-month period, require the
holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be
made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an arrangement and reconstruction is thus approved, or if a tender offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which
would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholders' Suits.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a
general
rule&nbsp;a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the
Cayman Islands court can be expected to follow and apply the common law principles (namely the rule in </FONT><FONT SIZE=2><I>Foss v. Harbottle</I></FONT><FONT SIZE=2> and the exceptions thereto)
which permit a minority shareholder to commence a class action against or derivative actions in the name of the company to challenge actions where:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a company acts or proposes to act illegally or ultra vires; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not
been obtained; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> those who control the company are perpetrating a "fraud on the minority." </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Executive Officers and Limitation of Liability.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cayman Islands law does not limit the extent to
which a company's
memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to
public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our post-offering memorandum and articles of
association provide that that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such
directors or officer, other than by reason of such person's dishonesty, willful default or fraud, in or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>243</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=246,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=266425,FOLIO='243',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_244"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>about
the conduct of our company's business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including
without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil
proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General
Corporation Law for a Delaware corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in
our post-offering memorandum and articles of association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have
been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors' Fiduciary Duties.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the
corporation and its
shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would
exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant
transaction. The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal
gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director,
officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest
belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be
presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he owes the
following duties to the company&#151;a duty to act bona fide in the best interests of the company, a duty not to make a profit based on his position as director (unless the company permits him
to do so), a duty not to put himself in a position where the interests of the company conflict with his personal interest or his duty to a third party, and a duty to exercise powers for the purpose
for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the
performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an
objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our post-offering memorandum and articles of association, directors who are in any way, whether directly or indirectly, interested in a contract or proposed contract with our
company must declare the nature of their interest at a meeting of the board of directors. </FONT></P>

<P style="font-family:times;">


<FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder Action by Written Consent.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation may eliminate the right of
shareholders to act by
written consent by amendment to its certificate of incorporation. The Companies Act and our post-offering memorandum and articles of association provide that our shareholders may approve corporate
matters by way of a unanimous

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>244</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=247,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=269439,FOLIO='244',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_245"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder Proposals.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the
annual meeting of
shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the
governing documents, but shareholders may be precluded from calling special meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general
meeting. However,
these rights may be provided in a company's articles of association. Our post-offering memorandum and articles of association allow our shareholders holding in aggregate not less than twenty percent
of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our
board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders' meeting, our
post-offering memorandum and articles of association do not provide our shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings not called
by such shareholders. As an exempted Cayman Islands company, we are not obliged by law to call shareholders' annual general meetings.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumulative Voting.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted
unless the corporation's
certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority
shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder's voting power with respect to electing such director. There are no
prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our post-offering memorandum and articles of association do not provide for cumulative voting. As a result, our
shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Removal of Directors.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a director of a corporation with a classified board may be
removed only for cause
with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post-offering memorandum and articles of association,
directors not appointed by Peter Peizhi Luo, JSR Limited, and General Atlantic Singapore AI Pte.&nbsp;Ltd. may be removed with or without cause, by an ordinary resolution of our shareholders. A
director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her office is otherwise vacated. In addition, a
director's office shall be vacated if the director (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his creditors; (ii)&nbsp;is found to be or becomes of unsound mind or
dies; (iii)&nbsp;resigns his office by notice in writing to the company; (iv)&nbsp;without special leave of absence from our board of directors, is absent from three consecutive meetings of the
board and the board resolves that his office be vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provisions of our
post-offering memorandum and articles of association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transactions with Interested Shareholders.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law contains a business combination statute
applicable to Delaware
corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain
business combinations with an "interested shareholder" for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group
who or which owns or owned 15% or more of the target's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>245</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=248,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1008238,FOLIO='245',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_246"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>outstanding
voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be
treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business
combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any
acquisition transaction with the target's board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cayman
Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although
Cayman Islands law does not regulate transactions between a company and its significant shareholders, the directors of the Company are required to comply with fiduciary duties which they owe to the
Company under Cayman Islands laws, including the duty to ensure that, in their opinion, any such transactions must be entered into bona fide in the best interests of the company, and are entered into
for a proper corporate purpose and not with the effect of constituting a fraud on the minority shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dissolution; Winding up.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, unless the board of directors approves the proposal to
dissolve, dissolution
must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of
the corporation's outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions
initiated by the board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay
its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the
court, just and equitable to do so. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Variation of Rights of Shares.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares
with the approval
of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law and our post-offering memorandum and articles of
association, if our share capital is divided into more than one class of shares, we may vary the rights attached to any class with the written consent of the holders of not less
than a majority of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. </FONT></P>


<P style="font-family:times;">


<FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment of Governing Documents.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation's governing documents may be amended
with the approval of
a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under the Companies Act and our post-offering memorandum and articles of association,
our memorandum and articles of association may only be amended by a special resolution of our shareholders.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rights of Nonresident or Foreign Shareholders.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;There are no limitations imposed by our post-offering memorandum and articles of
association on the
rights of nonresident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our post-offering amended and restated memorandum and articles of
association governing the ownership threshold above which shareholder ownership must be disclosed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


History of Securities Issuances  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of securities issuances by Adagene&nbsp;Inc. in the past three years. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>246</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=249,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=465803,FOLIO='246',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_247"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ordinary Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From August&nbsp;17, 2017 to January 19, 2021, we issued a total of 6,761,534 ordinary shares to employees for an aggregate consideration of
US$7.9&nbsp;million upon the exercise of certain share incentive awards. For the purpose of this paragraph only, such number of shares includes the 2,262,500
ordinary shares, issued but deemed to be not outstanding as of the date of this prospectus, held by Great Han Fortune LP. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;2, 2018, we issued a total of 3,358,412 Series&nbsp;C-1 Preferred Shares to SCC Venture VI Holdco,&nbsp;Ltd., Gopher
Harvest Co-Investment Fund&nbsp;LP and AVICT Global Holdings Limited for an aggregate consideration of US$30.0&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;19, 2018, we issued a total of 1,679,206 Series&nbsp;C-1 Preferred Shares to King Star Med&nbsp;LP and WEALTHY TECHNOLOGIES LIMITED for an aggregate consideration of
US$15.0&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
May&nbsp;16, 2018, we issued 559,736 Series&nbsp;C-1 Preferred Shares to Chief Strategic International Limited for a consideration of US$5.0&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;13, 2019, we issued a total of 1,567,260 Series&nbsp;C-2 Preferred Shares to Mega Prime Development Limited, Poly Platinum Enterprises Limited and Chief Strategic
International Limited for an aggregate consideration of US$16.0&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November&nbsp;21, 2019, we issued 293,861 Series&nbsp;C-2 Preferred Shares to MODEST CHAMPION LIMITED for a consideration of US$3.0&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;19, 2019, we issued 4,452,441 Series&nbsp;C-3 Preferred Shares to General Atlantic Singapore AI Pte.&nbsp;Ltd. for a consideration of US$50.0&nbsp;million. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrant  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;2, 2018, we granted warrants to SCC Venture VI Holdco,&nbsp;Ltd. and Gopher Harvest Co-Investment Fund&nbsp;LP to
purchase up to a total of US$7.5&nbsp;million worth of Series&nbsp;C-2 Preferred Shares at the exercise price of US$10.2089 per share (as may be adjusted from time to time). The warrants were not
exercised and have expired. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Award Grants  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have granted awards to purchase our ordinary shares to certain of our directors, executive officers and employees pursuant to the 2015 Plan
and the 2019 Plan. As of the date of this prospectus, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan is 3,601,522. We have not granted any awards
under the 2021 Plan. See "Management&#151;Share Incentive Plan." </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Cancellation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;16, 2021, certain management members surrendered a total of 491,119 ordinary shares for cancellation to settle the balance due
under their respective promissory notes issued in connection with the share purchase plans. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholders' Agreements  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a Fifth Amended and Restated Shareholders Agreement and a Fourth Amended and Restated Right of First Refusal and Co-Sale
Agreement (collectively, "Shareholders Agreements") </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>247</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=250,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=267651,FOLIO='247',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_248"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>on
December&nbsp;19, 2019 with our shareholders, which consist of holders of our ordinary shares, Series&nbsp;A-1 Preferred Shares, Series&nbsp;A-2 Preferred Shares, Series&nbsp;B Preferred
Shares, Series&nbsp;C-1 Preferred Shares, Series&nbsp;C-2 Preferred Shares and Series&nbsp;C-3 Preferred Shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Shareholders Agreements provide for certain special rights, including information and inspection rights, right of participation, right of first refusal, co-sale right, drag-along
right, redemption, liquidation and protective provisions. Except for board representation right and registration right, all preferred shareholders' rights will automatically terminate upon the
completion of this offering. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Representation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Asia Ventures II&nbsp;L.P., F-Prime Capital Partners Healthcare Fund III&nbsp;LP and JSR Limited shall have the right to designate,
appoint, remove and replace and reappoint one director so long as they each hold at least five percent of the shares outstanding on a fully-diluted basis and an as-converted basis, respectively.
Notwithstanding of the foregoing, each of Asia Ventures&nbsp;II L.P. and F-Prime Capital Partners Healthcare Fund&nbsp;III LP will cease to have such board representation right upon the
effectiveness of our post-offering memorandum and articles of association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
long as Wuxi Pharmatech Healthcare Fund I&nbsp;L.P. holds at least five percent of the shares outstanding on a fully-diluted basis, it shall have the right to nominate one
independent non-executive director and such one independent non-executive director shall be appointed and agreed by the board. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
long as Peter Luo holds any shares or is employed by us or any of our controlled affiliates, he shall have the right to designate, appoint, remove and replace and reappoint one
director. Notwithstanding of the foregoing, our post-offering memorandum and articles of association will provide that for as long as Pete Luo holds or beneficially owns any shares or is employed by
us or any of our subsidiaries, he will serve as one of our directors and the Chairman of the Board of Directors. In addition, during the period commencing upon the effectiveness of our registration
statement on Form F-1, of which this prospectus is a part, and ending on the earlier of (i) the date upon which Peter Luo beneficially owns less than five percent of the shares outstanding on a fully
diluted basis, (ii) the death or legal determination of Peter Luo's incapacity or (iii) the termination of Peter Luo as an executive officer or principal scientific advisor to us or any of our
subsidiaries or for cause (as determined under his related employment or consulting arrangements and subject to all related cure provisions), Peter Luo shall have the right to designate, appoint,
remove and replace and reappoint one additional director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
long as General Atlantic Singapore AI Pte.&nbsp;Ltd. and its affiliates hold at least five percent of the shares outstanding on a fully-diluted basis, they shall have the right to
designate, appoint, remove and replace and reappoint one director. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to our Fifth Amended and Restated Shareholders Agreement dated December&nbsp;19, 2019, we have granted certain registration rights to
our shareholders. Set forth below is a description of the registration rights granted under the agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demand Registration Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At any time or from time to time after the date that is six months after the closing of the IPO, holders
holding thirty
percent or more of the voting power of the then outstanding registrable securities held by all holders may request in writing that we effect a registration on any internationally recognized exchange
that is reasonably acceptable to such requesting holders. Upon receipt of such a request, we shall (x)&nbsp;promptly give written notice of the proposed registration to all other holders and
(y)&nbsp;as soon as practicable, use its good faith commercially reasonable efforts to cause the registrable securities specified in the request, together with any registrable securities of any
holder who requests in writing to join such registration within fifteen (15)&nbsp;days after our delivery of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>248</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=251,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=668710,FOLIO='248',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_em17601_1_249"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>written
notice, to be registered and/or qualified for sale and distribution in such jurisdiction as the initiating holders may request. We shall be obligated to consummate no more than two
registrations that have been declared and ordered effective; provided that if the registrable securities sought to be included in the registration are not fully included in the registration for any
reason other than solely due to the action or inaction of the holders including registrable securities in such registration, such registration shall not be deemed to constitute one of the registration
rights granted. We shall not be obligated to take any action to effect any registration unless the aggregate proceeds from the offering that is the subject of the registration exceeds US$5,000,000 and
at least 40% of the registrable securities then outstanding shall participate in such registration. Furthermore, we have the right to defer filing of a registration statement if, after receiving a
request from holders, we furnish to the holders a certificate signed by our chief executive officer stating that, in the good faith judgment of the board, it would be detrimental to us or our members
for a registration statement to be filed in the near future, but we may not (i)&nbsp;utilize this right for more than ninety days on any one occasion or more than once during any twelve-month
period, or (ii)&nbsp;register any other of our securities during such period. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration on Form&nbsp;F-3 or Form&nbsp;S-3.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We shall use our good faith commercially reasonable efforts to qualify for registration
on
Form&nbsp;F-3 or Form&nbsp;S-3. If we qualify for registration on Form&nbsp;F-3 or Form&nbsp;S-3 (or any comparable form for registration in a jurisdiction other than the United States),
holders
holding ten percent or more of the voting power of the then outstanding registrable securities held by all holders may request us in writing to file, in any jurisdiction in which we have had a
registered underwritten public offering, a registration statement on Form&nbsp;F-3 or Form&nbsp;S-3 (or any comparable form for registration in a jurisdiction other than the United States). We
shall be obligated to consummate no more than two registrations that have been declared and ordered effective within any twelve-month period; provided that if the registrable securities sought to be
included in the registration are not fully included in such registration for any reason other than solely due to the action or inaction of the holders including registrable securities in such
registration, such registration shall not be deemed to constitute one of the registration rights granted. We shall not be obligated to take any action to effect any registration unless the aggregate
proceeds from the offering that is the subject of the registration exceeds US$5,000,000. Furthermore, we have the right to defer filing of a registration statement if, after receiving a request from
holders, we furnish to the holders a certificate signed by our chief executive officer stating that, in the good faith judgment of the board, it would be detrimental to us or our members for a
registration statement to be filed in the near future, but we may not (i)&nbsp;utilize this right for more than ninety days on any one occasion or more than once during any twelve-month period, or
(ii)&nbsp;register any other of our securities during such period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Piggyback Registration Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If we propose to register for our own account any of our equity securities, or for the account of any
holder (other
than a holder of registrable securities who is a party to the shareholder agreement) of equity securities any of such holder's equity securities, in connection with the public offering of such
securities, we shall promptly give each holder written notice of such registration and, upon the written request of any holder given within fifteen days after delivery of such notice, we shall use our
good faith commercially reasonable efforts to include in such registration any registrable securities thereby requested to be registered by such holder. If a holder decides not to include all or any
of its registrable securities in such registration by us, such holder shall nevertheless continue to have the right to include any registrable securities in any subsequent registration statement or
registration statements as may be filed by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses of Registration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We will bear all registration expenses. Each holder, however, should bear its proportionate share of all of
the
underwriting discounts and selling commissions applicable to the sale of registrable securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>249</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=252,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=412248,FOLIO='249',FILE='DISK103:[20ZDS1.20ZDS17601]EM17601A.;54',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_eo17601_1_250"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eo17601_description_of_american_depositary_shares"> </A>
<A NAME="toc_eo17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF AMERICAN DEPOSITARY SHARES    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


American Depositary Receipts  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JPMorgan Chase Bank, N.A. ("JPMorgan"), as depositary, will issue the ADSs which you will be entitled to receive in this offering. Each ADS will
represent an ownership interest in a designated number of shares which we will deposit with the custodian, as agent of the depositary, under the deposit agreement among ourselves, the depositary,
yourself as an ADR holder and all other
ADR holders, and all beneficial owners of an interest in the ADSs evidenced by ADRs from time to time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary's office is located at 383 Madison Avenue, Floor 11, New York, NY 10179. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ADS to share ratio is subject to amendment as provided in the form of ADR (which may give rise to fees contemplated by the form of ADR). In the future, each ADS will also represent
any securities, cash or other property deposited with the depositary but which they have not distributed directly to you. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
beneficial owner is any person or entity having a beneficial ownership interest ADSs. A beneficial owner need not be the holder of the ADR evidencing such ADS. If a beneficial owner of
ADSs is not an ADR holder, it must rely on the holder of the ADR(s) evidencing such ADSs in order to assert any rights or receive any benefits under the deposit agreement. A beneficial owner shall
only be able to exercise any right or receive any benefit under the deposit agreement solely through the holder of the ADR(s) evidencing the ADSs owned by such beneficial owner. The arrangements
between a beneficial owner of ADSs and the holder of the corresponding ADRs may affect the beneficial owner's ability to exercise any rights it may have. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
ADR holder shall be deemed to have all requisite authority to act on behalf of any and all beneficial owners of the ADSs evidenced by the ADRs registered in such ADR holder's name for
all purposes under the deposit agreement and ADRs. The depositary's only notification obligations under the deposit agreement and the ADRs is to registered ADR holders. Notice to an ADR holder shall
be deemed, for all purposes of the deposit agreement and the ADRs, to constitute notice to any and all beneficial owners of the ADSs evidenced by such ADR holder's ADRs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
certificated ADRs are specifically requested, all ADSs will be issued on the books of our depositary in book-entry form and periodic statements will be mailed to you which reflect
your ownership interest in such ADSs. In our description, references to American depositary receipts or ADRs shall include the statements you will receive which reflect your ownership of ADSs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having an ADS registered in your name on the books of
the depositary, you are an ADR holder. This description assumes you hold your ADSs directly. If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures
of such broker or financial institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution to find out what those procedures
are. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an ADR holder or beneficial owner, we will not treat you as a shareholder of ours and you will not have any shareholder rights. Cayman Island law governs shareholder rights. Because
the depositary or
its nominee will be the shareholder of record for the shares represented by all outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder or of a
beneficial owner. Such rights derive from the terms of the deposit agreement to be entered into among us, the depositary and all holders and beneficial owners from time to time of ADRs issued under
the deposit agreement and, in the case of a beneficial owner, from the arrangements between the beneficial owner and the holder of the corresponding ADRs. The obligations of the depositary and its
agents are also set out in the deposit agreement. Because the depositary or its nominee will actually be the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>250</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=253,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=784047,FOLIO='250',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_251"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>registered
owner of the shares, you must rely on it to exercise the rights of a shareholder on your behalf. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary, it may not contain all the information
that you may otherwise deem important. For more complete information, you should read the entire deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the
deposit agreement which is filed as an exhibit to the registration statement of which this prospectus forms&nbsp;a part. You may also obtain a copy of the deposit agreement at the SEC's Public
Reference Room which is located at 100&nbsp;F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-732-0330. You may
also find the registration statement and the attached deposit agreement on the SEC's website at http://www.sec.gov. </FONT></P>

<UL>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Dividends and Other Distributions  </B></FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How will I receive dividends and other distributions on the shares underlying my ADSs?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it will
pay to you the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, after converting any cash received into U.S. dollars (if it determines such
conversion may be made on a reasonable basis)
and, in all cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate of JPMorgan to direct, manage and/or execute any
public and/or private sale of securities under the deposit agreement. Such division, branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an
expense of the depositary. You will receive these distributions in proportion to the number of underlying securities that your ADSs represent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as stated below, the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Cash.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The depositary will distribute any U.S. dollars available to it
resulting from a cash dividend or other cash distribution or the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable
basis, subject to (i)&nbsp;appropriate adjustments for taxes withheld, (ii)&nbsp;such distribution being impermissible or impracticable with respect to certain registered ADR holders, and
(iii)&nbsp;deduction of the depositary's and/or its agents' expenses in (1)&nbsp;converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made
on a reasonable basis, (2)&nbsp;transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the extent that it determines that such transfer
may be made on a reasonable basis, (3)&nbsp;obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and
within a reasonable time and (4)&nbsp;making any sale by public or private means in any commercially reasonable manner.</FONT><FONT SIZE=2><I> If exchange rates fluctuate during a time when the
depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</I></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In the case of a distribution in shares, the depositary will issue
additional ADRs to evidence the number of ADSs representing such shares. Only whole ADSs will be issued. Any shares which would result in fractional ADSs will be sold and the net proceeds will be
distributed in the same manner as cash to the ADR holders entitled thereto.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Rights to receive additional shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In the case of a distribution of
rights to subscribe for additional shares or other rights, if we timely provide evidence satisfactory to the depositary that </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>251</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=254,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=162108,FOLIO='251',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_252"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>it
may lawfully distribute such rights, the depositary will distribute warrants or other instruments in the discretion of the depositary representing such rights. However, if we do not timely furnish
such evidence, the depositary may: </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>sell
such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if
it is not practicable to sell such rights by reason of the non-transferability of the rights, limited markets therefor, their short duration or otherwise, do
nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Other Distributions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In the case of a distribution of securities or
property other than those described above, the depositary may either (i)&nbsp;distribute such securities or property in any manner it deems equitable and practicable or (ii)&nbsp;to the extent the
depositary deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute any net proceeds in the same way it distributes cash. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered ADR holder, the depositary may choose any
method of distribution that it deems practicable for such ADR holder, including the distribution of foreign currency, securities or property, or it may retain such items, without paying interest on or
investing them, on behalf of the ADR holder as deposited securities, in which case the ADSs will also represent the retained items. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be withheld without liability and dealt with by the
depositary in accordance with its then current practices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>The depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>There can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights, shares or other
securities at a specified price, nor that any of such transactions can be completed within a specified time period. All purchases and sales of securities will be handled by the depositary in
accordance with its then current policies, which are currently set forth on the "Disclosures" page (or successor page) of www.adr.com (as updated by the depositary from time to time,
"ADR.com").</I></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deposit, Withdrawal and Cancellation  </B></FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How does the depositary issue ADSs?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary will issue ADSs if you or your broker deposit shares or evidence of rights to receive shares with the custodian and pay the fees
and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this prospectus, we will arrange with the underwriters named herein to deposit such
shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such deposit, be registered in the name of JPMorgan
Chase Bank, N.A., as depositary for the benefit of holders of ADRs or in such other name as the depositary shall direct. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
custodian will hold all deposited shares (including those being deposited by or on our behalf in connection with the offering to which this prospectus relates) for the account and to
the order of the depositary, in each case for the benefit of ADR holders. ADR holders and beneficial owners thus have no direct ownership interest in the shares and only have such rights as are
contained in the deposit </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>252</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=255,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=331855,FOLIO='252',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_253"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>agreement.
The custodian will also hold any additional securities, property and cash received on or in substitution for the deposited shares. The deposited shares and any such additional items are
referred to as "deposited securities". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deposited
securities are not intended to, and shall not, constitute proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in deposited securities is
intended to be, and shall at all times during the term of the deposit agreement continue to be, vested in the beneficial owners of the ADSs representing such deposited securities. Notwithstanding
anything else contained herein, in the deposit agreement, in the form of ADR and/or in any outstanding ADSs, the depositary, the custodian and their respective nominees are intended to be, and shall
at all times during the term of the deposit agreement be, the record holder(s) only of the deposited securities represented by the ADSs for the benefit of the ADR holders. The depositary, on its own
behalf and on behalf of the custodian and their respective nominees, disclaims any beneficial ownership interest in the deposited securities held on behalf of the ADR holders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
each deposit of shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement, including the payment of the fees and charges of
the depositary and any taxes or other fees or charges owing, the depositary will issue an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to
which such person is entitled. All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary's direct registration system, and a registered holder will receive
periodic statements from the depositary which will show the number of ADSs registered in such holder's name. An ADR holder can request that the ADSs not be held through the depositary's direct
registration system and that a certificated ADR be issued. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do ADR holders cancel an ADS and obtain deposited securities?  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When you turn in your ADR certificate at the depositary's office, or when you provide proper instructions and documentation in the case of
direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying shares to you or upon your written order. Delivery of deposited
securities in certificated form will be made at the custodian's office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary may only restrict the withdrawal of deposited securities in connection with:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> temporary delays caused by closing our transfer books or those of the depositary or the deposit of shares in connection with voting at a
shareholders' meeting, or the payment of dividends; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the payment of fees, taxes and similar charges; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
right of withdrawal may not be limited by any other provision of the deposit agreement. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Record Dates  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as
practicable to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated, as the case may
be):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to receive any distribution on or in respect of deposited securities, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to give instructions for the exercise of voting rights at a meeting of holders of shares, or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>253</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=256,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=272256,FOLIO='253',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_254"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided for in the ADR, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to receive any notice or to act in respect of other matters, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>all
subject to the provisions of the deposit agreement. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </B></FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do I vote?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise the
voting rights for the shares which underlie your ADSs. As soon as practicable after receipt from us of notice of any meeting at which the holders of shares are entitled to vote, or of our solicitation
of consents or proxies from holders of shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit agreement, provided that if the depositary receives a
written request from us in a timely manner and at least 30&nbsp;days prior to the date of such vote or meeting, the depositary shall, at our expense, distribute to the registered ADR holders a
"voting notice" stating (i)&nbsp;final information particular to such vote and meeting and any solicitation materials, (ii)&nbsp;that each ADR holder on the record date set by the
depositary will, subject to any applicable provisions of Cayman Islands law, be entitled to instruct the depositary as to the exercise of the voting rights, if any, pertaining to the deposited
securities represented by the ADSs evidenced by such ADR holder's ADRs and (iii)&nbsp;the manner in which such instructions may be given or deemed given in accordance with the deposit agreement,
including instructions for giving a discretionary proxy to a person designated by us. Each ADR holder shall be solely responsible for the forwarding of voting notices to the beneficial owners of ADSs
registered in such ADR holder's name. There is no guarantee that ADR holders and beneficial owners generally or any holder or beneficial owner in particular will receive the notice described above
with sufficient time to enable such ADR holder or beneficial owner to return any voting instructions to the depositary in a timely manner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
actual receipt by the ADR department responsible for proxies and voting of ADR holders' instructions (including, without limitation, instructions of any entity or entities
acting on behalf of the nominee for DTC), the depositary shall, in the manner and on or before the time established by the depositary for such purpose, endeavor to vote or cause to be voted the
deposited securities represented by the ADSs evidenced by such ADR holders' ADRs in accordance with such instructions insofar as practicable and permitted under the provisions of or governing
deposited securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that (A)&nbsp;we have provided the depositary with at least 35&nbsp;days' notice of the proposed meeting, (B)&nbsp;the voting notice will be received by all ADR
holders and beneficial owners no less than 10&nbsp;days prior to the date of the meeting and/or the cut-off date for the solicitation of consents, and (C)&nbsp;the depositary does not receive
instructions on a particular agenda item from an ADR holder (including, without limitation, any entity or entities acting on behalf of the nominee for DTC) in a timely manner, such ADR holder shall be
deemed, and in the deposit agreement the depositary is instructed to deem such ADR holder, to have instructed the depositary to give a discretionary proxy for such agenda item(s) to a person
designated by us to vote the deposited securities represented by the ADSs for which actual instructions were not so given by all such ADR holders on such agenda item(s), provided that no such
instruction shall be deemed given and no discretionary proxy shall be given unless (1)&nbsp;we inform the depositary in writing (and we agree to provide the depositary with such instruction promptly
in writing) that (a)&nbsp;we wish such proxy to be given with respect to such agenda item(s), (b)&nbsp;there is no substantial opposition existing with respect to such agenda item(s) and
(c)&nbsp;such agenda item(s), if approved, would not materially or adversely affect the rights of holders of shares, and (2)&nbsp;the depositary has obtained an opinion of counsel, in form and
substance satisfactory to the depositary, confirming that (i)&nbsp;the granting of such discretionary proxy does not subject the depositary to any reporting obligations in the Cayman Islands,
(ii)&nbsp;the granting of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>254</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=257,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=382177,FOLIO='254',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_255"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>such
proxy will not result in a violation of the laws, rules, regulations or permits of the Cayman Islands, (iii)&nbsp;the voting arrangement and deemed instruction as contemplated herein will be
given effect under the laws, rules and regulations of the Cayman Islands, and (iv)&nbsp;the granting of such discretionary proxy will not under any circumstances result in the shares represented by
the ADSs being treated as assets of the depositary under the laws, rules or regulations of the Cayman Islands. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary may from time to time access information available to it to consider whether any of the circumstances described above exist, or request additional information from us in
respect thereto. By taking any such action, the depositary shall not in any way be deemed or inferred to have been required, or have had any duty or responsibility (contractual or otherwise), to
monitor or inquire whether any of the circumstances described above existed. In addition to the limitations provided for in the deposit agreement, ADR holders and beneficial owners are advised and
agree that (a)&nbsp;the depositary will rely fully and exclusively on us to inform it of any of the circumstances set forth above, and (b)&nbsp;neither the depositary, the custodian nor any of
their respective agents shall be obliged to inquire or investigate whether any of the circumstances described above exist and/or whether we complied with our obligation to timely inform the depositary
of such circumstances. Neither the depositary, the custodian nor any of their respective agents shall incur any liability to ADR holders or beneficial owners (i)&nbsp;as a result of our failure to
determine that any of the circumstances described above exist or our failure to timely notify the depositary of any such circumstances or (ii)&nbsp;if any agenda item which is approved at a meeting
has, or is claimed to have, a material or adverse effect on the rights of holders of shares. Because there is no guarantee that ADR holders and beneficial owners will receive the notices described
above with sufficient time to enable such ADR holders or beneficial owners to return any voting instructions to the depositary in a timely manner, ADR holders and beneficial owners may be deemed to
have instructed the depositary to give a discretionary proxy to a person designated by us in such circumstances, and neither the depositary, the custodian nor any of their respective agents shall
incur any liability to ADR holders or beneficial owners in such circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADR
holders are strongly encouraged to forward their voting instructions to the depositary as soon as possible. For instructions to be valid, the ADR department of the depositary that is
responsible for proxies and voting must receive them in the manner and on or before the time specified, notwithstanding that such instructions may have been physically received by the depositary prior
to such time. The depositary will not itself exercise any voting discretion in respect of deposited securities. The depositary and its agents will not be responsible for any failure to carry out any
instructions to vote any of the deposited securities, for the manner in which any voting instructions are given or deemed to be given in accordance with the deposit agreement, including instructions
to give a discretionary proxy to a person designated by us, for the manner in which any vote is cast, including, without limitation, any vote cast by a person to whom the depositary is instructed to
grant a discretionary proxy (or deemed to have been instructed to grant a discretionary proxy in accordance with the deposit agreement), or for the effect of any such vote. Notwithstanding anything
contained in the deposit agreement or any ADR, the depositary may, to the extent not prohibited by any law, regulation, or requirement of the stock exchange on which the ADSs are listed, in lieu of
distribution of the materials provided to the depositary in connection with any meeting of or solicitation of consents or proxies from holders of deposited securities, distribute to the registered
holders of ADRs a notice that provides such ADR holders with or otherwise publicizes to such ADR holders instructions on how to retrieve such materials or receive such materials upon request
(</FONT><FONT SIZE=2><I>i.e.</I></FONT><FONT SIZE=2>, by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have advised the depositary that under Cayman Islands law and our constituent documents, each as in effect as of the date of the deposit agreement, voting at any meeting of
shareholders is by show of hands unless a poll is (before or on the declaration of the results of the show of hands) demanded. In the event that voting on any resolution or matter is conducted on a
show of hands basis </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>255</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=258,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=432894,FOLIO='255',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_256"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>in
accordance with our constituent documents, the depositary will refrain from voting and the voting instructions received by the depositary from ADR holders shall lapse. The depositary will not
demand a poll or join in demanding a poll, whether or not requested to do so by ADR holders or beneficial owners. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons who hold their ADSs through brokers,
dealers or other third parties, will not have the opportunity to exercise a right to vote. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reports and Other Communications  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will ADR holders be able to view our reports?  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement, the
provisions of or governing deposited securities, and any written communications from us which are both received by the custodian or its nominee as a holder of deposited securities and made generally
available to the holders of deposited securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
if we make any written communications generally available to holders of our shares, and we furnish copies thereof (or English translations or summaries) to the depositary,
it will distribute the same to registered ADR holders. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fees and Expenses  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What fees and expenses will I be responsible for paying?  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of shares, issuances in
respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or issuances pursuant to a merger, exchange of securities or any
other transaction or event affecting the ADSs or deposited securities, and each person surrendering ADSs for withdrawal of deposited securities or whose ADRs are cancelled or reduced for any other
reason, $5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, or upon which a share distribution or elective distribution is made or offered, as the
case may be. The depositary may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distribution prior to such deposit
to pay such charge. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following additional charges shall also be incurred by the ADR holders, the beneficial owners, by any party depositing or withdrawing shares or by any party surrendering ADSs and/or
to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADSs or the deposited securities or a
distribution of ADSs), whichever is applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fee of U.S.$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fee of U.S.$0.05 or less per ADS held for any cash distribution made, or for any elective cash/stock dividend offered, pursuant to the
deposit agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an aggregate fee of U.S.$0.05 or less per ADS per calendar year (or portion thereof) for services performed by the depositary in administering
the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during each
calendar year and shall be payable in the manner described in the next succeeding provision); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without
limitation, the custodian and expenses incurred on </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>256</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=259,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=740623,FOLIO='256',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_257"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>behalf
of ADR holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the shares or
other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in connection with the depositary's or its
custodian's compliance with applicable law, rule or regulation (which fees and charges shall be assessed on a proportionate basis against ADR holders as of the record date or dates set by the
depositary and shall be payable at the sole discretion of the depositary by billing such ADR holders or by deducting such charge from one or more cash dividends or other cash distributions); </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to
the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were shares)
but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those ADR holders entitled thereto; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> stock transfer or other taxes and other governmental charges; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of shares,
ADRs or deposited securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> transfer or registration fees for the registration of transfer of deposited securities on any applicable register in connection with the
deposit or withdrawal of deposited securities; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fees of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or
private sale of securities under the deposit agreement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions and other corporate actions, the depositary
may engage the foreign exchange desk within JPMorgan Chase Bank, N.A. (the "</FONT><FONT SIZE=2><B>Bank</B></FONT><FONT SIZE=2>") and/or its affiliates in order to enter into spot foreign exchange
transactions to convert foreign currency into U.S. dollars. For certain currencies, foreign exchange transactions are entered into with the Bank or an affiliate, as the case may be, acting in a
principal capacity. For other currencies, foreign exchange transactions are routed directly to and managed by an unaffiliated local custodian (or other third party local liquidity provider), and
neither the Bank nor any of its affiliates is a party to such foreign exchange transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foreign exchange rate applied to an foreign exchange transaction will be either (a)&nbsp;a published benchmark rate, or (b)&nbsp;a rate determined by a third party local
liquidity provider, in each case plus or minus a spread, as applicable. The depositary will disclose which foreign exchange rate and spread, if any, apply to such currency on the "Disclosures" page
(or successor page) of ADR.com. Such applicable foreign exchange rate and spread may (and neither the depositary, the Bank nor any of their affiliates is under any obligation to ensure that such rate
does not) differ from rates and spreads at which comparable transactions are entered into with other customers or the range of foreign exchange rates and spreads at which the Bank or any of its
affiliates enters into foreign exchange transactions in the relevant currency pair on the date of the foreign exchange transaction. Additionally, the timing of execution of an foreign exchange
transaction varies according to local market dynamics, which may include regulatory requirements, market hours and liquidity in the foreign exchange market or other factors. Furthermore, the Bank and
its affiliates may manage the associated risks of their position in the market in a manner they deem appropriate without regard to the impact of such activities on the depositary, us, holders or
beneficial owners. </FONT><FONT SIZE=2><I>The spread applied does not reflect any gains or losses that may be earned or incurred by the Bank and its affiliates as a result of risk management or other
hedging related activity.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>257</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=260,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=870521,FOLIO='257',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_258"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, to the extent we provide U.S. dollars to the depositary, neither the Bank nor any of its affiliates will execute a foreign exchange transaction as set
forth herein. In such case, the depositary will distribute the U.S. dollars received from us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Further details relating to the applicable foreign exchange rate, the applicable spread and the execution of foreign exchange transactions will be provided by the
depositary on ADR.com. Each holder and beneficial owner by holding or owning an ADR or ADS or an interest therein, and we, each acknowledge and agree that the terms applicable to foreign exchange
transactions disclosed from time to time on ADR.com will apply to any foreign exchange transaction executed pursuant to the deposit agreement.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from time to time between us and the
depositary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
right of the depositary to receive payment of fees, charges and expenses survives the termination of the deposit agreement, and shall extend for those fees, charges and expenses
incurred prior to the effectiveness of any resignation or removal of the depositary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fees and charges described above may be amended from time to time by agreement between us and the depositary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as we and the
depositary may agree from time to time. The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of
withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of
distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by charging the
book-entry system accounts of participants acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution exists and
payment owing is not timely received by the depositary, the depositary may refuse to provide any further services to ADR holders that have not paid those fees and expenses owing until such fees and
expenses have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment of Taxes  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADR holders or beneficial owners must pay any tax or other governmental charge payable by the custodian or the depositary on any ADS or ADR,
deposited security or distribution. If any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian or the depositary with
respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon, including, without limitation, any Chinese Enterprise Income Tax owing if the
Circular Guoshuifa [2009] No.&nbsp;82 issued by the Chinese State Administration of Taxation (SAT) or any other circular, edict, order or ruling, as issued and as from time
to time amended, is applied or otherwise, such tax or other governmental charge shall be paid by the ADR holder thereof to the depositary and by holding or owning, or having held or owned, an ADR or
any ADSs evidenced thereby, the ADR holder and all beneficial owners thereof, and all prior ADR holders and beneficial owners thereof, jointly and severally, agree to indemnify, defend and save
harmless each of the depositary, us and its and our agents in respect of such tax or other governmental charge. Notwithstanding the depositary's right to seek payment from current and former
beneficial owners, by holding or owning, or having held or owned, an ADR, the ADR holder thereof (and prior ADR holder thereof) acknowledges and agrees that the depositary has no obligation to seek
payment of amounts owing from any current or former beneficial owner. If an ADR holder owes any tax or other governmental charge, the depositary may (i)&nbsp;deduct the amount thereof from any cash </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>258</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=261,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=417446,FOLIO='258',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_259"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>distributions,
or (ii)&nbsp;sell deposited securities (by public or private sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder remains liable for any
shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to effect any registration, registration of transfer, split-up or combination of deposited securities or
withdrawal of deposited securities until such payment is made. If any tax or governmental charge is required to be withheld on any cash distribution, the depositary may deduct the amount required to
be withheld from any cash distribution or, in the case of a non-cash distribution, sell the distributed property or securities (by public or private sale) in such amounts and in such manner as the
depositary deems necessary and practicable to pay such taxes and distribute any remaining net proceeds or the balance of any such property after deduction of such taxes to the ADR holders entitled
thereto. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an ADR holder or beneficial owner, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective officers, directors, employees, agents and
affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes,
reduced rate of withholding at source or other tax benefit obtained. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reclassifications, Recapitalizations and Mergers  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we take certain actions that affect the deposited securities, including (i)&nbsp;any change in par value, split-up, consolidation,
cancellation or other reclassification of deposited securities or (ii)&nbsp;any distributions of shares or other property not made to holders of ADRs or (iii)&nbsp;any recapitalization,
reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all of our assets, then the depositary may choose to, and shall if reasonably requested by
us:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> amend the form of ADR; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> distribute additional or amended ADRs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> distribute cash, securities or other property it has received in connection with such actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sell any securities or property received and distribute the proceeds as cash; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> none of the above. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>If
the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part of the deposited securities and each ADS will then represent
a proportionate interest in such property. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment and Termination  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How may the deposit agreement be amended?  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at
least 30&nbsp;days' notice of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges, transfer or registration fees,
SWIFT, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or otherwise prejudices any substantial existing right of ADR holders or beneficial owners. Such notice
need not describe in detail the specific amendments effectuated thereby, but must identify to ADR holders and beneficial owners a means to access the text of such amendment. If an ADR holder continues
to hold an ADR or ADRs after being so notified, such ADR holder and any beneficial owner are deemed to agree to such amendment and to be bound by the deposit agreement as so amended. No amendment,
however, will impair your right to surrender your ADSs and receive the underlying securities, except in order to comply with mandatory provisions of applicable law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>259</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=262,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=347984,FOLIO='259',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_260"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
amendments or supplements which (i)&nbsp;are reasonably necessary (as agreed by us and the depositary) in order for (a)&nbsp;the ADSs to be registered on Form&nbsp;F-6 under
the Securities Act of 1933 or (b)&nbsp;the ADSs or shares to be traded solely in electronic book-entry form and (ii)&nbsp;do not in either such case impose or increase any fees or charges to be
borne by ADR holders, shall be deemed not to prejudice any substantial rights of ADR holders or beneficial owners. Notwithstanding the foregoing, if any governmental body or regulatory body should
adopt new laws, rules or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith, we and the depositary may amend or
supplement the deposit agreement and the ADR at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the deposit agreement in such circumstances may
become effective before a notice of such amendment or supplement is given to ADR holders or within any other period of time as required for compliance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of any amendment to the deposit agreement or form of ADRs shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific
amendments in any such notice shall not render such notice invalid, provided, however, that, in each such case, the notice given to the ADR holders identifies a means for ADR holders and beneficial
owners to retrieve or receive the text of such amendment (</FONT><FONT SIZE=2><I>i.e.</I></FONT><FONT SIZE=2>, upon retrieval from the SEC's, the depositary's or our website or upon request from the
depositary). </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How may the deposit agreement be terminated?  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination to
the registered holders of ADRs at least 30&nbsp;days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have (i)&nbsp;resigned as depositary
under the deposit agreement, notice of such termination by the depositary shall not be provided to registered ADR holders unless a successor depositary shall not be operating under the deposit
agreement within 60&nbsp;days of the date of such resignation, and (ii)&nbsp;been removed as depositary under the deposit agreement, notice of such termination by the depositary shall not be
provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement on the 60<SUP>th</SUP>&nbsp;day after our notice of removal was first
provided to the depositary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the shares are not listed or quoted for trading on a stock exchange or in a securities market as of the date so fixed for termination, then after such date fixed for termination
(a)&nbsp;all direct registration ADRs shall cease to be eligible for the direct registration system and shall be considered ADRs issued on the ADR register maintained by the depositary and
(b)&nbsp;the depositary shall use its reasonable efforts to ensure that the ADSs cease to be DTC eligible so that neither DTC nor any of its nominees shall thereafter be a holder of ADRs. At such
time as the ADSs cease to be DTC eligible and/or neither DTC nor any of its nominees is a holder of ADRs, the depositary shall (a)&nbsp;instruct its custodian to deliver all shares and/or deposited
securities to us along with a general stock power that refers to the names set forth on the ADR register maintained by the depositary and (b)&nbsp;provide us with a copy of the ADR register
maintained by the depositary. Upon receipt of such shares and/or deposited securities and the ADR register maintained by the depositary, we have agreed to use our best efforts to issue to each
register ADR holder a share certificate representing the shares represented by the ADSs reflected on the ADR register maintained by the depositary in such registered ADR holder's name and to deliver
such share certificate to the registered ADR holder at the address set forth on the ADR register maintained by the depositary. After providing such instruction to the custodian and delivering a copy
of the ADR register to us, the depositary and its agents will perform no further acts under the deposit agreement or the ADRs and shall cease to have any obligations under the deposit agreement and/or
the ADRs. After we receive the copy of the ADR register and the shares and/or deposited securities from the depositary, we shall be discharged from all obligations under the deposit agreement </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>260</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=263,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=222032,FOLIO='260',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_261"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>except
(i)&nbsp;to distribute the shares to the registered ADR holders entitled thereto and (ii)&nbsp;for its obligations to the depositary and its agents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the shares are listed or quoted for trading on a stock exchange or in a securities market as of the date so fixed for termination, then instead of the provisions in the prior
paragraph, after the date so fixed for termination, the depositary and its agents will perform no further acts under the deposit agreement or the ADRs, except to receive and hold (or sell)
distributions on shares and/or deposited securities and deliver shares and/or deposited securities being withdrawn. As soon as practicable after the date so fixed for termination, the depositary has
agreed to use its reasonable efforts to sell the shares and/or deposited securities and shall thereafter (as long as it may lawfully do so) hold in an account (which may be a segregated or
unsegregated account) the net proceeds of such sales, together with any other cash then held by it under the deposit agreement, without liability for interest, in trust for the pro rata benefit of the
registered ADR holders not theretofore surrendered. After making such sale, the depositary shall be discharged from all obligations in respect of the deposit agreement and the ADRs, except to account
for such net proceeds and other cash. After the date so fixed for termination, we shall be discharged from all obligations under the deposit agreement except for our obligations to the depositary and
its agents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary, in connection with any such termination, the depositary may, in its sole discretion and without notice to us, establish an unsponsored American
depositary share program (on such terms as the depositary may determine) for our shares and make available to ADR holders a means to withdraw the shares represented by the ADSs issued under the
deposit agreement and to direct the deposit of such shares into such unsponsored American depositary share program, subject, in each case, to receipt by the depositary, at its discretion, of the fees,
charges and expenses provided for under the deposit agreement and the fees, charges and expenses applicable to the unsponsored American depositary share program. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations on Obligations and Liability to ADR holders  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limits on our obligations and the obligations of the depositary; limits on liability to ADR holders and
holders of ADSs  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the issue, registration, registration of transfer, split-up, combination, or cancellation of any ADRs, or the delivery of any
distribution in respect thereof, and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian may
require:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment with respect thereto of (i)&nbsp;any stock transfer or other tax or other governmental charge, (ii)&nbsp;any stock transfer or
registration fees in effect for the registration of transfers of shares or other deposited securities upon any applicable register and (iii)&nbsp;any applicable fees and expenses described in the
deposit agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the production of proof satisfactory to it of (i)&nbsp;the identity of any signatory and genuineness of any signature and (ii)&nbsp;such
other information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial or other ownership of, or interest in, any securities, compliance with
applicable law, regulations, provisions of or governing deposited securities and terms of the deposit agreement and the ADRs, as it may deem necessary or proper; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with such regulations as the depositary may establish consistent with the deposit agreement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of ADRs, the acceptance of deposits of shares, the registration, registration of transfer, split-up or combination of ADRs or the withdrawal of shares, may be suspended,
generally or in particular instances, when the ADR register or any register for deposited securities is closed or when any such action is deemed advisable by the depositary; provided that the ability
to withdraw shares may </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>261</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=264,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=887486,FOLIO='261',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_262"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>only
be limited under the following circumstances: (i)&nbsp;temporary delays caused by closing transfer books of the depositary or our transfer books or the deposit of shares in connection with
voting at a shareholders' meeting, or the payment of dividends, (ii)&nbsp;the payment of fees, taxes, and similar charges, and (iii)&nbsp;compliance with any laws or governmental regulations
relating to ADRs or to the withdrawal of deposited securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
deposit agreement expressly limits the obligations and liability of the depositary, ourselves and our respective agents, provided, however, that no disclaimer of liability under the
Securities Act of 1933 is intended by any of the limitations of liabilities provisions of the deposit agreement. The deposit agreement provides that each of us, the depositary and our respective
agents will:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> incur or assume no liability (including, without limitation, to holders or beneficial owners) if any present or future law, rule, regulation,
fiat, order or decree of the Cayman Islands, Hong Kong, the People's Republic of China, the United States or any other country or jurisdiction, or of any governmental or regulatory authority or
securities exchange or market or automated quotation system, the provisions of or governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism,
epidemic, pandemic, nationalization, expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure or circumstance beyond our, the
depositary's or our respective agents' direct and immediate control shall prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which
the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without limitation, voting); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> incur or assume no liability (including, without limitation, to holders or beneficial owners) by reason of any non-performance or delay, caused
as aforesaid, in the performance of any act or things which by the terms of the deposit agreement it is provided shall or may be done or performed or any exercise or failure to exercise discretion
under the deposit agreement or the ADRs including, without limitation, any failure to determine that any distribution or action may be lawful or reasonably practicable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> incur or assume no liability (including, without limitation, to holders or beneficial owners) if it performs its obligations under the deposit
agreement and ADRs without gross negligence or willful misconduct; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of the depositary and its agents, be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in
respect of any deposited securities the ADSs or the ADRs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of us and our agents, be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of
any deposited securities the ADSs or the ADRs, which in our or our agents' opinion, as the case may be, may involve it in expense or liability, unless indemnity satisfactory to us or our agent, as the
case may be against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be requested; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not be liable (including, without limitation, to holders or beneficial owners) for any action or inaction by it in reliance upon the advice of
or information from any legal counsel, any accountant, any person presenting shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice
or information and/or, in the case of the depositary, us; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may rely and shall be protected in acting upon any written notice, request, direction, instruction or document believed by it to be genuine and
to have been signed, presented or given by the proper party or parties. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>262</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=265,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=922655,FOLIO='262',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_263"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the depositary nor its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities, the ADSs or the
ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities, the ADSs or the ADRs, which in our
opinion may involve us in expense or liability, if indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as may be
required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with the deposit agreement, any registered
holder or holders of ADRs, any ADRs or otherwise related to the deposit agreement or ADRs to the extent such information is requested or
required by or pursuant to any lawful authority, including without limitation laws, rules, regulations, administrative or judicial process, banking, securities or other regulators. The depositary
shall not be liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system. Furthermore, the depositary shall not be responsible for,
and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch or affiliate of JPMorgan. Notwithstanding anything to the contrary contained in
the deposit agreement or any ADRs, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, any act or omission to act on the part of the custodian
except to the extent that any registered ADR holder has incurred liability directly as a result of the custodian having (i)&nbsp;committed fraud or willful misconduct in the provision of custodial
services to the depositary or (ii)&nbsp;failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance with the standards prevailing in the
jurisdiction in which the custodian is located. The depositary and the custodian(s) may use third party delivery services and providers of information regarding matters such as, but not limited to,
pricing, proxy voting, corporate actions, class action litigation and other services in connection with the ADRs and the deposit agreement, and use local agents to provide services such as, but not
limited to, attendance at any meetings of security holders of issuers. Although the depositary and the custodian will use reasonable care (and cause their agents to use reasonable care) in the
selection and retention of such third party providers and local agents, they will not be responsible for any errors or omissions made by them in providing the relevant information or services. The
depositary shall not have any liability for the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall it be responsible for
any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection with any such sale or proposed sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary has no obligation to inform ADR holders or beneficial owners about the requirements of the laws, rules or regulations or any changes therein or thereto of the Cayman
Islands, Hong Kong, the People's Republic of China, the United States or any other country or jurisdiction or of any governmental or regulatory authority or any securities exchange or market or
automated quotation system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
none of the depositary, the custodian or us, or any of their or our respective directors, officers, employees, agents or affiliates shall be liable for the failure by any
registered holder of ADRs or beneficial owner therein to obtain the benefits of credits or refunds of non-U.S. tax paid against such ADR holder's or beneficial owner's income tax liability. The
depositary is under no obligation to provide the ADR holders and beneficial owners, or any of them, with any information about our tax status. None of the depositary, custodian, us or any of their or
our respective directors, officers, employees, agents or affiliates shall incur any liability for any tax or tax consequences that may be incurred by registered ADR holders or beneficial owners on
account of their ownership or disposition of ADRs or ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any voting
instructions are given or deemed to be given pursuant to the terms of the deposit agreement, including instructions to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>263</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=266,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=168744,FOLIO='263',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_264"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>give
a discretionary proxy to a person designated by us, for the manner in which any vote is cast, including, without limitation, any vote cast by a person to whom the depositary is instructed (or
deemed to have been instructed to grant a discretionary proxy in accordance with the deposit agreement), or for the effect of any such vote. The depositary may rely upon instructions from us or our
counsel in respect of any approval or license required for any currency conversion, transfer or distribution. The depositary shall not incur any liability for the content of any information submitted
to it by us or on our behalf for distribution to ADR holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited
securities, for the validity or worth of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the deposit agreement or for the
failure or timeliness of any notice from us. The depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the
depositary or in connection with any matter arising wholly after the removal or resignation of the depositary. Subject to certain customary exceptions, neither the depositary nor us, nor any of its or
our agents shall be liable to the other for any indirect, special, punitive or consequential damages (excluding reasonable fees and expenses of counsel) or lost profits, in each case of any form
incurred by any of them, or liable to any other person or entity (including, without limitation holders or beneficial owners of ADRs and ADSs) for any indirect, special, punitive or consequential
damages (including fees and expenses of counsel) or lost profits, whether or not foreseeable and regardless of the type of action in which such a claim may be brought. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the deposit agreement each party thereto (including, for avoidance of doubt, each ADR holder and beneficial owner) irrevocably waives, to the fullest extent permitted by applicable
law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the shares or other deposited
securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory). No provision
of the deposit agreement or the ADRs is intended to constitute a waiver or limitation of any rights which an ADR holder or any beneficial owner may have under the Securities Act of 1933 or the
Securities Exchange Act of 1934, to the extent applicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary and its agents may own and deal in any class of securities of our company and our affiliates and in ADRs. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Disclosure of Interest in ADSs  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other
ownership of, or interest in, deposited
securities, other shares and other securities and may provide for blocking transfer, voting or other rights to enforce such disclosure or limits, you as ADR holders or beneficial owners agree to
comply with all such disclosure requirements and ownership limitations and to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to instruct you as ADS
holders to deliver your ADSs for cancellation and withdrawal of the deposited securities so as to permit us to deal directly with the holder thereof as a holder of shares and, by holding an ADS or an
interest therein, you and beneficial owners will be agreeing to comply with such instructions. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Books of Depositary  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary or its agent will maintain a register for the registration, registration of transfer, combination and split-up of ADRs, which
register shall include the depositary's direct registration system. Registered holders of ADRs may inspect such records at the depositary's office at all reasonable times, but solely for the purpose
of communicating with other ADR holders in the interest of the business of our company or a matter relating to the deposit agreement. Such register may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>264</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=267,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=194823,FOLIO='264',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_265"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>closed
at any time or from time to time, when deemed expedient by the depositary or, in the case of the issuance book portion of the ADR Register, when reasonably requested by the Company solely in
order to enable the Company to comply with applicable law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary will maintain facilities for the delivery and receipt of ADRs. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Appointment  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the deposit agreement, each registered holder of ADRs and each beneficial owner, upon acceptance of any ADSs or ADRs (or any interest in any
of them) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appoint the depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in
the deposit agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws and to take such action as the depositary in its sole discretion may deem
necessary or appropriate to carry out the purposes of the deposit agreement and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and
appropriateness thereof; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> acknowledge and agree that (i)&nbsp;nothing in the deposit agreement or any ADR shall give rise to a partnership or joint venture among the
parties thereto, nor establish a fiduciary or similar relationship among such parties, (ii)&nbsp;the depositary, its divisions, branches and affiliates, and their respective agents, may from time to
time be in the possession of non-public information about us, ADR holders, beneficial owners and/or their respective affiliates, (iii)&nbsp;the depositary and its divisions, branches and affiliates
may at any time have multiple banking relationships with us, ADR holders, beneficial owners and/or the affiliates of any of them, (iv)&nbsp;the depositary and its divisions, branches and affiliates
may, from time to time, be engaged in transactions in which parties adverse to us, ADR holders, beneficial owners and/or their respective affiliates may have interests, (v)&nbsp;nothing contained in
the deposit agreement or any ADR(s) shall (A)&nbsp;preclude the depositary or any of its divisions, branches or affiliates from engaging in any such transactions or establishing or maintaining any
such relationships, or (B)&nbsp;obligate the depositary or any of its divisions, branches or affiliates to disclose any such transactions or relationships or to account for any profit made or
payment received in any such transactions or relationships, (vi)&nbsp;the depositary shall not be deemed to have knowledge of any information held by any branch, division or affiliate of the
depositary and (vii)&nbsp;notice to an ADR holder shall be deemed, for all purposes of the deposit agreement and the ADRs, to constitute notice to any and all beneficial owners of the ADSs evidenced
by such ADR holder's ADRs. For all purposes under the deposit agreement and the ADRs, the ADR holders thereof shall be deemed to have all requisite authority to act on behalf of any and all beneficial
owners of the ADSs evidenced by such ADRs. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governing Law  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The deposit agreement, the ADSs and the ADRs are governed by and construed in accordance with the internal laws of the State of New York. In the
deposit agreement, we have submitted to the non-exclusive jurisdiction of the courts of the State of New York and appointed an agent for service of process on our behalf. Any action based on the
deposit agreement, the ADSs, the ADRs or the transactions contemplated therein or thereby may also be instituted by the depositary against us in any competent court in the Cayman Islands, Hong Kong,
the People's Republic of China and the United States. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>265</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=268,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=349011,FOLIO='265',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_266"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the deposit agreement, by holding or owning an ADR or ADS or an interest therein, ADR holders and beneficial owners each irrevocably agree that any legal suit, action or proceeding
against or involving ADR holders or beneficial owners brought by us or the depositary, arising out of or based upon the deposit agreement, the ADSs, the ADRs or the transactions contemplated thereby,
may be instituted in a state or federal court in New York, New York, irrevocably waive any objection which you may have to the laying of venue of any such proceeding, and irrevocably submit to the
non-exclusive jurisdiction of such courts in any such suit, action or proceeding. By holding or owning an ADR or ADS or an interest therein, ADR holders and beneficial owners each also irrevocably
agree that any legal suit, action or proceeding against or involving the depositary brought by ADR holders or beneficial owners, arising out of or based upon the deposit agreement, the ADSs, the ADRs
or the transactions contemplated thereby, may only be instituted in a state or federal court in New York, New York. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, (i)&nbsp;the depositary may, in its sole discretion, elect to institute any dispute, suit, action, controversy, claim or proceeding directly or
indirectly based on, arising out of or relating to the deposit agreement, the ADSs, the ADRs or the transactions contemplated therein or thereby, including without limitation any question regarding
its or their existence, validity, interpretation, performance or termination, against any other party or parties to the deposit agreement (including, without limitation, against ADR holders and
beneficial owners of interests in ADSs), by having the matter referred to and finally resolved by an arbitration conducted under the terms described below, and (ii)&nbsp;the depositary may in its
sole discretion require, by written notice to the relevant party or parties, that any dispute, suit, action, controversy, claim or proceeding against the depositary by any party or parties to the
deposit agreement (including, without limitation, by ADR holders and beneficial owners of interests in ADSs) shall be referred to and finally settled by an arbitration conducted under the terms
described below. Any such arbitration shall be conducted in the English language either in New York, New York in accordance with the Commercial Arbitration Rules of the American Arbitration
Association or in Hong Kong following the arbitration rules of the United Nations Commission on International Trade Law (UNCITRAL). </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Jury Trial Waiver  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the deposit agreement, each party thereto (including, for the avoidance of doubt, each holder and beneficial owner of, and/or holder of
interests in, ADSs or ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary
and/or us directly or indirectly arising out of or relating to the shares or other deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the
breach thereof (whether based on contract, tort, common law or any other theory), including any claim under the U.S. federal securities laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we or the depositary were to oppose a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case
in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. The waiver to right to a jury trial in the
deposit agreement is not intended to be deemed a waiver by any holder or beneficial owner of ADSs of our or the depositary's compliance with the U.S. federal securities laws and the rules and
regulations promulgated thereunder. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>266</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=17,SEQ=269,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=392813,FOLIO='266',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_267"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eo17601_shares_eligible_for_future_sale"> </A>
<A NAME="toc_eo17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon completion of this offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs outstanding,
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, or approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares, assuming the underwriters do not exercise their option to purchase additional ADSs. All of the ADSs sold in this offering will be freely
transferable by persons other than our "affiliates" without restriction or further registration under the Securities Act. Sales of substantial amounts of our ADSs in the public market could adversely
affect prevailing market prices of our ADSs. Prior to this offering, there has been no public market for our ordinary shares or the ADSs, and while our ADSs have been approved for listing on the
Nasdaq, we cannot assure you that a regular trading market will develop in the ADSs. Our ordinary shares will not be listed on any exchange or quoted for trading on any over-the-counter trading
system. We do not expect that a trading market will develop for our ordinary shares not represented by the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lock-up Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, [our directors, executive officers and existing shareholders] have agreed with the underwriters, subject to some
exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our ordinary shares, in the form of ADSs or otherwise, or any securities convertible into or exchangeable or exercisable
for our ordinary shares, in the form of ADSs or otherwise, for a period of [180] days after the date of this prospectus. After the expiration of the
[180]-day period, the ordinary shares or ADSs held by our directors, executive officers and our existing shareholders may be sold subject to the restrictions under
Rule&nbsp;144 under the Securities Act or by means of registered public offerings. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our ordinary shares outstanding prior to this offering are "restricted shares" as that term is defined in Rule&nbsp;144 under the
Securities Act and may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities Act or pursuant to an exemption from the registration
requirements. Under Rule&nbsp;144 as currently in effect, a person who is not deemed to have been our affiliate at any time during the three months preceding a sale and who has beneficially owned
our restricted shares for at least six months is generally entitled to sell the restricted securities without registration under the Securities Act beginning 90&nbsp;days after the date of this
prospectus, subject to certain additional restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
affiliates who have beneficially owned "restricted securities" for at least six months may sell within any three-month period a number of restricted shares that does not exceed the
greater of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1% of the then outstanding ordinary shares of the same class, in the form of ADSs or otherwise, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ordinary shares immediately after this offering, assuming the underwriters do not exercise their option to purchase additional ADSs; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the average weekly trading volume of our ordinary shares in the form of ADSs or otherwise on the Nasdaq during the four calendar weeks
preceding the date on which notice of the sale on Form&nbsp;144 is filed with the SEC. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliates
who sell restricted securities under Rule&nbsp;144 may not solicit orders or arrange for the solicitation of orders, and they are also subject to certain manner of sale
provisions and notice requirements and the availability of current public information about us. In addition, in each case, shares held by our affiliates would remain subject to lock-up arrangements
and would only become eligible for sale when the lock-up period expires. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>267</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=18,SEQ=270,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=212073,FOLIO='267',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eo17601_1_268"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Persons
who are not our affiliates are only subject to one of these additional restrictions, the requirement of the availability of current public information about us, and this
additional restriction does not apply if they have beneficially owned our restricted shares for more than one year. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our
ordinary shares from us in connection with a compensatory stock or option plan or other written agreement relating to compensation is eligible to resell such ordinary shares 90&nbsp;days after we
became a reporting company under the Exchange Act in reliance on Rule&nbsp;144, but without compliance with some of the restrictions, including the holding period, contained in Rule&nbsp;144.
However, the Rule&nbsp;701 shares would remain subject to lock-up arrangements and would only become eligible for sale when the lock-up period expires. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, holders of our registrable securities will be entitled to request that we register their shares under the
Securities Act, following the expiration of the
lock-up agreements described above. See "Description of Share Capital&#151;Shareholders' Agreements&#151;Registration Rights." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form&nbsp;S-8  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to file&nbsp;a registration statement on Form&nbsp;S-8 under the Securities Act covering all ordinary shares which are either
subject to outstanding options or may be issued upon exercise or vesting of any options or other equity awards which may be granted or issued in the future pursuant to our share incentive plan. We
expect to file this registration statement as soon as practicable after the date of this prospectus. Shares registered under any registration statements will be available for sale in the open market,
except to the extent that the shares are subject to vesting restrictions with us or the contractual restrictions and the lock-up described below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>268</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=19,SEQ=271,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=795187,FOLIO='268',FILE='DISK103:[20ZDS1.20ZDS17601]EO17601A.;36',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_eq17601_1_269"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eq17601_taxation"> </A>
<A NAME="toc_eq17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  TAXATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following discussion of Cayman Islands, PRC and U.S. federal income tax consequences of an investment in the ADSs or
ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change. This discussion does not deal with all possible
tax consequences relating to an investment in the ADSs or ordinary shares, such as the tax consequences under state, local and other tax laws. To the extent that the discussion relates to matters of
Cayman Islands tax law, it represents the opinion of Walkers (Hong Kong), our Cayman Islands counsel. To the extent that the discussion relates to matters of PRC tax law, it represents the opinion of
Tian Yuan Law Firm, our PRC legal counsel.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cayman Islands Taxation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation, and there is no
taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us or holders of our ADSs or ordinary shares levied by the government of the Cayman Islands,
except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax
treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
of dividends and capital in respect of the ADSs or ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a
dividend or capital to any holder of the ADSs or ordinary shares, nor will gains derived from the disposal of the ADSs or ordinary shares be subject to Cayman Islands income or corporation tax. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Material PRC Income Tax Considerations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the PRC EIT Law, which became effective on January&nbsp;1, 2008 and amended on December&nbsp;29, 2019, an enterprise established
outside the PRC with "de facto management bodies" within the PRC is considered a "resident enterprise" for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise
income tax rate on its worldwide income. Under the implementation rules to the PRC EIT Law, a "de facto management body" is defined as a body that has material and overall management and control over
the manufacturing and business operations, personnel and human resources, finances and properties of an enterprise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the SAT Circular 82 issued by the SAT in April 2009 specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be
classified as PRC resident enterprises if the following are located or resident in the PRC: (a)&nbsp;senior management personnel and departments that are responsible for daily production, operation
and management; (b)&nbsp;financial and personnel decision-making bodies; (c)&nbsp;key properties, accounting books, company seal, minutes of board meetings and shareholders' meetings; and
(d)&nbsp;half or more of the senior management or directors having voting rights. Further to SAT Circular 82, the SAT issued the SAT Bulletin 45, which took effect in September 2011, to provide more
guidance on the implementation of SAT Circular 82. SAT Bulletin 45 provides for procedures and administration details of determination on resident status and administration on post-determination
matters. Our company is a company incorporated outside the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records
(including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside the PRC. As such, we do not believe that our
company meets all of the conditions above or is a PRC resident enterprise for PRC tax purposes. For the same reasons, we believe our other entities outside China are not PRC resident enterprises
either. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term "de facto
management body." There can be no assurance that the PRC government will ultimately take a view that is consistent with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>269</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=272,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=516237,FOLIO='269',FILE='DISK103:[20ZDS1.20ZDS17601]EQ17601A.;33',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eq17601_1_270"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>us.
If the PRC tax authorities determine that our Cayman Islands holding company is a PRC resident enterprise for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences could
follow. For example, a 10% withholding tax would be imposed on dividends we pay to our non-PRC enterprise shareholders (including our ADS holders). In addition, nonresident enterprise shareholders
(including our ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC.
Furthermore, if we are deemed a PRC resident enterprise, dividends paid to our non-PRC individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or ordinary
shares by such shareholders may be subject to PRC tax at a rate of 20% (which, in the case of dividends, may be withheld at source by us). These rates may be reduced by an applicable tax treaty, but
it is unclear whether in practice non-PRC shareholders of our company would be able to obtain the benefits of any tax treaties between their country of tax residence and the PRC in the event that we
are treated as a PRC resident enterprise. See "Risk Factors&#151;Risks Related to Doing Business in China&#151;If we are classified as a PRC resident enterprise for PRC income tax
purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Material U.S. Federal Income Tax Considerations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the opinion of Davis Polk &amp; Wardwell&nbsp;LLP, the following are material U.S. federal income tax consequences to the U.S. Holders
described below of owning and disposing of our ADSs or ordinary shares. This discussion is not a comprehensive description of all of the tax considerations that may be relevant to your decision to
acquire the ADSs or ordinary shares. This discussion applies to you only if you are a U.S. Holder that acquires ADSs in this offering and holds the ADSs or underlying ordinary shares as capital assets
for U.S. federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of your particular circumstances, including alternative minimum and
Medicare contribution tax considerations, and tax consequences applicable to you if you are subject to special rules, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> one of certain financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a dealer or trader in securities that uses a mark-to-market method of tax accounting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a person holding ADSs or ordinary shares as part of a straddle, conversion transaction, integrated transaction or similar transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a person whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an entity classified as partnerships for U.S. federal income tax purposes (and investors therein); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a tax-exempt entity, "individual retirement account" or "Roth IRA"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a person that owns or is deemed to own 10% or more of our stock by vote or value; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a person holding ADSs or ordinary shares in connection with a trade or business conducted outside the United States. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a partnership for U.S. federal income tax purposes, the U.S. federal income tax consequences to your partners will generally depend on their status and your activities.
Partnerships holding ADSs or ordinary shares and their partners should consult their tax advisers as to the particular U.S. federal income tax consequences of acquiring, owning or disposing of the
ADSs or ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury
regulations, and the income tax treaty between the United States and the PRC, or the Treaty, all as of the date hereof, any of which is subject to change, possibly with retroactive effect. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>270</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=273,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=65496,FOLIO='270',FILE='DISK103:[20ZDS1.20ZDS17601]EQ17601A.;33',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eq17601_1_271"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this discussion, you are a "U.S. Holder" if for U.S. federal income tax purposes you are a beneficial owner of ADSs or ordinary shares
and:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a citizen or individual resident of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a corporation or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the
United States, any state therein or the District of Columbia; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, if you own ADSs you will be treated as the owner of the underlying ordinary shares represented by those ADSs for U.S. federal income tax purposes. Accordingly, no gain or
loss will be recognized if you exchange ADSs for the underlying ordinary shares represented by those ADSs. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Taxation of Distributions  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described under "&#151;</FONT><FONT SIZE=2><I>Passive Foreign Investment Company Rules</I></FONT><FONT SIZE=2>" below,
distributions paid on ADSs or ordinary shares, other than certain pro rata distributions of ordinary shares, will generally be treated as dividends to the extent paid out of our current or accumulated
earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect
that any distributions will be reported to you as dividends. Dividends will not be eligible for the dividends-received deduction generally available to United States corporations under the Code.
Subject to applicable limitations, dividends paid on our ADSs to certain non-corporate U.S. Holders may be taxable at a favorable rate. Dividends will be included in your income on the date of your,
or in the case of ADSs, the depositary's, receipt of the dividend. The amount of any dividend income paid in non-U.S. currency will be its U.S. dollar value calculated by reference to the spot rate in
effect on the date of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, you generally should not
be required to recognize foreign currency gain or loss in respect of the dividend income. You may have foreign currency gain or loss, which will be United States source, if the dividend is converted
into U.S. dollars after the date of receipt. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
will be treated as foreign-source income for foreign tax credit purposes. As described in "&#151;PRC Taxation", dividends paid by us may be subject to PRC withholding
tax. For U.S. federal income tax purposes, the amount of the dividend income will include any amounts withheld in respect of PRC withholding tax. Subject to applicable limitations, which vary
depending upon your circumstances, PRC taxes withheld from dividend payments (at a rate not exceeding the applicable rate provided in the Treaty) generally will be creditable against your U.S. federal
income tax liability. The rules governing foreign tax credits are complex and you should consult your tax advisers regarding the creditability of foreign tax credits in your particular circumstances.
In lieu of claiming a credit, you may elect to deduct PRC taxes in computing its taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax
credits must apply to all foreign taxes paid or accrued in the taxable year. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale or Other Disposition of ADSs or Ordinary Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described under "&#151;</FONT><FONT SIZE=2><I>Passive Foreign Investment Company Rules</I></FONT><FONT SIZE=2>" below, gain or
loss realized on the sale or other taxable disposition of ADSs or ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if you held the ADSs or ordinary shares for
more than one year. The amount of the gain or loss will equal the difference between your tax basis in the ADSs or ordinary shares disposed of and the amount realized on the disposition, in each case
as determined in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>271</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=274,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=881157,FOLIO='271',FILE='DISK103:[20ZDS1.20ZDS17601]EQ17601A.;33',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eq17601_1_272"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>U.S.
dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described in "&#151;PRC Taxation" gains on the sale of ADSs or ordinary shares may be subject to PRC taxes. You are entitled to use foreign tax credits to offset only the
portion of your U.S. federal income tax liability that is attributable to foreign-source income. Because under the Code capital gains of U.S. persons are generally treated as U.S.-source income, this
limitation may preclude you from claiming a credit for all or a portion of any PRC taxes imposed on any such gains. However, if you are eligible for the benefits of the Treaty, you may elect to treat
the gain as PRC-source and therefore claim foreign tax credits in respect of PRC taxes on such disposition gains. You should consult your tax advisor regarding their eligibility for the benefits of
the Treaty and the creditability of any PRC tax on disposition gains in your particular circumstances. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Passive Foreign Investment Company Rules  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, a non-U.S. corporation will be a passive foreign investment company, or a PFIC, for any taxable year in which (i)&nbsp;75% or more
of its gross income consists of passive income, or the income test, or (ii)&nbsp;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that
produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of
the ordinary shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the
other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active
conduct of a trade or business). Cash is a passive asset for PFIC purposes. Goodwill is an active asset under the PFIC rules to the extent attributable to activities that produce active income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for the
current or any future taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. We cannot give any assurance as to whether we will be a PFIC
for the current or any future taxable year because (i)&nbsp;the value of our goodwill may be determined by reference to the market price of our ADSs, which may be volatile given the nature and early
stage of our business, (ii)&nbsp;we expect to hold a significant amount of cash, and (iii)&nbsp;a company's PFIC status is an annual determination that can be made only after the end of each
taxable year. In addition, prior to commercialization of our
product candidates, we could be a PFIC for any taxable year in which our interest and other investment income constitutes 75% or more of our total gross income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we were a PFIC for any taxable year and any of our subsidiaries were also a PFIC (any such entity, a "Lower-tier PFIC"), you would be deemed to own a proportionate amount (by value)
of the ordinary shares of each Lower-tier PFIC and would be subject to U.S. federal income tax according to the rules described in the subsequent paragraph on (i)&nbsp;certain distributions by a
Lower-tier PFIC and (ii)&nbsp;dispositions of shares of Lower-tier PFICs, in each case as if you held your proportionate share of these shares directly, even though you will not receive the proceeds
of those distributions or dispositions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
if we are a PFIC for any taxable year during which you own ADSs or ordinary shares, gain recognized upon a disposition (including, under certain circumstances, a pledge) of
ADSs or ordinary shares will be allocated ratably over your holding period for the ADSs or ordinary shares. The amounts allocated to the taxable year of disposition and to years before we became a
PFIC will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect for that taxable year for individuals or corporations, as
appropriate, and an interest charge will be imposed on the resulting tax liability for each relevant taxable year. Further, to the extent that any distribution received by you on your ADSs or ordinary
shares exceeds 125% of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>272</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=275,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=924449,FOLIO='272',FILE='DISK103:[20ZDS1.20ZDS17601]EQ17601A.;33',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eq17601_1_273"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>average
of the annual distributions on the ADSs or ordinary shares received during the preceding three years or your holding period, whichever is shorter, that distribution will be subject to taxation
in the same manner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are a PFIC for any taxable year during which you own ADSs or ordinary shares, we will generally continue to be treated as a PFIC with respect to you for all succeeding years during
which you own ADSs or ordinary shares, even if we cease to meet the threshold requirements for PFIC status. If we are a PFIC for any taxable year but cease to be PFIC for subsequent years, you should
consult your tax advisor regarding the availability of a "deemed sale" election that would allow you to eliminate the continuing PFIC status under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alternatively,
if we are a PFIC and if our ADSs or ordinary shares are "regularly traded" on a "qualified exchange," you may be able to make a mark-to-market election that would result
in tax treatment different from the general tax treatment described in the preceding paragraphs. Our ADSs will be treated as "regularly traded" in any calendar year in which more than a </FONT> <FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2>
quantity of the ADSs, as the case may be, are traded on a qualified exchange on at least 15&nbsp;days during each calendar quarter. The
Nasdaq Global Market, on which the ADSs expected to be listed, is a qualified exchange for this purpose. If you make the mark-to-market election, you generally will recognize as
ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the
adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market
election). If you make the election, your tax basis in the ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year in
which we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
mark-to-market election) and any remaining loss will be capital loss. There is no provision under U.S. federal income tax law that provides for a right to make a mark-to-market election with respect
to any lower-tier PFICs that are not publicly traded. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not intend to provide the information that would otherwise enable you to make a "qualified electing fund election," which would result in alternate treatment if we were a PFIC for
any taxable year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you own ADSs or ordinary shares during any year in which we are a PFIC, you generally will be required to file annual reports on Internal Revenue Service Form&nbsp;8621 (or any
successor form) with respect to us. Additionally, if we are a PFIC for the taxable year in which we paid a dividend or the prior taxable year, the favorable rate discussed above with respect to
dividends paid to certain non-corporate U.S. Holders would not apply. You should consult your tax adviser regarding our PFIC status for any taxable year and the potential application of the PFIC
rules. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments of dividends and sales proceeds from the sale or exchange of our ADSs or ordinary shares that are made within the United States or
through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&nbsp;you are a corporation or other exempt
recipient or (ii)&nbsp;in the case of backup withholding, you provide a correct taxpayer identification number and certify that you are not subject to backup withholding. Backup withholding is not
an additional tax. The amount of any backup withholding from a payment to you will be allowed as a credit against your U.S. federal income tax liability and may entitle you to a refund, provided that
the required information is timely furnished to the Internal Revenue Service. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
U.S. Holders who are individuals (and certain specified entities) may be required to report information relating to their ownership of ordinary shares, or non-U.S. accounts
through which ADSs or ordinary shares are held. You should consult your tax adviser regarding your reporting obligations with respect to the ADSs or ordinary shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>273</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=276,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=837814,FOLIO='273',FILE='DISK103:[20ZDS1.20ZDS17601]EQ17601A.;33',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_es17601_1_274"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="es17601_underwriting"> </A>
<A NAME="toc_es17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and the underwriters named below have entered into an underwriting agreement with respect to the ADSs being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of ADSs indicated in the following table. Goldman Sachs (Asia)&nbsp;L.L.C., Morgan Stanley&nbsp;&amp; Co. LLC and Jefferies LLC
are the representatives of the underwriters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Underwriters

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number<BR>
of ADSs </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goldman Sachs (Asia)&nbsp;L.L.C.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Morgan Stanley&nbsp;&amp; Co. LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jefferies LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>China Renaissance Securities (Hong Kong) Limited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are committed to take and pay for all of the ADSs being offered, if any are taken, other than the ADSs covered by the option described below unless and until this option
is exercised. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
of the underwriters are expected to make offers and sales both inside and outside the United States through their respective selling agents. Any offers or sales in the United
States will be conducted by broker-dealers registered with the SEC. Goldman Sachs (Asia) L.L.C. will offer ADSs in the United States through its SEC-registered broker-dealer affiliate in the United
States, Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC. China Renaissance Securities (Hong Kong) Limited will offer ADSs in the United States through its SEC-registered broker-dealer affiliate in the
United States, China Renaissance Securities (US) Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have an option to buy up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs from us to cover sales by the underwriters of a greater number of ADSs than the total number set forth in
the table above. They may exercise that option for 30&nbsp;days. If any ADSs are purchased pursuant to this option, the underwriters will severally purchase ADSs in approximately the same proportion
as set forth in the table above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the per ADS and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full
exercise of the underwriters' option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="es17601_paid_by_us"> </A>
<A NAME="toc_es17601_2"> </A>
<BR></FONT><FONT SIZE=2><U>Paid by Us</U>  <BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Full Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per ADS</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs
sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any ADSs sold by the underwriters to
securities dealers may be sold at a discount of up to US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS from the initial public offering price. After the initial offering of the ADSs, the representatives may change
the
offering price and the other selling terms. The offering of the ADSs by the underwriters is subject to receipt and acceptance and subject to the underwriters' right to reject any order in whole or in
part. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[We,
our officers, directors and existing shareholders have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their ordinary
shares or ADSs or securities convertible into or exchangeable for ordinary shares or ADSs during the period from the date of this prospectus continuing through the date 180&nbsp;days after the date
of this prospectus, except with the prior </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>274</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=277,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=226872,FOLIO='274',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_275"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>written
consent of the representatives. This agreement does not apply to any existing employee benefit plans. See "Shares Eligible for Future Sale" for a discussion of certain transfer
restrictions.] </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the offering, there has been no public market for the ADSs. The initial public offering price has been negotiated among the representatives and us. Among the factors to be
considered in determining the initial public offering price of the ADSs, in addition to prevailing market conditions, will be our historical performance, estimates of our business potential and
earnings prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
application has been made to quote the ADSs on the Nasdaq Global Market under the symbol "ADAG". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the offering, the underwriters may purchase and sell ADSs in the open market. These transactions may include short sales, stabilizing transactions and purchases to
cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of ADSs than they are required to purchase in the offering, and a short position represents
the amount of such sales that have not been covered by subsequent purchases. A "covered short position" is a short position that is not greater than the amount of additional ADSs for which the
underwriters' option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional ADSs or purchasing ADSs in the
open market. In determining the source of ADSs to cover the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as
compared to the price at which they may purchase additional ADSs pursuant to the option described above. "Naked" short sales are any short sales that create a short position greater than the amount of
additional ADSs for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing ADSs in the open market. A naked short position is more
likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase
in the offering. Stabilizing transactions consist of various bids for or purchases of ADSs made by the underwriters in the open market prior to the completion of the offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the
representatives have repurchased ADSs sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases
to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a
decline in the market price of our ADSs, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the ADSs. As a result, the price of the
ADSs may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These
transactions may be effected on the Nasdaq Global Market, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate that our share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus in electronic format may be made available on the websites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The
underwriters may agree to allocate a number of ADSs to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>275</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=278,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=564035,FOLIO='275',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_276"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>underwriters
and selling group members that may make internet distributions on the same basis as other allocations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment
banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the
underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for
which they received or will receive customary fees and expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array
of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their
customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise)
and/or persons and entities with
relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express
independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets,
securities and instruments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters do not intend sales to discretionary accounts to exceed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ADSs offered by them. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
address of Goldman Sachs (Asia) L.L.C. is 68th&nbsp;Floor, Cheung Kong Center, 2&nbsp;Queen's Road Central, Hong Kong. The address of Morgan Stanley&nbsp;&amp; Co. LLC is
1585&nbsp;Broadway Avenue, New York, New York&nbsp;10036, United States. The address of Jefferies LLC is 520&nbsp;Madison Avenue, New York, New York&nbsp;10022, United States. The address of
China Renaissance Securities (Hong Kong) Limited is Units&nbsp;8107-08, Level&nbsp;81, International Commerce Centre, 1&nbsp;Austin Road West, Kowloon, Hong Kong. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No action may be taken in any jurisdiction other than the United States that would permit a public offering of the ADSs or the possession,
circulation or distribution of this prospectus in any jurisdiction where action for that purpose is required. Accordingly, the ADSs may not be offered or sold, directly or indirectly, and neither the
prospectus nor any other offering material or advertisements in connection with the ADSs may be distributed or published in or from any country or jurisdiction except under circumstances that will
result in compliance with any applicable laws, rules and regulations of any such country or jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and
to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities
offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>276</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=279,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=281013,FOLIO='276',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_277"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Australia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to certain categories of
exempt persons. Accordingly, if you receive this document in Australia: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>you
confirm and warrant that you are either:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>"sophisticated
investor" under section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act&nbsp;2001&nbsp;(Cth) of Australia, or the Corporations Act;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>"sophisticated
investor" under section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant's certificate to the company
which complies with the requirements of section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>person
associated with the company under section&nbsp;708(12) of the Corporations Act; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>"professional
investor" within the meaning of section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act; </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>and
to the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act, any offer made to you
under this document is void and incapable of acceptance;  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>you
warrant and agree that you will not offer any of the ADSs issued to you pursuant to this document for resale in Australia within 12&nbsp;months of those ADSs
being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bermuda  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which
regulates the sale of securities in Bermuda. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable
Bermuda legislation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


British Virgin Islands  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by us
or on our behalf. The ADSs may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (each a BVI Company), but only where the offer will be made to,
and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus has not been, and will not be, registered with the Financial Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in
respect of the ADSs for the purposes of the Securities and Investment Business Act 2010, or SIBA, or the Public Issuers Code of the British Virgin Islands. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ADSs may be offered to persons located in the British Virgin Islands who are "qualified investors" for the purposes of SIBA. Qualified investors include (i)&nbsp;certain entities
which are regulated by the Financial Services Commission in the British Virgin Islands, including banks, insurance companies, licensees under SIBA and public, professional and private mutual funds;
(ii)&nbsp;a company, any securities of which are listed on a recognized exchange; and (iii)&nbsp;persons defined as "professional investors" under SIBA, which is any person (a)&nbsp;whose
ordinary business involves, whether for that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>277</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=280,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=985944,FOLIO='277',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_278"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>person's
own account or the account of others, the acquisition or disposal of property of the same kind as the property, or a substantial part of our property; or (b)&nbsp;who has signed a
declaration that he, whether individually or jointly with his spouse, has a net worth in excess of US$1,000,000 and that he consents to being treated as a professional investor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 </FONT><FONT SIZE=2><I>Prospectus Exemptions</I></FONT><FONT SIZE=2> or subsection&nbsp;73.3(1) of the </FONT><FONT SIZE=2><I>Securities
Act</I></FONT><FONT SIZE=2> (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the ADSs must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a
legal advisor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National
Instrument&nbsp;33-105 Underwriting Conflicts , or NI&nbsp;33-105, the underwriters are not required to comply with the disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts
of interest in connection with this offering. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cayman Islands  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus does not constitute an invitation or offer to the public in the Cayman Islands of the ADSs, whether by way of sale or
subscription. ADSs or ordinary shares have not been offered or sold, and will not be offered or sold, directly or indirectly, in the Cayman Islands. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dubai International Finance Center  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document relates to an Exempt Offer, as defined in the Offered Securities Rules module of the DFSA Rulebook, or the OSR, in accordance with
the Offered Securities Rules of the Dubai Financial Services Authority. This document is intended for distribution only to Persons, as defined in the OSR, of a type specified in those rules. It must
not be delivered to, or relied on by, any other Person. The Dubai Financial Services Authority has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The
Dubai Financial Services Authority has not approved this document nor taken steps to verify the information set out in it, and has no responsibility for it. The ADSs to which this document relates may
be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the ADSs offered should conduct their own due diligence on the ADSs. If you do not understand the contents of this
document you should consult an authorized financial adviser. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area (each an "</FONT><FONT SIZE=2><B>EEA State</B></FONT><FONT SIZE=2>"), no ADSs
have been offered or will be offered pursuant to the offering contemplated by this prospectus to the public in that EEA State prior to the publication of a prospectus in relation to the ADSs which has
been approved by the competent authority in that EEA State or, where appropriate, approved in another EEA State and notified to the competent authority in that EEA State, all in accordance with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>278</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=281,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=248953,FOLIO='278',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_279"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
EU Prospectus Regulation, except that it may make an offer to the public in that EEA State of any ADSs at any time under the following exemptions under the EU Prospectus
Regulation: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any legal entity which is a qualified investor as defined under the EU Prospectus Regulation;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
fewer than 150 natural or legal persons (other than qualified investors as defined under the EU Prospectus Regulation), subject to obtaining the prior consent of
underwriters for any such offer; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
any other circumstances falling within Article&nbsp;1(4) of the EU Prospectus Regulation, provided that no such offer of the ADSs shall require the Company or
any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the EU Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the EU Prospectus Regulation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to the public" in relation to the ADSs in any EEA State means the communication in any form and by any means of sufficient
information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs, and the expression "</FONT><FONT SIZE=2><B>EU Prospectus
Regulation</B></FONT><FONT SIZE=2>" means Regulation (EU) 2017/1129. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), or (ii)&nbsp;to "professional investors" within the meaning
of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a "prospectus"
within the meaning of the Companies (Winding Up and
Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to the ADSs may be issued or may be in the possession of any person for the
purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to
do so under the laws of Hong Kong) other than with respect to ADSs which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning
of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Israel  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the
Israel Securities Authority. In Israel, this prospectus may be distributed only to, and is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law,
consisting primarily of joint investment in trust funds; provident funds; insurance companies; banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange&nbsp;Ltd.,
underwriters, each purchasing for their own account; venture capital funds; entities with equity in excess of NIS 50&nbsp;million and "qualified individuals," each as defined in the Addendum (as it
may be amended from time to time), collectively referred to as qualified investors. Qualified investors shall be required to submit written confirmation that they fall within the scope of the
Addendum. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs have not been and will not be registered under the Financial Instruments and Exchange Law of Japan, and ADSs will not be offered or
sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>279</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=282,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1020121,FOLIO='279',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_280"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>including
any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to any
exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of
Japan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Korea  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs may not be offered, sold and delivered directly or indirectly, or offered or sold to any person for reoffering or resale, directly or
indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the Korea Securities and Exchange Act and the Foreign Exchange Transaction
Law and the decrees and regulations thereunder. The ADSs have not been registered with the Financial Services Commission of Korea for public offering in Korea. Furthermore, the ADSs may not be resold
to Korean residents unless the purchaser of the ADSs complies with all applicable regulatory requirements (including but not limited to government approval requirements under the Foreign Exchange
Transaction Law and its subordinate decrees and regulations) in connection with the purchase of the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Kuwait  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless all necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No.&nbsp;31/1990 "Regulating the Negotiation
of Securities and Establishment of Investment Funds," its Executive Regulations and the various Ministerial Orders issued pursuant thereto or in connection therewith, have been given in relation to
the marketing and sale of the ADSs, these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any related document), nor any of the information
contained therein is intended to lead to the conclusion of any contract of whatsoever nature within Kuwait. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Malaysia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No prospectus or other offering material or document in connection with the offer and sale of the securities has been or will be registered with
the Securities Commission of Malaysia, or Commission, for the Commission's approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made
the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a
holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the securities as principal, if the offer is on terms that the securities may only be acquired at a consideration of
not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse
exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of
the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual
who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total
net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million
(or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x)&nbsp;an Islamic bank licensee or
takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the
preceding categories&nbsp;(i) to (xi), the distribution of the securities is made by a holder of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>280</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=283,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=986228,FOLIO='280',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_281"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>a
Capital Markets Services License who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not
constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of
a prospectus with the Commission under the Capital Markets and Services Act 2007. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


People's Republic of China  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been and will not be circulated or distributed in China, and ADSs may not be offered or sold, and will not be offered or
sold to any person for re-offering or resale, directly or indirectly, to any PRC resident except pursuant to applicable PRC laws and regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Qatar  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the State of Qatar, the offer contained herein is made on an exclusive basis to the specifically intended recipient thereof, upon that
person's request and initiative, for personal use only and shall in no way be construed as a general offer for the sale of securities to the public or an attempt to do business as a bank, an
investment company or otherwise in the State of Qatar. This prospectus and the underlying securities have not been approved or licensed by the Qatar Central Bank or the Qatar Financial Centre
Regulatory Authority or any other regulator in the State of Qatar. The information contained in this prospectus shall only be shared with any third parties in Qatar on a need
to know basis for the purpose of evaluating the contained offer. Any distribution of this prospectus by the recipient to third parties in Qatar beyond the terms hereof is not permitted and shall be at
the liability of such recipient. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Saudi Arabia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations issued by the Capital Market Authority. The Capital Market Authority does not make any representation as to the accuracy or completeness of this prospectus, and expressly disclaims any
liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due
diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this prospectus you should consult an authorized financial adviser. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of our ADSs may not be circulated or distributed, nor may our ADSs be offered or sold, or be made
the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the
Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions
specified in Section&nbsp;275 of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
our ADSs are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (a)&nbsp;a corporation (which is not an accredited investor as defined in
Section&nbsp;4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
(b)&nbsp;a trust (where the trustee is not an </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>281</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=284,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=578673,FOLIO='281',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_282"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>accredited
investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor; shares, debentures and units of shares and debentures
of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the ADSs
under Section&nbsp;275 of the SFA, except: (1)&nbsp;to an institutional investor (for corporations under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of
the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are
acquired at a consideration of not less than US$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or
other assets, and further for corporations, in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (2)&nbsp;where no consideration is or will be given for the transfer; or
(3)&nbsp;where the transfer is by operation of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


South Africa  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due to restrictions under the securities laws of South Africa, the ADSs are not offered, and the offer shall not be transferred, sold, renounced
or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
offer, transfer, sale, renunciation or delivery is to:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>persons
whose ordinary business is to deal in securities, as principal or agent;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
South African Public Investment Corporation;<BR>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>persons
or entities regulated by the Reserve Bank of South Africa;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>authorized
financial service providers under South African law;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(v)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>financial
institutions recognized as such under South African law;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(vi)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
wholly-owned subsidiary of any person or entity contemplated in (c), (d)&nbsp;or (e), acting as agent in the capacity of an authorized portfolio manager for a
pension fund or collective investment scheme (in each case duly registered as such under South African law); or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(vii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any
combination of the person in (i)&nbsp;to (vi); or<BR>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
"offer to the public" (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or re-enacted) (the "South African Companies Act")) in South
Africa is being made in connection with the issue of the ADSs. Accordingly, this document does not, nor is it intended to, constitute a "registered prospectus" (as that term is defined in the South
African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission
or any other regulatory authority in South Africa. Any issue or offering of the ADSs in South Africa constitutes an offer of the ADSs in South Africa for subscription or sale in South Africa only to
persons who fall within the exemption from "offers to the public" set out in section&nbsp;96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by
persons in South Africa who do not fall within section&nbsp;96(1)(a) of the South African Companies Act (such persons being referred to as "SA Relevant Persons"). Any investment or investment
activity to which this document relates is available in South Africa only to&nbsp;SA Relevant Persons and will be engaged in South Africa only with&nbsp;SA relevant persons. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>282</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=285,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=757990,FOLIO='282',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_283"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Switzerland  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs will not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or
regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
this prospectus nor any other offering or marketing material relating to our company or the ADSs have been or will be filed with or approved by any Swiss regulatory authority. In
particular, this prospectus will not be filed with, and the offer of the ADSs will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of the ADSs has not been and
will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the "CISA"). The investor protection afforded to acquirers of interests in collective investment schemes under the
CISA does not extend to acquirers of the ADSs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Taiwan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs have not been and will not be registered or filed with, or approved by, the Financial Supervisory Commission of Taiwan pursuant to
relevant securities laws and regulations and may not be offered or sold in Taiwan through a public offering or in circumstances which constitute an offer within the meaning of the Securities and
Exchange Act of Taiwan or relevant laws and regulations that require a registration, filing or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been
authorized to offer or sell the ADSs in Taiwan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Arab Emirates  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is not intended to constitute an offer, sale or delivery of shares or other securities under the laws of the United Arab
Emirates, or the UAE. The ADSs have not been and will not be registered under Federal Law No.&nbsp;4 of 2000 Concerning the Emirates Securities and Commodities Authority and the Emirates Security
and Commodity Exchange, or with the UAE Central Bank, the Dubai Financial Market, the Abu Dhabi Securities Market or with any other UAE exchange. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offering, the ADSs and interests therein have not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities in the UAE, and do not constitute a
public offer of securities in the UAE in accordance with the Commercial Companies Law, Federal Law No.&nbsp;8 of 1984 (as amended) or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
relation to its use in the UAE, this prospectus is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person
other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the ADSs may not be offered or sold directly or indirectly to the public in the UAE. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to the United Kingdom, no ADSs have been offered or will be offered pursuant to the offering contemplated by this prospectus to the
public in the United Kingdom prior to the publication of a prospectus in relation to the ADSs which has been approved by the Financial Conduct Authority in accordance with the UK Prospectus
Regulation, except that it may make an offer to the public in the United Kingdom of any ADSs at any time under the following exemptions under the UK Prospectus Regulation: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>283</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=286,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=33703,FOLIO='283',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_es17601_1_284"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of
underwritersfor any such offer; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
any other circumstances falling within Article&nbsp;1(4) of the UK Prospectus Regulation, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>provided
that no such offer of the ADSs shall require the Company or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the UK Prospectus Regulation or supplement a prospectus
pursuant to Article&nbsp;23 of the UK Prospectus Regulation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United Kingdom, the offer is only addressed to, and is directed only at, "qualified investors" within the meaning of Article&nbsp;2(e) of the UK Prospectus Regulation, who are
also (i)&nbsp;persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article&nbsp;19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (the "</FONT><FONT SIZE=2><B>Order</B></FONT><FONT SIZE=2>"); (ii)&nbsp;high net worth bodies corporate, unincorporated associations and
partnerships and trustees of high value trusts as described in Article&nbsp;49(2) of the Order; or (iii)&nbsp;persons to whom it may otherwise lawfully be communicated (all such persons being
referred to as "</FONT><FONT SIZE=2><B>relevant persons</B></FONT><FONT SIZE=2>"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to the public" in relation to the ADSs in the United Kingdom means the communication in any form and by any means of
sufficient information on the terms of the offer and any ADSss to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs, and the expression "</FONT><FONT SIZE=2><B>UK
Prospectus Regulation</B></FONT><FONT SIZE=2>" means the UK version of Regulation (EU) No 2017/1129 as amended by The Prospectus (Amendment etc.) (EU Exit) Regulations&nbsp;2019, which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>284</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=287,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=815853,FOLIO='284',FILE='DISK103:[20ZDS1.20ZDS17601]ES17601A.;41',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_eu17601_1_285"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu17601_expenses_relating_to_this_offering"> </A>
<A NAME="toc_eu17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPENSES RELATING TO THIS OFFERING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, that we expect to incur in connection
with this offering. With the exception of the SEC registration fee, the FINRA filing fee and the Nasdaq listing fee, all amounts are estimates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC Registration Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Listing Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA Filing Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and Engraving Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Fees and Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting Fees and Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
US$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>285</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=288,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=618358,FOLIO='285',FILE='DISK103:[20ZDS1.20ZDS17601]EU17601A.;30',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eu17601_1_286"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu17601_legal_matters"> </A>
<A NAME="toc_eu17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are being represented by Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP with respect to certain legal matters of U.S. federal securities and New
York state law. Certain legal matters with respect to U.S. federal and New York State law in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp;
Watkins&nbsp;LLP. The validity of the ordinary shares represented by the ADSs offered in this offering and other certain legal matters as to Cayman Islands law will be passed upon for us by Walkers
(Hong Kong). Legal matters as to PRC law will be passed upon for us by Tian Yuan Law Firm and for the underwriters by Commerce&nbsp;&amp; Finance Law Offices. Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP may
rely upon Walkers (Hong Kong) with respect to matters governed by Cayman Islands law and Tian Yuan Law Firm with respect to matters governed by PRC law. Latham&nbsp;&amp; Watkins&nbsp;LLP may rely
upon Commerce&nbsp;&amp; Finance Law Offices with respect to matters governed by PRC law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>286</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=289,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=582296,FOLIO='286',FILE='DISK103:[20ZDS1.20ZDS17601]EU17601A.;30',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eu17601_1_287"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu17601_experts"> </A>
<A NAME="toc_eu17601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements as of December&nbsp;31, 2018 and 2019 and for the years then ended included in this Prospectus have been so included
in reliance on the report of PricewaterhouseCoopers Zhong Tian&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offices of PricewaterhouseCoopers Zhong Tian&nbsp;LLP are located at 11<SUP>th</SUP>&nbsp;Floor, PricewaterhouseCoopers Center, Link Square 2, 202 Hu Bin Road, Huangpu
District, Shanghai 200021, the People's Republic of China. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>287</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=290,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=314059,FOLIO='287',FILE='DISK103:[20ZDS1.20ZDS17601]EU17601A.;30',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<A NAME="page_eu17601_1_288"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu17601_where_you_can_find_additional_information"> </A>
<A NAME="toc_eu17601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form&nbsp;F-1 under
the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the
registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as
an exhibit to the registration statement, we refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all
respects by the filed exhibit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
completion of this offering, we will become subject to the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information
with the SEC, including annual reports on Form&nbsp;20-F and reports on Form&nbsp;6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and
other information we have filed electronically with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be
required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>288</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=291,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=571569,FOLIO='288',FILE='DISK103:[20ZDS1.20ZDS17601]EU17601A.;30',USER='CHE106465',CD='31-JAN-2021;15:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fa17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fa17601_index_to_the_consolidated_financial_statements"> </A></FONT> <FONT SIZE=2><B>  INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=1>
<A NAME="FA17601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Consolidated Financial Statements for the Years Ended December&nbsp;31, 2018 and 2019

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>PAGES </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin1"><FONT SIZE=2>F-2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Balance Sheets as of December&nbsp;31, 2018 and 2019</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin2"><FONT SIZE=2>F-3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin3"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Comprehensive Loss for the Years Ended December&nbsp;31, 2018 and 2019</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin3"><FONT SIZE=2>F-4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin4"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Changes in Shareholders' Deficit for the Years Ended December&nbsp;31, 2018 and
2019</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin4"><FONT SIZE=2>F-5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin5"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Cash Flows for the Years Ended December&nbsp;31, 2018 and 2019</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin5"><FONT SIZE=2>F-6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin6"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to the Consolidated Financial Statements for the Years Ended December&nbsp;31, 2018 and 2019</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin6"><FONT SIZE=2>F-7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fa17601_index_to_the_unaudited_interim__ind03006"> </A>
<BR></FONT><FONT SIZE=2><B>  INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Unaudited Interim Condensed Consolidated Financial Statements for the Nine Months Ended September&nbsp;30, 2019 and 2020

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>PAGES </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin7"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Consolidated Balance Sheet as of December&nbsp;31, 2019 and Unaudited Interim Condensed Consolidated Balance Sheet as of
September&nbsp;30, 2020</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin7"><FONT SIZE=2>F-46</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin8"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Nine Months Ended September&nbsp;30, 2019
and 2020</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin8"><FONT SIZE=2>F-47</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin9"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Deficit for the Nine Months Ended
September&nbsp;30, 2019 and 2020</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin9"><FONT SIZE=2>F-48</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin10"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September&nbsp;30, 2019 and
2020</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin10"><FONT SIZE=2>F-49</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#Fin11"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to the Unaudited Interim Condensed Consolidated Financial Statements for the Nine Months Ended September&nbsp;30,
2019 and 2020</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#Fin11"><FONT SIZE=2>F-50</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=292,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=519208,FOLIO='F-1',FILE='DISK103:[20ZDS1.20ZDS17601]FA17601A.;23',USER='CHE107325',CD='29-JAN-2021;10:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fc17601_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fc17601_report_of_independent___fc102279"> </A>
<A NAME="toc_fc17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  <A NAME="Fin1"></A>Report of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To
the Board of Directors and Shareholders of Adagene&nbsp;Inc. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have audited the accompanying consolidated balance sheets of Adagene&nbsp;Inc. and its subsidiaries (the "Company") as of December&nbsp;31, 2019 and 2018, and the related consolidated
statements of comprehensive loss, of changes in shareholders' deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial
statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2018, and the
results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>These
consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a
reasonable basis for our opinion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers Zhong Tian&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Shanghai,
the People's Republic of China<BR>
September 22, 2020 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have served as the Company's auditor since 2020. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=293,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=216122,FOLIO='F-2',FILE='DISK103:[20ZDS1.20ZDS17601]FC17601A.;10',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fe17601_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin2"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fe17601_adagene_inc._consolidated_bala__ada02110"> </A>
<A NAME="toc_fe17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    CONSOLIDATED BALANCE SHEETS    <BR>    <BR>    AS OF DECEMBER 31, 2018 AND 2019    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Current assets:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,058,455</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>92,532,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>33,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accounts receivable, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>480,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Amounts due from related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,170,029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,433,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Prepayments and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,588,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,476,973 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total current assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,816,973</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>103,922,947</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Property, equipment and software, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,550,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,879,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>49,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>87,227 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>TOTAL ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 54,416,916</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>105,889,499</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Current liabilities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>558,977</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>712,714</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Contract liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>993,378</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Amounts due to related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,674,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,895,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accruals and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,574,441</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,540,164</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,207,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Short-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,331,274</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>716,723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Current portion of long-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>322,525 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total current liabilities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,346,355</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,181,283</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Long-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,515,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other non-current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>142,114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>TOTAL LIABILITIES</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 10,488,469</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>8,697,151</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Commitments and contingencies</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT (CONTINUED)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Mezzanine equity:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;A-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,473,957 and 5,473,957 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;A-2 convertible redeemable preferred shares (par value of US$0.0001 per share; 2,370,414 and 2,370,414 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;B convertible redeemable preferred shares (par value of US$0.0001 per share; 7,494,537 and 7,494,537 shares authorized, issued and outstanding
as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;C-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,597,354 and 5,597,354 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>48,481,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>48,727,343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;C-2 convertible redeemable preferred shares (par value of US$0.0001 per share; nil and 1,861,121 shares authorized, issued and outstanding as
of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;C-3 convertible redeemable preferred shares (par value of US$0.0001 per share; nil and 4,452,441 shares authorized, issued and outstanding as
of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,000,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total mezzanine equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 84,955,111</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>154,201,294</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Shareholders' deficit:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ordinary shares (par value of US$0.0001 per share; 500,000,000 and 500,000,000 shares authorized; 15,159,136 and 15,193,136 shares issued and outstanding
as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,519</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Subscriptions receivable from shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(197,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(197,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,405,318</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,789,542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(410,693</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(344,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(46,825,737</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(63,258,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total shareholders' deficit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> (41,026,664</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(57,008,946</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 54,416,916</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>105,889,499</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=294,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=529226,FOLIO='F-3',FILE='DISK103:[20ZDS1.20ZDS17601]FE17601A.;11',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fg17601_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin3"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fg17601_adagene_inc._consolidated_stat__ada03489"> </A>
<A NAME="toc_fg17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS    <BR>    <BR>    FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenues</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Licensing revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,511,168</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>480,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,080,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,211,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,575,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,507,444</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,504,591</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,704,306</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,765,134</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,437,900</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,334,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,169,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>710,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>922,680</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(91,085</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(138,096</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>901,713</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>723,476</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange gain, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,867</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>534,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207,415 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss before income tax</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other comprehensive income (loss)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustments, net of nil tax</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,799 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,277,472</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,366,509</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to ordinary shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,302,843</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678,492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Weighted average number of ordinary shares used in per share calculation:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159,136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159,136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss per ordinary share</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=295,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=895532,FOLIO='F-4',FILE='DISK103:[20ZDS1.20ZDS17601]FG17601A.;17',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fi17601_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin4"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fi17601_adagene_inc._consolidated_stat__ada03971"> </A>
<A NAME="toc_fi17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT    <BR>    <BR>    FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Subscriptions<BR>
receivable<BR>
from<BR>
shareholders </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
other<BR>
comprehensive<BR>
loss </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
paid-in<BR>
capital </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
shareholders'<BR>
deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance as of January&nbsp;1, 2018</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 15,159,136</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>1,516</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(197,068</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>7,687,811</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(399,405</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(32,745,740</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(25,652,886</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(11,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(11,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>126,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>126,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Modification of convertible redeemable preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,186,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,186,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance as of December&nbsp;31, 2018</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 15,159,136</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>1,516</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(197,068</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>6,405,318</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(410,693</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(46,825,737</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(41,026,664</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other comprehensive income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Exercise of share options (Note&nbsp;9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,697</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>611,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>611,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance as of December&nbsp;31, 2019</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 15,193,136</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>1,519</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(197,068</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>6,789,542</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(344,894</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(63,258,045</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(57,008,946</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=296,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=973328,FOLIO='F-5',FILE='DISK103:[20ZDS1.20ZDS17601]FI17601A.;9',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fk17601_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin5"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fk17601_adagene_inc._consolidated_stat__ada03130"> </A>
<A NAME="toc_fk17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF CASH FLOWS    <BR>    <BR>    FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>909,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>816,686</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gain on disposal of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,841</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>611,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(534,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,207,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange gain, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,867</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts receivable, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(480,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepayments and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,337,063</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amount due from related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>268,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(704,253</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(28,808</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(38,040</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>389,124</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>153,737</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contract liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>993,378</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amount due to related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,135,397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,778,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(913,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(34,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(142,114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash used in operating activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,264,665</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,153,556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Placement of short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(58,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Withdrawal of short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from disposal of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,697</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchase of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(514,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(151,829</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash (used in) generated from investing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,509,537</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,855,868 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,417,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,651,874</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of convertible redeemable preferred shares and warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,033</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>68,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from exercise of share options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>459,796</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,360,051</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,417,192</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash generated from financing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51,057,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69,694,477 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate on cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>38,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>77,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase in cash and cash equivalents</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,322,351</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>76,474,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at the beginning of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,736,104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,058,455 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the end of year</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,058,455</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>92,532,788 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental cashflow disclosures:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest paid</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,085</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>142,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-cash activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=297,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1024439,FOLIO='F-6',FILE='DISK103:[20ZDS1.20ZDS17601]FK17601A.;11',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fm17601_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin6"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fm17601_adagene_inc._notes_to_the_cons__ada03491"> </A>
<A NAME="toc_fm17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS    <BR>    <BR>    FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. ORGANIZATION AND BASIS OF PRESENTATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene&nbsp;Inc. (the "Company") is a limited liability company incorporated in the Cayman Islands on February&nbsp;25, 2011. The Company, together with its subsidiaries
(collectively, the "Group") are principally engaged in research, development and production of monoclonal antibody drugs for cancers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2019, the Company's principal subsidiaries are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="91pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="124pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Entity

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of<BR>
incorporation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Place of<BR>
incorporation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of legal<BR>
ownership<BR>
by the Company </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal activities </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adagene (Hong Kong) Limited</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>December&nbsp;12, 2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Hong Kong</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Investment holding</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adagene Incorporated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;20, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>The United States of America</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>Research and development<BR>
of innovative medicines</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adagene (Suzhou) Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>February&nbsp;28, 2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>The People's Republic of China ("PRC" or "China")</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>Research and development<BR>
of innovative medicines</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adagene Australia PTY&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>May&nbsp;30, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>Australia</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>Research and development<BR>
of innovative medicines</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of presentation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompany consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles
("U.S.&nbsp;GAAP"). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principles of Consolidation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant
intercompany balances and transactions have been eliminated upon consolidation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of estimates  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting
periods. Significant estimates and assumptions reflected in the Group's consolidated financial statements include, but are not limited to, the useful lives and impairment of long-lived assets, tax
valuation allowance, share-based compensation expenses and the fair value of warrant liabilities. Management bases the estimates on historical experience and various other assumptions that are
believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=298,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1557,FOLIO='F-7',FILE='DISK103:[20ZDS1.20ZDS17601]FM17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fm17601_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign currency translation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The functional currency of the Company, Adagene (Hong Kong) Limited and Adagene Incorporated is the United States dollar ("US$"). The functional
currency of the Company's PRC subsidiary is Renminbi ("RMB"). The functional currency of the Company's Australia subsidiary is Australian dollar ("AU$"). The determination of the respective functional
currency is based on the criteria stated in Accounting Standard Codification ("ASC") 830, </FONT><FONT SIZE=2><I>Foreign Currency Matters</I></FONT><FONT SIZE=2>. The Company uses US$ as its
reporting currency. The financial statements of the Company's PRC and Australia subsidiaries are translated from the functional currency to the reporting currency. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transactions
denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People's Bank of China (the "PBOC") prevailing on the
transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in
terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements
of comprehensive loss. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets
and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and
losses are translated using the average rate for the year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in
the consolidated statements of comprehensive loss. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash and cash equivalents  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments
that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three months or less to be cash equivalents. All cash and cash equivalents are
unrestricted as to withdrawal and use. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Short-term investments  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments are deposits at bank with maturities of greater than three months, but less than twelve months. Short-term investments
are stated at cost, which approximates fair value. Interest earned is included in interest income. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accounts receivable and allowance for doubtful accounts  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the
passage of time is required before payment of that consideration is due. Accounts receivable are carried at net realizable value. An allowance for doubtful accounts is recorded in the period when
collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer's
payment history, its current credit-worthiness and other factors. Accounts receivable are written off when management determines a balance is uncollectable after all collection efforts have ceased. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=299,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=788003,FOLIO='F-8',FILE='DISK103:[20ZDS1.20ZDS17601]FM17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fm17601_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair value measurements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group applies ASC 820, </FONT><FONT SIZE=2><I>Fair Value Measurements and Disclosures</I></FONT><FONT SIZE=2>. ASC 820 defines fair value,
establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a
three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>Level&nbsp;1&#151;Observable
inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Level&nbsp;2&#151;Includes
other inputs that are directly or indirectly observable in the marketplace. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Level&nbsp;3&#151;Unobservable
inputs which are supported by little or no market activity. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC
820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&nbsp;market approach; (2)&nbsp;income approach; and (3)&nbsp;cost approach. The
market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to
convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the
amount that would currently be required to replace an asset. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
carrying amounts of cash and cash equivalent, short-term investments, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to
related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term
borrowings approximate their fair values since they bear interest rates which approximate market interest rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
more fully described in Note&nbsp;8, the Group has issued warrants to purchase its preferred shares. The Group measured its warrant liabilities at fair value on a recurring basis.
As the Group's warrants are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of warrant liabilities. These
instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents a reconciliation of all financial instruments measured at fair value on a recurring basis using Level&nbsp;3 unobservable inputs: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Warrant liabilities </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial recognition during the year ended December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,741,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value change</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(534,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,207,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value change</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,207,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=300,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=938898,FOLIO='F-9',FILE='DISK103:[20ZDS1.20ZDS17601]FM17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fm17601_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group did not transfer any assets or liabilities in or out of Level&nbsp;3 during the years ended December&nbsp;31, 2018 and 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&nbsp;31, 2018 and 2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property, equipment and software  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed
using the straight-line method over the estimated useful lives of the assets as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="234pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Category

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Useful Life </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Machinery and laboratory equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vehicles</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>4&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and tools</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3&nbsp;- 5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Electronic equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3&nbsp;- 5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Lesser of lease terms or estimated useful lives of the assets</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repair
and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are
capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and
accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of long-lived assets  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying
amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is
less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined
by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is
depreciated over the assets' remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of
the cash flows of other assets and liabilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
impairment loss was recorded for the years ended December&nbsp;31, 2018 and 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=301,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=452591,FOLIO='F-10',FILE='DISK103:[20ZDS1.20ZDS17601]FM17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fm17601_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment reporting  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with ASC 280, </FONT><FONT SIZE=2><I>Segment Reporting</I></FONT><FONT SIZE=2>, the Group's chief operating decision maker
("CODM") has been identified as the Chief Executive Officer. The Group's CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance
of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as substantially all of the Group's long-lived assets are located in the PRC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue recognition  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the
scope of ASC 808, </FONT><FONT SIZE=2><I>Collaborative Arrangements</I></FONT><FONT SIZE=2> ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope
of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a
vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is
determined and applied consistently. Under the criteria of Accounting Standard Codification ("ASC")&nbsp;606, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers</I></FONT><FONT SIZE=2>
(Topic&nbsp;606) ("ASC&nbsp;606"), the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which
the entity expects to receive in exchange for those goods or services. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations
in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and
(v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect
substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance
obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount
of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licenses of Intellectual Property:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upfront non-refundable payments for licensing the Group's intellectual property are evaluated to
determine if the
license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees
allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=302,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=750020,FOLIO='F-11',FILE='DISK103:[20ZDS1.20ZDS17601]FM17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fm17601_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Milestone Payments:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments,
 the Group
evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to
be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for
which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of
achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up
basis, which would affect revenues and earnings in the period of adjustment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the
license is deemed
to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which
some or all of the royalty has been allocated has been satisfied (or partially satisfied). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, no milestone payments or royalty payments were received. Substantially all of the Group's revenue has been derived from its out-licensing agreements with respect to licensed
products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the
customer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contract assets and contract liabilities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability;
When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights
to consideration as a contract asset. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elements of research and development expenses primarily include (1)&nbsp;payroll and other related costs of personnel engaged in research and
development activities, (2)&nbsp;costs related to pre-clinical testing of the Group's technologies under development and clinical trials such as payments to contract research organizations ("CRO")
and contract manufacturing organizations ("CMO"), investigators and clinical trial sites that conduct the clinical studies; (3)&nbsp;costs to develop the product candidates, including raw materials
and supplies, product testing, depreciation and amortization, and facility related expenses, (4)&nbsp;other research and development expenses. Research and development expenses are charged to
expense as incurred when these expenditures relate to the Group's research and development services and have no alternative future uses. As of December&nbsp;31, 2019, the Group has several ongoing
clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group's option. The Group did not record any accrued expenses related
to cancellation of CRO or CMO contracts as of December&nbsp;31, 2019 as the Group did not have any plan to cancel the existing CRO or CMO contracts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=303,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=193989,FOLIO='F-12',FILE='DISK103:[20ZDS1.20ZDS17601]FM17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fo17601_1_13"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government subsidies  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their
jurisdictions and compliance with specific policies promoted by the governments. The Group's PRC based subsidiary received government subsidies from certain local government. The Group's government
subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies
that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or
performance of the Group and the amounts do not have to be refunded under any circumstances. The Group recorded specific subsidies as other non-current liabilities when received and recognized as
other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Leases  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leases are classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if
any of the following conditions exists: a)&nbsp;ownership is transferred to the lessee by the end of the lease term, b)&nbsp;there is a bargain purchase option, c)&nbsp;the lease term is at
least 75% of the property's estimated remaining economic life or d)&nbsp;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the
fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception
of the lease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office
space under non-cancelable operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over
the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive loss  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances
excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive loss of the Group includes foreign currency translation adjustments
related to the Group and its subsidiaries whose functional currency is not US$. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group follows the liability method of accounting for income taxes in accordance with ASC&nbsp;740, </FONT><FONT SIZE=2><I>Income
Taxes</I></FONT><FONT SIZE=2> ("ASC&nbsp;740"). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets
and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if
based on </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=304,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=498237,FOLIO='F-13',FILE='DISK103:[20ZDS1.20ZDS17601]FO17601A.;16',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fo17601_1_14"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is
recognized in tax expense in the period that includes the enactment date of the change in tax rate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized
in the consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group recognizes in the consolidated financial statements the benefit of a tax position which is "more likely than not" to be sustained under examination based solely on the
technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability
approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group's policy to recognize interest and penalties related
to unrecognized tax benefits, if any, as a component of income tax expense. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any
difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the
effective interest method. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share-based compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group applies ASC 718, </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation</I></FONT><FONT SIZE=2> ("ASC 718"), to account
for its employee share-based payments awards granted to certain directors, executives and employees. Share options granted are classified as equity awards and are measured based on the grant date fair
value of the equity instrument issued, and recognized as compensation costs using the straight-line method over the requisite service period, which is generally the vesting period of the share
options, with a corresponding impact reflected in additional paid-in capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification
as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group
recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the
remaining unrecognized
compensation expense for the original awards over the remaining requisite service period after modification. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net loss per share  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with ASC 260, </FONT><FONT SIZE=2><I>Earnings Per Share</I></FONT><FONT SIZE=2>, basic net loss per share is computed by dividing
net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net
loss is allocated between ordinary shares and other participating securities based on dividends declared (or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=305,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=102204,FOLIO='F-14',FILE='DISK103:[20ZDS1.20ZDS17601]FO17601A.;16',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fo17601_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>accumulated)
and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company's convertible redeemable preferred shares are
participating securities because they are entitled to receive dividends or distributions on an as converted basis. Diluted net loss per share is calculated by dividing net loss attributable to
ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during
the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible redeemable preferred shares using the if-converted method, and ordinary shares issuable
upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For
the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not
have contractual rights and obligations to share in the losses of the Group. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee defined contribution plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care,
welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on
certain percentages of the qualified employees' salaries. The Group is required to make contributions to the plans out of the amounts accrued. The
PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group's obligations are limited to the amounts contributed. The Group has no
further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$947,244 and US$1,145,165 for the years ended December&nbsp;31, 2018 and 2019,
respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentration of risks  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentration of credit risk  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018 and 2019, the aggregate amount of cash and cash equivalents and short-term investments of US$422,210 and
US$801,923 respectively, were held at major financial institutions located in the PRC, and US$48,636,245 and US$99,730,865, respectively, were deposited with major financial institutions located
outside the PRC. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts
receivable are typically unsecured and denominated in US$ and are derived from revenues earned from customers. As of December&nbsp;31, 2019, the accounts receivable balance is
from one customer. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=306,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=994261,FOLIO='F-15',FILE='DISK103:[20ZDS1.20ZDS17601]FO17601A.;16',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fo17601_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentration of suppliers  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of the Group's research and development services were purchased from its one supplier, who collectively accounted for
40.67% and 23.13% of the Group's total research and development services purchases for the years ended December&nbsp;31, 2018 and 2019, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Business and economic risk  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group believes that changes in any of the following areas could have a material adverse effect on the Group's future consolidated financial
position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry
standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group's ability to attract employees necessary to support its growth. The Group's
operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign currency exchange rate risk  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of the Group's businesses are transacted in RMB, which is not a freely convertible currency. On January&nbsp;1, 1994,
the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the People's Bank of China (the "PBOC"). However, the unification of the exchange rates
does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized
to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form
together with suppliers' invoices, shipping documents and signed contracts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
July&nbsp;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was
appreciation of approximately 5.7% and 1.3% in the years ended December&nbsp;31, 2018 and 2019, respectively. It is
difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
functional currency and the reporting currency of the Company are the US$. However, most of the expenses of the Group are denominated in RMB. Any significant fluctuation of the
valuation of RMB may materially affect the Group's cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group is an emerging growth company ("EGC") as defined by the Jumpstart Our Business Startups Act ("JOBS Act"). The JOBS Act provides that
an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those
standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be
classified as an EGC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=307,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=108859,FOLIO='F-16',FILE='DISK103:[20ZDS1.20ZDS17601]FO17601A.;16',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fo17601_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU No.&nbsp;2016-02 ("ASU 2016-02"), Leases (Topic&nbsp;842), which modifies lease accounting for lessees to increase transparency and
comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No.&nbsp;2018-10 ("ASU
2018-10"), Codification Improvements to Topic&nbsp;842, Leases, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No.&nbsp;2018-11 ("ASU 2018-11"), Leases
(Topic&nbsp;842): Targeted Improvements, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity
initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an
entity's reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic&nbsp;840,
Leases). In November 2019, the FASB issued ASU No.&nbsp;2019-10, Financial Instruments&#151;Credit Losses (Topic&nbsp;326), Derivatives and Hedging (Topic&nbsp;815), and Leases
(Topic&nbsp;842), Effective Dates ("ASU 2019-10"), which extends the adoption date for certain registrants. The updated guidance is effective for the Group for annual reporting periods beginning
January&nbsp;1, 2021 and interim periods within annual periods beginning January&nbsp;1, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards and the
Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use
assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2016, the FASB issued ASU No.&nbsp;2016-13, Financial Instruments&#151;Credit Losses (Topic&nbsp;326): Measurement of Credit Losses on Financial Instruments ("ASU
2016-13"). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other
organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and
supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit
losses, as well as the credit quality and underwriting standards of the Group's portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about
the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective
for fiscal years beginning after December&nbsp;15, 2022, including interim periods within fiscal years beginning after December&nbsp;15, 2023. The Group does not plan to early adopt ASU 2016-13
and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2018, the FASB issued ASU No.&nbsp;2018-07, Compensation&#151;Stock Compensation (Topic&nbsp;718): Improvements to nonemployee share-based payment accounting ("ASU
2018-07"). The amendments in this update expand the scope of Topic&nbsp;718 to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments are
effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted, but no earlier than
an entity's adoption date of Topic&nbsp;606. The Group adopted on January&nbsp;1, 2018 this guidance which do not have a significant impact on the consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=308,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=840059,FOLIO='F-17',FILE='DISK103:[20ZDS1.20ZDS17601]FO17601A.;16',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fq17601_1_18"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2018, the FASB issued ASU No.&nbsp;2018-13, Fair Value Measurement (Topic&nbsp;820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value
Measurement ("ASU&nbsp;2018-13"). ASU&nbsp;2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The amendments in
ASU&nbsp;2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2019. The amendments on changes in unrealized
gains and losses, the range and weighted average of significant unobservable inputs used to develop Level&nbsp;3 fair value measurements, and the narrative description of measurement uncertainty
should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all
periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU
2018-13 and delay adoption of the additional disclosures until their effective date. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The
impact of this ASU to the consolidated financial statements is immaterial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic&nbsp;606. This update clarifies that
certain transactions between participants in a collaborative arrangement should be accounted for under ASC&nbsp;606 when the counterparty is a customer and precludes an entity from presenting
consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal
years beginning after December&nbsp;15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC&nbsp;606. This guidance should be applied
retrospectively to the date of initial application of Topic&nbsp;606. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this
ASU to the consolidated financial statements is immaterial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This update simplifies the accounting for income taxes as part of
the FASB's overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC&nbsp;740, </FONT> <FONT SIZE=2><I>Income taxes</I></FONT><FONT SIZE=2>, and
simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on
income. The update is effective in fiscal years beginning after December&nbsp;15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be
applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU&nbsp;2019-12 and is currently evaluating the
impact on its financial statements of adopting this guidance. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=309,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=996864,FOLIO='F-18',FILE='DISK103:[20ZDS1.20ZDS17601]FQ17601A.;22',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fq17601_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. ACCOUNTS RECEIVABLE, NET  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts receivable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>480,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Allowance for doubtful accounts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>480,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. PREPAYMENTS AND OTHER CURRENT ASSETS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepayments and other current assets consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deposits(a)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>970,407</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>970,394</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest receivables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260,173</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>227,278</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepayments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>295,476</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Others</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,866 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,588,489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,476,973 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <P style="font-family:times;"><FONT SIZE=1>Note&nbsp;(a):
The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO
agreement. The Group expects to recover the deposits when the programs end. </FONT></P>
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. PROPERTY, EQUIPMENT AND SOFTWARE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, equipment and software consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Machinery and laboratory equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,408,277</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,462,343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>779,837</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>767,205</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Electronic equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>576,421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>605,882</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and tools</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,396</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vehicles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81,452</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71,056 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total property, equipment and software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,010,764</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,085,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,460,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,205,690</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net book value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,550,756</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,879,325 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
and amortization expenses recognized for the years ended December&nbsp;31, 2018 and 2019 were US$909,002 and US$816,686, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=310,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=532009,FOLIO='F-19',FILE='DISK103:[20ZDS1.20ZDS17601]FQ17601A.;22',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fq17601_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. ACCRUALS AND OTHER CURRENT LIABILITIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities and other current liabilities consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll and related liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,230,898</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,370,523</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Professional service fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>93,801</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Utility and maintenance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,595</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other taxes and surcharge</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,982</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Others</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>114,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,889 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,574,441</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,540,164 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. BORROWINGS  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term borrowings:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank loans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,331,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>716,723</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current portion of long-term borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>322,525 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,331,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,039,248 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-Current</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term borrowings:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank loans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,515,868 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total non-current borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,515,868 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total borrowings</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,331,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,555,116 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Short-term borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2017, the Group borrowed a loan with amount of RMB4,000,000 (equivalent to approximately US$612,164) from Agricultural Bank of China
Limited for a term of one year and at the interest rate of 4.79% per annum. The borrowing was guaranteed by Peter Luo, who is the Chairman, Chief Executive Officer and a principal shareholder of the
Company. The borrowing was repaid in March 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the Group borrowed a loan with the amount of RMB3,000,000 (equivalent to approximately US$459,123) from Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and at
the interest rate of 4.79% per annum and the borrowing was repaid in May 2018. In June 2017, the Group borrowed a loan with the amount of RMB2,000,000 (equivalent to approximately US$306,082) from
Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 4.79% per annum. The borrowing was repaid in June 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=311,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=985597,FOLIO='F-20',FILE='DISK103:[20ZDS1.20ZDS17601]FQ17601A.;22',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fq17601_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. BORROWINGS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2018, the Group borrowed a loan with the amount of RMB3,000,000 (equivalent to approximately US$437,114) from Bank of Jiangsu&nbsp;Co.,&nbsp;Ltd. for a term of one year and
at the interest rate of 5.22% per annum. The borrowing was repaid in March 2019. In June 2018, the Group borrowed a loan with the amount of RMB2,000,000 (equivalent to approximately US$291,409) from
Bank of Jiangsu&nbsp;Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 5.22% per annum. The borrowing was repaid in June 2019. These borrowings with Bank of
Jiangsu&nbsp;Co.,&nbsp;Ltd were guaranteed by Peter Luo and Kristine She. Peter Luo is the Chairman, Chief Executive Officer and a principal shareholder of the Company. Kristine She is one of the
senior management personnel of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2018, the Group borrowed a loan with the amount of RMB3,000,000 (equivalent to approximately US$437,114) from Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and at
the interest rate of 5.00% per annum. The borrowing was repaid in May 2019. In June 2018, the Group borrowed a loan with the amount of RMB2,000,000 (equivalent to approximately US$291,409) from Bank
of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 5.00% per annum. The borrowing was repaid in June 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2018, the Group borrowed a loan with amount of RMB6,000,000 (equivalent to approximately US$874,228) from Agricultural Bank of China Limited for a term of one year and at the
interest rate
of 5.22% per annum. The borrowing was guaranteed by Peter Luo, who is the Chairman, Chief Executive Officer and a principal shareholder of the Company. The borrowing was repaid in July 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2019, the Group borrowed a loan with amount of RMB5,000,000 (equivalent to approximately US$716,723) from Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and
at the interest rate of 4.35% per annum. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-term borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2019, the Group borrowed a loan with amount of RMB7,500,000 (equivalent to approximately US$1,075,084) from Shanghai Pudong
Development Bank&nbsp;Co.,&nbsp;Ltd. for a term of three years and at the interest rate of 5.46% per annum. The Group repaid RMB375,000 (equivalent to approximately US$53,754) in August 2019. As
of December&nbsp;31, 2019, RMB1,250,000 (equivalent to approximately US$179,181) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2019, the Group borrowed a loan with amount of RMB6,000,000 (equivalent to approximately US$860,067) from Shanghai Pudong Development Bank&nbsp;Co.,&nbsp;Ltd. for a term of
three years and at the interest rate of 5.23% per annum. The Group repaid RMB300,000 (equivalent to approximately US$43,004) in December 2019. As of December&nbsp;31, 2019, RMB1,000,000 (equivalent
to approximately US$143,344) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing". </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=312,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=233966,FOLIO='F-21',FILE='DISK103:[20ZDS1.20ZDS17601]FQ17601A.;22',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fq17601_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. BORROWINGS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Future maturities of short-term borrowings and long-term borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future principal maturities of short-term borrowings and long-term borrowings as of December&nbsp;31, 2019 are as followings: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,039,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>870,818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>645,050 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,555,116 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2011, the Company issued convertible notes ("Series Pre-A Convertible Notes") to certain investors in the amount of 4,590,908. The notes carried a simple interest
(non-compounding) of 6% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the
convertible redeemable preferred shares of the Company at a price no more than US$1 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2014, the Company issued 5,473,957 Series&nbsp;A-1 convertible redeemable preferred shares ("Series&nbsp;A-1 Preferred Shares") to certain investors upon conversion of
the Company's Series Pre-A convertible notes at a conversion price of US$1 per share. Concurrently, the Company issued 2,370,414 Series&nbsp;A-2 convertible redeemable preferred shares
("Series&nbsp;A-2 Preferred Shares") to certain investors at US$1.27 per share for a total consideration of US$3,000,000. Series&nbsp;A-1 Preferred Shares and Series&nbsp;A-2 Preferred Shares
are collectively referred to as the Series&nbsp;A Preferred Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
January through June 2016, the Company issued 7,494,537 Series&nbsp;B convertible redeemable preferred shares ("Series&nbsp;B Preferred Shares") to certain investors at US$3.74
per share for a total consideration of US$27,999,995. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
February through May 2018, the Company issued 5,597,354 Series&nbsp;C-1 convertible redeemable preferred shares ("Series&nbsp;C-1 Preferred Shares") to certain investors at
US$8.93 per share for a total consideration of US$50,000,033. Concurrently, in February 2018, the Company also issued warrants to two Series&nbsp;C-1 investors at nil consideration
("Series&nbsp;C-1 Warrants"). The Series&nbsp;C-1 Warrants allowed the holders to purchase Series&nbsp;C-2 Preferred Shares (defined below) at the exercise price of US$10.21 per share for a
total consideration of up to US$7,500,000. Series&nbsp;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&nbsp;April&nbsp;1,
2019, ii)&nbsp;a deemed liquidation event or iii)&nbsp;the closing of the Qualified IPO. Series&nbsp;C-1 Warrants expired on April&nbsp;1, 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
June through November 2019, the Company issued 1,861,121 Series&nbsp;C-2 convertible redeemable preferred shares ("Series&nbsp;C-2 Preferred Shares") to certain investors at
US$10.21 per share for a total consideration of US$18,999,999. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=313,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=103412,FOLIO='F-22',FILE='DISK103:[20ZDS1.20ZDS17601]FQ17601A.;22',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fq17601_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2019, the Company issued 4,452,441 Series&nbsp;C-3 convertible redeemable preferred shares ("Series&nbsp;C-3 Preferred Shares") to a certain investor at US$11.23 per
share for a total consideration of US$50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series&nbsp;C-1
Preferred Shares, Series&nbsp;C-2 Preferred Shares and Series&nbsp;C-3 Preferred Shares are collectively referred to as the Series&nbsp;C Preferred Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
key features of the Series&nbsp;A Preferred Shares, Series&nbsp;B Preferred Shares and Series&nbsp;C Preferred Shares (collectively the "Preferred Shares") are as follows: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of the Preferred Shares will be entitled to receive non-cumulative dividends when declared by the Board of Directors prior and in
preference to ordinary shareholders. The dividend should be paid at the rate of 6% of the original issue price per share per annum on each Preferred Shares in the sequence of Series&nbsp;C Preferred
Shares and Preferred Shares other than the Series&nbsp;C Preferred Shares. After the preferential dividends relating to the Preferred Shares have been paid in full or declared and set apart in any
fiscal year of the Company, any additional dividends out of funds or assets legally available therefore may be declared in that fiscal year for the Shares and, if such additional dividends are
declared, the preferred shareholders shall be entitled to participate on an as converted-basis pro-rata in any dividends or distributions paid to the ordinary shareholders. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Preferred Share has voting rights equivalent to the number of ordinary shares to which it is convertible at the record date. The Preferred
Shares shall vote separately as a class with respect to certain specified matters. Otherwise, the preferred shareholders and ordinary shareholders shall vote together as a single class. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation preference  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution or winding up of the Company, or the cessation of the business of the Company or of a substantial
portion of the business of the Company, whether voluntary or involuntary, or any deemed liquidation event (unless waived by the preferred shareholders), the preferred shareholders shall be entitled to
receive a per share amount equal to 100% of the original issue price of the respective series of the Preferred Shares, in the sequence of Series&nbsp;C Preferred Shares, Series&nbsp;B Preferred
Shares and Series&nbsp;A Preferred Shares. After such liquidation amounts have been paid in full, the preferred shareholders are entitled to receive a simple interest accruing on each Preferred
Share at 6% of its original issue price per annum from the date of issuance of such Preferred Share to the date of distribution of such amount, in the sequence of Series&nbsp;C Preferred Shares,
Series&nbsp;B Preferred Shares and Series&nbsp;A Preferred Shares. After such interest amounts have been paid in full, any remaining funds or assets of the Company legally available for
distribution to shareholders shall be distributed on a pro rata basis among the preferred shareholders, on an as-converted basis, together with the ordinary shareholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=314,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=570420,FOLIO='F-23',FILE='DISK103:[20ZDS1.20ZDS17601]FQ17601A.;22',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fs17601_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shareholders based on the then-effective
conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of share splits, share combinations, ordinary share dividends or distributions, other dividends,
reorganizations, mergers, consolidations, reclassifications, exchanges, substitutions, or dilutive issuance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Preferred Shares are converted automatically into ordinary shares at the then effective applicable conversion price upon the earlier of a Qualified Public Offering (public offering
of the Company's shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than
US$650,000,000 and with an aggregate proceeds of no less than US$75&nbsp;million)or a date specified by written consent or agreement of the holders of at least 80% of the voting power of the then
outstanding Preferred Shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Shares are redeemable upon request by the holders of the majority outstanding Preferred Shares if the Company fails to consummate
a Qualified Public Offering or complete a deemed liquidation event on or before March&nbsp;31, 2025 at the redemption price equal to the original issue price plus any declared but unpaid dividends. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accounting for Preferred Shares  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Shares are classified as mezzanine equity in the consolidated balance sheets because they are contingently redeemable upon the
occurrence of an event outside of the Company's control (e.g.&nbsp;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&nbsp;31, 2025 ("Target QIPO
Date")). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares are
initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any
Preferred Shares issued. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company concluded that the Preferred Shares are not currently redeemable, but are probable to become redeemable. The Company accreted changes in the redemption value over the period
from the date of issuance to the earliest redemption date using the interest method. No accretion charge was recorded as the redemption value is fixed to original issue price for the years presented,
except for Series&nbsp;C-1 Preferred Shares issued with detachable warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Modification of Preferred Shares  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company made several amendments to the Preferred Shares, mainly including: 1)&nbsp;added redemption rights for Series&nbsp;A Preferred
Shares upon the issuance of the Series&nbsp;B Preferred Shares; 2)&nbsp;extended the Target QIPO Date upon the issuance of the Series&nbsp;C-1 Preferred Shares and the Series&nbsp;C-3
Preferred Shares. These amendments are accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=315,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=856251,FOLIO='F-24',FILE='DISK103:[20ZDS1.20ZDS17601]FS17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<A NAME="page_fs17601_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>not
significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred
shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;2, 2018, the Target QIPO Date was extended from January&nbsp;19, 2023 to February&nbsp;2, 2025 (7th&nbsp;anniversary of Series&nbsp;C-1 closing) upon issuance
of Series&nbsp;C-1 Preferred Shares. On the date of the modifications, the Company assessed the total fair value of preferred shares immediately before and after the change of the terms with the
assistance from an independent third-party appraiser. The combined change in fair value of Preferred Shares immediately before and after the modification was US$1,186,187. The increase in fair value
of the ordinary shares of is US$1,186,187, in substance, a transfer of wealth mostly from the preferred shareholders to the ordinary shareholder, and therefore are recorded as deemed contribution from
the Preferred Shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's Preferred Shares activities for the periods presented are summarized below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Mezzanine equity

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A-1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A-2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;B </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C-1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C-2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C-3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,473,952</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;C-1 Preferred Shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,258,313</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,258,313</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of Series&nbsp;C-1 Preferred Shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>222,846 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,481,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84,955,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;C-2 Preferred Shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;C-3 Preferred Shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of Series&nbsp;C-1 Preferred Shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,184 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,727,343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154,201,294 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
warrants are freestanding instruments and classified as liabilities in accordance with ASC 480. The warrants are initially recognized at fair value, with subsequent changes in fair
value recorded currently in earnings. The Company recognized gains from the decrease in fair value of the warrants of US$534,305 and US$1,207,415 for the years ended December&nbsp;31, 2018 and 2019,
respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has measured the warrant liabilities at fair values on a recurring basis using significant unobservable inputs (Level&nbsp;3) for the years ended December&nbsp;31, 2018.
The Group used the Black-Scholes option pricing model to estimate the fair value of warrant liabilities using the following assumptions: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year<BR>
ended<BR>
December&nbsp;31,<BR>
2018 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.92%, 2.37%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>US$10.2089</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturity date</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/04/2019</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Estimated volatility rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63.78%, 71.00%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=316,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=472040,FOLIO='F-25',FILE='DISK103:[20ZDS1.20ZDS17601]FS17601A.;24',USER='CHE107555',CD='29-JAN-2021;09:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fu17601_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The model requires the input of highly subjective assumptions including the risk-free rate interest rate, maturity date, estimated volatility rate and fair value of underlying preferred
shares. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates. For expected
volatilities, the Company has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Company. The estimated
fair value of the preferred shares was determined with assistance from an independent third-party valuation firm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free interest rate, interval between valuation date and maturity date,
estimated volatility rate and fair value of underlying preferred shares. Significant decreases in interval between valuation date and maturity date, estimated volatility rate and fair value of
underlying preferred shares would result in a significantly lower fair value measurement. Significant increases in risk-free interest rate would result in a significantly lower fair value measurement. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. SHARE-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;7, 2015, the Company adopted a share incentive plan ("2015 Plan"). Under the 2015 Plan, the Company's Board of Directors has approved that a maximum aggregate number
of shares that may be issued pursuant to all awards granted shall be 4,336,126. In September 2017, the Company replaced 2015 Plan with the amended and restated share incentive plan ("2017 Plan") and
increased the maximum number of shares issuable to 6,336,126. In December 2019, the Company replaced 2017 Plan with the second amended and restated share incentive plan ("2019 Plan") and further
increased the maximum number of shares issuable to 11,391,131. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the
Company may issue under the respective plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
options granted to each grantee under the Share Inventive Plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting
schedule. Grantees are generally subject to a vesting schedule of no longer than five years, under which the grantee earns an entitlement to vest a certain percentage of his option grants at the end
of each month </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=317,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=48868,FOLIO='F-26',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. SHARE-BASED COMPENSATION (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>or
year of completed service. The share option awards shall expire no more than 10&nbsp;years from their grant dates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average<BR>
Grant Date<BR>
Fair Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$ per<BR>
option</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$ per<BR>
option</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Years</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at January&nbsp;1, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>848,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,907,569</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(274,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at January&nbsp;1, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>574,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,734,644</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>372,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(34,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>866,028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,328,171 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>866,028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,328,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>527,278</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,018,019 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting
date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate fair value of the equity awards vested during the years ended December&nbsp;31, 2018 and 2019 was US$165,609 and US$366,113, respectively. As of December&nbsp;31, 2019,
there was US$1,554,053 of total unrecognized employee share-based compensation expense, may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be
recognized over a weighted-average period of 3.32&nbsp;years. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair value of share options  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party
appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected
volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to
the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the
market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. The estimated fair value
of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party appraiser. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=318,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=4983,FOLIO='F-27',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. SHARE-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions used to estimate the fair value of the share options granted are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year<BR>
ended<BR>
December&nbsp;31,<BR>
2019 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.78% - 2.73%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility range</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67.5% - 71.0%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise multiple</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2 - 2.8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual life</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10&nbsp;years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
share-based compensation expenses recognized for the years ended December&nbsp;31, 2018 and 2019 were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>126,540</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>404,620</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>207,091 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total share-based compensation expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>126,540</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>611,711 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Up
to the date of the issuance of these consolidated financial statements, some proceeds of the subscription capital arising from the exercise of vested share options by certain
employees remained outstanding and such amount was presented as subscriptions receivable, a contra-equity balance on the consolidated balance sheets as of December&nbsp;31, 2018 and 2019,
respectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Guilin Sanjin Pharmaceutical&nbsp;Co.,&nbsp;Ltd. License Agreement  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2018, the Group entered into (i)&nbsp;a collaboration agreement (the "Sanjin Greater China Agreement") that covers Greater China
with Guilin Sanjin Pharmaceutical&nbsp;Co.,&nbsp;Ltd. ("Sanjin") and certain of its subsidiaries (collectively, "Sanjin Parties") and (ii)&nbsp;a collaboration agreement (the "Sanjin ROW
Agreement", together with the Sanjin Greater China Agreement, the "2018 Sanjin Agreements") that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China
Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the "PD-L1 Project"), including patent rights,
patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of
Sanjin Parties' rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating
thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes
of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=319,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=534078,FOLIO='F-28',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>deriving
from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group
(i)&nbsp;single-digit percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&nbsp;a low to mid-low double-digit percentage of the
profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB10,000,000
(equivalent to approximately US$1,511,168) upfront fee upon the effectiveness of the agreement from Sanjin Parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&nbsp;the collaboration under the agreement that
the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&nbsp;improvements thereto for the purposes of exploiting its rights and
performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual
property, and any intellectual property generated from cooperation between the Group and Sanjin's affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership
of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new
antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent
transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the
Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit percentage of the consideration that the Group expect to receive
from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount
of the offering price that was included in our notice to Sanjin. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group agreed not to (i)&nbsp;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&nbsp;grant any rights associated with such antibodies to any
third parties during the three-year period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&nbsp;developing or granting any licenses to third
parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&nbsp;continuing to provide antibody
screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the
Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party's ability to comply with its respective obligations under the agreements is negatively affected by
contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon
the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the
2018 Sanjin Agreements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the failure of the development of the product candidate solely arises from the Group's research and development basis specified under this agreement, Sanjin has the
right to claim </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=320,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=272278,FOLIO='F-29',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>back
all the payment made to the Group. The Group considers the possibility of occurrence of such event is very remote. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2018, the Group recognized revenue of RMB10,000,000 (equivalent to approximately US$1,511,168) for this agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2019, the Group entered into (i)&nbsp;a collaboration agreement that covers Greater China (the "Dragon Boat Greater China Agreement")
and (ii)&nbsp;a collaboration agreement that covers the regions other than Greater China (the "Dragon Boat ROW Agreement," together with the Dragon Boat Greater China Agreement, the "2019 Dragon
Boat Agreements"), with Dragon Boat Biopharmaceutical (Shanghai) Limited ("Dragon Boat"), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the
Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the "Specified Project"), including the patent rights, patent application
rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat's rights under
the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted
Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and
performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee,
licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&nbsp;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including
milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug ("IND") approval in PRC and completion of clinical phase I test in PRC) and (ii)&nbsp;a
single-digit percentage of net sales of the products that use the licensed antibody after such products enter the market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&nbsp;the collaboration under the
agreement that the Group
controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&nbsp;improvements thereto for the purposes of exploiting its rights and performing its
obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any
intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key
intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody
developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent
transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the
Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=321,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=377197,FOLIO='F-30',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Group
a deposit equal to a low double-digit percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can
proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2019 Dragon Boat Agreements, the Group agreed not to (i)&nbsp;independently develop any monospecific antibodies that bind to the specified target or (ii)&nbsp;grant any
rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from
(i)&nbsp;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the
specific target and (ii)&nbsp;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the
independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party's ability to comply
with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take
effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the
intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the failure of the development of the product candidate solely arises from the Group's research and development basis specified under this agreement, Dragon Boat has
the right to claim back all the payment made to the Group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2019, no revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2019, upfront fee of RMB4,000,000 (equivalent to approximately US$573,378) that was received by the Group was recorded as contract liabilities in the
consolidated balance sheets, as the performance obligation had not been satisfied by the Group. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADC Therapeutics&nbsp;SA License and Collaboration Agreements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2019, the Group entered into a material transfer and collaboration agreement (the "ADCT Collaboration Agreement") and a license
agreement (the "ADCT License Agreement") with ADC Therapeutics&nbsp;SA ("ADC Therapeutics"). These two agreements are combined as a single contract as the agreements were negotiated as a package
with a single commercial objective. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ADCT Collaboration Agreement</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to two exclusive targets selected by ADC Therapeutics.
Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group's technology with respect to one or both targets as further detailed below. ADC Therapeutics has not
yet exercised such options as of December&nbsp;31, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=322,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=342592,FOLIO='F-31',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group's exclusivity obligations, upon achievement
of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics' election to proceed
with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any
additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis
upon thirty days' prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party's uncured
material breach of the agreement or the other party's insolvency-related events. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group also granted ADC Therapeutics an exclusive target reservation right for one year from the commencement of the agreement and an option to renewal for another year with a
consideration of low-six-figure dollar amount. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ADCT License Agreement</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an
exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody
drug conjugates that comprise masked antibodies generated by the Group under these programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in
development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of
clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit percentage net
sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product
basis, until the earlier of (i)&nbsp;the tenth anniversary of the first commercial sale of such product or (ii)&nbsp;the expiration of the last-to-expire patent licensed under the agreement in
such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADC
Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&nbsp;for any
reason or no reason upon thirty days' written notice to the Group, or (ii)&nbsp;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each
party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party's uncured material breach or insolvency. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the years ended December&nbsp;31, 2018 and 2019, no revenue was recognized for this agreement since the licensed product has not been transferred to ADC Therapeutics. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=323,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=440375,FOLIO='F-32',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fu17601_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2019, upfront fee of US$225,000 and exclusive target reservation right of US$100,000 that were received by the Group were recorded as contract liabilities in
the consolidated balance sheets, as the performance obligation had not been satisfied by the Group. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Signal Pharmaceuticals LLC</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2019, the Group entered into an agreement with Signal Pharmaceuticals LLC, a subsidiary of Celgene Corporation, for a purchase order of delivery of certain
sequences with total consideration of US$480,000. For the year ended December&nbsp;31, 2019, the Group recognized revenue of US$480,000 upon delivery of such sequences. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. INCOME TAX EXPENSE  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PRC  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective from January&nbsp;1, 2008, the PRC's statutory, Enterprise Income Tax ("EIT") rate is 25%. In accordance with the implementation
rules of EIT Law, a qualified "Technology Advanced Service Enterprises" ("TASE") is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file
required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene
(Suzhou) Limited was first recognized as a qualified TASE in March 2015 and renewed in December 2018. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate
of 15% from 2015 to 2021. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cayman Islands  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene&nbsp;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&nbsp;Inc. is not subject to
tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable
income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the years ended
December&nbsp;31, 2018 and 2019, Adagene (Hong Kong) Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of
the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance
of dividends. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=324,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=716886,FOLIO='F-33',FILE='DISK103:[20ZDS1.20ZDS17601]FU17601A.;48',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fw17601_1_34"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. INCOME TAX EXPENSE (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Australia  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene Australia Pty&nbsp;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the
taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Adagene
Australia Pty&nbsp;Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. Adagene Incorporated is also
subject to state income tax in California of 8.84%. Adagene Incorporated has no taxable income for all periods presented, therefore, no provision for income taxes is required. Reconciliation between
the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss before income tax</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax computed at respective applicable tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(30,560</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development super-deduction<SUP>(a)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(579,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(230,126</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-deductible expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,306</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>605,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,945 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <P style="font-family:times;"><FONT SIZE=1>Note&nbsp;(a): Due to the impacts of research and development super-deduction, the Group's subsidiary, Adagene (Suzhou)
Limited did not have any taxable profit for the years ended December&nbsp;31, 2018 and 2019. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=325,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=831006,FOLIO='F-34',FILE='DISK103:[20ZDS1.20ZDS17601]FW17601A.;27',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fw17601_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. INCOME TAX EXPENSE (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred tax assets and liabilities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax
effects of temporary differences that give rise to the deferred tax balances as of December&nbsp;31, 2018 and 2019 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Deferred tax assets:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carry forward</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>735,717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>928,989</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,213</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,886 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Gross deferred tax assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>739,930</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>938,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: valuation allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(739,930</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(938,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total deferred tax assets, net</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Movement
of the valuation allowance is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance as of January&nbsp;1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>739,930</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Addition</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>605,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,945 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance as of December&nbsp;31</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>739,930</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>938,875 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be
realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group's operating history, accumulated deficit, the
existence of taxable temporary differences and reversal periods. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated
operating losses will not be utilized in the future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2018 and 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits
associated with the tax positions. As of December&nbsp;31, 2018 and 2019, the Group did not have any significant unrecognized uncertain tax positions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=326,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=614223,FOLIO='F-35',FILE='DISK103:[20ZDS1.20ZDS17601]FW17601A.;27',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fw17601_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. NET LOSS PER SHARE  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net loss per share for the years ended December&nbsp;31, 2018 and 2019 are calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to ordinary shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,302,843</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678,492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of ordinary shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,159,136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178,232 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the years ended
December&nbsp;31, 2018 and 2019 as their effects would be anti-dilutive. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible redeemable preferred shares</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,430,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,977,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>293,133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>582,526</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. UNAUDITED PRO FORMA NET LOSS PER SHARE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The unaudited pro forma net loss per ordinary share is computed using the weighted-average number of ordinary shares outstanding and the automatic conversion of all of the Group's
outstanding mezzanine equity into ordinary shares upon the closing of the Group's Qualified Public Offering, as if it had occurred on January&nbsp;1, 2019. The Group believes the unaudited pro forma
net loss per share provides material information to investors, as the automatic conversion of the Group's outstanding mezzanine equity. The disclosure of pro forma net loss per ordinary share provides
an indication of net loss per ordinary share that is comparable to what will be reported by the Group as a public company following the closing of the Qualified Public Offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=327,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=72214,FOLIO='F-36',FILE='DISK103:[20ZDS1.20ZDS17601]FW17601A.;27',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_fw17601_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. UNAUDITED PRO FORMA NET LOSS PER SHARE (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
unaudited basic and diluted pro forma net loss per share is calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year<BR>
ended<BR>
December&nbsp;31,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$<BR>
(Unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Numerator:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to ordinary shareholders in computing pro forma net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678,492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Add back accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,184 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator for pro-forma basic and diluted net loss per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Denominator:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of ordinary shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,178,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Add:&nbsp;adjustment to reflect assumed effect of automatic conversion of convertible&nbsp;&nbsp;redeemable preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,977,914</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pro forma weighted average number of shares outstanding&#151;basic and diluted</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,156,146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pro forma net loss per share&#151;basic and diluted</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. RELATED PARTY TRANSACTIONS  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>a)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Related Parties</I></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="187pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of related parties

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Relationship </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman, Chief Executive Officer and a principal shareholder of the Company</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Four senior management personnel</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Management and ordinary shareholders of the Company</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec&nbsp;Co.,&nbsp;Ltd. ("WuXi AppTec Group")</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>A principal shareholder of the Group</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Controlled by the ultimate controlling party of a principal shareholder of the Group</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>b)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Group had the following related party balances at the end of the year:</I></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>739,051</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Four senior management personnel(i)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>622,420</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350,865</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo(i)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>508,359</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>338,818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,452 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total amounts due from related parties</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,170,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,433,186 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=328,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=317103,FOLIO='F-37',FILE='DISK103:[20ZDS1.20ZDS17601]FW17601A.;27',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fy17601_1_38"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. RELATED PARTY TRANSACTIONS (Continued)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,368,735</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,379,741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>220,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>432,784</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo(ii)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,254 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total amounts due to related parties</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,674,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,895,779 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>c)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Group had the following related party transactions:</I></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Receipt of CRO and CMO services:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,535,512</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,567,962</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>969,079</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,136,344 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,504,591</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,704,306 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
October and November 2017, Peter Luo and other four senior management personnel elected to exercise the vested share options that granted under 2015 Plan. As of
December&nbsp;31, 2018, the balance of amounts due from Peter Luo and other four senior management personnel represented the receivables arising from the exercise of share options and related
withholding individual income tax amounts. The receivables arising from the exercise of share options were subsequently received in the year ended December&nbsp;31, 2019. As of December&nbsp;31,
2019, the balance of amounts due from Peter Luo and other four senior management personnel represented withholding individual income tax amounts.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>As
of December&nbsp;31, 2018 and 2019, the balance of amounts due to Peter Luo represented the Group's receipt of personal subsidy on behalf of Peter Luo, which
was subsequently remitted to Peter Luo in May 2020. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating lease commitments  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future minimum payments under non-cancelable operating leases with initial terms in excess of one year consist of the following as of
December&nbsp;31, 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>For the years ending:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>173,854</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,305 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>257,159 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
under operating leases are expensed on a straight-line basis over the periods of their respective leases. The Group's lease arrangements have no renewal options, rent escalation
clauses, restrictions or contingent rents and are all executed with third parties. For the years ended </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=329,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1036756,FOLIO='F-38',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. COMMITMENTS AND CONTINGENCIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>December&nbsp;31,
2018 and 2019, total rental related expenses for all operating leases amounted to US$176,268 and US$175,812, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contingencies  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group's business,
financial position or results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


16. RESTRICTED NET ASSETS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group's ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of
dividends by the Group's PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the
consolidated financial statements prepared in accordance with U.S.&nbsp;GAAP differ from those reflected in the statutory financial statements of the Group's PRC subsidiary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has
reached 50% of its respective registered capital based on the enterprise's PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of
the Board of Directors, from the profits determined in accordance with the enterprise's PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not
distributable as cash dividends. The Group's PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018 and 2019, the total restricted net assets of the Company's subsidiary incorporated in PRC and subjected to restriction amounted to approximately
US$1,267,900 and US$1,267,900, respectively. Other subsidiaries are not subjected to such restriction. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of
dividends, as general reserve fund, the Group's PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign
exchange and other regulations in the PRC further restrict the Company's PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
the Group has a consolidated shareholders' deficit, its net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries
should be zero. Therefore, the restrictions placed on the net assets of the Company's PRC subsidiaries with positive equity would result in the 25&nbsp;percent threshold being exceeded and a
corresponding requirement to provide parent company financial information (Note&nbsp;18). </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


17. SUBSEQUENT EVENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group evaluated subsequent events through September&nbsp;22, 2020, the date these consolidated financial statements were issued. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=330,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=407307,FOLIO='F-39',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


17. SUBSEQUENT EVENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March and August 2020, pursuant to the 2019 Plan, the Board of Directors of the Company passed resolutions and granted 1,944,565 and 4,028,808 share options to certain employees,
respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2020, the Group borrowed a loan with amount of RMB10,000,000 (equivalent to approximately US$1,412,529) from Agricultural Bank of China Limited for a term of one year and at the
interest rate of 4.20% per annum. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
in January 2020, the emergence and wide spread of the novel Coronavirus ("COVID-19") has resulted in quarantines, travel restrictions, and the temporary closure of stores and
facilities in China, US and elsewhere. Substantially all of the Group's operating and workforce are concentrated in China and US. Consequently, the COVID-19 outbreak could potentially delay patient's
access to hospital and the progress of clinical trials of the Group, which may adversely affect the Group's business operations, financial condition and operating results for 2020. The extent to which
COVID-19 impacts the business and financial results of the Group in the longer term will depend on future developments, which are uncertain and cannot be predicted, including new information which may
emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The Group will continue to evaluate the impact on the results of
operation, financial position and cash flows of the Group and react actively as the situation evolves. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Events subsequent to original issuance of consolidated financial statements (Unaudited)  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2020, pursuant to the 2019 Plan, the Board of Directors of the Company passed resolutions and granted 340,000 share options to
certain employees with an exercise price of US$2.26 per share. The fair values of these share options ranged from US$9.02 to US$9.23 per option and were determined by using the binomial option
valuation model. The share-based compensation expense related to these share options is expected to be recognized over a weighted-average period of 4.06 years.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of 2,375,000 share options granted to certain management members. Pursuant to
this board resolution, these management members exercised all these share options at the original exercise price per share ranging from US$1.83 to US$2.26 and as a result, 2,375,000 ordinary shares
were issued to them. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$5,197,650. These ordinary shares are subject to the Company's
repurchase rights before the share awards meet certain conditions. The management assessed and considered that such change in terms met the exception for modification accounting (as defined in
ASU&nbsp;2017-09, Scope of Modification Accounting), hence no additional amount of compensation expense was recognized.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2020, the Group borrowed two loans with the amount of RMB5,000,000 (equivalent to approximately US$760,086) and RMB5,000,000 (equivalent to US$760,086) from China Merchants
Bank&nbsp;Co.,&nbsp;Ltd., respectively. Both of these two loans have a term of one year and bear an interest rate of 4.10% per annum. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of 491,119 ordinary shares as repayment for their respective promissory
notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=331,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=408288,FOLIO='F-40',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


17. SUBSEQUENT EVENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


by way of new option grants with an exercise price of US$13.85 per share. The fair values of these share options were US$7.85 per option, determined by using the binomial option valuation model. The
share-based compensation expense related to these share options is expected to be recognized immediately upon grants.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the same board resolution, the 2021 Performance Incentive Plan was also adopted, under which an aggregate of 2,994,000 ordinary shares shall be reserved for issuance, and the
share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&nbsp;5% of the total number of the Company's outstanding
ordinary shares on December&nbsp;31 of the prior year, or (2)&nbsp;such lesser number as determined by the board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;1, 2021, the Company entered into a collaboration and license agreement (the "Exelixis Agreement") with Exelixis,&nbsp;Inc., pursuant to which the Company agreed to
generate masked antibodies with the Company's SAFEbody technology against an initial target and a second target to be selected by Exelixis. Under the Exelixis Agreement, the Company are entitled to
receive an US$11,000,000 upfront payment. In addition, the Company could be eligible to receive, on a target-by-target basis, up to US$127,500,000 in development and regulatory milestone payments upon
the achievement of specified development and regulatory milestones and up to US$262,500,000 in sales milestone payments upon the achievement of specified commercial milestones. In the aggregate, the
Company could be eligible to receive up to US$255,000,000 in development and regulatory milestone payments and up to US$525,000,000 in sales milestone payments for both targets under the Exelixis
Agreement. In addition, the Company are entitled to receive mid-single-digit percentage net sales-based royalties on products developed under the Exelixis Agreement, subject to certain reductions.

</FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with Securities and Exchange Commission Regulation&nbsp;S-X Rule&nbsp;4-08 I(3),
"General Notes to Financial Statements" and concluded that it was applicable for the Company to disclose the financial statements for the parent company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
subsidiaries did not pay any dividends to the Company for the years presented. For the purpose of presenting parent company only financial information, the Company records its
investments in its subsidiaries under the equity method of accounting. Such investments are presented on the separate condensed balance sheets of the Company as "Investments (deficit) in subsidiaries"
and the loss of the subsidiaries is presented as "share of losses of subsidiaries". Certain information and footnote disclosures generally included in financial statements prepared in accordance with
U.S.&nbsp;GAAP have been condensed and omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements should be read in
conjunction with the notes to the consolidated financial statements of the Company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company did not have significant capital and other commitments, long-term obligations, other long-term debt, or guarantees as of December&nbsp;31, 2018 and 2019.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=332,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=804850,FOLIO='F-41',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Balance sheets  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current assets:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,748,281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,168,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts due from related parties<SUP>(a)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,822,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,362,724</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepayments and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,237,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,211,891 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,808,175</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>106,742,774</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investments in subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,172,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,507,052</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,916</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,299 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>TOTAL ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>54,990,692</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,254,125 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current liabilities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>391,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>326,762</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contract liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>325,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts due to related parties<SUP>(a)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,383,956</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,247,674</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>162,341</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total current liabilities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,062,245</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,061,777 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>TOTAL LIABILITIES</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,062,245</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,061,777 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=333,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=280895,FOLIO='F-42',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Balance sheets (Continued)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT (CONTINUED)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Mezzanine equity:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,473,957 and 5,473,957 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A-2 convertible redeemable preferred shares (par value of US$0.0001 per share; 2,370,414 and 2,370,414 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible redeemable preferred shares (par value of US$0.0001 per share; 7,494,537 and 7,494,537 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,597,354 and 5,597,354 shares authorized, issued and
outstanding as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,481,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,727,343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C-2 convertible redeemable preferred shares (par value of US$0.0001 per share; nil and 1,861,121 shares authorized, issued and outstanding as
of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C-3 convertible redeemable preferred shares (par value of US$0.0001 per share; nil and 4,452,441 shares authorized, issued and outstanding as
of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total mezzanine equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84,955,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154,201,294 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Shareholders' deficit:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ordinary shares (par value of US$0.0001 per share; 500,000,000 and 500,000,000 shares authorized; 15,159,136 and 15,193,136 shares issued and outstanding
as of December&nbsp;31, 2018 and 2019, respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,519</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Subscriptions receivable from shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(197,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(197,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,405,318</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,789,542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(410,693</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(344,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,825,737</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(63,258,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total shareholders' deficit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(41,026,664</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(57,008,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>54,990,692</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,254,125 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=334,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=296140,FOLIO='F-43',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statements of comprehensive loss  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenues</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Service revenue from a related party<SUP>(b)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>288,983</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,803,341</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,318,724</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,810,899</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,844,722</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,992,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,474,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(556,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(787,568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,359,723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,817,309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>691,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>908,981</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange loss, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>534,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity in income (share of losses) of subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(132,214</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>268,652 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss before income tax</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other comprehensive income (loss)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustments, net of nil tax</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,799 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,277,472</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,366,509</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,266,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,432,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deemed contribution from convertible redeemable preferred shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,186,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(222,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(246,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to ordinary shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,302,843</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,678,492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=335,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=737043,FOLIO='F-44',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_fy17601_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2019 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statements of cash flows  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash used in operating activities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,346,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,521,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third parties</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,919,363</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,660,397</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Related parties</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13,427,337</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,861,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash generated from (used in) investing activities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(28,535,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,941,876</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash generated from financing activities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,018,733</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,999,999 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase in cash and cash equivalents</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,136,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,419,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the beginning of year</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,611,906</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,748,281 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the end of year</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,748,281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>91,168,159 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Company had the following related party balances at the end of the year: </FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene (Hong Kong) Limited<SUP>(i)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,522,425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,032,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene Incorporated<SUP>(i)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,300,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,790,233</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>517,168</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene Australia PTY&nbsp;Ltd.<SUP>(i)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,557 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total amounts due from related parties</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,822,425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,362,724 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene (Suzhou) Limited<SUP>(ii)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,812,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,126,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene Incorporated<SUP>(ii)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>571,543</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,743,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>377,752</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene (Hong Kong) Limited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total amounts due to related parties</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,383,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,247,674 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>As
of December&nbsp;31, 2018 and 2019, the amounts due from Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene Australia PTY&nbsp;Ltd. represented the
receivables arising from the expenses paid by the Company on behalf of these subsidiaries.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>As
of December&nbsp;31, 2018 and 2019, the amounts due to Adagene (Suzhou) Limited and Adagene Incorporated mainly represented the payables arising from the
research and development services provided by these two subsidiaries. </FONT></DD></DL>
 </DIV>
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the years ended December&nbsp;31, 2019, the service revenue from a releated party was for Adagene Incorporated, with zero gross margin rate charged. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=336,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=549081,FOLIO='F-45',FILE='DISK103:[20ZDS1.20ZDS17601]FY17601A.;41',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ga17601_1_46"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin7"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ga17601_adagene_inc._consolidated_bala__ada04853"> </A>
<A NAME="toc_ga17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 2019 AND    <BR>    <BR>    UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET    <BR>    <BR>    AS OF
SEPTEMBER 30, 2020    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$<BR>
(Pro forma)<BR>
(Note&nbsp;13)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Current assets:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>92,532,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>82,894,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>82,894,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accounts receivable, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>480,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Amounts due from related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,433,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>407,381</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>407,381</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Prepayments and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,476,973</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,303,782</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,303,782 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total current assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>103,922,947</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>86,606,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>86,606,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Property, equipment and software, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,879,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,844,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,844,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>87,227</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>626,394</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>626,394 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>TOTAL ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>105,889,499</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>89,076,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>89,076,779 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Current liabilities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>712,714</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,207,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,207,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Contract liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>993,378</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>887,363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>887,363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Amounts due to related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,895,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,386,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,386,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accruals and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,540,164</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,789,161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,789,161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Short-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>716,723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,202,611</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,202,611</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Current portion of long-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>322,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>943,452</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>943,452 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total current liabilities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,181,283</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,416,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,416,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Long-term borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,515,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,135,049</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,135,049</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other non-current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>58,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>58,736 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>TOTAL LIABILITIES</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,697,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,610,367</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,610,367 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Commitments and contingencies</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT (CONTINUED)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Mezzanine equity:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;A-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,473,957 and 5,473,957 shares authorized, issued and
outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020 respectively; and none outstanding on a pro-forma basis as of September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;A-2 convertible redeemable preferred shares (par value of US$0.0001 per share; 2,370,414 and 2,370,414 shares authorized, issued and
outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020 respectively; and none outstanding on a pro-forma basis as of September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;B convertible redeemable preferred shares (par value of US$0.0001 per share; 7,494,537 and 7,494,537 shares authorized, issued and outstanding
as of December&nbsp;31, 2019 and September&nbsp;30, 2020 respectively; and none outstanding on a pro-forma basis as of September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;C-1 convertible redeemable preferred shares (par value of US$0.0001 per share; 5,597,354 and 5,597,354 shares authorized, issued and
outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020 respectively; and none outstanding on a pro-forma basis as of September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>48,727,343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>48,912,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;C-2 convertible redeemable preferred shares (par value of US$0.0001 per share; 1,861,121 and 1,861,121 shares authorized, issued and
outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020 respectively; and none outstanding on a pro-forma basis as of September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Series&nbsp;C-3 convertible redeemable preferred shares (par value of US$0.0001 per share; 4,452,441 and 4,452,441 shares authorized, issued and
outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020 respectively; and none outstanding on a pro-forma basis as of September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total mezzanine equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>154,201,294</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>154,386,921</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Shareholders' deficit:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ordinary shares (par value of US$0.0001 per share; 500,000,000 and 500,000,000 shares authorized; 15,193,136 and 16,466,897 shares issued and outstanding
as of December&nbsp;31, 2019 and September&nbsp;30, 2020)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,519</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,646</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,372</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Subscriptions receivable from shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(197,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,974,542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,974,542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,789,542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,499,520</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>170,883,715</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(344,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(559,674</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(559,674</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(63,258,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(92,887,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(92,887,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total shareholders' equity (deficit)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(57,008,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(78,920,509</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>75,466,412 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>105,889,499</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>89,076,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>89,076,779 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these unaudited interim condensed consolidated<BR>
financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=337,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=765431,FOLIO='F-46',FILE='DISK103:[20ZDS1.20ZDS17601]GA17601A.;11',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gc17601_1_47"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin8"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="gc17601_adagene_inc._unaudited_interim__ada04943"> </A>
<A NAME="toc_gc17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS<BR>  OF COMPREHENSIVE LOSS    <BR>    <BR>    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020
<BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenues</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Licensing revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>309,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,517,923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,567,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,388,214</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,133,614</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,129,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,434,165</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,268,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,448,069</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,785,961</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(30,706,348</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>711,964</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>612,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(101,506</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(113,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217,404</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>654,755</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange loss, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(67,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(76,986</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,207,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Loss before income tax</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other comprehensive income</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustments, net of nil tax</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(214,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total comprehensive loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,537,336</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,844,194</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(185,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to ordinary shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,002,371</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,815,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Weighted average number of ordinary shares used in per share calculation:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,172,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757,463</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,172,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757,463</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss per ordinary share</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Basic</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=338,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=872476,FOLIO='F-47',FILE='DISK103:[20ZDS1.20ZDS17601]GC17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ge17601_1_48"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin9"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ge17601_adagene_inc._unaudited_interim__ada05425"> </A>
<A NAME="toc_ge17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT    <BR>    <BR>    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019
AND 2020    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Subscriptions<BR>
receivable<BR>
from<BR>
shareholders </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
other<BR>
comprehensive<BR>
loss </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
paid-in<BR>
capital </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
shareholders'<BR>
deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance as of January&nbsp;1, 2019 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>15,159,136</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>1,516</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(197,068</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>6,405,318</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(410,693</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(46,825,737</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(41,026,664</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise of share options (Note&nbsp;9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,697</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>438,888</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>438,888</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance as of September&nbsp;30, 2019 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>15,193,136</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>1,519</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(197,068</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>6,678,889</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(129,672</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(58,644,094</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(52,290,426</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance as of January&nbsp;1, 2020 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>15,193,136</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>1,519</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(197,068</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>6,789,542</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(344,894</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(63,258,045</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(57,008,946</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(214,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(214,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise of share options (Note&nbsp;9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,273,761</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,777,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,849,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,547</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,045,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,045,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(185,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(185,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance as of September&nbsp;30, 2020 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>16,466,897</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>1,646</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(1,974,542</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>16,499,520</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(559,674</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(92,887,459</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(78,920,509</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these unaudited interim condensed consolidated<BR>
financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=339,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=384611,FOLIO='F-48',FILE='DISK103:[20ZDS1.20ZDS17601]GE17601A.;11',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gg17601_1_49"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin10"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="gg17601_adagene_inc._unaudited_interim__ada04584"> </A>
<A NAME="toc_gg17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS    <BR>    <BR>    FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020    <BR>
</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>
<!-- -->
US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>602,687</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>647,220</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss on disposal of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>323</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>438,888</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,045,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of warrant liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,207,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign exchange loss, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>67,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>76,986</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts receivable, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>480,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepayments and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(420,268</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,826,809</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts due from related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(64,915</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,025,805</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,759</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(70,722</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>494,591</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contract liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>985,539</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(106,015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts due to related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(540,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>490,911</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>230,081</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>248,997</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58,736 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash used in operating activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,790,931</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,988,199</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Placement of short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Withdrawal of short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>38,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from disposal of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,040</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchase of property, equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(57,545</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(574,447</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash generated from investing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,942,455</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,433,593 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from employee's exercise of share-options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,547</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,699,114</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,505,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of convertible redeemable preferred shares and warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,000,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of deferred initial public offering cost</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(543,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,389,081</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(936,825</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net cash generated from financing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,310,034</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,097,138 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate on cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>152,933</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(180,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase in cash and cash equivalents</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,614,491</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9,637,948</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at the beginning of period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,058,455</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>92,532,788 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash and cash equivalents at the end of period</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,672,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>82,894,840 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental cashflow disclosures:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest paid</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101,506</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-cash activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>184,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>185,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payables for deferred initial public offering cost</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=340,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=564216,FOLIO='F-49',FILE='DISK103:[20ZDS1.20ZDS17601]GG17601A.;13',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gi17601_1_50"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="Fin11"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="gi17601_adagene_inc._notes_to_the_unau__ada04945"> </A>
<A NAME="toc_gi17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  ADAGENE&nbsp;INC.    <BR>    <BR>    NOTES TO THE UNAUDITED INTERIM CONDENSED    <BR>    <BR>    CONSOLIDATED FINANCIAL STATEMENTS    <BR>    <BR>    FOR THE NINE MONTHS ENDED SEPTEMBER 30,
2019 AND 2020    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. ORGANIZATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adagene&nbsp;Inc. (the "Company") is a limited liability company incorporated in the Cayman Islands on February&nbsp;25, 2011. The Company, together with its subsidiaries
(collectively, the "Group") are principally engaged in research, development and production of monoclonal antibody drugs for cancers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of September&nbsp;30, 2020, the Company's principal subsidiaries are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="116pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="153pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Entity

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of<BR>
incorporation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Place of<BR>
incorporation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
of legal<BR>
ownership by<BR>
the Company </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal activities </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene (Hong Kong) Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>December&nbsp;12, 2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Hong Kong</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Investment holding</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene Incorporated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>September&nbsp;20, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>The United States of America</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Research and development of innovative medicines</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene (Suzhou) Limited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>February&nbsp;28, 2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>The People's Republic of China ("PRC" or "China")</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Research and development of innovative medicines</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene Australia PTY&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>May&nbsp;30, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Australia</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Research and development of innovative medicines</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene PTE.&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>March&nbsp;27, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Singapore</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Research and development of innovative medicines</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adagene AG</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>August&nbsp;31, 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Switzerland</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Research and development of innovative medicines</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of presentation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted
accounting principles ("U.S.&nbsp;GAAP") and applicable rules and regulations of the Securities and Exchange Commission regarding financial reporting that are consistent with those used in the
preparation of the Company's audited consolidated financial statements for the year ended December&nbsp;31, 2019. Accordingly, these unaudited interim condensed consolidated financial statements do
not include all of the information and footnotes required by U.S.&nbsp;GAAP for annual financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the opinion of management, the Group's unaudited interim condensed consolidated financial statements and accompanying notes include all adjustments (consisting of normal recurring
adjustments) considered necessary for the fair statement of the Group's financial position as of September&nbsp;30, 2020, and results of operations and cash flows for the nine months ended
September&nbsp;30, 2019 and 2020. Interim results of operations are not necessarily indicative of the results for the full year or for any future period. These unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&nbsp;31, 2019, and related notes included in
the Group's audited consolidated financial statements. The financial information as of December&nbsp;31, 2019 presented in the unaudited interim </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=341,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=94617,FOLIO='F-50',FILE='DISK103:[20ZDS1.20ZDS17601]GI17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gi17601_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>condensed
consolidated financial statements is derived from the audited consolidated financial statements as of December&nbsp;31, 2019. Significant accounting policies followed by the Group in the
preparation of the accompanying unaudited interim condensed consolidated financial statements are summarized below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue recognition  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the
scope of ASC 808, Collaborative Arrangements ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the
activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple
elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore
within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the
criteria of Accounting Standard Codification ("ASC")&nbsp;606, Revenue from Contracts with Customers (Topic 606) ("ASC&nbsp;606"), the Group recognizes revenue to depict the transfer of control of
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including
variable consideration, if any; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a
performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange
for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or
services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as
and when that performance obligation is satisfied. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licenses of Intellectual Property:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upfront non-refundable payments for licensing the Group's intellectual property are evaluated to
determine if the
license is distinct from the other performance obligations
identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer
of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Milestone Payments:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At the inception of each arrangement that includes development, commercialization, and regulatory milestone
payments, the Group
evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=342,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=814802,FOLIO='F-51',FILE='DISK103:[20ZDS1.20ZDS17601]GI17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gi17601_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>revenue
would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance
obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent
reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price.
Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the
license is deemed
to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which
some or all of the royalty has been allocated has been satisfied (or partially satisfied). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, no milestone payments or royalty payments were received. Substantially all of the Group's revenue has been derived from its out-licensing agreements with respect to licensed
products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the
customer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contract assets and contract liabilities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability;
When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights
to consideration as a contract asset. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elements of research and development expenses primarily include (1)&nbsp;payroll and other related costs of personnel engaged in research and
development activities, (2)&nbsp;costs related to pre-clinical testing of the Group's technologies under development and clinical trials such as payments to contract research organizations ("CRO")
and contract manufacturing organization ("CMO"), investigators and clinical trial sites that conduct the clinical studies; (3)&nbsp;costs to develop the product candidates, including raw materials
and supplies, product testing, depreciation and amortization, and facility related expenses, (4)&nbsp;other research and development expenses. Research and development expenses are charged to
expense as incurred when these expenditures relate to the Group's research and development services and have no alternative future uses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share-based compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in
accordance with ASC 718, Compensation&#151;Stock Compensation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=343,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=387095,FOLIO='F-52',FILE='DISK103:[20ZDS1.20ZDS17601]GI17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gi17601_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based
compensation awards are measured at the grant date fair value of the awards and recognized as expenses a)&nbsp;immediately at the grant date if no vesting conditions are
required; or b)&nbsp;for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c)&nbsp;for share-based awards granted with service
conditions and performance conditions, using the graded vesting method over the vesting period if and when the company concludes that it is probable that the performance conditions will be achieved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification
as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group
recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the
remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee defined contribution plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care,
welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on
certain percentages of the qualified employees' salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical
benefits and the pension liability to be paid to these employees and the Group's obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions
have been paid. The Group recorded employee benefit expenses of US$885,255 and US$663,034 for the nine months ended September&nbsp;30, 2019 and 2020, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any
difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the
effective interest method. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group is an emerging growth company ("EGC") as defined by the Jumpstart Our Business Startups Act ("JOBS Act"). The JOBS Act provides that
an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those
standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be
classified as an EGC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=344,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=385558,FOLIO='F-53',FILE='DISK103:[20ZDS1.20ZDS17601]GI17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gi17601_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU No.&nbsp;2016-02 ("ASU 2016-02"), Leases (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by
recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No.&nbsp;2018-10 ("ASU 2018-10"),
Codification Improvements to Topic&nbsp;842, Leases, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU&nbsp;No.&nbsp;2018-11 ("ASU 2018-11"), Leases
(Topic&nbsp;842): Targeted Improvements, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity
initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an
entity's reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases).
In November 2019, the FASB issued ASU No.&nbsp;2019-10, Financial Instruments&#151;Credit Losses (Topic&nbsp;326), Derivatives and Hedging (Topic 815), and Leases
(Topic&nbsp;842),&nbsp;Effective Dates ("ASU 2019-10"), which extends the adoption date for certain registrants. The updated guidance is effective for the Group for annual reporting periods
beginning January&nbsp;1, 2021 and interim periods within annual periods beginning January&nbsp;1, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards
and the Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use assets and lease liabilities on its interim condensed
consolidated balance sheets, with an immaterial impact on its interim condensed consolidated statements of comprehensive loss and interim condensed consolidated statements of cash flows. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2016, the FASB issued ASU No.&nbsp;2016-13, Financial Instruments&#151;Credit Losses (Topic&nbsp;326): Measurement of Credit Losses on Financial Instruments ("ASU
2016-13"). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other
organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and
supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant
estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group's portfolio. These disclosures include qualitative and quantitative
requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain
registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December&nbsp;15, 2022, including interim periods within fiscal years beginning after December&nbsp;15,
2023. The Group does not plan to early adopt ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its interim condensed consolidated financial
statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2018, the FASB issued ASU No.&nbsp;2018-07, Compensation&#151;Stock Compensation (Topic&nbsp;718): Improvements to nonemployee share-based payment accounting ("ASU
2018-07"). The amendments in this update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments are effective for
fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=345,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=549584,FOLIO='F-54',FILE='DISK103:[20ZDS1.20ZDS17601]GI17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gi17601_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>December&nbsp;15,
2020. Early adoption is permitted, but no earlier than an entity's adoption date of Topic&nbsp;606. The Group adopted on January&nbsp;1, 2018 this guidance which do not have a
significant impact on the interim condensed consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic&nbsp;808):&nbsp;Clarifying the Interaction between Topic 808 and Topic 606. This update clarifies
that certain transactions between participants in a collaborative arrangement should be accounted for under ASC&nbsp;606 when the counterparty is a customer and precludes an entity from presenting
consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal
years beginning after December&nbsp;15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC 606. This guidance should be applied retrospectively to
the date of initial application of Topic 606. The Group does not plan to early adopt ASU 2018-18 and is currently evaluating the impact on its financial statements of adopting this guidance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This update simplifies the accounting for income taxes as part of
the FASB's overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, </FONT><FONT SIZE=2><I>Income
taxes</I></FONT><FONT SIZE=2>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal
years beginning after December&nbsp;15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified
retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU 2019-12 and is currently evaluating the impact on its financial statements of adopting
this guidance. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. ACCOUNTS RECEIVABLE, NET  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts receivable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>480,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Allowance for doubtful accounts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>480,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=346,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=819036,FOLIO='F-55',FILE='DISK103:[20ZDS1.20ZDS17601]GI17601A.;17',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gk17601_1_56"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. PREPAYMENTS AND OTHER CURRENT ASSETS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepayments and other current assets consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deposits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>970,394</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,744,176</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepayments(a)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,417,962</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest receivables</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>227,278</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,620</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Others</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,024 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,476,973</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,303,782 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=1>Note&nbsp;(a):
The prepayments mainly represented the Group's prepaid service fees to its CRO and CMO vendors. </FONT></P>
 </DIV>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. PROPERTY, EQUIPMENT AND SOFTWARE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, equipment and software consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Machinery and laboratory equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,462,343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,791,884</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Electronic equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>605,882</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>851,996</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>767,205</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>785,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and tools</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,396</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,602</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71,056</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,986</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vehicles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,087 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,085,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,727,472</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,205,690</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,883,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,879,325</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,844,382 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
and amortization expenses recognized for the nine months ended September&nbsp;30, 2019 and 2020 were US$602,687 and US$647,220, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=347,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=861661,FOLIO='F-56',FILE='DISK103:[20ZDS1.20ZDS17601]GK17601A.;19',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gk17601_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. ACCRUALS AND OTHER CURRENT LIABILITIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities and other current liabilities consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll and related liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,370,523</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,407,232</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Professional service fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>331,493</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Utility and maintenance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,595</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,176</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Others</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,889</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,260 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,540,164</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,789,161 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. BORROWINGS  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Current</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term borrowings:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank loans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>716,723</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,202,611</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current portion of long-term borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>322,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>943,452 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,039,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,146,063 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-Current</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term borrowings:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bank loans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,515,868</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,135,049 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total non-current borrowings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,515,868</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,135,049 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total borrowings </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,555,116</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>6,281,112</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Short-term borrowing  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2018, the Group borrowed a loan with the amount of RMB3,000,000 (equivalent to approximately US$437,114) from Bank of
Jiangsu&nbsp;Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 5.22% per annum. The borrowing was repaid in March 2019. In June 2018, the Group borrowed a loan with the amount of
RMB2,000,000 (equivalent to approximately US$291,409) from Bank of Jiangsu&nbsp;Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 5.22% per annum. The borrowing was repaid in June
2019. These borrowings with Bank of Jiangsu&nbsp;Co.,&nbsp;Ltd were guaranteed by Peter Luo and Kristine She. Peter Luo is the Chairman, Chief Executive Officer and a principal shareholder of the
Company. Kristine She is one of the senior management personnel of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2018, the Group borrowed a loan with the amount of RMB3,000,000 (equivalent to approximately US$437,114) from Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and at
the interest </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=348,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=316358,FOLIO='F-57',FILE='DISK103:[20ZDS1.20ZDS17601]GK17601A.;19',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gk17601_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. BORROWINGS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>rate
of 5.00% per annum. The borrowing was repaid in May 2019. In June 2018, the Group borrowed a loan with the amount of RMB2,000,000 (equivalent to approximately US$291,409) from Bank of
Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and at the interest rate of 5.00% per annum. The borrowing was repaid in June 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2018, the Group borrowed a loan with amount of RMB6,000,000 (equivalent to approximately US$874,228) from Agricultural Bank of China Limited for a term of one year and at the
interest rate of 5.22% per annum. The borrowing was guaranteed by Peter Luo, who is the Chairman, Chief Executive Officer and a principal shareholder of the Company. The borrowing was repaid in July
2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2019, the Group borrowed a loan with amount of RMB5,000,000 (equivalent to approximately US$716,723) from Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and
at the interest rate of 4.35% per annum. The borrowing was repaid in September 2020. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2020, the Group borrowed a loan with amount of RMB10,000,000 (equivalent to approximately US$1,412,529) from Agricultural Bank of China Limited for a term of one year and at the
interest rate of 4.20% per annum. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2020, the Group borrowed a loan with amount of RMB5,000,000 (equivalent to approximately US$734,204) from Bank of Ningbo&nbsp;Co.,&nbsp;Ltd. for a term of one year and
at the interest rate of 4.20% per annum. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-term borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2019, the Group borrowed a loan with amount of RMB7,500,000 (equivalent to approximately US$1,075,084) from Shanghai Pudong
Development Bank&nbsp;Co.,&nbsp;Ltd. for a term of three years and at the interest rate of 5.46% per annum. The Group repaid RMB375,000 (equivalent to approximately US$53,754), RMB375,000
(equivalent to approximately US$53,365) and RMB 875,000 (equivalent to approximately US$125,148), in August 2019, February 2020 and August 2020 respectively. As of December&nbsp;31, 2019 and
September&nbsp;30, 2020, RMB1,250,000 (equivalent to approximately US$179,181) and RMB3,375,000 (equivalent to approximately US$495,587) repayable within twelve months for this agreement was
classified as "Current portion of long-term borrowing", respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2019, the Group borrowed a loan with amount of RMB6,000,000 (equivalent to approximately US$860,067) from Shanghai Pudong Development Bank&nbsp;Co.,&nbsp;Ltd. for a term of
three years and at the interest rate of 5.23% per annum. The Group repaid RMB300,000 (equivalent to approximately US$43,003) and RMB300,000 (equivalent to approximately US$42,908) in December 2019 and
June 2020, respectively. As of December&nbsp;31, 2019 and September&nbsp;30, 2020, RMB1,000,000 (equivalent to approximately US$143,344) and RMB1,400,000 (equivalent to approximately US$205,577)
repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing", respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2020, the Group borrowed a loan with amount of RMB16,500,000 (equivalent to approximately US$2,422,872) from Shanghai Pudong Development Bank&nbsp;Co.,&nbsp;Ltd. for a
term of three years and at the interest rate of 4.27% per annum. As of September&nbsp;30, 2020, RMB1,650,000 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=349,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1037585,FOLIO='F-58',FILE='DISK103:[20ZDS1.20ZDS17601]GK17601A.;19',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gk17601_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. BORROWINGS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>(equivalent
to approximately US$242,287) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowings". </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Future maturities of short-term borrowings and long-term borrowings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future principal maturities of short-term borrowings and long-term borrowings as of September&nbsp;30, 2020 are as followings: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remaining three months of 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,336,955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,226,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,615,248 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,281,112 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2011, the Company issued convertible notes ("Series Pre-A Convertible Notes") to certain investors in the amount of 4,590,908. The notes carried a simple interest
(non-compounding) of 6% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the
convertible redeemable preferred shares of the Company at a price no more than US$1 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2014, the Company issued 5,473,957 Series&nbsp;A-1 convertible redeemable preferred shares ("Series&nbsp;A-1 Preferred Shares") to certain investors upon conversion of
the Company's Series Pre-A convertible notes at a conversion price of US$1 per share. Concurrently, the Company issued 2,370,414 Series&nbsp;A-2 convertible redeemable preferred shares
("Series&nbsp;A-2 Preferred Shares") to certain investors at US$1.27 per share for a total consideration of US$3,000,000. Series&nbsp;A-1 Preferred Shares and Series&nbsp;A-2 Preferred Shares
are collectively referred to as the Series&nbsp;A Preferred Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
January through June 2016, the Company issued 7,494,537 Series&nbsp;B convertible redeemable preferred shares ("Series&nbsp;B Preferred Shares") to certain investors at US$3.74
per share for a total consideration of US$27,999,995. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
February through May 2018, the Company issued 5,597,354 Series&nbsp;C-1 convertible redeemable preferred shares ("Series&nbsp;C-1 Preferred Shares") to certain investors at
US$8.93 per share for a total consideration of US$50,000,033. Concurrently, in February 2018, the Company also issued warrants to two Series&nbsp;C-1 investors at nil consideration
("Series&nbsp;C-1 Warrants"). The Series&nbsp;C-1 Warrants allowed the holders to purchase Series&nbsp;C-2 Preferred Shares (defined below) at the exercise price of US$10.21 per share for a
total consideration of up to US$7,500,000. Series&nbsp;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&nbsp;April&nbsp;1,
2019, ii)&nbsp;a deemed liquidation event or iii)&nbsp;the closing of the Qualified IPO. Series&nbsp;C-1 Warrants expired on April&nbsp;1, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=350,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=772565,FOLIO='F-59',FILE='DISK103:[20ZDS1.20ZDS17601]GK17601A.;19',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gk17601_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
June through November 2019, the Company issued 1,861,121 Series&nbsp;C-2 convertible redeemable preferred shares ("Series&nbsp;C-2 Preferred Shares") to certain investors at
US$10.21 per share for a total consideration of US$18,999,999. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2019, the Company issued 4,452,441 Series&nbsp;C-3 convertible redeemable preferred shares ("Series&nbsp;C-3 Preferred Shares") to a certain investor at US$11.23 per
share for a total consideration of US$50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series&nbsp;C-1
Preferred Shares, Series&nbsp;C-2 Preferred Shares and Series&nbsp;C-3 Preferred Shares are collectively referred to as the Series&nbsp;C Preferred Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
key features of the Series&nbsp;A Preferred Shares, Series&nbsp;B Preferred Shares and Series&nbsp;C Preferred Shares (collectively the "Preferred Shares") are as follows: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of the Preferred Shares will be entitled to receive non-cumulative dividends when declared by the Board of Directors prior and in
preference to ordinary shareholders. The dividend should be paid at the rate of 6% of the original issue price per share per annum on each Preferred Shares in the sequence of Series&nbsp;C Preferred
Shares and Preferred Shares other than the Series&nbsp;C Preferred Shares. After the preferential dividends relating to the Preferred Shares have been paid in full or declared and set apart in any
fiscal year of the Company, any additional dividends out of funds or assets legally available therefore may be declared in that fiscal year for the Shares and, if such additional dividends are
declared, the preferred shareholders shall be entitled to participate on an as converted-basis pro-rata in any dividends or distributions paid to the ordinary shareholders. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Preferred Share has voting rights equivalent to the number of ordinary shares to which it is convertible at the record date. The Preferred
Shares shall vote separately as a class with respect to certain specified matters. Otherwise, the preferred shareholders and ordinary shareholders shall vote together as a single class. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation preference  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution or winding up of the Company, or the cessation of the business of the Company or of a substantial
portion of the business of the Company, whether voluntary or involuntary, or any deemed liquidation event (unless waived by the preferred shareholders), the preferred shareholders shall be entitled to
receive a per share amount equal to 100% of the original issue price of the respective series of the Preferred Shares, in the sequence of Series&nbsp;C Preferred Shares, Series&nbsp;B Preferred
Shares and Series&nbsp;A Preferred Shares. After such liquidation amounts have been paid in full, the preferred shareholders are entitled to receive a simple interest accruing on each Preferred
Share at 6% of its original issue price per annum from the date of issuance of such Preferred Share to the date of distribution of such amount, in the sequence of Series&nbsp;C Preferred Shares,
Series&nbsp;B Preferred Shares and Series&nbsp;A Preferred Shares. After such interest amounts have been paid in full, any remaining funds or assets of the Company legally available for
distribution to shareholders shall be distributed on a pro rata basis among the preferred shareholders, on an as-converted basis, together with the ordinary shareholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=351,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=410856,FOLIO='F-60',FILE='DISK103:[20ZDS1.20ZDS17601]GK17601A.;19',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gm17601_1_61"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shareholders based on the then-effective
conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of share splits, share combinations, ordinary share dividends or distributions, other dividends,
reorganizations, mergers, consolidations, reclassifications, exchanges, substitutions, or dilutive issuance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Preferred Shares are converted automatically into ordinary shares at the then effective applicable conversion price upon the earlier of a Qualified Public Offering (public offering
of the Company's shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than
US$650,000,000 and with an aggregate proceeds of no less than US$75&nbsp;million) or a date specified by written consent or agreement of the holders of at least 80% of the voting power of the then
outstanding Preferred Shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Shares are redeemable upon request by the holders of the majority outstanding Preferred Shares if the Company fails to consummate
a Qualified Public Offering or complete a deemed liquidation event on or before March&nbsp;31, 2025 at the redemption price equal to the original issue price plus any declared but unpaid dividends. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accounting for Preferred Shares  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Shares are classified as mezzanine equity in the consolidated balance sheets because they are contingently redeemable upon the
occurrence of an event outside of the Company's control (e.g.&nbsp;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&nbsp;31, 2025 ("Target QIPO
Date")). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares are
initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any
Preferred Shares issued. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company concluded that the Preferred Shares are not currently redeemable, but are probable to become redeemable. The Company accreted changes in the redemption value over the period
from the date of issuance to the earliest redemption date using the interest method. No accretion charge was recorded as the redemption value is fixed to original issue price for the years presented,
except for Series&nbsp;C-1 Preferred Shares issued with detachable warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Modification of Preferred Shares  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company made several amendments to the Preferred Shares, mainly including: 1)&nbsp;added redemption rights for Series&nbsp;A Preferred
Shares upon the issuance of the Series&nbsp;B Preferred Shares; 2)&nbsp;extended the Target QIPO Date upon the issuance of the Series&nbsp;C-1 Preferred Shares and the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=352,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=512480,FOLIO='F-61',FILE='DISK103:[20ZDS1.20ZDS17601]GM17601A.;15',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gm17601_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Series&nbsp;C-3
Preferred Shares. These amendments are accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were
not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred
shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's Preferred Shares activities for the periods presented are summarized below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Mezzanine equity

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A-1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A-2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;B </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C-1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C-2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C-3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,481,159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84,955,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;C-2 Preferred Shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,000,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,000,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of Series&nbsp;C-1 Preferred Shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>184,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>184,014 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of September&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,665,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,000,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101,139,126 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,727,343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154,201,294</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of Series&nbsp;C-1 Preferred Shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>185,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>185,627 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of September&nbsp;30, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,473,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,999,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,912,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154,386,921 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. SHARE-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;7, 2015, the Company adopted a share incentive plan ("2015 Plan"). Under the 2015 Plan, the Company's Board of Directors has approved that a maximum aggregate number
of shares that may be issued pursuant to all awards granted shall be 4,336,126. In September 2017, the Company replaced 2015 Plan with the amended and restated share incentive plan ("2017 Plan") and
increased the maximum number of shares issuable to 6,336,126. In December 2019, the Company replaced 2017 Plan with the second amended and restated share incentive plan ("2019 Plan") and further
increased the maximum number of shares issuable to 11,391,131. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the
Company may issue under the respective plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in
accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than five years, under which the grantee earns an entitlement to vest a certain
percentage of his option grants at the end of each month or year of completed service. The share option awards shall expire no more than 10&nbsp;years from their grant dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence
of their applicable performance conditions (including but not limited to the occurrence of an initial public offering ("IPO"), the completion of business and operational goals, etc.). Upon being
eligible for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=353,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=222908,FOLIO='F-62',FILE='DISK103:[20ZDS1.20ZDS17601]GM17601A.;15',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gm17601_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. SHARE-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>vesting,
each such performance-based option shall vest in a series of four equal and continuous annual installments for each full year of services completed following the award date of such option. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of September&nbsp;30, 2020, the Company has granted 2,178,808 share options containing both service conditions and performance conditions. All other share options granted contain
only service conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August&nbsp;15, 2020, pursuant to board resolution, 184,692 share options that granted to a senior management was modified and the vesting period of the 184,692 share options has
been shortened from 5&nbsp;years to 4&nbsp;years. Since the fair value of the modified award is lower than the fair value of the original award immediately before the modification, there is no
incremental compensation cost to be recognized. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average<BR>
Exercise Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average Grant<BR>
Date Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted Average<BR>
Remaining<BR>
Contractual<BR>
Term </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$ per option</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$ per option</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Years</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding, January&nbsp;1, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>574,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,734,644</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>372,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(34,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding, December&nbsp;31, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>866,028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,328,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,973,373</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.04</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.09</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,273,761</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding, September&nbsp;30, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,551,640</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.96</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,495,526 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at September&nbsp;30, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,551,640</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.96</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,495,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at September&nbsp;30, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>412,387</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.86</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,217,567 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting
date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate fair value of the equity awards vested during the nine months ended September&nbsp;30, 2019 and 2020 was US$&nbsp;243,927 and US$7,699,049, respectively. As of
September&nbsp;30, 2020, there was US$&nbsp;20,941,290 of total unrecognized employee share-based compensation expense, may be adjusted for actual forfeitures occurring in the future. Total
unrecognized compensation cost will be recognized over a weighted-average period of 3.42&nbsp;years. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=354,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=319481,FOLIO='F-63',FILE='DISK103:[20ZDS1.20ZDS17601]GM17601A.;15',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gm17601_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. SHARE-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair value of share options  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party
appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected
volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise
multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods
within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over
the contractual life of the share options. The estimated fair value of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party
appraiser. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions used to estimate the fair value of the share options granted are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.73%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.71% - 0.83%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility range</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72.3% - 73.1%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercise multiple</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.2 - 2.8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual life</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10&nbsp;years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
share-based compensation expenses recognized for the nine months ended September&nbsp;30, 2019 and 2020 were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months<BR>
ended September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>244,846</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,971,881</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>194,042</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,073,830 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total share-based compensation expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>438,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,045,711 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2019, the Group entered into (i)&nbsp;a collaboration agreement that covers Greater China (the "Dragon Boat Greater China Agreement")
and (ii)&nbsp;a collaboration agreement that covers the regions other than Greater China (the "Dragon Boat ROW Agreement," together with the Dragon Boat Greater China Agreement, the "2019 Dragon
Boat Agreements"), with Dragon Boat Biopharmaceutical (Shanghai) Limited ("Dragon Boat"), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=355,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1005766,FOLIO='F-64',FILE='DISK103:[20ZDS1.20ZDS17601]GM17601A.;15',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gm17601_1_65"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>China
Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the "Specified Project"),
including the
patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the
exercise of Dragon Boat's rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights
relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the
purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including
but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&nbsp;certain high-six figure dollar milestone payments upon the achievement
of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug ("IND") approval in PRC and completion of clinical
phase&nbsp;I test in PRC) and (ii)&nbsp;a single-digit percentage of net sales of the products that use the licensed antibody after such products enter the market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&nbsp;the collaboration under the
agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&nbsp;improvements thereto for the purposes of exploiting its
rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such
intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the
ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research
and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement,
including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any
country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit percentage of the
consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction
price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2019 Dragon Boat Agreements, the Group agreed not to (i)&nbsp;independently develop any monospecific antibodies that bind to the specified target or (ii)&nbsp;grant any
rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from
(i)&nbsp;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the
specific target and (ii)&nbsp;continuing to provide antibody </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=356,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=414444,FOLIO='F-65',FILE='DISK103:[20ZDS1.20ZDS17601]GM17601A.;15',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<A NAME="page_gm17601_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>screening
service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the
Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party's ability to comply with its obligations under the agreements is negatively affected by
contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon
the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019
Dragon Boat Agreements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the nine months ended September&nbsp;30, 2019 and 2020, no revenue was recognized for this agreement respectively since the licensed product has not been transferred to Dragon
Boat. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of September&nbsp;30, 2020, upfront fee of RMB4,000,000 (equivalent to approximately US$579,836) that received by the Group was recorded as contract liabilities in the consolidated
balance sheets, as the performance obligation had not been satisfied by the Group. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ADC Therapeutics&nbsp;SA License and Collaboration Agreements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2019, the Group entered into a material transfer and collaboration agreement (the "ADCT Collaboration Agreement") and a license
agreement (the "ADCT License Agreement") with ADC Therapeutics&nbsp;SA ("ADC Therapeutics"). These two agreements are combined as a single contract as the agreements were negotiated as a package
with a single commercial objective. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ADCT Collaboration Agreement</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to two exclusive targets selected by ADC Therapeutics.
Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group's technology with respect to one or both targets as further detailed below. ADC Therapeutics has not
yet exercised such options as of September&nbsp;30, 2020. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group's exclusivity obligations, upon achievement
of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics' election to proceed
with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any
additional research and development services. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADC
Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days' prior written
notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party's uncured material breach of the agreement or the
other party's insolvency-related events. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=357,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1001906,FOLIO='F-66',FILE='DISK103:[20ZDS1.20ZDS17601]GM17601A.;15',USER='CHE107325',CD='29-JAN-2021;10:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_go17601_1_67"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. COLLABORATION ARRANGEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Group also granted ADC Therapeutics an exclusive target reservation right for one year from the commencement of the agreement and an option to renewal for another year with a
consideration of low-six-figure dollar amount. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ADCT License Agreement</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an
exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody
drug conjugates that comprise masked antibodies generated by the Group under these programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in
development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of
clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit percentage net
sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product
basis, until the earlier of (i)&nbsp;the tenth anniversary of the first commercial sale of such product or (ii)&nbsp;the expiration of the last-to-expire patent licensed under the agreement in
such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADC
Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&nbsp;for any
reason or no reason upon thirty days' written notice to the Group, or (ii)&nbsp;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each
party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party's uncured material breach or insolvency. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the nine months ended September&nbsp;30, 2019 and 2020, no revenue was recognized for this agreement respectively since the licensed product has not been transferred to ADC
Therapeutics. For the nine months ended September&nbsp;30, 2020, the Group recognized US$100,000 as other income due to the expiration of exclusive target reservation right, which is not related to
the Group's major operation activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of September&nbsp;30, 2020, upfront fee of US$225,000 that received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance
obligation had not been satisfied by the Group. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=358,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=571754,FOLIO='F-67',FILE='DISK103:[20ZDS1.20ZDS17601]GO17601A.;29',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_go17601_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. INCOME TAX EXPENSE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated
operating losses will not be utilized in the future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2019 and September&nbsp;30,
2020. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. NET LOSS PER SHARE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net loss per share for the nine months ended September&nbsp;30, 2019 and 2020 are calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Numerator:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to Adagene&nbsp;Inc.'s shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,818,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(184,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(185,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to ordinary shareholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,002,371</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,815,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Denominator:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of ordinary shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,172,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757,463 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effects of all outstanding convertible redeemable preferred shares and share options were excluded from the computation of diluted net loss per share for the nine months ended
September&nbsp;30, 2019 and 2020 as their effects would be anti-dilutive. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible redeemable preferred shares</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,562,018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,249,824</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>526,910</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,238,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. UNAUDITED PRO FORMA BALANCE SHEET AND NET LOSS PER SHARE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The unaudited pro forma balance sheet information as of September&nbsp;30, 2020 assumes the automatic conversion of all of the outstanding convertible redeemable preferred shares into
ordinary shares at a conversion ratio of 1:1, as if the conversion and expiry had occurred as of September&nbsp;30, 2020. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
unaudited pro forma net loss per ordinary share is computed using the weighted-average number of ordinary shares outstanding and the automatic conversion of all of the Group's
outstanding mezzanine equity into ordinary shares upon the closing of the Group's Qualified Public Offering, as if </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=359,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=731398,FOLIO='F-68',FILE='DISK103:[20ZDS1.20ZDS17601]GO17601A.;29',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_go17601_1_69"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. UNAUDITED PRO FORMA BALANCE SHEET AND NET LOSS PER SHARE (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>it
had occurred on January&nbsp;1, 2020. The Group believes the unaudited pro forma net loss per share provides material information to investors, as the automatic conversion of the Group's
outstanding mezzanine equity. The disclosure of pro forma net loss per ordinary share provides an indication of net loss per ordinary share that is comparable to what will be reported by the Group as
a public company following the closing of the Qualified Public Offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
unaudited basic and diluted pro forma net loss per share is calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the six<BR>
months ended<BR>
September&nbsp;30,<BR>
2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Numerator:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to ordinary shareholders in computing pro forma net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,815,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Add back accretion of convertible redeemable preferred shares to redemption value</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>185,627 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator for pro-forma basic and diluted net loss per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,629,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Denominator:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of ordinary shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,757,463</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Add:adjustment to reflect assumed effect of automatic conversion of convertible&nbsp;&nbsp;&nbsp;&nbsp;redeemable preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,249,824</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pro forma weighted average number of shares outstanding&#151;basic and diluted</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,007,287 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pro forma net loss per share&#151;basic and diluted</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. RELATED PARTY TRANSACTIONS  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>a)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Related Parties</I></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of related parties

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Relationship </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman, Chief Executive Officer and a principal shareholder of the Company</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Four senior management personnel</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Management and ordinary shareholders of the Company</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec&nbsp;Co.,&nbsp;Ltd. ("WuXi AppTec Group")</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>A principal shareholder of the Group</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Controlled by the ultimate controlling party of a principal shareholder of the Group</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=360,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=1047543,FOLIO='F-69',FILE='DISK103:[20ZDS1.20ZDS17601]GO17601A.;29',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_go17601_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. RELATED PARTY TRANSACTIONS (Continued) </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>b)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Group had the following related party balances at the end of the year/period:</I></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,452</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>367,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>739,051</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Four senior management personnel(i)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350,865</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo(i)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>338,818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total amounts due from related parties</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,433,186</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>407,381 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,379,741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,032,352</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>432,784</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>354,338</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Luo(ii)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total amounts due to related parties</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,895,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,386,690 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>c)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Group had the following related party transactions during the periods:</I></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the nine months<BR>
ended September&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>US$</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Receipt of CRO and CMO services:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi Biologics (Shanghai)&nbsp;Co.,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,815,862</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,107,176</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WuXi AppTec Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,313,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,326,989 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,129,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,434,165 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
October and November 2017, Peter Luo and other four senior management personnel elected to exercise the vested share options that granted under 2015 Plan. As of
December&nbsp;31, 2019, the balance of amounts due from Peter Luo and other four senior management personnel represented the receivables arising from withholding individual income tax amounts. The
balance of amount due from four senior management personnel and Peter Luo was settled in September 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
May 2014 the Group received a subsidy from the local government for attracting high skilled personnel on behalf of Peter Luo, which was settled in May 2020. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=361,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=428843,FOLIO='F-70',FILE='DISK103:[20ZDS1.20ZDS17601]GO17601A.;29',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_go17601_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating lease commitments  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future minimum payments under non-cancelable operating leases with initial terms in excess of one year consist of the following as of
September&nbsp;30, 2020: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>US$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remaining three months of 2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>230,084</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>104,289 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>559,781 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
under operating leases are expensed on a straight-line basis over the periods of their respective leases. The Group's lease arrangements have no renewal options, rent escalation
clauses, restrictions or contingent rents and are all executed with third parties. For the nine months ended September&nbsp;30, 2019 and 2020, total rental related expenses for all operating leases
amounted to US$135,750 and US$116,061, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contingencies  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group's business,
financial position or results of operations </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


16. SUBSEQUENT EVENTS  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Group evaluated subsequent events through February&nbsp;1, 2021, the date these interim condensed consolidated financial statements were issued.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
in January 2020, the emergence and wide spread of the novel Coronavirus ("COVID-19") has resulted in quarantines, travel restrictions, and the temporary closure of stores and
facilities in China, US and elsewhere. Substantially all of the Group's operating and workforce are concentrated in China and US. Consequently, the COVID-19 outbreak could potentially delay patient's
access to hospital and the progress of clinical trials of the Group, which may adversely affect the Group's business operations, financial condition and operating results for 2020. The extent to which
COVID-19 impacts the business and financial results of the Group in the longer term will depend on future developments, which are uncertain and cannot be predicted, including new information which may
emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The Group will continue to evaluate the impact on the results of
operation, financial position and cash flows of the Group and react actively as the situation evolves. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2020, pursuant to the 2019 Plan, the Board of Directors of the Company passed resolutions and granted 340,000 share options to certain employees with an exercise price of
US$2.26 per share. The fair values of these share options ranged from US$9.02 to US$9.23 per option and were determined by using the binomial option valuation model. The share-based compensation
expense

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=362,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=151395,FOLIO='F-71',FILE='DISK103:[20ZDS1.20ZDS17601]GO17601A.;29',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<A NAME="page_go17601_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
ADAGENE&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO THE UNAUDITED INTERIM CONDENSED </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2020 </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


16. SUBSEQUENT EVENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


related to these share options is expected to be recognized over a weighted-average period of 4.06 years.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of 2,375,000 share options granted to certain management members. Pursuant to
this board resolution, these management members exercised all these share options at the original exercise price per share ranging from US$1.83 to US$2.26 and as a result, 2,375,000 ordinary shares
were issued to them. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$5,197,650. These ordinary shares are subject to the Company's
repurchase rights before the share awards meet certain conditions. The management assessed and considered that such change in terms met the exception for modification accounting (as defined in
ASU&nbsp;2017-09, Scope of Modification Accounting), hence no additional amount of compensation expense was recognized.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2020, the Group borrowed two loans with the amount of RMB5,000,000 (equivalent to approximately US$760,086) and RMB5,000,000 (equivalent to US$760,086) from China Merchants
Bank&nbsp;Co.,&nbsp;Ltd., respectively. Both of these two loans have a term of one year and bear an interest rate of 4.10% per annum. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of 491,119 ordinary shares as repayment for their respective promissory
notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way
of new option grants with an exercise price of US$13.85 per share. The fair values of these share options were US$7.85 per option, determined by using the binomial option valuation model. The
share-based compensation expense related to these share options is expected to be recognized immediately upon grants.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the same board resolution, the 2021 Performance Incentive Plan was also adopted, under which an aggregate of 2,994,000 ordinary shares shall be reserved for issuance, and the
share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&nbsp;5% of the total number of the Company's outstanding
ordinary shares on December&nbsp;31 of the prior year, or (2)&nbsp;such lesser number as determined by the board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;1, 2021, the Company entered into a collaboration and license agreement (the "Exelixis Agreement") with Exelixis,&nbsp;Inc., pursuant to which the Company agreed to
generate masked antibodies with the Company's SAFEbody technology against an initial target and a second target to be selected
by Exelixis. Under the Exelixis Agreement, the Company are entitled to receive an US$11,000,000 upfront payment. In addition, the Company could be eligible to receive, on a target-by-target basis, up
to US$127,500,000 in development and regulatory milestone payments upon the achievement of specified development and regulatory milestones and up to US$262,500,000 in sales milestone payments upon the
achievement of specified commercial milestones. In the aggregate, the Company could be eligible to receive up to US$255,000,000 in development and regulatory milestone payments and up to
US$525,000,000 in sales milestone payments for both targets under the Exelixis Agreement. In addition, the Company are entitled to receive mid-single-digit percentage net sales-based royalties on
products developed under the Exelixis Agreement, subject to certain reductions.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=363,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=215100,FOLIO='F-72',FILE='DISK103:[20ZDS1.20ZDS17601]GO17601A.;29',USER='CHE105918',CD=';1-FEB-2021;04:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ja17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_part_ii_information_not_required_in_the_prospectus"> </A>
<A NAME="toc_ja17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  <BR>    INFORMATION NOT REQUIRED IN THE PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_6._indemnification_of_directors_and_officers"> </A>
<A NAME="toc_ja17601_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cayman Islands law does not limit the extent to which a company's articles of association may provide for indemnification of officers and
directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide
indemnification against civil fraud or the consequences or committing a crime. Under our post-offering memorandum and articles of association, which will become effective immediately prior to the
completion of this offering, to the fullest extent permissible under Cayman Islands law every director and officer of our company shall be indemnified against all actions, proceedings, costs, charges,
expenses, losses, damages or liabilities incurred or sustained by him in connection with the execution or discharge of his duties, powers, authorities or discretions as a director or officer of our
company, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by him in defending (whether successfully or otherwise) any civil
proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the form of indemnification agreements to be filed as Exhibit&nbsp;10.2 to this Registration Statement, we will agree to indemnify our directors and executive officers
against certain liabilities and expenses that they incur in connection with claims made by reason of their being a director or officer of our company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Underwriting Agreement, the form of which will be filed as Exhibit&nbsp;1.1 to this Registration Statement, will also provide for indemnification of us and our officers and
directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling us pursuant to the
foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_7._recent_sales_of_unregistered_securities"> </A>
<A NAME="toc_ja17601_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the past three years, we have issued the following securities (including options to acquire our ordinary shares) without registering the
securities under the Securities Act. We believe that each of the following issuances was exempt from registration under the Securities Act in reliance on Regulation&nbsp;S under the Securities Act
regarding sales by an issuer in offshore transactions or pursuant to Section&nbsp;4(a)(2) of the Securities Act regarding transactions not involving a public offering. None of the transactions
involved an underwriter. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="101pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Purchaser

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of Issuance </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title and<BR>
Number of Securities </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consideration </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>SCC Venture VI Holdco,&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>February&nbsp;2, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>1,679,206 series&nbsp;C-1 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>US$15,000,011.36</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Gopher Harvest Co-Investment Fund&nbsp;LP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;2, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>559,735 series&nbsp;C-1 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$5,000,000.80</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>AVICT Global Holdings Limited </FONT><FONT SIZE=2><B>
<IMG SRC="g934962.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="15">
 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;2, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>1,119,471 series&nbsp;C-1 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$10,000,010.55</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>King Star Med&nbsp;LP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;19, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>1,119,471 series&nbsp;C-1 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$10,000,000.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>WEALTHY TECHNOLOGIES LIMITED</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;19, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>559,735 series&nbsp;C-1 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$5,000,000.00</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=364,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=842736,FOLIO='II-1',FILE='DISK103:[20ZDS1.20ZDS17601]JA17601A.;18',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_ja17601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="101pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Purchaser

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of Issuance </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title and<BR>
Number of Securities </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consideration </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Chief Strategic International Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>May&nbsp;16, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>559,736 series&nbsp;C-1 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>US$5,000,010.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Mega Prime Development Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;13, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>685,676 series&nbsp;C-2 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$6,999,998.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Poly Platinum Enterprises Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;13, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>489,769 series&nbsp;C-2 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$5,000,003.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Chief Strategic International Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;13, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>391,815 series&nbsp;C-2 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$4,000,000.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>MODEST CHAMPION LIMITED </FONT><FONT SIZE=2><B>
<IMG SRC="g140919.jpg" ALT="GRAPHIC" WIDTH="88" HEIGHT="15">
 </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;21, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>293,861 series&nbsp;C-2 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$2,999,998.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>General Atlantic Singapore AI&nbsp;Pte.&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>December&nbsp;19, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>4,452,441 series&nbsp;C-3 preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$50,000,000.00</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Certain directors, officers and employees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>From August&nbsp;17, 2017 to January&nbsp;19, 2021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>6,761,534 ordinary shares<SUP>#</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>US$7,912,715.40</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B><U>Options and Warrants</U></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>SCC Venture VI Holdco,&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;2, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Warrant to purchase up to US$5,625,000 worth of series&nbsp;C-2 preferred shares*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>N/A</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Gopher Harvest Co-Investment Fund&nbsp;LP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;2, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Warrant to purchase up to US$1,875,000 worth of series&nbsp;C-2 preferred shares*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>N/A</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Certain directors, officers and employees</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>From August&nbsp;17, 2017 to January&nbsp;19, 2021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Option to purchase 7,154,992 ordinary shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Past and future services provided by these individuals to us</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=1>Notes:
</FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>#</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
number of ordinary shares includes the 2,262,500 ordinary shares, issued but deemed to be not outstanding as of the date of this prospectus, held by Great Han
Fortune LP.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>These
warrants expired on April&nbsp;1, 2019. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_8._exhibits_and_financial_statement_schedules"> </A>
<A NAME="toc_ja17601_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules    <BR>    </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Exhibits: </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
Exhibit Index for a complete list of all exhibits filed as part of this registration, which Exhibit Index is incorporated herein by reference.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Financial
Statement Schedules </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedules
have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements and the notes thereto. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=365,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=157607,FOLIO='II-2',FILE='DISK103:[20ZDS1.20ZDS17601]JA17601A.;18',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<A NAME="page_ja17601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_9._undertakings"> </A>
<A NAME="toc_ja17601_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby undertakes: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations
and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is
against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933
shall be deemed to be part of this registration statement as of the time it was declared effective. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=366,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=13600,FOLIO='II-3',FILE='DISK103:[20ZDS1.20ZDS17601]JA17601A.;18',USER='CHE107555',CD='29-JAN-2021;09:51' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_jc17601_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> ADAGENE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> EXHIBIT INDEX  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Document </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> 1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Underwriting Agreement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-3_1.htm">Sixth Amended and Restated Memorandum and Articles of Association of the Registrant, as currently in effect</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="a2242824zex-3_2.htm">Form of Seventh Amended and Restated Memorandum and Articles of Association of the Registrant, as effective immediately prior to the completion of this offering</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_3.htm">Form of Registrant's Specimen American Depositary Receipt (included in Exhibit&nbsp;4.3)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_2.htm">Registrant's Specimen Certificate for Ordinary Shares</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_3.htm">Form of Deposit Agreement between the Registrant, the depositary and holders of the American Depositary
Shares</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_4.htm">Fifth Amended and Restated Shareholders Agreement by and among Adagene&nbsp;Inc. and shareholders of Adagene&nbsp;Inc. named
therein dated December&nbsp;19, 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_5.htm">Fourth Amended and Restated Right of First Refusal and Co-Sale Agreement by and between Adagene&nbsp;Inc., non-investor
shareholders and investors named therein dated December&nbsp;19, 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-5_1.htm">Opinion of Walkers (Hong Kong) regarding the validity of the ordinary shares being registered</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-5_1.htm">Opinion of Walkers (Hong Kong) regarding certain Cayman Island tax matters (included in Exhibit&nbsp;5.1)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_2.htm">Opinion of Tian Yuan Law Firm regarding certain PRC tax matters (included in Exhibit&nbsp;99.2)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-8_3.htm">Opinion of Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP regarding material U.S. federal income tax consequences</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_1.htm">Adagene&nbsp;Inc. Second Amended and Restated Share Incentive Plan</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_2.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_3.htm">Form of Employment Agreement between the Registrant and an executive officer of the Registrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_4.htm">Shares Purchase Agreement by and among Adagene&nbsp;Inc., its subsidiaries and General Atlantic Singapore AI Pte.&nbsp;Ltd.
dated October&nbsp;15, 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_5.htm">Shares Purchase Agreement by and among Adagene&nbsp;Inc., its subsidiaries and certain investors of Adagene&nbsp;Inc. named
therein dated June&nbsp;9, 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_6.htm">Shares Purchase Agreement by and among Adagene&nbsp;Inc., its subsidiaries and certain investors of Adagene&nbsp;Inc. named
therein dated February&nbsp;2, 2018</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_7.htm">English translation of Cooperation Agreement on the PD-L1 Project by and among Guilin Sanjin Pharmaceutical&nbsp;Co.,
&nbsp;Ltd. and its affiliates and Adagene (Suzhou) Limited dated December 2018</A></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR></FONT>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=367,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=264265,FOLIO='II-4',FILE='DISK103:[20ZDS1.20ZDS17601]JC17601A.;46',USER='CHE109574',CD='29-JAN-2021;23:04' -->
<A NAME="page_jc17601_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Document </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> 10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_8.htm">English translation of Cooperation Agreement on International Interests of PD-L1 Project between Guilin Sanjin
Pharmaceutical&nbsp;Co.,&nbsp;Ltd. and Adagene&nbsp;Inc. dated December 2018</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_9.htm">English translation of Cooperation Agreement on the Undisclosed Project between Dragon Boat Biopharmaceutical (Shanghai)
Limited and Adagene (Suzhou) Limited dated May 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_10.htm">English translation of Cooperation Agreement on International Interests of Undisclosed Project between Dragon Boat
Biopharmaceutical (Shanghai) Limited and Adagene&nbsp;Inc. dated May 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_11.htm">Material Transfer and Collaboration Agreement between ADC Therapeutics SA and Adagene Inc. dated April 11,
2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_12.htm">License Agreement Among ADC Therapeutics SA and Adagene Inc. dated April 11, 2019</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_13.htm">Adagene Inc. 2021 Performance Incentive Plan</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="a2242824zex-10_14.htm">Collaboration and License Agreement between Exelixis, Inc. and Adagene Incorporated dated February&nbsp;1, 2021</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-21_1.htm">List of subsidiaries of the Registrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="a2242824zex-23_1.htm">Consent of PricewaterhouseCoopers Zhong Tian&nbsp;LLP, Independent Registered Public Accounting Firm</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-5_1.htm">Consent of Walkers (Hong Kong) (included in Exhibit&nbsp;5.1)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_2.htm">Consent of Tian Yuan Law Firm (included in Exhibit&nbsp;99.2)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-8_3.htm">Consent of Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP (included in Exhibit&nbsp;8.3)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zf-1.htm#sig">Powers of Attorney (included on signature page)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_1.htm">Code of Business Conduct and Ethics of the Registrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_2.htm">Opinion of Tian Yuan Law Firm regarding certain PRC law matters</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_3.htm">Consent of Frost&nbsp;&amp; Sullivan</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_4.htm">Consent of Andy (Yiu Leung) Cheung</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_5.htm">Consent of Min Li</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_6.htm">Consent of Man Kin (Raymond) Tam</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_7.htm">Representation under Item 8.A.4 of Form 20-F</A></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>To
be filed by amendment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>#</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Portions
of this exhibit have been omitted because they are both (i)&nbsp;not material and (ii)&nbsp;would likely cause competitive harm to the Company if publicly
disclosed.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Previously
filed. </FONT>

</DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=368,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=708398,FOLIO='II-5',FILE='DISK103:[20ZDS1.20ZDS17601]JC17601A.;46',USER='CHE109574',CD='29-JAN-2021;23:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_je17601_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="sig"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="je17601_signatures"> </A>
<A NAME="toc_je17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form&nbsp;F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San
Francisco, State of California, on February&nbsp;1, 2021.

</FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><B> Adagene&nbsp;Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;PETER (PEIZHI) LUO<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Peter (Peizhi) Luo</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on February&nbsp;1, 2021 in the capacities
indicated:

</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2> /s/&nbsp;PETER (PEIZHI) LUO<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Peter (Peizhi) Luo</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer, Director (principal executive officer)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Yunxia Yang</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>*<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Yu Miao</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Lefei Sun</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;MAN KIN (RAYMOND) TAM<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Man Kin (Raymond) Tam</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer (principal financial officer and principal accounting officer)</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="29%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="29%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2> *By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;PETER (PEIZHI) LUO<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Peter (Peizhi) Luo<BR></FONT> <FONT SIZE=2><I>Attorney-in-fact</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=369,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=329958,FOLIO='II-6',FILE='DISK103:[20ZDS1.20ZDS17601]JE17601A.;22',USER='CHE107325',CD='29-JAN-2021;11:34' -->
<A NAME="page_je17601_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="je17601_signature_of_authorize__je102511"> </A>
<A NAME="toc_je17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES    <BR>    </B></FONT></P>


<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Adagene&nbsp;Inc., has
signed this registration statement or amendment thereto in New York on February&nbsp;1, 2021.

 </FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2>Authorized U.S. Representative</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;COLLEEN A. DE VRIES<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Colleen A. De Vries</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Senior Vice President</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=370,EFW="2242824",CP="ADAGENE INC.",DN="1",CHK=138501,FOLIO='II-7',FILE='DISK103:[20ZDS1.20ZDS17601]JE17601A.;22',USER='CHE107325',CD='29-JAN-2021;11:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>a2242824zex-3_2.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;3.2</font></b><a name="29876-2-PG-01_Exhibit3_2_123043"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE COMPANIES ACT (AS AMENDED)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF THE CAYMAN ISLANDS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY LIMITED BY SHARES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SEVENTH AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MEMORANDUM AND ARTICLES OF ASSOCIATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAGENE INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:15.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 19,&nbsp;2021 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY&#146;S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS ORDINARY SHARES)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=148822,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE COMPANIES ACT (AS AMENDED)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF THE CAYMAN ISLANDS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY LIMITED BY SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SEVENTH AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MEMORANDUM OF ASSOCIATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAGENE INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:5.25pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 19,&nbsp;2021 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY&#146;S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS ORDINARY SHARES)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The name of the Company is Adagene Inc. (the &#147;<b>Company</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The registered office of the Company will be situated at the offices of Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands or at such other location as the Directors may from time to time determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by any law as provided by Section&nbsp;7(4)&nbsp;of the Companies Act (as amended) of the Cayman Islands (the &#147;<b>Companies Act</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company shall have and be capable of exercising all the functions of a natural person of full capacity irrespective of any question of corporate benefit as provided by Section&nbsp;27(2)&nbsp;of the Companies Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company will not trade in the Cayman Islands with any person, firm or corporation except in furtherance of the business of the Company carried on outside the Cayman Islands; provided that nothing in this section shall be construed as to prevent the Company effecting and concluding contracts in the Cayman Islands, and exercising in the Cayman Islands all of its powers necessary for the carrying on of its business outside the Cayman Islands.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The liability of the shareholders of the Company is limited to the amount from time to time, if any, unpaid on the shares respectively held by them.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The authorised share capital of the Company is US$80,000 divided into 800,000,000 shares comprising (i)&nbsp;640,000,000 Ordinary Shares of a nominal or par value of US$0.0001 each, and (ii)&nbsp;160,000,000 shares of a nominal or par value of US$0.0001 each of such class or classes (however designated) as the board of directors may determine in accordance with Article&nbsp;9 of the Articles.&#160; Subject to the Companies Act and the Articles of Association, the Company shall have power to redeem or purchase any of its shares, and to sub-divide or consolidate the said shares or any of them and to issue all or any part of its capital whether original, redeemed, increased or reduced with or without any preference, priority, special privilege or other rights or subject to any postponement of rights or to any conditions or restrictions whatsoever and so that unless the conditions of issue shall otherwise expressly provide every issue of shares whether stated to be ordinary, preference or otherwise shall be subject to the powers on the part of the Company hereinbefore provided.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may exercise the power contained in Section&nbsp;206 of the Companies Act to deregister in the Cayman Islands and be registered by way of continuation in some other jurisdiction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=798979,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Capitalized terms that are not defined in this Memorandum of Association bear the same meaning as those given in the Articles of Association of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="89%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CLAUSE</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">PAGE</font></b></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TABLE A</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">INTERPRETATION</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRELIMINARY</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MODIFICATION OF RIGHTS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FRACTIONAL SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LIEN</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CALLS ON SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FORFEITURE OF SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TRANSFER OF SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TRANSMISSION OF SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ALTERATION OF SHARE   CAPITAL</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">REDEMPTION, PURCHASE   AND SURRENDER OF SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TREASURY SHARES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GENERAL MEETINGS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PROCEEDINGS AT GENERAL   MEETINGS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VOTES OF SHAREHOLDERS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CORPORATIONS ACTING BY REPRESENTATIVES   AT MEETINGS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CLEARING HOUSES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DIRECTORS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ALTERNATE DIRECTOR</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">POWERS AND DUTIES OF   DIRECTORS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BORROWING POWERS OF   DIRECTORS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE SEAL</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">ii<a name="29876-2-PG-01_PB_ii_132059_4714"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=292044,FOLIO='ii',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DISQUALIFICATION OF   DIRECTORS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PROCEEDINGS OF   DIRECTORS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PRESUMPTION OF ASSENT</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DIVIDENDS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ACCOUNTS, AUDIT AND   ANNUAL RETURN AND DECLARATION</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CAPITALISATION OF   RESERVES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SHARE PREMIUM ACCOUNT</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOTICES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">INDEMNITY</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NON-RECOGNITION OF   TRUSTS</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WINDING UP</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AMENDMENT OF ARTICLES   OF ASSOCIATION</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CLOSING OF REGISTER OR   FIXING RECORD DATE</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">REGISTRATION BY WAY OF   CONTINUATION</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DISCLOSURE</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">iii<a name="29876-2-PG-01_PB_iii_132120_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=193636,FOLIO='iii',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE COMPANIES ACT (AS AMENDED)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF THE CAYMAN ISLANDS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY LIMITED BY SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SEVENTH AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLES OF ASSOCIATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAGENE INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:5.25pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 19,&nbsp;2021 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY&#146;S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS ORDINARY SHARES)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Regulations contained or incorporated in Table &#145;A&#146; in the First Schedule of the Companies Act shall not apply to the Company and the following Articles shall comprise the Articles of Association of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INTERPRETATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In these Articles the following defined terms will have the meanings ascribed to them, if not inconsistent with the subject or context:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>ADS</b>&#148; means an American depositary share, each representing such number of Ordinary Shares as set out in the registration statements of the Company;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Affiliate</b>&#148; means in respect of a Person, any other Person that, directly or indirectly, through (1)&nbsp;one or more intermediaries, Controls, is Controlled by, or is under common Control with, such Person, and (i)&nbsp;in the case of a natural person, shall include, without limitation, such person&#146;s spouse, parents, children, siblings, mother-in-law, father-in-law, brothers-in-law and sisters-in-law, a trust for the benefit of any of the foregoing, and a corporation, partnership or any other entity wholly or jointly owned by any of the foregoing, and (ii)&nbsp;in the case of an entity, shall include a partnership, a corporation or any other entity or any natural person which directly, or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, such entity;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Appointment Period</b>&#148; means the period commencing upon the effectiveness of the Company&#146;s Registration Statement and ending on the earliest of (i)&nbsp;the date upon which Peter Peizhi Luo beneficially owns (as defined under Rule&nbsp;13d-3 of the Exchange Act) less than five per cent (5%) of the Shares outstanding on a fully diluted basis, (ii)&nbsp;the death or legal determination of Peter Peizhi Luo&#146;s incapacity and (iii)&nbsp;the termination of Peter Peizhi Luo as an executive officer or principal scientific advisor to the Company or any Group Company for cause (as determined under his related employment or consulting arrangements and subject to all related cure provisions);</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Articles</b>&#148; means these articles of association of the Company, as amended or substituted from time to time;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="29876-2-PG-01_PB_1_123639_2047"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=904559,FOLIO='1',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Board</b>&#148; and &#147;<b>Board of Directors</b>&#148; and &#147;<b>Directors</b>&#148; means the directors of the Company for the time being, or as the case may be, the directors assembled as a board or as a committee thereof;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Chairman</b>&#148; means the chairman of the Board of Directors;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Class</b>&#148; or &#147;<b>Classes</b>&#148; means any class or classes of Shares as may from time to time be issued by the Company;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Commission</b>&#148; means Securities and Exchange Commission of the United States of America or any other federal agency for the time being administering the Securities Act;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Companies Act</b>&#148; means the Companies Act (as amended) of the Cayman Islands;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Company</b>&#148; means Adagene Inc., a Cayman Islands exempted company;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Company&#146;s Website&#148;</b> means the website of the Company, the address or domain name of which has been notified to Shareholders;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Control</b>&#148; means the ownership, directly or indirectly, of shares possessing more than fifty per cent (50%) of the voting power of the corporation, partnership or other entity (other than, in the case of a corporation, securities having such power only by reason of the happening of a contingency), or having the power to control the management or elect a majority of members to the board of directors or equivalent decision-making body of such corporation, partnership or other entity;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>day</b>&#148; means calendar day;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Designated Stock Exchange</b>&#148; means the national stock exchange in the United States on which any Shares and ADSs are listed for trading;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Designated Stock Exchange Rules</b>&#148; means the relevant code, rules&nbsp;and regulations, as amended, from time to time, applicable as a result of the original and continued listing of any Shares or ADSs on the Designated Stock Exchange;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>electronic&#148; </b>means the meaning given to it in the Electronic Transactions Law (as amended) of the Cayman Islands and any amendment thereto or re-enactments thereof for the time being in force and includes every other law incorporated therewith or substituted therefor;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>electronic communication&#148; </b>means electronic posting to the Company&#146;s Website, transmission to any number, address or internet website or other electronic delivery methods as otherwise decided and approved by not less than a majority of the vote of the Board;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Exchange Act</b>&#148; means the Securities Exchange Act of 1934, as amended;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Group Company</b>&#148; means each of the Company and all of its direct or indirect Subsidiaries, and &#147;<b>Group</b>&#148; refers to all of the Group Companies collectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Independent Director&#148; </b>means a Director who is an independent director as defined in the Designated Stock Exchange Rules;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Memorandum of Association</b>&#148; means the memorandum of association of the Company, as amended or substituted from time to time;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>month</b>&#148; means calendar month;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Office</b>&#148; means the registered office of the Company as required by the Companies Act;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Officer</b>&#148; means the offices for the time being and from time to time of the Company;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="29876-2-PG-01_PB_2_123653_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=424732,FOLIO='2',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Ordinary Resolution</b>&#148; means a resolution:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>passed by a simple majority of the votes cast by such Shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the Company and where a poll is taken regard shall be had in computing a majority to the number of votes to which each Shareholder is entitled by these Articles; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>approved in writing by all of the Shareholders entitled to vote at a general meeting of the Company in one or more instruments each signed by one or more of the Shareholders and the effective date of the resolution so adopted shall be the date on which the instrument, or the last of such instruments, if more than one, is executed;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Ordinary Shares</b>&#148; means an ordinary share of par value of US$0.0001 each in the capital of the Company having the rights and subject to the restrictions set out in these Articles, including a fraction of a share;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>paid up</b>&#148; means paid up as to the par value in respect of the issue of any Shares and includes credited as paid up;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Person</b>&#148; means any natural person, firm, company, joint venture, partnership, corporation, association or other entity (whether or not having a separate legal personality) or any of them as the context so requires, other than in respect of a Director or Officer in which circumstances Person Shall mean any person or entity permitted to act as such in accordance with the laws of the Cayman Islands;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Register</b>&#148; means the register of Shareholders of the Company required to be kept pursuant to the Companies Act;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Registration Statement</b>&#148; means the Company&#146;s registration statement on Form&nbsp;F-1 (as it may be amended or supplemented) filed with the SEC under the Securities Act in connection with the initial public offering of American depositary shares representing its Ordinary Shares;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Seal</b>&#148; means the common seal of the Company (if adopted) including any facsimile thereof;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>SEC</b>&#148; means the United States Securities and Exchange Commission;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Secretary</b>&#148; means any Person appointed by the Directors to perform any of the duties of the secretary of the Company;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Securities Act</b>&#148; means the United States Securities Act of 1933, as amended, or any similar federal statute and the rules&nbsp;and regulations of the Commission thereunder, all as the same shall be in effect at the time;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Share</b>&#148; means a share in the capital of the Company. All references to &#147;Shares&#148; herein shall be deemed to be Shares of any or all Classes as the context may require. For the avoidance of doubt in these Articles the expression &#147;Share&#148; shall include a fraction of a Share;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Shareholder</b>&#148; means a Person who is registered as the holder of Shares in the Register and includes each subscriber to the Memorandum of Association pending entry in the Register of such subscriber;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Share Premium Account</b>&#148; means the share premium account established in accordance with these Articles and the Companies Act;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>signed</b>&#148; means bearing a signature or representation of a signature affixed by mechanical means or an electronic symbol or process attached to or logically associated with an electronic communication and executed or adopted by a person with the intent to sign the electronic communication;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="29876-2-PG-01_PB_3_123700_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=80390,FOLIO='3',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Special Resolution</b>&#148; means a special resolution of the Company passed in accordance with the Companies Act being a resolution:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>passed by not less than two-thirds of the votes cast by such Shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the Company of which notice specifying the intention to propose the resolution as a special resolution has been duly given and where a poll is taken regard shall be had in computing a majority to the number of votes to which each Shareholder is entitled; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>approved in writing by all of the Shareholders entitled to vote at a general meeting of the Company in one or more instruments each signed by one or more of the Shareholders and the effective date of the special resolution so adopted shall be the date on which the instrument or the last of such instruments, if more than one, is executed;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Subsidiary</b>&#148; means, with respect to any given Person, any other Person that is Controlled directly or indirectly by such given Person;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Treasury Shares</b>&#148; means Shares that were previously issued but were purchased, redeemed, surrendered or otherwise acquired by the Company and not cancelled;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>United States</b>&#148; means the United States of America, its territories, its possessions and all areas subject to its jurisdiction; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>year</b>&#148; means calendar year.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In these Articles, save where the context requires otherwise:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>words importing the singular number shall include the plural number and vice versa;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>words importing the masculine gender only shall include the feminine gender and any Person as the context may require;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the word &#147;may&#148; shall be construed as permissive and the word &#147;shall&#148; shall be construed as imperative;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>reference to a dollar or dollars (or US$) and to a cent or cents is reference to dollars and cents of the United States of America;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>reference to a statutory enactment shall include reference to any amendment or re-enactment thereof for the time being in force;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>reference to any determination by the Directors shall be construed as a determination by the Directors in their sole and absolute discretion and shall be applicable either generally or in any particular case;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>reference to &#147;in writing&#148; shall be construed as written or represented by any means reproducible in writing, including any form of print, lithograph, email, facsimile, photograph or telex or represented by any other substitute or format for storage or transmission for writing including in the form of an electronic record or partly one and partly another;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any requirements as to delivery under the Articles include delivery in the form of an electronic record or an electronic communication; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any requirements as to execution or signature under the Articles, including the execution of the Articles themselves, can be satisfied in the form of an electronic signature as defined in the Electronic Transaction Law (as amended). Sections 8 and 19 of the Electronic Transactions Law (as amended) shall not apply.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="29876-2-PG-01_PB_4_123712_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=518656,FOLIO='4',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the last two preceding Articles, any words defined in the Companies Act shall, if not inconsistent with the subject or context, bear the same meaning in these Articles.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PRELIMINARY</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The business of the Company may be conducted as the Directors see fit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Office shall be at such address in the Cayman Islands as the Directors may from time to time determine. The Company may in addition establish and maintain such other offices and places of business and agencies in such places as the Directors may from time to time determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The expenses incurred in the formation of the Company and in connection with the offer for subscription and issue of Shares shall be paid by the Company.&#160; Such expenses may be amortised over such period as the Directors may determine and the amount so paid shall be charged against income and/or capital in the accounts of the Company as the Directors shall determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors shall keep, or cause to be kept, the Register at such place or (subject to compliance with the Companies Act and these Articles) places as the Directors may from time to time determine.&#160; In the absence of any such determination, the Register shall be kept at the Office.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to these Articles, all Shares for the time being unissued shall be under the control of the Directors who may, in their absolute discretion and without the approval of the Shareholders, cause the Company to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>issue, allot or dispose of the same (whether in certificated form or non-certificated form, including fractions of a Share) to such Persons, in such manner, on such terms and having such rights and being subject to such restrictions as they may from time to time determine;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>grant rights over Shares or other securities to be issued in one or more classes or series as they deem necessary or appropriate and determine the designations, powers, preferences, privileges and other rights attaching to such Shares or securities, including dividend rights, voting rights, conversion rights, terms of redemption and liquidation preferences, any or all of which may be greater than the powers, preferences, privileges and rights associated with the then issued and outstanding Shares, at such times and on such other terms as they think proper; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>grant options with respect to such Shares and issue warrants, convertible securities or similar instruments with respect thereto;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and, for such purposes, the Directors may reserve an appropriate number of Shares for the time being unissued.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors, or the Shareholders by Ordinary Resolution, may authorise the division of Shares into any number of Classes and sub-classes and the different Classes and sub-classes shall be authorised, established and designated (or re-designated as the case may be) and the variations in the relative rights (including, without limitation, voting, dividend and redemption rights), restrictions, preferences, privileges and payment obligations as between the different Classes (if any) may be fixed and determined by the Directors or by the Shareholders by Ordinary Resolution.&#160; The Directors may issue Shares with such preferred or other rights, all or any of which may be greater than the rights of Ordinary Shares, at such time and on such terms as they may think appropriate. Notwithstanding Article&nbsp;12, the Directors may issue from time to time, out of the authorised share capital of the Company (other than the authorised but unissued Ordinary Shares), series of preferred shares in their absolute discretion and without approval of the Shareholders; provided, however, before any preferred shares of any such series are issued, the Directors shall by resolution of Directors determine, with respect to any series of preferred shares, the terms and rights of that series, including:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="29876-2-PG-01_PB_5_123723_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=984170,FOLIO='5',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the designation of such series, the number of preferred shares to constitute such series and the subscription price thereof if different from the par value thereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the preferred shares of such series shall have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights, which may be general or limited;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the dividends, if any, payable on such series, whether any such dividends shall be cumulative, and, if so, from what dates, the conditions and dates upon which such dividends shall be payable, and the preference or relation which such dividends shall bear to the dividends payable on any shares of any other class or any other series of shares;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the preferred shares of such series shall be subject to redemption by the Company, and, if so, the times, prices and other conditions of such redemption;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the preferred shares of such series shall have any rights to receive any part of the assets available for distribution amongst the Shareholders upon the liquidation of the Company, and, if so, the terms of such liquidation preference, and the relation which such liquidation preference shall bear to the entitlements of the holders of shares of any other class or any other series of shares;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the preferred shares of such series shall be subject to the operation of a retirement or sinking fund and, if so, the extent to and manner in which any such retirement or sinking fund shall be applied to the purchase or redemption of the preferred shares of such series for retirement or other corporate purposes and the terms and provisions relative to the operation thereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the preferred shares of such series shall be convertible into, or exchangeable for, shares of any other class or any other series of preferred shares or any other securities and, if so, the price or prices or the rate or rates of conversion or exchange and the method, if any, of adjusting the same, and any other terms and conditions of conversion or exchange;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the limitations and restrictions, if any, to be effective while any preferred shares of such series are outstanding upon the payment of dividends or the making of other distributions on, and upon the purchase, redemption or other acquisition by the Company of, the existing shares or shares of any other class of shares or any other series of preferred shares;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the conditions or restrictions, if any, upon the creation of indebtedness of the Company or upon the issue of any additional shares, including additional shares of such series or of any other class of shares or any other series of preferred shares; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any other powers, preferences and relative, participating, optional and other special rights, and any qualifications, limitations and restrictions thereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and, for such purposes, the Directors may reserve an appropriate number of Shares for the time being unissued. The Company is not obliged to issue, allot or dispose of shares if it is, in the opinion of the Directors, unlawful or impracticable. The Company shall not issue Shares to bearer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may insofar as may be permitted by law, pay a commission to any Person in consideration of his subscribing or agreeing to subscribe whether absolutely or conditionally for any Shares. Such commissions may be satisfied by the payment of cash or the lodgement of fully or partly paid-up Shares or partly in one way and partly in the other.&#160; The Company may also pay such brokerage as may be lawful on any issue of Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="29876-2-PG-01_PB_6_123734_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=424007,FOLIO='6',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 29 20:58 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may refuse to accept any application for Shares, and may accept any application in whole or in part, for any reason or for no reason.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MODIFICATION OF RIGHTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Whenever the capital of the Company is divided into different Classes (and as otherwise determined by the Directors), the rights attached to any such Class&nbsp;may, subject to any rights or restrictions for the time being attached to any Class, only be materially adversely varied or abrogated with the consent in writing of the holders of not less than a majority of the issued Shares of the relevant Class, or with the sanction of a special resolution passed at a separate meeting of the holders of the Shares of such Class&nbsp;by a majority of two-thirds of the votes cast at such a meeting.&#160; To every such separate meeting all the provisions of these Articles relating to general meetings of the Company or to the proceedings thereat shall, <i>mutatis mutandis</i>, apply, except that the necessary quorum shall be one or more Persons at least holding or representing by proxy one-third in nominal or par value amount of the issued Shares of the relevant Class&nbsp;(but so that if at any adjourned meeting of such holders a quorum as above defined is not present, those Shareholders who are present shall form a quorum) and that, subject to any rights or restrictions for the time being attached to the Shares of that Class, every Shareholder of the Class&nbsp;shall on a poll have one vote for each Share of the Class&nbsp;held by him.&#160; For the purposes of this Article&nbsp;the Directors may treat all the Classes or any two or more Classes as forming one Class&nbsp;if they consider that all such Classes would be affected in the same way by the proposals under consideration<i>, </i>but in any other case shall treat them as separate Classes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The rights conferred upon the holders of the Shares of any Class&nbsp;issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the Shares of that Class, be deemed to be materially adversely varied or abrogated by, <i>inter alia</i>, the creation, allotment or issue of further Shares ranking <i>pari passu</i> with or subsequent to them or the redemption or purchase of any Shares of any Class&nbsp;by the Company. The rights of the holders of Shares shall not be deemed to be materially adversely varied by the creation or issue of Shares with preferred or other rights including, without limitation, the creation of Shares with enhanced or weighted voting rights.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Every Person whose name is entered as a Shareholder in the Register shall, without payment, be entitled to a certificate within one month after allotment or lodgement of transfer (or within such other period as the conditions of issue shall provide) in the form determined by the Directors.&#160; All certificates shall specify the Share or Shares held by that person and the amount paid up thereon, provided that in respect of a Share or Shares held jointly by several persons the Company shall not be bound to issue more than one certificate, and delivery of a certificate for a Share to one of several joint holders shall be sufficient delivery to all. All certificates for Shares shall be delivered personally or sent through the post addressed to the Shareholder entitled thereto at such Shareholder&#146;s address notified by such Shareholder to the Company prior to such delivery, or if absent of such notification, at the registered address of such Shareholder as appearing in the Register.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Every share certificate of the Company shall bear legends required under the applicable laws, including the Securities Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any two or more certificates representing Shares of any one Class&nbsp;held by any Shareholder may at the Shareholder&#146;s request be cancelled and a single new certificate for such Shares issued in lieu on payment (if the Directors shall so require) of US$1.00 or such smaller sum as the Directors shall determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="29876-2-PG-03_PB_7_123348_9023"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=108917,FOLIO='7',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If a share certificate shall be damaged or defaced or alleged to have been lost, stolen or destroyed, a new certificate representing the same Shares may be issued to the relevant Shareholder upon request subject to delivery up of the old certificate or (if alleged to have been lost, stolen or destroyed) compliance with such conditions as to evidence and indemnity and the payment of out-of-pocket expenses of the Company in connection with the request as the Directors may think fit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that Shares are held jointly by several persons, any request may be made by any one of the joint holders and if so made shall be binding on all of the joint holders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRACTIONAL SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may issue fractions of a Share and, if so issued, a fraction of a Share shall be subject to and carry the corresponding fraction of liabilities (whether with respect to nominal or par value, premium, contributions, calls or otherwise), limitations, preferences, privileges, qualifications, restrictions, rights (including, without prejudice to the generality of the foregoing, voting and participation rights) and other attributes of a whole Share. If more than one fraction of a Share of the same Class&nbsp;is issued to or acquired by the same Shareholder such fractions shall be accumulated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LIEN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company has a first and paramount lien on every Share (whether or not fully paid) for all amounts (whether presently payable or not) payable at a fixed time or called in respect of that Share.&#160; The Company also has a first and paramount lien on every Share registered in the name of a Person indebted or under liability to the Company (whether he is the sole registered holder of a Share or one of two or more joint holders) for all amounts owing by him or his estate to the Company (whether or not presently payable).&#160; The Directors may at any time declare a Share to be wholly or in part exempt from the provisions of this Article.&#160; The Company&#146;s lien on a Share extends to any amount payable in respect of it.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may sell, in such manner as the Directors may determine, any Share on which the Company has a lien, but no sale shall be made unless an amount in respect of which the lien exists is presently payable nor until the expiration of fourteen days after a notice in writing, demanding payment of such part of the amount in respect of which the lien exists as is presently payable, has been given to the registered holder for the time being of the Share, or the Persons entitled thereto by reason of his death or bankruptcy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For giving effect to any such sale the Directors may authorise some Person to transfer the Shares sold to the purchaser thereof.&#160; The purchaser shall be registered as the holder of the Shares comprised in any such transfer and he shall not be bound to see to the application of the purchase money, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The proceeds of the sale after deduction of expenses, fees and commission incurred by the Company shall be received by the Company and applied in payment of such part of the amount in respect of which the lien exists as is presently payable, and the residue shall (subject to a like lien for sums not presently payable as existed upon the Shares prior to the sale) be paid to the Person entitled to the Shares immediately prior to the sale.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CALLS ON SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may from time to time make calls upon the Shareholders in respect of any moneys unpaid on their Shares, and each Shareholder shall (subject to receiving at least fourteen days&#146; notice specifying the time or times of payment) pay to the Company at the time or times so specified the amount called on such Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The joint holders of a Share shall be jointly and severally liable to pay calls in respect thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="29876-2-PG-03_PB_8_123419_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=1003423,FOLIO='8',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If a sum called in respect of a Share is not paid before or on the day appointed for payment thereof, the Person from whom the sum is due shall pay interest upon the sum at the rate of eight percent per annum from the day appointed for the payment thereof to the time of the actual payment, but the Directors shall be at liberty to waive payment of that interest wholly or in part.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The provisions of these Articles as to the liability of joint holders and as to payment of interest shall apply in the case of non-payment of any sum which, by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the amount of the Share, or by way of premium, as if the same had become payable by virtue of a call duly made and notified.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may make arrangements on the issue of partly paid Shares for a difference between the Shareholders, or the particular Shares, in the amount of calls to be paid and in the times of payment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may, if they think fit, receive from any Shareholder willing to advance the same all or any part of the moneys uncalled and unpaid upon any partly paid Shares held by him, and upon all or any of the moneys so advanced may (until the same would, but for such advance, become presently payable) pay interest at such rate (not exceeding without the sanction by Ordinary Resolution, eight percent per annum) as may be agreed upon between the Shareholder paying the sum in advance and the Directors. No such sum paid in advance of calls shall entitle the Shareholder paying such sum to any portion of a dividend declared in respect of any period prior to the date upon which such sum would, but for such payment, become presently payable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORFEITURE OF SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If a Shareholder fails to pay any call or instalment of a call in respect of partly paid Shares on the day appointed for payment, the Directors may, at any time thereafter during such time as any part of such call or instalment remains unpaid, serve a notice on him requiring payment of so much of the call or instalment as is unpaid, together with any interest which may have accrued.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The notice shall name a further day (not earlier than the expiration of fourteen days from the date of the notice) on or before which the payment required by the notice is to be made, and shall state that in the event of non-payment at or before the time appointed the Shares in respect of which the call was made will be liable to be forfeited.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the requirements of any such notice as aforesaid are not complied with, any Share in respect of which the notice has been given may at any time thereafter, before the payment required by notice has been made, be forfeited by a resolution of the Directors to that effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A forfeited Share may be sold or otherwise disposed of on such terms and in such manner as the Directors think fit, and at any time before a sale or disposition the forfeiture may be cancelled on such terms as the Directors think fit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Person whose Shares have been forfeited shall cease to be a Shareholder in respect of the forfeited Shares, but shall, notwithstanding, remain liable to pay to the Company all moneys which at the date of forfeiture were payable by him to the Company in respect of the Shares forfeited, but his liability shall cease if and when the Company receives payment in full of the amount unpaid on the Shares forfeited. A certificate in writing under the hand of a Director that a Share has been duly forfeited on a date stated in the certificate, shall be conclusive evidence of the facts in the certificate as against all Persons claiming to be entitled to the Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may receive the consideration, if any, given for a Share on any sale or disposition thereof pursuant to the provisions of these Articles as to forfeiture and may execute a transfer of the Share in favour of the Person to whom the Share is sold or disposed of and that Person shall be registered as the holder of the Share, and shall not be bound to see to the application of the purchase money, if any, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings in reference to the disposition or sale.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="29876-2-PG-03_PB_9_123431_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=264609,FOLIO='9',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which by the terms of issue of a Share becomes due and payable, whether on account of the amount of the Share, or by way of premium, as if the same had been payable by virtue of a call duly made and notified.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TRANSFER OF SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The instrument of transfer of any Share shall be in any usual or common form or such other form as the Directors may determine and be executed by or on behalf of the transferor and if in respect of a nil or partly paid up Share, or if so required by the Directors, shall also be executed on behalf of the transferee and shall be accompanied by the certificate (if any) of the Shares to which it relates and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer. The transferor shall be deemed to remain a Shareholder until the name of the transferee is entered in the Register in respect of the relevant Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms of issue thereof, the Directors may determine to decline to register any transfer of Shares without assigning any reason therefor.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Directors may also decline to register any transfer of any Share unless:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the instrument of transfer is lodged with the Company, accompanied by the certificate for the Shares to which it relates and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the instrument of transfer is in respect of only one Class&nbsp;of Shares;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>the instrument of transfer is properly stamped, if required;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160; </font>in the case of a transfer to joint holders, the number of joint holders to whom the Share is to be transferred does not exceed four;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Shares are free from any lien in favour of the Company; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160; </font>a fee of such maximum sum as the Designated Stock Exchange may determine to be payable or such lesser sum as the Board of Directors may from time to time require, is paid to the Company in respect thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The registration of transfers may, on ten days&#146; notice being given by advertisement in such one or more newspapers or by electronic means or by any other means in accordance with the Designated Stock Exchange Rules, be suspended and the Register closed at such times and for such periods as the Directors may, in their absolute discretion, from time to time determine, provided always that such registration of transfer shall not be suspended nor the Register closed for more than 30 days in any year.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All instruments of transfer that are registered shall be retained by the Company. If the Directors refuse to register a transfer of any Shares, they shall within three months after the date on which the transfer was lodged with the Company send to each of the transferor and the transferee notice of the refusal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TRANSMISSION OF SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The legal personal representative of a deceased sole holder of a Share shall be the only Person recognised by the Company as having any title to the Share.&#160; In the case of a Share registered in the name of two or more holders, the survivors or survivor, or the legal personal representatives of the deceased holder of the Share, shall be the only Person recognised by the Company as having any title to the Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any Person becoming entitled to a Share in consequence of the death or bankruptcy of a Shareholder shall upon such evidence being produced as may from time to time be required by the Directors, have the right either to be registered as a Shareholder in respect of the Share or, instead of being registered himself, to make such transfer of the Share as the deceased or bankrupt Person could have made; but the Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the deceased or bankrupt Person before the death or bankruptcy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="29876-2-PG-03_PB_10_123656_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=372848,FOLIO='10',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Person becoming entitled to a Share by reason of the death or bankruptcy of a Shareholder shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered Shareholder, except that he shall not, before being registered as a Shareholder in respect of the Share, be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the Company, provided however, that the Directors may at any time give notice requiring any such person to elect either to be registered himself or to transfer the Share, and if the notice is not complied with within ninety days, the Directors may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REGISTRATION OF EMPOWERING INSTRUMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company shall be entitled to charge a fee not exceeding one dollar (US$1.00) on the registration of every probate, letters of administration, certificate of death or marriage, power of attorney, notice in lieu of distringas, or other instrument.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ALTERATION OF SHARE CAPITAL</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may from time to time by Ordinary Resolution increase the share capital by such sum, to be divided into Shares of such Classes and amount, as the resolution shall prescribe and with such rights, priorities and privileges annexed thereto, as the Company in general meeting may determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may by Ordinary Resolution:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>consolidate and divide all or any of its share capital into Shares of a larger amount than its existing Shares;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>subdivide its existing Shares, or any of them into Shares of a smaller amount provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced Share shall be the same as it was in case of the Share from which the reduced Share is derived;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>convert all or any of its paid up Shares into stock and reconvert that stock into paid up Shares of any denomination; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>cancel any Shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any Person and diminish the amount of its share capital by the amount of the Shares so cancelled.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may by Special Resolution reduce its share capital and any capital redemption reserve in any manner authorised by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REDEMPTION, PURCHASE AND SURRENDER OF SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the Companies Act and these Articles, the Company may:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>issue Shares on terms that they are to be redeemed or are liable to be redeemed at the option of the Company or the Shareholder on such terms and in such manner as may be determined, before the issue of such Shares, by either the Board or by the Shareholders by Ordinary Resolution;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="29876-2-PG-03_PB_11_123706_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=659883,FOLIO='11',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>redeem or purchase its own Shares (including any redeemable Shares) on such terms and in such manner as have been approved by the Board or the Shareholders by Ordinary Resolution, or are otherwise authorised by these Articles;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>make a payment in respect of the redemption or purchase of its own Shares in any manner permitted by the Companies Act, including out of its capital; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>accept the surrender for no consideration of any paid up Share (including any redeemable Share) on such terms and in such manner as the Directors may determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The holder of the Shares being purchased shall be bound to deliver up to the Company the certificate(s)&nbsp;(if any) thereof. Any Share in respect of which notice of redemption has been given shall not be entitled to participate in the profits of the Company in respect of the period after the date specified as the date of redemption in the notice of redemption.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The redemption, purchase or surrender of any Share shall not be deemed to give rise to the redemption, purchase or surrender of any other Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may when making payments in respect of redemption or purchase of Shares, if authorised by the terms of issue of the Shares being redeemed or purchased or with the agreement of the holder of such Shares, make such payment either in cash or in specie including without limitation, interests in a special purpose vehicle holding assets of the Company or holding entitlement to the proceeds of assets held by the Company or in a liquidation structure.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TREASURY SHARES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Shares that the Company purchases, redeems or acquires (by way of surrender or otherwise) may, at the option of the Company, be cancelled immediately or held as Treasury Shares in accordance with the Companies Act. In the event that the Directors do not specify that the relevant Shares are to be held as Treasury Shares, such Shares shall be cancelled.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No dividend may be declared or paid, and no other distribution (whether in cash or otherwise) of the Company&#146;s assets (including any distribution of assets to Shareholders on a winding up) may be declared or paid in respect of a Treasury Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company shall be entered in the Register as the holder of the Treasury Shares provided that:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall not be treated as a Shareholder for any purpose and shall not exercise any right in respect of the Treasury Shares, and any purported exercise of such a right shall be void;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a Treasury Share shall not be voted, directly or indirectly, at any meeting of the Company and shall not be counted in determining the total number of issued shares at any given time, whether for the purposes of these Articles or the Companies Act, save that an allotment of Shares as fully paid bonus shares in respect of a Treasury Share is permitted and Shares allotted as fully paid bonus shares in respect of a treasury share shall be treated as Treasury Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Treasury Shares may be disposed of by the Company on such terms and conditions as determined by the Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">GENERAL MEETINGS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All general meetings other than annual general meetings shall be called extraordinary general meetings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company may, but shall not (unless required by the Companies Act) be obliged to hold a general meeting in each year as its annual general meeting and shall specify  the meeting as such in the notices calling it.&#160; The annual general meeting shall be held at such time and place as may be determined by the Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="29876-2-PG-03_PB_12_123747_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=156425,FOLIO='12',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At these meetings the report of the Directors (if any) shall be presented.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Chairman or a majority of the Directors may call general meetings, and they shall on a Shareholders&#146; requisition forthwith proceed to convene an extraordinary general meeting of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Shareholders&#146; requisition is a requisition of Shareholders of the Company holding at the date of deposit of the requisition Shares which carry in aggregate not less than twenty percent (20%) of all votes attaching to all issued and outstanding Shares of the Company that as at the date of the deposit carry the right of voting at general meetings of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The requisition must state the objects of the meeting and must be signed by the requisitionists and deposited at the registered office of the Company, and may consist of several documents in like form each signed by one or more requisitionists.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Directors do not within twenty-one (21) days from the date of the deposit of the requisition duly procdeed to convene a general meeting to be held within a further twenty-one (21) days, the requisitionists, or any of them representing more than one-half of the total voting rights of all of them, may themselves convene a general meeting, but any meeting so convened shall not be held after the expiration of three months after the expiration of the said twenty-one (21) days.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A general meeting convened as aforesaid by requisitionists shall be convened in the same manner as nearly as possible as that in which general meetings are to be convened by Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOTICE OF GENERAL MEETINGS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At least seven (7)&nbsp;days&#146; notice shall be given for any general meeting.&#160; Every notice shall be exclusive of the day on which it is given or deemed to be given and of the day for which it is given and shall specify the place, the day and the hour of the meeting and the general nature of the business and shall be given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by the Company, provided that a general meeting of the Company shall, whether or not the notice specified in this Article&nbsp;has been given and whether or not the provisions of these Articles regarding general meetings have been complied with, be deemed to have been duly convened if it is so agreed:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the case of an annual general meeting by all the Shareholders (or their proxies) entitled to attend and vote thereat; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the case of an extraordinary general meeting by a majority in number of the Shareholders (or their proxies) having a right to attend and vote at the meeting, being a majority together holding not less than seventy five per cent (75%) in par value of the Shares giving that right.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The accidental omission to give notice of a meeting to or the non-receipt of a notice of a meeting by any Shareholder shall not invalidate the proceedings at any meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROCEEDINGS AT GENERAL MEETINGS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No business shall be transacted at any general meeting without the consent of all Shareholders entitled to receive notice of that meeting unless notice of such business has been given in the notice convening that meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No business shall be transacted at any general meeting unless a quorum of Shareholders is present at the time when the meeting proceeds to business.&#160; The holders of Shares being not less than an aggregate of one-half of all Shares in issue present in person or by proxy and entitled to vote shall be a quorum for all purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="29876-2-PG-03_PB_13_123936_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=460700,FOLIO='13',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If within half an hour from the time appointed for the meeting a quorum is not present, the meeting, if convened upon the requisition of Shareholders, shall be dissolved.&#160; In any other case it shall stand adjourned to the same day in the next week, at the same time and place, and if at the adjourned meeting a quorum is not present within half an hour from the time appointed for the meeting, the Shareholder or Shareholders present and entitled to vote shall form a quorum.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Directors wish to make this facility available for a specific general meeting or all general meetings of the Company, participation in any general meeting of the Company may be by means of a telephone or similar communication equipment by way of which all Persons participating in such meeting can communicate with each other and such participation shall be deemed to constitute presence in person at the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The chairman, if any, of the Directors shall preside as chairman at every general meeting of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">66.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If there is no such chairman, or if at any general meeting he is not present within fifteen minutes after the time appointed for holding the meeting or is unwilling to act as chairman, any Director or Person nominated by the Directors shall preside as chairman, failing which the Shareholders present in person or by proxy shall choose any Person present to be chairman of that meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The chairman of the general meeting may with the consent of any general meeting at which a quorum is present (and shall if so directed by the meeting) adjourn a meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. When a meeting, or adjourned meeting, is adjourned for fourteen days or more, notice of the adjourned meeting shall be given in the manner provided for the original meeting.&#160; Save as aforesaid, it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may cancel or postpone any duly convened general meeting at any time prior to such meeting, except for general meetings requisitioned by the Shareholders in accordance with these Articles, for any reason or for no reason, upon notice in writing to Shareholders. A postponement may be for a stated period of any length or indefinitely as the Directors may determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At any general meeting a resolution put to the vote of the meeting shall be decided by way of a poll save that the chairman of the meeting may, in good faith, allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands, and where a show of hands is allowed pursuant to these Articles, before or on the declaration of the result of the show of hands, a poll may be demanded by the chairman of the meeting or any Shareholder present in person or by proxy. Where a resolution is voted on by a show of hands, a declaration by the chairman of the meeting that a resolution has, on a show of hands, been carried, or carried unanimously, or by a particular majority, or lost, and an entry to that effect in the book of the proceedings of the Company, shall be conclusive evidence of the fact, without proof of the number or proportion of the votes recorded in favour of, or against, that resolution. For the purposes of these Articles, procedural and administrative matters are (i)&nbsp;the proposal of new resolutions which are not already set out in the notice convening the general meeting or any proposed amendments to the resolutions; and (ii)&nbsp;those that relate to the chairman&#146;s duties to maintain the orderly conduct of the meeting and/or allow the business of the meeting to be properly and effectively dealt with, whilst allowing all Shareholders a reasonable opportunity to express their views.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If a poll is required or is duly demanded it shall be taken in such manner as the chairman of the meeting directs, and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was required or demanded.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="29876-2-PG-03_PB_14_123943_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=657485,FOLIO='14',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">70.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the case of an equality of votes, whether on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall be entitled to a second or casting vote.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All questions submitted to a meeting shall be decided by an Ordinary Resolution except where a greater majority is required by these Articles or by the Law. A poll demanded on the election of a chairman of the meeting or on a question of adjournment shall be taken forthwith.&#160; A poll demanded on any other question shall be taken at such time as the chairman of the meeting directs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VOTES OF SHAREHOLDERS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to any rights and restrictions for the time being attached to any Share, on a show of hands every Shareholder present in person and every Person representing a Shareholder by proxy (or, if a corporation or other&nbsp;non-natural&nbsp;person, by its duly authorized representative or proxy) shall, at a general meeting or extraordinary general meeting of the Company, each have one (1)&nbsp;vote and on a poll every Shareholder and every Person representing a Shareholder by proxy (or, if a corporation or other&nbsp;non-natural&nbsp;person, by its duly authorized representative or proxy) shall have one (1)&nbsp;vote for each Share of which he or the Person represented by proxy is the holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the case of joint holders the vote of the senior who tenders a vote, whether in person or by proxy (or, if a corporation or other&nbsp;non-natural&nbsp;person, by its duly authorized representative or proxy), shall be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority shall be determined by the order in which the names stand in the Register.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">74.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Shares carrying the right to vote which are held by a Shareholder of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may be voted in respect of Shares carrying the right to vote held by him, whether on a show of hands or on a poll, by his committee, or other Person in the nature of a committee appointed by that court, and any such committee or other Person, may vote in respect of such Shares by proxy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No Shareholder shall be entitled to vote at any general meeting of the Company unless he is registered as a Shareholder on the record date for such meeting or unless all calls, if any, or other sums presently payable by him in respect of Shares carrying the right to vote held by him have been paid.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">76.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>On a poll votes may be given either personally or by proxy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">77.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Shareholder, other than a recognised clearing house (or its nominee(s)) or depositary (or its nominee(s)), may only appoint one proxy on a show of hand and on a poll, each such proxy is under no obligation to cast all his votes in the same way. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing or, if the appointor is a corporation, either under Seal or under the hand of an officer or attorney duly authorised.&#160; A proxy need not be a Shareholder. On a poll a Shareholder entitled to more than one vote need not use all his votes or cast all his votes in the same way.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>An instrument appointing a proxy may be in any usual or common form or such other form as the Directors may approve and may be expressed to be for a particular meeting or any adjournment thereof or generally until revoked.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The instrument appointing a proxy shall be deposited at the Office or at such other place as is specified for that purpose in the notice convening the meeting, or in any instrument of proxy sent out by the Company:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>not less than forty-eight (48) hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="29876-2-PG-03_PB_15_124008_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=472686,FOLIO='15',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the case of a poll taken more than forty-eight (48) hours after it is demanded, be deposited as aforesaid after the poll has been demanded and not less than twenty-four (24) hours before the time appointed for the taking of the poll; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>where the poll is not taken forthwith but is taken not more than forty-eight (48) hours after it was demanded be delivered at the meeting at which the poll was demanded to the chairman or to the secretary or to any director;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">provided that the Directors may in the notice convening the meeting, or in an instrument of proxy sent out by the Company, direct that the instrument appointing a proxy may be deposited (no later than the time for holding the meeting or adjourned meeting) at the Registered Office or at such other place as is specified for that purpose in the notice convening the meeting, or in any instrument of proxy sent out by the Company. The Chairman may in any event at his discretion direct that an instrument of proxy shall be deemed to have been duly deposited. An instrument of proxy that is not deposited in the manner permitted shall be invalid.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a poll.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">81.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A resolution in writing signed by all the Shareholders for the time being entitled to receive notice of and to attend and vote at general meetings of the Company (or being corporations by their duly authorised representatives) shall be as valid and effective as if the same had been passed at a general meeting of the Company duly convened and held.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">82.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Votes given in accordance with the terms of an instrument of proxy, which has been deposited in accordance with Article&nbsp;79, shall be valid notwithstanding the previous death or insanity of the principal or revocation of the proxy or of the authority under which the proxy was executed, or the transfer of the Share in respect of which the proxy is given unless notice in writing of such death, insanity, revocation or transfer was received by the Company at the Registered Office before the commencement of the general meeting, or adjourned meeting at which it is sought to use the proxy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CORPORATIONS ACTING BY REPRESENTATIVES AT MEETINGS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">83.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any corporation which is a Shareholder or a Director may by resolution of its directors or other governing body authorise such Person as it thinks fit to act as its representative at any meeting of the Company or of any meeting of holders of a Class&nbsp;or of the Directors or of a committee of Directors, and the Person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual Shareholder or Director.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CLEARING HOUSES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">84.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If a clearing house (or its nominee) is a Shareholder of the Company it may, by resolution of its directors or other governing body or by power of attorney, authorise such person or persons as it thinks fit to act as its representative or representatives at any general meeting of the Company or at any general meeting of any class of Shareholders of the Company provided that, if more than one person is so authorised, the authorisation shall specify the number and class of Shares in respect of which each such person is so authorised.&#160; A person so authorised pursuant to this Article&nbsp;shall be entitled to exercise the same powers on behalf of the clearing house (or its nominee) which he represents as that clearing house (or its nominee) could exercise if it were an individual Shareholder holding the number and Class&nbsp;of Shares specified in such authorisation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DIRECTORS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">85.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unless otherwise determined by the Company in general meeting, the number of Directors shall not be more than nine (9).&#160; The Board of Directors shall have the right  to change the size of the Board of Directors and determine the exact number of Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="29876-2-PG-03_PB_16_124105_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=640754,FOLIO='16',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:22 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to Article&nbsp;85(f), the Board of Directors shall have a Chairman elected and appointed by a majority of the Directors then in office.&#160; The period for which the Chairman will hold office will also be determined by a majority of all of the Directors then in office.&#160; The Chairman shall preside as chairman at every meeting of the Board of Directors.&#160; To the extent the Chairman is not present at a meeting of the Board of Directors within fifteen minutes after the time appointed for holding the same, or if the Chairman is unable to or unwilling to act as the chairman of a meeting of the Directors, the attending Directors may choose one of their number to be the chairman of the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For so long as Wuxi Pharmatech Healthcare Fund I L.P. holds no less than 5% of all the Shares in issue on a fully-diluted basis, it shall be entitled, by notice in writing to the Company, to nominate one (1)&nbsp;independent director (as contemplated by the terms of applicable Designated Stock Exchange Rules&nbsp;and/or SEC rules&nbsp;with respect to audit committee independence) and any such Person shall be appointed and agreed by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For so long as JSR Limited holds no less than 5% of all the Shares in issue on a fully-diluted basis, it shall be entitled, by notice in writing to the Company, to appoint one (1)&nbsp;Person as a director of the Company and to remove, replace and/or reappoint any such Person so appointed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For so long as General Atlantic Singapore AI Pte. Ltd. and Affiliates thereof collectively hold no less than 5% of all the Shares in issue on a fully-diluted basis, General Atlantic Singapore AI Pte. Ltd. and Affiliates thereof shall be entitled, by notice in writing to the Company, to appoint one (1)&nbsp;Person as a director of the Company and to remove, replace and reappoint any such Person so appointed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For as long as Peter Peizhi Luo holds or beneficially owns (as defined under Rule&nbsp;13d-3 of the Exchange Act) any Shares of the Company or is employed by the Company or any of its Subsidiaries, Peter Peizhi Luo shall occupy one (1)&nbsp;seat of the Board (the &#147;<b>Founder Director</b>&#148;) and shall serve as the Chairman of the Board of Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In addition to the Founder Director, during the Appointment Period, Peter Peizhi Luo shall be entitled, by notice in writing to the Company, to appoint one (1)&nbsp;Person as director of the Company and to remove, replace and/or reappoint such Person so appointed (the &#147;<b>Additional F</b><b>ounder Director</b>&#148;, together with the Founder Director, the &#147;<b>Founder Directors&#148;</b>).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In addition to the Founder Directors, one (1)&nbsp;seat on the Board shall be reserved for and occupied by an executive officer of the Company who is responsible for clinical development or research and development.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to Article&nbsp;85(d), (e), and (g), the Board of Directors may by the affirmative vote of a simple majority of the remaining Directors present and voting at a Board meeting, appoint any person to be a Director either to fill a vacancy on the Board arising from the office of any Director being vacated in any of the circumstances described in Article&nbsp;108 or as an addition to the existing Board.&#160; In the event of a vacancy arising from the office of an Independent Director being vacated, the Board may only appoint another Independent Director with the affirmative vote of the Founder Director to fill such vacancy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>An appointment of a Director may be on terms that the Director shall automatically retire from office (unless he or she has sooner vacated office) upon any specified event or after any specified period in a written agreement between the Company and the Director, if any; but no such term shall be implied in the absence of express provision.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="29876-2-PG-05_PB_17_123248_7438"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=700717,FOLIO='17',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Director whose term of office expires shall be eligible for re-election at a meeting of the Shareholders or re-appointment by the Board; provided that no re-appointment of any Independent Director shall be effective without the affirmative vote of the Founder Director.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">86.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to Article&nbsp;85, any vacancy, including newly created directorships resulting from any increase in the authorised number of Directors or amendment of these Articles, and vacancies created by removal or resignation of a Director, may be filled by the consent of a majority of the Directors then in office, though less than a quorum, or by a sole remaining director, and the Directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced; provided, however, that where such vacancy occurs among the Directors elected by the holders of a class or series of shares under Article&nbsp;85, such vacancy shall be filled and appointed in accordance with Article&nbsp;85.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">87.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Director (other than such Director appointed pursuant to Article&nbsp;85) may be removed from office by Ordinary Resolution of the Company, notwithstanding anything in these Articles or in any agreement between the Company and such Director (but without prejudice to any claim for damages under such agreement) but with respect to a Director appointed pursuant to Article&nbsp;85 and other shareholder agreement(s), only upon the vote or written consent of the Shareholders entitled to appoint such Director. Any vacancies created by the resignation, removal or death of a Director appointed pursuant to Article&nbsp;85 shall be filled in such manner as stipulated in Article&nbsp;85.&#160; The notice of any meeting at which a resolution to remove a Director shall be proposed or voted upon must contain a statement of the intention to remove that Director and such notice must be served on that Director not less than ten (10)&nbsp;days before the meeting. Such Director is entitled to attend the meeting and be heard on the motion for his removal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">88.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board may, from time to time, and except as required by applicable law or Designated Stock Exchange Rules, adopt, institute, amend, modify or revoke the corporate governance policies or initiatives, which shall be intended to set forth the policies of the Company and the Board on various corporate governance related matters as the Board shall determine by resolution from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">89.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to applicable law, Designated Stock Exchange Rules&nbsp;and the Articles, the Board may establish any committee of the Board as it deems appropriate from time to time, and committees of the Board shall have the rights, powers and privileges delegated to such committees by the Board from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Director shall not be required to hold any Shares in the Company by way of qualification.&#160; A Director who is not a Shareholder of the Company shall nevertheless be entitled to attend and speak at general meetings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">91.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The remuneration of the Directors may be determined by the Directors or by Ordinary Resolution.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">92.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors shall be entitled to be paid their travelling, hotel and other expenses properly incurred by them in going to, attending and returning from meetings of the Directors, or any committee of the Directors, or general meetings of the Company, or otherwise in connection with the business of the Company, or to receive&nbsp;such fixed allowance in respect thereof as may be determined by the Directors from time to time, or a combination partly of one such method and partly the other.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ALTERNATE DIRECTOR</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">93.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any Director may in writing appoint another Person to be his alternate and, save to the extent provided otherwise in the form of appointment, such alternate shall have authority to sign written resolutions on behalf of the appointing Director, but shall not be authorised to sign such written resolutions where they have been signed by the appointing Director, and to act in such Director&#146;s place at any meeting of the Directors.&nbsp; Every such alternate shall be entitled to attend and vote at meetings of the Directors as the alternate of the Director appointing him and where he is a Director to have a separate vote in addition to his own vote.&nbsp; A Director may at any time in writing revoke the appointment of an alternate appointed by him.&nbsp; Such alternate shall not be an Officer solely as a result of his appointment as an alternate other than in respect of such times as the alternate acts as a Director.&nbsp; The remuneration of such alternate shall be payable out of the remuneration of the Director appointing him and the proportion thereof shall be agreed between them.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="29876-2-PG-05_PB_18_123321_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=935111,FOLIO='18',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">POWERS AND DUTIES OF DIRECTORS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the Companies Act, these Articles and to any resolutions passed in a general meeting, the business of the Company shall be managed by the Directors, who may pay all expenses incurred in setting up and registering the Company and may exercise all powers of the Company.&#160; No resolution passed by the Company in general meeting shall invalidate any prior act of the Directors that would have been valid if that resolution had not been passed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">95.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to these Articles, the Directors may from time to time appoint any Person, whether or not a Director to hold such office in the Company as the Directors may think necessary for the administration of the Company, including but not limited to, chief executive officers, one or more other executive officers, the office of president, one or more vice-presidents, treasurer, assistant treasurer, manager or controller, and for such term and at such remuneration (whether by way of salary or commission or participation in profits or partly in one way and partly in another), and with such powers and duties as the Directors may think fit.&#160; Any Person so appointed by the Directors may be removed by the Directors.&#160; The Directors may also appoint one or more of their number to the office of managing director upon like terms, but any such appointment shall ipso facto terminate if any managing director ceases from any cause to be a Director, or if the Company by Ordinary Resolution resolves that his tenure of office be terminated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">96.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may appoint any Person to be a Secretary (and if need be an assistant Secretary or assistant Secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as they think fit.&#160; Any Secretary or assistant Secretary so appointed by the Directors may be removed by the Directors or by the Company by Ordinary Resolution.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">97.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may delegate any of their powers to committees consisting of such member or members of their body as they think fit; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">98.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may from time to time and at any time by power of attorney (whether under Seal or under hand) or otherwise appoint any company, firm or Person or body of Persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys or authorised signatory (any such person being an &#147;<b>Attorney</b>&#148; or &#147;<b>Authorised Signatory</b>&#148;, respectively) of the Company for such purposes and with such powers, authorities and discretion (not exceeding those vested in or exercisable by the Directors under these Articles) and for such period and subject to such conditions as they may think fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of Persons dealing with any such Attorney or Authorised Signatory as the Directors may think fit, and may also authorise any such Attorney or Authorised Signatory to delegate all or any of the powers, authorities and discretion vested in him.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may from time to time provide for the management of the affairs of the Company in such manner as they shall think fit and the provisions contained in the three next following Articles shall not limit the general powers conferred by this Article.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors from time to time and at any time may establish any committees, local boards or agencies for managing any of the affairs of the Company and may appoint any Person to be a member of such committees or local boards and may appoint any managers or agents of the Company and may fix the remuneration of any such Person.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="29876-2-PG-05_PB_19_123414_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=506769,FOLIO='19',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors from time to time and at any time may delegate to any such committee, local board, manager or agent any of the powers, authorities and discretions for the time being vested in the Directors and may authorise the members for the time being of any such local board, or any of them to fill any vacancies therein and to act notwithstanding vacancies and any such appointment or delegation may be made on such terms and subject to such conditions as the Directors may think fit and the Directors may at any time remove any Person so appointed and may annul or vary any such delegation, but no Person dealing in good faith and without notice of any such annulment or variation shall be affected thereby.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">102.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any such delegates as aforesaid may be authorised by the Directors to sub-delegate all or any of the powers, authorities, and discretion for the time being vested in them.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">103.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the Companies Act and other provisions of these Articles (including Article&nbsp;48), the Directors may agree with a Shareholder to waive or modify the terms applicable to such Shareholder&#146;s subscription for Shares without obtaining the consent of any other Shareholder; provided that such waiver or modification does not amount to a variation or abrogation of the rights attaching to the Shares of any other Shareholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BORROWING POWERS OF DIRECTORS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">104.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may from time to time at their discretion exercise all the powers of the Company to raise or borrow money and to mortgage or charge its undertaking, property and assets (present and future) and uncalled capital or any part thereof, or to otherwise provide for a security interest to be taken in such undertaking, property or uncalled capital, and to issue debentures, debenture stock, bonds and other securities, whether outright or as collateral, whenever money is borrowed or as security for any debt, liability or obligation of the Company or of any third party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE SEAL</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">105.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of the Seal and if given after may be in general form confirming a number of affixings of the Seal. The Seal shall be affixed in the presence of a Director or a Secretary (or an assistant Secretary) or in the presence of any one or more Persons as the Directors may appoint for the purpose and every Person as aforesaid shall sign every instrument to which the Seal is so affixed in their presence.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may maintain a facsimile of the Seal in such countries or places as the Directors may appoint and such facsimile Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of such facsimile Seal and if given after may be in general form confirming a number of affixings of such facsimile Seal.&#160; The facsimile Seal shall be affixed in the presence of such Person or Persons as the Directors shall for this purpose appoint and such Person or Persons as aforesaid shall sign every instrument to which the facsimile Seal is so affixed in their presence and such affixing of the facsimile Seal and signing as aforesaid shall have the same meaning and effect as if the Seal had been affixed in the presence of and the instrument signed by a Director or a Secretary (or an assistant Secretary) or in the presence of any one or more Persons as the Directors may appoint for the purpose.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">107.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding the foregoing, a Secretary or any assistant Secretary shall have the authority to affix the Seal, or the facsimile Seal, to any instrument for the purposes of attesting authenticity of the matter contained therein but which does not create any obligation binding on the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DISQUALIFICATION OF DIRECTORS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The office of a Director shall be vacated, if the Director:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>becomes bankrupt or makes any arrangement or composition with his creditors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="29876-2-PG-05_PB_20_123527_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=230030,FOLIO='20',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>dies or is found to be or becomes of unsound mind;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>resigns his office by notice in writing to the Company;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>is prohibited by any applicable Law or Designated Stock Exchange Rules&nbsp;from being a Director;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>without special leave of absence from the Board, is absent from meetings of the Board for three consecutive meetings and the Board resolves that his office be vacated; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>is removed from office pursuant to any other provision of these Articles.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROCEEDINGS OF DIRECTORS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">109.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may meet together (either within or outside the Cayman Islands) for the despatch of business, adjourn, and otherwise regulate their meetings and proceedings as they think fit.&#160; Questions arising at any meeting shall be decided by a majority of votes of the Directors present at a meeting.&#160; At any meeting of the Directors, each Director present in person or represented by his alternate or proxy shall be entitled to one vote. In case of an equality of votes the Chairman shall have a second or casting vote.&#160; A Director may, and a Secretary or assistant Secretary on the requisition of a Director shall, at any time summon a meeting of the Directors. Any Director may appoint any Person, whether or not a Director, to be the proxy of that Director to attend and vote on his behalf, in accordance with instructions given by that Director, or in the absence of such instructions at the discretion of the proxy, at a meeting of the Board which that Director is unable to attend personally. The instrument appointing the proxy shall be in writing under the hand of the appointing Director and shall be in any usual or common form or such other form as the Board may approve, and must be lodged with the chairman of the meeting of the Board at which such proxy is to be used, or first used, prior to the commencement of the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Director may participate in any meeting of the Directors, or of any committee appointed by the Directors of which such Director is a member, by means of telephone or similar communication equipment by way of which all Persons participating in such meeting can communicate with each other and such participation shall be deemed to constitute presence in person at the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">111.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The quorum necessary for the transaction of the business of the Directors shall be not less than three (3)&nbsp;Directors provided that any quorum shall require the presence of the Founder Director; <i>provided</i>, however, that if such quorum cannot be obtained for a Board meeting after two (2)&nbsp;consecutive notices of such meeting have been sent by the Company with the first notice providing not less than seven (7)&nbsp;days&#146; prior notice and the second notice providing not less than five (5)&nbsp;days&#146; prior notice, then the attendance of any three (3)&nbsp;Directors shall constitute a quorum, <i>provided</i> further that matters discussed in such adjourned meeting shall be limited to those stated in the written notices and agendas of the Board meeting, and resolutions passed in such meeting shall be subject to notices and agendas of such meeting as well as copies of all board papers shall be sent to all the Directors and each Shareholder who appointed a director to the Board at least seven (7)&nbsp;days prior to the relevant Board meeting. If at any time there is only a sole Director, the quorum shall be one Director. A Director represented by an alternate Director or by proxy at any meeting shall be deemed to be present for the purposes of determining whether or not a quorum is present.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">112.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Director who is in any way, whether directly or indirectly, interested in a contract or transaction or proposed contract or transaction with the Company shall declare the nature of his interest at a meeting of the Directors.&#160; A general notice given to the Directors by any Director to the effect that he is a member of any specified company or firm or is to be regarded as interested in any contract or other arrangement which may thereafter be made with that company or firm shall be deemed a sufficient declaration of interest in regard to any contract so made.&#160; Subject to the Designated Stock Exchange Rules&nbsp;and disqualification by the chairman of the relevant Board meeting, a Director may vote in respect of any contract or proposed contract or arrangement notwithstanding that he may be interested therein and if he does so his vote shall be counted and he may be counted in the quorum at any meeting of the Directors at which any such contract or proposed contract or arrangement shall come before the meeting for consideration.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="29876-2-PG-05_PB_21_123547_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=494085,FOLIO='21',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Director may hold any other office or place of profit under the Company (other than the office of auditor) in conjunction with his office of Director for such period and on such terms (as to remuneration and otherwise) as the Directors may determine and no Director or intending Director shall be disqualified by his office from contracting with the Company either with regard to his tenure of any such other office or place of profit or as vendor, purchaser or otherwise, nor shall any such contract or arrangement entered into by or on behalf of the Company in which any Director is in any way interested, be liable to be avoided, nor shall any Director so contracting or being so interested be liable to account to the Company for any profit realised by any such contract or arrangement by reason of such Director holding that office or of the fiduciary relation thereby established.&#160; A Director, notwithstanding his interest, may be counted in the quorum present at any meeting of the Directors whereat he or any other Director is appointed to hold any such office or place of profit under the Company or whereat the terms of any such appointment are arranged and he may vote on any such appointment or arrangement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">114.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any Director may act by himself or his firm in a professional capacity for the Company, and he or his firm shall be entitled to remuneration for professional services as if he were not a Director; provided that nothing herein contained shall authorise a Director or his firm to act as auditor to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">115.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors shall cause minutes to be made in books or loose-leaf folders provided for the purpose of recording:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>all appointments of Officers made by the Directors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the names of the Directors present at each meeting of the Directors and of any committee of the Directors; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>all resolutions and proceedings at all meetings of the Company, and of the Directors and of committees of Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">116.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>When the chairman of a meeting of the Directors signs the minutes of such meeting where a quorum was present the same shall be deemed to have been duly held notwithstanding that all the Directors have not actually come together or that there may have been a technical defect in the proceedings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">117.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A resolution in writing signed by all the Directors or all the members of a committee of Directors entitled to receive notice of a meeting of Directors or committee of Directors, as the case may be (an alternate Director, subject as provided otherwise in the terms of appointment of the alternate Director, being entitled to sign such a resolution on behalf of his appointer), shall be as valid and effectual as if it had been passed at a duly called and constituted meeting of Directors or committee of Directors, as the case may be.&#160; When signed a resolution may consist of several documents each signed by one or more of the Directors or his duly appointed alternate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">118.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The continuing Directors may act notwithstanding any vacancy in their body but if and for so long as their number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing Directors may act for the purpose of increasing the number, or of summoning a general meeting of the Company, but for no other purpose.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">119.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to any regulations imposed on it by the Directors, a committee appointed by the Directors may elect a chairman of its meetings.&#160; If no such chairman is elected, or if at any meeting the chairman is not present within fifteen minutes after the time appointed for holding the meeting, or if the Chairman is unable to or unwilling to act as the chairman, the committee members present may choose one of their number to be chairman of the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">120.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A committee appointed by the Directors may meet and adjourn as it thinks proper.&#160; Subject to any regulations imposed on it by the Directors, questions arising at any meeting shall be determined by a majority of votes of the committee members present and in case of an equality of votes the chairman shall have a second or casting vote.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="29876-2-PG-05_PB_22_123602_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=1035121,FOLIO='22',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All acts done by any meeting of the Directors or of a committee of Directors, or by any Person acting as a Director, shall notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director or Person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such Person had been duly appointed and was qualified to be a Director.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PRESUMPTION OF ASSENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">122.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Director of the Company who is present at a meeting of the Board of Directors at which action on any Company matter is taken shall be presumed to have assented to the action taken unless his dissent shall be entered in the Minutes of the meeting or unless he shall file his written dissent from such action with the person acting as the chairman or secretary of the meeting before the adjournment thereof or shall forward a written form of such dissent to such person immediately after the adjournment of the meeting.&#160; Such right to dissent shall not apply to a Director who voted in favour of such action.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DIVIDENDS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">123.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to any rights and restrictions for the time being attached to any Shares, or as otherwise provided for in the Companies Act and these Articles, the Directors may from time to time declare dividends (including interim dividends) and other distributions on Shares in issue and authorise payment of the same out of the funds of the Company lawfully available therefor.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">124.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to any rights and restrictions for the time being attached to any Shares, the Company by Ordinary Resolution may declare dividends, but no dividend shall exceed the amount recommended by the Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">125.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may determine, before recommending or declaring any dividend, to set aside out of the funds legally available for distribution such sums as they think proper as a reserve or reserves which shall, in the absolute discretion of the Directors, be applicable for meeting contingencies, or for equalising dividends or for any other purpose to which those funds may be properly applied and pending such application may in the absolute discretion of the Directors, either be employed in the business of the Company or be invested in such investments as the Directors may from time to time think fit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">126.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any dividend may be paid in any manner as the Directors may determine.&#160; If paid by cheque it will be sent through the post to the registered address of the Shareholder or Person entitled thereto, or in the case of joint holders, to any one of such joint holders at his registered address or to such Person and such address as the Shareholder or Person entitled, or such joint holders as the case may be, may direct.&#160; Every such cheque shall be made payable to the order of the Person to whom it is sent or to the order of such other Person as the Shareholder or Person entitled, or such joint holders as the case may be, may direct.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">127.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors when paying dividends to the Shareholders in accordance with the foregoing provisions of these Articles may make such payment either in cash or in specie and may determine the extent to which amounts may be withheld therefrom (including, without limitation, any taxes, fees, expenses or other liabilities for which a Shareholder (or the Company, as a result of any action or inaction of the Shareholder) is liable).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">128.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to any rights and restrictions for the time being attached to any Shares, all dividends shall be declared and paid according to the amounts paid up on the Shares, but if and for so long as nothing is paid up on any of the Shares dividends may be declared and paid according to the par value of the Shares. No amount paid on a Share in advance of calls shall, while carrying interest, be treated for the purposes of this Article&nbsp;as paid on the Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">129.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If several Persons are registered as joint holders of any Share, any of them may give effectual receipts for any dividend or other moneys payable on or in respect of the Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="29876-2-PG-05_PB_23_123618_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=753296,FOLIO='23',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">130.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No dividend shall bear interest against the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">131.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any dividend unclaimed after a period of six years from the date of declaration of such dividend may be forfeited by the Board of Directors and, if so forfeited, shall revert to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ACCOUNTS, AUDIT AND ANNUAL RETURN AND DECLARATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">132.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The books of account relating to the Company&#146;s affairs shall be kept in such manner as may be determined from time to time by the Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">133.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The books of account shall be kept at the Office, or at such other place or places as the Directors think fit, and shall always be open to the inspection of the Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">134.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the Company or any of them shall be open to the inspection of Shareholders not being Directors, and no Shareholder (not being a Director) shall have any right of inspecting any account or book or document of the Company except as conferred by law or authorised by the Directors or by Ordinary Resolution.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">135.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The accounts relating to the Company&#146;s affairs shall be audited in such manner and with such financial year end as may be determined from time to time by the Directors or failing any determination as aforesaid shall not be audited.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">136.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors may appoint an Auditor of the Company who shall hold office until removed from office by a resolution of the Directors and may fix his or their remuneration.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">137.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Every Auditor of the Company shall have a right of access at all times to the books and accounts and vouchers of the Company and shall be entitled to require from the Directors and Officers of the Company such information and explanation as may be necessary for the performance of the duties of the auditors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">138.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Auditors shall, if so required by the Directors, make a report on the accounts of the Company during their tenure of office at the next annual general meeting following their appointment, and at any time during their term of office, upon request of the Directors or any general meeting of the Shareholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">139.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors in each year shall prepare, or cause to be prepared, an annual return and declaration setting forth the particulars required by the Companies Act and deliver a copy thereof to the Registrar of Companies in the Cayman Islands.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAPITALISATION OF RESERVES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">140.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the Companies Act and these Articles, the Directors may:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>resolve to capitalise an amount standing to the credit of reserves (including a Share Premium Account, capital redemption reserve and profit and loss account), whether or not available for distribution;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>appropriate the sum resolved to be capitalised to the Shareholders in proportion to the nominal amount of Shares (whether or not fully paid) held by them respectively and apply that sum on their behalf in or towards:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>paying up the amounts (if any) for the time being unpaid on Shares held by them respectively, or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>paying up in full unissued Shares or debentures of a nominal amount equal to that sum, and allot the Shares or debentures, credited as fully paid, to the Shareholders (or as they may direct) in those proportions, or partly in one way and partly in the other, but the Share Premium Account, the capital redemption reserve and profits which are not available for distribution may, for the purposes of this Article, only be applied in paying up unissued Shares to be allotted to Shareholders credited as fully paid;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="29876-2-PG-05_PB_24_123627_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=877854,FOLIO='24',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>make any arrangements they think fit to resolve a difficulty arising in the distribution of a capitalised reserve and in particular, without limitation, where Shares or debentures become distributable in fractions the Directors may deal with the fractions as they think fit;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>authorise a Person to enter (on behalf of all the Shareholders concerned) into an agreement with the Company providing for either:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the allotment to the Shareholders respectively, credited as fully paid, of Shares or debentures to which they may be entitled on the capitalisation, or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the payment by the Company on behalf of the Shareholders (by the application of their respective proportions of the reserves resolved to be capitalised) of the amounts or part of the amounts remaining unpaid on their existing Shares,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and any such agreement made under this authority being effective and binding on all those Shareholders; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>generally do all acts and things required to give effect to any of the actions contemplated by this Article.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">141.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding any provisions in these Articles, the Directors may resolve to capitalise any sum standing to the credit of any of the Company&#146;s reserve accounts or funds (including the Share Premium Account and capital redemption reserve fund) or any sum standing to the credit of the profit and loss account or otherwise available for distribution by applying such sum in paying up in full unissued Shares to be allotted and issued to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a).</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>employees (including Directors) or service providers of the Company or its Affiliates upon exercise or vesting of any options or awards granted under any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or the Shareholders;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b).</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any trustee of any trust or administrator of any share incentive scheme or employee benefit scheme to whom shares are to be allotted and issued by the Company in connection with the operation of any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or Shareholders; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any depositary of the Company for the purposes of the issue, allotment and delivery by the depositary of ADSs to employees (including Directors) or service providers of the Company or its Affiliates upon exercise or vesting of any options or awards granted under any share incentive scheme or employee benefit scheme or other arrangement which relates to such persons that has been adopted or approved by the Directors or the Shareholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHARE PREMIUM ACCOUNT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">142.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors shall in accordance with the Companies Act establish a Share Premium Account and shall carry to the credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">143.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There shall be debited to any Share Premium Account on the redemption or purchase of a Share the difference between the nominal value of such Share and the redemption or purchase price provided always that at the determination of the Directors such sum may be paid out of the profits of the Company or, if permitted by the Companies Act, out of capital.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="29876-2-PG-05_PB_25_123700_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=389300,FOLIO='25',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:23 2021' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOTICES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">144.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as otherwise provided in these Articles, any notice or document may be served by the Company or by the Person entitled to give notice to any Shareholder either personally, or by posting it by airmail or air courier service in a prepaid letter addressed to such Shareholder at his address such Shareholder may have specified in writing for the purpose of such service of notices (or if absent of such notification, at his address as appearing in the Register), or by electronic mail to any electronic mail address such Shareholder may have specified in writing for the purpose of such service of notices, or by facsimile or by placing it on the Company&#146;s Website should the Directors deem it appropriate provided that the Company shall notify the Shareholders of the placement of such notice by any of the means set out above. In the case of joint holders of a Share, all notices shall be given to that one of the joint holders whose name stands first in the Register in respect of the joint holding, and notice so given shall be sufficient notice to all the joint holders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">145.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notices posted to addresses outside the Cayman Islands shall be forwarded by prepaid airmail.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">146.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any Shareholder present, either personally or by proxy, at any meeting of the Company shall for all purposes be deemed to have received due notice of such meeting and, where requisite, of the purposes for which such meeting was convened.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">147.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any notice or other document, if served by:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>post, shall be deemed to have been served five days after the time when the letter containing the same is posted;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>facsimile, shall be deemed to have been served upon production by the transmitting facsimile machine of a report confirming transmission of the facsimile in full to the facsimile number of the recipient;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>recognised courier service, shall be deemed to have been served 48 hours after the time when the letter containing the same is delivered to the courier service; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>electronic mail, shall be deemed to have been served immediately upon the time of the transmission by electronic mail.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In proving service by post or courier service it shall be sufficient to prove that the letter containing the notice or documents was properly addressed and duly posted or delivered to the courier service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">148.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any notice or document delivered or sent by post to or left at the registered address of any Shareholder in accordance with the terms of these Articles shall notwithstanding that such Shareholder be then dead or bankrupt, and whether or not the Company has notice of his death or bankruptcy, be deemed to have been duly served in respect of any Share registered in the name of such Shareholder as sole or joint holder, unless his name shall at the time of the service of the notice or document, have been removed from the Register as the holder of the Share, and such service shall for all purposes be deemed a sufficient service of such notice or document on all Persons interested (whether jointly with or as claiming through or under him) in the Share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">149.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notice of every general meeting of the Company shall be given to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>all Shareholders holding Shares with the right to receive notice and who have supplied to the Company an address for the giving of notices to them; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="29876-2-PG-07_PB_26_123956_4815"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=971530,FOLIO='26',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:24 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>every Person entitled to a Share in consequence of the death or bankruptcy of a Shareholder, who but for his death or bankruptcy would be entitled to receive notice of the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No other Person shall be entitled to receive notices of general meetings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INFORMATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">150.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No Shareholder shall be entitled to require discovery of any information in respect of any detail of the Company&#146;s trading or any information which is or may be in the nature of a trade secret or secret process which may relate to the conduct of the business of the Company and which in the opinion of the Board would not be in the interests of the Shareholders of the Company to communicate to the public.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">151.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board shall be entitled to release or disclose any information in its possession, custody or control regarding the Company or its affairs to any of its Shareholders including, without limitation, information contained in the Register and transfer books of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEMNITY</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">152.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Every Director (including for the purposes of this Article&nbsp;any alternate Director appointed pursuant to the provisions of these Articles), Secretary, assistant Secretary, or other Officer (but not including the Company&#146;s auditors) and the personal representatives of the same (each an &#147;<b>Indemnified Person</b>&#148;) shall be indemnified and secured harmless, to the fullest extent permitted by applicable law, against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason of such Indemnified Person&#146;s own dishonesty, wilful default or fraud as determined by a court of competent jurisdiction, in or about the conduct of the Company&#146;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such Indemnified Person in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether in the Cayman Islands or elsewhere.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">153.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No Indemnified Person shall be liable:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for the acts, receipts, neglects, defaults or omissions of any other Director or Officer or agent of the Company; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for any loss on account of defect of title to any property of the Company; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>on account of the insufficiency of any security in or upon which any money of the Company shall be invested; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for any loss incurred through any bank, broker or other similar Person; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for any loss occasioned by any negligence, default, breach of duty, breach of trust, error of judgement or oversight on such Indemnified Person&#146;s part; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>for any loss, damage or misfortune whatsoever which may happen in or arise from the execution or discharge of the duties, powers, authorities, or discretions of such Indemnified Person&#146;s office or in relation thereto;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">unless the same shall happen through such Indemnified Person&#146;s own dishonesty, wilful default or fraud as determined by a court of competent jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">27<a name="29876-2-PG-07_PB_27_124048_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=1032168,FOLIO='27',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:24 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FINANCIAL YEAR</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">154.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unless the Directors otherwise prescribe, the financial year of the Company shall end on December&nbsp;31<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>&#160;in each year and shall begin on January&nbsp;1<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>&#160;in each year.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NON-RECOGNITION OF TRUSTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">155.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No Person shall be recognised by the Company as holding any Share upon any trust and the Company shall not, unless required by law, be bound by or be compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any Share or (except only as otherwise provided by these Articles or as the Companies Act requires) any other right in respect of any Share except an absolute right to the entirety thereof in each Shareholder registered in the Register.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WINDING UP</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">156.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Company shall be wound up the liquidator may, with the sanction of a Special Resolution of the Company and any other sanction required by the Companies Act, divide amongst the Shareholders in kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may for that purpose value any assets and determine how the division shall be carried out as between the Shareholders or different classes of Shareholders. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Shareholders as the liquidator, with the like sanction, shall think fit, but so that no Shareholder shall be compelled to accept any asset upon which there is a liability.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">157.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Company shall be wound up, and the assets available for distribution amongst the Shareholders shall be insufficient to repay the whole of the share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the Shareholders in proportion to the par value of the Shares held by them. If in a winding up the assets available for distribution amongst the Shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst the Shareholders in proportion to the par value of the Shares held by them at the commencement of the winding up subject to a deduction from those Shares in respect of which there are monies due, of all monies payable to the Company for unpaid calls or otherwise. This Article&nbsp;is without prejudice to the rights of the holders of Shares issued upon special terms and conditions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDMENT OF ARTICLES OF ASSOCIATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">158.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the Companies Act and the rights attaching to the various Classes, the Company may at any time and from time to time by Special Resolution alter or amend these Articles in whole or in part.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CLOSING OF REGISTER OR FIXING RECORD DATE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">159.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For the purpose of determining those Shareholders that are entitled to receive notice of, attend or vote at any meeting of Shareholders or any adjournment thereof, or those Shareholders that are entitled to receive payment of any dividend, or in order to make a determination as to who is a Shareholder for any other purpose, the Directors may provide that the Register shall be closed for transfers for a stated period which shall not exceed in any case 30 days.&#160; If the Register shall be so closed for the purpose of determining those Shareholders that are entitled to receive notice of, attend or vote at a meeting of Shareholders the Register shall be so closed for at least ten days immediately preceding such meeting and the record date for such determination shall be the date of the closure of the Register.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">160.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In lieu of or apart from closing the Register, the Directors may fix in advance a date as the record date for any such determination of those Shareholders that are entitled to receive notice of, attend or vote at a meeting of the Shareholders and for the purpose of determining those Shareholders that are entitled to receive payment of any dividend the Directors may, at or within 90 days prior to the date of declaration of such dividend, fix a subsequent date as the record date for such determination.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">28<a name="29876-2-PG-07_PB_28_124106_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=57643,FOLIO='28',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:24 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">161.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Register is not so closed and no record date is fixed for the determination of those Shareholders entitled to receive notice of, attend or vote at a meeting of Shareholders or those Shareholders that are entitled to receive payment of a dividend, the date on which notice of the meeting is posted or the date on which the resolution of the Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of Shareholders. When a determination of those Shareholders that are entitled to receive notice of, attend or vote at a meeting of Shareholders has been made as provided in this Article, such determination shall apply to any adjournment thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REGISTRATION BY WAY OF CONTINUATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">162.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company may by Special Resolution resolve to be registered by way of continuation in a jurisdiction outside the Cayman Islands or such other jurisdiction in which it is for the time being incorporated, registered or existing. In furtherance of a resolution adopted pursuant to this Article, the Directors may cause an application to be made to the Registrar of Companies to deregister the Company in the Cayman Islands or such other jurisdiction in which it is for the time being incorporated, registered or existing and may cause all such further steps as they consider appropriate to be taken to effect the transfer by way of continuation of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DISCLOSURE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Directors, or any service providers (including the Officers, the Secretary and the registered office agent of the Company) specifically authorised by the Directors, shall be entitled to disclose to any regulatory or judicial authority or to any stock exchange on which securities of the Company may from time to time be listed any information regarding the affairs of the Company including without limitation information contained in the Register and books of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">29<a name="29876-2-PG-07_PB_29_124126_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2242824",CP="ADAGENE INC.",DN="2",CHK=759718,FOLIO='29',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-PG-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 16 13:24 2021' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>a2242824zex-10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.14<a name="29876-2-RC-01_Exhibit10_14_121123"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Confidential</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Execution Version</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">*** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1)&nbsp;NOT MATERIAL AND (2)&nbsp;WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLABORATION AND LICENSE AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS COLLABORATION AND LICENSE AGREEMENT</font></b> (the &#147;<b>Agreement</b>&#148;) is entered into as of February&nbsp;1, 2021 (the &#147;<b>Effective Date</b>&#148;), by and between <b>EXELIXIS,&nbsp;INC.</b>, a Delaware corporation having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502, USA (&#147;<b>Exelixis</b>&#148;) and <b>ADAGENE INCORPORATED</b>, a Delaware corporation having an address at 315 Montgomery Street, Suite&nbsp;900, San Francisco, CA 94104 (&#147;<b>Adagene</b>&#148;).&#160; Exelixis and Adagene may be referred to herein individually as a &#147;<b>Party</b>&#148; or collectively as the &#147;<b>Parties</b>&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, Adagene, a biotechnology company, has developed proprietary technology platforms to enable innovative antibody discovery and engineering;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, Exelixis and Adagene desire to form a collaboration to discover masked antibody candidates for further drug and product development and commercialization, under which collaboration Adagene will be responsible for generating such masked antibody candidates using Adagene&#146;s SAFEbody<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;platform technology, and Exelixis will be responsible for the further development and commercialization of the candidates; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, the Parties wish to establish such collaboration, all on the terms and conditions set forth below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW, THEREFORE, </font></b>in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Exelixis and Adagene hereby agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DEFINITIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Accounting Standards</b>&#148; means with respect to Adagene, that Adagene shall maintain records and books of accounts in accordance with United States Generally Accepted Accounting Principles (U.S. GAAP).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;[***]&#148; means [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Adagene Indemnitee</b>&#148; has the meaning set forth in Section&nbsp;11.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Adagene Know-How</b>&#148; means all Know-How that Adagene or its Affiliates Control as of the Effective Date or during the Term that is necessary or reasonably useful for the research, Development, manufacture, use, importation, offer for sale, sale, or </p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="29876-2-RC-01_PB_1_121150_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=977076,FOLIO='1',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other Commercialization </font>of any Lead Compound or Product. Without limiting the generality of the foregoing, the Adagene Know-How existing at the Effective Date is described in <u>Exhibit&nbsp;A</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Adagene Patents</b>&#148; means all Patents (other than Adagene Platform Patents) that Adagene or its Affiliates Control as of the Effective Date or during the Term that (a)&nbsp;describe or claim any Adagene Know-How or (b)&nbsp;would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization of any Lead Compound or Product (considering patent applications to be issued with the then-pending claims).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Adagene Platform Patents</b>&#148; means all Patents that describe or claim any Adagene Platform Technology and do not specifically describe or claim a Compound or a Product and do not use and are not based on any Exelixis mAB, Exelixis Technology, or any of Exelixis&#146; Confidential Information.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Adagene Platform Technology</b>&#148; means Adagene&#146;s proprietary antibody engineering platform that is known as the SAFEbody<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;technology.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Adagene Technology</b>&#148; means the Adagene Know-How, the Adagene Patents, the Adagene Platform Patents, and Adagene&#146;s interest in the Joint Inventions and Joint Patents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Affiliate</b>&#148; means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such party, but for only so long as such control exists.&#160; As used in this Section&nbsp;1.9, &#147;control&#148; means (a)&nbsp;to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance; or (b)&nbsp;direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.10</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Alliance Manager</b>&#148; has the meaning set forth in Section&nbsp;3.6.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.11</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Applicable Laws</b>&#148; means the applicable provisions of any and all national, supranational, regional, state, and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, Regulatory Authority, or governmental agency or authority having jurisdiction over or related to the subject item.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.12</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Auditor</b>&#148; has the meaning set forth in Section&nbsp;8.6.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.13</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Available</b>&#148; means, with respect to a Target, that such Target is not Unavailable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.14</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Binder</b>&#148; means the antigen binding portion of an antibody, such as Fab and CDR fragments, single chain antibodies (scFv), and single domain antibodies (sdAb) (including any humanized versions thereof).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="29876-2-RC-01_PB_2_121211_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=920539,FOLIO='2',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.15</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Biosimilar Product</b>&#148; means, with respect to a product in a country, any pharmaceutical product that (a)&nbsp;is biosimilar to, or interchangeable with, such product or may otherwise be legally substituted for such product and for which the BLA references or relies on such product, (b)&nbsp;is approved for the same indication as such product, and (c)&nbsp;is sold in such country by a Third Party that is not a Sublicensee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.16</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>BLA</b>&#148; means a Biologics License Application as described in 21 C.F.R. &#167;601.2, including any amendments thereto, or any corresponding application in a country or jurisdiction in the Territory outside the U.S.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.17</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Calendar Quarter</b>&#148; means each respective period of three (3)&nbsp;consecutive months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30, and December&nbsp;31, or such other quarterly dates as Exelixis may elect by written notice to Adagene to correspond with Exelixis&#146; fiscal year.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.18</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Calendar Year</b>&#148; means each respective period of twelve (12) consecutive months ending on December&nbsp;31.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.19</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Claim</b>&#148; has the meaning set forth in Section&nbsp;11.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.20</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Clinical Trial</b>&#148; means Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, or other clinical study, as the context dictates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.21</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Collaboration Program</b>&#148; means the performance of both Target Program Plans under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.22</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Collaboration Target</b>&#148; means each of the (a)&nbsp;Initial Target and (b)&nbsp;first Target designated by Exelixis to be the subject of a Target Program Plan pursuant to Section&nbsp;4.2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.23</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Collaboration Target Designation Notice</b>&#148; has the meaning set forth in Section&nbsp;4.2(c).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.24</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Combination Product</b>&#148; means any pharmaceutical product containing (a)&nbsp;a Product and (b)&nbsp;at least one other active pharmaceutical ingredient, either co-formulated or packaged together and sold as a single unit for a single price.&#160; For clarity, &#147;Combination Product&#148; does not include any combination therapy that includes (x)&nbsp;the Product and (y)&nbsp;at least one other product which is not a Product, either administered or prescribed jointly, but which are not sold together for a single price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.25</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Commercialization</b>&#148; means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical support, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering products to customers) of products, including sales force efforts, detailing, advertising, market research, market access (including price setting and reimbursement activities), medical education and information services, publication, scientific and medical affairs, advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales (including receiving, </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="29876-2-RC-01_PB_3_121251_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=22886,FOLIO='3',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">accepting, and filling product orders) and distribution.&#160; &#147;<b>Commercialize</b>&#148; and &#147;<b>Commercializing</b>&#148; have correlative meanings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.26</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Commercially Reasonable Efforts</b>&#148; means: (a)&nbsp;with respect to Exelixis&#146; obligations to Develop, seek MAA Approval, and Commercialize a Product under this Agreement, [***]; and (b)&nbsp;with respect to Adagene&#146;s performance of each Target Program Plan, [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.27</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Committee</b>&#148; means the JSC or any subcommittee established by the JSC, as applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.28</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Compound</b>&#148; means any Masked Exelixis mAB that binds to a Collaboration Target in the intended tumor microenvironment and is synthesized or created by Adagene using the Adagene Platform Technology, but excluding (a)&nbsp;Third Party-controlled compounds that are tested for comparison purposes and (b)&nbsp;compounds (including Exelixis mABs) provided to Adagene by or on behalf of Exelixis which are not further developed by Adagene under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.29</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Compound Invention</b>&#148; has the meaning set forth in Section&nbsp;9.1(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.30</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Compound Research Activities</b>&#148; means, with respect to a Target Program Plan, (a)&nbsp;the activities required to be conducted to generate Compounds directed to the applicable Collaboration Target (such activities referred to as &#147;<b>Part&nbsp;1</b>&#148; of the Target Program Plan) (b)&nbsp;the <i>in vitro</i> studies of the Compounds to be conducted by Adagene (such activities referred to as &#147;<b>Part&nbsp;2</b>&#148; of the Target Program Plan), and (c)&nbsp;<i>in vivo</i> studies of the Lead Compounds to be conducted by the Parties (such activities referred to as &#147;<b>Part&nbsp;3</b>&#148; of the Target Program Plan).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.31</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Compulsory Sublicense</b>&#148; means, with respect to a Product in a country, a license or sublicense granted to a Third Party (a &#147;<b>Compulsory Licensee</b>&#148;) through the order, decree, or grant of a Governmental Authority in such country, authorizing such Compulsory Licensee to make, use, sell, offer for sale, import, or otherwise Commercialize such Product in such country.&#160; A Compulsory Licensee shall not be deemed to be a Sublicensee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.32</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Confidentiality Agreement</b>&#148; means that certain Mutual Confidential Disclosure Agreement by and between Exelixis and Adagene dated as of August&nbsp;26, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.33</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Confidential Information</b>&#148; means all Know-How and other proprietary scientific, marketing, financial, or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement; provided that all Compound Inventions, Data, Exelixis mABs, and Exelixis Technology will be deemed Exelixis&#146; Confidential Information, all Adagene Technology and Adagene Platform Technology will be deemed Adagene&#146;s Confidential Information, and all Joint Inventions and Joint Patents will be deemed both Parties&#146; Confidential Information.&#160; Confidential Information shall include: (a)&nbsp;the terms and </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="29876-2-RC-01_PB_4_121340_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=656493,FOLIO='4',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">conditions of this Agreement, and (b)&nbsp;Confidential Information disclosed by either Party pursuant to the Confidentiality Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.34</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Control</b>&#148; or &#147;<b>Controlled</b>&#148; means, with respect to any Know-How, Patents, or other intellectual property rights, the legal authority or right (whether by ownership, license, or otherwise but without taking into account any licenses granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such Know-How, Patents, or other intellectual property rights to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party or triggering any payment obligation to a Third Party.&#160; Notwithstanding the foregoing, Know-How, Patents, or other intellectual property rights will be &#147;Controlled&#148; by a Party hereunder if such Know-How, Patents, or other intellectual property rights are owned or in-licensed by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Party (a)&nbsp;acquiring such Third Party or a portion of the business of such Third Party or (b)&nbsp;being acquired by such Third Party (in each case, whether by merger, stock purchase or purchase of assets).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.35</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Data</b>&#148; means any and all scientific, technical, test, or other data pertaining to any Compound or Product that is generated by or on behalf of Adagene under any Target Program Plan, or is generated by on behalf of Exelixis (including by Adagene), or its Affiliates and sublicensees during the Term, including research data, clinical pharmacology data, chemistry-manufacture-controls (CMC) data (including analytical, and stability data), pre-clinical data, clinical data, clinical study reports, and all data used in association with submissions of an IND or MAA with respect to any Lead Compound or Product.&#160; For clarity, Data shall not include any data that Adagene generates to the extent that such data is only generally applicable to the Adagene Platform Technology or its use or to Platform Inventions and does not also pertain to any Compound or Collaboration Target.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.36</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Data Package Part&nbsp;1</b>&#148; has the meaning set forth in Section&nbsp;4.4(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.37</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Data Package Part&nbsp;2</b>&#148; has the meaning set forth in Section&nbsp;4.4(c).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.38</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Development</b>&#148; means all development activities for a product (whether alone or for use together, or in combination, with another active agent or pharmaceutical product as a combination product or combination therapy) that are directed to obtaining Regulatory Approval(s)&nbsp;of such product and lifecycle management of such product in any country in the world, including all non-clinical, preclinical, and clinical testing and studies of such product; toxicology, pharmacokinetic, and pharmacological studies; statistical analyses; assay development; protocol design and development; the preparation, filing, and prosecution of any MAA for such product; development activities directed to label expansion and/or obtaining Regulatory Approval for one or more additional indications following initial Regulatory Approval; development activities conducted after receipt of Regulatory Approval; and all regulatory affairs related to any of the foregoing.&#160; &#147;<b>Develop</b>&#148; and &#147;<b>Developing</b>&#148; have correlative meanings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="29876-2-RC-01_PB_5_121407_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=840606,FOLIO='5',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.39</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Development Criteria</b>&#148; means with respect to a Compound, the criteria for designating such Compound a Lead Compound, as reviewed, discussed, decided, and updated (as necessary) from time to time by the JSC.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.40</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Development Costs</b>&#148; has the meaning set forth in Section&nbsp;7.2(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.41</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Disputed Matter</b>&#148; has the meaning set forth in Section&nbsp;14.2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.42</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>EMA</b>&#148; means the European Medicines Agency, or any successor agency thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.43</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Executive Officers</b>&#148; the Chief Scientific Officer of Exelixis and the Chief Executive Officer of Adagene.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.44</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Exelixis Indemnitee</b>&#148; has the meaning set forth in Section&nbsp;11.2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.45</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Exelixis Know-How</b>&#148; means all Know-How that Exelixis or its Affiliates Control as of the Effective Date or during the Term, including the Compound Inventions, that is&nbsp;necessary or reasonably useful for the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization of any Lead Compound or Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.46</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Exelixis mAB</b>&#148; means any mAB that is (a)&nbsp;directed to a specific Collaboration Target, and (b)&nbsp;is provided to Adagene by Exelixis for use in the generation of Compounds pursuant to Section&nbsp;4.4(b)&nbsp;under the Target Program Plan for such Collaboration Target.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.47</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Exelixis Patents</b>&#148; means all Patents in the Territory that Exelixis or its Affiliates Control as of the Effective Date or during the Term, including the Product Patents, that (a)&nbsp;describe or claim any Exelixis Know-How or (b)&nbsp;would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization of any Compound or Product (considering patent applications to be issued with the then-pending claims).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.48</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Exelixis Technology</b>&#148; means the Exelixis Know-How and the Exelixis Patents, including Exelixis&#146; interest in the Joint Inventions and Joint Patents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.49</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>FDA</b>&#148; means the U.S. Food and Drug Administration, or any successor agency thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.50</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Field</b>&#148; means any and all uses.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.51</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>First Commercial Sale</b>&#148; means, on a Product-by-Product and country-by-country basis, the first sale by Exelixis or any of its Affiliates or Sublicensees to a Third Party for end use of such Product in such country after Regulatory Approval has been granted with respect to such Product in such country.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="29876-2-RC-01_PB_6_121420_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=313209,FOLIO='6',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.52</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>FTE</b>&#148; means the equivalent of a full-time Adagene (including its Affiliates) employee&#146;s work for a twelve (12) month period (consisting of a total of at least [***] per year of dedicated effort).&#160; Any such employee who devotes fewer than [***] per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such employee on such activities, divided by [***].&#160; For clarity, only hours devoted by qualified scientific, medical, manufacturing, technical, regulatory, and other similar employees of Adagene, as measured in accordance with Adagene&#146;s normal time allocation practices, shall apply toward an FTE, and in no event shall &#147;FTE&#148; include hours devoted by personnel performing administrative, managerial, or corporate functions (e.g., human resources, finance, legal, and investor relations).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.53</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>FTE Costs</b>&#148; means the FTE Rate multiplied by the number of FTEs applied by Adagene (including its Affiliates) to the performance of Compound Research Activities in accordance with a Target Program Plan and Target Program Budget.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.54</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>FTE Rate</b>&#148; means: (a)&nbsp;for any work carried out in the PRC, an initial rate of [***]&#160; per FTE per year, and (b)&nbsp;for any work carried out in the United States, an initial rate of [***]&#160; per FTE per year; in each case of (a)&nbsp;and (b)&nbsp;which rate shall apply through [***].&#160; Thereafter, the FTE Rate shall be changed annually on a Calendar Year basis to reflect any year-to-year percentage increase or decrease (as the case may be) in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics (based on the change from the most recent applicable index available as of the Effective Date to the most recent applicable index available as of the date of the calculation of such revised FTE Rate).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.55</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>GLP</b>&#148; means&#160; in respect of laboratory activities, the then current standards required by Applicable Law of: (a)&nbsp;the United States, including the FDA&#146;s Good Laboratory Practice regulations at 21 C.F.R. Part&nbsp;58; (b)&nbsp;the European Union, including the Directive 2004/9/EC, Directive 2004/10/EC, guidance published by the European Commission or EMA in relation to such Directives and any local laws, rules&nbsp;and regulations that implement such Directives and guidance; and (c)&nbsp;such other countries in which a Licensed Product is tested.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.56</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>GLP Toxicity Study</b>&#148; means, with respect to a Product, an in vivo toxicology study conducted under conditions of GLP that is required for filing an IND for such Product with the FDA.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.57</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Governmental Authority</b>&#148; means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.58</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>ICH</b>&#148; means the International Conference on Harmonization (of Technical Requirements for Registration of Pharmaceuticals for Human Use).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.59</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>IND</b>&#148; means an investigational new drug application or equivalent application filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="29876-2-RC-01_PB_7_121443_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=794470,FOLIO='7',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.60</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Indemnified Party</b>&#148; has the meaning set forth in Section&nbsp;11.3.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.61</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Indemnifying Party</b>&#148; has the meaning set forth in Section&nbsp;11.3.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.62</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Initial Target</b>&#148; means the undisclosed target already agreed between the parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.63</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Initiation</b>&#148; means, with respect to the GLP Toxicity Study, the first dosing of the first animal subject in such GLP Toxicity Study, and with respect to a Clinical Trial, the first dosing of the first human subject in such Clinical Trial.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.64</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Injunctive Relief</b>&#148; has the meaning set forth in Section&nbsp;14.3(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.65</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Inventions</b>&#148; means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice in the course of activities contemplated by this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.66</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Joint Inventions</b>&#148; has the meaning set forth in Section&nbsp;9.1(d).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.67</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Joint Patents</b>&#148; has the meaning set forth in Section&nbsp;9.1(d).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.68</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Joint Steering Committee</b>&#148; or &#147;<b>JSC</b>&#148; has the meaning set forth in Section&nbsp;3.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.69</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Know-How</b>&#148; means all technical information, know-how, and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models and other physical, biological, or chemical materials, expertise and other technology applicable to, development, manufacture, registration, use, or marketing or to methods of assaying or testing them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, and analytical, safety, nonclinical, and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise and information, relevant to the research, development, use, importation, offering for sale or sale of, or which may be useful in studying, testing, or developing products.&#160; Know-How excludes Patents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.70</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Lead Compound</b>&#148; has the meaning set forth in Section&nbsp;4.4(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.71</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Losses</b>&#148; has the meaning set forth in Section&nbsp;11.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.72</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>MAA</b>&#148; means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="29876-2-RC-01_PB_8_121509_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=251311,FOLIO='8',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.73</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>MAA Approval</b>&#148; means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a product, but excluding any pricing and/or reimbursement approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.74</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>mAB</b>&#148; means a monoclonal, bispecific, or multispecific antibody.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.75</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Mask</b>&#148; means a masking moiety (peptide) that binds to a mAB via a linker with a protease site so as to inhibit such a mAB from binding to the intended Target except in desired microenvironments.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.76</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Masked Exelixis mAB</b>&#148; means an Exelixis mAB that contains a Mask.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.77</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>MHLW</b>&#148; means Japan&#146;s Ministry of Health, Labour and Welfare, or any successor agency thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.78</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Net Sales</b>&#148; means, with respect to any Product, the gross amounts invoiced for sales or other dispositions of such Product by or on behalf of Exelixis or its Affiliates or Sublicensees to Third Parties, less the following deductions to the extent included in the gross invoiced sales price for such Product and determined in each case in accordance with generally accepted accounting principles in the U.S. (&#147;<b>U.S. GAAP</b>&#148;) or otherwise directly paid or incurred by Exelixis or its Affiliates or Sublicensees, as applicable, with respect to the sale or other disposition of such Product:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***]; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In no event will any particular amount identified above be deducted more than once in calculating Net Sales.&#160; Sales of a Product between Exelixis and its Affiliates or Sublicensees for resale shall be excluded from the computation of Net Sales, but the subsequent resale of such Product to a Third Party shall be included within the computation of Net Sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="29876-2-RC-01_PB_9_121526_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=419237,FOLIO='9',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event a Product is sold as part of a Combination Product in a country, the Net Sales with respect to the Combination Product in such country shall be determined&#160; [***].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For clarity, Net Sales will be calculated on an accrual basis, in a manner consistent with U.S. GAAP and this definition of Net Sales.&#160; To the extent any accrued amounts used in the calculation of Net Sales are estimates, such estimates shall be trued-up in accordance with Exelixis&#146; internal accounting policies, consistently applied, and Net Sales and related payments under this Agreement shall be reconciled as appropriate</font>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For clarity, no deductions from Net Sales shall be made&#160; [***].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.79</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>NMPA</b>&#148; means National Medical Products Administration of China (formerly known as the China Food and Drug Administration), or any successor agency thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.80</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Part&nbsp;1</b>&#148; has the meaning set forth in Section&nbsp;1.30(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.81</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Part&nbsp;2</b>&#148; has the meaning set forth in Section&nbsp;1.30(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.82</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Part&nbsp;3</b>&#148; has the meaning set forth in Section&nbsp;1.30(c).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.83</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Patents</b>&#148; means (a)&nbsp;all patents, certificates of invention, applications for certificates of invention, priority patent filings, and patent applications, and (b)&nbsp;any renewals, divisions, continuations (in whole or in part), or requests for continued examination of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.84</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Phase&nbsp;1 Clinical Trial</b>&#148; means a clinical trial conducted in a small number of patients designed or intended to establish an initial safety profile, pharmacodynamics, or pharmacokinetics of a pharmaceutical product.&#160; A Phase 1 Clinical Trial can be further divided into two separate trials:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Phase 1a Clinical Trial</b>&#148; means a single dose or multiple dose ascending clinical trial intended to evaluate safety and tolerability and determination of dose(s)&nbsp;for further clinical evaluation; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Phase 1b Clinical Trial</b>&#148; means a clinical trial of a product, the principal purpose of which is a further determination of safety and pharmacokinetics of such product after an initial Phase 1a Clinical Trial, including as a single agent expansion cohort, prior to commencement of Phase 2 Clinical Trials (or phase 2 of a Phase 1/2 clinical trial) or Phase 3 Clinical Trials.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.85</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Phase&nbsp;2 Clinical Trial</b>&#148; means a clinical trial of a pharmaceutical product in human patients in any country to determine initial efficacy and safety and dose range finding.&#160; A</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="29876-2-RC-01_PB_10_121705_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=224844,FOLIO='10',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-01_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:13 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phase 2 Clinical Trial is typically conducted before embarking on a Phase&nbsp;3 Clinical Trial, but may be registrational.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.86</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Phase&nbsp;3 Clinical Trial</b>&#148; means a pivotal clinical trial of a pharmaceutical product in human patients in any country with a defined dose or a set of defined doses of such product designed to ascertain efficacy and safety of such product for the purpose of submitting MAAs for such product to the competent Regulatory Authorities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.87</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Platform Inventions</b>&#148; has the meaning set forth in Section&nbsp;9.1(c).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.88</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>PRC</b>&#148; means the People&#146;s Republic of China.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.89</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Product</b>&#148; means any pharmaceutical product containing a Lead Compound as an active ingredient, whether alone or in combination with other active ingredients, in any form, presentation, dosage, or formulation, and for any mode of administration.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.90</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Product Infringement</b>&#148; has the meaning set forth in Section&nbsp;9.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.91</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Product Patent</b>&#148; means a Patent that claims a Compound Invention.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.92</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Public Official or Entity</b>&#148; means (a)&nbsp;any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military, or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b)&nbsp;any candidate for political office, any political party, or any official of a political party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.93</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>R&amp;D Cap</b>&#148; has the meaning set forth in Section&nbsp;7.2(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.94</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Registration Trial</b>&#148; means, with respect to a pharmaceutical product, a clinical study of such product in human patients (a)&nbsp;with a defined dose or a set of defined doses of such product designed to establish statistically significant efficacy and safety of such product for the purpose of enabling the preparation and submission of an MAA for such product to the competent Regulatory Authorities in a country or other jurisdiction, and (b)&nbsp;that would satisfy the requirements of 21 C.F.R. &#167; 312.21(c), or its foreign equivalent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.95</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Regulatory Approval</b>&#148; means any and all approvals (including MAA Approval and, where required or commercially beneficial, pricing and reimbursement approval), licenses, registrations, permits, notifications, and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of a product in any country or jurisdiction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.96</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Regulatory Authority</b>&#148; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="29876-2-RC-03_PB_11_122411_5891"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=776062,FOLIO='11',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">import,</font> transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.97</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Regulatory Exclusivity</b>&#148; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Product other than patents, including rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity), or rights similar thereto outside the U.S., such as Directive 2001/83/EC (as amended) in the EU.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.98</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Regulatory Filing</b>&#148; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, manufacture, or Commercialization of any pharmaceutical product made to or received from any Regulatory Authority in a given country, including any INDs and MAAs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.99</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Royalty Term</b>&#148; has the meaning set forth in Section&nbsp;7.5(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.100</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Rules</b>&#148; has the meaning set forth in Section&nbsp;14.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.101</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>SEC</b>&#148; means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent in the Territory, as applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.102</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Sole Inventions</b>&#148; has the meaning set forth in Section&nbsp;9.1(d).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.103</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Sublicensee</b>&#148; means a Third Party to whom Exelixis grants a sublicense to offer for sale, sell, have sold, or otherwise Commercialize any Product in the Field in the Territory in accordance with Section&nbsp;2.2, beyond the mere right to purchase Products from Exelixis and its Affiliates, and excluding wholesalers, full-service distributors that do not promote the sale of the Product, and other similar physical distributors.&#160; In no event shall Adagene or any of its Affiliates be deemed a Sublicensee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.104</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Target</b>&#148; means any human gene, together with the protein(s)&nbsp;encoded thereby, the expression or modulation of which is intended to, as its primary effect, treat, prevent, or otherwise have a disease-modifying effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.105</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Target Nomination Notice</b>&#148; has the meaning set forth in Section&nbsp;4.2(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.106</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Target Program Budget</b>&#148; has the meaning set forth in Section&nbsp;4.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.107</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Target Program Plan</b>&#148; has the meaning set forth in Section&nbsp;4.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.108</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Target Selection Term</b>&#148; means the period of time commencing on the Effective Date and ending on the first (1<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>) anniversary of the Effective Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="29876-2-RC-03_PB_12_122431_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=202581,FOLIO='12',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.109</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Term</b>&#148; has the meaning set forth in Section&nbsp;13.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.110</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Territory</b>&#148; means worldwide.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.111</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Third Party</b>&#148; means any entity other than Exelixis or Adagene or an Affiliate of Exelixis or Adagene.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.112</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Third Party Infringement Claim</b>&#148; has the meaning set forth in Section&nbsp;9.4.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.113</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Unavailable</b>&#148; means, with respect to a Target, that such Target is the subject of (a)&nbsp;[***], or (b)&nbsp;[***].&#160; Notwithstanding the foregoing, [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.114</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>U.S.</b>&#148; means the United States of America, including its territories and possessions (including Puerto Rico).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.115</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Valid Claim</b>&#148; means (a)&nbsp;a claim of an issued and unexpired patent that has not been revoked or held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer, or otherwise, or (b)&nbsp;a claim of a pending patent application that has not been cancelled, withdrawn, abandoned, or finally rejected by an administrative agency action from which no appeal can be taken and that has not been pending for more than&#160; [***] from the date of filing of the earliest priority patent application to which such pending patent application is entitled to claim benefit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.116</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>VAT</b>&#148; has the meaning set forth in Section&nbsp;8.4(c).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GRANT OF LICENSES</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exelixis Exclusive License</b>.&#160; Subject to the terms and conditions of this Agreement, Adagene hereby grants to Exelixis, during the Term, an exclusive (even as to Adagene), royalty-bearing license, with the right to grant sublicenses as provided in Section&nbsp;2.2, under the Adagene Technology to research, Develop, use, make, have made, sell, offer for sale, import, and otherwise Commercialize Lead Compounds and Products in the Field in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublicenses</b>.&#160; Exelixis shall have the right to grant sublicenses, through multiple tiers of sublicensees, under the license granted in Section&nbsp;2.1 to its Affiliates and other Third Parties, provided that&#160; such sublicenses shall be consistent with the terms and conditions of this Agreement and Exelixis remains responsible for the actions or omissions of its Sublicensees.&#160; Exelixis shall provide Adagene with written notice of any sublicense granted in accordance with this Section&nbsp;2.2 within&#160; [***] after its execution, including the identity of the Sublicensee and the scope of the sublicense granted. If Exelixis sublicenses its rights under Section&nbsp;2.1 to [***], Exelixis shall&#160; [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="29876-2-RC-03_PB_13_122449_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=740343,FOLIO='13',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Reserved Rights</b>.&#160; Adagene hereby expressly reserves (a)&nbsp;the right under the Adagene Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more permitted subcontractors, including the right to perform the applicable Compound Research Activities in accordance with each Target Program Plan; and (b)&nbsp;subject to Section&nbsp;2.8, the right to practice, and to grant licenses under, the Adagene Technology outside of the scope of the rights granted in Section&nbsp;2.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Research License</b>.&#160; Subject to the terms and conditions of this Agreement, Exelixis hereby grants to Adagene, for the duration of the Collaboration Program, a nonexclusive, royalty-free license, with the right to grant sublicenses to permitted subcontractors for the performance of Compound Research Activities, under the Exelixis Technology solely to the extent necessary for Adagene to perform the Compound Research Activities allocated to it under each Target Program Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>No Implied Licenses</b>.&#160; Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Technology Transfer</b>.&#160; As reasonably required under Section&nbsp;4.4, and in any event no later than the initial designation of the Compounds pursuant to Part&nbsp;1 of the Target Program Plan, and otherwise as and when required under a Target Program Plan, as reasonably requested or required support Exelixis&#146; IND filing, and as otherwise reasonably requested by Exelixis, Adagene shall disclose and make available to Exelixis all Adagene Know-How existing as of the Effective Date.&#160; Thereafter, on a Calendar Quarter basis during the performance of each Target Program Plan, or more often as reasonably requested by Exelixis, Adagene shall provide to Exelixis, at Exelixis&#146; reasonable expense, any and all Adagene Know-How, Compound Inventions, and Data not previously disclosed to Exelixis pursuant to this Section&nbsp;2.6.&#160; Adagene shall reasonably cooperate with Exelixis to provide a smooth and prompt transfer of all Adagene Know-How, Compound Inventions, and Data.&#160; Adagene shall reasonably assist Exelixis, at Exelixis&#146; reasonable cost, in the use and understanding of such Data, Compound Inventions, and Adagene Know-How and shall provide reasonable technical assistance and make its technical personnel reasonably available to Exelixis as necessary or reasonably helpful for Exelixis to Develop and manufacture the Lead Compounds and Products.&#160; In addition to the above, Exelixis shall have the right to select&#160; [***] Compound sequences in association with each Target Program Plan at the end of Phase 2 of such Target Program Plan (in addition to the Lead Compound sequences) in consultation with Adagene.&#160; Adagene shall promptly disclose such selected Compound sequences in their entirety to Exelixis.&#160; Such Compound sequences shall be the Confidential Information of Exelixis hereunder, and Exelixis shall have the right to use and disclose such sequences as otherwise permitted under this Agreement.&#160; For the avoidance of doubt, (i)&nbsp; [***], and (ii)&nbsp;[***] under the Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Third Party Licenses</b>.&#160; Adagene shall promptly notify Exelixis if it becomes aware of any Third Party Know-How or Patents that are necessary to Develop, make, have made, use, sell, offer for sale, or import any Lead Compound or Products.&#160; In such event, Exelixis shall have the right to negotiate and obtain a license from such Third Party under such Know-How and Patents at Exelixis&#146; cost.&#160; Adagene shall not obtain any such license in a manner that would prohibit </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="29876-2-RC-03_PB_14_122534_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=967298,FOLIO='14',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exelixis from obtaining a license under such Third Party Know-How and Patents to Develop, make, have made, use, sell, offer for sale, or import Lead Compound and Products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Exclusivity</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>During the Collaboration Program</b>.&#160; During the term of the Collaboration Program, Adagene shall not, and shall cause its Affiliates to not, directly or indirectly (including through a Third Party), research, develop, make, collaborate or consult with Third Parties, or commercialize any pharmaceutical product directed to a Collaboration Target other than Compounds and Products under this Agreement; provided, however, that Adagene shall be permitted to (i)&nbsp;conduct discovery activities for the discovery of novel antibodies that bind to an Exelixis Target and (ii)&nbsp;produce Masks that have less than a&#160; [***] sequence identity to any Mask provided by Adagene to Exelixis under this Agreement, in each case ((i)&nbsp;and (ii)) so long as no Compounds, Exelixis mABs, or other Exelixis Confidential Information is used, referenced, or relied upon in performing such activities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>After the Collaboration Program</b>.&#160; After the term of the Collaboration Program during the Term, Adagene shall not, and shall cause its Affiliates to not, directly or indirectly (including through a Third Party), (i)&nbsp;research, develop, make, collaborate or consult with Third Parties, or commercialize any product directed to any Collaboration Target to the extent that such product contains or comprises a mAB and the variable regions of such mAB have a&#160; [***]&#160; or greater sequence identity to any Exelixis mAB or (ii)&nbsp;produce any Mask that has a&#160; [***] or greater sequence identity to any Mask provided by Adagene to Exelixis under this Agreement for a Collaboration Target.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Limitations</b>. This Section&nbsp;2.8 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party&#146;s Affiliates) that becomes an Affiliate of Adagene after the Effective Date as a result of such Party (a)&nbsp;acquiring such Third Party or a portion of the business of such Third Party or (b)&nbsp;being acquired by such Third Party (in each case, whether by merger, stock purchase or purchase of assets) (such Third Party and its Affiliates immediately prior to the close of such transaction, the &#147;<b>Adagene Acquiror</b>&#148;), provided that (i)&nbsp;such Third Party activities are performed without using the Adagene SAFEbody&#153; technology and (ii)&nbsp;Adagene establishes reasonable firewall protections and safeguards designed to ensure the activities of its personnel under this Agreement are segregated from all activities of the Adagene Acquiror that would otherwise constitute a breach of Section&nbsp;2.8(a)&nbsp;or 2.8(b), including without limitation ensuring that none of any Adagene Acquiror&#146;s personnel have access to Exelixis&#146; Confidential Information, including non-public plans or information relating to the Development or Commercialization of Compounds or Products under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exelixis Exclusivity</b>.&#160; Except for Compounds and Products under this Agreement, during the Term Exelixis shall not, and shall cause its Affiliates to not, directly or indirectly (including through a Third Party), research, develop, make, collaborate or consult with Third Parties, or commercialize any product directed to a Collaboration Target to the extent that such product contains or comprises (a)&nbsp;an Exelixis mAB used in a Compound being Developed by or on behalf of Exelixis under this Agreement, or (b)&nbsp;an antibody the variable regions of which have a [***] or greater sequence identity to an Exelixis mAB used in a Compound being Developed by </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="29876-2-RC-03_PB_15_122603_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=676549,FOLIO='15',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or on behalf of Exelixis under this Agreement, in each case ((a)&nbsp;and (b)) that utilizes a protease-based masking technology that uses a peptide or small protein based domain (and in any case, [***]&#160; amino acids in length) as the blocking moiety.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GOVERNANCE</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Joint </b><b>Steering</b><b> Committee</b>.&#160; Within&#160; [***] after the Effective Date, the Parties shall establish a Joint Steering Committee (the &#147;<b>Joint Steering Committee</b>&#148; or the &#147;<b>JSC</b>&#148;), composed of an equal number of&#160; [***] of each Party, to oversee and guide the strategic direction of the collaboration of the Parties during the Collaboration Program.&#160; The JSC shall act as a joint consultative body during the Collaboration Program.&#160; The JSC in particular shall:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>oversee and monitor all Compound Research Activities under each Target Program Plan;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss, review, comment on, and approve the Target Program Plan for the Collaboration Target selected pursuant to Section&nbsp;4.2(b), including protocols for non-clinical and preclinical studies outlined in each Target Program Plan;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss and review the use of any Exelixis mAB with respect to a Collaboration Target;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review and discuss the status of each Target Program Plan and the Data generated during the performance thereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss, review, comment on, and approve (subject to Section&nbsp;3.3) any proposed amendments to a Target Program Plan, including any additional non-clinical and preclinical research, and protocols for additional non-clinical and preclinical studies;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss and approve a transfer process and format for disclosure of Data, Compound Inventions, and Adagene Know-How to Exelixis under Section&nbsp;2.6;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>identify the need for and create subcommittees of the JSC, which shall be subject to and report to the JSC, and assign responsibilities and authorities to such subcommittees, as the JSC determines necessary;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss any Third Party Know-How or Patents that come to the attention of the Parties as set forth in Section&nbsp;2.7 and determine whether it is advisable for either Party to negotiate with such Third Party for a license under any of such Know-How or Patents; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>perform such other functions as appropriate to further the purposes of the Research Program, as expressly set forth in this Agreement or allocated to it by the Parties&#146; written agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JSC Membership and Meetings</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="29876-2-RC-03_PB_16_122635_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=289976,FOLIO='16',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JSC Members</b>.&#160; Each JSC representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the JSC&#146;s responsibilities.&#160; Each Party may replace its representatives on the JSC upon written notice to the other Party.&#160; Exelixis shall appoint the chairperson of the JSC.&#160; The chairperson shall oversee preparation and circulation of agendas to JSC members at least&#160; [***] before each JSC meeting and shall direct the preparation of reasonably detailed minutes for each JSC meeting, which shall be approved by the chairperson and circulated to JSC members within&#160; [***] after such meeting.&#160; The initial members of each of the JSC shall be determined by the Parties within&#160; [***] following the Effective Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Meetings</b>.&#160; The JSC shall hold meetings at such times as it elects to do so, but in no event less frequently than&#160; [***].&#160; Meetings may be by telephone or video conference or in person.&#160; The first JSC meeting shall be held promptly after formation, but in any event no later than within [***] after the Effective Date.&#160; In-person meetings shall be held at locations alternately selected by the Parties.&#160; Each Party shall be responsible for all of its own expenses of participating in any JSC meeting.&#160; No action taken at any meeting of the JSC during the Collaboration Program shall be effective unless at least one (1)&nbsp;representative of each Party is participating.&#160; In addition, upon written notice to the other Party, either Party may request that a special <i>ad hoc</i> meeting of the JSC be convened for the purpose of resolving disputes or for the purpose of reviewing or making decisions pertaining to material subject-matter, the review or resolution of which cannot be reasonably postponed until the following scheduled JSC meeting.&#160; Such <i>ad hoc</i> meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than [***] following the notification date of request that such meeting be held.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Non-Member Attendance</b>.&#160; Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the JSC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#146;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.&#160; Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Decision-Making</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All JSC decisions shall be made by unanimous vote, with each Party&#146;s representatives collectively having one (1)&nbsp;vote.&#160; If after reasonable discussion and good faith consideration of each Party&#146;s view on a particular matter, the representatives of the Parties cannot reach an agreement as to such matter within&#160; [***], then either Party at any time may refer such issue to the Executive Officers for resolution.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Executive Officers cannot resolve such matter within&#160; [***] after such matter has been referred to them, then (i)&nbsp;Adagene shall have final decision making authority, which shall be exercised in its sole reasonable discretion, with respect to the application of the Adagene Platform Technology in the conduct of the Compound Research Activities as described in Section&nbsp;1.30(a)&nbsp;(i.e., in connection with the initial assembly and primary screen of Compounds, but not with respect to any <i>in vitro</i> or <i>in vivo</i> studies of such Compounds) and (ii)&nbsp;Exelixis shall </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="29876-2-RC-03_PB_17_122706_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=267332,FOLIO='17',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">have final decision making authority, which shall be exercised in its sole reasonable discretion, with respect to all other Development, regulatory, and manufacturing matters with respect to any Target Program Plan, including, for clarity, the selection of the Lead Compound(s), </font>preclinical and clinical Development work conducted solely by Exelixis (alone or in collaboration with Third Parties), regulatory activities, manufacturing and commercial matters with respect to the Lead Compound and the Product.&#160; Notwithstanding the foregoing subsection (ii), [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Limitations on Authority</b>.&#160; The JSC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.&#160; Without limiting the generality of the foregoing, the JSC shall not have the power to amend, interpret, or waive compliance with this Agreement, and no JSC decision may be in contravention of any terms or conditions of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Discontinuation of the JSC</b>.&#160; The activities to be performed by the JSC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services.&#160; The JSC shall continue to exist, on a Collaboration Target-by-Collaboration Target basis, until the first to occur of:&#160; (a)&nbsp;the Parties mutually agree to disband the JSC or (b)&nbsp;the completion of all Compound Research Activities under the Target Program Plan for such Collaboration Target.&#160; Upon the first to occur of the foregoing (a)&nbsp;or (b), the JSC shall automatically dissolve and, thereafter, each Party shall designate, to the extent necessary, a contact person for the exchange of information under this Agreement or such exchange of information shall be made through the Alliance Managers, and decisions of the JSC, if any, shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Alliance Managers</b>.&#160; Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the &#147;<b>Alliance Manager</b>&#148;).&#160; Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Collaboration Program and Term.&#160; If not already a member of the JSC, each Alliance Manager shall be permitted to attend JSC meetings as appropriate as non-voting participants.&#160; The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate communication between the Parties with respect to all such activities hereunder.&#160; Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.&#160; Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.&#160; Each Party shall bear its own costs of its Alliance Manager.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>COMPOUND RESEARCH ACTIVITIES</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Overview; Timelines</b>.&#160; Subject to the terms and conditions of this Agreement, during the Collaboration Program the Parties will collaborate with respect to the performance of each Target Program Plan.&#160; Following the completion of a Target Program Plan, subject to Exelixis&#146; diligence obligations under Section&nbsp;4.7, Exelixis shall have the sole and exclusive right and responsibility, at its own expense, for the Development of the Lead Compounds and Products corresponding to such Collaboration Target in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Target Selection</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="29876-2-RC-03_PB_18_122741_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=686336,FOLIO='18',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Target Nomination</b>.&#160; The Parties shall collaborate with respect to the performance of two (2)&nbsp;Target Program Plans.&#160; Subject to the remainder of this Section&nbsp;4.2(a), during the Target Selection Term, Exelixis shall nominate Targets as Collaboration Targets as described in this Section&nbsp;4.2 until one (1)&nbsp;further Target in addition to the Initial Target has been designated as a Collaboration Target under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Gatekeeper</b>.&#160; Exelixis shall nominate a Target as a Collaboration Target by providing written notice thereof (a &#147;<b>Target Nomination Notice</b>&#148;) to a Third Party gatekeeper mutually agreed upon by the Parties (&#147;<b>Gatekeeper</b>&#148;).&#160; Within&#160; [***] after the Gatekeeper&#146;s selection, Adagene shall provide to the Gatekeeper a list of Targets that are Unavailable to enable him/her to make an accurate determination as to whether such nominated Target is Available or Unavailable.&#160; Upon the request of the Gatekeeper, Adagene shall provide supporting documentation to the Gatekeeper that is reasonably required by the Gatekeeper to verify that a Target is Unavailable. The Gatekeeper shall notify Exelixis of his/her determination within [***] after his/her receipt of Adagene&#146;s Target list and supporting documentation (if requested), and the Gatekeeper&#146;s determination shall be binding upon the Parties. [***]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Available</b>.&#160; If the Gatekeeper notifies Exelixis that a Target nominated by Exelixis in a Target Nomination Notice is Available, then, if Exelixis wishes to designate such Target as a Collaboration Target under this Agreement, Exelixis shall provide Adagene written notice confirming such nomination to Adagene (a &#147;<b>Collaboration Target Designation Notice</b>&#148;) within [***] after receipt of Adagene&#146;s notice of Availability.&#160; Upon Adagene&#146;s receipt of a Collaboration Target Designation Notice, such Target shall be automatically designated a Collaboration Target under this Agreement.&#160; As soon as reasonably practicable following such designation, the JSC shall mutually agree upon a Target Program Plan with respect to such Collaboration Target, which Target Program Plan shall be substantially similar in form and content to the Target Program Plan for the Initial Target, but taking into consideration any differences in research activities required to achieve the applicable criteria for such Collaboration Target.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Unavailable</b>.&#160; If the Gatekeeper notifies Exelixis that the Target is Unavailable, such Target shall not be designated a Collaboration Target and Exelixis shall have the right to nominate another Target as a Collaboration Target at any time prior to the later of (i) the expiration of the Target Selection Term and (ii)&nbsp;[***] after receipt of Adagene&#146;s written notice of such Unavailability.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Target Program Plan</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>General</b>.&#160; All Compound Research Activities for a Collaboration Target shall be conducted pursuant to a written plan (the &#147;<b>Target Program Plan</b>&#148;), which shall set forth the timeline and details for such Compound Research Activities.&#160; Each Target Program Plan shall also include a reasonably detailed budget of the costs by Calendar Quarter for the Compound Research Activities (the &#147;<b>Target Program Budget</b>&#148;) on an activity-by-activity or study-by-study basis, as appropriate.&#160; [***].&#160; If the terms of any Target Program Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern.&#160; From time to time during the performance of each Target Program Plan, the Parties, </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="29876-2-RC-03_PB_19_122822_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=667774,FOLIO='19',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">via the JSC, may prepare updates and amendments, as appropriate, to the then-current applicable Target Program Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Revisions</b>.&#160; The JSC shall review each Target Program Plan and Target Program Budget on a Calendar Quarter basis for potential amendment in accordance with this Section&nbsp;4.3(b).&#160; In addition, from time to time, either Party may propose updates and amendments, as appropriate, to a Target Program Plan to add, remove, or modify the Compound Research Activities under such Target Program Plan (including any consequential changes to the Target Program Budget) (&#147;<b>Plan Revisions</b>&#148;).&#160; The Party wishing to make such a revision shall provide the other Party, via the JSC, with a copy of the proposed Plan Revisions and allow the other Party a reasonable opportunity (not to exceed&#160; [***]) to review and comment thereon.&#160; Any Plan Revision must be approved by the JSC in accordance with Article&nbsp;3.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Performance of Compound Research Activities</b>.&#160; With respect to each Collaboration Target, Adagene shall use Commercially Reasonable Efforts to perform the Compound Research Activities set forth in the applicable Target Program Plan in accordance with the terms and timeline set forth therein and the terms of this Agreement to generate up to&#160; [***] Compounds that meet the applicable Development Criteria set forth in such Target Program Plan&#160; to be selected as Lead Compounds.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Binders and mABs</b>.&#160; With respect to each Collaboration Target, Exelixis will provide to Adagene an Exelixis mAB directed to the applicable Collaboration Target for use in the generation of Compounds pursuant to the following Section&nbsp;4.4(b).&#160; Each Binder and mAB to be used in such activities shall be specified in the Target Program Plan for such Collaboration Target.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Part&nbsp;1 &#151; Compound Generation</b>.&#160; During Part&nbsp;1 of each Target Program Plan, Adagene shall generate a series of alternative Compounds that are directed to the applicable Collaboration Target and are considered suitable for further evaluation.&#160; Prior to each regularly scheduled JSC meeting, Adagene shall provide Exelixis with all Data generated to date for a Target Program since the last such provision of Data pursuant to this Section&nbsp;4.4(b).&#160; At each such meeting, the Parties shall review and discuss the Compounds Developed to date, and any Data generated by the Parties with respect thereto, and whether any such Compound is determined by Exelixis, in consultation with Adagene, to have satisfied the applicable Development Criteria and to be suitable to advance to Part&nbsp;2. On a Collaboration Target-by-Collaboration Target basis, following completion of the Part&nbsp;1 Compound Research Activities, Adagene shall prepare and deliver to the JSC a data package that includes the Data generated by Adagene in the performance of Part&nbsp;1 of the respective Target Program Plan (the &#147;<b>Data Package Part&nbsp;1</b>&#148;).&#160; Within [***] upon receipt of the Data Package Part&nbsp;1, Exelixis may select&#160; [***] Compounds from the Data Package Part&nbsp;1 to advance to Part&nbsp;2. For clarity, Part&nbsp;1 of the Target Program Plan corresponds to Stages 1-3 of the study plan agreed between the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Part&nbsp;2 &#151; Assays and Studies</b>.&#160; Following Exelixis&#146; designation of one or more Compounds pursuant to Section&nbsp;4.4(b)&nbsp;for a Collaboration Target, Adagene shall perform the Compound Research Activities under Part&nbsp;2 of the Target Program Plan for each such Compound.&#160; Exelixis shall have the right to audit Adagene&#146;s</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="29876-2-RC-03_PB_20_122906_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=46542,FOLIO='20',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-03_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:18 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">performance of any Part&nbsp;2 Compound Research Activities at Exelixis&#146; cost, and any Third Party vendors conducting such activities on Adagene&#146;s behalf, in each case upon written request, and in each case only one time (in the absence of cause); provided, however, that if an audit of any Third Party vendor by Exelixis is not reasonably possible under Adagene&#146;s written agreement with such vendor, Exelixis shall have the right, upon request, to review Adagene&#146;s audit reports of such vendor.&#160; Prior to each regularly scheduled JSC meeting during the performance of the Part&nbsp;2 activities, Adagene shall provide Exelixis with all Data generated under such Target Program Plan since the last such provision of Data pursuant to this Section&nbsp;4.4(c).&#160; Following completion of the Part&nbsp;2 Compound Research Activities for each Compound, Adagene shall prepare and deliver to the JSC a data package that includes all Data generated by Adagene in the performance of Part&nbsp;2 of such Target Program Plan (the &#147;<b>Data Package Part&nbsp;2</b>&#148;).&#160; The JSC shall review the Data Package Part&nbsp;2 and determine whether any data or information is missing from such Data Package Part&nbsp;2.&#160; With respect to any data or information identified as missing from such Data Package Part&nbsp;2, the Parties shall cooperate to promptly update such Data Package to include such missing information and data, provided that Adagene shall not be obliged to perform further research activities, including any further <i>in vivo </i>studies other than the studies described in the applicable Target Program Plan, unless otherwise agreed by the parties pursuant to Article&nbsp;3.&#160; Following the provision of such missing information to the Data Package Part&nbsp;2, or if the JSC makes no requests for additional information, the Data Package, and corresponding Target Program Plan, shall be deemed complete.&#160; Upon the Data Package Part&nbsp;2 being deemed complete, Exelixis shall have the right to select&#160; [***] Compounds from the Data Package to be lead compounds (each such Compound so selected, a &#147;<b>Lead Compound</b>&#148;).&#160; In the event that no Lead Compound for a Collaboration Target is designated, Exelixis shall have the right to terminate such Collaboration Target upon written notice to Adagene in accordance with Section&nbsp;13.3.&#160; For clarity, Part&nbsp;2 of the Target Program Plan corresponds to Stage 4 of the study plan agreed between the Parties.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Part&nbsp;3 &#151; In Vivo Studies and Manufacturing</b>. Following Exelixis&#146; designation&#160; [***] Lead Compounds pursuant to Section&nbsp;4.4(c)&nbsp;for a Collaboration Target, Adagene shall perform the Compound Research Activities under Part&nbsp;3 of the Target Program Plan for each such Lead Compound. On a Collaboration Target-by-Collaboration Target basis, following completion of the Part&nbsp;3 Compound Research Activities, Adagene shall prepare and deliver to the JSC a data package that includes the Data generated by Adagene in the performance of Part&nbsp;3 of the respective Target Program Plan. For clarity, Part&nbsp;3 of the Target Program Plan corresponds to Stages 5 and 6 of the study plan agreed between the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Development Costs</b>.&#160; Adagene shall be responsible for the Development Costs incurred by Adagene in the performance of the Compound Research Activities in accordance with each Target Program Plan and associated Target Program Budget.&#160; Exelixis shall reimburse Adagene for Development Costs associated with additional Compound Research Activities added to a Target Program Plan as and to the extent set forth in Section&nbsp;7.2(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Diligence</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>General</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="29876-2-RC-05_PB_21_123122_7441"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=628104,FOLIO='21',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the Collaboration Program, Adagene shall use Commercially Reasonable Efforts to perform the Compound Research Activities under and in accordance with each Target Program Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Following the delivery to Exelixis of (A)&nbsp;a complete Data Package Part&nbsp;2 in accordance with Section&nbsp;4.4(c)&nbsp;and (B)&nbsp;the material specified in Section&nbsp;6.1, in each case ((A)&nbsp;and (B)) with respect to a Collaboration Target, Exelixis shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for one (1)&nbsp;Product corresponding to such Collaboration Target in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Development Updates</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene&#146;s Obligations</b>.&#160; At each regularly scheduled JSC meeting during the Collaboration Program, Adagene shall provide the JSC with regular reports detailing its activities under each Target Program Plan, in each case to the extent then-ongoing, and the results of such activities.&#160; The Parties shall discuss the status, progress, and results of such activities at such JSC meetings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exelixis&#146; Obligations</b>.&#160; Following the discontinuation of the JSC pursuant to Section&nbsp;3.5, Exelixis shall provide to Adagene written reports on&#160; [***] basis regarding its significant Development (including receipts of Regulatory Approval) activities with respect to Products for each Collaboration Target in the Territory.&#160; Each such written report shall summarize in reasonable detail Exelixis&#146;, its Affiliates&#146;, and Sublicensees&#146; significant Development activities, and the progress made with respect to the Development and Regulatory Approval of Products in the Territory, and shall contain relevant information at a level of detail reasonably required by Adagene to determine whether Exelixis is in compliance with its diligence obligations set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Compliance</b>.&#160; Each Party shall perform the Development activities assigned to it under each Target Program Plan in compliance with all Applicable Laws, including GLP and other good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Development Records</b>.&#160; Each Party shall maintain complete, current, and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities.&#160; Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.&#160; Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws.&#160; Adagene shall provide Exelixis, during regular business hours and upon reasonable notice, the opportunity to inspect and copy all such Development records created by Adagene in the performance of any Target Program Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Use of Subcontractors</b>.&#160; Adagene may perform its Development activities under this Agreement through one or more subcontractors with Exelixis&#146; prior written consent, provided that (a)&nbsp;Adagene will remain responsible for the work allocated to, and payment to, such </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="29876-2-RC-05_PB_22_123154_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=381404,FOLIO='22',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">subcontractors to the same extent it would if it had done such work itself; (b)&nbsp;each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article&nbsp;13; and (c)&nbsp;each subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work to Adagene.&#160; For clarity, Exelixis may subcontract any of its Development activities under this Agreement in its sole discretion, provided that any such subcontracting shall be consistent with the terms and conditions of this Agreement, including the confidentiality obligations and the intellectual property provisions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.10</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Regulatory Responsibilities</b>.&#160; Exelixis shall own all Regulatory Filings and Regulatory Approvals for the Products in the Field in the Territory, and shall be solely responsible for preparing any and all Regulatory Filings for the Product in the Field in the Territory at its expense.&#160; Upon Exelixis&#146; request and at its expense, Adagene shall reasonably assist Exelixis in connection with the preparation and filing of such Regulatory Filings, including by providing any and all documentation, Data, and other Adagene Know-How reasonably requested by Exelixis in support of such Regulatory Filings, in each case to the extent not previously provided pursuant to Section&nbsp;2.6.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>COMMERCIALIZATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>General</b>.&#160; Subject to the terms and conditions of this Article&nbsp;5, Exelixis shall have the sole and exclusive right and responsibility, at its expense, for all aspects of the Commercialization of Products corresponding to Collaboration Targets in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Diligence</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>General</b>.&#160; During the Term, with respect to each Collaboration Target, Exelixis, either itself or through its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to Commercialize one Product for which Regulatory Approval has been obtained in the Territory.&#160; For clarity, as between the Parties and subject to the foregoing sentence, Exelixis shall retain at all times sole and complete decision-making authority regarding whether to launch any particular Product in any particular country, and whether to launch any particular Product itself or through its Affiliates or Sublicensees anywhere in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Commercial Updates</b>.&#160; Exelixis shall provide to Adagene written reports on&#160; [***] basis regarding its significant Commercialization activities with respect to Products in the Territory.&#160; Each such written report shall summarize in reasonable detail Exelixis&#146;, its Affiliates&#146;, and Sublicensees&#146; significant Commercialization activities that have been conducted since the last reporting date and that are planned for the current year with respect to the Commercialization of each Product in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MANUFACTURE AND SUPPLY</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Manufacture and Supply</b>.&#160; Adagene, itself or through one or more Third Party contract manufacturers, shall be responsible, at its own expense, for all manufacturing activities necessary to perform any of its obligations under each Target Program Plan.&#160; In addition, Adagene shall provide, at its own expense, Exelixis with the sequence of each Lead Compound, </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="29876-2-RC-05_PB_23_123242_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=410869,FOLIO='23',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as well as 10ug of cDNA for each Lead Compound for a Collaboration Target, in each case promptly after the designation thereof pursuant to Section&nbsp;4.4(c).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exelixis Supply</b>.&#160; Following the completion of a Target Program Plan in respect of a Collaboration Target, Exelixis, either directly or through one or more Third Party contract manufacturers, shall provide all Lead Compounds and Products for use in the Development and Commercialization of such Products under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>FINANCIAL PROVISIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Upfront Payment</b>.&#160; In partial consideration of the rights granted to Exelixis under this Agreement, within&#160; [***] after the Effective Date, Exelixis shall pay to Adagene a one-time, non-refundable, non-creditable upfront payment of eleven million dollars ($11,000,000).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Reimbursement of Development Costs</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Development Costs</b>.&#160; Adagene shall be responsible for the costs incurred in performing the Compound Research Activities specified under the initial Target Program Plan for each Collaboration Target (including FTE Costs and amounts that Adagene pays to Third Parties subcontracted to perform certain of Adagene&#146;s obligations under a Target Program Plan) (collectively, &#147;<b>Development Costs</b>&#148;).&#160; In addition, Adagene shall be responsible for the Development Costs incurred in performing additional activities or studies added to the initial Target Program Plan pursuant to Section&nbsp;4.3(b)&nbsp;to the extent that such Development Costs do not exceed, in the aggregate, [***] more than the total amount budgeted under the initial Target Program Budget for such Target Program Plan (the &#147;<b>R&amp;D Cap</b>&#148;).&#160; Exelixis shall reimburse Adagene for any Development Costs incurred by Adagene in performing additional activities or studies added to the initial Target Program Plan pursuant to Section&nbsp;4.3(b)&nbsp;in excess of the R&amp;D Cap to the extent such costs are incurred in accordance with the applicable Target Program Budget (as revised pursuant to Section&nbsp;4.3(b)).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Estimates and Invoices</b>.&#160; Within [***] after the end of each month in which Adagene incurs any Development Costs under a Target Program Plan in excess of the R&amp;D Cap, Adagene shall submit to Exelixis (i)&nbsp;an invoice setting forth the total Development Costs incurred by Adagene in accordance with the applicable Target Program Budget in such month that exceed the R&amp;D Cap, (ii)&nbsp;monthly timesheets indicating the percentage of time and the hour equivalent of such percentage Adagene personnel allocated to such Compound Research Activities during such month, as reasonably necessary to confirm the manner and circumstances in which such costs were incurred, and (iii)&nbsp;documentation confirming any out-of-pocket expenses paid by Adagene for such Compound Research Activities during such month. &#160;Exelixis shall pay the undisputed amounts invoiced within&#160; [***] after receipt of the invoice.&#160; Adagene shall notify Exelixis as soon as reasonably practicable in the event that it becomes aware that Development Costs are expected to deviate from the Target Program Budget, whereupon the Parties shall discuss the causes of such deviation, and an appropriate adjustment to the Target Program Budget. The Parties shall refer any Target Program Budget increase amounting to greater than [***] of the previously approved amount to the JSC for prior approval. Unless such budget increase is approved by the JSC, Exelixis </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="29876-2-RC-05_PB_24_123302_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=112688,FOLIO='24',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shall have no responsibility for, nor any liability in respect of, any Development Costs </font>in excess of &#160;[***] of the amount set out in the Target Program Budget (as revised from time to time).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Development Milestone Payments</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Development Milestones</b>.&#160; Subject to the remainder of this Section&nbsp;7.3(a), on a Collaboration Target-by-Collaboration Target basis, Exelixis shall pay to Adagene the one-time, non-refundable, non-creditable payment set forth in the table below upon the first achievement of the respective applicable milestone event by a Product corresponding to such Collaboration Target (whether by or on behalf of Exelixis or its Affiliates or Sublicensees):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="78%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:78.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Milestone&nbsp;Event</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Milestone<br>   Payment</font></b></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font></p>    </td>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font></p>    </td>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font></p>    </td>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font></p>    </td>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font></p>    </td>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font></p>    </td>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font></p>    </td>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font></p>    </td>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For clarity, the foregoing milestone payments shall be payable one-time only with respect to each Collaboration Target, regardless of the number of Products corresponding to such Collaboration Target to achieve such milestone event. With respect to the milestone events and milestone payments listed under number 1 through number 5 above, if any such milestone event has not occurred until the achievement of the subsequent milestone event for a Product directed to the same Collaboration Target, the milestone payment for such milestone event shall become due upon the achievement of the subsequent milestone event by a Product directed to the same Collaboration Target.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notice and Payment</b>.&#160; Exelixis shall notify Adagene in writing within [***] after the achievement of any milestone set forth in this Section&nbsp;7.3 by Exelixis, its Affiliates, or Sublicensee(s).&#160; Exelixis shall pay to Adagene the applicable development milestone payments within&#160; [***] after the achievement of the applicable milestone event.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="29876-2-RC-05_PB_25_123633_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=626866,FOLIO='25',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sales-Based Milestones Payments</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sales Milestones</b>.&#160; Subject to the remainder of this Section&nbsp;7.4(a), on a Collaboration Target-by-Collaboration Target basis, Exelixis shall pay to Adagene the non-refundable, non-creditable payments set forth in the table below within&#160; [***] after the end of the Calendar Year in which the corresponding milestone event is first achieved by all Products corresponding to a Collaboration Target (whether by or on behalf of Exelixis or its Affiliates or Sublicensees).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Annual&nbsp;Net&nbsp;Sales&nbsp;of&nbsp;all&nbsp;Products&nbsp;in&nbsp;the&nbsp;Territory<br>   directed&nbsp;to&nbsp;a&nbsp;particular&nbsp;Collaboration&nbsp;Target</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Sales&nbsp;Milestone&nbsp;Payments</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exceed   [***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exceed   [***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exceed   [***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For clarity, the foregoing milestone payments shall be payable one-time only with respect to each Collaboration Target, regardless of the number of Products corresponding to such Collaboration Target to achieve such milestone event.&#160; For the avoidance of doubt, from and after the expiration of the Royalty Term for a Product in a country, Net Sales of such Product in such country shall be excluded for purposes of calculating the Net Sales thresholds set forth in this Section&nbsp;7.4(a).&#160; If more than one sales milestone event is achieved in a single Calendar Year, then the sales milestone payments for all sales milestone events achieved in such Calendar Year shall be due.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notice and Payment</b>.&#160; As part of the report provided pursuant to Section&nbsp;8.1, on a Collaboration Target-by-Collaboration Target basis, Exelixis shall provide written notice to Adagene upon the annual Net Sales of the Products for a Collaboration Target in the Territory first reaching each of the values set forth in Section&nbsp;7.4(a)&nbsp;above.&#160; Each milestone payment set forth in the table above shall be paid as set forth in Section&nbsp;7.4(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Royalty Payments</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Royalty Rate</b>.&#160; On a Collaboration Target-by-Collaboration Target basis, subject to the remainder of this Section&nbsp;7.5, during the Royalty Term for a Product, Exelixis shall pay to Adagene a non-refundable, non-creditable&#160; [***]&#160; royalty on the aggregate annual Net Sales of such Product in the Territory, as calculated by multiplying the foregoing royalty rate by the amount of Net Sales of such Product in the Territory in the applicable Calendar Year.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Royalty Term</b>.&#160; Royalties shall be paid on a Product-by-Product and country-by-country basis from the First Commercial Sale of a Product in a country by or on behalf of Exelixis, its Affiliates, or Sublicensees until the latest of (i)&nbsp;ten (10)&nbsp;years after the First Commercial Sale of such Product in such country, (ii)&nbsp;expiration of the last-to-expire Valid Claim of the Adagene Patents, Adagene Platform Patents, and Product Patents in such country covering such Product&#146;s composition of matter or method of use as such Product is sold in such country, or </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="29876-2-RC-05_PB_26_123753_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=1040048,FOLIO='26',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&nbsp;t</font>he expiration of Regulatory Exclusivity for such Product in such country (the &#147;<b>Royalty Term</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Royalty Reductions</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Biosimilar Entry</b>.&#160; If one or more Biosimilar Products to a Product is sold in a country in the Territory in any Calendar Quarter during the Royalty Term for such Product in such country, and during such Calendar Quarter [***], then the royalty rate provided in Section&nbsp;7.5(a)&nbsp;for such Product in such country shall be reduced &#160;[***] for such Calendar Quarter and each subsequent Calendar Quarter during such Royalty Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Patent Expiry</b>.&#160; If during any Calendar Quarter of the Royalty Term for a particular Product in a country no Valid Claim of any Adagene Patent, Adagene Platform Patent, or Product Patent in such country covers such Product&#146;s composition of matter or method of use as such Product is sold in such country, then the royalty rate provided in Section&nbsp;7.5(a)&nbsp;shall be reduced by&#160; [***] for such Product in such country for such Calendar Quarter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(iii)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Royalty Floor</b>.&#160; Notwithstanding the foregoing Sections 7.5(c)(i)&nbsp;and 7.5(c)(ii)&nbsp;with respect to any Product in any Calendar Quarter, the operation of Sections 7.5(c)(i)&nbsp;and 7.5(c)(ii), individually or in combination, shall not reduce by more than&#160; [***]&#160; the royalties that would otherwise have been due under Section&nbsp;7.5(a)&nbsp;with respect to Net Sales of such Product in the applicable country(ies) during such Calendar Quarter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Compulsory Licenses</b>.&#160; If Exelixis or its Affiliate or Sublicensee is required in a given country to issue a Compulsory Sublicense to one or more Compulsory Licensees for the sale of Product(s)&nbsp;in such country, then the sales of such Compulsory Sublicensee shall be excluded from Net Sales, and Exelixis shall pay to Adagene [***] of any royalty payment received by Exelixis from the compulsory sublicensee for the sale of such Product(s)&nbsp;in such country.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PAYMENT; RECORDS; AUDITS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Payment; Reports</b>.&#160; Royalty payments due by Exelixis to Adagene under Section&nbsp;7.5 shall be calculated and reported for each Calendar Quarter during the Royalty Term.&#160; Royalty payments due under Section&nbsp;7.5 shall be paid within&#160; [***] after the end of each Calendar Quarter and shall be accompanied by a report setting forth the Net Sales of the Products by Exelixis and its Affiliates and Sublicensees in the Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including the number of Products sold, the gross sales and Net Sales of Products ([***]), the royalties payable, the method used to calculate the royalties, the exchange rates used, and whether any sales milestone under Section&nbsp;7.4 has been achieved.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exchange Rate; Manner and Place of Payment</b>.&#160; All references to dollars and &#147;$&#148; herein shall refer to U.S. dollars.&#160; All payments hereunder shall be payable in U.S. dollars.&#160; </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">27<a name="29876-2-RC-05_PB_27_123817_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=1023058,FOLIO='27',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to conversion of Net Sales in any currency other than U.S. dollars to U.S. dollars, Exelixis or its Affiliates or Sublicensees shall convert the Net Sales for the Products using its then-current standard worldwide currency conversion methodology applied to its external reporting.&#160;&#160;&#160; All payments owed to Adagene under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Adagene, unless otherwise specified in writing by Adagene.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Reporting</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of the Effective Date, Adagene shall provide Exelixis with a copy of Adagene&#146;s most recent unaudited financial statements prepared in accordance with Accounting Standards aggregated summary of programs by development stage (i.e. non-clinical vs clinical) and aggregated summary of resources (FTE allocation) (&#147;<b>Initial Financial Information</b>&#148;) as required to make a determination if entering into this Agreement imposes on Exelixis the requirements of the variable interest entity consolidation model as described in Accounting Standards Codification 810 (&#147;<b>VIE Accounting</b>&#148;). During the Term, Adagene shall provide Exelixis its annual audited financial statements in accordance with Accounting Standards within four (4)&nbsp;months of the end of each fiscal year of Adagene. In addition, Adagene shall provide Exelixis updates to the Initial Financial Information and information pertaining to other material changes to its business as reasonably necessary for such determination on a quarterly basis, as set forth in <b><u style="font-weight:bold;">Exhibit&nbsp;D</u></b> by the end of the second month of each Calendar Quarter.&#160; If Exelixis determines in its reasonable judgment that VIE Accounting is required in any Calendar Quarter (the &#147;<b>VIE Determination</b>&#148;) then the provisions of Sections 8.3(b)&nbsp;and 8.3(c)&nbsp;below will apply until such time as VIE Accounting is no longer required.&#160; In the event that a VIE Determination is not made, or a VIE Determination is removed, then the provisions of Sections 8.3(b)&nbsp;and 8.3(c)&nbsp;below will not apply, but Adagene will continue to provide quarterly updates in accordance with this Section&nbsp;8.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to Section&nbsp;8.3(a), Adagene shall continue to provide updates to the Initial Financial Information on a quarterly basis, and annual audited financial statements on an annual basis. In addition, Adagene will provide information reasonably required to prepare consolidated financial statements in accordance with US GAAP.&#160; Adagene may choose to remove any confidential information that is not required for Exelixis consolidation reporting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to Section&nbsp;8.3(a), should Adagene enter into a Relevant Transaction, Adagene shall disclose the occurrence of such Relevant Transaction within thirty (30) days of such occurrence to Exelixis in writing, and, upon Exelixis&#146; request, shall provide to Exelixis additional information about such Relevant Transaction solely to the extent reasonably necessary for Exelixis to confirm the VIE Determination in accordance with Accounting Standards, and subject to any confidentiality obligations of Adagene to any Third Party.&#160; For purposes of the above, &#147;<b>Relevant Transaction</b>&#148; means any of the following: (i)&nbsp;a bona fide equity financing which results in a material change to Adagene&#146;s capitalization, or (ii)&nbsp;any material purchase or redemption by Adagene of any shares of Adagene&#146;s capital stock other than (A)&nbsp;repurchases or redemptions of stock from former employees, officers, directors, consultants or other persons who performed services for Adagene or any subsidiary in connection with the </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">28<a name="29876-2-RC-05_PB_28_123849_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=147164,FOLIO='28',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cessation of such employment or service, or (B)&nbsp;the exercise of a contractual right of first refusal by Adagene, or (iii)&nbsp;any material contractual arrangement under which Adagene licenses to Third Parties any Adagene&#146;s technology or platform, any divestitures, reorganization of the entity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Initial Financial Statements and any other information provided to Exelixis under this Section&nbsp;8.4:&#160; (i)&nbsp;shall be deemed Licensor&#146;s Confidential Information under Article&nbsp;12, (ii)&nbsp;without limiting the foregoing, may only be used by Exelixis&#146; Chief Financial Officer, controller or similarly situated employee (and personnel working under such controller, on a need-to-know basis) and Exelixis&#146; independent auditors solely for the purpose of confirming VIE Determination in accordance to U.S. GAAP, and (iii)&nbsp;may not be shared with any other Exelixis employee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Taxes</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Taxes on Income</b>.&#160; Except as otherwise provided in this Section&nbsp;8.5, each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Tax Cooperation</b>.&#160; The Parties shall cooperate with one another and use reasonable efforts to avoid or reduce tax withholding (e.g., withholding imposed under any U.S. federal, state or local statute, regulation or code) or similar obligations in respect of the milestone payments, royalty payments, and other payments made by Exelixis under this Agreement.&#160; To the extent Exelixis is required by Applicable Laws to deduct and withhold taxes on any payment to Adagene, Exelixis shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Adagene an official tax certificate or other evidence of such payment sufficient to enable Adagene to claim such payment of taxes.&#160; Adagene shall provide Exelixis any tax forms that may be reasonably necessary in order for Exelixis to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so.&#160; Adagene shall use reasonable efforts to provide any such tax forms to Exelixis in advance of the due date.&#160; Exelixis shall provide Adagene with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Adagene.&#160; Exelixis shall have the right to deduct any such tax, levy, or charge actually paid from payment due to Adagene.&#160; Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Tax Liability</b>.&#160;&#160; All amounts payable under this Agreement are exclusive of value added or similar taxes (the &#147;<b>VAT</b>&#148;). In the event of value added or similar taxes incurred by a Party with respect to payments made to a Party hereunder or the activities underlying such payments, each Party and its Affiliates will use reasonable efforts to secure available exemption(s)&nbsp;from VAT or cooperate with the other Party&#146;s efforts to obtain maximum recovery of VAT paid or incurred by such Party or any Affiliate, to the extent permitted by Applicable Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Records; Audit</b>.&#160; Each Party shall keep, and shall require its Affiliates, contractors, and Sublicensees to keep, complete and accurate records pertaining to, in the case of Adagene, the performance of each Compound Research Activity and, in the case of Exelixis, the sale or other</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">29<a name="29876-2-RC-05_PB_29_123931_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=711974,FOLIO='29',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">disposition of Products, in each case in sufficient detail to permit the other Party to confirm the accuracy of any payment due hereunder.&#160; Each Party will keep such books and records for&#160; [***] following the Calendar Year to which they pertain, or such longer period of time as may be required by Applicable Laws.&nbsp; Upon reasonable prior notice and during regular business hours at such place or places where such records are customarily kept, a Party may inspect the other Party&#146;s records via an independent certified public accountant (the &#147;<b>Auditor</b>&#148;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement and of any payments made, or required to be made, to such auditing Party pursuant to this Agreement.&#160; Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.&#160; Such audits shall be limited to once each Calendar Year and once with respect to records covering any specific period of time.&#160; Such auditor shall not disclose any of the audited Party&#146;s Confidential Information to the auditing Party, and shall only report </font>whether the financial reports provided by the audited Party and the amount of payments made to or by a Party are correct or not, and the amount of any discrepancy.&#160; In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within&#160; [***] after the Auditor&#146;s report.&#160; The auditing Party shall bear the full cost of such audit unless such audit reveals a discrepancy in the auditing Party&#146;s favor of more than&#160; [***] from the reported amounts, in which case the audited Party shall reimburse the auditing Party for the reasonable out-of-pocket costs incurred for such audit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Late Payments</b>.&#160; In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from thirty (30) day past the date due at the interest rate of [***]; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>INTELLECTUAL PROPERTY</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Ownership</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Data</b>.&#160; All Data shall be the exclusive property of Exelixis.&#160; Adagene hereby assigns to Exelixis all of Adagene&#146;s right, title, and interest in and to all Data.&#160; To effectuate the foregoing assignment, Adagene shall ensure that all entities and individuals that perform any activities on behalf of Adagene hereunder are under a written or other legally enforceable obligation to assign all right, title, and interest in any intellectual property created pursuant to such activities directly to Adagene or to an entity that is obligated to assign all such right, title, and interest to Adagene.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Compound Inventions</b>.&#160; All Inventions other than Platform Inventions, whether or not patentable, that (i)&nbsp;constitute the composition of matter, synthesis or manufacture, use, or formulation of any Compound or (ii)&nbsp;relate to an Exelixis mAB, in each case ((i)&nbsp;and (ii)) that are generated in the performance of any Compound Research Activities or other Development, manufacturing, or regulatory activities under this Agreement solely by one or more employees or agents of a Party or its Affiliates or other persons acting on such Party&#146;s behalf, or jointly by one or more employees or agents of each Party or its Affiliates or other persons acting on their behalf, (collectively, the &#147;<b>Compound Inventions</b>&#148;) shall be the exclusive property of Exelixis.&#160; Adagene</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">30<a name="29876-2-RC-05_PB_30_123947_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=872716,FOLIO='30',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-05_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shall notify and transfer to Exelixis each Compound Invention promptly after its conception, development, or reduction to practice by Adagene or its Affiliate or contractor.&#160; Adagene hereby assigns to Exelixis all of Adagene&#146;s right, title, and interest in and to all Compound Inventions.&#160; To effectuate the foregoing assignment, Adagene shall ensure that all entities and individuals that perform any activities on behalf of Adagene under this Agreement are under a written or other legally enforceable obligation to assign all right, title, and interest in any intellectual property created pursuant to such activities directly to Adagene or to an entity that is obligated to assign all such right, title, and interest to Adagene.&#160; Adagene shall assist Exelixis, at Exelixis&#146; expense, in securing for Exelixis any patents, copyrights, or other proprietary rights in such Compound Inventions, and to perform all acts that may be reasonably required to vest in Exelixis all right, title, and interest in such Compound Inventions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Platform Inventions</b>.&#160; All Inventions, whether or not patentable, that (i)&nbsp;pertain generally to the Adagene Platform Technology or any improvements, enhancements or modifications thereto and (ii)&nbsp;do not specifically describe or claim a Compound or a Product and do not use or incorporate and are not based on any Exelixis mAB, Exelixis Technology, or any of Exelixis&#146; Confidential Information, and in each case are generated under this Agreement solely by one or more employees or agents of a Party or its Affiliates or other persons acting on a Party&#146;s behalf, or jointly by one or more employees or agents of each Party or its Affiliates or other persons acting on their behalf, (collectively, the &#147;<b>Platform Inventions</b>&#148;) shall be the exclusive property of Adagene.&#160; All Platform Inventions shall be included within the Adagene Platform Technology.&#160; Exelixis hereby assigns to Adagene all of Exelixis&#146; right, title, and interest in and to all Platform Inventions.&#160; To effectuate the foregoing assignment, Exelixis shall ensure that all entities and individuals that perform any activities on behalf of Exelixis hereunder are under a written or other legally enforceable obligation to assign all right, title, and interest in any intellectual property created pursuant to such activities directly to Exelixis or to an entity that is obligated to assign all such right, title, and interest to Exelixis.&#160; Exelixis shall assist Adagene, at Adagene&#146;s expense, in securing for Adagene any patents, copyrights, or other proprietary rights in such Platform Inventions, and to perform all acts that may be reasonably required to vest in Adagene all right, title, and interest in such Platform Inventions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Inventions</b>.&#160; Except for Compound Inventions and Platform Inventions, each Party shall solely own any discovery or invention made solely by it and its Affiliates&#146; employees, agents, or independent contractors (the &#147;<b>Sole Inventions</b>&#148;), and the Parties shall jointly own any discovery or invention made jointly by employees, agents, or independent contractors of one Party or its Affiliates together with employees, agents, or independent contractors of the other Party or its Affiliates (the &#147;<b>Joint Inventions</b>&#148;).&#160; All Patents claiming patentable Joint Inventions shall be referred to herein as &#147;<b>Joint Patents</b>&#148;.&#160; Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign, and otherwise exploit its interest under the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Patent Prosecution and Maintenance</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exelixis Patents</b>.&#160; Exelixis shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">31<a name="29876-2-RC-07_PB_31_124420_7552"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=986099,FOLIO='31',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">reissue proceedings, reexaminations, inter partes review, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) of the Exelixis Patents (including Product Patents, but excluding Joint Patents) worldwide, using counsel of its own choice.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Patents and Adagene Platform Patents</b>.&#160; Adagene shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of all Adagene Patents (other than Joint Patents) and Adagene Platform Patents worldwide, at its sole cost and expense and by counsel of its own choice.&#160; Adagene shall keep Exelixis reasonably informed of the status of filing, prosecution, maintenance, and defense, if any, of the Adagene Patents that are listed in Exhibit&nbsp;B (but not the Adagene Platform Patents), and Adagene shall consult with, and consider in good faith the requests and suggestions of, Exelixis with respect to strategies for filing, prosecuting, and defending the Adagene Patents listed in Exhibit&nbsp;B (but not the Adagene Platform Patents).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Joint Patents</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to this Section&nbsp;9.2(c), Exelixis shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) the Joint Patents using a patent counsel selected by Exelixis and reasonably acceptable to Adagene.&#160; Adagene shall reimburse Exelixis for&#160; [***] of the costs and expenses incurred with respect to the preparation, filing, prosecution, and maintenance of the Joint Patents in the Territory, within [***] after receipt of an invoice for such costs and expenses together with reasonable documentation evidencing such costs and expenses provided by Exelixis.&#160; In the event that Adagene does not reimburse Exelixis for such costs and expenses for any Joint Patent or notifies Exelixis in writing that it elects to cease reimbursing Exelixis for such costs and expense for any Joint Patent, Adagene shall execute such documents and perform such acts, at Adagene&#146;s expense, as may be reasonably necessary to effect an assignment of Adagene&#146;s entire right, title, and interest in and to such Joint Patent to Exelixis, and such Patent shall cease to be a Joint Patent and shall no longer be subject to the licenses and other rights granted by Exelixis to Adagene under this Agreement.&#160; Exelixis shall keep Adagene informed of material progress with regard to the preparation, filing, prosecution, maintenance, and defense, if any, of the Joint Patents, including content, timing, and jurisdiction of the filing of such Joint Patents, and Exelixis shall consult with, and consider in good faith the reasonable comments of Adagene with respect to filing, prosecuting, and defending the Joint Patents in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If Exelixis desires to abandon or cease prosecution or maintenance of any Joint Patent in the Territory, Exelixis shall provide reasonable prior written notice to Adagene of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).&#160; In such case, at Adagene&#146;s sole discretion, upon written notice from Adagene to Exelixis, Adagene may elect to continue prosecution or maintenance of any such Joint Patent at its own expense, and Exelixis shall execute such documents and perform</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">32<a name="29876-2-RC-07_PB_32_124441_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=799222,FOLIO='32',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">such acts, at Adagene&#146;s expense, as may be reasonably necessary to assign to Adagene Exelixis&#146; ownership interest therein and to allow Adagene to continue the prosecution and maintenance of such Joint Patent in the Territory.&#160; Any patents so assigned shall cease to be a Joint Patent and shall thereafter be Adagene Patents subject to the licenses herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Patent Term Extensions</b>. &#160;Exelixis shall have the right to apply, in its sole discretion and at its expense, for any patent term extension for any Exelixis Patent or Joint Patent in the Territory. Adagene shall have the right to apply, in its sole discretion and at its expense, for any patent term extension for all Adagene Patents (other than Joint Patents) and Adagene Platform Patents in the Territory to the extent that such Patent Term Extensions are not based on Products approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Cooperation</b>.&#160; Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance, and defense, if any, of Patents under Section&nbsp;9.2 and in the obtaining and maintenance of any patent term extensions, supplementary protection certificates, and their equivalent with respect thereto, at its own cost (except as expressly set forth otherwise in this Section&nbsp;9.2).&#160; Such cooperation includes (i)&nbsp;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section&nbsp;9.2; and (ii)&nbsp;promptly informing the other Party of any matters coming to such Party&#146;s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent application and the obtaining of any patent term extensions, supplementary protection certificates, and their equivalent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Separation of Patent Rights</b>. In order to more efficiently enable the prosecution and maintenance of the Product Patents and the Adagene Platform Patents relating to the Inventions described above, the Parties will use good faith efforts to separate Compound Inventions, Platform Inventions, and Joint Inventions into separate filings to the extent possible and without adversely impacting such prosecution and maintenance.&#160; For clarity, it is also the mutual intent of the parties that Adagene Patents, if any, shall be separated and prosecuted as either Product Patents or Adagene Platform Patents to the extent possible without adversely impacting the prosecution and maintenance thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Patent Enforcement</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notice</b>.&#160; Each Party shall notify the other within&#160; [***] after becoming aware of any alleged or threatened infringement by a Third Party of any of the Adagene Patents, Adagene Platform Patents, or Product Patents in the Territory, which infringement adversely affects or could reasonably be expected to adversely affect the Development, manufacture, or Commercialization of any Product (collectively, &#147;<b>Product Infringement</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Enforcement Right</b>.&#160; Exelixis shall have the first right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate; provided, however, that with respect to any action involving any Adagene Patent or Adagene Platform Patent, Exelixis shall only have the right to enforce such Adagene Patent or Adagene Platform Patent, as applicable, to the extent such Patent directly and exclusively </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">33<a name="29876-2-RC-07_PB_33_124714_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=587623,FOLIO='33',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">relates to a Compound or Product (and not to any compound or product that is not a Compound or Product).&#160; Exelixis shall not compromise or settle any such litigation in a way that could reasonably be expected to adversely affect the validity or enforceability of any Adagene Patent or Adagene Platform Patent or result in an admission of liability on the part of Adagene, without Adagene&#146;s prior written consent, such consent not to be unreasonably withheld.&#160; If Exelixis (i)&nbsp;elects to not bring such legal action against a Product Infringement (the decision of which Exelixis shall inform Adagene promptly) or (ii)&nbsp;Exelixis otherwise fails to bring such legal action against a Product Infringement within&#160; [***] after first becoming aware of such Product Infringement, then, to the extent such Product Infringement pertains solely to one or more Adagene Patents or Adagene Platform Patents and not to any Product Patents, Adagene shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with Exelixis; provided, however, that Adagene shall not have the right to bring any such action to the extent it relates to a Patent claiming the composition of matter or method of use of any Compound or Product without Exelixis&#146; prior written consent, which Exelixis may grant in its sole discretion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Collaboration</b>.&#160; Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party&#146;s request and expense, including to be named in such action if required by Applicable Laws to pursue such action.&#160; The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts and shall reasonably consider the other Party&#146;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court.&#160; The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Expense and Recovery</b>.&#160; Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a result of any litigation described in Section&nbsp;9.3 (whether by way of settlement or otherwise) shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated <i>pro rata</i> if insufficient to cover the totality of such expenses).&#160; Any remainder after such reimbursement is made shall be allocated as follows:&#160; [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Infringement</b>.&#160; Except for Product Infringement as set forth above, each Party shall have the exclusive right to enforce its own Patent against any infringement anywhere in the world.&#160; For clarity, Exelixis shall have the exclusive right to enforce the Exelixis Patents against any infringement in the Territory at its own expense as it determines appropriate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Infringement of Third Party Rights</b>.&#160; If any Product used or sold by Exelixis, its Affiliates, or Sublicensees becomes the subject of a Third Party&#146;s claim or assertion of infringement of intellectual property rights in a jurisdiction within the Territory (&#147;<b>Third Party Infringement Claim</b>&#148;), Exelixis shall promptly notify Adagene and the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a &#147;common interest agreement&#148; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.&#160; Absent any agreement to the contrary, and subject to claims for indemnification under Article&nbsp;11, each </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">34<a name="29876-2-RC-07_PB_34_124842_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=286940,FOLIO='34',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Party shall defend itself from any such Third Party Infringement at its own cost and expense, provided, however, that the provisions of Section&nbsp;9.3 shall govern the right of a Party to assert a counterclaim of infringement of any Adagene Patent, Adagene Platform Patent, or Product Patent.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>REPRESENTATIONS AND WARRANTIES</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Mutual Representations and Warranties</b>.&#160; Each Party represents and warrants to the other that, as of the Effective Date:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it has the right to grant the licenses granted by it under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Covenants</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Employees, Consultants, and Contractors</b>.&#160; Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions in a manner consistent with the provisions of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Debarment</b>.&#160; Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Product.&#160; In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">35<a name="29876-2-RC-07_PB_35_124858_7672"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=703737,FOLIO='35',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Compliance</b>.&#160; In the performance of its obligations under this Agreement, such Party shall comply and shall cause its and its Affiliates&#146; employees and contractors to comply with all Applicable Laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Additional Adagene Representations and Warranties</b>.&#160; Adagene represents and warrants as of the Effective Date:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exhibit&nbsp;B</u> lists all Adagene Patents and Adagene Platform Patents as of the Effective Date and all such Patents listed on <u>Exhibit&nbsp;B</u> are (i)&nbsp;to Adagene&#146;s knowledge, valid and enforceable, (ii)&nbsp;solely and exclusively owned by Adagene, free of any encumbrance, lien, or claim of ownership by any Third Party, and (iii)&nbsp;filed and maintained properly and correctly and all applicable application and maintenance fees have been paid on or before the due date for payment or during any extension thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each of the Adagene Patents and Adagene Platform Patents properly identifies each and every inventor of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Patent is issued or such application is pending; all such inventors have assigned their entire right, title, and interest in and to such inventions to Adagene and all such assignments have been duly recorded and are enforceable in accordance with Applicable Law; and there are no claims or assertions in writing received by Adagene regarding the inventorship of any Adagene Patent alleging that additional or alternative inventors should be listed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Adagene has the right to grant all rights and licenses it purports to grant to Exelixis with respect to the Adagene Technology and Adagene Platform Technology under this Agreement, free and clear of any rights therein granted to any Third Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All Adagene Technology and Adagene Platform Technology is owned by Adagene or its Affiliates and is not held under license from any Third Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Adagene has not granted any liens or security interests on any of the Adagene Technology or Adagene Platform Technology.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Adagene has not as of the Effective Date, granted to any Third Party any right under the Adagene Technology or Adagene Platform Technology that would conflict with the rights granted to Exelixis hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(i)&nbsp;No claim or action has been brought or, to Adagene&#146;s knowledge, threatened in writing, by any Third Party alleging that (A)&nbsp;the Adagene Patents or Adagene Platform Patents are invalid or unenforceable, or (B)&nbsp;the use of the Adagene Know-How or Adagene Platform Technology infringes or misappropriates, or would infringe or misappropriate, any intellectual property right of any Third Party, and (ii)&nbsp;to Adagene&#146;s knowledge, no facts or circumstances exist that would reasonably be expected to give rise to any such claims described in subsection (i).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There are no pending or, to Adagene&#146;s knowledge, alleged or threatened, (i)&nbsp;inter partes reviews, post-grant reviews, interferences, re-examinations, or oppositions involving the Adagene Patents or Adagene Platform Patents that are in or before any patent authority (or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">36<a name="29876-2-RC-07_PB_36_124917_536"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=60775,FOLIO='36',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other governmental authority performing similar functions) or (ii)&nbsp;inventorship challenges involving the Adagene Patents or Adagene Platform Patents that are in or before any patent or other Governmental Authority.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To Adagene&#146;s knowledge, no Third Party is infringing or misappropriating or has infringed or misappropriated or is threatening to infringe or misappropriate the Adagene Technology or the Adagene Platform Technology.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(j)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The inventions claimed by the Adagene Patents and the Adagene Platform Patents (i)&nbsp;were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof and (ii)&nbsp;are not a &#147;subject invention&#148; as that term is described in 35 U.S.C. Section&nbsp;201(e), and (iii)&nbsp;are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. &#167;&#167; 200-212, as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. part 401.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To Adagene&#146;s knowledge, there are no issues or information related to the Adagene Technology or Adagene Platform Technology, which in Adagene&#146;s reasonable opinion, are reasonably likely to have a material impact on the Development or Commercialization of the Compounds (including any infringement of the Adagene Patents or the Adagene Platform Patents of Third Party patent rights) that have not been fully disclosed to Exelixis in the course of Exelixis&#146; due diligence.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Adagene Covenants</b>.&#160; Adagene covenants to Exelixis:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Adagene will not during the Term grant to any Third Party any right under the Adagene Technology or Adagene Platform Technology that would conflict with the rights granted to Exelixis hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Adagene shall perform the Compound Research Activities allocated to it under each Target Program Plan in accordance with the same level of care and diligence practiced by recognized firms in performing activities of a similar nature and the Compound Research Activities it performs will conform to the requirements and other terms in the applicable Target Program Plan and this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Disclaimer</b>.&#160; EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS,&nbsp;IMPLIED, OR STATUTORY,&nbsp;INCLUDING WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE, OR TRADE PRACTICES,&nbsp;IN ALL CASES WITH RESPECT THERETO.&#160; NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT ANY OF THE DEVELOPMENT, MANUFACTURING, OR COMMERCIALIZATION EFFORTS WITH REGARD TO ANY PRODUCT WILL BE SUCCESSFUL.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">37<a name="29876-2-RC-07_PB_37_125009_5926"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=791283,FOLIO='37',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>INDEMNIFICATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification by Exelixis</b>.&#160; Exelixis hereby agrees to defend, indemnify, and hold harmless Adagene and its Affiliates and their respective directors, officers, employees, and agents (each, an &#147;<b>Adagene Indemnitee</b>&#148;) from and against any and all liabilities, expenses, and losses, including reasonable legal expenses and attorneys&#146; fees (collectively, &#147;<b>Losses</b>&#148;), to which any Adagene Indemnitee may become subject as a result of any claim, demand, action, or other proceeding (each, a &#147;<b>Claim</b>&#148;) by any Third Party to the extent such Losses arise out of:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Development, use, manufacture, or Commercialization of any Compound or Product by Exelixis or its Affiliates or Sublicensees or the contractors of any of them (excluding any activities by or on behalf of Adagene or its Affiliates);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the negligence or willful misconduct of any Exelixis Indemnitee; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the breach by Exelixis of any warranty, representation, covenant, or agreement made by Exelixis in this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">except, in each case (a)-(c), to the extent such Losses arise out of any activities set forth in Sections 11.1(a)-(d)&nbsp;for which Adagene is obligated to indemnify any Exelixis Indemnitee under Section&nbsp;11.2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification by Adagene</b>.&#160; Adagene hereby agrees to defend, indemnify, and hold harmless Exelixis, its Affiliates, and Sublicensees and their respective directors, officers, employees, and agents (each, an &#147;<b>Exelixis Indemnitee</b>&#148;) from and against any and all Losses to which any Exelixis Indemnitee may become subject as a result of any Claim by any Third Party to the extent such Losses arise out of:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Development, use, or manufacture of any Compound or Product by Adagene, its Affiliates, or licensees (other than Exelixis) or the contractor of any of them;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the negligence or willful misconduct of any Adagene Indemnitee; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the infringement or misappropriation by Adagene or any of its Affiliates of any Third Party intellectual property rights resulting from the use or practice of any Adagene Technology or the Adagene Platform Technology, except to the extent such infringement or misappropriation is caused directly by the use of an Exelixis mAB, including the Collaboration Target to which such Exelixis mAB is directed; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the breach by Adagene of any warranty, representation, covenant, or agreement made by Adagene in this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">except, in the case of (a), (b), or (d), to the extent such Losses arise out of any activities set forth in Sections 11.1(a)-(c)&nbsp;for which Exelixis is obligated to indemnify any Adagene Indemnitee under Section&nbsp;11.1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification Conditions and Procedure</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">38<a name="29876-2-RC-07_PB_38_125026_4688"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=645853,FOLIO='38',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notice</b>.&#160; The Party claiming indemnity under this Article&nbsp;11 (the &#147;<b>Indemnified Party</b>&#148;) shall give written notice to the Party from whom indemnity is being sought (the &#147;<b>Indemnifying Party</b>&#148;) promptly after learning of such Claim.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Control</b>.&#160; The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#146;s expense, in connection with the defense of the Claim for which indemnity is being sought.&#160; The Indemnified Party may participate in and monitor such defense with counsel of its own choice at its own expense; provided, however, that the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Settlement Rights</b>.&#160; The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, conditioned, or delayed, unless the settlement involves only the payment of money, no admission of wrong-doing or fault by the Indemnified Party, and no restriction on the future actions or activities of the Indemnified Party.&#160; So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle such Claim without the prior written consent of the Indemnifying Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Backup Right</b>.&#160; If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i)&nbsp;the Indemnified Party may defend against and consent to the entry of any judgment, or enter into any settlement with respect to, the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith so long as the settlement involves only the payment of money, no admission of wrong-doing or fault by the Indemnifying Party, and no restriction on the future actions or activities of the Indemnifying Party), and (ii)&nbsp;the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this Article&nbsp;11.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Insurance</b>.&#160; During the Term and for a commercially reasonable period of time thereafter, each Party, at its own expense, shall maintain commercial general liability insurance, product liability and other appropriate insurance (or, in the case of Exelixis, self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement.&#160; Without limiting the generality of the foregoing, Adagene represents, warrants, and covenants that it possesses and shall maintain during the Term and for [***]&#160; thereafter, at its own expense, comprehensive general liability insurance&#160; [***].&#160; Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Limitation of Liability</b>.&#160; EXCEPT FOR DAMAGES THAT (A)&nbsp;ARISE IN CONNECTION WITH A PARTY&#146;S (I)&nbsp;WILLFUL MISCONDUCT OR FRAUD OR (II)&nbsp;BREACH OF ITS OBLIGATIONS UNDER ARTICLE&nbsp;12, OR (B)&nbsp;ARE SUBJECT TO INDEMNIFICATION UNDER SECTION&nbsp;11.1 OR 11.2, NEITHER PARTY SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, OR OTHERWISE FOR ANY SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY (OR ITS AFFILIATES OR</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">39<a name="29876-2-RC-07_PB_39_125047_2983"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=593996,FOLIO='39',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(SUB)LICENSEES), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>CONFIDENTIALITY</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Confidential Information</b>.&#160; Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [***] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the other Party, and both Parties shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement except as permitted herein.&#160; Each Party may use the other Party&#146;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights and performing its obligations under this Agreement.&#160; Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the other Party&#146;s Confidential Information.&#160; Each Party will promptly notify the other upon discovery of any loss or unauthorized use or disclosure of the other Party&#146;s Confidential Information.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exceptions</b>.&#160; The obligations of confidentiality and restriction on use under Section&nbsp;12.1 will not apply to any information that the receiving Party can prove by competent written evidence: (a)&nbsp;is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; (b)&nbsp;is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; (c)&nbsp;is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or (d)&nbsp;is independently discovered or developed by the receiving Party without the use of the disclosing Party&#146;s Confidential Information.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Authorized Disclosure</b>.&#160; Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>filing, prosecuting, or maintaining Patents as permitted by this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>filing Regulatory Filings for Products that such Party has a license or right to Develop, manufacture, and Commercialize hereunder in a given country or jurisdiction;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prosecuting or defending litigation as permitted by this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>complying with Applicable Laws or regulations (including regulations promulgated by securities exchanges, subject to Section&nbsp;12.5) or court or administrative orders;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">40<a name="29876-2-RC-07_PB_40_125057_6228"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=1019269,FOLIO='40',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-07_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>disclosure to actual and bona fide potential investors, acquirors, licensees, and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, or collaboration, in each case under a written agreement containing obligations of confidentiality and non-use at least as stringent as those herein; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>disclosure to its and its Affiliates&#146; employees, consultants, contractors, agents, licensees, and sublicensees, in each case on a need-to-know basis in connection with the Development, manufacture, or Commercialization of the Products in accordance with the terms of this Agreement, in each case under a written agreement containing obligations of confidentiality and non-use at least as stringent as those herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, the Parties shall use good faith efforts to agree on a redacted version of this Agreement within [***] following the Effective Date, it being understood that no consent shall be required for a disclosure of such agreed redacted version pursuant to Section&nbsp;12.3(b)&nbsp;or 12.3(c).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party&#146;s Confidential Information pursuant to Section&nbsp;12.3(a)&nbsp;or 12.3(b), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such </font>Confidential Information at least as diligent as such Party would use to protect its own confidential information, but in no event less than reasonable efforts.&#160; In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.&#160; Any information disclosed pursuant to Section&nbsp;12.3 shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article&nbsp;12.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without limiting a Party&#146;s obligations under this Article&nbsp;12, a Party shall be liable for any damages incurred by the other Party to the extent arising from any disclosure by such Party of the terms of this Agreement to any Third Party in breach of this Article&nbsp;12.&#160; Each Party acknowledges that money damages alone may not adequately compensate the other Party in the event of a breach or threatened breach of this paragraph or the other provisions of this Article&nbsp;12, and that, in addition to all other remedies available to the other Party at law or in equity, the other Party shall be entitled to seek injunctive relief for the enforcement of its rights, including requiring such Party to enforce the confidentiality and non-use provisions of any agreement with a Third Party in accordance with the terms of this Agreement.&#160; For the avoidance of doubt, the provisions of this paragraph are in addition to the other provisions contained in this Article&nbsp;12.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Publications</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Regarding Adagene Platform Technology</b>.&#160; Adagene shall have the sole right, in its sole discretion, to publish or otherwise disclose any information regarding the Adagene Platform Technology or any improvements thereto; provided that in no event shall Adagene disclose any Confidential Information of Exelixis in violation of Section&nbsp;12.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">41<a name="29876-2-RC-09_PB_41_125354_6726"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=149189,FOLIO='41',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Collaboration Targets</b>.&#160; Exelixis shall have the sole right, in its sole discretion, to publish or otherwise disclose the results of or other information regarding any and all research and Development activities performed hereunder with respect to the Products, including all Compound Research Activities for each Collaboration Target; provided that in no event shall Exelixis disclose any Confidential Information of Adagene in violation of Section&nbsp;12.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Publicity; Public Disclosures</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Initial Press Release</b>.&#160; The Parties agree to issue a joint press release substantially in a form agreed by the Parties and attached to this Agreement as <u>Exhibit&nbsp;C</u> announcing the signature of this Agreement at or shortly after the Effective Date within the time-period required by applicable securities laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Subsequent Releases</b>.&#160; If a Party wishes to release any subsequent press release or other public statement or announcement about the terms of this Agreement, the Parties&#146; relationship under this Agreement, performance of this Agreement, or activities conducted under this Agreement (each, a &#147;<b>Release</b>&#148;), such Party shall first obtain the other Party&#146;s written approval of the proposed Release.&#160; The reviewing Party will have&#160; [***], or such shorter period of time as agreed by the Parties or necessary for the releasing Party to comply with Applicable Law, to review and provide comments to such Release and the reviewing Party&#146;s consent of such approval shall not be unreasonably withheld to the extent such information has been previously disclosed.&#160;&#160; Notwithstanding the foregoing, a Party need not obtain the other Party&#146;s approval for a Release to the extent such Release (a)&nbsp;discusses a Product which such Party has the right to Commercialize under this Agreement and such Release does not mention the other Party hereto or the relationship of the Parties under this Agreement, or (b)&nbsp;discloses text previously approved in any filing with the SEC or in an offering circular for an unregistered securities offering, but only to the extent the underlying facts disclosed in such previously approved text are still true and accurate, and where the circumstances surrounding such disclosure have not changed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>SEC Disclosures</b>.&#160; With respect to complying with disclosure requirements of the SEC or other stock exchange on which a Party&#146;s securities are publicly traded (or to which an application for listing has been submitted) (&#147;<b>Exchange</b>&#148;) in connection with any required filing of this Agreement, the filing Party will consult with the other Party on the provisions of this Agreement to be redacted in any filings made by such Party with the SEC or other Exchange; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws and will not rely on any statements made by the other Party related to securities laws or regulations.&#160; If Adagene reasonably concludes that it must make a Release, or that any portion of this Agreement must be disclosed, in each case pursuant to the requirements of the SEC or other Exchange, and Exelixis would prefer that such Release not be made, that the information so disclosed within such Release be modified or limited, or that disclosure of the Agreement be limited, then Adagene shall modify or limit such Release to address Exelixis&#146; concerns, including by incorporating statements suggested by Exelixis (to the extent any such statement is true and accurate) and seeking confidential treatment of the information included in such Release; provided that Adagene may provide to Exelixis a written statement of why any particular modification or limitation proposed by Exelixis would be contrary to requirements of Applicable Law or the rules&nbsp;of the SEC or applicable Exchange or are otherwise necessary for </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">42<a name="29876-2-RC-09_PB_42_125437_6479"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=42,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=324643,FOLIO='42',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">appropriate market disclosure; provided further that any statement proposed by Exelixis which does reduce the information disclosed in such Release shall be included by Adagene in such Release (to the extent such statement is true and accurate).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Equitable Relief</b>.&#160; Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article&nbsp;12.&#160; In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article&nbsp;12.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERM AND TERMINATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Term</b>.&#160; This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this Article&nbsp;13 or by mutual written agreement of the Parties, shall continue in effect, on a Product-by-Product and country-by-country basis, until the expiration of the Royalty Term for such Product in such country (the &#147;<b>Term</b>&#148;).&#160; Upon the expiration of the Royalty Term for a particular Product in a particular country, the license granted to Exelixis in Section&nbsp;2.1 with respect to such Product in such country shall be deemed fully-paid, royalty-free, perpetual, and irrevocable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Termination for Cause</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Material Breach</b>.&#160; Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement, such material breach to include a failure of Exelixis to comply with its diligence obligations under this Agreement and Adagene&#146;s failure to comply with its exclusivity obligations hereunder, and has not cured such breach to the reasonable satisfaction of the other Party within&#160; [***] ([***] with respect to any payment breach) after notice of such breach from the non-breaching Party.&#160; If the breach is capable of being cured, but cure of such breach (other than non-payment) cannot reasonably be effected within such&#160; [***] period, the breaching Party shall promptly notify the non-breaching Party thereof, and the Parties shall agree on a plan to cure such breach&#160; promptly, but in any event within an additional&#160; [***].&#160; So long as the breaching Party is diligently carrying out such plan, the non-breaching Party shall not have the right to terminate this Agreement.&#160; If the breaching Party fails to diligently carry out such plan and cure such breach within the additional cure period as provided above, then the non-breaching Party may terminate this Agreement upon written notice to the breaching Party; provided that if such material breach relates solely to one Collaboration Target under the Agreement (but not to both Collaboration Targets), then the terminating Party shall have the right to terminate this Agreement pursuant to this Section&nbsp;13.2(a)&nbsp;solely with respect to the Collaboration Target as to which such material breach relates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Disputed Breach</b>.&#160; If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party, and such alleged breaching Party provides the other Party notice of such dispute within&#160; [***], then the other Party shall not have the right to terminate this Agreement under Section&nbsp; 13.2(a)&nbsp; unless and until </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">43<a name="29876-2-RC-09_PB_43_125510_2639"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=43,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=301207,FOLIO='43',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a panel of arbitrators, in accordance with Article&nbsp; 14, has determined that the alleged breaching Party has materially breached the Agreement and, if the breach is then curable, such Party fails to cure such breach within the applicable cure period set forth above following such decision.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Bankruptcy</b>.&#160; Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee, or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation, or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within&#160; [***] after the commencement thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Safety Reasons</b>.&#160; Exelixis shall have the right to terminate this Agreement on a Collaboration Target-by-Collaboration Target basis immediately upon written notice to Adagene if Exelixis reasonably determines, based upon additional information that becomes available or an analysis of the existing information at any time, that the medical risk/benefit of a Product directed to the applicable Collaboration Target is so unfavorable that it would be incompatible with the welfare of patients to Develop or Commercialize or to continue to Develop or Commercialize such Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Termination without Cause by Exelixis</b>.&#160; Exelixis shall have the right to terminate this Agreement in its entirety or on Collaboration Target-by-Collaboration Target basis at any time, for any or no reason, upon&#160; [***]&#160; written notice to Adagene.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Effects of Termination</b>.&#160; Upon any termination of this Agreement in its entirety by either Party, the following terms will apply.&#160; Upon any termination of this Agreement with respect to a particular Collaboration Target, the following terms will apply solely with respect to such terminated Collaboration Target.&#160; (For clarity, during the pendency of any dispute regarding material breach and/or any termination notice period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Licenses</b>.&#160; All licenses granted by either Party will automatically terminate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Return of Exelixis Property</b>.&#160; Adagene shall return to Exelixis all of Exelixis&#146; Confidential Information and shall deliver to Exelixis, or destroy at Exelixis&#146; request, the Compound Inventions (in each case to the extent not already provided) and any other deliverables specified in the Target Program Plan (in whatever stage of development or completion).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Non-use Covenant for Masks.&#160; </b>Exelixis shall not, and shall procure that its Affiliates and Sublicensees will not, use, commercialize or otherwise exploit in any way, assign, transfer, license or otherwise grant any rights to any Third Party under the Masks Developed and assigned by Adagene to Exelixis under this Agreement.&#160;&#160; Provided, however, that in the event that Exelixis, its Affiliates and/or its Sublicensees do use, commercialize or otherwise exploit such </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">44<a name="29876-2-RC-09_PB_44_125548_2794"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=44,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=948792,FOLIO='44',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Masks, such use or commercialization shall be subject to all of the milestone and royalty payment terms and all of the associated reporting terms hereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>License to Adagene</b>.&#160; Upon Adagene&#146;s written request to Exelixis within thirty (30) days following the effective date of termination of a Collaboration Target by Exelixis pursuant to Section&nbsp; 13.3, and subject to Exelixis&#146; agreement to such request in its sole discretion, the Parties shall negotiate in good faith, for a period of&#160; [***] (or such longer period agreed by the Parties), a non-exclusive or exclusive royalty-bearing license under the Exelixis Technology for such terminated Collaboration Target to research, Develop, use, make, have made, sell, offer for sale, import, and otherwise Commercialize the Compounds and Products directed to such Collaboration Target, on commercially reasonable terms taking into account the then current stage of the Product(s)&nbsp;for the applicable terminated Collaboration Target and the license rights requested by Adagene.&#160; Following the expiration of such&#160; [***] period (or such longer period agreed by the Parties), Exelixis shall have no further obligation to Adagene under this Section.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Right to Maintain License</b>.&#160; Notwithstanding the foregoing, if Exelixis would otherwise have the right to terminate this Agreement pursuant to Section&nbsp;13.2(a)&nbsp;(Material Breach), in lieu of such termination Exelixis may elect to continue this Agreement in full force and effect, except that, upon written notice to Adagene, Exelixis&#146; diligence obligations under Sections 4.6 and 5.2 shall be deemed fully satisfied, and any amounts that would have been due to Adagene by Exelixis accruing after such termination with respect to any Product under Sections 7.3, 7.4, and 7.5 shall each be reduced by&#160; [***] .&#160; Notwithstanding the above, if Adagene disputes in good faith the existence or materiality of such breach and provides Exelixis notice of such dispute within&#160; [***] after receipt of Exelixis&#146; notice, then the preceding subclauses (a)&nbsp;and (b)&nbsp;will not apply unless and until a panel of arbitrators, in accordance with Article&nbsp;14, has determined that Adagene has committed such breach failed to cure such breach within the cure period.&#160; For clarity, during the pendency of any dispute regarding material breach and/or any cure period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Confidential Information</b>.&#160; Upon expiration or termination of this Agreement in its entirety, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#146;s possession or control containing Confidential Information of the other Party; provided that a Party may keep one copy of such materials for legal archival purposes subject to continuing confidentiality obligations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Rights in Bankruptcy</b>.&#160; All rights and licenses granted under or pursuant to this Agreement by one Party to the other Party are, and otherwise will be deemed to be, for purposes of Section&nbsp;365(n)&nbsp;of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of right to &#147;intellectual property&#148; as defined under Section&nbsp;101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.&#160; The Parties agree that a Party that is a licensee of such rights under this Agreement will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.&#160; The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party to this Agreement under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">45<a name="29876-2-RC-09_PB_45_125628_8299"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=45,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=644965,FOLIO='45',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, will be promptly delivered to it (a)&nbsp;upon any such commencement of a bankruptcy or insolvency proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b)&nbsp;if not delivered under (a)&nbsp;above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Survival</b>.&#160; Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.&#160; Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement: Article&nbsp;1 (as applicable), Section&nbsp;2.2 (with respect to liability for breaches by Sublicensees solely to the extent such breach occurred prior to the expiration or termination of this Agreement), Section&nbsp;2.5, Sections 7.3, 7.4, 7.5, 8.1, 8.2, and 8.7 (solely in connection with the payment of amounts accrued by not paid as of the termination or expiration of this Agreement, and as applicable under Section&nbsp;13.4(c)), Section&nbsp;8.6, Section&nbsp;9.1, Article&nbsp;11 (solely to the extent the applicable indemnification claim occurred prior to the expiration or termination of this Agreement), Article&nbsp;12, Section&nbsp;13.1, Section&nbsp;13.4, Section&nbsp;13.6, Section&nbsp;13.7, Section&nbsp;13.8, Article&nbsp;14, and Article&nbsp;15 (as applicable).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DISPUTE RESOLUTION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Objective</b>.&#160; It is the objective of the Parties to establish procedures to facilitate the resolution of any disputes arising under or related to this Agreement in an expedient manner by mutual cooperation and without resort to litigation.&#160; To accomplish this objective, the Parties agree to follow the procedures set forth in this Article&nbsp;14 to resolve any such dispute if and when it arises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Executive Negotiations</b>.&#160; The Parties will try to settle any dispute, controversy, or claim that arises out of, or relates to, any provision of the Agreement (&#147;<b>Disputed Matter</b>&#148;) by first referring the Disputed Matter to the Parties&#146; Executive Officers.&#160; Either Party may initiate such informal dispute resolution by sending written notice of the Disputed Matter to the other Party, and, within [***] after such notice, the Executive Officers (or their respective designees having the authority to settle such Disputed Matter) of the Parties will meet for attempted resolution by good faith negotiations.&#160; If the Executive Officers (or their respective designees) are unable to resolve such dispute within [***] after their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with Section&nbsp;14.3 below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Dispute Resolution</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Parties are unable to resolve a Disputed Matter using the process described in Section&nbsp;14.2, then a Party seeking further resolution of the Disputed Matter (other than an Excluded Claim) shall submit the Disputed Matter to resolution by final and binding arbitration.&#160; Whenever a Party determines to institute arbitration proceedings, it will give written notice to that effect to the other Party.&#160; The legal seat of arbitration will be San Francisco, California, U.S., and the arbitration will be administered by JAMS pursuant </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">46<a name="29876-2-RC-09_PB_46_125657_8247"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=46,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=135458,FOLIO='46',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to its Streamlined Arbitration Rules&nbsp;then in effect (the &#147;<b>Rules</b>&#148;), except as otherwise provided herein and applying the substantive law specified in Section&nbsp;15.1.&#160; The arbitration will be conducted by three arbitrators appointed in accordance with the Rules, provided that such arbitrators must have significant business or legal experience in the pharmaceutical business.&#160; After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators will render their opinion within thirty (30) days after the final arbitration hearing.&#160; The arbitrators will not have the power to award damages excluded pursuant to Section&nbsp;11.5 under this Agreement and any arbitral award that purports to award such damages is expressly prohibited and void <i>ab initio</i>.&#160; Decisions of the arbitrators that conform to the terms of this Section&nbsp;14.3 will be final and binding on the Parties and judgment on the award so rendered may be entered in any court of competent jurisdiction and the Parties undertake to carry out any award without delay.&#160; The losing Party, as determined by the arbitrators, will pay all of the JAMS administrative costs and fees of the arbitration and the fees and costs of the arbitrators, and the arbitrators will be directed to provide for payment or reimbursement of such fees and costs by the losing Party.&#160; If the arbitrators determine that there is no losing Party, the Parties will each be responsible for one-half of those costs and fees and the arbitrator&#146;s award will so provide.&#160; Notwithstanding the foregoing, each Party shall be responsible for its own attorneys&#146; fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding the terms of and procedures set forth in Section&nbsp;14.2 or 14.3, any applications, motions, or orders to show cause seeking temporary restraining orders, preliminary injunctions or other similar preliminary or temporary legal or equitable relief (&#147;<b>Injunctive Relief</b>&#148;) concerning a Disputed Matter (including, but not limited to, Disputed Matters arising out of a potential or actual breach of the confidentiality and non-use provisions in Article&nbsp;12) may immediately be brought in the first instance and without invocation or exhaustion of the procedures set forth in Section&nbsp;14.2 or 14.3(a)&nbsp;for hearing and resolution in and by a court of competent jurisdiction.&#160; Alternatively, a party seeking Injunctive Relief may immediately institute arbitral proceedings without invocation or exhaustion of the procedures set forth in Section&nbsp;14.2 or 14.3(a), and any such Injunctive Relief proceedings will be administered by the ICC pursuant to its emergency arbitration procedures then in effect and applying the substantive law specified in Section&nbsp;15.1.&#160; In either event, once the Injunctive Relief proceedings have been conducted and a decision rendered thereon by the court or arbitral forum, the Parties will, if the Disputed Matter is not finally resolved by the Injunctive Relief, proceed to resolve the Disputed Matter in accordance with the terms of Section&nbsp;14.2 and 14.3(a).&#160; This Section&nbsp;shall be specifically enforceable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except to the extent necessary to confirm, enforce, or challenge an award of the arbitration, to protect or pursue a legal right, or as otherwise required by Applicable Law, neither Party nor the arbitrator may disclose the existence, content, or results of an arbitration under this Section&nbsp;14.3 without the express, prior written consent of both Parties.&#160; In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy, or claim would be barred by the </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">47<a name="29876-2-RC-09_PB_47_125735_5893"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=47,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=8994,FOLIO='47',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">applicable California statute of limitations.&#160; Any disputes concerning the propriety of the commencement of the arbitration, or the validity, or application of this Section&nbsp;14.3 shall be finally settled by the arbitrator.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GENERAL PROVISIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Governing Law</b>.&#160; This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of California, United States, without reference to its conflicts of law principles.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Entire Agreement; Modification</b>.&#160; This Agreement, including the Exhibits, is both a final expression of the Parties&#146; agreement and a complete and exclusive statement with respect to all of its terms.&#160; This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein, including the Confidentiality Agreement.&#160; This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by an authorized representative of each Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Relationship Between the Parties</b>.&#160; The Parties&#146; relationship, as established by this Agreement, is solely that of independent contractors.&#160; This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties.&#160; Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Performance by Affiliates</b>.&#160; Exelixis may discharge any obligations and exercise any right hereunder through any of its Affiliates.&#160; Exelixis hereby guarantees the performance by its Affiliates of its obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Waiver</b>.&#160; The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.&#160;&#160; Any waiver by a Party of a particular term or condition will be effective only if set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Assignment</b>.&#160; Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld).&#160; The Parties may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#146;s consent as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by either Party in connection with the transfer or sale of all or substantially all of the business or assets relating to this Agreement to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or otherwise, provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the </p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">48<a name="29876-2-RC-09_PB_48_125804_9862"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=48,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=629412,FOLIO='48',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiring party to such transaction shall not be included in the technology licensed or assigned hereunder unless used by such acquiring party to Develop, use, make, or sell any Compound or Product; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by either Party, to an Affiliate, provided that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, the Agreement shall be automatically assigned back to the assigning Party or its successor.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#146;s successors and permitted assigns to the extent necessary to carry out the intent of this Section&nbsp;15.6.&#160; Any assignment not in accordance with this Section&nbsp;15.6 shall be null and void and of no legal force or effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Severability</b>.&#160; If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.&#160; The Parties will in such an instance use their best efforts to replace the invalid, unenforceable, or illegal provision(s)&nbsp;with a valid, enforceable, and legal provision(s)&nbsp;that best implements the original intent of the Parties and purposes of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notices</b>.&#160; Any notice to be given under this Agreement must be in writing and delivered either (a)&nbsp;in person or (b)&nbsp;by (i)&nbsp;air mail (postage prepaid) requiring return receipt, (ii)&nbsp;recognized overnight courier, or (iii)&nbsp;facsimile, in each case to the Party to be notified at its address given below, or at any other address such Party may designate by prior written notice to the other in accordance with this Section&nbsp;15.8.&#160; Notice shall be deemed sufficiently given for all purposes upon the earliest of:&#160; (w)&nbsp;if personally delivered, the date of actual receipt; (x)&nbsp;if air mailed, five (5)&nbsp;days after the date of postmark; (y)&nbsp;if delivered by overnight courier, the next day the overnight courier regularly makes deliveries; or (z)&nbsp;if sent by facsimile, the date of confirmation of receipt if during the recipient&#146;s normal business hours, otherwise the next business day.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Adagene, notices must be addressed to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adagene,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">315 Montgomery Street, Suite&nbsp;900</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">San Francisco, CA 94104</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn: General Counsel</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">49<a name="29876-2-RC-09_PB_49_125841_9111"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=49,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=486714,FOLIO='49',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Exelixis, notices must be addressed to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exelixis,&nbsp;Inc.<br> 1851 Harbor Bay Parkway</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Alameda, CA 94502<br> Attention:&#160; EVP and General Counsel</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Force Majeure</b>.&#160; Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#146;s reasonable control, including Acts of God, fire, flood, explosion, earthquake, pandemic, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction, or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, or any other event similar to those enumerated above.&#160; Such excuse from liability shall be effective to the extent and duration of the event(s)&nbsp;causing the failure or delay in performance and provided that the Party has not caused such event(s)&nbsp;to occur.&#160; Notice of a Party&#146;s failure or delay in performance due to force majeure must be given to the other Party as soon as reasonably practicable after its occurrence.&#160; All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.10</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Interpretation</b>.&#160; The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.&#160; All references in this Agreement to the singular shall include the plural where applicable.&#160; Unless otherwise specified, references in this Agreement to any Article&nbsp;shall include all Sections, subsections, and paragraphs in such Article, references to any Section&nbsp;shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.&#160; The word &#147;including&#148; and similar words means including without limitation.&#160; The word &#147;or&#148; means &#147;and/or&#148; unless the context dictates otherwise because the subjects of the conjunction are or intended to be mutually exclusive.&#160; The words &#147;herein&#148;, &#147;hereof&#148;, and &#147;hereunder&#148; and other words of similar import refer to this Agreement as a whole and not to any particular Section&nbsp;or other subdivision.&#160; All references to days in this Agreement mean calendar days, unless otherwise specified.&#160; Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.&#160; This Agreement has been prepared in the English language and the English language shall control its interpretation.&#160; In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.11</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Counterparts; Electronic or Facsimile Signatures</b>.&#160; This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.&#160; This Agreement may be executed and delivered electronically or by PDF or facsimile and, upon such delivery, such electronic or PDF or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">{SIGNATURE PAGE FOLLOWS}</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">50<a name="29876-2-RC-09_PB_50_125907_2270"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=50,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=616311,FOLIO='50',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-09_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 13:25 2021' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:37.4pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.4pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF,</font></b> the Parties hereto have caused this <b>COLLABORATION AND LICENSE AGREEMENT</b> to be executed and entered into by their duly authorized representatives as of the Effective Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXELIXIS,&nbsp;INC.</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAGENE INCORPORATED</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Michael M.   Morrissey</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Peter Luo</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael M. Morrissey</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Peter Luo</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President &amp; Chief   Executive Officer</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Executive Officer   &amp; Chairman</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">51<a name="29876-2-RC-11_PB_51_130302_3780"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=51,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=311108,FOLIO='51',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-11_ZDS17602.CHC",USER="DCOMBA",CD='Jan 31 06:04 2021' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">List of Exhibits:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A: Adagene Know-How</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;B: Adagene Patents and Adagene Platform Patents</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;C: Press Release</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;D: VIE Reporting</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=52,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=471086,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-11_ZDS17602.CHC",USER="DCOMBA",CD='Jan 31 06:04 2021' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adagene Know-How</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=53,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=800831,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-11_ZDS17602.CHC",USER="DCOMBA",CD='Jan 31 06:04 2021' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;B</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adagene Patents</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=54,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=300539,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-11_ZDS17602.CHC",USER="DCOMBA",CD='Jan 31 06:04 2021' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;C</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;of Press Release</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=55,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=344384,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-11_ZDS17602.CHC",USER="DCOMBA",CD='Jan 31 06:04 2021' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;D</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Quarterly VIE assessment</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=56,EFW="2242824",CP="ADAGENE INC.",DN="3",CHK=336591,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RC-11_ZDS17602.CHC",USER="DCOMBA",CD='Jan 31 06:04 2021' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>a2242824zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 23.1<a name="29876-2-RM_Exhibit23_1_082405"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the use in this Registration Statement on Form&nbsp;F-1 of Adagene Inc. of our report dated </font>September&nbsp;22, 2020 relating to the financial statements of Adagene Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ PricewaterhouseCoopers Zhong Tian LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shanghai, </font>the People&#146;s Republic of China</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Februray 1, 2021</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2242824",CP="ADAGENE INC.",DN="4",CHK=723319,FOLIO='',FILE="DISK104:[20ZDS2.20ZDS17602]29876-2-RM_ZDS17602.CHC",USER="DCOMBA",CD='Jan 30 09:59 2021' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g705756.jpg
<DESCRIPTION>G705756.JPG
<TEXT>
begin 644 g705756.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@ S35),3%]'4D%02$E#4SI;4%)/2D5#
M5%]!55)/4D%=041!1T5.15\T0U],3T=/+D504__; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #P!#@,!(@ "
M$0$#$0'_Q  ?   " @,  P$!           )"@<(!08+  $$ @/_Q !:$
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MG=#&"=5L^$96A1AZ3>W-HDQL#R]4JP(@Y8+5N&*@Q]SH%_UNRN5!*X!!$$#
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MC7EGGC:PP>1EEL8*20G=AQ^<<=ME*^DL%2:T^;IJK6D$V4IE[+UK&,9.U6;
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& +P\D__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g836147.jpg
<DESCRIPTION>G836147.JPG
<TEXT>
begin 644 g836147.jpg
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M5F*2E;7!T1<W.$-49')T=H+4)32#E-7Q)U-SHK+"D[/A_]H # ,!  (1 Q$
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MRYA(F.8"$20O%<*N8XJ^R4I4%I%)83'5_0F )_RAA#T>H! 12:M83[]>9?\
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M3_!A_P#*'[2_Z%<\_P"\&8Y9M\5C_*'J/^B.$_[67'G-?7/_ !@W_P#N=/\
MU?4UMGJS_DYU/_$*?ZYLZK+XXXY%ZY&UY 1#["(?T"(<_!R$4_QA"*?L_E"%
M/]/'CQX, A]OI_1]/MS]<<-&OMC).2A%RNH61D85R00,1Q#2#R)7*(?82K1J
M[54!#^8_V^GV^G,]5;MIV6IOM%@MLOWL(^GVVDU+$M+, *'@"?+VAO,@!/
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M7<KN7*I@(DV;(H)J*N'"IQ*1)NB1190QBE(0QC  ^ZP +$!06).  "22?
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MC "!1XT\ 2%'=V51CN2R,>" JHYR')XH, ECX&/)/C78>?D#E'U>D?4)1 #
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M3S&6QL*R&6>O5'U2M3]24HK-FD=U$V%ZH\A4TY%T912NS]+;M<AAD;?5M+V
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MK:K_ %C+*QJU567CI4&^PU";I$&X@IABBUH.@IJ(R*ZG2MP^&GUISNE=M(Z
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M:EB\C$F1>J6Z-5C4G-JH4>];BLF\8Z#6T$7$$")C(KVJ*JCD%B-_?,;1B?\
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M =R=DCYO)/(G)BB%I9<\%! &P)_!A_\ *'[2_P"A7//^\&8Y9M\5C_*'J/\
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MS=RL<[;;*_4D[!999].33]3Z&=2,BN=PY4*7[)HE,<$6R)0 K=JDB@0 (D4
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M-+AY?J"1\*?^0'!'D<RY!P1J%]M/M /7G5\[U)B^P[+W=NV55),<RJX]\W(
MG!-^= T; *33AIAE#J^7''')'6H=....&C00 0$! ! ?H("'D!_I ?I_^WZ\
MM@Z=_$,DZ2>*S/>I1W,4P/980&ANQ6>S543 /;096A4/=>3==3\$30EA(O,0
MQ/H]/(1A 4CJG^/M]N(6:T-J,Q3+R'ZK# =#_61B#@_D01X((\:M71_6>_\
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MU*KV9O.5FJ/FJPQ4-&2$*RKT8V:1K$6YF[]-J=JJ@W0>OHAO,),7"9[R _\
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M=BBF@@DS;HI%309IHM3&;)I-4BE032;F,W3(F!$/Y(I.6N[NL+05++0169[
M+EF(BDIR0*B,L,D!2R \WZ93)(4X$*@]2L=%78/+&'9%3 \#DLJOD@LK90D+
M\)P,Y\GY9@A@_P /_-<TZWS'6K39J9W>A3]H=6=S%7@IF,3#B+]"0BHVL1<.
M_ U>)&N&C>4=.8N23!]9U9.=:IQR3\C!#),R]ZI_#PP2QVQZC4<-QJH>J7FG
M:"+I9Q)R\@<C5JG_ (4A9;I;YI<&\9$,@/*SLDH#>/9$]A$I$<T[!KN>8-F=
MSU[5K-'T_/Z%!NY^RS\D<01:,FI0 B#9!,#.)&4D7)T8Z&B&*:\E,2KII&1S
M=P\=(I&_GK?$T^)IIOQ"M-*H<LG2<!I,FZ/E.5'<E]PAQ(JT_/E\^64.TE+_
M "S)51(B1#KQM,BW*T!!*+*KS<S-R'2'2^Z=97Y!+--%M44XFW*T#Q1I&P3%
M7CQVFN2IZ-P*PIB20$&..6F=?==[=T/MP*K%9WJS$R[90.3X&5]ZME2)$IQ-
M\@RO8<&&(C$LL+XFOQ,]-^(5IH'4+)TK *3*.5,IRH[HHF*H4%&I;[?/E5%&
M<M?Y5H<Y42)G<1M,C7"D% *K++34U-5@\<<ZFVW;:6TTH-OV^!*U6L@2.-!^
M;.['XI)9&R\DCDO(Y+,23KBS==UW#>]PL[GN=F2U=M2&2660_DL<:C"QQ1J
MD42!4C151%  &G''''VH[3CCCAHTXXXX:-....&C6T__  <SO=^6;1/]%=&F
M0)!W)Q+WW W,@X("4?;4VYG]_P [;*+#Y(C9&+92[5YBF8"?C$?<"D*9>5;)
M&Y/^$:]$ AIJO=[LXA?3&6%6&S_L"VCVWZ&LZ5,D=G>DNBI ;TIR[=-*@V-\
MI[20/FM(,/K6?.U1U<J;<+1GENJU]I,T[KERI-BAK95+ P-Z'D+8Z](-Y6&D
MVX_8QVCYJBH=(WE-PD"C94#(K*%'^COU@VK(?BI=#V\U:H5C(P.M4J:S#<:(
MF?R:KWE"/3C+O ME5064:G:/5VUFILGZA=%BG];F4S)N! $])=85Y^C.JJ/6
MFWQL:&X2^[;S!'X5I) .\"/ 'OD2>\1DY O5S(YS(JGH3H2U7Z_Z+W+V?;G*
MHW/;(??.G[,IRR1Q,/=^).6(I32>ZR@$,=NMK#$N(F8?S8^.21[==9;MT^[$
M:9U[O@J.I.AS8IPT^9$4$+C2Y0@OZ;=&1/'I]BPPAT%G2:8F(QFD)>*$?<CE
M "-W-S5K,%RO!;K2+-7LQ1SPRH<K)%*@>-Q\\,K X(!&<$ ZT';JV*-JQ2MQ
M/!:J3RU[$+C#Q30NT<L;8R,HZE3@D'&02,'3EDW2+M'A&%TRY5V]R7:3#-.D
M;A$V>K=GNGMIBRZ(>LM(\&,CC]_SN\VF#SVUT5=V9>PQ3]RR?RD?,NE2K)BR
M3%)]6SR1W3W*:ONW:SKGBUW4ED:?JVQ4FAV=6!?)QLVG"6&2!F_/%2"K9XFR
M?%2'RW<G:.2IG#R*1OV,MZKU+&V6A>,PJP1-;E[#<9"M53.1Q.8YE(0AH)U>
M&4'C(A&,2&P6[M3=J3;<*[7)YDIP"R@:+N7&6NI+C$L#!I%*V('CGA(Y1N#D
M&Y.P_%_P+6Y_5HB^9;=LPI<KO>6[WG]ZJ&-=9]RU.>L&>Y[%YU89#1J[K[%I
MF];TJ^-H5A9([4Z*R>2]$E"IQJ"<LP;+JRGZP[XA'7/L5V!Z7S'8)QKV47S!
MNXFI:'2[-&2N4M\LLU=[!Z.6VNYW?+D]<Y^PI<Q2S DWN]EJ-"".O<.5]' G
M -Y556/P=(=..F>P,>UL+UX@=]SW4^F6G5ME::[K>H5J\4/:\U7V\^/6$\/8
MZ_1X.PYO/E<,U9)JX-'SH,V[U%(K.;7 RD?BZ_?"UU&5VQS6LYD<MK%#L?8O
ML[B:?XI?[O;H/!W/6NNO;_;$-6OTGF\!)R4&:@M%)^L6=K6CR]CCRI#*0$-(
MKD;*:]CH=&F.6NOONS3)5G57LNBRU%^R$20JW<L&9+>UV^ZP+SPD<TC>O:PA
MV=)N77RRP63]G[[!);@=XZD;O#>8;XSQ*RF*L(&I;Q2,*E8Z\ZG@\J6J1[@D
M7#?$(ZB5(:)*6NI;_-['@52[V]?JNI05<Q>8];*?V.O6ER<'HZ\Q+S[&RJ.X
M]O9TVQ()@S(Q6;/3S:,G))LF+)_T71_B:YA=L,F"Q-?OU2WBY=3L_P"J-UJD
M'D76=OFDFPJK&,K\Y;WV]OZY,=@Y^G2L%#1[Z#QA5M"-8"S(M7+.WM6[%-VI
M'&Q_"\WVM8O-ZPXGJ8\GJKD%=[!6W(&4-J(7&N8I:%V 1=P<W%U0$,BD)UM%
M2T79[%FD3?'=ZK%:>E?2D:5VBO'$RU(_!MV:%U&\Y));]USD+=D]!>:7K\/G
MRFR:S:LUJ:J]70J:LMG=!RN4O\U,W?\ ,Y7T3 UNOR+R*@XMY.3YV+5Y$)OW
M@J]#)(L[[@TTD<\L@+O8F $-A;D\<<78<BK):OQ21O&"97GACJSMS",Q-SVB
MRQ-6CVP0125X8B(XJU8DSU31KRR3">+E<BI[;+%)'*WZ&*O/)<KJ(V=,JR_Q
M;J.UW'N!ME8S"]2;O=>QO1?<LWKELD:^W9PT;U,D8]W8:S<GK"6E31SFRM61
MV=6=UIK.-HU06KF030(V]@_!Y[\0+J5U\V]GH.14[M#H]9TC3^P6@;BGL=AJ
M3(U?A^P55E:Q(5S,\I9VBVY'=;E5UI49:1UK06$78+W%,CT1^DPKLLX,RX_!
M_AEU2US];S_6+CGZ;(WQ!:)U>L&YYYL]@>L;%7K/B;G3V]%SVCIY18(8EKMH
M U)"7&X2D1*U&X"XH5TIC!LV>S+7#LK\+C0YO1:/ X_LF':5G6E:WV#S&-TZ
M,G;XVJV6O.O4._NET:[0^G\XKDA"/(:BM1D'#N!@YAA+/6;[\(]QFM'+.<%@
MZ)9YZAFLP1&C%',S3SI5M4Z^V+4KAYHRP#0TMO::.-FAF:02221R%@@R>Q[0
M1'6NK!5LS+N<KU@E>L]RG?L[N;MKA7D"DI8O[FL$LJ)/76,I''+&J%]8F[J=
MF*3N,?A.>9B_NTOGF$5"TP\/*W;*<$P\5Y>\V%O8+ WJ63=?8)G4J+4VZS%J
M<(]S9+2\F9Q>3GC#"F=':N8)\_1P3 YP172=(@<X(ND04!%TB!S BZ0!4B:H
M(.4@(X1!5--4$E" JFFIZDR_GFPJ%*#;ZL52LI6&,R,.04,SS2O/,[!%1 TD
MTLDC*B(@+$*BJ HUEN-^SN=R6[;8-/*(D/$N56.O#'6@C0N\CE(H(8XE+R2.
M50%W=B6+CCCCO3+6S=_!A_\ *'[2_P"A7//^\&8Y9M\5C_*'J/\ HCA/^UEQ
MY63_  8?_*'[2_Z%<\_[P9CEFWQ6/\H>H_Z(X3_M9<><U]<_\8-__N=/_5]3
M6V>K/^3G4_\ $*?ZYLZK+XXXY%ZY&TXXXX:-<I!R9H2;A9HB)7)X6:B)DC8Z
MADB.#Q,DUDBMSJE*<R15S-01,J4AS)E.)RD,)0*,O;IV[CIAUJ]BHF,P>>Z)
MM$9(P-UT(UYLUNEDH&9*U3F6%9BI%G&PU>7E4635!T\;MU2^TD'I:BH"9DX7
M<<2DACE96=>148'Q, 065B&4,%8%D4D,""0/&IW:^I=ZV6K:J;9;2M#;D6:4
MFG1GGCG2M:J+8IV[-::UM]E:UVU +%":M.(YW D&01..Y]UY>[Q9C3--EG]C
MF I;:X)2&KWD,SEHZI*L%'J,%FD&K M*V\N 1;,DZ\/,S!6*GS#V$0:2*Q7:
M?WS/=Q5X^K"T?GLJ];UQ#3"$=Z!I<A?;8!='J#ZI&@XVY/JRSEV5-KJ3]208
M03[\7>/G:2'S<LD9(BW(&\<2]RJ@ "+PO+B.<F!R7@0!SP!Q\ >@'IC4^WM,
MZW=Y9&WOE+.:IFF.V[1WI&IV_?X7>44!(S^^$V)G9BUAS_2#(OPZLMB=QR!E
ME,O8)NPT:=TN5ZH/<$ T=7-!BM35EG,4G7(N$D8===WF#: @F9 =26@L93\3
ML\<W9L4X>(5(HV7CO>>STC=C;T96G1\=_'K7LCK[[VIIRY&N$R88<6KIH*D:
MB,H>;&()\PDO\D##WS>T=U[8>N+7'".G"C,WQ.2P(Y-@(%=)%50O$!5>-"!C
M]4+]WQKS<_:+U%N56O31J>WUH:TL$Z4JP+7I;&W[EM5JY=FMM:GEMV:&[[A!
M-,)$+FPTYS:2.='''''6J)IQQS*^(9)/[CJ%4S2N^M%Q/O@&2DP3$Z4%7F0
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MJG,HN51)W6:6J:13!.1L4&Y;Z5@ 4I2E*4I"$*4A"% "D(0@ 4A"%#P!2$*
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MJ"O5TFKB.?C&C(QRJ*=7[Z&%-=D:Q>@IUY;D($\MJM(]2C*6MP5:XQWY[,D
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M<9F8)WDR\B^B$6\LSH]Q<NBO9-VV<KF3^2 J#51H<BP.051E!7OB\2\/;;)
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MKC2YQ5DLV*7\NI1U#R)FUHD&O0:?-WQW-SCN2LBUMGFI),(Q(BC%JW*C75V
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M"TN/=V9QCNST^VW&1DXXSJH6RY2-G@:J_MAV H?ET$0<1P@JL@R4:1:R;\I
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M...9:9DDDDDDDDDDY))\DDGR23Y)/KJ3O4WL5*=<-5CK0*CIQ2IOY>$T*%0
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M[7U+6EZ@]G&[P[E#*S2S[1:LDSQRN>;11V;!$\,QSGW;=0DC9,AN,&53H&<
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M*'<OGT57V4Q-(1K*)D7RL2U09IMX=MZU@L5I%OM+V^["[6+<4T,JO;VXB2U
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M=P047U?/P@Z2:>% "7!!!8%<OE0<$CB#D ^I^6#J[7G5[M=*QG52L=[NLNA
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MJA?NN>OQ,(%N+&F( /TW].DU).%O-:*8 $9VM+6"%*!D0>*1SWUM$:B.]O\
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M8SIYM.P7QO>1_"%VZGRTZ=FZ@HUN_B8I59VHVE5U85J^=QI6SBT)IWJQAP(
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MV\S?XSI5J=RZ2"YUHFO-0&.JL"!A'TEAX%%0S5%8A!!,9)V+V87*'AS)+!]
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M% OGR8OT_0)>BAY'P4H"81'P4I0$PB;]Q2AY$3#^X \C^[GDQ#D$ .0Y!'[
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M7&&1QY*,K>C#2A2.=2\) 88YQ^ 58@'BP!^!QZ$$XR"/&"=3%[8_#>Z^]L]
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M?0(!IQSTG<MDS"51TV3,'W(HX1(</M]RF.!@^X?</VA^\.>\0$H@!@,41 #
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MN\<KK*&LA\/[2/IZ _/S\R/0_0Y]<8[L  4/I^\1$?N(B(^1'^D1^P!] ^@
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M4GX)G!Q$H&\D*JT1$) A#"#Y["F#TFR;4:+3.M[5!])HQMVV]5 %0]0"XKM
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M=>S-[#*5"K.+5(0M7,276403L#>J-HL)1L8\(UFGMC<I1J,:\?I.TP([>*H
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M43M+I[)LXIUL8ZE1'5YU7,BN'Q%FDO4(: U-X QM@<M"(R,J$9)KD9K$54D
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M1$3';G(/XF)NPEVJ[TB&K\U?J'%1M>MT>HTH-?KLN_E[JE)-HYNK78.>;.R
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MU:^FN2ZT5>] V&;-A^&?C;)6+SW%ZU98<4IIY,D,JNF[MTW\U(LVCE$2%DR
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ML$+8+?HP.VSO\*JG$N'D<\ !%$@^/G?1T^WDU(L".<V9Z 4^TO2A"NW"G\C
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MFT8LT$B_1-%JU11;I$#Z$33*4/MSD...<8DDDDDDDY)/DDGU)/S)UW\
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M5WC;=PVFZ@DI[G2LT+49_7KVX7@F4?0F-VXGU4X8>0-:8 >? >HADS>/U)G
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MQX/R]<'T+WIS>QL&X2WFI0[BLNW;EM[U;#E()$W&E-38S (YDB59BTD(X&9
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M SJ1]OHD<W1,NA$,Y7/725@5KY%3(1$JBHJ"P>H%!JC%@[%V5@+!X+\I_!6
ML70ORJ%+[@ 5D*/S95"D_E ]*(' G\H'@GZN=[J&GZ!G47<X.HS2M?:7N.-
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MIEBB "55V ?J*F/W(W^ACA]5O!1]LV6B$(F4I$RE(0A0*0A"@4I2@'@"E*4
M I0#Z     'T#GZYP4O.(QH"DF +O!#R"7G]"0"'DIUA#ZAY\^2IA^LX?[DH
M@;BBJL8_M/S)_O\ +Y>?QU@22?[!]-<PLLBW(*BZI$DR_<ZA@(7]_CR(AY']
MP!Y$?V /.N.;4R2$2MDE70A_G?XE(?Z#' 5!#]OD$O _L'G2'3QR]4%5RJ94
MW^: _0A _P!RF0/TD#^@/(_<PB/UY\Y2F.8"D*8YS"!2D(4QSF,/V*4A0$QC
M#^P"@(C^P.8ES\O']O\ NUYKLZEL?&\^VW:IA^SU JH/]8^M,!_]T//G]G/6
M%IE/(>2M!#S]0]E0/(?N\^_S@%&[A$ ,LV<H%$?2!EFZZ)1-X$?2!E$RE$P@
M B  /D0 ?I].?KY5WZ/<^4>>WZ?7[GRCCV_1X\^OW/;]'H\?7U^KT^/KY\?7
MF/(GYG]^O<'Z'7:4;<J ^'#,A@\_X2"ABB ?M_0H!@$?M]/6'[?KSL#.=CGH
ME(1;VE3#X!)P )G$?I]"F$13./[@*<1']W,8B0X$*H*:@)G$0(J*9P2.(>?(
M$5$OMG,'@?)2F$0_: <_//0Y'X_W^NO-9HYUR?K+">2$5"@@](7P@]3+_*%\
M?8BQ0$H+HC^TAQ\E\B*9B&\B/68N?<L1*DL)G+4/IZ##Y52#]Z1S?40#_P"C
M./I'[%,3[\R$V<HNT2+MU 42.'D#!]P']I3 /U*<H_0Q3  @/T$.9Y5P01^T
M'^T?[_77H)'IJ-TK%O8IRHPD$O28"F\!_AMW"*@&(*B7J#TJHJ%$Q#E,7]ID
ME2 /J+RMOLOUSL\[K%$TVEU)&8@ZQ2ORY70K,W4J?(8'=F=T)<#:_#56SFC:
M'=JS.1A58#4*Q(':OI:MMEVB"AA=I.&MS]@@F\\Q,V5])'"?J49N/'DR"WC]
MOCZBDIX JQ/\XO@P!ZR$$([2,=Z#/8J4:I*E,1PR?,W! 50<(+I'0<-UB#^E
M9LZ;J'3.4? *MU1^P&X03RT)A+'A@592&Y896!!#<64Y /U"L,JP:-G0^NBS
M+Q;U!!&,9\$'(R#C)'T)'@C#!2*O.M&_U/'6M+P1ZB:XUY92KV*8WFE#%1V-
MQ]M[/6:SVR@5NI5=R="S,<X>21W53@ITK0K*&FDR1,I'QY#@HG:?'/W,4^0>
MMA$J[<X^2&\@"A?J55!4/]RH7U$.'W*/@P>#% 0A%FO2VHT*]$LTQ;Y;0ZO6
MZA7:)EM M==KA8[/:U4;P;0:BBI-,4225PE*7/G,G3YN:20D8B,.JS75?@J<
MQIGB(B(B(^1$1$1'[B(CY$1']HB/U$?VCQ3<I:LM@2U69F<<YI"&4/*^'9@K
M!>+ER_,(J1+A5B# &1_(%D5.,@  ^%5\'"CP!D$Y& ,$DL?);&0!@;8*6WK<
MVWFX9+T5FUE6D(U,H?ICGP& TG$&   " V6/[S8OCP#=04B^?EC#R!/9.C2\
M['T/0(&LHZ#)XY:EKDEE[QNHY9WTCU@6%,T0*3UE1GH,ZR<U!.'+5^S*HW=I
M.6:I% *:W.2@BW6JS-/$""^$AYNM*&#ZI3;!,QQ; ;[%3D6WNME/(@ %.H?P
M)O'(1J)@('263^@@=)5%8GGZ& R:J*I#!X'Z"=)4A@\#^HA@$/(<8Q3-5L1V
M$ ."V5).&5E,<T9*D,H='9>2,KH'!1E8!@YXB6-HV)\8\X!(((9&P<@X('@@
M@E3D8.-53L%SW;;SFT:S2!KQ;)JIR:O7_KV]D9&!K3ZF,UF]1F-STF ];=N2
M(6!,)9&-4>K-E'*B[PJ"+0K,+G,3-*:GFLWE6B1#.MS]]JR<ZC"H2C>:9U71
M6#<KP[>.F$BE1>()K-V[@KE$@>^W8K(F\"JKZJ:=9A&&9:'-4^L3UCQK.:;%
MT:UL<]R'W*I9]1ITB24_C7N\;9DO=D+A:,Y="T=IUAZY>^S#,'HIM6R*QG/+
M"^LMOT%+.,MNEZ2>I7EHV1DGXR30D=*OF[.3=A$NIR.3(5./FINMD8.IA@!"
M^R[?K"8A14$H3F\ -6IVDX"N5AB2,AD=(Y("P2- !&4[*1I.2UJ2-TAC>W*Z
MR*K.J3W)8R3W 7?((8%E=1R)/Q9YEBOB,$,Y[2@J3@=XS=1[MVP?(':OF#IP
MR>ME $#MWC-8[9V@8!^QD7"2B8_SE\AY#P//FY)_MM4VT%JREEBRE_ ])AV%
MVCCD  )\T[2(VF"?3Z>M1TDE(G\>!\R7U 1\B,8.5)UX.R_U21GZCY'\Q@C]
MNIA6Y*K?4 _L/S'Y'QJ4?4&^#2]FAV#A84XN[MU:F]*/@2 ]<&!W KB!A  .
M640*R*?SY*214 /(&$!NE^X?T_U#S7!8OG<6]9R;!0R+^-=M9%BJ41 R;Q@X
M3=M3@(?M*X13'^KFPW3["VMM5KEH:>GY:PP<7,I%(;U 0LDR1=BD(^3?J2.J
M9(P>1$#$, _4!Y(47RKH?U2&'[&]?W$9_/Y_)G:7#*WU&#^T>G[P?X:J9K&O
MP_6;XL4OU398GD.=T#N=E4WV#A-2J$/)QVA:COM9=O"W1GH<PO*J0<DJA!1E
M@>1C-E$M7B2C]DX.Y55E7":MQ/W^W*@_B\:+%=8,[Q+NXTPK,=;NO7K9ZI"(
MV6_M+ YD\LSS69!M7+]:J1^"2D:W3LZ_R,+#L7<P1XSCS2(NRH*A\RS?6VQ<
MDQF(UA*QCE)Y&R3)K(1[M ?4BY8O6Z;IFX2-_G)KMEDE2&^PE. \?:;'T!_+
M\QC_ &$:^_CCCAKS5%OQ9J,9C?,LT5! A4+%69>H/U4R@ F?UF0++QXKB'W.
MK'SSTB7J\"*;(P%\@0?%2/-B?XG]13G^M?YA*W!1U1;S5YLC@ $3H,I99Q5I
M OG[%24_&VIU//@/4@D(B'@.:['+IL\O<HQ@^L3/$?R/)?W*ZC\M?.7^4)LP
MVCVG;K*BA8MZI[=O,:@8 ,L'N5@^@\O;H6)6QGS(?.<X<<<<E-:1U8#D6ZYM
MG_69LY>2Q%]VRZWZB\QFLF8*K%;26FP$/"H7=T[,V49I-:J5S/OD$#N4UE9)
MNT,5$#IM5!R2[[$5R)8[77\WVQO7583K#C6;9;.*.YF*96.R5Q5:4T&6CU_P
MA5X>Z^Y+2[&*6=-D#OY!Z\5(X3;*.'J5:-;K5AN,[%U>J0TC8;%-NBLHF%BF
MYG3]^Z,0ZHIH(E$ \)HI*KKJJ&31;MD5G+A5)!)10N5'?6S>6<V2NCF%E>3*
M]?>VENUASP\ZD\KT;(M8F3E&4A"2LA&/F\;)/6C&13:/5W3%PX2*Z;I%-ZPC
MY*E4.QDEPS.9>+M'C'=23 5E^X'5_7/^&E!)R..W-HZZZV;;*<.T[%+8I;=3
M@V46]LH[QS:5=HM[,'FN4I\#<YJ5O;,LI1@VR[*T42+',+,YE>S]<<Z5=*+6
MM6A*_0*SA\/2^OEOE(M5E3875(>IPT6:^2[Q&%5G&DNH@YM$' 6649O0@Q5
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M,-,KIU!_O>0KLZW2'R(>'S-]&.CA]? #ZHQH _0!'Z>1'Q^G.FV)@/ZRL/\
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MC!&/%EXL X8:J6XY;3_<,_BC_P#%D#_G?Q/_ ,P>/[AG\4?_ (L@?\[^)_\
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M_P"8)?7Q_?"G\PB )$#]O[/4/[/V_?[AQZPPF!Z  #]G@:;ZZ7SV(@!ET"B
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M.XV)LM:53^909+J.$2E4^UU\1;L/%4OK!9Y?IA'H6#N9JK>D8)G?\?\ #-;
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M5^!Q/^\$/[#?^+C\#B?]X(?V&_\ %SE>.&!]!^X:-<5^!Q/^\$/[#?\ BX_
MXG_>"']AO_%SE>.&!]!^X:-<5^!Q/^\$/[#?^+G)D(1(A$TR@0B92D(4/H!2
ME "E*'\P   '/UQPP!Z #\M&G'''/=&G'''#1KQX /L !_5SSQQPT:<<<<-&
MG'''#1IQQQPT:<<<<-&G'''#1IQQQPT:<<<<-&G'''#1IQQQPT:<<<<-&G''
M'#1IQQQPT:<<<<-&G/ E ?OY_J,8/^H0YYXX:-....&C3CCCAHTXXXX:-...
M.&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C
M3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CC
MCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAH
MTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHU__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g314883.jpg
<DESCRIPTION>G314883.JPG
<TEXT>
begin 644 g314883.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?1%!,4$Q!5%\T0U]/4D<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!%0$2 P$B  (1 0,1 ?_$ !\   (" @,! 0$            (!PD&"@$#
M!00""__$ $80  $% 0 " 0(% @0#!00'"00! @,%!@< "!$2$PD4%2$Q(E$6
M(T%A%Y&A)$)Q@? 8,E*Q)C,T<I+!T?$*)39#8H*RX?_$ !T!  $$ P$!
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M*?[,=YV72'/F;FDF;G,!7S*]/TW#TDT\5,JQ.>](C+A\I-]9(BJOYNS?"O\
M2/&C=G \GR');= H4;&RTT6FZ>0@+ +DRS8= DS'RU)!#@L"$?R+-OZE>T/;
M'M'@N+?)\T.>C7/QF*V>OQ-R=>.)KS?.:YL&J@795<.(2>+2:2T#6B4$_*[[
M551MGC.N9JK"I<SW/+/V_P"B5;&Q5>:WU7:EYGJ^7KH(_P#*#KP=F 1>4P#5
M:@.?U%0+%%&/'#]5BGX2'0P+R][%ZJ[5C+/!=;Q%S?C5!2N<,ZR$#'SFQ"C8
MJ.B8V_R=F/-,YS41DN>CD^'22_+:^;"-#_4'$'$K+(1F_9CH6>J'O;_0-4:?
MD^'TML%"]?W6.6[IAK!\7_NQ3S2R-^'$/59+_#KLR:KW3X),+/+"IFDO*@C[
M3D:LP=IB=0,0/(BHJ/AE_H65B_RC$5/AS6JA#?(6X?=$D^65-'POVWDIQ.U,
MS!NRWFJ3FK/V2Q\B>^_48]K<@_&?U!]L\A$ )R^CB%V14*)T3GH0R\M,Q4":
MP>VK52$ /":?" %*#JNOK7/+#DG4NC<NM4F_/\\V^FQTKYVJV4B*AMR@0#7?
M*N^I+"MC#L&/1SDDC*9(USD<BK'WE@7XIE('0^^OL".#"Z"&PM,9?S-=^Z/.
MO.=9(X^=O^OTSEOED^/X1RN_O^U?OEC<9H;9QO'ZW_UZL670W_>M"=&_^;'T
MQYW$G&\WS''3_P"SP<IOQS__ $\VJL4_(!/[$'9Z'?YZ]'AX>'CWT*]/-Z@?
MB =S]0+48',62['E<Q:37?)=*:0N?D9(Y5*+R9Z-()Q-U(CG/_,U<,U0;,B.
MN*2P?],T6VMZM>W_ !?VYQB:GEU\J6M?'"S682[4<+9XXV5$^F&YJHYIFS 3
MO^IM;?UDIE':(U[1#5)B)%'T0_)&Y-UKH?#M]0]-Y;ISLGLL[.L@%F'],D)
MTBHAE1<5\WR'<T5E&BP6=-81RAEQ*CE;&3$.3!#?<GL[#S:TT9PF/D^B1=1U
M+0W7TNI%![[_ !\Z#Y5[!;Y543]6A[&_J=RWM6DL6QJ\GP)8*^2C^6C$I(!I
MQ]7/[0H_<<CL,]#V$,'=J^MWGW1ZCT?BOJ]V+JG):86^WN(S$=W35YU85<A,
M@AMZR.[LS*L*8<HX6EH9;.W)AB(@5(0GROE9'&]?*3MWA,/V?V5Z9@,=<\FZ
M;)^(?P$/KG*NB#D)?6G$._<LRB'"E#WE7*7KL=F"Y:PF8-1R(C*LA@E>8(<R
MD/KR[1_0WWUP?NGAR*\X:NRO9,S71)O^>.G^Z*6))\"NUF14Q[R+7'V,SDAG
MAF^\?G39FU%RLK)JVRM<*ZIZ0[G#[&79>A%?ZU^MVAUM5HV]'W-CS JZW<]A
M.^ BIKL9*]]GE<S07,R2-T40><"<,1 -:?;N/AH(U9\94\'HU\;NG_A_(J;J
MNFI(@21FOF_44FM*_#FTY):\SYYW&GY*091*QHM[^X,__2S)QO/<17_&^#;]
M([\?F4-L4*VW)N_0QM2&<ZMV#DM/';I[K96P?#'9-S;-\+6&8(*\S^$PM)M+
MR*\UM=E<U3:.]61R-T&F!I QKJSA69&2/=9V(YAS6?3]U6RJY[$7Z_B-O8GU
M_P Y[!XB&A/LK'([+,VPNOY;T[.?3%KN8=!J4<ZEUN>(56I)]ISG!7=/.[]/
MT=$0=36+'0$-?%K]>M_)MA[*>VO'J7;:/V/*ZMZWVI?0O;36]6Z$:=#F=IEK
MW],Q7+^5 43ZNCJJ#4G!-NXKT%'79V5+.%6?[ ,K2-D+,=4YQLM5L\+E-MFM
M%K^=3UHVZSM/;"GVF5)N(IYZX>Y&'DD<%,0P8A$B>JOADAD'G2*=BQ^#>3X^
MO#:Y/#4;:EG^LNT,_P <LHI8SB0PI5'AH4K21=9+2%H]S\:J"<]O\U#W1QNF
M6WCEQ\?2XXS$FK:;:.1,<J6TJ5:4*SV8G%)765+TAKRZ2M_DS,X@WUA[QH^A
M1:KD_8ZVNR?LAQR8*JZ;G*_[D5+IZP])$S'7.??F?IF/Y[OQX)"@E1'SYZ\B
MM,M9_0971O(;+Q.O:GC.NOI,K[ </C%']C.'16)N2&G>X:NZGB#G1$;3B&ME
MB3YGIMF(,LN:+(1_^%]M!478CQV./66;>(=CR/>^897J6+E(2IT@3W$U5C'^
M7O,S? 3R5^BR.D!5?N5VDRUT,;27@$J(\<\.7Z?JA?%(]AKE.LUWYD"1H_QZ
M(+_IR:BI;XU_)_3W4-3*6_< M8$NT#6AGC=%\]WX;D*-;3"1MBV/T&Y/CU99
M_-3H!?UN-WGGY!4'B[/GV*LDVK",L>'AX>#O1ST>'AX>+TO1X>'G044,",0:
M9/"*()!,2441(R* 88>-TL\\\LCFLCAAB8^261[FM8QKG.5$15\7Y_'K!( )
M)  ^R2>@!_<D_CTL'M%U+5Y:DRW+.3S0?\<NY6Y&,YW+-$XD?(U\ R%[?J=M
M UJ_--SK.NEM6MD^8SM!/15/T2N.6-9<Y!RO+<4YSEN:8Z"9E+F*]!OSADBS
MVEU9DRR&W6CNRW?UFWNBMR#;FX-D_J)L#9W_  UGT,:M?J\$7V'7[CV_TD$B
M0="B=B."5YD2QRY[@.?LIGU]VR![W/$L^M:"(G;6BJGW)*1N5$5WVA6QM=Y?
MV_Z)_P _V\>Z3\*+C7\S(?21^6T]=%"?Y7,"8J/L"INZDK0>H[PRGDKU]Q5!
M*ZIG-PR,/^PX?S5QH4'[6O,5FFZC#Q)QKQL*(*Y7+5R_B4!9Y_,>6FS66CS'
M0B>U9#'\DWU+O+? UO.MMLHS0F[/565>T@<G.5-8$8X\6<&4TACU"KC:M3"S
M&P!GN;7VC[?0^L7N3Z]\@]B;&]R<^UHO9#!459E= +F:HDD.6RZ)$,VAN 7I
M;.&I(3J X=QYYX7V@K="RS1>OM_0^^>QN.]E])GZSUWT'K_PG;;O%:3A_3*:
MY.U>[!Y5"PK1Z6QV 5D$_!6Y;H3SL&ZN97&B)!"0ZP<2B/D<WTX]>.'\SQ-'
MU?EV<TU?9=;P6-N7F;C5W6RT5)E;2K%T=1AP#[MZNK:&EEL?A@(4 ["IH822
MUG?$/]DP'_0<:J4;NZM99B1)IGM595F/U"5C;,9J6HTIK?/=B?(^8;XZ\.5?
M=7O&VC) +QE98+:6VI-<O*<=AMKQZF_PJ^+D,',ILI.666[57C^5XR2+\*#.
MT_U/V>EO#MIP# ;C$:4F,7,2];W=URK'1WTNK3"\VL#HEHJ232$#!D'S&S1F
M7LPT@Z)6R6;A72SD*3,^)?Q"_=P+U>P[,EBB1#>W;FO(_P -#2?9*@QE*YSQ
MB=S<B/54D=%*V47,5T[/M6MQ&^:=DE;5V#'MC[#]TR7KER75]6V#EE#H1$BJ
MJ>&:.$[2Z0[ZH*+.5RR?/_:K0WZ623(Q[008S+*9OY8*94TS^K]1V/:.B:KI
M^]L5LM1KK-]@?(Q9?R8,#&I!6TM5%*^1XM+2 ,@K:H7ZE^T) U[U<1+/)(XX
M+C'YG;7D-J@YYT#. .ET: %/QGLDE0.GLQ)9RP#$EV8#?ZF^\X?T\]O8_:GM
MZSIRVG(99W9P]>*XSR>9TJ5"K.SMYY^/E-)RSI-WDLES1F^$6-C87%@?;6QQ
MEI:VII=E9V=@1*9865B?/(4<>>7.Y\Q1AA,LI!)$KG22S2.>Y?E?V^/P\/++
M       Z 'T !^ !_ 'KCAF9F+,2S,2S,Q)9F)[))/V23]DG[)^SZ/#P\/%Z
MQZD_B>W#YKV+EG0+)GW*K'= RM]<L6-94=1B6P[+[_*1S5E5*2:P<R+ZD21Z
M-C<CFN<UWB]<P97,.G;WGQ;EE_PEJKBG",1K6PVE+$4Z?.W(JL58I KS/$55
MP%-"Y\$HAT,D#W1.:OF%?LORBHBHJ*BHJ(J*B_LJ*B_**BI^RHJ?"I^R^,^R
MDC]BL-4MSR$&>P7,LV/166:=*D]CV3EF9%6//6^2A54GL^B<PHHHZ"]S,*36
MFJPM=37%' ;:4-N/,W=A"ZZ&^I-/X;M_$^G\H4<D@+-6>LW<GI35&;I%=@8R
MHW(\;7BY+Y[8:CR''R!Z;0*16'(Y9+_ZW52<,6C//Z-$QZ(R\]%HRHN&:U>I
MQMHRZR&DOLK<-&*"2US=Q84=D@9T2P&C?GJP@4K\N7 OVB8?N_:F8UJ2,<K6
MJFR%=N<_TI_#?>]5<Y_;O4%SG.57N<]9;!7.<]?ESG.7Y5SG*KE<JJY5557S
M6@^ES%^7-5/I<YJ_4UR?#HW*R1CD5$5KXWHK)&.^E\<C58]K7M5$L(L_Q!M@
M=P_URXZ-@,^--Z^;; ;*#2SVQI#-4[F4I#LQ73T[1H%J(R(B%9>$QV)\I$L3
M) 8Q&O<Q!_.8+[C@?--7:.@TJWG-")B+A26<CR ;H #LCR)(Z[(E?]/?<O&\
M!+W)/E=58INXF>?#,2O97U?XE@M556:NDF:,6=Z4^-6$0I8OX*T^_C'W=Q5>
MS= )5VUK6BW7"LZ!<C5UD:"-;@LVNTF8#;0"3Q060;94^Z@IS)X$?_4C$5?*
M>/W<OPB?NJHB)\_/[K^WQ^__ $^5_P#/QK?<+VBLO;CJH?2CLB'BH:W)562K
M*,.TENY&B5YME8RE&64@=<A)))UN5]#(01XQQ&#1*DLS9IY,'Y)RZJNPC>G]
M/E.H>'Y(U8+ZU'<T2UW^@AC0@7D_.G3_  EIKM"B)!;68;2:_ T,IFDT$@_Y
M< 2P<<9,\=Q65-$Q.TY).B+XN[V/TDP49A2C#Q155B21T/P>AON[4GNSWMS>
MOB*MHP[.0OHS:++7/&6(!6KKL+HK9<TP&M5Z(O@G;LODWB<BZ%\93@' L Y[
MH[75G;WOVB">JI(()K)JSGW-OO1.^'0..R.'M+Z&-6?YX-^$8DCXR(F,GG\,
M''%ZWW-YD5"V7\IB*_8[BSECB65L8U=FS:05DB_"MB0FUT=?"V1ZM^%^48JR
M*QJIIT7?6W3]K?;>Y'! )NR!VATU2QT5-G*.K"&I\WEJ.%ZJ^&DS- !74=6Q
MZ_=<*$R:=7$33.=>Q^&5S>G];O77J_N1U5B4P=]F3K*FE+1L!0W+<>PBRD,@
M29K)&R[?0Q(M= GREB'7YZ>)LB%PKXQY:S9.(NK+WJV_)%(K^YGT;J-Y23Z_
M?\2T94;K[6:CKL@>I%["X]/</O\ XFD.QQ' ''R%]5 TTEQOMZ$%CJNI(^%M
MU\T&JG?4ZZZ?95"?5-?XH>A#TGOC["E@K(Z&NO<MFY5D_G\[F\!E*H]&?VC8
M9!,QB+_\*JGQ\K\H+YEN_P!I;]'W>UZ'?N>MWN];H]C:H^1TKHSM+<&7$XZR
M/>]SD$4Q!(U5[D2.!C456HGF)>65QV8X^/PXR>SEQY<S$?@M""2)_P#$J3_^
MY]!^;W+R?,\MR2 A.0Y/=M0'Z(35JK=01_!"N 1_\O1X>'AX\]#/1X>'AXO2
M]9[R_IVXXSOLQT[F]\3FMID+*.RIK4;^MJ.^%B+ L!7*D-E36PCI:^YJ2OJ%
MLJ^>8:9$58Y(]U?TA]Q<?[D\B&VE5"-1;G//%I>FXB,E9Y,SHWP++&2"LCOS
M).7T$<4I^;L)D^N49I-<6Y+.L/8S1K\9CU*]G=GZE]ISO5\FI!]?$K:?=91A
M+X!=IB2R(I+:CF3ZDA;8P_;;9YLZ=KVUE\*),YKA)389XE[L]M2Y[&:155Y/
M,C'+7Z'RJ.V.6C?0*4/?QLQ_RJGR!"-0-9'].??5_:'*+'2[TX+?1%WP^V&=
MSTB\A!!V16(Z%T0=Z(#P(:DX%-D;6>F_LC1[?H?(O6_80<=X_P!NT.B['V[V
M8N+V;8=NT.FU-I9#LY=E1E2NL*6OSE:T:(*\D.D-6I.(G;I!K)Y5:="GK1ZT
M:#@^;YQVFGH:3U@Z?Z[;S4<C]JK7H=U<A<I]B>0$'PV>AZ57Z6TF,FLBYUDJ
M[[%6/Q &%HXS<\OV:\(6%MUN#Z)G>M<WSW2N:6X%YGMIG(+_ "EI*K_R<\9P
MSGBML(X'_?'E#+1P=P$CFF!%#&!O:PF%6IKK;W,>P/L=2=,[S[#7O_%C5^H7
M>:T;JGH73TMI4\_K>:T<KBK>WH0 [$RPV]S?YTINPQ>@-0Y+FIJSZH@BR;*M
M7%6O%;-NY-635;/CC-\\=A:+G9IM46Q">A&8);Y?D&<TVTEDX^@RF)SOXI6\
M?</%\1Q%>.Y+CLF[D]5Y;-/&!-4TXSC\L#EY1K9*HC5R_I_A.Y8\3#1R7,1;
M>NI=D?DI'9!Q6TRG1LGG]SA[ZNU&1U=4)=YZ_J9T(K[6J.C^X,6-*B-=]+VJ
MK7QR,CFAE;)#-''-&^-J/:!KO4CV;%V8WU"^O7MMJP*'H$*RJRJYE[+F0, R
M>[1GQ]FOHNVB##8_42)'&/'O:_-VI)+)+LG[G9ZA\_TG --T/!!$5@_JOT&R
MI.G>L3+^V2DUN8L^C"G:+;\;&QEPR"Y@K*$J)^EI@Y(A2:H:S,KY Y2(;#]/
M;KL7+,MV[E^XY1M('SYO<Y\VC/D@5&F5\DS4EKKNKE_D:YH+2$*\I3&?$@=K
M7ADQJCXD7R._Y&#=6'R'1QVE!.C *:'-8)1&9 >DV8W\':?8"ZH-)B9,WE.0
M-G,<3FUF*X^<P4:TE)80&_,7C9$H06?C.4E\DTJ5+/@UIH55NLRDEI^_AXH_
MIWU75;CG]WSWJ<K5[CP'2D<BZU\_4Q][94@L$^6Z,-%(]\BU/4,?/4;$.9%=
M AAUH#&]7@2M:W'@_3!\MZ0IT6FW7DI[1U(#)6;?7E.J%:3;\,C*P^CZ-X=D
MM^2&R(94N@8SH/&L: E*PLGWX7SU5XWF?N=9NA^U/H\/#P\T>G?H\3'W M++
M8@\^]7\P>37Z'V0T!6?TUD!.L)V<XIEQX;SKU[$]B_,4MC1J+A:Y\J,C?9Z^
M%&R?7%]*N:J_"?/_ "_T^5_T3]_[K^WB3<!<[K?L!WWV#(5"*#-6/_LV<DE;
M+%,,[.<_.2QZ??AOB8D<K=+TV>>L_,L>_P"X'C0X_K>QK?H>8QX-341]94%$
M[_!T,P3./OZ/C0_,5/TTXN#]>H_[@8Z99.%F2'YO1^ET%3TT^+DIORKDCID%
MLJ'CYV4AHZM^9Q]]>G)J*JMH*FLHZ<(>LIZ:O#JJJN$C;")7UM<-&&""+"S^
MF(<06&(>&-O]+(XVM3]D\1'V$]X\;BRM+R/DNEP]C['";S!\X"RO02;"@H*4
MS>'5([=A9SR,"=?YB@$M&R6:9\V::$]&"%K Q'+(WG6>E9[CO--SU+5.F3/X
M+,6VGM(Q6M<62/5BOG:$&UZHQYATR1!"->YK'$D1(]R-55\J [+7^V?7.>)V
M3N/J1ZV]1Y2700ZUO,:RXT-?WW%9"41MDTNMWL+()DT0E-(IQX%2YSDE18HZ
M?[T#A8W7%Y9VJ+:0IB**B^>B,?EOVK_&%L5%QX_3I\L%'FGE9?)0P+WKS>OC
M<1X_A7I/D#E?1?\ 3\7OWC%Q86F?]2U>/2K<:17_ .[7&+DJ,<]Q'CZB5:0,
M[Z\5FX]M3.:>X/+,NG1.@XDWIL>W]?\ <[S-<R[/58ZYJ:^W Z[S:4V".2PC
M(.&^\=.P$&[^5%*'++(4Z6[H006O$&!!&@#""'A$$$%AC'&%%&C;".,-!$UD
M4,$,3&10PQ,;''&UK&-:UJ(B%>B7"^.X[+F=UY)JMMLZ#N.7QI^:FZ2<-HM3
MA\S6"EK/AQ--)&MI)7#W<Y#3ZN4F808^KA;%(6Z!#)9 ]YN_N]<?7'<;FM*C
M'V-I#%C>?H]%<Y=AI6S"A'1M;_/Z "RQT;_K18U;4)&]%21&NV;FIOW0Q1:C
ME3+*B.*31;L5G3PSN]?TRJ0LW179!\19?&?BBMO;$<?MCVUR?N+D(Y,ZZ%V<
MSHTP?)LTUXU!31D%N4S9LG^+4NK5U9KUA/0XW)*_R:A6U:'?Q2O:&3MO:Y>9
M9JP^]S?BYQ]+"HTS7AZ'?N;^5U%ZJQ.6(B"E^E^7IY%=(C/L7A,+D99+Y5]Y
M^GO?(]\DLDDTLCWR2S3.5\TTLCE?+--(O]4DTTCG22R.57/D<Y[E57*ODW^O
M&/Q.PZ2/_P 3#ZJOYQE*&_VNT6XTK\@'9UM$%]%=G/\ $4$)1U5-IM$;2TR&
MU@9MD(,468(+*\942T,\(\7@2,U8SS2)/B 7JX!9R%['=*T)*KW]LP4'KKUQ
M5RO)<C[U]SZ-VFDUV<SN4*;4*YL<683A-J>)*9,.<(KT\"5C)JL&;R)@[P\L
M>L/7KCN:H+YIPM)?Y^#5>QL=AU\3I$[)<CB,]A<QKN 7M-GQM /6:4W4E7X]
M4RD-H#K+6%/*JXOTNP#F<-XVOXWR&DL,B9/D*F'GS^W\SQ-3<TW5+:'4=4YG
MKZ1WYC>3'FSZ3-,KRK@>4ZWL*"JS,V%F2;$FBR%R-LJK4O*YV("SN?(,5/C,
M!O$^/0[J"'8]%48*_B5=E5&5B\K[(Y2*LU=/'S,VBM5--;-/Y9K4NQ3&RM&2
MDJ^B34SFR4SRK71*DTKZ\/+'.>\%X)=U6?)TD3FU\]WLV/TH.W?*?H=I2=&Z
M514G#!,\E]700/L\1GLAH@[1LM==V$UO$]-2.)?!/&37MF9I,;U3:9K.($RE
MJ[$)H P)I9\5>TREJ[(BIGG.LKDMEE3&F$U-R%/=73JNX"/JVW%I&&PZ?=#?
M'1>D$6H>:LQ+J A"N)GQ8,W9[(/1 ('^H _7H?R?MG?Q7'YN2T6Q4AJI&<TA
M9WNK7S-J0TFT9A5^-2"X9D9QU,NO;>HM\[@BCJRP#MJL\VKM*XL<^MLJXJ<&
MQKCPY&3"'UYPLD)01HD[&3#%C2Q$#S,;)%(Q[47SI\/'O]_]P0?]P?R/4>!(
M(()!4AE(/1!![!!'V"#^"/3"679<IT?[,O<N;1:K2HU6&=6YY<C\[Z;=?T-8
MPG9#24][@=[:M1O^9?6N;J=(;\J^SOCB/F=W#L]ZDD+!/%T[V,J6N3[A58=Q
MOFEV2/\ 4[]A1[>NZW3A&21-7]S):L.&;X54$@<Y(T7S^?X\F3D?KWVOO!R@
M\DYMI]JUDZC$VX ;!,S7SHSZUCL]7:3 9P"1J?'S!/9M)^7-1(%5[$<T><<T
MRPTTQQ0??^<BQ0'KZ4:%I*2@#Z6811]?7UZ/Y=F_E=*9SQ,.?WV($U.+17D+
MN.NW>G&4S;-E2?NE=3Z*-^7;\^O?2]]9\:0PG+X3IG8+$27[H<O8;J@PV'EE
M17K'+8X7FLUIH[@:-WVU?5$](K RT21"_N1/^PL<]&Z=M>IV(=CL+>&0.E#?
M79K.5%>#G<5BJ7Y1ZTV-R=5&-29FI16-D(8".TD^5J%6YE@9]12VGX#\&+NM
MVT0GHG2.=X(:9%<2#2CW6YNA4^EKFL<C69NE=(KE<R3[5H1'&K%^A\S7-=Y9
M!P7\*OUOX\?7Z/4PVO9=973-)%+W<8+<N&5'(DD) >(KXTJ)I853YA??S7SH
MG(V2/[<K4?X$T>X>&QDT6[[M*@JI7SJP['WX4H%A$-^',.BP_*L H]63QG]*
M?ZA\\$RUXS+[;XJSH]A<Y\<V52CJ;Y<S6Y/;279;.G(!_C?M1:7DS>JF/0S\
M.[4^P-M2=+ZI5'9WA(!,1L0Q\<X%OU11WLD964L#VQ%#8\AZ?1;Z7_+2S&^Y
M6YU27SD6==FGXP?NE1VT<'IGQTD2'+Y NM7KAU"^."H6PH$@?G>65D07VP_T
M_,R1#66F'A1XPUJ'39]K(Y:FV@2TG\0S7^YM#S63(^H')+*\6ZI)XM3TK.7.
M>_Q3C:Y7N#6FP6*(L [DS1EB?UQZ$,<IE"*]%IP";?[957IOZS,:S&Z _/;G
M/:3*ZD:666QI==56M+?LEE>Z68@L*Z@'L95GE>Z60U[96DR2.G6>59%D<_\
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M9%))7V0DH14<4[/NPO6"5K')'*Q?KC<U%:[]T^?J:]K:9Y;G=O(6+VH7 /[
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M=S K7W73_5[/<NU/17VM  %E+"GZ[11:')OQ&H"NC6Z8A*Z5'V<)%12-&?\
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M 'F0P:&Q:WX_A?B4*-WQ_P#V_/\ IYJZ>;2/XP8GYGU%;,B_'Z?UCGI:_/\
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MGZ/'W%R](4>3IR>TK2;LCJWST#%74AE/98=@CZ)'KMGV?">GV5[;AKC+1&G
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M3GMGVORWNSDEXWB8JS*AMJU7;XL>#*A IJV7Z(E%._X#4HW231V/7I#/7_U
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M=6.<R&@XUZQOKNW]BYUL+[@&HT%EJM+S[L-IBM5GY;KB>AVQ]F)FV=)L$K]
M5?W-!"LE-,.U?6Z#T[:^LGK/<&T^ZN>3=<ZCT#!W_+Z^F5H^SN\9D%OJW;V6
MBJC YFUF%G2RB&JGWT'V[R^'5M>!(@ZF,J*Z#T+;=6UMSN^CZ:TV.OT$D4EQ
M>W4L<Q1:00-%&';%#% $& (,QHX=8 *+7!P(L0PL37O1P#!R?(\:#^AW[,@=
MOD=,VBT%9_BK ._Q.ODXA>TU)'8G9P#XL09?KR9=W:Z,T+*O[%>DTHWB&2A5
M2RD!31%8CL@E!]=_8V4K#\'WT\I.9\*Y-3<WVD?/_67I^G[!P0G.=?Z95ZGG
M.JVEFVYTT5;IJS00Z%^6NS(V.,RI91U#(.BC0LB&DEA?ESO03U=,I_:O+6_'
MX]3G?=7>2]+]C\SJK/2:"HVVUE'0>&XK@C#?KQDE<]D)U,S)2U*TUL*':UD@
MQPD$S**.#?B&>U'KW7AYW);YNFQH#(X0<7T8&37TM;!&B-C&I3)# M)2"1-^
M6PU];>15<7U*K*]%^GXLFZ5^+=WC+<@]?]S3\]Y+^M=CRO3KBV_-Q[ JNIC,
M5TNPQ%:^G&CT(\I(Y( C#2XCS95_/*]D4K1T^WX[?G.7MVU.7Y,GY6N?+9H<
MBSZTWM4.:AOD.]%V%_ICJ T=_+^\L1Q>:?2)CR>+()=+&:J9K'X C+X=>(SC
MX?'HCXNI]> \?4_<;_!\]'^)9OLJ5W-;NKJ^P\CN^.].W73NN]#WF];Q:QIY
M:ZZPE!O-UIK"XYWC)*]J3ELHBZ9D<@@A+IG,!$8.J/N'S?@^RXAZ?<+Y;GF7
M/J5ZY6&(V?KUIJ+;75W7V&WX_76.3SPY.F;8DV=H_! %'A'4NG)E.NR#7VUE
M"6+&)+Y6UWWW7]DO92*6LZ=T0M^4D>CTP66&9EL2Y62)+%^>IJ^1\]^Z"1/N
M02::PNI('_U0+%\-1)[] M (9GO9+G.FZ=A,KGKKG=-=YK,=2U%;F<E+O8]=
M4"3[^LLKGYAK=!D\K"=#/)4._5+4:S"A(#LAZ^)@^+\[S.A_DIRW)4MYBWS5
MVZ'K\JP.=6#-0E2($P4J0PFQ0'P+*VR/%88 =X\GCT$::PF$\#44(/[0#U7J
MI[!'F/+\],(BOO4[A>EKO8"JN,M9DA>S]C4VO9XH]5?C.TAU(V)E;+72P&-?
MFFPI#']<5&HC)_A?NM=\JGEHWH%R.#0=AR#1 G-R7'Z,&V^F9\A#8G4P$>?Q
M=>I$Z2.G*83'$<V29WWI&TT\[I/N_P!3H0M^7W@\F-GRMC0].S_17M&PFNYN
M;/H<SJK1A'Y(^CK#9! B([NJ.1P]A6V @9$,2)8?;6N<I#+W_5_A0W!N:"49
M:#SZ^[D;>;6Q@5KXY;:2%(XJP6?Z6ODK:(7X #<YRMFE_.'M:QQSVHR.O?L*
M2UZ]5Y19:+.]J4173/FR(55V*AAER9<X( (SYHS!\)S >43+F1FSRC.E5:?E
M)$5F1JTNX8@ D&UK5(/_ *VKN1YLQ]5._CN=<BJN9<=X@&5_V_::\_H%X/&Y
MGU-S^& =6U;"45/N?;,TFBB)'^E?H=+1S*_^IC/*#>$8/,79.QZ9TL8@KD7%
MZ0/4[2K&)D +W5[;'K5<\Y)66$/^<$=T;2,<):6(_P D4>,J]5>1_;G"&D\<
M3\8+?D;7WBW50ICRJ[FN4PN$K8OJE6,27]$;KKF-D;WN8V1]KJIFSOB9$DOV
M(4>QSHON.5O;$+E/4OB&5$D?%)UOHO6^R:F/Z?MN-'PA-?QOG<3W,<B$ U_Y
M;HAPT1#7.'L+8V:#[:2.63H3VYD;#[;XC+,E+<FRUI1>U91KG3;5@1]K1<,3
M*3C_ $5$V/8'7KB?WQR2\M[Y]R<A9%MGX%*1AG<><Z/QU(<9!'4]BD'Y70NF
M\C]4SFTNQY>0DWEGKU[6_B-[W1ZO)UE&M9G6UV=GN;:P7'\KYM2QQ.ES7-<-
M7#B6,H%)0UJQMJLKFZDQP0*Q6EW(TZS<<<F>ZR-QSW9:S#7A-83<XW37N4MB
M*.SCMZ:>TSME/56+ZJU@:R&Q!0H=Z1%1L9]35;]R*&15C;8=^&+NCKOLM;ZS
MZ_L_4N><=ZZFB^]F>?:R7&QZ7I#Z: :CKR]( ,M]11W]:&57SNHK&LDNC@Z2
ML-EEB>V*2W;J'IO0]*]0.A>G--25T'8O4\M=)QVU_)B"6N[REK^K7V'T$\PP
M3))I^CT7Z_S_ &$J/0:?IF8/LY611PA1M\:O<+<%RO\ A^J<!QY7&,RP1Y?H
M\=7,7VWM0D6,[JDZ1DBA$HM/D=E8-GC?9<_=OMW_ !CC[:WYE6Y)MM->B=O\
M1Y//&6N7&9<TNGS"V,TM#5HK1[6A21C.;39=52)L\\C(84EEED>R..*)'R2R
M22.1D<<<3$=)))(]49''&USWO5&L:YRHBN+K?2?V2YEPO"^U7Z57G\POJ_/Z
MP73XC4O/O\&EH6Q,]8Z8(:&OLLZ7">D$:VM2381YZX=")8GUA[6HVP'\(+U[
MHZD[HWNKUX3]*P7#*[0U^2=:!HKTUE?62D[31-"G8^60W%4DGZ%6P1Q+._47
M<L(RI8U36-9WWOUNBX5Z.[">[U.@QG4O<KI5IHS.2/DK[:FR^2V#?U'7X4&K
MM*\F/-04^.=5+N+W.2 &6O4+@^PCF9^L.;YGD/<]EYO-P_'3C;K7FSZ:4\Z+
M9K#ST0E\?_9_H\_C:]R*K.G4J2 ';>>%]AYC[5V^Y>;T:LY/&[MW'QSLD:9D
MS-.>+7H-R!4<CM\LN7&/@I:0;1"[, J4L;HJ/V)Y7<]O=$*SM'*R*.M[THT+
M()NFX_2&LILEW8D0>*(9NMK= HV'ZV9"Q'7Q=KDMP<C3K"]GE4YJ?+D3^ZHG
M_7X_CQEO34F KON6PEE(J9[M=9KN$:B'Z$D2>HZSF;'-AN;$YS8G$U^K=F+J
MN=,CHA[.K#*5J.@:]BTL$.F<RO2)ZVLSV5S86M<LBVLKT";"UC4<]7J>Y(D8
MQ'O5R_2U'.^$62Y (6TXQ]1DL=&<?\,H:39?@']DC;/8S4=+.%(Q10LQW!]Y
M.S+AY,_NTZ7T8]C?\5]>-,M/U;?_ )FG/LSK9CV]]4=&FC&EF/K=A_"XHWT'
MH9Z[#2N5TECEKK2+\M5J,CU.RTF@@B1%:UWQ$/80L^I?E'*BN:YS5:JO]Y&O
M&L-%S'DG,><PM@:S"8#'Y%?RT7V(7RY_/U]61,R+^6??(&EF5KOZOJD57*KE
M5?)*\YJY'0-?(;M0_&G9INO_ "M9Z#^W\,/X]=V\)C;CN%XCCV_U8>,P8V_[
MV;+*+?R?Y0_R?1Y^7?Q__DW_ *.1?/UYX>GN(\]G+^^E=$R*DI;:WD?.Y&0L
MCK*\DY[Y7K^S(FM'59'JBHUJ*OQ^WC0 L0H'98@ ?W)/0'_GZ),P16=CTJJ6
M8_V"@DG_ ,AZT/=U@[K5[;8ZF""98-+JM#?PK\._>*YMS+&-?V7X_=A*?Q^W
MAY=5P_T,N.@<5Y!O"I9D)VW+N?ZXCZ9(_I^_I,G4W,WT_O\ Q]PUWQ_MX>7<
MWNO'!F@;Q!BQD?MOS,A/]O[#^!_']OKDI/Z=<KL1-8QZ2NI5T ^0'8N%KW_H
M/Y#D_D_Q]G^;8>&1?X=]K_<W+/:P>'2%\-Z_50LE:GWQ]/STC#7!"C?6YS94
MNN=3*3.C4;*L\'U?2K6_4Z?B8[)K,7[R<9TOVV,%[-Q/IG)BIF0R-:_0\\N:
M3I^7A(G8]L"3R416X0-L\:R.B'*9$Y4_9KDP3PDQ,G'FBGAD3YCFAD9+$]$5
M45621N<QR(J*BJURI\HJ?RGE-[/W-"O\5R9^O^<4_2-W_N7SN?\ ?OUTO[>Z
MC/E,!Z#XN=Y7R _'CR.@<Y( =#I4S\M! /X\>N^^_7;X>'AXT]2#UPO\+^WS
M\?NB?W5/W1/_ #\TL/;[F#N.^S/:,"V!1P*_<6=S11K&V-O^'-=]O64?VVL5
M6?:@!N6 M5JHGR&Y%:QR.8W=0\U]/QHN+/$O>7]^JA%06V%EYAL2(V.^EE@$
MIE]BRB'?*L^HD.32UWW%^VJN#!A59'.C1DI]I;!GY(P8])LD9CO\?+,_),]_
MW(%$']RX'JDOZ\<"W*>STY.*>5^ VSU,0.V_0Z@,NL ?V6C9;NWX6>=V/T.P
MGGX;7JN)[(]L=;;"N0[EG*HP-'K1)XWJ'I+LJ:5,ICYGHGT.&,)$(N;J!_RT
MBGJGU\K4CM4<DF?B&>V%][%=37BG-"##N68O20YNEIZ)JS+TC?P%I4?JS8 W
MO99@B6CUI<2"SZQU>V6[8S[YH:AMAR"9WJ9^%)>]*IU0#H'802;L,]&-B,AM
M>DV<..R$\,[)7/<ZAQT8]P$J(W[<\<CWPM<LSEJ:X7/_ ('I.J]MA<QEOS7-
M5>:Y[+*UCWB=-ZJ2=EZ*_A67ZOJ/QN6"V6KKY&MDD@N :HM?M+$V>.XO9.!-
MFWEO=>B*Z1Q.E.$]O9J]B)Y.SQE32Q\3XEKZ<TDN%;XIUI3HM"96O^/X]/;G
MM/@?;L"<VSW)C7W-[FUH!\YX\SIHR8QWT6GFQ1J[9BRA]*'KH::!O8UNF&]?
M1;+F',+,=W4'PD4_7NQTY3930K![/M6O+>56L2.=29K/$++5;+;U3X;K>7<!
MP0)8F/"'&M+2\7ZY\#]B>+>O'Y#"9CE'(]@#>5"Z'"OKKKJU7W9$)J:,3I^^
ML::,RQH[>6"]DEIDC@B-V4^9JB2FB%4S'4'O1$1J)\_")\)]2JYWPGPB?4Y5
M57.7^7.55<YWRYRJJJOC-\']@^R\XS6LY;@C82LAN+:DNK^DLJR.Y"%)K9&C
MOL XY:NTEJ9BV_D"";"M_3K!EA1TI@]G!.'],\L]]\7HXWV]7G<?(WAOX07Y
M3D-JO07W3&5Y7,XHQ2FJ (?B<K(Z2*C#F$AH9CGV][@Q2VZ,W*85OQ=\PSYL
M4YRK\!E5+SBIIX,9Z?%I[JK2=-+.-%C1Y*HSODOI'T;;^U=CZU:: NC?B;,D
MSH^D%'^1:S# OBEBT=7(3&X>1=:(56LRWWFR1J3:-D(9)%6GLC;3VYY'QSF_
MI[33@X^CDF&ZI)E?7/HZ25]5T_8<Y;.58V]ST*(.JKHMC2E?E[ME'8?0DT]"
M3C=')!7EFD-,G<_L.K6+M?0+S15!F@Z!R3G&8OXL]DQ39[>L#3;PMK@!A]4#
M'&5]N[/B-?3VME9OC*':;2T#HZM3JD?:'V Z3W[8T)_0 4H1<7F <KE<L-2R
MYFNJZX=5_,V<.?<4; "9>210.*40J<1HP  (CVC 11MJOV!_4[1_5GWGEX_/
M?_#I>V<'&\KORIS/MVUKU2,1HM_A_#<]R'*9_P!9KUIF9.2R9<\,2O"B-JO\
M8/<G+V_[:X/=&&;5HW<TNP9*[./O,2QUT&6>;6TR$/+'&/SAHN]J['E1*"4.
MV\OG?4J8ZB!Y'VEA-_R97DCT-TV!3M?Q0^Q1S5U&")_^U%9R$B1I>NYB3++F
MM-7,+DK1*G2(':)=1Z3>Y=GS[2Q^I7LQH@G7U(ZOK^4=4ELE+SVUSED) 9D@
MI] 4K/S@5W2D@'<_U!;T;?51,%+:RPWX<2V.NS'^R?M_?_\ 3QGQ:XWL7"\P
M"+ PS;\<Z!F>;"3RN<Z>RYCVBU,CQ@!<CONHHF)Z8/9U@DTS8X@:G;" 0J]@
MT$$=S^[O:O%<KE^#8HABUZ M+3"J>,Y&Y*9N4S ]*OZC0R8^0S@">S]1'10S
MIG>M(_[7]Q\EQNA;96-M>:'DDG+,O(88@-HXZ_7[F^"(?7AN27RF%8H'G9)I
M=+^(9^&Q+[(6IG:N/V<5=V)*X0*^S=_9$-SF]!IA$%JH0CBGSQY'1 BL_*"O
M8QF=M6JQMG#6&+-<R:SFYP.VYEISL7T/*7V+U=:YS2Z#1UTU;8-8CG-0D=DJ
M+%8 2JU7#6=;,96EL^)!2YHU1RWP>N7NAV7UUQ D75[*'N7(JF"R'@L05N1.
MD8ZMS>KS6.L(@#].'7C;&F!FV.7,K@[HH0R2K/<M-?DUP(T1-EM3O_2SWHR\
M%$7-S?J3)HD>N-V 0@6YH9E:V:?\O3VJ!:FG)@5BM?8T,B#O1KG#GSP/21_+
M'/\ LKE^&>]OA;;QT[4D.4QRJ^-F0CR6_D@KCL.P'EH5/W>7QFJ@4/27!>\>
M-Y18Q-!DVTBE3QVJDDU*K@=&)#&>J1^_!XLW[>O,28^ T]^=7>5S6^QF@W.2
M;O,;2:6HL]1BW'.K&ZFC#*9+84BG-_\ LZ&PHK?EZI!-]/Y4ES19YG-:CW8N
M+7:WO+>H@[D?5\CZ'CM"3Q'.P8<+FB\MR.8UI.<N.<S8>H4BAK9J"^@<(ZXI
M[.T@U#!F6KBFL_+Q)=KT/\&#UATQ$YN'TO3.833D_=;7UUX!JZ(>!R(CAA0M
M=7G6L+?EJN8YU]*K'.5/I=&UK&_#K_P@<7L,'QG!%]QV(8'':7>TH9PN2S3C
M[V/<[LS<RSF).4\0*2MF+6MC8-!(PJ&-"7_9D<L;8C\5.B.A_'\C[/8_W'\=
M_G^?L?[RLZ)$JWE_<$$'\$?D?1'??0[!^^_OL==:OJ(J_LB?*_V3R4.2<5ZA
MWC5CXOD^)N-M?22Q(0RN'1*NDC>Y6H?H[TG[=1G (D^7.,M2QE<B*P2,DAS(
M'[+O-/P=/4[&2AG;*3>]9,@1RSCZK1-I\[/(JM5DCZ/&B4;WLC^E?\DRU,'D
M:]S2&2M^$2<]U[1>F?IIF'8^E.QE214M6(/E?(*RF/O7%P(D"ML*ZDD@KJDG
MY8GYBQUEE7RR.:]SYYYU^A[WC^(Y#E-"9<&31LT.0%CEB]Z??\E9J0JC_B=B
M%4 EB "?33?S&#CH-HV:898H"3735(S^OOH%R"['\!%!9B0%!) ]>!Z)>F</
MIMS.]DW>Y_Q'J="5!KM6W\_(-SC%E5-62-(3F1+/[+(38:P@L?0[@V.O.N 8
MX!Y1Z^K!@@=ZG#?>G'^POLKNN.<^@&+PV3P)-W4;2196S;*^K=%75=U+30ND
M8QF:%$M!?TLJ6!2KA[2K!J#5[0_S5%_MI^(!UCV?<5F($=SWDJS(L>$J#G$%
MWS89'/@(V]XR,=]RJ+],K*(2(7.C2MC=*-:$PQ'I%7IEUX?B'LORG?64Z#T$
M=\[-:F=[OIC@S.Q'?GK,V?Y_98:F0P.ZD147^BM<J*QWP]MZ<9_1Z^7VUR^W
MENGYIN-N_&<=!_-<EY*++\U)D)?7?XSG6:%L\11F\K49#&E^0_JG+3S_ !>7
MC>UXD;X)R&ZR>#:94;X6^*;@-'-$.+%W"VJ9A?&2*PK&GXGM";G_ 'O]AQSD
M5'6FCSFC$<J_4DE?>X7+%".:ORO]+?IEA^/^ZZ)S?A/CX\B'K#%M_6WU.T<#
MVR#T0O?>6V+(D<]H5O2=0CZ&'$4]&_1$38T'213(!W/6204926)]I7?3:!^.
M7Q(JAZWS3O\ 6#.DH>C99N#T)D+&N'@UN+<2?2R3S,C:B/O,K92QB++)(Z6/
M,3I$J1QM:E9_"EAZCA.@^L93HFZ'9VM9TSA,TZM:V3MF1J#J@C!LED>QD"]E
MPI9F3K7?*-DVU+B!I/J0I/I?\/K31[?X'>I!3"D!H _*B.:_&:78#LJL/D?2
M_P!=_'(^(/8!H_W/QU</O+W?Q#AEIRM=C8BW9^1]>W+SF%$[Z#OK^%,4_OQ%
M[J&(\&Z5FHMK*AM*V[ICRJNWIK *VJ;(*5T!E=:5A41M<>+*Q4=&0$9!"3"]
M%3XDC;\_LJ^;8?HS[VY;W,[MB(7<XLLSU?#>O&IAZ7KYC0&4U].1K>?0NJL^
M!7RK*722W4$^I$?>0#%9XD\FKK(YXRSSB=3$D:<2>84J"<4D>64<D4J&48H4
MD>5\!(I0T[63#%"D12CE#3L9,.1%)#,QDL;VI;1^#7U+G/*?9[66_2]KF<'3
MV_&]%4 7&MN :&HGM(=-E;AP'ZG93#A1%OK:XXD>":>-Y2"RQ#I+,C8W8]X<
M9#;Q&K48-77ARW;(TB_F!?XTJ")GNLS/]_BP905\P.N^_'],>>V\5[EX_CAJ
MG#C>4Y#$O(ST"7Q$Y7>D'#V'_5ZJY^/Y$9'*N9D_8 LQQG1:3D/X<G1NF:+*
M,V^>Q'N/T'076.4Q*Z/1 UWN#(1^1<0L<@_U0D1C6$ YD,U<64".+8Q/"EG1
M*+O>;V]N?<KM,W0YJRQS6.HZ47,X#'V!PQT]'4Q/4NT..E!:P&2YT=M))86<
M@R21QP05=<R<B.M9/)8SM^]<:M_PJ>[X.NZ1DR=OH_9'H!M)CFVPS=38U][[
M$OWM5:#4#WMM'U)>2>ERRU_+)7M'^8Y"6%-4=*&43Y5$3_7^R*J_\D_=?&7M
M/BI+HY/D=&:B[9\OR&>#66BA8U3(S-.=.D#.P*FJKY%>T+%?H%/ZB>X=+XO;
MW"8MT:<7H]M<'IUQSF+E]>9]TTG:T^Z^,P5;],[^"T"U"!_W%G_2\+\U[3<(
M*?*T8+-=$J][;F2HJ#@47-A#N@7AQ<B-<V ,:KS1*D$R(D(['?=E<UC57S)?
M2#G<G=/<+A.8F!D* M^F ;?1C1I*C8L]ER"-_<I+)"QSH(5CJF +*Y&,24J*
M)SXUE14^# P+QCA&UZA9MF$W'>J*_P".\:#DB^W-'SDR> 3N74HU<J31@%B#
M1\@RQ;6)%96%WMYAY)H:*=%MN_ L]?B"KWI_LQ= JT"M"?RC!2S0_#)[ V2O
MN]U:".<U/A 1H*"ABFA=]/W2KH61%=$Y&/\ G>17#Q_-\D&\0N:?&96!/^9K
M#:%9YD?ZA.NKXVZ/:OCT=_Z>_0WV?P=.5YGVGPCS+%M].=Y"9!(EQI3#2<[@
M_2-?-Q[6GV.GGR.0]]OT-DMO\)_I\_NJ?[JORO\ U7SGP\/.>?7:OH\4_P!Z
MM7-C/3SV0NA?N?GYN1[#.U/V9F#S?K>RKGXZD;#-)_2R=]K?"-A1/ZWR*UD:
M*]S4\;#Q$O>)L6P9ZU<+;"XY_9/9SF:7=8@\Y#"<)R6<SLNSE)^R]C6!M@Q=
M6$2Z=70JVQ:U\:HJJC_BT5^0Q^8[G.Z7M_\ H9S\]S_X1FY_(_'Y'H/[@H\^
M%Y+XSU:V6F3,?P3KW=8\BC_=M-Y*/H_9'T?37<QQ5?S_ )MSW!BBP0C8G#Y/
M(CQ*V)ZQ09NA IH8U>U%:_Z(PFM^IJ_2[X^4_94\/,[^AKOW7ZD5?W5/E4^/
MG]_C_P O#QF[L[L[$EG8NQ[_ "S'LG_Q/HG*22G.4T G)$F@Z Z1%55'70_"
MCKKH?C_?U3O^+#Z[=#V7/)NX8WI.GAJ^8USC])S4JX*AS<0#H)Z8K;Y>,7[+
MZ_0 5]L3!HX")9!KC-N,^P\8F"42VM&Y!C:SGG*^<X6G_*K69'$9;/!O"?\
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MD'2J:.,SR5% \GJJ@#S'6*=:X3UGAQ&8#ZQCR,:?KZ-VBI*TVPJ2[)U6TO\
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M@6$ .*'#V/?')%-&YS)H7(^&9CG1S0O1?E'PS,5LL+T7]T=$]CD_OYQ\*O\
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M!"SO!2OA+7W70T64DM&"7[9>TD6+![!/8W,;#H7 _1;)9+3NSN;+X!9V/4=
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M[\6M)+I?91-.>I2;;)SE(L"J2\1\3G,+3I$L] 9TZZ#LYK.^GV<%S1S=/0Z
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ME@$C=+(444POAX><P:]>K?IOLVWIIU::-6][,7I2C'[9B?\ P"J.E50%4!0
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M5P$=PZV73Z*A-W]^=7:PO0FZ!#GA&GV$^NF%GUC6W904U[7B:F8(-^CKJJS
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ML!4<<K'R#3.BCG;$0QCE=#*Z":*9(Y48]8I8Y$:L<C'.J#W)_4GW-[D6F=]
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MKE8CD5[4:YS45%<UKE<C5<W^6HY6.1JN1$<K7(GRK5^.55$_=5^$_P!_V_\
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M<[0QKEY?/]X)RIH6CVXU89:DU^//'9;/755?CSI1GF'=CWEA&F&5\E_FL,A
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M4^4_CY_?^W\K_P OY\P;<=/YQS.O2TZ)O,AAJ]S7NC+UNCJ,_%-]M/J>T?\
M5"QGDR-:J+]L=DLB_*?#?W3QKEYSGS;$L-NW53&4_00?RVK&DY-"%(YJK:9O
MGDWAFJ)FN<+,19!- KG1P_""6QK9,F>>L-^MNGCE:LWJMZSKHFTW^&]5#:)^
M8G8L_P BL:/Y9U__ -_G_=?_ ,OX3_;P^43^5^/]/_/^WB</]Q*;7N_*>O\
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MZFAS.#CM,U8@?%Q^+ Y_9W^ZO'PRU<]_?D[L>_OOOU7OO/3K]OP%>*V[\[D
M_P"9NU[$'^9,?MGNMIFHZ8CI5 Z/77T.O/JOQF[,@",@OUY!?,[X^I1^HDP1
M_NG[_2R7 E/3_;_-7X_W\]%OXRI+E:G_ +.T"*OU)\_\5Y/C]D^?X_X<)\_\
M_P!O#P\M'_[-_99\R>%'?;?CD.5 ^O\ 8;@/X_'7_P!3ZK<>_O=H,@.7/[E'
M?>+CB3]#\DXR?_GZQ K\8SH%S;LILUQ;'T<LLC8V&7FHO-+'&K_^\\0 +*ND
M1/\ X4*C^?\ XD\<3FO2_:[V D<^GZ]RKEHD=>.4D=/PBRU![E)8U?A3--V
MD7ZXOJ56.;6(Q7HU9(GL1S''AY$/>WM[@_;?&ST\1Q6*%OC[+Z(KR()-)J24
MY+]8A^B0.U^N^QT?4K]I\[S'/;FAR?):[2^7Q\86;">O#RZ#X/TKC[_LW^WX
M^O4W/]6==HF_<ZI[4^PVV:\=@Y%5E;[/\:ST_P#7]4RO"YC04EPYLJ(UB-FT
M,SV1_6U97J_ZDSG&>H_KA@['];I.290S1K.XIVLUHY.]U[BG2QS*2NJW).BO
MDG^[%'(V1A[%C5C?M_2B*BGAY2U.;Y6B-(;:P@PZ;/B$\&9@?X;-B3/ C_8S
M^OX]6S/B.-G04.25JK_IOK+[="]!>B-&MKW!^_R*??\ /X'IBVL:U$1K41&_
M"-1$_9J(GPB-3^&HB?LB-1$\_7AX>"O13T>'AX>+TO1X>'AXO2]'AX>'B]+T
6>'AX>+TO1X>'AXO2]'AX>'B]+U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g340646.jpg
<DESCRIPTION>G340646.JPG
<TEXT>
begin 644 g340646.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?3U9%4E9)15=?-$-?5$),+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 44"BP,!(@ "$0$#$0'_Q  ?   " @(# 0$!            " 8'"0H!
M! 4" PO_Q !L$  !! (! 0$'#@D&" 8." <% @,$!@$'"  1"1(3%!@AUQ46
M%S%15UAAD9.7F-'5&4%45I*6TM;8(E)9<8&5(R0R.(>4L=0E)Z&FM_ F*#,U
M-T)#15-58G*9J#9$1D=(:(:BP0HT8V3'X?_$ !T! 0 !!0$! 0
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M36Q+9KQG2;E4,($*MN\Z_3S_ '\0=*P3KTVD;#,21>,D8TG$;+Q $,D>,P_
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MQA+SS^'''4XQAQ2L8[.OVB\N]Y0L+Q$[G?R)BX<PSAS$<GJMC"_%X[45CO\
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M-6M^O %6N9TTZH0!C#B1>SD2\6*V88 RA1*RV(B2K _QO[JIXQ1?%]A;.9D
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MNT/9/D'\!?Z0FM_W[JC_ 'OH\@_@+_2$UO\ OW5'^]]5S^&&Y>?D^G_Q8_\
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MV-$RITCJ^,VYF0+@D<*CR'9ZVR+>,3.]7)BH9:8>2[ <0J3%>=<]'R#^ O\
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MYP?<]?DSB/1_!8C]G\[;O-T]-C>0?P%_I":W_?NJ/][Z\TMP>X"#(>)6>Z#
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M%[NK+EC_ *^YUNA)SCLQ[?M8_%GW/ZNM2>$G]_+7_=</_57E=(^ K_-+$?\
MW#=__'857UTF')(CPOEG]=W+DA8*%ZLZ&OUHQ2466PST-@[QL?05YJUO$3ZL
M.EYC6E97CS?+Q--UX\(-#AM&)3+C.@P(D*.:C.8O^4E6,9SC.4YQC/8KS9SC
M.,9]K\6?/UBD%<:-_P!?Y!6K==/&4&QV^E[UY*% ,/;96QUNM7W6')K6&BY
MBPUZ[UFL7TK6[5J8_J,)JU8E5.4R7I8VQQ,S1;I007GZ]K=-5\%[F3W'UW6J
M\!-?U*P4#518(;-66-O?<-L6FNVO4^J(58UO=KPC9A4S=M!%])"=-#Z]H>SF
M3^DG];CJ3%'4I0-,5+ELVON37&%WCYS T#JZ=MK58+F76=K"-FR<[CW#L\#
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M XYUJ&/O-FQK$\LKMG:XGV4+":L@F-%I#;\VNI70-EK<SI]B>WM[%=N?_?\
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MDYM#=-2V-<*D=KY[9@$"+U%3];5&R")D8H7I^QL7*!99=CJM-N]&<@LT8O\
MR.K +F!/IK!(A:L<V='ZZU"Y>ZC:KI6J]JW9 'AG2[C9@-9&&:M-,U"F.7C:
M]S=4*L \%$L0FQ3"\]J-!.-IR)]B<=F?Y7F]WO\ /;_7V_Y79^+*NWL_%V=?
M7;C_ -KV^WVE?B[/^3S>U[6?/V^WGI2L ![FGW16IQ$1[+3JNW!M;\4W[),;
MCQLD:"U+" &N65933S-><N%DEVJ=M>?Q_P!4RQ)CQV'*JZ]QNC8 LV[8=99Z
MYMG-#GD9=OC1D'7M"-5G9.H6K&.CZRO]K,:VH8GDIQEJ!@_&-EPXP;?:MNR@
M[#V4=E23$"EF*M1Q#;P /+,5G8DH#G\SA.?;[[Y5XS[><^;.//CV_/V9\^.S
M'M8QCH[$^?\ RL=ON97CL_'YNSL[WMS[?>]G;^/MZ4K .[S&[H!KG2478#>M
MP3X8'7:!24U:[:BWG8[F ($>%U8WK;=QWJZS=B2;/<@]&VB1,TPC3&:Y'L=I
M]0Y%+3<T;(G1WLV88Y><G;%Q/F;8J@,5M#:FM>6G(?5\-S7NO-R4FM7(#I*M
M[R8IQNRZNB78I<XXVR6&JU2#9*T8LDX&5GDFL"<-ORJY)8S'VBK5B[UTS4;E
M7P]JJMB'21!^N6(9%,@S0N:UEF6.*BR+,F%/A26LY0_&E,.LN8\ZD9SC&<=*
ME46EZWK0^FT"K J951:Y[P^OUD5%"B8KY4A*+%9+<* RPSXV4+3IQ4G+6E<H
MB3FRR$UY^9)>?6I6,W8>QN6T_CCMX3<))Z">H/)?3FOKSM#06K[A4;M+XPG1
M&@KWNG8FK:9+L.Q[$NPUD)?]A4U9VD3K18QHRK&C]/#N;$",CV:,I6VMU678
M%D'\?=B[]):#H//OC!4F4["JMRL%JLVO[C4E,;[JL&U[E"SMM&./(NS2ZY=*
MCMI4UV 1G8NE6KMV*ZX'QQXK.AGLSV]O;Y_B5_R>;S=G9VX[.SLSY_;\_7&,
M8QYL=_[?;Y\KS_RYSG/9\7M9_'CI2L/G..^[UB\C*15-";$VM6+]7]75^\@0
M<YA8CCT9+2KE;HV:E-@Q:F2>W]MC<+0.-KF/0#-IIM2T=6EQ]NS;6"M!JLB[
M4BBMP\G3H4!3Q&\>5];8L;%9L6LMI;$!']>UP!MKV#-:EMWD-V69W65ELEFI
MVHML'$O4SC2(KD -LG8]PV!J-Q876&IIA/7&S=G"<YQG/?>;\6,KQC^U..S&
M?C[<9[<>;/FZX[U/M?R\?U*<QG^W.,XSGL_%C/M?B[.E*4[C?(V\G9G,,/L^
MUV2W@0W($#G4$\W5Q]7%B];G^/>E+2NLU) L?"C&P%>O)RY#U'I4DP8EF$%(
MI@L_-A+8C-KUQVX^/Y%?9YO[.CMQ\?R9^SI2N>CKCMQ\?R9^SH[<?'\F?LZ4
MKGHZX[<?'\F?LZ.W'Q_)G[.E*_G4=3>J;*OU$%V@/2K>>J4*Z,A(UG56R#H4
MB5C5PDX8#15&QV8YR'%BDW53'(PTE"8GNI922;F-,,-MPCKY2I*\84A25ISV
M]BD*PI.>S/9GL4G.<9[,XSC/9GS9QG'M]=7/&DBE)$21"5)5U#J2C!T)5@1F
MKJKJ<LU90PR(!K\ZXI98'$D$LD,@5T#Q.T;A9$:*10R$-JR1N\;KGDZ,R,"K
M$%D;%RZY&VP%8*Z?V?.G#;3'M$,^XFMT>$9(P;O*9FW0=FS#ZM$L\,=<)3"'
M[2/'&8<,^XI_)1F3B7*P]';7R/WA>JAFB6_8A0_5W$59$V%-&5I,\SFD93ZS
MGK'8XP./:;1+K#2?%0DVQFRLN!"6]":?Q%?>:72.%)5YDJ2K/N8SC.<>?.//
MC&<]GG2K']:58]O&<8^<.-JSC"5H5G/9V82M*LYPK.4ISC"<YSG"E)4E.<=N
M%*2I..U258Q2IA]A'JE+*SCY-^50I;0KJ2#5/**0@U7&JIUQDWT5V[!5;)C&
M+S<H)<4Q*7E8N0E$E]=/RD)#+R,@:4Z\15W7DVS7)F&63'.^Y?)[?\X=?1,C
M:=C\1V=9"ENNZ6&PT227L1W(G)XC&(Q13).O>N#($%ZX(=7F!!YW 87@M$F)
MA,X3$MG[BV;N<L.-[/N!"WDQ,*3 '/S(H@>U%9GD9!@J^B""&BAZB1PQ+DF+
M"9<B+,6$N^Z3-SI\Q6'L5GA2<]F<*3G"LY2G.%8SA2L=O:E.<9[%9QWJNW&.
MW..]5V_Y.>S\O&(_>Y5XS'PG"LIRK+[.$]\G':I/?97WO?)QYU)[>^3CSYQC
M'7N.RLXG62*TMHY$SU'C@B1UUD6-M5E0,NM&B1G(C-%53L4 >)L3Q*>-X;C$
M+Z:&34Y2*:[N)(WU)'ECUT>1E;5ED>1-8'5D=W&3,27T[F?40UZYLZ7K!]9I
M HBJ^JDJKMHL],,8S"UO;)S'BMDII@#8A^/#QV\/I@%8R9;&78DO#\1YYA>V
MICB9I_LQ_C6Y_:Q_^)SDSZ7NM5'N4'^?SHC\>,^R1G&<>?&<9U7<NS.,^UG&
M?Q9_'UNAI]K']6/]G6FO"3^_EK_NN'_JKRNHO 43\TL0VG9I#=Y;>;_!V%'T
M[>VEK\DS3_Y5N?ZSG)GTO=4_O>E<-N,.KK3NKD!M6\:DU=3(*Y]BN=TY9<DQ
M0J(A+;BV(<;"MO+F%S1%32HP6OAHI \<G9:'!ALZ<\U'6^O;TNO+O03/*OBM
MR/XTNV)%.QO_ $9M;33=P<")L6:B]LJCG*:U:$ 5D!'JNZ 69]4VQN"HM<Q<
M;Q9)&$IWQAO7M;IS/6>/@.ZD'NG('N6>NKUL/6UYY-VVK7+56MG-LWT2:Y+<
MOX+8&FLU:KW=[OBSE_\ 40E;6:;=J9:G]<!B1+8[->MU7+N5-,$^*>E?A2.1
M/<L=BW346O*=R5O)BY[R;RG7@+'(7F= D22BB][K\2J6M\I=H,/6E^*G]7[*
M @M=[-DTZ]V WKZ[B0==(3ZJ;CPEXY!=PID;[OFRCTSE1(J].LMJE;TH%8'Z
M:@$3M,Y1R]!<== N7H_:IVPL1;GJ1H%QJJ!YO4<:LU<^LR<L+;VTU0?4YF-/
M:9W'[8P3:/'6^VOEH+L0C4G*F_\ -^ZA@.@\4T\>Y);4V7O?8>REZWM$/;9.
M/4=.7R'N[-!-Z^VM6]\V0#3ZBRO76PZ/8;79C,A3,]9X^ [JR>XXF:>SC&4R
MMS=F?/C..3G)GLSV^?M_\+WG[?;[>N?),T_^5;G^LYR9]+W3)IQA*4X_%C"<
M8\V?<[,=N/;Q_;U]=*9GK/'P'=2@7#BEJ-D>,4V6VA"RJV4UK+AKDMR7D1G4
M.V<4TY$B(7M65A!F:A:H@.1A#:XQ9Z(^B3%4C$AN5>29I_\ *MS_ %G.3/I>
MZNJXJ<2/&9;<!M*S:Z<E2CZ&EQ5-JM I+C</#S;B<''6\J;KZTX2Z@RJ"IEQ
MMW"'$ROJ.D]@]>_=U=],SD-O2?\ MI:O),T_^5;G^LYR9]+W1Y)FG_RK<_UG
M.3/I>Z97/FQG/N=8Y+ORTV36+YOVU2R&A:1QVXO;@UUJK9WLE$[0*V%98%CU
M50-G6^YU.R#B3]>#E!K&W*<&UGK A1SY?;ID(;$P[/6IMDK/BLTS/6>/@.ZF
M&\DS3_Y5N?ZSG)GTO='DF:?_ "K<_P!9SDSZ7NDX+]UBUX#C$&B/'OD*W9 .
MOU[?M-32QI[!2NZDD@-76"OW>1->VVT!)JLJ=KA0\"K S!&TCCP2SQ+ ,$CX
M8@L;\,%W58=%O=S:V;HW8="U31(NL:SL.XX=HM@DZ9VO9=V<GM%6T!L!L)L&
M;-MM88N6@AK=:L.IZU:\>IMF9+'6XK4A40.IF>L\? =U/'Y)FG_RK<_UG.3/
MI>Z/),T_^5;G^LYR9]+W70XV<J*WR03;(4.C7W6MHIP_7%@*5+8,>M9*+J>W
M*:S>=>62*0IEEMU=>CFA'JA#FB_5I)L";"%1Y4>S']2R!5I.E,SUGCX#NI*=
MI\:=-U>BF[(^0VNQ% ."#,U1/DIR3EL.P19P;.G1(T>3MIQE9>=$8>A %+PU
MX(](&O)DQ%-XE,XQD<\. +B$.8IW-?&'$(<QA>^]S87C#B<+QA>/*:SC"L85
MC"L8SG&,]N,9S[?6:OD)W_L*;*\&X%:5BK3\]^?PC([O<81WZ,8<0XC))U'?
M-@NU/?8.*&Y1E"\)6G46T]QD.[3TCL_;,*:2B9H$=A-<#QP;A"/;EU\/$LNQ
M&Y!1#R/4ARK5"9$*0,^ DI-%'LB<994VMU.38!A^&WD5Y+B)=5BEM(HRDC(
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MMEI .,]!G$Y6O)X"KP3XL9@X6E1V7I W$D;ZHR,"T;*,X>8HFKKL)I,EUF5
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M\EY(_*';:$:<CX:7M:6GU0F(6J&&=\#A4<R_ D(>C+:3):<#J*713B0:,M.
MVE^KU1QW]B0TL;WBK:$2XA*7FW4>J;K>5- E=YX1!U8Y;2VW4H<31'F/8:R(
M$YC;TCTCV#NJE<\3-/YSG/C6Y_[>3O)G.?[?^-[H\DS3_P"5;G^LYR9]+W3*
M]'4TS/6>/@.ZEJ\DS3_Y5N?ZSG)GTO='DF:?_*MS_6<Y,^E[IE>CI3,]9X^
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MZ/),T_\ E6Y_K.<F?2]TRO1TIF>L\? =U+5Y)FG_ ,JW/]9SDSZ7NCR3-/\
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M^)!YMB 2WB-?-F <H*H6;)5\L\HT$DE8TM0TPAL@QV/87X3:?[SD+\*?CO\
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MF%2QFUK89&QQXH*2*V>:^)=3/G%AH6C 9DPE+B^..> +89'2!S,!7B&7(H^
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MC.,XSUC-B]S#UC,UQ#UV;V3M8*+):7%\;]KQ-8'AU(%[WTI1V3U8U8"V6Q-
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MT=<=N/C^3/V=';CX_DS]G2E<]'7';CX_DS]G1VX^/Y,_9TI6FI^$PO7O7?\
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M:<^6.)FG\XQGQK<_GQV_YSG)GTO=:J'<H/\ /YT1_I)_Z*[EUNAI]K']6/\
M9UJC3K#;'"\6M[?#[9+6%\/BE:-"[ R-<72%R9'<YE40;#EDHV<]=%^"/'L7
MT@T;O;S&;Z6_N8L:N+:.:41JRP)98=*L8$21KD))9&!()S8[<@ %K\DS3_Y5
MN?ZSG)GTO=&>)NG\?_6MS_6<Y-9S\F-O=N>F5Z1;NF6B+KR4X#<N--ZPQ<G]
MK7+C]MD?J8=2-E'=4E3>TUT.P-Z]!3;4%L]184 ,6MT7!/!;.912C@YUT?;X
MTL$Y,95A5;3S/6>/@.ZK2SQ.T]C.<>-;H\W_ .9KDWG']6,XV[V9S\6.W/;V
MX]O&>N<<3M/9[.R5NCS^[R;Y-XSCL]W&=NX[/B[>SM_%V]:S?+7N<'='MB[U
MY&VS5&O+C'FV\!-\8VA%Y$5NH!]O\6W^+7$W7T7@A7PL78#9NK6YK<6M-\V1
M)@O5ZCKN'(O;UK:VKDI;2_@W?XV\%N3-)LG<S;L5I>PJ-7M&\R>?=R-Z>);Y
M</@N/?#W=E4Y<RN,^M+53!>RCVL+?;]<*O\ J37T.?2O9#,T<4YBJ!;>_0@;
MZXJF9ZSQ\!W5F&\DS3_Y5N?ZSG)GTO='DF:?_*MS_6<Y,^E[IE,>;&/ZL=<]
M*9GK/'P'=2BVGBKJ.+!'+;D[_P Y<LM5CJ]1>2O)*1)\'*L0V.YF6B1MIU"
M^$.JR;?1A+\<3XV_'<;?;;6F2^29I_\ *MS_ %G.3/I>ZNFXN^!'"U>-&XG?
M6RFM>$ MX<E.^&M EKQ68G+C7>A)>5^+'G.^5EH.[-<\&[WO@U5/R*Y,ZTXO
M ]=63:2ST<)LS=FJ]#!B 04V48%7#<%BQ6*J2LBES8?J34HI-2,V$_\ XR@+
M"5F>_%7%:D.-1TG;U>3GXZ/33,Y#;TG_ +:\[R3-/_E6Y_K.<F?2]T>29I_\
MJW/]9SDSZ7NH/0^?G%Z]6;:E35L@11RVJ>2%EXJRD;)(!:2W=]M5 'KTM8X.
MML%2^)%N#"B.S*Y3I)=B/$;Q=<RJ_AC+RAKI*<KYD\340[B1SR2T?F#KXVQ6
M[M+1L^GN,5<_).6*LLAC2VRRL02:['4+: S"<_QA!JJV86XA$X 78AS3,]9X
M^ [JX\DS3_Y5N?ZSG)GTO='DF:?_ "K<_P!9SDSZ7NH;=>;>L*]=&];TBL;(
MWI?GJ].N,>KZ7! ;(_+I@JEU^]E[7 -G[75*H1%0 MWUPRTU /R2IPOLNC":
MR.-2S#V(,Q1S&XO-Q)T@QO/6U2EAJC6[Q9@%YM RCVRG5^UMTY05V[5&UOB;
M+3B+S^PJ*.D@[&+&FAQ>X5D21'Q2)T5&EJ9GK/'P'=7/DF:?_*MS_6<Y,^E[
MH\DS3_Y5N?ZSG)GTO=5R=[HQPN!MB9B>0NKS06=LJO:K,60#=:O/K=*LMLH>
MQ-@UI^ZFE&(\,(%-B]77 0.)H7-1(M(V17,-8(CC;8F_ZIOW1][M[NOZ5MW6
MUMN[-;'W!=5K=UKAL]ZU2HJNG1UB0-&D9,ET-,"6^I&6"#+;D90FU5DEES$$
M^(?FJ9GK/'P'=5([#XT:7K-0*6&9-Y -00KHHF1= <D>2L\FT-A&!\@BZF(Y
MME_PL)J"W(<+^":5)0(3.<B91*0RM*(IY8=S)6E*T[*Y'Y2M*5IS[*'-;':E
M:<*3GL]D/&<=J<XSV9QC./:SC&?-UE3Y#.>"TGLE?C!B-_V,3D^&!(\(0_PF
M6V_!=[WR/^#Y'?>+FE=]CO KI!?8KO>]SI_:UXZGME:L*WZLV$:1+!E$8C6O
M0PV8?M;Z@T$+(;=(1!TOU1"P[!@JXS6ROJ&5K[SPHGBQ&ZNRTT^YDF X787\
M=U)?2S1+#);QQF)E4%IQ,<GSBERS,8 8ZJC;F=NS3GA0TWTKT6O<$L]&+'#[
MZ2_M,5N[F.]AFED$>'M8 &'D[ZS!R%PVM&.5D?)1&N8(.:_RKNYE>^3R/^E#
MFMZ0^CRKNYE>^3R/^E#FMZ0^L/,+B)L=0TV0)S@"<C%$F1[%7*AKNR>EB*]M
MTF9A02P<VR):G5VP:=L-.L@UZ4HF.,/M+B1"2&FF)_0D<6+C L-)JA6W:Y&F
M[@/W3-DJS:H)(%5I.C6BSEM"F[&&=(CE&\.A2,%T>QC#@@A&?8(YPTRJ3F_?
M-W1XEE%[<DJ&) FB8Y+&TK$96QS"HCEB,P"I4_3R4ZL^^]X60D<C:/8.B2-"
MB-)A]]&->>ZM[.!6U\84HTUQ/ D:OJEUD$J@P@R#,KY5W<RO?)Y'_2AS6](?
M1Y5W<RO?)Y'_ $H<UO2'UA8&\5MS%"N S BM,3<R7X65$+O61\+$U@KKD$F'
MZH2IJ(GC,LSMBA#1S>7,9G2C?>L_R(4Q;7Z.<4=TMI95@559'CT)HB"1#O\
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MC2XSR4N-.MJQG&<92K"FU+0K9YX2<[5<H-?3*3>D'@^Y:&[2)I\M4!;F8%Q
M/7:O"&+&QECP<(&[.F2&AEU!//,-^I\DF5K[4L=XR/%X[CVC9PZ/QJS:26U4
M 3"0JTL))R#YJJ*T;$@'Z(*'+/-3FNW/!?X8UTMO/D/2&.UL,:E=FPZ2T66.
MROT5==K8)--.\-Y&J,ZAI6CN$!":DB!)''\DS3_Y5N?ZSG)GTO='DF:?_*MS
M_6<Y,^E[IE>CK%*WQF>L\? =U+5Y)FG_ ,JW/]9SDSZ7NCR3-/\ Y5N?ZSG)
MGTO=,KT=*9GK/'P'=2U>29I_\JW/]9SDSZ7NCR3-/_E6Y_K.<F?2]TRO1TIF
M>L\? =U+5Y)FG_RK<_UG.3/I>ZC07BKJ-XQ<&5R=_P"$1#0]EK)'DKR2:'Y2
MNL@I*L@'6MM(=DCN_?7B4[)6ZZDS@FPE:6&66T-UU$P#OA#MY1XT;?\  'QK
M?@";>$#87?5*N.^ KJ_"+\*-<\)XU+7E#/>FY!5OO%=YX5<=7;ZCQLH"=NWH
M]:U2WDF:?_*MS_6<Y,^E[H\DS3_Y5N?ZSG)GTO=,KT=33,]9X^ [J6KR3-/_
M )5N?ZSG)GTO='DF:?\ RK<_UG.3/I>Z97HZ4S/6>/@.ZEJ\DS3_ .5;G^LY
MR9]+W1Y)FG_RK<_UG.3/I>Z97HZ4S/6>/@.ZE%M/%74<6".6W)W_ )RY9:K'
M5ZB\E>24B3X.58AL=S,M$C;3J$!\(=5DV^C"7XXGQM^.XV^VVM,E\DS3_P"5
M;G^LYR9]+W5TW%WP(X6KQHW$[ZV4UKP@%O#DIWPUH$M>*S$Y<:[T)+ROQ8\Y
MWRLM!W9KG@W>]\&J6=1TG;U>3GXZ/33,Y#;TG_MI:O),T_\ E6Y_K.<F?2]T
M>29I_P#*MS_6<Y,^E[IE>CJ:9GK/'P'=2U>29I_\JW/]9SDSZ7NCR3-/_E6Y
M_K.<F?2]TRO1TIF>L\? =U+5Y)FG_P JW/\ 6<Y,^E[H\DS3_P"5;G^LYR9]
M+W3*]'2F9ZSQ\!W4HH#BKJ.1.MJ')._\8BV7$=KU4Y*\DF8V6\UVO2.T$MG;
M3:Y(?OY"\>'DY=?P6P58PYX!EE")+Y)FG_RK<_UG.3/I>Z]K86WZMH[7^[-L
MW5^X3:QKV>^9+Q6!B2,]N.S7*DAL73(*IL=N?"E29T?,?#TF SDY-+)><8::
M7)S[(3==8>B+7?(LK3154UZ/"KFUC=!!'"L%HQ6ZV@Z+9"76S09@23:;;7JM
M&F((I<>L1@4)Q&3)+B$SX'-SY\_I\O'/0DY\_0OH'L%0SR3-/_E6Y_K.<F?2
M]T>29I_\JW/]9SDSZ7NO4\K+BUFN8N">26A5U/)UBKXLS6X->N@,V:2+BG&*
M]@PW8E#\FW0DZ&:0,Q(S,R'E1RG@?$'42%>JODKQU;]?&5[ZTNGV,IF!VR.W
M:5%QG7Y!1V35TP+MC)[&:K-5984RO)BG<0'\G(DD1X/U08=C)FF9ZSQ\!W5%
MO),T_P#E6Y_K.<F?2]T>29I_\JW/]9SDSZ7NI$%Y(Z5,%H8)S8M-"%CMMGTZ
MD#S]OJ(Z9LDB/%U@NY*US$]7WI-O'/0K>!<CO"V7)+F)\52H;;4R [+]*O\
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M>/\ BF1YFVC!NQU0G?1189#'GIE*>HF:2"/V0GLIZ\1]?UYH"8"V.QB;3!<
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M]"Q+#QN3#T1JG30^2ZYHT9JZLT':(H19*]:F[/8PC\05,LQ)6XM@LU!2LW9
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MRP W831VUFZPF6#Q92\0HJ/DI$)$J_"8P[%<7E(6V+$# 0/H.ZEK*$9ZD1D
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M^O!ON3H\N_F/\(W9?^O!ON3I3.CIXA8?4;/]5@W?S>X4^=6E'Y2Z0?USB/\
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MZ-:_QR-H]Q,&I(43M"NB(0"P7)VH7=.M=VLA"9U[J+;-]K-XQ*!ZAN ^"!&
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MR<9[/".>;MQV]G^5^+VNN?!I]U?SCG[72FS?W^[MX&U.;1S3XSK@CL0]Y4F
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MKCM=SR&M'_#KU?\ 1?=?OOIS1_=K0D6>=E/\>CKS!.?%E06F+\#B/Q&&0XZ
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M"."$I\+*F2&(L=OM[YZ0^TRWA2W$IR\:M?K-O^GBW?;WBGR%CGXFQ7^KKO\
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M3''O0'%*[;CES+G!,V_DR0U:$]13F7B5B?U=J6JT'C+JFH24/D+)<KZ/J:;
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MHGTK](B,X>VXA3AA=^\U /L$\"WG8*_IHN*N4>WF(W'4X;";.'(L+8-ZDCK
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MEN0Y+\,I^/CQ@:VTHE":\+C,B;$CQ\-OY=PP[IKUK2.PK%JJ7MP>R*33ACQ
M9A^666P2)$0$(+)+0!T1N$_$R2;9.#E#Q1,B*+61;KS-4@'GXDEIO(L"PBSQ
M)+E[NXDMQ%);QQE&C4.TPE.J3(C9ME'FH!V#6)&0SK4'A-\(&/Z&W6#VV!83
M9XH;ZTQ.\NA<Q7,C018>]@IE7Q:XA"QY763M(IS<QJK9MJG8D\KFI_TF.DOH
M(@?OMT>5S4_Z3'27T$0/WVZU]T\<-S,1CDDY4"E3S7XR9<R%9XI,>4?CNU>^
MVUA\<-C#Y\F='<'ZVMD1^2VE,<68@I'&'!Z_&W(7VKC3O!HU3:S,I) 79[V)
MOAP!7#,J,',^I>MHTF9:I).,1=C-C,QXT20Y"9D/Y?FK;S&PVS+PN.F_?-;!
MLR/E*78"Q_#6W[E4,C,#R>158PSL1F%7:3ESZP7PW^$,A6&A]ADS1H/VAB^?
M*2W,5I'&5\;U@\EU(MO&C -)*>30,P85L"^5S4_Z3'27T$0/WVZ/*YJ?])CI
M+Z"('[[=:ZP[1^Z"Q# D9K"]SBF?&_\ @Z,"EN3.V"]78\U&6?,KPD:3;ZK&
M=1CM7XS8@T=&%O$&$*_9_1&\(K91V3JG8+#05 9PLZNNS_!0&["B*X%=><2G
M*'&IZ)L-2'8^7VXR93"IZHF'49S/S4PCF^49<]FSEK7/:0HV:F>UCJCK8@#,
M\_R^_MI]JZ_S1L-4$@M\GXSJYHG*.,_&LLUC5Y&&>Q 6/T=8UL1^5S4_Z3'2
M7T$0/WVZ/*YJ?])CI+Z"('[[=:Y-LU#MBACGR]VU[<*H+C&W:V^0.BGH,5H\
MRN4V\)6XM>>R6T]!G1EXQC+29L"? R[X]!F1F*X[]?\ .5^EG[>OHFA^&2+K
M1WMS(N>6LCV[+F,LQFL9&>[HS'EI9_N@],;23DKK1S!K:755N2N+;%(9-4Y9
M-J2WJMJG)LCED<NVME\5RNJ\<G9WU]T:T&.1.*PGV)\31@]<H\VT $1%$"B/
M7RKP,N*[&<#L([UOM'C8;G>JPYAQ7O>5S4_Z3'27T$0/WVZU@N_7_.5^EG[>
MCOU_SE?I9^WKU\R[#ZU>=\']EV^_I^/[(W2G\2:/]'^AB/0%'3?GJ/P)K9]\
MKFI_TF.DOH(@?OMT>5S4_P"DQTE]!$#]]NM8+OU_SE?I9^WH[]?\Y7Z6?MZG
MYF6'UJ\[X?[+MX&V/V1FE/XDT?Z/X/$-W].W'@FMGWRN:G_28Z2^@B!^^W1Y
M7-3_ *3'27T$0/WVZU@N_7_.5^EG[>COU_SE?I9^WI\S+#ZU>=\/]EV\#:_9
M&:4_B31_H_@\0W?T[<>":V??*YJ?])CI+Z"('[[=2&O;;,[HD.U/6'/+2.R[
M''DU\NY6,:2K\=WU/BVH(A\PPW/V+ S)D!'7&24-J,MUS))B VII?AD(<U8>
M_7_.5^EG[>O:KEE/5"P [762LP+8ZT5A&P1B$M*98PJ.D(E0IC&7$.-*4R^V
MA2FGFW8[Z,*8D-.L..-J^<NA=H8W$-W<"75/)F01-'KY;-<+&&U2=AR.8!SR
M.61J;/[HW'ENK<W^ X0]D)4\:6S\<CNC!FO*&W>:[EB$H&;()$*,0%8H&+KN
M39UIRFSVX\J&M9QY\?YO '.,X_MV-CMQGX\?V=?/L9<I?A/UGZNP#TC=4CP.
MYY5OE37$52UK'US>5='X=/U]M6(\"W0(V&VW;?4&G7%+7$4M;>3@/"WI==EO
M)QE4@5(@S7,BW6!W5K/93R6UPACEC.1!V@CH93S,C#:K#81OS%=28'CN&:1X
M9:XOA%REU972!D=0 T;C+E()D/THIX6^A+$X#*P.>8()5?V,N4OPGZS]78!Z
M1NCV,N4OPGZS]78!Z1NFHZ.J>KOGV=PXZ/3UFE7]C+E+\)^L_5V >D;H]C+E
M+\)^L_5V >D;IJ.CI3/L[AQT>GK-*O[&7*7X3]9^KL ](W4;"ZRY0X,7#O>1
M]%B*R:'9<EP= 5Q^:65BL L)F&F4;+<7$G1V\(&QF7FV%K%0A\A#:VGT/..9
MU$Z_'6R=O3JAL"$F4?&NMS(DK#\HPE%1KD?,THQB4_F%+CK96,984S#RY @P
MY>&',2,2GXZNWU'=[.WH('GYN;J&W:/9OZ>NJ#]C+E+\)^L_5V >D;H]C+E+
M\)^L_5V >D;IJ.CJ:9]G<..CT]9I5_8RY2_"?K/U=@'I&Z/8RY2_"?K/U=@'
MI&Z:CHZ4S[.X<='IZS2K^QERE^$_6?J[ /2-T>QERE^$_6?J[ /2-TU'1TIG
MV=PXZ/3UFDSM&LN4.8([#G(^BDL>N:J92R7T!7(L>.XFQ#<MDHRW-ELI<*BU
M][/$1TJ6[))QXL=EE]QQ+2I)[&7*7X3]9^KL ](W5^7*.N2.%H;&P"F6[;3)
M&6",K$1F.B-:1+[A)AQ4J)AV>*0VHB.BX<<S,G1F(J8LO+N(SLLZCI\@]>[U
M^0=+/8.;G/0-WL]//2K^QERE^$_6?J[ /2-T>QERE^$_6?J[ /2-TU'1U-,^
MSN''1Z>LTJ_L9<I?A/UGZNP#TC='L9<I?A/UGZNP#TC=-1T=*9]G<..CT]9I
M5_8RY2_"?K/U=@'I&Z/8RY2_"?K/U=@'I&Z:CHZ4S[.X<='IZS29@=9<H?'K
M=E'(^BPLYLW:X\.T!7)$@HYZW:]CU2,H1LMQ40KE&$0/%W4L.Y&0!LC+.&WV
MW79)[&7*3X3]9^KO7_2-U'.5%ZMVI..7)B_4JR4/5%L&N-OUO8=OBFCM2$D2
MH^AUV-;[VBOA;Q)JT" [+<ADK04J16KT(0/B; NU?FTL.=7*Q5L]U$VEH[6S
MLBP1Y.U#P[=-DAFXVU;3JG/BFNX%DXUU^>#UOOK1J!FEMQB 3VZCKHZ\8$"=
MHC#8N%JVX:4+&P]EOL2!ZSZ>P<=)YZ$]G,.@=0[>KT]9K+O[&7*3X3]9^KL
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M#IR+3:);X$2$%O$:\5FQJ[9K6,+0/;Z>P<=?/4GU#T"OR.]UMXQU?5\C;%F
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M[/TM4 K[J;#F0^T&UEN?9]7;E.O+GRFK@1)SY<LVU )PX/O[N<.KMV['!WV
M=(Z\1*L-9.[3'5R%(<F[,S3KMI*[UYB::R?@>*-1).A*0&]3S@NY5B"/R5-5
MVL5^^3EW/I2LB>$ISCMQE?MYQ_W1SVTYRG/_ (_NXZY\&GW5_..?M=?6,=F.
MSX\Y_M5G*L_\N<]<]*5_.KPT]C/;AE[MQY\?X)S]GJV@>Z]G5QNO>H\X;$G5
M<8& ASRJ55Y5G;K%>L<:VA*E.LDL*\7+5(;8(4*?'KI.3*'Y;A0QSR'1,5F
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MCS;NQ8ZDWEJ$],(CH8B0:"N2\%H;+^1CQ[_-2R?2QN3TA==:9PIX\2V/ N5
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M/37M*Q;KJRA1I^^=8V.[U880T[4X-C%ZPU36#G):3)N59+CQMJ B1A@ 0-A
M"A,R4O9RG'6!39%DH5AN'R"]C;V#MN>S&?S5]2^QU;\[,/\ CSXY(NA8"3/7
M;)=F18\N4RQ@'XZW(S%C/R5L..-1VEO.(QE?]L N"E[M7B.WG=13KI;Z6.L.
M6[38&@]F:H(8 :K(N<ZXX5&%:A5V VW3P>)AYP"-ER[S/CH1*,E',95%4W0N
M2W#,?>@5?K?'>?K_ &4$.ZOU&:$O:4H51/:EA;5*U>Q:>'6$G&*M#8(6[$;?
M LU5K5+,6:QJ=&V@M*JL&13+,X*L&W=TOXQTH= ,G)NPXH8BX<&L$96M[&*2
MW:X5LV/2ZK1YD$^V'+P+?LPSJ38"Z +F#662 @$T=/3:V'.5V:6[>=3=S\II
M>%=);VFAABDV2<Y-/F-HHD3)%WU85G[BE3KW)*W:2Y=KSK(BLE?V2%]Q8K51
M4.33,1\1"6\O/I9T;P/V#-!/0Q6HRYB>/#4JJR*_>O$CS<@"XSLP,BJO@+9"
M,#;N,BF&;$Q8@:HE]8KQ-"72V*Y,\7=4J7DN:NDAE<UQ8E2K223M.@'-@50=
M7:S)M,AV."D:_%.U6:4K<@K5HE]*6C:5#J%<J&+$\3LEAL++0;$L9#)%(<)I
MG=$>/EYF!8@5K9:L6,S2*L$F9UN?F#IMOMNP@>JBU:40#^JL:"]KG8%C$UC8
MI\BN'2@9-Z2P-M)U0TEB)V'XO N]4X)5&Y6EETEN!8]8UV.%,P:J!"N";_K>
M*7J8@L"G@8U8MS&Q:EK-8N'&("[J^?K@&: R^X)Q(9[="IO RL%Y4_7;_'X:
M1D76C251ZW=JGF/$N@9XV*H< <(B61T<'G8+R+')#U\5"A,D[;).GL#)MJ?(
MDEJ5,+'S<XK5*X66A6+=-2%6VG6,)5;4&DX,Y>KY8^R3D05%I#(EV#"$LM!R
M>3%B>E)KE=5"?;L184ZG",Q.Q=T XW5S79O:,BREI-1$;EI6B(DOU"E!9%GO
M]WAU$Q"8JD6W.5MPV&%UJWQ[:8.M8:')JP:PFA+I>(.;5+A5=TOW.4E:-EGP
M C1I"Q; M2!^Q)J+@Q-:L]IO=H@WG MW$NRNB)\FT6PC$G."PB%,$RLYX,Y&
M==D31:NZ9UUW/2FTBF@+-C2GK/M\J^BJ4NTW9BSYLI"\O"A]_G"#IZRFBQ8C
MENI#AQJUM$WIE2$!%P<FZ^'CRV>E*Y(]T:T8.D6* X!VFX4%BSEHK@[UH#8J
MM@T"KV#8E<LVR:F1)6> "A46OS-7VB25,WPO1WHXQVKSTP7&;M4/5KT;WW1;
MC9K@18[#:B5V@ :5ZWYUW-+H1YH94ZH8UU1-IE[\1ERD1FI]&I-/V?KYZY6"
MNJ.-CCML%5 ;',6SQL+%\:!Q][GR6JHJ P'UH^")60L#"3"5_.1RQ28Y$(:F
M)TD4?,7!BSDZ85&V2=46]?PR<F@V 79&VX( A"/Q'YTQN6HN"NPP NQW(1HJ
MQ5(A:YE:'$2%GK[E2-6LE5ZKK9^H96U8&Z\>G>H>MJ0'B4^3B?B"2H55(P!,
M:PU400@*5ZE>YPZ(/ZH!;BR2L8NJGK^#UVW'EUUXB<"D[':IM4$&;>,J\FQ)
MI=3=D#"1"=9+3*$P < =/:/9&&8<D.W7,#ND^@RCST* "W ^5AND(!01G6LV
M/.!GLU$CL6IUVP9E$F(8(I?-9B"NR CA:7$$URECIAG:!37:65,]2N(UP3"A
MX>M&2FE2(^.HA;9PJ19A=NERTP7]@P35SOQN66-$R\5@DYL6*?M^PS$V*T>=
M.,EB:#3V4J@3G&;N;IXT UNBOZ8)6PJ@4)!5L=L23(N1B?6(SNUH!'"!=T59
MRELCAF,V>3;)CLBUDJJQ';(FIU9:C1,*584WN@/&D7$K*B]I-!3%LINK+N(K
M1FJG!1=P7MX:6,5>*_)FQFJY&*PQ8280M$1T_AJLQ7PSA24TJR5M!?V:#SOX
MJ;/NM6H%&VX"L%CO#"W:=%B1#"4V1^)-M<$S!'>'&M/M3*Y(J$]%A04CC6!:
MYX!AR0N2<'L.QN\:WX&[&P><V"_I.VJN]70/.OV39 PH\;J]8(@*6\ZJ1+N#
MCJHHXW6*]7RA6(XV\JP"X<,I-<-)RE<!J%#[FCINZT$K5%:(J]LK$:WDZ,71
M=4S(HC,699:];"Z"Y"R$*ZR8&$)]MK[Q0O,]6P\LE8 L)^&\1GQ)"E6@2[H9
MPQ$13LPAR I$>-62-F$'7<I/N)'$JE)JT,O#>PR$<6IY4NZUB.(2REW%D>+,
MMUK)=3,O$:QR_*_CV"M"Z<4V@ CG6P\,XMI+)F2/3$GUI5TAQE'8@I\ DS(I
MB<7!NNJ*8L.:FMJRY%8"/,SG%C&\9NYD ->$:N/K?'J#KLHR%N4]G.PX"A+P
MZMG/6F*,Y*R+JXZT"B'<9J+BV"#025,RNKSD25J6.S<A;C?Q!Y&HMUDD5:G[
M(A%[3D):)8.V'Y 5JX:L@DM5%!?BM;LT8,)- Q4>?KNWQ!D:"^3%CTU6V()P
M1D:#&4KI1>Z%<,Y:Q"6]_4IE!X@&&!7YR+ -B$Y-@>GLBEPYA$'$B/PI"!SL
MUPFA_(R&*DBS,Z9%$FPLTAY<;NC/$"99058C[:AX?/"99MHO. 6@'6AT"(S;
M75),V"Q!@X\61>]9A5,4-)7@Q(1+ 2VX.8%D"2YL[/\ ";BK:(M?@G=(4@A"
MJ^'$ X;L2<B+"972ZGKW$?,=@@RS*B-5&B4X3'B3D2HL7UM!I\9EHK!9G8\F
MV<&.--O,QCD_7@^)*5<ZK=;"U"SAV+<Y-,N3&QP(2S,%FRJ5UMK80T!<" P)
MZB+-SJV(#F94^I^J-=(J5,4\K-'IV6*U)+N+(Z\'Y8>#7Q4^'-:48F'*L(N$
M&,G+3#RPKS@8^&\$W:VZZN=/(QQ@M)"?X1A%#U#NF/%NWWE='9/V40MTK8A8
MRV%*YF11"?K8M!>FDY;ELKI"P#ZRSBPBF(3$6])J9=QNQTV:L8U"N-;D$FFQ
MH;46+S(V5ZPP7KZEGA=FE67P4C!&2>""3 ,43D*Q)PR](@"SQ6)&[]G+3:96
M'<->'C1'8\:M/%7CY=::,U[:=5U@U2PU*1KL97)C<_(R%3&R(4PD PTU/:6F
M)DK701):\N*EN3A Z6Y)4_$9<0I56-]T5X4N YMD3R'H6 XZM(MLZ4XX<:7%
M#/7,CKZ+EZ&Z%1/04G6\.7##J]XKFQ$711*5!$R!\&5,9F)3F-HD/MFO:;F6
M6=FT6I%1]1)\0$5(U>2_>FX2ZM&D6(='EPQJC#ABM0XDHHF$+<)6VJ"\$?5$
M^/BO0AKN<?"=D<L3CCW278*F8L=#4IZRS5Q8\<U+L#L>#(EV!^4.8*EYLF78
M6H#\9NS>$RQ8TE8J&V$7*1XS:*+;$%[6G:W!/7P/-A$()Q*R;&$2AD2GQ!*G
MQ4<@R$G-!O8_I,P)&GC)44*7JP0X*9AFH#!!*E4\0[H=Q"#V"U@3>X1(1JFH
M'.&K(7$V2#34M$G33#<V+:W0WJ-)"(EAVQN+4F0FH3S9NN5T+82MA-1174[K
M?,SB];<V[U"W71I6*#K:#MV[+?(2!K=2UZ0&Q3#5BL3I6'!:#M,"YXT@2'3U
ML&1$0J)?+#8*"P[,J*R. 7$:6S-CR-,AG6R,ER5,[X_=^_><0D>D0CPN+3AY
M$:I9%0'*!#:<1#UR_'3(H+%:D+==7( ?"?BK6@VPZ]7]'44*$VI5AM*O(L9!
MF0X9FK"8$8?!"MLL3T8#Q&FH4-]SU R*>DD8L8O+=?+,-SDJ5'6NZ!</9#@-
MB+O.JS)=A@!2P^#"@VF9/0(L#$^4*+E!\6O/30(F1&#GY+A0_'&0(<>L6QZ=
M(C-5.R*%?"NZ#\-6VR+[F_J0U%#O75@S-=]7FH =[7T&23LS9:>X$3#&J9@0
MIDH1X\_'Q:&XDGUJY-J8=2CR7>YR\/UV@#:(^H1,!P*(*!)86 0-1Z];!T\7
M'!PX=X&^J2U6\?7PV30NOA3LB8 @1+9:T."I*C3RT>N([GUP[ U$A1@VC*N-
MK).=")3!\,C:V7'9XT;8!$"6DDFQ>J[+\,=:;#%C+CD&<LH+S5-]ZX[X3"E?
MH[SYXI1I)"-/VN,@*A8A>+*=&'I?JNX3!@SHN ,8%"B,S-C+QS2HP2D$(H^_
M'9(2Q.!*J0'A9D]/MW[FKQPUR,$DSVPFI6+%K8)MFLPJ\!L]B(66E6E!%=0F
M@V!(:0U-)7+ <PFG5U4AFQVE88NV"%3UBYR6.P,X5\6@A4:8"Z5IHB4&=&R@
M[(Q@C!%B2(=UMP68&!(I%H) .CV66!\0_$'-&V T:*";()"QF![?S&X:<?FK
MNQ?)=+]52@H!JFL5,:3*$Y%=HX;2S<[&O&:B!1*9'C)@)XH5?9-/M33O84)0
M4$VQ,Z4.>4KPWN??#V,44%D[\HL4HE^CQLPI3Y:.[X78L J5JF.UX2VWWDL:
M#-3R3O?^"K4404>M*PB!\O+-ZZEW'K+>M.C[ U)<@]ZITHB6$QCX-R0N"]/!
MSG!Y)AO,J/%>5AF0WVMO>!\7EQG(\Z$[)@RHTEY;&NYO<(&9!)]/'.@K09F1
MIQB"^D_*#EGH>2KD5),')..AI\:/*-DR+4*7 >A(+2E%TQ\%&F)C3/:OU7K_
M $Q2Q6O-8U@=4*>%5.=@!AN93K:)!.=()$9<B60DS2,^=/GRGY4R<0FRYDEY
MS*GGU]B<)4JP>CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E
M*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CH
MZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*.CHZ.E*
M.CHZ.E*.CHZ.E*\\H0%BX+\TS.@#AS?@D2)9.5'APF\R'VHK*7I$IQMA&7I+
MS,=K"UXRX^ZTTC"G'$)SCBV7P/X?\KMA6B\GK>8O)0D>AVLD"J>R $L&'(PW
M(>LS[^(0D7.()8L4O3*J89P;)D5"#%!,CJB[4S(0MB.YF_\ 3T#?VFMBZ<)6
MJW46+L*LS:[FYT&=#%W:J/R%LOP[%4R4^"2B#["'F1H\\3.?@2DQ)K#3^&5K
M0GL1ZE=ROTGK[:.L=B5>\;*&PM8[/O.T!-%9*P6ZS(EGS39:F5_P;,1J6R"U
MO'Q,"AEJ7,+&1AVVNV I**W:WD3BE=^5W-_AV8AMKC2CL841BYUY(0/N(G$0
MX3K7> H,21)F!9<F9:*]<J[.LKV(LI$LS>V)\FW1K%'@1!0[U-7]S3XE\?KO
M5]RUUNUC"FLS%[O4(G8;JWZB09EI$*AEBIM_(X:IP8("M+5AJ61:%RUQ89VV
MMV$R&$EAU7W7N1>J+C#E*<VUM(?9YQ<[8"%U:];;UH(FB:C?J3-E$O4Z.^WZ
MV(YEX: 2/=@O"Q4NPPQDD>JU&Y#_ %2W<?\ 3$ZIQZG'V5?FXCU><IUE?+C:
M59_7=470[=<BB3< \$E"GG:>"8BQM63E0G<ZN((D&ZE'BE)LA]2E3:+W+[B)
M9*ZD%&,WNQ,LU==)*EF-ACB1,E1K%4&@F:V1E1 JXD1@S1I(6(JPBX8BY%A4
M:&6>L\N:;/E#_HW'N4'$>WEJL6=%WFN.U2; (PH-4M^08B=)$6.%:A#I<.D1
M('SG@I$</8%2O ,S1HF(R'C26AZG6'9^.X%4 ?RA)<HE7&Q.64G<%WA()H-4
M842 <AZP;U(!9%G(P?%AAB8-/PU&,B6)B6;DY7J+&LV9P>FQ1,U:)7<B:V3C
M8R7Y0;VG&&:!*U_%,L(I8J1D0^*I%5;B$&!(>(S+%S:90A("QQ(^1Q&S)FGW
M9YUN >+!IBE6)=>Y=\'ATMF^V& 9I(H$6IM@(.>O]5>JBY],JP[7%,E$$SX^
M8<"0,KT,%7A\H7)$D)"8D.(J2^X1(-E+,MG!;BYL KJ*"1R34%H^M:97Z?KL
M4?&1JO9:1JETJU7"!48D*\6-0!2-I%H!?Q0M#!'$6]CUQ#24Y 23!@U_[F9J
MR^-:S&$=BW:,)U;JC5>JJ;X6#2R=E'(U3ZOK'F1=O+@IAL.]:6C*I5Z#@%C1
MUHG *S+GX5$K8X>Q%_P4.I67A*A&R[W#A#7(SDH--$T.T YAE-,"5DG=G =F
MKQ8/G:$X_7AE_:OTR!/+B[GXT5A,)E/,2(BE>M8NY7\([5<&GYXP\BXL$8-W
M=BP;\J.8<88 CJ8J=@?F,[+A#2A4*P=+%Q;(^>5NJ)4N68=:=<%)]RS\!N-^
MQJGKNJ!+L5#:@FS-DV6-7:/9@T-&PIFQM4"]9(E@K@/:7,@0:_K$86C"YU*Q
M&L34::DO"M0YN%+63B=([EI2*+IR_:JB;GV"<E["-5@P<L]J T&P(D,5^Z6N
M\R ,VI3PCE;,5TZ<MTTB7#EF94*83& R<EJ2Z/<:E5%&[BIK.$'L8N)R!VYX
M0W&0+A%95?U=*G@P+08?561 SLJK$&*AZF0Y-/)3!\0;-(UX@\/6XRQCP;JE
M7$QW('B,S2I]$=QM"8+(3XQ=Z7+NL5TKDPQ8;!9<%79**RU'G279]E)MO,%8
M9 >J-F*UB$AV(P^FQ=:<$>(H,Y-,ZTD3)$RMT+9&BRK("]12BPH^^D3$^TP"
M4Z$Q(.C+H-;.2!0\A(*QC80,P/&91F-"8QB%6CN86O+4T,8G;.MDML'K?4.L
M0KIRK:ZM<Z-6=85*+2I@:5/LE>)/$JO;(<./<)M*EX55(>V(\39"Q94L-%Q(
M56QNXTZF%SF)X?=^ZL^(UM\3 @6&=7[6'DDI<B,T5)6<23'(@6\?<0#& &R
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MDG;C:3ZAI[-6L8-H'9F61**XX(/ABD26_6JVQ#%TZQ2T/3*Q/KM'.CH"95(
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M'FSC/48DWFEPW)+,RW5B([".1ZS-:E'Q,=R'8Y<080B@)3;TQ"XYN3!-AIC
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BHZ.CHZ4HZ.CHZ4HZ.CHZ4HZ.CHZ4HZ.CHZ4HZ.CHZ4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g178576.jpg
<DESCRIPTION>G178576.JPG
<TEXT>
begin 644 g178576.jpg
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MXF&UYAYA#X@Z_!0(!'XK2+9 @$@Y$RDK)UA.NZ[<[@LYK=@B?@F*+9/P2@<
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M'9GM!JMFZ6>D'$!IN3)10LE]KH2@$""H(K=6+H]U%$2#P)<N$<34PR5)&@P
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MR';%HWQ2[<V6NW[)U[)__L=K^#VL';[N'B5\(UW(BPV77LQJ>YFXX%4NO+R
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MP<!*+>=;M3YNB0^U&&I%T9\.8E)K--M]F*YM/(JQ5*=:R6714YNJ)A*5$Q3
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MLNIP'5<N.VL'S)PG9%6I0FVT%R&VV!$$ILW4236\<?3ID:17XP]UM%)52GI
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M+;'Q]K,V@0AGBOQH[)S>"F;+C&$YL1BS7>T60 5N&&,5N*Y) =#JS2FS;O\
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M.3G^+"#=;[L;R(^6'*4-3I&ZBJ* =T7Q@P/*#6E9KI+@L5'$'Q;CH.-?-I.
MR"5/&4Y(7CBH2(FSQ J7$P7)^HA38)3S$E*:50Y%*]/\*[.7AES(,?JJ]&CX
MA7V!+38;,:2<25C"LQ4DX\F G+SN.)//RV9YX=R0S'.TTASG[96@Z.&-K(Z9
MW59\,O-TD'$I;-M#9L%!3',D%6RE+:5&H,?R*PDLC?#,8M'4^G":6]9R;MA\
M@)"=**B&5>PH*43P#N]9T?:"G**Y+Q*?7.WWB>W(3-S44PDI\;C$T)X$M41-
M.CC)\#6TI8!5&8KQ3W@V<$.8X.0!V!BJJ>M%"0UDL'$Y?AP!)T/D(Z2=O7>2
M>33E!(G]CRZ89,0J;M$V*YW=YM_3)+!$^3&2)D6Y;;SY<;!?:&X0TMNEF.;)
MI+&(,TR@-@\AY,5M&D%R)FR15U;'.MQJVT&G38T^D!Q'TV/0%(HA(&<UCF'\
M@%TXJ22$YRGC&P,A8E$+!.]A+?32S-1T= !3VV.$LXH,<,MO&)V(3@)M0ZS!
MQ)).Y*2F^H-.+5#!.;[ZU6:6LS@:1)QC@6<91FE!64FR>U&L6. )+<>"\^\<
M0#X;L$/)_B.<+AFEDV.3+.V@>31?D*QIHXPX>? "-'ZB(UU/1$"74AA.=>0A
M<RQ!X6DAI3Q*;.EEN&QTU&5D5?+9M7V)**46.YY$CW2@NRE37QG'Y=//9@P3
MM'/V[*DY72$QT=:>$P3D+-HJ<RD@@R[))8@T&<O3](CR43*B3L:$')L= )CK
M)$9:R19-[+J'C:UK*Z7R6M:UO_M$EYK>2W_W]<\_(GMNE^^)+Y>G/R)[;I?O
MB2^7IS\B>VZ7[XDOEZ<_(GMNE^^)+Y>HW>+BJ)IOA\;!!%5 B8$L%%65\ #A
M8;.UKSM%@=KWQ#%RRM:X@@8=KWMR7SSPPM?NLL;7DT"_>W_E!O\ FYU]*4I2
MHO9*//AK;KR[*L@QP_I-9\<ZH1PG:?L!IM=3<"2[I5=[PEJ^P0)!2Q*'FNVI
M-7P4B!V+=>>AIM)K7C0^J*P:T5:2C)!LO$=$$+RHQS$.0]([D=\ADX4<L"1<
M]&O'[=#?*(88VD$5.7>+:I)B)O\ L9,*QMG+^TDA0%JDED4FY59<6$=M-A8F
M2B>2!0 ,U2"6WV6F;')O)O/]5<\$'MFGVR7TS832AVZ4E%QCL?3O6MZQ PPV
M,2%+-@NVI:G/9IXL=]M)S+S$1$YQM9/470U@F.^;;-2#+?$:7TN0O%4U':E/
MU71]AF222CS'22S-A]W.'8YC0=J"NI1]7;I[-\F42.PWQLG.#F"S<#+*L((Z
M%B3+D%N-^\9SA=P[;K>TSUCY^O=Y%(ZAR3E@$ PO1+X,%,T8."*<7*AG_9BC
M1TVXN*IX4EOK-(;2DSWRO/1MMN%4AB/EL*;Q=4A/^I/*4I2E*4I2E*4I2E1Q
M;:?3I\+'[_>ROYCT^5([2E*4I2E*M5\,9ER8T')'TBM)MOQB/)&/MQVLUX(B
M<Y&LYT!5 R+*:(OH*N7-IBNDJ!?/, ZGGRPY4R#ED&,%GA>]JTUOPL^&G>][
MWT!TUO>_EO>^ML1\M[^F_P ZE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.
MBRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU
M[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.B
MRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[
M-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BR
MX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-
MD1^JE.BRX:?4 TU[-D1^JE.BRX:?4 TU[-D1^JE;'0KKG &MZ(L-K7V$XIA!
MO.%9LXE]#B=@->/TI;7[)Y-(Q6E8@UDQ,+*"KBE)Y!-Q4#88IK$@2*E+"V +
MA!X^:;-:-=MDTY 2=A8+B*<4MJJ)M8;"?+4=M20B;>5CY+)-.J2(7=*6J!)9
MXXG99$#1HEB".8)Y7+"YY@WOA6O719<-/J ::]FR(_52G19<-/J ::]FR(_5
M2G19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J
M::]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52
MG19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J :
M:]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52G
M19<-/J ::]FR(_52G19<-/J ::]FR(_52G19<-/J ::]FR(_52O8G<,+API"
MBG*Z7H9IZGJB0HIZNE*)/7*)BYQ.54DZ I):D2,!-7$4L>3E J6/$30.6 Q4
MV7 , 9X#!89X[T6M:WFM:WEO?R>3RWORWO\ =O>][W]-[\M*4I6O(;DVDNDX
MC"1%!^"WS)W_ "3\)[>N:99P^P-"4.;+*EX P,W2?&48<;5YYYJL;LS4M'?'
M,O/"V<8J'4SBI/1LR:(&HNA\V@&5(TGC"&Y><^8YMM#.]]IES)E)$AD0IF>,
MQV3CUP&$7,^*3LYW4\F=SJ*DLQ*>#WQ@R&+)$=X<X,;636)EK([50F^9S:\H
M+:1CD20VY&PZ:W.<B&OQ4R.@)#G69@1TX00OA>Z&RH]7[IP1Z1%M C3)@B_L
M9B*)B'%T.Y!]],8@YB34[0Q1 ,#<K8 9YAVA(2V @I%'A4R.%B(+B 9?DD%<
M11PHO;IN4^0U[8VX@5A(MA[ *XH%AL\)I=N>> .1R*,3 @8=X1#Q$$")*\U&
M00KYAXCFF'&Y7,4 .4'&;BSRYN'9JQ000.)X6R/6(#"!E\YS>.!7-3Q;TF&0
M"N9NT$9B!DQ72E1$D#'\2@@X2&]9 7\2 QV.$%OR35,5W82ZC@%G&D38I5U@
M,$0YC,3JR/XH5WFQB(RABGWAK$#)4P8!^17(&DW4<"PCK;#0:&2L&EO17>+)
MHV3DVBYJR&QB.$;K5D+(QB0O/+TLFW<=F O*."7=3\05S&*/E)A=M-3):LEW
M-XLM567U9$R64,FPUVN<^3_SOWGQ;Q3S'S]X/SAXWW3SG[&O&'S;SKS5XG?!
MN>?%=\]W,?.W@?LX^<'GWF3]T"J'9R;1<U8C91'"-EJZ%B8R(6GEZ73;..[
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M! P\H1#Q$$"(K$U& 0LA \1S3#C<IF* %*#C-Q9Y<W%LU8GGF'%$+9'K$!A
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MQ$$"(K$U& 0LA \1S3#C<IF* %*#C-Q9Y<W%LU8GGF'%$+9'K$!A R^<Z/+
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GF[#U.U2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g762069.jpg
<DESCRIPTION>G762069.JPG
<TEXT>
begin 644 g762069.jpg
M_]C_X  02D9)1@ ! 0$!GP&?  #__@ \1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?5%)!3E-?-$-?3U)'+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M 6\"E ,!(@ "$0$#$0'_Q  ?  $  00" P$             "08'" H!!0(#
M! O_Q !>$   !P " 0($ 04'#@D(" <! @,$!08'  @1$A,)%"$Q%18B05%A
M"A<C,G&!D1@D.%)4<I27H;?1T]7P)3,W0E=8=['6&31#4V*RP=0F)U568X*2
MDY4UHZ?2\>'_Q  = 0 !! ,! 0               @,$!@$%!P@)_\0 4Q$
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MW:QZ1J?5NC3U]MTXYLMHML?)7"K35@G'ABG>24PYJUEB$Y!T[,0@NE'")Q7
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MY$WAX^GS],ZD7XY@O"?$<ZG2XD*YOLK '/X#Q/TJVLR%,*@D #KM8I^W+^:
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MGX-^D/W2>Q,LU>1[M,?(^2KME \"/ZQY&_V ^%3B&GYYGM)PRY:3TK>Y';]
MT+.9;JY-)Y_&1MYTH6 V:=L%99)H-[$5P+ B;=LG)0RK!HX>L(YVS8NCMP-'
MPGYJ<]_48^@\_P R=2@@("'D! 0'[" ^0'^<.<\AIGKE\2CH/U_SE"3IDQ\4
MJ9C;_?%-1N56_!\PTVMY&@VAT,Z:PM0:M9B4T.V&6-)NI^0!G// ]I5%T[51
M49R">4/7KXC'7C=<PHFCS\A,==G6A7FU9C6Z'V12C,GNDQ?Z.V9+6NO5]C.R
MA&UD&,5>E:D>Q+E1-TZ279D13?(*M"&L<3YCN,X!'^SS_,#6>O'."F P 8H^
M0'[#]? A^@0\_<!^X"'T$/J ^.<\-8TXXXX:-....&C3CCCAHTXXXX:-....
M&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3
MCCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXYP(@'W_P#]_L /
MN(_L#Z\-&N>. 'S_ +^!_G ?J''#1K%OM%W3ZQ=,ZF6W]CM?JF;LG*"R\1$/
MW*LE;K&5 3%5"M4N&1D+3/%14*";EQ'12S)D)@,^=-BCZAC_ -]VSXJ6\ZY-
MXYTAR'-,-QR+1J\NW[L;1*MKE 7VO6>OQ5IBW^4T5FQ54=%49R)XR3;O86?<
M-7C9PV=RE474:NS9_:!TLZRZOOU2[-:9DU9ONO4.F-J+3)VVMAG8RMPS2<F+
M"@YCZR_,M7C3R$G-O5F=@?1SR4BRB0L0XCSBJHKE*!2E_BE /H ?0 #Z!] #
MZ?H /H ?8/T<-*! P<9/?\7EZ8P/7'?S[?348QOA*]0+;V,M_:W;J4]W;6KJ
MO#RBT3J<]+73)Z1+,X:-82:6=YW8%WK&/@G[]DO*,X6SNK2S@U7:J,&E&H !
M.2:(-T&R22#=%)!!!--)!%(A4T4$DB DDDBD0"IHIIIE*0A$RE(0A0*4 * !
MSW<<-8))QDDX&!]!]-...>M15-(ISJ'*0B93'4.8P%*F0H"8QU#"(%(0I0$Q
MCG$I0 !$1  $>&L:]G'(M>SOQD>A'5M9_"V+86FEWM@/H6SS$T$=(L2"XE/Y
M;RLI&/$*57%TU"E(NWL-JCGB7K 1:&\"'((-^_=-.M3P/(KK1U^J>?,S@X00
MM^P3+F]V,4S@)4'K:G55:O5J,=)^?7[3VR6AMY "G25*)N6W:.ANJ-Z"25-J
MGCKO@K:N8IP%3CXT:<H\R=QW@CE^@.J-OGM(Z-Z?,D5W>J\UJ/(:G0Y7[(<=
MC&ZU@\<#_2S+#CU(UN3B<H>?(_;^-X\CZ?T_G>//I#Q]?(^ \?7[<PTV?XB'
M2'KZ+I'6>S^/5F39J*(N:XVM["T6])9/SZD1IU/&?L_O>0$OMC%%-Z@$!\#S
M\^C??B&=UNS9GB.R]D-,L$&]](+4V#F0H5#])!$2$-3*&E78)V4GGP!Y5M).
M#!]%%U/J/,,$TTT0,"*::('$3'!%,B0',(^1,<$RE]1A'ZB8WD1'ZB/GG2=K
M]B[%5?>=Y"DXY5]MAY8^>+5H+W],>YX'GD^6N2[Q_*  9DV'825&>-G=Y\$]
M^Q-*FQ[>9_X?DYP0#K>+V/\ =)_36EF=LLBS[9MOD4#J$;OTX6-S&I.A*( 0
MP2MU=_E.""G@1]Y.DJ"!/ E3.)@ (K=6_=+/;RT*NF^39!B&3QJAU/E7,Z2T
MZI8T4S>H$O6Z<R-+KX*$*("?Q75TSJ% 0\$$2#KD\<OFW^S+H^AQ)VY[TBX^
M]W"Q+.3Y?BA0PU3GZU_77-MT]KO7>YE@-V7;8FS]SM=:&L!G^;.ZS7!],6?W
M]]2:Z/\ &/\ B5Z<59*7[5W.L,UBF(+',H2F9JBFF<! 2)/JM76D^3P!A %1
MFS+A]!]WR4/&!]ZV#6]1=*O=,U73=%=+&.=56]Z#;[<"ACCY.(HV"9D&X>H?
MJ($1*4? !Z?  '+=<<MM3:-IV_'N.V;?3QZU:=> _M:*-2?UDG5'O;YO6YD_
M:.[[G?R<D7+]JR,_19I74#Z  #T&O01JT3$3)-&B1A\^3)M4$S#Y^XB8B91$
M1_2(CY']//I]9_'CUF\?J]0^/^_GCQS8ZU>G'''#1JY^(?\ +;BO_;+DG^<>
ML<_2*^(3_8A:O_?U'_.!6^?FZXA_RVXK_P!LN2?YQZQS](KXA/\ 8A:O_?U'
M_.!6^<(]KW_&W2O].U_Z^WZ[7[/_ /DV]KW_ &:O_P#LF\:UEN...4[7C33G
M(B)@\&$1#]0_4/I]OH/ZN<<<-&O $DBF Y4DBG+_ !5"I)E4+X^P@<"@<! ?
MJ @(>!^OWY<FK;#K5'$OY':?H-:*7P (Q%OGFS7P41$ ,Q%\HQ,4!'SZ#-C$
M'Z^2_4>6YXXEE5QAE5A\F 8?D01J34N6Z$HGHVK-*9>ZS5)Y:TJGYK)"Z.#]
M0PUFE6/B#=KZR"28Z0A96R8@/L6ZKUZ6,H >/H=ZS91,F/GP'D?GA-Y\CY\C
MS*&D_%HNS(Q4M$R>N3R7@"F>TV;D*Z[  \?GC&S:<^S6-]Q$I9)F4PCX#T!]
M>1&<<BR;=2E_%6B'U1?#/YQ\3J^[3[7/:3LK(:?6&\RJF (MRG7>(>(\E\/=
M4N*J_P!#B1Z$'&MCBC_$QZS6KY=&>D[1GCQ4H H6V5QRM')J_0!+^,5M2=9%
M3\B/A9R#4O@!%0$P^^8M(UO,-*0(XH-_J%O*9,53)U^P1DDZ2('W^88H.#/F
MPAY#R5PV2, CX$ YJ! (A]0'P/ZPY[6RZ[-TD^9KKM'R!RJ(/6BRK5Z@<H^2
MG1>-SI.43E$ $ITE2&*(>2B \UTNPUVR8I98CZ!N,BC]GPMC];$ZZSLG\J3J
MNH8TWW8]GWB)<!I:CV-IN..V69R;]4MV)PE2%3GT[$;G?G_?_3^KCFKOG'>?
MLYF@H(,=(>VN*0$H!"Z"W);FHIE\>E(DB\41LC<I0#P0$)PA2!] ((?3F?\
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MFT#$L(AN_G9A<7,K,/48]NW3=RLDX_AG\BX*H\>*_P (X64-X$.^$0#[C_\
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MZM"-?&X.[2.+<%V=3)DI%91 WPE5N5B'_+;BO_;+DG^<>L<_2*^(3_8A:O\
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MC,H&7E)IZ! $2L(6-2<R3L?'YR;?V2>55DRFQ*(S&XF"F(*2X< KQ R20<C
M S],9UC9)MX@W:@VP3WJ^\R6H:^W/MTTL%UK5B18HHH)(61^4SNL?$-Q?EQ8
M%21K9/Z?=BK#V4S=Y<K!0S4Y>*EQKXOVD@#V LSYJV36DGL DX*G*LVS)99)
MJZ;OP<D2=F4;MI)^9NY,EEERTD'$T#KCC;6-262@J!EM156=/7 E]P&$4V5>
MR<FY^I?F925="Y>N ( '>2CTQ$B"=8A.05P7Q)=P@M:M5X.HE8J#99Q1TGE\
MZJ";*$@T0(UC&E>ED$%'<#+(QJ*)I!<B;Z,D951TZ>QJYU"+)TV.D]Z2R]2-
M8XD.41V/?)^% S9^(J"QR<*2!D @Z^BN[>T7;_9CM/1^V]>[I8W3?-S@6/<K
MU.K QA,,2FWN,]:NM<^XPV9(ZD1@@:U84/*L,LL4XUL7\X$I1^H@ C^L0#S_
M $\QNZ_=JLE[&10*TR9%C9VC5-Q.46<%%E:(CR %55*V!0Z,O%D5_,),PZKM
MB/J3*Y,S<G%L3)+D"2.2)S'(C(Z^:L,$?_@^8([$=QVUT[:MVVS?*$&Y[/>K
M;C0LKS@MU)4FA<>3+R0GC(C926)^,D3AHY%5U91AQDW23)LC[#ZUV4BG5EL-
M^U11=7UVR03FTZ::6<B\LR=6>KH_B:*,\JC&MO2^=.E8>'C&T!$KH0XG:C;S
ML)U^Z%8NSM/:S6,4SQO)U5="S+R*42?W9^U)JE)"-&%02>MZQ-VN<EC-T6(.
MH=4[N3.21D%?#59XC(5S#/NYTZK?<O+FM)E;1.4^P5F2<6*ESD>Y<N89K/*L
M%8\0LU8!P@RL$:NT55; H!FLW$ LLY@I-F==Z@^F5[3O:B:U;L1Q,(X)I8W?
MF*R *(\*02@50",-CN_!V[-+>,+&PCC1F&756 P7)R3DY[_+R]!D#RC-Z/XW
M>>\N_3/?_LA&":GQ4P=EA5&=B9>$]ZO.UD8IRQ06(";NJY\L*P,G8)%3M>B'
MEK$MY)%%3<3_ '(A^ENZ=A,@T2L=%>SN2/4IN%K;Q#)M<SZ$25H%@HM/8$!)
M295C6K"+;,V3--LQ2L+9NQ?EDG<=#VZN1LX]3E)2783  !^L1  \_M$ ^OZO
MO^L/(_0/J(<=W9I6M .(U@6)!32!Q) M49$1C8>?+!+E@',G(,%P%":P41]N
M7,L3*6!5O%."W('Y9 &.V,8)\]>7'("G/Q/NVEQM6U:%B?7BH7;KE@-G5AKL
MW<O)%+1SP!'DD@6R+JMYKYAB99I R4NX3BJ;.L*W'JD":4=E;.W;:8SKYN]&
M[)9-4]>SYRLK V=JK[K%Z4J<I S+!8S*;KTNB03$3DH:126:+G1,HU=IE1?L
M%EV#MLNHQ9V^U419)E4*2JMPD20Q2,@D6*8*28Y&C(<*V.2Y*DX.%QS1R$JI
M.0"1E2 R@\2RDCXE![$CR/GJ]/'''(6G=....&C3CCCAHTXXXX:-....&C3C
MCCAHTXXXX:-....&C3CCCAHTXXXX:-....&C3CCCAHTXXXX:-..<"/@/(_[^
M/K].1(;%W,[2:+N^E]?.C.64BW26(-D@U*^:2_!O$%GUA B=7KC-2;K[(KLK
MHCF+*YDGRYW\BREB@VBHV*-+/)%:M):9EC,:K&G.22618HHTY*G)W8@ %V50
M!EBS  'OA#R+& 6R23Q55!9F."< #Z D^@ [G7.Y=XG^A]G:!TXZVQ%?O4TK
M=9N$W:7G'LW4UJU#U=!%Q:66>6Q!>.6BKK7(HM@D4+7$$DY&"L</&-H)FZ<J
M*O6V#I(^1^'KHMHZI]I6CW4^AW85291KUUEF[UX:I*RSL'#J3,]*J"D--1#H
MK*4T)G'*)/1<MV.KUDI7B<LT4H*4::+W4F+OK5*I(85\1?JC(,9V[U:K,G\0
MGK,-"+G8-)-C'R:[E6)TFLNF#B#4BY)[),K7$OF<(L_D(>5BCQ$Z..LWG:SK
M=F<OVLPF'B++('B+7*9_<8=%ZS:6"NR"BE?MC6#E/=D*^>5033F6T#,D3F(9
MM(N(*6371]X'-@E\+;8HH_#4Q,J17H1*GOBV\&>"Y!*"59 K!JTL2!.&8YOC
M88A+SG9CR^(9:)N)\(Q'"/$ZGN"2,.K'.?B7L,G!/K%\.+8<ITR,*Y[,%M_4
M*%D+;9:AFL4NYDT-$BM"@U8IW"7B(?LG--6K$O#.T5YTT<YF8ZQN4QF(6-KC
M^6>R!9DH&!A*M"Q5<K<3&P,!!L&L5#0L.R;QL7%QK%$K=FPCV#1-)JS:-D2$
M20;H)D22(4"E* <[1---%,B21")))$*1-,A2D333(4"D(0A0 I"$* %*4H 4
MI0 "@   <BH^(]\6/"N@$"M6UO:T[L+,18/*ICD)))-UH]!T0WR5ETF83(Y&
MEU0Q@]QJ4[5S8[&!#(UV)70!S*,==!#NO45Z&I4KO<N2X5(H(D3EC)>:4J$C
M4 L7FL2E54$L[JODUN.Y;7T_0GW'<[<5&E .4DTSL>YP%BB3XI))'("Q01*\
MDC85%9M9U]@>QV+=6\XEM7W;0(+/J5$B" R$NN8SV6DU2'.T@:W"M2+R]EL3
M\$S@Q@H1D]D7 $45! K=)99/28^(U\<C<^VR\WF6#KV+ NO*QG;!RE'R/X?J
M^GQJI3-SFN]@B'!QJL ]0%0#T6IR)BN$%SHV:Q3J9PC6<7_:OM]O?<_376I[
MW=7-EER?,MZU7F1%(VD4"&<* ?\  *+6077;0C#TE3*]>J*O)^=53*[L$Q)N
M0(=/&7GH;H_V9;?L@BO[N(MRW8<71"O.E2?L1X,;C[^9#W]XE4!6P88XW42M
MY1Z[]KVZ=1F;;=C,VT;*24=U;AN.X)Y'WB6-O\6@<=O=8&)=21/-*K^$G!2E
M(4I"%*0A ])"$*!2%+]1])2E "E#R(CX  #R(_3G/^_Z_P#OXXYU/7&M;LG[
MGD[X?OO8W)].=$F/>T/!(I.2S!T^<G4>V?%%WA&R,4F=8#&7>Y=+ND('T^^)
MR5*5JA$D )&NU>1)_'VZ(&ZW]CR=BZ#"BUQSLK*2$I*)LFPDCJ?MB:2DA;H<
MP$.H1JSOC0BMZABF]A-25+<VC9$J3!$HP_=9.PM\ZI[QFG8#-UQ+:,WL2$J$
M<94R+2S0+@AF%IILH8ABB,5;:^X?PCL1,'RYG2$@GX<,D#D_0VUK/\2^*ST+
M4CHN12=4/?,^C+CG-K,@FK)46Z-BC(5><$@D5.WFZ1;&JD19H],Y%5TVM@@%
MS^P\7*;AN^QO[/\ K6MU#61EV'?G:+<HD!*12R,K6PJ#L&5N.X5AV+,+$"<8
MPV?173<D?M.]G]OI2TZMU)TS''/M$TC //!$I2F2[8)0IRVNT>X16J69.<S*
M1^:EQRN-,SBYX_H=WRK1(96OWO.[/,4^VPRH&'Y&<A'9VCL&ZARE%Q'NP*G(
M1+TH>W(1#QA((B*+I,PT/SM\<B2QI+$ZR1R(LD<B$,CHZAD=6&0RLI#*0<$$
M$=M>>)(Y(9)(94>*6)VCECD4J\<B,5='4]U=&!5E/<$$'N-.9V_#$LD15?B#
M]0)6<A:Q-1RFZTF(-^5JK]O&0;J;D C&%L:+Q\M#BC/UIXX1D:\>0<N8?\5*
MW+*Q4JU.+)3#JDTFW:3<*SG]!KDM;[M<IIC7:K5X)J+R7G9N25]IG',&X&(4
MRJIO4<ZBJB39L@FL[=KMVB"ZZ>2V_P#1'LWUGJ;2]:K2( *4O:5Z+(6J@Z+0
M=5@:M?&J0.3TB[R&?3\^E3;8*93G:Q4]\I\XJ@L@P<.72)D0UNZ24)X9MGL7
MJ]:QNE6Q5@B>:-;#B>*2$O#"9(Y)>))P%(Y%2H8'.-ML\6XUIX-]J[=:MU=F
MNU;EB:.O(]:,UIHYQ'/.(I8H0X4 M(#P#!BI& =@%G#5-=GU^Q'?NFN1LV.U
M?&)WW,)_,;>RTMHPHE6NF?U#WKQ2XU;0UI)E=KU$O8.[M+1+2\TP8+3;YQ5X
MB*933 D50G6#H5@=BQ9K'VWKM3[7#WRI=YG3+5(NF:EH5XC9O'K;?(+,#SV^
M'O=/HF#VZ(2K31M!9%6*3IDYH*+92QS3V-*I/*--7K\1*H!E0DRJ B8%CK?B
M7N B<P>D%CJBX,"1C 7TE6,8IC 7TE.(%\!<S'\ZTS>+[5,9Q^,E+M=;C,.Q
MK=0BIYLT0=2C:)?24K+JJ24M'P$26.K\=)R,U8I)RR280;%\X?OR,T50Y4IN
MD+5:G*8NHYMOC#&W9F5;4<">%[_*\N)-T*PJ@M1,[-*W_!%EDD,A$D=VAZYI
MW+T!EZ5@W24J*=.!GJ36)?&.V1)!F/:.4[N:<R1HD:\3=:**,1AHI92_B@2;
MJX=??AAZ#$X?1ZE1YSI)D\:RU"EMK6HP1M<>:ZGGL#CY&7N-@C$X6B)&):DH
M5TP4N#"3FGHRUE?L@1C6?H^&V6V6/JM\1;,>NCQ\U[FW>FXJXS&/J<FI ZG;
M\7KMY5?[=4LNF4).)??C*K$S-_.Q$2]1DY6*!JF@1R9- B$2%SKTG0K7/4.R
M.X0LY5IE["R*$):J_:H0\BU6%-=2#L%:E9:M6%BNJ(BUF:](R$9) 856CQR4
M?5RG49$C-PFY;21&3QDK[B3IM(@S>,5R_P '[B3E!PBY9KE]SV_<3425+[GM
M^H/<])MVFP!MBCVN*XDBK;BOUK!B>:"58]S3=:\4\+VG-BO)P2&8)8C6:)F>
M/PN0"UY^I67J23>9J,D3M3EVZS52>.O8A,FT-LUJ6M.E-!5LQ\Y+%<O6E:"4
M)'*TW%F;8HA,&UJQV:D5/NH>G]I.U>0_#]U+1.O'3RZH.Y+2T;#'7&(5H.8=
M@IF$L*=IV:QM:>]LVCU;)5+(WM2,;'*Q2X*-P4!RO77[K3D-?WW9KAU.R8VM
MYU\//KIV*OW5:Q3.@(YQBO8>[[2O49>&7K,/=65QJD?9J8I V*9R><LSQ>$%
MZ:,.JU8RQ2FUW/Q@YWQ9/\84/**.@>DE/Q=0\JH_*) *]))_-#('?E,*8%=E
M<B[*(I@54/S0YX.90#JO5WDI[CE<57,BJZD3+.W)P 7"[A^HLN=RZ5])!755
M="JJ8"^Z81](&"$.EKI=/_K+0PDQM+!1@GHQ$>]I9GJUXJU](:]64"0 B-KO
MBR&66Y,I>)Y_^&6WB-__ *#'8G"RI#9W"S6W&?E[BU2M;LSVMMDGLW8,1,09
M4H&&(10T*[!)H]E+M/@74R%#X@5+S?K+EN82W5.3^']K&8:)49J[N+J^E>R-
MZSI?0*K+J3=GDH(U BF%C7BJK4H:(CV4"BV^<,*SY1-=GE_NO7&B7KMUN]WW
M#K37L2-7OB(='HKKMOU>F;[4KOV77UC2ZE!Z_67=O)<54+6BQJ*;RP,GE"3J
MDADSR%_#FZS*2CWKHNJ_.=>MIK9]'1M=6-5I#+Z)1=*O,19[=4X>>;4G1C1@
MT29BX5Y8PDK>,ZWEXR09Q59;S4RRBW2<F_CF#-)55*RAYAPLD1HI,N'"$>LX
M=I-%)A=PWCW"I@*\>(MCNSHL7"QR@#QXDFBLL8H X6.)0\:^+I.:PD)K=32S
MM!&D3V0UFS,!-5V)YC'*-U<*EUMMEL/#+XT)AW:41*"B32[27K6"L]A;?2,-
M9;$S3)49*E2 FO<ZB2N)(#LR%WV]-VAJQS0^!.+&RP^*Y#O#%M%YAUQZ@O=/
MZOYM>.LV:Z4^[?\ ;7XH.4:!IERM6D.] JU7PW3+O^]N_J,D6[%C6]I:$0C&
MBMPGF$I..V#1?R^-)2;V6-:^,ZA=0&/2^GV-MD;V_4ZS]&[3L-\[2U_-Y1[9
M,[['1QI8CQ&3[%6/<J?EM*:4"RLHZGK];PR^2M%T8K@[9*3<K+*H)ZWR3X%C
M *#X%C)B90HH/A5,F90?SU"BDL8R8J"/YZA1**@C^>8PCSVA*KI-E(<)5=)D
MY=)/5H<)19)BY?$ @(/%XD')6CA\0"I_+NU6JCH@%)[2H 4GB5_@CN"E#'U+
MN"8GCFE7-DHY2UN4R\5:ZPB\.O<J5HTCXPD4$DDC<R*(82];[85=9.D]KDS7
MD@B?C4#H)*>TP-S9=N7QA)9H7;<CRAI^6Y21QS1K$YL;"W>3J)C]4Z66?2Z)
MUHJ_7I]F#;K40CZ^56S1-\M+[1(J-;V-7+NR52US2\2[BQ]JD%'L[(,FD16I
MK.8,%G2A63]HE'):\G/:>97=MF<4I,KNV4:*A8Z*4EUW;*-,;UE6+&QBCI5K
M'&-X4*L5DV0$WA0% '\\.7-HN+Z/I5!V33J3 MYRDX!!5FRZW,$GH!F>IPUP
MGU*Q7G0QC^3;2LR>0FT56?RL$SD7;4$E'+M!!J0RP;W:*4NQTI(MPW0W/$N*
M\=BR7B$?O/N]>&L&LV;#L9+/>/E*9)); C)EF)EEKN][A#U#N$4VU[.*/AT6
M62K4$<QE]T]YM6+C)5J58T$57_+<(%BBAK&0"& +##X8A_RVXK_VRY)_G'K'
M/TBOB$_V(6K_ -_4?\X%;Y^;KB("&VXL _<-FR0!_E#1ZQS](KXA/]B%J_\
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M8YZ!P]WN,+U,&8M\(,%0YFG-]G0OT<6O*1]<C#*TU:_$JIDU[)&54IVBRZ0
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MWC8\V_5:OUTQR?O#MJT08U>(0C*O7D 3;)24RHD6/K%;8H)F1]""K@J"2A4
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MZ3J.6>QCA$C^,<+MO3[J*IDW";60;$<).FWS"!Q34]A4Z"B8@4\ $-H^T_#
MV.1RWL--VW8.G^RSLVYKNIR2TC-6*L2<\==Q-/';@3N'19LI7*[V[U-)04IE
M'WKS1D0<EFH)6;4IM<$JQ2+[PBAXJY!#V%&3((3^$R(N&$9PTBYXY*X+4DHB
MXEE/ DAG'DA[<2WJ%))!;T.,COVKGLC\2W9YYZ:W]+LXMUTQG#[H_+N&D2%
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ME=?;C\T[+4I7YRFV1PB"2=USJ:,J\I5N;B4ZB1U)&++\E,II*J@QLT9.1AS
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MQ&'>1EY2N=&.NX8%CC(TXR*AH=]!I9[J8Y?ZYCC*-_$+5O4/@03K[!42.2>
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M>"'SZ-GB6-HTVJ#G:A8):<;0A$($SCW$EG%GZ]\-W2*UL,;G6L!7KNQ?USL
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M^L/U#QS I1"42 M@$,$Y-CQ Z/S)Y=SF-?3)'PDE0%"G]I>^OLLNUF*G[S-
M]"7=/=JPL?9+[?>VYMOCC6!1$A@W&WE@YC5Y/&A@BM-)9DO!OVFLMDV*]Z='
M13V$96^28OD(J1<-G3UF5I!1,0<CAPS$6RAE%8Y1<HI")035(4WYX&Y9_CCD
MI$6-$C485%5%&2<*H"@9/<X '<]]4;<;]G==PO;G=<2W-QN6;]N142-9+-N9
M[$[B.-5C0/+([!$547.%   TXXXXK4/7=UJMS=PL4'5*VP5E+!9)9C"0T>B
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M^)?LI2*?/(R3CG2+Z.DHYTLRD(]ZV."C=XR>-CIN&KI!0 .DNBH10AOL/@1
M?CXX>?GK*LR,KHS(Z,&1E)5E92"K*PP592 00000"#G6PUTA[OLMK9,\STQX
MUCM<CFHECY P)-&.B,6B7J4>LDR^A%M:&R)!6F89$"IO$RJ2\0F#<'K*-DF^
M_P!N:9+%\]BWK.3C'CN.DHYVW?Q\@P<*M'S!\T5*NU>LG2!B+-G398A%D%TC
ME424*4Q3 (<V%.CO=EMN#)KF6D.6[+7(MB<[)^!"-F6A1K%(#+R+1,@%1:65
MF@7WIR)2*1%TD"DQ%$*V!\RC:MNFU^%RLUE^Z\Y8@/\ )>7Q(/6,]RP_0\Q\
M'X/<?L1]MHWY:O1_5UH+OBJL&T;M,P"[RJ@*E2XYP%W4#"Q2DXW #BW^.?\
M"I(#%\@/CR ^! ! 1 ?/Z/J A^GFN1JL]D76GXFNS;'W6KD]/5:=K$5;.N\^
M:L.[57#NHV(@XM-JUB $[=Y-UILTDH6**Y(=K7YHZDRY18*R\1+%V.>4]8ZI
M5[<S)'VNMP-GCR*E6*PL,-&S;(JH?F^Z5K)MG*!5 ((A[A2 <"_3SX^G-=1M
MK4>;FCO%8@:O*(Y/"E",Z.3')Q?B24"L"I#H64XR"/3\T9D"8(#(X=>2\ER
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M46CB<D6L>4&B+N1.E\PL1(5!]9A,JNX6,HNI6G*NP 8@$, 2 P! 8 ]B 0"
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M OG**EOEV+E9K+9%4G[8Z1%*?'K)"UT&=;*K)6A\1:HQY_P-G.+36K7_ /\
M   #P  'T   /H  'T  ^@!] ^G."E*4I2$*!"$*!"$+]"D(4/!2E#Z^"E
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M4JIF<"*B"DZ]%27E")@<D%6V(%<3TVJ!A GEDR\D:$./AQ)N8]IX$7 <M)Y
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MF(]%]-0#Y&)D48ZRP::[)TY;&2,B@!TS&2MRNZDEL J&(=3V5HTD'(8/'*N
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MFZ1"MS44@LG%%GWC)O'_ "3FVVQX;UY9XD9$446MQ-8K0LTI:?$(253-(K?
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MA,J:1$TR7X[;]IM-[E;S=]\U5V49VU.RMX6O-7"B\)1*;''6)6:+70/X L7
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MV19VV=^_O&WS%C Y;R:2+#5YR,#QX9"HX%27'''++JI:<<<<-&G'''#1IQP
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M3?4#H)J$%/\ A?/M@)@H2;PG;JUZAG\>T^*(3SZE'5$LQD0\>WZA]]O&KH"
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M2<!X6;^JR3S0Q', W,;1'*4I2E(0I2$(4I"$*'@I"$*!2$*'Z"E* %*'Z
MYW3V3=)#'^%%^('\<6T1N/+!,<][!]<\J]<GR^_DXY\%QYL]MW7!Y#HW;)B
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MH[=.?B9]-OB)5AS3("5C8R^2\.NUN/7C6V<.G9WL>NU,$LW813PSVN:963)
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M0KG<0LZJ]NQX4<34H#*'=FK5]GL+O(U^Q9<5)1'7L/;2&1Y*FYI"Y>/: 5W
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MS,P 3U4%5<RSIE4V" B')9NE^L>A)9+O2ER3>-HY&2;:IE,LH7UYU%*K.V
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MZ)5W;A)L];B8?0%HFA!"1LBAB^GW6BI64'Z@\DA_44%38?        %  *
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MK-F2K]H4.JDU8,YOZN3Z O.#%*<IB'*4Y#!X,0Y2G(8 $! #$, E, " " "
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MX0;C7Y3;?9)[@1V J\)" 2(+"PSX!;PN.&-LN...6353TXXXX:-...<@ B(
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M(V*C&[9DS;E^_MH(D QQ,H?U',8PTOI.Q9]E# 'ERGV[-RJD91C"MO#V?DP
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MV D:R+-JQ"3CYM.*5EBH!(*1R;L?FB,5'!FQ' BL5(%/SN69V/K-C^Z6W&M
MT2JHSMWZ\VZ4T'&9MR_ERMJ9>9&%5A260T"UD6L'8'<>46KZ-3L#&0382#%L
MZ8BU4]XRT;F9]N]8H"C=G+OQOE?3$I#QME64-*HH@)?/R%C*120(<"%]*9),
MLJW]/@"II^1/R2+*.R>9ZR"+&+DS0=F.4H'JU@,@RDU%/2 G"+5!4S.:3*;U
M?6.64<%( &<-&_GT\1'9CEP.1#>05O/]0/D1\@#GZ#2'A>/OCM_.7R_;ZC]O
M["=1GXBV^*-TXUU&F=A+]0>XG2Q5O>;5/]F["X+1=IQ&KUJN3MN<.;I78UD\
M-<&ZZC 8V/BHII:5557+<C>TUJ/:HQ!9#NJW<OK?W1H*6A]=M.@K[$IIMOQN
M)1.K&VZI.W28G286^H29&U@KCI3TJ V-(L4VD@5)16,=O4"BKS* 0 P?4//W
M#^GZ#^T/U#^GD8^C?#<S&H:AH_;SI[5:ACW<R6RR]U*G33MW.16(OKG<&B35
M.[Z%FE83&*FYED0JZA'18U:.=2+C\9G(&;E$47R+^D=CY]CZ$>7[1_K'Y:DY
MXY%%T0[S[AI,[HW7GNS@L]@?8G"(6"D+M>DVA4\ T2%L$XC6*K9Z;=UW1H5G
M*7"4,J$=66TE*-),S5^M!R!5FDA7H65P! ?J ^?](?<!_4(?I ?J _?AK!&#
MC7/'''#6->M5)-9,Z2I"*)*$,FHFH4IR'(<HE.0Y# )3D.41*<A@$IBB)3 )
M1$!@8[V=&QS@TOL^0QO_ -7RAU']SJ#,GD:.JJH)EYN$1+]35!54_J?1Z8">
MLJ'%9N4T$8Q(B>OGI<-T':"S5TBDY;.4E$'#==,BR"Z"Q#)JHK)*%,FJDJF8
MR:B:A3$4(8Q#E,4P@,NG<EIRB2,Y4X$D9)XNN?(_)AWXMYJ2?,$@T7K_ * V
M7VA;')M.ZQB*S$'EVO<XT4VMMMLN!+&3@R02$*MJJS".Q&!W29(9HM,7[<<D
MA[Y]./WD9H^G9Q&G#)K$](E(1C8BBB>>S[Q3TIL1$3',G5IA8WB%6.)4XI\<
M($X@BK$>Y&]R[UYX[,2S1-E6'EZJWJK#T93V(\O4$@@GYJ=5]+;OT9OES8-[
M@\&Y4;*R)R:O<K.3X%VI(RKXM:PH+(W%71@\,R1SQ2QHXXXX]JN:<<<<-&G'
M'.YKU=G[;-,*Y5H25L=@E%?9CH6$8.9.4>J?\[Y=FT356,1,/)EEQ*5!N0!4
M<*I)@)P"0 22  ,DGL !YDGT TN**2>2.&&-YII76.**)&DDED=@J1QH@+.[
ML0JHH+,Q  )(&NFY=+*,6T[;K!^3F9U.0L;Q(Y D7Q2@T@8-,_U!>?GG %CX
MM,2^3$154._<@ E9,G2GYG).>N_PNW[T6-H[$R1H]H/MN$LTK3\!?K!_&*C:
M;2S.9-F4?  M&5I198Q3 !K @8%&_)>(F%SC&J6+*)95?.Z)6FAW"P)@P@(&
M+;$ />>/7*ID&Y5%! #.'SU8SARJ/K7755.(CI+>]119CJ@3R9QR[^$#]".\
MA^07"GS#'RUZ2Z"_DY[YO*1;MUI._3&S@"=J)\,;U8@4<V,JRAH-IC*9+/;6
M6TG%EDI1 B08"]=OAJYSG)H^SZ\X::C<4#).4H8[8Z>?PSD@^HH)Q3DOOV==
M$P%$'4^0K QO)TH) X%.&<NF:YE^'5@L]H-GAZC#()?+1K54?+V0,W2 $HVO
MP;)-1_)N"D*0B;.,:*@B0 ,H"*)1.6-'L3\4*%BBOJQUYCTK%)!ZD%=&L#19
M.N-#?4HJUR!6^7?3ZA?(&1D),8Z* Q/6FTED#%$8;+O?+GI-B=VR^V:8MEB>
M!Z5I6:=F<KD1 PF(T9I ";6.8)?9&/CF[1BB ![;<HB(C$BVZ[?<37Y6C3S5
M#CG@^BI^"('YD<NW=#GEJ^[S[7O9W[+:$O3GLPVBANM]1PL7XB[;8)T!437=
MSYFYODZY/%8)O=@I*1WHN'@ZD4[$?$PT*_"_K6+-G>9U-05&Y[.N9!70)=N/
MJ*)VRJ0KL:@BL00$"QYW\VF)2G),,3B=N6,1PX<.W#AV[77=NW:RCEV[=+*N
M7;MRJ83*N'3I<ZCARX4,(BHNNHHJH/U.<P\]/'-_7K05DX0QJ@]3YLQ^;,>Y
M/ZS@>@ UY4ZIZSZEZTO?:'4>ZV-PE4MX$#'PZ5-&QF.G3CXP5T("ABB>)+Q#
M3R2R9<N.../ZK&G'''#1J87X5.U"QF;?@\PZ\-IE->]4HBIOXLHT30:VR*0\
M^1\NV!(Z:11*  !F,PN/D5#",W?-/3.+Y,9??:AHD 82RU-GV$\V3 1 KM)H
MIX?QRH!_&1E(U1Y&+%'Z"D[/]!$ YMW5>Q1=OK4!:X-<'4-98:,GHIP'C^&C
MI9D@_9J" "/@PMW"?K*(^2G]11^H#RI;Y6\*PLZCX9P>6/21  WT')2I^K!C
MKWM_)JZP;>ND[73-N3G=Z7F1:Y9LO)L]YI)*@&?B;W2PEJMV^&*O[G&/, =X
M(>0$/MY^P_J'] AY_2 _4/V\AFQZ"Z]]%OB7:CC\;>=.;VSXD 2&^5'-UJ?7
MF&'U2T4-I-GNA8:Y _)+.+U<'I;%+JPB$>BT0CE(QDZ3]PL(Y=3-<BH^*EC.
M4OJ+D/<O1;SHF;N^@FDQ^^,[)E5(C[_=)>MINXEC9:*VK\B\8M3Q=D=H5]:6
MD'"BK>+CHY\NZ2(Q5>N4=)KTFO<X^?;L,GYCM^L#R[ZE7^_VXY0F7:/4]@S>
MAZK1)'\5I>CU&O7>K2 E(FHZ@;/%MIB+.NB0ZGR[DK5VFDZ:F,*C5RFLW4_A
M$C<KOAK&G'''#1IS@1\!_. ?;S]1$ #_ "CSGF+'=;?\XZR=8M;U_5;78:53
MX2MFA'%FJ$,A9+;$2EU=(4R"D*U77"R"<Y,1TM.M))M'&/Z52,E3J%.DF<AC
M60,D >IQ^>L$^BT/U][-]TNW7Q#LLN.H6V5([)T^)%WVGU^(I]34RE6'4LK[
M([!%R3]U8:I;B,:]+ ZD46<@V7D) RX$-*K,6<R?,%?AN=7:-U#Z>Y-D=!LD
MI=HM6/?7][>IZL+4RPW23T9ZI;1G9^K.73QS RH14C%1*\4Y<&<L4XM)LX!-
M9,Z1,ZN&ACD^9('89^0[#]VOG=NFS)JX>/'"+1HU05<NG3A5-!NV;H)F57<+
MK*F*FDB@D0ZJJAS%(1,ACF$"@(\_,5[[]DG';;M]N^\ Y67@;;=GL=1$UA^K
M3-JD4M7H3<A  I4P<U^+;33@A0 /GY=ZH/DRAA'>(^-CV;4ZT= M56AI$S"]
M;/\ +X51U$%2$=MW5];/D[7+(%^JI30M 86IZDX3* (OQCP$Y#*I^K\[@"E*
M!2$*!"$*4A"!_%(0@ 4A"_\ LE* %#]@!SOWL:V7C#N6_P J?%*PVVFQ'<1Q
M\)[;#/F'D-9 P\FAD7YZ\Q>WW?\ Q+&T=,PO\-=&W:\ >QFE$E:BAQY-'$+4
MC*?-9XFQY'7/'''.Y:\YZ<<<<-&G'''#1IQQQPT:<[NM6:R4RPPMNI]@FZG:
MZX^2E*]9ZU+/X*PP4D@8#)/H>9BUVLC'.B"4/X5JX2,<OE-7UI&,0W2<<PRJ
MZLCJ&5@596 965A@JP.0002""""#@Z4K,C*Z,R.C!D=25964Y5E8$%64@$$$
M$$9!SK9]Z'_NBO0*$$/G/>"$?ZA5$OEV#3<:9',D-(AFY"%036O-/:E8Q%\;
MI 5,[J<KGX+:@3*NNO#6N05]0[)=HI/1KXHN$LUY!'-.Q>5RI5Q@;/"O"'L%
M,F5TB>\I"3S$S*Y9O;V8@B#Z..>%EDQ3!E,QJ[8RK53\S?E]>O?9G=^JM\0T
MG -+L>;6HOL)R)XA=->#LS)NJ54D3<JP_(YK]MB!,7P#.<CW1FP&,I'+L'(E
M<%Y9U#[,*-N;[2Z;L'8=UC;Q8Q TD=)Y1W#((3XM%_E)6!C R/=R6+#LG2_M
M@W&C!]D=5UEZFV25/!E-E8Y;\<)P"KM.#%N$8'_-W")6)'^-*JA-3:=[_P!S
MX;KAOXSH74Y_+=A\P;F7>KT%TBS0W&JL?6J?T-6;1-G#:@R:(@D4R]?0A[8I
MY$"5.3,11T;7@?,7L8]>QDDS>1TE&.UF$E&R+1S'R,:_;'$CEA(Q[U)!['OF
MQP$CAD]00=-S@)%D2&^G-U?H?^Z&\<UX(3..XT9%X/HKCY:/0T^..Y5Q&SO3
M&%,BTNN[5=2^5NW)Q1 Q9Y>7J*2AE53VV-2!-J617N;\+[IW\0> 2MUDA6=?
MT:3B$'-5[ 92O$M;2[8KMP6BEI5XW3=5W2JVHF=%1NVLC>4]+,YA@I>)45*Z
M#3T>OM_Z7LQ[5UUMT[)GA#NT$:EY$&!XC>'BO>C48+O T=A 3XL4LQXZWVX^
MS3IGK&I)O?LWW6NL@'.QL=J1U6)V&3$OBYM;?*3RX1V4EJRMCP9X8 &U^<3Q
MR4SO1\(?MET<5E;/-U[]]O$&BJJB&TYO'/GD5%,/<$$#Z+51%W/9XY!,4@<O
MGII6G NJ5%K;W"PBB2+(! 0*8H@8IB@8IBB!BG*8/)3$,41*8I@^I3%$2F#Z
M@(ASKVW;GM^[UDN;;;@N5G\I87#!6\RDBG#Q2#(Y1RJDB_I*-<,W7:-SV2Y)
M0W:C8H6X^[0V(RA9<X$D3]XYHF_0FA=XG_1<ZY !$? !Y$?H !]Q']7-HGX"
M'PO&NDR<1WEWNO'7I%9ES*]=J=+-/ZSMMHAG0IN-<DT'!1*\KU6DD%H^AMC)
MF;2MF:/K,?W6<)!G>10_"SZ!3/?_ +(Q]*DB2$?BN?)1]PW.R,CG;+IU=1XH
MC&4B&? 42M[/H#QJZBV2Q1]V)@VEAL"917BVB3C]&BKUBOTJMP%/J<.PK]8J
MT-&UZNP44W3:1D-"0S-&/BHJ/:I 5-NR8,FZ+5LB0  B210^H^1'E/M2ZS.W
M5VZ=VV4K>MQ@[C-&V&JTY!VKJ1W6>VIR_<&.L?+,Z.G:?8UT N[65ZJW> /M
MM&8KM=>5<I=OPL.5EE;L]:DXP@P5EMC!.*TB/W@  !X#_3_2(_41'](C]1'Z
MCSGCCGG/7J[3CC@1  $1'P ?41'[ 'ZQX:-!$  1$? !]1$?L ?K'D9O9/NZ
M2;M6O],^EMXSRR_$!@\S6N%7JES8SCO/:X="3B$IMG:+5','59C+S%5F25L$
M/5; \20%V:(&P-Q8NS,EZ*[#?$4 W<',N@'6W/GVYZ?:7RI^R,_6+>O5H[KK
ME3N/<LYJ=7MT4@_&)T>$2?,; U9O :)Q?_ D0"IK7;*^U:Y"=&^@N+]$:+/U
MS.E)VX7B]3KVS:CLM^<(2VFZ9-N7[UXW=6>;312]32.!ZL#&,:D1: \<2,V\
M(ZGYB6DG9I6,=R/, J.W?ZGZ?3MG(([:H/X?'0N2ZB5B]VG6=@N78'LANTY
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M%1<>9119H014,0[II[V*C"=5LT'G<@?1YR\3NFSA*+JV43,BT62]B7!TA/\
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M$ 79NTD72!A %4B^0\ZHU V*5-9YZJ7N3CGI(&J+6V>LIZM*T!2F*-WJ;9S
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M21S^&%9L$!CK9:Y1.E4*O:IGEZS.VM2O:OH-0LE*L30Q2F!Q"VF&>0DDGX.
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MI!12GS+"LI'*(^AV_+(S/@0.FA#N"@/(VM&U'0=;L2MJT>URUKFU/<*BO(K
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M!SZOEV#+YM=#YM^X]!O89-O==+^DWM(G])O'?M9.6:";Y-\_2$ $QBHKKF*
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M;9,QJ\K5F13=#0>GL.IJJE*HETK%;C&E,R)R"<R\MUWF;!:= CEC+N:]"5.
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M5(WJ*!QC%?H8I>1R\U=R7D_AC\*>?U8^?Y>7Z\ZFUDXKS/FWE_1'^WS_ "T
M1 0$!$! ?(" ^! 0^P@(?4!#] A]0YU=#QR%DM'%S1ZLT1O5]5903A9B"K=)
M^8SD7)G3IHD<&+?VQ*9[+R2;=-4[5H99P<WM',IVG,\>N]<2R_.I?;I1%/\
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M2JB8OE-W,B0P?PQ3"1MY$C80)Y7=5"X<.'KA1PY54<.5S )U#B)U#F$?!2@
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MN#6X9*,[.97AN#Q!'S:6-H&D<.R$SB2-XS.P@BDFW!UB@LR+#&I$6: 1,LR
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MDH3U%27,"FK( "(@ ?<1  _E'Z<_0!^ #D'[U_PX\\L3A!)*4VVXWW7GA@3
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M^H$(ID7U?4",XQ%HV H_84S#]Q'E&\?Y/V!]@_DXYHB222>Y)))^I\];0
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MB8%#$!V8YE59%^?0T:KO7*#1JF*J[A0J:1 _28WZ3#]BD* "<YQ^A"%,8?H
M\F5[T]=/#C\,@.9(B\22/!*RJC2P,P)1V55!QD$HC<>:(RM/"CGD<CL P#$!
MU!SQ<#L1W/YD'()!]C9J[E'A6[5$R[IRHH<$R?0 $YA44,(F'TI)%$PF,8P@
M0@?<?(AYO+7J4QBBD<ORIOI$/!@,8OJ;-C 'T!!,P>#G*/\ Z=4!/Y\"F5+Z
M@/:UVO-H!H"9?0L]5 !=N_3X,H;[^TGY\F(W3'Z$)Y#U" J'#UF'Q4(B  (B
M(   (B(CX  #ZB(B/T  #[CQ,<04 L,GY>@_9\_[/3YD9R?+L/WG_9KGG@HJ
MFB43JJ$2('W.H8I"A_*8P@'^7E)R=G(D8R$<!53AY*9R?ZHE$/H/M% 0%40'
M_GB()^0^GK#E&N'+AV<5'*RBQQ'SY.;R!?O]"%#P0@!Y^@$* <67 \N_]FD:
MN,M88E$1#YGW1 ? @@FHH'G]A@*!!_F-SY!M<=Y^B3L0_7[:8?Y!5 >6]XXG
MFWT_C^/W_JP:N.G9XI0?!CKH_M50-X_G%/W/'C](CSMV[UH[#RV<(K?3R($.
M43 '_M$\^LO_ .8H<M#SD!$H@8HB4Q1\E,41*8HA]?(& 0$!_: \ Y]>_P"[
M1J\_*<G*Q&SI!,LF"#P \)OD2E!8/ >"E5#Z X3#^T4'R4//MG3$?5RGH^RN
MVPE3=^7:'T 1$0!P0/UE./@%/']JI^</_K Y7;5VW>I LV5*H0?H/CZ&(;])
M#E'P8A@_24P /Z0\@("*OA<8(S\Q_']HT X[C6(NM9+ 7BJ6+--(A@G*=;6
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M@(6X[;9C-.)J,\=*C3(D:Y-F+*]<\<B75"EAJ%HL[3=V&1.,RHE(LSUY;(V
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M#' @FAYV28**"0""F)BEG$B^LQRG])O20AR^L2:W=T#;?/\ -?#<?K$B@_\
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M[>+'B]8TX/2ML51?^]+;ORD_7X2@_9CTTXXXYUC7%-.>28@!R"/T #E$1_4
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M:1-.O4"TEI0/+5EFE:6+D(#S'(7?KB1+,=,[V97N31VO?(XZL$7+K+;XMO\
MLFS[E+,*[=,G<&OV(X;D->%8IN+6!P?X[)\6+>*+6-4JMUQ_%D]VPGN-USZU
M: YI=NM]OQ>RUC>_RA7)::7)'7BK)'VB"0KZZ#J#FW;M!JX5)\XU372>QS6?
M)PF"+ARB B8J#EP@41\>HQ45E$BB;QX#U"! $W@ #R(^  /IR'_M[\-R+>]5
MJ=AO1;+,<S*0K/9K)-^?P<U,RU4@+(XSU:8=2#JQ6L[*V627F7AE8N.06?J.
MEDHX%R-%FI$")*9O]?K'W&GY*X&[49CUZSYBFWC7%,7P_5+IH[R7DG3Y^:?1
MLJ-KJU;1B&C-I^'JQB[#Y@[QPL[2731313,>O;VFR6Z%>]LR5:9CGMK:J2V8
MXKTB^%ML4,J4WLSOX<M@7K"0PR3BM'(8C*Z1AS9^GY.H*.Y6=MWZ2[?$E:FU
M.]#4EEV^-_%W.6Q#)?CJ5HS+#7-"L\\\5=K<L8F$,;2L@R<Y]K!^XCEP60-]
M!\ JD(C[:Q _YIP#](?7T' !,0?J'D!,4WQ<<J.KOJ[S)XB_;)N4!\D.'@2C
M_&3.'T.F</T&*/\ 2'@P?00$>GL\&2<C5$2@4'B'J69*#]/2L ?G)"/CS[:Y
M0]LX?8#>A00$4R\I6!DA8/ (H;^MG(E35 ?L0XCX36_9Z1$"G'^T$1^Y0Y<S
MCHPZD$?0C_6/]7U_5K(.#GY:Q8,4Q#&(<HD.0QB'(8/!B'((E,4P?H,4P"!@
M_0("'Z.<<KB^Q0,9<'B1/2A)D%8? >"@Z3$"N #]IP%-8?UF4.(?0.4/R&P*
MD@^8/\']NG@<@'YZ<I/7H@9ZA1E@2()W],>A&OCE 1,>!ECD*U54-Y'\QH^(
MBD7Z!Z2'5$1^OGE6<[B*9)S2$Y6%_3[-F@I&+ 3CX*1V+=15DM]P_.25*)B^
M1_C"7@!G*_S@5_:?PG]C :SG&#\B#^S/?]W\9U'?:JI7[S7)BH6J-0EZ]861
MXV6CW)E$TEVRIB& P+('3<-5VZQ$G35XV43<M'**3E!0BJ11Y&+(VQYGL^A;
M\U@:_!7!&9W:AS=[UV2>:%<+-3>N->0FVL')+-3-'==E+8V2=Q+B>,U-*J1,
M3657\B_01%9S*ZHFHBHHBL42+(G.BL0WW*LD84UB#_>J%,4?Y.6K)BN6)Z,[
MUHE+B?WP7[1PS>6 PNU!<$>, BGCA6,4<FAS2#R,#\.>2(Q_SCID(H++'*8X
MFF;;?BJ"=+"RRQ/&Y6%3F)Y"C*%E1G5.#-X;NY27!@C'A.>+)BQ"TI0H55E8
M9<C#!>2DE6XD\@ P !7\9/(8(.3'66U,K4X@ROF:[.#UZ@)-7L6\*)5VB=D@
M4IANS7*H4H^^@59Q'B90@"<5A/Z0 _CF!-C@G57L$[6GH&!W7IF3A%Q,'@QE
M(IZLQ%00_1[I4"JA^CPH'CZ>.9BU^34@IR%F$!]!XB4CGY * %*4C)TDJ<@%
M#P $%$AT_2  'I'TAX#EN.W-?2@MTL[AJGZ&=F90EI;&#^*J:28%:O52^  /
M"C^.<JCX\_G*&$1$3?3638:,LJ\0LK87/+BDG<+DX)XE<9([D^F=28\J^"<\
MD&3C&63 )QGMD'R^GGK&CF2G4FT#6-UJ13J&(ULJ<G5'0 /@#C*-#.(\#?H'
MQ+1[ "A]1\G$ ^H\QKYWU5FE:W:*W8D#>E:"L$+,)F ?'C\-DVKLX>0^P&32
M.4W_ +(B'(Z-P=&_FL#^P'OIYUY*R_-2/VD=M;%/T$/V"'^0>1%5Z@Y!U]^+
MY=KLYW-I&:+WKP6&9PG7-'/K)[DW-8@W!29U%71VSDU2:@TK]<<1B=<>MD)I
M\\DWSE-55,404ES3.15,BB9@.10H*$.4?(&(< ,0P#^D!*("'[!^GTY$1\1G
M)ZJT[)_#F[<6'<\MPI#!-^DJ7).=(4FT%].CMBBVL8EFE17AVKA$+3+EAY<D
M<$N=O%I)O'#MPJ<&XMU]]K5+YD9QD$>6<^H'KYD#^W4O7'."^ *  /D #T^1
M^H_F_0?/[?(?7]O.>&L:<U[/BG58(?L'7K(D3PC<<XBE%%/[=_6I:5BG)1\_
M43%9.(KR/D0$HE#[E'FPGR&3XN<,46V%V(B?YQ'E\@%U0*(CX<M:Y*MDQ,*G
MI !^0=F*4$O4/@PBH!2@4=ILSE+\0])%D0_JX%Q_YD&N(_RAMO6][+=ZEX@O
MMEO:-PB.,E6&Y5J4A'_]>[/GZ9_486N...737SETY)KTMC**G2(J8LY,S>LG
MVSI0=[0G8O)!FXVE*P+=-LM<Y[5IAP^9T5^_<J)P\9FU60LKV;]WYJP$0.8C
M2,KGB9-,X@8Z:9S  @4QR$,8H#Y\@4Q@$2@;R(& ! # /@?(<8L0F>(Q\RF2
M#D#/;OVQD?/(.>S 'OC!LW2/42=+;S%O#;>FYF&*1(Z[V#5"N[QL)/$$-A64
MK&T,T3PNDU>::(E"ZR)+#0)#&8<<-SYU 8:I7[K%]LH[392;B*9(3S5*OV6Z
M?O8,W5M=K*OH$OL-HL:^N#E)Y)M18_(.UTB,A+5>-/JI7X3/I:HJXA$Y"MU;
MLK*>L$L^H+#5U=XD*W)IVV)DG;^02OOXF[7'TFC024KRD,5K[  H5AYBNS+.
M)[6KY6\XJ@19;!;'BS&,&7<&8QOOM(YY)F%XZ1:/%$DRMF"P)B5JN;W/;3*0
M -ZBWFK?3S8;7I>G9:QCJVA9LECQD;>\DY)PVABM3%26C_PV2+$.'#TTJV4%
MY%$49M2K-D5UE3-C)B08,U>%>:R6@F5,DBOW'%Y90),%QA@9%B1_0(!@YPO4
M]@ZSZCMKMEK:^AVO0Q7(=FVR?;I#%(;E#9MBG?:%L)M\G*O+#L=O>KU)$C:9
M]PL3B:(0.T]==6:YFS[/)).]*4O\2O>UX1G[)2QNX)*3K=-A7JEYT:>;!+*E
M7BHZ2AV 5M]*E(BU7.M^%*N%3./E^=ONUYSZX8;-2455\J@)>5[/6UIGL51J
MK6*U-UW*ZY#OBG=2JD,0DM(M[1*.VQ_F9,",E54@&.2301:(M\'"0\DO%FG"
MPTFI"E5(T5FOPEZ>(3<G](@Q6E@;&CB.O48H?)G= L)S% $Q,8 &X= QR[:.
MTM<G 1R+9A4:%9=$?R<T1_&,)*O5 S4LRC!2'X:X:S$HW,[1*1@DN0A1]95W
M+<2^!DO @E,[S$ 2*^"<*I 5>.<]N05 >WERSV=M4W;^IMRFV2'I3;>G(I))
MMHM43/&ADLW(IK$UP7)%-93(*[6=Q:#E*R(\U:17\3;J^<WL1O6=U7J_5=+M
M4S /[CURTK4Y_.\[>.TS3-EMURB()&F.2QXNBO @86=DG-A?.F[4R!5X-$X'
M!5LO[E9-HG"KP\L>9W:PYU&N&777&+=<=7<&K)YV4T)2^GOVQNX>PI"H[D+E
M+5^86A#M6;IU)N#(IQZADD6_M$C%@Z989Z3J;%M$NV@W:;BZ[6Y>48/V$+(/
MY>0;QK<C>959&;.6Z3AR0SLS$[LR"155!2,)!*/V6C.[149ZZ5U_#.7BN>V.
M6K5GDX:.D9.OQLK#/UX]V92828$:MD#N$%#MG#[Y)19(Q5?;)ZQ*#;5$,CD3
MLLC.TBXXY3[Q6POH0)&DSRSR,N&!"J-;BGU_NE?:]NBFZ2IWMKI4:FSVQ8$[
M1;DT>RRT99++^$9(Y;.T5]HX&!E%6':!) P:Y8D$G5(E<]MZ&?Z-0ZC@%6H=
M@TJWN>R+:YQF;?.4/+*R\;Q](I;6"LJ)))HA,T)$9->7IS%>5L-ZD57+MV02
MJ >*^SJP:]FLBU806;5E:PSBU;;.?7\PWKRLJ\4@T%P4$5 51BS-$U"JB*I3
M%$J@B<#<Z$2)F,4YDTS')_$.8A#')^G\PX@)B?7Z_FB'/+C\%<0,Y#LP88 .
M<A0S,H8ECS*A@BG PBJ,9R34NINKY.I:FWUY=NKU):CM-8FA:/PYK,E.E5G:
MG6BK5TVZO;FJ2;E;K*]GQ]SNVK/BI&T4$+CCCDG5-TY(O\+V;&,[,N(WUB4M
MCS2V,/1X\^XI'OZ],I@ >X4 ,4C)<P")%1\ 8"E* G.$=',S?A\OOD>W.4B9
M8B!'A;E'&%3T>%?FJ18#$;E$X#X46512 GH\'$2^D! #& 8MY>5.T/\ ]B0_
MM52P^?J/V>>KU[,+1I^T7HF=3C/4VT0$Y PENY%4D[D@ >'.V<GRSG6SGSQ,
M(@ >/OZB!_,)R@/W_8(__#Z\\OOS@?H'\X?T>0\C_,'Z?T??E!U]3M0W?">[
M2Z]L63]E#[U? NEOS+NWV$R.(>SJU<8R413J>M558"M*IP+.,9JIP82SMJ@Z
M617?.$?0H[>NE1%47,5,B^(/NR&H=UJ3;&-+D4,I[L[3FE-*A4*K6',=1:^P
MICJN1\H6+AA/.R1$I1=TM9)51>7E$7;?YM8Y$$?#AI17N<#U]#V]/U?,>GJ?
MKK(3X#/8.X=D>I.B7>[53)*C*QG86V5E&.QS+:[DM:79,Z)G,DF^?UZL@#%[
M.*KRKA%S,K>7;EFBQ:*#[;)+DW/(9/@9;##;GU!ME^@.O^%=<(Q;>;Q")T;
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M!/T 'DI1   /2'V#HN/5ZOSQ^Y_SQ#] ";\X0#[_ $ 1\!^SCCA[DGYZ; P
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M).A>OG+CR(E,H)4P']"2?YB8!^H!*7U"'ZS"/W$1'X> ^@ 'ZN.-Z3J-W?\
MNOME"[;USJ!@75F.[ WV?PL=U,\E-PALB:LX%O;)*J23$!G:I,L7"K)PUCER
M'_$D5W?XD9-)H4K)152@<=^*7#;!9NKM-:XE8:A:]Q["[OUGT^O6:WQJS[%-
M'P6DM+C/)MW41$N8_0(R7(^;-&#I%:MF:@98S@BJS8R:M+]CNB%N[(_$FJ&J
MVDFHU;K]$]/WM">Z-D6R.\FM:>G-]!EY>/J2CNJ3#6[KPS^%E573],L<I7':
MI&8/')G#)-'GTW[H)^]3IOP[8GJ3EL8RRSK[I_9B\Z(^LMG+*@A.:CBKBM0]
MKT&0L<L-NO2MKN ,HZR+QB<H_1AT11(S81C=L1/H$4/2!I;?7E2'[1FV::U-
M86Q82**ZNV;M)PN3ON;P>*]Q-O%>G#1KN) %EDECE$,G,II^N5W#<[4,DWV7
M!OM>G#4>K6>::A)NNQQF2C73:4LF%*4NZ&S?GW"U&827BCB> V(<TH#O3TVM
M%DL%1@.SF,REAJL9:9J?8-+>@8C*'HK=P[O$HTDE$$HB>8TYJT>.;,O7)&7"
M'0:.57@)$15,3 &>^-YUS0ZRQ>Y5:,B)31+%JCC*X7![%JU5KD]&JDLLC"H:
M!>+6C&2;"L9L:&8M[@[G$H>2<L8"6C556Y@4672QVZX]5>Z)]M^'%;]5R#2J
MO%]9M!UAQL<?)3O6:IX#0 M]7M$<Q4ZPXYC(QT@VSAXX>1X2%@F475DD'#M%
MN>+.FC(R!/32NFG<1KT[RSK/8.OB$58<.^)/F^X-;4TTO-IJ'T/'GFR7O0[;
M<HI%*4:OH=M2XZ2BV:\%,'&>L!7Z*L5$@HV>LD)T6Q=(5)E6>]!?5;6WM*/M
MVE&BUS9WBM: >)(6FBD%;;;#HBQV88;B,LJ1!YI-?+U)UO=@=JNWS[<S5-S6
M$GIV_([V5J;#;J,8YI9DKRQ&YNM6-Y6EJ6)Z,BM$\S)7BF-D^ZO62CS6?T+7
M=ZQ'-M<O=:ITXEGC[3(J14;.KC%L7L8V;3P-F;!2)E'3P6]3G9LE=3MS/Y62
MC&94GJ:):KMG;'K)1+J[S:Y;[E%9T-C8("J/:-,7"/:VUK8[3".;+7XA>!$3
M2!'4K7F;F;;G!$6J44B9Z[<MD3)B>(+>^K7:)B?XG>)5'J^RWF.^(9H1;AF_
M896[9M#U?,(Z=K\- ?@VPM+<^0O<.3&W$<M.4/\ ).)L2,HH9$(H(YV<XEO;
MBW1FZT_?.]F@:#GT#=7UMZ[=?LHZ_:U/?DK,3]GFZ+UJ5SR_/H'Y]T\FZ.O,
M7F(@#O7\HC!O'_H9K_.+LVRQR:B39.G$K-:?=3D4TGCKP7*$DEB:6395 C0E
MY:D<#;C>CEK6A);*;9+8!P)HXMW'U!U4]M:B;,I7WYZTMF>AN<4=6"&+?7)D
MDPD-Z2PNV;?+%;I^'2#[M#6*AC!+-FLS[_\ 1V0*].Q[<]>'9(ZIEO3PS?4:
MZH5&IG.W3),^?F ]Y,QW;0OR#;WYD#.VH#&![Z0FR#S?3LZV*G1.A93>:KHU
M%G1=A#VZF3+2>@)$[!RHS?HMY!F<Z?S+%XDHU?-%02=,W!#(N44CAX&%WKGT
M<V6B/_@J+VO'H*,2ZGT#=4.Q)C/:$]&C76XU8R58>+@SD'0VF6?6(QW*<Q61
MG#,9 QY)P[;J',X'-+X<.$Z1U]S#=JKI532IKJU=Q^R>H4Z*;R,$_;.,YOEG
MC']-EFQ*\]?,HQ"28-E%$HA86LA'D3!)XP:'$A!B;SM.PU*TTFW;F]F>*0!4
M>U3F$T8W+=:#<4@1&#F&A5W%6#,HKWXE*LOASRS=CWKJ2[=KP[IM"5:TT3EY
M(Z=^ PR_96R[DG.2S)(A03[E<VLJRHS6MMG8,CB2K#(3RZ<*[%[&MU3#ZE"E
M%%41^XJ)#Z!,/[3@!3__ )N6LY7%15$4GJ C_$425*'ZO<(8AO\ *D'*JA^+
M]8Q_K_U:NNO5?F0.H%1P ![C!=%R4?T^V<WL*E_D$JH''[_5,.6,YDI.( XA
MI1$0\^M@[  \>?S@1.8GT^GU X%$/K]^8T@<@@'YQ?KX_P"<'Z>-SC# _,?O
M'_XQIU/+]O\ '^O7ESL(ES\G*1SK_P!0];'-^TGNE*H'\Z9C!]/U_P W.O#Z
M_;Z_R?7_ +N>8)K" &*BJ;])?2DH8!$/MX])1\_7]7U\_MXT,@Y'IWTO6,.H
MQ?X/H=Q8@3VR%GGCI$@?0 0DA))I> \!]/0\  \!X^G@/MR@N7HW\GITN16,
M!2B\B*^[$!+[9@$T<5 WK]7@1/Y;_G&$1\!X((^2#RRWJ+_;D_\ UE_T\8<8
M=A_I''ZL]M/)^%?Z(_L&@AZ@$O\ ; )?_P!0"'_QY]?;] 9!EAMO_-\S.=J1
M2Y@]'DSB'5CG ^0*<P_0TJX#^+X+]2B(&\D#Y .F @/N)_00_P#2$_\ \N=W
MV3%NXPG GXJD%5M)6J+ P^V0/;]"WK(!C !C>T:.1*7T&$AOJ8WJ,!3%QYQR
MC_15OR=1_83K/E)&?JP_-3_LS^S6#O/%0/4FH4/H)DSE ?U"8@@ _P!(\X%5
M( \BLB ?K%5, _\ >YP5=#R'\.A]P_\ 3)?K_O\ D;4G6PKF<B>8SJARRAS*
M*25-K+U4Y_XYU7$*Q45,;P8_YQE#&$?SS?4?J81Y'!\9/K],=ANE4Q#5Z^YC
MF,[G>I9-KD3?-CO2.;9Q65Z7:TDW<A9+FY92+:&2&,EWK=D==HJ1S)+,VA?0
MHNF<N=/6]T+S"LL7,"8?_0V*1#VQ]1!(V(=L0P#Y$!$Y$2G,(#X]1A]/T\!S
MY^S'7C/>V&%:1UXU4)P<_P!2@DZ_91K4H6%GDVB,G'S#=>*E#M'Q&;QN_C&:
MR:JC-RF/MF(HBH0YB\WR'*(?FJG\P-:D_"_]%O0?(_+_ %:N] 2!)6#AY1-Y
M&R))*+CI C^&=E?Q+XKUF@Z!Y&/2$2(\CG0*_,,714TRN&JB2Q2$ X%#M^4I
M0Z9"YS1Z=GU<!X6O46JUVG019!XK(/PAJQ#LH.+!Z_7_ (9Z[!BP0!R[6_A7
M*WK64_/./*KXK2=.1:_%ACD%L/S^3/\ ^<,-59-T/S2"'MR53M)5P$XE%0H>
M6B)O!#%*82@)P-Z">)2N1[_$NJ]DMG71FPJ\!,V20:Z54)!5A Q;Z8D",R-I
MUHJZ(RCD'#LZ22CQ BZB:1BHIJ^M42I <P3=N;C>K$D >*H))P #D'O^HZYW
M[6JKW/9MUE7CC>61MDL21QQQM*[R0,EA B+\3-RB&, D'O@XP=<?CEQ_WG-?
M_P"B?3_\7MP_V+Q^\YK_ /T3Z?\ XO;A_L7EX\2/_I$_\2_[=?,W[&WC_JK<
MOZC:_P!UJW''+C_O.:__ -$^G_XO;A_L7C]YS7_^B?3_ /%[</\ 8O#Q(_\
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M)(1':CCM+;<H !2@4!*4  "@/CU 4  "@;T_F^H \ ;T_F^0'T_F^.<\N/\
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M>.&C ^0_C^X?EKCP'[?Z1_T\> _;_2/^GG/'#1@?(?Q_</RUQX#]O](_Z>/
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g609923.jpg
<DESCRIPTION>G609923.JPG
<TEXT>
begin 644 g609923.jpg
M_]C_X  02D9)1@ ! 0$! @$"  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?1%!,4$Q!5%\T0U]/4D<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!3 %( P$B  (1 0,1 ?_$ !\  0 " @(# 0$            ("0<*!08!
M P0""__$ $80  $$ @(! P," P<!!04'!0,! @0%!@< "!$2$R$)%#$5(A9!
M41<C,F%Q@9'P&"1"H;$*,S1BT1DE)D-24\%$17+A\?_$ !T!  $% 0$! 0
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M%I)S)$U:BG!>R#$B!<21]HPS7'4:!:83GH1EBJM:OY1%_E\HBK_RO/4>."4
MT62$4B-($0$B.8;"A.$S'#*(PB-<,@BC<YA!O:YCV.5KD5JJG!;59&!7'P'3
M [DFMLW@@^\=B%=^/\FMGV \=>)<'F;$<B3=V9-#)&R%:F/P,,1++H_3:Q5^
M4)Y\ 3<P!_B$G8UT/ISY[]0N!A4")K'!*W9>B*RH2-C<3;-N/!*,*H\:-'KS
M,65TR^EQA%1[CP/TZ]Q@#'R1Q#P9W[5PEWE[,?4&MMQ:^U5M[!X>D,&N=BX
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MS23*#&J^CPNA=.DH:R..MJ8$2+&:"MJH &,]D1IAX%:)PXU9')]],KXA_D[
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M(GA"H69;F<PC4^&N8K5:GPGA.=\Q+M+V'PA@XU!N78BU+%*AL9R#)K#,\.L
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M_?&D2,2F2'JYTS'U>&$[(^X.PKN-$EK&,^0IJ"S1<1\Y H]R40 6$4>[Q!7
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MK5[#ZIS?KCLBT[H=:J"3=/F  G:;1-0U!1=Q856HXA=AXK!&YD>+N3"8:S+
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M\ 'K FN;S'<9S["\BR['QY7BM%E5!<9)C)E1HK^AK;2-,MZDB*BM(V;!"8*
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M(T0?2E6>]/0= /LHJRNH]] ;]AOJO?NKA(]=]N.QV(@C#APZ_;N7SZV*$:!
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M-ESH$*,\\43I7W,F. JA,E^X.,3LTTBJD,"^HZ1* J1Q)L;$,*A4!( 5!R(
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MB)-J+6)(C$\>L:!.C#LRY.R#K#LHB2\CPS->ON3RG!2=/U&&'L35!2J9ZR;
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MZU<?HTR9%#!F3*C]3E?I4R9!CM9'@RY5?]M(E0@#&"&<A(P1C$)@V\7QQRP
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M)F&$W<RBO(!/4H_N(KD4,Z"96M;,J;6(^/:5$\7J#.K)D62-W@BM;T7FR?\
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M(/>,.8]_]:@D?I['WZYZ\Q]U''QV0Z[QFX_B*A%?-CX]=#MY="TLV;!_1<J
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MQ _\@ZYT^/>,0U,%EU74D5FSC9'^[)/'\S I\>T9KV"/;S*?<:U$3CCCFO\
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MQR*GA7-O<]RNT"__ #0D>2%Z*OE?"HGX1.6#<YRSS!\YF&'L<I?(_P#S4O\
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M-\.(B.GG^>5.[IOE)A[2TH!_O6#4R/Z_W8'^A!^_5[[:'H?CV//@T>X\FWZ
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MQ)7GC+&7%VMJ8[]1CN1.#A3:A4ZMUPT;CUEKRP[<W6WLGKOL]KV)G&"S?9F
M]B)EF)S#A7(,,OG"]PE5;@&Y5<$JM>:HM1M^QNH'IDQW(1LJ+&HZ[[?2SS#&
M[S)=R]<*ZTS3%+>;89#EFMFR9-MF>-SYYI5C;6N+NEO).RRA,=Q#EIED3,JK
M3G4=>*Z@>EE?$/\ 5-G=/>R-\[2>0V,@](@+W'I46-*LZ[-]2WM3#SG'?XIJ
M /1+2FDXE.@2;L9"#+6V,69,ASH,R..4W8#ZV]_]?;B%78MLZHL-'[6+)#4/
MQG-HUA4T&07*UL>R46(Y);Q($8DJ5#D!GQ<;NG0,D^UD#)#CV\5JV#^8>\OA
MU/C%3+8+U,E@;D*W:X0%[]&O,JR!;-?S-) BL/[RJ$(!JT(W :3HCM/OV*\6
MQN7X4,S6E:I/S^FE<FB8QDP3?X23.RG\AG!8G=<R(Q5-/8@R!(4)AD"8!7@.
M$PR!. XG*TH) 2M84!Q.16E 9C"B>BL(QKD5$_'_ %_7_P OCS_RG-S[L5T'
MZT]FWR;C-,.2AS:4HB/V-@A8^-YE(]MB,8EK+;$E5N2!431C:W(ZNU<,3&)&
M,#TM<E1&R?HA[.KI,Z3J;<>'9/7-_O(%7GM1:XI<JQ?5YC&MJ$>0TYS#_:C)
M"5M<(W[G/#'5$:[*FA<>PY#]1[_[@_\ PW_7K4$LQL!L\3^_D?[$?;^NOZ=8
M*KLP@Y;TFL\'ZJ7&%Z_NL1UK-R'N)@MG1/A;CV?34[HT/(<UI-A2W3ZK(]<>
MFPC_ '.(P1T-]4C5T!)"@E,JYM5R_E?/Y\KYY=IU^^G'VUU>/LE$R7!* S<^
MZM[7UKB,FESS&+"-;YEDDO%R4M9XD2Z^57CF#K9COU"RBQ(,?VD;).)Q!H[
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MYSG>%\-:U%<YR^/Y-:BJO^2<U_%8JIBH)(::,%L6)+4KR-ZDLDTY'(M(0&8
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MR'7&3.0#)\<$D4:TA("!,D0,FIXY8F$]UXN;L[N*QW)7ADD[<SLB#,K"I?\
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M<C(LI)7Y#O3-ZZ,+,;Z*WWJ[&*M'I+%@V*'*GN.K8LA6$O;EK0$R>TBQY3@
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M'4XZLO9W76=-D'7]:T]DUI*/88;#).5'2YVK+XIJHHHI)"I33(A_;!'C+XL
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M-E-SW @V.2Z-G24<V>12S;?71Y1_;!3Y49&*Z12.*0,6DRHKO)R$%6W?M6*
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M.WFHNY"R0NWUV,?,ZUK)Y,CU;)6VD/;QTJSMD<8\=>^543QR<A3R2(-)%=5
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MEY%+ M?9N[T[:R9,@R49,B.G54.%+$*:,4E8Y1$>-K2,\V <(GCX_P"O^O\
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M#N\C,[LSN[%G=V+,S,=LS,22S$DDDDDD[)ZFU5454151%4*JJ JJJ@!550
MJ@       >!TXXXYYZ]=....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=
M....'1TXXXX='3CCCAT=<3=4-)DE9+I<AIZN^II[/;G5-S7P[2LFC]2.]N7
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M',UX2L<GPYA&.:J?"HJ<D/Q7&VM?B.#K%_Y[.(G?$V'\:V8#'<Q: >#Q@QL
M)V"?.PS_  W(5]_(9B<+_+7RD*9*%0"/ F#U,BQ/D%I[\Y\[UXZQE@^\],;,
M]I->[6UWFI2C&1L?&<RQ^XEM:5J.9[D*'/)-$Y45/V%CL>U?+7-1R*B94147
MS^?C^J*B?\JB)R,N?].NKVRSLD9?H[7TNQ\+Z;NII!8M?L=X\->R]Q5U+;(]
MB>/0Y9:JWTM\?CF(+/H?KK%(,RTUOMOLWJZ5#B*X;,/WOELB$_V6^!,-7YBN
M607B&WPQHOMVC1C48C?3Y17%3%X7*2K#1O92M/(0JP6Z%2>%6)T UV'(P.RZ
M]R,>I'^4[\-K.2R^.C:6Y3QL\*;9IJUVU#*R@^=5):,J!OV-XC]QU/E%1?PJ
M+_HJ+SSS7]S_ 'WV6TO=3ZBA[&;(R6%" 8@DSFFU+D,AWMJ]&M++364*4]%1
MJ>IWO(1555]?GQXB].^JIW#H)3@KEF(W+$>Y$_5L"QUKD1%:B)YJ(U2G_EY_
MJO+(WPLSXV5NX@KQ#@M/=5BI!(VHH, ?'D!B/WZ@5^)&%)XM4R@;D5($-1EV
M "=,;JDCS[\0?VZVH^.:KK/K!]N6M<QP=4O7ROA[L)FHY/+4_",R-C/C\IY8
MO^?E/CGS+]6GN#:'9'%=8#4H143W*[!*YY&>I//EGZH>S'Y3^7K&]/ZHO$(_
MAGGI&"+;Q ).O,]S7V_2@?U_3I9OB%A4&S5RFOVAJ?\ ]T=;5?E$_*^.>/4G
MCRB^4_\ E17?^GGFN3A_<;M9LL=9#L-YY#CS+"2D<Y<5Q#5%?):UZ-\O#(G:
M]M"#(GE?2J.5J?"^E53SRQO!>H\/:=#&N]H=B>U>=-.X934LW<9<9H'JJ(]6
MK6Z^H<.1K//QX:5OA$3Y\HB\^6OAW?QL!M9/(5$KJ2&-%)K<WT^^H["T$/[;
MF'^W7VMWW2R$PKX^C:>9@./SCQ58MGVV\!NN!^I$1_H>IVY9L#!,#B?J&<9G
MBF'0?3ZOO,IR*HQ^-Z4\_*&MID-B_CPB-555?A$\\B]<=^NN K0E!@N0Y+NW
M(Q/*PE%HK"<EVE(8HFJ[P2SQZ"_'1(]R>VUY;IK$?_[QS&(YZ<EBG1+J?B%D
M&W%IS'\IO6O4BY!L>5<;+N'E]2N0KI>=65^C2(J_#A#&OE$7Y<GGDIZ:@H\=
MAMKZ"GJZ. URO;"IZ^'5Q&N5/"N2- #' B_Y^WY_SY6B>VZQ($>9R;KL?F-3
MP\0<'1#1Q_C$DB#_ $SP,W^9.K HS]@ E\5CT;1U&MK*2\2 ?IDD_"HT8_ZH
M)E7]&ZA*NWNZ6T6JS5O7+&M-T<U7"B9CV-S%K[X '(_U3_[*\"9/L6%8-6J"
M%;9'#<XZ(V2U!>OT?O\ [&N2[()]SV?[#;+W'%* 0RZ_Q,ZZ8U2C58U9()F-
M8-,#<9"-ST5C27F0%0@'*TT=RN_;.Y$1/PB)_I\<</Q^>#QBJ=##Z]IJ4+R7
M@?&G7)7I+=Z!]#R:<]9"=ZC .@?@D,WG)6KN5\[,5N98Z9_TM0II5IS(#_"+
M4-AQX^LGR>@Z^U7K?5%*/'=:X-BV#4K&"8Z!B]) IQ2% US1EFOAA&>PD(CG
M>J3/-)D/5SG/*YSG*O?N..0LLLL\CS3RR332,6DEE=I))&/NSNY+,Q^Y8DG]
M>I:***&-8H8XXHD 5(XD6.-%'LJH@"J!]@ !TXXXXGTITXXXX='3CCCAT=..
0..'1TXXXX='3CCCAT=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g706861.jpg
<DESCRIPTION>G706861.JPG
<TEXT>
begin 644 g706861.jpg
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MZ^K&,ON94]G&/7Y<6(@$"N9Y*&S\R/0B@1D>)CF9D5QU@"*/]1@,\!,:\[@
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M#/CI]+[D5D4N<DLY3)S1I&'G"D"M,BM1?U%S+,5MJ^LL9^KIR-8J;JPI-B(
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M3D%I6?-CK*NR25O-CZ7#?'&CR Z_-?A;#+QQ+F6E@NL#$/)=]YQ#U>N+@JM
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M;ZY43I9L=QJ#K^T[QKVU!5V:NMAL5@C(;9AE^ERR\/NXE(_8,48()D,9QL4
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MG':8G\?/''$<1SS$3,\__.N;VKN3<<U;];4BQ?3KW1+=$VV6LXED,?KD",?
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MF?286UR[:IFOEQZB",W,N*:*5&U&#A 6,$@/0[&)=+K8;#[8?O%3"0U-80G
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M4($9 +T(I93?U!HH9#22E#+8>:)<CEOP;<W:VS;LV5U\UBP<61A$,+$S0\2
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M1C(^#S((A+*D/XCL@2TUP'6OH3NCH3#WZH:M((WS6-G]5>JFD46$.YCZQO\
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M^S%7U7VSU5OTE-CDLLDO02)>C:8H3@3%G0*M>\AB<2;K5"!;M4U;UU+UA?\
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M(YXGF.>/VCXYU^8VYSJ6]V94J5B<I#\C;]JZTP3"PMA+X:P8(S@_<$TC!I$
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M^80B*J6QXH41Q$3-EGDF>QDJ)D%\D -CCN1R/&Y] _M%OUNL>\9F.75M>6)
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MHJM,BS<?0H8V<EQ$NDYDI-L-I1\J1E"<9>)(6E+Y#S;.%.*3ES"$^G'ER2;
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MF8F(F(YYXYF9F==[;!VUF=JX0L9FLZ>>=%MKJ[2AO2G6-:1&DDWFQY)6P&L
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M=JU/4& JU,B'+=?+>#)6.>3/%3RXF0KM%%'B@((1(, PF2@C5R"WS&W\DI<
M'%8R_;1SQ]2<9\O/[_;[8\\YQC\ORQY^6/T\_+&//\^8>SAP?:997;M5ALB
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MXM>6B76@FVG7\N#)=<2IUU*G_+.?+/N92K^]YV_Z.WVY78E?#V,7-%."A5+
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M M(@*[T4876UOM^V6>T%#4QAQ-%>BHR.L)9497R#QYF4(=8R,F1=R0AH*O@
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M!%6NV*Z$)S9*)9&^RNO6LLF04JZ9IBP8JN)6V0?U&60DNHL*9D8H[M#ZB_\
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M'\+K:];LM,N%GWCKVY3<-N3HWM>PML:LFJQ'29'3_6]\UU*-PP+-RFXRMN;
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M33CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33GYG&,_GCS_ "S_ %X_+/\
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M'@!:S!!*;!EBI8R/<!E6RLEX9%8<?QW*O#GZC_VEO5^J:?.(&,M9<G+7:^%
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MV8W ;;*3T'["6*GVX';LT>O8\^WK*OVBM;W$?8DWD 6FNR$")8*[,:^^AUP
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MV:4VY)Y2(C#]C]2+]9>NFFM7P]DK<I?ZEN_66]-F6JP$R8(%RMD+>']B[)/
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BS_,3\Q^)^=....>->]....--....--....--....--?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g879587.jpg
<DESCRIPTION>G879587.JPG
<TEXT>
begin 644 g879587.jpg
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M'9C4*>A!-M*V'0B:5.C*E%U^LHS49$R:,#P=Y0MICP^2%T3VM[+W"YN8#'L
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M0$P#V)"E(GRE#E"^V3?G,<QP,/.Y([.83''G=E-L#E3<WNG10,8"KFW5 #&
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MX)D)VDH\0A9_+\HI%E2=1)3M#*-J/6W*;]Q- J51X\:G:E1:H* <1D4FW2*
M 1(ON2"GN! $>S$1$2#T]X(B(B'@.X[[Z^X-Q-XE* &*!1W#^] =P 0VWV >
MH!YA !#P#51DG.ZRR=;B[;=1W@#>]CT\38 G%"RD#Y31[%!OW7W+;]3^:-M)
MV(Q%V8^WNXF<G,F-'JPQ\9&X3J5.DW<ZNBG8[9)D8/<G9'[(6@"UQ[4(Z9;Q
MD?""+N3EIBISYDQ:E?MNRNJPL<KKNIPM:KU89(N\T4./@%9>96<>QN/XY\@[
MR%<)9-)N;O"\W$H2<94(9(QEF<M(1SEXZ2005'6?.[!UW$/=<O-[G??E  +O
MN/7E   N_AL&VV@M_$0, CS ?J781.'0#;[C[H \#>(==O'354].<^UK#5TM
M;H-6QL%^H+T[ZN>FW9MT\?!?'NV/L!\-L8&@T\DO9"%4DJI!024AF:YJ',XG
M5':D'C*$6(RB#ORD; #VQW<K$TRP(@<J,*VDV3-T[64;*CJU:G(9<15I!;52
M:VF@[;YXM<JFPL@@>*A&LFJAB;&2:AV9"OKE*PLHU>V.Q?K$<S5KDNF07HR#
M<VI.G1Y=A,4-@$3[AX 8P]3?$8=NIO$=^H]==4[5$Q0 $R!R@<I0Y0Y0!3?M
M  /-V@"('VZ& 1 0V'02R]'EE(Z$:[$W!!Z@BW:86MNK$7%P11S6+7 1DMT[
M2M?LCJ&8?2-K"YTCZ1,=#/[ZPAFSTE3@YAY&X4MEB?1+*RF;J6"YO';]2MT.
M*<JLRDCE8T$2HSD\N4B"RCU,Z#)8K93?[R:UU:Q\XF$-6I!Y%8KI+%LJC8%4
M&]AO,NYB$I&98%.QYF56JY@=.7;98AWDHB""2#1$YQ$N<%8QH4 +W9$ *B*!
M0*F4-FYC")D0V#^Y&$1$Q! 0$1$1ZB(ZHZS!N B0[=$0.D1(0Y2FYD4S *:0
M_P#-D$H<I-MBB "&W*&UMXH2+H&N;CM!2O38$*JVZC<7&Q[)OM<YH^CX#8VN
M 18GSL#^WPP+;G66B/\ )+:'K-.>Q(/L%4^I.7%A50.:2D5SK9.RM+!W144Z
M9 1LLP:0M91%S)R+RLSRYS,R2+, K%B9VAX]F!BH>LL!=YVIL9"'D9YPJ,74
MHMVLI:;-+E2:G!\,_'M'C:LQ"0F,P?S#$[Q^DDQ7 N3W+)+W8F3((*"D)A$"
MB)S)@()\P#L)NS -B";WH= 'QU;[IJ0PB @!A%0%MQ ?[L #LMON(BJ7KLIT
M.&_0P> ^I!)&=22*O?J4%6'6_0]=U!W[^^U\4,5+<Q402 !0[*3<  $$@@D6
M+;7MN;=1C#E:<W9[8HLDW6:I%1,WQ.7Y%LH:W++N:AB:LU]LUC%9XA627LI:
M<A62)<2<0@U6(W@(6RPK5U).'#!T0U,AQN*TEAU96KU8L6H3B#M5S*6W.!=,
MZZUCIEGC[&D6?N)2N[I)NI6$DIBR* SCF4?6;$DB+]639"?)[F/2W$X)EW*N
M9<AQV$Q7)B@4[@NP;@J<I0*93<#FV !-T#5JNF@$Y"ID*0$NU @D$2"F"NX+
M%(&_N"K;B"A2[ IX& P"(:EM$)5LTLS?1#D,NL#;J+_.M<@WTE@#<KI-*GS7
M0-LI(ZJ"!<7!OT-C?J+;;XLN(:-CUROS$]!08/VW#G;;%8HIG=EP5?S<B[F'
M4;0XUU[&D(VEZVL0L9+V%9)%L\6>=JWBW";81U9WL>]+"2L=;&E->R,)PO8A
M:OYJ&N+UI&VS)4Z]B49>9K;(\4=>,J5)68D=ND'B:S^?:RS!%&':J)KB2\Y%
MDD8@E*D %!$[8Q *(!W90YA.W$H#MV*@F/SI[=F83&$2B(CO8<@Q2 #E%,
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MV^38 #;H(;]=7S');FW,.P[CL'7W(\H;].@;_-M\6K4CB (%,( (F$3;=?.
M (_\K<X>(;_1OJ_(]/J!NH\X[CTZE#8 Z=.@AT\?Y]M8J;8#>Q!^L^7X]QQ,
MC^<!X@W]MQW_ %GN^K%U1Z0>@!,'0?'W0[%\W\_C\@#TOR-1]SL(=!'Y!#KN
M >Z^8/CZ[ZM.-2Z%#8!'X0[[]0+U^/PV_)L&K\CB (B7IN B&_7E$=O$0^3T
M>.WQ],?(2-0\-[;;&V^)2*6-[Z=.EM^^Q 'A?RZ_:3B[XM$ *'4! =PZ=!#<
M0\!$.H@&V_IZ]=7S&-Q$  -NON=Q\=Q-X[;@ CT'KL'3?5LQR(B)-P+TZAL
M;#L;;?T].OCZ?B#5^QK?FY!-M[D3&  '83")QV\! 0Z;CU$/-MZ=8V0L &#'
M?YW?<V&_W#?]F)<=F.^]@K?^;Z_\.F+KC6W*4-P$VW*4!$>@^ZV'J&P]/-OX
M;AOXZO%DW W*(_WH@'4>@#S;#X=1Y=PV'XQWW'KJAL4]@* $'^" &]T(#XAX
M^8 W';IMU^*\F*6Q0V+N("7PWV#8P><1 -_1N/4?FWA.1?<';P^H[>?E[,7&
MW8+TW&_78VOMY?X8KC5N   B7F#8";B.QN@[]0Z; &_0/$/DVU<K- NQ2AYM
MQ,!1WZ?*.XCZ/B^;5,:)#N =3@&PAZ  -Q$1^3P-M\6VXAOJYV:)MO[T.8/1
MUZ><?1\0!YNH^;4<&[,2=NX]/ $[GV7VW'7P-ZUE )Z#:UP#N.X[^/G;O.*D
MV1*7J(& >O00#;Q#;Q+T\-5IJ@!MC" "'F#T"!@Z^;?Y-==!+G-R@(!L GZ]
M? ?#Y1Z;:N!NE_?"4-MA#Q\X"&W0!^+Y_/XZCL;DDVVV %_(=_@/JOXC%/X]
MV/VBEML8W4/, @.X#OXCYA ?DUWTTA'81V OCMZ0Z].GA_7Z=<)I\W4=]@VV
MZ!U'?J'C\OU:[Q2;AZ WZ" =!](> =?Z_'7@%S<B]]P/'Q)\!]^/-V.E?K/^
M /CX^'MQP1(H!T#8=NGQ>?KX[[_3K] 3X7Q; 'G^7Y/Y^GGUVDTA'E'S>YVW
MV'F#S^'A\_IUW"HE#?<H!X>CX_EU6; "^WD#8=U]N\#PQ=T(-)*@$ 7[R3M<
MGJ3N>[[<4SLM^H%,(#OMT$?KVZ[:"F >(&#QVW >OQ==NG7KMU#IZ=5;LR_'
M]7JUQV91\=Q^7;U:\U)X#W?C\ ^5_;+]$_6"?#\?4;>=%$@]>FX!O]'I_3K\
M6O@=,#^'00\/1\^JTHW =Q -NOCN&P[CXB'C]&WT:Z:B>P^Z#;T"&W4/#?S_
M %Z6N-C=? _5WC<?X>&*#&#NI%_';J?<.GC_ ([4<Z>P[& !]'QAN.P_U#JF
MN$ _OB\P=.NP[!U'8-P\_I#?PU7U" ;<OAL/CY^FNBJF.W*;IOL/38?T\^J"
M +$;C[NFQ[L4 [V/7Z[$>(Q:"R)@]R8 +OX> ].NW@/FU07:.P;;@.W4.G0P
M==OD'I]0:O1RD)B\H;%'<-A$/0(B.P^/7S#X?%Z+?72YBCMT^;S;"'C\8_7J
MY&UM@-C8W/<01X=;?5UZ8J'4=WGX>?[/#[<6,[0#H80 PB ^&X"("/+UZ^(>
M/Q_+T&U7[<.7J!O/X^?W7N?0/,(=1\WQ:OYXEX@)0 !#<!VWZ@ ;^'4/C'80
MW\/..K6=IF$HF-L( .P[;;@&_P ?G#;;I](]=2$Z@7L+?G6V-Q>U[7\"!WW!
M VP(+C3JM8[$[[]UM^OG<VZ>W'+U( $P  ]-B[&\2B B/7;Q#?8=@\VW4>NK
M&E$!W$?$ $>;;W)3!O[X/#;80\0VW^?637Z?B'+N B.QA .A@'S^?PW#S@&_
MIU9$JCN4P![XY>7XM_ H^ #U\^^X=!\0ZZD(=[="-[[$7OTMOL+^9V[CTM(0
M1IWZ&_U_]<8I?HCN;IMN/4!$=Q 1$.HCMM]6X>;5A23?81V#W(B&P!N(B  /
MC\@;>C??;KMTRG(HC[H *(&$I>81'H([FW$NX_%OTV\_GVU8$DD81Z '@&YA
M^(!ZAX>GS?/J;&S60@]6L>[5=MK^VQ'?TQ9D!N0#T('7N8#J/;]GV8OD4A*(
MCY]@V*/R& 0'H/I]>K%D$0$#AN.P=3#TW =O O0/'S^/RZR5(I[@?<.@"',/
MHZ;@)0$?2'F^/P\UAOR 43CMT  $W0>HB7?<-Q$/FZ=0'63CU>%P-_>1T_Q]
MNXQ$*Z7TW[QN-NMC]G=[\8U?I!L/-OX^Y, ]=A(  &WAX"(]?D]&K$D$]C 0
MP;AON #MMMRE$!#SAT\VX=1'IK)<@F ]IOM[K<P"'00 I.;;8?#<0V](AZ0$
M=6'()@)CE'F#?Q'8-PY2@8I@\?$=_B';;;<-]9*'K'O?<>5^UO\ ;_AB,WSC
M]7W _P"/X&,?2C9-=)1(Q"G24 Q#%, B!BG*(&$1Z"&W7KN AOOJ\L09OE,0
M3R!+'+VA.CIL64<UME38UZ:RCC."B$+<X:5[%IKJC)5Z)BIV8M#H;2P.P33F
M8]=VV,Z9@Z=G7MIZF8I!$=N4 $VX=-S&W$Q1#?IT#Q /4-I/2@)3D$ $!'80
M$.@[[]-]M]MNGI#;IL( .IS00544U/4QB6"33J0[,K "TD3BYCE78HXZ6L05
M)4Q#-+3R(\;LC*W0&Z$G3?6E[,&&Q'> +%2 1M%H%I6P5?Z[<<4LFDI!S49!
M,++@['USF)/%F,L8ODD[!9,Y9%N\I7&5?2N1&:2/LX@N,<K"2+AHM-2[Y"RU
M^%:[FZG;:U>J[%6VGSD99*U.-N^1$Y#NTGT;(->U50[5LY1,8AP(JBJBJ7<#
MHKIJHJ%*JF<I?,GP[99<PC1]@6T/3NJ#85)I_3H6:R"YQGC=I/3+%[[:F&4K
M!'(%?R=4M44@:+3B7+DC!I+.Q=(/*^K).YYILGX0\PEQK?F^''U@]M&.LBO)
M>3QY+PC :QB/##MB]FTD,)0CVTQ-<G;!9')D6QA1!HT=OCNXB<:0 HV%U)+:
M?FN7RH\D$K\VI@C,U-.;AJ^@6^K622IJJ4#MCLLZK(2TSM&3GJ.H1D21%*1.
MPCEC%BM-4$"P4  B*:]U.X!*@!%# ;9]- ZZ:UG&3PTTTTPPTTTTPPTTTTPP
MTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPP
MTTTTPPTTTTPPTTTTPPUJ[\H!<8*R6O%6 )^?K$+4I0KW*N46.0XV2BJ5:*+3
M5%9).#0R0P:/'54L"JD#-D:C'( X.JY8E7=I]LWCY':&([ /GZ>&^VX^8-_C
M\-:<G;ZT9!XG.(RRQ#W+R=/B;#6,7/HVIN<895H%OB8&-:R=O@4XC(ATJU09
M=5I&MGB::QG8*.WTE$':R<HZ<,$<CEUXFJ:Q?GT=,\L.Z@BIE=*>G90P-VC>
M;G+I4L#&"&0C6L:ILXBA/S9Y55]B;Q*#)*#;H&5-!N=/;L00=)@'Q49+F[!+
M0>*$9MX[J$0WBK=.13++BN9Z$\G5([NM25I=A?QL<^KZ%<J*K>O2U=8M(UB6
M=0E'KI.<D73NSS<=$"@5(H!X>Z'Y.HAY@#H ;!KKV&RO;O=[G=I-;O<A:;--
M2SEZ>$C*ZX=@J\4*BY>PT,0D6P?KH%25D4&("@$@9R8%%CF.J?OL]M@YAV+R
MF PAX@43^Z^K?IY]=,I:5:*C@I%M\A&@D(! DF95::1K[L7D8[L ;!18!0!J
MD\QGEFG))U.2HO?3'=511W'2EM@;7)-[DWMN?RWC7'TE&P]ON,5$S<JS=24?
M!)MY:;L#B,:'Y'<O[7ZW&S4VC#-U %!6:=1Z$2"^[8KPSD!1UE+']TI^0HD]
MBI-GA+; DD9&)&9K\BA*1H2D.MW26C>]-Q,EWR,=CW.1:@/:L7A5&CDJ3E%9
M(FO;@1?2<CE3C_E;DHNEF!MQ>S=9L**H=A(QF':_4*^7ARC6HIE272J+FD.Y
M.;KY2#W)V_?2\B05)!=VL;+%UMTK7\[4OAUPV5C5'V7:SQ#9GLTI7)JNUB?>
MY!JDMC.,EF$.YG*3?H0+"=6\#D*ZQ2E:/+3A&22SAVS1=S:CO&"I/+$SV",[
M1JH5N8#S>6@)# :B1VAH&DW2Y(),M(@&TKNP4,3<:3=%9K=D6 !%C<DC>P4@
M":JV4<>PF1*IBB6M<:PR-=H"SVBI5!1-^,G.5ZF-VKBTR[0Z3)2/(SA4W;87
M8.GS=P;O"16R"XG !R#BK)-$R[4F=\QI9XZXTZ1D9^(86"*(^38NI"K3C^LV
M!LB6291[SFBY^*D8MP91J0AG+144#K(\BIM95=-E4_$]Y,%#-DQ2K#EIEB[C
MJB\C3>-U'!Z-+6N(I^+8E])PB2T?% R,Z(S;GE6"<:T;QDY[*1K)(&;1N(RO
M\GB@=Q@IZBX%7F7XG>,-(YS;F5$%N+3+R1C[J@(F/U$2B??F.  ;?KK'-.SR
M%"JA5NPN"' $=-( W:(!!F8, .@%K;DS%4*BM>Y\K$7U2J"#8;70'SOO?$_(
MTH#L7;<P  !\O3KX^&WI_KU?L:F!C 4>G3E$>GI#<?'XPZ>&V_AUUJ/X9<G\
M4W$9'\.6?X2WU*MX;R98\N5G+=)=6&MOG\>W"4O%2H$%B"&^U2K.069\=W"J
MLVUHB[E>+%$6MD%C<RD<F+>,:)9&X(LIYPRCD_*V%\NYY82EVP?&SD+%2E9H
ME,CV'$!3[KDBT1] XLH5@M3HIDRKM'2BU<%R]+J;M]3G&7J;;G\_)OF+JN)2
M$"6HO8JA EV4L+"VE&4C<$W!V-NJD'>VJ\JD%@2ILH!%R2.T%L0/,7VN>T"+
MB]MM4<  < Y=]MP -Q =@-MOOX" CY_R!XY"BD@$QNG03%Y1WZ\H"(#MOX["
M&VX@/Q"/01\^."LX\9SFM>3,S#:^)%S?83C4EK/A3)F-5,)8FB(ZG32F)<RY
M J.;*1,0L.TGU+!!/\2J+W>"GG4A1):+F191E?@V;%MSWWPZ\3_%6OPI>3\S
MAD?.YKW;?*"6W >)5861I>*,257$$W-U7-5UG)NG7*.I,ZN6X9?&@URAL/;O
M V2KP-BE.]U"O,5W$<R;8UY@38A@ME(!T@VTQL+V)L3J4=_7>UMIJ(%%]KVT
MG?8G< "XV MU)/E;'H18EZD$.O@ =?-S!N(CN ;;=-A\^W35Z,4@$@B ;!MO
MN(B/4AC"/0.OP?Z^NM-\[D/CRP/C1)WD*%GN(UW5N)S(AKC7^%Z0Q[/\5K+A
M!D,?+V;&[P*I9,?4&E9%R_C&S2D&.3:Y3:U"3%]QPK SD6Z1DY&9:.K71XW<
ME5AEP\9'L.3+Y=^#[+>(>$SVO<<&)<94Q[CJ'S%;+V^9Y,6XO\52<(ED/#5)
MSA#O:76:#;8.,:5S%4[)3*<DWBWK;V1)8=AVB+C:^_F%M]O> 0-@3T. 4EK@
MBP*[^>VVXW]E_9??&Z>C9+H=\L>2ZC4;$A,6+#EMCJ+DV,383;-2K6V5JL+=
MV$,X<RD8Q82BCBJV*%F >5YW,129'Q62[Y*20=LF^96B9.0OB/B ")AW$-O/
ML/IW]>W37GYSYQ<<6](KWE(U:EF/V*E>&SRE7 3@'$JLABW'LPT@L.\1B7"2
M%ZH+Z//%(^RB:3K.%I6):UGI[HKV+--K/QFY%6]^9-XE.,S!5]\I3A:LW^9X
M@9; K'R>64\:VV<QKCMG?J#CKBKR98\?\0</5*=1*]7X#)CW&U6Q_9L@X;KD
ME"3]OD)Z50IRJ%\581L?,1F;L%1W[DVO_P!.EN_KW;7N$'IL;6 WZ=/.V]Q_
MP&-];,A!*!_ 1 P"8!\V^WAX?0&_QZC%<>//@VQOD"P8FN_$7CBMY,JB2;NR
M4&1>3(6Z&CW#E5FUEGT&VA7+U.$>.T%V;"=(F>&?ND%V[)^NJBH0N,^$I_Q-
MSF>N,0^3K?;[#PU5B^T.M<)KB\XRKU)L=JK<EC"G7#)%G<SJ=:J]PMK"K9&E
M[#CF&E9F*91[UG'*IHA)OX5:8=0RR"&>?U;'B.^Y]-CD+_\ J.. 2PALI.+:
MW@"S'W5W$B%;!%>KD672*$SR]Y%RDHU!+H9,R(O &QX#S[M_^O\ CA;KY+?[
MC_PQNYH%YI>4*55LB8ZL\)<Z'=H1A9*E;*X^3DH.PP,HD"["5BGR?N73-VD/
M,DH  /0Q#%*<ABEOI(G.([B.Q-C?%T'S[_IXZU%3&4LUY@XC.+?A!PUF6(X2
M[1PP\-'#Q?Z),EH='ND=:;YGQ3(]FG<H6ZIV!B0DUB6C/J(2DS58J[V!1?3%
MJLTQ)V1E*IU065R9ER'QG8*>YZR9"9*K6>J3G/#MD;\'N*86@UVJ'Q7Q)Q<!
M!QN$Z3"6@!<S.3*UQ!.9^3N5KD;ZX>K4>7IBC:O$4J,JZ28UZ[#86Z6\+=-M
MAMM[SBI5"K<=2 3<D@D^%A?[\2@O_'[P7XGR'/8FR9Q(XIH61ZHR:RUGJ%LL
M P<Q7(%XL9NUM$ZD^:)(1%27<)K($MK]="LBNW=HC+ HT<E2R1EOBEX<\#X\
MK^6\PYFH&/\ %UJ6B4*_D6P3[9&C2JD^1N: [I:VO>X)1.P"[9I0"_?P0FW+
MQHUBE'CET@DIYVL[6WB]X<^/K/D[6:E6>,K.^-_(,<*;/-;Y]&KP<ADMY$<3
M/$''Y5R50\-4^N(P5_FG10M5RC,"M)O&4?;T&Z-)A[9$NY1(NKCXH,38CP?]
MCCX,QA@?,;CB"Q%6;!Y.,]#S,JD#3[8<).\?7#S92V!O%)NWXUV/5=33MK&U
M!5Z[7IK%JUJ[E=1U#J&U;.Y)\<5@6_'[;^&-ZSWCAX2XR]PF+9'-U-9Y+LE.
M)D*!H#L\TWN<O13,BR"EP85H\067<5IJ@8I'\RFS%A'.S%CWZ[:0,#767<)Y
MHQ3Q'8LI>;,)W*.O^+<A11YNF7&'1D4(VP11'[R,,^9)2[*.D"H=]CWB!3.&
M2 J"B*A"F2.FH?6#80_]_P"\'C[K8/))<4.P[FVW^[-X:N@]=O 1Z#\7G NV
MM#R8=]XH\ 8 \BQ.0>='MYP)Q7Y*RSPV73A@D<:8];,*5'EK'%'F"MY=HV0X
MV&1RF:<J\EB=1*^)6:RS]2G(.Q $; 5A9DV7.Q[CU<J$$NX#T 1Z#TZAOT].
MV_HUU54P'W/I .O01#8?ZOKUK+\I%Q'9VX>"XSLN.JUD6S8@3JV8Y3B"=\/D
M71+[Q&8FCV4%76V.,ZP6%+L@LOEO"^.K(_E?MS5^F@I=&QY6F/V$;/0S><@G
M\.G?&QGA\W\HL:E\0[*\5'"ODA>%_C2X?LH0>/Z*R8N\CY"QCQ,6>7R'%L)V
MHJC)4K(JN(*=94:C<VDJC#,I>6CHT(<%TDV508CV>&/+?X_;W^W;&^E0-@$-
MAWWV#?SAOZ!#Q_0 UARC9MQ3E*U98I% N<9:+9@RWQ]!RQ#,$91)S2+?*0#2
MTL("5,_8,VRSQS7Y!G*IJ1BT@T[JY1$70'4*0=7="XC.);BON'%9BVB9Z@^&
MZ^\,.#N!^X5^Q2./:M<*I/6#/.'3YPR!DC+-7GD$'LKC-^DUD\8Q,%59ZD$K
MSJO6^;3FEIGV+]A8E<4N1L\X4EO+J\5?#_FN1QI,<.;KA0S-#UR.H=$N->RF
MZJO!WAJ9>4^^+7N$GWQ*%8JZ1[!.$:,O3[;&KRJD^WMBJS-G'E]+ @[6OUV%
MN[?NW^OP^JET#6.^H=-^[O\ ?]WMQZ.G">_NA'IN =/'S]>O3;5N+I%(82@(
MB7E =]]AZ@(>(#M\G7X]8"XQ\HR6+>'V8M\'DB'Q'8).U8BJT#8Y&H.,A2SJ
M3R!DFGUT*'CRE)"(VC+N0&4J^HF(V3YN]B4;_-P,M8&#J%CY$"ZJF'%]QGD@
M.*QK!4>_YED^'/REC/#"^,*\]PQ$<7-CX4U>%S&.=[56,6<IS8HR?G/'<SD4
MLZZADGR<[9,5P<]7XZTJ6]!E85:;[>[V>>W?O;W8M@$[CQM]V_VCSQNP>HB!
M3;=1#PZ!N)1]'CL/F$/#Q\^VL72EOJ36YP^/7=DAFEYL5;L=Q@:>N_13L$Q5
M:C)5Z(M%BC8L1[=S#P$K:ZS'2KXI12:.YZ-1./.X#;''!KEAGGKACQ+E.(R;
M)9H3N3&QB6^35!+BVS2DG'Y"ME?=5RW8X+'Q1*5>:"[8!C>Z5]*.:H-;94Y9
M9N"R#E-ROHUXU,H9#KN4Z]Y42$P;G^0J/![G]O%,<AMHW'\=B^R>3L0:2N%.
M)\_(AF V2)5I;;[8[%Q!P$H\P\Z258XVH1FZ)(<K>T,Y1;LJ2#8Z3>XZ&US8
M>7U6\,5 ,+@>8OOWD#J;#N^P^6-P.:.+'ADP-:H"D9ISECW&%QN#1T^JE8N#
M^183-G:,2'6>K5IFA%/!GC1[8AG4FA$F=NHIL)'<D@T;*)+'_;C-&&WN,#YI
M997QN\P^G&J3!\I,[K7'=!]C$7'=%7'MK;R"L.8Z;P0CS,@=#(^R9B1(,_90
MY&8ZX_*'RUF6\I!Y#B<Q8K7[/*.L@\>TK4%I:S35=I\VTD.#UDZ8R?MFK4):
M9".83$,NG(,9.-@I;MTEFAC(*ME!4+#2;X8[IPO<6/D\:3F"TP,]BOBC\I1Q
MI<7F38:H0KZ*PE5>+NY8@8SW"GB"KL[ 4SYW#5Z9B+K8ZE)3;2$=W7)S5W:O
M:[&3#:/00O*Q#,0+J"%[[#4([7-_UNU;H!MBRJV(!N"5OO?I<[=UOF[>WOQN
M&KG$5@W(UA:TZG9-@)6W2L?)S4347;:P5JVRD##MF;R3GHZKW"$KL^_@&"$B
MP.[G64:M#HG>M&YWI7;A)N:MVN7BZ_#2D[-/4XV'A63B0DY!5%TX39L&J9E5
MW2B+%N[=JE13 QSIM6RZY@W[-$X@!=7C=*Y4I2VT:U6%I'N;M6"W&/H,Y*G(
M:PL4+/"HI7N-A7+HPOE&4K$QC%W98] YFJ@Q$5(R"8+QS)9/J' Y9"/%(5"J
M%?LA Z?,FJ4XN4MC%,3E,4VX#L8H@8-MP$/'4V)C?>UEL1;VJ!<;GN-]]P>Z
MXQ1( -]SXV'2PO>YV[NF^XW\,05J_&-PF9+7BVE#XCL06A2P/21T"I'V]JV9
MS\F9PLS3C("5ETXR)G)59Z@JR1B8A^\DU7B2K1)H=RF=(+BR;D6AXPBVLQD*
MU0]3CGTDC"1IY51<7LQ-+D$4(2"AV+=Y.V"943356]B8*,D9!-JDL\6;)M&Z
MZZ6JCAJB\=S'D"3MLVI1[C&+3A^XK9:9/92$6C8=_%9;SQ(5F;BC/^9*.M,7
M;$(9]49*.%&;:VE.+5A5BRHMM\<<$$OF>P\7/#JEQ2&?CDN!\D7ARR8E2L*R
MZDLM9;-=V+#/5O0*^*15'*SN ;U*%R8[9[3:4"(M9!4L6^=D6F15+?)@JNJ=
M(R" =*%B 0PN3N+A3J&HW!T]3'= 79[V"M8@VN=*KN.G3\[8V&^^-K-7RGC?
M):LRWH=QAK,]KP,PGXQBH\;35=&3/(I1J=A@)5I'3L"O(FB9(6+>9C6*[U!D
ML[:IK,Q2<*?613$><2^)0,7Q#;E O-U$1\PB(@/4=MP] :K\A%5UO<I:?2;L
M4[I,UJ 83;P.0)B2K4#(3@UHTD(_K[EG&R,Q/-(ATY$X(]Y>L&A@2(=(E'?E
M$H]1 0$=^HCT]SN(^;QZ[@/0.H 'AMFJ9KZ%8"X(O;I;5ML2;;$ W)WOX8A3
M6[-NGZUK_FWZ?[.+!>\H@<@AN4O78-]Q#J ["'3?T!O^3K9+X#%5'<!#F H[
M#U\.;S^?P#SCY_3J^7>P]ML #U, #YQWZ@(><!Z] \?IU:#Y'F4W$1Y0V =M
M@ !'PY0'?8!WW'YNGCK)H07V/>._8C;I;;_A[A!EMN3X>%OH^(\;6'7;Z\63
M,,P=(*IB &-L"R(F#F JR>YDQ H>^$!+R@ @("(]0'P'842XRV7L+P&1)R:J
MXY!J:1\A0-US9G-&3;0^3<:NF9[@_JG#[%QZAF;*=J\"W/7X=BV<0;F0:.)%
MQ7X>3DEY*P0%=_\ L_G:E_P/O9=\ZR=28IK-=LQ4@,CQC^N8MQUD!] NUA/1
M)BS*GN2C>P!(1\1.(-ZRRI+DLQWEQ,KF1>LN^,'%C.E(H4K%_?<MFBJD-NTT
M+LD-3%?>T<J.O,6Q5E2S*PN,7J _NDT[&Z5D;1F][!U421.!T+(RG2;J;ML1
M;'H.PID>,RYBFAY'B'2CYE:ZZRD!=*13N$,L^3 S*6.6*?"=RR1]EFKX&Z9U
M5TS( DH@Y<H'374RCJ _D^Y2T-<9WC&MM1M?LCBG)UDJS1Y=[-%SEH>0KP4Y
MJ&"2BV"BBM5!JP=I((PB_P"L)#VHL@12*=FUGQKG5="M/65$2$&-96,1#*X,
M3]N(ZE 4WC92;*NYL54[#9:=S)#$[ AB@U@@BSC9Q8DD68'J3[3U+33343%[
M#3333##3333##3333##3333##3333##3333##3333##3333##3333##3333#
M#3333##3333##3333##3333##3333#' ^'SE_*&O-W$2T)8:OG%R@OPUNEW=
MNS]<IB--A_*L[<Y-E"0"C>-=L<>1@1E<J$8T=/E7K?*\N]>+UEV_? QBC2$>
M_7/Z1!\/G#XO.'7KZ/$=:.(Z'NT%0>)"KW>4N=6AF>3<MQZCO,'$A2*33$3W
MFO*#4W4E*0J;:U'GK&\,U]K\1((GI,P9\9^=$#'ER#ELO95IZK40+5.6.PUH
MI,251YE@P+$ E"2NRFS."+#$.H!,L-OT56%V8@.8AIW&PVU  B[;@$;WU"0B
M8$9,P#?<6X<VXB/4PB8=Q'J([^(^]$=Q+[D0'5ZL_ /X)O\ 7U9,*;]B-T^=
M)042*(F.@H55$QD3B0134()B'3,  9,Q#"F9,2"F8Q!*.KV:> ?P3?ZVNI3?
M.D\=9O\ TNOUC[,:?'^]G_R__P"DQ9,_@3%ESN3;(TE7WT1D)".8P2]\I-IM
MF/+=+UQBN+II5[)/4:<K[ZT5ELX.9=K!V(\FQ9JF,9B1H)S\]8O_  NX%S%5
MZU3K_CF-E(:D3HV:EK1<I8ZI8JG8%U#J/Y>NW*J3,+<(N0FA55"Q.F\Z"UD!
M509T[]4P*%LB<XF,4T^SP=7GGE@0)8LFML,Q=K:P"CZCGRZY8+/F>.'%A;O1
M5;V=\HW4@VA%(T(92V\E/5F4+&H6/U3<!\8U6RYCP+[(4?)%(6F\VW?"U&J<
M]37S:S7.?K=SN=:C8V";G=&8R,ZVC:1-2^0"$D&T%CU6/EV\[,(-HE=X;7Y7
MI2#$1$7;=AH4ZM.@L7VW-V3KNQL1>QMDHQ*$# 2#2$TL#:U[V"[];*>FWC;O
ME3#8*Q''3&+IV.H</%RF&(24J^*EHAQ,Q*%!KTZR:1\Y#UR.C91K%-V4RR9,
MFTL5RQ=J22;-MWQ18Z"9BY;Q5C.C8H@G%9QY7D:O N9V=M"T8TD9R00-8;1)
MN)RQRY59R5EG:;R;FGCR8DS).$TW4H\=R!TN].5U#XOPKEREYKJ9KC1W,LI'
M,;7;*/-L+!!R%;L-=N=$FUZY<*O/PDDF5PPEX&8:JM7)4U'3)PF9!Y'O7C-R
MBN>14;X#OX_S;!L/SZA2K'8NBIN-F4#H5&X(\0%'F /HBTE2P4ABW4[$D]]S
M[#>Y^LGOWP[1>"[A?IN2[QF"JXBA*_D'(9IYS9Y:*E[6QCC2]NC%X:XV:OUA
MM8$JM2[E<HEPO'6N[4R&@+9.LU547LP<%EA4SQ!8#Q'!6K'&2X+&L0KD+"E!
M=XWQ/*^V"RQ;RO451-!4V/F\B,J\:#69-=BP3=A8(NQ @9JS?"DX<L&O+=$7
MX?-_-_6&LA1/@7Y?Y@UC)40+LJC<G90-[@WV'6^]^M\7XV8L+L?#J>@T@#W$
M^_$.N!7@RC\$X"PO2LKUV&?97QE4+?4U9" R3>KM38)Q=).<-;YW%A9Q.MAC
M]_?(F7!I;7U:KE=FW/,_8!(&8.U^]RI/P8<+<[P[$X2IG"M2D.'-%JBSC\4N
M5["Y@*^1C)&EHQQ5'[N;<62J2$'+J*2M=DZ]-QK^NR"BCF%78BJJ4^68_P#N
MOX?Y=9#B=Q!/?QY1$?I 1U!9%'9L"H2W3<CEK>]AO?:_C;?&00DJ&/4[_623
MC$=1X/.'VITS'M"I]2GZ=#8RG[%;*;*5/)F3X*\LK=<8H8*XVR6R.SN!;W;;
M-;X<YHZT3-PGY]W--Q*#HPJ-V2C2[XG@WX;H]Y'*Q6,VL)%,JYCJFJ4R"L5O
MA\;3-4Q \<2>+J_9\:,K E1;1&427=.IJ!2G8%\H$RX5D)-:36,'+FI@?;E$
M ]Z(?3N'U:O%B.YB;=0W,/AML&^P;C\O3PU$8;BP &P(( M<#8 [B]K"W=8=
M,>PWNP-SM>Q]M^A[\80F^#+ABNXY24MF(XF=^W;D*D98RT1Y9LAD3O\ DO&R
M\,KCZ\6!%I=&J)[#2U*U6S5QXP38DC KT"5) 20T<5MB'C&X$8+,E0R--8BQ
MOA:<RUENSX'<YI2SE9\QQD)G+'6!;.I::A0)#(E)E;%:<36&K38MI_'63J;4
M)69I\JWDFS=HBG:9B50GTQ$0'E'8 $-_CW >;S_+^75T)#NF4=MM^NP!MMZ?
MKU8D7LA@!T-[C>_=:W3\XC_ ;8N$VL ;_LL+7[N[:WWX@;P'\(-TX=92\7&T
MNY>B^WJ"C8=S@R(XO>*'C%QS%R\7.O97[8C6^<4QV<]"6M]&NTZH,%0JI5ZT
ME7F*!I9U8Y#N)HB8D/PYX9B<W3G$G'TE)OG&S4YACR?R*-@MZ\Q*T2(E'4W$
MTYTS=6)>!&L14R^>3$9!IPZ<;'2SMQ),6[=ZLHN;*S;Q_P#JC_K!JK(F#EY=
M^O4=OBZ>O5L !R/=>W7;I_PQ:<FVWD#[/P!B+><>!CA3XE\B8_RMFO#T-<\B
M8XBWM<K=J+-VZLR+RG2K[V4DL=W4*?8:^UR5B]_+"$P\QGD-O9Z,YF")R2T$
M=R!S'[/$OBC.>1,F<%<YB.SU:O4K#_$^;)^>X^=7<-Y"TXM0P5F6BLJ_646\
M+*(O95.[WBM28,EW$$BDU8&?IRI1C@CWLJD_%/Y2_E#53((B([B(]/3\8:\(
M[((VV%_.]L2!>RV.UM_/88PY'\-F&6.=)'B;;4Q-+.TW1H_&LQD0L]:C2LCC
M^*E74[%TMRR/.F@E*O%SSY[.1D(,0$>PF7;J5:((OW"K@V)'WD\>#>0Q=:<(
MJX-KK?#ESR,.6I_%49,W2&QTOD,;:E?@L[&F0]H8UZ#>%O*"%Q3;P+"+CD[0
M@A/)LB2:"3DDSTQ#D+U\VOWJC%6(_J<+N$5LTU;B)<4]PZS73*.[QI7,CN[=
M>G=CCZ!(2+29E*@9=S:%6SZOR\S'L9J9C9)J]0F)AFVE90'D@BFY+:V(."GA
MIP1,Q<SC#&S>OC6'%L<8^A'-AMEBJ.(AOJQG-Z;X4IMGGIFK8987-RHNM:(_
M&435V<R9TZ2=HG:N5VQY4Z:88P%EKAFQ!FRSUBZ7V&L"UJI]7NE'@IRMWZ_4
M9ZE3,CNZL\OM4?C2K- (S5?MJM+K)9F,FDI!NLG%(%0!N83G-B/(_D\N#;)\
MO#R]OP;7ECP^ WG"\A$P,O:Z;57W#^X1.@PQ7/TRGS\%4K15:H*J[K'S2RPL
ML?',DY=2M'5@9)RJZ&;.NJL8#"&P[[ ._P!.F&(%V_R;/!#=+GBW(EDX?:L_
MN&&Z!7\3TR52F+G&IN\6U-PU=57&N0XN,LS2*S#0*P_9M)2NT[+C.[0$++()
MR3%BD[ 5!O&Y<&/#-?FF?XZY8KC[%'\5'L%]T+'R-DO9V&6DZU&(0<$VMS%*
MV(M7+*,@VC2#:L62+%D6%:M8@[<\8W1:$EDO[P_RA_K!JFG\0^3^<=7; !;#
MJ5O[OQ]_7%N4V1B.HM]XQ@7-'#IAW/F)76#,M5)6VXW=>U9RG&J66V14_%2U
M'EX^?I5FKM[AIV/O=<N51G8B,FJW<H:R,[/$2K%!^UE2N .<\=$O)Y<(L'.3
MEMK>,I>JV^Q96C<XR=PJV5LOP-L^V[&XQ6PZ3(;*PL;X2396B0Q^NYB+$_27
M$MN=O'DY;4IR:7[Z6>JAN8V^VVW3Z!'UZM][T)U])?\ VM4&Q+6Z6%N[O _;
MBT";#?N'^&,.06*\>T;'B&*Z=6&E9H2$?/,$H"#=2D8 )V>0E)FT/3R[.01G
MSSEEG9N9GYZR>RP6&5GYB3G7<H>5>+.S8P></N&SX06X<%*(Q5P:K3%,<JXW
M6F+4O"JT%9D,<K35'Z]@5LAZZK&",4I'&G13/%&/&&$6"BC8TD'H@!>OP1V^
M?W.WCN #T'Y=6>\-L0P &XB(%V'T[\OS_5J4!==Q<@BV_6Y'?W;;?5XC%8[A
MY@GV;6O[/LOB&Q^#/ADCGF"9%GB6,1?<,4<\B>'ET%HR(HMAJ+D8A.NOX^A&
M6N:H1+-[7$&];=H+ \(XKK9M J@:);HLT[CS+B'%^=:5*XXS%0JQDBC2[F-?
M/:S:XTK^/]DX9X60A)EBHF=N_AYZ"D4TY"!L$*\CIR#?ID>1,BS<%!36>I#P
M#?S#MMYAV,(;[].@C\^K,?=#' ! 0'IU^/\ 38?3OTVU(C!WL !92P/?\T;^
MT#Z]@.@M9[6KM'M76]M^\'J+@=UK=Y]N(73O"SB-7'=^QNZA)RYQ>0L?6O&L
M^[RQDS+&2IZ0I5N:*-)JI*7BS7.3O\169 ADP?LJM8H1ZX*W:J ]!XS8NFOR
MQMB>$Q/AF@84C).>F*]CR@0&/8^5E)>2+87L3 1I(QJLXF6SXDN@X(V3(@T7
M0DQ?L6:+5N2065;]Z5DK)EW$YA';8.78>GOA$/1\6^L>/A  -N.W0 #?S]!'
MIJ1$%U V [-O]H?X>./)?S/#4?L&WWV\^F(/QO!7PK5:#K55A<(U(E2I$VA9
MJ;395_;[12*O8VDNO8&<_"4BVVB>J#*:93[IS/,9,D(+MC-KJR[-5"1-WD.W
MF+"&,,S^UXV1JN29EJ9)/9ND6V.E9RJWVB3D@Q-'R$S1[]4Y.%N%3DI./$S"
M56A9IJG*L3"SE$7K;]:U)22'8%!#Q* B'R]/YAU8+\VYA,/G*;?\ =9"%%TJ
M-*VNH(TBVUK BV]NZ_3ZL0-3:V)8]0 ;G;YE][W'7?VXACEWA>QCD?#EQPV_
MBEEH:YN:R\FYJ>L%UL%G?2U/E8R5K=DE;6M:&]PGYZM.HIH]@ D[*$8B^;H$
M>-5XHSZ.>92D0VY $RBFP$ 3K*=JLIL0 YUE>4G:K*;<ZRO(7M53'.)2\VP7
M[)"  H CXB<0^3;??Z.NK#D0W$/B !^@FLI J@DJH!*J+@#<+T&W<"S;>)/?
MB/.25 N>XC?O.B_W#%BOP #GV  ZE'H !UV\=6FY][]'Y1U=;\Y1,<?  $-]
MP'S>([>.P;]=6HZZ!L/CTZ?..LE#>\=^NU_;;?$&H^:__E^\8M-Y_P"S^=K(
M/#[&L97)TBR=QV/9 WVMKM)- R;C^[Y)K+*1@HLTNRDCPE"62G8APS59%.-U
M; LM2F OYY@@K*-VB2F/GG_L_G:D-P;1,_(9<GY"LP,Q9I:&H,BW2AZQF-GB
M*T'3L+QK$O'E?7<,'Q[5+Q+)5S+,JP8["+<OF#)6:?=B9K'O[V9L%RO,"VP-
M!.O4#=U5%ZD7N[*+ W-["Y-C72@FLI .O/B/]$:B? 6 )N=A:Y(&-H_D_P!\
MS2S%Q60K$V)FX*3U*GWS'&+B[V5J>2D(U\#YXGD&WQ\6M;(L[L[HRJRC%N\&
MR.9MX9$$7 *K;4=0!X-XB9=9$XE+W,1^>X8T_=X&%;-<S-H6.;3#6N08LT;!
M Q\)$1+9%8Z)$63I%-)1*-8A'1YG#IX5XH2?VN;YHP:KO>["FH5<Z@UY$HJ=
M7[2@ V8$7WZ;DG?&S4HM#TM>6<C8KV3/(5V.XN"#;;R&&FFFL?B3AIIIIAAI
MIIIAAIIIIAAIIIIAAIIIIAAIIIIAAIIK"W$DLLVX=<^.&RRS=PWPME-9!PW5
M407062HTZHDL@NB8BJ*R1RE.FJD<BB9RE.0Q3  A<BCYLL45]/,D2/5:]M;!
M;VN+VO>UQ?QQ9J9A3T\]05UB"&68J#8L(D9]-[&U]-KV-KWL<9GY@]!OP#_F
MZ<P>@WX!_P W7\\E#(%^%!#>^WL?UA'_ ..UK^]E_P#EC7U]O]^_=[>_\]K7
M_3&NH'T82@D?#,>QM_W%O\W^+>R_ /C]IO\ Z8F_O9/+_P"W>9]WGC^ACS!Z
M#?@'_-TY@]!OP#_FZ\#_ +4>)[VJIW@K#-BM/5JSF\)V-M/VUW&'I;)\$6_M
MQ5&DXNL-:CY(>X24WV/L=&//V/(.&JON=618YO+U/?-HNUV/)M;DGD-$6-HP
MFK;;8]VZK\^P2E(.;007F"G4BY>-71?Q[TH"BY:*D63,)1Z6D]' E)6//J:1
M@64A*4.0R:0ZD+6$AD+ ..JD@$ D7D2^G)H%5Y^#ZZ%&6-U>7,#&K)*"T;*S
MY8 5D4.8V!LX0E21T_H+\P>@WX!_S=.8/0;\ _YNOY]U2E,QWVR1-.I5@R;:
MK9.N>YPM<@[=:WTS*N^P6= V8,B30*N%S-VZZQ$B!SJ)I'$@&$-AM]7(%]04
M617OUY15;G.DX35O%H(=!1-0R)R*E-,AV9BJE,F(&VW.42AN.JQZ,I"Q09U%
MK"JQ3U(ZPKDA6*^MZ@K%7"L19BC $E3BU\?,0193PK4B)G:-9#FBZ&=!&TB*
M_P &Z6=%E1G4&ZAT) #K?^ACS!Z#?@'_ #=.8/0;\ _YNOYY?VP[UMS?;!N_
M*)N0#>WFT<HGW$.0#>S.PGW 0Y0$3;@(;;@.A<AWH_0F0;N8=S!L6\V@P[D]
M^&P3(CN3<.</$NX<P!OJKXL9OY8C_L+?YO\ %CY7H^/VF_\ IB;N_P#W9/+_
M .W>9]WGC^AIS!Z#?@'_ #=.8/0;\ _YNO 3!QO$-98Z+EZ\;,DS&3LHX@X%
M\PG[FJA8)IF*8/(BN<TNFI8Y)D9= CYE IR3ABHN@D\30562(>B6:4S'2UHA
MO;K#DVMKS]>B[;!IS%PM+0TQ5ILJQXBPQHC-F(\AY(K=P+-\B8R*O8J@ @)#
M %H>C?4_+&>TYD%[H*0%QI-FNHK-79-P=MB#?%]O3IHC$S\(5JPD*1*V8D1D
M.%*D.<L"D,&!4W[0L1<,,?T$>8/0;\ _YNG,'H-^ ?\ -U_/2;7G(;UTV8,[
MS?W;YZX;-6;)K<[:X>.W3Q8C=FV:M49<[APX=N%4F[9%%,ZKA=5-%$AU%"%-
M\E<@7U$ZJ2U^O**J!E"KIJWBTIJ(F24,BJ54AYD#)BFJ0Z1P. <JA3)FV,40
M"Y\6,I-OAB._6WJ+7L3:]O6_';V@^5[/Q^4]K_DO/:]K_"J6OL2+_!UK@&]O
M+S&/Z&7,'H-^ ?\ -TY@]!OP#_FZ_GS(3V7'-<E+BWLN2UZG"3$37YBRI6ZV
MGA(N=G6T@\A8=](!,=W;2,JTB9-RP:J&!1RC'NSI@((FU1/MAWKE _VPKOR"
M;D _MZM'*)]Q#D WLSR\^X#[G?FZ#TT'HRD8D+G,1*MI8"B)*M96TM:KV;2R
MM8[V(/0B_K>GJ%0I;A:H4.H="V:J Z%BNM;Y<-2ZE==0N-2,+W! _H:<P>@W
MX!_S=.8/0;\ _P";K^>=]L"_#U"^WL0\PA=K4(#\8"$QL(?&&GM_OW[O;W_G
MM:_Z8U[\6,W\L1_V%O\ -_BQ\KT_'[3?_3$W][)Y?_;O,^[SQ_0R 0, ^.WA
MU 0_* #K39E=O2,.<8&1YB0@<(TQY;8"!R;5[K*2%@NN7I*:$[2'M!Z=C5R2
M9@'ULFB$L$96(,8B/55<%4FXM_(@G*11.UY$:8EYOA,N+N:EI:9=$SM<$".I
MB4D)9T1 E3H1B($<R3ETN5$ACG.5$J@)%.HH<I ,<XFSKQUQ=EJ$CB;/%2?3
MD0>JS3NA79[CW&\!<<H.:=>$^[BM S4RU<)0+>OG2D7:"SH[=HA+2#1TFN#C
M]8<:6] :#-,RR5IA*62:C63MPI).FB>G)16>VJ>*- KEE!:Y9-I$[)E&;KGF
M1Y5GRP&F6JCAK>0769H8Y+I(O-*1ZM,;LQ8(A(!&EOFMH6R55).C97R+5)9A
M-QKF-M4LX;-K%&0T++FBI9R>4BW;F(K[AU"L2O&+MNZ11B%SQ94%DNY BB)4
M$J>S,! *81 -@$0W\-P. AN'G#IU#SAOYM9^XGL5K5.8C+C$UXL0@V9,82[0
M$4SE[/)5=FZ47''MRS%E!L_E:1*9$RO )M[7(MX0\**!G;=LZBQ>*$?RL=VQ
MP43#P';T=2B!NH;>.X#^G36]T54M;04U4I!,D2+* -)2>(".=2O4$2*2/%64
MCP&-J(3!// U](<E#>]XV(>,@VWN-O:#OTO#C$V&,R8\RI=:FKC3!MVPW9\Y
MVS.59SE8'T4YR92F-[MQ<A6''CK'$E395S8[-#V=U,L*)>4+=#P\1"/VC]\@
M:1B&\:YMZ X9N)C&]&Q\]H#7&%BOV .+S/N;J?5Y"\R\'"YHQ-GV=RJM::I/
M3[NJ+-<:7)O7\GHHP+ERTM,>SF:TX6?R*;*920)L3C#B'* CMMN  /F$.H=/
M#WH#L'T==]7JP.)3@/B)^NPAN.W*/Q[;^'COOOU\^L<:./YIYG9#"/< H"T;
M+I[(NJLB,A?6>S8LR=G$F.9RQL%MMJ&]F*C3=M_SE8Z@NE=[V#786I4YG/";
M+'2T]C^@&?V>WOCY-C8G("Q6^'J,K!N'$2$#)K5A+[<MI;S;9K'S:S=E26#U
M27<OXM!*-BTA7E1&G$"D,8  3@ &#X(@7S?3MX!\FVL=QZ@"!1*/0P!ON >
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M!9#IUFHMG0<.:[;821K\V@T>NHYRM&2C8[5XF@]9*HNFRAD5# 51%0H@.P&
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M2U &:>*MJA+R#H&Z*L-?6C=@_5G*XHV(N8D8J3NRCA0[-\5>%DIEB\U*34!
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M1$P"',&P /0"AUW#Q ?#81$=7S'*CS (#N4?>CX;>X#KT^,//ON >/76,F!
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M_P"/'%834Y>H"7KMN CU^0/CZ^?S[:[*:Y1.0!W*':)"(B( &P*%$1$>@
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MU%,+ZU0N]')VA8K%<R0OIV)1F!T [%NS&EIRZVE4U-F&EB529$MN-=@K]H7
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M \D)$O8IK&RU/FE1('62*GJ&[-G6O@I0 &6,C3.AU:B0>MU!U#L@VB)2Q"1
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M55%%EE3'564.J<YS7%IIK',S,Q9B69B69F)+,Q-R23N23N2=R=SB2
M  !8 #8  ;  =!AIIIKS'N&FFFF&&FFFF&&FFFF&&FFFF&&FFFF&&FFFF&&F
MFFF&&FFFF&&FFFF&&FFFF&&@CL B/F#?Z--!Z@(>G3#'E$\K3Q>YJ+Q82V*Z
M/D>W46H88;U(8UG2Y^6K)W]UE("/M#^RRJ\8\05DGL<$PUBHA)T)V3!LU<&(
MU,J^<J'B?<?*<<9]LNE/NS?,EAK#JFPU9C6]=K;@T=3;"_@6B"<E-VZLEYHV
MP/KD]35>6)%\DHQ1*Y,SA$(MJBB4N?/+08>4H?%LKD1.7@G+'-=6@I].(1E&
MQ9N%E*M&Q]-E%I6,44!PSAI0L9'O(N:5*5BY<!+M.U!6,6#4!,O\.]LP]E2N
M8EE+'09V=M5>QO8(B;K]MB750*EDR)CY")*^LBCDD:Q:L%GPINI9TLC&NHQ-
MO8V*JD+)L%U/IWANCX:GR'AW71Y?+*V3NZ&>FB=F:-($S9V+H02*EOE6:Y-R
M4.@L<;53)3-3T_8C),-QJ1238*)B;CZ?SCW]1MCW+8-R6AF7#F+LK-VA8\F1
M:#5+F:/(8ZB<<O889I(NH]-4^QU4V+M9=JFJ8"F432*<Q0$VLJ:Q-@C&B>&L
M+XJQ2F[3D!QWCZI4Y:02*<B4@[@(5I'O7Z*:@<Z:+QZBX<HIF$QB)*D(8QA*
M)ARSKYIJN3ZU4^K7]7Y\WJ][WY/,;E7OO?EZ>N_COC5WTZWT_-U-I_U;FWV6
MPTTTU8Q3AIIIIAAIIIIAAIIIIAAIIIIAAIIIIAAKCE*/B4.OCT#S>'T:YTTP
MQQL'H#T> >'HTY2^@/#;P#P\=ODWZ[:YTTPQQL'H#Z TV#T!]&N=-,,-@] >
M._S^GY=<;!Z ^C7.FF&.-@] ?1IL'H#Z-<Z:88;!Z TTTTPPV#T?'\_ITTTT
MPQB+.F:*IP^XRG\KW9I/O:U7'->:OT*S'(2TR96SV>&J,9W6/</XTC@#3,]&
MI+@5T4Z2"BCCD.1%0 K]-O86M.P!(5.WT5U7[6O4C,KQ'QD6I,N4HN(E496M
M.HN:G(JP0#U*7(T9RD;(K%4DX^8C5$4GD6Z2)@SC?P-9.)GAER1A&J*UU&7O
M(TYL![7)S,/!&CH3(-2M<R@]DJ_%S$RU,\B:^]8-5(]@=<KQV@?MFI"&<IXD
MREPA3[NU8>88RA\6S6$H&N90J=_Q?EZ6R%(#"O+_ )(I.58K*>.):,)-2#^Z
M5FSUN7:KPD[)0!)6,EXXD+=JBG#+-)9AB4.9<]T#".)+7FBRKOIRG4^&5GI(
M*:G'6"6<Q#268PS]Y%,O9-DC))QKV1;%?%0><R &$@%.OR(GPA)\>^#X> R9
M+R+2^MI;#?$ABKA6RE2SU=N%NIN6<V3&+HK&+=XT&:")E:Q:TLS8WF8ZWUR:
MFH,T)8@?&< >*F6\?$/(/"*PS&AQQXAQ'27N-GE4@2X$PXVMT0^Q_@^/B<]M
M,2\2V;;%C)Q5JV^=2$-9KP:(:6A[!,W"3.]4R0@VQ(M=)^^&ISG #F!ABW+&
M$J9,8RDZ?;>.C ?&-4;Q<YVYGRRY9U+B2Q-Q#9.H^9+6K6K-)Y2L4(MCU_C[
M#61Y676F/M8%QU1+BDW3QS[8[&PQ+RC\;^';]<:_28>/O3:2LF=N(?AW9/)2
MNL6D2WR-PR,IQ[DM)\]3G')T(4/:W,M:[,D;K(SCIF)2)-45FZRLQN@[#]'3
MJ'\X?&'TZTF37DQ;[;:[*PER6PS:6+_C \H#GD:W81L\O7G5*XQZIE> J97O
M/64#A<\=OLA1\K)1I&9XUXK$K*U^V1\B$=(-MMV'J(\Q;B;&&,Y"V35\?X\Q
MW2:,^O%E,92Q7)Y4:Q%5YS:Y]0R[DQYJQ+1QYB5.9PN)GSQ<165$14,PQ?SM
MPV:-G#MXLBW:MD55W+APH1)!!NBF95=9950033122(=14YQ A4RF,;H Z\1>
M5I+%66\XVZ;\GW3['BJF/K'+JO92P3K=]1[<\4.(NY6AXH&!&2H</(/^W=,T
MEK<=NY;*%51K$$54K</;5,1;*;BI*&DD0<Q\LP>1CYN8QB NSD&RK-T@)R"!
MR=LW743YBB!B\W, [AKP<^V-CPDYMRG0L5N'.2L=4K(-GKM-LSATPC9A[%0L
MFO'I'=HG K%UW==NLT(_:"BE(IM2/^YM>\]U2[1Z'$IS4Y_+SZI:Z*CI?5*=
M9IH<NJ%>:02^O".R321GEM313]@7F=59U!7F'I,RG/LVILICRG*3F5'#5329
ME+2T:UF9T:E(Q U&EFF1)B)5J'IE,EEC5BL>HM*/A'LN&\,\3V.)7CBIT_<I
MM2ZQ+?'F24K.V#&./;:\?LVM9F[1BD8%DY6.PF%$%DKBXM$XTKRX(2IJTEW,
M9!#V9E -@V#Z?$=O.(^<=^N_7?QW'??7@TK-NKW$EQ(X4B<V,7M:Q5+Y5I#*
MX]QD&3R9>1[R?8MTVIU$P[DQBG3\[1K-.BF6>MX9P_68I=\20$/>2D0J:9"$
M*4I2% A2E  *4">Y A0  V*4  I>GO0#?5GTQ00)F625"S5<E749=)ZY')-+
M/00-%,HCCR\RD\K9G-1#$%A4\IT%Y&Q>]&N59_E.6YA!G&5+EM-)6\S+&FI4
MI,QJXM&F>6OA54D+*PC6&2H43.I8&\:QDP)\I7>>&>C<*%X5XIZPXN] L#N)
MK\'2H@X-K99;^[55=5-O39,'+-2"L$8[9JS9;(1TB2OQT<_DG)739)5@[\F<
M53<YS<--R>+'[NG8X5$RD)5;A+M;_:(N+Y=TV<C=F-6JK21=;"8".2UU,$@$
MI3 ZY!54]/OEAL0T'*'!)?YN[2[^OR&(Y&#R50IB/;$?F"\-G85F)A7L:=PU
M![%V@EC7@'IB.$EXTKU.90%52-!LX\M])XJKI3:>XJ0T\7@K-P;*N6<U'%9K
M<H<I3[.R)N4R"(<P%%,Q@\-A'J.T^B=84X9JYJ2:HDKVSAHZFEJII4RZ.)8J
M5XYJ6('D-4E6//E(YZ@1("(R-6N^D;(>)<VSJEEI,CGK,ICH1'#7950"KKS6
M:Y&EIJR2-'J8Z=0\+11V$#<QWNT@8+OB\BY?^%PKO*&,JCC^S4+B>+',+'D>
M3O=L;Y!E\BU2-=(QR<I4[>V@ZTV85J#FY(O?:.C7816)<R[%^L>P=H,FVW[[
M!Z \-OF]'R:\M'D,(ZD67B2SCD"V.'B.8T<;MFE+@FRJ9ZXA0):Q1XW9^JN*
M1'+VRMIAG4V90YD6+>)?N#H-W"ZJZK7U+ZYCZ3*>GI^,,R6FFK9T>.CFDDKI
M9)Y#-+2Q-*L,\S-+)2QM\G 9&+(J\KI&,;_P329Q0\-Y?2YYE]/EE=$)0*2G
MABIPM,TK-3/-!#\E%4RQD/4(EOE"3(JRF1%\UOEF[IPQRV7:ACV+Q]:+'Q@1
M5.9ND+Y2[6THD?2JA*KR"]:C,A/'<#9D+XBN[!Y*1-03AT'T<R=JNR66$3ED
MTG6I.3J65ZZE!3.>DIG)6+44.UG*ACZS(8ILTHR[,HBDSMSRLVE-,NQ3@=LB
MSCU7@;$2EHPP=Y)-GRS;*J43CH@<@447TC?9G$]2=9/AW[ELC""+!Y*P]-6A
MG)4A=-Y92!CE!F6STJC R"$*LR.FLN_*$!<C\4=TR#5$:LE4?8_LF9FJ3F2F
MF"C5(1)R@8I&!5'*H 81V 0)[X-QV#IWG@:""+A7AR."HJFAJ:1I*]ZNLJ8Z
MFD:5Y.8N6!'!I8 26IVI2C,K"5KR.2.1\8<+\8UW$>:U<?#<\Z2RQ-D\F7Y5
M%54-? .4(I,SF"/&\S!+3K7D! ME B",?99P.WG .0^%[$\]PS0A*OAY"$<0
MM;J)FA6$A47<+)O64_7YMIWIZH2?9SI9!67>+/'BDP[<GFP>O4Y(CI:66P>@
M.@[AT#H/I^76O_R7V+,<XHX)L*QN,II]98>VP:V19FR23+V,?S5ON3D[^S*.
M(PJJZ<<6)D$C5QHQ(NX%!E"M@5<NES*N%-@.OE[/$IX\ZS:.DDJ9:9,RK4@E
MK;^N21+4R!'J=5F,[  RE@&+DE@K$@=YRI*R/+,OCS"""FKXZ*E2LIZ:PIX*
ME(46>& +V1%'(&1%4E54 *64 EL'H#3336*Q/PTTTTPPTTTTPPTTTTPPTTTT
MPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPTTTTPPUP81
M !$/$ $0^7;5)GY^&JL',66Q232&@*_&/IF:EGZQ6[&,BHQLJ\D'[Q<_N46S
M1JBJNLH/O2$'8!'8!U08,\KMBS/G$Y!8"J&-[:VKEN>3D34<ER<E'HA+24/%
MR<R@X=5 B OHJ$FF,2Y&.<N)%66145:>R<0Q*JN5I/I,KKZ^*JGI*62:&BB,
MU5*ND)#&JLQ)+LH9M*LVA-3E58A2 3C#9GQ#DV3U.74>99A!2U6;5"TN7T[Z
MVEJ9G=(U"K&KE$YDD:&631$KNJLX+ 8T5>5GE)>2X]<UIRHK G$-\>PT0DJ)
MN5"$0Q]77[0J &Z%16>2<D\'E]R9=TNH.YC&$=<RRBCD?V2HJMNBFW$RJAU#
M%;HH%;(I%,H8PE20;D(B@F @FBBFFDD4B1"%+ZGN/[@DQ;Q7Y7J.2,=35QD;
MHNT]@,HJXHCJU=V"M:K(=VCG[]:2G(^(B;JS6=I5^.8'D]WL:55[)1BB4$11
M:.N0?);8CF<BT2?C*3Q#8DQ&T3K$)DV)?Q%0F2A'Q35",>W%&QM["_DV"]B6
M207NW9PCXC$SV1GH!NT!$[)/Z#X>XOR>FR3)::;F0SPY6L,D>A%>.2BB2'04
M:197>M>)WIA$CZ^SS.6SH&VU>),JIE2FFDG22!8HI=-)5/&C:(NLJ1-%ILX9
MFUZ8PK<PH5.-W/!I.3MDX3N'"=LJKAQ.2F$\;.I)T[,<[IVX/5HXH.W*BFYU
MG#I(B3A9=03*+**&5.8QCB(R7U _BDXO,<\'7#DC?Z1 PV0(NNS]7Q+5JC5+
M-%H0\5)G8NT6$5)RC'V7]AV$##P3@%6Q&CA^;N[=JDW RIEDZAP4<=F,.-6J
MS#ZK,GU/O=1%H%TQY..FSR1BT) 5"QTU$2;0J;:=K<@L@Y;(2":#-XU>-E&D
MK&L55&AG?!:K+J^>&KSI*&2/+GK9E,@TZ8&DD#K&Z \Q$7FI&)"@B+$(&U$#
M&IS<1Y*N??D\]=#%G,T!K8LO<.DCP,9&!C<H(7D"QR.85D,PC1I.7RP6Q.#3
M336'QF,----,,----,,----,,----,,----,,----,,----,,----,,----,
M,----,,----,,----,,----,,< &V_Q]?$?T#YM<Z::88::::88_)O#Y!*(_
M( @(_4'R^C7@;S]A>]XYXD,D8<D(&7?6]#)LY$P;!G%R"KRU)V*PN7-6?P+0
MR .I-"QLY%BO'*-DU0<'6.F!NT16*G[Y3>'RB >.WB(!T'T]>GQZ\'O$+Q&9
M(R+Q57C/1;'+Q-MBLE/WE#>-GR@.*5%4RP.FE-BH8^Q2MFT.U8I&,B5($W;E
MU)+.R+&D'0J]<]$IK/7<[]76$P^HP&0RE@?61+)ZH!I5FY; U'-(%P I%S8'
M,9/KUSZ=.G0M[DWU7.CH#L1KN>[8V/3&-L;8JNELSC2L.MH:8C[S*9,@:4ZB
M%F#I&7@I5.QMF,N=^R,F5PS-7DT'K^047*FFT;L5G"RB:!.UU_0(2+R)D)S"
M;D*4G,8=Q,!0 H&$?28 YA^,1ZCKP5XLXCLDU'B?JW$B]LTG(7U3)K*V6Z9
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M(>Q,FT"B4YZ9U'O6Y6;F B4F[LR[95,K9=5-F51-%<YBI**)F*H0IA.0Q3E
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M(:MSA$XF,?UW'[6/F';%D]9-DH]ZBLNU(+5^W0*V40 3B3F2,=+G:K)\Z;E
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M7I 6RQ'#;OT+.LW\8[%NX3(N@*[4YD5B%42$AP VKKU^3 (E'E]]MT\P;AU
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M96\A-1D7(N10]G'\=WE%5G#-"D47=2#@4T")I@4IC**I%/X-/*#SBEA^RP^
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M1]B_(,U,.W%JL.4.&>3>3I3%:/5I!WC>M0J;HIVA6Y45DRHI(D% J12]D4"
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M:0<<B<.4XH=L8.FX"X,9< -UZ"4BA0$!Z@.X:IR#9_<G;=RNW.RKC-7MT$G
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MV2!LF&W4RK@P$*4  >H\H'-T\ *(B&VNNN0T74S OL0R$25N8!$.JJR'9%(
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MB)F<VVBUW"$89FUBV*#N '=5/A$^DWYNN0;*E$#%.4#%$#%$#' 0, @(#N4
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M0QG"I#J'2(IV)];(;ZF1*OKE$XBHN]9H(AMU,J*XGZ=?,1,Q@\=_#SAKO6)
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M4CD43(<HE"Y-8<@J2K A@2"""""#8@@[@@[$'<'&Z(ZR(LB,KHZJZ.K!E96
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M1$?J\-?J0E7<U(/9)ZHHHNNL4"@JX4=&1013(BU:E76$QU$FC8B;9'<=@33
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MGGD5G,BO*5<Q+IIQ\6N_:&W'<>0>HCO_ 'Q?/Y_EU4">*OR%_(.J>U_NAOX
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MJH<H&#E$-S /343/N<,Z_P"*^T?]%'_TAK>%W<X^)=_F\WZ>;Z].['^"'CZ
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MVHN0JTH5D][%PF0J3ULLU.L9.+5P<^(L@59HOE(6O:SK8@6W!! (-Q;M'40
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M,D@G).CE0,EVQDUNT2)(9)+M-^H@.^WF_GUJ_P#(^%,7R>F 0,4Q1[_F8=C
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M]!_I_JT[H3T'^G^K2Z_2;\?5Y??XG#ZA[AY>7D,6SW4?2/U>O3NOB B(@("
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M82J]S9)I$;LD2)L6^/T?>_IZ1UU 5.MS** ':',8QQ =P$YAW.(#Z!,(B ;
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M\HM0P,ZS201R"#4Z,RP.I+HC!]-T )T[1&QB@5 !,4/UP0ZCL >Z,(B/B.P
M/,;H.Q>NVH@VGCMQ31L;<5&4Y^F9A1@>#R]%Q]EB+2IT,>SJ22D!4["2:KD4
M:VE0=508RZP#GV9E9"(< V<F=#& 0"$4BIP_VO/W$#0>'WBI89UKV.VRN<+C
M&9EI<W:;Q.U"RUI;(MKQ<;AZ'%YHQM4:1?(%RSK)Z/88^3<6,EF[:6E%YQC9
MEB-<!\3:9@X5?L@ O(;_ (Z6VP<H]=L$<+QM]@#;< $#B(=.H&WV$!U GJ6(
MYB*5#1.RE@.TO(>5&MU&Z@$$#OM<$'&<H\MB$[05#\QEG@BD6(LIB=LRIZ29
M"Q72UXY2R,I.Q4E0UUQZ#HET5ZS9O2%.0CUBU>ID4  4(F];HNTB* 4QB@H1
M-8I5 *8Q04 P%,8NQAN!-$IR@(AY@WW$0Z]?1\GZ>:TZSTA(,! 0$("$ 0$-
MA 0B6 " @/4! >@@/4!U>C4 $I0'PV#^?5;;E/-1TV_-&,?'M( +[$#SV1OV
M8_'=0^#]9].ZA\#ZSZN,B*8E+LF41Y2^CT!OX_3K]=@7[R'XOKU1K7S'M>WA
MXGV^[VVE7;]8^RY^[VXMKNH? ^L^G=0^!]9]7+V!?O(?B^O3L"_>0_%]>FM?
M'_;]GGY_9[;+M^O[F_'?]_@<6UW4/@?6?3NH? ^L^KE[ OWD/Q?7KD&X"( "
M("(B     B._H !$1'T &XCTV\=-:^/^W[//S^SVV7;]?W-^._[_  ./+=Y>
MA/LLFX&#80 :'.CUW_=$[#IOUV\V_AZ-;#_(SH IP6Q1A !'V_6@ \0Z R@_
M,7Q\W4>NH >7Y2,CE/ 93)'1$<?SIN4Y#)CM[97H;[& !\0$-PZ#MZ0'6QCR
M*S<RO!+&* @=4I<A6H#* 0QB$ K"!$=S[<I0*&PB B&WB(ATUVK.6'Q1Y$;[
M&J@L0>[UBM[[^'7?K<7QS[+K_EWFUKDFF\[WY-'Y7[R-_'QQM#[J'P/K/IW4
M/@?6?5R]@7[R'XOKT[ OWD/Q?7KBNM?'_;]GGY_9[;=!NWZ_N;\=_P!_@<6U
MW4/@?6?3NH? ^L^KE[ OWD/Q?7IV!?O(?B^O36OC_M^SS\_L]MEV_7]S?CO^
M_P #BVNZA\#ZSZ=U#X'UGU<O8%^\A^+Z].P+]Y#\7UZ:U\?]OV>?G]GMLNWZ
M_N;\=_W^!Q;7=0^!]9].ZA\#ZSZN7L"_>0_%]>G8%^\A^+Z]-:^/^W[//S^S
MVV7;]?W-^._[_ XMKNH? ^L^G=0^!]9]7+V!?O(?B^O3L"_>0_%]>FM?'_;]
MGGY_9[;+M^O[F_'?]_@<6UW4/@?6?3NH? ^L^KE[ OWD/Q?7IV!?O(?B^O36
MOC_M^SS\_L]MEV_7]S?CO^_P.+:[J'P/K/KYK1R#I%5LX1*J@NF=%9(_.)%$
MC@)3D, ;")1*([[" AX@(" #JZ>P+]Y#\7UZ=@ ;B"0;AX>]_F'?^KSZ<Q>H
M._\ K^SS\_L]MG:.Q#$'N()!Z=01;O[_ #\#C(5.EKMD+'[^@1X9.FVE6:EK
MSBAX5JU,H])0=-C,0Q3'V#)DX\C;PU'O:$RZL*[!:7B%F)$BO'42Z*T+9-IN
M$,CLLH8[A; BYA5)5L482T,8&:4L#*$L\8FB24A32RR:2SQPT!1 ZJQP4[45
M@4(X<D,5PKIH8,X%&R1KB?941PC+?VA8263$+!::]4YYPFI[7;# XZKCB/E[
M+;$)$HHQYXB7BI-%-TJV:/V1GIESSKX0K0\"Y6V%8-; O1K=!LK=7U&.*'N)
M,95*?BGKFOVJJ5J#L94;&M(+.4$7+M18%R@#$2K DHF<P82NB4-.HV# 5D-V
MZL>7'51BW9)^9*!V6"C<M=0W0,AKV*9<[=I@WP-6:5#$!(Y:G+*AR2)%4CG4
MK,IEC,C@Z4 <Q;"----8?&[XPOQ#7YAC/#-_MS^;KE?%E N&,;(VZ/DY6N%F
MYH2P\*VEXZ'(K).V+V2>MVBZ;5-02IJF55*9!-4!U!6Y@WQGA-S8L>=VBV=P
M:0M)L%RX>+G"SF%[4I"&>O)UM=:U.NI>R1EK@YZ1<45V\2/&@O$ QBG(-F;-
ME6";).+Z9F"0N-:A#/\ )T.-OR"Q&6EL=XXB\D-20%;:+S4K%VJ.F$EV3*.D
MTR)'9.5$7) >,A6=,WL>U>-5=/\ Q+V>OV:6@G,<_P 1VB9=LCR]AO&.HB?J
MM@FWLNLN[0+>*B^!O#05B)$C$-YYFW;+S"$ZR>)2SIJN88>/V'*Z<.<OC(U"
M2HJ*V5=V4PTP2&$LI15_?FF ;FR6O^]H=IN?<9UOJU%FTX.F5:6FR>E?5RW$
MN8R"JK!%(KRO<TD$)91# 2%)$S:0]/&E#?F4$=]^4 W$=Q'8P &X^<=@#KXC
MY]=Y'Q#Y1_)KH-_$_P#!#_6#7?1\0^4?R:W8"UP.E_\  8X2O5?:,5)K_=#?
MP!_UBZQ]?L*XMRM*T^;R'3F=JEL<3S>UT)\]E+(R5J%H;E,5"QP1(:;BT&DX
MBG^M)2AD57B:/ZP54$1%/606O]T-_ '_ %BZJ!/%7Y"_D'4:H56!5E# E;A@
M"#87&QVV(!'@0#B9#))%(KQ2/&X# /&[(P#*58!E(-F4E6%[$$@W!(Q4DTR%
M22(!=RD3(4H&$3CL4H%#<QQ,8PB !S&,83&'<QC"81$<&9*X3.&[-E\J^2\K
MX=J%XO5-8H14#9)<LRB])#MI(TNU@IA&)EXV/M5>:RJBDDVK]L93D*B]446(
MQ 5%"GSL3WA?X)?R!JI-_?C\WY=1V57%G56%P;, PN-P;$$7!W![L9&":6&5
M7AEDB<W4O&[1MI?LNNI2#9@2&%[$'?&"LI\('#)G>Z5S).7L*TN]WJGMF\=!
M6:52F&DB2);/C2;:"EP@Y>(:6BNMI$YWK>NVIM-PB+@YQ(P!(ZB1LOEP[C17
M)CO,XU-L3*<A30QV[O",K8V\RI1>^>R9:FF1O-)1;2%2E##+(-F4<V.WE_[:
MMU4I$ <ZO%O[Q3Y2ZK2/@7Y0_(&K#QQZ[Z$N1J)TK<L#8,3:Y8 D FY VO;&
M4CJ*@H$,\Q1 T:(97*I&X4M&JZK*C$ L@ 4D D$C%I8CQ)C3!M.88YQ+4(N@
MT:,>RDA&U:&<2BL4P>3D@XEIA9DG+R4FX;^R4JZ=R3M))P5!1^[=.P2*LY7.
MIF%J<FX^Z+X_"#T#\>O/?Y7+BQXC.'K+V)X#"V6;'CV%G\9/YN8CX1"#51D)
M9&W/X]-\N,K$22H*D9))MP!)1-/D('N.81,.IO\ 5.^/)+83<3][3YO<@*C>
MED P[>83U< ,;;;PW'PZ:W_)_1CG.=Y719G25F60T]4A>*.9ZE9$5)7CLRQT
MLB#=#8*Q%K;XUFNXOH:*MEIJF*MFGC<-(ZJDA=G"2%M3S!F)!N2=[X]S30Y.
M0/=%]^/]\'Q?'JM)$3.7?G(&VWP1WZ?*&O"B7RH_'T4#%)Q37T.3<3@"%(W)
MZ1.'M6W( ><3; &NT3RIGE RA[CBER%RB " @TI8@(#U 0'VJ" @("&P]0$/
MB$=Y[^AKB-C<9CDP]LM;^KW>I>1Q2OI RE19J7,!<W_>X>A WWG'D?8??[J.
MQ3^^$^@OYVG8I_?"?07\[7A9-Y5/R@Q #FXJL@D#<"E$[2CE#<>A2@)ZF&XC
MX &XB/FW'7Z_54/*$_OI\A_Q&D_[I:I^)CB/^4LF_K*OR_T+R/N'AB[\8626
M!-+F/MY4%B1UM^Z<>Z3L4_OA/H+^=IV*?WPGT%_.UX6?U53R@O-R?=5W_M/.
MF#6C"H&P;CNF%4YPV#J.Y>@=1Z:Y+Y5/R@QM^7BJR";8=AY&E'-RF#Q*;EJ8
M\I@\Y1V,'G ->_$QQ%_*63=W\)5^7^A>1M[!CWXPLD'6DS+H#^]0=#T/_>>A
M[L;WO+<5O)UIP_28^"H8S-,B+A&R@VZ'D^\NFTR_.S8*0<_"JM$$X=%0B(.8
M:7))/$)8XKL#-V;ML!5MG'"2SO#/A[QA%Y J*-&E82I0D+'PRLFI(3*T/'QZ
M*+.5L+11DR)7Y62$%%S5XJC]:.;]CWMWWA8[='QRK^5)\H"Y2,@YXH+XY0.)
M!.@YBZ(X1.*2A%DA.BM4#IG%)9--9(3%$4UDTU2<JB9#!]?U5'RA/7_^*C(@
MB(CO^PJ2(B(CUW'VI=1W\=^N_CUUL%5Z-^(ZGA[+<@,F01KEU7452U:U&9%Y
M#46N!$U*41R2YD8ZE/8$4<-FU8J'C#(X<UK,TTYJYJZ>" P-!2!$$!)!#B<.
M18@*-B.UK:2ZZ?=)V*?WPGT%_.T[%/[X3Z"_G:\+?ZJAY0G]]/D/^(TG_=+7
M >53\H,;?EXJL@'Y1$IN1I1S<I@\2&Y:F/*</.0VQ@W#< W#6O\ Q,<1?RED
MW=_"5?E_H7D;>P8RGQA9)O\ N7,=NOR4&WM_=./=+V*?WPGT%_.T[%/[X3Z"
M_G:\+?ZJCY0C]]/D/^(TG_=+7!O*I^4&+L)^*K(! $0* G:4<@&,/O2%$U3#
MF.;8>4@;F-Y@'3XF.(OY2R;N_A*OR_T+R-O8,!Z0LD.PI<Q)\!%!_F<>Z7L4
M_OA/H+^=IV*?WPGT%_.UX6_U5'RA'[Z?(?\ $:3_ +I:?JJ/E"/WT^0_XC2?
M]TM/B8XB_E+)N[^$J_+_ $+R-O8,/C#R/^*YC_5P?YG'NE! @CL!R"/H  $?
M];7/=@](?@!Z]>1/@(\H;QK99XR^'#&^0^(>[VND7+)L9"6>N2#2IIL9F*7C
M9591BZ.QK;1V5%15!$YA0<HJ;IEV4 -]_861NH)"#XB)2B(CR[[B'GZ_D_JU
MHO%'"U?PG64]%73TM1)44RU2-2&1D5#*\6EC-!$=6J(FP! !4W-B!M&1YM2Y
M_3255'#4+'%,86$RJK:@J-<:))!:S@;D&_=;% [L'I#\ /7IW8/2'X >O5P]
MV4]'^K^=IW93T?ZOYVM9[7@>[N'EY?\ 3_RG&:Y!_1OW>/EY>?V^1Q;W=@](
M?@!Z].[!Z0_ #UZN'NRGH_U?SM.[*>C_ %?SM.UX'N[AY>7_ $_\IPY!_1OW
M>/EY>?V^1Q;W=@](?@!Z].[!Z0_ #UZN'NRGH_U?SM.[*>C_ %?SM.UX'N[A
MY>7_ $_\IPY!_1OW>/EY>?V^1QT(1VO!3$5.,C;.X>18RC8>I=EV#I)TGN("
M(["=, ,4 'F 1#SZS9[5;>6X9#I-42SF:CNY%"VQ-?PA6<8XSHAJAEV!2:S,
M<]LMQ157LTFP7>-W"DA!2+=W'NX]_(D1:JHCW;$(MC[=0](^(=-O ?/]'G\^
MP>-XW=B,M&X7LZC?'YU&M=R'C)62R]DB3KM$82[--U/58XU&'>QLS-2I ?IJ
M-9>"?IR,8Y)%N$#LW["/?DBU0)1A8AC&[*P5;!X0)X]SI(:\3(MB3\J5 8W1
MLGEA$%1"SHV@5-.CJ3+I:GKF&6U*NJ*X*6JX:@B1=%Z12SQ:1,DZ^%&9D76(
M(>LV!M&15HQZ[D:+/5]ID&/R1)PAH%XNWC&]DG6"RO9SKF+!LY=L5^S.VYRD
M31;H@1LC)76N3@IL-5C<AYEQO"R&#DG2C2GWY.!PL:WV%)(7L6E'V!_9L@65
M(GMCEQDG# %VRY@EV3EXY,^2*L=T)MC>L7F*!:MW52J5"0U2#2ZC351)4676
MSL5!D*JQ=[@?/;KCH64.3011%@STC34+G5&QU44STMW,2H@=EB5F41QV+6Y:
M?-#337 ^ _S>/Z?)N/H 1U!QDL:\>*JQDG,H5NF1=FQ\PL-+JLA:H6MYAQ5,
MV;'4W=;0H,!01D+LP%,:\W=RX$A';A)=D+-1\DLV/*R?=XLFO_/CXE<IR\%'
ML)BL1U@L$96(JJM\M-\I41I5L=L$W[LM.<%3%_&1S"ZRBL8@V>NCE(FT5:D2
M36;K)H2^R!8)1M?,J7:0G<\T&(-<9F/;JVJGQ.8^'&TP^.:TL#V#GZY$M32T
M) V4ZR;B%7;OHIP%@;JLV=C<R2<O$H:ULV2$<XF:O&QJ-6(G&4V+>/'--@GU
M:@I.5M2SJT/))*&D03=LWAVDC&,7I%4&R8*, *T;(LB-BZVC*(0U8EQJ2FAA
M0; KK8"IDLRA5)69XP0Q=K6N;!=')>+J\1Y34$,%FS2NK)R"660P1N,KI 4E
M9Y@CT<%0ZF,4\.HLP0L[K)B-'W@[AM[H?Y@_3P_G&H(^]_3TCKH(^\#Y1UWT
M?>_IZ1UMXZ>RX]Q([[XY&GSA]?W'%4:^\-_"_F#6.&V#\4ERL&="TMB&7U8!
M.GJY "4LGL\I4"/_ &1)53E]FQBC5PDC_; D(,;['%?;O"MP<"*@Y':^\-_"
M_F#7?0]ZE_#+_P!9J-4*K%=2AM+%EN ;, MB+]".XC<8FT\DD;MRY'CUH8WT
M.RZT8KJ1M)&I&L+J;@V%QBIE*43!N4!\VXAN/@/G\=8.K/"=PX5O,DUQ"06'
MZC%YDGWK^4E;PU+,%=.9N4:'8REC3A%)92J,K5*,5EF<E:H^OM+&];++IKRA
M@<.!5SF3WP?/^0=5-KX&^4?R%U'958J656*G4I8 E6'1EN-CYBQQD:>66)G$
M4LD8E3ER!'9!(A924<*1K0D E6N"0-L8-K7"#PR5K-#[B+@<+4N)S5,OGTG)
M7MDE+INEYJ3:KQTG8B0(RQJ@TM$DP7<,I"SLJZVL#MLY=)K2)N]NA6NJ1X6N
M'Z?A<L5F;QA$2U?SS+MY_,T.^F;BNQR5,M$F2+>1M*8V8#NG";:+C&>S11DB
MHRC8]BLDHS9-D$LS-?>(?PQ_UC:K34 %9 !Z@)R%$/2 B "'S@(ZBO'&'<"-
M "K$@(O5A9CTZL+ACU()!N#C)QU540&-34%ETHK&:34J1-JB13JN%B8!HU!
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MU28526J3*4P+4+3&R%VB$56F ,AY8L$.U(U1M;<&E]>-W]>:7F749O6<'7K
M^0;.S1YDXEK-.T%FK6S4*;02$;)*(I#;?E55X)-3+=[69;#0^YMWE'R-!J5:
MRE-@T]*]73*SH!Z]E3)F%+HCDTQ\R\#EVY\!$8!U IS8-Z:*J2Z2:R"A%45D
MR*I*I& Z:B2A0.FHF<HB4Q#D,4Q3%$0$H@("(" Z:L#%-H+<,:T6S=O)NC3-
M7AW:KR8@C5F2>N.YI).7SJ .)O8DSYPDJ[39IG403163[LJHW%(YFM<=2CLA
MV*LRGKU4D'J >H[P#X@8ZA#,D\,4R$%)HHY4((-UD574W4L#<,.C,-Q8D$$P
MGXE8Z2MF>X!I$0.4'[NG8HF7:4UB+.4-3;3%25CDCMTE6>.S]N_L$Y!MB$L,
M21Z@6$FDT!:S;66AV:L<ZU8<1MGG[-E*P'GY.V2R\>]7C6CF\TZ*I-G*Q:&[
MNW*_B8INU%0BP) Z0<OTDW@E7,11LU/VB(3^R.&/;#Q29:&<6X:).?B7^*6#
M%A.V'(&-,J$7KS)E8TRER>S<1\' 6=F=FV>QOL1[)JSL-'I0;[NK%J_ VK*X
MNBO;'*.2(-FY5G;A4J3*S.KDR)VZQUS@RLSU9RXEV@G4,9!TJNJ<2F#F4,<#
M".YY3':J4,I'J^5T**64@WJ$-8]N9(S@$S&W+"HRD'0M_E..\>U-Z&E19+"L
MSO-YY K]A_4>5E\:L(HTB<JL=[3.\JL" 9"/DJ W\3_P0_U@UWT?$/E'\FN@
MW\3_ ,$/]8-=]'Q#Y1_)K8AU;V_X#'+UZCVC[\5)K_=#?P!_UBZJ!/%7Y"_D
M'5/:_P!T-_ '_6+JH$\5?D+^0=1YNI]H^[$E/G#Z_N.*J3WA?X)?R!JI-_?C
M\WY=4TGO"_P2_D#52;^_'YORZL8R"?/7_67[QBMM_>*?*75:1\"_*'Y U16_
MO%/E+JM(^!?E#\@:LR?/'^J?O&,E'T;_ %O_ $KCS.>78_X]<'_^AV4_]>I+
M43/)594QEC3C7Q/$YOKE/LN%,R/'."<GDND1!R3"M0>4R$K<5D"->3T=(H5N
M=H=H<0D^SLK5-!Y&,4I0"N")+JZFIY;^HVRQYPPJO7:K9K @WQ%)H.%X*O34
MR@@N-WD5 166C&+M)%84Q*H"2ARJ"F8I^7E, CI0+B_*!3 8F-\C%,40,4Q:
M);P,4Q1 2F 0AMP$! ! 0Z@( (=0U],\*P4F8^C^@RRHJ4B6KRVJIV99E26$
MRSU(25.T&62)BLB'8AE4C'+,RGJJ#BHYE!3/.:2KI)U0Q,\4PCCA+1/V65DD
M4-&XL00Q!!Z8]$^4>'NET?A$L%&L<]BEQQ#^1KXI$9+.,FUJ-(BBY8P[DR2F
M3X:JTI8V[))]ERQQ]M@:=5E6-B;2"K="X3=2?$2-'N%5-?%\X-\(UK"V![YD
M++MO#.W%%B?#?$33JM0J8]MR-K1RQQ,6W%V3,<U"AUFH T3GL=T=I$7:"=N[
MU$(V6ZO%\8LZZQ!]6CKP=E/NF9Q;(CF9C<WRKG+DHPFLH.)"M7MVO?Y>+G5+
M-'25L56B3J3+YE855)ILX=F.HE(J'<@/.8=7FWR#QJ-<>4C$[68XC4,<8TM9
M;QCRH(0U^3B:1:22C2=2EJL)(<'L(*$^P9V%LP8/$8AK8FY)]M')3(G?&]H\
MCS*A5.5Q#2ZWS%:RI,<D5.6ADIQ/5T\;&"H AFSJ6JJ! 8P/4YHX!,DT*2'*
M56>997,_.X>J=*Y>:6G#QRSVFCJ!!33R(LM.&G3*8Z: SZB?6X7D,;QSLB[Z
M<"^3CQ!@#/W#C86CPMSB<TTWRL^*[?1,O+T"SQ<+,<,&/KFTHECF% ADH*GV
MU)HM!2>1*D\=32V)\EP<K%I61-2)?L6&@_BGX<)GAQRW 81&O6$]M2Q[B>25
ME'%EKMSK&49Z_5.&FF=UP]/5:)CXR6Q-;7LLDVH3Q1W-3#I!%8)U^WF"O(F.
MR1/\2?E'[4_:RL[D_BUD)5C-WZQL),$LBM)"/E\IQC>%R0XCGL=#,W,>WO,2
MV3CK/&,E$(B7:J.TG+ P2$CWO$DK*<7-@D,92E@)Q"6-_A>/@(C$:]A@,A3W
MVM(6JR+>7K4%249>(>MZ[ 0,HU;OXF!CT4H9BY3 Z#$G.H![N29?G=!7/6YC
MGF65YFHWIYXQ42J6GCK<PJ**0/I162GIZR*B9'A+NL8EUAHT1K.=5^2UU&M'
ME^1YA1)'6QU$,@IDLL+TF7P5D6CM.'GGI9JI768*K2<K1I<LNY7%V2.$+&;O
M-/"EQ18UJ$EPXN[MA;@>L^5V=<@'>2\!9%H&&[.YO7$3C^V-(]W.BDZXB(*S
MS=Q:-WJ[:5IQFAP9NF,8[A);%^:?)\L*+-\1HYWO3&[,."7&? =C>+;86DZG
M6F^7@XG\BA5JEE-A8TZ[.(&K"5!64M;QRZBY:Q35GFJK#2EA.S:NU7NII[ <
M2,I"RM;D*OFU_ 3ML4ODW#.Z=?',=+799)ZBK;9)LI"F(\L:B$E(H&EU^T>B
MB_?(]J"3I<JE[U*S<95$G"V2JI9^BIDE,@,="Z-3+E)IK4.IJ1ZU1J3MA-UN
M3BWT#47,1#O*DP?,G!*N_AH=_7QC7L3'.&T<<.UE+*:G+\_IX995IS4QR5!:
M.HF@?+TDJ8I#J>CJ*^C@K*.L>%7U\ZEJ!>:G8RROR@I*F-*:OX>GE@C>7DRQ
MTYYL44JUI6GE6RK40TE7-25=*CL ABGI[<F=%BK?$'PH'Q!QQY5X.Z_=XN90
MHN=)O$\9D2PKQ\+%I0+&1*<+A;W +%B81*M5M127NZG;)QT0>&FS"9%JVY4]
MEG$MP)XCS5+>2]R!PYK4W&^+.*69QGP0Y9<5:XUG*L;C'/\ 0;'%4Q];;-;*
ME(KUB9L^1\:R\5D T8G(H.9"5BW0/5$EI!0R>HIE%\3L=:IV\LH3/"%TM!+*
M2S6T:QD5Q9;$6Y)ND;>,Y..XEQ)2Q[2D^?)6)5^X<*S2;UXG(G<$=+E4K<;(
M\8$+CXF)X<_$C$8O3M;&]I8\BXO*,=3$KQ%K-W$9=$:ZRCD(U&W1JS1JI'V9
M) DXR%L@#5^D1%,I<I5T>;3/E,T'$%'%49?2^KU$C-V*V2HI)8*NIE@5A#J2
MH%+64L;(X#P-'S(HY91)B:2KRZ%<UAGX?K)*;,*D5$,2J2](E/5PU%'3QS-'
MS=#0&JI:EE=-23JVF1XXBFTC#_"7P5DD^/\ 82E$XDIZU<(?"9Q&O;72KM.T
MV%/ Y?IF=9#$$/*5*63Q^[&4EWN,96I7-BA.5@&]$O,E*D1CK2R/67L5DK-/
M 30LS/,3XWC+U/J9\>^1\X?.*+ANK2T7A7&M0LRL0ZLLMDK%=T=U'&U<<6F<
MK>/$9FY0=[FGZ%RLI8&7;6B9DA:- #5-<,N<?U^NTKDFW7#BKF;]/4YSCV=M
MYF>3H^=G*0_:-F4G5YM[#Q4:,Q$S"#)G[-HR1'2DXNU;/9A5\^02<DM-_8N,
MV5G:Q9Y9WQ*RUBI-$?8NITW*Q63I*3JF-9* F*J]H-==O8M=6&IRU;L$Y!^U
MQ@9&*2C):0;(-DBN5!-BADF=&<5AXCIDJ1&'CUU<E6D%0M/$HAC,J1DT<E3&
MYGT+#-+2SO"[/)&DS99LXR<1^JCANJDIC*4D"4BTCSP/.S&5^5S/W5'"Z\G6
M98HJB))454<Q+._A=\GQ@SB3K5PLT=:,K04$[D^+Z)QW9YEU7(N#>FX>L%ER
MY1']7=KUDQ\SGL;F*G0RO&PT;26.-ZU(5(I[&WLTO'M)R7=;X4,!UJXLJSAY
MA=*"_E/(&67B]N\]:D\396:7"P7S&Z.0Y6'/$WC%#Y*NSKA22=0RMWK;R,FX
M.&CZZC2RUD[.2<2VH#&V6N/C#M3BZ'BZR\3=$I4),VJPQ-4KL!?6< PF+S6'
M%-N#QO&'KZS4OMDK3I>+EVIDS,'95!>G:A)E3?$MZ(N/&]7T8YO"3W%1%-XC
M'<CB&+19%R\BG'8HF!*,MC)D46I@;4"3Y"%?T]+E@'21$T%F!FZ9$B^UF2YW
M5U%26XCI326=:."2J>0+J:4++51F,0RND0IU$;K+&'$DP(E!>;RDS;)J2GIA
M'PY5BKO&:N9:0(QTB M'32AVEB5W,YUHT;LI2-[HP6/:*?R2V'V4VK2W>3[:
M[FL;7[R5-6R98H2?J;J#OL;Y11D_):%L6(*UEP$4OC.3&*<TM_)O;0WMM<;S
M3Z;9IKJ-5F<:/*(<$&%^%JC4FVXBG\GR*CCBIXV.%VUM<DS-2FC23OA2OE>J
MT1>(+VJU*J)P:5J:3+D\G77GLV9DNW:JMI395='47/;[QP! T6M)2G$HVAL9
MR53F*&V9P.0F2]9E: V=,L>2#"39P:$LLYQRQ?/H_'!Y)^^^UY'OGT?2BP+)
MXY05MV]2/%_DZ+0@\CFXD+["M;7:+VVBKA$Y/L4>WN]X<%=W6XHM)2-<HIVB
MX.DTW-IGB%"3L+E))>6<NU4DSDF4%!G\&84=36\3TU32PRDU%,LNE:B/U+U=
MKJ4"WEK-5<$)TTYD]6B9HXHW,/,*S))Z"KIZ/ABJIZJ>+Y"I,+%H)/7!.@!N
M6TQ4I%$SCM5&CGR*&E9<9<\E\&_E!^$8NV_-F6& 0Z^'L1.>C7OP3;AV9/UL
MWO"^8_H#7A,\F/C')$3Y0#A+D9C'E]B8QIF*&5>R4K2;5&QK) L3. 9=X^?0
MZ#1J@41*!E7"R:8"8H"8!$->]=-B;LR;B0/<%\^WF]?JUR#TT2"3B#*S#(KJ
M,H4$QR!AJ]<JS8Z3:]K;'>UNXC&\>C6GF3**L2))$3F#$!U9"088-P& )'7?
MIX;[&WN[A][-^/Z].[A][-^/Z]7'W$?A$_"'UZ=Q'X1/PA]>N/6E\7_I']OF
M/?CHO);Z3=W_ *?/S/V>.]N=W#[V;\?UZ=W#[V;\?UZN/N(_")^$/KT[B/PB
M?A#Z]+2^+_TC^WS'OPY+?2;N_P#3Y^9^SQWMSNX?>S?C^O3NX?>S?C^O5Q]Q
M'X1/PA]>G<1^$3\(?7I:7Q?^D?V^8]^');Z3=W_I\_,_9X[VYW</O9OH/JY)
M%=RWQ5*S+27)7GV-<A4B]LYE''3?)-@CFSU96M/S52'=-7J3*8.JNP<^R:[1
MPT3*S3([*!.0P<=Q-\(GX0^O5T1D;(OZ3F2%BQEQDI7%\R=@%?LK6H2QG<4Y
M:220-K&^$K**3 B*IWR[HY45H_O+4YB OS!2=0*ER0HDCU:BI&EG5#?7=0"K
M$78$ &YQZ(7T3@%RS4U08PO-+&98&> J('28L)UC91&X<E0 1WU?$<C.5;B!
MQXT>6G.]Q:6>L7.KNVDA@:L8UK48HC(+6R&L>2W]7B8&NNIIVR56;,7M>@HH
MQ_V&J_919G+UH_V8!U#?T^GQ^?6FJM1SZ,M^#I]&GSQ(V,R?C^2D[%8N-R.N
ME&),6NE-VLLBWA)6TKSY+BDNU[RO2F\,>JO1:.O:RY=LI5VD;<H4-B@'CL !
M]'3YOC#S>&L96H!#0MMJ6&:G>W+%VIJJ9%)T,23RC&-3J"P (+J0QZ!EDC/)
M7W! DFIJM 1*++5T--*P D4 #G"4Z8V95)*E8V!0<ZHEEF6]=KT[/.WD7'MH
M6(D95=[-O0CH=HE'M%G1G$H_$B@,H]+LN=XZ[-06[<%%0(<2@4:WK"'$G,GK
M^!<MRR<BA%*,Z)/F(^=5<+HV1.JT%N0'%6,DNG--UC+ @LT714;=FJ95T06R
M2H:B4\?-GAB_2RQQ]"?GNJ]%5F/7HJL3W*3L9U5+R*6HG_0P2R]5'S$9NK,J
MCIU9E7Q91N-8$/%B;&ABU*C2D&_M2<.PD[)PP<0-?L*4E)Y+NR_>ZI:ZW;I.
M1F6;]FRAV<Q"J-0=I'9R$A$EF(AN-H:F@IF";5L64\@2ZJ[AT+FU2B":[L4C
M.5&\6J$.U,X%$"H&7,UCT#K&0*5 5C*=@4$N0 G0#NKNI'$B%@EN'.:D(*VT
M(L<Z>T"_XFR:,7 T].TL*^I6(^(CXE5FP?RB[RDS;E9.%?-Y!*/5*F\4FE7&
MMI\Z4?O7CY4W.J^>.WJAQVW.H[<JN#G$0Z;F,H)AVZ;B/+TUN>2+J-3,RG4\
MLSAB'O9ZCEV!<DL 8 3<*5Z'4;XX3QDZQC+J)64+3T&70B-'AMJAH8JAG,4$
M:QQLYS)CV69' UII5E!Y1]X'RCKOH^]_3TCKH(^\#Y1UWT?>_IZ1UGQT^MOO
M.-'3YP^O[CBJ-?>&_A?S!KOH>]2_AE_ZS70:^\-_"_F#7?0]ZE_#+_UFH\_4
M>UON3$J+YX^K[QBJD]\'S_D'53:^!OE'\A=4PGO@^?\ (.JFU\#?*/Y"ZL8R
M$7SQ]7WC%>:^\0_AC_K&U6VG]W;_ /G$_P#6#5$:^\0_AC_K&U6VG]W;_$HF
M(_( AN.HTGSV_P!3&0B^:?\ 6;[\>$;BM_\ &AXCO_3KEC_UZG-8"U+#BCQQ
MD1]Q,<0[UEC^]O6;O-^4W+5VSI=H=-G+=>[S:B*[=PA$J(KH+)F*=)9$YTE"
M"!R',00,."@Q;DX?#&N11^2AVX?R0NOLS*ZFF&69<#40 B@I 098P013QW!&
MK8C'":JFJ#55)%/,0:B8@B*0@@R,0;Z>\;XO[A;<P3+B1P5(6G$[[.U8C,J4
MN7L>&(SE&1RA 0\PWE9BD,4CB"3IW.QS)RV08K#W>14Y8]R MW2I1]&&#>#/
MA=XG^)'@ZG:KG%/B[X%\OYWXAG#:.LE0@<6<2.,,NT? 3S."N!<YO&M::N[O
MBU2)K;%U&Q]>+&PK!&0=DK(PD-/N7,_YM*E6,\4.SP5TI-3R_4[?5Y-K-UNS
MUZHW>*GH"98F$[*6AY1G$).XZ29*CVK-\U52<M5@*L@JFJ0ARY.<7WC.7G:7
M9VS[B AK#CJ1=35$F*I6+C2GM5L#]N@TE+/#*4ROU\C>V3+1LV:3UM$BEFGV
MC9LTFY:0;-D$D]<XCRFIS:?GY?G-/E[C+JJC$K5 ?1)/3U<<<T<00M#-!/+3
MRQU5+54LQ59HJA:F(Q1Q[5PYFM-E-,T-?D]17J:^EJS&*;3J2"HHWDA:4]F:
M&>&*:*6FJX*B/4T,D#4[B1GF[8.#+A,0X;^#_+;>4XAH?(7'C<\W8PQ5"3-M
MQ0M0,1W.@YOI.-ZW:\H2B>.JY,V6D&A+8=Y9(BL-Z]*B^33=QLA'QZ0-%96U
MOR.G#_:\^Q>-$,FY7B:?%<;_ !@<$UL<>RM'?72:>\-G"R'$-7LJUI%Q4D(F
M,;S\BQEJY::@]9RC:.8NZ^XCK U=J.U'&E"V.>*Z_P!<K-0O"7$+<JK2WT])
MT^MV:(R5.0E6DK2["0L[^O1LA'N&T,]L;\I'TZYCR(+2SPB;I^===)(Y,E2&
M9./Z4LM6N;BX<4Q;?2BSXU>U1[#(\38HAW;(=O7;;,)3$/$,'[JRVVOM&<!;
M;9)+/;3:8-DRAY^9D8UDU;(Q*C*^(#$RTO%<,+N,[[4E2TRP^MR3'*.7K0LX
MH:=J>!]9!YD;5(,LDA7$J#,LB##UKA665(SDUA'3<EJCU:.#X5,Q0V0UE0D\
MR!"5Y<JTY5$CU-,6Q\"'#0C4Z-DNM6G*"3+(_DWJGQD47#MMO% :VNV9(D<[
MCAVTTQ')Y*7!55A68*!27R"BU5KR,X\,4T(TDG35F[<&@WQ&81QC5^+BZ8!X
M8<A*YEH47?8J@4?([N4@)EK;)%9",;34LE,5.-CZX]KT//.)9JI,0Z+B)4BX
M-[,-921BQ1DEI#<.G%7QHX#>V5^-+S5?GDCAAE@FENKC39BYM,68_:Y#K^1E
MJ_3:3E#&>3,7.*^^EZ^1,U<G:*]CH==XXL%9-"68B<F.*<S9(XG,JY]?\14%
MB"[8=OSV$KT.9[B3$\[C\3.HBC,Z'-V8[:D4BJ0#&S7UBB_D+LM6:[7(>1?3
M<JW9PS&.7[J-_+%S^FS&J6KS*"II%HJI*.>7,86A:I=J1Z434XAYY6%%DC%0
M9#*[/5&99$:C,=K,SD=304[4F5STU2]9225<$67SK*E,@J5J1#4EN4'G+1.8
M1$L2JM/RF5A.&G;QC\'F([MP^\!69N&HV/HB""UQG 'Q$V*I7JFWZ!;Y?BKD
MHGB[.=JD:3-RK-LIFZD3,I>GK1XLRDHQFC P$B(/DD%W%\X[X(N!ZL<27&CA
M*RP'$9=[1P=</_E"YZV0]DFZ=7X"6FL *5Z+PMD:IS3:F.Q5E;M3K-)W,*K-
M0C^NU&R-*G+B:ZP#LT:?4+%#Q905 L6*(-EQ"PV+[?+,9^UXZBJ]DB/I%DGH
MI1)2*FYRL-(E&(DYB*.@B,5*.VJKZ+[(A8]=L4H%UDFUYD\H1>+=$W^UW;BQ
MF;U!TQQCN-N*S;*+:S)TE]&)0TE7'<U'Q;-_+1\Q$H-XZ=-,KR#R>9-FC>:=
M/TVC4$8IR?.5IA0)Q-3FF0YGRY5K9H*EA5U$=33"=TYDDHA$E52@+/&8H132
MJ\KK+&\D9ME#5#5S\-5 JY!EO,C:CCGI@::$T]28$98TB:33!4DF)Q-*\T96
M->2Z;'VW!)CWB+B.$/%!;3=BY?RCY*.WYNX5:O%L</5F/GLQT+(>6I=EA&]2
ML5CN"F+M[<86#EUH6XS4D6YA-,5(N3GE(E9J2+Q_P0^3;P1Q?6^4KS6[99A(
M)YE/(^(("\."5V(J9I:C\+EHRVRF*C-2< !LLV-YDJHR?MHQ;#P\&^I&#E(V
MY3]H:24U$O7.N925XQ5G^.)5<_$BXDL/0YJ_B=^O#Y.6>8T@3&=G&%HCA2,,
MK5HGM9!^L$=#F:M"N'SUR5$'#QRJK>.(\K<?& X!I5<+6/B=QA6F%W3R0S@J
M;!9 B(IO>25]6J&LR;).!.C[).:TJ:"D ,4S25C"(-95J](U:]C[)E6>145;
M!E_$U'!-,'-)JF"Q4DTU36222W6)BX$+412/E@FH2KDD>1)]!19ID<M;135_
M#%9+#$5%61%))-511T](D<9#2($)E%8K2!S:!Z5(T1HM0VN\.W#)@1M7_)^N
MJ-#7&I90SEP!<?6;\CW^16QID.'FY>DP&6H!Q$FHU]QG/Q:2:S6H$C:B]CWD
M:[J<"NHX;'>W([RVKQ\'R9^*&6/9 [J]W1:[T'A;\GGQ1V^;9RE=+3K7$<:V
M6X*C35 J4>X@7#V'=4FKVZOKU.VOYF?]M5MB9Y*2@TXN4C6L5 FNW/CBJ+6
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M8&^ 'XOKT[ WP _%]>KG[B/H^LWYNG<1]'UF_-TL?I#^E[/Q]7LPY)^D??\
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M/>G/H#S]IUW#Z=5UN[>;)_LQY[[8?V6Y#^__ /.^/Q^.MLQ<#8?+L!<>UL
M-@_89_ /-_=M?8N#\2D  +0:Z&WA^PS#\?B*HCJRV9PM_!/W;V6^W_F]GNQ*
M3@ZN7_Q5*=[_ ,-Y?S?E]@^K5DU>/?=#WU[T_P K<^?;_G?DU7&3Q[[K]FO?
M$1_[\<^/N/\ G=;."X7Q83WM%KQ>FW1F(>?_ ,YK[%P_C$@[DI,"7T_L3Y/^
M7L ]/';5M\PB8*!&_9).X7J;;]>N):\,5H"#UFG[-[G5+OVK_HQX_?C7<R>/
M=R_LYZ&_+_Y8Y^%Z.U^?Y>OCJN)N7QMP[^^'8=@_9CGT /WX-3^)BK'1.I:?
M"%_@M1+^0_A\7R^G7U+C&@%][4X<//\ ][B([] \1/Z U9>KC:PT.% L1V=S
M>]^NUAMB4O#U4+7G@-@!UD\OU-QUVQ #MG_^'/OXZY_V^G;/_P##GW\=<_[?
M6P,,;T0-O^Y6'Z?Y*'YWZ?-KG[6]$_<K#]/\F#U]?GU3ZQ!]"3WC]N*OR?J/
MTT'=^D\OU?+[/,XU]]L__P .??QUS_M].V?_ .'/OXZY_P!OK8)]K>B?N5A^
MG^3!Z^OSZ?:WHG[E8?I_DP>OK\^GK$'T)/>/VX?D_4?IH.[])Y?J^7V>9QK[
M[9__ (<^_CKG_;Z=L_\ \.??QUS_ +?6P3[6]$_<K#]/\F#U]?GT^UO1/W*P
M_3_)@]?7Y]/6(/H2>\?MP_)^H_30=WZ3R_5\OL\SC7WVS_\ PY]_'7/^WT[9
M_P#X<^_CKG_;ZV"?:WHG[E8?I_DP>OK\^GVMZ)^Y6'Z?Y,'KZ_/IZQ!]"3WC
M]N'Y/U'Z:#N_2>7ZOE]GF<:^^V?_ .'/OXZY_P!OKY'(LH/,JJJJ;8 YE5#J
MFV#P #*',8"AY@WV#<=@ZCK83]K>B?N5A^G^3!Z^OSZ?:WHG[E8?I_DP>OK\
M^GK$'T)/>/VX?D].=N=#[Y/ #Z/A^-SC7GV)OTV]>G8F_3;UZV&?:WHG[E8?
MI_DP>OK\^GVMZ)^Y6'Z?Y,'KZ_/IZQ!]"3WC]N//R>G_ $T'OD_]OM_!VUY]
MB;]-O7IV)OTV]>MAGVMZ)^Y6'Z?Y,'KZ_/I]K>B?N5A^G^3!Z^OSZ>L0?0D]
MX_;A^3T_Z:#WR?\ M]OX.VO/L3?IMZ].Q-^FWKUL,^UO1/W*P_3_ "8/7U^?
M3[6]$_<K#]/\F#U]?GT]8@^A)[Q^W#\GI_TT'OD_]OM_!VUY]B;]-O7JS9P[
MYM<,=ILG%G1]E'=MA%BU+$%6RC+*$DJTX1,F5Q9VCUM"-EB'.B\:@@LC,,%'
MY%DC=CSDV??:WHG[E8?^+!Z]6!<^'3&MVD:S(OFT[#&K"TLL@TJEBE:PSE?9
M=D5BNE.$B5VZ[]-!(H'9\KANHW4,J *'06604K2J@76-,@#1RI<A6W:)U78D
MV[1&XW7J-P,42</U:\IHI(6>.KH9B.9-&=$%9!-*0RA22(T<A+A9+!'NK$8T
MQY&FR0EOD6L!+9/91:C.!7;LZ5P1TVN5IJ8:]%(KH1\/9W"$PR42704)(I+I
M]B64!Z5F8S0$1TULOLW -BBW3"T[.7W/#F2<-V#558<KRIN9&,8-HQF7=9BJ
M<139M$"&,8XF4.4RJ@F54.<S6V46>Y/#1TD,QE,L5/!'):@I'&M(T5K.\99@
M"I 9B2VQ)))O@Z[AO/Y:ZLF@$/(EJZB6+5F=:AY<DQ=+HKA4.DW** J_-46
#Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g498056.jpg
<DESCRIPTION>G498056.JPG
<TEXT>
begin 644 g498056.jpg
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M=1!TU72.11!R@HHBLF8ITU#%, CI/\[=)<=;I,PFD27*%C[VUGJIMYCK2?\
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MKK%76[U2JJ <#F[;E#_;?D'S-ROV3R>1WX/<<GBJX/P,. R_51^5_MKY!P_
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M7UZFX#I\=AZ=:)2%$6AGY0EHZ#?O(T3,2_6>!ZQ%'JU+]9Q_S(>Y\EHOPL>
MK'J)A6^R?,.&[^4]CP>,U1<X%O.2SH!#+EX_PBC8V63D>=>Z\CS <BOQK5U8
M'VNJ"]MA79+2\I55=60K]J5B^+/N(%@M,E>,B)($9NPDCN0<-2H(E;K =$J2
M8$ A>[9'^IIZ;M.K-:V>RD\NQ6*@4V=GT_1GCO+FI>MQDA*D^'J "C'M?N7
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MIEV(%Y'F4GUKBRT**YU3Q'K,4%A;VLLTCBV*3%8MK,(41YI)I& "HB1,S,0
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MYBOQ]6BW\,\1(]JLE88UDY2NRK\&C*+)"I.7"K)U(H2!V46LY<EVXPZ] Z@
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M""/<0]9=\0;*X(Y!A8@_ C(KG: *&UML$$3 54:1;03,8.I2G&O2($,(>_4
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M-1CXUA44_HD*.T;QLY!"7-8;BC6XJ0,I($/%ECJ2K-)5_P!%'E;IB@MY$Y(
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ME.N'B1A-L."G5!W[2 5W8/:F<&$ #J8>@>P>_P!HB(  ?M$1$  /M$>@9SG
M@ AT$ $!^8"'4/X#EJLFM4/G5HK16[^?4/;^,.FKY);8@;$Z+NG8%#AK*OKZ
M[7PR0P M@BR1BE97F81F+D;E=8MW&EE9A(C5\O)NV<C)#G#X8=-VCM6F?2[:
M!8;4ZP/=N5UWJF//.-]T:]FM?[8GM<106L\H"L7#/G#""4LJJAXAL=:3D(E_
M50DZSV2[R]H"%#V ! /_ &>H]O3[NWKV]/V=.G[,%(0HB)2@ FZ=P@'N;I[!
MW#\Q[0]B]>O:'L'0/;-%L/ MC!K-]K=[.MW=7=T+F.&"U2QM+8 ,!&(DDF:8
MN2LDTSR!YID,CCZR57W#4_&>J:CINFZ6SS=#3+%;"*2ZNI+VX,*-O1%ED5!%
M#$2ZP0JI2&)Q$AVQQ[:W4O"OXPD<+.U7&U7;MPLJX<NWNPG#MRZ<KJG7<.7*
MZL6*JSAPNJHX754,8ZJZBBIS"<YA&O/F'X;_ #%86I5#A2YHZ>LW]891Q_CN
MQYFM;>C+ H=V2??M+(O'-(]I'NV:K9DQ&)DT'!60/TG:)E'9A-L88SHNF7:Z
M9>17D=G8W3Q$,D=[;]> .&5DDV!T(D1E!1U8%3V/-:5>QR7MN]N]U=0K(,,]
MM,8I"N"I7=M8%64D,"I!'QP:TTZSX$G/><*)YJR<?:2"IA451D;W:IQ<5#CU
M.94M?H;I!14PB/>?UAA./41,8?<<6>67A7<L>'E4/M;8"VL+/0DI.,@I"ST.
MVN7)HN1F7(-8E-[ 6>'K4T<K]T8J":L0WEQ;G_6O"-6H&<%WB]N2]X@=;6^8
MUJA1W%Y81"R];3V3/OZQ12R!3IE!:S3D6QD7S&-;(F6<'!NV SE5))H9RR37
M.\0T,>=FY>1FR=\NX;D#O6H;C>UPWFQK/4UU;6;354<N$SH+QM5CX5NSKS"9
M:HI VFERMGLV(G*G(S3XRINWMG@OQ-XF\1ZA(9+C2(;.W4M<V_LC&XEC 7*P
M!9 R=PO6EFV*3D1SE62N;^(=&T?2+5-L6H2W$Q"Q3>T 1H^>#*2N&[$].--Q
M VEXP0U>'@Y/O*KO^%&?<IHL;+!3=8;JF Q2%E7WHWT4F!Q'M[GCF-%FGW=
M,LX2)U^OUR[O5W![4MTO-PMVR]EV*R4B\\RM>\YYW4:=9@8:'DMP:EUG6-<Z
MQAY>W!)2<Y(4"L'JD=<'\ R80CZTV  92TLG7B+1KR@:EHD6,U/U.DNB9!5!
MRD8R;ANLD8IT5D%4S%42414(4Z2A3 =,X%.4P& !"U'67*&R1$6V96>/=RBS
M= B03D,J@FY>>6 % \A'+G01*Y$O0%G#9P5-8_506R9SG'+?CS1)-6N([J
M2)$L4D8VJ3L+%9%!(#9#[67[0VJ1NRQ6OPSJ*6$30RL=C.TBN2S?:VAE; )
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M;NN.<XW -7SHJ(BH*/9Q,+&L(B+CFR;./C(QFWCX]BT2  2:LF+1-%JT;I@
M 1%NDFD0 Z%*&?1QC(\DDDDDDG))Y))[DGU)J2 "@*H 50  !@  8  ] !P!
M3.C60 %^3J #_FR?S#_WU<[SG1K'_I G_9D_^-7-(\?_ /1]O_;+;_-ZEM&_
MEG_PI/\ -:Z_T#[@_@&.@?<'\ SG/T!#F#J5-0Q>H!W%3.8H&$0 "B8I1*!A
M$0 I>O<(B   B(9PW ]W^'N_^P_56U$@=R!Z<G')[#]-8^.^4W'AEO(G&IQM
M:JEWJ=O'NCZU)\67GVB,K7W=KC!D5F\4K#11Y&ML74TQ2DY5HJZCTA72(8#)
M@>14=G:Z<7M#6+>Z5EQL%U41OK:GMY5HO..::%A<50;&V:(G.#F,+9&CJ$.J
M@HHHG(MUT%$BBDH):R>0_A^MK[N_DQL9_P DZEKB$Y6ZNB]4VJH6*FV96TP*
M,SIV2XTQ+ZGS2'(BBTEXK.REGBUH]*UZ=M4JXL9V]9K\^S?R,8NPZ?9/!=UF
M\M_TOI-Z9ZS?5B5:36ET*UI>NE2T.N'*6M\E9T=:I?'6;:#;6E*)L&MK(DP:
MQK*<KMWM"TVC)-)>8@969%II#+%NO9HF:"+?FVE=4N"B&0Y"+F-'(78H<E49
MQ)G8C88FN,$[8SYB?MKDKG 5<'G(YW$]R <#)%R"4O#K@W,A*12P/%U6K,49
M%@J#QT@LHW7;,Q3<&!VY0<(K(+-VWFK(KHK(JD(JDH0OZ^)Q8^4 2$>(KR"D
M0@ /6@BO+H^;YT2@ +=5I5'R5O.BTN^01\E;S&Q/*4[=?G6/@ U'7Z*9Y#D)
M)S$U%+1$QKZ48:=8P;C5-S0V5Q$V-8[UJHJU]EE*19;6XXN3,>Y>U;X.$:7=
M-M"/(6+C1A9[Z<CX$$=*QVH8U?D0O#FU#9_C#-Q1M,NM>N[=)D6U:Y)N6^N:
MEMB-E;?RZE#ZQ$UGW[+2(C/)7.TH#3FS,Z"*U?T?HVX :RQ&2"?HZ<$#;E<#
M=YCD*" <CDXPH)\]HN<$]!!VQ]8"",J"1@YQRV./Q<'O5ZUEOE%IM:E[G;;C
M5*Q4(!4$)VTST_$Q==AEQDFL,"$K,NW2<?'N EWK.*,@Z726)).F[)1,KE4B
M8]@7D(UKYGJ7\<W\DW:J*[YDB"9O-51Z*"JN0I!%9!=$ .(=5D5D@_6)*%)3
MQKSPA(VE\,>3W#F0W"E9:UR(O%=O$9)2.H&CV%HLW7).DSZYEX"9N4U8+Z-D
ML=';34TC9+X=S$&?.(NM/H^/9-0".;WX+E3M[[94UM[?L3-T2R/YE. K$WI:
M#C*U3X"1G^<]BJT=-NYG8;Z*LLW4;SSHDI2%GCLJXGZC5M';,X=G*/59)C;%
MEI)+K])OY9"$(L9F,L16 HRH,;7+/(I1G(^K!#892??:)QWB09 Y,B@;CG@^
M8G QCD G)X &3>9\1C.]LGZ^.\QZJ[19)^M:>8\68 <7Z3,GG=SM5B":@O4F
MX*J,P34]45+RS]OG07;.B"HV6;N4P.=,5&ZR*Z8*)B *)B=$YR <@B '((]Q
M!$ , =0RCAUX0.M=96FO70V^:O1:;4]HRVWF#.RZLKD8[U5'QVP*=N>TEX]7
M*0OT4UT9*VYU39N*WU>XR)F37W6]@E&$S'10L7,H_M$XC<;:KQ*XV:9X[4DC
M-_%ZNH4!6WEEC*NA63WZQLXYLG:-CRL0P<2*86&]S)'%EL#I23EG+F2?JJ.I
M1\<07/CW5K911J]M>/<NS@",VDD.$\V6+LQ&Y2(AL ;)<<^7FY%-([ .B*N"
M21(#R , 8/.3NR>, =O6LB>@?<'\ QT#[@_@&<_+V$! ?M 0Z"'[! ?<!_8.
M,CL#W#]7[^X?JK)K]=W_ +I?X8S\XS(P/</W_P#L/U5Y@>[]^/\ 05QU /F(
M!^_/7=-F;YNLS?-FCUHX(*3AH];MWC5PD(@(IKMG*:J"Z8B ")%4SD$0 1+U
M ,EKTK;\.A^2G_AQZ5M^'0_)3_PYT8?<UN@01JT ((((M9,CMV/7[]\'Y5!'
M7$(P;9B#W!D!!_1LJ(1CXT4S(_#X[RCD43.D#%F"9TUFYFBR9D_)[#)K-3G:
MK$,42*M3F:J 9N8R8\I,8]!!!J@Q8(-6P=&S5!FT1;-@\LR/1NW31*@@'DG.
MCT13)^J.=(?U9S%&7?2MOPZ'Y*?^''I6WX=#\E/_  Y[_%M=$8.KPD=\>RR8
MSQS^'^?^'QKSZ;C_ **?=^$7M[OL5 D[2J?9HFR0<Y7(60C+A!.ZS:&YV#5!
M2<@'T.]K[F*D'C1-N^6:#"2+Z+;E!T4[%FZ618G;%/GZA*74*Y"UNNPE<@X^
M$IR#-O58U&-9F;U\C!@$8U4B?.2549.TX\/2'?HJ%?KHF4!RZ6,LJ8\\^E;?
MAT/R4_\ #CTK;\.A^2G_ (<J_BXO=NWZ9CVY!V^S2[<X"YQ[1C.W*@]\8';-
M>?3,.<^R<^_>OH2?S?O)/SYJ'W<;%OV)XM_'1KZ,4(DFI&O6+)W''30.11!,
M\>Y159F(@HDFHB0R E1433.D!#ID$HT;&'?*R9X^.4DUV[=HO)*,F:D@LT:+
M'<M&JSXZ)G:K5HY44<-6ZBQD6S@YUT")JF$XS!Z5M^'0_)3_ ,./2MOPZ'Y*
M?^'*?XM[O&/IB''N]EEQSMSQU_7'^"Y[5[]-19S[*<^_>N?U[/B?UU$:C)@J
MCZ=5FQ5;^F59@@JT:J( T<$!)=H")TC) U72*"2[4">G63 $U4SD "@29,$
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MMI0-5LT/.RVO;DI%-)LE7N+"-=N'->G1BWS9[\,DTV[H$CF 4P41<)I:@_\
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M358.Q#O:ED6[I)JL8$E$6_=-I:#U[MUNFSML4FX:G5)ZXJ12IJNVP#W*( L
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M_P"/]KY_N.8U^&2'X-Q^4;^6,DK&7/XNM/\ ZPO?U0?#_NOG^_9].3_F8?\
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M[02 %!)QZ X!)P<CZ5N&*CV?2^./]T:8,_/%IS\^_P#A7!XOD()$P3O.G2J
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MO30E[# F'Z*;L E4%O( 0QQ_3 (&(#H\4J8A0()D&T@@!RJ/FR\?[(1F_06
M37;40M_,*)DPUA<@6%+U$68Y2K?I9%,%!:IS293BB8I5WD6L*9DXUVA*3#C,
M3Z.A_/W_ *?]8WQ[?.X/Z??ZUDG5K@G/L^E]L<:1I@'IS@6@&>.Y'J:ATL9O
M[H?ONVHA$3&$G;K&Y !2>EEP(4W7;!NXP/%8%4Y@[0%LREVX$*K*,W,1XB1?
M(+ZXGO&GA'H/E]NJ[J4"B+B,$!-UVZ83AZ9.83,!>P17=QJP&!./=(2<SXQ]
M'P_GK_U_ZQOO7_\ D<_#/;TKSZ6N,Y]GTST_ZHTS''P]DQSZX[^M8XVN>WE0
M(E&T3MEU'.P[2?J+"3BF5'ME8>O6-@M;2MNRLIQ[LBPM8Y\DE-1CEDHXAI-%
M5S'NV:B';+MW$1D: ]0_>(?P$0_[OE]GR]\B'>O9^CA_W@(E^D>O>H G)*CU
M_2-4NT>R)DHAZ/0W01,1\1 @=3O$'K(KABYEXOR_>;_B'*+5#!>75NLLSPK:
MV4J)-/+<.DDLM^DK!YF>0*Z0P@+OV H2J@ERUR]E6YL+.Y:"WBN&O-0@=[:V
M@M8WAA@TQX5,5ND41>-YYV+[.H1(H9F54"\XQC)*HBF,8Q2F,8Q2F,8Q2F<"
M & 0$.H#[" YSC%*UM?&E_HYO'/Q.XV9W'JM2#X^<S&[8[E/9S&(,>F;>.V;
M]K6"W5 1ODK/'BA4DV<=LN&3&W0J9R_&&MRBFK6';_S=K':/$7\(7;_)CB8>
M^;+XT7NV5*1U)O>D5NRLUX*ZTNVPY%X^1:N6AY*$D$)NN2";^F;"KIV=E9P4
MRY+!346E*2+53^VF(=?8?EE>R7A0^' .U;;O"7X8<?[CMR]VB<NELV'L:@Q^
MS[5-6BQO5)"8F',IL4UI.1RY=*F,D1L1!NQ2!-LP0:M4444U*[WX<^U%MW\!
M>%FW7;H'LGL7BOH.VS3DO8 *STMK"M*SWU4Q,0IBS)7Y#D*(@0Y3$]A+TS,[
M(LL5HU!QVUPG(3TC2M2ZPIC!K&,D_+BZM6(1D@F8D?"PD4P0;-$C"1,R,7!0
MS(SA<Q?(8,5#?4S&*J>(OQUO,AZ&GJWNPI&6\E*1;U!6-8K>X@51/XX_BWHI
MG .XIC,B&$/F0!]LH9T3[3*OS./W[BJUCD<$HC,!W(4D#X$CC/PK-J;FV$!'
MK24BJ8B*7:0B:1#+.73A4>QNS9MR?K'+MRIT3;MTP[E#C\RD*<Y:J^5_)/<$
M8T70ILZM0VX"8J*$ FS<S*ACE(0I7TN[;.^Y?S!,)$XE%D@F)O+!9]VE7-,V
M]N1$6PE:<Y0))L8EQ%2CQD,BAZ/SI(7*#-T8$RK+(+JMHY1),A@54%%.2<%*
M!!6,(X2R4@SW3LMMT,56%C6C4Z2'=T35DW9SF=N#@ AWBFB""*('$0)T4$O0
MQS".%<W!/DC8CMDKW;(!X(YQSZ8S[^,5DV\8&)74%1D@$9'E8=QVY.1S\*JT
MO_,[Q!]<3"=C9[CV^R@TGY!.O.,(F<KOEG5 J9':4K!/V:2"@]I !46X&$_0
MA@.8,O$\/KG=LSD93)MKLVE,36*M&8D2OD W- 4^;%RJFFY9S"+I1XC&6!B@
M8)%1M"G>$D6AP\F+CCE RWP=MZ*KD-K^3?N&#)9J,4X,NBNDFJ@JB9$R9DUT
M1$Q541$_ZU,Y1*=,#%$ Z]0@.KW>%U71X^G:\CFT7&PS8&$+%M>\J!WCM7H9
MT[^L*SA1=TH=V]655.NL4!2\T"%3 EL7$D>-V<^HSG/ [Y['Y<]N<9K)813Q
MG;$B,"/,%VX[$CCOD9&"2.>.<591LSD)L:F+N#13.DO&I2&.@1Q&3[C^KU*)
M3O$IYF"X"<0.!DV;42%^H)##];(MI_B+U,EGBJKM:M?0Y*2<HL2W&*D#R==;
M/'*Y&[<\PQ<MT9*'CU%3@"L@5Q*-V!1\Q\*34BKI+'2#TG9]@L%;%8YN;EY!
M9,%#KK2#@B:11* @FV;)*IMFJ!/8")H)$*4  !$QA$PU]\L((NM&*BLVY46;
MN%1BFI%# +IV[<D4\EF3KT,<RB9%3'4-W"DB114XF!/H(7$^]3G*DC@J,$<9
MY';';O\ I[YHB@MWS&WV\8# D>;CG!.#[L$>_(!.:VDY^Y5:K-FSNQ3\3#(/
M1$K(\@^;H"^.!2G%-BF)Q5?* 0Y#B1HFN8"'*<0[3%$?GQ^P:O*@<[%S(KHD
M H@Y" GR-5 , CW)N3QA4CE  'J8#= ^T0ZAFMII3;ULLBT7;[S+35PF&$5#
M0<,V6< =1&.BF+5I'Q,>7L*TCV:#9LF+E<B!3N5@.^>B[?KG44LRH/*#8=5.
MW<V/5K%S5A  4- R[\MA:MQ$.BY D4OAD@HBGW&4:]K 5S%$$5TA$ -?6\!?
M! 50<$D$GW9XSCGY_.K$EHT?&0S8R0" /3@9Y)P?AR/B*M 82;"32,M'O&[Q
M)-0R*AVZI%?*6* &.@L!1$R*Y"F*8Z*H$5*!BB8@ (9J5?TQ'9.P=4<%>)][
MU5;K30MAU?G33YRJ7.D3<I7;77))IHG>K49&%F(99O(L'/IY%=J=RV72.#=R
MJ@(F3<'(;:!1N55G(FO;+K3Y-1@])'+N'J2"H*R$!(N4F+EK)-0Z+E=Q3I9)
MT*:Z9GD8[CW+7]6DL\(I*SM@RD4RI/FC5XF0X*%3=-T7*95"@)>\I'":A0,
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M%&$<I%9)D91GD"HKZ8E*[V;/(!R03D[1C [8_P ,\G&:N(T$3&##Y8$LQ7
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M0TTF=VJ)DUTVA !0TW8ST3*"GWO =J;"#U<.>/K'Q*//Q^+M3D^3M@UI(RR
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MVJ0NIHI-%T,&Y/5G6O8^%(^=KE9DE&@6@R#%)5RHV=OC(IIK39C/3,I+'V>
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MY%"@8  2B)1Z=IRB50G<0Q3#ZNPHIMNJT_!(5F1:/;)*/IERDD"B#9 H]K9
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MY4"'"R<_A5 E_P"WP*\%A %11)>XCG]H4G4M19C)QY9':Z+RP<#[VE9[;O\
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MC:/!9.86,B9L9X4IE'!DB3+C G<!1MA\DG4&;:W)+9)PQ,1+Q\GZIRT78;,
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MSO+$HB!8HKKRQ 3R"B/8V3G+()123_RE)!;S&_F_H/B4O+[V7J^P-AS9P.)
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M <\9'<G))^53MQ\HM)858[V5<LHJ'AX\[AT]=J)H,X^-CVO<=9=7IT(BV;)
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M9.18F34$@U3<TO"<>7#6O+FV<<MIRRE1Y,4.*G=XZRBJPZOF\-[ZHTY0GJM
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MRUMXB<FJF[)/Q[!:.*Y4;[X.SN$_%?<=E4N>Q-*TZ<MZXD%U:6S=[7["^,F
M F:2EJV]B'<H=,H 0AY)1TH4@=O?T]LL2PB3/;) !!SCCUR.<^G^E9MO=+$A
MBD0O&22,8W G&1R1D>O<8.??QK^7O;.V=HU-5A"-30D;*-3MG4LDY.Y?$;K$
M,1=)HH1-%%BL<AQ(+LWF+)%,/D@0XE4#VM*>%1<KIJ?<>P+!$RT!)IZML7Z%
MH<Q%6DO9+T5JG+PTFLP.0')8 _H"13!-<B9IIU,"ND!&S BSG8GHO&/0VM3-
MCTW6==BU6:@+-'#DCR:<-UBAT!=!>=>22B*X (]JR8E.41$Q!*(]<G?M+T$
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M1!):.@!6<5/73@RQWB-BN"3-[5=UDQ0,'0>OSZAT$0$!^\! 0$!]Q^0X  *
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M9B+1)8I3*8(50QR]- '$H=DGC:WBB;#/!+L9KB2GGT\PW"Q]'>RD)B!@=VT
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MB7F,&3IREF,;=^D-QUA@C>K_ *DD88[*T6]DLROL*S[8W7BR45>I]HY:6+U
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ME:4&36SLZU.O&JTK M;&UC8]M.MXIVT2EVS%HWD".$6Z1"<=LI8;=95N-/\
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M)TD5%N\$A4B*DI N_&_9&NWJT==Z-8H!0B@I]\A&G4CW':/4IV[]%)=@Y3,
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M+1+)>3/:H;<(Y$T8MI4\D:1R6ZN\LE=G8P,+%L31D;$QL?''!0#1[%@T9L3
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..IC&,4IC&,4IC&,4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g872988.jpg
<DESCRIPTION>G872988.JPG
<TEXT>
begin 644 g872988.jpg
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M1%988Y*7P? F)RA%9&:"DY68H]72UN'_Q  = 0$  P$! 0$! 0
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M*T^@HIM<'R-))64PO+8JKIG84;]&7-O51B2R..QZ=O[.XSEC;)"F(H>>5'4
MY7U=R'Y=-\$-,_!SQ;LWBJQDM8N+\AG%9F0.S(+3\ZM^3W;R(:ILW J9LB+'
M.)8_N,D P'HH+$V1ODSFWO:32I.?DPU\ZK$>+I8H6Q&L3C"'&W(3!U#@ZQ$I
MM?A-[MR&ZD-4RG:/;9*G5M,+2(.)\"+B[N(83',D3L_N38VJ9+ZAQ_**QNGW
MQDM:=6)/9M'K!<%%P.D(>+>AR"\;KC]46LLKQ@8HM%R[(J&/3YKK>:-A,;C+
M"Q/+$_QI:QRMI;"&Z5MSTC&>2;SQLX><=V:0))0W5_I.^(I.EF259J2RPP)4
MB13N];+2K])3'P:382IIR3N9XTCV1M#O4P]3Q)MMC#'$;218'P7JLH'%D@\G
M7TU/7ZF].]"4U8'((*^"QPM!R$NZB8)<;''BJ>22"0R $7+%8\#A\IDC;(G%
M)%9U,"&IN12>)QZ131OR3X<\WU7*I[E<<?Z*G5$OC74/'SD'%FF;R:"R==)*
M:Y+)IZ*O'=S]8KL\(8I,T;C64M;9;"5:YS]1M@9U2&0/);BH+;O60=,;AXUS
M2.S%O@4J2IXTCAVT4!!;5JCJ=;*J\JI'1\"LU]JXZ8&0N06S$*G;V^&,EDO#
M2KE1"9J8GH]>IE$;CKZU9,5WQ[J.J9&=+8'$],;^?4M24<:N]67YQT*L*,.F
MBBKXUI,Z.:U('ULG6%+AZ=@D:>W;U5['IQ<0HF_24BCKKWFY=TGXN=,BW%K9
M!S)QRNMJ,0>WVX#.O:V5"C547R,L%]2L0!N2Y1#5*255.QH5SHY;? Q]KT^[
M6(%!@>^3X*BZAG-6N:=MMXLZ9(HIR%/X[I[(*I&Z^($JK(FOK-*N^GJ]D[CQ
M]L*/21VJ#E-QZB3-;9R)Y<2+8D%@MCDAK>7.#CJ/6,X-<=F%B'3MXLPNR@V4
MV1*6N(FYSLI\AU<2FU;.E]&UJ_7,DE#?;CU6-&266.=60-=8;?-I@VO^V"+I
MDI#5*Y2TL*9E:Y,_HW'@C?TJ>'B>,R&&.[#;TSBCI7"NG8PPSWDER!FB.HZG
M6O$'?U%?T>9(+'7+*A83'>M8 H$;"536]B2PR,LXG@3(R-S:G(OI4;;EZ17E
MU/.)%V32&6\1N@(MR*@%CQ:O-U8^,Z)99DFJJ5P.;1E-+9<RNY>W!I8Y+"96
MT&,2A4E5RAB>V4PUB;G=QD*S'VE^,52T,]SJ60A%,'2;V9N/@G-@V79MCW!8
M,A;HD2XDQ2/*)K:4IETA1Q*+^K+V?'H>U+D$89U[Z_NB%I*<WUV5J\@L(F,8
MPB8QC")C&,(F,8PB8QC")C&,(F,\=NM>WO6O[<=NOAU^O6$7G,>[OY2TCQU=
MJWCUJR9\;9);[O(V*M(O%*YLVT)5,72(1M1+Y.G9XQ5D.FC\8!BC*52].2LY
MO(1I4!!IHU&N\V',@^W7PZ_7K(O.=O#.QN5'(S@/+XK.IO64'H2=<AY)94]J
MJPR*\M%C1SZ@'R!1(F).!K4\#7$NLI6I4$A2%HQ:"S&''&]I>MAV19XU)==8
M7G7\<M"K98ED\)E:EZ;V5UVB=V-48[1I]=HQ)6%>PR1O9I$R22-R-A>V&11I
M[:&Y^8GEI<FQU;DBM$H*+YBNE3,W/[+&E1J[3M($[PK;0$,STK0^ 824:AQ$
MO>$;>>S,XM%+D^T)3RO0&NX]*"F@"XU&L GUT^:'2FMEPF4)C''!CD$RJ5/1
M3G!*]=7ZR*\=IU07)>8\A)9=-L\JGZR+^;9C83#*[17S-LECM;U$(Y5=26:5
MPU,1$7*B3FA.:.R+MZ:MX/$.NM34S/$D=A758W.B:VHJ<+#<&)5<T3LZYX<^
MU+5<JF2$E6\L4?FE#QV35#H;>0:W5"FGSZH;6@.G)[VN(I]#7AK(;Q.IBY-I
MN 6([:P!H#4XBP:%O8BC"MC"=V]X+0 D[&(P8=EEZ$9^)GRX5,8U8D-B=@0Q
MU)?8?.8RPS&*/:<I40G>(W)VI(]L3J00M(2K"27!K7)5912M,G4E@."!002:
M$98=<X[I_P!X.;Y)YROX55\;QUG=A7VM@_3H4VK63+&Z#D%A\?J&K&#\@#3(
MVM.IAG? SVM;:?Y+'JJ=WYWK!!="RS:TW+[5421K'.MQ/KR2U#Q;XV5/-=(P
MS&L*"INO)8%O<C'A"&30JN8W&G[2)V/" YT2:=6Q7I,XF@ :M)T!48$(S1:T
M19 XSQVZ^'7Z]8[=?#K]>L(O.,\=NOAU^O6.W7PZ_7K"+SGQY#(6*),#W*I0
M\-D=C4::'.02%_>ER9L9V-C94)[D[O#LY+#"4C>V-C>E4KEZU4:4G2)"#E!Y
M@"BQ"U]?MU\.OUZS&;F91CQR;XH\B./L<D:2)R"X:>GE?L4A<0*3FEL>I&P*
MT34<^IT.MK54>,7B3II"D2:VJ5,9[@G3ZV<8 .R+KB"]1CB5/T4A<6Z>RB.(
M8_4+GR!*4V33MT53J746S&IB7BWJT)LFOXLJM&OFD;@SB=9%7Y$B3-A$CB:I
M>%,DET9/=LF+/MZMZ9ADBL&S)6@BL0B0&DR1/"HI<M"U ?7EOC[0-2A:4C@Y
M]ZO>'5 B3[+1&:&-1HS?806::7##/*2Z@/)27W!(Y-6<DI"&S_AO?=)2ZE)E
MRD@=FU<]73)85!&:LWZC8Q#HV:&&5WX^RS04BG<Q>XK.Y <^,ICM5;*C3J_%
M<0.0O2_Y76PUW5"6"A:X2SIWE'-&26/R;<+<CK*/G- ^0-NH)E3-*R]"SE+9
MY&V:!QO48)D:&Q6D<2J-=2\3;J2U+4,BV<P$6TT8XH"BO#G+$Q1/C&TGAC3B
MRRO&='B2[3^$&+0/#>,A$GT7H7?[/"(G0=F:V'7'H_.HG*7V<QI@>"7%\K5_
M;(O-V\LA84;'WYXB$<GC:W*3%*8D@\U5$I='7D)B$U40 AS*(-.+6%*4Q&ME
M=/3ZY+6-&I&AB/$&MX'4-F7W<,XBW&U!)^.+HX<<3';BM7]*Q&6-:2<-4\XU
MQ&-6K:#-8D\M]56< M"TX$SR%BD%6-NK#F=F#0RQ=-VBKIHZJGI-?"0I'/94
MQ\9AO0!RQ),W(R15KPOXY4A/E#L_HU:\MR5*;%K&6*$[D)>K.>&TY$\'F /7
MFDE$4C&,\=NOAU^O6.W7PZ_7K"+SC/';KX=?KUCMU\.OUZPB\XSQVZ^'7Z]8
M[=?#K]>L(NH[MO6KN/$(W8%LR0<>8#GZ/Q-H3M[)();*)5,)8YDL\6AD'@\/
M:GZ9SF92-R. E98K$6%Y?7#8%!Q*':5(L4)^O:QYC\>K;.1M\3FJ]+(E,[F-
M8K(9,H3/*\G4<L& PU+8DKB4RAD[C,>D<,=V^!+VV:)@2AO:DKW%75H?X^J=
M6MV;E2GKSFW5UN3%/QMM6D8RP6)..+W(YIO+=42*4)H8GM"-+*FMRE9='&.4
MN*54QL4Y:X];ZZ8P-5)-HHVODT:1L#X\QU \FR)IQCD7&R[.8DOJN;<LN.].
ML%<QVY+BE#?0DC>HM93FS5\^<5W&FHDHNU0V^JU;618+Y/WA_?ML<='(8E7,
M;'$4B*12=^CNGY*12NHI2RKULD;R3U12B).B)G>QKVMV:D92]Q9&B0) H')T
M0HVY[3#;7QNT8O8U;DWIW$:ED4*BGMO<6Y)]G:M+I2!'M03I684(\"79@-*!
MD %H S@D;%X410!B" 9N@;+ ,6@"%H6]:S7IKCI?6[*:OI2O^3T2@]J-D"JM
M6W/T;F4P!.XTLL4'3>XJ\9FIT<FETTH:Y1MNMFN[37MR]Y2+@-:L;38B$!#^
M>VN2/IV+\ N<+3R.XBV*^5.PK'NCY3T^SIK=;%8=-:>916U7\8(]3O(9ME$U
ME2-\Y%2N<H[)=YVLW7T2DE7T#*:K((EBA/8=P2-\:5Y%M 8S\ [ @"'8M;V$
M.@[WV^WO6NSM]O\ /[?TY^NW7PZ_7K"+SC/';KX=?KUCMUOVMZW_ &X1><8Q
MA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC/ A:#[?;\'DUL6
M_P!0=;W_ %[[.S7Y\(O.,\;%K79[?XWDUV:WO7]N]:WK7]&][UK?YL\X1,8Q
MA%@WSVN/D91=3-<ZXYM](/TG'+&2( B%Q_A%VJG4HGKFW0RL(1 05X,"@,CD
MU@O30W."]ZT)G8HZ-SD2W9:%G7'%\/Y!<G>1526AQ]KJ(U?7%@.<[(@7KTC3
M/(I.XSB5+'V?1Z%V6HK-B:T)AD*KVE8TXN=J2VX;B(00-P0 C5;D*&V9R8I8
MBP+ZD/76X$\(.1[=QMY*TC>MD3ZM2*]NN./,,@E;2:+L;X_-K^&+/C(LE-EQ
MIS32=E1&NY(E6F<K2+:_>T*LX8QF%1AR+NC3HB2F?--K/W"[DRML=A<#7=LF
M@:SJM%("%HY<98 QF+T-]I3%A.YL8=*0HENU"$#V<<O G"<:8(4FJZ,U3=KP
MVZF$O3UK,;98)HXVEDL;P"Q[3S#<.!!'3^!7)FSN(KRR03WX(IHG%DD;RX.:
MX?,$<O\ #H1U'1;H>NWL\NNS?E_S;[-;]O?MZ\O9V]NNWLWY<9U31%OQOD%2
M=17O#43TVQ*YJTA%IQAOD:=&DD"%@GT;;I0T)'M*WKG- F=DZ!S(*<"$3BO2
M%*P&@3K%)00'#9')(WQ2/BD:621O='(P_-KV.+7-/^+7 @_XA=1KFO:U["'-
M>T.:X?(M< 01_@005VOC,7.4',[CAPU9(I(N1EA_@^9YL\KH_&E?K7F$G]47
M9M;=NRQ+LF(,3ZH2:)0:V?X=:4G3F;["BS1';T7O#7V<WI??^<MK_P!DUU?[
M/<D>-T7K#,U([^(TIJ/*497/;%<QV$R5VK(Z-YCD:RQ6K21/,<@+'AKR6O#F
MNV(($<R6M-'X:W)0R^JM.XN]$V-TM/(YK&TK4;96"2-SZ]FS'*ULD;FO87,
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MK=L-/V7+8V-?-%K?;K6_+Y==OEUV;_MUORZW_1A%!E['MU@/T^]D_LZ.%O\
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MW6 _3[V3^SHX6_P&3FXPB@R]CVZP'Z?>R?V='"W^ Q['MU@/T^]D_LZ.%O\
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MM*\--,9?3N)R5R.Z;5RJV:8QW'1L+R]X_*P,(:-F@; _M569K5V7H92[4@=
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MP3[X[MS5;)]]*^4!];6;4G=>7G(J8]#."??'=N:K9/OI7R@/K:S9.@>YVG_
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MC+@"6N'R) *M]>CGYK#I^^B92OV.0YDER7Y9<;N*D>877DC9[563#.G!RC;
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M6-NC5GP7I9\9H98$?:9$9+6]FED5D]HL#NWIY,:G3#>]D'M_\Y7Z :48L$I
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M)Q]W8\TW<U)_1M_NEP7C<W_[6TL4?TE?[V,SX#"_^KJK ;DW_A(3_P"*S/\
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MR:K)6RMMD;JE591-?4.Y4LC:WLS-T3N>C2T-2)(VM;6V2[@V@;FUN0)RTB%
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MN0%J.9:V1\L*?HU7NK(,HY!05UB-4)=\<YQ-HAQO<&:#U6P31:99[S<+=([
MDZ:V[<N8E_XBT\DGT&0NZ)P?(!,FYPX=4'.WDM;5]<:XW-^1$EKF-/,'J;<F
M:FJYN %0MTP?3^7/*BII"^N#%;-)SN2<C"97$:GK]J4//$2506$2LTY<[U>2
MR;FL9/03?$\0M383'U\9C[-:.I5^((624J\KQ\69\[]Y)&%[MY)'D;GH#L.@
M"X%W3.*R%F2W9CG=-+R\Q99FC;^1K6#9C'AHZ,&^PZG<_JNL.C5)^?G3:X4L
MO&>S>D;S+FLL;K-M";'O=>S;A^&-C;IN])'-M3%"D7(ID<MKDQ1)A:X(VT!
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M)2DY$B(5(&QF2I5!+\2D2E/11Q0RW4M.06O"H 24$#&$7TC:FJXZ7.=@'5O
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2C")C&,(F,8PB8QC")C&,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g321006.jpg
<DESCRIPTION>G321006.JPG
<TEXT>
begin 644 g321006.jpg
M_]C_X  02D9)1@ ! 0$!60%9  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?5$%27TQ%4U\T0U]02%0N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!< &- P$B  (1 0,1 ?_$ !\   $#!0$! 0             ("0H$!08'
M"P,! O_$ &80  $$ @$" P,$!PX1"0<"!P0" P4& 0<( !$)$A,4%2$*,531
M%E-QDI.QTA<B(S<X05%A<W=XHK:W&!D:,C,T.5ET@9&5LK2XU=8D0E=8EYBS
MU_ E)E)REJ&U)R@I-4-)=<'A_\0 &P$!  ,! 0$!              $" P0%
M!@?_Q  ^$0 ! P," P8$! 4$  <!   ! @,1  0A$C$%05$3(F%QD=&!H;'P
M!A0RP0="8N'Q%2,S4A87)$-R@I*B_]H # ,!  (1 Q$ /P"?QT='1TI1T='1
MTI1T='1TI1T='1TI1T='1TI1TW3REE^25+VWID+7_()BK5+>VVXS6(E9>U!1
M["NC,IH<W/&3(TY*NJD; ^;(UIYSV,_ K8R)1;33V6PV4NN+=:LV)J"J;.G=
M66*QNS#9^H+ZUL6J)C#FPQG9]J"F*\EN8:6*0HZ.]@FS%9%;<%7DE+#OM&$M
MJ;7TVKJ&7M;B4+04.)(6TV\)*%:"$NI4D$.:#J ! !$P2#XO'["YXCP_\O:/
MW%O<)NK)U#EM?WG#E]DW=L_FT*?LG675)79FX0&E%2%.%"H2XAMQ"(:%SEF8
MS;\#QYOE7#GYK$O=M?HOXMYH[5QL=IUU5C[$5:[9IZKL&MZVJUW:B)'%;]6P
MFGI<0SE^&&96]@8J//G85]K6FY"J<8)AZT<@CI@K4M9E=IU:/&G*13ZVF:O5
MUEYYN(*:KHT6>XS$5^*/C_;[+@AF3SB+#6A*MJUC@;JBIVV"M$9;MJJ#J6P;
M]LFH4\JT1+M1K=BV<#-@7?(P.*TB2DV9EF?/R@B?EY:5B\Y;9BI(,7)+!&OM
MQ\1)"#UQQNI^CX"3GV./94K'0THC<4QJ?;\;7I:%<C7\5G9,5"2$&M$HO+8=
MNC)NMK]XQ/HNP9D3*!(=?]+5PEQQ*4,B5I *W%.MM)<"+DE9'YAM*0MS\J%H
M"PA*>U2T1W5GXCL/X@VMH^[<<07V;#RU-,6K=E?7J[5RYX"V&$N#A%V]<+MK
M4?B!5M<JMUW#KBK!^_:=/;6Z,&.\3P#-7I4E$:@;8M5FC]L6&6J=YVQ4Z$S7
MZ[J>[2%%,%:L<M'/@3U[L\U&EC5NE1H_G??'):(EVVFVR7MIZ5Y1; W#R=E*
MK&5H,;2,MQTUIN&I%2#X@=M%9NQ,BH*6F O9U&-D2A+!==*JRWO_ '<(K[DP
MJ1D&)H=@?#M/^'TQ":EUI&6^_7?7>V*H'M( ^T:1N+D>0W4]LW(ZX2VN2YVR
MP<L19HJ*>?$2Q8RH\&>][CDS(!8;Y2G%*TK7'"C5#:$3MBORUW#G8S5,!IU^
M,(L[TK!SM2JSQA%?>L+<P,?,2L_&$'ED(FW)I!19!#I$C@Q]:W%5?7PI"7T,
M-$K*;A"'%%Q8!#\M*$K( [)*0VM)) *@Z%SJK3@]M_$"Y<X7=<7O^RMPO@UU
M=6;:;&V<4@\+"+]APM6P<4?SSCKE[;N)0DE+*K!QC06@C>T<X;-JG8N_ZY9!
M86WNA<B:5J#3L%+SM=UC7(4*2TQ#;#LLE=MAR(1(T=!QJW#C'I61&D3UD& Q
M0(RVE94Q\G_$RA :=JJQ16MX]@_8+.SFI3&P-G0NOZ/#6/54JQ"2U*@MFD04
MS5[79K2>\@BA=U0D).PKX4N9+Q3).6V5'7+A?J^WS=OMC<_L.K76U;4KVY!+
MG5;$"!/TV\URDLZ]'+J+I<(>&)&R-6:7'S4/+!S($GE]QU]O&4L89ML]PHIT
MW5(*K(VUOJ/Q&P5KKL_+JOXEC-O\?=CW).PNW.,NU>M%6*EG37G5Q$Y#5Z$E
MJP,I,;6RXN,98$:)=X0I+)6PK6$MAXRX@$IMM"CI;,:2Z$N2D!Q:PLK.E>#M
MC_$5I?$DVW%&0RI=VYP\%%G=.(0]QI-RR@NWB X'T\/5<6Q0Z56;%LJV2PDW
M%NK5IZQ\SI2B7W<,G)1-NL4;':QXK&Z_U&A=%:RYL7?TM9(>*@A;7#H.5DB0
MD&0![#*'34W6HX:-<.K>2T/^F7<Y/GA:*Z\51[%Q]E1=YQVYM;Z>.UF#L2!+
MAGW=MUB?LM%ML+?WX82//@C45XL.59-B8LZ)=00\I!+;+:7]FE<#]#D0-CK;
M#%NCHR>UYIO7 6(^RN#%U(#0A!QVL;#4I!(>3XNVP4D>Y(.3+Y!R3R$)24(H
M=PEA^JK_  EU;$%14Y+6395VNX6X:9NV5V'<+0'(V^TVS7T%*5NH1T^4-"@Q
MN:I!Q$P<,)7X>+B&,+=R2M]1"EN+KVG"2"2TM1 0 -*T%12TPF2&W@D(4I-P
M79EU2U-E+D:XU%C_ !!2ZE#?$+=EIQRY<=5VUK=):;?O^*.J2A5UPY;Z[IMA
M[A2;*"WP]JW8O6G+0.?E]69Z)WZ7N36MRMTE1SJ;;=>7/86N[E3!Y1FVH$MV
MO"%L20T!-1H8GV0@F84*N/)1%AOD//+&]C\[:5.I4X8<@=SW^_B5+?MCL%=N
M$YJ=.P(K5]IX\-ZI4:*Y,1H<C.5JX_9M.'SH57(=]S2<3.5>K2I#DF/+(!:$
M82EQ;M"TA2=>0>R*[#^^BXK:M\ONPK6S)RKBWES6QUI78QHPN/:C2HV,SA/I
MQS+#V3 4YRMLY3V$.HUMIKB31]-W'[.V;IM38]E IR]>5.0VK<<6]VCT1V49
MF'ZQ6W<QH!.6"C10LF2LV_,6 QD$4<B5<:0M+F0=L@B]2E$=KI-N"TE:T0%=
MU#CG:*;3J,+.K64 0LK&?27P_P#$SES^%GG;HN*L0\GC)3>+MK>Y*E,#MKBV
MLQ:MW3Q9;6JW2&_RR+EQ87:H84=.WZSN'5MTMUMH-2V!4['=J&XIFY5:'FPC
MYVL/(*6"IN;CF'%D1ZTF-K&4DA",X?0IO./-C..F;-J\R>0-7LO(P^(W!*@&
M:PWW,Z_U[KA_C:/.ZUL$8++5X2$@[AO5MF.B:<3)N2I0)9<O."GQX[0L@I:U
M&C)4^:Q%QHI))@T>$.89G.2RF!!V22LY5E?<A]MI+K^?/G*N[JU_GL^;Y_CT
MF^<XDZNL&NMZ:Q-*MR*YR$O\KLB]NCS8S<H/8I<FN%%)KI:XMUJ,CDNU>-RR
M&0+(*0E12%ON8>3Z<63]FRXHO,EQ"NP "TM.D0X@OD:VB "@*@)2E9'=#J3W
MJM^)^$_B/B=FPWPWB2+.Z9/%'"Y:O7_#T.*5:/IX8TK\M?(<4I#ZF>T==<>M
MDN)+Z[%U %O2<)/E]=:/?]UU5JN3FU+<]R,U?H[4NNGY"JU*$ G+7IN+OTX/
MBY"03IK%7C4,S4L;+V0.6EU/^04%O "DI&PN2YO[LM=^U#"Z_P!/D1<^YO#?
M>D[YJ";M564[9)S6FL*[9AB_S05Q! ]7A8F5G2#WS8P.0*DXV-1Z8Y.9!D-G
M;G(;B#[\B+;9]7QIMAV!;]UZ]W)-*D-C26N[##3-)J+-$1-:EN<)#E!TVU-P
M0[*DMV*'GZW)X?E6#!1\O@J%HN+7#%^@)@KYM%\\?8$!NS<.X:M!QMWD+DQ"
M(VQ48>BF1-TMTU&,2.P)W$+#8E)"<2W%M9G9!]3*2!6487V)7PM+';EIM;@9
M+8;5,K?_ "H;DMH=3I:[3O\ :=F%Z]3@>UZ4CYQVW_':^+)X6B^O&;-=\+U5
MXSV1:8X;_KZ;O2+RYX:[VE]^1*V#9B\>MBP&K1?#OR_;/.8]5>9>S-H;-X9?
M89KX.%U[O>#V^[>(N;G8LF;!G=;'/05G$CCV@\Y2)1C(YR6%+81C%^$E6 FF
M(-Z/?6YN?=_*FSZ[V'+:TUCIB1W#8:5JQW<VR<(N<32!:W2%2$A'QPT*]*QD
ME]D]NEUP\P\%!(Q&BX9#;]:60X1Y&;W6.'&KZ=^86NNS6P8TCC[-[$F*44U9
M!%/R#.TYIR=N<':L+A5,S$))DNY&2.PS'EC@IP.V=C.5N*K-T<2Z+NBUXNQ-
MOV=KNR'4LG6UMD=7VQFKN7S7I1CQZJA;$D14J@D!@@N04$?')C9P)N1,:'E$
M-K;2USESAI?;AJ&$H>3I*7<J-R\II3NAY+B__3J0D%*TD.!(5+:2#[#=E^-F
MN$W:57_:\5?N^&/]JV[8RAA/!.'6_$6;'\S8.6=M/&&;I[2];.MKM5N*:T7+
MP6G0.AN26T]\<L)]B&\P/'@;0FN-@UB(]6LH+.9VB,5+UFWV#+T,_9DRYJ8V
M2ALUN-FQHRO>P/D2*IE1P+S>J-K;_P"0"^2V_-=5G9&V*U4M=FZW#K<?JGB<
M!OU+&+70(N>D5V6:;;;)AWLR;S[T<.>ZYDL19*F,H8"SA+A&M^.^MM37&8N5
M'#DHDB6UYK?5R(3V_#]>B:AJH>5$J8D2"L?VD<AH>7*;/*(.+6;E++BL(=2X
MMW6UPX=5:S['ONT(?;W(/6EBV4N =MH^K]E-U.(D'ZS7QJU#$9!17S7/6$C!
ML80MTE[L\\^XC"$N>FFS=S8"Y<5V*4,?E&FF0MEMP]LE3"EN.!:74E:@EY)<
M"25 C"9)'-<\$_%J^$6C)XC<7'$3^(;[B'$5,<3NK1*^'/,\2:M;2T=MWK!Y
M%JTMSA[J+-3Z4MEM94ITH2A6+V'EQ9JSO@/C0WIF>L.R9<B!D:A)_9$%$U>V
M:T?KTI(V79YLFJ"?Q66JS.1"ZU)U9T0Z1=ESQ,QA! >?5Z3!0_$2V)$:SIS^
MPZ#3I;9M_P!A[TC:XW)[,JFK*.S3-2V,B-EB9VU2X!<?%S$=*/BT:! 2,63=
MY054^E<.$:AAI99G#+6$AM$'=9MBV65M6*LU/GHF[O6QE4O&1=/KS]::HHB/
M='L'V!V($LXFWP3X;SUBECRI4N02:IMUO%5<"M8!!Q:*I?\ <]&FJY==C7.H
M6NL72-:L5/1MEWVK8%2@R).M20;E.L,AVE7HN9!EBQ95*3PY)A_'?JS3O"0E
M*5LE1*&2XHI=$O(:?"RE272I+*W%L*4E*0HA#A"1_M)%+RQ_B"M]]^VXBAE"
M'^((LFD.</7IX<_>\)<M@\T]8)9>XBQ96_%6F7'G%M-KN+)*W5S>OJQZJ\ZG
M]C6[5]=UMI2S6.,ONF8K>-BG9.SPE:SKVH.6JQ5"Q,3,4<*\_*2L',U]8H8T
M,4_B>63AT3T!&%E*QO5_B"2UY9KTG8M SM2A=@Z)V+O'5SHM_K%AE+:%J] J
MK' GA+$@@JP\?@P==;DY.36*<RZAV3:B.ZTM*@J'&77=*LX=MBCKF9,":3#T
M/DB?M)=@=,J E@D+.N2D395HF5D+6;,2AA!LV7(.I<0XEAH)EEII"-7G<!]%
M2=&I.O3W+P57*%I:_P"B(5I=F;;+?I6QE1#DX_)E,1;*BYX9Z$ ?C#VTCC,*
M0ZV4 :.^XSG,.<*)4"PM*3I"5RZIQ(TO*)([="%*#A91$)2IM*R-*B%5TJL_
MX@)0RZGBMJZ^CM%O6X18,6CR@_PMMMI*SPQ^Y::5:CBSX4'''&[I=L%EYE/8
ME*\SXAUPO6LKX13X"N4"_P!"O'&)!9U>NM7W349"H;IV5$UJ2CF9X*) C&[-
M'BHF(:>"9&,:AC%M/QTN40TOT5C;WVM>*1O'C)2ZW)BA5W9"M^IMX;T6":](
M?8+J0^U5GV<PEI9,=[%.,-%/^QK;]M;3D4KU&%91UBPW C5BAK,W8+OMRW'V
M]G3C$],6"T02CB&=$6ENUZ\9"9BZG%QD.* 4WB/. B@!03XY3JG&$2;Y$DZH
MF]:9J.PKMK2_3SLTW.:JS?<UA$=(-B@.9V+4R*;/^]15B/K-].))<7'>F^-[
M(;A!"_71C+.3KW#@XCL62&PFZU I*N^[9--M0IQ1<4E%T'%IUY0"% 2=(FPX
M;^,U6C_^I<1UWBW> ]DM%PVQ_L6/XFO+SB&MJS;1:M.W/ 5VEI<!A.BZ<0MA
M94V XIM;4O-7:#=5K%ZNSLEL$U/!*I[SF*?'-:\I%?G+O,;@F*8[-8GY%F/<
MKB_861FY5),C]C$?#".GAQ;TOA39.SZYXB2[547O<&I [%M8G>U=T)6ZA5MH
MPD_0+/8++57[N)88W:S$$R*JL1]:"D29<W%8<<9,$P,$V<R[DIG8LAX>&AY"
MG1U+5(;$9 AM0TG3,.<W9@52,?7]>['7M2K325.P3@1=E"MJ\//DGADQ)P+;
M814,M.,N9N!' [6A8%E43L#<9%RLFS*EN3\TUVW1&;Y!;,J%?=JH=HKQS=7:
MB(_V^OONQ,E!.0Q5<R I D?$QXS [3>ZGN#K4M194"726P$+;"4:FRD*2TXE
M!;@N:X"70$I"%$J&GS+;AO\ $>U;M64\1:6A%DE-VIRXMKIUZX+3X><9?O;1
MUYN[2M%J+8NJ=L%J=<<N&$AM0>4=I^^6/8U(#L5OUQ9-4VA$A,0\[2[*XP6^
M!(0LB1'.EQ$P*VR)8:U*X91(UZ?&8&;E8PA@A0HSOJ,(VAUJ_3^IJWI:DB4>
MLFV*7&:D)B;DY^VS1%@L]CL%AD7Y:=GIV5?2U@B0DY EU]Q HP8 J/3% "%%
M9:93M#KQW2V77"T(;UJT""(3)TX4I:@(V"EJ5&ZB<U^D</3=IL;1-\K5>)MF
M1=**VW"I\-I[4J6RQ;,J45SJ4S;LM$R6VD((2#HZ.CK.NRCHZ.CI2CHZ.CI2
MCHZ.CI2CHZ.CI2J;)HF,YQDAG&<9SC.,K3WQG'PSC/Q_6Z^>W!_26?PB?KZP
MU[^RN_NB_P#2SUY]9:ST'S]Z5FWMP?TEG\(GZ^CVX/Z2S^$3]?6$]'36>@^?
MO2LV]N#^DL_A$_7T>W!_26?PB?KZPGHZ:ST'S]Z5FWMP?TEG\(GZ^CVX/Z2S
M^$3]?6$]'36>@^?O2LV]N#^DL_A$_7T>W!_26?PB?KZPGHZ:ST'S]Z5FWMP?
MTEG\(GZ^CVX/Z2S^$3]?6$]\9^;.,]'36>@^?O2LV]N#^DL_A$_7T>W!_26?
MPB?KZPGHZ:ST'S]Z5FWMP?TEG\(GZ^CVX/Z2S^$3]?6$]'36>@^?O2LV]N#^
MDL_A$_7T>W!_26?PB?KZPGHZ:ST'S]Z5FWMP?TEG\(GZ^CVX/Z2S^$3]?6$]
M'36>@^?O2LV]N#^DL_A$_7T>W!_26?PB?KZPGHZ:ST'S]Z5FWMP?TEG\(GZ^
MCVX/Z2S^$3]?6$]'36>@^?O2JRZ;&HFN:\_;+W;8"I5H61KT01.S\D/&Q;,G
M;+)$4^L@.&$+2T@J=M$_"P$6SE7G,E90$-K"GB&TYRO)@B<J3DAG"DJ4E6,K
M3C.%)SE*DYQW^&4JQG&<?K9QTU]XI6<XX7V[MGM_^MG"W_;AXW].'D?VR5_A
M9?\ K#O4ZS ,#<CTCWI68^W!_26?PB?KZ/;@_I+/X1/U]83T=1K/0?/WI6;>
MW!_26?PB?KZ/;@_I+/X1/U]83T=-9Z#Y^]*S;VX/Z2S^$3]?1[<'])9_")^O
MK">CIK/0?/WI6;>W!_26?PB?KZ/;@_I+/X1/U]83T=-9Z#Y^]*S;VX/Z2S^$
M3]?1[<'])9_")^OK">CIK/0?/WI6;>W!_26?PB?KZ/;@_I+/X1/U]83T=-9Z
M#Y^]*S;VX/Z2S^$3]?1[<'])9_")^OK">CIK/0?/WI6;>W!_26?PB?KZ/;@_
MI+/X1/U]83T=-9Z#Y^]*S;VX/Z2S^$3]?1[<'])9_")^OK">CIK/0?/WI6;>
MW!_26?PB?KZ/;@_I+/X1/U]83T=-9Z#Y^]*S;VX/Z2S^$3]?1[<'])9_")^O
MK">CIK/0?/WI6;>W!_26?PB?KZ_22AE]_(^TKMV[]EXSV[]^W?X_K]L]ON9Z
MP?JO ^=[[C7XW.FL]!\_>E4CW]E=_=%_Z6>O/KT>_LKO[HO_ $L]>?5*4='1
MT=*4='7Y4I*$J6M24(0E2UK6K"$(0A.5+6I2LX2E*4XRI2E9PE*<94K.,8SG
MK!_S4=99[9QLC7><9QC.,_9]3OCC/QQG'_MOYLX^..E*SKHZP7\U#6?_ $D:
M[_\ KVG?[[Z/S4-9_P#21KO_ .O:=_OOI!Z'[_R/6E9UTD3Q MHWG2'!#FEN
M?6$RFN;)U)Q4W[LK7U@6%&22(.ZTC6-DL58EEQTT*=#G(CYF/#)4)*A%QSZ6
M\MFCO#J<1E0/YJ&L_P#I(UW_ /7M._WWUKC<3''S?&I-H:/V9=J),ZXW'KVX
M:NOT.'M"N0I<K3+Y G5FS1PLQ&6!B1BB#8>2+'9D0'FC0G'$D#.(>;0K$@9$
M@Q_CW'J*5&&X^>*KS2U/KS9G*:RWCD+SIXRZS\,2L<F=NO<A>+D;Q B*7R\D
M[)KX:-T[I;<<)H'6+6P*?:("SVR6)DQ:1M*%&A*[#S<1<#?>"7"-^W?Y0/NG
M6>P9?6U]X(1,9?M24_3FS-\ZEK>\KCL3;9E-Y"3/O37-:XZQ-%T3.5#96TJS
MITD':&RXF_V[6-79*9EZ;4IV3. ;.)>KV%I7A_M'B<;PFN5DJ,CQW/U#7-%O
MU-C=$:#+8UO5(J"A82)9M@UF3/-&C@5R);?F$DYD#'&''R77'7W5*T3MS@AP
M,W'M<3<,QL:T4FRFU+7-!V9%Z<Y@VG3U1WY2-0.OOZMK6^JW0+]"C['#HKI9
MK<(:0_&3:HXPB#D94^#6F.;MW?\ J?GX=#S^I!YTK36XO&DTU*V[66AN"L="
M\J.4&U.2<=QL$HMY7M;0.N]<3C-=N5PN%JV;>K%J63EEPM4KU#GUO@:[K=TD
MC#&5I8\Z6&6I)%O$#Q9N;VPI6:XZOZ<I&[.:>V/$&\1K7%"I>P=I ZOTCQWX
M_</'M>NRM:MFU=<Z>F;!?55F8M[.OJ++1NO"K%<CC<V*W2,;'C--O/-<N-#\
M3.:51I=9V]L<:)EM7["A]KZEV7JG?L?JS;6I]BP8QH 5JUW?ZQ86Y2O&.1DB
M=&&BI;)C#@WT)?!40''D")&&\*GPT8*C5.IT&\W75MGH.W]K;THF\]=<T;9
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M<E-4\F;[R:VK2>/VS9&^S^E:9.Z]UEKFV:+E-:QNA9#4-"K%FFR:52$4UH6
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M2E/9?YK7A0;A0)DVP; H52RP(K+E<AH2?LJHF/;80/D')L)#M(=-;<<;)4.
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M"(DF%-HD8K:T3&OS6SG)FW%LKEWU2Q6N3V6GH^<BV!I$9N-LLF6Z,U"Q"B<
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M;/5@*FY:+.<?8< D!&)*2]T*$)&9]A=B$3 K9 JF\.MD^HV1GS^1"9"/R/,
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ME'I$C6C_ &@B1S&)+5JDN!/<45)/=*>4$)CNS.1@J !F8$1692W(!2 <$$
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M9_9_Q9SC/^7&<9_Q=='^KF$#\NE(2AM)*%Z5)+;+S(4RKLR6B.U+C85VG9N
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ME^.EHPQE!47,Q9&4I]HC)8!U@\%[*4+4.^C#K;3R76D3O_D1'];XDW[GQ/\
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M8:+U!)UJ<BD2S#[\<%8,WZ2J\7 .F-L*>%//D?<TB"IN3B)*3C'&S%1X;/\
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M6HA.#D!(.QZ=8_F _23L!%,VPDK.  6@*(2SD6:@VP)]:HV.,?3#,341*?\
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M<9<%D(9LF3<LI=GG5 ,AI25(@T>J46*;>80_E*5'\:;5H7B!#V.W["-@+GR
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M<M#CL8U\+RXHE3U8!Q3C)VH4N@T<;[*K4Q1)!R4)OUA?.=2"[L^5R=(&2Y,
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M C^4\^A#ICQ<M><JM:W?56KIZE3X4S5B8&$K]QMAU>GZ];5>U#!/41ZN>C9
M+'"L.AS+0*#8XI;Z4*A7,!I(D,H*Y-\'[MNJ"E(&TZU5O*SS!J9<J<W"[7H>
MPSY$B.)C+X>Q'*;:I"6.4D=0Z9"SDD3OE2E!UD<RSE;D6_5_/+BY;7A&;CJ*
M:X5WQ>1W$[8XLD2UUTS)2C"7&Q<[%XX;"EY&>&@&5Y3E\W6.T&3H=I9#T+3S
M2TL-I= X]<F+)4Y"%LE(YW\%MLUJ/::=9J.UN4.V-)/26)57FDF)"#WQ6Z[8
M*X6#EM/N\:/LQD?&M^85C)*7<K7@II22-"BG2!I2X"<P,:TG;>.\"/ ;]+;C
M9$#2-658Q@)&Q5.?C,8G%/O<(O $\(FK:DJ.Q.3?&BZW_=T@,27:Z7/;.MDM
MKVO2H4H\RP+5XRD6*E1<Q%N L!K=594E$'O.EN/1P++S0C;T)\C0*QH1>BN#
M-6H_&6#D6RHZ+)K]/J,<UKH!")"'E)"E:QAGHV,A+D<@MZ,^RB39(4+G)$F<
MB;+:8*Z8 JOB4<KT1"<5?A1JG<[2Q5&!N:'YM:#VO%F.)(<Q[2[!QUXBI96,
M>DR\I @3Y+[:V%JPWA*QL?NP^([S^92D61X S-<DRHUC"6@I:.M36&S<8?7@
MN5&O];!&P()A?M;AK3B&"$NL)>R,VEYS,JN2,EL<@0MOPG=2MQB8C?%4#:-4
MQN9@@A/+$:0")W&?(BEP5_0U$UG)U33*KG:<V42K'E1\$*)"EF2T *T@ F4>
M)B(.5=".-RED?+$G,1TM+A.%Y\IV&7DXQ?4,WJ;DDYME]<GM/=A&FIN4IDK#
MBG1(-HH":LRX"UI<6)B&(9<^Q!C1)K=(E'&R190\N;A L!KC<ED-=[8Y=<YK
MC"QP(=IT;QN2ER9:MKLARDX8:FF+(0L'V=@ AVW;,V!::Z_!IP\TLR*P">2Y
ME7K8'3AH=+=/&W6F].,NS+GL767)[CK"R=O;7]F@4!XFW$Y^%GUF.OEI=L\-
M*V@^.FW13275QAA0IYH1)13C*\.NOJ7"620O4XD*P0 H$$@@D*(T@ @@#?)^
M V*R"G,Y$DR"#@DI@3F( D8R"9 J87QN<U=4CG]JZ-$VA2KG-5]_6X(MWGKX
M#+1]4A98R;=K(>JKI,$5N%$!L<G+&#I751W4S,@=(AFOXSGSN+UOD=M>0DVX
MLZ&AH\$2%CG??!J,,L34R:Z=@D$)M)C9B6X40>.(D9%T(<)]V8;;%4Y[&5Y8
MI=5YD>)Z*.\O6^BA>34(X,&\P53-J<9]G5NOI#':RHG%FUS=X0]KSI5[4J2M
M2887*C%,"^LRE*&:&Q<W?%#8=*(ND_X<_"2NOX<;)L/(#DYJ@6T03>6_,\>9
M4ZK9KM;2G\L)4L<),4H@MM.,-K$QY,XA*7@<.I Y#M02,C$#.V-LG'C62TH)
M,Y/6%'PR2(.W7._\PIW[G SQ:Y!;0K5IY3[(U3-D:ACGPJW3+;LB&B:%39.?
M=8S(2SE:*DQ2Y&9EVP1'#'9EB1:6S'!JCPL,BJPEOG;_ #FX]\180F.UAL:7
MM]/N$D&7+PE7/5":86H?#^6"#72H5PJV+9<:>8B1X-TX,1X-GUEL(9]G0S+N
MGD;HJ3M:+!R(\<?4.PY5QPHEZ&XZ\/MH;C]B\RG6FT0%KL\/!1[!R&6LH#P3
M,,#-..,/*>9%2VE;9^R/$SXUZ;EGY7ACH>:VIN0AIS!'+?G,#7+W:HI];:Q$
M8U=QTCS)C3]4Q'A*]*.F[T5L210M\AX*)AE^BEO5+!405K<68V@I3F)RI*2
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M]_V@]L6*TD=4US.NIWCO'5$W;9>WF')P?3T<C8]G^S>/TF\SN66:,!S4<+>
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M'1K=1-%/G6H1@'X&3MXCRQX^%*@U _(K>9/F[R?+[BTE';OY8\#<*UX5V_\
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+W[=\=_V.^.E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g299228.jpg
<DESCRIPTION>G299228.JPG
<TEXT>
begin 644 g299228.jpg
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M>)>A\!HG5[;!U1DE*$)&4F)HIM?Q)D1(8V>&HJ?A_\0 &P$!  ,! 0$!
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ME2R)LZ'DC'!%CO5JZ_\ H9005YR5)"2E8; "2I*SEA4$J2V$C*K]F5%(SF/
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MV5YLQ+K!)9II(D* E?'Y<(CQW*SR?$Z%8WQ3N1LLB.2P=-) 7([QDRP#RO\
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MRE2 ;BY-NIID+(2H-D!(@EM%HBUH$;0($7YFF]99T7;2Q)Y5[HSV@/6SJK)
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MX$0%-J"QF4$PI-\N4GO2; $R:Y<JDR,P!$R,VIB;1KR\;5Z2_P!2T9MF&?\
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MCP/Q32N>;&\>MLKO:O':,-YUI;%Q""#,<V-'/>O>26>=_:(40:%LA1QI#F#
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M$\M@2-]]:BS]HUUZXSTE:7MLKO<7$V25=6,&,5F#E9$-1QW<Q\KQ22)YYA[
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M<%=X[8ROG"+"_#MAE:V)Z"3PPJOIY6-AECB<G@;TI2 I1"B,\2@7"B#=0!4
MDZ"0-3>9)JO:9V2' 50J 4D BPB;$0>]J(VM8ATGL^O;5==OLW<HI1=?YU/L
M#5U!,3 5H'<9%[?:_'25X[2/K=2"QKLKUW:0>DCBC+PRZIXW1J0'95]D"42'
M++MU!==FL/;HG'YRS5V,: ZI,.QH*>K&K;$B_$EM:^EDJB2+4TU@LV7ZXSP:
M1<-RFLGKX"0PR@!+@4A[!;4SE-ESJY/:A620 Y3YD[W*MZ'',3*YT:LD?[U@
MD&MG*WLUWP(=$V1>[NSE5KM\UYM6SU'G^";EU2*['KO%+(:2QJ/6E&UI<[)9
M$- *4MTD[Z#*:J26N-!FDE2+\76.5K_3JPIH'O),*$+M8F+=X"RA!N#-KQ:J
M(6$J&;OH(RD$&0FUQ$@$1(@Q:\$UBMU:U)U[E!</NHFD$EL+.M*H395F-Q7*
M*4AHV48>7,Y$DG2F,EB(ICID\5QBMC0VZ/?(40D<[WU**O;VR^EE_0U+U(K_
M *M.9&O_ +.)1USZUJMQ8/J_JGQRI(H]>=3N.445M.>&4()1;*J_64.%9B,K
MHXH#0BK86QU?E5M$KT8A1!!4:S5XCD6+ZE7 ,J_;2ZCK; :4(^OU?U-!'!SL
M6.<0P34.3CE"S1N_#,E'GCDAD8OQ:]CD7Y<3(!%I@'0P9 4)T,&155HRKC5)
M(@\P8-IZ$<X-I,37JL\.'#@7 /,"LZ1+J4_*_P"WO\SI/]\5'%U,^S#/NPO^
M<2<0KJ4_*_[>_P SI/\ ?%1Q=3/LPS[L+_G$G('M'W_!%6/L)_J5\$5;\\[K
MZM6_++]$/_5ZV/\ TM2<]$7GG=?5JJ*O4QT0(GS7IZV/_2U)RU5KBQHZ6SR*
MVKJ*F#GL;:V,&KZT 9BO(,-+F9 ./"U$7N^221J=U[-8U'/>J,:Y4Z3?9?=)
MP%V;ANQ;$ XW",,OBJ["["N<D8F69,4UX&U-\PGG"O''%JJT6?7>ERBQ9((6
MU,N1L'B,MK)RP^])FB,EVIG^N-<8S5V!6P=[6K,=Q[W<"XNTQG6ZF35V9YB#
M'Y<JQ7&1I$9A^*SM2-S&MNY$?&\^MF=Z;6C]>Z&Z6>A?,^FC M>Q29R+D<6I
MQ;^P;7)69+L3#ZJH3+2L)($>19NP/0\\_P!9TATS PLFRD:[]&XJ:UL7\Q?5
ME3 4$D@F^F41?G>X&VN\5TL)@A9257 $6&U[Q.4&3[H,3$5^[=*X[U8;<R_4
MNOL>R#6'3-6W.-';1-JK6_J;0N@94U5E5Z3QBRJS6AS9IETM8RRVWEH9,XN'
M8?;('5JN0YA7PTDB^*8KAF"X[0XAA.(T>NL1Q>H@JJ'%,4ABI,:QNL![(.'6
M .C46N8.YS'SE1L<\^2=Y-C*845,3+^<<QX'',?935HXE3(+.DZQ#IX7&&V3
MI3;6S?&\E9"C#K B4M[W1).][WQR>9' C6[(,5ZN%T8#ARK0/S89:Z9A4T92
M]DC83"KQ)6>8L+$9Y3_^$SL\R%5\QK6\\U2BH9;A(VC?NW,&/ #02!N3V6UD
MZ) F^@$'7> 3,&3,B:R,<!%@UC*QC+;RO*:E>U8(K%8U<DLK*U['HA1#6*Y\
MD4<KW2K(V)BHC43FS75>-4JE0"5'/Y;F$79,PSD:JF).L-:&,]J01# .GA;.
M3!(US9V-?&]LOC1FL8V/7$9)2B'.602RLZYJ/B<QTWF3R.7S?Q1B3+(+(.J.
MGF)E65B,&<C7I*V79LRAC$R2UK[%QEB*P@N%)IY&#%0S%*G>)_CC8AT$Z+(D
MS622RN6-9/%(V15YGK<WMI-XMUU(N!&I$F8JFGA$R-Q(&FFHO/OF!6A&P7C*
MBRCQL46[NV@3S@QQ%S*A-@5*UH4<3YG+,QL9C%B(&DD]?)YCVQ,E6-5YF,"^
MP?19@%2AYF@[IC\7%OG79./D599"S'0&L#"D(I)_*:<$(2#'-,)(*GN^!['>
M$-)$L@1R ["UJ;(18B0B%D,C,]^@)'+$4^>.&127-;#$UQ<:2K'-"V,A(AY7
MNXGF#Y-!ENU-L9&?$?6V5A-1UI"W M14S//'JAI1R*IHCTGBJ[.O_P#C,>EC
MA2-TA/=\;Y)34>U20 "1H8N1:]YVY1$^%6V,R(F]S?NBVD2"8^5+;EQ=9 4&
M3CWJG&'"U<\3XX506K@(C1#Q#!AY2B1;%A#$=%)ZCTH[28&(/%- D$2393?I
M4@-=:REA0D1/:CF@Q$LDL7P3O9&*^=_JC22U=*4HL[8V/>QTLP[H6O\ +4(<
M1M:*8V7LXOPLFC@B:5&PB"*)DO\ P@N55<Z.199XI5C'[,1\<9D8T;W3.;%U
M(5%=]9PMR?<"4X>,Y!';V=B2(IPU52QR2+=7DP+_ $WO^,4:,GN,XB*&::=_
MHD.CC:CI$$@21)CK,)@@7M C<F8O1.H^)&M@?=%H]#>*@ZZJ,UM]B[+L58ZU
M&&!<75U]59,\Y&2AR0I*<^025D1)1<K'N8] V0#PS-'BC\+6RQMC+J#V>-28
M$9%-)Y#)D$9"LT*)'[P9(R(9!V*QJS*6YX\3(7HD3$:JNG:Y]=@:XSDN3,],
M9&#=X<5<6,E?E4IL4!YH].7*(8!8590WDB3>GC::#&><T]("4"4&-GJ$COWU
M8Q#HC1A0HWM4::LK!&,4\N"PBE+7WC730>>T=UFS_A(C8HV(Q)&QP^F5J\]-
M!*0E,%-N4*!@2)U!M!W]J:O L0?+2+:>/PTN:9]$I0SWPI+!)YDJ.,'(BB56
M3HL;!XD!5O:0F(=_GK-.BBO18"6->QSI$M99CY5>I+X198HW0DN@ECA>:+,2
MC&2ND<G><PF-SB?3P011>0Q6NE558QSM"\<#ANI["[9.]H\HS; J>N@JCC1I
M('RLCC]<OJH0H!E1'JDL;91E?"HR]V-1.[_ (!2)!ZTB2<=]JYDI"3"S@.(E
M225P8DC?PYD$P+WK- L0L(L3'*BMA[2K?M,T YA(-P2!WH*HB#<@3>=Q!)I<
M=?2W/6/&!N.44C>8()G5%CN [0K",YP2CG)CH*ZR,F;>XB0R9MBEGKC*@UGR
M77MJ$3,IHDU0? ,^Q%\JV .K73"OEH]G#L\#(*N_Z&]\9U+FF-7 =3:8AN3+
MHWV.07.HLUN8Z:INB%9+(/39=BF3 %85GYL32(Q\R" RR.-X]R.4^,?ZUV1P
MDA#HR9D+VQR$"3L<Y8AR7QLKQ_,F);Z;X/\ +BE\Z65?+CAC<SPQKJ^6;4RW
MI^P&JZB,-%D/O.F[/!;+,,9+@&FCS70.U;&JQ/8N'.+DCA1):G,JS"\UKVSN
MG$ MH%L_"V!2F35<&=, DJD008(7(A4S(*B<A.AF3.450@)!4!&A,03K?_\
M6)]WB#KGMR_9OW'2SMS, +:X=D./W!^/V<N=N:/%'/)DT!55JG==N+7BI!43
M9S'3EZTW)%7CQ@+>8_19"$V88$9&\N-I7G5%B?4V0Q(-A6ED GA&1NB*$,$E
M?"2,1$[XLF@G9)'(U?D]KOG\^>@KU<;ZPSVIVH]0[!QVHQ:?7%_I+)--WMIC
M8L]:9:XS8$J4*%=X[Y<_UIYEJO*6RF5]+&2M</*1?1>H8#9!/?Q"]1>I,CU]
MD&2XOEL#F[&U+=IA&Q2FR(\7):WS)(<&V#6(L*$S!6]9&/56QI,\[GF>XR9I
M%*M9VLT;7G20;*1[0,S%@ >H-CTC>:Y'T*.59@RD21H2( (V[P[VL>UL!7I6
M?4G2(GL=-<K^:_??4.Y?C\E^N:D;V3]!.S4^'Z/=?S>=*7.:[ZD\^'L<];I^
MAOGJ(_\ 6BFYTH\O7-]>6E7U9^2 ?[,G\1W%"XGM9^2 ?[,G\1W%"XJ=AXGX
M)K3\C^RQ_N=W\HO-?YL&1_98_P!SN_E%YK_%17U/FG;]'GEJ_5*V$BYS[<_?
MP=Q.0#BM)JGIUR;-+,6-DI(&+5&A\"=8(##(]B$V]K/,)C] &Q73%W]O6PQL
M<CG<]2G_ $]OM_H?;YY__M>= 4FZ/;R;-P^\$==8S9:XZ<MN;, &(5\UC2XE
MJJAP;6VO71QNA)%CN,J]]Y/=J,I4AHKZ!D<;)@$DCJ2 9.@2HG2;183N;@=;
M5=",Z@.9CW_6L20 3%(S[*?1)=-K$+9UA2AB[$Z@K2&QK:%PTCX<0UE0RQU.
M$8E33M?ZF&@H*JM 5\2RR*Z2,4B59%]0YW37C6+#XE7"TX44$OIPF^?(Q)'L
MDG2'Q$O>Y%A\1+_PCHD?*SSH)4\+'-;(K-ZVCTKZAZ48.F_6&!XI5BW6.8)E
MMYD]T,LHC2Y%GQBE#J@X>R1UE0#9+9R4T23(HT BLD5TD\DS<>;(Z68$QB$R
M0O &C*<I(I<WFI"^&<9Z#E.B<K%="C4>Y'Q=U5[621JO/*?4I3JLT V,9K#,
M!E2>>5,3X7KO!&5(3=,:F!,&,T:&2"8L+Z"+6SYQS/4>*573))&]T,A$?CC?
M'V8_QQ3B1R1MAB>U(II$D:UCT\,G='NYCGC1ODBC%@3PO@23M#-,L2/>K6/F
M5DTCE<Y1T<DT<2JJQ^&6/PL>JNJ/G=,Y\B0N19F*V1D<B31S2MG:YI8OF>+Q
M1R)'YJK R/P3*]/F[X6L)!+9)QO"C_&U!E<B*]CWHC?&]_C;'&YI:.>L<2$R
M,9*URO+1[EBCQ!T@#6.<7$;1($P=S)UD&0+&^D^!TC7GM:_.MVEPUT= V^ R
MO&SG*]OO.H4XD6S@;_BSLDKBA!U('B>^-C7LF6.1(X98)$3S.^M25<E<38@*
MU[I@Y$CDBKYHB("70.1SGL* (-;*,^.1>XT$SI'M5K%]/XU5M!I ,=<570PA
MI+(8,1$0\GQDQLB8]WD,EC>GCD&:OGI)/(1XV,\I8Y/"U4K5XPSX;J8RQ;52
M @1GUE?(#-,RQD;.Q9X8RHRW*/)(.Z6*(U(Y4D<V-KVM[I,V09(-SL+P=$@[
MB-[SJ1TJ1^8V@D&)YSXZS!"MC?WU ^B#$+F2JA%.$4RN*]8')!)"3*V".1.Z
M$#0$*G?SH35E<KXW0210RJ]78$H)1Q!#86.="3.1 DI,372E%AD(LKYV)"U@
M+'N8D0SHF>&9(I)E%6*3\)0B>0LT+3)X/ UI'G2M:6^%6M[-<@TTCX8W0NFD
MAE'&C5DC%A=%X>Z?ALC6V(T0K@YP ;P:64B;T=J68.D<I;58P^1XBPRJ_P Z
M1TJPN:J+'(V%?!$K%<B\7,&YT$]W>TW'(D\B;T /C!V(TM\AKJ(M)D:M;R(5
M))+*Z%RC*D_9D:O(A[2QK(SS6L?!*K7(D\S6L>D$;5\UD;4A:FW5,]+6X]*"
M2(TBVNWL*:A__!@:D$%K6BP-4:"$J*:R>C8Y&$$R,="D3FBQ22#N=KLH$AI1
MP:V$XZN5[6*&0Z9PG_"HG,'GD?YDJ*B-A<,X-R+/+ _QCLD<_P 6QFC44]77
MV,*3BWL4T(YD;YW%@'2M?(Z(MS98VD N+FF1A,<LTT(TG>99&K)VC#D=(G<\
MB),7L">5HL!4GES*8M;;GSY [>--8W7?Y+#L#IKJ8K0T-;W<@MV8RB%B =.'
M@-999)Y)$HL;2XQGR!1O[/\ ,$E5D<<C7O>L)'+SU2X%C6S=M9ULLFHI+*QR
M+);BZ,(EQVDBLRFFV94R%R1L ?"Z:9WDPNC:V!1XD<Z6-'-D5_4_GF]),6W_
M *<Z>L>OQZEN[*G8"9NV6E#M"8L:QZJ\^J419"H+.O*(R,JNA#FA?'&2Q)8"
M&JQZ3Q<\&:5/<^S .KI&W%?<VM5=2VD2/*D2 @J&3U\ ZRQ06PZ1*A<2N4E8
MWRROBC?VB=W84Y;P1*;28,9U"8Z98W-ASLU MR,Z\N8M?EI$DS8L5I<#I\=4
M2YJJ2F$NABHB 3HJ6D ]-+ ]LT$PSAAXY8&P2LCF:Q5\:S,8Z1SE8WP/>V7C
M>$]?W2QF6M,SQ7#8^HO#)K#)=99M.#/7V"31U]=$RH"NHBAA%@R:X%L6V $L
M<H@CB8B(AHU>Z9]Q=:YQYKH@3)O-2* V(3RQQ/+@(EC:JSS+%)\>[NZN80KR
M!XDCC5\DL+XY<+B%81B.88W:U$[12VGPC&#1SC^9(+(C_7RDL217-8D#F$(R
M2:(=)19HG-@E1\+.E2LT*%EI(4DZBQ!@\PH""-"*DI!&4W!%Q:-H$@#W?ZKD
MTN@BE)FK+*NEKKVC**J[>"1CHIHI G/@=$<,V!B"3"$0R033,C1).Z.):U[?
M,?9XZ[R[)U7--&R"YA6KE?XT?#'*2Z)P)2NC\:,]$:@Y*RHURQLBD1J=U5./
MU]IQK"TTMU[;_K8:TNGJ;7/#,GH"T&B'K[8>[% M[(VKD'>ZO+K&799\#WA$
M20Q21RC(]TD3V\8)?V,=E;36$ ,%.^162R!B.>H\<_X3O(+W[O3SD5LRM>Y5
M:[Q)XU;X43I"@I*7#K8GDH$)CE_"=)O<[F/**<BB- "1:QE)@P(( B(,D"0
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MKA2?,5\A7G]5JV.49"^+*<C-H9K8H& "M@IV#@4E35BRJ2REQZM$@($I:M+
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MA$AT$4<@D92Q# M<LLL!QP,$K1FK"GA0&NA6>)WB5[!FCPRRMMSH7^M#9YB
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M(@DS[5C8""2#!@6.D\MN;K1^\=6]9NGNK?9=<*S'-@Y!389@N7X<3.Z9[Z;
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MI8GJ]D;62) R=J>%L>>[?:U]!>DQ[/U?45A&P+.H2=PN,:RG,SRR+,AE]1'
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M,"A'!.&X;',<4>X/P<8+&8[!I<^Z.XASB&+QR<-A'W4H<Q.'P#&):P:,2MM
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M_:/7>UUN/88TS=P9QU;;8$>QB&:QZ4>DG:6 :SM'0>*/TI^9;3Q[$)YHR&?
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M\ECI,9C@Q5[,'.5RJY?FJ_;^'Z")W[KV1/@GQ^7',_X%?6*O_P#"AU++W_\
MZ#[5^/Z/_P!$^?/\"OK%_P"2AU+?'Y?^8?:OQ_\ PGRP$;D^/A'Y?*U<IS&.
MZ0 (  ,#X^_GJ;UZ7WU)W_Q.>MO^GGJ'_P#6BEYTH\YVOJ7' <ZUK[)/7V*;
M%PK+< R<7>6_BB,=S;&[K%+V$0W)*>4(N2GO@@+!@ID;7O&(<.D4Z,?Y3W^!
M_AZ)>35:OJS\D _V9/XCN*%Q/:S\D _V9/XCN*%Q4[#Q/P36GY']EC_<[OY1
M>:_S8,C^RQ_N=W\HO-?XJ*.5&SD,1&QDE1M3Y,B*(B8G?XKV9'(UJ=U^*]D^
M*]U7X\I\1S>._-8=.F)5>;;7M[BJH[W,<=P"DCQ[$<KSJ^N<ORI3O<5)5XSA
M=1>7YQ!K*RQG=)!7N'%'"((+FAB9XE4I:?4E_33OWZ7]^X>I+^FG?OTO[]Q%
M\$ZA-$[03&FZXW%K+.2,Q#G/Q:NQ;.<:N;F^%#K*^ZL'5M$+9/O)YZJIMJNP
MN05KF6%**>,^W$!5ZM;KM)U9=,N16&65E5OK4LI6$9+?XAD+B<_Q:O"CR+$L
M.I<_S&NJ[*PM1J[(5PS$\@J[3,R: JS$Q+S"0\AGK3:\\<:,PYCZ^OCR-*<5
MZDOZ:=^_2_OW!""455:46U5^:M*(:J]_BO=6R(J_%>_S^?QXC5OU :-H<8S+
M,[?;^M L4UYA]=L#.[]V;XV36X?@]P ZTI\MR.8"R+=4X]<5S5-J+4N.,.T'
M5LM?*2US56G;]1/3]C\@$5_O;3%%+:NE961W6U<!JG6,D"DMFCKT.R&#USXG
M!&,D:)YRM>(4Q>SAY48S#G]6^8^@:F#R/E]<QYTM/J2_IIW[]+^_</4E_33O
MWZ7]^XD0N^-('6-=4 ;EU.?;VYF)UU55!;*P@NSM+'/:8C(\%KJT""^D+L+#
M-<>%)OL1""AG*R6E'(M:2(X""8AF)LNI/I_ISYJ^UW/J^N<,<13FG&Y[B0M,
M!D(N15>)2XG879%S'5@9G]<EU64\>(EE0Y#*>7$-'7K.YL;F8:3K \XCSD4@
M\CY4N?JB_IIW[]*^_</4E_33OWZ7]^XE[MOZ\(P^ZSG&\B@V'04,1TAK=30R
M[8O"9*VSDI3PJ?&M?)D-[>68EM 57SUE4"4=$4$?&^!J@E^3I>/=4&D,F&TA
M.!F$X,W4:!EMKIZLR3&<IQ:[RBIP2B-R;+K8NHOJ<$W%ZFBHJ^>Q*L\KCI09
M8904#(*?8@LG9D\QYT@\C;6VEI^%_"G">I+^FG?OTO[]P]27]-._?I?W[C=<
M;ZL.FK*L/H<]K=X:S"Q7)<178%-8Y3E]+@Y!."?7 3BC,TFILT,H+VOQ4C(Q
M)J<.]LJP.M--</"(1,\F!)%>Q'-,/S^DBR7!,KQG-<=F+. BO\1R"GR>ED.K
M"7AV0<=M1&GU[RZ\ICAC1FDK.).BPD1Q2(K>,PV(/AUT^O'D:$$:@CQ!K;/4
ME_33OWZ7]^X*24J=E+,<GZ#BR')__E*O*/#DU%54():BHTHIG?Y^ HAG?M\N
M_AD3OV^WS[ZDOZ:=^_2_OW*/#BE5O4E_33OWZ7]^X>I+^FG?OTO[]RCPXI5;
MU1?TT[]^E??N?ETY#T5LA)4K%[=V2E$2L7LO=%5DDCFJJ*B*BJGP5$5.RIRG
MPXI1PX<.*4B74I^5_P!O?YG2?[XJ.+J9]F&?=A?\XDXA74I^5_V]_F=)_OBH
MXNIGV89]V%_SB3E1[1]_P15C["?ZE?!%6_*C)IHNZ13SPHY>[DAGEB1RI\$5
MR1O:BJB?#NJ*O;X<I\;OM?J4Q+4^>X7K2?#=J["S+,:&TS*:GU/A<6;&XA@-
M1D^.X6;GN6@>^ZJT;CC<LRJEI(X,7 RG)9'26-K];S:&DN+8*T@:F*K3C_5&
M?33?WX3]]X>J,^FF_OPG[[R.3'_:6Z@O\M"PQVI.I>FN(<J$P3.%M=:8N0-J
MS-;K.1];8AC&<KCVR+XHD[-,X.J\8I3, %SNFJ[^RAQ_-++%+X.XK*Q8M.=8
MVM]T9IB>N:G$-O8?G>5![GGDQ_/\#BJH,:/T+E.&8AL/'K_*\?OLIP>?(P;7
M/<>>-5XMD^3N:-(<VVFJ+&O(KDC,D"9$?+Z_.I@\CMZZ?&G<^J,^FF_OPG[[
MP]49]--_?A/WWC+Z;V@/2+<8)C>Q7[DIZ7'<L!$L*5E_3917WDX]C+5,K4=C
MT-(;:I/9Q7U$;7CQ#SS%5]U6&L;Y!#G1?EWM"^BMM37WJ]1>!)2VM)/D=?:>
M5E*!%4L0Y9HYS9EQM/*;<U]?86>+#$-A.S.JKS[7#Q+VN#(*C!0.XI!Y'ZY<
MZ>BA!+556E%M5R]W*THAJN5/AW<J2(KE[?#NY57M\._#U!'Q_P"$DJJ_-5(F
M55^VJJ_NJ_;5>-SRWJIT7A>6E8+=YP(W+:LF@BOZ 8&UGM,<%R;$KG.*>QM@
MU!CG="1C-&=:.K:MEGD<(J(1+1-&B+F&IZFZMNFW>MB13Z@W%B&P;<6 0DFJ
MQV2UFL8(C:DN[A\T(RK#G9*VN ->5 YB3 &BS4]@P6Z9[NXS)YC;XB/6*93N
M#ST/G\*<?Y\_Z?/]K\7E[I^LOC[I\U_UKSZA)*?(HI.R=D[$SIV3]!.TB=D^
M*_+C$0>OW6%II'8N]J[6F^C:#4FT,HU3LG%H,)Q+Z]L*NL)QZ'+,ONLE%DV+
M'BE+C6-T$\4UL18YB-=C7DD.#)0/SXH3&"#4?M%.FC<3>H<RFN<LQ2BZ8LAJ
M\:V=DFP<6=C-=!8W5];XQ4Q5M8/97&7,/L[VH>#68SD.,8[FEHRTQL^LQ@RO
MR:E)*2.8V]=*0>1\CRGX7\*?<X@ER=GE%/3Y^%Y,[V]T^2]GR*G=/S%[=TY\
M:02Q/"PHIC?BOA83.QO=?BJ^%LB)W7\U>WQ_-XV'!NLGIAV7G\6K,$W+B^3[
M!G<8R+%J\+*8SW.!7*VDIZBPQT*L;VFP3.!8/$>GK#L-RL +U)V/6PXCF>3(
MYU%5E()7XN**<OZ+B9W+V_0[ND7X?F]OEW^/SY\]01](G_=I?[?*7#BE5?/(
M^D$?Z)Y45/UE1_=.?5)*5%12RW(OP5KBR%:J?H*U9%14^TJ=N4>'%*K(24B(
MC2S&HB(B-:60UJ(GP1$:DJ(B)^8B(B<^^J,^FF_OPG[[RAPXI5?U1GTTW]^$
M_?>'JC/IIO[\)^^\H<.*5^GO?([Q2222O5$17RR/E?V3Y)XY'.=V3\Q._9/S
M.?GAPXI5]6?D@'^S)_$=Q0N)[6?D@'^S)_$=Q0N*G8>)^":T_(_LL?[G=_*+
MS7^;!D?V6/\ <[OY1>:_Q44<0_??3EI_J;QG%<*W=A]?GV&XELS"MKBXE>1"
MGXS=91@,U@1CPV5T1XIM;DV-I/9SS6./60SPK!\8JRJSR$\2X<.*5'G<>RTZ
M*LDS[&-C9-JN7(;O$LKW!F5576&1VL&,27.[,MNLVRQ#\?IW5(Y=;6WV27[\
M0K&3#BT %FZLE;:!AUL8.I%^R,Z-K,&WJ[FDV5=UM\DL%Q7VNR[,@,^I!Q?&
M\1P7'YQXJ\=CZ'5-7B..S:X ?XE L:R,G*)\O@(-#)DYX<KE'+U/CSYWJ<RN
M9'@8^%1[Z[]F'TEZLCW6N'XYG0]CU :D%TULB_M]E9-D60GXU%6C '6U;;74
MADM9EMQ-74UK8738R!H;2CJ5I:FFJH)ZDFXJ_9H]+]=GQ.R2@-@Y%D\[L@2*
M3*<Y?>5U>-DV846?6M?65A-,T<*O?EM$RX'&8K_2RVMW!#(T8Z*(20#AR<H]
M(U.G+6F8\SS_ %YZ5'[K#V9?2GJ+8&J=EX;C^9QY/I*W'O-9.M\X.MZK&;%V
MO;_7%Y-#4D!L&)7+:K()K?)O4*]9\FK*6TI_<@P,M87C6>R_Z9J^WM+K&C]R
MXB7<;/EVJ>/0[2)=42W1&Q:;:QE$E#>T=W2LPX[/J*NR8ZA0'S3KF".W-LB+
MD8"R#D4X<91R]3SGXBF8\S?S\]:9UH?H5T#TTZKSO3&G0,OQ?7^PZS+*Z]K7
M9:18V8\N9"6M5:VU-D10/OVLMAZ ZOQ^GE0\@&JK<<HYX:Y]XVYNKO 9K[.O
MI<V,?AY^:XYG5NW L(I]7XM5UVW]HX3C]?JZBP*XUY6:VEQS765X=1FXB-49
M%D1R0%5\EU)=7MF3->25T@]2,^3AR,HZ^9^=,QO?77K]1;EM4?\ C/LSNEG$
M([02BK-DI57T-$Z^J;_:V7YR+=V^+W]U>8SDED9GY64WL]]C\.06N.U,R7+*
MX;&"$KEJY#8H[5KF-&Z#UUT[XK9X;K,"PKZ*VOX<D*'L#_7O2R'PS"\"B4=S
M1Q8X!_K>P''6R0-B5)+",X]7H\UT<:T<.,HY>IVTWH5$ZGGZB#;2]'#APY:H
MHX<.'%*.'#AQ2CAPX<4HX<.'%*1'J47MT_[=^WATG^^*CO\ +OQ=B_LPW[1A
M?\XDYK648U3YECMQBN0C/-H[X-0+0-D\PKB!EFBG\M"!GQSPKYL$;D?$]KD1
M%;W\*JBY][W2/?(]>[Y'ND>OR17/<KG*B?)$5RJO9/@G?X<J <Q)B(V.]N@Y
M?&K2,H%Y!)\PGY'X]*_/$7VOT\Z;W>?BUIM#!@<ILL,2P;CI[[/(J4T*"R,J
MK2<*4O&;JD(LZR*^H<>RH&HMY+"KK,SQG%\TK0P\JQNEMPEHX<D@'45 )&E,
MJQCV=_1]AXV&!46IC(P]=TY5%@PMIM7=>108O7RV]CD0"U<61[)M8FGXUDEO
M;Y/A-N0R>XP#*+>VR;![#';ZS-L9]AUGT.]-6GKS4N1:ZPS*L>LM$X]?XGJ6
M-VZ=[W=-A6,901 5D&/@8UDFSKG&SZ:VG#KI30+VIMH9)*BC>U&/HZAP3M.'
M&4=?,_.DF(DQRVIH-9T$](M-<5U]6:3H [2GKX:FFGAO<X2"FJQ[!MF,!45K
M\K?55@XY$(D$#0@8%CJZNDHVK[EHJ>O!KLZ$>DJ-,=1FDL9;]:E'CV.4'_QG
ME_@KZG$:JHHL2A\I,F2(TO$Z6E'JL5M[*,VZQL _(Q:6R"BR[*FW+M^'(RIY
M>I^=)/,VZTUC;?1/TN[UR;*<UVMJ.IR[+\TQT?$\BR26_P UIK<O'A@+*K2N
M#+QK)Z62C0FNMB@[$K'UJ3+:&*N2TG,=4UBB;#K+I4T%IS(\CR_6NO!,7RC,
MI(9\SOH<@S*SM<U)BJBZB4O-#+S);23+2[!AQEM<%Y"MB3=Y641FUO,;F<TE
M^YPW#C*(B+<I,?&F8C0_7UY[ZTS^]Z#.E?(\4;A-IKFX7&DR^ESYP(&W-WTQ
M,^8XP\)V)WQMS3;+K[VQ+PV"LJJW"HK&S+"PREIZ:DQ<2IJ:BO#'V>OZ.>FF
MJJ-CT06J*=E7MF$(;.X";?++"6S&KLFL,WKQJPVQR$L_$!P<\N+O8846$E8V
MT78U[=;!@\&8VIUU.YGAQD3R]323S.T]8TGG2 8CTMZ"P/*Q,XQ'6U3196!Z
M'T=R)8Y%(1"VMLMLW $?DF710<D8MIO3;9T39!G=ILYM5<KFP5;:]?\ APY(
M &GY[4))U)/C1PX<.344<.'#BE'#APXI1PX<.*4<.'#BE7U9^2 ?[,G\1W%"
MXGM9^2 ?[,G\1W%"XJ=AXGX)JC(/!,J.EABE5$[(LC&O5$[]^R*Y%[)W^/*?
MH0_HH_[C'_9Y=<.*BK7T(?T4?]QC_L\/0A_11_W&/^SRZX<4JU]"']%'_<8_
M[/#T(?T4?]QC_L\NN'%*M?0A_11_W&/^SP]"']%'_<8_[/+KAQ2K7T(?T4?]
MQC_L\/0A_11_W&/^SRZX<4JU]"']%'_<8_[/#T(?T4?]QC_L\NN'%*M?0A_1
M1_W&/^SP]"']%'_<8_[/+KAQ2K7T(?T4?]QC_L\/0A_11_W&/^SRZX<4JU]"
M']%'_<8_[/#T(?T4?]QC_L\NN'%*M?0A_11_W&/^SP]"']%'_<8_[/+KAQ2K
M7T(?T4?]QC_L\/0A_11_W&/^SRZX<4JU]"']%'_<8_[/#T(?T4?]QC_L\NN'
M%*M?0A_11_W&/^SP]"']%'_<8_[/+KAQ2K7T(?T4?]QC_L\/0A_11_W&/^SR
MZX<4JU]"']%'_<8_[/#T(?T4?]QC_L\NN'%*M?0A_11_W&/^SP]"']%'_<8_
M[/+KAQ2K7T(?T4?]QC_L\/0A_11_W&/^SRZX<4JU]"']%'_<8_[/#T(?T4?]
MQC_L\NN'%*M?0A_11_W&/^SP]"']%'_<8_[/+KAQ2K7T(?T4?]QC_L\/0A_1
M1_W&/^SRZX<4JU]"']%'_<8_[/#T(?T4?]QC_L\NN'%*M?0A_11_W&/^SP]"
M']%'_<8_[/+KAQ2K7T(?T4?]QC_L\/0A_11_W&/^SRZX<4JU]"']%'_<8_[/
M#T(?T4?]QC_L\NN'%*MVB"L<U[!X&/:O=KFQ,:YJ_+NBHB*B]OA\.7'#AQ2C
MAPX<4HX<.'%*.'#AQ2CAPX<4HX<.'%*.'#AQ2OG=$^:HG^GGWD;OM!*?*\?H
ML V+ANV]S8-:7&VM*:J/I<'SP_'\6FQW,<_96Y!93THT2QID$M;93#1WBRND
M@8. B#O09$?@?\);)],[9Q#1E==8IM+"PMOX9I:WM+O+]H9KNNO/V 2-,->Y
MQFTF#C:S'N:DRW2-<%(OB;U<;BK)F'1SN>"/TC"N*:9<;_:%XO#LTI5F0& A
M2RHQE((<&4@D$A0)! GY?$_:G"8#B.,P./97A6\*K (1BNT0\,0OB(Q!82C#
MMR^"E.%Q"G92<J4!0"DE11*!PY%5+UO;K;A&=[*EUKJRLP:FWG:]/..VQV6Y
M>381977;.*P\G-\LI:O'BRDP>GQ^!3CJ^@F.R8^XBD2 4&D\P\?!IU\;>6KP
M&MGP' @,MV3=[7+QFZ=6[DML3*USJ<L7'VY=%C5'BINP"7[&RB21N*)%7(!3
MXNZ/(KLJ9C8AC8.$Q"206X4"01F%BD!2KB?9!),3 228BL5?;C[/(("\1B$$
MLMO@.8/$MRT_C&^'X9?[1M$(Q.+=;98<,-K*L^<-@K$N/#D9&N]_]1NS.HS2
M4,&-4.$Z^SSIMDV1EFMLM-O@KZB* SF@HLNM$;-B(UA+D].:6VLPT J6NIKO
M&[*>WO/=MA&,(KE:;(K^7JXV'C$UW;28M7].^J<B%QYQ4TE(%=VFP-HA6EP*
M$B+%'9GU]57B%D-[RD# "1._"0L[%X5UI2DN94J2R7BF22$AWL2DD @*"@K<
MB ()D5W8/[1X+'A"L.SB^S<XJ.%(6\PK#YG58#_R*7TH>RN%@LY4@J0EP.'*
M4 @TZ+AR+#4W7AM':%U6G5&DDR+$<VH-L6N&@XD)L:2^QPW *ZUL,/K,ZRZY
MP\/6I\^SW5,U<*N(W)+<4N9A*HV6VE(62'6EZF\@VS@NC+W,!Z,;*H^L'I]P
MN[P_7V5;>UID&O+/,@3"C,;VECF0U-1:VQ6/3S3#349:FX9G 366C6!M:P9H
MX5\&"V9! 4 0HIDJ$J"22D H4#FC;^9,\K7VQX)B6FW<+B"ZEY*EL*4V\TV\
ME"<,X2VLM*[0EG%LN9&TK<;"LCR&EI6$RZ<.1G8CUK[*R'(-8Y<9K?"A]#[F
MWSD^@,*,#RRVGVE67=$7EE7797D53+6LQ=]-=6F(G1OI:X_WI3B3#D2D&R>*
M%/G3SUF;AVCD?3R3G&L->XSK[J.JMG#X<9CN8Y!<Y;6Y%JL8XNVGO:PZC$J1
M:2Y: 0+5"BV!U@.Z)##RHT(8$R?N>) 4>R,(!*KID0EU:@1,A24L/%28E/9J
MD B*LU]L>!O.X=EM[$E>*>;:9_\ 1Q@24ON<-9P^)4KL<K>$Q+G%^')9Q"RE
MM9Q(N.S>[.3+NGZ*?#Y_:X<BB]H1<;$UW$/LC#,HZC\6@$)U]);YWC&9  ]/
MVKJ 7,6 Y)99OA=8AF5Y/86=>0B64$>.VX<D)5:K;*L8,4-,_G8>WF8!48]<
MU>N-H[3#R2611FZHQD'*)P15"CL!K&S8=>TC!*XZ&:-@,S)2'23?B2QL1/%R
M#AU]BP\DYP^MUL  @I<92TM:238]UY!%P;F4BQ/:SQQA>/XM@7FG,,KA+>#>
M6ZY=#S&.5B$-.-H #Q 7AEI4H-K9E24I>4ZA]IE9/T/^_P#U+_[>W#B/:]VB
M3LVCR*QDUMM+6;Z>202,/:&-A8S9V*R5ZE(?40 7EVTD"%SD@D)?,.]I;'1-
MB<C?&L>^KNJO.M:] G3KLS()B]C;+VAE8NNQ+O.#\CM&>]K_ #K-H$R#)IL=
MK+K*;H3'\=I)98Z>BKR;NY00*I!\F25"(B,,XX#EC,'FV<A,',XAU8,^R$I#
M*LQ)$"^@-,7]H.'X(MJQ#BD8=SAN/XF<3E/9H8P&(X=AW$%'[TN..<19[,!!
M!RJ!()3,M/?M_P#HJ_[.'(4MT;7W7U"8ET^8I;8/2X]7Y'U7%:NRX$R^W+K"
MCVDS'L:L,BQ6UII'T-)G5=K7(JUQ]L<D[2+NHRO'JRJ\BQ%D*-&=;T0;'WYL
M*??#=KEXC;8]AN]MD8!0'5=I:3W50;BMM6@NQ(86?'ZT4[#Z:JDA?49)8'S9
M1:V$YWOD.+PQ$2ZKP+B,.,05MZ%2D9N\$A[L 4G1R5A4Y;)$2HJ*DI\_ ?:W
M!\1XI_X[#X3&E#@;[#&]@[V#BE8%K'N=H5(2EE"&GV6T.9W.T>4I)2A(:6\_
M_NGR[IW_ $._/O?_ +^0SZ&R/=F5YQU$Y+%8]0F4W."[<ZC:S!;S(-GPA=,@
M28IZH7&,&R3%8;$[*WRUR&2S02BXD;5PE152>>Y!GLBP6,;-ZH,SKO9V9:R3
M",HV?G-7N<_');S+LAH\9S"@)U#C[X,KVQ'1XU T._KY9K.PGQK&*FW DGB"
MBJK020HB8:PX>Z5N)"VX:S!:B2!F3A7<7%P  4-*3*BDA0/=[J\O$C[<853.
M'>/#.)#[TM'8!.'=6%,*XOPOA"G)2T270]Q1MQMEI+J74-J >25")M>'(K:#
MK?W9L;&-))K356N),VVAKS>647L.8YED=9B^,VNC<P$Q>Y<"154UC:W-7=/6
M=U4(X<0U)S@5-.%%".FEM,$]H+L(L+$<SV+J/%Z7 -D]-NS]^X-'BV8VMQE4
M3=14\5K?U&4I:T=;5 KD,:S24C*Y3W5<$@*61Q9,A< =%8#%HG,VD1GL'6RK
MN*?0>Z%%0,X=ZQ%PC,)2I)/4/MQ]G2MI)Q&*2AU#"TOKX=CTX9*,2QP_$-EQ
M\X?LVX1Q7AR5A2@4.8MMM0"D/!N5WAR(?8_5EMIV"Y7B&XM<XQ2_@E])>:=0
MV %:GV9F5?:UU5CJX])889DF0Q5M7;U.0-#R$ @?+,4?Z-TB$#0C,7\4=J?5
M[U#;4SBMV_AN(4-#0ZLTOO[IXUIDN9)F61U6S;'+K#,\"R"<FDI@P(JV;$_&
M?%CQT!UN(=9P$26HWKQ&R@\EK /NK;1E"2M0!*E)RI07&V0L$*[\O.!O*D$Y
MA%S(33$_;;A3&%Q.(2C%.*P[04,+]UQ3>*4\<+B\;V;C*\/+#?W/"_>>W7*$
MM.)*P@E(7-)P[_U_:_U_+C NMP3>J!ZVR+6;=DVFM,7R#)+#=V*:7S&'!=MW
M-%)4MAH++&;R9&O,K<>*]XG6^-AE!%W#W JV9S(%6!NMEU64>&#VNYM83YCM
M&BQ[H'H=D8_:;"SK)7R9*E5MV?&)Q<JQ8=&4,&;MEC+BR'+PA&6YA8TH#B)Z
MY63NAG!N/MH6V0HK44A(*#"@M+:4K.<%M2BJ4A:05)&9.821TX[[4X/AN.Q6
M$QS3N%1A0VX,0^%A.*PYPWWE_$X)MIIU6)9PO[AX@I4C$)4VXEL*PZL1,/PY
M%CE?6YNC7./;NDS_ %;KH?*]=8UT^[!Q@#&LPR2XH#\0WML)N#1U.06=A35!
MOUU8VHYI1$]6$VI-F=#% QP[4))4C;W5ALC"<AZA,>PS60.5?@-91H2D6WA9
ME5W[EQS;&.G7V59[EV.XP"9?V%-@C!(725>+Q.L31)UGGE&BBEF;!P.* ![*
M0I*5!06@I*5##$=X*(G_ -MA)!((4L),$&+_ /RW@O9+=4]B$!L.9VUX+%H>
M06AQ@K"FE-!:83P+B2I4 D(90M1"7FRJ0;AQ*M(9]^"CJG"L^][X7?+DM4XY
M;C7=C;6F&6"L-*$<11E7U=574<+G#*A0%J##85)[2ZHET\@2DS*KSE(*24J!
M"@2"#J"+$'J#:OH674/M-/M*"FWFT.MJ!!"D.)"T*!22D@I((()!%P2+T<.'
M#D5I1PX<.*4<.'#BE'#APXI1PX<.*4<.:E;'ECFOBBG>QB1Q.1K?#V[N:JJO
MX9KE^/YJ=^WVN8[WL?\ 29?GW_._O?R^U\N1)Y'T^=3[QZ_*M^X<T'WL?])E
M^??\[^]_+[7RX>]C_I,OS[_G?WOY?:^7$GD?3YT]X]?E]0>D[]PYH/O8_P"D
MR_/O^=_>_E]KY</>Q_TF7Y]_SO[W\OM?+B3R/I\Z>\>OR^H/2=^X<T'WL?\
M29?GW_._O?R^U\N'O8_Z3+\^_P"=_>_E]KY<2>1]/G3WCU^7U!Z3OW#F@^]C
M_I,OS[_G?WOY?:^7#WL?])E^??\ ._O?R^U\N)/(^GSI[QZ_+Z@])W[AS0?>
MQ_TF7Y]_SO[W\OM?+A[V/^DR_/O^=_>_E]KY<3T/I\Z>\>OR^H/2:^>ZWP?9
M]764N>XZ%DM739+C^85@9SRF1!Y+BQ[+3'[:-12!WJ16'QL)A9(]\#WM\,\4
ML:JQ4V.Z6M"6.>S;,,UW7RYE/EU+G\EBVTR" %<[QYP+JG,VX\/;Q8XS*8&U
M@$$]\RI;9GB"Q!V!)0OCA>H7O8_Z3+\^_P"=_>_E]KY</>Q_TF7Y]_SO[W\O
MM?+ETNN)C*IQ,3&5<1F]J(4(G>-=ZXWN'X#$K[3$8+!ON9FU=H]AF75YF0XE
MI69;:E9FDO/);,R@..A) 6K,W3<O1YA^<:T"U[KIM%@ 0VZX][6578T]EDN*
MYAEDY]I:WXF4 Q9!2WL==DEI:26![L>R"HGC(A9'&UX$I0)&O:TZ$]<4N OQ
M':SOP1C8]B9-L7'2:XO*\/!UG/E,(HQN):J)"RPS,L4PU!1(XC*EV6E174\A
M!-E$Y)(X(76>]C_I,OS[_G?WOY?:^7#WL?\ 29?GW_._O?R^U\N:_>\3ER=J
MZ!FSR% *SDSFSSGF=\U<"OL[P5>,..7@,.IXX=.%*5A:L,6$%*D-_<RHX3*A
M20I/[#NK3G3"X4=)?TTZ0DN-5Y [ :]MUI0)E;K.SCL+V(O&ZZ-8W, 6:.U:
MZY#9+%&2T:_6UB0UC3?"I/>5?WG/3;I/9.<46R<UP0.ZSC&8*@6DR);7(*\P
M(>AMIKRH@='56P(A<0-J1,9#&:,2U7RO9*DD3ECYN?O8_P"DR_/O^=_>_E]K
MY</>Q_TF7Y]_SO[W\OM?+F7:NV[SG=24)[^B%$DH'>LDE2B4BQ*B2))KM5PS
MARDJ0K 8%2%NM/K2K",%*WV$(:9>6DMD*=9;0AMIP@K;0VE""$I2*2ZIZ1^G
MBBOK[(JC6P%>=D@^6#6@8USDT6.I%G84U?F"U>)-NTQ:AFR,,B>&T(HZ:N(G
M261[98Y'N<M[1]*^A,>JP:FNUZ%)!7["Q[:L!EI;Y'>W<VP<2@07%\GL,ANK
M@^^M3<>$:T.FAL[$L&O$9&,.*R&-C$43WL?])E^??\[^]_+[7RX>]C_I,OS[
M_G?WOY?:^7 ==!)"G 5>T0LRK74YKZG7F>=53PGA:"@HX=P]!;+A04X/#I*"
MZ$ATI(:E)<  <*8S@=Z8%)M0]*'3QC&S"=P4.K<?K-@DFV5G[Y@?9J(';W+)
MH[>[J<>D/DQJEO;6,@AME=5%.%:&^I)6<M[B9W2;+C>@-.XA#K0?&L$JJ>'3
MKLK=K.,6>R5N(NS>,J+*_=R3'2^:ES&84TE#O5I&DSO3)"J-5NR>]C_I,OS[
M_G?WOY?:^7#WL?\ 29?GW_._O?R^U\N27WCJXZ>Z$W<)[H2M(3=7LA+CB0-
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MY</>Q_TF7Y]_SO[W\OM?+@N.$J)4X2H$*)5)4"H*(5*K@J 409[P!U%0CA^
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MYMC8(^J]>91L$NL(N!\9%KR9JT0B$4@MMA>U%$UD1$['PQ.BDMXR7.>QR+'
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M\KOJ+7_7M_,E3_N^?&?\Z$L@I223H"9\!8_4U12BE1$1&WE;3Q%N?2O3A_\
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MGM=#86V"P6LCG,CJ;:WFIJTS'["=Z>$3WD'Z4QZ+' 2LKVL2V0SES@*@'*2
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M<;)@R3(B0;3:!L.X=J85M6HQ+;0L(%;1;)UOD.G-KC1O#+=4Y%>5MR'56@J
MR^&>O#> (T:S\YJ6$+X)!92(Y8"9^8WJ7+L+?>.4PR.-L3*H7$L=&;,^8N:)
M*7!\<$<(*UR/?$/'.TAL4;.S6PJKW)\55.A+KIZ<1,0W7M 7IMS&H;K;8F7Y
M24N-'O2PJZ;(I[6:^'Q:G&%B';CX8AH9PA'A'+J[^(3$K^BDA(GRN#G.ML'8
MVP1LEN*,I)<4LJ.&3$;6",)HUZYU:L@1$-J62I1*$C#HRG%(&D@F]S@5['33
M2I(3+O@\HA2"#*! -E)!((G0R(B1TO&N6)5"4SW"% @@9K@ 6$IC68(!$7N9
MJ8CI.Q\Z/ +V^CR(&WO,:)K#K<>JN:RPGQXUV/XSC];#?>C*E."(D'FO0AQ2
MAX)%,<@W9Q0\,3%>VT/6X8[$+60R/'1[!AED2YZ&BAUMY6#1FFRR1'Q,-@?9
MC2HI\8*."F/!:2R%Y<YDDD)G3-M@S3Z[FR,$N]B()UG&.)%26Q%5++;3YQB@
M4+RYX_$D\*A6%NOI)FJTHIT3_&Q\?CXZN]V@?OZVP'S;LOW/CH9ML>$0[WAD
ME<!#Z"/U-C"D\[)#,EE0.EQ\)ZO8XMQ#I&/;),Z3/$X4O$@K4@!:'$NMY0MI
M3<*24!06C6Q"T+2H=TA4D'TN#\75P[$)Q*<.QBDN,8C#8C XDN=CB\'BT%C$
MLN*;<:>3G;RJ2XTZT\TZTTZTZVI"54]SIUV7'A&:R;(K,9+SFRQZ"^N\$P6.
M(J;)-AYI8Q"U@9* 5\$A=9C6)P&Q'6EL7+%6T3B*_P!XGP6%P%'#():U/4_C
M-!;7V^]5:ZO=O9S87%?F=1DW4KIW%=@XG@R!J'+KS56$E64U!B8XS%C%>TV]
MIR\F9$YA,[WP5X0S\_9!=/.J=!XY7YCM\0L.NW'D@>&YQF;X+P7+3,I%:'E%
M+@-[,-!7W<.E6BDBBXO@6(OIOKYR"5N:[0@MZ.ZH!*"'CJ(V=)E^ZMDD8^P@
M*I)R&^,KA208AY1*R>Y.E %0*)\B 1"@I'#$*R5?*:G@5[_F[D:;0E2D-RH9
ME*6XX2I;BE$*424EL"22; 3<0D0!KQ+B.(XKBUXI]+>' 0TRQAL.A+>%PN&9
M3V6'P^'0 J$LM ()45NNJS/ON/8EY]]Z,_J;'PO*LPN)]4TFR,4FJ:ZM%R#5
M>=5;I<IUO9#RQ@5RF(I-B//6-9Z4NON0BB8C8C63P'SAV$DY3GN@RPP_*\7V
M3H7/0J\ VZ99YE7-&K"W1C;.QRA>B$MF&\N<VFV=A$)>+R!BERN==4S7!E,-
M*:[EEU$X3/G6J6;CU91%V.U-"T!]YL:>1\$L63:D)MZT FF=2K)$7=R8Q[Q;
M8O!&4B8*C&L+...$2F?,QF6GC&8IMS4-E@5ZV>#8%UBP=(=76L8<-'D4]R-(
M-5V9IGDC,2HMVC'N66,@8Q6MA;$0UY<3^XC.V4@D9=)U"DP0"=2".\F9)%CH
M2?*G(YF(_E3;0I4=8V4%$ C0"#9*B1/7T':3Q^#VRWLP.HC$DM4/RK/\EQK:
M@EK4/J[5F2@Z.VF#47]T(K4<#;6,(1 EY$7X9Y[1J$0+,(]CHO13C_&V?\QO
M^Q.<?WLTJ:OO.L+1L9E(P>PH-FW.6C'3N>9-!88ACN6TIH@Q#.S(6P19A9@D
M*]K4D2.%B>!H;8W=@3?@UJ?_ &4_V<P:7G$?R=VY&EB(ML#'SFV&)2$N2/XA
MF-M]#\)\2:_7#APYK7/1PX<.*4VWJ^_*V[7_ ,DXW_2#AO',E?9AOW:9_.9>
M-FZOORMNU_\ ).-_T@X;QS)7V8;]VF?SF7D[#Q/P36A_=(_Y'?\ JS5#APX<
MBLZ.><!]6'8O;9I[2_I:QJC$G.L[;HZQ $0,9BRE$D$[TW&,..+"WNZ8DHF>
M$8:)J=Y9Y6-^"=U3T?\ G"A]4$$4PWMY?9_/NAARH'=*&.H)$3V\MMO'N+=\
M]1-V5>SY(+",:>!GP59HH_#^&[<B0#)O 48Y@#-$[3'QCI9 !4 =%%(-XL5)
MF\':3H:A]T+[/\7'JJ\U)E"356!Z_P !KMJ]6.84J,GO,ZM'),?@W3MBQK(W
M."Q8:X'$L,RE;"XG+\I#B\]BUV/"020;[ J:BAR\ZJ&.DLGUMG*VZD#,K)6L
MEEF>0+4,O:WU8UI9#"3QQW]U*%$Z6^:0/*/+(,4LO4=U-[(N-7]&6Y,THYT"
MN[W)"P[FSDC[S%+BN VH\$9#$)A?(L^4'L?&WS(E?/X)FMA:^>*7GLZ3=!9M
MU#;FUEIB)Y-%46[[#++#9/HJTF7#<!P.B-S38V100DMB6[?74S3'5;3'O$.R
MDZI"1B^K;$FF%<5+CJU=T0D@1!@2HV$Q<P-,H2 ($'I>0D9&TI,F>40I24Y3
MWHD@D2005&3[:E"8;H=Z+M*T>HLNN<TZIZW06:;O;4Y1@&JK_- 1+BC$H8"9
M,7R#-M<I=VJY*);V:>=/9-"H,IQ^M-))Q6]K/43UY<L%!N1F]-&EZ&W)-B$_
M4MT_K3YYJC/L?R"*^QK;=#C9C80<BQ3,:TA$O);'&G&#S"S1UN1,MP1:G(ZV
MMR"+TSV8[)ZH-=8#J$[4O2M@-%T_452M)>6=I0/+/V3M)L8; C6YIL"69F:&
M6,]@-'<&PLMDIB2VE0#U8HGIH6[1M4MF[>F[2>4VE@#CW4GALN8 Z^VO.T-+
MVUI9986T^'9J4)Z2YL<2&L/2@75A+,=>U@XU5D=21ZBAF!M>)84LYE@@*<E,
MQF1:0;?PD !:94;3K(KH2D) "0 $W"4S^A*C,:"# M!$//M.781CNP8=OZZV
MC>ATN\MG9EG<N,!'/%RC$&7&J=>%6X9-R%)$]7'Y";94Q$X)<?K80G,F<JK+
M FM>S6/VLEF)48]1CY/CV5X=N[6U<F2M/E!'Q_:4^&#9C#CQC9(VORL$2KR#
M+*80:1L$MI7)&4V0FP\$K2.I@;9&FLZD,VOKP:?+KD:.7'I[R*PL\-J'PE3/
MR& :KE<-6'Y'56D?NLL9[W!ACHDTX14<X'DMQQCJ#V55[<Q#:Q.46;K[%;>J
M.KF@.AJ@11JM4;!4 55=#!55U6^#QB/$&!:.^*:5T\<KY)7N[;=FEL95'*(6
M8@2+ D&XB H]W>Q-ZY2L=MF5F!D#+R@I,F29T%@ #X#O31""7>^.H#873YLO
M6%IBZ8IL/-]KZYO;_'[+%+"366.B,E0VQLC((*PR2.KJWMK\@>_PF&6;JHJ>
M8:9KQ7ZZ/MM!T%>N7VWO?-\>(SXG(J/6E%1D9)FFULDK9DH\%UGB%4 .5:W9
M=QDDQ<CQZ<.5/==#:'SM;"U[TA@U_P!>?4[OW'\RU#?;&O+*ZNZ"2LPD.P+C
MLH[.&SN:\4_"J]3(E.JS#0C2[,2X@L%KZL:OLUGJE'FB>/.WT;8#:]*^F;'8
MP](!=["O\=B@I]F)52J1JS5UGYM)75VLR9Y9F8W;9U!&2^RMVOCO",?*;5"D
M^2;;/GXL0PVX6'71^T840R$+4)4H^V28N#!02#E*9$F /<P'&\=A.'<5X5A'
M0G!<83ATX\%I':.(P[A4TVAZ.U:&53C;H;6@NL.K:7*5D#4MT5%SMNUV5MSK
M$U)GF7[FRNO'I,,PW7^6ZCL:'INU54QHR'$0,#BRR?(<AS P6"5F52TE7[\K
MZMQ8%0\>8J]EM(-.H2H!RC* <BUNY'8^'7SP4AR"!1J'#A@LXUI;9" -$,(R
M5U3%)!?BG0"W!]5&R>V%*.68ITU]?E..WF\!RB\F6FIF5,5X442YTWFJ/-')
M*,!&U8VLE()51U16.9$JL>_O R1BL$]J'I'"L'RS".IS0%P8N"YF57U.\]>]
MA_%CV:->\J.^' 5J5)6-9=41>@C+\ CQ[L,@.9K(289'[L*R+""/: *0E)R#
M3N09@;B#<B_>-_,?'=43H5!2B+&Q"BK>!8YA!.7<!,4J/1WB."[PZ/>H;'P*
MT;'<AP[+<#V* 36P!QY!0YK70.I;4F*V$CC*L!&.%!)I22.TB 'C/(1Q4<\O
M(XO:N4H55U/PGL&C@N\HUOB.39;/!'#!#8Y2?3)%>6*0#*L$<AMH.:7*V)&M
M9+/(U&-[*B/&]F)F6-@[\SC J0DQ<+W1K.\'I('L=!'*6%Z!EB!.Q92(G$4Y
ML-7*.2R9\[*][997-5TD;-6]L[J[W=:ZDV=! V,CR\NUGD:QO1R(91RPWM+.
M]J-:]J%UUS-)&YZ-:YK$1K6]D3A4A]29)"DYT@V,*2@D1)B,DF^I$29-9+[V
M&).4E) .6XE*@)'*4JGJ#Y>I_P!''Y4#I-_ZL'3U_0[A?''\;AT<?E0.DW_J
MP=/7]#N%\<?RR=!X#X5Q4<.'#DTHX<.'%*KC?C\/[+%_*LXI/$V&_'X?V6+^
M59Q2>5'M*_M^%*T:]_)*3]BA_BKS$<R][^24G[%#_%7F(Y:E'#APXI1RN+]E
MB?=8O\XCY0Y6&^R1>WS]4-_+Q\4KS8M,U[JKJP]HMD9)K0!+;VB6]ZR*>5B*
M/&M!9;D,<Z67NQS6RGY)5C>6DB,E>R&-S5_")R([=^:A7_6'D,-(3(H%MLD^
M,N-71.\VDP<(40)Y#W+(V8JYODM#9FJZ17HU/,:H[.[Y8-NN#PC-NL:SNV!A
MTCNK_KAVZ1-&9(-;'971;O?B&NJ.89S&0+0$R 6EX;*\B2<J>I4*,:1LBRI%
M;TN8[):YN/MJU@A,;#:V1T\]N-"9"8A4QHPP[1IF2>!2;J VQ,^"23 A0HU6
M)$CUE,9WG")L$A-M1$";_P LSR&]P/0 4$-(!%CVA(!F"K,K* .Z3FB01JJ-
M"%.MS?,-IWM60W(9;ZX!E$=&*9=S&&>EBB@:-&UA!7G*- / B1,'%>P6.-K(
MDB:R.-&X?IUSZ?7F1C7HL\8QE3*T^NFE=)&J&01JHWAEC:Z1CI)XT<DB,1[%
M5'(WPIXN9C9^:9#34]GC,92R.LWO:L2?%DQ9TCDEE@1_=&*KGJV5$3\/"UCN
MW=O?FGZGUI?9D3;PUX3G#8U6-MLD/GG'!!JX)%\N*0RQ.G@$@1TWAA%:YZ2S
MR_B,;'N7P+6V6X2$P;W@@\[ ;].IK:9O)@_,&# ,CQT,@W-I4;;4UUO[H;V+
MFN)[*QH#>VE+VMV!188$PN;/3-<48H%B5DH%<SPRV5/29185DA3*[USZBDCO
M;.> 0*)[B(-(NAP3=NVWF9%L:SP ;/L5+S)^1Y7C3O309D9)5@ 8[ WWDB68
M%G:>K>/=P$>80&8.^< 8@0J/DGNE,GR'3^?81D>-9=+!?4=J!:4B@3/E-C]%
M(V.S%:[PMB*KK6L>;4G5SUF&LJXHBNEBE#FFA?+-DGLIP][%](N1D[U@U?@^
MR-)4_5/1Z_DQH>>2B-L,-Q<_("H)S)!ZV*B;96P4!M;>GBABM$I#Z"#SH[Z-
MF0<["840E4D*RR1F M!2=P"#I<S6;B&UPEP=0"HB2F"02D@D7-P=X@VJ,F^^
MIVLUZ2]0C9ILG?\ C-_-O37AD+:K$<: .=6S6&.1Y+B>%9$%E),R#E&VWN6X
MBN:P!98;6N%(K;&*&N\1:*>SC]G-JZLV8[)NH]MYC&NM6XSD>X=LW@]\@U\R
MOP@''JO#M3G8[-%#*)E.8[FNZMEC6!H59I0@!J#'5V),DB=#4FFEW%0Y'G6G
M-\[)WY9:R)N,8M,2%T]EE#BF99'JZI22EHJ&ZM'"F7M7 JU=5A-AC-Q<5<L;
MQVAN* 6414?]J'K#7?3KHGHW=J.$JK W)KG.L@VZ^U18,GR;<+;W7&9Y!9[(
M7R0CW9;5&Y#8590-@*,37LKZZ B-BUHKVU0^ZYG25SGB=C$ &("=-1-A:^QJ
M$-I" -= 0#: -E3J!EG>28-Z0;K#]I!0;.K]8 8'0R81%J(':%5CM<0H1!QM
MCF-Y5>[L[L/1,9$W)0L+K%Q0!6I,RN!L+!L!4J%.BB@:O<VGFS,FY57PPEN5
M"T[>%R"HUS$=(]?CYD#>R.5?PRM^/=5[\=U98309036J-.%23V;F1(:9)/($
MV9\K(V/*G:KI!.\JHV2:9LXZH_XI&Q$>UI6R\8=C-W=4A<@TQ57/.SS17I)!
M/%XU2/RYT1CG1N:[NUCT1R=G)V5J=UU:2A-AT%];$"+:6^9N:U L F($S>TD
M@S>=YC6"1;6E$H"HF6+'5Q+65Q#/%*--*R1JM,@?&3 ]$\37MFADD#>WLBS#
M/>R1C6R.3D7V>X4FL]F;&U?+416F,8[F<69U\*2.!&M,:(#BOZH>!J^20RNG
MQFP%\YR-5K3PIYFHKX)&+*3J.JUQ58-)EF1VS)KF$HJ&OQYI2/<Z<7\-VD#'
MCDGAB[R1>&6608144A'K,]J1JV#K+QNTN:?$>H49ZDOBR:IU?DCX V)#6 '4
MA1N#OF)1/C#/+1W51'&]BQ/6%D/=JO=&N[2CF*?YA .DJ$%,:<B/$UCB$DMA
M>I;DF!,IB%" 0>IVA)!@&NI_V.NYX\LZW< I214JJR,H^WH(FRQK"V#;V$8]
M>T%4C87/53Q1JLJ.P=,YD2R/20*0MDDRQ]H[?BB*GR[)_LYY]WL;,NK+KJG]
MG_-7N'2XR39V+CVDC98TLCJG"M<;CKQ89HD_%B!::!*<"=RM<T)PXR>.)DS8
MG^@A'_B,^?\ B-^?S_Q4_7YSH3D*A$2;CJ D'W&3[HK'$F5)_H!!&A!)-O3>
MOUPX<.:5S4<.'#BE-MZOORMNU_\ ).-_T@X;QS)7V8;]VF?SF7C9NK[\K;M?
M_).-_P!(.&\<R5]F&_=IG\YEY.P\3\$UH?W2/^1W_JS5#APX<BLZ.>>Y]5(S
M6X_MG^@"6A27WLG3SJAH20M5[W23=1&W('(C&N;XT6.1Z.9XF^-$5B_/LOH1
M\X5OJA;&0;'VV71]F-\>RDQ75G0XW:&19(2(XNNQX7#-M;F/#L[!K6N:P:.Z
MGJ!6OE\,;BRAHE>U)%>R-#/(*,<X@Q[XCGR!J[?MIV[R;\N^F_2#>=NFM1U^
MT>-IQ>DAV)-L:KZY;O9HHX52YL,\I<EUFF3GV!IZ/;'Z6"#$\7/B'\*>-U:X
MKQ2-:V)DL8O1WL38]Y7Y]F6)N?!;W/?#H \9":*V+#8)!)I* >$2)Y(]8:4
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MM=O7+_D:3/AQ3/)B_2H_VC?ZN'DQ?I4?[1O]7&8]-MCOEZ_B]*!(MKMZY?\
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%SJE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g62211.jpg
<DESCRIPTION>G62211.JPG
<TEXT>
begin 644 g62211.jpg
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M+LJ[DDBQG'?GFK+M<YLXW45,8HR5\RU-/72*(GT=C123)W]D;0GB%)G@EI.
M*"C%@G&3V*2&$N*/ A94>'RQ\I6A1M5(Y/TI9S;**&#8GRH98QR.22MI;'!
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MH=-;#8T4SPD4DA/3+SX>E/6R9(VJ2A!&0XK&I.A.P('E*!^,/<TH!/0 D^.
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MV?VF*Z6].&V"3S"C=<ZS;*5>W^S+9MES4L3@Z7]8]X2)98*56V91/RCK]_\
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M1S<5II"- W-Z(@]6M6JSB4R1,2:H4&EE%C'A-1L26)Y\R#@."W7'@1R 8#V
M@$>P:BE'.GSHC#F&PXO$-,=6(I';;CI,1M)EC-!5<PMMBQA*N]J)&";I&J,)
M"9.T)'3&'-&A> JR$CD$+@F"2L  \.<ZIIVJ:%KUFJRE*YA545Q&2%1;!!Z]
MC33$HNTX6'FK5QB)F94J1$4>O7'GKG!5DL2I>N//6+#CU)QAHH<-_53TD?\
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MTG]A&5,@/ND8I$1YJ[$?5Z7*$$%)B2DY!19!))8"BB"0!+))*+#@!9118,!
M644 (2RP #@( !"$.,8QC'/;QQRYJSJF+JZ-JZCC]5.I1&$JH;GHU<R,5Q ;
M@E85/6I5Z&(*UOA"?CP#&K*B^%D9GR8LP!A2+,?7+L>4( C0W'MCBA=VY"ZM
M:Q.X-KDC2KV]>E- >E7(5I!:E&L3'%YR6:0K3&E*"3 9R$91@1!SG&<<Z=:U
M:Q*Y*RL&I9ZVE.\)LR%R:!2UL."6("V.2UF6,3P1CS0&! 8)"N.$29X<B*/
M6:#L, <XK2Z.-G2U=K-(M6+8<U#A=^@=I2K4&P5"\P0W!^CM=B)/I>=9\6,Y
M,032GU\35I5GFFA5J$"XP(Q8Q@0J@^BML/!+2<Q[!/"%5A]\D/ @>R!SYZK#
MZ.R5_P!FPG,?VT056'WO%PP/(0L?/5MG'''+>K.G'''#1IQQQPT:<<<<-&G'
M''#1IQQQPT:<<<<-&G'''#1IQQQPT:<<<<-&G'''#1K\BSX<=_\ [@X__L+
M?Z._?FO'2_7IB[6XVBX[R4E(M:Z*:-G-@-?ZKVUC:>067KN]N%(V<^URHC=Q
MN[,UK)+15@+CFE.XMIDL9S(!*42PU2R2=&:VKT!.PX/MC&.^,YQX@?#Z\C#C
M&?WL9[9S^KFIG36Z]A12"NFO>@&G%6R9TW ZE74&@=9I-IKQ>76NS2*E<%LY
MV1LB]DK?%Q.\/=YQ/#7T58:^H4:QY+@Z?#X-<[^4("H'4X]Q_ACKX^0SY'4\
M*A@X*!O#KRX\0 S,02<#"J3U##IC&<:V>:9O.F=B8*WV=0UJU]<E>.JA6C03
M6LY:R32,*5S<,!3BW@>6!8M18<&XTP!+@@,- L0GBP2K()-_0YDU8E3KDBI$
MK3D*TBQ.>E4I5)19Z=2G4%").3GD'!&4<2<4,19I1H!%F%B$ 81!%G&:R.DO
M=41NC6B7!8M;ZFU7F-2;$7C1MV531(HNKIXN\*WDY"*PI97;Y$VAB;9%'IBI
M6H7L#LH;"'<M:>L:7<U8N:S5JBS_ (:B=>+LO48..N,_OQT^6M:Q=H7>3)KI
MU%8I*]4'NWF.T>KTY;:U]3-=;$,E#SJ?T UN5*/+#,*QG46=24L=F30ZPE8\
MQ^O9-*:L<'LQA,:U,IB2A<UKCY!::ZI[[I-%+KJTB^K7T;G4YVBL&P]6C+#.
MA6YMO:QZKK9)&E\,I.9K;-E=A124O"YK;)0 :97-IF9 6Z6IFY%(W%>SX"3>
MAVQVSCMCMGOWQV]V>_Q[_7W^GGY,QC!0\8QC&, %VQCW8Q^CGZ.*3G^?N'_+
M3VF9E92%]8JQ/K9'%0HQEB!D*,G&3X9QTUKQ=%"#VI6VV'6:A-VW<NV.M)AV
MVHHB7W4YP"'U:NGBU3JU"'!(X'P& E$1"-Y0-2M Q@2,9):8\IK N,!A4K4<
MV(.4A=,__6']<_\ VP]>_P#A K7EW1I@"BQF#$$  !R(8QYP$  AQG(AC%G.
M,! #&,B&+.<8"'&19SC&,\346J;^KI+9%:[/0O38K!U6MUA;^3TZ(6"\,YH1
M.$!U-KW"*4['S)4$D\M4C*>HT!)7#4:9Z<A<NE:M(4K">5@L=N,0BL>@L4C,
M)B+2D8(I#V!FB\884!>24#)'H^W)FAD:$1.1"\I*W-B-*C(+P+/A+)#COGX\
MIRZ<Q0MO]I]L.IV^%"6PM\=ENGNEXU99N (]=*4D:LJP[ : '%")\BZ+G)>'
M5.O(.R<:RQM*GSG"4T)>;K^4ZOTK2VCX3$)#[JT61&1[I7,DP(QE'C!^J-5J
M_P!(9+!_6D+%[H(\A"/[1B\N?$JZ _5&G'''+FK.G*5[.[Z=]7JH;;*R)NIW
MJ75X'6^RQY&<!K0;4T>@72FA9&N\ ,$!<K K8Z4UPER/N8K6LR$ ABS@. W4
M<KKZJ6MTEV:TKM&-UN8:DN^LC6#8+7IU39."N:[RHUT+G\"] (G&1 4/RAK6
M1$S/;PB2R(\ \X#G.<5K:,T7.,$RP,L\8'BS1Y+(/?+&9(?ND/WZ@LJQCYH,
MR0L)D \24ZL@]\D9>//QZL3QGOC&?KQC/O\ =GW_ %X^CGGD:=.=CHWMUJ]1
MNR,5#@ALMVO&&5J6W.!X,89$:1E%,(PI"/\ 3 MB\M1/<?6ECQ@9:EM,"((<
M^[$EN3HZR(KH0R.JNK#P*L 5(]Q!!U*K*ZJZG*NH92/ JPR#^\'.G'''':=I
MQQQPT:<<<<-&G'''#1IQQQPT:<<<<-&G'''#1IQQQPT:<<<<-&G'''#1IS7;
MZL72LTQ>8W(=J(9T[&78C9*;WC1J":-$(<=AHTHE#=85M12&65:TBB^O,\AH
MW230J$ODAF"^<JV\9R,*%8\2E8L;,.6#]B(?P^'?](&>W?MV[##G(N__ -O^
MEV^GMVS\>:=L[>>@^3 +A=-\:>LK7'8C4R>S^N9MJ^Z[);2#MR2NEEVE/K1B
M;Y1<=C5OLRJZX=>SO+'69061M0#V>-)'L48=W6-1:/M9V%'0^.-3U^0?*M*I
M! ^A7DQ!/ACO$."<#S'7KY [6E#4+3FLM5Q6E*#KF,U35<(3JD49A42;_9[2
MW%J5JA:N5#R,1JQQ<W9>H4.;P].:E:ZO+DJ4N+DM5*U!APLD2$]\3,#XIC#>
MV.LD3L[F?'VMZ=5+$SN3X4B/,:4#L]HVE^5L[:L< ITR]T2L;RI;TIIRLAJ<
M320(SJQ^CK&,1S3!F/;]2)KI-$)19-G2^NZ*LZQYY9EH-U?OK\49%Y;8SK8\
MGE,F89=.4A Y&X0HU8E11(E6D:4*$)1>5BZT_..^,XS].,X_CXFHY!Q=@26(
M8Y)QDG/7/%F&?;AFZY]8^.M9ALZFN]9^M>S9<J+HB,;1$=8J'=,^K7"+Q^23
MJGZC;9\^4TQ&R-1[7!")#;/R.;Y1,79L>I0@K\4H>3&=*XL;6E*+:5$Y]2-^
M5D4H_;UYZ@MTTU$!Z8;GV+JC)-@ER1OIN 3QG1MM<26LY>\L2^1OS3#)+(FZ
MT6:/.3(B>5+<8^(O$WB#E6(D&6Y3TK]9I956RM4K%]IH4>S6UQFZ[[,&F;$(
M)[6FQ:=T@CY'9S3S^!AR5$<Q![KN.N<>;7)OD2/ \NB!XP[M+JJ0"RSKSHM1
MNO%.S*H0)'FZ$=FVE,+RN"87YF.6++;=N"<.2)U?Y_."Q1MIB!CMDQJ9D;0@
M8(FQL4>;&1H0,C6B+1 $)3CV?]^G\/''4_<-32/"48(N&)&/5 QT3)#9SCHP
MXG/4\CU)(K+Z.]N5A>^YO6KMBF9]$[1K*8[=4,MBD\@SXADD4D:-#JE V=6J
M9GML./0.!"=T;5Z TU,<86!4D4$^+(BA<E5U=+NFL+US8M<*2</2[*[V3UJU
M/I,9>/$;'L3\DT-J66H_Q8\I6RM*K!)GX]SQG&6YS.9CL8%G/;$?>E=&XY#M
M].N%'(FP,L8CS7N!0!;8PQUJ0,C,WEGZD5TJ-*0-;8G2H$@#52@X\P)!!81G
MG&G#\1A@QB[-K4'Y[?4ZV"V^4F"<J0T81/VE&L1P#1F-#[<;GZ1VVRM!O#A0
M808J:%.6*H&MU3 RF5MJ)VP4:9D O#4MEBBP(2)++=T"/%(\%IY ?(K$&"'P
M[UHP?$:SK#$JL*DAYV[O(\53!,KY\BL88*?*1D'B0-6JT!2<&UOI.JZ&K1OP
MVP.HX)&H!%TV<!\X35&FQ.W%+%@P>XYQ<S"C7-S4Y_34N"Q4H'G(S!9YE[CW
M8_5_?X8_Y<B1>^ZU'4.[IX0X.SK8=Q.H?#'*,J9I43ZV'Q0/&/(!F,LOF_)]
M&9D0!"=I2I96PLKQG>H,P#(,EBU4V^#O;,T-6!.,:M(ZQKD^K'&@)!9VZ+'&
M@+N<*BDD#26+52A#WMF:*M G% TKJBDGHD: G+NW18XT#.YPJ*20-=KVPOI1
MK-1$QN9)$<3M5%U<00I8KE]#&\.RJ6S./PY.7EZ&V.X$.$Y[\6JR,3>>$S!.
M2A9*"9DXN&C_ +Y;'P)S8@V3J)"X]'U5MUG4,H=(]M;!IX[PV06?)&Z/LF'B
M+1Z(&.A!^ K\. 4:[+>,Y, (LF%%&^>#%&PM-=1C>"H96VR!)6&N$(<S(XX1
MC7LY[S(IU,A-LH97@D=N6P@;G!OA@&U*F-=D+- VI4L]MHD"1R4E@+,,S&65
M],W9]S4P1;5=%:P:^R.(2V*215+8OL-<LS+F1T7DQ$J:E=JQV50@TFQW1MD)
M);RGD+FL!(BA>J1D*A)E11";A-WW;M'+;DEVBGO,=$5*QK+Z'"C69S/:$\@@
MGVJ[,BF/T;Z.[:VB0(C%8_IA,.$W?=NT<MMYMHJ;Q'2%2LU9#3AC:S.9[0F?
MN)]KN3(IC-;Z*[:VF0*C%4 E$R[(^,]_X\X_BSG']/&<=\9^'?XX[]^W?'OQ
MW[9QGMC.,>[OR!-';I&.DX3:_;1PT&O6RF0#]D,+@MRHK.XDA1GDYD=(SE2/
MT4A2JS<>8.(KE():T",RD-3KQIU!I4]\9QGWX_O_ ,LX^G'QQGG=4KU:_$9:
MTG(*QCEC=6BGKRJ 6@LP2!98)DR.44J*X!!QQ()[FG>K7XC+6DYA6,<L;J\4
M]>4 %H;$$BK-!,H(+12HC@$''$@FE;I\Y^:INOO+T\EA9C=!G"1$[V:JI#"1
M$H@5+?KN<DN.&L?F&Y"!NKB\4SEA,C)P+)*25X,$$L&<"'=3RE_JOI#]>)CJ
M)U,X\F-"+46V2('L -$G",UUU$V*5MU?6B:OQ@6!*B*]DZB'V$WE& &4B,0.
M2[ BA!$/%S"14F7)4RU&H(5I%9!2E*K3&EGIU28\L)I"E.<2(91I"@D8#B3"
MQ" ,L81ASD.<9X5?HS-6\.Y?E&/L)B7CQ[%1N\A4>2Q#VZ=7]0RP?[IN48^Q
ME)9,>Y&$D0]@C'MU]''''+>K.G'''#1IQQQPT:<<<<-&G'''#1IQQQPT:<<<
M<-&G'''#1IQQQPT:<<<<-&O&<9SCW9[9[ASW[=_=@6,YQ_\ RQC(>_T=^_T<
MU<K]Z!^[&PNQD"V>F/5V<S+3I::O\HH*6CTGJ(4MJ9K<9"X/;)$T<F03%K4R
MQBC9*TM*B;YFG?&KU1:EV3M:)8XJ\CVCN.*"1X:DBE>$EHRH)&"2B/T/B!S5
ML9\#C&1T.1TU%33:FK_HBED4!V5VC>-O[.3R63.JFY'RN8W5J]8QNRTM0Q1P
M<5BJQ<TEEQM*$:,MP"HRH<?,$>H 6+& 8E7QQQ-,)+$DXR3DX 4?N   _<!K
MHME6A6U,PE\LJW; A=75Y&2TATCG=A2=EAL/825Z]*U(37F22%8WM#86L<UR
M-O3#6*R0GK5:9*7D1QQ8!<!4-[TEL/#E$^H.WZQNV#$NSC'3IE4L[C%BQ8I_
M:BDQKFR&/\2<W9K [-Q2Y$8N;A*L*TI:M,,\H 3RLB@1UC8LT3+2U>RRE1>C
M;!2;NUQD\\D6OE+1_82;1"+P2YXE.CI<ZU-(51A$H@3 Z1MI73ST44LEP:8X
M6K=RZSFJ5&L:15-8M.[F/HI;FS^Q6B0O,"BNT\H-HJQY+43/JU:-W:H,MJUH
M.#6[,ZQA$ JI,U2N9*2GB/E.Y<!@SC*8PD;).H8D>#2A+:M^R:5"Y<6(SM4J
MV+(A#\#,8(FD$0?@_$R%>/+BW'.>+8P8;TII[9<W!8S.]2&>98 _#OC#$9%C
M#]V_%I""N0&*C#=VPU\Y^STAU5M3\H)EM<HC7F^;*W7U;H/6>,)\&^KE&P-Q
M:FUO$Z^1(PE $,P3&:H<)HN#C)80-487&FG$E!$8&UZF9CK/TKM9:*U)6RU=
M/K9C$30H3:\KMJ-GEU6W:$B/&_SR7BBC(#+@6KFDV=WEYR\2A0VHO(4E &Z'
M!3X%G1"HB[?G-]1*K52A \T[")[L!"5=6P"$2ISD9]/R-X#%(:C<4%CR0DN7
M2^0-9*5X?&&92LE8\,[\Z$HD)26.IB4!7](RA-3*(UO3+S*QA*9/*'P9ATKL
M>1JU4LLZ9K31>)4OE4]?C%LA=#E9N/4')L+"&T!PA>F0D [!QR]3<MVW>Y86
MI!1I^CPPQO=DFL78HUG>5F]$KM6V^2Q*_<H)'G:M'"43"6 &#<Q7W#=]SM3Q
M5H*-,P0PK)<>>>[%&L\DQ/HE=JU"2Q*X@7FTYK1PLJ82P P:*JB);S[<!#\N
M'T[1FD%H@C'"X [()3L_+FLS ,Y322?D@-B54DK"19$8@BB=ZD2,8AI%B_&0
MYY+BA-7*.UI8CF:HX*VL"IQSDZ1RQ8(Y[GDP6C%@P]QE\V=AJI'(5AYV,GB]
M<O$E)&(04B5,5@)89!8QC'NQCMCZL<<WJNT5J\PMS-+?O@%?3KK++.@;ZRUT
M5$KTXVP.4=.&!'P#(';+'8J[36KS"W*TMZ^ 5].NLLLZ!AAEKHJI7IQL/K1T
MX8$?Q<.V6+&,8]V,=L?5CCCCFIK4UAN\J!J;8Z#+*]MZ(-\K8%!F%:$P[S$C
MU'7@K&?1R&*OR013K&Y"WC[&(W9J4IU(,XR6;YR<9I!D#"K V,T!&6V7:JE6
MS6HJ082&V^FYL-=[PI%JR+ $Z:Z8\V@&HL.&-900ECL=C(&^I"L"-?$)N,ID
MV+5^?@PHLX RC0 ,+,"( P#"$8!@'C(1@&$6,A$ 8<Y",(L9"(.<A%C.,YQS
M+N[6EB47*LK4=R1 B7(E#"6-22M>[ 2L=RMDG$<A66+D[59ZTK&367<VQ)Y1
M<JRM1W)$")<B4,)44DK!=@)5+E;).(Y"LD7)VJS5Y6,FL!31AIO<K7*:0P+V
MPV#35^5I)H8N>&!:C=VQTC,T8UC*N4(E)8QEEK4):P1X0&>4L;7%* "@I,J(
M$ $)>CQ;4PE>IO[ 5NN UE^Z/V#+=/+B$J- ):Y+J@4EH*]F(@]\G'(YS52F
M&R!*XCR,#D<8N/+,'C L\[9.=0+$H:5/ETZ#NS-#'A[6F/-C:P2=0-'05NG"
MQXE2MA3D]L5#8"G&!>FDD? 4QKU'DD/"%.C&J-.JPB6]=0Z]]5E194ZP]:ZQ
M7=BG2JZVBJ^TTYK*Y5!M?KJD"JK"9NQJ5&)L>8S:U4N[C#V.9LF5"!]6,;::
ML$B.'A.5F_E;T6U77=TCV^UAX'E,A_)UV%@'[^I9<*.4+H&DJV.[LUHGGDXR
MUD]*>B-V]&L0Q;ND>WVL/$92Y_)]V(CF9J=IPH#1% TM2QW=FO&9I.,M=!:?
M9]XY$ZL]Z=1;DFC/7=7W]7<WFT@PNRS1MA=3U;FX8;6Y4[+LIRA(RP"],VHE
M:PWQ&![$D&"QWSC&,R*E,UAT&:S'N:RN-P]E)P+)SO*7QKCS85@./$(1BYW5
M(TP<8Q[\YR;\.;D%ZE9B>>M<JV((V*2306(I8D=0K,KR1NR*P5E)5F! 921@
MC6Q!=I68GGK6ZMB"-BLDT%B*6)&559E>2-V16"LK$,00K*2,$:[/QROY_P"I
MIJ>G<E$>KB42W8:5IAC 9&-<J]EUOK,9!GL+)KS'&W,22%8%WP-0LD1"<K&,
MC,-"#&1<K.OOKO+H?*15C5M#MZZV5"GTK55[K,L7!>*DXS'<DM10.N!$[D#*
M9V\(CBI?,8OZ;Q8"J$3V%D.9-VDV:+(CMBXP;@5VZ*;<,/X<'>FDT439Z8FD
MC /B1K-E[1[.F1%;]-93Q*[=%-N&'\.#O3CFBB;/3Z:2,#S(U;7MUMVDU435
MIDRN7BQG"S)#)&%O1-LO@\(2-((M$E\R=G5ZD5@NS%&FUL3,[8M-/5N#JB3D
M8)$(P[&1%@'@?6#J8QO9BUHC6;352MC2S6/SQ]8YNT7%2EJQ@TRO ,@WUI4G
MU1+I4)O= 8?VW($CF-">(H\"DLDY,+S0ZY&]="==7J?4ND<+!U:9HE6L3>%,
MZBM7N<AKB 6D[B @.2F )@"E_<7@LQ6A'CP1N=R\MT-5D$DD-9*W!9AD<NF/
MTTNM3JY8[[L=2FO,*KB1-3$[Q8R*;%RN-1H4Y1JRV]6N0-3$UN#V>2I5DEEM
MK;(G<;,C"88M2%NJ,LLY0' DW3?Y;WI$%;=H:)M5&BHO1I\Y*2^BBUR)BE?O
M)2;+1-Z?$$#1<Q'P=3BO?WR:V;,,6Z05/2ZACV^2E1Y24QZ*+/)NZE?G-FRT
M;^GQ"(-%W@C*.NOZ ?'-= OK:W]K0>4S]23IVWQ02=.I"C76Y6S8*PZB--SX
M<8.32%L4O47+)%CQF>'Y>F*.P<!]($0\!Q9?KOU2-#-HDJ(RI=DZZ7.2TL(P
M1R2.Y4-D03!>'&$X6^2Y;RU9_B'@. -RI;@8NX2Q#R'/.FBWO;97$3V!5G)"
M^CWD>E,6/^RBV5C$Q!Z9@:13Y,1UUT46\[>[B.2?T68D 0W4>G(6_JIZ0L:3
M,/L&E'F"1UU8!QSUEG%'%EFE& ,*- $99@!!$68 8<" ,LP.<@,"(.<""( A
M!%C/<.<X]_/WG.,?'O\ P8SG_=C/-;6IKSQSQ@6,Y[?I?PA%C'\><8QSSPT:
M<<<<-&G'.AS*TZQKHU 18%BP2#'NI:@YL)F,OCT8-<2D@R2U1J M[<4(UA:8
MQ0G H&GP8$D9Y(3,A$:# OEB-PU)8#D<S0.T:ZFSNF1F.*AKB,WC,D<2&\HX
MA.:N.0LSHM5%(RU"E,08J,*"0 Y024(S S2PBA-BN).Y,\(FR!W1E029(R!P
MY<LD$$#'4'/AJ$V(!)W)GA$N0.Z,B=YD@$#ARY9(((&.H(/@=9&XXXY-J;3C
MCCAHTXXXX:-....&C7C.,"QVS_1G.,X_7C.,XSC/Z\9QGF,[AIZL[ZK265%<
M$.:)_6\U;@MLIB+\%28V/*,E00M)*592J$JL(B%B5,K3GIU)*A.I3D*"#2S2
M@##@O>#;=OTRI$FT?V/G^VYA*+,J>E:KJN-.C8P.EA6O=4\9Z^@D;^4CT UH
MC;:8ZNV7![?W A44U,K>O4E(ERH*=&?Q&DNX!FWL"MEQD-5/E)6C0E\V/K==
M%7N\C:IN5&;(KLEC<U(X]-&)&W()?%7^-2F-R)A?BFEI,/2.F2%+<F/3#\;7
M19$9)$5XW5E='4,K*PPRNI!!5@<$$$$$@YTK0]Y$W-%>)@8W5PK*P(PRLASR
M0AL'*E3GB?9K7^Z3_2LU BO4/ZC85T1?YT1I%L+55?Z\IIY(U#TGBR684S#;
M@42=S*2D-N)%-61_>#FN-/SMYWLED**_R50]F*GI1ML]NWP_7G^//?/]/*0.
MFB/&.H=US\YP+_ZQ->\>X Q9_P#I K;Z ASGM[L^_P"'PSW[9QWN[\T/U&?R
M)O\ 4Y%!5K50PKP10A\%^[15+8SQY$#+<>3<020N3C&3J"&O!7Y=Q#'%RQR*
M(JEN.>(8@98+R;B"2%R<8SKV<<]?FA^HS^1-_J<>:'ZC/Y$W^IR?4VO9QSU^
M:'ZC/Y$W^IQYH?J,_D3?ZG#1KV<<]?FA^HS^1-_J<>:'ZC/Y$W^IPT:]G-;7
M\I2C30T:R4Y>#2)'#;-JJZVA\AELI&<\Q_CCRQQZ02&),07QM0JEZ9$_2Y V
MMZ!*HR8WE/"TE885@HM6(6R-YH?J,_D3?ZG($]2O2-JZA6I,]UN5S%97SR\N
M,8EL,F(&H]X0LLSA+P4]L(WQD >A-=X^N&!0UO"-.M2K0(UPUK>>%>C3!%F;
MQ3:_MUBM&<2-W4D9PN>\@FCG506("ES'W?/(X\BWEK.W6FUZC-71N+DQ21D
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MODDG=9PR&LS#:VR(*HCTAK"C'AB"^'M=TUR!#94=>9?9C8IKINDC:4*.SO.
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MJ802$*>@Y*64'/4 <O81U7KXX \2#TUV7\WWZ>_[MMY_/RV\_M:X_-]^GO\
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MYLK3N<QL&5O\UE3@0@2-R==(I,YJ7AY5D-R,LM&WDJ7!6><6B2%EIDP1X))
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M:J39:SK^$'6=4C&HV.:ZV96EL9; ;8[-FN9JD405N[=AU3,B)N4J&\><$GO
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M!K8JQ?JA5VN-;:.6QO=LA2(]E -M[0;7JO:I5V%(J\C*-4Y1E',)M,WYPBF
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LNH,LA!_S?B"V#KH.RFV[='VBV=XZ%*-UN(5=*L"LI[L]0RQ@@]3U!\SK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g816723.jpg
<DESCRIPTION>G816723.JPG
<TEXT>
begin 644 g816723.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?24U-7T-%3%]+7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ S@&W P$B  (1 0,1 ?_$ !\  0 " @(# 0$            ("0<* 08"
M! 4#"__$ %80   & @(! 00%! \$!@8+  (#! 4&!P$(  D1$A,4(3$*%187
M42(Y05@8&6%Q=7>!D9.7F+C2U]@C)+7P,CBAL;+!0E)R>)+1)28G,S9(8H+(
MX?'_Q  5 0$!                     ?_$ "$1 0 ! @4%
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M^4!02NXIC-Y6 EZ>_+DJ2B>1)<*/1@@@DDHHHNZ#@.... XXXX#CCC@....
MXXXX#CCC@.... XXXX#CCC@.... XXXX#G&0X%CQGS^_C.0YQ^\(.<9Q^[XS
M\<?#/PYSQP/'  XSYQZO_B%X_?R'SXSG\<YQYSGXYSRMK7S\Y;V+?Q0: _\
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M39O>5FU#<D,OVUDQ\\K/L"[0'*]I]6.P]=Z>61.Z;U!8K 48K37C%IQ"\&Y
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MO\AN*2J\("6T^12BW)"\Y0)4Z!.XI6XE G*M4O\ ZN)QJ$4*:W)V&=']$+?
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MI$TPE(4?O1H;;O''' <<<<!QQQP'.,XQG&<9^.,XSC./W,X\9_[.<\\#,9$
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M/ 1 KU;Z,+((!*%MP0&&JL%%X4Q8)>&(_!8/:MX_0'P'[*+)KM(%R&JGD,3
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MR7D."M24L4@-]1'65<MY#6E00&%(DS(QOL89DZ2*,"8AIC<H/2JI+'VPHAN
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M.)$7%+BJ_%(U<5(41Y]<GAN6'%BDCH9U50[5VVMM+JL>NM,G:;;6)XBWR3-
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MF6;;Q%,J<C34[:E50:XDZES4$)S%9Z9N3'UL YQ/3I"C5AY"0L\TA(2:K,
M@H9@?<_;N>K_ #_^:I@_JZNS_+'F58@[ZG=A4LUJVJH#8N+V^PZF6U93\QN%
M.2^-2^*.4QFM)S&H'N+SD],6O7MPVR,6*=(D*$DUI7C5X:5A@U#0I&6IL "
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MD^LPNUXW'.;G?F[RV)42;#<TOD\<&IEP,GWK+2C196G*EV5"DX(0?MW/5_\
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MD*V/NV[=OUNM!O["=Z_ZY^/NV[=OUNM!O["=Z_ZY^69\^<[NS<PM;B].ZLE
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MYQY>D/P_)Q^3_P!'X8^'[WX?R<"LSJ'I*4:WZ+UC14TK.?U5**PD-H1A[8+
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M5.(&:$&SURM!Z>KA?FU^?G*]+==YJ[+#@V(YDQ@EL:3G)*DC_OC^[+3+%..
MXXXX$#-VM'HEM6@C,W9&>G&S9*K&6<Q^DK5NFIC[OAL$:[9;443M-*^527,8
M*@GR*1P7#LSM[4_/V&IG=W M_"D4FD')E6?]8J(8M7M=J/URB[Z_2:.4;54%
MJECD$H4X5O[RUP6.H(\C<74T.<E!5*RD(3A)DWI2(BQ%HD@ I4Y(<9TXX#E=
MW8-"]ZY,V47)=%I-"VR4559L@LJRH)8+P)OB%^P9FJZ:MZ37I_*RA/)1H+3D
M[LTM1$X.6%!K)X3M$W$V/I+6<AQ8CQG'G&<9^6?AG@41==.@[:USRE-P8Q-+
M@KNCXY6MP$:^:77)5"&)6YJ>;?KU'SK=H!_M$]T,D<HH6 2^#J%=0U,I9#&.
M).)R=]C<WD<.20Q(AO=YQC& XQC'PQCX8Q\<^,?A\?\ G'.> XXXX#CCC@..
M.. XXXX#CCC@=#M*Q(S4-:6%;$U78;(96$(EEB2YS%C.0-T7A# X2=_6CP$(
MA9 F:6M6:+& BSX#GQC.?&,Z#M96-,D&C_8K7>U<$MBMVS>B):9=EDG1[!HF
MAEC$F<+-W9JJ&;A/L*D:.4O(5M)-D$E&N:1.?)38B]LK0L7_ %M&VE(,E0;_
M $$'1K;7ML<65Y;T3LT.Z%6UNK6YI$Z]M<FUP3F)%S>X(599R1:B6)334ZM(
MJ)-3J2##"3BS"QB#GJ4AJZM9:B*;I37T'DC>0PJ(L2A?XC'7E&5&5:AI5JH\
M4E<VU406Q*53"R*3V@!86XY0SM1QB81K<C&0&F<ZI=)&VT)?5\$D]?XZ'%/9
M1K&TS]3"[$<G/3\FS7W3"])')X:KFB)\75^EUQ=-FTVM"^U$2=[^Z9+9SFC0
M/AR(:UV0YR50S9"+4TWUZD]3N$CI2E=7N]^DX/&*2IO9PO835>Q12G;G6LO+
MA!+)45Q"5T@U_KU7.)C]SU=1@P,+8)>)>^*G26J6AA"S;<8*HK N!*:L!74$
M!6:Q K:E==@A\<#!536X&#.7MJF'A;,1P]O6G&F&K$1K8-,I-,&8<4,8LBY[
MK97<!98PP0IGA,0:H=%3FA1&8HVQEC01J.GQ]<4Z,1K$PI$!32SF,KD00O:3
M&Y&F&VK22E:(1"DL!N T#[\D;FCE>YKI")-&B=AIVX=BS'V=)Y#.)6C;&6J(
MSVMZD0#5[]D(3%7<4E@]3M^K;W,6>++V IG7*]?7*S#XPJ,;/KA8GM>,G+\1
M]'SD"RG+ AFK;73VS:6ND]MZ]2=_F.O;C74([%X]"I59%#2:Z)'*'1KUDDS.
MM<Y1%&QUF#Q&8S T"J%)7UPKXLP1^T9]V==_6<W>OL)#</%EMR)HL5UQ%F#Z
MRGS2VMJEG;FR:KOJ[WN5MS>TK%;6B0OYSBE2-RI0A(*+2GFE"_+-65H*O?ND
M%7L'%5GU#B*_=L*(QW,!^S 2L$!CF(9EMS&L,(2,8)"SX:_J[!6,%X38#CQP
M-1BX>RCL.KN%2F>*=MX8W5W9.\_871-;6,?7VIU<Q>GHOH\MN=JJN-/-A74Z
M--;3$W9)Z9V>13%0XJ S3[MJR?8]2B<4\D0Y(+'&Y/:UM;8<IV.HJ ["ACXY
M=HKNTAG57PN,T\SKJ.M^B.O*'[(J5-*O#;(G7:&1"DLS4RZ.MUZ3E+#ZYDD5
MEK<32\.!+J\/G;ON-O%)4W(8H&"/]3UH]P@$@+E@8>[P*).<6#*"7$3N3) Q
MU<SGLV'\EV&)S*><(L.1;@(2T*G"D0C<^T;3]4GR=YFQ]:5^=,9$$H+_ "PZ
M%1@V3/@2(^OB9&'A_,:A.[G@B+.CE&R0KEAX2F!P6LP,!;%:A*8&IN=N=V H
MFNK8Y3F^L3=Z^?C9Y0L2G+;0-%SOW_[H.GB$;_E7,AD)>5;(_P B>+":G* I
M&X'O,*1162250XMCX_)HVNCGQR^Y#>J46',EB*=U5"P,6LJ>4HZ7=5%!MZM\
M;7'JCQN=C9&!0]\='#9"5/B6\EN4#4$M@5ZT8J:-2*&NRY;9Z-0Y@VW&:F:B
MCK4SL;!5M<L;+'O;_4#0SP6*MC6R>]1;[#J<-#>A:"$;9@^&?_5([W$DCVT8
M_P#H SUM'^Y\X%3%0C=RI .K:Y$^D0,RK2'D4&BHG8FM#0A ;7A3EEHRM+@Q
MH0 "9$ 'ACH\!#@3;G&,8X&J:U[1;ES':+2:"7MN\@:(\P;;Z+3=XD:*M:GK
M>/23.W?7GL39JRE'1+C")I<8GBQ*W<(C5!3X:\350Y6J0H,<Y%-8; 5Z';[!
M_P!$/[WRS\\?_ISY^/D/RSY^/P^/Q\\QRZTY4S[[M]=5C7COA&ZP]\2X=(1%
MW#"9ZKW!@8&[I_?&D[V#I"@FFAB+@5Z5<9P89AD.08,'ZLD8QX^7_/\ S^G@
M.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.84V+O^N-6Z5G]]6TX
MN3; Z[:DSB[B9&1RDS^XK'1U;X]'(Y&XVS$J'60RB529X9XU&6)N)&L>'UU0
M-Z?&##\"#FOD6]SM:4^W.NDYHW,V<:U>'U?!)9"K$:VA'(5<%LFJK"BMJUG+
M1QUP4HD4C0,4\A<?7.\=4KF\I^:2US5]8MPU8%R<*SZ9[LZ^?HY?4DMZLK;;
M7.*[L7EK72].UC0=LRW8-^@5#4O45KV-,;&J0DIRD4<<ZX+L!T#/UF"&ME3I
M@1= Q(G1[D#4G>)=UYVE:I6_=$;INHG&R[4#(HU6,G-M:OJFFTII2+)+GK-;
M<57$SFQ&UO-20W[7URA-D29W?F])%VD9B5BD<A9I(K3M X@L?4%:T*DC[=M?
M[JXCVUDKV!V@NA_M9;KJP/5?#9=N*KI.M+6KIOJ0ZR4ZE*CC2JAX1-:HD2FP
M5RYB>FM*VS1#/F<Y[3O7P8IT3UE!;EU,G41M9O9X5J/%:;AT-5H*?9X_LZ]Q
MBJ*\60-TK*2;,PN714R64O<1CDNDMG0:Q*QGCLE6*EL=K>70*'*RV)&%B6IG
M87KGNB[2QDIE;8!#A'8W%["906-6$SK(%E4].GB1Q^#7A5(IBW-HI]4<N>XC
M)&QEE[.'V8U+7_OR1"4X-)J^$S-W=Z]Q&M6^T+R2S)$P6%C9RX*O#3]1699V
M&W3W7J_@T4?>]H+V1$XIH\WF%#;;(D2TLM*V-L3DS4D;4[DZ),@=,G]:_5C&
M>O)9)CV^<P>PL!KB#TW7;NRT!"JLG;954$=WIX0%6E8#2\2*16M/'HUP:R)"
M^%'0J$G"C+:[,]<,S\YR%T=8"Z^=5\9O_7>Q*B=;@?XF*GM?^R;J-*5((JW/
MY!L#LC:Y@GT5M,@]2ZLQRI]BD'A$,8ED=4HTB1S?%3X>%U*3(D2AQ"Q@GN"U
M)4PQ%)T3;L$ODCEL1(]94%.(==;157NKL2)5@WWG(EI-1$LPI<*%M-&.S7<*
MJ6"2 0!@R](I"6)Y. R9B5>W=DWLJ6FK5H1H@KQK%.XGHM8$MMVW4TCAP8]#
MMU-R5NO[.O4)3GQC^RPV*L:WNFP3SY0E$F1J69@6KO:-)3B@60[[>FZO^JTR
M#[P.MEW.F>K)W]D]B(I;4\/K*2R>L\61HC']:);#2*TLY8DAMHL\KB],-[BG
M>'6:P%Q@,F<D4D2(YFE8C8J_9 TEZ9()=_6/KM#[PGA#Z3<4'ZU+'L&.DQO$
M@B#A6>I:-#,V2C!%.*]D4KHW88Y+-\RI\,2H5:!7.WGW1M7D(4N%(6(V9W9Z
M45/ XE9<M!L"5#)71YFRISRW:W6RY@A-#NDX<*[KJT;,2)V+"ZOHM<4I;5*2
MJU,F3(5,H;P_7YR5J8<#<02OUDV;=KFM/<*EYBRM#'.=5[Y00/.6+ZS^K)-5
M]E5C"KII>8XPZ&''ENSA#)J*.RLDDSW$,OB;Z<VE)4"A.B2Z??<-%DVG<AJO
MKA;+TNY]E^Y.C</TO@\Y51JLG:-2^ 1#;V3%ZXP>[UCRF%,H4FIN,6>\0^4V
MY6QTND=NQ,)#4;7,#?DJ>9XVD-"X@-SV"[*MA5"T'JM+;-GJ5E90D^DUGBVH
M]*U_1@3W _ O9G+Y).4=@28@!/M"T["YL9)IV%F%2-&%GG''' <<<<!QQQP'
%''' _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g514725.jpg
<DESCRIPTION>G514725.JPG
<TEXT>
begin 644 g514725.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0TQ)7U1225]+7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ _ 'O P$B  (1 0,1 ?_$ !\  0 ! P4! 0             )!@@* 0(#
M!0<$"__$ %\0   & P ! 00$!0T*"0<-  (#! 4&!P !" D1$A,A,105%E$8
M&4%AD0H7(C)467&!DYB9TM@Y4G-UH;&RN-;P(R@S-TAYL]'7)$)#<H*2\24F
M*38X1DE8:'B6HL'_Q  5 0$!                     ?_$ ",1 0 ! 0@#
M 0$            !\!$A07&!H;'1,6'!4>'_V@ , P$  A$#$0 _ ,_C&,8#
M&,8#&,8#&,8#&,8'F%VV>W4E35M7*[MJUY:JEK.>V8YM#<:02X.K? HF[RQ:
MVH3E6])BEBY,T&I4IJC>B"SS2QG;]WH68_RK]491"'57(+%N#BR[:P7+N/X3
MV_2T;':E"SS]>BC)I95;UHF<4CQ )<^@K=^3N%HQYSU'[,;(^Y*$*=U3;3I7
M5*4A4SX]!U>?=U#793*9Z!&U%MU'958D2(Q")S+83I]"GR)E/0VT"E$-P U&
M.X5XD(%B02L*?:<*DC9FC00QOG@+YR9_&/..'Z,8J9I2]+3H>AZFM3K".TPC
M')+%D=/R&NY<\3"5-1+^DD3DBFLH@ZA]61P<STG3N;L%8H4+E*(LT87T\C][
M.70-O6QS=<W.%E\E](5-"J]M5=55CRRL+#)E516<YR!@B]AP^=T_)Y9#W-N!
M)8N]1Y]:5*Y$],KH204>E,T<9M/;O5_G!X\M2K.A)"S25G:+NY[AW7,Y?^;)
M--8Y'YZ\1WD>2SI@E"]%)74**#)"WQ##"96(I0[FJXA$I$T2*5I$;*(;@+V+
MD#AJYJIZ$MWKWJWHZ.=%=#VA5=942T'UW3.J+K*M:=K"0RB8H8TP153/K*?'
MQ]D<QECG()'*'J3 T,)3:TMK.B2HAFJ(R7#P&V]+8H\53/>NH"XU-%VWR=22
MC$<9Y]=8[/(M;'DGBEKP![66/+%-L/*&>U]4\:M)X=&:/LS##GV5R):(EZ?2
M65BCZ9.$N\2\F/%D@MBJ>=7?H"L(MTG;4#K^<,5'N$L1KI00*R(4CGL7C)[P
MW%&Q04I>H\K^LXW']O9+Y+F@ 7N--3BUJ4R@SR+\=[XGM%JS1]UT,46A,80*
M1'/[J1[),@=ES$G7E:.9"]J&AJ=FY6@EKTGT:T04\L&ILNCP3TXC;/6KPEV$
MVV*P,?X3L4.Y;<>E.2NTK/@>Z87_ *]KMT/R55]:U\QM$'M\^QE+-%Z?GSM5
ML6ES\RKX&\2Z,ITKA$(E(4C<^+W(/F:3]3\2!+1RBHM].L1BT_Q=WSX[]2+5
M1+2R0/%U=5)NE!6SIN#.]FA0M("/LLKAX5NE+H>+3S]H4P0?0-A, M\E'"S?
M<UB<^+>F:S3W#54:FLLG<*&O<MK&5IKB')["L LIR U"87EZA$'5$2R61B/N
MSM)X\P&!<W1G3)?:,#:?%_.IX_9E>+[6D9N*,/58LU-1>RDW0S8[B75W)9E+
MKMW1S/2\.:DS69+YE8*Z0FH'!N*BC4]H79O6"TVC4";W,Q):/.?!K>=D],R6
M[9QV:U2:.$)>RV:N&IXKB>JY='(KUYR2]<V)8DI,%<FJH:H_2*I:W/$4^PM4
M1:33MG3*4UARMS>QH'-O[NUO XNFEM\F= 0GHIM@-R<-\8\J\]<UOY=:N;A'
MXU;'-=C_ &G<+(DD433IK;9/ [.@*Z2U>\UPL]%K&V216]-,HTX$%@,"4(SR
M;\$%RV^8*/J:I_M7S)&I7+[P: O*PPV!QV!*D:"P'-6H+;AH7@NO7)Q;VJP2
M(RJ?%<%=UR-IE:=H<5)*4?E=]^77C6F^)7KNN-6$3<U1'/$C@U9J:[;90XI[
M5M=E5/;2AK]@=R8NM);M/,A8%[*GE[FBU% G%A-3.*\2EN(71CB_4]DC$AZ=
MA7X1$!^P%F5=VY"Z0<5E66@]6A6KYW4_$R:<J9.^/-^K:]61N"*Q.;.@;*SK
M.N'.SVM:V.%CNA[Y&6U4;)UV;X]';J;D2B>4F.X9+5S15-@\WR:2/<(?IS!!
MS2*4&)M6&PTP$!DC&O3()"YL3(O:M*ERLJ'O3<T2YG#J41E@7)@LF7_J@2%*
M*(>>I(+QOT997-D%E=TEVI>$<5PZ.5[!JTJ&YF>FTDQ(=K14P R9S:P%CRCE
M\3I.)$+[!'$S@&JR0/ %K4AR#T2LE>D2K4_O-D+$Y"HG9I1I!FR5!0#BMF$'
M! <2/99@?;*-  PL7J 80B#O6L9IT\%W3T=K#B2GJD[AB.ZOY1:QV/**OZ0J
M&Q>E:\MKKE^7KGV0W@\L#Q>,.*U%HK)5ZB24[4KGIQB,!EJISG!J-UE3LK7[
MR8T!:LI$D*7J"E2XM,G L5$$;2DJ5820!4J"DVS#MD%G'Z,- 3LXW901Z+V8
M9L/MB#Z\8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,TWO6OCO?I\=:
M^/W[WK6M?Q[WK6OS[S7/ .IBK>4\_6FW4,RZ?K8>HP?'HBCU)TD-4HSI&I3,
M+J_MLD7*D2-M>XNP.+M)6#:A8D+4OK2VHQJDP5&U!05M55PUC>$1W/:DFS!/
MX;]IIK#?M%&UFES9N35W,GNOIHT!/"$/M*6"81QZ9%8@ZV28>A$H2FJ$1R94
M=8E7_F$\?]FV,T5;%K?EVI-))?:U?Q-PD?/W14-@4SG-(IY*JM"'PNTY;53-
M64MDT5(A\C$>R,$M7N#@-L,):2%Z@Y,2?YSXUN>;@YCLGJ2#I^>DM!\E65)(
M+=5-PU38U>3!]@EKK8FRP*]8WI#!'!W3ZBT\4PF*6ZWN0UH#MSV369]8)2Q.
M;>>=:%Q-X77*NX$=8G14GMV1WC [V[>MVBJ957RH?.::VDEW36Z4, L>-5XS
M)4K GFKO7=B?2'-6_+G?3(]O[PMTA1.?O D!)/S'Y5^&NOIK#J\I"V)(X2^Q
MX"Z6C6+5/Z1OBERK4K]C-2%/<IJMXN.M8*PV6VLNUJ<UW^Q#H^J6Y(,:Y404
MB)/4%75Q'H.HIS:]NTA&)>2X6=12VOVZSXR8V/+<./KK0AXY["$R9R<F](T2
M$UXB19CR8&-KG;;60 13O]!4!V3K'Y\?O"O?*9X\3T1Z=I*K^?JW\4M:V.A*
MF$<OQKMZ>]#V!/*;74LV-S5'HQ#6QMK>O6IK>7:3RDEZE+XXOCFDC38WD!)1
M*5@Z:[!\6O3=O^0V\[X@-$58J-M?H+QO3FF.QW"W6]BLWEJ)\J$1!QOU2RP?
MZL4R!0.T&9F=*^:$D17)W23J5HD\V^C0Y*TN*,,D"LKE@-MP9EL6(.#N3&)"
M\R&/M)DRBDJK=Z5.T7D[S$'5)N*V&S1B3D;&]L#D!I-4-!1+^V@2OK$8XLCB
MWN"FOS'EI).VG-<V\H_6U.MDF+DH#M;1$%J5GJ4([1FOHB<TL]3Z@U]'(, <
M=[!8@BWALS3PS=H+Z+J.&S/G6H^F%#50'D'IF'5Y,N@$\0:N3>@>E.V+8O&F
M^RHVY_0%S8_+8U5\LBC0]J(4(%KQ)2PI&R(DFA,7Y6 _ U><IN!ML*](C7=^
MS$7D>X\G5BW/+9:WDR6U^.()QRV5#T\E?&P2@1XFZV[1:R5LOJ]:#Z38;<%,
M.0DKD"0H&@R]1O;.7IM$-T;@!>1  T[$N2ATZ#,+T:6%MV([6EXAE;T8 */W
M^Q%[T,.MA$'>_(;9Z2I:D%]4M=F3A''W"[+ABM"5JD)0.SZ?(;5FB>0J8W&#
M"X^A=!,H5Y<5?@C>GW3:PHCT DJ]S3*32"3<,2V?"'Y())05$TTVTI3;@[41
M7<]14A8K3:M=$6!3LG0>1">WO#(P;.+";)0]Q6 D<[*8:U5VGY[#"9>3)P&Q
M.R;#;X4SIV0^\&Q/!)=T[K^;+(BF::,Z5NGS/6OTU..G8+-&A7;L&X_?9E>C
MS73M#GA2I"26_P 7)L1O>DM=-1[8J)?G=X=1&%O(!*P!EL%OC.;M"$IT;C!.
M1BDIO !<D&-<:C]KZ64D"$[8E1J7V1?22T^C!I_9%[X(/3>-/;.+Z5Z.C=OZ
M"0)2M]%R07T1.$PXD2A5[)V_HY 34Z@L1QWL%A&0< 0M"*,T'#/'X8^Y7>9<
M>+'VH*_B:&HJ7Y*IR,BI"X*AAC)R;/.:.C7B7VQ=E;ODWJFP+$CK7TK&0-5J
MK3*4)36C,96[OU7W><8Q>[D(Y<N$_&J^<Y<Y=[;DM354@Z=ZJMGM5U%)5S=$
M[.03.M;$L6R9+0,6FK7(% HJ]0Y$W2T)KE6;Z>GCH1/;XA?=%_63F;L+B]^9
M7Q[!22U=J[5*M-#C3D2TIDKVP)2[O3T;T7,.5H[&(5&HG'7V4SV5SFZ(%+8_
M!(U#F1Z>)4TLJF6MJ0<7V4ZCO8YWZ,IWJNJV2YZ*EVIG 'U?(F8A>H8Y'%'E
MLD$0?G"+RR,2>(3%HC\NB,IC$C:G%E?HY)F-J>&Q>D,*4HP!$6,S$2Y+\.GE
M(\?5/]*3[GR+<G2GJ6P:GYTHVG=;JZA*_45R>FC;)9%LWHBGI8W,I;(ZTLJ2
MSRN(PPNY =6JY1:NK4E2;;)#8W%!Y*WB_I65\^<<UY5<ZI191LT8GB=KY<Q/
M=X,W1DPFTJDLQ=I+)KBGUO,46AJ"4SNW7]V<IS* $L*0IF<743(EU]!0) %A
M(-C&,!C&,!C&,!C&:"^&M[]?9^&_C\/A\/G\?A\/G\?A@/77R]?]_3U]/X?3
MX^GS]/C\LUUO6_E_O_O^3[\Q1.G^JY4B\M-R5?RUV3;,@O*I:+OR=2ZB9K<Z
M1)3+S,-<9S8= \@<T\LH$(FNX+A16:D9>E[3M)>B42&&(TB& JI"\#E!,4:Z
MC\3'1?9\TJ#IG?+LY,[WC4:FW&FH'-NQNBK 9VTB7V/R-"YIV%&VVY$U96K)
M3U=>WDN(3G564P;::[?'V30U+N.B8 L.PRF,99GX^NHG[L[D*H>D93!FNMI+
M81<Y3OT(8Y(JE[.P.\%LN95RO3MDE7,\?5O")2IB)J].K4,K<9LI4$ D^O8]
MH5YF QC& QC& QC& QC& QC& QC& QC& QC& QC& QC& QC& QC& QC& QC&
M QC+)_(?UNY</<E67T<PUP=;THB*^O&"*5H0X/;2.6R*Q;)B=>MZ8USCD6FS
MVA0-6I,?(G92UQ1]7%M3,M^BMJD_99>PO8QF.:\^=YQC;92;VHIREY[&U-=1
MBZNJIC3G1<EE\4IZK+&[/2\3P7=7J)'1<+?[2L9LGRE<_P!K5_-8[4#C7J.*
MR6,&'.<F+;R%4NT0[YXSGW0;WRC#NE*BD?2$;<Y8S/M+M4M1JK!:W6#)S%<N
M0*X^'6E!2J/)"C%+H3Z[&E)+,,'KV0#WH+O,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,
M8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,98UU_P"13E[AUU@#+?<IE2!TL!!*I*G;X-7,
MXM!?$ZW@6VK4_N"PF^ ,K\O@U004;XSERRPWU*0PLXW K1IH_=J=D>MT3U32
MG2;Y<3)3DM)F>J/FL9@LP>VPK2B+KG28U=![CC3A$)(F.4-$PCCQ ;#BSP@D
M3(I4-:K2X11!QNR1#$'NX65H"NVYA:VX+B(8AB7!0) K-C$#98A[5Z)THV/8
M-[!L7O?:V']CO>P_#.1.@1-R?9"!(F1$"5;4")2)R4Q6SU*K1Z@[99 "P;-4
M'#&<>;L/O#C1B,,$(8MBW]^<9O[77^$)_P"U!@1/>#G^YA\Z_P"/NB_]:6[,
MEER)KP<_W,/G7_'W1?\ K2W9DLN QC& QC& QC& QC& QC& QC& QC& QC&
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M;UO>]:]-ZWK?KO7KO6OOWK6]_=K>_AF[-AF]Z />M^F] %O6_NWK6]^OY/\
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MT5TZBC(HO=T-FY3A%EBZ;1$>VEQGK0U)&<:,B-6&D(23-L)0@+1M9KNNCY0
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M'<,AAC@QOR58NCKKJ6IRUD*GA+(\MD1G[4!HD[(<J=X<XN^WIM1J5P4*E4G
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M4?;$TXD4(CG+DC>(_$GN3DI@.[G'&-U6+')H9UBHY W+EBM4C().5*!FP,7
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M5+?/#9 ,E+HC[-DO!:DS19NP&2=-_'GZFZ>4"1\0U5XK52!U1DNB!<!WY_*
MH;' @*U"H*T.2DC+3'(3B32@"+)T @00;*+T'98>[\C7ZGG\?W?];PN&M5=1
M/DN30.5GR1HL'F2J:H@KPZ)') !M>8U+FU)%4;?)V5622D6(-+#"EC([(R5B
M!3HA0Y(E]W=&>(WQST53E;4RU\>\XSQMK>&,L-)F5IT74<ZL.6A:484RB0S:
M5NT+$L?I&^*-GN#NN, 42:I4F%IDR9( A.4%((_"OXB'!(E7H/'QR(M1+$Y"
MQ&L25)%5*54E4E@/3*4RD@LPE00>2,LT@\HP91I0PC+&( M;W(%35*U/SS6\
M;I^CZ]B=5U?#RUY,7@<(9TS#&&$IT=%KTXEM;4D"%.D"M=G%<X*=%ZUHU6K/
M.%^R,WGHB! A:T2-L;$21N;F]*G0H&] F)1HD*)&2!,D1HTB<!9"9*E3E%D)
MTY)8"B"2P%% "  0Z^O 8QC 8QC 8QC 8QC 8QC 8QC 8QC 8QC 8QC 8QC
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M0>2K]^BN3^9;Q7_L!@2Z^NOOU^G6/77WZ_3K(BOP(/)5^_17)_,MXK^?_P#
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M;L0C5;B[/#HK5NKV].:E8[O3JK5.;JM5KE)QXP]3QC& QC& QC& QC& QC&
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M]P!:YL"@:I^;O7_)A472-\<G3VN>49\1%+1$NC;V\Q(4@6053=M:-K@-1/:
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MX_[1'"C.JN=ZMOD==:?]0<5DQPN0;C 91MH%(0M'O#BM)@O&V%G^GA]!A/\
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MR-,<C[0D]YI(U,C$W)FEI;4H33#3 ID#<C3)2 C,&/W9(?;&,>Q#%WN QC&
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=&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g515401.jpg
<DESCRIPTION>G515401.JPG
<TEXT>
begin 644 g515401.jpg
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MDVW =-A=25(W#F(ZDCOUHZR22I!BO.?Q'"<;?5S#L _<1T8W HB( 8=-X<3
M CMN =0 VP;AL.P=0#T(Z>?@#2/YH5G^A&/TYY[N(\?V85<?/[B.C&_O^YQ#
M?U>S[<]".GH[4*D^/X(UKP 1_P"9&/LS.]_6?$O3WO4'[3J+F ?3'X?L#2_U
M7PH?^1TW[-/9_CO^'I6&,;[_ / 0^W&6J],8QBE,8QBE,8QBE,8QBE,8QBE,
M8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE,8QBE>?/TCM
M/N]PXF].;*FWM]483;'2?2JIVJ:L6CL-9=$[A"<1TQ(LM2^&528XL]+C-]3=
M=8A-*MNRSM(F'DU6H>H19AFP:VS2*1WJZAJ79*D6(=.FT<[NRC$Z%?)+/4V+
M%!XZ<)-S/E7"S-^@<T4U6<235JX;"W?NF;=@Y.V0<JKI>=/TM"&B[?CIT4;:
M@<-6K6KDW?\ 2*MT9JXK>H5IKC&YBE<M0G\+ :656%TIO$;8=3ZJR7M]5FG[
M^Z4DT/$ZZP+9LQ[[,MM0:/Z7^8J9#'.()D)VASF.(%*4H&,8QS&-L!2;;FW$
M=@+U$=NN4626DGTD?CV^H_?ZU=L!#'U@]O+Z]C_&:UCT>!XB8].DQ$^RUL)8
M(F=K;:E2D[<9*TLO5C'B6O:FI\AJW.1SI*$E#S>A1JN,(6R,5FR\8=NTI"#*
M=(=LWV&7HMF-5Y0*DO!-YCNRPIJ6-M(NXL&P(J]Z!1&+>,7HKF1W! Q7!2$5
M^,H4X!RY50+-S=D)54C=N F0$#%'M@VYQ,CL/RA0*/.8Q.8 +\<1VZYU)C[U
M20_]0>_ZJMFMB+=RV0 ^UT.UP&4[2(## (B 0>X@5CJ(NVKJF4W6W!:V2K"5
M(E2#*D=P1F23YUYS>(T3!;JMSB',.B&C',(<VPF^YO#[B&XB(!OOMN(CR[;B
M)NN9T\;5HLU8TEX<E:W8IVOJNXM1-VI!RS^).Z32J5=.F1P9@X0%<B9S&,F5
M7G*0QC"4 $P[X,<2'6X5@0'^\EHQOT\?VN(?V^'EM^<,S+X]NFD7#5_D]?\
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M#7N14C'XM6CT$#.9*H,EA%L^1<-E0.V<+DV52-R\W,40,!1"L^"3B&U<U<U
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M&37G1XAA!"UU4BY0>'#1O21<RK@3IG61<Z=Q!T&:A6QD4BH,"_(H'1(DZ4(
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M !,Z^@(=.]*[>WK2WF_S>[KX=>F^4)=]P]'/I=OT'X=M_$/^\%R\A#KTRO.
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MBL$6SY.\BH"/9F[(""J<1W#DJB!"@4)NTFVWZGL4D8P[B(]3"KN.V^P;^
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M[ V>M2D38X:,G8L[598\?+,D'[,ZS9!51NJ9NY(HF91!0 .D<2\Q#@!BB!@
M<QQIO%U5;D\K:3.IV1",E;!#4^:G@=UY_$5^TVF;LL%468+QTHX//Q%E<UH[
MIC8(--RQ1CIZM.WB:/?Y!.(R1N$]!UVN24G/S$9!QP-5F_?I=\VCVG>'2*B3
M5 7#I5)/MG"IBI() 85%E!!-,ICB 9KIB>;:-C<+G,39R]P?>6&W9MZMT]MN
M9[9FN?5;>1>]XV\H6GYG,V[-FT[M^[IB.^[$1.*IC10H$T;TG*4-BETVHX%
M/ I0K,8!2A[ *&P '@   !TRYV6CT3E6)]']+"@N',G2:=#G*)5-RR;:N,"+
MM!^)MSIF3.43E$R(B4>54P;"-?(6>#<N))J@_347B$UU9%,$W "V3;F$JQCF
M,@4A@3,4P""1E!$0'E V=6M2Y[YK.AS&IOEH4F)O,),# D@3VDUR</N6QH-
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M(I@(F<QN<JB8@) , <P;B'7:-C]/0_7\G2W5D+TXSU$*8G) [FG-M=1YMN$
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MMR6 *@(TL""05$200"01@@$CL:@WK(#,;ML*A*NQ=0%92JLK&85@S*""006
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MQ&E?^EO6>A?//]Z%""F*A)\1S6S1Z\.X<-])3((N3(*G4*X?7IFB8HM%G)
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M76O,JJMMV9W8!%4*269B8 '>28 CRBJ>T5* :.Z4  >&F]( -NFP?!J,Z![
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=+26K8>Y=O.$0;5#7;SW+MQ@ )>X[NQRS$DFO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g465293.jpg
<DESCRIPTION>G465293.JPG
<TEXT>
begin 644 g465293.jpg
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M Q4@RI SF.EWSS('O]*!$Y2;QG] ?#%6#$VA24JF[U05Y&KB!?B*,?WR:/\
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MYEARJODI9865B)$R>)E5%71R^6>!\]@+D&<)ES(Y?*QJW57*?9D_:PU^W?\
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M8F,XVTLQNER:I1R4C$_)Q(9I8N?#F"I#:+97&FCYV%&:MJ>I.V[$:+K2-5)
M/O!X(<.%T9F0AN8Y2T>P5,KG!29A55GN*OR<(=9JHR$1*6)20"B4=>JNRR;.
MN553,B%/ABP8K2PKR.:?L]V:2K)[NG8/7D.2P[Z^(\_/A#5T=Q34CLP=NC.
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MB5(3MD!IQT96#6#(;B(4Q+%B]BJ WR+<0D1O$,S&1! 2$Q$(Y&1,!3&1-*)
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M4,.(_P"3PWT^)AM']1[YJ9]0PXC_ )/#?3XF&T?U'OFB9M_DWX@OFX:ODZ-
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M=TKR@Y1P\!<;)5S:*<:B>F%\S %\LCV(*V/8J+:V!?(WA>XEOVLG)1#0"(R
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MV]=?D=RH^P6M4Q&U. =2DR"2+H0=;S#W/)[<=8.4KR"OJ[A>BH^U944US-S
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M1!\2F9W $8R"/V$/''D/#5\G1H'\2?57ZBV+63FRW[Z;3*_F5-@^7Y8>SJ'
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M-$-@.%D-!>8P)5,(@LQ9;*&J-0(FC7+W2"@;</D#"+@62[E2MTXOB1L"1N7
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M''",>,J).A,6O*$M*=5(CD,*Y5\QU ,6-%UIMQ[FL45>1V@EEE%O!F<A!>V
M6X8MD@!#8B98"!IN.0?(.^-JEO7C'Q6]ZWYJ\UI9-R3O2E*41*4I1$I2E$2E
/*41*4I1$I2E$2E*41?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g809625.jpg
<DESCRIPTION>G809625.JPG
<TEXT>
begin 644 g809625.jpg
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MB)?1UR<I0TA98FESF:C!UN@F1$95=7F3E-/_Q  < 0$  @,! 0$
M    !08#! <" 0C_Q  W$0 !! (!!  $! ,'!0$      0(#! 4&$0<2$R$4
M%2(Q"!8R02,S41<E0D-A<8$8)&-RD;'_V@ , P$  A$#$0 _ +_&,8P!C&,
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MN3+(F]T >@ >@;%*A7> +WO8=^N_7^R&Z^?X:-'K6OW:^6OU8!_3&,8 QC&
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M>Y=&M5B:G14L*DB\V:.EEPR.-5=*X 974-<M.;VY.)+B=G8^-_(IWW95_P#
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MC9S4%/6#-D<-ICF: WNTF2:@>?.M;2JJ!W1%)#(U<5>X\JM]R8I!&'V,RL;
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MC &B3%P::.3F_P 1<5;E'E3N]%-R=X7@;H8QC &,8P!C&, 8QC &,8P!C&,
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M1)DZ1$B2$%)4J-(F* 0F2IDQ  $)TZ<DLLDD@D "B2@ ++"$ 0ZU[6>&MZ"
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MR9M9@1[UVJVX+6 \EW3IOXYB$P!^M:"+-M-;UO6MZ^>MZ]=;U^G6_GKT_;D
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M498YX7/Z_G2)J=9%&H]%YR)YC+8S6+4EE.<M%6]BIDK@K<GC./'_ %"NEG#
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MEE2SF./]%IYE9<T<&N65(GB'1M8A6.S1$G>0-\M6G(-H8/Y0@3:QJ?0D\Q7
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M14/ED[%L7BUMNWF[C6F:QYY[DY]ZJE\KKSK:Q+1EBMCI]1* .,?9XB^<XP1
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M'(:]U*;24X'1V=E_Q#@H V/QC& ,8Q@'\C@C$4,)9GNC!!V$!OLA%[L8M>R
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MG/\ W0.C?\N,RS\D?/UN/R4+^XH\Y_[H'1O^7&98!9 QC& ,8Q@#&,8 QC&
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M%QU0O8P0GJREIR_3(A%*U[;'W/[AQR..TU,:'-6$AY*8!M6B51BP"4[XW/\
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M75<C;&MM2*7!Q<7!40B0($"(@Q4L6K5BDPI.E2)$Q1JA2I/,+)((+,--& L
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M8GD5TT\B\KS)*][_ -N>/1Y8SKDBE\5B*,3C*Y(P1EO"'8AKI$\MK&D $/\
M&$)2ZJDA(0AU\Q;V/TUKZ[S3RP?)=P561IR:6=54\%43H6C44<DX)PN"(.M^
MI>T<((D)_O-[UL.@;"'?M?P?KD')-%$G,LL<:?UD>UB?_7*B&KDL_@L,SOS&
M:Q.*9QSWY+(TZ+>%_?NM31)Q_KSP;3*+7K!*\CCJFQ8(G?RW +28R'S&-DNX
M'09P4P6T;88Z!7!7B4# 0%&)/I2(X82M%;,%H.^_[WK7UW_^.]_JUK7SWO\
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M!$%X2_[4FT?Y?GDB_P ]JZ<F R'_ ,)?]J3:/\OSR1?Y[=TY,!@#&,8 QC&
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MH!__ ++O3C84MZ L]P5*$^M[WH29N0MS0<>J%O\ L&MH_<*M[WL']AUZYL=
MNK?%/6)90*4YB<5BA,2%4E65UR$X*W8SW9NBSAEO3NPIEXQHQ>@U)YR_0 B^
M03C#]Z+R:5KK^",>PB9H7$V@0#MJ0";(VRMX@*-AT#9X=I$).PG; '0=FZ]#
M-AUH.Q>FM:SM0"2BP:*+ $LO6MZT O7NPZUOUWOT"7[(=>N][WOTUKUWOU^O
MSS(S$;4G"MS&L5'<<<U=3MND3[?YTVS.1??=]XN/:<HJ(J+,8S#?A-UV1)<)
MT'W&2='=RV[?4C2Z4LBJJJKI%QG1:*ZYZ_0CGNR;WNX<O>G**E%2WXFLLWL2
M8R^$TI+4(Y]<;A8L'A"FN3V66+F$F1)'PDS[HKMH]Z<!D)PJW1/\<4EVX*3A
MFKDQ9^C2[.!/:G8+_LLN'^-.Y=A-VG]TJG]FP&":]E1[9>QJ4JA.L-3;*4:U
MLTH1FQ%)O4X[1.]EZ%F:8>.WD&>68Z6_*JFTZV$\RA%,W%^%-)\FTHD;<>@4
MHW#[,1R8AI*]R<V(1Z2DH2T8O<:T,@6AF:'NQH =>OH'7SWO>]^FO7>][]=_
M/]>]^N575M%VG$6]@GN[9:KLRF26W"N,?4O*Z'R6'HCH<YAK3,>YKIG.2*J^
MQ&K7MB?(_P"'9++^ANIW6S\/N:PG3JAHWX>=/^*UO5X,5GY,YAKVF/LY6*#'
MPNLSY#I=NNOS[CWLJN8N0S]7'6F6&VK]>I7^<V:=.+_5P^55^V 31R%SY!RS
M-)M^U.;W.?3"_:,&4IT8GB998M"U_ 4@]G>] 3AV$/Q1YFBR@F/RZR8)9ATU
MXIK4&]%[,(:XY9,O4@V4>869Z[<M&)Q?$$#"HUH)NM!$463H1&S#1:E"QEQ_
M*\K^?BMHVJTB_=/F%2A[7CGA<1CL<Y/MZX=Z_;@Y#_;#3K>\/T>Z,X=R*BM<
MNL9S9>U&_I3MWG:=JC?PGIWD8_O^[^5]E:_R,4CV&BJ-D?+_ .DE]N*!NSBP
MPZO:4H!T;6YR=5Z/2U<FFCK%G5*J31I8SM1AHCGUFD#66_I&E,2W%&*#7 O(
M/"7)%N690Z=^B?;/5]/MI[H-ID4%'"2HBH;):S-C&%?]WE\S<G>0*HBE2FHV
MMG6(RF-(O B/$6W)"]')C+!V]:W]?7]V]Z_HWK&M>GR^?[][W_CWO>\KS.F.
M*39)<]->R5F.:@RFZM/E,Z^ZLC.$2P_+_.OB9&JSF):SHT@;%V-8UJHY[^H3
M?B^W->E-+IO1UW4\7:I;)/G8\K0T[IO#K[*LZ*JXNOHZ=/OE5=S9T;<3+-MN
MR;[CIY9YY8Y(H:\8A7CLGRLQ$=(_(+VV[&D>@%7P%CMC !23HT8]EDEHFH[2
M86PBT'WPQ*C=;UL6A>SO18?Y?UK"MEA)Z=_Z6[5D)!QA1VB7#H1T)*+-+$,?
MO/=HV8D!HQ"%K>A':%LO>O['[/M"]90<98?R1K"_S,6ECTJ+\7<OW.[EJ-7N
M^*M3=W+41%[N>53G[^SEJ?B#ZOQKS4W!V+]M<WY)@]:P21JV19&K$F'PU%(>
MUZJK?%V(UJJQJ(Q5:1@A\2/*QZ@A2]/%_28XLD!"@Q_ONP%8W LLH16@K!)U
MR0?L;]K8]DI1I4X=[V LH!.]E;^JB\1_""8@9"RHG9\ULWWI9CW9MF+#"/['
MHOW9/L2H@L /EL7_ &,0_:$+^'[._9U)3C/K=&TU%Y75L#(OM>9L52F7VB(O
MN:%Z^^$_Y]GR3\1/7IZ<-ZR=2ZR<-3MH[GG\>WABJK/HHWZ[?I[E1/7IJ]OZ
M41$K7>3GGKA+FN#12'UQ4K="[DE<DB$B;SFI'/'@E;73+*2$$\ M<5CDYL98
MSD!GP^T*P0')< T7P(![V8,%@BGI_!;2K&$SZL]CW ),P(UT2T-G5Q[9;&7H
M:)"2%D7)D:IK+(*2>X*1')2!$E%@#HH(/9UF0C4R<_>A'$$F[#KT#LPHLS>M
M>OKZ:V, MZUZ_HUOTS^H  + $LL(0 #KT"  0A"'7X:"'6@ZU^K6M9CPNK1X
M/.9C)4DQ-3'Y2K0KLQF.PS,<ZN['NL.9-)9AMNAL/E=<LI-Q1@5S4K(CD\#E
MFVNH'62UU$Z=Z)J6P+NF9V?3LQLN4L;AM.^S[1'E(MFBQ4-BA6Q-[!Q7L97I
MLP.*6BC]BR+8I'99[HW)D868_P L8QEN.(#&,8 QC& ,8Q@#&,8 SC?T_P 7
M\_R]?W?7?ZLYSC?T_;O6OY]ZUZ_I^GKZ_P#JP"$:FEG:;WY8K7DTVIKJ%AY4
M>XX\EP"43VU%#=4\0-C<&B4/^[K;3\'Z%DU9/0)K+8_(+!C,Q=ZF3SM&1*S2
M'AV1*2P(VZ;K*L?+?25I7EYY+297XSI2 1R&M5UM:>L7>?VF;3YC-#&)IK-I
M?10.1TK!XD7'+%415'8T66%NR@Y/*$)RB)2V5MRR2*'RTU[6O7>OGZZ_^:+T
M_=OT]-[_ %:WO> >61H\P?W0WR:_^9/_ )!Y'F3+F\B'+U$2"XHE/I3*RI51
MA5*CG4>8ZTG\@<Q'= %6 MK5)%0-[ -/-E+BTU;/7EW^ZBAU31INC;@)]5(5
MA?P6L <0V)!K4[B\D,XKF5,DSB;RFX;5MSZP+BEZ$XMPYS<GM*6;L&]&HU@F
MIV;5IK<N*2N*4E<FVK2$"- '8$L.>FXN+>T(%SJ[+D;8UMB-4X.+DX*B$2!
M@1$&*EBU:L4F%)TB1(F*-4*5)YA9)!!9AIHP%@$+7N9BN\Z_6VQ2UNU>VN*9
MH<;'K"P8&@=5I1QZ-L6S&(/,;2N"HE/O2@U,B/<RU)Y1&]'&%%# 5O0Q!P#
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M3*BMB"$80F>P8$!@1@"!V,ML;BG!0[%($1;FK3)D2IQ D3@7*4B(P\U&E4+
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M>8RCLYSDM+P/G)OG"FU*^3L:FRI"O<X&J1MY4YWLZUOUUK6M_P#7Y_M_7]<
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MH'_.7J# /R!Q?7?[=_TYQG(OKO\ ;O\ ISC &6_?R+3^Z?7E_(@L7_+7065
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MW%_21J5QWGQS1GD0\E15N]&5;7QB]]Y6C*$$GD0&_P",?Z_IQ^8IPTI![),
MJ6Q-[/(:7\I.(W[+<3BT:P1*@8"Q 3S9QZ_M_FW_ .K*W<]\F=76_P!772QQ
M/RYQ+E^@(/67/ZBLU4.@O/$X:+"G$N,MY1;8Q2>WJLFSHL6Q0EBKI*I;&=>D
M1,@7DGXU)I6Z%BUK/;2/D&ZIFHG<Q_*4NDVI\5-K8U&(ZQMBO:<B@4K26<6E
M,(A%61&)1!,X&!/'MP<R&8MP=!A)&XJ5(B"=E@6W/77Z_P";?_JSG*:9-+<,
M$[-W_JFGMP_WIYBC_776 CM$;-]G_6R;T1@]RB)]G_6Z;?O-E>V9ZFC]KY;1
MLG1=,TM3RB)5M^422^5;A$1DQD133Z+<IVC,'IT)1N[TV(WJ<6!2\DF\I4JG
M@XM&2)W?5S@-*),THCRBB499(%HG( /RH?\ N'?:G[*!_P Y>H,SIS?YD>''
MGFZAI->_9=#,-ONU'57(+D1O$C;XP<R60X5\P.=B)79I+1ID,<-:Y0<\DN+;
M["5,RF$'I!EIBTHBRXQ_RA;R!<8=+>(;J^G*"Z/J^WK3F0:3%%(% 'PR1R>1
M 9K\K"2NHVAK0(S%"X"!@:G!X4C(",!;>C/5"%HH'M; _++%]=_MW_3G&9%W
M4=I^N_\ W-Y]]=__ ,%R?\?_ .E9Q^:*T_\ :WGW^\N3_P#-. 8[RW[^1:?W
M3Z\OY$%B_P"6N@LJC?FBM/\ VMY]_O+D_P#S3EGK\E$M*!<@>0FW[(Z@D2>B
M8$\\B3J'-,MLU$[11A<96OMFF'A%'DC@Y-Y1)SJJ:V)W7DI BV:8E;E9H BT
M2/6@/U.L9K/079'+O4JZ3MO/-Y5Y;R^&)&E=*4L(? NYS$D?3UZ9H4.( DE>
MX*<#VMP*3"WL7O!I#]?+V/GLQ@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC&
M ,8Q@#&,8 QC& ,?]?P_HQC &M>FM:^?RUZ?/>][^7X[WZ[WO]>][WO].,8P
M!C&, ZM-WI7&X=+)"@ 0:N9(T_/"0M7HTQ*-4U,ZU>F >64:28(@9R< 3PE&
ME&#+V+03 "]D8:S7+'E?\C)E?>,7ISK./<9RGFKR5V]"J 9([S_";N@MV4]8
M-I,DZ<J^?W93-K+LF(3N-"7U^ZMLD:&IN8G=.!P;U34L6'%&)3[.<E8R)-'G
MV.JCCTZ9]9G5F4*$WN_B""'5O4MYQQ'O0&%>^*+4B,*]X 9?O A]L(@^NMPA
M<[>"JO*7US3'Y[V%UKT#5''"=]5\QTI8+E3\8KNK)H\1M^BB"QTVJRJZ(RF2
MS>%M4F?#J^>)5)'8R(.[@<ZM^A'>A>P/,/Y0#R8TGW0EL2F>L:H7TE53%?C^
MR3RMX GECA1#O>L8Y^<K4/@S#;+[-JY;H=+9>PR&80B[(_6%L--?+-RTF +D
MY)J0.6KO\TO*]*GSALW%K;L&01+K07%;,T1$BI6!!8UYME3L]RS!JADYM:W*
MXK=(S0.*/K<@DKM/)?"1J)<<"*1=%(W4TD!FE,5\#D$Y)INXG*LG2R.NY6IX
M(Z"X>BE!.S=S-0;)8]:W))X_*"4TBFD8KV&(U-LA<V!"?(+OL-V?G^3'E&.C
MIH"M&SHT^2:C\**TGQH\O<E6#=CG&[DKYT=[DOB1GPNL.D:MO&\[3(=G&TRK
MNJOH6)3&"WFP-;E(!((4^R)L:Y(S*8I&I&S.3:>4:D. D4L#R'TS5O!QOD+L
M"%7E$:?10R*S5W@TDJY=';R8TLNF#+!D+.Z5E('%J4E/B=^?46C$Q#LH1.;;
M[+O&W!];EK4H<-30^<CG%(UV0SR:A.PH-T% +JI*A&SD.9U!'&7HZS)[T>U2
MB14E^;QC_.*I@"R/SF+0:<2;<@DEAQE!%&F'OVYD-B5DI$JWIW5'BW?HQX09
M;XQ>35TML=]:8= (I!72?S./,<H=QINAX=:DM<]R166R1:+?9B,N2K8DS-J9
M QQA"@9HU'T/PZ% F,]U[\(D6EZBR+3G/8W3LM[#E5\TE?D%[ 6HZ4;)_53_
M ,R1R=0FAHU':YC]8M5,.L+8H;9,Y9Y\PN\&^&M%3+9 [OP$2U4ETB _K*O/
M=R?%83 7,ZJ.E%5Q3FZ;UY^7\O*XW4\/N^ VMS9&F*8V_%)FJL>Y8;30'-FB
M\MA;O%FZ+VU)7*T 3./I*S02MQ-<$C?F.D?)5(+P\@JKDAJYSM:(5FJX7I[K
MYBLVQHP&!RA,HM&52-ITPS"!2"2)Y/%D"<EL+BJ9"Y1A-+R;*CTY:G9I1Q9N
M89.^ZY3_ ,$4,G-(_FW<.K;>D<]E]T7'T#?EA6Y5O.5W1'H6U;T98?&Y5+)[
MS_8%8K*?9':#,$%CC11#C V:,N5/(D8R6A:YEJU0#=MN;?%_7'*]P4;:U7W%
M<II5,\/0'A%;#Y>KA<I:K*K6K99*9M I3+GQ?$M2MMFC%(YI(%(?N:\1R-'(
M3&UC"PD,;4E;L P5*O+K&*4N+IZ!VG'I=:>H1V]2/%%&5SSY3BY59[M95R\U
M*KUCT;DCC+K8*C4N.?#F%^2)9BV)8!'XP4H:TDE;@MB9VF*;Z:/S:47(X-4S
MG6_.'8EK73;,PZ0A1/*$$K. G= P5UY'=TL?Z%46"FD-KL%5LK; ']S86 M2
MWV@\'2Y_D36QPQ*_.I;HD;<DNOB?IUVZ'D'1A]C6:7)Y!WA3G?*AC*W%-,)%
MBTQSA+.:V*&D^VQ#<=PETB\O7/[MH:P3]]X$R3X)T3-VCDAV)G_PS1]H?4=F
M\^=;=#<WWZTWIV3;S3<4+:*>E:P$<[GL%IL2ZZD=H7/X"_1!]AR-[8FE97CH
MN1!E4->&](_%.J]P)#O0'M.?G+Y6<&RIGRFJGZSZ<9[$HF*]+2Y5SO1YLZ74
M13DQG[O5C1([?C2R3L,IV\!GL9FC&M@5:LMD3I*7!I0^;CQC E0.CCG%3Y6N
M9$JU@;QM]IZ423R.G^+MOUN'M@ AZ03,RE^-7J@FR@HY/6FVY(;[,G&5MZ I
M$6G/BA0_>:!J^F\&D"KM/531S%V+U[RRPQGGN!\O7&*IY7""II?=55_8LTME
ML<7:RG*&F3&KK6<YY8LX<7FT:C6Q9X&V2AW9&I$U)%.Q9]Q;X3:Y5]%I[H!T
M_P!&$5ZU=],'DF8.<]@J5;6C9T^D:BV.52(Z2N%=J;7<V.6-)(4@X^HG1;>R
M&JW=S0EGO+H:Y  U]K7ST)()R.R]%]5459TCVLL;L5-*I1SE!8\U537%5\V]
M%R"G6ATE$FN^Y(BU/EAN[*E;'+\UE<22<6Q*-HG^2L5:-\= DT+VK0\UDX16
M%VO$(;6":"0OFJR_')&ZZN:>0I;/X]949[8D4.1C,6PV+6W#Y&VN4H890%]J
ME<6:F+:&(M0[V.QHGY"7!G/TYK^3?<^2QI;V!+T7>#0T&5AU;44D+71.B9RM
M4Q'JRWYM=<H4P178-:R<FGYDU2><+F V>5TB:);)8&B119T=DX='N!NQ$Q\)
M513!PM(XZ^[M;&:XVC@C4WC2!%5XFP^9>/=PA JDG36L50@]^;'!\887N/2U
MC*=S(TI(D+PXHVPER3L9[0!DN/\ F&YYD'0K728*OZ+;8')NFIKQE">L'2 1
MI-S%.NIH&%W)>Z9C4E+GBBQ#'8Y]CTCB+%+G*LVVN9+*HX\MS'+EB=,%:/T.
M/?,MSKVA9=/5[!:EZ;KQNZ,JJP[=YXLFX:VC<5K^ZH]43PTL5IH8:K9)_*I$
MG=(.XO2("XV31Q@8GI,,"^+/3XA5MBEP^!%O#C!8UT!&[ %TM?SSSG >KIGW
M16W&CD766JDA?5<Y72UX=)REF:*#I;<<X8T22;2"8Q*K'&8#B[!+UISM[:X@
MY0@/R;SMXJZ?YP/\?Q\6L*RWP7CTI*_*-K34@%%=ZFL?Z!,@QDD=YW]FL*/8
MGEE%!&_["W'MM"'6EJ[[02J_4CW0$HOI\_7Y^OIZ?7?I^/T]?3U_7Z>OZ/7T
MWO.<8P!C&, ;UZZWKY_/7I\M[UOY_AO7IO6_UZWK>OT8_P"OX_TXQ@#&,8 Q
MC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8!KQ:G*E#759U/W%9,$*D5A4
M4Z'/%;O>GZ4-!+>K&[L<D3%O[*Q/;8PSA SRN,1J91QJG#9(FR-32/LTN84C
M=(6Y,X V%]C6O36O:]-:UK7\,?TU_P"5GEC /'V=?B+_  Q_Z6/9U^(O\,?^
MEGEC /'V=?B+_#'_ *6/9U^(O\,?^EGED=GD$[;?^/6:L4L.A<*D\NL];:*E
M$XVG-)+ JX9F"EJHD=R3-*>ZPF!V;-I%/Y''(TJ::Z@43A+L[R!?]KNPO1NC
M"Y*M WEGL$B=GP:9UK.V<J10BPHG(X/,8^J4+4Z9\BLM9EL?D3.H/0*DBX@A
MS9W%8B-.1JDRLH!XC$R@@\(#0?:9V9M8&EK8F=-I"TLS<A:6Q&6:>,M(WMJ0
ME"A3 &<:8<,*=*022$9IAAHM T(P8Q[$+<-#3YQ>=%**,.CO55U-<??I"./F
MS,D-6JX>:0QIN>4T]E<1TOLEDG<^C,,EG4=/173;'8 99DL.>W=[B=;.C'$Y
M.J:O1:_/1R ]RN+QAGAMUN1+Y&*>F#W(D2&IE31"6.Z".?B6$+VB*MO<E?7Z
M.2'I2N8O-8C7[#,I6Q.1,J7Z9U<?CJEW, FW]G7XB_PQ_P"ECV=?B+_#'_I9
MI[P_VQ5O>M,JKLJ5GET?CZ"<26OW%DG),;2R9M?HR4U*U)3@BC$EE"1#M0W/
MC4N*2*UR=Q**5!^(1%E"3GJMQ, \?9U^(O\ #'_I8]G7XB_PQ_Z6>6, XUK6
MOIZ_O$+?].]YSC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#
M&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC&
M,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#.F3
MNN:^M%E*C=E0:'6%'275K?26&<1ACEK*4]L:H*YE>"VJ0H'% !T:%P +&MP
MGTL;U0 J$AQ)H=#SN>, QDLI6G7$48&X536JX<)EY-@0T:R!Q12.)SQ.B^S4
M\UC(CF@8F"6D-^]H"9(T[1O12+>TH%P2/X&8S2<:<KH+2BET-]!U:W63!F^3
MH(E(6V',C<%@,F,@8I1(WMM9T*-.QIY<XO<=;58IN!MU,$Y?V@B2/A"%W=4R
MS9G& =0@U?0.L8^3$ZWA41K^+IUCBX$1N$QIDB; 0O=UAKB[+26:/H6YM+5N
M;@>>O<%($P3UJP\Y4I,-/,&/?;\8P!C&, 8QC &,8P!C&, 8QC &,8P!C&,
M8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P
M!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC
M &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&
M, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,
M8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8
MQC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!
)C&, 8QC /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g900185.jpg
<DESCRIPTION>G900185.JPG
<TEXT>
begin 644 g900185.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!#1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?1%527U)%4U]&4$]?-$-?3$E.12Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" $Z BX# 2(  A$! Q$!_\0 'P !  (" @,! 0            @)
M!PH!!@($!0,+_\0 2Q   00" @(  P4& P4& @@'!0,$!@<! @ ("1$2(3$3
M%!5!40H6(F&!D1=QL1@C,J'P)"52DL'1&?$:)B<I0F*EX3-$25-9B;7_Q  <
M 0$  @,! 0$              0(#! 4&!PC_Q ! $0 ! P,"! ,&!0,"!0,%
M   ! @,1  0A$C$%05%A$W&!!B*1H;'P!Q3!T>$C,O$S0@@D4F)R%4-$%E-S
M@I+_V@ , P$  A$#$0 _ -_CCCCBE4Q>=;L_/^M70FY7U9Z6]'9;)*]E&[.V
M*PK:7S=I7#4$3B>A'0_(8T-?#ZY>S!F;6!@);)5V(]CIJ9=#UE3C08W5I>[!
M=R>]48LGL]*J@,V2G.W2OE?C<BB2PE_E]6M#4+7/4(QU+E.L!?H;[PQ_%Q-C
MR^51TTY8(EC9N?RI8LY,;::,1VY.= !)0*>@I&(&'@A)'+<B',CV944_;YWT
M4R@^'$$'+)XC]HFGO]DY053^/33;X?BUUSCU-(C&$BQ(\G'PJ9TR.;!S!O02
M.T+EA++[7#,63)ZM</2 UIA=;#9@\76:(864PDCI\>?="F3/GWY#EMN.<[F"
M*N% "(Z\]S((Z]!/6!YUI0W5VP[F1,+>H"$S6=CX+U]-]^B/1 @.+N7J5@S"
MH_(7U J6G (LTLJ\7MS6(UC8MD5W&09)Y(42T5E)_P"]MS&[-!Z-V .S7D;[
M)=6>S%*5?-.AA!_UMO3LI0_6*&=JV/8^NDT5YS=[1+[-=6DT@;^=-F<:,-9$
M*6RZ>H-B&H35TF_;(D6GNU!.OH,BPC8M&'Q=$9#7;=_$!R4>#:,(J^:Z*IM7
MD:9:L<-0+MLFNLFW<B4F:Z.BJNJ:FN%-\;5"^:7&-17B\]?_ .9CH5G_ /6)
M_C_/U\OI_//KZ\!) @$"/GM \IG?/H8IJUP(ZF#U(GKB2,B2.8,DFKJL9]_W
MSC^V?7'.,?3^NW^N><\O5*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<
M4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'
M''%*<<<<4IQQQQ2G'/S5WPGIMOG;77&OSVVWSZTUU_/;;/O'K77'O;;;.?6N
MN,YSZQC.<8.Z]=CZD[20#:SZ5E;.8PO26SB$;EFF/@PG(:^DY"*2!JHCG??=
M-/+X=E\+6WSC0F#?"S#;XF9!OOMC4ZVEQ#2EI#CB5*0@D!2DH* LI&Y"2M.H
MC;4)W$U*T!24%20M25*2@D!2DH*0LI&Y"2M.J)C4)WK.O''',E6IQQQQ2G''
M'%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2H\]E^SU3]2ZY
M<VS<[^3!X",>,$9 >C<$F,]3C UZ28"U9-)6D,#F7H6*"G1-CJ8D#Q#1DPPZ
M1^/;?=373.%)CY'>K\!N^QZ%ETAG0235#71>T[,F3JH;.Q3$-B(*)LYH5W,7
M5^[6:VU.-@A(7C,8:R!Q(5"Q-B"2&[EUON>N/?)YUZN[MG3._6N 5C3\YK.W
MP$UCEA3*>V))X!/*&GB+4.0HF^:NU 1LZE)G]831L\E!,)J]CDC5>C8_B.F4
M=%2F.5T7/X;9W=9CM&ZC::'7V67!!K:K:P[##7I/['A?=5B=AL35J2S[FIXT
MR9 :PMN/67%6)V4E8F+<;"AF2(T&<E#0U]F(H2J<;2(A),C'/;F<XB-^=7 2
M0,CG,J C(Y=8.!ZY BK3BWDSZ=Q\+'31^T\ TS!R> 38\I&Y"U-5NZJVR8?3
MUEN;7$[,,NJY$P6T;!@L(D1B1X;CFY:6!EFZ[D6LL10BEYI<XV%>+SZ_P^9C
MH5C;.<9QC7_OJ?8^OKU_Q9QK[]YQ[SC'R]X]U\6GX1.PUDLKWD#<["@DC[L/
M>W82V8^ZE*SMM1,;[+]PNM_8T <$E6@35"QB,.AU'GHS(10U +^(RR1 EP[S
M<.U+$-<J^77IO6T-[&>._MH-F%YN["FWEHZ"PHA#C=W6"9I%@+14,A-7L?I5
M\64KZ/'<LXNP6V-" [9_J_=EWFB^JA9_AP&J#/;]!S'J<"/B (2(*5'GMDXB
M?+!,'F!RK9:Q]/Z[?ZYYSSC'T_KM_KGG/+U2G'''%*<<<<4IQQQQ2G'''%*<
M<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4ISC&<
M9^F<9]?7UGZ?RS^F?Y9YZKY\T'-7#U\Y09M&K==TZ=.5-$D&S5JENNY<K*J9
MUT31;HZ;K*[[YQIHEIOMMG&,9SRJ#QJ^1QGWAFO;*.J8&M&U86IJ]JC5%-%H
M\,48=24#1DH\0TWV5=OM#L>*D"#[;&,:-Y0%9^O2&O-)_B%M;75G9NN:7[XO
M!A.(/@-^(LJ)(T@B$HF2I9"4@Y(T;CB5I:WEA8/.A-UQ)5PFT;Q+AMFO&=G.
M $0 8,J(2,FK:N...;M;U....*4XXXXI3CCCBE....*5#GR$ES<?Z.=L#L>G
M[:K"@>A+,):6 Y$J'-XRS9Q8BN5>#Q:+X:JX-.!6CT<!4T>I99FGK!]\#C[M
M]U6KN\&70&X^C-%NW4WML;*HCV"B-8V_I4^D0)"']16$8B3/8\/UD3@\]:G,
M+ G 8&:WT$#5%RL=1>Z8UUW4TVDQY5F)&PZ2J;K.-5QIOVR[44!2)[1/.N7/
M^&[>6_XK6VKHE[SNHU_PYK8\S(>L8T^[/]DM]O2N,9LY0T3313T1TT31TTQJ
MBFGIA/1-'7'I+31/7&NNFFB>-=-=<8QC77&,8QC&/7.-^6;N>,JN5:]5A;,M
MM%*U!)=?4^IT*2DZ3I9+8(.2'?>'NHCF&W;?XI^95JU65NAMLA:PG6^7%.2D
M*TF&PB04Y"P3.E,?MQQQSLUTZ<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<
M<<<4IQQQQ2G'''%*BYVL[.L^LD!92(;5=KWY8DH+YC=;4=1T<;2:RK D&K-9
M^ZU:I$7XH#&(J 8H[$IA/)85%1:+L-FVKQZJ4)AA9*(75SR,7E9]CAZO[:>.
MWLAT7+3=XN-K&:3P_ +:J"7FDF;@@WB)BQJU>*-Z^G)EDT=;QH%+A3,;)7;5
M0('/.)"LQ$/>GIT!Y'8G=S>_K"[GFYW P=ZR+0;USBE<]?J]JD%0TSL 6B6.
MSZQY*)<V&7AE=TL-_%TXNS*(V$WM!J0*-Y=(8Z[:C&]E$,NWK];Y1:,5_:]2
M6@8&-&TD> X9.8?.'PYFP)-4V1Q\QCY0KNR1;&-VFK)^Y31U3)82^Z*?>$]<
MZT!)[;0#^\@[F#B.DU<@ #_=/,'H 3C.!.Y[\JS1]>.5Q>56W^PO7WIA:=\=
M;2)9G-:>8L;!,(AZ^A]E?:0>/EQCN=DY)&9;((^Y?0.,0O$@DDQ901QM9K\<
M.3;0A5J2SMOM35>/F[O^LI%<4XBPJ*2JNG17R4UY4T6<1S+=J >]+H=UD)U?
M9Q OJHA(2J,_)V[,#$Q!$EM&28=6)"!" 4@))OS$ZA)$'&>6PY[^G60:@))$
M@CY]NT<YWV!YX.UE[^G\_IRE?S3Y_P"Z?%U^N/,QT,S_ /K,^Y6?;/FB[6UR
MEV0CHW,>)DND[SND?DLC)PT5E:_PG7'NUUAZ^PB.&&3'+4;%LEZ\NJ7*R\E#
M&XMXZF V,D@V1#!L5$$\J^6WOG3\][9>/OH\*C%S-;=KKRQ=!I\;D1NII((I
MUP'5_$SV6(.U7'_U<.'-&4R%H?A;+?=?8@U+-=,;9'.=TP4#U&^\<HGGRD=J
MG3I()((,CMG&9 WZ?KBMH+'T_KM_KGG/.,?3^NW^N><\M5*<<<<4IQQQQ2G'
M''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4
MIQQSY)TT+C@@F=-D6@@,&'OBY<J_6T;LAHH6T6?DB#Q=7.J:+1BR;KNG*RFV
MNB2*6^^V?6.02$@J40 !)), #J2< #F3@<Z@D $D@  DDF  ,DDG  &23M5?
M/D+L.2&XS!^FU2$=F=U=QWYJNVYAJFFY4K.E&+/16];=?H[>_L$8]#7*T>CJ
MBV--'DPD8ALANHJBHGS/=$=,^L/6W=B^I:DJ_@!]I%&D-7EP*.#6,Q-@6VK'
M*B$CD;9%,B:7?.!K0@27?*J[O"6F7BF=EL_%R./1AB^[ 2NRN_DY"JLGMUIX
M@G6H<2140(1#J-%"BR\0=9;;YQLQ*W/*LF;4/9WURY6%OXBPV5^ZC44L67\X
MG#F47SKG&'VT++Y0GAWB-@J8L&B2RX@*!*'+MQ2[HJ20KPUL-J@M5Q;!AJ^>
M5QEYM#BGPA/#2XV"NWL$:BTXWK!4VY>*6NY6I.E197;M+$LQ3CCCG<KMTXXX
MXI3CCCBE....*4XXY^:N=L:9^'.<;9SKC&<8QGUG;;&N/>,^\>O>?GGUGU]?
M7RY!,9I57]@$5+8\K]"5VVVT< .J?5^U+^DNN,_:H-;#OF0"Z8K3"VOKX42K
M6%1RU'+'??\ CT9%76Z?K*F=N6AZX]8QC'OUC&,8]Y]Y^6/7SS^>?USRJWQV
M[Z6Q<?D#[;+9T=)6MV@(T;7[_&FN4U*EZC!T:G%[L%<?P98$K(4LPOC9+&<+
MKNME5-]\YTSBU/G.X6?$9>NC_P#+NWWD\SX25!BW,Y_NMV&E[_[NN*T[/WD.
MOG>X?<='_P"-)#+)QU9:;5YDSF:<<<<Z5;E....*4XXXXI3CCCBE....*4XX
MXXI3CCCBE....*4XXXXI3CCCBE0<\F.P73Q\]TMI&SC1 %CK'<_XLRF4J)PF
M)N6.8.6PNE))2&UW+!PF<>LDUQNFSU=IA5FVURLYUY0Y^SZ)4YB\KH5K)WX;
M7;Y2BHMDLKXR6G9,;8&Z>\R'J?:6VPNQTX M8ZHXSIL*;A-$3+0_LX;.M,L4
M\::;#7>:3Z0GIUV<F>[:IGF(C1=FRC5M>[?=Y3BRL?BQ LCK93#1);<E#\+-
M--S K37&Y9#3\-TVUV=XVQ1)X+>TD [%7Q;J<0[3=%K_ 'H.D0I1Z"ZG]#;!
MZARJ+H&)L-QHZG4BFX)EI*QNZR>S!M&QQ1?\*+XW(KL<YRF\YC5_<.T9Y#.9
MY#^/A<"4GU/P Y3_ (,>1OC[$=-Z"[2FJY/7-%SD@?5AK,F4?T#SZ=PP<3C=
MB#Q@N?P:<"8=(@8VPJ_FS *):R>$31J:CA=!@BDZ8;);KZ*]:)]!>IQJ;V7/
MC--QXP9MJ-S^,3-B2<$W<9<,K9!0^,6L^#Q51[D!&I!9<?KN "IQ(@#%@8/M
M(: PY>85;*JKR1G5G5O5[0*_LJP(37S&22(7$(\\F\K Q-J>EAM39$+& S@^
M0'HE) 75UV2&!F.ZY%\IKMJV;*YUSZZJ][#4(.LMY3!"ZZF8W"/ K2E_5#NQ
M8@WLIC&6PW<TXD;R#+&-),T MPZ:A5<PX&ICT1VN7JCC5MZ5S<@<^H^.,>L#
M%0"J(!5&8&8W!,>H$QZU'$EXUNG)P)$ 1VI$#3>*'9K('3TK)).\,SU]95@1
M2V+&2M<PJ6R^M(9.K.@D(G4I$354N-*R&(Q]=9MALPU:;1&\TFOPBO%]C7.V
M/M/,QT+^/&=]LXVQ^-S[?UZSG.,8^+7&WK&,8^+&,^O>,>K6$[NIU49##:5I
MUXH'L8CL'@)769QW(Z:%M'?W#<9%GGXC]W.D$W__ &!1D-4<.$G^=6*J>CM1
M-'>J?S2[8R*\7>=?KCS,]#,9]XS^1B??+_G\_P \?GZY  $Z8[#$#';.8$T$
MR)G_ '1/6#UYS\ZNHQ]/Z[?ZYYSSC'T_KM_KGG/+56G'''%*<<<<4IQQQQ2G
M'''%*<<<<4IQQQQ2G'.,;8V]^L9^7ZXSC^WZ_+\\?+Y_7G/%*<<<9SZ^>>*4
MXYX?::>O?S]?K\.<?\\X]9_3Y9S\_ESG&VN<9VQGY8]^\_/\OK_;B1UI7EQS
MPPIKG.,?/WGZ?+U^?KW\_G]??]LX^N,^O/BE....*4XXXXI3CCCBE.5>=U#)
M/LA9\"\>,/?/&HJR1&]G]M)"(WRD[B/64"73:Z09)ZGKM^'R*_Y0V3@[+X]L
M+Z0MO+"":.VFR:V)YW3;,-HJJYY<-A%=0T*KB,%I9)'^?ARI@<):J+Y:,TLY
MQLY)DG'W<8)9I?$N]*/&C5'3=1;77,5^AM82MG$)GV4N*/Y ]@.VQYE;%AAG
M"NSAS 8JB/T$T]3Z"V^?CT:5S7B8M DE\*7V\Q+2A\JCHJX^7$XF57CS'"&R
M0+E)>X@1(T\.;("VP1LJ]=TVHY^";I:<MUR.)3>.,\)0KW;D%[B!22"CAJ%0
MXT2-C?N1: 2%*MS>.-D+9!$Y0P<8 %#0H8>U%"1(]B+&#&*6C=D.'#FJ3-@/
M9-T\:I-VC)H@BV;(I:::)HI:::ZXQKCGT^..=H ) 2D!*0      -@ , #D!
M76          @ #   P !L*<<<<FIIQQQQ2G'''%*<<<<4IR.O;J[6G6[J_?
MU\NO@VVJ:I)W.![=37.^KXX$CSYQ'!F--<XVW4*2#(P>EII_'NJYTUTQG;.,
M9D5RJ_RA;JV0)ZH]0V>RBVW;'MI5T>F#)+7X]MJ:I55>_P"V%E-?^'=HY&U\
M' .M5,ZI;8/Z)[;9VWT3WT^(/*8LKAQ'^IX9;9S']=XAI@3W=6@5KW;BFK9Y
M:/\ 4T:&N[KA#;0GE+BDB>52)\?=)..O/2_K?5)/[;:3 *MCY2<+K^OMW5BS
M5-2=6,\7SKC&%%74WDAU793;'Q[8SKC;YZ\F/S\TL^]-<_K[V]>_?KWMG/KW
M\OEK[]8_3&/7/TYFMVDL,,,(_L9:;:3_ .+:$H'7DD<S65IL--MM)_M;0E \
MD)"1UY#K3CCCF:KTXXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCB
ME....*57'Y2+1B5<]0[8$V?(Y%5-5VI!)G5<O[&!JQ(W4&Z[.ID#6&1^Q)[6
MX449*/X0D[5<-'DE4'K 8R;V!;2=4:'(JFAM3OBC[+Q(CV->0.N_*[.O+B^E
MD(8A78 !U8!57$.NP 472*%K5L2WXO&QD;01)#6&D8#1,Z4<RR625ZP2!L'.
MFY4H-V*KOLN.4U45CVM+F#XK&J^AD@E9H6,18KORC 0.6<+"VFA5V/#Z+$O6
MK+5P;(C@;3"^71HBP%(O':,$>C'=&I+EEJ]&B:<A]"7 E3@^_)[4<$FM2V*U
M@216U)K5JX.<R.F<[P].8+O(L/D0YPV>$V4D G\NA!%QH&(;[T@3!.3$3DP#
MG,<SC,Y/0@5<3I.,2?(DQ,C>1B"*QUYHP4<G76494YSJ%?/:[-MR=G"G^W7F
MIPEF6#44)T(A)+.IJ">GR@0=#)(6' &<1B)W0V,=-9"7:&LK*CHZ02WK+[.=
M(NVEQV!W[F=""9P^(WQ6-ZUA+8KV*Z\5! Y]!R",%@1>N=NIW;.'C]9=8]0V
M,R![TH]@DNEQ%G]BH_)'&4:7&:Z+;76===O7Q8QGU[]>\>_K]?KSP^R2^?\
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MR[:-C;)Z@V=90440RX1TT6^Q4W3^/X-]L9_4?!X>))'C(N*QH:7E.$-9*58
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M8>HNV04]*)(J:Z;XQMC/,E^L8^F/7''.@, #I6S3CCCBE..<>\?KC^_R_O\
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MNMX].8@1,")4XC< =Q/:5Q\:0 I2)FR,;,6!HKN,U??"P?N&FJ]<VZ5JMUW
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MMMKNGOK_ !:*:[;:;Z^MM-MM<XSG]==]-LYQKMC;./KZSC/K_KUSU@@ 1 $
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M4K\-04AH*\,)4%)*W"A"5)4%*!!K47>VR3I2YXSDE/A6X+[LI5H4"AO5H"5
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MUFW5QC&-_@^SVTVVHF0\:7:5V9P:EL\KB<$5+1C$W(O)-9-J/FIDU![]JBW
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MXZFGLHKMKK'9T,D(;3XM\YW29I*_/537;,Q,_+&<_IS54_96ZY[T=8>K5O\
M4;N?ULMRD1E>6+K8U'2"? VS$*9C=DI[[S>&"W+<F]^R>1Z8"%91LU411PNC
M-'2Z.V^S=S\.U5M],^OKZS_I_/Y?WY(^/Z_?:HJ@SSB^6#/C1?\ 0 4&/,!K
M^^NX$%8VBV<:"EU]NL4->,D[H7TU(HK;#=EUY9$VR!9+#=5+5)ZF@Z1S]KOK
M?6T<(NT$W+=9-PW7UU50<([Z*HKH*:XW17153SE-5)=+;15-5/.4U--]=],Y
MUVQG.AC^T(>'[S!^47O<ZL2HJ.AA'KC4D$C]7TBZ*7=5<=?FANZ?[S3B7OP)
MF0M28Q\>F18@R11>MD'& @ +E33;/K?;;W\;@?LW&.CW6Z&=QHHRA_8^ 5H$
MKRRV Z2@9>R)OX)IO%0\I2/QM\1%/5Y9&Q8<^1T2<[*-"C]\U6Q\:7O, SGJ
M#SZ'IWG/3 -21CER/<R >O+$>IZU-[?.==-]M<9SMC7;.N,?7.<8SZQC^><^
ML8_GR@KH_P"5?_:,\QGDWZ%E9*S=1J@6%8K42PU6'?[U>NQ+2(]CVZ*[=%)9
MZ[2L*3"7"C559PLS1&O--,:(MU==;M+;)6"&JZQB]3QMI,;0&066/ZYB1 FP
M"#Y+.V@-\M$03\R46;CA3(F?U'M'9!ZNFU:-E%5EM]=-,YY_/0\;GA-\[G4'
MR;4]WRG5(PTZKO<1N17XY1[!TVH0E,,MYT3&W(Z^YM9/OET0V&R8O(1K-'3?
M7<P.8)IIJ8QIID3W_>>@[D3WVH!Y9D9@1C<D[9CY^1_HY<<\$_B^'^+/Q9QG
M./?YYQC.<:YSZ_/.OK.?YY]?ESSY-13CCCBE0>\C-^65U?Z?VU>]3;13:;U]
MB%/!36;@W\@C+Y ]8<2AQ)H1'BCD<)9S]PDCAVT<-2S?9!ZU;_::.&^ZR.V.
MY!VYG'7'ME .O798A!2M:WS5=ISNE+HC(@E$2@Z840G&B-G5E94.<FY.T<J%
MHS+ADFKB6Q9ZTV++CS$-(QC\8_!B!7*?D'Z\3[M;U+M6@:U*Q %++#Q#&S(W
M.G1MO'!;:/3^*S)^NZTCPHL5=+.&T:W'M&Z"*&F'#W5TLYU3;;(+QO[!]*^R
M/9*PM[RD%BU37MDTW4MHP/J3$X\-DDKB41F=S;1!*R+,L^8%1H(X9-E(U#FD
M%@[2+Q-DVK)N3+SM'][I9^"H ZGM,Y/.,:3&\9VY'>KI C)2$S_^W+;!,<AB
M!FI9Q[O!U>E4MB$#!V@@\E\Y:74ZCP'>+S9F\V6ZY&$H_>@8UL_C;5M%Y35I
MIPS'2Z(29<1*1RY ;MJ(61(LE5^U5]VIH:TRX %!9WH9)R@9L4!-U8[+!&K[
M1*)QZ=/!N5S8(<W:2,7#Y;%Y$9BKY5K)0HP^*6*"FFSK73%,I[I0:@0N'4 Y
ML=!MV<F??&W>WE.2>MHE9YQK':*O"1)QCM1%;%F\VU,LG+3:J;(L"(+OCLJ;
MFI 7Q7TP9#79UBHS;3_A?3:?0SND:[*Q:5Q^N8+)FTH8V/7T ,3C:/WJ.UA$
M2B-2$[&K"2KDX#&[;JW )ZGO=]?.1,EFT.P#@4C"KCA^S_D:E2( .8.#^^,3
M)(Q(D"((I2 =]B1G?:.7,'M$'I6:M>]O4C>W4:(UO.';6JK:+^DMHOC!GX6E
MOCXPC,]JR)'LB<1D3.2$76_&@$9)FFA63M$'W[N-BJHY^DV^L([G]93_ .*Z
M!+8!E70M.#N$1K!D=<%Y(QLR1$XE7A:"B=1/XC80*;R<*8 18]!VT@#&BHDF
MS9/E%6+C&E3$-Z^G^VW9+R#5:4-A8[4<:\D-'79(2Z#*7L+2?*5;UKH](4,@
M;HD$;17826L&'9!O9T*-.U0",<F$=2%/2#]J_%Y'4\6D[D\,K"/6V5I^RW-(
M=;H%U'AZ0]U:%7*R^M(/9T1GC.U%YG!WK>:TY?09*L*V<UI(((]D0ZM)JA-I
M,R6-#92VCX=J5R$[QC![[^?/,P!4Z4C!D&$G<1F.42-]N6Y)VJQJI^W%6W5;
MTRJ2O<R4XI$*IJJVU)K^[)QG""X&W24[81UF'-O1K9!P3:X@1+<FT74;KMW"
MFPW5#9^-*H,\2H=_>KT%-V4.L'M17TC>-;9N&(QR*QZ'R/6319Y15?PR4VS5
MFHJ/HR8U8TNKMB7_ 'P/D0PI!YL,D[ 2V#+JB%'+GXW4WJC?M#6:YE]G7.&N
MU*5]7Z,J6P)I(&1=*TC=D4C*[;<B#Z[Y%-G'C88C#+.9BSDA)LVTMD4CC"DB
M?LD%9&]T:1C%>/7LT'[3FKX1DM&/(VY[9=N.Q0P*L?L5N=R%OWJ)7O6B%1YV
MII#UQ[0O'2=?H2>2OFR[EHH+,.10/1-RTU<.XE6"9F3R,1 Z'X3/0QN(A),;
M"!)D<M]T\STY'X60-NX76=Z\K=FPN&(D-;::5F\@)(<X>/P!M.Z![\G3R*LD
M:,U@ 5]:S(6_4K@<?)"B$U4;*-H\U?NMDD5.NO>]O4T>:UC[RZ(XD37,0H(Q
MTU92%=L77L*UMJ+BA($0;AEAY^,/[EUTJ]W+PSI]%@LV<,P1TP-=/F>'%:M%
M^*BYH/3 6A;$LBKB4(F0+HR\N5[%6DN4D,?G727_  _$M5:;?EV331.-VI'J
MC@"^N9%J.+U9)5YD1$YEZ!<8B([$*\>'<$?UE>=9R5U==I''Z+EU.&^H<D6K
M*;A)8= TEV*A=\Q$!V7-M9&0USZ&0@;73]:JAC-$FNIO8A%LX)IMXVC,JZ=.
M1.\3S&TD_I(S,(QD["8/QCW>N!OC-9^M'OZ &]@>J82OK!@.:)EUG=RJL[*F
M92 /!CD%D_5RG)-."[/0T==@F\63B<DC+UG+=B,?*(%6"K1<.3;M/^T/,LR#
MR$=?!TPJ*%@2,MF!FU+[E'79R@ @LMPK6U@PNIREU2)I:+ F#9%H<FE &+ Z
M,U(L$U#88\-D0K[S'-'A5O7=)O&'V_>DVI^-7)UV&2A/L?Y![^8R(C!YB991
M-QW)IDG!(@/0A1[4Z#G;FO)D=)'2NLA<B Y@ U$CTQBQ!)VX<]VK'QP]EX+9
M,>MU]8E+DI2,[P1CMP0#+N[@/-7P\]TO:]4;>B[N92EX2DYF1X?-OWT@\D((
M),7NZ[AH>#B6V6P]K$JZ'D=B3(B1O@?7-(1C,XZQ.><#&_R[5-BN^\'75E2<
M%LF7=GJ_LD!*P$GG#>V8K%BT?B;NOAUCNH7F=EPX_>28@\"C1IZ+A!:>2<B/
MB[@PR7)JDF:+E=%EWZ'=XNJ%@V@/IJ%7;$9+8Y6669 AX 5J9<HNYU3K=-[9
M4)2/X%8C69C%!JOXP\C&3.#;D$@].C6+X./?/6]8U+>+?L+5]5/H*\L>G7Y*
MUNIML=/+MURC-BH$3$YA=MZ6O#;.K+#T8P>OI$)%]A)Q&YA Y,@.#R=X/BQE
MI+!28TB/+=TISQS]@*FL&F"J$GITC"ZI[^W7V?VPY.S]W+2-26'UV)=?HI'%
M%%8HW'/+.#LBZ\AD)%RNA&WZS)!B.4;ZO%W#>03L9Y?[2>0G,[S/+XP::4D;
MY[D1OT \]C&W+>[+CG&N,XQC&<^\XQC']O\ K_\ ?G/+UCIQQQQ2G'''%*<<
M<<4J&GD KF:6QU(M^OJ[C[J43*2#X^B$ L5F3=R069RT$2=:)K$'3)GIE)BT
M<N-LK.4L9U2VQKG;?.-=J'>GO1'MQ77:2BYW-:0D8")1:P&1B0&G1:(KMQ@U
M(>324=JHLI"X>;Z:;KI:? W;+*YSOCTGGUG.+)>VUVWC1'9DVX87I8#RGXKT
MG[3]RC%2-(Q1C-N5*];#E4:C*Y&S8O5):4"(G+0TGD#0X]?$"LA;/G+,B-.C
MDF>&>>P2_P D,NUFHVL:TZ_"YE/)';/6JHXVA([=;PZ,IE>Q766PNQ^IZ2&F
MD&E! 6#@0R KA2K48!-'3S=\F3"#MW.4!SCYS[3?AMP7VH]I.$>TU_=\38ON
M#BQ%HU:N6J+5S\A?+OVO'2[://'4ZXI+FAYN6X"0E?O']-?A5_Q0^W7X1_AA
M[:?A7[/<$]E.(<"]NE<?=XI>\7MN+/<6MO\ Z@X!:>S=X+%VRXQ8VC?@V5JA
MZW%Q9W&FY4I;OBLZ6A;+IKC777&,?_AQ[_M_;^W//E&,.\Q4E+P;>62KJN]C
M).95W#952448W1&SCJ82N4=J0W3)2'3TWO%!H2MF"5SR 07'2YLO,6;NKG2I
MPB-$S-JK!=LV13R!7A);XAW5_/6F&(7-BQ;JAENN6U_;.ZR@\>IB*==["6F\
M.DN*M2DL\3F<*[$QO 2*$H=#) &EH]T(E&!@7?,AT^B:@(!G/8_Y^_*?S/H5
MT'Q'2>OQZ'&^*MBXY1UY+.X_8WKW<#..4\=DX@2SH$).6;Y"%5<>IT#8$E[%
MQ:J0\D[1R*8ZZ3R*T2T%&%$I*9JIPV/@&OXM)'*^N@MLFO\ ?,>7Q*/F^S1I
M]UKM0E2?757LG&G-G @=@9P7G_6(FC&Y,,,DS=9!Z9B\;L"9??XC79%G=,JE
M"+YBD1G$1BXMZJX&M4$B-MS\,QOS^\PTD@$09Y2)F8B#$D\HGZU=)G?7&<:Y
MS_%M],?7.?R]_+\OG]<_+C;;77&<YSZ]8SG/^6.47W_W1[G4C=-?RN443',M
M8/U"[F7/<E&Q;L<->05[$:8D_6R1-;%C\T(U8Q+R"PF,0DLOB\3AA.*11BH>
M?DE"LC9QAT.D2WK=JO*29$[WS3]?1M%HF:Z^=J]*JO&!2>9&3,!N2HNI!WL4
MD*G6KVI!=41F7"PNB6^8=';@F]A10PW$.);$!HLOEPP:AGKT_G89Q\^8J="O
MWR"!\"9&1D>6X-7LZ[Z[>_6??K/K/RS\L^L9]>_I],^^>7* 6OD4LZCI-:8(
M@!F/8"<6'>5 5A2<)53F[L1'<;>-ZG>Q]F/'FU5U;:\[28$B6TI.:-0<"DCQ
M]+))LL\R&CC8H2&YQ!>42QSDU%-G'4B0PRMQA[I!%[6*V)9",3MRMY'W@9@V
MD:".:=<P991\0JJ4R(0/LA$G+(XLH$>;%(XW)DV! (W:NH(_3:9\IR=O7%04
M'L9[CMWVDP.M7&\<H8C?F9EIBO[2MIQUA4<5U'B5'0>L2,6F%E2(K+[D[!7"
M1JF)U'*F*E!B]1\DAC)F/G5G.JES<[$<#E$780U2:%S+)NM:_P!7+ID]]U")
ML"95=*:AD^YN5QPS$90'F0;"CJ*2%^!Q(XVE8<+KF<NH9*4&:)Z*$)5 H@;=
M"GR6'P)JJEMLK(4#\_E'[_6:%)&\>A!Y _J/6I$<<<<FJTXXXXI3CCCBE...
M.*4XXXXI3CCCBE....*4XXXXI3G&<8SCUGYXSSGCBE>.=-<X]9UQG'R^6<?I
M\\?\^>6,8QCUCY8QQQQ2O'X-?>=OAQ[S]<^O\O\ VQ_;G.-<8]YQC&,Y^OK'
M.>.*4YX_!KC.<_#CWGZY]8YY<<4KC&,8^F,8_P L>N>.4T\_737/K/O_ (<?
M7/US_7\_U_/GGQQ2O#[/3'TTUQ_EC&/Y_EZYY\<<4KCX=?TQ\_Y8XQC&/IC&
M/\OESGCBE/6/TYQ\.N/RQ\_G],<YXXI7&,8Q\L<YXXXI3CCCBE....*5X9TT
MSGWG'O\ 7&<Y]9^?OWG7W\.<_IG.,YQ],?+GG]/IQQQ2N,:XQG.?G[S]?>V<
MX_IC.<XUQ_+7&,<YXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE
M....*5C>0U#64NE:4WE,%C$AE*4"EU6X,FA3<FX4KJ>/0Q"90M=)YJJT=1R3
M.X^%5-"W*"S=_P#AS?1;79/7;3;"U8=&>I-,)A$ZOH*N89F.S&/V$'7$"5\/
M&DVBD.D%>QF4;/G3MR\<F@$$E1Z'"'SQ=PJPC+[\$;?9CVS-!M+'CD0#N!\*
MF3U/QJ+BG2GJBM&'4,<4#63J*O*]D55.0#N.-W@M2O95.<V:>BOW5UE;30:_
ML/X9K[3QH[:R5%N78NFKQNW51^U5_4[KK3&88I6-10^(O*_:S]K%2H]HZ6.,
M<VHZC3RQWKL\1=/C1PO-W,-BBLF-GWY4R6S'0^CHANFP0TTD3QQ Z"DGJ?C6
M)YM1=160O*G,\KR*RQ:<5D9IJ6['1B9#605;(';A\:@I31;.4W,>)/'3ARZ9
MYTQG=97.^%,9QKZQJ/Z6]6QDIFTQ:4G"?QNR(B2@T^U=-'K\),HX;",(T?:R
M2*/WSF*%WLCCPL>$DIUZ$6/R,6T18G"A!OKG3,HN.(!^^>/VH"1L2)W@Q-1/
MB/1OJ;!8JI"XM1$!&QUQ!;-K1ZQV8O2"Q."7)F/XLZ,%B95^^+%ALS1BD89F
M-2;]VLH/CP48W6;CQC-LE\LET Z;&)L<L0GUWKA[+Y(&DH$P77&/-\.ATTKM
MQ4LST3'X?ZB6;R9ULYWALO+,6#8K*0:;5J>>D,L62B$Q..('0?"DD;$_$U&.
M8]-NL<] 2.,RBF(80%2J2PV9F?L6[\425E]?0@76D+E#$Z&?#SP201VO0PZ%
M#3 ,F-()Q=)4&HX5'O'J#C[FG5N@$6A1FUJJ(-4S+VH"9'9 ?G"KDG0.HC6E
MB6ZJBBFV7]:9 AU(DYV^+<:J,9J;?;Y2S\4@..('0?#[Z4D]3O.YWZ^=51==
M/$W3%+HV&(F95A;,-GM<"JG?5^I6\,K:$&8P$FB\]&R^Q8]!=4&5CWDWD"B#
MAO=)'03)16&^RD>:A'+IRXVL@K*L813T)"UY70)..Q&/Z.M1@S5\5*JI[/GK
M@@]<.BIU\4-$WCQZZ<.73XH1>O7"JNVRJ^W\.,=]XX  V'[_ !H5*.Y)]:<<
M<<FHIQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ
M2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<
M<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2
MG'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'/CR"0@HH&)R.3&14>CX5BY)F
M3ITBT$!A UFGE5V0*%'ZJ#(>Q;)8RHY=NUT6Z">,[JJ:ZXSGF!<]R>HVNNVV
MW:7KEKKIKG?;;:[ZSQKC3&/>=\YS)O6-<8^>=L_+&/G[]<V&+.\N@HVUI=7(
M00E9M[=YX)41("BVA0!(,@$@FM6XOK*T4E-U>6MLI8*D)N+AEE2D@P5)#BTE
M0!P2 1.*DEQSU&+YH2:MWK%P@\9.VZ#MH[:K)N&SIJZ2U7;N6RZ6VR2Z"Z.^
MBJ*R6VR:J6^BB>VVFVNV?;S\L9S^G-?^1D001@@@[9K:!!$@R#D$;$=:<<ZR
M.F44+GI!%14D $I/$TPB\JC@\R->GHRA)&SEY'EI"';.52(1(\T9O'(50FV:
MZ%F[1RNPRX305VT[-[Q^O\_Z?KQ2G''O'Z\ZV4F$5"'8S&#$ECXJ1S1P4:0\
M"2-#6!J5N@@M8X:;1H2[<I/SS@.%;KF"B(IN[4'BT5B#S5!FDHMJI79..=;.
MS"+1A[&Q\CD8  \F1U.+Q)L;-#!+B425483-)QV.MR#ENL<.J!PQ<JF'%Z.B
M.XT62?ZMLM&+I9+LGO&?IG'T]_T_7_+BE.../>/U^OTXI3CCCWC]<<4IQQQ[
MQ^O%*<<>\?7W\OUXXI3CCWCU[]_+Z^_R]?KSK4>F43EJTC;1>3QZ1N(?(G4/
MEB( X+,JQB6,60\D^B\B3&NG.X21,AQ840=@RFK4HV9$Q[M9IHW>ME%5*[+Q
MQQQ2G''O'Z_3Z\>\?KQ2G''O'Z\>\?K]?IQ2G''O'ZXYUAQ-8@TEXNOW,IC;
M><FP)>4AX:N>%(RPK&0#T6-.R$;&U76IE^""DC@0>6,-&2PX:^,"VCUR@X(-
M$UE*[/QQQ[QCZYXI3CCCBE....*4XXXXI3CCWC/TS[YUR52^+08&\D\SD8")
M1L=LTU(R&3FAD?!L-G[]J+8X>ER[IF/:[/23YF/::KN4\N7SILS0PHX<))[J
M5V/CCWC]<?G_ ,OK_;\^/>/UXI3CCCBE.../>/U_G_3]>*4XXXXI3CCWC]>/
M>/UQQ2G'''%*<<ZT5F,6!%HX!-R("'-S$D]#1 .5,C1Q65EAHEZ?(#(T.>.4
M7ATBR!#2)IXQ%(NW342P>DG"23)JNNGV3&V,XQGZ>\8S]?I[^F/Z^_Z\4KGC
MG6XO,(I-QJIF&R6/RP.B4-@U"\9-#3XS0S&BSP!(A&Y 2Y=M-"@$Z/?A30_9
M;[V*+,7@U^BW>M5T$^R<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ
M2G'''%*A%Y*/@_V NXN5?L_L_P#9SM;X_M?A^S^']U7_ +^/X_X?A_7XOX?U
MY_,M>9%Y'//F+]Y8*9Q\Q^<X_P"S[>\>OBQMG;/S]^OY8SC/OG]9>01\'*@I
M..24.*D$?-,G PR#.#F9<.6&O$]D78\F,((N&3]DY3VRFX:ND%4%D\YT43VU
MSG',%YZ>]2\XSKGJ[UTSC;7X=L?X(UI_%KG'K.N<9C6<9QG&<XSC.,XSCY<^
MW_A5^+EK^'/#>*V%QP2YXH>(7S-XEQF\:MDMAIA+6A27&'2HE0U:@0(Q!KX/
M^+GX.7?XF<4X/Q"WX[;\)3PNQ?M"V[9O7*G5//\ C>(E3=PR$:1@ I49YQ7?
MJ4SKFGJJ^'&N,9K6!9Q\/KUZS%!'K&/A^7K&,?+U\O7T^7(9>2F[[GJ>O: @
M=!3.-559G:KM=4O5H1=,LC#&;#*996 ,F<F-3QC"B[ID"ELOW%P1S$J_ R%R
MF!>3B4 MRJ+]LAD8]L19LFH]LW9,6Z#1FT;H-6C1JBFW:M6K9/5%NV;-T==$
MD&Z".FB2**>FJ:2>FNFFN-<8QC%]WT14'9*MSU0WI7D7M"MI+]QW,1&7#="0
MQ=V*?-RH8HUVQNB\%'019HT+ #XATQ-@2S5L3$$&3YNBXT^*/+\5UUP#2''5
MN:3F-:RN)Y[[XZP-J^Z,(\)IELPKPVT()V!*$A,\X!(F/2M8=]97:/I\3\X4
MS)]C15I7]43'Q1 QM^(5K!X<<)QZ1NU0JG^)%?-TC5<C;#UB,P,C9(N #AHX
M[8O \F#1F,.GF&S::7DE[Q]AZ%LSR!1VG;+:!$NOWB!W[30<%B.PXYM%[V4N
M^UHV+E93!80](N$R<6BH=BF!,N%0"[)LH29C=7:RSU2Q^O\ QM]'ZPK^WZMA
M_7. -H!V C<8BEX1DWH>F+&V1,/'$A0!:P%)F<D#V4GF[,N^V>RPL[<RLT^4
M1*&S1$DR8NVW5HEXJ>@,'B=C0J-=<(LP V_3SF@[3^TD-@DC5B5,Y+OS>T4F
M<K+S$A*Y%E%\2<ILSY,VXD[ 9JT!,#38&/'CFN&%=MQS[R>7.8.TQ68D>L=N
M@'Z&J]+_ )KWK@3*@^O([OQ:$BOZS0,\O:?N.M'1NHK3O=I$C,CA8>* 8='I
MBFTH"G.M=<F#92*+3ZXR$HMB<D5PS)H==[BI27;0/C5Y=N^Z"'AY)D+UB]4=
MGFW<+RB]?'_85]55?E"FK*GJONVM5I@/J0/+)#3^;ID,+C*>C4,-D,JJQE,U
MGAML,DP%FD%>;(/8CH)U([6/X,7OBFP\V-UN.5"1"0('YM#I$QC;E9HY=P]_
M((#*(J9D4'?NV#-Z2@\E?%XD1?-4'KX,X=IZK<QLY\47CT<5]%:HUZM5TQK:
M!3.S+#@,)#;R@%'(!-K>%JAIY)("-"R,>E"21!DMOL&4B^16D,?_  %H3I'2
MR>CW40>I^/2.>3R)G[,A0YC/41^@ ZX,SL9Y5"%[6OF17KU)Z^=B;3C_ &!G
MG3CSC5M4#2_PL, 5\\M**3[QH7S=8%:<PJ(Y_<^/V=!]9RM#IIB)H# 1-PR&
MEVX($N^<L,8^I_R+>1NU)[%>T,;1O0W3<I[0/JG6ZJ8Z?5R'ZPAJ-&]BRM!E
MC3;N64GS"S\WY'PXU:?/BQ5).$%9:S<U0QJU'=RQ-:[!< Z$]1:MB520>OJ.
MB$3C5&VT[OJMF0G8XDZ%W21C$EAI.TSAE8RL<G4[+1J7R(69DD_)2DD8T(?>
M2:SIZT8.6O3,^,;H9M?._9;;K'6NUP*3+2RE3FS0QF.*V@F\_$4[84K3\9_P
ML4MI,EC4CI:6T*S/]2&B;[$BP[336U03_!(Z?ST_6JF('WG'?M^O0#%_E+N+
ML-4%3]>T>L]@B*TLNX>[W53KWO+)#$!$Z"#XI<M@N(9*'!"-%_LM"&K0<XU,
M-4&A 0\7(#6;3!1JT<O,*UI=E.Q/D&B/9$9TAK;L?V<?ENO/6NH+5LCL+3/0
MVCNQ-G=@;!N.:6L,$+61 WA2%5S6%21<97"0]^,K*.L)+-"STDU:3.++!,*$
M]AJSZ5K.YFT*:6;%FDL;UW9D%N*%I/71-K@#95:%\GH-+&^1CYCLN^CQ?/WY
MLV>[.ACA7^$@Q>)?[OF#NRO0+J%V].Q>5=AJ1C-@RV&CEPD?E_W^4Q&8-HR\
M>_B3^&/)9 I#%9$:@10A[>EH"<)DH85<;J*D ;G=13.\F9^'/SWSMMM)Y;4Q
M'WC;]C]S5%'87NGY3)97'3RP (*^J'CTHZQ[3_L6TZ.]>NNG<J\XC?B<[?Q5
M%U8%!VK8)"5-.K90%&R\H#OJ;UD\Y?%E"<+?R-F3$--GN=U.QG:SNMV=H>GN
MH_?^,U)3UI>,&M>V#JXH9UQ@\FE4VG#R\'\%=RVLJVN7\>Q!@D@1P@UL*,S5
MU,W,&"HL8R*282LFZF;2S2V?&/T1NP56 6=]:J]T84Q$FM>UAB":R"HWL.KA
MFJDX0K(64J,]!BF]88<(Z.5:W?/'D)<.?B<N02JZBBF\;K2\1?7VZ.V$6L6P
MJPJ]YUOKKI7$.L5855&L2NO)%7!V)W(6G:;J$$ZZ<1-2)05["WK6'$@T>DX_
M\>8).8_(0Y*-KJ(K1MF,X SW W[Q//O$Q0$0?+&)SCX<_N*@Q3/='O/W_?\
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M]<.CU6]M)3;]L=EZY.3-\2M1M/ST<!U]5(;]V<CD8Q70,1()<==RK#*<1=$
MQ';YE[^>'.]NWG8>U)8 7Z(NJPN^*#H,3L"UZ;N''8FG8OI 6$"59#0=6V#%
M*/[3$8ILW?2RFI#V: %#%2GR3= :N2$ 1C36SZQO%UT?NH)4@ZWZ0$6 7I:M
M8I4$1G+LW+(G8#RNH>/9L1L-EDOKF00PS,8<Y4:[$B4)D[DK#GA-X_=* L[/
M%\;S!QY'F<G&^_.>9QM(FDB-@#R[1I^1@[S55\'OGR7=VKRZ^T\![%Z>/]]+
M/&G%NQ=VC8K2=/73(QMW:=CY54KAQ7VUAJR^.QZ/2=J%U)%&)LE.-Q\4_#P(
M= ?*'!&5M.L41Y(^PQH;UEO.T6<.G!\1XI?)Y>EF!8S7L8!.K)M'I[V"JVO@
MY".G,BR,UA Z>L0I=^4@L:D;>).2AYNN\#D%X]'UAVP# ^K77^KIE'9[6U50
M^ R2(TN#Z[Q56'#=HX'C=*1F2+RZ/UR"BHE=K%!,>$2)RL29)L@B+Q+;?+?+
MS9GZ;XZQ6W2KK#4)* %ZZJ0!&R%70.UJQ@:R;V1$TX_ [PGPRT+6C:34V;)M
M'[&:3L..D!/<L@_=HKMM68YRR&*+,5$$>72=O[>O2"?\U!(Z=.W+/;Y=,;S
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MJ(,-&9A2.Q><EE'BI>?PJMW1EQ6$&L$PL1(K%YW#H8#EA18B06?&%U'KG=4
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M)*/DY>S0>PI*.OFSMX29.V:K!3,L5Z@74'[#>)6PUHX";Q7J3TOO*DKH7;R
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g662876.jpg
<DESCRIPTION>G662876.JPG
<TEXT>
begin 644 g662876.jpg
M_]C_X  02D9)1@ ! 0$!IP&G  #__@!!1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?5$Q935!(3TU!7S1#7TQ)3D4N15!3_]L
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M,RSQ)^S,+RR^2Z;Z:3,U*KMCU^VVMY=!-LFRA2NY2;HKU;6A<SPS'#*'X3%
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M>7''")S X@(]]?O]1Z$?3U$/81#H.A$!$.@ZYGCA%X_#CWWU_#L>@'ZACWT
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M&NO&J$P>3/RE7%::@I2BLWZ03O8#*KS6.<2-@>6"%PYK<W@F(-LH>G0"A/\
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MH-GUTL.R;[B<ME,L:K.U9I.RK?CF%XR)*G:GUOK^<2MX=$R=<8=F@P=\HPW
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MW6K$HG,W)FCZ6I* B+C ZRC<%;OL5)<)!EB#JM83E#3D.2]$9B*G 5!>!V/
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MB4APP2NY;2X*V/\ &!9S,$14AZ+TNH/7"V;XN2H(NIB4GV'::+8)RU(W,_\
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M4@5=4QB[;-HM7/Y_LADC?H>\0]98+7)VP@H_-,I85T&0*Y>F=<%7W(R-DY/
M' ARP.REQS"*8O*__*5A96>@FT_Z-%,&3*L:0M/.8C.D,@7ISJ^QKV3_ )TI
MXUC'7!N-33$T@4X,"QTR5L:<T#A<D*DO+ ,?;)\H_CL44N\[$I]T-<U%)1Z=
M(:R>K*3VA'3HNW6 YH<W9KB*A86IR-!]=&4HY^:T."?/-QCQ![^B$]F(.7%_
M5WLD<?F'CLVOEL4?&B31:4ZBW!(XU(V!Q2.[%((^]U4].3,]LKJ@-/0NC2[-
MRI,N;7%$><D6HU!*E,:82;AGDR/'Y'\*MU'4?5350=?<DGP]_#]V3]=]=]?8
M%]=]>G?7OUZ=\PX."!H0+75U7(VQL;4BA>XN+@I(1($"%(5F>J6+5BG,I.E2
MIB"\SE"@\PLDDK#,PS/'#'+(#?\ \!2?]53?[ OD9+EU;9;7BUG,V-@VVS.-
MAQN5L^&/Z6K)40UL5R-J5MY>6<$)E"6/J6%,8HQS/C6*8EK5I -0Y%8$FY!S
M6K)*N*"1]%31U4[62.9#)4>[A[VL<6,]H8Y -]X:PDAH:#O%U@NZV?I,#K<2
MIJ?:'&*K!,.DGIHYZ^EPS]U?##)41QU$KJ85E(_=@@=)-\!E>\L$;8G%P7?,
M2L""3TE:H@TUB4S3MII)#@?%)(RR,E">H*$Y.2L-9EJW!*:>3CD:26?D7F:7
MB)F&.6 "/.7<JJTV\9B76-BG+0_W)-9";+'EC=$QU:R&=4TF2EM+4>WF$NJ*
M+3#[%]/-,. Q,K68B:B(Q%*3T7GEW9ZP,I$=96QC2K'=P3M2,E$2M?WARD#T
MI+(Q^'$YS>W=0K<W19F'J<L7*3U)V7ZQIF0^O.NP&KQJMP^GGQS"8<'KI&/,
M]'%7,KO8O$SVL89(HQ$X/A#)2YDK[%VZ0"#;T_ZDX%^GVS^TV)X;^G6V]=MY
ML]35%.S#\=J]G*C9T5]/)0T\\TXIJRJ=5QNAK9)Z/V4U'3EP@,S7.8YA?7QY
M,/)[0'BSJ"%W!?33/)2WSRQD%>,$4K%K:'N8J,@8WF4RB5 UO#RQI\HO!8NQ
M+GR4KL%HFHTN27 LDPQ3B&/Q-R/)U#M4IYJ;6$1U^OK;2>;F,EL26F(YK8GK
M-V5.D?I^*Q*;R1X4*;#L* MIB%3%9<D>FLUO6K14HT2[(<<3!1EJH.[[>-W=
M#R ;^)YRGM.OM<-9=?M8IA4%1OTOJB&;,F7%+=I6ERC.S2E35CY.8RGAB!!6
M^#-7J)^>,4SPIRQ=/P@IQ9WE6:BAM!-,?+%0"KQ!R\[65@VLF7BU-WZU_<BR
M=C*JJL+?H>RX5":QUELII>)8H?@856$#1FMSS$'1 L?FS*$)\7/-,8^$'%=U
M?.UCKK:_+\ZGUS ^?6&6?J!ZW-L\L]-38*U3'S;:Q':XMMUI:TV-5VLZ['*M
M/$FEI=<MA.W..TK=@0O=:;5P%7*2(JB=6B,J"9NY255-BH<GAQA;D#YFN-):
MC.RZ:\JU.2YJV#5[&5-?>A3GK-%H]8-H(-PHHP0QFQKB5'&(V.=12P87*YY7
M4L:5+P6,=,:V>4&R8F1&)6D&,U0M2?:U*M?C2\@S6],'D=3US2YF[C7Y(;4W
M:/TL5V2VX5]^AJSZ!8]:'.E2+L2,&<-.O-'"HNVRQKM$^.%QC"5+E?W@\%'W
MM:OE#XTM8MZ5^SNTEY[?1B]Z\UCMB*1U+6NI.V6Y:#<YVCEGEVPXV1(YVP16
M-)%E,55"F]/@Q1R"15F6.C\QI(^VGE+?LC.D4N;]YZ7U-^)X"V6NB9=YV[\P
M;\"%WG'_ #=ZS2S3>&[@Q&M;^DZ2V]FGG4BAZ);(<QE7W=-SMTS>HFB88O$W
M>4MK0Q%.*.//4N5'3F1QK..1UL682(M ^XD,ZCUE_F_U_<*CU]G56T/M3=EJ
M;$NU^L4=U;KNO(K^GV'.^J2DM#LFWV&V2F=QV#QY14[BH1-2O!--7/\ .UU=
M6A'"?Q[[_B87 "1^-C<J+ZVTA949J1#-;VU/\S6P'D08=>1LJ#,3M<])V-=-
MI/:.-,,^4+W"$QJQ5T-F[/)&U!)WM$UEG-[DR/"M,YG(RL88R;PJ;3-$-U;V
M$L736';:2K*=^1^9[#Z.%7[%(V?%AWBEQ$PI<AHG[\,:KJ7K:3>"DBNS5A#Y
MB"5Y3(9#7PR)7&FE26N>^@UUMGD? WX*V%[$\!RUROGTOYY9K;.DNW]00O4%
MWW:F^<M@E-1^DE%[OZ6=Q%WAM@,$72QH9(<POD$D93<]M<ZQ$,6#&)JBRUY\
ME-(:4PGF*$YAM?\ =OFPJ?7M\0IK.U5W.;(1&XMK@^["W AJV*JZJUD>MHL&
M'&NX18\C53YO4R^3M:Z3,S=.L:8;+(:HNM7$),W):LRR2XQ?WSU8VCBWY-?8
M^N%H3)SNS96I]4JS=;2D[<XKI:X3+.DYY!K1L1L2O4A(%[EV::!P]YCY#VL)
M)?Y.#46X@46X.&!(?#W8B>_&YFU-)2J-:>MVV_BO@314%U5- HAMK3],QC96
MS7=!&9Q'K7OU#)_SC=)Y4=6@M(<ZWIQ*T-+#))<R)YC*%\D;#VIG3KG+Q'(F
MQRY?3U"@%^7S X\SES[UG@Q>9'7%^VVPU>(KR]DD:6[!3/4ABVJ71".%:RR+
M:6O88JG$PHUJE6$Q,FF4E:FY YM6+VI@I$062-H=FE,_9?<Q4YS8_MI:>@WO
M+L.UFMN+7'&2-R:1..5[57BA8(W,32"(C('I6,L!.U,DI/5)B(XZKC"$+V<H
M(*;#U69Q>.6NZC\;N]8["Q/7M=3D9SUBJ;RN;#^4..[9%6C"@(F$4MN#6NLB
MU"Y5(9F,V1V<DLFSG-GD3^>SM4#019"@=FYR6*LLOO$?=<_ G:<3J#1B.VEJ
M-0"R:5-XZ_(=4]V&KOT//PJ]G;CDZ=1KRXOB_ 594Y=DS&X/GX3-C_QQ%!,C
MS\<G)J4@CRS GB",AP/'7Y<DL,L]21>XX6S\\\O7GMI3C9+7BLBXF;9%\4S7
MQ4]:U+W!C)Q:4%B9<S9D2$MT6.T4S?W]OQD;8C;#BG%4O9A6I"$!I:PT[%.9
M@9E!;:[RWZ^:KSE)!%D6L&W%BJFZ1O('VILX*\1+"$;$[-0?5NH56$B=Y@T(
M%F4PF<Q62-M4-^:IN.A<2D#J2M-4Y-2)PU!-P*G5Z6TXX4_MO"]3;*O1_P#
M; Z 0Q79*Z(!%YGJY-*7.MA/E**#<YQ%GELNYXEBYS:OS#B^N<V=[)PM")L#
M,\-C!%<6B5-UGCUXU-P=G-)MD7:,0B50"S[FBWA=JF@SW24P"/S9EU]TRAE$
M6=/;!CF9TG,20YX(M687.^M,1DC@POZYZA#$*YC2JCD6)MOU'XR).8\;6M>_
MHMK?EEF.8'TSZ9Z+:@>=F];XTT3M]D-_THP,=6RLF"V8\/=L0)K:Z[FJG[/[
MM$9TXN$A(21&3J0.)%-'Y">W.YV)Q0E(LL<\>^F9/O\ :XQZU-9JW03)LF[3
MM3/K0I^ 6M7K_%)G5;/<]9Q,B;#4TRE;&_*R6.;S)@)D>40;,2E>2UUBSDR+
MQ;W)8SD.&JM>.ILM\<M5:;0;9>)Z[614.J_E)N68UN;>LZK&O8OY#8%L#4TQ
M41>Q[XL2;1]VK:*[1U"Y/2]!(WO8<V$Q^;)(BD-ADN<EJ-G3AQG3Q$%D:Y>-
M"JJYA$1CCY./RD&]-EH)&ZB5MLEJYFU\UQD]MSBS954DL:V=L8Y/2448W1E@
M4;FK:A96AW2.;&2V-^!:Q&W<7[[R/C8Y)WD>_P#:WI@$! ! >P$ $!#V$!]0
M'^/ XAE[]_O 1Q'^>(@/7[.^N,?[H"(==@ _#_T>_P#F^GIZ>W\.9Y5$   .
M@] Y@0#(.A#_ .0@/U 0]0']H#WS/'"+Q#$ ^OOWV.60B/7?78B(B(!WZ (B
M ?3T#GEQQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPB<<<<(G'''")QSB\VF
M\-K6(2:P+#E4=@T%A;&YR:73&7/+?'8Q&(ZS)#%SN^O[Z[*$K8T-#8B)-5+G
M!<I(2I2"\S3C<<<1'D)G'RJ^.1IIMCV#<=T=>$E+R.<.U9LUBFV.S!'%EA,3
M2#^\0L%..>1Y$F;F/,EY5LZI,0M):U:%?D5]U<$)J@BL!Y\YW!R%J<@9\D6#
ML+>M!LS<L%!K?@X"F-^XY+BTIA2HQ'BJ^R%5@G-*/S3@9B29@8..01::]]=+
M'BRY33C?M-1!UH0FO<[6E\&SLN,)I#&JZ)B[;-UDO>T2M>0+:RMD+>6B7O"A
M5F7FRQ=U;7]V*1-2Y*J-Y[K_ +/:\[80%19>MESUQ=\#3NR^.JY36LJ;)2TH
M']O(3J5;*XG-QQF;<Z%(UJ%>"%<4G4&MR] XDEF(5J50:N.>NGBBCAXX\9EA
M5MUX6(?&%,[QW'VU"6J(4E=D,1.? N-\^]F1Q&_+'%Z3-67ZGV!+FN5JL!^/
MXC\\?@Y,>?6Q6E6$MBBQYW%(.0\FJB&DV4/:!EP<CD191RLI%DN.*!08F*.*
MS.Q+'(2\32QRZ#,.XO:+_P#%K8WK_7<V]_\ C&]=_P"/)N')R%  !Y)1P8]]
M :7@8 ?%T ]?'CEUV !WUUW\^<4@F,1$#XF2V&X^:-TT8-Q?>8R6%SAN[P%I
M&YD&Y (.W1/H6543\2@JJFB!=[>"AJH:&JD!8X,$-5/1XA#"6R%CG%]',',:
MY@#'.$C*W4WE3U;4WN;1?XB_DFEO*IF_2@?G$\*CSR2L6;X+CA+,93F<+8?\
M'X60J_# ^-VRQ3#AB4/V_)RP&VJQM3!T,K>>Q.<8,F:,MXRB[X@>L6S-PQ49
MHL%PH3C039*L4BG(@#/A$T"#1Q[# >=5$:=:UI;ISV((JUKPN8QW4OV<W_%Y
M-DJR=U;-E'U"W\*S>\H^!AC1EDC' &D"L>_M\2\50 >$DB4Y"<! @DHH,NOB
M HO OXOA[Z[^#''OKL>N^^NQZ]QYT."0;51/K#M!78-4QNQ"J=1-PZDJ8WMP
MUS6^Z1RR2RQM94L=OF9OLJEN[8-J'D[S?I7ZA8A^C57!@+?TSV=V[PFJCV7P
M:':&;:G',(JJ:7:V.24XY4T-)1T-1-487/$8FT,IKL)D$EWR87"UACFC-NGL
M]$=+]4-@-IIQ\!L>H^KY3.\V_(P"3'YX;D.1$6BR4W++'#!?+96J9(RWCGGA
MB*UV(^+/$.\@H'J_RS[L(_%+Y$YUL2R5Y7WDIT)A"69RV)DPW[M#LHQ;D(C%
MM4),PARAX/S5M;G%9 \Q9VPS4)BAD\->"O\ 29%9&GW.^0O0R-^1.K(!0MF6
M))8K1J&YJ_LRZZ_C* @<KZA]>KS'U#3\BD&3DB7QB(/4D*:79_<&,HY\/Q9T
MB=N4MI^."\FNV7_D[>J#0&QC'JY*Y7JY6VUFI<CU>NRM&+\X;389*N4S%%+X
M3<*5QLZ?.S\VS:#?9.,>3-Q3B8P.<>=E2;[NV+/C6G^B)/*_R[_GYKY7WWWY
M\%TR?Y,=Y_'J]UF^^1*0T1LA0FP^I6P&Q5;SVA*ND=*3ZOK#UXI9FO1XJ.9,
M;I+9S'7UHG<1<%#1$)&WXIG$F3)C5+H6G:\?N ?E4F^?D=C=BZ'V#LAM3XLF
MB*;V*:LFF&E+ZX/5+W=!:4O10SC$7*FK,EDS7&7A9$0S?&ME>(XHB*)%+)%B
MX,L:S5'*D2YMEM57ADR73N/3?>3;NSM]2*TU]M'6JD87/ZLIJGH55E;W=$F^
MO[6S3M501]I42J3RB!M#?$BI'(URA<W-?WLX?OKD<E7(>J(YX(Y*,JU>C=I[
M[6C;NL&E]CUI8.N=22&@Z 0W-'DE*R<F4U%7,TVQ(CZNRY=6<*5H6Y$5&FYI
MBN3PVD"F=%.622/G,,%^(Y6TRR%[Z<?#FEQ;A?CZ6MED>?/G?3Z1WE4V/@^\
M>Z,,OV@BZ.UFUE\<5J[BU]&9&\,+];5L(ZHNJ2P4ZSGURB9[RCKJ-SQNBCLE
MAM>&D/[XG90:ID^+4R]ZRC;574'GJW2UOHN=6CM&Q:VSASN3QQ4=Y$M6#H3%
MIS HM7;IL;?,5H>/T%;1BB721SF3)7:F<QF;/<Z;!B[DZ-2&3-@*\SCVI2AV
M)+)T"KRV=L;+V9FTD=G1MMC0QXT(F%6 UMQ;(L@$BLV16(]R@N09&FN1;TL+
MDBY@Q;LD!B E.!;A]J8H 20K!BOY.[6[I55KU?L-M3;%Z%O>H-:Z'T))B(-7
M=;/NOVM=*6<BN6HT"8&1([HY_:,8L5G87)TL=U*9,) TLR5ERCC=@8<KY<].
MF?'7/YC2VGADG8R\!EP&M[Y>94P?$MMO<NT,*OAONFZZ!N^25!:+3$6^0U13
MMY:VV&@:Y!#VV4XI+IUUO=G12&!+#%:]0JK:2,;L\,%DUQ^%24<6QWP<TV<5
MVC>'?[9S76Q=D-<)?J?2&OCAM7M,WH]E-A6AX=F"B--M7DF=>(9PJ@#3)&/]
M*<VM^V(5.Y'B_*9>R1B 0I0@;CFE\5F)UR&PC1;1*1:I2C8^YK<V!?-G-E=K
M917+[<=M+J\B]2,2]JIR"IZVJ^.Q>MHJM>&^/)V2)DF ]+SGYT5R-^6+'@W[
M@7F4B*J&0^&&]+[U 5>/^<[ V9K72^KV]%^SNMOPJ$0&UH9M#2DNGZ2^]>C)
M='9G(7%M>8+5KI/9)%'^L9RV.4=?9O&,U;U'G-M9H\N43/+IGPXC,CG:YMY)
M?.]AT.GU)]?3)="%>;?R)6_1]./=;0'7>GK<@OC3O#RH[#EV9"++?(C=5+TY
M;LFKFO8Q2[7A(6E^K5OV&B<.=;,1O$J42!YA[8_1EL(-5%EGN;G/@[\HQU68
M&/"03&@=M4L;CC)J0YVY8,.K2.SBL:J5;G4E![EIU$Z/Z6;-DID!CO\ GPEA
M>#;'X.LE8OZ$Y:IC*-@6M;HN^]=?A7LZ\F>&/$F\A%EH[R<-<[:TJV4O%JUX
MH%H==AM.+>GBF9N51806/LS-!JGD\/2*#(Q7MD1!M5F1]J4N)ZJ,N2Y=F=A]
MN7>#"JG>+[ 0N)7)*(1%KFM?Q\V)'6=-"V-X3ULS>/. 5S75<PU'FI>D9TE(
MEK)6[89)7Q=DV*TZM8IR1HC2P^ QF#Q(RM<CP\\OB\<QJKEEIQOKY9VOIK;+
M(VM=<X1>;W7M36C[(U5";:M5W-&UB73!%IRX5K"QV<D5[N,,362W,3.S(;,6
M5ABQJ*Y/.FRB5NEHML?:F9$>2Z+4KH>W(%_!C/+:9LBFUR8]6X;8U636P/)+
M,M/+1C6P%<,K?,XO$=9:LD]V[/.IL5;Y8^@P?<8^PML+0N;P>4Z,[X\&GG,Y
M88(%"CHW?KQH69 S)_M)K:VW)<6P,F\C%=[KQA73J:CFZR-?P:*+2T1*,HC!
M[Q4Y0+8&/.$5:$Y<BKUZEM:.[LM<D#PSO!)D9!(O]3Q,^+N\(A(R]K-L':Q(
ME-L+R\C5E5Y45G95](+7^[[N/M+H0M>\9+6#N=7""U3H=4;DG50>"MRB/L*&
M;@C(>$F2)2S\ DW!%M=/+,7/"_+UR4TSZ:\\KCU[RO[.@'G[JBU]+T%Q;!#(
MY)*:+U/)V!W8N2K80TI*,J"9/$H=VB#448:IE!+HOO:R$A;4;$JUB;8_@4"C
M 9*]1]4H+2#RVZ_-H[O=)[;**5USV&H79?3G62#;P3.J]N:UA<82R"EBIT4L
M?828?%+*F61#U/*R9)$>V/S*H4_F:N<4);A\<N8)##$G4CM^3V5UK]J)9M4T
M$[S.RL9II.^:^7=2\;/@M(J-O;$ATQ=+-H>Z3)ZO_&HW5FPM:RYR,3,<Z?6F
M71F4,Y2&-3Q(#/A^()(:,VE7D^NN%>2&T;2K78-]L_:'06C?'57V&T*C7AEL
M!ZEDDGC\RV78Y4:U^E;["H#1E/1V6JY&[2!V>5\LLAY+D=B-;+DID&$/;!)T
MTOYGA>QO<D7/#AX9ASRUT/W].('VW$JYG3%:%?0:RHN?]ZC-A0Z,3F.*OB+R
M!2PRYC0R!G4!F3F:3F!K>XI\AS*,,*SR$1+SRQZ'G,^=<T_6K'3-3UE4,8PQ
M*C565]"ZXCI6))1&);'!XVV1AJQQ)) "B@^Y-9.7V98!AA\0XX@ !T'8W,E$
MXXXX1....$3CCCA$XXXX1....$3CCCA$XXXX1.8 0'V$!_<(#_3E)/DG\AF-
M<.LOH"F;MG5'S>M&B$S38JZXGI_(-F"*8KBQ0-214Q O>93#*DATR=#S4;VF
M<9]^?!"M@+5ML0@DPF0F-;5(C7W6/?VD+"8W*:^1M5MI52QTR*G4&OG6NK8E
M-435^%K$Y:^L[-HE17Z9F<T[O@W*EC5-X)-6IV0@L3)E,>69 NSE[G+S\,@1
MEX^6A5ME<Y7T\>^]0ND?,_#=N;*IF%UOISJ>%X3R=J9S#)S=S0^T'&[-UQIB
M;1,R(VOE1;W=TQB&#';UR1%U75TSR9K/5L\68U#T^R-"ZFI&1G64W*/'!N:7
M;<LKK636S8_4YBN&L%T.L!58NR-+VSJ&WZI%^/%;KC7E*$M# I,GD5V<@-KI
M8M#TJB)X2]H:6AH?+&3VD\Q.7*&Q!N6]=@'Q  CUZ_3OY]=_+CX<>_BZ#OKK
MOH.^OIW[]?L]N"V^I/IEIX>''0YC.R V&7GX]>'I]UH]P?0;R$1^4QG;]VT4
MFPA6*.AJ.7ZO)YM2A]QS%WK7Q;V/HB_7_',2[/SJ9QCK!=$Q9BHN].,P;'1Q
MI=JPG26%$&HL<>6]K=,KFH+P=L%065>-E0>=Z]>-^0P6QJ_KATK9YKR02*.5
MB[KW9C>G65US+I(Y(F[$1A6:V(RJ.H5+,A$QC%(&:1=CL$?#CUU\./7??70=
M=]]]]===]^O?OWZ\AUY#_P#D&;F>X_[UZ\_8!$?_ ,'$A^0 (_O^@>H^G)NC
MEX?3SRMDJ"21UY<[>0TU&:EX@'M$D'H [3)AZ#OH/] 7Z!V(CT'R[$1_;SV^
M>FW_ / 4?_54W^P+Y[G,EBG'''")S'0?0/Y<SQPB<P  'H   ?0 ZYGCA%CH
M.NN@Z^G7I_+CH!]! !#Z=<SQPB_,XDI0480>66<2<7F4:4;AB86:49B.!A9A
M>8989X9X998YX9 ..6(CCD @(ASY[(QLL:9VJ/1UH:V%@8FY$T,K(S-Z-J:&
MAJ;DY:1O;&ML0$IT+>WH4I12=&B1D$I4I!>!)!19>&.(?4XX1.@[[Z]?;OY]
M?3CH/I^S^'TXXX1<%F-7UM8:N.+Y[7\)FRV'.8/4262Z)QZ3*HN\A]GT[1Q0
M^-R\YC<_]"3_ .7M>:17_HB_]-^IAUSGH/;H/7U']H_4?J/[1YGCA%Q>8PF&
MV''G&(SZ)QJ;15WP++=8U+F%IDT?<RRC,3BBW%E?$:]L6X%FX8&EXJDIN.!F
M&)F 8YXAD'BTP6%,'YN_@<1B[.,09%D:B@M<?9VX8S'''-L,7L$>^YHB/P1D
M6YLK/FK:6O[HWJ<VIMR/3F9($HE<JXX1....$3CG')=,(E (V\3*=RB/0N(1
MU$8Y/\IE;RW1Z.LC>5EA@8N=WIV4I&UN1EYF%X9J5BDDG'+/#$<P'+$!X_6E
MNU1=# =+*>LVOK7BR9R/9E$EK:91V<,!#NE3I5:EJ->(RXN;>6XITJY$I/19
M* 4E$*TQV9>)9Y669%V'QQQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPB<<<
M<(G,=AWUV'?T[#O^7(([W;F1[5*'1*--JM[/OF^5<HANOD=8J4LF_3G&7QZ/
MB_NSX[UQ5ZEIDK[&8FVYIW![1)))'3E&"E/\;LUM13P]-$%M7JOWNN^JH%M)
M5'EJL>=.,G7SI2MK6_=*Z!9J)<'&-R=]ACO %]:ULJB=QP=/%I?&71D!\8-C
MI>>82C_$D#M)4!^*ARE\[:G[7'YNK;*^GD?Q^3X<5:SM5C(C-<+L*B-!L>TD
MJ/K:5)XUKO*%4,0Q>XW]0VFD,\"E"ZPE">&H8R^N)B<B1+7_ ".1I68%QV"-
M<JP3HC]166Z%[TNU4,5QS;23=5IW6>K<VKM.03^B-I]2HRJQVQO:D:FK^I+"
MPK-%+99!FK3F'$18^F<F!SL(^:0."QE1(9O%+)33]WS:MU]%]\%&E_$?NPK_
M +L1]]^Y@:"/[W]EA]Y^Z@>(G G^W^T^P [_ $H%? !GZ_Q#SV1QQ$.AQ 0[
M >A .NP]A_>'R'@B]KWZ9<P<]>0XH#;3YW(/EV5HVV;XC?*'=B:VM<Y9$6]K
ML(^:[\;52/<YHE$1CU0W+)-T-+Z]IUIH.),S,_MMB-"QRM)EE,0L-*^1QOA$
M/K>(Q1WSRF+8],K7A>7XY];-A7?'>R[K-BMM:,9[:W-1LFKVKT;K32^VJ\8J
M(UJJ2D),\.Q3>V6Q6+?A9$O@;_DC)Q+<7)PA29G?#$T>7NI.)5X_0=B/0=B
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M6EQ;&V[*Q&(LZ"+,[:S-;T:GGB^?(RDSHF/87 PX_9RS]@]O[V'N/0?W\?\
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M3&@B.6HTRM I5)"E(E9JDR=:C./(Q,**5)S,\3L"*%NB_P#Q;V-_^VYM[_\
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MM#_&U"R$MR'$,$;B;DOQ@OG?GE;C\^_+-46NVU]1?K=7X-__  %'_P!53?[
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M?7TXXYDHL=!UUT'7TZ#K^7(<^0__ )!FYGH(]ZOWF'0 (CZUQ(0]@ 1_>/L
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M[4#:7#_9#!7X-^TUWM]\UD5<:SWFFN(R!-$( WW8C>:7$^V&FZ5KX:/T=?\
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M-M\0K4S@C2+D9H'I%J9.K3'X8YA@<G4DX'D&X_%CCD&)A1F&8!ECCD 9!\0
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M'H C[ /(32;R=Z4L3DI8V*XR+6?$WQ8F-U&Q.:W421GB=@0(.,AK>/R"'LF
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MN=<-6\$Z)^<LY,G6LC5B1D*YL:GU5@86#887GR[],&_P>VD]'A__ !MJ@_\
M]6.3L_S_ )_S_4>.;MK<3;AD,A\EY\NN22 2=22XF_$W+LR>-[JMV:[-[Y0@
MR&%K-"ZZ?!FL^CM?ILHOMZZOF#$ID9+H<7)9/DFU: &>'M0-6>#T]9_:BB,6
M(,,$I_WC(2^;8W%O]D #_8GI$.P 0 =VU8"'8=^H?V6?0?J')V<<6/,^GX4N
M.0]?RJW[(V8WTK2 3.PEVA5<RA)"XVZR53&X1N"X2.8/I+2ES5&-4882=723
M'=\68X"4W-^)Y(JU X$XFXY9X]\U_3#O_P#ZD](?]MM7_P"%GDZQ#OT_H(A_
MB'KQQ8\SZ?A+C_$>OY4%<;AW]'+#'+2JC\ RSPP'/+=I:..'QYAA\608:KYY
MCCC\7>0889Y] /PXY9=8CU92NW^ZE\U?$+;A&DM2%1>:H%C@TDO6Z)J-U)*0
MO+FR'8+4Z;6)<E+,%4U'FE_=EJHK).83D)F)HF$E3IO.XH7KS2UM7U8QRXB
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MOMP @/?0@/0]#T/?0_0?H/*BSQSQRSPQ#/+++$ PQ'+,1$ ^'$ ['++L?U0
M/41'H #U$>N?@E6I%R<M6C5)U:4T!R*4ICBSTYN..66&619Y6691@8YXY89#
MAGD&.6(XY=9 (<(H+>2_3]VWLTKO;6&,2:/P266O&&2.,TYD3.K>4,?(06'!
MINY8*$S880ZFHW,N&)TQR5&I*P.58(#U.)F*/#X8.M7BTNU+Y%6^_P!7:-5_
MV5XUN-8V_L;C*1DE>-[&7E:6I[!JY(ZV<U.>.,"*JU'^"9V4DE12A7*U[@X9
M1/-C;DR3\>4WI]AZ>H>O77J'KW[=?O\ ES\CU*=,7D:I.*3E8Y88B:>9@26&
M1N>)9>/VAF6&'Q9F9X%X!\7>6>6.  .60 )7P^74V_"_7$/AQQQ#VQ  _D'7
M,\Q\6/7?Q!T(] /8==]]==_7OTZ^O B&(=B( 'U$0 /YCPHL\<QV'KZ]=>_?
MI^WW]O0/4?I\^/BQZ >PZ'V'L.A_</SX19Y3#MIXNI9L'L)M5=48FU0L[7?W
MC^@>H[-!K&J]98$4)FL,V)FE\+Y+/XV2Z,K?)H3,!DQ3 ^-B-6F?RU!C@^%*
M#E.)!9USO8"'?^0_?]/V@/MSUE:U&A39K%JI,D2%?")JI4>4G3EAED&&(F'G
M9X%8!EGECAB.68=YY8XAV(@'"=%63XL=&YQHY5-Q,,_7U.T/=UWY*;OPIK7)
MLD4?UGH-'((W%(]A7%),$J)2O"5B-4QM5*Y X9MS"D>9._."U)'6O$,_O%H'
M/'X\>P#X@[$.P_: >H]#[#T'J/7J " CZ"',_%B(@ 9!V/?0=AV/7H/7UZ'T
M'Z<(<UGCGB.6(=B.0?J_WO7V^?KU[>GJ/?L'8CZ!S/Q8_P#2#V[]P]@]1']P
M!Z]^W"+/(Q;D0?9"S-;[0K[4NU(K1U[S)CPCT-MZ7,CC)$->8.2Q.0^R9L9&
MW#(U;*$;#DX%Q0T_($36_GH'E64K*;ON*J3G8>GJ'K[>H>OIWZ?7T]?3Y<?$
M'J'8"(!V(!ZCU^X.Q_9[>_IPBU/7;P*;4KJVB$%:;>U/BADOU;L[0;88^-0>
M[<4RO7"SM@XCL6_W1$%,NF$NDLWVMD,F;)HTSQVGS\TQJ9KIJ7.,G-I<6 &5
MRVM&MM2,[<A:D!8DHFU&E0(RAS,-$I(B3EI4I8F&Y9FF"6G)+PR,,SRSS'$<
M\LAR$1Y[_''?H!KKP&J7[L!]$XXXX1....$5,>]VD&Z^T>W>L-JPJW]:B]9-
M:9)&+(9]>;HKNRY<D?KL0N2PI3=3L9#I-%FUWF4!BRY0@I)ND9KW$H5*5"F;
MKV!T>Q09MO6GCA\3=E:=[;3G8:5O&ML+C)-%.>O$?A.I\#EM:-M^$J+@<+1;
M]CMF8^^*U#,%XH6]<9$$C:PK)<E;"5;XXI9N8V.R&,LU\_');._7UM^%;G3O
M/+Z)QQQRJ)QQQPB<<<<(G'''")SJR\JK:KTI6WZ2?5RMK8[BJVP:K>G)!CAF
MN;VFPHD[Q)Q7(L#,L2\E:1([FJ$V)F089'%88Y"&(B(=I\<)HJ;O%KX[[ST^
ME=N6=LC9]6V'8$KI74O5J$D4_'97'XRAI?3.#R>$P:72/&7+#UV=D6=E*5<E
MFK&@+/CL06)R6://+TASR4X7(\<<(G'''")QQQPB<<_,TTH@LPXXS HDK#(P
MTTW/$LLLO !RSSSSS''###'$!'++(0QQ !$1  Y^"->A<"Q.0JTJPG',2Q.2
M*"5)09XACEE@)I&9F 9ACEB(X#D&0 ("(=" B1>WQS " AV @(==]@("'7U_
M=QV'?78=]=]=AWU]>OI^WA%'[:ZF7/8?6Z[*/9G:),CI:5<R:%(G&?05!9L&
M+.>T&:8$TS@#DJ0II;$W !%ND;)BX-JU8T*EF+8YMKEBD6D0_P#&)HE-=(XS
ML.9.GFDD;QL+>IER!4^L%;/%1ZW4XG)KZ&U_C&JK@;V]/2QM+?\ .(Y3"4J^
MT!2V0O)^."0S[L*]9:#V'8!V'8^P=^H]>_0?LYZJ9>B69*,$BM,JR2'Y)56*
M<\H\4RG#''+-,H K//[!1CCGAED0;\!N..6.0X  @/'??S[LB]OCF/BQZ[^(
M.O7U[#KT]_7V]/GSP--*(+,-.,P***+S-,-,R LHLLO$<L\S#,QQPPQPQ <L
MLLL@#'$!R$0 !$"+]..>&!I9A>)I9F&96>..>)F&>.6&6&>(9XYXYXB..6.6
M.098Y (AEB(9 (@(#SR$0 .Q$ #W[$?3KZ]\(L\<\?CQ[Q#X@_7[^'U_O" =
MB #["/0"/0>O0"/L B&?BQZ[^(.O7U[#KT]_7V]/GPBSQSQQSQR^+X<@$<1^
M'( 'UQ'H,@ 0]P[Q''(._?'+'(.\1 1_(]2G2D&J5)Y)"8C#(P\\XS HDDO
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MMU,DB\UH;$QRU3 DZF'+>HR=F_*Q3VZNO.OLQV4FMAJ7(_2QUKU78]>UI7\
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M3TX1O[!]1QFNR82Q%)VC"JVT;*V8W-U5V6I\S:/87:37)*Y>)E[?;DDE$5E
M7X=BK9VOA42VNU=-C@T,Q,+U *\8EC-:3[7CC%GIYJ5Z;VFOK-DTDB2Y_C<A
MW<>O?]OOZC_D/X<QCB'7S]Q#^]D(^@_7OOY>OU^??+WX)?.]N(.HYW/#Z66O
M9Y.U%A4CMSXVI;7UK6; 8["=?_(=$(JRQ>,PE3 I=<D=U[A[I3<-D;*77+C'
M4+Y-TS#(@942))'4V":)JF: !&,USF0YU8S_ &U\PE.)=2VR5[5322338#5"
MB]FZBE4FJNIJUK^VMK+CD4/;Y=J!)XS&Z GCQ+X-6,.!NR+KN"95;=CD?9$B
MLS&0J6Z,)FF.[L0AW]?X"(?T$._X\P.(#UV'MUUZCV'7L/O[^_K[]"(=]"/<
MMW\L^.8MEEX*WN +:97\+D\M?'P\3?2GV#W4W-O:WO(?0<;N79YCBK[K)Y68
M+E4JR#0MJE%=V?0D$8Y'K[&JQ9('0!$D@)%B1]!8Q,+ETIV%LB=[$5TL53IJ
MC%//V$*Q+Y(Q[3[]J%%)-5+[;W0=2*6Z?"OK'!\V*FJ7=BGVI]RM="$>Q=NR
M-_=J-./?WZ(/V9#E#E:90Q1^NY7'U"F7L[VC6@U9;FGPAZCZ^O??ZV7S_C_
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D7US^W<U%N/,  !Z!_41_K_GOF>9+%....$3CCCA$XXXX1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g408902.jpg
<DESCRIPTION>G408902.JPG
<TEXT>
begin 644 g408902.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0T%.0T527TU/1%\T0U]"05(N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@!" *L P$B  (1 0,1 ?_$ !\  0 " 04! 0$            ("0<!
M! 4&"@(#"__$ $T0  $$ @(! @0#!04% P<- 04#! 8' 0( "!$)(1(3%!46
M%S$*&$%182(C<8&1)"4F,Z$H,O 9)S:2L;+!-$-(4EAB<G-YF-'6\=+_Q  <
M 0$  @,! 0$             ! 4! P8"!PC_Q !"$0 " P ! P,# 00%"@,)
M   ! @ #! 4&$1('$R$4(C%1%3)!80@C,T)Q%B135&:!D9:QU1=5ER4T0T=D
MA).AP?_:  P# 0 "$0,1 #\ ]_''''$1QQQQ$<<<<1''''$1RK[U<>V4NZI=
M3M]ZEF.T%[ W_9U<=;:$E;>"$K2>0R;6@>T3D=I(UH$C<S-3IM2M6"I_;K^-
M#X?)=RR$-T&JB72;W"6]H/.KFX1#)*:BDCD,2C1V10,D_,0<^8!"R9J&ERH=
MY'BA2*%7K1=_'2)( 1( W[X.X9.G@=\\&.%E&3I=!1$\E0/U..R'9@%U],?O
M_A^A#J->G!V$M.Z7$NK3KZ^C4M[D=5^PX6A[&C]B1*]H2QEH2-DMA\ADZU>P
MXS64N9@SX9SHN-4;Z)J<+*_5K[>S^OK#[#R^_P ATGQUMZ>>G_V->]>H71%#
MVIFZ->R=8-+5MJV)Y';\F<)LH_0$<.?5TT(B-!VE#;9CY?1TX>/3<J<!A3KU
M"2KIIU#G1E.1S;JOUQF,A1DA>9)'I51U7R(TE+S[YD3.RI,H8BSU]I)#1(:.
M(ESNJ^"A-\/9/'KI=PU043[+9?6CKI<Y^*2JX*$IBU9/!&Y!I"9%9%6P:<G(
M@T+-5F15K&"TH E'X%L39N%VI!N+7:H/$%E$UT]\;[>42@7N5ZCW=2F^PG<:
M%A9Q4,3K$/U#Z+6WU[+-()@L^K0-VT[RCNLDNN6V%IANL@9EE:PY](IEO'DG
MFE3,6,=!+&F3K?\ $SQY!FR?6)[Q0"5S&NE;9W.P+J3(>RI>5=FHI6G75X0[
M10.G>Y=9T>S(DJ^F3B"1R;J1"*RHS!9U >JCJ S::6IN--1F4Q%N/80^9^P0
MO3-02!8XX.U76YIQ)X"WJJ2."T&BQ)>05@T</W;2N#BKT4ON6@39T5*.6\/(
M;.(ZBN2?K)C=5'CG93J&_5GK*H$K&-*==J+WCE)DE3%- -ZBKW8+4A=9XF05
M*UB*VCF6$!)*/DDGBCZ)MQ#I1VFFYW5V7TU4PB0([B^I1+^O/9V/]<:[JZHI
M,X"T=%>RML2J_.QP+K$#Q6$SO1I0@J.5 <F$4,Q:8V@//KNSYT1,CT#C0YGB
M)1G>0;2:P@B3."CWU_Y8.C,XL%'JK#I#%CL+N6>]=XF)[%Y8VZ_'43W7JOI1
M)XYV=A92IL(=>97+)+:H><PQ%F2L(:@U:DX/)'+"2"WKK3T!6)0M'VZ=@DHM
M:G*LLR2U::WD=9R&P*]B,R-UY(5-VZFYV#E9&')/HH8W49M%-R()=B[V4:-5
M-E<J-F^Z77F_5?K(T/61*6O7:C&\EN,@*+VW($:DK],U:)4$7:R (3L0II'L
M/IJ0#G6+(V,>21<DX8EVC4HV43?MTG.B)YW>POK1]N!E-=KX_I2=9T58L J_
MU08G +<KVX75Q*"K]].AA#2<CD+.$6#1<3"O*VE(Z=CT8P\DOU)].1 S&I^%
M)1UP,?N.S6/ZW-GU].+ UE]9@]S/5NK>W5BSR%4E>\-L&B+Q'0+J-0W:6K6F
M]JFZ&3FXJ5B ]H+QJ2-(@W! XS)]%2[E2SHF?CJ 7T,$^OM#&DR21BDZC+)&
M5K <ETB=:PM^F5<6QHT3M)<EHZ"*ZOEK)3'L-)\JZPKO,M&3361[$M6R.-.O
MB^J75X& 5B@;K?0HF+KZSC1:-C*=KH> 5ULYF.'V3JJ&:1M$<IK8+ 0*93C&
M[;.)8T&#VQ_!!!DU321**[_]<B]>O@*[8E->KE--^QM#S^XDY35H._[-G(B0
MU-5/4>K.XZDFA1B*=;ESSHQK";9!PJ>FYC'(15%8R%JI(BT\*@B(QFKT,-ZQ
M-]!;LM$_;(IGBF*^[*V O&*YI4K'#MD&::CGH]2[OPU@T\ R*I%#$H^K?"![
MT#)81+8.>_,I5>,O29FMHNX0EOH2L/JIUAMQTJ]M7KG1-EO'$@S+7#J?U%7T
MQ<.93M$V$#S)'*TBCQ%1R=S"!0J'Y++[*OLQ<8. 97R*8-&J/+B^N?7T',4+
M$"T73@BP&K,*/:SD76$('S%LPC<2?0&.LD).T!(G$6@"#$R,,"MDWVJ(J*/W
ML<8Z(!G;ADHB47U_ZV-^3]Y!*H!]5:'D'86V['ZJ1JOV\4[=D)#0H^&]Q^M/
M8GLC7IZ=VB-H=U*1,QKD5UZ.!;*@8:NB^Q4:9 S*!'"HXR/'9SY)/6*Q"_3X
MZA^H))Z!<(P3L"\0CUIQT?8&SQU2\G.0FSTX/HR*)0Y1O-P,ROB"Q>EF9-RC
M$W##-F1^3KM%U&3H"XM%@'5_K75 ]B)J_KY2%<BA<Z=6@,&P2J(%$1XVRGPD
MF >V$P9Q^/CV[*;NP1HP$<2MLFD=4#E20O+_ .@?.6RO;%*;J):!,:J5JRN%
M:P&+B7(VN5(/%]X&/< 3S>4@W#*'["LQUHL&DS1I(Q2J U/<<>:MS#/9$B@D
MYT1/,[-_7#O&V(E^*Z@J$U2L@@T![:Q621J2S:'R.*+]LJ ]/"7=EKDIV?CB
M]+$9:0$=7;-; H<B:A$@A:EB3%-=&0LV,82?!U-]T_\ 5X[D&+0B*MU0FM+.
MI^U9QZ4-0OR\5L(?&W]23OO/U)CDW=EZ]C(ZGT-K#CSVR':<KG;28SD$ZA.L
MDQ$(#F5#@+DCKZ2$:,I1LZR];U!5R#W:1SN89>(U]$4W69;:3)R.LR49<:!\
M*YD5B,'CQE.C>=\DY>T=N6TA=$4%U4]^%BG6?KC!!; '"* I.'!11R*286'B
MM4P*/"QLC@F%-80?8#Q !FT9FX=JJKB*E6Z*;^.X54P'<,\;[>42I3M1ZQAS
MKGW-<]<Q=,0ZPX#&I;#ZOG4L%V'.V\RBMD6%UGM3LM%F9YHE3SNJXZWW UJW
M&Z1-[:+^S3@B2;3P=$VD=";:%(AGO6F[BS%QU7'!^OU'TF5MKL=Z3Y<N@1NX
MK9PHMUE]22)W@;C\4)&W=)1G,/M$*8I<T*E)P.*,B J+H&K%G$I6?/\ Z7T.
M27JSUEFEB;V[,.N]&2NUE&HYCO9<EJ6 'I_LR$,GPP4TS,"L?=R'Z<:.)D![
M%+[C\+5B]=,D<:-5U$=N0+];NO$@$;Q\]0],&P*@^NA*@0O5L%)"%!50+OG5
M3C-QKT"NSV'U@Z)DG->,LHY;0EP0>K1E(6H[<;*(E#DL]4RX%/2UONR(2)[+
M#K\CW5+N9=D([.22FXE**<C)^GKGNF!12.FK.!UW%J2<6.,:P9AD-73V 9<.
M1& R<B4D19<B8*83.W]ZHL+3JB$79V:NWJY35W=[Z.INM^T/8.KNA,1[.N(
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MOJ)U7B1J>"J8S#(C]#/ZBG%-I3"99?)V5,"Y=-2:(6B*1$;GX^^'H,-$P97
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M:=YJ.F%C*7% 324 EQ"@",<L&>1%^;AU63*ZR]7-9[6 P1!M8N2-1VC 5@2
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MHTCSV,,2)(Q.G$.,RGM_6269:U?QULR"EV"O7(#=# E$"A$*XAAPB%=+$1F
MTQ*HF**1N'O$])5U*83B?W)I<\9Z[)229S^MK=3@%(!Y>SZE"K#E@P2QL(-4
MMFN7I28]A9 N,C Z,S6H'T)<C[!6VC@=^(==<N/U#N^/7R$BG]T *F@AJ1T*
M1M^/&"%&6'G1W: 1](0RG71.ND[G7D[O+W5K$Y#(;0;E=FD"TE(<(:C^-I;%
MG^WH6;-V[='1-NW1;IX^/?"2*6B6FNZRFRZNV---==<;*+;[JJ;8QC.ZFVRF
MV<[[9SGCRL?!'<CMC0827V#D4"XK8F-9$,C"K7XOIB0_+Q!;+$@W^+;Y#UKE
M%TC\6WRU=?.>(E'5G=D>_5!2ZW;K>UL:-TU(J3+V:V:6"ILA%J5E+.1]BT:Q
M@BPINZCK8"T(5[#ZLD-Z2HE+55HE+B@:(J!V:-EH32 9CZ*=L[F[#6;?Z;DL
M%L@)#H](!0-PQB\GJ>*JR2"=CNP=5P]_]GDCV:&X>^M"%0AB0E39?8OHU<Q-
M&1CP I(QN(6MS<M6SUNNT>-T'35TBJV<MG**:[=PW73W270715UW261624W3
M524TV343WVTWUVUVSC/'A@ ..LT1X$.+"L&S=!HW9"1S,:T;M6N-\-FR#9B@
M@@BW;X44P@BFGJDEC??">NN-MO*)7[-YSW(L/J4U$HUFYJGL9<<N9U2V=P*2
M/5DZEB<AD#YK*K>>R8U"'N8,4BM;BI$3B3U_%I:RQ/EX+ILU?:GM136&%E7E
MZKB]*R8-#ZT<Q><1VH1=<D"[2F)1.9H[NH+3O8\A/[;@LC_$PB-2F+.K.I^K
M&-=LDZ^6:FF%SBMW*KHL3"#&M]'C'\L<T\8]_;'O^OMCW_Q_USQ$J@F)ONA,
MZN'B1,"DXE=UW4'#<F1\ZLFOY7*:+2[.R1H37-,VD9+S>JJ]+5 S%&OOXD^_
M78!R344P"A1NFVS?"<:$=VZYGCJ)%Y=V*M*W@5K=6F%<%$A\\_=L*TX5V:F.
MP0R?2\X$4KTJ+AT#?RV(JV%)=TKSDD[BT+DHD1I)3^P%Y>9XQ_+^O^?\^:>,
M?KXQY\^?/C^/Z>?\?&<X_P ^(D- "?8AQVRKV02IW*0U4G^L%II2ZLA;H#)J
MJA=O@[6IE.($T)RU@T6DIJ72F%E)KE%J<=9&-A@8GJ "L=TB[U_,SC_Q_P"/
M],<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$1RLCU!E+Z5:(.HH;=0
M:C*]K>:6;9<A:VD7J)M,287R@.@YFQXE,ZREM?LT=L"=_O.MEPB,[!I/*9A(
M#!+%5M(+.;-^09]22%3.P.E]S1RO8X7E,SPG7\@ #(Y$VL\E:+N&VO YDH<A
M<')OAH&9SJ+-0"\H@\3ECK$)D<M#!A$X;O8B\-,G")Q76*#]<",N5GO6#M7,
M[$$1YEL)L6MP'<$_VKK%1[(1N=A'WQM9,PMDO"C+!<>H3!DH8=@3DW](]U,-
MC(M=RRTGWR#'28W-#3"R=YC)+ND:B)>/_;U;IZTP_KF[;I+,RF[C %M$@P?2
M8(+J:I[DG[]-502XU;MF^$='BFF9S\1''''$39$EEFX]^NV:*/G"+-TJ@R25
M015=K)H*;I-4UG2B39+=PIKJCHHX5303VWQNLIHGKMMBK+TGS\CE4.[ER27P
M0O6$H,^H?VG>G*\D!B+R$W#WVSN$)9#E#<),R*(DW>B*2+C=S'CI4=\+C1+1
MXHLFMKK:FY4T2;N%%-]4TTT5=]]]]M=----$]MMM]]MLXUUUUUQG;;;;.,:X
MQG.<XQC.>5H>F>1'EVW>@F*?,R8U[ZCW:E9F0'ND'K%VEA6!I_-;.VVZK==/
MYB>^GQI*;Z_'IMKG/Q:[8PB6;<<<<1''''$1QQQQ$<<<<1'*%?5)_:#.I'I4
M=@J<Z[W!#+0L"66)'QT^FKRN6\>79U36I<^1C@N3&&Y@FR=R,L0>!#KYI$@N
MJ3[8,&<OEWR"[T,R)6W]DNR57=5JN(VI:A(FF.T)"8O%(I%@[N56+:%B2=SD
M?":JJF#"\;FI[9DZ+YT%16)ADMW3UQE=Z\5'A!Q4JP\M_=O]G?N7UD[HK3NW
MVQN,;U!GAEE'XC(^LL.AC"U7T!Z]1UZ^+Q&#%K4:S((&,=AU?ODI<6)+!8<K
M680C(A\8B+&1CJ^S*)\B>O2/GPTJ!!I-'2#<L D(H:<"%6FV=VA(079($1A!
MMOMC7.[=ZQ<MW2&V==<[)*Z9SC&?.,<OSK\3BX6$Q>.PZ.,\#X]% 0>- F&J
MBBNK(,!&M1(IGA1;;=53#4>S;H?,4VVW4^7\>^<[;9YOC)<5'Q),Z=)L H4,
M/>E2Y@J\;CQ@D6.;*O"),D_=J(M63 >S07>/7;E5)NV;(JK+*:)Z;;8R 6(5
M069B J@$DDGL  /DDGX 'R3,$@ DD  $DD]@ /DDD_  'R2?Q.2_^''/+_Z<
MGK)3CL7VP[N00/6TYOR%E+$?V[20>!2VMVTKBU*QIO'ZI53"1:R)A!43H\AH
M(B,[>"0!O)-D5EYYU@6YV>[*9NM0[]]=1:C1E:A2<]>"KK=9+#/L95\^IL9H
MLA_WDTIW+ +>L"6-L?VDUPTY)-E-/.R:VV-=LX[/J+H#JCIKDFXK?QMMNQ,F
M'991C\==U5>[%3M479J#9IH-(M:BUKJ:T]ZFT(S* QY?A^LN YK&-V;:E.=M
M&K.ENL/EJL?+I?.?:OO6NBWW/!;46JQV\+$\@">TFGQR*O6'N#3W;1Q>*=1G
M&IUK15S'*9/DF1!B2'&R(<(",HR>/O1ZJ[8A%C6"[IJ%*H++-R.X8@NU65;X
M3WVE5SE=N+9QVFS'OS79-50K-N>]&KMK%M275^:, R^=5B6*" ?%@?XSH<NO
M-NH35COKTY[/,5W4L'K?P=JW\6'P?%T921\=P8XY 3U!.^T6Z 5U!K$E=>2B
MQFDXGGX$;#(J6!"';!U^&C4D^X.5CVZ;=5K\D*JU^4AG*_SET]_'R]=^<G7/
M?NIK"K>M9F/B]L/I58]9PVS4JR@]6S^TI)'Q<V$I&!3$\:@L9(PP:[^D5TWV
M4)R$8AMIG5;SHCOIOM4'D<*Z;<;::UTTHEEE3>2E4L_LSY$!&+?P56+'Y^WX
M,C-R_&ILNP/KJ37GKKMMI?R0JEW]D0S*$<OW^U$9G/S]OP9.C.<8_7.,?X\<
M\W7K.]J.T0"DJ,E=*"^S/64B4MR4!7R+=V'$RN7QU"N5B;=Z0&5I)YTX%!FA
MCPFW8RE8.5V?I_/T'82SKOF[+IS))!+>J/6V0R\P3/3$O153$I>6.KJN#[Z3
MD8& ?FG1]1QC1W]Z=/'6[LCAVFFZRNXRHLGKLI[Z,W*U:>1U\<E5ROEIIN-K
MKXUV+<JL JMVL!'E\^2@$?()!$C9.;HV<MMXFNB]7Q9\^@WV)X56KH56545_
M&T,H;Y\T ('DI(()DGQQGVQG/\N55L?5CIZ5=J9QTLKZL;7D=^Q@Q:,2"MC"
M4.B]=R:9UG%CDD4%YF>TG+E @<[L$W'M3SF(NU&>SC1RY$[:Z;([2].S+D-(
MTW)4=%JT4!NY:VY_W:T502SM^ H'<GX'S)VOD,6 YQKT)0VN]<V96\BU^A_W
M*:U569K&_"J!W)[ ?) E@%O7+!:3C*$EF[]WKDH781J*1H&/<G9E/)@6WVT"
M0N#1<?JJ4DLH,*:;_2CV264VK1%V7+N1H,>1)M//]TSZ!=J*K]7.Z.T4ZJ!"
M.4Q,)-V<* YM^*J]?N'C6QI+H3BFRH8-(7TD0W*M<[;*ZKCM<M-]<ZOLI9SC
MS=A3_7TD'E6UW7C(6-F]@R8U\,2-M&CEI ZEC9=5!=[75(QX@HNYCL=5U:L$
MI1+2*BTYLP@P1*RE^U%H@XG'92>,?RQ_IR#HXY>2MQ:=7N4G!J37DIK9/+S7
MM_[T2MBGR[#^KJ*^WV_M7+'QK-7$KS&CCMF[W<_[,V5[L.>IJ_/W$^?\\8K:
MI\^R_P!305]OQ_M["Q":\TVQC./?.<>/?VVVU_USKG'_ %YKRJ7O7V-[<UUU
MNLF01"BW5>;HI)"R5FC[*BTL(P:,D7F6)*8#P8=BF^;/&S;=+1 NKOLWB^[[
M!UYIOH,VVU<YS6;@..U<EJIVW59,NG4R8L6G6[)EK-KJ6HJ>J@D#LMFFRBG]
MYFL5$L9?J_I[T!S'J3U1PW2O"[> P;>9YCB>&IT=0<_Q/!YZ[^7V+CHL1.0U
MT;.0%;MY6Y^)R[]I_JZJLUE^C-5=:SC&,8\8\YQ_7.=L_P"N<YS_ ->:\KNZ
MF7UVNL*E*:D%A==U'3Z1 PF3$W6L6,1E8P&5=:M6T[6A)-EN98K%PFJ,A5$_
M,TV>J*[*C]&[9\U22GT?/!HL#,261$V04!'A9 X<,$G";0<)#"&BY J3?NE<
MZI-F; >V</'2ZFVJ:*"*F^^<:ZYSS9Q/*YN8QT;<M>RJJ^C/H5-N+5BL"Z*E
MN0>.FJL6%58!VI:RL-\!R"I,+K+H[E.AN>Y'I[EM7!:]?&\CR7&VW<#U!PW/
MY7NXS99BO?W.(VZVS)9967HKW5Y-+UGN:%*NJ\MG7&?UQY_Q_E^OC_#^GZ<T
M^'7^6/\ 3^'\,?X8]O&/TQXQXY2I5WJ-W5;Q&#PQ435=#3.:V-89'*]P0&TT
MF@'KR0H _P!@*)FQ*-266U&46(D1H<O!K'D[(VK"T9;7-A[QA/(Y-@HU_&GO
M4\L*UF=86"1!U;7$*F-XT;0#VNI*.GI";DI%=,&A9F+S47.F!-OI'HA8\AL(
M0\HW4E3<@8S^NP1.7G)5$/N:Z$3LYRDNS\?X_P"N>;!Z*&$MV*A$>Q?[C'R1
M,=N]:-W6S D@FNB@09;.$U,M'R*+ERDD[;Y3<))+K)Z*:Z*J:[482KU4+N@L
M'%2F6UO3[>21$?.#UBU['34S/O[,W ]]3G31I J$,$,QDBK( @X-B;%9&<AD
M@WD94I&X\E 8:VD&2(K/=0>H'-9M2^9)(8]&];1)W_UDID8*:QY\!C(-OV>"
M4]+8X6/K,K*L@.6U!Q:R"3]%2,V(Z)'E&4?9GHO7IXT\CHU$M8;L&3/=XJU:
M-6RA%UEZ_4;MT4=WKS+=NTR[>;)::;.G.6C-HU^H7RHM].V;H?'\I%+37=8Q
MC'Z?X_\ ^_S_ ,^4F23U*+TBA=J)DL'I((6"6U<T>DP!H<F9_27Q: =TZ.ZK
MQJ(UO(GVT.<[3]V N=G-Y#(B,-)#=) U!Q$? DQ\IUDPK/\ <'J3"*GL>R8-
MBA[(E@JJR%F-I3,!$DKABPPQIBHJ=O"RR8X.9DC0X\2&02Z8TD"9_2)OY#*&
M!<3JW'#=&1YXB6%F(-"Y =C\G.Q&,&I)$U'"L7D!:/B"1N.*NOE_4J@2[UFN
M1#*./E)_/W&N6NRWR],J9VSIKG&_D4:CLN"OXW*@(:2QXHEH@2!2 6P-!B""
M:R3A-%\+)MW3!VEHN@BMHFX;J::K))JZZX43TVUI\F?JQ_=X'93^FZR11FL8
MK/6\XCK81P.?!FJ6:0"[[',3"1A*XD#N1PTJP&TBM&7\1D;H65"2NQZ]8$%5
M7;LF,:=CD/JNQEY%XRO7U:'7,CF4=&+--YN0C\30A<JFY^](/78>=08H>'6$
M@^_&E R]M:408LDII40UR.;RQ@G)TS,?#(EL0..@(PRU&QP(( #M,-M=& 48
MQ$LM=6;!F+::ZM!Z#9OKAL,'L![?&J>,(L631HE\+=L@FGS/(HM.W<"4:]95
M7,7LOY_:&.A)'$?LE=3>6B8\V.U\YL!LWE,CC$=* 1KA!FVV9O457R;A@GG[
M^2;L8RBY+(2NXB8CNN[(+0<*4G,^7+ZC=R30(+'1X"4DA\\>().UV(<0)%(+
M*J.%D&+UVY>O5& 4.-9/C!XJ*#L7K]#!,3[EY.'H6-E76'M96<>L!R'8QBQ)
M) (--H N[D2Z;8!DX:HFT+A?0D8547:92DDW$1V*M-'S10H='IJYWT[]V:JB
M!SV'(3:80EK8!*ED9/9<1BA,I'A860'PT5)N6(8RXF+$G$F;5R39B7S,X:::
M)1DT+%2##UNV8/DG<"_2X[,?FY$J\A(FU.L,FB3*B@TP#06HQEWJ6!'MB*\>
M=++2"4V<[1%'1K)U('K$F^:Q\$[*%'3)\.%!@^WVI!$N(XXXXB:9QC/Z_P O
M'ZY_\>?Z_KC^&>?/R]?&,?VO&,^?^_OYS_CM\7G./Z9SG'Z>WMS[XXB?/P:^
M<Y]_?'CQ\6WC']<8\^-<_P!=<8S_ %YCBX4,K5)9[?1;=OE:O)PEJXUER$#4
M1V5BQ;3"VLZ>,R;:';)YV^/65NF#]".9UP969NDF.S=3)/.EV.,=FJ^G(=@U
MB#Y\5ATH&LV5@LE24$=NWX(@T;-9H.1VU6?Q-PLMHC)&26VJCH)N^;I[8W4Q
MG")YOOV6QEL-ZR=]AVY)R8W8^IY>S78L\N\9V6=DLI5#0&OUKGL,%!1<1=J[
MC'A12SAL<!LI9MG)!N+::;?!STZ\\W_[-K$SL$J7U*X7)P=&1B1Q7U8NQH$[
M'.L<?>1/KH"*CJJH)%X*HZ,$-MWT?J]FKY2B0EYOLY9C\:I*Y^+'/2!Q$<<<
M<1.&9QT".*&3@\.-8F)%N/W/E&;)NU?FMQ+/[>,W*NT$TUR&X]AX9,]W>ZVS
M=IKHV2SHCIIIKQDV@D,LF-/X=/XL!F<5**#UW\?DPMH:$.7(@DS,B':C%^DN
MA]:(,CAY@2]TTU=C"S%F38+-WS5!PGVSCB)UZ+1*+P>.!HA#8^&BL5CH]N*
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M))/7&B::>FF,::::::ZZ:::XQKKKC&NN,8QC'.*D33+^/G&. XV0Y>AR;3
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M#X>TSMXSC&NB:NZF^V==---MMM=<X9E4%F8*H'<LQ  'ZDGL /\ &8)"@EB
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M\O\ M_#RK#TF_P POP5W)_-C\&_F5_Y0[M/^-?R[^^?@;[UEY"<J?A?\2_\
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M$?=QF20MT%]3B]!KF(S"G(GUXE4:7:U#0.B@614/ S$AA5.F&.WE-]7,4.F
M$75S] .(N4M?CYZ>^>:G]F6A*U;45ZBM?N*>_=Z7A?JI=@XTK1.+1?7?^3VX
MNIJ!0S77YQDU5B-H_ACV8?CE\JHYD'P?5J[[9V\\]*W$1QQQQ$<<<^?CT]_[
M>OMCSG^UCVQ_//O[8_KGB)]<<P[=G86BNML+=V+V N"M:6@K+SJO*[0FL>@X
M+*WC7Y;1L_D3]@D^?.-MM$FK!A]4]=+*)HMVZJJFFFU/9KUM=NP>Q.)>E=TV
M[)=_)$I]8.'W2VB^_7KIV%(Z;;C]W9;L+=C,&T/ZAWV^K_<5#XF;V.#V;K Q
M_OC='=5$O/-GPD:#E9#(BPX" !#GA<V<-/6PH,($CVZCM^4*%7ZK<>/',6J2
MKEX^=N46C5NGNLNLFEIMMBA29^I'V8]0F4GZ-]&F,A'-?B2CN,6EZHMP1UX\
MZR5T\:+;-#8CK=$':39]V@M 9X7^C>M4TZJ#D$ARQEX8 EVYA#S/>G-Z27K%
M]B?4</QGU8P/924=.E99*9[VL'63?4ITI3L!(@# Z^JL)'QL6G&H>QX[K8CP
M <8!(Z/:Q,)#A3P.1P&;ZM0#K^AY#(5$*ZBH"#P&+QZ%0R*"F@.,Q.)A1T=C
M4="L$M4&0@$"$-F8L2,:(Z:IMF+!JW;(Z:XQHGCWSE$@#T<]+^@NE1*2VEJ0
ME_8#MG9NGS[H[AWR3Q-;VL5\OHE]8.9G'GSF]>P%+9)%L(KJ#Z# +(6Q%M":
MAYT.1(YLEQC&,>,8\8Q[8QC],8_EQQQ$<<<V!0J,"#WI8P09"A8UJN^(DB3M
MNQ8#V+9/95R\?/72B+9FT;I:;J+N7*J2"6FNVRBFNN,YX) ^2>P_4Q-_S$GY
M^T;^8!2I_P XZL_-$(-7,F:XS8,2Q.Q(ALVR]<$R<3R7P=8L&[+7+Q=TZ8I)
M(,_#I;;1OG"N:WYMZI2EM2TM3WIJTV1[N62*7<#I):[(QM">GM5$4%-TM\SJ
M_GC-R-EA!GMIASF(58UDY4HCJJU;D6KK&VNE*L"_9Q^RDU[K-+N[:6=U^G=4
M2JSB%RW<QAJMC[&YZ2DY8A)9;60X(?$M73.-%2KO,9=2 E-%EU8-MMHDQV?*
M:CV]/IY*_P J5XS)^T UPKOM#FO/2I[#N+_!DL*GOYFOW!5XD./(A967[K?*
MI<.<[ ;0EM@8I36I^.XN\2C]ODL:_,( 0P\B ;V[.]73JR EKVJNOZ=@]W+P
M:JK-%*KZ@Q56V5!#M/QIYF=C-EV5409B@MG&C]T?F::[+3&RF['?&,:[8ZVB
MWJZ]ML;_ (OF=5^F=4Q'=3&\9K'49V0[9/!*NFGQ-2-BFD&E+5T07T_[CJ*@
MI83&*[J8T=[[H:;*VE5?4-6TG$!T!J&NH36$*%)Z)L(I 8N&B4?;?"GHEG?0
M4$9LFNZV^NFOS7*R:KE;;'QK+**9SMG(OZ?IR1]+HN^=>I_'_08_+-6/Q\-<
M&.IR.W8E+:4<?FH?B;_I[K?G1H;Q_P!#G[T)_#X:P,;V(_!*V5*P)[U]OB5Q
M41Z5?3RD99K:12%'.P-[J;?->=@.T4H)WU;:KGSIMAP+-3C+T/$<Z;:Y^2C"
MP,>21TV^5IYTQC')[9A4/S)D9IF*QS:8-V&12$JV!BLR5$7G&V,C4CV6F2R8
M_.-]\99:/-6N==MM?E?#MG&>PKN$6J*KAPJF@@BFHLLJKOJFFDBEKG=5513?
M.NB:2>F,[J*;[:Z)ZXSMOMKKC.>>:;LWZ^:C_N[$^@GIX :%[&V79 /,)!W!
M-[1=1ZCH5?CT\Z5U"&CX%L]UGX&-0@(6>%!4&?;%)#-"D?A\>++DDRC'/2]/
M]*[^;LT9N%X]'3'GMW[;C[6?)CS4*7MU[-5I2JI416;SL?W+/%@@=_B:M&GC
M^*KK]TUT"ZU*J:D4&R^]R%1411YV6,Q +'OV)!=@/F7J]G.V77GIQ6!.W^R-
MIQ>K8,/VRV;O3KO;<K(B^VOQ-HU#(TQT=2*:RI_G^RPC47&%##G/G?5KJAHH
MMI4?]5ZB7JR:>!WYE>F#Z?AK&,X)K:)@_4([)QA;./<>VSE\+ZJ5\?;9SG1X
MMN4M$@RQHHBGJ*+;:MY%=8/2NC\4L\=VR[MV>5[R]U=-='0>SK($-6=541E;
M.CI6-]7:5QEQ%*K#,7.-=4)/EJ]G1-1#[DJ5%+OGK3>V_&N-<>,8\?\ 7.<_
MSSG/OG.?XYSG.<Y]\YSGEI];Q/!?;Q*U\ORB_#<SKS]\&1Q_'A^-TH#;8I_<
MY'E*O,=PV;C<=]2:F>SIV?.DG-G/8C+4_P#76+^FJY#V4-_&F@]NQ[/<X[J*
M>X9Z!_I,0,I$Y%'NH<<;RV%E $@!S)6P[D5E:,GC;]F6&2E<UK8J3A>1ZF6*
M!EP5SKHLY*8W=J:_$IMKRX3&,8_3^><_YYSG.?\ 7.<YYKQRGY#E^5Y9JWY7
MD^0Y)Z0RTMOV:=C5*Y!=:CHLL-:N54L$[!BH)!["2J,N;,&&;/10'(+^S4E7
MF0.P+^"KY$ GL6[GY/S''''*Z;XXXXXB....(CCCCB(Y%WNC/9[5O6&WK'K&
M8UK YS!XZUE "17$22#5CJL&/!WKT+-3"C=\J'!RL6D^BBY@<,,G!2QM A'0
M9P^W&B7LHN0C]1EQ%F736Y2,O&3HD-%(P0P.6K>3Q6$RV.3 1:$')U_/&DTG
M;$K!(<+KB>-(W/Y/+9T'.0B-1:-&C4O G8XR)"'J)^G37MN^[3,K#U-P4)6<
MDKM]%F1B$Z3&4EI@,Q*1+PNQ=26&3ZHZ9G41%$6[;*L1+&(ID=,V";UX)=Z+
M"BC)K-CE:70B-SY_,+QMNXY<XL*U),+JR JRY2X:/L=FC!('O8)J.1@3&*(K
M*M(W!6C$_.I:>>N3:$@DLO*R)VXW*, 84, %V6\1''''$38D_K/MS_[=]-]?
M]$[^B^M^=])]7].I]-]5]/\ W_T_S_E_/^3_ 'OROC^7_;^'E6'I-_F%^"NY
M/YL_@W\R_P#RAW:?\:_EW]\_ WWKZN$?'^%_Q+_Q!]K^E^E^#[M_M?S_ )__
M ,S\KEIY-XV'#G[]XI\EJR9.W;E7X%%/EMVS=1==3X$M%%=_@23WV^%/3??;
MQ\.FNVV<:YJP])RP8A:\+[DV5 "_WZ%33U#NTQJ-&OH"8O[D,W=PAKJY^W&F
M0TLS\KM5]/DD&#5QC.GQ92^#;3?9$M=YYP/VDWU#*_Z(]::.8S2O4;?<75;[
MX<UK%2932#X,!(#&E#A60N2L,.QUPY'QD^5B&NXXB]=-%2A84[2'+.66CP?Z
M/LY\8\_Z?USGVQC_ #S[<\-OJI]=YA^T'>H^PZ8U%-P%>5OTZA$^FKZ]"D<>
MR\> U?%!4 +"6@$9(X]H;S:5G@U1@1;!%%=$15!TZ@NX9MLCW-?R%.;;7^R]
M5!TT\A7>FBGPKLK&2NOROLU+;W7Z5G:C&_='#W[,U'CWN!%GQFSDN(N3G^(Y
MK9T_RG#Z\%_$\GQNO3@Y:OECI6S*O$;,H]W-R-&>C;RBWBW.:LG&;+*;QJ3/
M5;*CJ)T*8>M-48SMM>Y:Q*<ZJ7?#(H5BE21FUWU@VE=EGU^F]B>EPW%84X5G
MC@55M82T=)%.OG6]V_E#(?)MR%OV2X1E#T+#X[=[Z<OI9T%Z88:T(UUYE-G$
MHQ:Y6.R _'9V^A3L4/D,>:DQ^IP&A$X1$=FI$N/(I,3:SO=[AZW$A]==4<LL
M9WS5T!Z@@.A'3NA^HD9EA&=!Z0AZT92F!48@%?21X0D!N3ERZPAL])(#,/"Y
M]^HBQ3(/-6S?Y27U"NVF=]IB<O\ %R6WC.#MZ9PWIGX2VP678:<^:NJ^X6U7
MG0["A+?=LNHIM=PR%S6BL/!504&K%3R'+CJ#D6U;^</FUG)[=>F_7:]JV+:U
MS-<:K'<76EB4(\K'9>Q;O/S5236TW253T434TV34T4UUWTWTWQG7?3?7;&==
MM-]<YUWTVQG7;7.==L9QG.,P@DU3 >J"H^W:&A3<)7P,=L(N^J(</4U1D,"U
M($"NMD1L0W^;L\L.L'10F440334?3& N#44TRY)"84@QG'S3/OC_ $_]O\/X
M>?Y>?;S^OMRBVX*=JHY"U:Z/)L6T5HVC':2C>53'LWMNU=:Z*/(5:J5-%X:M
MBLZ[I_J3=P5EU"O;JX3DC57SW 6:KJN-YS+6M]2U;*4+5_4YJ]6A^+Y#VGU\
M1M==^!ZM52/*/:1]*_8)Z@4K[^XNZ%6#7-K%K6FS"NVL#<.6Y.-W1&UVPG3$
MI7E!$&:'H-B#=_ES@#EH6;YUPDBWQMC;6T:X>J_7'L"M'W%VTE6=IK11D1'1
MI2<Q$5(=@3 MNS4)LQ>7R"F&39\H/8[N44,::*[-$,[8_NM?%,%3I=H>L7J!
MVZ6E08X&ZPATWCJ9J A<DD54P^D)6;DQNM2</$:.5UP3:-2IR7<GM031RC!V
M[B?ORXUI$L8=-_08++##8U@9#D6)8259MB PH,=MWXXBP>):+M'S!\T46:O&
M3I!319LZ;JJ(+I;Z*)*;Z;8SGF.D=^+E<?)T-P]W%Z*.7W4[L&\-9]3=3>*F
MY',NCN]F#1=4PI?P6M+Z;JE[O4S'IO5#T3XKTGU<5GX?F^&ZRZ9ZQX7BNL<O
M+<8_UV?-JY['1R5G \T3;LS9.H>-HLQZ=7'UZ&\<FSC^02JBO=76NX:-6S%J
MV9,T$FS1H@BU;-T=,)HH-VZ>J*"*6FOMHFDEIHFGICVUTUUUQ[8QS<<<<[6?
M-_Q^(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB..
M..(CCCCB(XXXXB....(F$>Q+2P'=0R[-;70!Z]GF+1$P^M^0U^-LQK"XH$7U
M+3(DTBYN01\!N5S&69)$87/JE@H!UOH8)1N2-F>P=U''JWTPH: V&Y[C"+"G
MG9&^;>JP7%UNS]D2L*8+2RH#[H)-PX6,@ZWCT!J )#B#QF&/#,Q6!,G2S?1G
MC)9TUQG7>8]D/SHNO9R3C$84FTD'0Z4/H_#DB?V926'&@(@X$QE,O^@O<^03
M;"-".?\ Y#L\PZ_5+'*&_2R AX!<E> *G98E$6D/7&6O[DCHFA^P="1WI_.&
MTC@9 '4;-E:$P,QW7\1E",L!)5G*QA"ZA.\"=SO,HTBI(R.=HGH9XXXXB...
M.(CG4+!;@74$FC:5'58O&7$2DJ$ADJ!W,76CX)8(^3+G$I)JLWVCZH@=LY(I
MF]5T<B=VV".%4\MOCU[?SC#3,40$%6!UJ/?!7HU\T+LBR#9R+=BW+59 @U(M
MWNN[-=@X9J+(O$76FS95MNJFOKLEMOC*)YW?V<0;6X:LO4W$T]8[NX:H&^K5
MV195S:[^QLW ]L:'(5906H29.[5R_*_F,X.-O#I28_<R'WS.?JOJUL9QOGT:
M\H,]!T##(MMZNT:KH+&(Y @/K+]JA,- 0H<*$1 +&V5:4$D+&1D4"1;A1P1H
MAC";!D*018((XQHW2TTQXY?G^G$1Q^GZ\Q59UY4Y2T"F%I6U9\#KBNJ_255F
MLUF4J"@(W&,I:I[?3FBI!XBV8OUMEVZ+08KO@F^<N6S5DS<.7*"*E(CGO7WK
M]3UPO%/2K@>_7/JT^658&O4[[.0-\FG)AF=LHN7_ $UZW2)(>;L]Q\/]H78]
MG(@X%AP@18+#&A!LS=.$2??J#^H]U_Z)5XY;3"=M'O86P09D9UTZ_P 1"$[)
MNBX+$=L'K.'C(C4L4PXE1@,O)OH&A0ZY3$QEIIMLU=GVKM=LBKXU_26._M+7
M;SMM:E/7GV*[K]6:J/"#YF\K=M[KX.>:0%X,>?[)#:$&VY$@D,@4PEY1=< /
MUKQ+Z2-QS5_)4@+O -AMCV,])_2UZT]*C!VTQ24OO/M1/4]E+6[A=A#ZMF=B
M+ >.4M4WR'XQ+)[:PF+*ZZ)-F\*@;4"!T8-![<DF8<,M'V\_0LQA\A*' T?E
M$=.&(RYT9R,6(.C"A&/NU-E-=&AI@R>.'0=PILBKKHW?HM5=\HJ:ZZ9REMC7
M!(! ) )_ )^3_A^LQW [ D=S^!^O\?C]?CYE3M)>ACT)K69L[?N**3SO'V$0
MUTPXO[O=/B_9>=*;IJ[N6^PP!,L8J^+ZC7*FVX;\-0$<Z%::(:-WN=D$U,6^
ML1S 8S:#QS-LQ8,$$6K%DT02;,V39NGJB@W9M4-$V[5!%+75-)%NFFDGIKKI
MIIC7&,8WG',S,^<:ZXSG.-=<9SY\YQC&,Y\Y\Y\YQCSGSGWS_//OSZYIYQ[^
M^/;]??\ 3_'^7^?,075V!I+KC"WEB7O:L#J6%,=5/FR*>R49'&"ZJ>GS,M!V
M2"Z3@N0WT]T1HE!\0<9\:(-E-LXQGRSHBEG94502S,P50!^222  /XDGM,,R
MHI9F"JH[EF("@?J2>P _F9F#FR($AXEDZ(E'K0</8H*.GS]\X1:,F35'7.ZS
MIX[<;IMVK9%/&RBJRZB:>FFNVVVWC'*>E/47[&]I=MA/IM]19//(NZWV02[9
M=K$SM =;&Z6RF4]#$.C;]C^<UQ,]<>=D](Y&H^Q7WPGG[I](MASC<,/2PDG8
M!VTE/J6]G+"[?.]5TGR5!17ZNB^H$>7T\J)LTZBAA%,W8NK%3^Z1*6=*C6Y!
MOC7[@*WW_2#]<UWQBH?3W_\ CL31D'\Q>RLUR_H<U5ZD]P661/JC9\9:FO\
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M478=6NG'7U#]8U6B_F>5I2[Z/1LP:N,.CCQAKL1ZI/5JF(/L:AMB0RZ)T1&
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M?KG^G*Y3'J"X8YO\0WZ^6BA-ZD[ TWUN@D,DQ.'QTA<4UO%M$U87*AC]L4D
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MQW%@=5)2@-)$- ;0>F:="F#@QH]W1UQCFT:7K=OJ[T1 +I:.BP<UIKI()/C
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M3!"4/WY7+A)/=NS;7):Y^+'G^N<9_P =<YUS_EYQGQ_3F.;?EDP@E8S>85_
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MQ%8$,VBSC>22J(8$J:08S@LQS'M"YC/T[S=PVW9COH">DN<MVO[;QTNHX-B
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MRT9^@4N<[4<KB<;O:(JM8O5#$^<9OF.KCB)D_&_;Z&P@Q#JRI;O"P$V]2D:
M4"-FEGM9U*:>*QWM_=$@(YM.=.9FB[J\MMU[G-<F8V/DY*0RIM HP-ILK.YC
M8$)U8.L*3&G>W,'LFE_M-3=B&C"JYI6$N%XJ[\R#@E_!#WJ#W!.^QJ;-Q"NP
M5;U7 C>W7XY'V4H"S&O+MG%OPTY'PM<B8HO&9 NU<<1.Q1KK1VDJVDTZWC=;
M]JV=7P5W8 JTX)&+MDCFP+$AFWJ%Q6?SE*GI.]MU[)EG5D=8MRKN.J@Y3%9&
M<CZTXB8YW%K#E*NKK(#3JWV#MJ%RT;@5VR@]*!:N[XFNK5<R&^+#@UD1:4%G
M?693JVG/G FQ&$U5/"YD![ 3&C 5BR,X2JR"2,5&Y8H"=M1T7!..(E[==_B7
M\ PG\9?.Q+OPC&?Q1AQ]-E?\1_8V'WWY^6><M,K?=?K/FY:YRWRI\7R,Y2^#
MG<N..(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(
MY3IV,CEJHVGWH@P[JA9M\ NV5!5+6L%?BD:[2J%X72@MQ0>0L;4DLNGL=<12
M-1Y]*0A63NT )TOF/JJ.(D%DQ_1J%4<<1(+2&A>W^O8I[&#)KLU7$7W'3OKM
M..P4=-6JVBD=K#3I%F!5'V 1L5;L&UKAE%?SXC(2UL0Z&T@M-ZHG6APM;MKO
M'4C=;R[AI>([G]J>L55]KR:5_9E-Z2^?6 +J&L'=I2ZO(DP 4W#JDI)FS"U+
M?M"SN":6=*X',;PK2]HR<E%<5J6N/\0VM7,G9K1TM%G'$29GJ@0WM79M:T2
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M)F#XILZF>\[BC=XU!X?VY(,<Y[;S7K=HC'[FBYB&SY4!3C:GXV/KE+NWB;U
M,WDPVU)Q3L[[6W/8P.!-'LIA^E)-DY-7\>1<<1)AQ+J'9DOM&P0;F#]HH;3E
MH=L;GOJPDW][6C$A4\B5H]/Q6:S3<:#+?UE M*.7&N_%2:$-48QN!GL<C.2
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><<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g133668.jpg
<DESCRIPTION>G133668.JPG
<TEXT>
begin 644 g133668.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?4$1?,E!$7S1#7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MQ\=:?ZRW_P"71_ZSC8^@^_\ F/OQR7Z2_>/?SC[\]KCGJ_'6G^LM_P#ET?\
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MO/PXXV'H'O\ Y#[L<F^DWWGW\P^[/W^-.?\ 67/_ #EQ_P!;Q\:<_P"LN?\
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MJB(EDS#O&52P<RL@V.0RJVJ[9VMO\D*J873EDN65&2&?*H)JJ"4=HU%G*NF
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MTLLJ\K;JYE21E5B[ODP_B[JB &(5O9>U'P[L!8+SL_6]/RMC+P.DI;TK2LC
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M/:N8^N4=5/UT@1-=%^YI+KJ+-:(.&$>RX0:[V%:1,<RL*[C[/0S*,AHJPB$
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M,D@J!P3LRO90J=]P-CMEE+L'VLO+S31+T$0')I;5>6!54C<,8V0SE2"-BL+
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MMQ^ZC3H=AN/#H,M<UNW8&UBU8G&^^TT\LO4;]?WCMUZGKX]3Z3ESF'7CM!*
MLBD,.\H%N$@,QBP8E41P;1?2R0AQ&Q"+K[HR<B3&TBDQLN/&"[L7)!3<*O#4
ML@4E!"1M]L02D#6TDVC-]P6R(/\ .'RV)QBI1"!>N[ETF\>Z0Q>Q=[[E[."$
MJ+C4,R]Z_P"L;":280K.RQ6%R;+N8&VSZ$*Q#9VS3+O%\_\ KG59*C*&IRF3
M<V>6,7K"MH?!"$X)#&05[+'<8"-12YM40Q47188?;MME$FFSLBZ20^#U?E"K
M_P"-$744_<;P[-.RR%^:PBX@E0..PO94+=YXD#KQ^D3C0,SU'^B+=H82O&IW
M&6DAEEHQ=T4DQ20R<>^%/G#S8"> D?:WD&M9E/F72W5KN3L#0;-_)O<R4@TF
MZ9-R84ZW].EABU?ZS!4@M$$@>*917;R?>#[(Q;2<[G%V*4B2WF.T(49JXAZ5
MAHUO9<RFY<='_,D%+Q"SAZ44ZR)Q=ET,E<XDEJ0IA*T[L9/QC2BVPJP&L.(N
MH ]2B\$=-SX1HA)F$M=,%'XA^VEF(BT78!X%SA@Y1=B7(O&AUE@J,<)KL5&6
M$RS#*[/!%FMIO[)!E\9:Y>M]ET,*H?"_")P0TGX=K<K:>T!+YMV+ZX3IO6-Y
M;W?;K<!TN<UB=NTP!2@["E0R4@CG8A?2JH5UT#P@2QI6I82*0I0*^"0>12>N
M)<>AK=\28S-TOU_[0PL/');.O*?:(*'P>&G2%SG35%=*HN%+NV4>';:S ;("
MU,[C*LBX,HS.'S \[M-M%@KUJ+WD@S80N;)V3@(F]+'6>U\$\RP(I<!\Z_M2
MN M<Q/HS8[PKU5>3IF_@\B=P9*G DC*E#]9*I!RMD@GF]?M9@6;R((Q,AV:0
M(G(EV5JV0W70UH53#9'!8A+IG$W@:*S"QJH!WE#X=)/AF[D%+RE328F)CLX5
MBQ5HU.B0IY]H(V.#AKDBB]:M56+F-CIAXLI7U2[!0RYU;JAY5H"HM:M9PR@,
M%M6)F;HEK]SJY=RFS59]V M^(NV2!S)NRD'$<B<=G#NR9Q*EBDP7AF1L4T8R
M]-F5C>E1MI9-;#\L$TKR"$Q\=C->_P )M<=&X&,$V41^7VK9*13\Y1C8=)FT
MM*.8VU"Q47'P!IG\DETFI*0.#;;0+UE65?V1L!A'!"?E=D,GL>KL,HOVDCU6
M5QTHEXT7:'S)^ -1D1C%%:R"L-6,Z^&/#AL[%&9$[B3;0$^8,"*ZIYK=;R%=
M29AW2I$744'LJO*M>?/5H7D,CG=.[6^H6K][&)7#[!@$75'S^M9369"S8E*2
MT D]E0.6"9TQK:03B+1DF"?2O,@%6F\=GCE>]%ISVCF+RS@DY3[ RX*4%A8U
M!24'$Q@( F-OS8>EL-)S::#Q3A->Y2,8;16N6T$JT4%B0J1,(3BP9A8TID3&
M=+<U5]N82!S$(MY7E@-\6A/=6U! KGK3IQ$PA^.,Y+%'DGB#>/#:*=3"QYD"
MK[,IR@7B*8]%>1$HR]*1H2&:/DG]XH]1=_R]\ZE42\G-QR6N7PIP)"H@*GZ1
M'54)<#DY\;(""TV%]?EQ)5FSPU0C+R,MP#!X'D((RL[.**NM@PGUNWO2J2]G
M[HZK6 SL&&1"(4-:<-LN6"']:.3\\DZE?6#%+'!!(Q.A\RCC0;') ZC#B,S*
M(SV,V)#UT"XVPXV% VI 85)F%[NG?6H5U%H",4&!+#BX*)2FW#@10/&6\/$"
MPUEW)8%J"XN*CC1^2:#!D-839O$6&C5SJW<- B+Q!F.2<:CFK&8RQR/]A:SN
MZ@HE)O)3&[8?Q<3))OVCJ&THEUEKV2S2JDJREX<;/JSAU:UH%GT)'#+EQ%SA
M F>F9"+M(D./!'!PD2U2RYD=CDCC\PCX.61,Z&E$6DP@;((Y)8Z48FP$@!&&
M:) 2;"&1B[H:6$%&#A!Z.),'+AD^:+(N6JRJ*FF^T4':GQ?GNU79Q:W35\I5
MG6ZU52V!+@ZRK "SM@SO.XFPA$Q 3";2PA+*XF-?R($)8-G6QJH%;3&Q]Q):
MUC]E!ZYEY\&ZSPZC4.ZZN]7NOW7%Y-G%CKT94$!JG,X<Q\7%-Y*G!8ZQCS<F
MG&@VR@X"V5;L4M&8INX>98M$T$%WY!SHL]<,9D3QQQQC''''&,^=/QSGTS]F
M?[,\>F?LS_9GG6.Q]!^XY\YMQZ1[_P"8^_...<^F?LS_ &9X],_9G^S/&Q]!
M^XXW'I'O_F/OSCCG/IG[,_V9X],_9G^S/&Q]!^XXW'I'O_F/OSO(M_*J*_UI
MC/\ MX?SZ'6/J_3M_?GGSQHMC/SIBONS_*F-?BS_ //H_GT-\;8]_NV^O;_B
M[9_'G[,<U'\)_P YHO\ )?\ _-/.DO@!^8[4_P!71_P:EGGQSQ]K'V;?J;_X
M>/:Q]FWZF_\ AYJK.A\\N.>/M8^S;]3?_#Q[6/LV_4W_ ,/&,\N.>/M8^S;]
M3?\ P\>UC[-OU-_\/&,\N>.^,YTVQCZ\ZYQC^G.,XQQ[6/LV_4W_ ,/'M8^S
M;]3?_#QC-:.^/'?Y E.SW::^^M7S$JN73.Q[0GL5O>*7L]#6Q;57S^A*8IX3
MUO/PXW6)6(0]E!)1%IC;L1F9D\:^0)8, I1#:%E9<=EP2CV5'^= O"K8JUWV
M/F3^R:VZY405;348Z&P:/6-V&L0S$8Y<$#@MF2."A0LGBL%IZF<S5&1QUM$G
M8>W.QTM$_/0.8#Z.1FT9[6/LV_4W_P /'M:_7Z;>N?KS[&WO]/J_XO&,U_.Z
M/63S W6EURBM-7F#KZ.Z=/)'6W9_(ZVVHP1*+HF-33B&3$DP53J%I*B!#$L*
MP,_ [$&: MPF@:3D&<<A)3=LG)\;%/'UYGZ=>8@?63M>XC-4AC5PJ5XUD5J#
M98W"I&JL@PFNTYBWE5?JO]J_$IQ\M H]"(HV=N(!,5M;2#;I($\K"-I;VL?9
MM^IO_AX]K'V;?J;_ .'C&02=G^@?=2X8KU"BP;L+8)!:(]?T*X['29Y>3F,%
M3-I+=ANG%P/;6:M U?:A99(!$>J2[@\*,H"8VO&3)N%HM1/S<>2-GGL>G/73
MRV0?LD8*=J^SK:SJ)TI(W$!(D:? ZL23]ND.!5YDLB)AT=E;"YA:X\W,; N$
M D+$RMM)F8Y(8N1&M6,=G*]K'V;?J;_X>/:Q]FWZF_\ AXQFII5WC-\I%)Q%
MPXI:3Z5<0CY6WM!D8%]H&.\BF<EF77-*OMK2F\D94ZSJRS'V]@L$BL0F$HJF
M!W9(GSW:P;J+K3M%J>%92=:NF7EW83_K?8O;'M2;G_\ !#?=2/3L%AMTM@T2
MD5)#^OUVP&P"<R%,*I$ZSZ?.;(D=2'"XLN4V$R,6%EI4:[&RM=J4>[$_M8^S
M;]3?_#Q[6/LV_4W_ ,/&,U_ W2KR661V2%2/L%>.#%#U_P!YJW[ #HFC9Z#E
ME*XU79WL>?C3N'1T+  BD$KT-%91UFAY&D)._D*LBLZN)G:>\G;*_)Y*76E)
M^.KO]$KP[07!1^T)J$Q+Y_VFE#^=5W?CUA:/;:N+Y[&U5/HC7!9&1523B-"3
MZFJ1BUDPZIK6)J6$YADWF0CY$3 QE>2/DMEWVL?9M^IO_AX]K'V;?J;_ .'C
M&:T83J'YM)$=<![;ON(3*+)0+K 8$/2=E"DQ8&?U7?E-6(0:#P@6K6KL]-QL
M.A\X83.RB[4&G-Y$2:&!3MP,.#XA6E&V%57F:I0_U;@J-V7]=R1NT*R>F#\$
M.#SS,.N0(=%=[SS>DT2I1 .ZJMDNCW53KN)2-] 6K2*'@)9G-WAX.!B3':.]
MK'V;?J;_ .'G&<ZYSC.=<YSCZLY3VSG'OQGW?Q?MQC/].,9XQG.OKZ?QOK]K
M;^SVL^S]7_T?3_\ 'W\\N>/M8^S;]3?_  \>UC[-OU-_\/&,\N.>/M8^S;]3
M?_#Q[6/LV_4W_P /&,\N.>/M8^S;]3?_  \>UC[-OU-_\/&,\N.>/M8^S;]3
M?_#Q[6/LV_4W_P /&,\N.>/M8^S;]3?_  \>UC[-OU-_\/&,\N.>/M8^S;]3
M?_#Q[6/LV_4W_P /&,\N.>/M8^S;]3?_  \>UC[-OU-_\/&,\N.>/M8^S;]3
M?_#Q[6/LV_4W_P /&,\N>*F,[:;ZX^O;3;&/Z<XSC'_3Q[6/LV_4W_P\>UC[
M-OU-_P##QC-9RP/'9Y!PG83MQ=W7I6"U/+)S+.STIC5OPJ]';&S+ZA]XMZ:
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M$Q0"XK!U%1T]TB49$P1E -@2W72-PUOJ(AU)1S9)LZ;,9D$<\C?2ZYZVO4'
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M17=+7+4+'AS@D]PWT560U</G":'Q0:ST4U6?DG#1BWQNX<):;8Q]":SET7J
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M"OPK\GV=UW@\#(EHE=53!5;"=8CB\.$A.,9LLYSZ>_\ NQG/_1CW\\?:Q_\
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M8]-$DM<9SMMG;;-3<<9SC'OSGTQ]N>58         &P '0  =  .@ \,J
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M4(]U[O@]TTM\Y]FVH:T>Z-= I2!@?C4K(,"@PMH\CL<@O;*O(V-G"K@2X)*
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M,CHP#*RD,I (((R1*=>53NS/HH2A[^RPL>8FFF[$R7@\)!Q64$6BR.47".9
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EWYS^G.<YSG].<YSG^?/''&,YXXXXQCCCCC&....,8XXXXQG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g336902.jpg
<DESCRIPTION>G336902.JPG
<TEXT>
begin 644 g336902.jpg
M_]C_X  02D9)1@ ! 0$!+@$N  #__@!"1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?25-465!%7T903U\T0U],24Y%+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( 1L!8@,!(@ "$0$#$0'_Q  >  $  @$% 0$             " D'
M 0(#!@H$!?_$ %D0   '  (! @,$! @'# 8)!0$" P0%!@< "!$)(1(3,105
M05$6(F%Q%Q@C,E*!D=$S6'*2L=7P&20H-T*7F*&RL\'6"B4G.$CA-39%1D=5
M<WBW5V)H=O'_Q  ; 0$  @,! 0               0(#! 4&!__$ #X1  $#
M P($ P4' P,$ @,   $" Q$ !"$%,1)!46$&$W$4(H&1\ <C,J&QP=%"4N$(
M%?$6,V*B%R080Y+_V@ , P$  A$#$0 _ /?QQQQQ2G'''%*<<<<4K0P_"43>
M//@/(A^/@/KX_;X\^/V\A ]]0/KA7-RTC +U:'5"O.?7%&G_ !6%BL,-:#HX
M?5.P%AL</(10R18RJTVAW&*_2J?M18!A'R@*MBJK(F;N%IO' 1*( 'D1]OKX
M^OU_ZOP_'Z<AWH70WJ[JMUE[YH67-K5-V/08[4;.VDK!9!KEFO,-E33%8:=L
M-62E4X&65BLV9I5Q@W=L3-6Z)G#H$1=O'1U:+XI$?."8SVGXCH(G)JR>&?>F
M(_IB9Y;X]:PT3U:^D3BX4BJ,M&L;MM=(;49E>V_P;7R/K%#)DSW(FL^QT\TS
M!1=@H3N4;[CG4W7'4[7T860K,XULCF58PSZ*>2';6WJD="';Z78H=D:=\$"Q
MM[^6EUXRW-:NT3HT+9[)86OZ7N:ZC5G$JG7:5;)^)A6TPM+V2%K\G)UUE*,V
M_P TWY4YZ7O4Q]1+14H6D24).67/=ZSI?1'MNM]UNSJ*[%9K6LIOQK5*W6?F
ME-#;#5*+G32'A[P:9B88,[IQ8MNQ+#HFYCK.O1VZ;4A>>0FZC*Z+5I/-,RRR
M$H%PF'PT*H0.<8*/7@9>%J<,[C81:[V:CN9H\I?I5D_N4:^L4V%?FXQL].ER
M)7GT']/IG;Y[]A&1;[O_ ,X^ ._Q!QZ;?/-COU <3LU2PJQX,E.=BW_8^ZW6
MCY/7\[&'AG<C*9?$6*9T]Y9'NB25184Z.S]&L2,98OOM5&31L*\7"-XY=P_*
MHEA^T^KCU7K]5U9X5+1CWW+;'OU34R>9S^RP%IM<IUGD(>,U5_7Y5:.>U)"J
M1,A.QK!C;9V<BHF0E'*$.DH$PLFQ-)J6Z781-9QG69/H"T!%Y+/KVG.;2PTF
M_P 1J%1LCYA,1$K/1&JQ-@8WU&1G(:?FH6P">=40G(>2<QLDBX;?+3)^ ?H#
MU847U59;,3.B;2TT*/T5L\N%T>-)IEK$S3[)H[=HU<V!5&#+<++1*Y99L8<&
M0NI]!]*_JNY>45=Q*]XWP<3RY8'//3?%!Y?,*(!/J1(B3,9'( '&^16,=7]0
MNJ9)HNP5-_D6DVVOXO<>I.>7&UT@]9?J1-N[;3#F/KKR5A9V;@#M*93FKRG.
M+//,'LQ,+/;BP81=:<D:.WB?V4/U+L!MEBWYE.Q]WSBF8%3]3TB7U&Z1$>C2
M[5G.':E=<8UJYUU."E9NRMX^FZ!G]@9K,YZ"C)64@C1-@BF;EK(@BAVG1_3\
MQ'6KML-JO;F^OHC;U\ F;M3(*\3]*B5;GUM5FC9O<6DO37L'9P?M4Y"%,_C'
M4PXA7+^FU26!D60BDE0_99^G_P!4F"._-6V3,2M>S5<ME.UUNI8+.X:R]4OD
MO8;+>:_7FKB850HD3<K;;[3<[,QI24&A,W&<D+,](I*J)N$Y'$-I^(Z #EGT
M_P"8?=QSF!M./P]=S^+E'3D:QN/JS>G\6O6:SJ=@6+:.J*0JS+=]0]1C9L 2
MGY6L/TXNNR5)9SL\XAIR%D6-@:PD?(.*\=!-2:38HNFAUNCW;U7,$H&[PN9V
M2*GX_.)[^"V'CMP7\HP+O1==RBZ;15LT84L[ ;O,W!W1H&EBUKL/%OK2_G]3
MI\(A7@6,Z43XNS?I$=7NQ57B8EBQFLKLD/:Y>SM;A67/Z1.U0L]Q7O\ :HM[
M#7%>5B7#66NYV=V8.DDVS^ M\%7)./7%C%JQ+WO5<],#K2G0!H^LQ]J[$/ V
M>\[V%\U^Q.'N@'TZZPK"IEMXV*M_H\HWM58IT)78*JVR-283\"M Q\[$O&$T
MB1T2IXSO.W('?&^W.>4&,14CRO\ R.2(VQR,X'PQOF8K='^I7U\M^UY-DF4R
M_P#"8C>]LL6 6^W1"$]$P^=: TR33-6JB!U9R 9L;E%V]#);I6TI*L2;Q&+E
MV*'VD3HJF,2QD! 0 0^@@ A^X??E2G7/TD<PZZW^E7.+V#7+C'4'?+SV'@*9
M9UZRE65M NF=Z/G*E@GFT-$L33%K0C=4M#V4M@ S?61TQJ1)%JDG6DQ>VV '
M@  /P#Q_9S(D0-H_+D,_'X]*HH)!'"21&2?\@?\ $<YIQQQRU5IQQQQ2G'''
M%*<<<<4IQQQQ2G'''%*AEW+[MY;TGK6?632H6[69/1-"94IC$4"/B967A(1K
M%O;)?M0L#>6F81-IG.44Z,?VZ_RC1=Y),89 OW;$R;UPBV/&*\>KOA>7S6A(
M7W,=LB:Q5-#WC(:G<HV%J%BC]-U?KX^K,9:,[K$3'6\LY&6.Y/K5'IY::U,X
MB&MB3267=2\$5D0'$SM_Z>=;>TKN(<]@\?J&NEKM3T"F5YG>6BDW%04/J,?'
MQ-X7AHEPM]W1M@F(N*91Q;2V;%L46S2%&)DF9%EP/AB*]+_I/')V)L\Q="TQ
MEEA;E"NH.]W.]WF C":-&U>+T66K4+9K)(1U7M=^1I=77MUT@6["VS3^%:2*
M\T5X*ZJN(@Y@'F._+E&T;1MUBKC@C,SG/RCGOO.(CD372&WJ>9>UF,]A[%G=
M[CT[GIF_Y)8['6Y[+=$J647CKGB]CW:]5O1I6GWJ0DHVQK4JJ3Z<=7(^#DI,
MLI'G)(E9,'D6_?XDH7K5=:+W?J'E:]6O=!T._C2)YA":9,9=2XQEF.EY]EVF
M9[H;VV/;VI61&W5[8:/&Q5&0D3WC]+EYNMKQ*:D3]K=R?;>FWU4;.ZM(GI]S
MD96K:I=ML^]9O8=4GI.UZCHU&:Y==K=HKV9MKU?1GMCR]H7-I!O<3RK$U%7>
MUM-L1@]=$5ZW&^E%T/BVL2T0P:/<)1;QDHJ:3M][EEI^ AT*(UK>>6]Q)69T
MO<<HJ3;+,P0I^6V0\E1JN3.Z:$-!M!A&YA@!41!G&8]!M!SS[YF:G[L'F1V!
M$?,_EU.^*^*V^HW3Z;HMQJ+O*M!LE6J_=3KUT3-?:@M77[!EL&]0M$D2S%JB
MYF6@'T'0J=(Z;2*Y(2T0-FF).7E'0,X1)HR^TJ_+DWJG=:M%K6J7VQIW3'\[
MS#.(?:?TVT>)C@B+3C,_IFBY!%:)#-:?*6F:9M7-_P LM46>NS<:PLR3$\%)
MGC/ERX)-<@6;T]L-NMOTVR6Q2\R$9I'83).U0U2&O%@I,35]]QZK5BL5W0H9
MY3'T'+O'BYZ13+&XC9M[(Q3:T5IG,,6B*RJQ#?I0?IU=/Z[2];SR*QN/1IVV
ML6<)?8-Q9+:^07JL9:)B[1=)K:SV<7<TFB1=RL=DM,;2Z@K#5QE.62=?H1Q5
M9)Q\4Y&R3C(QML>DG;K,8ZU'N1'4#(!D'$[F.NP[<Y&.);U=?3TA*[<+/+]B
M(Z.C*(Z5869-]0]293#)^TEKG!3$>UK[RDMYN6D*U,9[=(RW,HA@^<5)[7GC
M>Q$C55&A''2=+]6#"\L[!P.26V%EV6;6"S43,DMP%P<(E#9K[C,WO41EI:*$
M<>Y2]C7S]3,_L,?!,Y"=?675ZU $@TEFLBJE\_:#T?>L78^+C"L LF26EAH]
MDTI>X4]X6;D)&;NMQO6A6M9>/MBDC'-)%6_Z+8[]7)J-(T?5>Y%AY%H5U&Q2
M,,?)#/TO>KTO1HNI;#7)?>)J,V>^=@OX1]#G'S:_O-@O+%&OFT%::J2T +>W
M5FG1=8JU0L#$C63K;2J0+V'<,7K)(Z8\9,D''X=N8$3S!F23$>E6'DX)*CO(
MY@0(C8',C?F#! KY67J>]9[;J6<YMD]F2U-&S=A6G66]V" ;3<6WS31['G&K
MZ#0@<!/0,<QMT):%L;NE:5D:O)O2P\HDR<KE59KBIRR-,P&3(8/H8I1#_)$
M$/S_  \?CRHGKMZ0F6=>K?7K$RV#7KQ"57L:\[/0E(M#BL(UK^% U)U6E1]E
MF$XF(;.Y>RF0V"T2]GLIEFSVWR\93EY!NV3K94WMNY ^$A2^/'PE /'GS] \
M?7EDB#D$&,[0=HC)Y#,_I%45P@PDR.I!!/K/["(C<R:W<<<<O5:<<<<4IQQQ
MQ2G.IWV:DZY2+A8(9%LXEX.K6*8BT'C*:DFBTC%PSY\Q2<QU;9R%A?MU';=$
MB[*"8/9ETD8Z$6S<OU&Z"G9EW"39(ZZRB:2*1#JJJ*G(FFDDF43J*J'4,0A$
MTB@)U#G,4I" 8QA  Y^1!V*"M+ DI7)F(GXE4ZJ2<G"2;&68&6;F^%9(KV.<
M.6ISI'#X%"$6$Z1O8X%'QR)Y9^7ID<L32O-*Q]43U#$V=11CLK@+\LKF]OEI
MNVP^!; VIU[3A76I!<]YS)60"L3L5E>2KU:CQ+#.KY78G3;VI8Y1$R9G7W,]
M<RLZ]=]^YMXUV2K%APM[H\)'=:9'3XBG4G.)3+[;?)%BWS17/[M"7G7+=!9M
M!-]N<VRYL6&;6>7BY.FFI9UI"6*!')'%XGR2"'\XX^X"(@H81$0\>!'R(^X>
M \"/D0_ ?( /-!2*'P_K&$0,3V$PB B"@"!OA$1#XOK\1OYQA]Q'VY0)5_<>
M4<\8DY)V[$S\:R%:2(\L QO)WQF!&^<;9Q%83ZU;G$=E<-S3<X&O3]2BM)K*
M%A;U>U!%C9*\J+MVP>P\T>#D)6%4D(]\Q<MG"L7)/F"IDP5:N5D3E.;.G(">
MEY_[AG7'_P#T^6'P'T][M:_/CD^^7&P])^=44()'0D?(TXXXY-13CCCBE..8
M/I6ZUR\[;M6'Q,/84YO#(7*)6U6%VT:I5=\\UN,M$W#P$&\(\4>.YB$A:XWE
M+$BNR;(,VUDK_P!G7<F<K@CG#BGU\Z<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'
M'.OSEKK593:JV*P0D$D^=IL&2DS+QT4F\?JB )L6BDBZ;)N'A_(?"V1,=<WD
M/A3'X@\J5!7U >Q&P]>:MCT_DC1C,.;!L$- VFHH4BY7"^:!7%F:Y0H64'A(
M&6IL#?IZ378N&LMIDC7JU]R1LTV9RJ4PHU,E3Z3U5O4R_1]A*1?7&&M=I5LU
MGC8*E,L%V2*_A%M4=$YXYO&.,'SR=^?5WV !9KQ+R.@2APA]0;48L7!$(\+)
MG-ZAA3*81$#&*(F$1^$PE$1#S[#X'R)0\B(%-Y OGZ>_-?DE\B/DWD?VC[AY
M$?!@\^# 'D?A ?8OD?A //,9"IW5RG(Y ?\ EN>?SG:KI4D  H"B#O,?M_-4
M_P#5[U!]JG\UZLR^\X-=)DG8G9KSCC;;Z978/,J'#.V5CGV&8S=HRG2KNAL$
M6CH,9 28MUJ]7;#&-EHLT@]7C6,HR(%PA1^(I3!]#  _VAYY!'O 4"ONF !Y
M$?X].&^1$1$PB$#HX>1$1$1_M]OH')V)_P"#3_R"_P#9#EQS$S$;^@^OW,U!
M@P0(R>9/0C?I,5OXXXY-5IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ
M2G'''%*KM[^]8W>^4<\M9=KO52QO-ZQ-W/1,6KM=H<Y4=M_0^5A= 1A]&:7=
MJ9M+UX8^I/X4($9: C7*LQ]IEI$62*[=7%GIY:)UDL7771NW&-]5*IU?B+"V
M>2%TJ>31U=L$K98#.JLA:XB0-6\FB6L1*6PL1/O(YG!0T,_L#UZFE&I/)<J[
M  L%[ J@EB&N #9%^JKF6@MVT<NS+)DDW;BFSB36+")%RS&7/(KF(S)%$=-E
M)$RP-$UDC+?&6K[T)6,C%]%H.+GIBPR,Z6\SC]]'VE:QEEZX#RLTLGZ/(Q=K
MIM$F8*)A72#F/CHDL*ZCXT&YV3*<E1045)B((6.Y&^3B(/SWZP1.*R;H,\C
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MEO@^6_EK/-1#6T@@7X3Q]8S:.<+H%;3D>=>^<HG*4"@0?Z)#>?("< \>##^
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M[B$N J)-RX@2T>&5B'Q>1^+V#X0  ^@!^[\_/L/G\/H'MSD6,)4S"40^+]4
M^GN(F#P7]X^? !]??VYQ&7*D'D0$0+Y 0#P'P^_]?GZ>WO\ LY6YWIWVRE>U
M?J/AY#3.Z[LR<E>M6#KY"],RY056DW8YA\DLDXKS&?33?Q"EA1,1_ U]M9)R
M%-^DC:LMWW<U/4F=*LG;JX/$4!#;32)+MQ</$-VULTB"5.W#RDMH $ J*B0E
M*U)ZMY=M6-NJX>V!0AML'[Q]]Q0;98:&2IUYU26T 3[QG"02.E4!M2.[_=.P
M;+\R2E\IZ3JJY#G)#_$-1T;;;.,+=;KH:*8@4DS#9FBPKM<J"RA5X]U:!E;
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M=)_?\NE"D P5$'H4GF)J:GQD_I%_S@_OX^,@?\LO^<']_(5_Q(Z__C%]TO\
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M(O\ G!_?Q\9/Z1?\X/[^0K_B1U__ !B^Z7_2MU7_ %GP/22O@ C_ !B^Z7L
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MNY,]<76<3H$&M)V%.,?9RH%RA7$<O$&JLVQ?P\S]^N9!Y)).Z21 Y$9,$SC
M&-S.\X!B  #(6F1,'TF(GK$C&QZXJ8O4SIOFW3^+O$71)^Z64UYFZ^Z7DKS(
M1#U_#U>CU=C1LXHD4,1"P3<]<H5.C6<#%/Y)N_LTLFF>1LDY+RBJCLTP1.4/
M^4 C]? " C_9Y\\\\%8Z>>K)GM*M:5$V5G]].LLW6D9_%6GLM<)ES"6*V;;G
MERH.G:5+2.7S$+HFOLZ.AHD&-XA8RF1*#(8*.>U1-S.3SM*6^*8)ZB47M^7:
MAN>]%M,4T'L;$WJCUR\%897',+12,E;87+(9HQH4,-V7KELK6E*RZ4G:(V6B
M%+8RD8R5=,1<Q*$)) @)/K!GEUW[CN=H-%)&3QI)_/ '2>6,<QB1FK9 7(/G
MP B(?7X? @ ^1#P(^0 !'P/CR(>?P\C[<BOV>ZL5CM9&T*LW>]:#6:=3[] 7
MR:J5,>U^)8Z$O5YF)L<!%664DZY*V:%0C)Z"CWS*;H$W4;0V15E8U.:%A+O$
M1KSP/J7ZBCKL5F6O]HMK86*K9I0^S,!#5.&TUV_3_3C4:SC,%"7"1CH/-:)"
MSD2YL,'L=@HD;)-U+!BE+M%=HR<[;7",A)\P%BW37U?LJA,R95C;ZQ4(I$^4
M15_I,[OMPV,H72AU"HP=WW5W<-)S*QS$_4-=EFMUD[5UUKAZ:09-Y6;$WT!C
M(A,M0'B,$@D GD03ML('>)(V'<4"8.%I!',D1SY[=.^=H$U;_P!0>HN?=-*#
M/4"@V&XVM*SVU&U3-CO<C$/IITI$TRHYM4X9((*&@(AM$U#.*%3:C%)-HQ)V
MZ;0OWM,N9":D'[Y>6X" ^0 0$0]A ! ? _D/Y<H)9=9?6'5& E_XP=&KMA13
M.G9YY"X1DK8;FSJ,[N4W0&%K%;'_ -'4&,DM;L^;VZ'J4;%M_NB,>1$=+I)H
M_.-*STO;'W(M-,W29[FP.NUF[/MTGE:;":6QIL="QU !B@6*:9^WK!_O (4B
MH**S 2H.8QO-KJ,JA-6&NH-Y18E1&.%0'*9P,  2!\AM,'.\J1@JXTJB)ZYC
METWSVR*M+Y"CM7T-Q+N'.Y'9-96OR$MC%H6LE34IU]L%89+HR ?*GH.;AVBZ
MD1(,;"U*BS?R0,4;(V8H&814TQ8/I-J]FOQS(1.^W3K6,$@R#!J,75#JU4>I
M.9N,WJ=GN-V&5M<W=[+<KZZAW-ILUEG&T9'+OY$M=AJ]7VA&T-!0<0T:Q,*P
M;E;1B:ZQ%GKARX4D[QQR0(H2223DG)IQQQQ44XXXXI40.S_3'-NUE@R.?ODY
M<(97)IJ0=$9U5[$LVEUJDY-4JS6//;:$G#RJ_P"C,]8\WH<L[=U]>$LS=2O_
M &1A.-6,G)(.)>$)\'Q?_P!QA,/CZ>3#Y$??Z>1$?S_#WYOXY$"9YG]JF3 '
M(3'QWIS8!RB)@]P^'V$P@(%$??R &'V'QX]_?F_E*78#JWW[F>U^U;/@MNB(
M&%DH)B^S23F^Q6D0<5)1Z'7A_FK_ !62Q]C4[#2*PWD=>>,=A0UE-"4F(*0K
MC,D?%JN9J3.WA1($@$YV S]<OC,B*E*0HD%03B9.VXQ4L^T'I\91VDM=BO=C
MN>ATFWSF8TK-6$]0Y"MLW-<4SW9X?<JE<8I&<KDXS>6>.M<*WCC$G&\I".:Z
MX=QZD5\Y1-TG++)<UJ^)Y;F^.4M%TE3LKH=0SFIMWCG[<_1K5)@(^MPA'[PQ
M4U'KP(Z-0.[=G3*9PX%982D^,"!1[1<U];4S>:I5RV.K2M@J-4ZJ6A&TI/(6
MJ4Z[7R;NC0O8BAH7!//)"<>4RKT+-H]\E(P=9AIYY8]ALT<B[5:,6R8YC[.=
M6?4-[ ]F;"U::Y"TGITGI'6BXU^OU;3YF$N[MMF=IBIN^F<M&U",I'-Y5JK-
MD?U$U@D*_;7<=6W+U5N=$X(4DF2E)!!@GKB2-CSQ,&.V!5^&8"G$P!(C/]HZ
M"209$\@<[U=)\1/S+] 'W$/I^'MY^G[P#W^G-@K%\&\#]/;R @/N(^/KY\>0
M'SX\C[B @'O[<H2Q+K'ZR$"?.ZMIG:>'/1X2D]8*S:Y-A=6=OOTHG3[143]@
M7KNY6?,C24K?K>PBKQ)1]W.R1+.UZYP53=M(.6JA9Q7)VP]2O4$F>PVMZAE/
M8*3A:[_"PTT7#(^=U1X\@H&M2F/8S2+)E\KGTAGTM"QU.6N%3TJR/8EJ]>"_
M6LL),QLK#3A)95:>)6821D<CF8SMTD?N,5' ) *TY$R,QC8[9G'Z365=^]+6
MD=C]8U/7+]V W0LMH49GL35(V*-F9F^'LLV5>JQC#'WLIGTI)P$783SUK=WR
M)DW$NUNDK8BRM@%T[J],&OV04&GP&<4:G9_6$U&U:HM5KU.KS9PY,[7;P-6A
MV4%$(KNE?"CE9*.CVQ%G"@ =90IE#>!,/*:IGK-ZH-QZDW:E:9M5<NG95+M!
M"Z/FDU6[\]S7,$J- .TG+6#OP5:I,;1;,>EI3YTC.8ZBY@+*A%+HQT3?2.82
M-%SC&R=:?6QAEX.M93V,IC6#0L?:%];+S>-?DKE8)V-TR[V^>R-I6X"PXT]2
MJK'.*])4V(J[5U*3CBM&@9N/55E(EZQ*: 2,A),C)R9,;GE&,0<SRYR4R "X
MF 8$$1L,S@GID3@UZ$ .42B;R'@/Q\A^_P#/QS:*I1\@ '$?'T H^1 ?8#%^
MH"7SX_6#R7]OX<I_LW7GU%ZKU]V.B97NTQ9--ENWEQO5&NF@;"W<V5[UJL#5
MPO5Z7%6R4R"PQN;RE3G5H%S)5DM,L45(PE?LL)"S,4E<&JD-CJW='NXS7#74
M$2Y'UO2[3W@OW833VI^QNCXRQN6>VC*K31H"M0=YJ%=//TZO5.X.Z;=8//6;
M):*@&]:3:1KUPZ:LR&GB5CW3W,=QVQS^'PJO /[QV'P!SD1O\\=8D-V2]+K,
M>S]_MVD:/M&Y-Y^<;PD54R5R3SV,9YI6VT9;H2QUBN)*T!RK/1EKA;_=XP76
M@+VR<IC6U39<_EZT#Q3Q99 Q,;7(.(@(I(&D7!Q<?#QS8RAU!;,(MF@P9(&4
M5,94XHM6Z*8J*F$Y_A^,PB)AY1U"=>O63JK'[D'LG2KJ>O+8HP).25R;QS32
M&55F*<%A751>9!,6K.&JM1C;A&::[3G[C:=9M,S#6F(=5!NTDX=Y&[3<?]:O
MKSU8G3T_3W^HWA%M6J#'4+#5*[-3=?K*RV-@-MHR$_G\6^;6:/D4]P5L$K(R
MTT5S&RE-1+&-6";UW"PDD&>$^\),S,^Z!R(ZDDD<]XFKE/% +J#&!T @3R!Z
M0(S'(XKTW?7Z<T$/("'GQY#QY#Q[?M]_(#X_(0$!_$!#F/,B-8CY7FQ[<2QI
M6H]!IAK,G</N4+:G81K,7]]IV@*VX=UX+&24^UDG @G3F&"4!V$8X68_(4-D
M3F6L-5/:KZ/76K4-)T750N&WTZUZI-M)JY# :&,S%/CO(_3*]?6K2+O<5;4(
MQMI%,U>T4V;^PBDM78(D2E0EJLHP ZEK;9NBT;H-6Z8)-VR*2""11$2IHHIE
M223*)A$PE(F0I0$1$1  $1$?(\YN.0$@;"K*6I0 420-IY?7Y4XXXY-5IQQQ
MQ2G'''%*<<<<4IS:)2F$!$ $0^GG\.;N<9U ((^2F'Q_1 3"/MY\ 4H"81_8
M ?3R(B'CD$@;_G\_VI7)QS80X' !\&*(_P#).42F_L, #^\0\A^0CS=\1?Z0
M?3S]0^GY_NY-*UXYQBJ0 $1$/;Z>X>_MY  \^ \C^'GV_;X]^;?GE\@ @(?$
M'Q (^WD/S#S]?S]O80^@CRO$GK_/RWI7-QSB%8@>_OX]_?P(A[?4?8!_5\^P
MF'P4!]A'S[<W@<HAY\^/\H!+[?G^L >0_:'D!_ >2"#L?KZ-*W<<T^(O](OM
MX\^X?C]/[?PYP_:$Q.HF!B_&F!1.7XBB8I3?%X.<H")B$'X3?"8Q0*;P(%$1
M 0 2!O2N80 0$!]P'V'FPJ29?'PE O@0'V#Q]//C_3_MX#F@+%$1+X\" ^!]
MP$ \^ #SX'R'D?/U /H/.7C!Y3ZC^:4XXXY-*<<<<4IQQQQ2G'''%*<<<<4I
MQQQQ2MH$*!A, !\0_4?Q'\O?]GX?A]>;N..*4XXXXI3CCCBE....*4YL,F0X
M"!B@8!'SX$ $//U\@'X#Y#SY^OGWYOXY! .X!]:5M*4"% I0\ 'T#F[CCDTI
MQQQQ2G'''%*<<<T$0 /(CX#R ?UB(  ?UB(!Q2M>.1J@^X_5>QKP3>%[ Y.^
M5M$_<JQ6BEND.B%AF\^C#S-U9P9W3A!.5"M1B:CR5=,3KL6Z2:GAR<Y#D+^O
M2.U/6W29>D0%!W++;A.:35I6ZT*(KMT@Y62MM5@WRL;+SD&R:NU'+YC'OVSQ
MHZ.FG\Q-=A)$%,?NV0%M$CJ/F*GA5T/R-9^XYM*8I@\E$#!^8>X?V\W<FHIS
M$6\9VQU?'M+SR3BSS32V4N?B21:<J_A5GD@>.77AR)2L8_BWT<J2918*I.VL
MBS5143*<5R)_'S+O'U^O!$[T!@STS7FIIF/^L%@V7]?LXZYQ<!5FM/Z,4F1L
M$%<Y2NZ.WNG<M]G%X-N43K5NN-LD)Z/L+K0R9C(9K<F%G=9\FZ):$9>&G(V4
M?A%Y'T,GK-&E%QQ>:O;2IQ_6T/T*)J]>Z\RFB6O5G-3NOZ3H:8>O*QM+JNEQ
M&EC17E DX@7F=/<X9KPDG7Y2;F)J:C/04"*8?0O@/'CP B >/W!]/ZO'Y?3C
MY*7]$/H(!]?8!^H /U !'W'W^OO]0YC*"9S$]#Z3RYP3VQGI<+B#PI,<R"2?
MC/+E_-><ZZ9?ZS"-\L,I5]8V59R2)TK)Z!96CSK<YJB=5:=SL]=U37+SG$E%
M,ZT[T9]U3F+P[K\JRB$"N'U82A9F(CGRB#&6_,?._5)Z\;G2XP["XH=>KAW?
MK==2FZ14\8M*=UH^K]O;='WNZ;LU9-WUZK1[#AQ,\F:Q8:%$PD3 2LQ;G5Q+
M!%;I-F?I#%!(?^2'MY\?L\^//C]_@//[N:@BF'T+^?D0$0$?/U ? AY ?/N
M^P_40\\@-D1D8]2>7I.1\.56\TP!PH,"/PC/<_M$ '(KSYVJA]A+!V*GK!5*
MEO$[;J!ZR%*T31'55LTO7J<7J:UZIU&MUAT_B)JYU*MZ#2V36;8)%KL TM/V
M:RL+BX-'-;(BJ8_X/5/"?4[R?KKV!:_%H]1VJU5[I;!,%[EIE+U>6F]V@M E
MX_O)O]-&VV&XU./KN@4&8A)"MH2A8M*87JI%V-*AG31!H_\ 17\E/V_5^GT
M1$0\C[B( /L B(B(^/'D?<?(\ DF >/A#QY\CY\CY'V]_P!_D ']_)X")V.(
MW@YCML,]R)]*J%D"(D>[@Y!X8B1M&(C;/S\K79+8O65ZZ92P3MEUTQV\TO0Q
MJS&^U[.<;M]IH+2NV7MNUBUXJ-H%)FX8267,*?U=NK^(LL*21TN_V>5S:EV&
MG6"U.65?_5OV0]_MDUFD][.LU4O;*UR/970*9+A;)*(HU[+TGQC)W>'5EW!4
M+2QA:U'[;J-EF]RTB@H7BMNJ=%W*XUI]8(F/CHQ@[)ZCQ1)^ "3\/U#&(/CW
M'P(E$!$/(B/CSX\^_CS[\T%!$W\X@&_:;R8?KY]Q$1$?P^H_@'Y!QPJC<;1&
M8'2/3E([\LSYD;)3\MQ !! C>,]<S,S7E;ZA[EW-[']@NL%MV)QNZEQK_>N\
M(G@)W*G-%SRAX"MU9[*-+RQDY6*J=<9-BS,NTR\'><7]W9;#0K22F&1L,C*6
MINNEZJ2^?A+\7\[X0\_O\>__ %\V@F4/Z0AY\^#'.8 'W_ QA]O?Z?3V#V]N
M;^62($8WY3^]54KB(P! C'U]9IQQQRU5IQQQQ2G'''%*<C7V\[&5_JEUVT_=
M)\\$;]"X9HC7V%FL3>I0,[>[3,QM0SVLRUG<HN48"/L=VG8*(?S(M78Q+%VY
MD1:. :F2-),QBD#XC"!0#\1YUNQ5>I7!HUC[77J_9F,?-0T^S8V&)CIIFSL-
M?D4):OS39K)MW+="9A)5JVE(:133*]C)!N@_9*HN44U2U)Z%(ZR?K\ZD1(D2
M)R-I'2:I A?64<6V&RJ^5'.L]L5!D\KQJUZVQB]2>.[RWO\ I/:VU=/[AGV)
MMVE9<0NBRF;Z/3YB69-)-Q!/M'@OLB4($2_<-A<:I^L+9'V)ZSK\1E-!=252
MQS/^Q54S*7T.W5^71Q:X;5.XX^D+Q?#YZ]I1='@7E>?&GLSKROWC6+B16AS\
MFW71&<4MX3ZZ=>?TIA[PCA^/!=:[*2LS V]'-:82SPDS,S;JQS4K%3R<*63C
MI.3L;Y]/2+]HZ1=NIQZ[EEEC2#E9P?X)/JQUDFD+LUFNN^'2[;2GK22T5O)Y
M11'R-^D(^1<3#%]=4G,"J2TNV<N[=RS9Q.%?*HR;IS()F*]767/7A4=E<YWG
MD(,\^XQVC$7"D#^F=OU!//I.?AMM41K'K-3^<ZC<\Z88A#3:3K1M"R;*W[.[
MS<]96]ER?<*KB=OL>P4*OU!U+URI3I[$^NN<$K3R5EK3%P;>&$$7UA:OV.?M
M*]12VMXB&OV'5W/M-H7^YI:3WY46L,W:<^97D[!U0R9G!5NQRT"O(U2OR4;(
M7:7LJT_3'\^@1.IQZD?%.G;DQK!WO6KKO)$MB<CA&./R7V/@HJ\E>YE2G7Z9
MQ=7%D-:CK69>$4-86->&-C30;:6%VC%&CV1F1$3-$#)_FV_J]@U\M-;M=OS.
MLV!U5\JNF(Q\-),4W-,=91?I&F2UCHDY1% &H6"NJ2.?U1U%L)B%>(P9XPQ8
M@K)-X\(N 4-S.1UC!';]9('4;)1R2>?.=XC]_P!1OBOG&?5%?:QV:J.'FRZ#
MC*M;47%=2L;'01E[C'W>'Z?XYW%FIEU4"5]NR#*G-9V-AGE?LWW[]XO+E!K.
M5VQ6,LU:M>K1GKF]67-=GKE+Y_O-5IU?H/\ "$ZLT_7:1]VN(V5R-QN%*CVB
M<9?I%\,G>,ZB[#,Q97;-JPAA@UD+2\AE'L>+BU6J8/B-$F6]CI.09A3[ TJS
M*C-9VL4*K0,RWI4:5,D=3T)6+BFK]*K,"(HD9U\BX139-%%)%J1)%(A,>Z3T
MWZPZMG%FRFUXGGQ*9:X-G7Y1G6:W%TR13C(N,"&B$(J<JS:(F(88B'^*&C#1
MSUN5I"JKPJ9?NERZ9+"DP,[1SY>Z<8/0Q'4= * HV*3&,['<2<=A\S54.]^L
M\ZI6=9QN>>9<_B\MCL>S_L+V%AM4@I=70*=DNT=FJKURR5U56- E)QO*V2TM
MVVKZ? 0[ DZ>S5:J5\&A&Q;!]H2[;JGK/TA.-V1GB>:7N:LV!9Q@^W:'*6V.
MKKG/24C5KIA!%J$A8:A=)A5/2)K-=K1L-)=L6\Q6925KMA18.YM" ?$/8UB_
M2/K1A$#8J[1<RCU8VW/:=)V0ET?26A*RLC09%_.5!XJ>Z.ILK92NV26E[5#(
ML$VC2)M$K(3L8W9OW JEQ.;TN.D87^ZZ(EC"#27OQX(]AB8ZTVZ-IJB4!9\R
MN#>/CZ0PFFU8BX5U/X[FSI_ LXY.$50JZ#!"/;,'TJV?1"@!).1M.=T\PF0-
M]H)D"00*F6I,@P/PX[@F1Q=)$2?6LF->WE3E>VULZ:QE/T]+1JWC<5KQ+G*9
MS<6N2NF4S8;!7&<3^G/W,2'%8CN$*K]XIOC1<FNL[@(AXXL<3(QK> >;^KPC
M',Z+']@LQD0N^J=@^QF+TFN=;X6[:J$;6>KVUJ8!I&K7496+A7S&O'N[B"DV
M\3!LI>:BJU,+/GR+DD')N.77%8,RNCO@;(?;5$2-U'?RD_M)VZ:RCA-N9P!
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MG1P0M0'6G'''+52G'''%*<<<<4IQP(^ $?R#SSY1=$*8"&^$#F*)BE^+P(E
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M=);1[_=[GKL;?Y*!L,MK%QDM&7A;TC0JPO,18A]H:-X^NQ]J<O#K5:M+,H1
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M)G<:Y13#XB*A+!TY013467732;E**RJYU"D12;D 5%%C*F\)D322 ZIE#&^
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M+@LV]E9(4WI^E6+0MM,TYM<%P6MLDG[UXI0JZO'U/7]\ZD/WUU<ODN5H
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M_DZBE,G8F!V K"Y]H/\ I&="3_\ CUXZME >\FV^UV]4A1]W/_VM(N%  @P
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M]L=;TV*B9>8L= @==K[E]*J55M!G]8_-HE ?KY]_/_*,'U^H>P_3\@_ ?</
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I<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g766726.jpg
<DESCRIPTION>G766726.JPG
<TEXT>
begin 644 g766726.jpg
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M[9_YH[:^FHXD"@VC(TC5\9ZJW%T=I\S2?4XZ+Y-/6>K7/L12T++2]'IN3VV
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M:X%].ZK<)'/M&.S/8HR13B3(S1H=TZ16CWHBS!4+D7?CZ!Q'QX I_@1\ /\
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ML,KL*L#,.(JJW1H+U.5MS&?P[@'/6/321/[@T\O3XDZ ^DQCUSZ:9R8M_G#
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M!X]6G,"A]@]/'<Q_Q'LE@WG_ %\\L=Y6_-G]WJU9>/QY'T\=S 0^0'R'9+"
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M@LTTM=KN.O36LO+!5)J1A:A^Z22 WOO#>$#^1]H"0_N,(@ %*!#>XQA'X*4
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M*,'5;E$7M\N4=)2\49%[+UZQRL!(&<1S@$B8#F?1]Z+34;<(/^R^Q0L#<I.
M>N8.MZGI$#%UQA$,)^+FZM16K"R)!2J9I#"V6QKK%6KYFL5HY;)*J61%TL=!
M5O(*MYU&J=I3Z ;P9[^DCR\3S:"?7$^WTSKBOT&L4)8?5FS12$EXN6_#^G=M
M)G98]^U=JLP>]BL&=,BO$$53.&2CEJHFX33>)(*G2, @3W 8I;.N5C&KE?KW
MJT9V>%@H:'<2/IZ;6:17BHQDQ7D!9=B\%:LC/W#5!%9\9JV(1NW.\47.DF4"
MD,'DPFLYY9,YDR9_0?TVJJHQ&G*/UIQQQRU5IQQQQ2G-BAO87W?I^7D0\_Y
M(B/Z!\>1_7X#G$NZ2;@)E!]I0 YA,(@!0*0HG.8QA\%*4A0,8QC"!2E*8PB
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M[J2Y.=NNM5G^M:#+MLPG[HQ61,WE5[G<=&VBT-TD6K/')3PR9N*C;VGT^&#
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MHE-WO09M"MTFJQ_F!$ZTO99YTVBHQ#V@55XNDDH=+WE$>[#V]KH"(#B/;+P
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M3F_*KD$)2/\ Z5$9V3GWVJR#R'ZA_F''N+^H?'P/R'W_ $YYL=L]9;NTRO\
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M2_ (4NT05D(/GZ(,IN..D7\4]31-!RH; 1@0"=.XQL=1CU%6$@$%!,@B<XD
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MU^<BZQBE,'R E*(#[O'D! ! ? @(AY^_CR/'/W D0  /:'P !_EQR85]-_\
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M1U]>T[^_J/(!#@( 93X^!#WJ%$/ _80$0$/D/\O'V\B'-_TB_P#B. _F(',
MC_40'R/C\O(C[?R\<JOP0O:;K)EW2K.M)E:T];W;4K'E]YJ%LF+1J^BTB!MA
M=OT[-Z^QW=[:V:5R?992Z]2\VEI.7JD\>Q+1LC(-IU=$6CM2U,@B8A3&  $2
M@(@'V#R'\_GEDG7!'6?^S[Z$S)$U0B.X,P?2MAD@'_O* /D1\@<_GS_+^+P
M?R   ?Z_/-BB0"'M HF P"!O<(G+X\>!#V&$2C[@$0,'L\&*)@'X$>?HXY)$
M_>?O%174Z?2:MG];AZ;1Z[$5&I0#,(^"K5;8MX6!A&!%%54V45%,"H,V#-,Z
MIS)MVJ)$B"<2D(0@> [.*8 '@!-Y^1_O&\B/\Q\^?O\ ;R(^W\N<O'  '7&G
M;TB !^DC0TUUJ/NG=5>MVV6>*NVPX)CVHV^"@7]6A[)H6=U:WS<=6Y3\8+Z
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MBLWW!UILLJU:J0;1A^U%^N]/EVZ[57]\K3&+H.-*D(I=9]4JH[:5)-$EFO#
MT=SN)WZ+"W+A 6\J4L,E1;#CD<Q*E\JO+::0%.OND%+3*%K.0 ?+=W2+5HN$
M<RB2EIL$#G<CFA2CAMM" IQYU7PLM)6ZH%*34<=^NUM[JZ/1<OSE^^C,MEK/
M*HT2?C5W*!;*2A.VS;3^S3_V@9%YGV6&6+5>MY%@-':#N<LC<W;1Y7:7"NEK
M?*!3:_GM3KU*JD>E%5NK0K""A(]'Y*UCHY C=N0YQ_C7<'*05G3I03+O':CA
MXY.HY764-%OJ/ETDRBIO<;=5FU-N6M1U;95NA!$IPZV,8-46JB.-8F6-1*1O
M&/:K$/WDW;FS5LU(6Y6"48?0!M#, 3FHF42A^7CP'V^_N#X'S_L?GSX\!SF<
M"L5!=QQBX*G+WB9!*U(4V&[-$?P[;;9)+84(=*5?$)0TX5+:*U>/A=LI(=O[
M@E=W>A)4M04@H83'E-I;5\322#YGE*^)L%+2RXMKS#N.8"%,8?   >?(CX /
MZC^G/.EWSW>1A?4_ZQ.DM-J37 L7K\4VW%0=?SZL,\MTB1T6/FTE;_7%=/HM
MV3/(9O(1;Y@$Q"7JKO&#PJ<=7D)9P=R\]%I@$0\!X_Q^W^/P/G^GQY^WD.4\
M=Q-4NU)[Z]0,]K41TAD*EJ;)RA=B;),U!EV.8O4[E&,6%BSV"D6KJTV&O!"M
M9*O0R<"U,+F[R2*4E)Q[&,]CCZ%<P=-,",SG2<3_ $$9SV6_Q=R#'K_42/KB
MI)]KND-6[C6+*)6Z:UI\#G%&//2$WEE,6JS>K:4XF(>1CX&6E9>4KLA:J])P
M+2=EVZ;VI3$4,Y!2\A S*;F/<&*$* ]$/-'H*N;'V3W2R2MFC9A]J<DZBLMC
M0TC3V9;@7*-4=-(NFM$*K)X\2ZR?[&J-3_9M*MYFD>:\PTV(//Q5Y@?;\ON/
MV_J/G_'S]_Y^>:\<@[;3@YB!UUQK\H(H%K&BB/3V_8?*J=9;I5G'7JU>GK-(
MVG3K_I%*[*34 ^O5DOUGB8BWR6JTWLYI^B6B?QRHRL'B'[?FKO:IU_&R+>@#
M)UF.79PT-)MV+! @W$$_N$_X2_Z!R(O:8WMN'37P43>[MU7BC[?R]V'[UY,/
M\@#Y']/O^7)=$_N%_P"$O^@<)$$B9B-^N3C[^M%$D))R3S3\ZW<<<<O5*<<<
M<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2ND:4Q+)T"ZQIUE&X2%
M0M+'ZZ*3199$'=?D6PJHI/UFS%11,JHJ$(]<(-#F*!7*R2 J*%J)]#N>A_\
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M$5]WK+;*K=-+[=SU.LM?MD(ONE6;I3-9F6$[%*.6O7[(4W+<LA&.'+,SAL<
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MTG66T]#.L%45:QFI=;,DK3<R0O6L+;Z+'G=.$TQ!-Q()Q+YQ,3$B<H&.=])
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M[(Z<239-)M)NSR2:Q7LHW230DGA%WR*94W!1'BJ\,\'=)\VW?<('+\=_Q!<
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MTVFX1N-UP/0&SM,4G+>[=PO4+EVCHAU2+B+AFW=L6JP*'* '3%/Z)DQ,3V"
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M99,1U 9==/V;GG7#^T"]VA@RMB&[14G75*\F1RA4IEI5FL,W@H\734B\TA*
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M.<STT-:<R-T[C?TG2/I]340>P'JD8W@VL]>,P?UJQW=IV&H5/U&"O52L=#-
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E*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g895358.jpg
<DESCRIPTION>G895358.JPG
<TEXT>
begin 644 g895358.jpg
M_]C_X  02D9)1@ ! 0$!A &$  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?4%)/5$5!4T5?-$-?5$),+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( -T";0,!(@ "$0$#$0'_Q  >  $  @(" P$             !P@&"0(%
M 0,$"O_$ %,0  $$ 0," P0%!! #!0@" P0! @,%!@ '$0@A$A,Q%!5!40D7
M(F%Q%C)RUR,D-C="5UAW@9&5EK&VM_ E4J$F8L'1X1@S-#5#4V.21++"TO'_
MQ  < 0$  @,! 0$             !08!! <# @C_Q !4$0 " @$" P,%" X'
M!@4$ P ! @,$$0 %!A(A$S%A!Q0B05$5,E)QD9/4\",S-$)35%5U@92TM=+5
M8F-S=)*AP21$98*QT0@69'+A)36#\46$I/_:  P# 0 "$0,1 #\ _:DE)E6X
M>[>ZM8_=?<G$:?$8-O1J>GPTS$P &+=8T1:69)"V^(7ADY)):M<Y[BTC9'''
M'%%&B/\ 'EGU)7G\?^_']N;?_JVUQVZ_?GW]_2VH_P DS:GS6]-/)&R(G(JB
M"J0.RB/5JT+,22A));TB22222>\ZKNWT*UN&>>QYQ)*VY;LI8W+B^C'NER.-
M0JSJJJD:*B*H"JJA0  -0+]25Y_'_OQ_;FW_ .K;3ZDKS^/_ 'X_MS;_ /5M
MJ>M->/G4WM3YF'P_J_ :W_<>A^#G_7;WTG4"_4E>?Q_[\?VYM_\ JVT^I*\_
MC_WX_MS;_P#5MJ>M-/.IO:GS,/A_5^ T]QZ'X.?]=O?2=0+]25Y_'_OQ_;FW
M_P"K;3ZDKS^/_?C^W-O_ -6VIZTT\ZF]J?,P^']7X#3W'H?@Y_UV]])U OU)
M7G\?^_']N;?_ *MM/J2O/X_]^/[<V_\ U;:GK33SJ;VI\S#X?U?@-/<>A^#G
M_7;WTG4"_4E>?Q_[\?VYM_\ JVT^I*\_C_WX_MS;_P#5MJ>M-/.IO:GS,/A_
M5^ T]QZ'X.?]=O?2=0+]25Y_'_OQ_;FW_P"K;3ZDKS^/_?C^W-O_ -6VIZTT
M\ZF]J?,P^']7X#3W'H?@Y_UV]])U OU)7G\?^_']N;?_ *MM/J2O/X_]^/[<
MV_\ U;:GK33SJ;VI\S#X?U?@-/<>A^#G_7;WTG4"_4E>?Q_[\?VYM_\ JVT^
MI*\_C_WX_MS;_P#5MJ>M-/.IO:GS,/A_5^ T]QZ'X.?]=O?2=0+]25Y_'_OQ
M_;FW_P"K;3ZDKS^/_?C^W-O_ -6VIZTT\ZF]J?,P^']7X#3W'H?@Y_UV]])U
M OU)7G\?^_']N;?_ *MM/J2O/X_]^/[<V_\ U;:GK33SJ;VI\S#X?U?@-/<>
MA^#G_7;WTG4"_4E>?Q_[\?VYM_\ JVUX=LG>(U5^O_?A>$5>%O=OT3LG/=5V
MVX3\5[)J>]<7_FN^/V7=N$7GLOP=V7\%[?/MIYU-[4^9A\/ZOP&GN/0_!S_K
MM[Z3JA..X?O_ )7;Y0E3N==P8UC^ZN087 63O)C-U?&8ACM+/"1?&B8MLS94
M]+F!.;-'!3##SV.J,4?.7=E#Y0R.G7N0-INJ%[:Y;3=$B!SYL#2V2NW0)G;!
M 6TY=SG5KB]@H%(FI7LK4V^:8T>.]9,>N5NHG0"I/8': <@<7<!"*\^O6;=S
M<<B)I]%AM"XL>6]5T-@*S#)98K0 QO[*'>Y%X,QMHOVSDT<9Z^'4O:P+4V!Z
M2=P/VJ'P_H> UGW(H9]Y-ZO]]O>KX['R_IU1^#:?JB=$,XK="=D[JV@D+8/N
M@5)#';S9?,-E PSY=@8Y)*L' D@M,=*FCC,L,S=+46PH&.MCMW^F?:CJH065
MPVYSGFH#D+H8Y]TCHQ'64.5P#XI#+)%T_P D[ #L&4FTR2=D3RJ_,&#U-/"?
M0/EMF7FTUGSF;X2?-1?P> ^36/<BA\"?]=N_2/\ XU20_:;J<8VY6KW2,G?%
M)GB8^ECN;..PN$.*L7;%]VHFPA#@Y;J>2X;N"RM:8RBA'JWXI)>R$FL&YR[2
M]2Z&S,AW4L75K3+1H\TNYDC3W@1X9$52RSP1[#.%8:1N$LU3;0QSO'&PAL5R
M#,3DKI*=MV--/.9OA)\U%_!X#Y-/<BA^#G_7;OTCP^N3JE NTO4LZ6J0[=2Q
MB@D,Q-MV\/<N2:8:O(QDHC.9JAA&P\,99U9F30Z[#X#WBC6V*R%6=_/4WD<%
M;+ZQ=INIMT-2IVZ1L1,@^#+>,#W.FE@%**M;&/<IE/(1L)%*6/3T;*@K 7V#
M!);RX(LP\I925XP99-V]-/.9OA)\U%_!X#Y-/<>A^#G_ %V]])U2%NTW4_Y+
M%=NB2D_NZ)[V-W/)6%+9<Y00@=CUV#21:UNVO-S 4YB&.S[_ (&\5F+?\<UR
M.VFZG&-LUK=TC)GL%S9U.A^YT\+9S1;D6+;F.T<+L',X<2WQYQI>=3!-(GI+
MN(0/&8KJME(,CNYIIYU-\)?FHOX-/<>A^#G_ %V]])U2DK:7J4;-:H#NK9RP
M1F9HVC>7N6^&<H 6C!EV[EMV0;#S1"&V^2/L@\YB <6-34,(!N-2W5I.4#![
M6;2=1ZS(DFZ]N@_O&!GC9N2BS^Z78-*65/X';$I'[SCW+2&F&'5ZARX Z6\E
M(CREC*1]T=-/.9OA)\U%_!X#Y-/<>A^#G_7;WTG5)P=I>IA[JE+/=2PA;)/@
MS;Y:_<R2=PHI=<>_<N2F0O8:!I9--;,K!\!BL%$BO*R>P(RF6B,@$'G]4&TW
M4ZX>N4G=$N,IX&)/MV#[GD2#P69&1E09W#623;!QS3U]7B+0C\.F,C@+MLFD
M+KL@AJ::*"QEN[IIYU-\)?FHOX-/<BA^#G]7?=NGN^.QJD$NTW5 D<RP;HDN
ME2MLI(&S;GDMC=;LSA@E./,YFP;WMK"-MUDN+0B-KS1L]2.D"@)QASKQON,V
MEZF&^]O=^Z9\OEQ9][C]NW,EA]IF#F!3:Y+CV;86;V6.\'=9NW$=7^U/H)H0
M&XFV_CG*?#=G33SF;X2?-1?P> ^33W'H?@Y_UV]])U2DC:3J40FQ07=6S>(R
MPR-E0\G<MS"2*N#$X"<1GLXX=AWPC6-AG*DU>30!R$AUN'L@MJ:>RR!\M2SP
M-M+U+*7 TO=2QC 4O'FDRC;F/D-C!GQ LG*Y!X9MA8QY3 <]:%5XW'+-&.?A
MDA=O<2 9#$/3RW7TT\ZF^$OS47\&GN/0_!S_ *[>^DZI"!M-U0/;2^]-T28'
M2_D+^4*5VYY,[1/:YK%-S$HU+V"'4Q*49E2_ %LT#]^3D6<>5I1Q#!R$?/%M
M/U4J&UTVYSFV"A5;WQ1;IG/"2QDS&4:Z@9,_I_83["-M^D-M53NA]J*S9TE,
M<.+C;8[A]YM-/.9OA)\U%_!X#Y-9]R*'X.;]=N_2-4@.VFZH&L/6MW1)FD8!
ME3ZQ#MSR8&3V@^50CX1#8*-L%.X>NLL(4BRRZ<5""ZK+F055#!:T+Y+1G(W:
M;J?:XU*[=$J9K)LZ;7>W;GD0NF'$K0G[9O/]FV"G2">YMWV,&X$8OGQT=9""
M1BLEX9,2/!=W33SF;X2?-1?P> ^36/<BA^#G_7;OTC5*)=I>I9"2FP[J6+A&
MV1; I)=RY&%24[<+]J"(+C9L,Z&*TDW$_P"$%BP22A18,JW,!4N3)[FUY!VE
MZE7S!)9;J64([Y\+;8O W,?//",50FS;B/!85L./'-/49.RN"P:,J2&*YQZ8
MX_)9*:VA& GNMIIYU-\)?FHOX/ :>X]#N[.?]=N_2-4?"VFZH7#5+K'=$B(R
M2+"EO(P=T"IA19RKNSBW%93R$[ PS%PU&.,IC,%?81B275Z1:@Y,RFK!@32>
M,FT_5(@#GQ;H3+:)73/9!)NB6E<MLF;1B#CN(9L"XM*U^W*RW$Y"#N,CSML=
M+$/)C#WW3;Q::>=3?"7YJ+^#P&GN10_!S_KMWZ1X?7)U22QVFZFV,L?=.Z9T
M[XX<Y6I2SW-F'800):B1[:QV:A["$.'@N:1QQ.?2AH1+16T08F+1W@$I!<7T
M';2=2+"S6UNZUK."TS+&U\MAN4L!DH ^+!$8-(;$)L1/!";9YJ^QK<OB%FE'
MJL2A!M*"6UO9RJN"Z>FGG4WPE^:B_@\!\FGN/0_!S_KMWZ1_GZM4N@VDZCE.
M8TK=:X97>\:YDDH^Y*2')4OPH@JV(CAEV(8*MG!N*@M16CNF0,G!7DW1A V3
M1Q4LGHKMI>I=[JY+;=2Q'9([ _>ZUFYDA#AV%CF.W.6L0S88="74A; (]OD-
M<,E\+,;)E:T,T0T<UV--/.9OA)\U%_!X#Y-/<BA^#G_7;OTC5'P]I^J)P03C
MMT"(K)P.-OL(0]T"I0(K*;+#1\OA"F(V!B*F K\&;7V>,3$PPE6683'55U#6
MX_ -:S\BMINI]H)#PMT29;)*^]>)"7N>3$!):19B*-C,),T&P4I,=<;M^XZV
MR":&"0L#-HA*>J@.QR:>XAN]IIYU-\)?FHOX/ ?)I[D4/P<_Z[=^D:I-8[2]
M3#'625.ZA\[&)GON=UEN;*.\AP;0_JO2T:'L*0T9MV]U@FX:A*0M"V$)V)^_
MG3$I#[RMI.I!I\S MUK:2L2TN8QYB]RECL'TL6'0DX^3/ /L1((RV+W 4BJN
MQ8IG@AX4V"XK2C,C?)3LNEIIYS-\)/FHOX/ ?)I[CT/P<_K_ -]N^O\ _L:I
M6'M)U)N*':?NK:1 J;C+2Y MRG3%QU\^(EDYC*-$3L/%!*=7YXT&KQ:*:6,:
MRPV4RWNY:W(81ZB;YZW:;J<>M;[WW2,'1X^".M_=>YTY*CE%V1;-S8ZSVW80
M9"1Z6H:"1M_*9[-->V<I@V5Q4040Y,MW--/.IOA+\U%_!I[CT/P<_P"NWOI.
MJ,LVHZJ5#&=)N<Y#W5XSS(H]TSE"CM79I(*9 +,_I^0B2NCV\2.W%(FAB+ES
MATE+.-%C2,NG>PS:?JD:/:K7[H33%1P9@ZC8=N@7 .42-D $. 1V[QM@9IA!
M[7%7VAV:2 ,+EJ,C@KJ_'([>H(+L(+Q::><S?"7YJ+P_H>&GN10_!S>W[MN_
M2/#5)CMI>IEI%@VMW3.F$8_-DJ9#]S9H"2(A:<*7;EUE&+L+/"/);Y ^R$SI
MH<A#*6DA -QAUU8SE!0>8]I>I=286S;J6+0EM&QD2Q;F2/+92_D6A3B8(G[#
M,@?;)N'S4-%DE8 N#<7*EIDR^YM78TT\YF^$GS47\'@/DT]QZ'X.?]=O?2=4
MC$VFZG'2!(=ND;%$Z;!TL5#W.GFDB'+I3)=R'@M(V#A9-/3Y$T 3 V$K#'=T
M<IAF424EG$,'-P VFZGWQUZVFZ)4$KP,/?:MK]SR2(Q[0G)B(,^@K7%[!#N)
MKZK#FBV.%SF-'+M\ID(K,B'J*2.*SDN_IIYS-\)/FHOX/ ?)I[D4/P<_Z[=^
MD>'_ %]IU1]NT_5%[%*]^Z$Z6*55C)!"W= M0'W<>9,%J1IIUV"0EE01M\LE
MM9EQPO/%S=L=,$(3C;WW#?:?M+U.,CMUK-TC)IHTSSW"VPW.G@C*40JM;MC[
MY<+L).\1+H)]O+N"M>PM:(L>LBQ3W[ 2;,-=O33SF;X2?-1?P> ^33W(H?@Y
M_;]VW?I'^7=JEA6TG4@V0I MUK>6)I^2-">7N2L4LE9!B(Y.(2EL'V(E9%86
M&>.+J\GA@=*)78;&+;4LUCD,LU1'XBVEZDE* ;/NK:L"?8T3+.2'<ISRX:F;
M#YBLFGKXY-AV03V06?I!58^.5) &?A;YK>U( R)D=.^ZFFGG,WPD^:B_@\!\
MFGN10_!S_KMWZ1JDX&TO4N]]4EINI801R)@/OQ:[<R4B09QB'?6C[H0O88=I
M24;F5OU=^WJ+[_28_P#*WW!Y(OG>J#:;J?6.!2-T2F3+7TSRFP;GD/B9:RYI
M*+D$ [I=@V/?6B;=I!;TD\K6%F9R^:ELH \99'=/N[IIYS-\)/FHOX/ ?)I[
MD4/P<_3_ -;=\/\ U'AJD,NTW4^@A[H-TBGGLK\F?5Q3;GD1AS6D&5"CX=#8
M31;!/(@K[#"''664S"0SEUN71"55)#94,L]I#[;#:7J88VW]U;IV$[HY<\2B
M]X[F2CH5"&* [;%UQ[)L*0HDMV<^TBW!97^UQT(<-?-BC[Z><J&"[.FGG,WP
MD^:B_@\!\FGN10_!S_KMWZ1JEDNTG4BA#FP;K6SA?>![&23;E*TA:IF$0%5<
M[XX]B'1)93[CJ33V(Z2*(/@C(+L2<C)Y):1GB#:3J2=/5H3NM:1BR&X<VY>/
MN4Z0@:N*QXR;<"6JCEV(CB*.J<K: !A41T@HUQC<IMCD<M/<0CU\UU--/.IO
MA)\U%X?T/ :>Y%#\'/[/NV[](_S[]4NQ#;C>@C(XL>W!W<W!J728+37ZE8/E
M*70;<G]XD@934K:Y'L;34S:8/S*J;&_&<F56<<EH5:4P(0@\TTL[)2Y +9;R
M8M>9=D6:089N<+245KE3ZB:YAJ3ML=N<G>#.12T]((1%#;9!:2P/>%Y[(YTA
M?-(R*/PY9(X?ZWQ6>< A7U<'N0=3<F2S6#\JZU%F;7M9^2#@4D5&/,ED_*-A
M+HQX&+4O)<F,[3?NZZC_ .>*G_T0V?UZ+*\L-D/R$+&C*1'&"I[>%<AE0$>B
M2O0]QQZ]:LM."E>VAJW;Q]K;GAE!M6I$DC]S+\H1HY9G1@)(HW!*Y#(K @Z^
M7;K]^??W]+:C_),VI\U >W7[\^_OZ6U'^29M3YKSM?;%_N]3]DAUL;-]R3?G
M/>?WO>TTTTUKZE=------------------:G^O7K6WUZ)=S,1W0M,/Q+*>@T#
M#1JOJ8S:GQS)K?>3ILRC-K7)JC;??LJN O65.;=/%3<4(]!O)2@T,.982-=
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M\-(]U_E60UKFIE-="I_Y%>Q*+,K%<@R90M@V<=)%IVANC*<0S%=IOW==1_\
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M[('OQS/*("WB-# *$"%K*C.L.2^QJON*;(&90(!$0)*%B/CC8Y95A7ST,QJ
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M+QKI%*^79?O5$^'X\I\_Q^&OE<5XG<\M[HG\->53^AW^TY3XZM"Q!555&%
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M5U=76(Y-AU9DL?CD3V6P8U&PGQ,17JB>D9#.6I/$B=D17->S^ ]J>)KJIO\
MP\;S+=HE8[L95RAPJSLA5D8-T"S+R]&;T&Z!BI]+5TX9XH]S"*5[FDH/E5D
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M.E+3@8_45M'5P^SUU2"+7!0\JY8QA(60PM<]>[W>!B*]Z]WO5SE[KK [7>'
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M5A#1AY(G8UM-^[KJ/_GBI_\ 1#9_6Q#]JM_V*8_6(/\ 7.HN_P#=FR?G"?\
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MG$F/1+L028"3RQ\<6$-0;1M\32 Q//'3N+856'*S*\MEZJ/@Y[1H#&"<A ,
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MA[9MIBAFG6:Y5JW+S2F3$=3SGFRD8B^S-%#8F+R00Q1%Y@Z7=RS>=-TJY@&
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MWU:GJB*N5>]/+_*VLY5J-_[%>P>/CQK+_P!J/:?+0?\ X/[3K'-IOW==1_\
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MW;A5^"_!.Z_@G=?1.^N6N+OS7?HKZ\HGI\53NG]'?Y=]--0ULQ"'")N,@8
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MT7C\^*1/22"9BNBGB=RV2-SFJGHJ7_QZY'R&DK+L9/#%8B1$>7SXEAE5/#/
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MJ^&9R/*1R*2QJ*J(2GVW-\,BM5RO39K^5'=4&U[=Y4]JB]T%K&)M[VV./L)
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MBD6-9(V/=$_S8G.8USHY/"]GF1N5%5C_  2/9XV*CO"]S>?"YR+#O4+LX!U
M;+[@[/65P9CXN<TJ5S;H&&(@BL-$/#MJPWV69S(RX(;*O%<8&Z2'VL3SQVSP
M/E;,R9M-?<<CQ21RQL5DB=9(V&"5=&#*P!!&0P!Z@CIU&O"W4KWJMJE:B$U6
MY7FJV8B642P6(FAFC8J58!XF9"58, >A! .OS11?0Q[V/OWT\V]&R\;&PM.=
MY,>83WB5<A$@T9ZXXZNA<R)\T;XFJZW4?SV/@0M[F*NML_2']'YM+THRNR@0
MDS/=TR@9:\C/;X6 7W4$4C4-K\2I(7SC4 AB-2(PMQ!MT>.B#%62B<BIDE?T
M^93!UIV_4,_=^UD&)VX#Q27;AN,BLHW8:LY\0%)[U=<2F(0#DHKLM2R:*UT]
M@42(HT8<GA2Z6IO<M[W"U$D#WA+%)#&\R0PBN.=AEH9"$5I O3)4F-\YP<8'
M,N#O)KPILEVSND/#3TK]+<;4&W3W]P]U":T+ 0;A53MYHJKS MRB5!=@Y64N
M V6::::@==5TU\9M@%70K.<5"-$G\*5Z-5R_)C?SGN^36-<Y?@FL8R7+(ZA'
M"!HR<]6_:5Z<PBHY.461$5%?,J*BMB141.4=(J)PUT(65B2?.\DR>0B5>?MR
M.553E?S6)V1C&KSX8XT:QJ<>%J<<+7]TW^"B6BA46)QT;J1'&?8Y'5F'K1<8
M/1F4@C5GV?AJQN06:=FK56P5/+F65?:BGHBD=SL#[0C+UU*MEN6 /XV5X4Y;
MD3[,T[D%A5?FC%1\ZI]SHXU7[NW.%F;G7\CE]G0$1OHC6#NG<GW^*:1>5^?V
M$1%3T]4U'1$Z\N_ZK\ON_'Y\K\N5XUU$I*\_97CA>_?OSW]5_J[+PNJ'>XHW
M-R<6VB4GHL 6/!Z'HP':8^-C\>==%H<(;1&%_P!D69@!E[+-*6[NI4XC!\%C
M4=^>FI'=N-E2K_\ ,6HG/\$()$^7_P!GGO\ CZZ]T6Y&4-5%<;!(G/YLH(W"
M]_G$V-R?)>_IZ:B=Q2HJ_;1/P3GT]?CPG]"?T\KQKG&4O"*CD7^G^KGNO;_I
M_AJ(7B/<N;/NA<[QD><RD$X'>ID([O _%ZM2[<,;21@[;1P!CI5A!]0[U0$G
MI[=3Q7[I'(K&GUXQ+47AT@TD@TB\KZ^"19HU7\7,3X(O.L_JLUH[161^>X(A
M_")"8C8T<Y>R-CG1SH'JOP;XVO7_ )-59A(153A>%^7S_P!_A_1QZ]R/,CD1
M%7U]4_#CO\>%^'/]:K\;%M_%>X)RB21;*>M9E',1@=TBA'YO6"W.#U)&>^N;
MCP;M<@8Q1/4D]3P.W+GOZQ2%HR.O<@3IC# #I;M%14Y1>47NBIZ*GSUQ?^:[
M]%?7GY+_ ,O?^KO\N^H(QS+3ZE602.<6"G".&D<JNC;ZJX9[N?+7COY:KY*J
MOYK7+XDFP0X:P#:8)(DD,C'*U>5:YKD1?$R1/SHWL7LY..47NG**BK?MMW6O
MN29CRDJJ#)"WOE[LE3T#IDXY@ 1TYE7(US7==GM;5(!+B2%CB.= 0K'OY64D
MF-\ GE)((!*LP!(A[9!@+ ]RT!:"UKMZ]TWE>PB9J(BG.R)5+4E,VDDF(-=)
MW*+QM6861)]O%HVUW":F[4+[+'-.$W'<RS!LT%WFW/!<X'+\DR]H3Q<@=&ZM
M*ER04:3'S05_82L1ITGQS&Y/VA2$SB?;U-&I(=P^(:B3_P!N_P"+ZX\-----
M9TTTTTTTU0/J@VDS:\RYN6X\!96];8U -80ZG&A.L:,BO0AJSJ"0DD<HSX9?
M:HI7Q2"-(9+$:UD;T>_4EO1])YG.)K8[8]- >!XC3TUI: 6NZU%C$CRL[E&F
MF"&NL?Q[)GVD&-P2!-ACE(LI\E+(*A>15FP5CPW/_2[8 CV8!M<4CG#'B$A$
M(QRQO6 N"0>9&2-X<QRQ2.1KVKRUW#D[IK\[66_0G[F0Y*1%@.\6#%X6\J7V
M"?+ZO( <GKJ[QJHHYHU,,?5W!8\'ABD,')IXBY6+*@8B/\ME"\EOD9\GO _E
M#\H7E$<FSNW'-NIN1BW6E3N>Y%W_ &T[L=HW%:?NA!5W62TLUK;Y[$M?M(D[
M("-(XHZIY<>,_*MQ!P?PAPGP?%-'2VA;E7<+6TW#3O3UQYD-KCGBELQP@P!)
MU\]JHE@*%$CH'D:;7]1=>/6)CUZ-D0G4#N+:FB3J2RKR"PBR+'S7_:1!#,:,
M%?7%#3J[RE&'@'FY<WV26"=(I&_L$V_M[[(,$PN]RFI;0Y-=8ICMMD5&USG-
MIKRQJ S+6K:YZJ]4 .FG%17JK^(N'*KD55UK]+/T5.U&Q60T^X.X.0$[NY[1
MSQGTD1E5#2X/CUI"])!;0''73V)EM; /1) #KVS(&#(1AP=4,= ,5!M6UV'B
M+<-MN20)MU>-%A#\]A(5@[7FY0J*H56*)RDAG4$LQY0!DM2?))PKQCP]4W&S
MQ=NMN>7<#7\VVJQN$FY&CV0D,D\DSRSQ)/8YU1HZTC)R1*TSNY588 P_=^;*
MMVL\Q!6@@X[B /LHTTRHPTZV%M& 6),A$DS8VC-D2:$8>./GRXVD2R>.3RV=
MAN1L+@^YUC!>V;K*MN$'@&ELJ8F&-QPD*JL,9<)$!(LSXV/<R$IK&D-B5L:R
M21,C8V%<XZ5;#)MR#KZONZT3%;^S=;V\1#"'6P4I,C9K48&!D7LI3#)73/%E
MD('07VA62QSI"U9;ICCPB00BCQMB@'BC@@B;SX8X86-CBC;RJKPR-K6IW]$U
M^0N MAXQ\H.V\?\ !?E^X"I;GLFW<9;E9V#==WN5K]?B&K:W;<[FW/M&VP0)
M)M-#8MJDVZG1NBWYU.MF6%Q%8AO1C]7;_?V;AZSP]O?D_P"(+%6]9V6K'N%2
MG#-6EVV:&I4ALI<M22E;D^X6ULSSP]CV49C1E+Q/7;6&89AF);9TPV/4$4=>
M,07(_P PPM)3[6PDC5TDLY$SF2&%+!"J-CB8C81X?!!#'#&J)[ZC/<9O,JR3
M#*\Y9;[%6!26HRQJD:,,8UR.'G:YT<RBR/8.:Q/#(*0]D<C>'M<N'[V;83;I
M8G%4@6$=9<U=E#<5!,Z2J(XJ."<62 IT".GBCF')D1A,#72C3-CE1DC$?&_
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M0*6 .S<WW87#(,<,7* 6,3)BFWO4WM3NL>\+;NPNLK9$)A9\Q]=CMHROA"W
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M, O)*S*H11T'4DDDE5499B%!(MM<P01/+.ZQPQ(9)'<X55 !8XZY ZX49))
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MTTTTTTTTTTTTTTTTTTUCV6FVE;B^16%(/[7<!4EH55C>'Q^?8#@SRB1^7_\
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M[PFJMG.GA\5>6Y>72CL:L,CEYY64=5:QRNY[N8Z-R]^555U'7U7;I_RD\_\
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MD8L.Q'35$-'6UF4R9S6U[(&;1-C:#7YK++EX(C6I )E$LF0#QQV[W&+D01@
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MS51.*VM8C?&MB"C/ LGC4P;P^!"/9%?XO-X\*%*@RNY\*$+Y//F_8U4L/I%
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MQ3TE6.(/58U7M:C EFEG=/--,]TB(WT CBBG'G$4C2(J*D:SYR)HW))D@C7
M5#]]G. !CKK79K5RYMS';;=2*I9FL2RV9-N*E6H6ZRHJU+]J0N9+"=Z! JN2
%X(4-_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g593559.jpg
<DESCRIPTION>G593559.JPG
<TEXT>
begin 644 g593559.jpg
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M7YP2%71HK[]EL,.C3"9&6]'E3I;Q I)<D8Q*>PTTII*66,XL5<+MMGJ8 ($
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M?01$ X!\@W''KLCS,R *:D*G/LO-L*;56Z%VLL+7:/176&SZRC #^V.K]P[
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M%GYL!X_%6W'6V5MATBF*[&:CCP86'':',SWHX*/K^H=;B1;<AF%%IH'*&I)
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M-Y:).PLPWIZEQ'I&6UJB)>RZIIW+65HRG.,8KWV(^H)K799*KU6YZN.9I%6
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M\561MW&%%:99%:T=:%J6'Q62(QN!7&2)E8Z)EPFI8)K,(Z]E3F#$:Y[0&_\
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M7$6JZ+"T#\Q).239 NSIJ=(G)S84Z2*.$20<^L0.;$2%YN.8!0R&P24)^;L
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MEIUSH=\J;#LA@8PHG2[*+)N0,2\LK9B,E 31<$\M37H3%)NM_P *,_'1"Z@
M%10 *K675H*5)^/6K360Y*65@*3*!)CY:Z9Z5]?8I2 $@A6U6L%BL%C +6'6
M 1$#"UQQ@ #;U @(P$1Q]#$>Y]S,Q_O^W'/%/QC&/'C&/.,8_;XQG/CX_P"7
MCGES51&T1$_I$1J_3CCCE=-....--....--....--....--....--....--.
M...--....--....--? 1@1R49V',B1)T22TY'EQ)S29$61&>3Z'F'X[B5M2&
MGD94AQIY*FEISZ5ISC.<<U^73K;IJ-OZCTE%2="TC9&I]I,'JC7#1T!3CBJS
M8J(1P#(!!Q!D=@%,A&Y[LZOQ&80Z8^VB=B.F2PXXO8ER(MHZQ@W]0,LR</5&
MWTYV;*J-RK+\5!4$X6:9C&(SL(E%G"#04O&C1FC 8K!D1YK<5GVG(DAMJ4WS
MGD>%JY6JLF8VID;%>W2>I5E:2DU)MI;:KK-PR S9JBY, P@2PF"#S!)&8ZW)
MT@N)#>LBRQ+4F(.!1221>LK2!)@S ]]<6+XE(K,B@3(1F2BBM,IXO7QWL)U]
MO$]ZWZ0L-GK4YG8LEYN+8->7/8%>C+$U:VD\9CQGV:I J5.>K-VB(C.CY;E<
MCV-A$N4LF[;_ $ 1S;]. LFQH.0[EJRULW)"P(T:J7%\4:) 2MK$#V6(\982
M\JC/V#TYC-(<63EMI2MO"7GM=1Z]*-U#>?7;;#PD'9;9V3KU,V];A+WJC'J+
M=\"RA6R-AO\ :O5H,JD!ZO3WY<B40"!91_#<R>MV+.0G<&%#B@ <6!"CHXL0
M&@1!0L7#2AJ,/'P6418L%AI'\"&(T=M#2/3Y_AQ_FSG*L\X[PH@R.0M-KF/Q
M:5.U6?7?$S=ILMYJ\=7"O%AL9 85--H@;I.(==>%-S:OTKU&");W,E$Q**Z;
M""6V)^0F7W[!CCVB6Y<* I,!D^4<WL6IA ,\:66+K]L(I%$:T;#5 O2*)98M
MFU/L0[=+B)NFO!N8JXK5;@1JC^//DYM>9=EAH,YRVC(!NK.0QIE3CS#N>4D>
MTV[HCL;3-+VZV#K@$W*EPM2MH'JRS%O>OK3ARS$,E!UO=,K?@V")>8=8=#QI
MCY5BSP"A$80SB9C*YN\-;B<(7E7E.$X5ZLYSA.4IQCY5^_GQC'G/G'G]L\UC
M;02/V[W&U&1:>'$*GU^V('U_/AOMQ9KA;95TI=MO<OW6W,.90.J BO5QZ)(\
M?-FDO);0EX4\ZWK/-O$\)0##W:ZF.R[,[B<?CA<R)&:!O$;F/,50B'4JV)79
MD&6?E6ZX5ZZZS>P4AJ-G,564-)J!([DY*DFN)LD FJ;EC;KLA<J[4*H V0-W
M<Y4(4*V;B S8X!V&<%#TU2]4G9)#:5>=_$6H;0M:VVPARDN.AO+%H &8@]H)
M^G++'RT3'I=*-/P,27!LYMEZ&O.<;$ZR3M3;5=VE_AA(U$&I#V"K9":.@5/:
M>Q[*M3B6X=B37"$G#.N1C*TRI XY)D$[.9PTR]%@AQ[B2=RTLJ]*/XOV^<X\
MJRG/G/G.<XSY^<YSYSY\_//:AM+><^E*4^<8\X3CQ\^<YS\_TSG/]/G^?/0/
M[ ^S\963R/\ <*=1H.0F::5-,D&)UCLVB)SF,@@!CBK_ !(>P(YC"38@M_./
M-T*"Y8^4I#%M6$I 3(DD)I)[9DR8P2$28:HKBTQGDN%D2Y\64K3A7KQC&<^/
MVSY\_&/.<Y\Y_GG./VQ^W[?MGGNXXYTT1M&T?;_[^VMGIQQQRNFG'''&FG''
M'&FG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FG'''&FG(>W;4KU<
MJ.2$ZZV7+U7:$N19\.RQ1< M&>:@J=>DA#D>7AN;&!%V\8CDB0">)L(YG'W0
MHFPZA3;\P\^ D-AE84L>0CMRX4^)(@S8CR4K8EPYC*X\J*^A6,X6R^PZXTZC
M/CU(7G&,XSXSB/;KC:KNKGRD6K("@7-KS,$,QMW(F&KWW_R">4?>/>L;5PU3
M%%OQ8!!/$S44Q,>XABY%@;_]P3!1^G[:U+ZXUI3H@<]N_:\*,X#CUO8-,M=M
M'F#MK)[_ +)LPB@3*&UB;84,ECM+$.1 =3UB_D4/-7.U)4>:8B#XS#L_9!I>
M+?(&KZ+#V<ZAZ^1*V.BV)W$A,QW,QEKVVLD)C:4,RRR8B8Z3<J/A,2263.D1
M,8CNM8Q339E;O&@;%K<ZD5:-L]?=7SCI ;6XSP]X_KA)$:T-"D"N2,N&S8*[
MKIO+F*=8R+CTZJAIYV.63+=AB#D:P2[!VF+LK+ *?I6O#F&FY<&L62U6JQE[
M##SX4AIZUU@5&KE5?DQ_"X\B*.ND9*UM^ZG+.5.X\K\2A&$OVZ9X[*5[U-"$
MVZE3'V&+NNMIK-?EF6EC\)],2K12Q<B^;9E6R+[</R5^P*^9Q2UT&,3%>T%A
M"P!Z$59.'DX$L9=-RQZ6+B5S7K3)P^859-G?:<WC-M^9N:Z?8O\ #R37XMX0
M)E.5AZU0YDVMJ+LHR[$CFF(,Z!-P/E+3F,^]'EMN1DNXD>A]+*H[NI77X,X)
M3;.P=ELMD:OG7S=AN#9=2%PM9JL4F-MY+$Q;,^-6XI$P7/R9.S2\C6AV=8#H
MDG'0S#'92-,.N0[7;#[2;/&EP&M VC;I7MAGQQ T6+SA+>QZG6ZF)EC!YBR@
MH]!++,WS*91>'#&0E1JNE$J0T^;S"C)RR]!]3KDPK<VX)(CLHF(VGV<U2R<M
M&RJ_(J5AO.=4Z?/[%FX<!2A(=D;7$V^N!A P4*%1!4:,'7#9]Q>'IDK#Y7>Q
M^=RF.#'S=?;QS+-<A>%FG5IY%J L8RQ->Q"7,LU,JG&&Z>@Z@@739DFD"#CY
M6Q7O7J8H*P;:YFKB<-0I-IJ8L4VRELJ,F)M#4EDFHZ\ 9*;/; KG:PR[E>,X
MRA2<IRK&/./Y)SXQY\Y\^KQXRK'SC&?.,9SX\\]_/!",8_B_]2L8]6?C'G/]
M?&,<\^>PC$Q$1,[S$>Y_>==E^_\ ]V_C3CCCE=-....--....--....--...
M.--....--....--....--....--....--....--....--....--?%.'PR,:3
M$FQF94:8PY%EQWT8<9DQ7T*:D1GFU9]#C+[*UM.MKQE#C:UH6E259QFHNI7M
MTZEI([6A;5=NV(ND$+,!"7.+=M<LL6"FP[,9S0WWVRYT849GQ*4\!&3X\N"T
MIJ7 >3ZWF_2\Y<?GCZ4_OZ4^?.<^?&/WS\9S^W[YQ\9YKKF/FRQ+T6G4+"A:
MOY%9-)C32XEFQ)3<J6A@"8E3)D!$N01O,Q,QK U':0&+6),!(8-4)DI$I"9&
M>Y+HV@@ HXP,[CMOM,Q-1Z<#VC;^P$?:]NURSKBKU;65CUZ#ADKL$L]IL1&T
MV>M6"076)J[$T.#$P&02XZ%R;),*2WG<>!D)AK+K^0]D,3@(G6NS&&DS(6I=
MK5BWV-K*EX=_214:?U[9IS2D-.9\@Q]T_43V%^EI4(3,]:T)\JQ9?"4I_9*<
M>/C'C&,?']/C'.*/@AEF!F:Z8CIE"3PHB$)QLYRG[@:5AOP)S'J3G"DX>BR'
MF_4G.,I]?JQ\XQR$_";X[(5:]AL6;A_*BTZ0DHR"U5Q18(%*6J1!E2LPE H%
MGQ*.,04ZCG2CXMA*V%+GEW=S)C?Y(0J4L(5@ 1 &A4R(! R(S''W.OO97ZL)
MSAS#J%)QE"TY1E*T^/X5XRC'C.%^,Y3E/E.<9\X^,XQB"G.RNJ6M^,=;%EYW
M^*#X'\^@?@7(R*PSD:Z:P/<,X5]JV84'9442-7C#RH64/8SX6G&9,AQ@VN*/
M%:FDI2@5%J;;$LR8E+E3?PM9$IP\1*37,X5(DI@05/S);N?6\[AQU:O4O.>=
M?R7MO6+VM,]K4[(H:^QZ^U<7?F*(FR#?ULWJ^),7KV+KC\5[_P!]EQ% _P")
MN#<>/6RXI2T+5C"L\OYKYB_QA>'A9X]-AD.RV63>=$E&!Q45O[NJB7:J79,S
MN("@,0?=P>4)/KF(PY"^=2$;2H3+D^P)EO$5D\/D"F=PW;NP(5],\H@IX3M.
MV[_=W8:A:#:IZKI%MY"3>SDJNUD92ZD5N)<B5B#G"CL9H6'0[-6K,1IQ;>&F
MG5N*0I*4?PJSC :5W2TK;[<$HTW-_P!>V6TR,PZG"VMK6XZZCVF>E*E*' B=
MC&QA<TCC"<)1 5,9E2'%MLQ6WWW$-*B;LT:'6/;'T]["'D)EB#N\I!D5+;^$
M2AI35AF? D(_?^!Z(^TO'C/SA7CY^>2/WU!@R_47=4@UA#;M9ILFY5PBK/IE
M!K=5W&2E8*C9&<9<BD&2S4=AEUA2'7$278^590\K&:7L[Y +_+[]"[BO[=XO
M"'JH6*#63D:XX#'YJP)9,,@J*IOBRU-=\5'KKSU-8FP,&LS+%KE?8IB.JGP(
M5DJ2[1BJJP<2Z&C 2?,A$^!0'HI$XB1F>MJ[?UUI.JN7+9=EB5H)B4P.B*=:
ME3"!<M+PO,,,##CV)10T8F>VO,<:-B2)*T(<=4A#+3CB(##=X-0RK'7Z[;0&
MW-3XMTY@94[!MS5MFH54L9&6I"8,.#82C2H,23.4XA$1DPH8X\M:$8QA2L8S
M#8V1+V?W(ZU,[ ;4XBE=1E[B "".&7XN=G6HP&KQLTAE;:([Q8(-SG$>2PAQ
M<%Y>)+/VR\H7B0>W>RA4>K; UYL/K%N3:FJ$T_!NTW*HKJD2N11\2.\7F28I
M*;;@]A'%:S^/3-60AQ&WX;R6W83[N?7XQ7/)\LZOE\Q2NT,9C<7=^!4K7</D
MLB=]ZJ->[89DGX]I/QM8S:RJMBJ3OB"GYSCLB\*0T9<>0O>MBE*2SJ6+$.;+
M"%8,.7$HI)(3)2$2*RX0/84G!0N+O$",$3 FE"4IF$.'1)4^?-DKPU&B0H3#
MDF7*D.J\(:9CL-..NN+SA*$(5G.?CG T^[5B^T\!?JJ4;)5*SA8=B"%U,R8+
M4P-/CXEQ9RF"#,65%;<CJP]E,MAAQM'G+J$>,^*S[=UEKO?_ %W"'#;=W: P
M]62;=7A,>]VD$X\T3H\8H.CW!L :CQK8N(B-!4ZP<65B9F(E/)P[]T^I[Y>M
M]0B['Z)ZDHQ,H7#P;OUZKM;)%0$B/#-0HE@J:($V0+D28LV-'FI8E._;NNQ)
M#;:\XSEE>,>.=%&;R3,Y_;U4J;*3O'K&7Q[@MMFQ=LJ;06*60==2J:-[<@#.
M5DW1,-**T+E397R&S8A0K7*RJF]90R>;#$E1 SN$"L?S-HG<Y+T6P[;3D(SN
MYU:,6J'3AVW@4@L1+I #IOV%A:JI$TN0J(V,'W=X.W3ILMZ2E4=A$<XXA]_&
M667'',I3F4MH[RU9IIH.O8MLC!)5AD/Q:^&C0"Q^RGGHK?NRTA:O7!Y:PE$0
MT90J8_#&.QXF'&\276E.-I71'?96A[(U(3Z+=;JTK9%CB"*[K^>4$0&UZZTI
M# 2Q6';'=KJEF.!C6@0S">F1 (5Z;8YASW$/Q(SRUMN<<$*[4QW)W<"UW3A6
MQ;SKC6>E]<A;GLFQ3:[2Z12G*SFS6&5)EAQ=@L,NT[#M<UI:0X: A#D4*].*
MEFV(K$9_DC\TS=9OPC/$Y)EF[CL;6RN(Q65M8^OE'5<S>RN*BHG(6GYBSC:V
M'B)=3N5 %U],7E41KNF8,W[ %USTMDV*4#T(<:@<06&.3P%ID\U C:96P(@F
M1V0N!+6Q_7>RZ+MFKQ;GKNR#[16Y<B7#20@9>0J//'O9CSQI&#+9C$112 ^G
M+4T83B1)\5?IP_'1A:,JY"O72M6K%C6")HFM5.QE*D>?RQ)C1X9X&U%<,0D2
M);+#,M(W,MMB7+AK?ALRVY4-4C[J'*:9I_JS:U5J SM/8++K$;JW;NNB"+IN
M\$%L,H]7KD4?I29]2NU7)R&8&),*YB!C(UA/X025P2B+AE(LB:VF2]@.][*4
MZR=#WQDXI'&[.O8INJR2TYV.PA&TMS$)I:^'I,IU2<-1@LHY:C2Y:\JS%AC&
ME9]"&TY3OI\N^/B#RMHJCDX[#Y?)Y=M9-NO LQUDZ:*H5KW79HVK=BO>6RG9
M[VU;5)]&6N(8L%*^;P1+SD)!2'N?(B8;2HY 0@&;$HS(61*SY$!K)>Y3'.;6
MZ([):J[&P;60U>7G$V*:?_3QK!$5)$NIDN,*D1)D1N3YS+%$&4/+@$&\X9D^
MP\E.,*;5CF$;![CZNUWL2Q:NG5_;-EME5@ B1V-0=5VN\1!\.QPDSQ+TB97X
MLM#*9+.<I3EY+6,OMNLIRM;2\)HQH2XZ.TUVVU52--;)H]SHNUM"@=46#]('
MAQ*/#VAJ=EQ^O'"C(Y]U3<FX"W"<9B7)PIR:0DO(]6<>G*;2ZB\9[[=O_G/C
M.N>NN?C.<?\ X4_G'[?_ #QYQ^V<\T&,\MSF5Q>&K!>PJLZWRQ_CF9MTD3D<
M:$+PF3SJ'4E!?7S[ZJL=$E-HQ V60VDAV&(J]8<FN$,KQ9*Z52PQ8=J8VK.L
MB2QA@[\@%7OG/&9./<QMJ?=.]C]5[QD'1-++E(UJJR8[EGH]NKINF78 S+4I
M,640K-CAP2.(,C*<);GQ42H6'%MLN2&WG$-*X_;'9[5FHK"-I)=^RVO8AB'D
MD-UOK>J&K[>9 S"EHP3?" 8[^18Y;C:FV9QB0/C/KPKV%NI0XI$'=C8\>O=L
M>D]O!1L-6ZQVS9&N3;L92&I)G7DNBRS1&(1RK"ONQX(Q'@E8R%^<QI3V5,90
MZXA2?#I'$8L9[M3M<VS[U_LG9;8-.*RI7AP@*JVO<C0M1K#2W<8DQAD$>K,I
MF)G#3;BGT/Y;<REMSFR#R'/,R'_# MQHYE67L4GYB*3YI3C:^%Q^:FTK&E>D
MAR!CE*E#XYY TB8OR,028"E.:+5F6_#Y*^1#R63^LNOJ"NFQ)BF6?_+,.!?"
M6R,3R=M(Q"M3=J+M%J_<5C+4<5BVT[8@.%@H2USLRI%J)=6A.5M-_EHP@PWA
M!0:AYYMIZ8*E36HZUM^_[:7&U+EF\;"IVMQ< S=3; ,>5L==J0UYYJ2^N=8K
M85CA0 J+'B,2)#TB<0DMM^4-9;C,)>F2UL0XTA]JC!G<E9LV^]!$-E=7=XZ]
MN3%Z/TC6&Q;!+J8H2F?8J\8P4'$/T[=)DXR#(AQDN>V*(0),9MU*)C<=N4E>
M<<9WHT[3?O-7[G6NSOW-/8/KP&BHE7*SRJP/A3+T%$3%#:6^4<JPZ9,A-MIE
M3X8IJ:^[ZWW'\NN.J<MGRK+)\>SMZL>+S-S"W)43F5\GA(BE-6O9[[>-MUV.
MBZGND!KHL#5O+%5D+=/N*NA\QPU;+0E+V5SVF9!U?\O@!\C48$78,%/T"4 V
M($H8OE(!LA($8(F!-*$I3,(<.B2I\^;)7AJ-$A0F'),N5(=5X0TQ'8:<==<7
MG"4(0I6<^,<X.F7.M[!J->O52))*U:U!H5@ E/MY4-,X0183)AS,1I[,67'2
M\PM+F&Y3#+R,9\.-HSYQR%>S^FJ9M[6IU%R79UQJO7+@6@P0-SM%6'S9?X-Y
M]M)^!7B@^+8XC+\",ZQ -M38;2\.Y2QX??2Y4J?;2]-^DV)LH>:^/*)ZR5"
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M;5J9.1KKJ=E@%QW*:=12JKF4G5#LUU+3:EZP@8R,IJ;+9DFB+XV>M;" ';#
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g348093.jpg
<DESCRIPTION>G348093.JPG
<TEXT>
begin 644 g348093.jpg
M_]C_X  02D9)1@ ! 0$!A &$  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0DQ/0TM!1$5?-$-?4$A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M32E>O07M[]O\HW<.>>#=_K!]QN0X$0]A'3H#D1[\B AV,8 [_,  > '_ "@
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M+^?I^"I)TU&OQ.1_CKC^6'_#3XG(_P =<?RP_P"&G^Z1IG\PO_\ X;\O^/\
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M@"B90,0$RE('6(<CV#ZPB _=[?JC4$-I";F]+/+(%9("Y6.-'P4++[=SL K
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MC<U]I>!HPD[#N*HRXY#CP&8+G8Q^00%)R5^@O'KHE^R?CW%D.:>R)<J]3HH
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ME----*4TTTTI33332E----*4TTTTI37Y+_O"W^B4_P!@VOUU^2_[PM_HE/\
M8-K'-_%2_P#)O_T35R?C7_.7^T5%9?8/P#^C7G0H"/2  (B/2   "(B(\
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M%4M;BJ3T[!-9J1H2BUKC5V<N\A9VKM5K7 2LG63MY98UG=HG<:WF5#GDHP.
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MN[<-VJ0'<+I)GLU$O_BD7'R0H':B_9MG8ME3%,H@+A(J@HJ&*!2B=,3=!A
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MGW^0"EG,C7;?)E22:*7W'\R:O7V(4 AO(93BS($GPK-RGY3BKA$O$T1  *U
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MVE.U6DVC):*1543*H+C8KQAB&CE\\ZYZ1FUI$U321&-9M(C%VW98UO[4,76
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MQ(#DA47Y)+,Q9W+.S,?<M$T:ST#3;?3+%6$,(9GD?!EGFD.Z:>9@ #)(Y)P
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MFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*::::4IIIII2O4PB!3" <B
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MD"I^&6]N.Z6/QVI3*!MUO>[S;SDNZ9LI-LD%U;%1'37&F3J?BIH\M,G%NV-
MA\T)1]U;E=/*BHTVI\+35[L>'\5V#*+>HM,ESF.:1+Y":T!Y)R-%;W>1K48[
MM:5+?S39G,/:D6=6?_1MW+-&TFXAA9*/T$G1E2@I4F::::4KKEPJ5:O]3L]%
MN<+'66H72O353M=<F&Q'L18*U8XUS#SL'*LU/R;N-EHIZ[CWS8_U%VKA5,W
M&YU5W#.S&GX)PW4\ 4;)^:38CQY3+!CW'-1L-NA)XM+IDO#2->AJ\C.NZF6S
M6Z,H<)(FC:*VR),W L*V9Q978RIXI@HA<732G^W]58PL/^$]MTPC$8O;4VVY
MH/:L$[59_9[@3),K<*ZXN^$L5VIP9S9)?'@,:5&U%EDV:53BRO<BS-3FYP6D
M'%1C;TT6F\9ON(IWA(8-K-&QU3+!F;=)EQYB9SF)MCR\9DRI!WJVUBE9VPPT
MP5D;&+-%>A,:<XH<K362;YLT?5)U.LK<L_M 6!9]*2A'N5332E1?A/#M V]8
M@QC@K%4*-=QKA^AU7&U$@S.W4@K%U.FPS2!@V:\B^46?2+E)@R1]5(/5E7;U
MR99TX4.LL<1D\?\ O#^D->=<3//_ (5"2\GSP$?&OGHCP ]FK9581[_8!.?T
M:J!D@#R2 /U)P/\ 6:H2 "3P ,GZ "M%?$R#AIDBYM7;=9JZ;9!N[=TV<I*-
MW+9RA;YA)=NX06*19%=%0IDU4E2$42.42'*4P" ;!NSXAU+11RID.<P3,0<2
MD*8X@1-P110X@4!$")ID.HH8?JD(4QC"!0$0X#<#MZQMN0NSK(>)TX>K[B42
M"O8:J0[&*C,TL&I"B:2:JJ*(-6^08QHF4%G2YO\ EJ-1(D_,8&[9XSLSBQ>C
M;8V32E+2499,PN&B 7-^R43<QM,!1,BI:S'J#QUON@2F?G 2JJG*59R1%$6;
M4OK6N:['J-G&8K>9;U[<K)9,IWPG:JM*S[0&M?!CG ^\+"/:LH>-/.[&Q6TG
M)DN83:).-EV"-LAWAEB5<Y]1P0\7)109"3'M9I^W39>3HC*N5=LL8CVR'=/G
M14^>LT;'J(H)(E$H\F%V_7(7RR@8RA6QB<"!C!J+Z37,TV4\=,-:HO#,".VK
MM)U9WA8$RI$%DURF!BJ1:7!-4I0 JIHX"F*83DZP[#RF\_+<7MLK>/\ <VMC
M%KDP8BW5*D6E RPA/UZC6E.:56GZ0#LXQ#>R,[(I#&4,]2(,I&F<1)9"-.N@
M]0K-OO\ $D^B&R"9S+LP5-E/*%PL5>QQ5FD%6I>TV+&TM9F$G*2EIMV.VT6^
MF6SJJPL2^,T93C!.&5GW45ZI=]'F,DZ^--:T^VO>KNH9>H^KI;9;"TMKO3>E
M])VP7[:2MNH%P9KN-_5&YNXKH/#8Q?P>0J);M#(JKZEIG1NL]0WVG^GW&WU:
M_CTVSE5Q':PS$Q(WKK@AO3JH?O,2JDQ%FB,C J*HXT\(;<YCW;KLZIZ.4\++
MY<V9[QLJ;K*HU47R([Q??D<H7W.C^0J$]+)U>.LE;?M*+G.32B;5'UZ;&#M\
M$W<)QDG#2;KR?NWW[ ]X.XR8V^SX6)MC5IAY7=.$Q><$7>TNLCU]GG;;O,X.
MJ,Q051KL7(3$[57$HG/69*1:UR*DH1-S7(XJ8*ED0U6WV7_$67NW[IC^^[VP
MOA%S+%MRCK/3650.HH*IDD3)-$&#5IU"/3&H,D8LA !(C$J)03#<5\-+Q,7&
M1MF\K>MZ$HOC[)F';0?'UHG+779"J2.4$?@32?JUF@*LM',7\O9IB*<+1TW&
MUJ).V7GHIT\9H-4'HH-K+'5=!URXN2]QJW2MS;Q:E>0:I=7MO-9K'<I*USZ@
M7L+6T2Q&>6XCA;VK@JET@5(SZ9US]AFJ=(Z9;:O:ZU::XKSQVUQ%IHD]3:SW
M>4C*6[M.+JV:4]KN#M2K(\7W(5B4G_PNYVT5; >/MNM[B,90%KPSC.I5D\/A
MMM.QV,63:K-TJHHG3(:S1\=/P4.X39QLL> DD%5H.1DY"-(_DV[=&1<Y/M4#
MV99E@-V;_).X>,QD- 80M\FL8T63=@9K:[E46=?J<D_FKL@T6/%J/E9M=0L6
MR2%TM!,4",5Y%R\,\$+^:] Z"EO9NG+>6\U6UUN.2YO9-.U:UAGMX[[3'NI'
MM)3;W&9("BLT"1B6X3LQ1.D\BN,>3M87FF226-_CU5NY60#&5W 2!' 9PKQA
M]CJ'8*RE=QQ333379U2FFFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*:
M:::4IIIII2HON0D ''5Q^< !SQ[@(A\_F/8 ^8\AJJ]T06_NGEHMR4IA/RV4
M'H >KCKY3^J' #W-QSTCQW*/');]*=G'(>UW/M(VTW%&@YZM&/9F)Q=;5I52
MO_"+*LNS.8K>RHH.5ZK(2T0E+047;$6ZRM6DY1I8$R :.!5/$;O3P#FF\63&
MDE@K'&0JG7(W#^\6NV&NIYV:55Q&9)O^!:E3MM<ZLZ1R:Y*T6I.38]U+*VV$
M<2[Z$?1SR^ T6D9KF0Z?2I&C"E8GD($?M7\39V A>.6 Y.<#Y\5R.L1K*^UI
M4C!$@W-X7:BMELLO#<*N,\YR/&<S.W!,OQF4.4I0 (E4.2D  Y.]:" =0  <
MB4O(!SR(=^./;$;XIM-97#+^0V[_ "4SP^P+2,)QLSDAU;8&B/*O6K%;G<+8
M'%<N%G.2 KUP=1[M9A5).4$4VTR[;G:IJR(,4E+#>'EC?>%6MQDS8,\6VN7/
M'[79]B#'9)RMWFP.6DOF.HVI\I=;.OC>5@8AG#3]O1=KS5FM;-S)$F2*5^.0
M>^5'GB(*$_$]A8>S9/RE5YFIS%Q2M->VMU6*CX7'%'S"K#VBS9FC(&IW25Q1
MDM(^/<D5:BV*1CK3<*9<EH^!G*Q&2K=>9@G(-)ECRO68%S=1(RL@>^LTPP!(
MRC#.#P?/@\'QX-4AM8WTG3(&9)4EU%#E<,O*S8'N'." >0/H0*H3M\PY6J?#
M6?Z(9FEL[T:C96H$-5;M8,J4O,T\BK-M*S,RD&ZR!4):2?3,:PD7+@\(6\(Q
MMK9HG>-"(OJVW@9-SN&![?I-_2.M6C!N.H;&&#\DU1FF:1L,3NMJT/=KK [+
MH'8;BBX6&*K-"'TV(L$0\/%R*,10DI!6DWFU6IY9IV;R/'6%-O9G==904;$;
M2X>WZ3?TCJ$TFW6UN]2A4D[?2$D@ L628EB!\DG)^"<G R:D]*M8[2\U**-0
M!MLV8@ ;G87!)('&3QX^<UYTTTU/5.4TTTTI33332E----*4TTTTI33332E-
M---*4TTTTI33332E----*4TTTTI33332E----*4U2+Q(?^@QN>_[)K!_OF.K
MNZI%XD/_ $&-SW_9-8/]\QU)Z+_OSI/_ #G8?]JBJ/U;_>K4_P#F^]_[-+5U
MV_[RE_HT_P#=DU0';H #OH\1P! !#XCM+[#_ -ACC^OXZO\ -_WE+_1I_P"[
M)J@6W/\ Z=/B.?\ TCM+_P#08XU=IW\DUW_FJ'_YYHU8[[^4Z'_SE+_\FU:L
M@'EE#GL/?_*-[_:'?L8>>Y@^L/S$> T\LG^*'X=^./D''MP'N << /(AP(B.
MO?3454I7KT%^?(_B8P_H[B/8?80_P@[#R&HSRYAW'N<Z2[QWDZ )9:B]EZU.
MN8A9X^:MUY6H6"-M-=7=%9N4"R#9C.Q$<]6B9(KV%EDV_P /FXV2BUG+%:3M
M-*5$V'L&XIP'5W]-Q'28&C5Z6M5DO$M'0#!O'-I*X7"0&5LUB<MVB:+8LE,2
M @X=&;(-FY!*FDV;MT$DTB<?F;;YBK/S?&[7*-><SR.),OT'/% !I/3T >"R
MIC%\[DJ39S'@)*--*%AGKYRX&%EQ?0,D90"RL8^(FF4DTZ:4KT!,@?+\!Y'D
M/?N \\@( (@ \\@ \ /&N"M%8B+C7)^J3R"SF%L\)+5V8;H.W3)9Q$S<<YBY
M%!)XS61=M%%F3M=,CIJLDY;G."[=5-<A%"]@TTI4:8=Q%0L"8GQKA'%L.O7L
M:8BHU6QMCZOKR\Q.*0%*I4.UK]7A F9U](S<DG$PS%G'I/):1?2#A%LF9X[<
M+=2II+ ..W]?Z_?III2FO110J1#*&$I2D 3&,<P$(4H=S'.<W8I"% 3',/L4
M!'Y:]]>!#D.._N ]AX'L("'^L.X>PAV'L.E*Q@[4-]>4][F))/<UMYPQ3I/;
M_(9JL.-\4*W');ZOWO*N-\>Y./C#(V;VZ+&I3%=J;1"3B+E*8^QU)NI&4ND-
M6F+B8M=,>V9".BZU0OB]VZ+GK9-9#PA7D<.4[Q;K%X4MCM-4O$DM;Z].O5:O
M#8LSJZK,S!)14K5+'<[="UF\U!A/M9FD1[KZ4PTI=BMW$"2^VW;8M0=J<-9Z
M#@J_Y.I&&+'EFU9C:8<;R=;>5:EV&\VHEUN5:H$P[JZEQJ^.+%9S2$P[I2-@
M=-F*TW.-(1_%1<B=@G"5<\)G ,799>7LETRS?*U-[^K'XE+['=@EZJPISG<]
M,L&36#D7Y*S4H2>EJ+CZ0BXJT4BE24XX:H6R,83%D?64K-JS24JH>(_'-8Y2
M<7ZOJ8)/4[[4<T;=MM$[19^Y&:6?$FY#<GO!N&UFK8FR]!K0J<L<D!7:[&9T
ME,@45I-4J7K4RK3H=]\?9L7\Q-<[XL4Z3:]-9^H>VJSY+LU$J6_.RY QI5K&
M"[YK_:)9=?8'L@0+\T,+F0;W^] QL->25BPE$*,RM9VK&<LD 2+?=WJG@V[3
MJDI49!DOD)[8\:8ZP?C#%MLE)F!>V*EU_;CN,0W2X=D%GQZR4ESM-4RNS9+&
MLEV1G'TI6FZ\"_*H:;LLA-]X3\*S;8&(,J876E,GJ5C+M=3AK"\3MC)I,1DH
MYW&9,W6V2VUUPT@DFC&=NN;LI3%BMS5XQD:W+P\)5:@I!%K<0JP>J54:B^.C
MA&\5S',FU<8WCH;*.3\X,:QFJ<OLE!X+;[;,$VW'-"L>YFXR#FM.+CCEO.9"
MRG4\8US%]ZAX*2"\J2*]EN5:HT>M<!S1Y0=>7BS(#PAR'\NB6AR11(>4CB2"
M>*%.F(";DA^QDS <P"02FZC /.L9%F\%K:=:)3.-B5D\E0=FW-QVYRN;@9BL
MR]9B"9'IF[HV(ELS5(8@:FZB:NRD)#"-&F(&8K39C:(>;^D<RO-RDG9I-R;*
M3/5%H^H<Q1XHB$:R>5-]5HX@E4.WCVJT.>)9%Z>LRIT&J/E%$O694R:?YQC<
M\Y(65)H6?\*RQLWSPKJ3XR? K%.K-!,J#+M%(J#CEBC!1R0/)'D@?G6G!N'W
M&6C'LW\?AI60BY&$>)OHZ0C';AF_CWC54JC=XR=(&(NW<(F#J362.4Y1 0 >
M/JBVX9]GK@_++/7SMXO(KG=.7#I999RX7<JK.'+ARLJ)E%G"ZQU%5UE#F444
M.<YS"8PB-E=S&T&P-[5)0L_"J(NFRB@JD,4JK=RB<YO(>,UN.ATR<D#S$%R?
MGEZB&*18BB9.6VO;,[#*V>/@J_$G*919)5PN=/RH^,9$$0<OGS@"]#=LB0_4
M*8"99RH*;=LFHNH0@_2_[4Z9_N:#L(>_LRT^%P854.H)QX#$D>[R<^>:^95T
MSJ1^H>UB;M]S A]^1,7"$XR,$!<'@$ >? K8BS1B5AG7;_/8W?E1,I8:K&+1
M2RW/EMK!&),9>!=&,'<I$I1FW!40 P"B=0!(8!$HZA-W9[B-N6^/'U.AG=E9
MX\SQ"RF&\<K5B-7K]KQGNDBZ^TO$-$RESK+>+EQIM_I@6=T9G9I!RR82="EQ
M17:ME2IFW;(UIZ&.8L3&!06C-JU$_3T@?T[=- 3@41$0 _1U 41$0 >![AJF
M^Z=EA;#]5G\[6ZCE=^?8*JWMSJMPL*M.2CF641I#*?<@\]*:0?Q$-)*1ZB@O
M"/EX(SB*;*="HH*_$/6G0UAU%>Q:SZ:":^M[&>PS(%5S"TOJ+6>"8C?!<6-P
M9)(WC*/)'+)"7".RM]@:%KESIMN;#N.L,LT4WM.1W JQRQNARLD<\85"K!E#
M*K@;@"-.S%GB(>)58L:[491]N8S]=U\Q[+-^6:[8G287%02:MOVZWXE2I5K*
MYG(V%>Q%8A&;D'5B8QT\Z=O54FPG9R)_4IJ>VU*_;@]Z4W2HO*.3Y-O<([8K
MMNW+S%[M<? V*V9=L^?T[0O)S$:2SIGC(K#F+WD"VKUBBZLSC'CFS3+-&0M4
M(D1-J]V(HW('A9QT5#+1D;C*)0K]=L=9@(9GM[=Q[Z!K%Q5,YM]5A6#*C$:Q
M,%;%SF7L\#&N4(6Q.#"M,(O51\S5\,([>=L-JHF*;[6,18_5JK&G,UL2Q;[&
MU2C6](J,RDBZ0BH"%)&'0J\>LFDU65KL4+6(160;J*,E'+9%1& ONA3KJ&TO
M($9#+))!/=,EVM@KWEW.#%;2%XG$=M=+91Q;%C58HI%VFWMS%(PZZU@1-$Q4
MA%1EC1H6G9884.Z4!7!:6(SL^XLQ9E;<)'W2-M,PX7!. \?X^649N9EK%C,V
M=['D(FR>6>PJ#+S:S0J:BI :$=.?2M>E54HMFR0E4.7I$;':\%*!2E*4  I0
M H 4 *4  .   #L   <  =@#L&O.O5M/L+;2[&STZSC$5K8VT%I;QC'MAMXE
MBC!P "=B#<<#)R?)KD[B>6ZGFN9F+RSRR32,?+/(Q=C_ %DX'P.!33336Y6&
MFFFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*::::4IIIII2HFN)A'S0Y
M !$QN1#[! ?Z/Z?GSJJ5S.!2N#"(!P)A#J'@ Y[CP(\!V !Y^[O[:[!N4W&U
M/%GJHAF 66XB4PIP;!0ITF9S!P0\HZ+RFWZ1$!41$PJDX,4P>9^2'#-DW)>6
M\J.ESS\R[81:IS"E 0JBD?&IIB<YB$7,D8CAZ8@&Z>M=0$S '][E]@ZK2F<*
MKHHV\?>2G;&<8SMQEI,8QA0%SE6D0C%<GJEN)WVLQ V@%$4M)X'!' 0$<$L=
MW((1@<UENQ7G_#&-7$L:Z9%JT*LHS303;J2:#AR90'76<@HMCJF(8I2@(@H!
M.X<<B(<:JKE:V8[R]N4FKE5LNU:O0J]3QHXJ5W-*E=-XC(./IMY:()6=J#.T
M5*9M%=C[ A#KSU27F(B'N461U OY'X<[= .,OZ!K (B#0H"(\B($( B///(B
M!>1'GOR(CW$>^@T-8?SFI1_SB$-_J$NJ:GH-KJLJSSW[QR+-%.O9B14#PKM4
M;7=V*D>1OSGP16*%WAMK:V%NQCM9A.C&7[QG&[AB(=I [AP @(P.3CF\<S@:
M-V_83@JU#;B,J;B(F6OF)Y$L_E:U#:G\1.1D= PMTD(1Q\1?H0T9DJXIRN17
M]8C",*]6IR<=PE;8H0S1DBGL%A[?I-_2.M32 8VZK+%7K\K)Q0E,4PH-ENIB
MH)%"JE!:/7*LP6*"A"G#S6IA*8.L@E/P8,M6V'?%9G,BPI6<127(\4*UC;PD
MB*!DUE!X22FD$^HABG,)2 [* #WY$1-PD: FT":PGO+Q+E+N*X$)8(ACDB$
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M-+D'BCT_U]>(W"$['FJHJ[A,^2GT:7E5G19*9QT<MM+)J@HDWM0-,9LQ<(1
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M^#9U@2OD4W#Y^D1@K(O8'"DA,XX.>QMEQBA+6+!Z;&+4JU;;_#%@;H1I8N5
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M?/1--F*9N1O&"[O?G2IQP#_*;+@X0XXN/@LP/Q]V<9#+F2-AIHSC7;0\G_\
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MT$:*P[T]QW)5BCX)8B-X078$!(PS%FR"RJ&9<XA# <I3EZ@ Q0, &(8A@ 0
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MKA<43)+"D*J2J1CD*H0QTA 2@:#IR,=U=P[=6T7M8:1QC/9>9<,';A"+;IG
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M$( < $5<+(AD+VEO:,"-L<#H^WW 8)2)$X^""<C(P.*VH61V4I<2S[6P6D!
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M2FFFFE*::::4IIIII2NGY L4M4Z59[+!5UY;)B$AGLC'5R/Z_63#ILD)TF:
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MXSG82ZV-X$)8;'6',#7V:,21&]#3>]3'8%$*%?T>HO4'G)5XH"'5T]A":'D
M-R41#D ,4P<\@.NV,]V%7>B )TVYD,(<B50D&!@^?< E1$.P@/X" _,-0ICO
M^2T#8!8GR!ECN/ <#&3GCY_08E0]H3Q(N[ &<9/& /W?.!C-5V\.3:AG':U2
ML@US.MQJ&0K/:]R^X_,3&U4R*GX1BXK67[>:RPY9:.L]HMLJTL"RBCMW)119
MV98U_P!6A L9N=;QQ)9SDDF(B-GXJ1@YAFC(1,NQ=1LDQ<%$R#MB]1.W=-E0
M*)3="R*AR&$IBG+SU$,4X%,$7TW,<7<IIM"MH">C5G*3E4%I$L>1%,K=N9P(
M*%0>++ )R%X)P00$1 1$"CU:E23DF,/'/Y>3=(LHV,9N9"0>KFZ$&C)FB=RZ
M=+'[]**"":BJAN!X(01 !'@!TW$RR("K)(-FP+D/G/M*X);=N\8.0?'-;"]L
MHQ#!D.=Q;&,8 (;( QCSD>//%8['FRM'%-H-EJA7Z129T07MQC:K)LS%=.BP
M;962^C2UI:.15)%RJ*"\8\>K0KQT1BX,55M('ZS'Z]D#?O=XQI4)&K8E-7XR
MV5"MV^/>W]99V+]E8HY*32+%#6GOPMPV11722%R$NJ\*KYB;Z,CER"W#MLIO
M:@\BV-3%=!H\Q+(W87=.B;/(NRLD@=3S56,;3!Z^@T<28PK([D7S\%7+20^'
M(+*E01. $U&>2-D6:WD71(.$R-%7J$I=.KM1CH^>57JB,02"C48\RT;&-$9.
M*,B\*W355='.$NL<.7SAV8I#AZ-:*DD]J>N.P)^VHL3?.\<ALPLA;?Z/$9=9
M]G%^5E)+X+,&%<=.95:7^YONFUV,;GTH1T%V)(!'M[Y[NUH#*/X*&B 1=P&4
MKG;)OJRBSHM=GV>&#P;F94?I*66?1G7%-=>E42(B,%T(1CAR=<BAS*%?/T$T
MS$X9*22?F*I60VK9]N6<XFP.;92DX'X&>.(SL46E(I5Z?.[]85RV9$D^LY'L
M:+5,SLC5[(H 1REYBC57A$]:K'LVSY)8MK56/EUO.*PSR0=J4J2DYI*L-DW8
M-/0MXZ6417<O%8\".^E*38A'-_4G")29=:XN9_VF8#R+A5G8#7:XH2#6:29$
M84^)>/9&&AW+=98[B3!R^2;D(_=)G3;G2C&S=L=$!,[.Z6(@*.EJR=*#1+O]
MGG3QJ NV%OV9+]Y3$+D8V"< G,&02P:V R4<N5QNV)UO]HP>I]4;4P*9=ZVP
MC#F$9W=L\$2^ I$V<;QMS5RM--->?UU-----*4TTTTI33332E----*4U7RA1
MJC?<#GR3-6&\:G)5S"22=G3F#.W%E%A%WLAVCB'%ZL6()7O4%106*R9#*!)*
M',H[](!D;!ZKY0HL&VX#/<I]&!C32=<PDD:S_'TWX67X=%WH@-0@2F%2"^C_
M *D41<J%*$U\2\U/D&)N(O4!F[T0XSMU.9OPEMO]YM67=GLRA/Q;=Q>WSNV"
M9BWI[B:TIMMCU*-VW?HL"XW[=^.HM ?;M]5;]S&S?L$5]C9W/2H(S>V=@]--
M-2E0M--1;,Y&^!9:I>.)!DQ;Q]ZJ-VF86<7EB(N7-EI;VKJ.JJUBCM@!RNYK
M,[(V4'!7H*ILZ])=#11)%==#O+FP0[=RY8&D61Y-LV4='C".VXR IIH&7$2M
M14\X1%,O4 ='/2('$.@>K5C2(A4.ZH7=8T#,%WR-^%%R1N8_"C)//T-7K'(P
M8JCN$C:5RJEMD:_BD;:#M1?WF. /DBN9TU7RI9Q3EY=*.GHYO%-GZQ4V#YNN
MHHF@=8P V0D"JEY %1,5,7:1BI$6,4%$2)"*I+!AWUN7-I/:.$N(]C,NY3D,
MK#P<,I()!X(SD<9&""=*UO+>]0R6\@=5;:P(*LI\C<K $ CD'&#S@Y! ::::
MUJVJ::ZA=+E'4N)-(O2BNNJ<4(]@F<"+/7/'5Y8&$I@212)^4<KF*8$D_P T
MJBITTS]"H&5SV(L^K8TXR';1";9V1X1=1)L1LZ452*@X.Z./4N4Z8 FH02"X
MZA*1N!R@ Y_32BTEOF"I:P<R32.J* " S>XC*J2-S?A'.3P<:WJX3>0V"EI+
MN<@1PQHSL202JG:#AGQ[%_$<CCW+F;--1K(Y6J;&PXXK:#D\J_R>^LC6OFC#
MM5D4FU3KKZQ3<J_!9P@X)&LRMF<4JHU0=+I2\U$-E6Z:+A1PC)6M9'21%DC=
M9$=59'1@R.K ,K*RDJRLI!# D$'(-;CQO$[1R(T<B,R.CJ5=&4E65U8!E96!
M#*P!!!!%----75937@WYIN/?@?Z->=>#=BF'[A_HTI4!;>Y$)*%R4H%E1LWI
M<]YQCQ<(0GP((H6&0YAL-;41].W^(+5[H^%K3?2K\94;B_\ 4+^;YAI^U 6W
MQ\9_"Y).:QQUD%OGK.+$%XV&/")Q1660YAN6NNDCQ<5Z^1KX$",?S)4WA)=R
M@H^)*20*^K4GW4;I!SIED<Y^X7G=OSYYW=V?/Z]Z3G]XU,=0#;K6I+MV8NG&
MW9V]OCC9Z:SVX^GI8,?\&*::::DJAZ::::4K';O5\.ZG[TI^H62RY;RE2'5,
MB58N*@(%W$RU#%95ZY>J3J]1FF9T4[*MZ@K)S-LG[5VXC6C)D?@K8AAKW2/!
MJQC5_+^+YKR3."00$WP^&J4$0X!_@AYS.;6+R'81\TP_,!#OK,MK\U5"(IJ*
MJG(DFF0YSJ',4I"$(43&.<QA*4I2% 3&,80*4H")A  $0F8>H-9M[6.QAOI(
M[6+(CB5(?9N8L0K&,R<LQ/XO)-1[Z5I\L[W,ELK3.0SN6D]Q  !*APN0 !^'
MX%4$B_#MP76VIU&]DR.0Z*(G5>/;!!&3(FF41,HJD-;2;$(4"B8YQZ"% H]R
M@'(05.5:E4NR_!:)=0NT<@CRZ>E10_Y.>D<&2,P,_9@$?)G A?-,X8D(DESY
M1^I0.=<GN<N6/[=8IHO]M>[EVC=,A8O$E+K))Z :K V3**,C/04TQBI!=9<#
MJ.7,Z]>*,RJF2;LR^6")X%I3Q!!N@98Y40* ?,1 > 'ZI0 H#P'^"/ <?( X
MUNQQ7<L)GFN99G< ]IXI(P"Q4_CEC4L0/)C&S(P&8><!,(E[<4"( <[U=6SM
MQX5&(7G_  CNP"2H-=]S%#O"M:A=VR9E6\&JK$2RG(\M6TBJW<,'8@0HB*?K
M"*ME3'$$B"LB B J (P?);0L3YYM.YVVW+,F1ZY&[P-NN*]K&:*?5&%-8$?X
M<QI)6YTZ@:Y:)2,EY: ?Y BK];ZI<9P&3]\E7I<1JPUV>8L)QO8]QD:*4C5X
M9V5JZ8ND#M';)V":B+MNH'2=)5(P<G(;@O/U>H#$*<@E.4A@@IQ$-HY98]6L
MAX]H<XG3C) %UR( (!RDF]2-YQTRB4 **J!E@*'2=50>3B].9X%@E!78Y96P
M2&5@,+D?A*DDDGR#@8P,WF7LR23*-QD5 4+#@ICW+X)W#&0,_)YYQ]%PV]XF
MPQD;,63-NMTLF&F^=:5BJK9+QO QE1LN.7TEA"EAC3&U_JL?:(5]+TN]0V.D
M(ZER;QE*RM9LD7$1#Z9JB\ZT/+.+*X!@U8?&[J0>J*&7LLL:5: Z5*J^4BFK
M)K%QSQT(%3ZG$@"#A^H8"$*H1<BQ2$*J4A:WUNNIV*?A8V3E1L+^3DV4?'PR
M)56[)R_>N46S5-TLLN955 5#\+I$(@50HF%0QDR^6;(7*X"R@S*1.&F:O)-B
MI)D*0RCR%.D)2 444T/1/$ 03 .A Q%R 9,I?R*0?4+BG6"TACMU?#2.9':3
M(! ((C0?NJ&Y)/G;P3SA$6G;O,I]JE44 -M#>"<>3C(V\\'G&!56;XE^_F-P
M(&ZN.XB(<F.'/(A\A^??Y=A]M31C3>ICRK,V58O543I#=DF@V"9J$:5Q7.D!
MZ#.7D0T($K'%*0/-<*-RRX'.)S\% 0 /VE-M>6Y=(4W(U+D0'\H,Z[!0/?@@
M]$,)1* ]^?<>?D';4%VG8MFR;*N#1W0D_.(8H>=89,O B' "825XX_CP _=[
M!JD1L9PL5U,BQ@G#K+M9>.2/:0?'A@1^IP*JXN8W#0QLV?.4&"/.,9R/)R00
M>3]:N'D/$6U7>[53*NU*U<UDD#H,;K3)5LSNU<$YC)@7X@V(:00(0Y3C\(LC
M!U&&/R92/,?I.&,(OA>[F-K68(+.>S#+M3MCR'=BE)4/*@NZ>>T5)ZHF>;IT
M[.P#.6@IR-E002%)8T/ N(J02833$POHY/S?I3\,S=6PFV]@I^3*!1IML<#(
M34+<KO&2B7!@.0/50E90753*< ,*"JID3B  9,Y1$!R][<:EGBE8]2@MP>2Z
MUE2YMY!8S6R5VN+P!BPPHHE;,9==11%*>DD'!7!QF486!%9LH@BY9.'**CYS
M(?M"71;=X].UJWO[.<-%-I=U"TZ-'*N'4J4:+81P[1RVSY(VJ3DC4-JFH2@W
M>GRVT\9$D5["XC8.A!4[@0^X<;5=)E(!#$#@SHQ4<K-&RKUN1H[4014<M4UP
M=$;.#I$,NW(Y!-$')4%1.B5P"20+ 0%033 _07ZM--<?_MQX_P!9)_K)_6IZ
MFFFFE*::::4IIIII2FFFFE*::::4IK&EG_;UD*2MD]+1\=(WVN6.05E$TDEQ
M=O8I=;V9+QZ[A-0I&?4=*.>QY3%*TZ43@W4(8%,EN@@ ^X /XZYSJ7IJVZEM
MK6*6]U'3;FPNTOK#4=+NFM;RTN45E$D;@,,[6(!*[T.&C=&&3U'2O55WTK>7
M5Q;V6FZE;W]H]A?Z=JMJMU9W=K(RN8Y$RK##(#PVQAE9$D0[:QE5>L57&T4U
M0IT99:7:GB;4M[8KS$@NC\88%.5-%HY4DEEDT8U==V1-NH4 (5T83+JJ$$Y^
MY[@,+S6[7:[DC 62*Y*S5<R!&NZ9. +E.&DYNFVRO3<!8!:R"IB%2>LX^4.9
ME+) <P+JM5P(Y.@H*MLKAB:LV]V:26]5&R9P %G<>9(H.ND *4SMLLF=%90I
M Z06+Y2QB\%4.H!2@' T:LY?I]A-!R-DIMOQ<1675A7CN-EH#(M;8*"FK!5M
MV+(\E5K@UCU#N683WDT^0)%)L$G,;*R*3N1=RVE:GU2&N+3J%K/5HX#"UAK;
MEOVE.$*H5O5! >1HE7N.%0*=RKW5[;11&L:=TK(;;4>G_7Z7<7 E74M$X.FP
MLRAE>QD.YHXTDR(D+N[*%9NTP<38C+;X4T_E+;2ZVQY,R-D:9JR\;AF):VIC
M&XI@[>P;81M56MM=>',RA5(61GY]_38%M;IAW' W?-&ZX0L17UW3A528E/#E
MF RKG/+=<R;E?']@W#RN))?(3*I+8M)&@MA?'TOCJI,H569J4M*L(E[%RYY&
MTQJ\@\3L$FPCTU5&\.1W%OLO^FIEKZ5FW$+D  ',N1@,!@]S/&]\<Y&X\\U#
MQP+&,!F^3SM^0N>-N.=H^/@?/-8>:)X26WRH6G*$\ZHLA9X#*4U3[>YQM9)U
MJIC^CY!J^*(W"LMD3'+&'^%V*MW'(F/H6%B<@R#BR2C>67AHN1BVD*]: L?'
MG>MF])V39&EL;8SC)N,H-ML%GRG$-YZ??6=XA,7ZP.)^S,$IB357D5XZ-DW?
MHXI.0<O7Z,>DBF^D9)X5P_<;26J2[WL+*9+QRC:(5IY]FH*BLL@1(G*[V'$O
M,FT#@HF.9,@"X3+R!2\*G'GI$!RV%[Z>Z21]JQN'AD('X4E(]V2> L@1C]%#
M #)K'<V_=A=079QAT!.<LOQ@#DLN5'YD5CZQ!^<S_ G^V&KFVC&U9R-56[.5
M=NH2<9MU1@+-&II'D(I18I1.DHFJ $?Q;E0A1>1RITP.)06;+M70%6&BV.IQ
MK"M4G+HY4SE*!4DSB '$_)>YB"'(%(;GK ?<0$O(<:FLN71*'3ZT!+_@E$>Q
M2@4"\!QQV 0[<^P#V^^1NHI7F#PL59"#N S\YQY&002#G*D9!R,BM6+8841S
MQ\\'!!P?(Y'ZXS]*K]<,%;G:Z]42@486]1PJ*%;R$#/,V"YT2CRFJ\BK XCG
M+-10!#E))P_(0W4'GJ!P<>=Q_M^W!V)\W/>)6&Q[" I_=BB\FVL%@,D40$Q&
M$3$+KL@55+R5)9_*H(I&X.JBJ4/*-,O[KX_QHGZ_]?</Z=/W7S?QI/WY_3^K
M_5[?=K,UQ=%-H@MU8C'<[)+_ !R 9.V#X/X/(\<8%GIK;=N[TY&<["YV_'&0
M@8C_ /=GR"<>;2QU:J]+IR=<JX*F31$5WSU\J165F'QT@(M)RCHB:97#I0I"
MD(4B:;=J@1-JU2103*75%,R>SO\ !?\ WR>I%-EX1*/]UD]N.!X !Y^0]A[?
M(1X^SGN.H<R+.-)YHX<(*IBIY9A.0IB@(B)@,(A[<!]4>_'S]^=:L$4R39<%
MF?!))P?@9/XO!(S_ -WQEN9(1%@$*,@#@\<C Y _^G'SCFF-TQ-DC,N'=Q])
MP]:243*U@QK8*YCB\+.';)*IW2>AYEI 2YY)@BX?Q0)/0*G\7CVZ\A#BI\68
MHJNV**9OJRIL'3R3A_'<-4L"4VM6NM9?VOV23@Y2RUB2:H4JDY-HMCS8@TDE
M7:T*^6F*E 2\*],8Q)G**9B$GTB&D7*1LKWA]X3<D6M.6;&R,#*3 (6LLW9#
M&0=HIG,H\DS-E ,@J4!.*+=11,5"=8"F8O)P'*,$+#E#@(J-  ]@!@T  _#A
M$-5O-33NR1*G<5%6+?N]I*J-VT$$ JY9=PQDJ#R ";+6Q(1)6PKLS28PP;!;
MVY((X*!2!@X!/@EA6N9A7;3EG &3MW4O1L15V0K>7\U4"?P\[;W6EQ\-4L>5
M';)C['B2TG77TJE+E"+RC4'QFU((FT3D8*6<3@R;10ZC5QW3;A@'?3B3'4_B
M<<B86E$:#E3,:.-,I9@@;ED.QY)Q'<EV]TQ0^DBTW(,1(TR;QQ;[!;ZE:&%Q
MA[?(6:FP53<0I(]55R!=@,(J,#VC6 ?@S;A_^'KW".CP]F#,/P:H?/W_ ,#Y
MZCFO2QR0P_%P& 'N.X^%&<'ZYX _,5N"V7.3MR=N<@D^T!1SD_&1]/GSR,47
MAK8@S[@+;#C2CY[<0ELSI4667EYY[ V:9N#6>7GLCWVT5E5U:;"[<RTW*N8"
M<BOB;E9T(E6 &!1(NV4U--D?24Y(O(G):]@6BY%%1M8(1-5=HJO&/"<K1R+(
MCIHDQ2<IB5,H@*9T4S%7 #* 437$NS*\_#6Y,9!1H^;4> FYD+G'33^-9,#-
MUP,Y0BZZ[B'DFZ(Y]. ,5)F(;K-Q7 S]%3R^8]@,#LDTF#Z]6>1O%F%!!>R2
MWH65<C;!.FY4DI!.$CQ<C$QCI<QBLH5.3>"P9$0:+24@J15VO$ZIJ6O6UL%Z
M<@L/72R1QM>W[,6LX%#$R0A<;I-VW!VMM.6V2-C9)Z7IN@75[W>I;G4O06\;
MRI8Z<%7UEP63;',YP4CVAL@,F[ 421@MNH$UVZ3[RVNE,6X^EH:L/U@3@Y^6
MDE1(:&,4J8O7LT[?.'0 XX5.Y9LB''H J!6ZQ@ZE,J-'KSFIU&O5QW)KS+J&
MBFC!>3<F4,L\503X45$53'5!,#B)$"**'.1 B13G,8!'794$$6R*2#=)-%%!
M,B2*21"III)IE A$TR% "D(0H 4I2@   <!K]=<_H_3;Z?JNJ=0:CK.K:[KF
ML!5N[S4KIIDBB5^X+:TBP!%;H^!"CF0PQ(D411=X?IM>ZL;5M)TGI^RT?2=#
MT/126L[/3;81R32F,1&ZO9V)::ZD0%IW18EFF>2657<H4::::ZBN0IIIII2F
MFFFE*::::4IIIII2FFFFE*:KU0HSTVX+/DG]%',6,E7,(HC:U)15RVM/P^*O
M9/1MHLR94HP]:]2*+A5)10TB,HF=0""V(!K"ZKY0HH6V?\]2GT5?182=<PDD
M%J7DSN65I^'15Z(+-E&&2(6-4K?J01>*E55-(&DT3G!/TQ0-%WXS>:(<9VZG
M,<[-VW^\VK+NW=F79^+;N[EMG=L[S;_3SS6E-ML>I1NV[]%@7'<V;\=1Z ^W
M;ZJW[N-N_M]J]QL[OI4[?K+2P>FFFI2H6HQRIBJO99@&<1,NIB%DX28:V6H7
M"L/PB;=2+5'HN6S&RU:6,@[29R*31Z^C7K9ZSD(:=@Y&5KMABY6"E9"/7J!:
M("U4V=*QL]E<6FQHI,WSBX&B6E=7GG!TB\RI(J,,:/C5!4(9NJVC1*S2504*
MBD@D8J!,ANN@7W'\7>F"23@XLI-GUC'R::8*'1\SCS&ZZ0F("[14Q2F.F)R'
M(<H*(G(<3]?)]8Z'/KFE".S(%[:7"7=NI?MB5D5T:/?PJ.5?=$[8"R*H+(K,
MX[#HKJ"#0-7,MXI:QO+=[.Y8)W#$LCQR++L +.BM&%EC4$M&[D([JJFC((.#
M-2/3I* U776;D<]/2B=RD!#K( H4 *"Q2+)J>4'2;RSD.0HE'D+[T-^YDJ=6
MWCXQC.UXEJ*QU.QU3$**0*F]N3*E3*H8>.1$_(]QUCX-FB,K]6RIC-6+<@Y?
M-;E'PEH(8BY$IYM&.HF+5/$J(BLR(J]:E,W>HN'"[)59%4Z0 F91.GVW3</:
M<+VR,(\DY%[0)%ZW1M=>=++NT6S=8Q4EYJ+07.864M&@;U"@-S)%DDD5&CP%
M1,BJCVO0&H+]HW23O::C;7>N=.=FUU.W]YNI9A%*FZ0,J,CW(@)295EMKJ>.
M01RJ$;;RW773D_V?=5R-<:?<6>B=0=V\TF0JOIA;O)%*5B=&=2ML9PK6[F.Y
MM8'C$L673?GVT$0#N(\!]HZ_)!=)RBBX04(L@NDFLBLF8#IJHJD!1)5,P"(&
M(H0Q3D$!$!*8! 1 =5'WA9VD,.41BPJ[DK:[75PZ80[L4TUAAHUBFD>9FR$4
M*HF+MOZEHRCBK$%,';SU(E4]&*9K["QN-1O(+&V4&>XD[:ALA5P"SNYP2$C1
M6=R 2%4X!. ="ZN8K2WDN9CB.)=QQ@ELD!57D L[$*HR 21D@<UZYR=NG5S;
M,#>89%I%,P9-R@)Q,J^6747,FF7DQU53II)"4"B<P(D H<!QJ%7I';19Q'."
MJH'0<<.6B@B44W2 &((+)\\ LAU*)\& 3)")P^J83:JIM9RDO1,@VZ[V!24L
M8N:P[2.V<KJ/74S8GLM'JLEG$D^%P+-9!-.0<N)$P*."MQ60335]0"0WRPI&
M1N:']CMTRB:.196-0SFOMSG<-W1WZ82:132*HI+"U#S5$ET"HE64$G[\1(_3
MKD/M9O@NH:=]EVD:E;3ZJX@N]3AC+Q$6RVQNE2[.&BA4%A>FW,KW,T:03+#M
M90W<_97HK6EMJOVI:SI]S'H\(DL]+N717S=RSI;.UHA82S/A6LDNA&EK$\DT
M+SAU<I(.%,0-F4TURY//Y*3G5JPZK=.AWY&Y(JC5^7DV\I9G4$B1 CD9C(+V
M)KKJR2;MPN*T76:O%L$6;9FZ._M#KU(F1(A4TR%33(4I"$(4"D(0H 4I"%*
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M+D(NO2L-(2U0PVWB[;,.'#RL3S]C!W])LE&QH1[4J'T:<ND2SX-Y)^H^!^T
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MD ]QXU0!CLIR0T=,7"N^?=H](S<M'!VSFU5P4'A&JZ2RC=T4L"!CHNRI&1<
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M3A8VPV%,942-DA1E5Q[@?@XM2\U%K.:X?2)8[I)%6*Q-Y9L\R$QYD$ZR&",
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MXWM,@>(J;^ <1V<,G7)C@.J4E"ZFR.6=AI*QR+44GXLXI2LQ8&*(\ 8HCW[
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MDDG$7FH.BR;!B==_7I%5-LZ<L"NXQ8Q@.Q?NDN5 4J5=->O67[_MY IA#]8
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M?<1XJRQ$6/)>UR?9UK/M+=Q-GJT[C25D"RIV0336WP< 5W&.B0LH=&?A5)2
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MI$1_IUXX^??]8_T<\:4K7#N&TG,,KXDN#]W^W>O+H8RW&LMV&SWQ#R7&L6>
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M!SL-B7187&K&I;Y<>A-PE/QT]!F6$W2FD9^FE'/6YU1$I2F<1A&X''I.X+R
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M\/;Z3W?;<?(.Q;.E#F9Z[XZQ-::9([E,/8VVL3^T:GS&3GB\[)2;;.$+C1_
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MO.!-U&"MR\"A/8AOT/9 4;)NG,+YZ;6Q1Q%"]7#V'44%?I3#@%'+(SUB4P\
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M2 @#R)AUCUD4<AS#]65EJ=$RDFNJ9=61?M6SIZHJ(\BH+E= ZQ#"/YH$.0I
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MIIII2FFFNF7Z^US&U7D;99W9FT:P)TE30)Y[Z0>* 8&T;&M0$#.I!V<HD01
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MK&^/WE&R>3:3XW1JV.2H/%9W\P[UMNF%6S@+)?HZ?G4BJ^54:,HA;K*NJD(
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MRB=%RV5*9NZ;*KMER'164*;/?@+=%7LJL6,)9T4JAD(B**3F*<J E$SKDJ8
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M_AEVD<SL\I$:O;QQ;FA254)1F4)*K +F[RX$6=P5U)!]OLB+JJ\YVEB<,PR
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M;-LJ+DK[002=JEMN1P?)R#P.?Z !5GXZIMFX@4J*8@4W1YB?09,>DPE$Y50
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MFS-$W-.RS7*C59JIY-;U>J5@,27.JU95RC%)04>[+#6U#>C$B+O9/Q%@?J
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MW[CN7&!M(;!W9;) &#RQ,YGD)FG53*^U/>H6/V%< HP.?=D9   \\XE3$/B
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M\EG)$SH]M-+WDN4([(4*K(5PT@)EBD&#Y#8(P_8Z@WU0RQ5V,BX25<HR*15
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MP'4 "'7Q];G4)9KRY!W^MN6[:4$SA--50C0SE04!$2FZU$$3'%)-41$1/T$
MQ^1,(\CK$"M6[\582M\C5E9 1[+J&G4#@7GCZS?TRW!N._!%3!_E:E6@QT/
M.TI2Y6X]L<('!1"+0(JR@"G*(&*9ZDNNH]E.DP=D%/3LU _?D%B@ :CUZ,TO
M3V2[@O\ O2QD/''##*TCL"I"G=&BH,C!,C+CD^2 =A.JK^^+6TMDT$3@K)+-
M)"J1J>"WW;N[;?("*Q)Q\'(CJ1ISB'B+%9GZ!D7-D=I)1Z:A#$5+#M%SJ)N!
M >."R+HXK)<E 10;HJ<]*H<Y>O"AHXP>%[A<5T%"+W6\NSH**D$G7'0J";!
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M/.FI*TUX"W2O3#NTC].:$SNQ9W;2-/9G9B69F8VY+$L2222222>2<^J^OOL
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MA+\_O#X\_/Q\_2N9TT_$! 0Y 0$! 0$.P@(#W 0'L(#[#IJE74U]3'^_6?\
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M2]N1 1X#D!  $0#@.P"/MVQZESN)>H >]R@7K*!SF,0#  $ZB]Q+U"(%3YX
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M^#VUW6:RDI4K'6*\0Z2ZGTGCTX62E$DS@86S2*6/\30(L!>A9P^:LRD2.)D
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MC<23%8M4V2NIO%CGE\9*5D+$0 >!Y_'@>/TCQP'Z1UXY >WU@YY[\&#V[>_
M<?=W[^X<AK O<(K=AE#.&%L^PTA?K;B&8JF#<OOK#AXLPQ588U?;P7V18.DT
M&.BII"J72>887<TZN9N/+Q\A.Y'P9(Y"2KL8_LWT:A%+"[;Z-G"(W#8OEK9
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g779657.jpg
<DESCRIPTION>G779657.JPG
<TEXT>
begin 644 g779657.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0E)+7T=,0DQ?-$-?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MUDK6[S6JVRKFG<,!"()2^N;"A-N9PKQBEK@7*QK]?$E5JXKY@T(RFQ2FP*;
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MRE/PD,HC<2C[I+)3(&2-Q=D;SW5YD;^[-[,PM#6FP[ZI<G-Y<E*5M;T"<O\
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ME@:;60[I9Q;6<37LE/0M^(7QVHG=!C/JOCH+O1*S4KX/ACI)74/G X)W, $
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M3NXW(F271YBE4:=$CW'9*S-;^PO+>8!R%V9GI G<VIS1'   :D<$"I.K3&
M!F0<7ER#GRTI22?"W22>?/T/^";SY=SS]$K?#S[GL[GYG_9R\79H!VZ22 <@
MK_@F@'TK*WQ>/D(_XO\ QB "/E$ \FGH:-*4C#PQTDK]X'!.\?\ C+WQ>,0$
M?\7_ (Q !'Z8 /BUP+MTD@1 1K[@F"(<N0C9.^'F'(>8<A]#_JY#UAY!T]#1
MI2D8@\])*#D P'@GAB'(.067OBZ@^D'G Y=G8'9IL^WH[<&?3<%-W4HJ?;K_
M ,VY8-DHJ#7S)TJ$AV!X<L4&,)7V"C;YBH;\F &@Q9D^(R5.#OFXE$AFCP3&
M9WGT:4HT:-&E*-&C1I2C1HT:4HT:-&E*-&C1I2C1HT:4HT:-&E*-&C1I2C1H
MT:4HT:-&E*-&C1I2C1HT:4K#O>#OFHK8['8;*+SQM+)KG;ZX1UA"KJ6M&Z%_
MA)L:_"ZKPFUU?&9,X,R3S'^PKG).G2J#P%.2;F;CGB& X]((X>P@("3N\$!Z
MA =AF[OD(>0?[$NG=98AEVCD'+]SEEC]_N1#G]W5L;AL!15%<R2=M\!G]I.;
M,6V$-%?UHW8O4SE3R^/3;'6=J:4RU>W-B,DQS=DAKP_O;DVQZ+L1+G)I$Y-[
M&T+U9*E(%*XI'!,)FTHL@K;99^$]FV,QPF4NQX8.XWP]*\+#0JFR?8R-Q&D!
M.>@FK>M6(I8#D*D)"F5*278%99YF.570SC#<(&NH DJJ!4M=L,K-"^(),C@$
M8X:>Y9CAR:1M3\VRAL?RHXW4FG:L7INDC,SOR%U%,*]*[M3:X$GX*4"4PK+I
M]XJ,1C;2L4+]OUTN+]6^5GN6Y>/1ITKU^_4_0RH;%:ZQF,U<'TJ9)F.S$);X
MZ&.C<P5FK?)<;'X[,<G-B:)-'3(NKOQ--]E?PY[W01HRM[H6ONV/*@FQ<C61
M+.();6E&Y.6.T#K!FJ1WG3I&VF3,ZZ;($T9<K"4K&VO4#FK688R)1A'9!F@4
MI9C-QA.$!';3D%X,%*W8RW)+$IR*3VHU<-'<HWV#(4JE.V)%1#S+TE(E/SCB
MK2,K*D6"J7&YK$K.TIE69Q#:A+3_  L^*[P8,[25W?EM^MX;A7KU+JOL[];,
MW*A.5SHLCA<06.2V2A2GA16O5Q0DF-*E:E0:>I82"&DXS-"041@W^#;KFJ7T
M19MO&5;:1$MIIVL6'V+1<;1MEAV@CL>M#,2W. QC&%/3I&)>[/\ BK95<56M
MKZ2VJT$@;CWXZ.'IGQ(SXUR+B8$1IE>FL[;#=C[=L+E5M,]@T=$I/4LA>XQ'
M:/K&LKBL>7)IT18*>N9 4W0>YZO3M47;Y"5+W:;RPJ'"SHC6EZ=$"E81P;BX
M\&ZLH$OJRNJ%M^"UHZ/261N4 B7#(W'QZ&N#^@4-*E \K8VU4@E:53H@.8&+
M-O7*$IBA#X$:,$AA);8AP(^L5QC^$01;2N^R*;O F[W!G+CZZWBN&IN6+LM:
MR$HRFXIJ53;"DPD:A"6W$$-N)!KCGB#<02WA_61):?%BT=W\0MYM.)11WK6Q
M8-4]DI)5G5U_SQ9%XK"9X=!ZD17?)WEOC+M(T]@-M<)*_.<U"2U'>.)8:L>8
M\YMF2M*0X15RDEC7OBL0Q;'*T?Z]K0W$NSK5W$ULR&W[;$4VTM>"/;PH3%K9
M4<YS5(^&$)[#0N#5(H!'7%O;9,JC+@6YOS>QJ$ZQO(4JVGI@CA[_ $'=Y[0W
M=Y\4NCTP1P]_H.[SVAN[SXI=-[JV6G6%74)G"I,R(E,KC32_'I(M-T%@QQ,:
MY)<%.9+)-V0E&T2MLP'/N4C\VI4Z-R*#%005@7F :KWO6/E,_'&_#TI21_3!
M'#W^@[O/:&[O/BET>F".'O\ 0=WGM#=WGQ2Z=QWK'RF?CC?AZ.]8^4S\<;\/
M2E)'],$</?Z#N\]H;N\^*71Z8(X>_P!!W>>T-W>?%+IW'>L?*9^.-^'H[UCY
M3/QQOP]*4D?TP1P]_H.[SVAN[SXI='I@CA[_ $'=Y[0W=Y\4NG<=ZQ\IGXXW
MX>CO6/E,_'&_#TI2,)!QZ>&U*V%ZB\G8=U,AC<D:7)@D#"]</_=FYL[VR/*(
M]M=FAU;EE0FI%[:YMZE0B7HE)1B=6D/.3GEYE&9XC;:<<87A V8PMD6L.EKN
MF\:98RMAC.PRKAJ[F'UH:8DXGQE2NC+8WN-*'I4#$J4PN'J3VM(42BS41:.G
M"3WQF;\D[8=UFZ)5MB8BY&125I6PRM,*L2TK"?H<KBC!%:XK*J43,X3!\D4M
MG\FC,>-DJM,]DC"( @6G229^#)$J28(6N/.KD105;[\H995\)ZB;*PM-MALF
M>[:AM9WB[$LJ:"6%8-#IVY1;$-2,/AWT1(RI8P5NY#([2R)M+1*E4*FA3<I)
MQ;V8R0*4L^*\7C@]06*-D%A=+WM%(8S3MNL]KBL=X<&Z1GCZ.Q&E:C<FR:DM
M*&G"$/GE;W)O;W)&[Y$Y+$SB@0KBC,5:-,<54=>\:7A.U*;+3ZNJV_Z[/GLD
M6S&;G0CAO[GHN;+I6XF''+Y'(S&6ED63R]*SE"@Y0XKQ/4F&J%!N6??%!V1F
M4SEQ6*H2S?=+$V^)ENY&UEVE$6E'>;MI-!,G:41F5UK 3SSJR=IPAF$%K3&:
MV8W,[Q<]AIHY6L20L[S))2]-;&6C5+,H-LF[F([JB43I7<5DQ,9"M89-'Z2N
M3DQJ&MDE,U6//F&MBU3"[O"%_?D4>9<9HK?&%>MBBR'2FOY$Q.SNUS9J4XJ5
M@%Z8(X>_T'=Y[0W=Y\4NCTP1P]_H.[SVAN[SXI=.X[UCY3/QQOP]'>L?*9^.
M-^'I2DC^F".'O]!W>>T-W>?%+H],$</?Z#N\]H;N\^*73N.]8^4S\<;\/1WK
M'RF?CC?AZ4I(_I@CA[_0=WGM#=WGQ2Z/3!'#W^@[O/:&[O/BET[CO6/E,_'&
M_#T=ZQ\IGXXWX>E*2/Z8(X>_T'=Y[0W=Y\4NCTP1P]_H.[SVAN[SXI=.X[UC
MY3/QQOP]'>L?*9^.-^'I2DC^F".'O]!W>>T-W>?%+H],$</?Z#N\]H;N\^*7
M3N.]8^4S\<;\/1WK'RF?CC?AZ4I(_I@CA[_0=WGM#=WGQ2Z/3!'#W^@[O/:&
M[O/BET[CO6/E,_'&_#T=ZQ\IGXXWX>E*2/Z8(X>_T'=Y[0W=Y\4NCTP1P]_H
M.[SVAN[SXI=.X[UCY3/QQOP]'>L?*9^.-^'I2DC^F".'O]!W>>T-W>?%+KXJ
MGCR\-=8_M,J5Q[=,JDS"VO;,QR%1P_-V)SVSM,E/95,A;&QT,J#):A;WU1&X
M^>[HTQQ9#B<QM!BO W-N2"4]+O6/E,_'&_#UA=N5WI07:Y<FUZL+!B\J-CFY
M.12Z+*+4;3TQD0J)Q9UU>QF(+[)),/Q<D$:L"Q;0A-:-DE2%&MC'+I/'BY#F
MB:W3)Q1J4JR,\77@XPQKC;'$:&M^+LT.E2*<Q-ICW#&W&LS9&)HVIWM(W2R/
MH&ZCDZ5GD:!-)9$0C>6\I.X)2GUXP3GE Y*P-N,R<=7AD1MWEL@CT2W.L;[/
MGA%(9P\-'#VW6MSG,']MC[1$V][DZU)3Q*A]=T47C[%'$KDYF*5A+$RM+26=
MBA;DA!.:\EXAE81*OI58#U%Y46DA<-W8S>1-:9R:37!"V[7;K<*%);>X/6I1
M-D%Q6"CQ9ZU:"B\S%2P5J1Q-(,;5&>60^UR^6G<[1-?W2W1I_@RN5(71#+*]
MDZHDV45I8L/D#O"+-K&4&H#,D)DFKBP8Y)88_&(A%(:YLJ@Y((IC2<A4I8_I
M@CA[_0=WGM#=WGQ2Z/3!'#W^@[O/:&[O/BET[CO6/E,_'&_#T=ZQ\IGXXWX>
ME*2/Z8(X>_T'=Y[0W=Y\4NCTP1P]_H.[SVAN[SXI=.X[UCY3/QQOP]'>L?*9
M^.-^'I2DC^F".'O]!W>>T-W>?%+H],$</?Z#N\]H;N\^*73N.]8^4S\<;\/1
MWK'RF?CC?AZ4I(_I@CA[_0=WGM#=WGQ2Z/3!'#W^@[O/:&[O/BET[CO6/E,_
M'&_#T=ZQ\IGXXWX>E*2/Z8(X>_T'=Y[0W=Y\4NCTP1P]_H.[SVAN[SXI=.X[
MUCY3/QQOP]'>L?*9^.-^'I2DC^F".'O]!W>>T-W>?%+H],$</?Z#N\]H;N\^
M*73N.]8^4S\<;\/1WK'RF?CC?AZ4I(_I@CA[_0=WGM#=WGQ2Z/3!'#W^@[O/
M:&[O/BET[CO6/E,_'&_#UP)>(!SYFCU@'4:</:(!XL^P.?,1\0<Q\6E*1,LX
M[/#,<90PS=?%=SZV8Q9ID+%&I4KX?&ZY1(8^RRT]B52EI97@VGLU[6W213%X
MV>^HT1Y)#J:P,V:[ _)L1B58J0<3O@@RJ2-\QD>V2RGJ6-2Y2Z-TD<>%]N-4
MOB-Q635^LA4N(<\Z0%9@J/L&4R:;FG=]$S.5R)]?QR\)NZ]2H8ZY\2%HCCA+
MFF7;<+[B;WFR-+[2<7?<86AF-W)9'?T4VR1,HF)J9@0\U*=+;7GT%QC^=O$1
M5(?"I)G+EREOQC,P:6"K91Q X)"MGT_W8S&OYG$<JMGJ^H9]5<HD,)9I%&K8
M;+J;:%41A?,SI.96@,1TU=VQR0SPN49Q@^%+TLG.4),/-"%,I2Y)SQ>^#W9Y
M$M2V12EWV EG;O$WZ8I9KPU]S<I321Y@B7!%#')W3OE+KB5BN+)<1)8#3,.Z
M:\#E7F3O0K%8GWA2\?\ X=R),G1HT6[9*D2DE)DR9-L(W<$)TZ<@O$H@@@@J
MH\"B222L,"RBB\,2RR\<<,,<<,0 +W(>*U1Z264U%YFUX,*.V*_DMB'3J,VS
M4EGU\PL;.;<1S<L9Y#!)JXJ;19U#31<Y6RR35<TRA@JY:IB##82UE=Y2F(2L
M=KF1.LU@</ES_$'VOWF3QQG?W&#R-44;(HDI=T!#AE'I!D@.,0X/K3@HP1O)
M"(]4E2N12I*0K5ED H-4I/?I@CA[_0=WGM#=WGQ2Z/3!'#W^@[O/:&[O/BET
M[CO6/E,_'&_#T=ZQ\IGXXWX>E*2/Z8(X>_T'=Y[0W=Y\4NCTP1P]_H.[SVAN
M[SXI=.X[UCY3/QQOP]'>L?*9^.-^'I2DD!T@CA[B(!WG=YUB =>PW=V =?E'
MT)>K36: O2";E:?A%X5F$I""V"WK'./>?6%RBNY/YE0O#DQG^%H;-&QFD[&=
MYN:E0DD.S:E-4)!3KB,<TBI.:9=[O6/E,_'&_#U^P    #GR#RB.0_='(1$?
MNCI2N=&C1I2C1HT:4HT:-&E*-&C1I2C1HT:4HT:-&E*-&C1I2C1HT:4HT:-&
ME*-&C1I2C1HT:4HT:-&E*X$0#MY_< 1]P!U8C<Q4DCOFD)W4D4M"34T[S9(U
M-HV%$DRHY_:FDB0-+E(6M&*-YC;@F(EK A<H>Z+VA_9'UO9WYP5L+PUO)2%>
MFM7O)V ;5M_<<A43W3U^^S]BKU_<9/$TK%:EM58<VO;JU"R+E9SA4TWA#BYX
M'-HY)\4CJK6HR!RR.(3EGY9&BKV3<!K@6PJ5P^"3&O#HG-["4'I(##I+OUW6
M,4JG"M-F7@I2P^/.NY-(\292FS.*Q/(9$:XTG(TO$S''(S !4K)E]X7!\ABL
M=AQ%[EUG&U%62S;U:<7HFBX15,+F^WV26.DLI-"8M$R'F0MU6RMH<C9:S>B(
MQYO"YX9; EA[LQJ))FSR%JRWN/:>V6OEN35ES-0P..XNGZIJ1R\WP.#6 PL:
M"J7ZTWU&I51"?LS[&I<@D_HHN31)6-\;\,<FA)B+&YLKT<G>FY2!O!%X Q V
M8!\?:"1I8P@JXN^\0W<V7Z$YJKN_,Q=E]WN;Q&!F* +SR(PE7@G(X,,^]!F.
M.0!5"'@'\#ATB\7F[;62]PADW5,"&&2Y#OOW8JXQ+5LK6DML721E_3[D#&E^
M4R5Q4)T# G:EBLYY6GDI6W!2>;@7DI6:,?X:=?0S;^Z5K )>IKJY5(W@\1O<
M/ 8>WQ%_K.9;A?,R2Q)!5T+8W1$Q0Y.#"C0Q^-I2'-6^LQ#<DD)TL<IT8Z2U
MSHQ5PSW_ !K2#PR'[@4E.2""IKVA+;(*4H.&0EA4T_N0C$9:+3BZ^%.<EE1+
ME8:N2Q)CL9GNEXD#I+ G"(7*6M\R3N#VE=<&HMP;>CTSBREM.0QO9I7:S:Y2
M9F<*[CO$#W5/,Q1.\,-5D2YL4L#?N0/<27",*$"Y._I#",3VE0B5D+L"#4QV
M&%?'<!O@6I[%2T^?7AQ-M+F7.2(JO-W[;K"[$6QTK$[(U_20G/<GC)E#*6"=
M0)CJ2UYH< (.'(\ *,'%2LLHOPO8PBE]F%V!822U:@LZ$J:B<89)J\6-UFLE
M$-\8BD:A%%12_H]8K=,8A5\5&%,3\XQZ&LL:+GLJS>I5-LG:2OBUW'SJ.%NQ
MQE2S.M2W ^,[TUWAN'N@T^ZXJOW0H%JG<2V1YJD++FGMZ>JW4@QD(C#6:VOA
M3\*IQ5FNS@^(USD].*T[![/@S]'F+K]7;)F$/+JQ!)3(8NLO/B0[C<:_13 K
M/$LV**YGENC"-IY*4;EB28Q'.>#K@9D&.20!$-?:4<$/@#I)VFJU7'VA+9JQ
MC&3I*Y4<0S<Z5/%4;!D7249 FB&>YH)"H9 CK8Y/PNI+=F@\"MZYT\T>84AY
MY:E/MK",/4)K^)1.1O;3)'J/LJ5K<'R/PQ#7[*XG)>[PQ/;(6TK7-MC:,">]
ME$M2)>I3I\2_ZF9RR[G&O.Z#R9?@9_!U&\J#@R='QW +7)NHYG;;=7,[6A>W
M1+7&_P"W6S Y S.APD-KLIP8MQZWO3:X'8Y%HEN7];JL@_J!F8" ZOSZ7 X0
M/K<K&]N'O0_2 TI3RNZ#R9?@9_!T=T'DR_ S^#I&OI<#A ^MRL;VX>]#](#1
MZ7 X0/K<K&]N'O0_2 TI3RNZ#R9?@9_!T=T'DR_ S^#I&OI<#A ^MRL;VX>]
M#](#1Z7 X0/K<K&]N'O0_2 TI3RNZ#R9?@9_!T=T'DR_ S^#I&OI<#A ^MRL
M;VX>]#](#1Z7 X0/K<K&]N'O0_2 TI6<.[S:)*-S\GJ=Z16VUQF.U=YYG,*P
MG50M=S59*9NZ*8Z?$[$DL'>Y;%F5[EE88LB\:]SD2>0-,<<Y&Y25O:TTI1L;
MTUV_:M@4ECULR&S6#<I-$2)#)MP-F4S"E<#C#HQ5/;VY\I ;;,O4*%2P%]@L
M9+P;,W:OH5(LTJ&(9V')4;@Z2E*CC ,6)CIT=C@ULA*=2\T+-FE.K<6MG2J'
M/>AO'0$*'9\<4S0RM9)RO<*26:XN[LL1MC6A+RR5.+BJ3(D91RD\HK/@OH[/
M!J-=U4?*H::F/J)N0O"QEPWH;Q\G9*TN:IP1-KHH;0W"BM);7!:TNJ1"N,(Q
M2JU38X)TYQAR)5@4I6>C+LR4Y;@RKBL"W'&R(?%GB[WZKJM<ZMK./$Q)9N$2
M-S=837(II%V-N>+#C!#:E7-L<:GMM1.)J9S\UV"^V*]LT>>&JVD*X<+5$KXJ
M._,[FEJR3P4IU?)N2CBS*S#/["?EMBK)0^MSBF5'**_AD[(L%N8K K-E(<66
M3QBF=N[%X0;4]0MF;C@DY\#?@)LLAG41>(HA:955\4">67&7/B#;H$$@KR#B
ME)78S.<LJK<R4Y1&*9(E!"O&12!*W,XI3BE'FSO1I>>=4,O  X(TD5M*".U(
M^/RU^B2"?,B9EWQ[NG4YX@SJ<6G:YBUX(-Q:@5\7<SSBBFY_2]]:EQAF.*16
M</, 4I_ 9   'R8\@ .8XYB(\O&(]SUB/CUSW0>3+\#/X.D:^EP.$#ZW*QO;
MA[T/T@-'I<#A ^MRL;VX>]#](#2E/*[H/)E^!G\'1W0>3+\#/X.D:^EP.$#Z
MW*QO;A[T/T@-'I<#A ^MRL;VX>]#](#2E/*[H/)E^!G\'1W0>3+\#/X.D:^E
MP.$#ZW*QO;A[T/T@-'I<#A ^MRL;VX>]#](#2E/*[H/)E^!G\'1W0>3+\#/X
M.D:^EP.$#ZW*QO;A[T/T@-'I<#A ^MRL;VX>]#](#2E/*[H/)E^!G\'1W0>3
M+\#/X.D:^EP.$#ZW*QO;A[T/T@-'I<#A ^MRL;VX>]#](#2E/*[H/)E^!G\'
M1W0>3+\#/X.D:^EP.$#ZW*QO;A[T/T@-'I<#A ^MRL;VX>]#](#2E/*[H/)E
M^!G\'1W0>3+\#/X.D:^EP.$#ZW*QO;A[T/T@-'I<#A ^MRL;VX>]#](#2E/*
M[H/)E^!G\'6,]Y[6:SW%2!N56JCSDL."EKWHV30!6F_Y&ED2OI75*J0YKEQ6
M9+FWKV@:J;<F54V&D*4BQ?DZ)U*5Q;&Y06KQWZ.OP;(^TNC\_4)-F5C9&Y:[
MO+R[;T-XS:U-+4VIC5KBYN;BMW"D(T#>@1DG*EJU6>2F2IBC3SS2RB\\PLX5
MP8.CVGQ6(SHE-%#H38$F\Y<#F)7$=W(&16;3'S88WA$XC(<-T(M$DDN2\HU$
M#"S+%KJ*LHU-YD[]AE@"E9AQ7A'05'2;%1ECWM;-PQL9?5+K93U,TC$DE5N0
MRIKAL[<(WP>7/L=):UZ;*7W79&<]L"5LIZ)\DJYB1)N2$I0:85FIM:VJ0O:4
MAM^,5L\R ZO[-N:272R0Y]5N+UC7SU.F*,%S]I9I$\N+K('IKED]9Y!9JLZ0
M+53DGDTXD96*LY"*3$E1=D\##@,4UE'L;?B"6JLI<M4MT4QLCB!;I(-E)G!'
MYD!6@CX2C<NU"]+4OF]#YH2MOFD\CS8E[Z7CYH)[OTIN!%P)UILF(10 U:?"
MYJS5O,2$6_;=8M/BEAR)8TM[!!)*0EW)'',4R>US\QI&J,.F"1[<%#RUDI$)
MN:]-B8I4A+N@\F7X&?P='=!Y,OP,_@Z1KZ7 X0/K<K&]N'O0_2 T>EP.$#ZW
M*QO;A[T/T@-*4\KN@\F7X&?P='=!Y,OP,_@Z1KZ7 X0/K<K&]N'O0_2 T>EP
M.$#ZW*QO;A[T/T@-*4\KN@\F7X&?P='=!Y,OP,_@Z1KZ7 X0/K<K&]N'O0_2
M T>EP.$#ZW*QO;A[T/T@-*4\KN@\F7X&?P='=!Y,OP,_@Z1KZ7 X0/K<K&]N
M'O0_2 T>EP.$#ZW*QO;A[T/T@-*4\KN@\F7X&?P='=!Y,OP,_@Z1KZ7 X0/K
M<K&]N'O0_2 T>EP.$#ZW*QO;A[T/T@-*4\KN@\F7X&?P='=!Y,OP,_@Z1KZ7
M X0/K<K&]N'O0_2 T>EP.$#ZW*QO;A[T/T@-*4\KN@\F7X&?P=<#D AR^3#K
M >K#+L 0$0^5[! .0_2$=(V]+@<('UN5C>W#WH?I :/2X'"!];E8WMP]Z'Z0
M&E*O)&N&K,FR*V^S/NYD]ZF=G2Z$6J7=Z6CXLW7?Z,54W2V794\MGLZ<I9)
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MU*I4I/S+(3ITY)>9QYYQF!116&9AF>.&.60?T D@ $DG8 <R2>\ /I)K^$@
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MD*MJ\Z\R?XAF!KND;VM.K\V&,62_#O:$CO!:G%/EWS,K(W/*P>S[N/NAI2?
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MTF6\T>*Y4EVK4D0>=@<K4F$S.=%&+#R4X]R:JS+;,,E!O>RL"@-.RR, K''
M,PQQ  [5_P"F[I;_ * L_P#CN&__ +:XN.R.Z)R0!GKK<D #N1E.^=A]-K_C
M_?RF?:P2XGGJ>F\SV.EH_FVJUEO6LI4SBO(),UB0A KEL,BTF5(DQAAR=&H?
MV%O=STI!IP8FFDIS5N1)1AN(&9EX8Y9@&0B 8D<3SU/3>9['2T?S;5:Y9IF)
MX=6Z>AD&TD6HL3&X!! 9,E;JPW&X.Q!Y@[&NH:GE2;2.H)HSO'+IW*2H2""4
MDQT[*2#L1NI!V(!'>-:T[/Y?+Z[+W1U^,OE<_K,_R!U^\_E\OKLO='7XR^5S
M^LS_ "!U<+5/B]\?E'[:V=6P7YQS9[[&*B_>UCFJNW??.G;G_8\77[VDGU2.
MP7YQS9[[&*B_>UCFJNW??.G;G_8\77[VDGU4#=^.]U[53?%VJWNT\1;7V3A^
M#K6M A-+3&=09^F[$?&101AJD;@<TKI&D1R9T;X%%&^739>T,G>SC#$$:CC@
MA7JEKJH9TCDH5%LD=.>Y"!C3A^GNGI7%ZX@MIO62!)'[!R//BJ429'DXN"%'
M(9'&CEXJAC>,4*+%UB;W@6@"5&/F:1-BO\$8I#.^X_0JZ\'>K(K*6-@BL45.
M,SBTGB:Z4K_/&4\A%IY%DL:DD<<4;5(&V.R]C\R$%NT=:YJROZ*(RT!ES$00
M]8E'%>Y?>[NLK9?533$XQ&6!Z51\IW4M2R9KE2YGBDLD4QBS2"&1RM[8$*AI
M=Y,KP429K9T,H?6]&B1O+HI$]^/?;6))-3=OE8X+=K 96UV?BA1VQA25;O<F
M>5U,9:WEB(A::>>*XMS';03Q7,-5J1Z9-J6DGN%OCC;G= LTBC)B:!K8@=7$
MC!PMS%(#,D,,4EO,#<2Q2PS; [A'>IN;/?M-LW])O&LY[&_O F_V(2?^@G#6
M#'".]3<V>_:;9OZ3>-9SV-_>!-_L0D_]!.&JJ]7^/>I_:S,_%[BK4=+>(NF_
M93#?"+:M4<3^PIQ\8$$" ^,![S@',/(/+JYAU\A$.P==N/+F'( #K#L  Y=?
MBY=@?2#JUU$_L"?^#I_Y'#7;CVA]4/=U;RO>'Y!^RJAG_';\YOVFMAEP,O4O
MMM/U+9]^JPM-L'L^[C[H:4GP,O4OMM/U+9]^JPM-KR[ ^NP_+QU49TD>4/77
MMAJ7XS>5;ET;^3S0OL?IKX-9UJ@IPL1>?69!YN0\PF$L ?Z]2]0A)'3F'[-V
M@/4(>(>8:I;S8B_[\A_^-2__ %=*[LG''T1K#^1#^_\ G7B#]]SUJBN0>0/O
M!JQ*UZ3I%M;9>XR'AMX1OV^PWVC4;_-*A#=] \#W5RYU/*.*XF.W<A#MO(W+
MPESVY_EV^C?EM4^CQFE'<.9@S),+-P]&6Y@[LHPLW#F$B1@(=V7EECS >H0Y
M\P'M -/+,^5#Z\O^4QU&[Z*H !PG(L   !Z/^X+LZO\ M8AU)$,^5#Z\O^4Q
MU79TB7IR.N]77YC$)O-09.X,0;C$?6W4C\''PIQ<.^W%PKOW]AWJG3HC%C":
M1TYB!.;D8[$6-H)S'U1FZB!(^L,8>3@XN'?AXWX=]N([;UIA-\88_JU]XOR.
M _VUNX[K'#$1^;/-NT>77K%SN<?W&'X&/^S64F^+Y]?>+[*W<=[\\VUBYJ6^
M, [FX[E_F-I]Q'_V'Z*XS>_/+OTF?[UZV.'1">0<.&Z.0 ']N9874   ?,AI
M#Q  !J5>/9]W'W0U%0Z(3ZG#='LS+"]Z&D-2KQ[/NX^Z&HAZ]\<=0>L)/L)7
M=--^ L9Z,OVFK3@\3;U1[?U[,O<I[[LKU@]K.'B;>J/;^O9E[E/?=E>L'M2Y
MP_@G%^KK+W:*N&W_ ,^O/29_O&J?KT.+YW;>G]OVNO>H*U,KU#4Z'%\[MO3^
MW[77O4%:F5ZB;TB^.N?])A]SMJ[AIGP#B_1A]MZ-&C1K2J]VNH\[%.2:?F C
M@248;D&( .0XEX99Y  "( (B&(@ "(!SY<Q .O4=@WI'FPXHTTK*G-R(Y%&F
ME9"$!JP0'(HS(O(0$;0 1 <L1$!$ $0Y<P >K4A]R <F]:&(#D(I%0 &("(B
M(IS    .8B(B(  !UB(\@Z]:LI;1=VY+%@A35N\A6*Q ?0MGX@("I-$! 0C@
M@(" @(#XPZ]2)Z ^CO1NOCJG\+9)X^Y7<7M#J,B,?OVZ<IVSQ;@];MVI;[=[
MJ^?\NH[=/?2'K/08TL=(Q0R=U#F>W^MQIR&W:7<KM7AV_@=^VI]_Y>P/\2IU
MNT#C0[4-XM]1:@JMK>Z8[-)4URIT;G>91*!-,?3IXHPJI Y%JUK'.WMS*-4(
M49Q23$EM/+,4#@6?F07D)@-7<;3K!I;IF[NMB0-M:*Z=D[#83HX2Z/(VV"OB
MM$RN25FF2Y2XEI8PZJ&Z11Y>0W/AJ%8:B?65463D0Z(##X-/ QJNSXOQ)J:>
M9-6MB1QG3Q&Y2U#M(('+F-J(S4UH]DIRSW)V94:$G-0=EB21@:?AD<;EB44&
M9F6.(RH;[V6MUE;T:*M).R/8U4_'>?#=#%VQ0R)H#:=@[<L&E^V>2.S&<\H'
MAZ>:ZEK_ "-R9U#1F64^F1" (9V#PT5]"43;K'3?H_3>B-86V'TL\KXV3!65
M\YFO!?/VU-=Y"&4=< -E$=O#M'M\GFW\:MHZ$=7ZDUKH^XS&J4C3)1YR\LD6
M*R-@O:L-GCY8OW \R>LGFWD/XPV7^+3,/ZGUC\AVCS'J[>ZY9=?E#,.67DR#
MD/6&N>>(=?/$ Z^OF !V]?TOEA^^/E'4<"KJ2XE\EE\Y0V',]S,4"23Z -EP
M.3&^&Q)C?6X_?/7KPZR.F9VHW46.4PH&3:RUSUM4&TQ1=",;A6DK(8I&U9VL
MQ,:-MNE+*DXB#6HNN)9N^X][IF@IW%HO5J^N[L;\;JW0;>[EW"1:[+=<F65R
M:8H)*3:&WNE&U)MKAKY*Y'%IZ\MV-CN4&ER:7/K)(5O':[#3[0[@>L.Y'KY\
M^H>L1$.?U1'F'/M$0Y>+0 8 /( Q >KJ#D ^/EU?5$>7U1Y:CL1G+>VP;@]H
MNWQ1:-RMS%N-4VK+9O&+$M-')[QV^[8=L&Z!3=]4O<X7Q]Q?3U$LO6KYJU;2
M[(E0OKX[*$!D0:)3-Y)-6%S=QOEN2:M[ROB$5K*:[B&XHBEH?9.V8%[G#K!5
MN50R>J'0):RWJK>(*FNFOH4RC'ELK0XR5DE])WW9\F3,[3,(#)8&TQXA.F4I
MVG,OF \\.?,  ?D>?/F(  #Y>8B >/GS -4L1.8,K0LCHFE\44MTC><X['7
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M4[ G8'2++ICZ,LE>6F/L=88RYO;ZY@L[2W070>>YN9$A@B3BME7BDED1%XF
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MLFS%2<H\A,8>5@H4@8*<C,S#$X\"0#(X22AR#,T"L<L<C1+QR K'+'(SN0R
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MP-16>E _WE[-OLPNO\VH%J"70%Y7=&^DY3X%E*G=T\^2/6'HN+\_^G,7]=(
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M3A)7B],*SS"YII_M_+)4]X3J.XP4W-$DYX=Z4E'$Y=V3GGASRP$<>?=8B&0
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M,](,]4>EOVGZ;_HI]U/D[O#]UC^$'^W4!KI!@A^N/2SK#YC]-^,/_9+X/N"
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M=P_WX*XTX9JRQ\&-_P EC^T4?C#QI2>7CTGCI!^6(\''?+RR ?['</[! ?\
M'!6^H;:;\8L!ZZQ7OT%=YR/@V^]!NO=WK4]F?LAGU^7Y0Z\BS]HK_P#R]?\
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MLQ!R"PC-Q%(4#%5+!=N(JI.^PVQA]*L;!/7!<0?VS+-\56LF:]X%4!J6(M,
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M0QM-98^TM96C8JS1F2"&-RA9$8H6X244D;J-EK_K..7^=0XRG4("'/?'S#F
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MH\>^)6HY4H;$[F8DJL,E13>>N6FI,,QY$YJU X_LN7.Y;=Q"=T+Y*DK:ABU
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M*U/+*XH'AG=$.X.-IUS8[-2PEP;')"HPJ;NTZUO7IDZQ&HP$,R%)!1N AG@
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-LR.6#W[5R]&C2E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g964339.jpg
<DESCRIPTION>G964339.JPG
<TEXT>
begin 644 g964339.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?2%5-7T-43%\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MB\U0>*9PEI%2M/ ?!Z\QU7*O.SET3J552AV& ]DU9=*;+6A79&%]NP$H6[,
M(G"!=JC4NN#^Q[3,@K7TD->%R!$>>BH_[=DN3RB<9HD[>U_D>K[JYV-ZM]:%
MH'+;'FW8JP:^BLB>QAT-8"*.B=J3Q&K:YG]AK%=,;JL9U8N2<:AX 5\1D]^%
M9J2;X38Q=^IFQO&?7&,_GC&?Z^407+X#.NLRF-;S*E[M[.]>E87:G5V<&8[&
M+VM*4Q>0QKJZ<-F(D!:-I3+WI\5+4LR61[1JQ2<EDA"&DI :*#A3G<BNWS>_
MC'IC&/\ M_1C]F/RQ^S'MQ$YXXXXB....(CCCCB(XXXXB....(CCCCB(XXXX
MB....(CCCCB(XSG&,>N?ICCD$?(\/[.R#JO+H;U/@QF=V'/9%!H/*F,5L:$5
M7.A5*R24,&=WF*XF5AJ-XH'L;]&F) %A!,BZ;[@9"<92=GEP\ H,G*).WXL>
MGK[^F?\ O<^OO_WOI\7\OM[8]\^W&,XSCU_9_'ZX_KQGTSC^3/-.^,+=B7'B
M(Z)]8K>ZQ=PJ^#4_:G5J4]XX'FM+CECB5]"<]C;4B4WB"96N!I:=3\HT! X5
M*+7HV,-R%K,*@W;DY!'2D?,K-G?N2)]Y9NEOAQ@?9..=J,T0(I8'JA^]PM_K
M&PL>\EH!-^\9V/TZS+7#9EA.BM?.!W6RP*PCN(-*ZLE,AAK*.;@"SEK(UU7$
M=1-P7CGCKG.<>_O^MMC^C&V<8_JQ[?Y_?GEQ$<<<<1''''$1QQQQ$<<<<1''
M''$1QQQQ$<<<<1'(IWC+NY &6C6?7VE*)L6%JA&JY,Y9=[RVM#[8_N_>IO!S
M<"#IZ=LUAB(Y-@X0*9,9<+N'#I#<:EJU3V<RLXYRMK:U/%;;:3V#YU>OS'7\
M?Y:[4Z/\_I[_ .")QOJ:ZLHE]V8D@^VCU>P='OQ'NJN3H_S^COK]B)2Y0=^^
M9*6&+;:V3T\Z]"6L=G"PJ**2NUI-5;)P,T4?:JIQ8B%CMO[V0#0238JH31TS
MA*;S9SC#<8YW5<M@]M==/[ )06-/[2CL9B5ANQ:*DJCD.DS^9Q<08WW4U4:!
MY.3CT5?F&6NGR=\.W,?&;XWW42PBIHEJNKW?&,8]<XQC&<^^<XQC'KG\\_GS
MGD?)DLRKXONU[/IAWI-!/ZG+ ]U45-VH_0.V*^/[*/KJ)@PVXE\;>2W[^@X[
MV',Q_587#=TYJ7+*#X#R9E"_04?76G[<_EK[G-)1W#>(RJT*AH:V)]7*O2JY
M5:%B Z/5U4E&]YZ3ZQ]H9% IE+HA,15GI651LYD/8E"167&';:O$FCY$(.?@
MF*2R?Q;1\JO<*"0LX;G]\V1&: @#;L\5ZT]EX+6%#U_8WDG4K>Y(A&X#'(Z_
MNJG9=1;:2AZS,2,\ AE>5Y!"G<@D):O:7)1@4V)Z*[C7P:XSG.,>F<_7.,YQ
MG/Y>N<9QG/I^SUSGTQ[8],<\=DD]\8QMKC;TSC;'Q>NV<;:[?%KMZY]<_%IM
MCUTV_A:9]],ZYY-EC-:2?^2J4Q.:>7V+69W-D4 C_7Z%=39Q1GZ'Z,J\W<U5
MKSIJ['694L2B4O 3^,S^S%; *UU6TND5DZF(Y Y).4R!(9 0PQ95CU'J[Y'.
MX,B[8=$*8NV>:6@'GW7OK9DZ8ZU/*=WBU^6C:$*[$D+SNU^#(5%*C,YHJAI5
M5$;K^P)'1UFT@.JB>D&9F1!9<$LJ*1,5M%_#C\]O^=M_U\XRGIG?53.N,[ZZ
MYUUWS[[8UVSKMMK\6??X=LZZYVU]?3;.NF=L9SIKG")Y:Y]==<^^/77&?3/M
MG'KCU]\8_;^?\?.>..(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XY^
M+E=-JW6<K;8T2024654SKMMA--+39113.NOKMMC337;?.NN,[;8Q\.N,[9QC
M.NYXUO,<X[C=B^\S*4SVM=:QAM?4Q:G6FJV80C#)_& $MF]TURM!+)/29LV7
M.VW+7$0J21D(VT:;(Q4W;@J 1_0^^$D7*B)L4\<UB^AOE*[OSG"IF=5B<[Q*
MW#TCZB]ZHE7/6N'U!5LEHIYV:MR\*XD-&Z&K$M6+1>8PN!":P#G!!^7R7:U'
M;Y:2*$6Y,'\:\4NGZ =P&G>_JO!.S;.MC]1:S.26[%W5=2@T)D)^,DZCN&>4
M^6:%2P))(0X>+DX*[>KI#LN&;)1SLQ;ORB+;0F[1)F\<<<1''''$1QQQQ$<>
MF/RQQQQ$<<<<1''''$1QQQQ$<<<<1','W1V6Z_==$8\O>URUO4:4L5)(1G>P
M9:)C&#RH=-HJ5T$X)N$=GV1R;YEL]^1C?#?#MM\W.N5T\;9PY\HJ""G-$4S(
M@86T;[;[H:$Q[,AJCNIKC7?9+5X@MJEMOKC&N^VF-<[:XQC;.<8].>+!8484
MLBV?7BUB-8@^QWY(KUL>U[ Z=>CT3V!T>5PN-;#.]27?7@UU;VUC]0\O*M+*
M6;M>P.K%Z8@GL J:[0OEX\=1R<2:#(=HZY'N(PV0<;RD^\=1^O#^RBFB3EK#
M[ +MFL6EKL>HJGAX@$(.LXURJLUV=(-'JK:=-96I6]SPT78=3SF+6+!C6[](
M5+(::8GP!!46^<#"*34F/56;*JL2#5PS=IZ[_&@Y1414UUWUSCG2P767KS&)
MY*[/CU)U<%L*<H(-I?,1T'CK:02)!OLAOHF4(:,/F.-=E&K99?VURY6;-UG.
M5E44]]<S,A[$:T38#F;5@R1QMJDT9-D&C9+7??;??";=NFDBGC???;;;X--?
MBVVVVS^MG.<Q<B\BI;\VW'8.[/ 9J+JSX^?^(LUNBP=BOZ=0G^W73D ]P\2<
MLI<\C?Q]J^5OK7'FT4L%]G^$L]VJX$BKL6**_P#<CQ<@'RJR[$^7[K7UKL_L
MQ4\RB%SG9%U?HO\ 3?*7\4B\97C<VV:.*PS(JIKDZ>F0!D9MN&@[LJ"82V-E
MM@0T/$;%CQK8VJGJ338=5F?F.J2'BSL>?4;=(OL-#Y_94'L'K=-I%UVKJ3U>
M,J* 5U:DYM2R[>EEXM>M<3IM" V_4Y./V$K<;P=*C-DQ.)!FZTC4.,@7T[F\
M)70N]2UCRZ;P>8IV9;4YM:;V#;T>GA0#:4F3MX#K&9!!R,M:M]UEJW#@V$78
MP^$[-<BXSB#P]=EG=R(W6=^Q,?#1U0F<'> G4G[#B[+.2FTY7,^R0V[#;GL+
M8+F[Z_C=3VT"GDSD(TZ E$(FM8PJ$0=S 7\.S#0(>%1)U$ D=.1\<62FRQF6
MAOD-CTDMJ:T=#>O=^RRS8QU0J_MG'X\,TIM!E9L7M@[O&0</KN8$+>;0(Q(@
MQY)89)I*\E0VKVBK5ZX#3P^/:*/<X,H3S.=<.Q-B=7ZJA<5EP*=]D("I8:L9
ML2;T+ #M?B-YE:M=BV6H*26XR-W,6.2RF)^Y$MNO0ZT4G$"%-;(W73BYL$J2
M[@<\1'7 P5D3]I879J+L9%T\BG1/,>B-ZFX^$"]<8:(#"@L1CVK43DH*?XW%
MO2CX_H55)$2<GEBKS=5H=<,M/H0OQ)]7H=-J,G>YBY903H@=68\.,E%C:NXY
M-/T!R">R/K.[L,&)CP5H;<=9WEFS9I2Z(C$=' Q)A$7(&$H: X^F+1+0,9]<
M8S^>,9_9GZ_QXSG&?Z,YQ^6><\XQC&,8QCVQC&,8Q_%CVQSGB(XXXXB....(
MCCCCB(XXXXB....(CCCCB)QG.,>GKZ^_Y:[9_K],9]/Z><_]OR_S\U6_W224
MC"4UZ% [&(5,E695#M60/BNQ<G[@H=?2)X,#II*+K2F$=)6>UN&K"89*&%*Z
MEI4@C!HN,5G00H->GIC&GXK8.Z8X%8ZA]7, L1+ 3'7FF\!L0'%D8@N!.*^
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M7ZCG1GG1;;5Q\B?F_)W%U?BMH]6XV=I\5"[@BV7DCMIWO"K2E4_8N%MDH/1
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M[\OK/4A[KB)ZC2#K2U:5,!G,]>E;IC<S=OZ,,US([M9;';6D$\;0.$2*5FS
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MJZX=WZBZ:]ZNHU80@Y<BE:L0CVCKC<S=^$5M>?Z02+G">) Q9BB 9L[9FEC
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M@&U4=LQ7V5J\<I*V*PBOX)64:90NMX7$Z^B S9WN-BL'C@:)1P=N_=+/7V[
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MM(.0R/EV+"/PZ!8=UY6T_8!+\L6&45)7Y^7M9-K<$JJVA)*51;" AROT3^6
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MY(8KY$8U !4@=2MJX !(Z2"GJ0DF7C*1#YS74BTW4!@-QJ@LDB7:%K7K #%
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ML$!D OX[U"-FE8S7@&)M@^_6&INL-7275H $F\CG#V[U>N*TNEQC11B1&G;
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M$:+ ]C3%:-NKERQ:;C*GE-FDZIC$CDB<[BL;!PG642(&:<19O,S -63"1RI
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MK'F=,U-+,JGP\7<^*FRRQ@&E.T]\8U.43UYG"M$#.T<WDM<P.8FJQJ4'V_[
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M)HX4QM)Q8]/([,G'XZGOU[M-&/+16K/9=ITVI3156BAF=[+75$559F9@%!)
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M=B[G\61_X/O-NB0_\*1@$ZI*Z0[:KNJ-$S"/7.FC.J3ZS]&K9\?1B!OR=>Q
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MPW#]DHR:M'T\CTMFNS<%HV&;+279=1'+]5QA*2_]Q2\2G_<Y^GG_ )BH3_\
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M&>%-6C8J58 S+T>Q5</&HHBX139K_%BMFUO.C4UCD)L"$S"0UN=3B]B HM+
M$A,P.2K--7Z4>F8L00>/HJ<58;IO4Q!U!@04:;Z.=6^4=L;\[QQ$U-+(:>1'
M?RZ4-8=_];H18$C0,]-@=0Q" Q'L]==&5;5Y\I< /N9<-5]JF;FF*KIF<58T
M>1666&"O:FR4KN)@0KR"PO8@(%)NWNV [V>)L7.P]!LX?Z-5\LF[M=5FT6=Z
MH[Y:I.'*3=XLV;JK83T66T:N5$$MMU-4%]],);^UG77.?7./?V_D]O?&<X^F
M<XS],YQZX_9Z<YXB:I_D!JGL=..T?1"\[DH6*6EVT@9.'1F*]3*E@?=^[>M3
MZ/ENV,#D!V] G=>&L^MU<4G:-05X ?260 NQ$)EL+=!4&Z*0,\B=8:-]J[7X
MO3^#C&?CV]LYS_!^//ZWK[^^=?UL8^GKGT]L?3G.,9]/7W]/V>N?3^G'TS]/
M;UQGT_9Z<YXB:KWF6COEXMNN(L,9=2QLQK6M[/#VL%'=,^R+F2R:23:+WW3S
M2D-K6C<^K>JY\^%!(.I9TBD<3KH?,(:-F!.&S2621.-5R337VDA:[IR.9.7S
M%08\<-D7#L:LLW<JCW*Z>JSABHX:J*M7&[-;?=MLX;**-U\I960WW1WTVS[_
M !Q$<<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1'''
M'$2!'<J8VBT@]Y1<S#Y+#>NV>ODM*%.QE,6Q-=.P8&;*(.&K:*P*GZXJ61SS
M#IS\3/1M.HA,E)"QR^<9%1]L[:IE$-9)_85P2SKIX-W\?QVZ.]M*_P!^JD>M
MN)/ 7D3AETG<1"W(G'NP(H&2> FO5+)A$1M*E+_EW94864/T^R39QT_@::"&
M4-V/./7'IGU]_P LYQG^O&<9Q_1GGC\&OMZ_%GT]?;.^^<9]?]]C.WIM_)MZ
M^G[.(D>KDEUN@C48#Q:MQQ>I#8::[W!;36TW48GU1BV A=4>9@-:L*PF[RS3
M3C3[2NS9M3L=<C7;1IE!J<66T9[:>LHG3V8^+>,U+(#?DL<WXGWB[31*F[R*
M!O)2F:H""2.\3D^K7M3=C.N8^-LR[D8/07X?(T]$B\<FZ)N?R9I%W(F*_P"O
M4M%-Y+_M^7^;GA\&/3T]=_S_ ,)OZ_U_%Z_T?3B)'V<S2WP520R14)6XF^)2
M3WA>B@BR+&?4,HO%"@S18G+B!1_6TX(-Y"W3^QN5H>]B@QVX=OG;1R^$+L5$
M]];HO8<N^XOW15 4+4[_ *HYT]%3+JW+-8QVO3FKTSK24:B1F+4+*4*X0=,(
MAMVR>J5Q^'*J3',T()JL1&J)5PW7F&-LK_M^?^?GC\&/?WV]_K^OO^?K[?K>
MW]'I[>WT]N(E>'3^T[8/>-#K9/X+"#5IWB/ZUU &*0>ZS,UHD](;4B<5C<.L
ML?.))8-?'Y='";.4BI4NY/%(,:UD+MEH^8;OAQEJ9WHM[EV?W)8]J?)V%Z[D
M^WB%P6#XEX;O7\,!LK[G%5USW!C9R8RBW*WZSSE6NHU6&LKCM(;QQ_%#T)1&
MF)Q,B>5 2[RQWSV/C=N+&/3'ICU_ISG.?Z\YSG/].><9UQZ^N?BSG/[/BWSK
M]/R]?AQ_%[8]_I[\1*</#@W)(P?MJM"-KBSU >=L"KGI'I>*UT*RS-+;4O3N
MLP6!8[";;V\C G-[ZVFI'])7G7"A3\2.PJ7W&Y8++XK\PSSL++*@?!9(+"5)
MUW@78VC3;\F$M/M3('W<.M78N5,)K0]B >FE#2B]:%#/9$2!FA)X YGHF9'X
MB!A\B4!#Y;CTOCQ\.N,XQG'ZO\+UV]<X]OKMG.<Y^G[=L_3'Y8Y\PP:# ARI
M4Z6'!A:*K5)8D3(-AC%)5Z\0'LTU7KM=NW3W=OG39DVTW5UV<.W"#9+&ZRR:
M>R)!?Q8C.Q(;QX]0AO;#>6[]@&U)13%B:SY5XO/&SU7#I<(QG*I15<SO-!T4
M4 ,)7D\JI(?OYL_Q(-OOK#_'.A^4&:]H ?63LQ'Z2IR?2>.D^I=X.4+3H.U%
M1/9B)6FI$S["%!Z@J-O7Q1W+2VY%0035D0RP8^<$#\EE(Z$+R$>*9DK+7C]B
M-:.'Q!VV8,6:>RKEX\72:-6Z6F<8W46<N=TD$D]<YQC9113737.?3;;&<\]5
MT=!LRHL"\,"VIHXB3<!A#@BS0*%FX75KN77&#U5]'C]$5J^9;$56B*VC##QK
MLZV1PX1SNB4?_N?_ %LIMU-N(=/LRE^&:=J+"5J^0*J]AM*?+UX^@]:.6R77
M 9VW_P#UE@M2!I-^)1;UC:*Y=5>T4K$)1@X[C3T>P%VMW>ZM1VI#(1":H!V%
M +%(E8?=4E>W:6IZ15E 3#) :^E,,0 PT\;F1_5F_*[M1PB55V4&N&#5V/E#
M5XNBY995'S&($I&?AHR41XC+8HW$NY/&&)P:_D<=:GD57 -R>"-W:Q8.V,((
M+K"ER;5JD011549[K)I[[8\Y5,(I!@KJ23231^(QYDLQ;NSLH-#(\%:N";YN
M,'(."QATR'HK/R+MJP9)*N=-W3UR@T0U4<+)I[(E0/AGI:0PV%]H+N<)W]$J
MR[ =C)+MUPIWL!9][6/*:[ZZ4NDK4L"D3U/L1*I;8\;D5XFPLRNHR-*/T<HA
M9A$!B*&& AAMFT2Z)-<45BPTA2-6Q6VY6XE($<2CDPM3>H10Z*/%EM3TETDR
M< L=1\]"I:(;MX[H!0W+X75QH68;-\?.RYC&,8QC'T_CSG/U]_KG.<Y_KYSQ
M$U?_  L2SMB^[F]G1?9.LIB5GAV-7"<[ 7+)D^V8=6NK4C?:Z6!J=H'=*V9H
M2ZSSB.GJ#+"9[4)KK! H0.AU5A! Z6;&G4I1).]E*?%)B%A4I+5]%1<YG X&
M1>12'FI5^!Q,E/(-]]QH4C,/N&4_AIF0<8T;KF?PX;^P:;97^[7?P_*V[;C7
M&,YSCU]_SSG.,?R8SG.-<?GC7&,9YSQ$UIHL6N=GYL*_DQ\'8=@3&T@<>2M^
MC DC[S-JNZ#@!/5DDU=SH39V%8%T1[&U[8LN9L0^?OBK$Y_I8\P](J\9R6%F
M6;/9/>*.TF3E5DV3=/4VJZC5FLY^R).'6B.^Z#95W\ES]F366QHENY^SK_)U
MWRK\E7X/E[>S\./7XO?U_G;>G]&OK\.,_P >,>O\?.>(FL)WHGWE:E?:+HE)
MB_46[*_IVN>S'55T3&]5NRD!LNO9>?G-TE1EN-[O67>TO/C<4BU0A08^.-"]
M9MZA#E9I-CD\F"66,67QL\Z_P<?7VQZ>_P"W&/;&?;.?X6,>OI]<>OIGW]<<
MYSC&?K_[<?T9]/KC^+/MG\N<\1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''
M''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$1R+'>>$2JR^E'<"N8,(=R";3[
MJWV#A4/ L,:[/C<IE51S #'A#+7?;33+LD7(,V3?&V^FN5E],;;:XSG.)3\9
MQC.,XSCUQGVSC/TSC\L\1-12U+,\M$RBO6X/UJH_OQUYTKSJA4=4TM#'-?U6
M!BISO+")U!@\_+]Q-'YJ;IM.J+REFZ:<//DC :/$E=;%USJQL)M#&R^8_%7W
M"N+L=Y0.U8>T.Q-HEXL+6[@-:<I7\1")C4DUA]:]QGE6CK'8AHL$01HE.FX@
M"C-6QN,3=[I);D<R$_:>'Y%S]M:);0N$T\>GIIICT]\>FNOMGUQGUQ[>WOC&
M?Y<8_+G6@\(AL>-2.1@8I&@D@F#EL\EAP0!$C#$G=LD,-F;J1%&+-!\<<M&V
M,-VRY5P[5;H_WI+?1/\ 5XB:,P[J_P!_>XG3[KS&:.KAF4L#HNMWS[.'9U)+
M'/5BX(^4-#R!VPZC3$*R8P.7:V=:E>!ZXGVA>$S+->Q$@P["1UR^L =HFW:H
MS7ZZ1;N'7_>VYK/F5:=LZ2ZQ]A>TO9/LSVMB5O@JZ:],6W363=$H,R)%9637
M9NY@V[+@;XC(R&ZCVIINT=0:-O7J0=>(ZRXEC;=9C1X[#G5@Q9LL/7CD@\PT
M:H-L.G[S;&[MZY^0FG\]VZWQC=PY6^-=?;&-E5-\XQGGFZ8LGK9RR>-&KIF\
M;K-';5RW17;.6KA+9!=LX05TW27071WW2615TW352VV3WUVTVSKE$U4(@Y/0
M_P 5/[F_?=@RHX.N)[7^/E8P3G+]B/8B8^[IF[4ZO0-OCFS9JP>( 7L$%LM'
M^Z;M,UE@RTVW)[(XWJ7DOBY\FKCH3..E32DK55I:15 4\B?W(W?ZZ2S?O&R>
MD:?1ZIY8[O\ ;=0<8E> W;S9EJ0P%U4%8:J9U<K;MMOZ!!". "P]L)*A!!(6
MS58KM1Q 8Q>L&RXS?10<L@S=-U6R*K!1-/=FHDEINUW3TV;[)[:ZYQ]?.FF?
M7UTUSZXSC/KKC/KC.?BSC/M[XSG.<YQGZYSZY]^(E(WC^=AGWE@\W"P)V*?M
MVQ?QUAR[D0Y9.TDI:'ZPR5K)AI-=CNKIK(AKWX$#C1WO]YLW.=4WZ::F=<9N
M[Y\L>##"7!-T+$C!SHT\R1+N& ]FS7*/\IZI9>DEFR*2C]WE+75/+IWLLOG3
M773*GPXQC'U.(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....
M(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB.5"^1206+5_:KQJ7
MQ'J;["7)6U5V9V6;6P,Z]5I++5.A&5B]<#L'A1:0Q>))K._N#\7D&B2I)P@N
MF.VPHZ22W62QCEO7.,XQGZXQG^7&,_Y^(FF#)^[7F!IZHKBL*U'?9,(?.QRE
MZ]L:,6%5%452-@G<6V^_$*J\+2WCYE\FJ= ;/H-)NII.6+-+-+,^Q *'GOP)
M.BCHG,U93%D)-F;<L:U_%CXN;(L:])#V)%R/RJ=2VG:BQ9C'-8_LUC\?[C2H
M.K6DM%LX-7B!8?4MT@:MJIT>3AS05.9!%D9(RT=!CK3;FSY,H1#+%BYF$6!$
MHQ.89(FGV"01*8 !,GC!UCE71;+(P .,WXDFTV53T4RV>LUT<J:ZJ?!\>NNV
M/4;5S7[.&CJ[:0>(-H (:BF(J$-XP#1B QD#=-GP5F/C"3#4&R:!WC)F[%MF
MK!)$>Y:-G#/1%9!+?1$T?[EZY^3^9UIY#)Q)>J][.F?EBZR]CI(Y@0HT?L>1
MP6V*ZN\!*NHD/GE4?A48KU[+MNK)8G4+@'H;EB4LF4:0>&WP,GKL+Q/V%3'M
M',+E\=CJS5;S,R\1YBK:!=8)/VFJ\!3?9^5]%V_C_M!;LF6L> Q&'UZ('0X7
M9SM^!BI%6)A<' (>NWKAJ11_#1LSM:_#KGVSKC./?V],?MSZY_KS[Y_//UY\
MIR!!O"HLZ[#BW1L(B2;!B[@<S7*"6YG1HF70&D%4=WC!$IHP8Z$4FBR*;[5D
MTU=:JZMD,:(FH%W/ZOV1VS[/]]:VZ\[E UXBO+%UAG[R?P7T1E=8B('X5",E
MH:;SY^(41,,:I9]H!\(%I??ZGX4>2$N\'II*/W;K7D;[WKGM;(J$\M/=SN?4
M<YJ-UW)\6!N8%8#9+9\G!Z5GT5OF00?K_0@[:2?*$M+,C\!AT)L/ [5DPE'X
MJL))SHUT,?9]L[O["&Q(7))!,1D7CH^6RMN):2B3L08IG(I&U (JMP;8\<;-
M$BAAN&0771%(DG;I,<DLLDRU0T4WUSQ+(9$9X"=1B;Q:.3"-O562SR/RD$*D
M01VL.>(D1ZKD29:/1[A1B0;-WS-19MONU>((ND,IKI)J:HGUA7_S:P_X$T_Z
M,ESW^<:ZZZXQKKC&NN,8QC77&,8QC&/3&,8Q[8QC&,8QC'MC&/3'.>(CCCCB
M(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(C
MCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB..
M..(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXX
MXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB
M(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(C
MCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB..
M..(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXX
MXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB
M(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(C
ME4%Z^5**T'Y)Z(\?<JJ(\L'NJ#5\><]ADY:-;1>"S:XY'=$0IV FH<H%5)O-
MK"E5*F(N.D*)YJ@VD1^.B]ACC=[A7-K_ "GOO1XD([W:L&_[)>WI*:MDMP]6
MJ!H"'%(O%6[TU3D[ZX=DY5V8KB]8J=TE 0DO)1\LD:0K[E:J =TAK)QNA)4]
MRBJ39$QU0_G=ZTV@<[D$+)C9JE*;ZQSRHX=6]L/'Y2RW?:%E=MA7-5M;EJGJ
M^O(:3GQ G-YC2$K3A$/CP^:R"5 U6)YHBW:?:-4I8Q?RQ]!YE%I',(_>N'0B
M&T#?O9F9MG5<6N(DD+J7J]+6$&OM],H>9@X^6128UK*"@X8<JV0!1UFJX?-'
MXR)/QKA)YM"0UX*(B(;;O*4["%ZHE$'9>-)_U[?JU8!ET>J^<>-(!;L>@A^7
M1A>4!=+/"6@TN*1KSN/ZD8620(:_>;"3N'[C=;3%LN\ 4I.C9:5 =[)3%;5[
M$5YW;K3NE86O7V"'6-W1OO5*XA-;2:5K"B<NU&T.D-,P*+B0>[<C/R:$/;D&
M"!1E)'VLH;(EGY;RE='@)*V&AFX"0P/1E>,+,MN?.ZGN9.IH(!*U[$[5$!CU
MO?H^VK-"Q3, G41D 6ITI2M9IG0^P&"HH\-;[C=,FUCWFZUV]4%Q7?#)H;3A
M?7UU,Q]VL9O7%DU5/ZM)P"'M; DPJ=5=:<3AMBQDBUA;\?)F38O&6GWN&(L'
MXO=VV<Z*<J0OGP!A.P\MLUY+.S+B#PBP>L 3KJ2"TU2PZ 3"PG$3AM2@(!*N
MRLI<63(8MV'855(ZD82JKPYNN(S*H\U-O(B2L4T"$ <L[#.J'CYC5$]<;KZ_
M6-BC92QO][+TK*<=?>NS'JU%Y!'9C78NMB;$E%1MAV<3*R1P$:$,NYB2F#A]
MLF0:BAS$6'!BV::)!Y[Y;^[6.J!WO<(\7#5[U/UHF0]J(I+"_=VM@-CNNO 2
M+.YTRDDRK1&ISOX<GLG@B+:7@8'&Y-.&.@]PL+-RX5)&R0A[(WKCY*K,M?L+
MUMZ[V_U7:4?*.Q_5*V.VH9R-O<5;*(""0B8UE'80P=Y$UQ%&CXE/0]@N#[]/
M1ZU5ARPAN(40.[DUG@SJ%9>+6\XCT]NGH?/.^TGM/K7+>G$ZZ94C'"G76K8O
M+*>A,FA[VO8S*I9-HR9;$K?E$"@RS.-"DL(5V%+M6[Q^<'NC3QL2&]CM#QFV
MP0O7J5V'Z^=O$J.L/J[U9<=35MS_ %\CUPA["@)(Q RYI^L.*V+$<18L1W@;
M-#11HJ7RQT=[[-UO5+?5RB=@IORH0^W/(Q<O0W2JS<: 01C/!%6=A7\E;.8E
M>ELT2QJ@AV:JB+1K0&W=#3=((75!]2KU0Z3T,+)2=/1F.R!WPO\ KY1?*+'?
M&]!X:895&:OZ>R=]I("U>QZ4MH;M"*0"3"#P>P;LEDB=@)(W&1Z,RNRZ\AP(
M4J.T>S6;S0+'A2Z.J19Z/C36?@/I&KCO6BU0]SVJ8[%4Y>EH7)<-KRN16%)H
MKV)9=AV%C".S4+>T*;M1_3U2)W6(GZ+ Q*JZCK>0M=8G'ER2DC<:.E%G9K]S
MO=%KGJN4P"F=;*ZGEY#!8W7.ABG[2MM"'*14!;3*W]V$NJ?])(N)V+]HD:3Y
MVQS+E7J8(VN*DXM%,Q&@VZ*)?9C/KCU_CSC^K.<?^SG//EA!* $,*"-G)-XW
M$#6 M!V:*D3IAR@/:(LTG!4V8<O"Q@DNFCJJ_*DW;H@1=[K/7KA9TNJKM]3B
M(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(C
MCCCB(XXXXB....(CCCCB(XXXXB....(D /(]W=7Z%4=#;9:0J'35Y..P5%4&
MT3L6T\4Q7<57NV<-H;B?3ZQOP9/?PU#(5HON=DC_ /#3S"(ILY7WW031W4Y%
M2F_-/4Q_K 1['7K4=J00: MWL-6)=_UW@5P=U*B+Q;K8_9HSOL1![CI>H4V!
MCK5N,(MB+"V9-'(<+<KM#XU@@1W O7&)U]S>GD-[I0FJ8'.S;H2 K'LI0/8Q
M1BF#"R(=+G=#SYE.FD%D8D^FL.=1>7[M-@LAU40<;9&.%]-&Z^-]DMJM+D\"
M$0LJ -*>C':&?02DP5M]OIE!J:>5G ; K.MJW[E186)F=:0&%R=SK&A!2II(
MC*)3URL-\(*OZ:S8<U% 8^OA\-)#$2?O4_R/4]W![ =I:(J^.6#G7K4ZJ95&
MRR,+F#6MK1C=N5?$;-C\FB$M>1=C'6S9R.F _8 ))&\FYO&<:6-#F):!N4C6
ML;Z!\AW<GN $E%V=5NEM0S+JT2E=QUY1U@V;VX?5C/[#D%,3@S7Y":2R BJ!
ML!I ZRF4NB\HC\64''YI/6NP\4=/Q%B%-J[A\X=+_'0TZ66Y9]@0V\9E+(;;
M50=8X#**PD<2AZ Y&<]8*+KGKM%[/%2P>CK*FRQ^MZV&-S,-<NW@%,R1)%6R
M^5,M4F_R>H7CFE?2V>;AJF[>6WGIT,F-NSZ%=-3-?TLYB<0/7'(#DQ-"&MOH
MPQ*X"$&CLTE,BE$3C#D\DZ9OW;%N8/'![#=J]1(H=0?,3=W8:6],Q]F].X)4
M<,[K7SVDHFO9'%^SQ*TSP(IU)B-YD[*.22+.Z KQHBR?3"E',:BS=I)72Q,0
M;UD[[82HQ3!$)#7=Y4P5->1>E.C:E1/Y'!9ZK5\1M7L:UF*#,%2-S]AA5U%>
MM=2FH=O'G"YPO;J=(2#1(AI)!*8')R)X59D%#S-)3&B_AQ<Q6JNHT0HSMO8M
M-V5TVO?MC>M7W A5M73]^L7[<E[@>S@*8@\W;OX@Z9!A5R'@81RLW<J_(:MG
MZR&A'*:S7J%D>!&B+DS=EI6C<EN23N5;-SUO>8/MRP)D(K):PF-.,JP8U7I%
M*AC<F84J1'PE"MUM!&9'$"1)HG,9,B.)#4MAVK)$L![Z=U&'3"BEK%C\"<7;
M:TG-[0VF*0#2'2.$K-FS8 ;FY]DO)= TE2B49@];1*:V78$N>A7S*+PV(E7Z
M[99QNR;.,Q=2[WT[1]6NN'99*-YAJ78*BJGNM*);%<G=HRE:$&!S5(!DUD<(
MR6R(T-:L<DLBAN7N4/M'V%I\SY&D,[G\,OCWN &:9MJ)85!)2ANWIHE-.OTM
ML2@SNEBW;"UH-/IL:VIN9P369.3897[(2!2U0M'"@W9X$(C' @L6:O9>=.^L
M\7Z;=6J%ZLPL[(I1&J(K&+5P-DLK(/B)^08C[#1!X:?;/R!/[NP3?[.GK2/#
MG6L?BS%9M&HPS&QP2*'-$22?'''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$
M1QQQQ$<<<<1''''$1QQQQ$<<<<1'''(&^23MSITMZIS&W&;X,(EIB00BIJ\D
M$K'G'\%B,]MN3L(3'Y]8WX?$&G[>NJX^\GE@S79)GE9Z C#P*PVR5*CTE42>
M7'-6FG/*GV&NGQ2^/V;1B_(2Y[9=NNWM5]1+$N]E7L)7*5H(FW9*R:O(W2/I
M)TU:0S[R= 84$CL?;F ZD&TF,L9Z[HEGS; ASW6$>;#L14OC7@_;NX^F-O\
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M<QBEBM ,:B,-;17>'- T6C%@VU8 F26:XTEDD9VO>[K2V5()(K@9AZ_2.U_
MX (5A;<D-)EB=K7$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$1SC.,9^OYXS]
M<X]\>^/I_'RESRN]V;_ZPV%U8J^BYA$H'F[ _8*2RR4.>I5]]WI^T0IP=6"P
M5G&Z'Z^R2,2M&*$W4^>-YC9#]R0&18CI$A2K!+61JOV]I="R.13"CZ?EDN);
MF95)JQ@I^2%U*WE-.*%#I>,C7Y4CO4TX=/IG66SUZNLYS 98\=R2(Y4^XC3E
M8BQ<*;(F)S?0[I-(XJ2@YOJ/UL)1(O7R%3DH^YI2N]ACJLFL\?6DS@&[?6/Z
MXUB#&SB9&QF$?2V3&L9Z]=3!F@A(5U".T O.7"8=7/A%[Q02 16.PB%1#K0O
M'HK$8D%'1V-1H"+/15J-"@08ALT&"10]NFF@S8,6R#5NEIKHDGKC'+KN4\>?
M[_$X>03_ ,0!;_UEC'$2WH;_ + 9?\$:_P#1TN>[STAO^P&7_!&O_1TN>[Q$
M<<<<1''''$1QQQQ$XVSC77.V?IKC.<^GU],8]>4UG_.9TNAW=V2]&)WK8-?S
M:'R@U%9-;,Y1KV+44"= X-O.WA$Q-2]A-B8L+NQUU$MR)".MDU#:S=OG35JN
MD[VLL[%WU7/5^C[.OZV2WW-7U5Q(G*I$Z3T^<\<I,T\)L PEMZXV?'9"468@
M0 _3^^$#))BT3Q\2WKBI7IYXR*\N,O(N\_>FD($>["=BIPE>8ZE3( 27A?7L
M(3'-](5!RB;EAA:Q[#:1Y,20L8[,\D0K>9:;#XI'PK$(DN]W'Q;#\;KX[F^8
M^79>1NX[\6SC.$/&ZDS:K/D5OIM1Z:[:GKUT\;D+:=Z6-514M^-+;/=KR4WY
MCG=/-G5QN#X]9B&OWIKY/\Y7:FOBE+(?)JT=TLTW U9U0"RPUW.C!*+67$TQ
M_=)_3*.=I4:%CD7F]I5JJ[#H:=C*K<L9W#7S8A%_OT@]CT)CS%_8,I3!E,+1
MQXU!"GCYR\:NWH]NY8(ZJ*93._NAGH<$G[6N-0?94C)R"H5$8#2H&9"9:6V.
M-=';3(FNI,F"L(AG9/;?[.BE&M71?5+=P"0)M5&R[BT9/ISU52M,==Z/7BG$
M;>$/1Y$79*%?1MO,QSX2)U!#'3$\W8)/6BS -IJ+:;(;I_(88^RZ8PEZZYQ9
M-?&WTRL/M-&^Z4OIQ(OV2B)"'E0%B9FM@L_L9"!,-AD4=[Q9A*FT.>+"&6V$
M4\O0#C5QE)!5YJX5;H[Z7"\G_2.YJ5N^+_,<->?@34UF3Y#@V6;_ )#7]U7:
M:]7'TI1BTDD:KLEE?I4#\?C.SV*U\7]0.K2G-<!Y/ROG4IXZ\+3Q+>7DGGY,
M7T(/#PJ:MO(@^6X>4BK!?.OT'E]OPVC3Y:\*AL2PB<;"0L1=/7JT:[P?,S ^
MVC498(J$0KA5BF9+N?L[0L6;CP&/L[K98LE]GWQRY#U]?I_'C^K/IG_+RKCL
MGXGNO/:#M-!>VM@/I)K9==8JC6*JLMD/D!]*BF3R;@M6&VRNFF/O N^<8+9(
M-">5$=_A;9;Y],XM&QCT_KSG^O.<Y_S\S'R1OA]E7#V_%:>:S7V8F/.Y>6OS
M:J*-X=?!>-TTY\UEN8U$^;:*UL-H)4!".[OA6^0BWD:N<7$U-6@+QFG(AJ?3
MF_6&?13^1H];]A"H\E_2Q# L#USQQQS+2^CCCCB)QG.,8]<YQC&/KG.?3&/Z
M<\]=5ZT1VUT5<MT]M_?351='3;?W^']77??7.WO[>V,^_M]>=$MF!/[/KJ5P
M(98M@5,_DPW[N;6+59 &*L&*[_:F[G)&+D)+'I4#:$=M&^S3*I"/DD\-7+G5
M-)-?9)PCK_\ ;+]S^2KLY:-0V01\D?9TNYJQ-#5N\NB/P.S9@TRC,1LJQF#R
M2',:A%1;&NXY-1+!R+33=,XDR*[**,&NX1QJ/C7$?'.4O*?(OEE?Q?./</<>
M%Y/F;"4H-E)6G JKXW7]9R6N5JNS:490 U-R^[EL=8;B^$?F+/T$HN_'A4>5
M@5P7TMWW77W:.D8/T$!4GL;(6-M=LYQKMKG./KC&<9SC^7TSSK,LF\,@0]D6
MG$MC,-%D3@.,#R4J/B8ZP?223DVX6-1]F\,/&39T;D)AVU$@Q*"JA N3<MV
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M&NNNN,8QC&,8QC&,8Y< G_@T_P"9K_9QRH+R1?[;SPO?\H%./]"+M!RWU/\
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MM&AD=*61^MB?&I9?8FN8F.\C?:6U[T(MQL8<EJ@K<N*J>D6!D,VSMC<IK#0
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M&-W@_0256D3L:D.)[OV6K%YLBZV=ML)96TUX]9)YQ(;64A@H.-=F-P4*D47
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MO\OD]4ZZ;6[,>T]R/[%ZJ^/>:7+%-776R*4U7W:&L?(O1UW]AHW((U!!T)4
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M[2U29#W;Q* /E[[ 53VC\!_<Z]Z3DV9;6M@=<9(\ %U!1@"_3<!YZ)C<B!'
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M-]_P7U9**U_Y=U'8[[&>^4=OQ+9E[\]^[BN.  #%DV\GDHT=@_7BN5[W?O\
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MJ(O%,[9PS%TK6C&8S-@TSKM\O*6]B6P8P[VSC*F73'Y6V=<)8TQ9!RL7Q(2
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MUQ\K ^BB]'V]<8FW[)ZDV?2IL_YDQ<*FTC*UZ2:%BQBR>ME\]Q%K,[! J>F
MC)V -AM6J*N1(TS#HK'RF[! N8W)>:>/D@2HK3R>3($XD=RJXDUO=$9QVVKN
M'=6:.G,_"0NNSU&B:AOBI>S<AEP"V:EJ C9$JJ>G)3%X: F<\E<]2LY2F1C
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M@D;*"VJB(]L^F,N-S)T&;.W&ZC\W]SNCKABO(2.=7QYTFN3620PNFCI$N V
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M +M!Y O_ "'Z1?\ NO\ /GNK.VFM:UT:,Q%M5GLS,J6,*W#&LET<>NP#Q<
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M=M\:-7RCAOIKONKOIJGC399;;7*N]HB)6BUUJJ(BA41%"HBJ.E554 *J@
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M$R(),W]@5XYI&NVD6>3H$"C4DDKJ%2EX5O;VUQMCTSZ^GU_5VVUS_7KG&?\
M+R*]5=(>J-(W;:'8VJJ.A$*NJXU"RM@SX2U?Y*%=I$6:2&5ZBVCQ^[#Q%*:R
M5@QE,\0AHR/(SR5LVLHF"9L^W2(Z(F=K&L**5/ IC9LZ?NA4,@4;+RV4DF(0
M])'C ""9*D"CML BXPU(S*Z#1%11,:#$DBCS;7"+)DX7VT3VI0AGD6N65>1V
MM8B;D>T Z&=BF,*'=.Y*:Z?V'LGV@E1^@CEAR>-JWT:M6*FJ2GD4E &0OFD+
MGW7-5M((U&70G!X6;(MU,7Q9QC.,XSZ^F<>F?3.<9_KQG&<?T9Y%?]Y'U7V[
M,9[AN*:C#_L?HT^RLK.*N#Q<@&5VC#:%+F(X#*&7D2C,I?0YHA$R4PCT?%RH
MI&4\ 2!ER+VW;;HDI\;8SKC;U]<;?#Z9QC/O\7IZ>WU]_7'\G[>:SGE+\^T$
MZ_U)&W_32>U*4LI622<S*W'8N.3RLQZ4 J2R*YKFPHQ H79#*K)19%B22266
M,3C>L2R3##85$+0L!RZ<"H?NIG9E^GTYAF[.O%(]CH64KR\ZPAMHPTTF/1)@
M9B%;%FKM 6=%R9BWW65QJ]3;(G0HLEEN@Z10779I8<)K)9W3W1,KBR8XT-8&
M Y!B6$E6;8B+*#'2#X<2&OD='3!^P>M5%6SQD]:+(N6CMNJH@Y;JIKH[[I*:
M[9]_GCIIHGIJFGKKIIIKC7337&-====<8QKKKKC&,:ZZXQC&NN,8QKC&,8QC
M&,8YY<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$
M1SK$VF49KJ&RRP)H7;@(=!HT<E\K.N]'"C4+&XV,<F#A5RFT1<NMVX\:S<NU
MM&S==?9-+;5%%53.NFW9^/\ M^7^;B)426[_ %D3KMATJBG7;-"6#U'[CT!V
MBG=?V@Y=66M/SMDT4"CI,?C(_P"Y@0B(5KEU)&0YXZ^QR^8R)?4OEN,BJ(AC
MF1>'B_[RW?V?>]Q(9V22KX9+^K]IPJ-M5@-*W5U=FA""3>HH_8K.43CK-V%D
MTMN&O0RIMU*0$#F$A=LAUKAHN_DP ,/;-U4MI=VWT1ZOWG=,-["6A C\CMFO
M@;Z-PV1HVU<\>'@01=H\'GQ;6'Q:PPD(4:2H<^5&3%-U&U\S$6B/&2C8LQ%"
MV[/[/6+I?UOZ=CYLRH& .HN\LDP(-S^4R6<V):=@3)W' Z<=BK:261;$LG$^
M+A8='TM04+CKR1J@8@'RJ/C@T:@Y=:KHD+B/D>?67V'\>"/5HU1]K]/.VMK7
MO3<XL[YMCJV<UL&J:)N&VF@R%Q]X$B\:" !SFKM&1^2G7LC)%7!3<0*BXEJT
MS)G?T.DG:_MO:/9WNM3G8$;U^E=4];-*_:"[RZ]1RTHS"PEIR%"0FK"ZXF2M
MC2.5,[3GM/1-"(&9[+X5F+-8^_E#"/R*%@SKW(@3+RZ.E77+L%:U27;:\.DD
M@LRB230U4LA&VS<<,;PHTS>/'>ID;'8-8$:B[@NZ3(D1!0F3"OWQF,D'\2+K
MOHN\<AU>J]9/'EU#Z<RR837KA5;VN#L\;$VLGU3LZWY4">ZFI.M,S#AG$YQ/
MY-$PA I)W+@N0* 0@PD\<+K:.':C=3='9$BZ1\CSZR^P_CP1ZMF:/M?IYVUM
M:]Z;G-F_.L=2SFU@U31-PVTT&PN/O0<8C00 -<U=HS/R0Z]D9(LX)[AQ48$-
MFF9.ZS5TJ[*7[=%O]]JLOZ+U-%B75[LQ&ZN@K>IG\P-L7==S:@JHNV+N)5))
M@W#KGYGHRLE)L?=AXI%0+1XDH+&#G[9BF>*YBNCI3UQ[!VK4EV6Q#9%(K*HD
MDT,U,?'VQ<4/:PPPT>/'>"["-PB?QN*NRCQ(B1#ER)4(0>'(N1(1 RL_BKYT
M&5XHKI1UPZV6+;%KT[#)%&I[>1'4Q:QLI;%Q3A*9F$E]%&Q8@%L"?RD V*,&
MR+4,,(C!3%X+C+ ;%!ZS:,C!XELB0BN#R7.34OZ6GNH!NC;?Z^6]WN8=+.PL
MQ,*V-F<Q68$(G*I F KJ-X#1H'A^*WC.[F22V2&G[%@FN-%A(J>W)O#0'$/0
M_P H78#L[V@@T1L"$U(*H;LW"^\T[Z]LXB.FC"V:S&='.U@KK$8&W%(#4H-P
M^PGMJ;$5)N/<0R-0-&!903C3A*7:N,F4+/.Q72GKEVM-UG([TATCE9BG#^LK
MK1V'MFXZ[UB<K2<(.6<J8M:SL"&LG$G&;H;)!Y"1;O3 5F\*L!+UDQ,EF[WT
MJ9Z*=4^OMQ61?=15&,B%J6KO)?Q3(TS\P,-6;>:RS$^G(V"QF02(M%*M#3Z>
MZISJ?!*S!Q(3-YHBA*)0S*FFS9VBB8K[]]\ /4BOY5&X"#2M_N%)*>M"P.M/
M6%@TDSN4W@=KD*X*/Q(-O'@Q!<C@8B@N4> Q[E&2GF@]P)C+=P8>,_3'?BO[
MM6?W(A78UA<#2)O)UUP[%OZ1=SN U%<M#0ZQA3JK*RM<)(6E.]@'I&VJX-,&
M5C_AP_&Y40?;KK"&<F&.=14C9M6UC]@P2-V?")77DP0).8O- !.-'T TBD<2
M+*"B[;=H\P+D\1+ I1'B.$E-MF1N/&11H8XU3=C2#1TDFMIT#K_URISJ_ U:
MYI.(YBD;?2,W,CSA_()1-);,9I)5459#-Y_8$[-R:>6#-3F6K30K+II)#L@?
M-V3!HL0RS8,F[=$P/W/[T5)U/B\JCQ&;5NU["E:)O.VJ.J^RY0O 8U8S^FX"
M?F#MD?L1ZPWBL&C.' A)L<DDB+#FXQFJJYURIG3'(]^([O)</=VL+H,W>/AX
MN8U9:D7A[1F'JN?]>9EO'Y;1E4VRW<3WKS:L^LJP:Y50-3P\"AITQ*-QMLPL
M$)LJ-C1X8Z@EM9I95;P2X:_FE5V?%@\WKNQ8N<A4VB$@:X>A)+%I(/7%&PI-
MKG;7YS0@P<K(*?!NFMI\6%4%4ETTU=,.]9^G_7WJ$#E@*AX4_C>)X?92><2"
M3SNP[3G<Q,B0 Z* W$HL:UY7-IX>;QR*B!48BXXE(G R,QT<S"@F; >CJAE$
M]J]NR-74X;K:J9)9\.@%R]C'DFA'745,@TC.C9?8HX8VV:LUAT>^Q;NQXY^7
M"KEF3B11E1\Q7W:LB[1RIAPWA;XS.RW;CL3,.Z8KL*?ZYS^N^O%\C^NM6VQU
MZK&Q*J$V'8,"B;5_V,U6CUAV];CMT!KN?'QE7B30TJW:DY/%)SG&5D6S=-M;
M!G7&WU]?;^/./Z?;./?'UQGZXSZ9QZ9QZ\Q'1=$5-UJK(%3M(PUE ZYC;N1D
M1,=9/3!3X"<PDQB9RHL^+R$B8/&"\BE4@-'S)8R4($B),DZ<N72FV^/A1.N=
MA.TE#=6 42D=]6&*KP1.YH.KN(.";(V0WD,U+LWK\;&QS8$*+.-R3]J.>;--
M%TD&ZJB6$<N-%%$]=ZR?$CY.Y9Y 'DW7LO>/P"0'ZRK_ +!U70>.OESU?+(C
M0]B2ZP(Q$Y6XN2QY@6AW98"94B[0,I8%;06L 0Z:"I8*9!3@'[D.KW:YQC/I
MZ^OMGUQZ9SCW_HS[_P F?7&<>V<9QG/(A]9^AG4WIZ;GLBZZ4\)KHQ8^6K>0
MNT3TODGV$ P-'I(+@L);S"0R!K6M8AY%*9(>"597:,7KP,9/%B0V--G;Y97*
M)D>]>R]&]:6,#(WC8@6NV5FV''ZJ@SDT@773D,^D^5\A(VT^Z1I+9%X0T;.-
MDEWV&@]/"6V7#Q''IZUT^*_NWV*[-%[IKSN!K"JU[#5V-A\K)=:!W6"^>OLW
MJ>&R^6V='XZ;,R^W;"G,6OJ*S-O#&N\:GM8-8L,8D1L@8F _QNA>R=Q*B>BN
MFR:FOQ:;Z[:;ZYSG&-M=]<Z;:Y],X]<9UVSC^GUQZ9]^11ZU=(.LW4<C/#=%
MU\^ 26S-@:<VF$KL"R[8G!L5%<$=(E%]YO;<QG,K90F'IERB<1@PTNSB49U(
M/?N8,TW=+[J(F0.P'9&DNK<(96/?=@"*WA9&5QV#L3QIN7<M7,KECA9I'0J:
M84:5=X<E'*"J2&^[;5MIG3;9PNCKZ;9JLZ7^6K3MYY'>Q/6"-E*%4H:&564D
M]%D([,VQ>[YI(JNNZ44?<A::@VTI=,X_'UY)''Q:"Q;,:82I.!I@;"/KX#3P
M CI>'G&,^V?7Z^OMG./?'T^F<?\ QY':)]2>M,#NLIV+A-)UY$+J-P=6N"T_
MC$<8@"Q"'.90ZFCP4Z;B4V@I58A)GBQ0H9V'_?Q13"#8D4=,FC1L@B2*XXXX
MB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(CCCCB(
MXXXXB....(E2-Z]^)'UY[^7%6\\6;J=9*4\3<][X2UB%C29&>J2>MKP+QH]L
M&(8=HK/T',"%KMF4<W3T17-8;.,.T<J*8VA=+/W0-O74%D#FRNHCR&6VR(=9
M'\<@*E_ Y'##<#[64'<O8.MS9"R8G5QLJ.ER0"C9;"3,&!5K+D$K$,0ADPEC
MV'R%S-1%S%Q]*^HW8"SX+<%X=;Z;MFT:Y9-QL%G=@00%*))%AK4H],(#A! L
MT<[MQZ90B_??8<XW:[N'CK=1+;"ZF-JU>X7B!Z0/>ND=A=65B'ZZQF&7HQM7
M("G(542\;E\OF4.D5"J.Y[#[<K.UH9*T8E +(D"%:)D([\ZL2: 5Y!' !(4@
MURB90M/NY;.EJ>(.'F!#_K-CM_K<EY=BHG(-!9\Q!H!2/4H[;IND)*8D\8$K
M!R",VE\+6F!\?'X\<'I0(X(:N!Z3YWAQ2'#//)VEN&F>P4AA,QJ9W92G8;H+
M</6V'0-O$V!S]Z+V@[E(484H*QW4W9G @VSVD>!@6<\FC]JW=1UO>8,L.<"5
M1K58?L:S7QV=?Y/7'32LY.ZL*4A>FVN8O RDLD[.622PH-(*#F77"P(#<Y:2
MA"WXXB5HUI,2#6>LFS<"](DF0AR*(!FC'(];*=E=&>FUP#8@(M3K#1]A"H+7
M3"J(<-EM=1LTQC5:"S,4D(N"!FCM@HW8Q48>A41,C0J*>K$>3C@AZR10<,DE
M-42LSKIY-[0OONGU@A92*E*NB]N0[R6T-</7]^3ATW:5=VG\>5TT\"-2V+VP
M% B2$XC$@CT]D<:T633'"'Z: 0DB 'OF3YX0@E=?E-[RT0>D$YCLL'6O% WE
M!\@<2L&O)/!HCK^'NE'1.+M)-+X+5C^* H^;:RE&NVDNGZTLF#^9'7Q\$@A]
ML0 Y7"N;YZHZ!]:J7N2H;#J>'9KT;077ZR*2J"JXOJ(&U7" MUV3&K"M:8C@
M6@?8VZLB=F8)&6TCEI22OU2+!H\W7:;E2Y<H^^34/C_Z^0&7W<:,"GMMIV'V
M!O6^!8BW1%>R<?5DJ[.Q5Q'KW"5F['00"?9P^QPSY^+/!Y>;F3I06^>!T2:(
M=PH/RB:\-R>93NK8<+\IEIT_.HU65.4@$Z?W1T2F<1@L9+FYY2TV[D3;J_)9
M/-%K$"2<?)(=>S6N9+-8WNT"!2PR+%8F^CID9LH\^W;D&N<YQ[^_ZVV/Z,;9
MQC^K'M_G]^5K]FO&=U4O&@B]",8?BC8?*XIUZJ4^4H8)7\0E;ZF.O=@:6!5M
M.)EI!!Y>V'5Y'9%JNHS'"QS$H/:OR;<*8%9(O%%K*<8]/;^/.??^/.<_^WV_
MB_/B)SQQQQ$<<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<
M<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$2NSR/\ 9FR^K\(ZP2"L
ME0"+VU>_?2KKO+MI"*T+-]JWO*[ L'GJ;#51TTU'&%0#QPF+,9W4R+<[8=:H
M[[:8](2V#YTXE6UE6T-/=;9FXI&!3'OE4D/MH78T36D]@W3X]:;)W%<T/4JE
MX)8J0R,2-C&Y;&*TG1B</,2 \";+%XW'PDDCQ,A<'?O7JC.SE?.:M[#5/!+H
MKAX5%&G4)L6/,)/&URX191P()*"R*2K?9X.65449K_#\:.RF^=,X^+/K"F<>
M(?Q\R2$77%H=UQ@%&&[IH*2]>I+9]&1J.02S0M:RB)MX6:8Q [L%+# 9,E%6
M0^/%RN0;QQ)00P8#E6#H9@V8)HD.;(\LES2SQ)]UN[L4I?%#3"M7Q6J*&DVD
MI5MB)S(U)WE;U]'K]A#R55=624E@\2L"SG#=!J7B#@<=,5S(&2Z;MCA1LIC%
MWY?+##>5V2=,6<^JV1T:)"SWJN#6=LF"%R/.X=7];QO8TA9QQPW4:!]8#(UU
MI!1Z$>:A4F*MIQA^BQT0UQE!:9?6_P :E!(^/.]NLA4U89VO>W*5B2&P-\N*
M_B6\++2<*.B3=Q2T.K:O(/4=4(Q7:' 97'&,8K5 ?O.6SB4R-K(B#Y[E><8G
MJ'UNQ7,:@AFGH!*0@JU4>P6V9#$HXX<D^P3LH[DAF]26K 4.8;6K(9.5,R,W
M+&3%DZ>%3)/;1-%HZV:81-;ZI?-1VJ-])J0EELQHI!;YKBO_ !5=HYS-F).J
MYH [>]:>VO:T1U3L]9X"CT/%BJ-E1HVYDY<?$QR:!D1L+ %&A,6WW+ ,2Y\I
MW=?M[U^[ W@!Z^6LQB[2N>@M'V% (+)(5")% BMY=@N_ WJ\A.)ZY(QQ>;O&
M,0B;Q)<*$!2T$"T(;KDC@H_C31GR?#_Q4]& L>80RJZ+A]"Q4S?G7:YI\ I*
M/1F%#+2*=9I*A/ZEA4];; 2>CRM LR#BY&O#P6(^@X*MW;Q)TV7.R/<QDBU^
MCE+VYVF9]@+"W/RE8SU_'T/,:C.M((=IR=12$V_I>4"-20"=@Y25)2Z#6:IK
M)(Z4CDTC['#ANSU+"BN&C?*:)2[2/F.[*]H^[O0;K]% <8KNLY]'K0Z^]X';
M2.?:YC ^^,0H6][$G=6UP7D7WH,%?H0=TT&//$BH@^FZ:67&V$@9$4-]-M;5
M_#=?UO=G_&YUIN^^9DI8-L3 =9;67S1<)&XXXD3B'7594%%DG8:(" $:9/%
M,9%:/-0P8:R6<IJN=&B6RV^,R>UZE]<09AW-8C35;PFP4;/M.]15A1B#1)M+
M@5Z6Y!7,!L6YACT@$),M['E\25P$D<@)CR69 .128'FY-A\QJI\[I#U<@/2_
MJU4G6FL34SD<)K,4=1$G;"(!"LR++RJ82*<FGYY]&X[$P2SMR>E!13345'!#
M)!KENW19Z82SONB2LXXXXB....(CCCCB(XXXXB....(CCCCB(XXXXB....(C
2CCCB(XXXXB....(CCCCB)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g189723.jpg
<DESCRIPTION>G189723.JPG
<TEXT>
begin 644 g189723.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?2#(R3$E67S1#7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MI%)T@ZC,<@4_?.>F4Y9(3Y@[R0? #UR.G6MRR?E.Z3!F$"+E++EK0;8@6J9
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M:(,!PT:P[<6^T8CV#)JFDV:,F31%%JT:H)IHMVZ*2*6FB:>FN)S^0??L\_\
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MXK^(+*2,:6<Z/"@X]NH&VV,L2+M))T_9DLNF[URFFNY356TUWQ]-2I:M5%Q
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MK)7XJ(=3$5ZD!RU*]I1?=(?:%D6U<UA=F!&(LQ9VG<EJ3HI+K2,:1:&;9C\
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MI"VRI)T.%Q*5@$9I)2 H$*$I()\K>X:NV&[EA2E,O)QMJ4VXT5(),*P.H0X
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M/KRO5W=G=E>6FR+D\6O4*=*0#KQ"QIJ#^1SN*&"-9.TCI(FSW2;=-*6U?*H
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M%]OYFX:<>89F5NM-1VCB(D%*,29,_P#L.8K<+G'O'ZX_V\XSOCUG_*Q]/O\
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M2=4"ZH%3VO[$GDBG3K2CSL4$S;,8D$)3CK,M+AS/\0R,)[[&V2:;1@XV!4\
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M+3!!QNA4%2BDQDAMQ1!)"%$0>9Q1[BK";7_%65O>K<NVF[H7%R+5#%HH$N7
M7"U*4@X1@0VZN%%26UX<)N=V]Y</'G3"[P:>[,P>725H[_+\PRGTC5V3)4AA
M3*6[%./58-E+K1=)37;1QEQL@DVWQZ<*)YSCW7?\DWF@[FS.85<]Z7.KPZ7T
MR/'O#3F4W+UPKQQ+;\D(TPKH49C15@.9H@.JP"(_)TW&HU".S$P8..]'S@4V
M'C]7.[%/>8SQ]5S#[!E-&>+7O]$8/29^:QVV977'CA;"0562JL&>KRQ@MA2
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M([;[:F6%("%M-*0!DA3:"@#HD@@#N%;BK9A;8:6PRMH"$MJ:0IL#D$%)2!T
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M;>1AS2Y]G,JNC$FJ2'=D*S29W31S>_H"ZB/9^#1Z&2B4BX@K,X,J&MRMW<3
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MP],C<5'S1E!K+((PQM)HK^#BRZ1G$SM[S'0QOSR],A'J/+?3WEK5@*.GATH
M!)*(W55%2 0,.#5%D%6JZ@\NQ;D66ZK9?719NKNU<I;*(+:Z*([YV34QKMKM
MC&@"ODTH) WW[!D(=>@=YXYZ^'VA=V\CK!S%$I9""D?L:0,I!3>DG,!W<_"O
M&M5S%N-/+-0$;/+L6[F.F"XEVD3YO9N7Q#H7L<GIH.AB-QK<O,I"T9KAP"&
MPC+^2&6[%T^*.18=/\*_?H-'!$BNP8:Z-U7CQ1'9=6(F(=,NQ$VOWN=VN!]@
M>I-B5/WSZ]59 H=!I-U<G,TBS:#UF+G#VCGDPR3[ (!K,C,LC%NR="WA/Y%'
M$9@S=!]HKB$Z,W;5_G"L.+"<,P5 '#BB<,G*8DQK&>58A2,6 J&.,6&1BPR
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M)FRI]? NLZQK,:I&M K&A>O-7BEGC*J8X[6*EWI9S,+--RRS9[(<;B&Q\L_
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MZ@M7QB,2U\F7<;J+%TG1X8_4T*+[;*D--M7:F<[+9SP/&8SUY;$Y>OYH1[\
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ML<BJ5&L42J*0XV,7P4#*$!"N[C9LB_4=-G:"'L?FZ9]>OBSC/KUGX-_A^O\
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MV!\0E48=0Z P%G7$,J83&](NQ%JUL$CR+W;<3)$9 0,/BSUR;)O_ $AHELM
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8N@NG.YQQP !D*I).M....6I3CCCBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g397522.jpg
<DESCRIPTION>G397522.JPG
<TEXT>
begin 644 g397522.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?3$5725-?1E!/7S1#7TQ)3D4N15!3_]L
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MM:MK6=&(= 'VS-C+OFEX3A!6E?*W)="ZV87V7'#4-\28%SLO6D@487OCBJ.
M<\/;@,@G(,869X<=';AKF4538M?R220V7[F2/?%Y2JY](L+1W]+S\CDRE&Y%
MF85H(.])1#;EL$3CPR&-XL)PX ,LDXI!P8R#GI&!L"0/*1N!OO0*'O22 0G
MG)!!WGN)ZSOOD:SGCS\D^\NI$;W=0W]B5;0[;75MMX[JAH2HK%F2N.P:(7[O
M-2DDN!XB[J\)4#D*%5[ TCB6B>4[2D%V&,M* @Q)]R8X$6V,_F/VC@DN5:^[
M)ZS5'&]FX!Y(])M*K02U?8\RD]1KJPW4BC[,8?<U>/+U&VR1F.S2V1YQ3*(K
M($F" 'X(,<3T SC42>PJV/$7IG=*C9Y?.HC-3GK:VSJ?NN<R1DLZ71R20RWJ
M%C!\3JBQJ=>F54C75?*(FUJ%&$RYB-,+6&*#RW A2C-,2"Z&9X4--55 SZB7
M93?LB<K-N:&;$S/8>2["6(^[5.MYUN6G25[9X;V<5A\C12.%-:?+3&@(TQ32
MUH%*[!#;A6L/5C01&-HF  /[.T>8/IZ1*03GKC,R.QZXB 1,Q,1N:_-C/.A=
M=7_Y3*"-TI3D;;J'\DJS2!PN^WI!<1]&UK!$-3&V*DN2]#*MA4KF;""1ON$D
M(92&5M#'4R]PPM=74DE* I;T[;_]H#LV@9NS0*NZ\U9L.05[J;1NR]TI06K<
M,D;;@D-REJ74BH=-9'7U7/;5+E)43;CY0QV#9>&!@?0NK0T ;RE0%9W+*FOP
MG:GQ6L9U5];3[;RIT=G6<MMJQIC7NV]OMMCSZ4OU?$UM,RYQ,W9S>G"9,\\9
M2S7*6-<H"[EJY0L529O-;'01)J?ZTI\,.I*]56*VL))LWK(IK.C8'K9A1JQM
M#;E&J[ I*LLKOW%@EI+HL\Y7S<F-_BSSE#(EBM/+?_&Z\)CZ, R D2 8'PQY
M2#)\]\?+K42GL3MT VCS(SGI^>,5>6&^YXTUEXKYU44GFD#27-Y1]#V21$(,
MJV)Y>*RL5/+71YATI;S" J@('!,-$2_LRPHKTJ$N"5)8!EXQC+&P?D+EE-;>
M[ ZV-E7L+^R4WXN[,W\02E8]/"1Q>Y= YXZQ5%6BU F1FHD,?<4C>4L->"#3
M'@LTW(24PBLAY)[<?1.CMXJDA=-W.98R2-UY8L-M6'/%;V9*:YG+#-X&VNK7
M&GI!.&!1B0%JD*=Y6&X/PJPJ&NPG<,*0+4Y1^(<3KP;Z:66U52V3B0[4R!15
MU<6'3:N2J]M;J!-K<IZS)>Y3N155>4V3R F46; "90ZJ7!JCSJZ)TR1.6C9C
M_O&1&G;RX(5DB)D9VV'GTGH2=OC4@I@2#B<;[QZ?+XU7;:OG#W9+B[2_:_:9
M4K/"V#Q,ZY>56Z'&>71*X@BAD*LB.RB1V/7,7:4<=6NTND*0IC C@)XC&T O
MMG59(Q&FA;&U7T^W/V@S8YWMF+0/5O7/7AW4RJ,:#&Q2L+PMJR6B\K3D6^4%
M:YTV.E7Q:#0A>D=ZTHXIV"WVO)3B#UR),D/?2D)) BT&+LV_Q7:GMC%,H\D8
MIR%#.M#H7XY'X9EC2$U49K1 V=\8X^SIE0NC4LR+0R%QPKG)7;PK/$4H%@!A
M8O70G=/@9W!:MDK3D&H[_754-T@=]5FO6K;Y%M9L37]QZIU+K[7$$K>0PUVU
M^AD2.@6PTIFT>AZ]K<)5/IN,3VE>PY=!(R0'(BQ"I@ 9$GH-T[[C8*D">G<F
MB>7J>GUQV@G,>4@F(BK!O+W9MWS#8;Q>>.V%V_+=>H9OW8]V-FQ=H5,L;VZP
MA5]2]:LTG=*QK^8/C0OQ&%-@.#ZH0AD2) 4^A3-Z,9 #$X7!M7X<VKORU/!Q
M2T,J"EKGJF\HHY)+FMN, \C&R<P7WJ!CB[9&UI5#4?'JBJYRG=D(#%I,@=$$
MYGGV;!#U\A1M$BDHDPTPR;C=R- -?M\*\A4$V':9*YN5:2=#.ZSLROYG(:LM
M>M9^B0?AXIG YO#5:%PC[FK)R/*M#@*QD49^VR>VG'-S>H30P</ SI6[)(8-
MQEFW2J71EJM*+R:TC]P;K-M>X()<I+,FL6NK;GHWH3U)('(D\?:B%$;:S8\E
M*((/(+']%P<0*I@D@Q&<C?MTVB<S.^=\4!$ &=]HQN,[S,#L>VU0 F?G7W'G
M@H*1J/II3LS4/WBC@GE'GBNV[FE$72P.)C=I>BL:O6\EEC8S9H\@,CA+17YQ
M)K#E:M6C=9$)$V$_1S)J$^5?;';*WJGK[1/6*G9HTHM1=1=N]H%-XV_)8&[1
M!IVV0%R./515>&:+JVY\FL;AB9VDBY_E&$4;583@:Q81.&2DZV<5=>)S42KO
M1F)QV<D>C18CQUX"NLF1K@YUI)=7AWPSY"9Z0XF'W;ZX9Q-P!"[A)$0G+P L
M@/?19%X8=/'F24-*F97?]<.U#TO4FO!1E2[$656I=PTM1IJ$^LZ_V #%G% .
MV&B/*$(%'UW<Q*YN&3!D.*U2E E(2@%#)W\HG.X[;YC8F9S%"4] ?S[>>1&#
M]*K I[]H-L*U[\?XHUTU3LCJ*6,N["RJ0PZ37(MN.OS-4H;8DQA#]L@A=:[0
M5TS1>^T=;N (X.!2=U5Q<]X:$#V;^(",(S8WXUMT=O=WM/Y%M3?U!UWKC%;&
MK-IGNN":!62NL&32*-+85(#7R42XM>B3E1H>9*V(7:&H E"6987),6[EB<$1
MYQV28-XE]=JYG4]DL2L3:UL@,^+NG!^MY>TEJYU=C"N_VJ3-=F.,-HO\3#$&
M-0YYF,F=F<@92YMBDA=CGV-M[<XED'DS'HS6NL==M<Z]U=K- ZHJKK"N$561
M1"[/:MW>B(HA;36HDE8_GA L6+LI#S?6N$$L>3<X&$!>  "&0%")/3[P('RZ
MYV)%02G/*",XGM'KO](-:/?CN\E^W]'^/78VJ[%NF7VMLIM%0NOER^.M]GKF
M%SF#K8>V]KOVHDSC$94K$^,O!=3W&V-UBDM@C#0M[8H6JU2<I'C*I5.CQ\[W
M;HTUK'K_ *;U2G:-P-S+LWL\A5)U[.-HK-D\=@<=J+45\-<)E/+ DL887V4.
M!))0D+='F!F3%'*USLM^U":! ! 9>9#O#GH["'#19V:*[D*AS\=A$M(UJ7O$
M\D#LJ: 3%S4/R_$Q,4"Q^_.6N0*#7Z,Y><8_=YW&)4W8 #(BA?(E?AETZD=<
M1J ,XKQK-U@>P5O[-5M;E27Q/:\NVM+4O=>J66FLA-D,*HER:V"6E*S&]?&%
M"9<T_8%I0 +PJ2$*@U (Y?(1 $  E.,;=>TC!& :L5),G,DYG8X.3U(&,'.Y
M'4579&?-3N1=!>N- Z_:>4^[;V3&V-TJVOVM+"N62QZEZT%HN_,$?L53%[!0
MQDYX?1V&X2=B3P92:A7)696H-"]%N*'&'(NJ_0GR^6+I/X\=+*8B\3J4R[=@
MI]Y$K?DD@V3F]F)*YK6+UAL3-"L112JJ:%3>72J9SR7+ET,BYZ%(CC[,K;LN
MSZ=AN6 R1LFR7PC:0/E54!5K*@NZMQ:Y22RY/"+/JO8*S8)>#TX7<K+7WEB?
MV^TN^)G-"KF6%%G3\;@O)6K0@"F:%C*DQ]OG\97@_P!*F"KJ0K2KC=@:*6ZX
M/MP.M)VQ1^QEE5Q=L$:;WDQTKM&$)K+:EYCN]0:3N9A(#(_)2GK"-*F+"C5D
MJCEZI=,'\H/RZ2=H\Y@[;FLI[&,8\^N>O6-LG.T&M;QQ;62+<[S/0C9!UALE
MJL%T>"6MYL]5.]*W8XF%3%/N&_QJ0MI67- T&KR@.+*M-9GA4T-RUS8%"!88
MF*"?Z>;6/(.4GX_:)HN[V/8J.+;7DUP,FM#/JD*;6?;\VLYZ?JO9IVIL<E3*
MU\P7.*^2S=7*5JA4OFCHL.=3T>2VP&"D)))0)Q\L)S(@D_L/TJ"9CR %....
M344XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3
MCCCBE....*4XXXXI3CCCBE....*4XXXXI3CD?MG%.P2>G94+6%[I.,6_C#0)
MDE&PR65N-419F"[I!S&1R-JA:]G?G<YFB@'9<S-A;ZQ-RIV(2X>7AO:P*C\:
MS@O,5Y&7+3S4V[C$.N%>([/MO="+65M*KU9VQO/7=QI_789":J+NC=?4@^/%
ME0N&W*L*>RVZ22)<XQT2!F,D(#4;2?C (G[^7[_9J0)^_P!!G[/:MN3CFK3;
MOF*VP97*Q;>IV0ZD69JYI?%?&N?LN_,L4L-T=ME'3><V*G2Z7:W2-//2FZNX
M5!(Y+FA^B3;,&F8/CFK_ !%G?%&5",)8\E:R>5[;.W-D-7IK*VFBAZ1;P;#;
MU:^T[%HW#)XBV K0G4AKM%[A5@3*4JY@ZQR9'6BVU#(S'R(M$+:#8T>[LR9L
M5N!I2@.8YA.Q^FW??;SVJ>4_8._09&YG;MG:MDSCE=6J7E%U/W)M^14933Q;
M95EQBM/Z6W.-VIKS=E&J3()B4(X:-]:_Z7H5#S'=."0KTK?G\-*4@R8([TFB
M$E5 )L5Y(,B?SJ""-Z<<<<FHIQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQ
MQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<_&K<$* &#%JQ*D (7H"-4H)3A$/&,Y
M](1'#!@0NL=^D.<YZ]^NN*5^SCE/MU^:_4RD;/M*$.D/V4G->4!*6>$[)[.U
M52#K/=:-<I<[)6M:9';2L)K= NN5["C>V=5,APF*S!)"2W-*7)E#>IP>G)MA
MCTHC\H;FYT8'UI?$#LVH7IL6M3@D7)E[.Z)B%K8YI#$II@34"]$J3*DBD/\
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M^0/RJ8O'(MSG:J(PBS)Q5H(G9$TD%;T8W7O,BZZAJV<K4#+)YDZ0FOXB@CS
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M;-*M[EZV6;_365+93;J*FKJ_MK5U"A<,/H \-]2DJ2E*TK2D\W+S)58N#.1
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MQ"U-DPNR:]E]=)"'%4IGL6FL:D4,(2M !FNRD^5-#FL8"$[86688XGG.!9:
M!8S%>20!SG'68;L#0ECQ63SRO;PJ*=PF%A4G2^80JS81*(I$RTR,;HK'(Y$Q
M/BYICX4S> :]28ZK402D01*QB"2$1F((&>LX[D1B<#I)GY;FI"R",;&8DC,@
MF9GL1WSVQ5 *GQI[3V.0Y7NBK^H*/?6E]\?KC#=:*;ME;&XW/(_IE%[>0&S%
M39"BGR&:!SN0&7*VF5HWO%:/P(TU5#"V24NC:>N*71>PAQT1E$E\8-U:B10H
MZG+"NV(W4O/02ZU76YVEKGEMS!YG#RAE$W;8K$ J(W.'A>I!/&R(1!*R,J:5
M29"P('\@H"MVGU*MB:%@33"'J:W=3L.9;*+0F5R\2NSH1'6N?EN9"52VF0IP
M>'Y$DE8'%.N1*$(V$YP"K(5ICB!& 4$B,^S++KJ2!RN*06;VC6T.FL\/+2P>
M'RN=Q>.2N9JC5A;<6FB4<>75$\R108X'D(2R6=$L&-6:!,#U*!@*$"0.YQ$Q
MO/7 W].E.96($9!$3DB !OTCYU6*X:][*3B[=&MFUVK^N]5O=%6U;+78]/Q2
MUT;T<16EN57#ZU(M)OG:&G8XRO\ +:[7Q<Q>WP(IF3GND/3QM&CEK8])E#<A
M_)K5X_)Y1\5\;[7ADK!F==:+8V1L6]546-^WS)#[@KZ_(\UNS8J(841\J?5<
M@LYE5OISME&<2 3HHPH5#3 +/M1DEKU_#I1#X7+)C&H[*[ )EJJ%QYW=DR%V
MDB.!LI<AFJYK2'#",Y!%&8Y,ND#@/)2%K)5H_NU)1BQ*6=ZJTN2IKE:G%]J6
MSZYM%D:70UE<WFN)S%YTU-SP06$T]I7N,7=75(C<R"Q@&<@4FE*BP#",1. B
MQG@)'<X/IF0>P[#RC;>G.H1@#$#!V]X;SYG(Z^E5GSMCV"K/<;>A[H"(L<KM
MJ_\ 2#7N1:_*[)6N\<J8%E43,;KKR1QN72I$R/04B9E!:U?SO+&0F&KD2)>Y
M) "0$?=.B;&%-Z+7.YQ#4!#<U50I+*J3W?=MH[ZELWM9EN>37]+9!0=J1-[O
M)R_":PAD98YP;9,OBY$:@;6T$LD A<996^*.B1NC+0W!O$%DLSKHP/>,9%CH
M6,^W^UC'?7MCO^MU[>_6<<^3()&R19A>),_NS:SQ^.M3B^/STZ+2$36SLS.A
M/<G5T<EQXP)T:%O;TRA8K5'C 20G)-.-$$ !9PY1),G<F,1T/:=QN"*!1V !
M)@29G "0,$"(Z$'J9K6LMKQV6-KKI7E;&ZX@ACM4NCGE\KVQ&*G6!<ZRF:OV
MWLD8915J&.LT8C:!XF)9*!K6K92 &0+6)6F+,9FU^/*)2&XLU0:I;<ZIOUE+
MBD@MUNO7;JC+2VJVYBB ;KKI/JCUEIJ+3AMJ]E6L&O.N$99'%N=*II*CI)'T
M,)$4_JY;(G1=)7MW#+H^P;+M/W[3^P#*J?JAL"/3AL0$10]URSJ3BW-@'-X1
M'+)BB*2,;@0B>XR[/<"ET:EJ-H?&]O=<,;ZUKC4A0%8,<[1++ AL PPFR^3M
M,?(DTNCD"CQ[PX83$NTTF*S+;%8VG-'Z@9=9 Y""VLZ4P8/O7$TA$1D2M026
M:C /,8$#M.W:-^N^<#.*!9$R,DSGIVZ3C$9'Y52-8>C=^U/M;MCO=&D3-:;9
M.3KP+0TZ8)XFC\P5[(=1ZNBK?:5%P\M*V?A.QRRRZI65U+XJSO32JN*GI*SL
M_P"^K&Y1=M;7"K;59-*!:4[758&,O%V7):>CVH.M<=LF#$FJX5#%#J\.E*U;
MJJ^LR36V@#VFTZM=K$E-AV@X+B;+DZ2) 4.$_D[23&&HA7N= %]8K LXZP/O
MV]_C LX]\?K[<\?H=9QGZAGMG&?<8L_'Y8SG.>L9_/&.N\>PN^.3L3$'?.\S
MV@=J<Y( (R(@SD<H $3,;=(GK7@D*P27@K&1BP4$!6!&9]0Q8)#@K Q"ZQV(
M808&+/YB%G./GGZN..6 C%4IQQQR:4XXXXI3CCCBE....*4XXXXI3CCCBE:H
MUK[4[#^0FP-3(9;^M.T.LNG=MVVWUL_K*5W"D%73^T$]^DVDT5>18;)7M<-,
MH&FJ\= 6*??M:I[,BA<)2RR+N>7*9I5WV:2Q^L_!OIO0LK8+ U5F6WNK<P:G
MA@>G-?66W5[/[/-D[0ZI'17'+#A%S2FT(+,XW(BDHVM];'./>O*)6<H:5#4Z
MDHG)--_?Y[>(QHSN/)(X\SJ.2%@U8V#>F*15<2!19C"\-E32U:W/5?$#4HL&
MS)L5D%+H^#"U&(;BG(P%6G%Z304X>":..19I4T=-?&6N%LKUO@+BNM)N\LED
M[Z*[)7N88LXK5ZJFIA)I"SU3^.*1G2(YZ:1BRV*S#(F2L/3'9]6..7!$R4SV
MW VR1U,$QCS,9"09(]T"8&^,8)Q.=\$Y /2MD@(?3CKOOW%G'\,9%G. XZZ]
M@XS@.,?EC&.>7'',E8ZXSG&,=Y_[_P"6,8]\YS^6,>^?RYQZL=8S[^_Y>D7?
M]H>N\?Q[Q[?GR 7D\F](5SI5=<UV/ONT=<:3CK2Q.5@6#2LHS#K6<6<B2-N0
MUQ I G3G/**1VFLRF@:0,8.;I0I ]FIV5X:%)GXDFU58;,9T]T#X^-9]I=\9
M_"J1GE=>2O8-WDL,VP0AL2"R6M66%S7476>W]FX=)2W%]L"G*SG+M8LIAZZ0
M 4/LG2E,+JD?HW%2 'U*HZ3V\]MO+/KY1FK!,]>N?0Q'7??'EOD5O4>K'>,>
M_O\ IC.<?P[SC'6._P N\X[_ "XP+&<YQ[]X_AGK^6!==9SC\\8SG..L]_&>
M?SWH-NGM_<-0@V:OC9"V(5NUK17?AWQIS2S=8JN!,FPB;:6P6UIM*92^D$AC
M<AOAUO6.N DDF7'L3NDBB1*%<QD,N"31<GCI#L!;LJW@TKN);L/8T@V@VPVW
M\J%+[AZL.=N.#]6D!J/79ON0=0,">F,J%R.G6RHWV U>QM4^1,+8]R+$C4FO
MZZ0JI$64<YCC&X!WZ8\L[Q&Y[9%3RB"9VQT_FZ#)&.I/3J)Q5TQG^L!%?[G1
M5_VU4G+B^:[6KDIVNEOG+>%VW504W34X3^)=2EC##2ES22[8\[13_+":31/#
MM(9-6=6K&EX"\#6HL,Q#,Y)LHB"%OXMDTXQ$EV)>$]1V,?( 56(C_"/H(GZ4
MXXXY:HIQQQQ2G'''%*<<<<4IQQQQ2G'''%*<Z%:-8P"Z*\F53VI$V:=5S84?
M<8G-8?(4V5C))(V\$Y2NC.Z)L#+R>B6IQ"*/+P8#(@YZP+'SSOO*S_,-;E]4
M/XT]P[>UF<%[-<T"J@Q\CDC:VY*[NT/90R%A2S^<,;6N3GHG!\A%>*I5*F9(
MJ"$HUR:4XLF%9+P/$$P"3M&?3S\N]!N,QY]O/X57%X!-/=9J?DGD@LNL*3@<
M&GL0\DFX^MT:E+ U'(W=GHF(2>!.4<JY$H,5'8*B+0N2)E*-N](A%G)RAF'F
M"+#S9-YI=^"[8&FY/N56+#H1;.PDTJ.^*2VMNG>FK+WMM3=+A'+0B%KPF&T?
MM/*7=2 ]/6UZ;0&&21WFE9-CH8H+BBAA4/Q"@QM;%8-T(8L!QG.>_C/76,YS
MW^6,8QWG.<YS[8QC.<Y]L8SGK&821!\C"MR9@;]NGPS4G?<8C;88!\MYGXUX
MF&?3]/>.\9SG'S[]^W6,8ZSD6<YSC&,8]\YZQCO.<8SK3[9>11@/\H^GZ*L8
M_(+%K;7Z3VE75ERZ+Q)^?D2Z46*E;XE92*'K6U*>"2%T^U$LCI*U#3]P0D6B
M<4A@\EI?J&V'79:5A[>6;+=/]8Y:_P #A4&6I$&UVT$=  P,63FA"8NU_IQX
M!]5,MN20)AY2S1_3JD^*I9##<X^M)529,G_)/*P@M,[E^+JL*RC;;#H'#8EM
MVS1R.,Y8R42!$16$0%D0Q"&,]8N5FB,5N;FM-4.+LX'J7!P4J%:@TT7F-7?N
M+YMM%FXEFW8U/3$.710'0]<_Q.V:2TPDJ0%-6SI"WW9*5N(%NW,/+;\CK3MU
MJ33;>GOBUM;;5M)2]?%OQ?Q-PC5[-'X:V3SH"FK=Z%73Q/(MQL6K7,1<+9M6
M+Z^F#K.,X]..LXZZ%[?\H/7MZ1?(<_GC..>?&,=8ZQ\8]L<<]2-AUKUM.<"^
M,_RS^?7Y<YYP+XS_ "S_ (<4J$WCFSD6E=!B%G.<YBSIWD6<YSGJ7R7KWSG.
M?CKK^'6,>V,8Y-KD)/'+_P!"J@OG_P EG3Y_]L)+_P 8_AU[YY-OG:XD_P"8
MM?\ _>M5_P#O/UK67_!VG_;,?_$BG,(7?7EI6"Q-+?5-]22@7=$\Y7N4AC4&
MKN=*GMMRB4)\,BA!8S*]M:-/A484O^]0D$K\FIP$?6^W,-+%F_CG"<;2ZA3:
MRL)5$EMQQI8@@CE<:4AQ!D;I4"1(."0<KK:7FU-++@2L02TZZPX!,^ZZRMMU
M!QNA:3$B8)K6YO[7;S#!W#K&75Y;5@6=5%6$!94%KJ2-6H?(@L]BDMJ>VE3-
M5?VK1%) >@;DB)-'Q39H&K&X- Q(S4B<U,K-NBHZG[Y@,B<GFT]LIM?;&L9L
MMZ"*R>JZ=@R5G=<KDJG#\2YUU&F5U5*@HRE#=]@L4G-V2U9A^2<J22# 2CZQ
M^F/[L<YYR[/1V;-]]\76H/%Y[QPA^^N%MMJ"0@ ("TAU(0$(_P#4>.KE;;'-
M[M<BPT*WL+BYN47FK7"[BX_$>'=ZG=O,M*\-+7(AKQ$I<;#:&T 77XE82V@<
M_NR8M;HSNS*[UEMY_I2,/TNN=?%LPNH6:/MXW%2&T+&<45?P)\<BPE'!21>)
M2:2MTMF3N> 25EB;(\.J@(BTN2C=>F=:[S;3*@-B]*6>A; >J!;K \?FX56*
M8%$)'=+(I00S9?6Z(;@1=:)I8#7!SG;A(JX6[(FPM.RN2IY8; F+TG  ]$L:
MB-KK.,9^<8_X_P"/\>/3C].OY9SC_#KW_C\_/Z\ZI!/7I&T[[D[2>T$ =C7>
M2H)Z3D&9@X@@?G^D9G52V$HB9WW-[VO;7/4>V6G2277!H#,MG*"65<94DZWA
M:J(L2R93=LXKFB)4;&9%(6I- GFGF*4L4M9H2\;$$5FKC+:TR8EM9C9!F%--
M$5^T!Y-Q7GK]!)O0 HI7C90\T@/C_P!@J3DUQRP3/:!T0KN;U3-P2^>6P[4%
M-3X @(F">),]?-C_ "%X6@:VM"C7";=DOT SC.,A#GOY[QC/?\^^^_YY[X](
M?X]_'?>?5UWWUZN_5UW^7?7*\A_O#.3C<X\_7YG-.<8Q$$1!C (.<9.,$[=C
M K5+LF?0-^\4NFVJ[UKG9H;4N?0N):R6/=DTTIN>QD>M48@<.@,+N]H?V9GK
M1WL1;/UKZA=BZ?B+2V C$AF38V6&\OB>'L9;BN[;EOV?J+>VT))6K'-I>JMZ
MS?'ZAUIA\WU=?)]')[I-&JSK.(6<9+=CGM.E6ZZO5(.YMSV/(F&0*(P_MUDO
MC8^#C<S/L1,VMNT/Z<?Q]O\ TA=_VY[[S_#OOK\N/2'],>_S^F<XZZSG'QG.
M.L=9SWG'7SR0@]QL!_+'J=]^QZ>=.<= =R<D&,@@?R@P(&)^54Z7R[1AB\HT
M6=+9C*Z:P5/XK=L%<%B*:+CFZN7'-5W5&X; Q5FA99"@Z82625^"LT*&*D)5
M"Q^1B<FL@@9*I:$5>%0'SBUW^W[SUG:-A-4I]M5L_P".V!SJM8?K5*JG>Z(U
M'KDN5P+)#TZ6%5X:QD=HN3$]2PVV9!!02N,UI'?Z/8\TO2H,22O:K9K>8##I
M!*HA-7N+1YUE< $^&0B2N#0B5/\ $ARAL_!9-F/.YI(ES2&0- 2VYX*1'DE.
M24D@I86=@@GZ?<,!QC]?[1"S_CG/]OZ_GP4DG! '3$G^4 $&<1TQOF@4 !(D
M@ 9(C!!VCK G;MM6KI*YAOQK93>R%RN]^[1/^:GE'DNIZ#&VXUQ-SBC?3E20
M"8.^IMH.R84(8RI7/'"<HX^5'[4?5BURL@Y>DBYY#\F5(&D[F/RV57'75Y:0
MOEV;)R2<;F7]2FON*EV7/G+3=U :PO=%EV'LK(77]\H+ 51K=9L!KR^SXN_Q
MQ.\I$+C,83&U3BU+F=4VM.S',H9%K"C#Y"IO'&&80Z4M*]AD\5E#4B?8[(61
MS)$F7M+TRN1*EO<VY8G&,E2C6)S2#2Q9"(&>L9QAVIM3-;Z(^V,I^CZMKY<D
M4NRQ.]1V'-*61 4OJ-N;7DT4E.3J9 8)S:V=G:U?U70S!C6T-;9UA @2IRH*
M53@X(VD@; ;0>DD9Z@00*GF$;01M &8,Y((&\ ^[,#?>J$!*]D-6=P_(181K
M#8]::FG6[()-5K[ XH$$9=+CK_QS5(WUTX7TJ<T)>2-2F-H@CK'XR]Q=S;XF
M7>#&!DN9Y:HRECA2S!#/9=G3W4_8P4]N7:*06O(*G\7TYJNE-EFR=-$L9+DE
M^Q\11GW3 TTCKV%LQ\-LB^"HRR0M/$USB7&00]T2J&F+HG1 VYVVWEE;) SN
M3"^-S<\L[RW+&AX:79$G<FIV:W%*8B<6UR;EA1Z1>W+TAQR5:A5DFI5:8TTA
M04848,&8WUOI3JG3Z0U%6>OE10Q.=*8E-!X9H6U%&8E%?GK%, =0'GE*%!9D
M#4.+@="$I1P$$0-6JS(ZD;C#S!9<JO4  0<#?>,D_3KO,!S)Q(((C(W,1F<1
M.>\8[9D^3WZ1]]_\\?\ /SU]4?7]G7Q^F.L?ESW<]90,@!@.<XSG'?Q\8[S\
M8[_+GLYD&P_3;X5CIQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2HP;L
MR<V%:>;4S$B(P:P#8IKE=TD+@=GK4;;7$U&QUI)7,,4GSDX*42!!#)!E-AJD
MRI<M1I"V=4KPH5I2Q"/+U^_V?>7ZU3J?2J64Y*/&R?-)+KU&I!,(-I;X^;?U
M,GT/)>'B,KU37,++L.3NS3/(NRNI_P"#Y:&UK0K%KN4A?P&A1I\E&6Y>4"^Z
MYJK7";UU=-3;)3>H-BJYMNF9]8FO]&&[ M]/-$NA2J/'OUD0AG5JI+AF<T+^
MORS+442D[$)8T*D\ERU)S48E=2_BUWCA+5:,+I6L-O\ R5^1^/.[##ZA8HK-
M]#FZGZYUX:VP;:F+LRQ;8>ZUIU62TQJ.M>6]V,>)'+7ET3G"RU-$@?3" YQD
M@D0-R,X/8]Q'7,Q F%#:Z9@CUC,3@#L0<],'.XC.TSQSUE9R(L.<YSG.>_?.
M,XSGK.<?&<8S_P!6/Y<]G,E4KJ,XK^"6;'5<0LB%1*P(HO-1GKHQ-XVRRR/+
M3VY46M;SE;*_HG!L4FH5A12M&8<E&-,J*+4$" : (\8:4Z:ZAK86"MUFJ^N"
MNO"Y4GG0(&IHVKSX6";HTI:%),0Q8R+"8PRI(B*+2)I#A!AW)2@ G KP0$)>
M))\<B!V%2"1L2/0Q6)'N@J,DL[A-HR*F:H?[,K5'^'5U8KU74/=9W 6_H8<H
M(5+ES,>_Q5'D)A@<I6)P0$8P,> @#ZA=^Q@H>D(K8\IN*,4Y5<<MN<)0HII:
M3#7D19[&EZ( BQ@1RB;M[.GDS^E ,HH8$[JYJBL"++%Z,B #(<K\<F!V\_CW
MJ*IS'C&/V@$K&,8QC_P.BKVQ[?\ [U4N?_GRXSE.AG^L!%?[G15_VU4G+B^5
M3M\O\J:=$_X4_P"44XXXY:E....*4XXXXI3CCCBE....*4XXXXI7B(6 !R+/
MQCYZQW^?7**?*_,&W:RPZE\2L8E^&)JOI$7=^^\L;74MF4TYH)6[P0JD"=TD
MJC!:*(/6QE@(62I(PN-/./+8,S%R4-^6\ %&;;]B+XKG66C;:V!MAY_ ZYIJ
M!22Q)DX !]946R1AM.<5"9N3>H(ECNYC**:F5 5G)R]V6HD9 !FG@#FJGQM:
MD!NZC+^VSW=JEE?+F\I1_P"_5MUE.$OX\CK_ %;5-H6C735E6C7E$!+9835@
MD#I,&[[%"H<)Y*I$H=L&JDY(4]3.P\N\[CJ-A_KVJ1C)$C_:=]\'\NE8%_9\
M&JBV)!Y*F>O4-6-[LS>4G<%EB:*(XB@WI!3;6MKM%$F]G&U"&["KQ((@@EE$
M0(3 -3@)B48U(QC%85L!<EC[$V6Z:<ZINY[,!O"%MVPV6:#"C$NOL;=TN#_Z
M.Z_4F!,0/6PDT:,G)D:9.-4&K&Q>1*'P@MR$WI2Z:-)J.JN"VYMC1_C?H2IJ
M8V!==E+X@=F;31B$$($&M^I IPRI&:/1ISSG*62S]_=8^HQ5T%2Y5-[,J8S9
M7(<$HVU,$S98U_U]K#6FLV>J:ICXF6,M2E>Z*E"Y:<[2&3R1Z496R&8S!^5"
M&ND4NDC@(2][>EPQG*#Q!*)"0C3IDY/!8N%:NV&[5*V+.5B\N![CCJDJY56E
MNM((E?+%U<),M((9:/X@K7:^>:N_XVCP[(+M[#F4+ZZ20EQUQ*RERRM%HQS$
MI*;VZ0HEA)-NPK\67';+Z5(4G7NO58Q6HJN82F"%0YM"WM209YJY>K/,,,4N
M;V^NBG(ECW(WYQ.4.T@?%QABYV=%2A8H'ZC, !"N\M9MQK%V=K.]X1=.OT;C
M](J)T36$7DM/SE\> ,UF1UAC\O3S!X;K+:DCROP6TGG,2IK0LI" 2@K[I,OR
M6/UV8<<Z;^GVUPPU;$+:986RMI%NXNW"3;J2ID#PBGW6U(0I"=@I"3&!72N-
M/MKBW9M5)<98MUV[C+=LZY:A!M5(7;I'@*1[C2T(4EO^0%"?=P*\08%@ ,#S
MV/ 0X%G'QD76/5G'\,Y[Z_ASRXXYNUO4YP+XS_+/^'.>8IN.\*EU_B0)U<\^
MCM<0\YW0Q\N0RA8)"V">70M68W-WW 2C>E*P")5D@ @XP/Z(\8%ZO2$65AA^
MZ>;M[9EVXN'EAMEAAM;KSJU&$H;:;"EK6HX"4I))V%56M#:5+<6E"$ J4M:@
ME*4C<J4H@ #J20!4>_'+U_D54%UW_P"2SK[?_P!ODO\ W_SZ]^3:Y5[XK=B:
M0LK66L:Q@5FQ663Z PE2X3**LZTP]XC:1?,W\M&<ZI1D%Y3 4#4$!)P(7J']
M0(@!R#/JY:%SM\66UQ:<3:\U=6[UL[_%]1<\*X:<9<\-V[><:7R.)2KD<;4E
M;:HY5H4%))20:U-.=:>L;1;+B'4&V9 6VM+B24MI! 4DD$@@@YD$$'-.8HMF
MV6NI&9N>72*67+2G)U"U%HJPKV2V*[IC,ICU>5*]KC"16K0MWH($5EP4  FP
MI,(3Y']0XL.<K\]8PYZSD&,8%G.,YS[X[]^_GO\ A^?M\]<XC*FD.H4^TIYH
M&5M(<\%2Q!P'.1SD,P9Y%;1&:W%!1!"2$JZ$CF ^$B?F*U"=F/-WN%7UO7PQ
M5XWLS5#8#-I SQ5IG&N,L+D:9I;D2=2F3RE6HE;88WNH3#!A5EJVPDU,5@)A
MY/Y"V2M8MF4U\1F*!4P>W([(E-:Q.7/CU-*@F4 ASFX.C6T#<2XT]OR,MK<1
M&KUQBI$A0JE \MG^DE#-3E"-SABRO%'HI;TVF5C6#2HG^83YY62"6.@I]8:
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MKZ33>[K%K\,:@%E4K%V&'2(+TP*S9&YL,[<AN1JIH:%9I[:?G!)Y@,J2"0B
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M48((5;8N1K",YP-.>4/ 18Z51-)P37FJ814%;-N&V)PAD3-241N &.CRM"#
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M[8BS,&4[!V#94^O"U[.C"@*1]:,NMK63))0\K(^M$-&\)6EE5-L=&;]NK(;
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MKI(CA,UL)0D.0D@BU?-S:ZRA;A:K+2"/1(G9V9$1I*$)F5:X1C@4(I(4:86
MXS 2A=ZYCZS@V9F(K\U&*!@G 3D0FT5D%2 Z)X2@5 $YX7%1@TEW$?E!@[#?
M] P)85GTA*.R<"#G24^BV2;AQARZ0P"ZNV:GQ;A*/>++?*I*N=P#D3RJ29(A
M0.:W;.U-[=VUF+FVLS=/M6XN[QSP;2V\9:6_'N7>1?AL,\WB.KY%\J$J/*J(
M,2_'8?-F+6^$5?850V=54HK9F_#7,,_:V)$@>SW5_D+I@<96,TB?/Q E"F4)
M@KQJBF\9)R@LLHL\.!&8GKR'FF=IW;>54M%LVP@JEK9YNUHW>$M==$RPIR0D
M 6NJ!U*E)DE6*TQIV3424QM$TB"6$L9^%.!9^GGDP^6_CK/$Y5Q$Q:KLF=:6
MO4F[=Q+B"E-XHO\ .E#SCKJ6WBLO-I<<4H-N)!/2NCQ%PO?<%:YJ?"6IW%E<
MZCP[=N:1?N:?<HN[5%[9$,75NBY;0VTZY:OH<MGU-)\,/M.)0I:0%J<<<<5Q
M:<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQ
MQQ2G'''%*<<<<4IQQQQ2G'''%*BMO/((9$]+=MY38[%(Y/7D<UGO9\GD:B#H
M:R2N0PULK"3JY*Q1MZ)(5',SX\,Y2QN;'8M,H$VJU!:W!!V2/I#U_P#P/LIU
M3W857$@KA]K@FR-/6RW*,8XWY+I_O35[/3C7-(0RK(T\09\3IHG5LS9E<CBX
M8[((P2%BD#3F4LD?R6%G=RP["6Y\V>:TU$VBL:.-T"=Y# ==[KF;$TVF8F*K
M-T=XS6TE=V]ML(:TTA$&%+U*0M))L+%"=(-H.5E*3R2### ZVG[.)(M<WRS+
M.>*6MW3N1RB=4/$YK8U9:X>.&U]0I'#W)2\L!_VSQ:\X6*HO-HS&7%V<6(B*
MPP*=I6.*@B3MI(42; QU.\G_ *0/_P"AUV^&>_4U<?RGXQW!@?&-MOCBMN+C
MCCEJI3CCGB(80_\ *%@/\\XQQ2O+CGADP&,YQD8?;Y]_C^?.<""+O 18SG'M
MG&,^^,_IG'Y<4JG8S_6 BO\ <Z*O^VJDY<7RG0S_ %@(K_<Z*O\ MJI.7%\J
MG;Y?Y4TZ)_PI_P HIQQQRU*<<<<4IQQSC.<8QWG.,8]O?/Q[YZQ_U\4KGG&<
MX#C(A9QC <9SG.?C&,8[SG/\,8]^>L1H XSGU@[QW\Y]O;]?X=?]W*3M]_(-
M9*VQ9;HAH.[1TG9YFB:&6['[,S9"B6:_>/2GG0@Q:KLVVW)<I+;7VWW./DK'
M"HZ=+ M-<%99,BF@$$;38*<*E24@J*@$@$DD@  ;DG8 =9H2 "5$)2 2I1(
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M*U*]8<;GSFH7&I7MLM6E(<2US)2E]+=NX[=!2TA9M6[MQIC\+X?--PZI1?)
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MSS33;+1]QN2$)9:44=55JZMI#-I:OO\ AO6JO"MK=ZX4EMNZ94M:DLH6L)2
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M4XNQA_>>6+ JA]95IC2PY*%8$$. XZ]\Y_/.<]YS_/.??GK4?\R;_P"K,_\
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M#,=FEA]7IS@ L",P'.,"^!>W>>L9]L>_SC&.0<???YTJGT><?_: 2L]XZ_\
M Z*O?OV_Z:J3'^/+AC#@E^K(O@&/4+.,_P#)#C'>1"_V0XQ[Y$+H.,?.>?RB
MK%\J7DG0[<"VP@NSKDMV'.FTQU9%7;L*O$B.)56AO]1B,:ZN<2_=\J929R>Y
M'A!(E<C:1HUB0G"I1^+$$$@SC; M/P[>77?)P$NWT\ES-'($[B*PXZYZT()]
M"J20HL%X];6Z1J/NT2=)P-.?DX)ILRG#[A6,0AY4?1" G!TM-^(&'/Q2F[BX
MMU):24P;?P@5%;OAH'-SR$*4'0!)1"D\VLQ<HN4.JMDEY3#BK=Q <8:6EYHE
M#B";AYE Y2F0KGA:5)6WSH4%5:_LMYH-#-;9J?4(K&?[]O\ +%]$.O>JT.=K
M]M<I1WD D[XEAV#(?!QE#R !XY_+XN6F^I@Q3DHDLTP&G5YI=[-EMA-HJ.GD
MQU4@L4J"#5).8;'JDL5SHK?R35O(YS*R_P 7O61Z]QJ4BHN/W.X1)O1PJ-QB
M=2"S3(2C)4/:T#*YGIS4FQ72W[-3K%6<?*B[[=UQN,<] 1K(M6B2'T]%7!1G
M(<GF+T#4UR%Q<0J,!Q@TUR<E3@:+&##EQ@L!R'Z]W_LZ&O,S7Q?-&64\4.S,
ML9-9WM$KC*FU'24NXW@YQ+D*MZ?9<S!;SR49A;6!"@;2TPB0&'C[--Z#:RM7
M;UQ33^H:5I!6RX6G[YG5+VT0XD!2$7*M-MEWC"W "$%BQU%H.\B7>5I2GF]7
M4AK;=@M_3CI*[WQ60W9AR\?=4TM82^MUZXM=.M+9QALEQ/(O4$K6GD 4()UP
M/''4E'OVM"1OV:S5TU:H;;-B)J,9?(]N--76G:;K AV)70^.-_C_ *8<U,(D
M\M"<Y.SX]"7(FF%IG-W$R,*D:)K$87>!#;A\=\4BJ.%W)O--;:A#<G+(;=?M
M/:AD.I^M;.1UD1[21!Z0:(HZRQK#GI.29*ILX@.3_4^Y)%]<6 6ZZ4>+FA]3
MZK5P&6QNK[XDRJ92&3YL664O#D+Z! ]$MA:6.X X"E"C[%H$@.$D%^)Y!TK&
M$*<G(1B-G@V4W43+@.&:K*X:< QC ,-D&BZ# <8^,!PE:BL!QC\L8ZQCDZEI
M^D(NWD-,7.M-H6$H??UU]C2G?<1SK:TQ'#6G7#MN7/$\$:@I-UX7(72ER0.M
MHVF<.7-M:W/%MQQ+=7KC*%WFE:>-.M=.8=6 IVV9<5=7;%TPTKW6G[[3;IU0
M2"1-4=U?Y,O'?1+0:S:NZN2I@39QG!IT3KB!5]EW.ZSZC7)[7/QLB=5)F>Q'
M*G3[Q2:(8AFC,,,'W]*Q_+B]3:NYXSPS7I<VFNT*EJ I>]2N>KG1&-;'W%.%
M0!M@M./J<1Y63<&E#*D1)830!$)80'&3@7Q)(XP(,XRA9&A%G&>\92-B!-G&
M?UQDE.#K/\>?4,*",L1><8Z%C(<XSWZ<XSCH6,AQ[9P(.<XSCKKK/77-6VN-
M7M'&?PUEP6RPRZVXAM6B<3.NA*'$JY0MKC>TM9*1RR;'DD\Q;(]VO>(N/8[;
MVQMV.#O:65!I2&R/:5P?:VB%E,!0LV?8VISPPH\Q;3>I5$I#L^_7\T73RV9L
MQ;/T0YII>FJAP:+'A*J2V.7%YM8CBRD(D!B;+X^1$M9DR1I$J?.51[0<1@"D
MK^KC.$83 YW)*_E]$6V>:GGOE:G<^7F"Q]6/QV:Q#5UL"6(/^<1F-+*R,$CR
M SO/I*,D %8?8 3<X]N6/0[5G7&OI:7/(/1-21"9E"P,N4QN"1YGD!8\(SV[
MU%NJ%"2K!G*%0<D%D)F,C3FF$BSD NL=]DE35;,BQ%2^MH#*BA=]ER2&QQ\!
MGO/><Y YMJG&??W^.^_?OOGTKVF^TK7^+]4T^]X=;TG2;:TL#;/M:MI+%_J;
MKQN7'N:UUEAUE^RMD-K2VVR+=U25 J*E")\CP9I/LZTJPO;7B;2N+[B^N+E#
MMM?\.\2:?9Z;;M)MVFEBZX>U30-05?72WDN.+?8U[2V7$J2/PJ%!2EQ2BFE>
MDKZ:2\$P>*7*N](3_P <L.>/]YJE0@B]05@S9K*I4D&;G/6<*"DQ><=8Z%[8
MY2AY98'X[:9V)J$$UC=OP:<2I56#K.VVEF)>R0,-!M0YO'W(QD11IK(:TTP+
M<4. '%I,9<1)S"S!CP TH&+VWO0/3E]/.5':]5VT*SQY,,6P]O601<(?Y"RL
MA:YA4>V?? ?J>D.?@/SW4[O!H7'")W5;56%-;=V:RH'AG=9L[1^>?O\ 1EMK
M5<K=RI)"X098DD4KX]."U*!K<$182RV#[-?]9::>J^F KY7=>T[VD<&I.N(M
MW-3<:3^%\+3^*=6\9U%TIMHH\%SAR^Y&4*BY*4AP)+")4( /VWV8^RWV$^T3
MBNVX=UCC3B;1;!^VO;QUS6>#>%;"UMG+*T=N6BG6'/:1;,N/..(%HA+EI;*>
M5<@-I,J";A-,XS4L/U=I!DHE-+4M/Y@;:\UZ1."UX)87').:HDB0+^!Q)(6E
M. ANIHQDJ2\&$EB 7D0@A",4F3%!1(!&'#"4 ..Q#-$$L <?Q&8((<?VYQW\
MX[Q[\K?@.@M32>*1B02>2[=$&N["UKE$(L;8RP@N$>^ND*%A@>FJ./R=G3K6
MH.0HCT[>:8E*&5DL@T18<9SDQ/XZ]/2A!,64^2^'XQCZBB2S:QI(8>+&>\C/
M \2U4G-$+X%G).,"Q[9QG'MS0_BW%NI+7?/:3IRGKPF[<N+[B*Z-P^]<D/..
MOAOAUQ1=<4M2W2KPU%:E2E*L#R>I<.>R32[RXLFN.>,5-VMP];-V^F>SK1KJ
MWMVV'%-I81=W/M*L \AI*0VA]EA;;J4AQ *5"I4.-AP)G (QWFL1:BP=^LQQ
MDS&B ' ?GU"5+R@AZ_/O/M^?(V7SL/J8XU58D:G-D458+(\Q%];':MW6U8,0
M3-4BA ?@^**<B=SP)PO8 _88,5%A3A,/!]88 >H8?K-FBVG;09@Y%K/2F#@Y
MQGZRJ ,3@<+(<^V3#7%*K,'G]<F"'G.??/?.TO=.:\UC&7R7H=?:]R5&VI4[
MFM\%IV*N4E6DMY63Q)61I:&(+@Z.1H0>A(B3>H]0=Z0 QD6<<I<+XG+#ZC_
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M10S,&!R+SCK&?G&,_P!G,3[:GF76D/.6ZW$*0E]D-%UE2@0'6@^T\R7$$\R
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M4*\EJ6X2/+6J^T<CQY+);E6"%9F4S@</&0DH3\%JSAA$$HD>0BZ]RR61UO$
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MY^WR#ZW^;X!!_+J,]L^M/OYUVGCGXF]Q1.J4I<WJDJU&>'UD*D:DA8F.!ZA
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M .(/4U!NH?';NE':4W[M.=:\MFF2I!I)25W1$I@KFKZ+K-AWBTNV!EVPR;+
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=*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g601073.jpg
<DESCRIPTION>G601073.JPG
<TEXT>
begin 644 g601073.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0U1,031?1E!/7S1#7TQ)3D4N15!3_]L
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M36Q(6F3DE3*C7Y&>C),D4XM=F0B8962BAC+ V0<*?$<Y"/U$Y%O-G @ @("
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M@U?.S' C4Q327;MT6J"+5LDF@W;I)H(((D*DDBBB0J:2229  B:::92D3(4
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M-;ENC"V;!DH>.V=L%=S9FM)C8:N)_P#DI![(!_3]?G_QV6U8QC &,8P!C&,
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MI:VB&GH1U'(,0HE45C:BH9U#) B@4BK@B!@;L&("D9S\,=NKSO('TG_Z0_\
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M&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QF@B!0$1$  /41'T
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M/HF3T^<W0]C] % ?K$,V^11;U4$4R?\ V91^V$/?]N8/I].RAZ==@.?<
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MMQL<W4[E:9666DH%6,29,RVL<)#"?AMQ-4$"@*G&;09A*0H$( FU-41$"D*
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M-RU)>UDV<)<&!&A),",C/864:KIOHJ:BQ? *))*,>-TW+<W91.0BJ)C>R44
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MM6T9.PUH\E5X9%"?A31[4J*+R5+$MHOXW:-XR.C2',+=^JF=<_\ E4C H4"
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M-<1Z8S6Y>(SM37?;[U[V6-=?=9"0BS;<_=CPBQTD-,^,3/7Q(QC&7Y?#&,8
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M)TDDY:.D56[E))=-1,H%L&,A;^V0>'O^_GX@_P I#4/]KL?MD'A[_OY^(/\
M*0U#_:[ )I8R%8^)'X>A1 #<Z>'Y1$0*4#<D=0!YC"'8%+W;@\QNNQ\I>S=
M(]= (YN#Q(?#W'U^SGX@_P H_4/]KL FEC(6_MD'A[_OY^(/\I#4/]KL?MD'
MA[_OY^(/\I#4/]KL FEC(6_MD'A[_OY^(/\ *0U#_:['[9!X>_[^?B#_ "D-
M0_VNP":(@ ]=@'H/8?A_Q[\Z=*:ZU_.2AIR:HU/F)HWLO-+RE9A)"4-[!,$4
M/-(/&*SL?8I%*DEVL/LTP!,GE(  $7_VR#P]_P!_/Q!_E(:A_M=C]L@\/?\
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MEAD)64?.W3Q:6_R#I0B(C4:N(B/8B->ANQ'ZQ^ ^OY\[9C .I_(.D_N0J_\
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MY!TG]R%7_B[#?U'.V8P#J?R#I/[D*O\ Q=AOZCCY!TG]R%7_ (NPW]1SMF,
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M7+2CO:9':=:WR)N,!5863I3"=)#2Y=L.[K&2@'M'\Y!]QRCWUU]L'S]]?/\
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M8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8
MQC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g37138.jpg
<DESCRIPTION>G37138.JPG
<TEXT>
begin 644 g37138.jpg
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M 0 # 0$! 0             ! @,$!08'_\0 0!$!  (! P,"! ,&!0(% P4
M 0(1 P 2(00Q0051$R)A<3*!D0840J&Q\!4C4L'1,T,D8H+A\0=3PA8T<I+2
M_]H # ,!  (1 Q$ /P#/XXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTY2K
M2MFR['V]<>ZA>JO0V=RO%>S6INK3-,H9M8M MRRS:K4V*7=J$(YL5B<H*MX>
M,*/UWJY!22 3> &JO( /^(1C+3*=>.G,;0)Z.J5[D/5'Z2M:=:96#&SQ=:M+
MBPW!& L4I6BKMAGV$+++M9%W$BY;!((H"U%PD!P.6DXJ<(4+SV[7_M_\]F^.
M)*<(O!*<8K=5N0M:>"[>'@=2T7OMYUERYUJC'2-SRVBN\-K-8N6R-K9=8."6
MR^JW9XI'4RPWA-^Z2- 0]MD4E(^M/78 2;?%!I'E66,!>4W-ZCG1,N*$['G[
M:=?D\$4L05!/8%M2K".?*6T45G(59.PG= W/8_PJ"CH8;VED ;)K."H'0144
M#&T9ZBATN[K^L;IWJ=VS.^V8T+JWT#F9I:$Q2)J-3TB8<6^ZK8Q26&9RDG=8
M5K*-K62':N;!)/7$<P6^K:WJ+-HP%OSP&$=D^CG3/TY=T[%:,_Z=]G]_[,]N
MK#KT5USSR1H%YZ]8-V=V2@2<7G>7%L9XI]2<]J>?9HU>R&BZ.+)E'BT2L:,(
MV$Q6Y%<6[XJKJT2FKIY?F?8^] FNDP8F(WD9.RN C*XQ9[1B-1=SN4&-)SK+
M[J'87%K_ )*AO-(TNF6W%G-=D[<VU.N6"/EZ*O6(5)VK,3Z=B:JG8_E,6$?(
M%?/#G*1N9BZ!0"_2'GFI7MMUMA*OB]VE-ISEG4.QMBK%3P6S*VB/&#UZR7-B
MK)U.%H,DF8[>P2-BCD%GL0W9F,#Q GO(?P(>8<^C% R3+?0GV#.<BW/,^PB,
M#U_[>R=ZOF-3T7.YVGKN@5?1-"T.GTU6$5.T1KM-G;0>M5]HFFD"\7&,Y%)N
M@D]2;-XZL5[CY?<^EG_#_89@/8.GS6ATOL3TDS'L73L^F:],VNAP]HRZ[0[F
M$MS1S'23JFOQF8]<J+IL:/E47T<=-%V@17VC9B\!MM#O9RR"GQ7-'(W=]M5^
M 7+\3&.24%+_  Q@R)?-$2ZNT+.T1UF/HR:!Q4*!3^XA@(( 9,_N.!?<8I!*
M;]9B>0]X%#P4HE4 3$, \WAD"  B*2I?! /Y,!2E^?(#^H1\ 0AO!553>U)/
MW%$3CY#F%KG_ '5]0R0K6\X>PT[9I7L!Z3/3[U$GF\SBD<$N[WW>UK62!Z<S
MMC8IPXM[BLWR1U+Z?$1K5#P,S H'E&\BD!D1HEGO:GNI'=%.Y&I5/NZTEVLC
MC?02=I+BG=SJEVZW+*=KT7LAG=.U?2)QFAG]0D<=A=/K=FD$7>.V%C(1E5G8
M]W6TS*(H?B%K#*FJKFN?FX\57F31?<Y\@2=+?\9Q.$5"XFZ26RO@JI=FMP--
M7G/3]J@ZO!2MGL\DPKL! Q;R8G)F:?-8V)AXR/;F=OI"3DG2B3-BQ9MBF<.G
MCA4B"+<HK"<2B #0'KUW4ZG]K_XF-UI["9)NP4IXS87 ,LO$)<35AW))NSQR
M,TE%N5%V8R/X%X6..9$Q7QFRY4/(I'\0U^L-@.CY)Z+FHX_5= W;L2WIUJS*
M?V6TWZ=<777;]A[78X:R;B69<UV/C'4K!?PVI*>V#C627X"MIEBR.%&S?Z@4
M4[;=ZO33'KA3O^2'1XJ-7L^E]=\GG9[J)K%!ZA,H*JVV T)YFU![&=I9?/+#
M'Y12(>+K,\M*P+A%W=8Z98Q\<Y28)3(KKTW*V[1*:7N]BN*;3]"ZYHK'#&04
MSDRG*)(B$0 24K;Y-U#1Q^+OK*5-(IE,!!34]P_/@0$O@OM X"?W  D$4Q,8
M"F !$2&3 /J![>;I7J)O;[0./O QB")?:4Y2?S'*8W@!*7[B8/)0 2B(@!@Y
MA.]>=^[9]GJ;Z7N%2G<CL+28+:>WGJ=XA?\ 0LUU&)LVCW/'\1@V4WF$0ML"
M]-:EN*D$1!&/@]18UF(E).-=C-,TF2K\$N>9P7N?I6JYOZ=<7WG]03:^L&/3
M/3SM5H;3?ZM?8W/;3M797(^TS_+Z1%VZVJUB0);[)4LK: \B,S!BJYT98ZCA
MPQ?F\BO?=/C\///XJ]K.8O:GGLOZ:?NS<C=^&2-16SFF)=R7;+Y0OA[E+G#?
MCD@]PB10 ((%'R00_4)B@!0\_'N$# 8I!$%#%^2D$.; RJ(%]XI+ 7WB0?@O
M\P (F /)@ P@'S[?YA#Y\>/ CAHT7M)W6T/U0;;"D[*5JE2^>>H<RRF)R37^
MXU5SEA=.IB4*DS94JJ=*W^;-I?4)#2:XHEI=8V.'NZ+]W9149H-6C5$YAE)]
M#)'9-4PR^=J=U[+;MMUIT/4-XS*'J&CV2/=9_GE,R3:KI$5$M5KK.(8+$L;]
M@51&<L\F]>2$G%_E\*9)-E%M3GCXJT "\][X\/:N?:WOJTNE80WRF54&J1N:
MT%\U0NY NSN)J7R@]G>OVK46UZAFFQ9Q?<[HDG:8:[7:I6Z&FJS492D-SN[<
MPL<NV=?A8AW6V:2KR;1>F2-'-45EW'L33$W.]Q_=LCWZCQNFXCH-2UG/)I63
M;0]US^=86:M2KB&>GCI5".E8]51L[6C7Z2K-^1,_EJX3.DI^H.8(>$P&IYQ7
M*1TTS2)L"]&]=!C4&:U@AC+-HC-[+C/;32:1W,E'@(J"K[KIU:;,WCIRW.R!
M9RH5$B2I&GU"^_Z[ZHQSC/NJ/6_1NV.D=".D,E9O5MMRFB9E=V67&LNPY5VL
MM4-E.9R.E+1;DK8E9I__ .=$33V[EF:Z.4THP4GRBZ!1B-M2=I<2=*G*G'9K
MOWY[/LZAP0L!FW(+(DJ-C*5QC)EN)$H!4;KMWUG86>[5^EUJPW"V/T8&L5.O
M3-JLLT_.)&4)7Z_&NY>9E7QDR**$9Q\8S6>+J$34$4B'!(BBB9R!TV9:QG^R
MY[3=8R^S1MUSG0JQ%72E6^$446B+'59QH5]$3C!1=)NL#!^U,"R"BZ*)_9X]
MY""(!S!SMO;[L;L/7#JO&=\^X>V=7HV\^DSV>UVF3,#(QF;R';+LNSTRPT"A
MUB_1*U5<%MTI8L@4@),N5)1S5Y:F=L?2S)HV52!X%($.R7<ECG/4C$\_[ P/
M6NN9]Z4/2>^=99W0NWM<Z=YJZUBR,P)H=L?LK+G]H:=I%XF0BX^C3^0&E8=*
MM13H'1_+]\F*NESI;A]+ESX%[57=*W7QR&G[O&CYU6>W<1_RZ+_B:/9N3$#B
MF3$EGFT#L#CNI7?6LWS^^0EJO&$6>'I>PUR+4<'?Y]:K#"(62#@Y_P"NW00(
M]DX)RC)-@:+.DQ0. '4*I^CE9.0 >D6M+.N\GK7.K">/4GWG:/K0\L"L2H"T
M.K/+]4Z>K-KPKCR8'$,I,G=C$.R"4'+ S98I$OJ@D6?_ ),6QY'E..W'M[_?
M_;6.2&R>T;^6$O\ ^\(S\>VZM....6UGIQQQQIIQQQQIIQQQQIIQQQQIIQQQ
MQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQSX81 !$/OP\"^
MVFOO/@F H>3" !_4><?\07Y H_5,'G])! 0 0^X"8 $"F#_Y1$!\#Y\>/GGP
MC?\ 4!CF$P#\B01 0\C\A^WSX'[?/[>>4W7^'\[OCFO''O?/]'37T53'$?I^
M/: ^WR;R'D0^1$/TC\?(>!_SYK!$I0 0#R?]SF^3?/GR'GQY\?T_PYN>TH_M
M_P#3_;FKC:OXN>U4OY_K_=::TE 0#P/]?_MS5QQRYP![::<<<T&4(3^<Y"_
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M-:Q6(4!]P^!^X%^YA#_ /N/-E(ZJY3")12*!O "/CW&* ^?(>/CP(> '_,?
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M_$__ +6[TWBF,80'K5ZARAB"8XE QG?6+]0%.81+_,)2?N4G@@#[2@ 2$U/
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MBQ&2,FY6($8Q),NRU<HW*KJ(*M>_'Z 1Y0Q1,!6X&-[A(0H+%]QU 3!;Z8%
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M1GV"+:-%&C$L*"2R#X522D[;U$Q_5L?M&3QM/K^?HS],T"A1EEH=8JT18*?
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MF-GO'L<Y7D[1TX:.I"?F)25;*."QB9BUE*JKN]OU./SOZ?KJ^.#DEM$.&2O
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M$#QX'SSP.K9"TU..;L'5DO-5,T>K.R/:-;I.JO7 J(_2*1TO&JD.X13 />1
M_@H*B!A'[\BAM7IZ=GW'8^)T*N[!-JYC#.&D(BA*:K<_X_4J#M5NYG"MYH?J
M?AW#ATD9<[$JR"!U4VJ@'$4P%/Y/UKU?UWT[)"/0_L_F]5Q9<V/''+AZF,<D
M85\3-*>".&3B"$98\63)D8N1CN&]KX7K/J7JOIST\N@]#GZO#+U/38<GP.KQ
MXYX,626W/GRXIPC+9AC<EA.;=5C>34W"3DZARE,F*8B;P(' Q1\>WR AY_2/
MN'^4 ,(^WSY* AXYY30K_6LQJD_?+M-1%7I-/A)2T7&U3[]&,A*W6H1JH]F)
MF5?+F(BS8Q[1,[IRX4$Q2(I*>"&-[0Y3W),,CLD<2#EA<-)M9YCZ/XD+[=YB
MVE9_0%8R9F))1RL1H8X*B1?Z/R< 3#R8"B/+7?4IA-;T7)Z'AF14.,NCG:=<
MHU=T=W;E9^,S&LXY4WRNE:$;3[)66$I,5^L79I36&<D591SQ64>VHL4*)D7*
M_/?Z;+U4^DCEZOI_W;J$^; 98=1L5 '+"&.$[7EC$ \J*^WTOQ<I#]YQPP9)
M+OA#+\6,8BA(R?#QW+8$I&P"=A?FM&D=V^LF24;-M-T3<,SJF?Z\V9OLSMLE
M.KK0UYCW==+<"OJRYC&3_P#,6?\ "ABV$792E;(1(B]=*()$.)>=;^Y77"B9
MC5MFM.S9M&9;?312>?7=.RH2T/?G$RV4?1K2DIPA)*1MKUZS166;,JZQDGJA
M$U% :^Q%?Z<)N80?8+KH^ZD5#7.NVL34)TU[3=LZLW7Z\9??]FJKW#]DQFVV
M3'Y.AMT(!M9)K/ZK(7@,5=K/XPJT#)5%O'3KAL=0A3[]7QG<,(?8+OLWAFMQ
MU+>7;U+YN)I639]#:WK?3!'N!J%6NV$7Z.QN+;2YYJ5C:S7YF'NL/6(B;-G,
MC<74(K&C!+6(2ZN67-'-Q*KDLAN>4&MSP5X; 0[CI\=AOL1=Q.!=?$0"E+C&
M+:-;PI6-S4I]S^M*E+S/0_[;LN)3-GML50LFL"]M8-6>D7>;F!@(ZH4Q%T9%
M_-V-2; T0XB$&97S!^@[1DD&/X<WGVC_ +%9#&:[6<%D-'H;'9KA7YVUUK+'
M=GCT[]-5RM-B.9R98UHJAI'\NC$E4UG+Q=%%L= 14:JKE*<Y82;Y.;1.]&>J
M,SM^#[OJ/8UMVSS#0WCJI]5'BVJ5[*,N[?0&@R-IN=.S:N*-,QL%EQVM0\^]
MKQ6\4[M,L4C &#^4451)7/>9]L^]27T_=>J_7+?74+6:_O:FQZE!=:;X:+B"
M;=EE$K651V@W-I7@\N:PJSDXFUM)-VZ'- 9NVMA)#(D !$YM-U>U_#?#6[@\
MQ[OL??57% 4J31DI)"7'B"-"QD_+=%O8.VI)Z1VOP71M6N6(4C3ZE:M4SPKT
M+U3H!T[DWE1<Q2C)&8C)R10:#"-YJ&6D6"<O DDE)N,_&MC/XYJ57R'37ON9
MUZS1[JK*^:37J>&*.,ZCM'?6!1XVCX*>U=D^E*%545F[5RK-6VQ1;))ZRJ\&
MA(SADY6&(5BHK)M4SQ*^FW0.VN/:30,GL3CL<I3*M5.RI.T<?L= KD3A"&A2
M&IJS>.6WK+H,72X"2TUW>2S5@FK3-%M-U.\K2K9S;GT1/I(QP>/ML!9V^Z:O
M=$<ZM^IO^O'K,TO?]GH])KSZ[7Y3$+ETS@J?C>F1-0BT#SUKC,ZDIEO.QD)
M,IB9;%KLZM"LE7C-X#=\29$>!NE3Z16CZ6^W9X\LF"#*029%&VD'<S(EL@.>
MU?\ FBBV#._2=SS?2\WBM>SZYU6UYE,Q;N;C[[&S"'\+JPL:=TG+2JD@X%N1
MHSB%H^2;RYGHME(E:/?%D$T!9. )V&1;/F6\42/TO'KU5-+HDL\FH^,MM(F$
M+#7)!Y7Y5Y"RS=C+L1.U>&CY-DY8.56YCH?BD%034,4 'D<O2PDAF.+VVL:C
MA>N,(C7M+[L]F(JB/<NDK&SK.3W7;9:WUS,KG L6[P8G3;W5K4WG87(%XM28
M>KO9J#=LF\C'.V(V$9?0=5T[%.M^0,\C[9Y'3FOJ?Z9:MKKR]*USK8JOUETM
M/L/<819\^BS5>4/F2P25'C+.E%23=.M3;^&AI(8F1%H8D?$E4>;LYXJI?+0\
M-6*T\T.H^!!)U)CMD M?-&I*U?*;:40M.XE9+(.%!$0,D*8![/!S@82F$?<)
MR![0\@9+V^T1$/!Q^2>0YX/3M0J^0Y_?].O+PL/3LVIMEOEGE%A I&=;JD.[
MG)9X *&3*<Y&;-4B2'O*=9R9- H@90H\QJ?X#[)=;\+G]/<RO8JHR<ETT]1J
MM:M:[_I.BR1(6U4C:XBI](VCP;C8I".K-E:YBL2,R:0KZ47:+9#.'[M]*S4T
MZ1DAY6*QQ+3$3W3B2C;='W;M'VYRB,W;#;%+[K,L<.ZWY7AM(V*])PLYML_,
M3+Z+UV/K,:XF!AF43"FGM==UYQ'/10:NI"QE;I.X5S=K5=JOGB@JK[]]6_=2
MMQ,D"C17$4)*[ECQ<HM-FW@9!K(=PSL#1NP4#,6"A.7:R=:F&%8MD3)Q<C%3
M53M[VDT[0%JG.-GB!42R\76[Y6EI$[)=Y'INWBC1)VJJV6 M</J'%(Y@3$%"
ME,($.(@ F#W>T!.)0#P;P'D0\^T!^>8R>CQ?9C M*]2+:YJ+U2N8R_+W?O/7
MRWUJ3?5.M93KJ/6++U(_8= :)*I,;C5M!KU;EJOC6ASA75.S.[5*8K/Y:-GO
MD)/1E5/3,US/\8LMMSV_RVG,=VVC1.N]'2PUZZWRW&H;*4P&>MT->&[C:+'*
MN"5O0TZ9H.I://5YHP1JLG*LHZPEE#*1<H[&;D$]R^UI^O=&ORU673.V4X.X
M",B,3=P]R4AX8E,N.+\#%E+EJ?=7K+AVA5K*]AVW.,ZO]PBXN7K57M<X>'DY
M:/F9IQ68E^B+AM^7H1\S9&;R#B7;Y^S2>2C<T>D)W)@*'K&W9G&7NB(9(ST>
MF.--<6NST5&B(RX*V92XTND5K3+56BQXI)>9J!SVX5>W2C 504:0D_&2 F5;
MK&,2"[U8L;W33NP&A%RZJ=C)V)O?1>ATBM5[-,5:Z%D.R:E5.R%ST.'QG=[X
M_@U1R^CR)58-Q:[)#V^@RT96)25=HS[A5L2*=>@V3+^S53K?<7L7GN'V>Q]C
M,N]0&D=C<+J$##NG;G18FZ=+<#ZTZ8IG\D=%(]GJL:[LU[$7)2(M));-D%I%
ML?\ +/<B,DAE?)$B]NY9NILM!\^1[G.D<$)1@[G=,2K.).S:OR\1N7S<T1+W
M783.L^UN(3,!5K%7=.HUBC[W?;-E5$5A)M*1+==.IQ;/_$F>UCZ(@,K<(M6G
M65L\B4 -^$<PSY-9<02]PU3RW3*IL.>4O4*+)MYFHWNOQUD@9!N81*LPD4@4
M(14I@*=!VV4!1H^:J%!5F]0<-%0^HB;D$O1KI-HW7SM)4,8M=2M*_7GK1%NN
MTN::;)M0<4NQ;SV"QJAX]J53:.'#DZ3.R4RXPVXZH](V!08]MK .G)$UGR;L
M9"O2Z34'I;F;U%%9O#S-X["V2H)*E.F!,ZL_9;7[#G1&Z9P3^DQ&DR4&M&I
MF!$8Q5H@F'TTR\$Y,N>#MMJE39;;XM0\//*!=<N/%"*PDR^:"-B;9_$0:"I!
M&*GADC2(2(\<<VSG*'Z?YC#\ 4!'R(_T$0^"_P"8B'-]<^MSCFVF"GZO?]A\
M>T//D0^_GR/_ &YN<::\S9I&/AV#R7EW[:+B(E@YEI21=+J-&\>RBRB\<R#U
MX4Q4V<:Q:IN'#YVL($;HD%0PE)[Q".3J5ZHO2+N3H:^:X'HCZ5M<LC=YB&:S
ME&L--0T>$S9U QMGM=-D)MNBE<(9J-CK\BS?E.9T\A91I*-TU(\3*\OFW"G0
M&AY5I=!M3U>,K-YS:]TJR22#A-F>+KMLK,E 3LH5\N*;=FI'1;]T\2776213
M%$RJJJ2:1E28N/I-XSGK#O-1AM?JD])NVTG@=2O<'ULQ[KDI!,M.DB-L?SS!
M)>\:BV8OS-@>5+%\LJ\*XA:HG(0KF9>2=D?.@>&*X<83W;Z*2S=[AQR?6_I[
M_9Z,4<;CR2DRWQBL [7W[;4>"VY1H++34EGK+Q/:^YT#'<:P#K)J/97(]+NS
MTW;V'R2W971+S,8K6VK661R*-M&F3,4RBHK9+0WCHB\OF"3Z4"E1LM%1ZC%2
M4%8(A+GZ<W;2W:-V+LF.=*K)UJ(R),[+HD8CO"%QSGO)<4>TF+]B\+I-!AIZ
MX2:5"ME I5,NE:GU)>&JU;J]TD$JC6'#FJR97Z69:;\,/M*L0AQ^Y?<D*G@H
M!]_/M,!0^X>1$/O_ (\ =J/N\$*/D \^$#>#^0 0\#[/"G[?;SX_TY;X>ZG<
MB4E!XJN_M2?7]10ZB4(D"$4+.;Y6[6D^9$![QJ+&DMPS+1Z?7>RTS&PWD.M-
MBB3^J3*:/':/7I&Z9X1]T;83O>&M;[7)G77+:=70LA%\GBWPR/\ 9^:Q':Z!
M^%CBIJ,%1?$ENNV,O<W]:OIS<%MFVG0H_4.OO?"5B\^T2RP,QGN0H0Z76A@,
M-D,/%U:$DZ]$3!%4G,RWG)FRN'#IHU,@[:IIF1-.()FGE,?H@(CY*4?PQO)/
M< "/D?I_W91#QY$? #]N15=@@\^KEZ;Y_CVCUE]0GQ_C_P!3U@-_L(#\_P"_
M&W:\M\E<'"R'P!RR6O'%:M'*S4D &+,'?G_*2 ;E!-H#&EKYKU*X*?D!#S]P
M$/MY^_\ AYYPE(TJA"D,NJ  )1\%\>T!*8# *93^\J8E\>$_ #[ \? ^.=EQ
MR^V/M_-_YUR]M=06)*42>%O!2$$@$(D":?@2J%]P)D.! .(J'\F]HA[#&3*4
MI3G]VXI&@H)?^H5 @%$#)B5,4U3>"_3,L4"E^I](2^4RB(%* ^  ! IB]GQR
M=I55_?W[^#4V_P#QQ_377$CB$\>5ESA[@,8IU5# IX*< !4#'$%  3B;Y#R)
MP*83")0YSRE\#Y\^?/\ Z_KS5QQM.&NW]_VZC3CCCDZ:<<<<::<<<<::<<<<
M::<<<<::<<<<::<<<<::<<<<::<I=L$NYK^=WV>8P#*T/X"B6^=CZY(O&D>P
ML#Z)KLL_;P+]\_#\ R832K<D4^=/Q!DBS>N%'?\ TQ%@&J/*+[O$,)_+=/@)
M)-\NRG<POD(\180RMF=*LY>JS3!TDRK+=TR<S[]1!=1-E MG;)6?=J-H@KYJ
M9V"R</9_^?\ <_KJT?Q'W/ZG]]G[:QX?0'T##[[8;A>LQ;^FOGURURCFONE8
M=U IFM0.JY?.J*5=1W1[L_O%IGJM^$IDB_=Q5C2I#"#KTI+GB'\9'&:MV[CF
M4-S'.]%$MAS60BNO<AH?:&<KV>8PG$T.I]D?3BK'2^8:4JI#2(&.=MKBUEG5
MDO0PWXII#B$B1\LL#@B4F].XB&SA?(QY3'V>WXGM]B^[??[?8UMU)67NORG+
M?-667&#37RV756W8>9N4E8(BKSTC4X5E9+0TB)1Q7:](RRD"PG)UO'.G$1#O
M9Q*.ECPK23D$F[%S+A%R(1:#A1^+%[^'_"K0!1WK+[\&G7WK7-]8<H4["0?>
M3$>CM7EZON%BG,+D+IK&/VK:[/,SMJ5S9A9V)\CJU558V>OQ\"]D926D&2"!
MHM<PLN3TZ=5YB[YY=J=7[/*4><M54L5<B;M!$;*SE,DIR%?13&VPB#S_ *)Q
M,UIV[1FHI%Y_TQW[)O\ 5$I0]Q8'\Y]#.]9[BM!R=GWRT=>7PS9ZKV.ZZ:(G
M@N+L[+FN\1/\2M[CH=S/]1X[V]YJ41;)>)O2&A3#A=VF9JHT?(),T6_$F1+@
MDQVHU139S;RO<X\/;SJ,7P@7)MO=&B1-XIN]CVNK*'ZUQJFL9Z\6R6W--+NU
M&ZBT]].]8\+U+=>U%6F=FEF80,=E786ZX))U#+)5IGSPEKG)E/.+AH;22GFT
M!&Q<0T8UYZFM)._QY;B<Q]8>WZ%MF(L#8'7&76WL-W+V#H_G>BMM(D'6D,]%
MR2AS%Q->K'2#U%&")3+>_K=CK,9$Q]G7G(E>++*OG#EH\;I#3N2] NNMZ3 4
M6C=L=NI$?:,FLF)=M91G7,[EYOMS0;SL\]NUR)9G4FW!+-)^7NENND8:7IB:
MHMZ3:74"BB9= CH;@\Z]("M4#M'5]M-NE_G,4S;L+I_:_(.JKNM4YI2\V[ ;
M!6'-2N-S)?VR1KI:89C&2<XZJ51E"(,X28F9&0!XH=< &NZ=EQEWYJFN._BR
M_'GOK:7[KLJ.UE\W(9#CC:?-*526Z>Q&K1WA1'+^X/67MWZT&*R?6S::/LK3
M.N@';"L7U:D/W#Y.I6%]O_7]=G#3(.FK11L_71CGYB("F)O#)<YP(04O?D$A
M]O\ 4W^X\ATM4)!PGK7=:$H6(BH@CCTY.VRK@D7',8XBZA>P?74"'<%8HHE5
M5+[U0 R@&,43*B ^XZ@C,6'V_P!3?[CRV._/U[%?Z?JZQSU_E;;V_!CM%%#=
M/A0!;MNCOVU]XXXYIK#3CCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCG
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M[C\B(\M%O/\ ^EY@_P#_ $QUS_\ VP_+O#CX(8?(AX*8?(>?(? _(>/(^?\
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MQ?$BRW!4HQ;'^(DC?;^%X_\ :\N[R']?_7^/]/GX^?W^.?# !@,7R(>X!+Y
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MR1B:W3ZA"1E=K->C$"&!&/@8&':LXZ+8)F$RB;1JB4@'4,)Q4-X-S'=-%N2
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MO=Q16MM?BEV(\!YHKF[+O7WCCCFNL=....--...;:JI$4SJJ"($3*)SB >1
MI0\B/C[CX#Y\!\_TXTUN<^>0^?D/CR(_(? !]Q'^GC]^=.XGHQHW=.WC@K-J
MP;KNW[IV(-6C%JV3^LX=.W:XIMT&J"'E95RHH"!4P,/U!$I@")32/5LS*R7*
MSXQT0RV]>H7O%8>JQL[!X8+:(Q*A/CF*!3ZAV:LZ2.20#<KCW-W32ORMPL15
M$5FR<%]7RJE24P\GVYOQX#S?Z_GJ\<<YWMBH%KVB'NR:B'M:6\'.JQ^J'VXT
M'IUUUC+]CSJ@OMBMVF4_-<LSV[4/1=.D=?N-G2EU&&99[2,LE(>UR]_L/Y>!
MXAP9ZE!1+)M(R<X8K- !&+KJ!ZZ.E7NH7&@[GC4SJ?>Z#MKNJFZ4]2<*U,N@
M9W(1,4T_-4MHM5^L\YFM6K S3U+\!J871E55XXCI'\K/*L7+7E'/4PZ8^I!V
M=ZXPNQ=E=%E'N@9M?(&^8=TRZ 9#)7:*K5TD&$O"O7.K;1+:3G.KW:'6JSF5
MIMBMV>R%!)56UF>R,#%SBP-#M[DO0/ZQS^71._[EIW76T=4M@U-UD]'L>()X
MN3&,BIU,S*JRR]2B\K0=7_0[GIC@\C:IR2T78-(FBVJZVEV4';0#,?Q[S-R"
MAOV[G;2A4J.+OO3Q&A7GVOJ^'"&"4F,<J3/G@2J[+AOJ-G%.WW:DB:KDXZS^
MI#WE,U>]T]L;]+,0<_53<]2NEER=2&B7:#<B<JT3M_:IU'M)9L"[<PM7L)BD
M17VR::BI0GG8F^ORL&Q]!ZQBW330\!]/7K/U4C)G2$$:Y9:_MJ4ZTJ5F@K$W
M>QULM5VN#&)M5TN-XC&SD)J >VUS* [G4DU'KMH()*I2O_6+X$2E.8"_ ^T"
M_'_<P?;X_P N4HUVVVFCT:5M%2B*Y/2460SM=C:+$K68XT>@BY</52OT6$F)
MWB:*7M:LP0_ZE3VIE4*(ASGZOJ<'1=-GZO/.;BPXIY<LL6.6>9#&$I;88R<Y
MS(O$(Q9(/"E:Y<G4L(2G((PPQ<C",);6J>8ANDT'+NE9RVZCN])/K=V-Z?=3
MJGUG["5'K=5CY'$UBJ4>:Z[OK%(?QY&,X@A+!>M--88""23T"9FTBJO%62;U
M-RV\O5W2IR"0DL"JAC>PA2D4'W%,8!,)0*0//D2B4#>3!Y#X^W^(?O:;FW8X
M9?*66K; UHV;P4NT92,.6.N*UG]\>_;BL@1ZB:+8K-9<YP^D$6W0=J@ A[3F
M4$2%ZIOJFQ[48$\4IZ5)I2H%)_:?K+%9!1XA_*J>JT) _P":OG(>?J-W4\O%
M,#F1$AB&(<!-\_']KO1,G3=//I<O4];U'6=/#JNG],P8,O\ BN3!DB.+/EZ#
M)##FZ+!E)##-U_[MT]\.1J0<<^OPY/A9(RE.?4Q,V/#APR<S%(R66-2.*+3<
MI_#(VEQHKU7:;57V28S<K4P- J21&:K*/CK!* P+)I/O>S=H,DR&^L[D0:K'
M<,&R0"5=5$2+&(0WS:#TNH%HVG,,BG]48MT,MS&OL(G,:4W^HFVLTG#@1LE?
M+@B<H$E!:@1RUA8M0IF"9U#2/@ZP)&+<ZWZT46IL+)=+Q,3.J7]> GA&UZ(Y
M+,H,UCQKL_MK5<7*O"UE!+^1)&*134 @)E%<XD P]GTO6(/5W!4P*!3-\UKK
M(R9#@/ZTVH?5.H01 ?>0WM*<X@'@QO(&\?//CY^D^I^N_MQZ?U'KU=)T/_Z>
MZ_-T_P"SV/JSK<6673^H>ERCE]5E#'BQYF>7-T^:?28)9^EADZ#%6;+%&7C3
MQ9<WKG39.JVXL!Z;G#H3)&;NQ=;T*2RSKYV9*$W"$HDL<9$YTL;JV3=-)N4I
M0$H )@ /:5/P4!$ *!2_!2@'CP'^O.41(A!$2@/D0\>1'R( (^1 /\!'YYH;
M ()^!  'WG^QA-_XA\>1, #Y\?</V'R'D?N._P _78QB$:.(Q"/T*H/TU]%W
MY[7R^.?K]=....6TTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXYMF4(4
M? C_ /S_ *?YC^W_ .0?&U_>K_("= @#X ?CZAA#[CX 3%]@_L/N\CX'X#]V
MFM2BPE$"D**AA'Q\>!  _<1^0^ _?^G^P$O=Y,K^H1\_I\_I /CP'@/W^/D?
M/SS4DD"8?^7Q_3[_ /K_ ->-WC36D"@7[? ?T_8/].:N..--....--....--
M....--....--....--4GVX*PIE6EH7B:<5NDJYO?"7*QM'1F+JO54]6E4;%.
MMGY"G.S7B(=5[)(N")J'1.U!<I#"D)1Q5?1:A.GM.[;9S"9=">JAD#2R91HE
MIZBM^XNE/WG7;LSE239HG8[AEE*1208,9*)A):,M<1!2)#/6T)*'FVX_3*8P
MY6NPURJW/-;_ $R]"D2D6^BW"LW-5=T@Q01J$_79*'LZKAZZ$&K-%.&?.C*.
MW(&:LTRG=.B_02,/,9[TOI#K?;^XN&4=UZNF6]Z9SJ#DNI95TPPVFY2O0;54
M*:]AHJN6>X:1<Q?R3'4;E6\QK4/2&4O')0S!2'1=2:+51PX./,9$6?-=XI;Q
MPQ^ISSQ]ZIO77AKX.;\1Q(L)/>#1\L6(*1);IQHM"7-2'>M[B-3T[JM2[Y-1
M-AG+/B?8;K[;: RBI*P?EK.=L.U9W59*?DZW#K SL3J(KCN4_*%9EH];0"CQ
MY*MTTG %<)8['<2AW"Z:7N.>9]F5\DM?Z\[OZGNT]ORQF<64']BZNZWVKP/2
M\=1=6(D.1'0H:V8_#'?5:M1\A)K*0E/G6;=DDV;E;'SP"E$0^!\!^W@1 ?V_
M</G_ ,_GFV9J4P'#VE\J>WW^1, &]I1+_>"'_P 0/ _;P3X#QYY38[M]T?)?
M E1?UY$&NX/UJN/J/AQ(,60;J^9/QT)V:*W/'.YC+^'G\_C3V"5E>=P+Y5\]
MMKK)N]BO:RE>F4O'Y);$HR;U.T=N.N5D@W%%APK95<X?60M6LVBPDM,-JNWD
M*_ R\@18@>QFKDB6RJ;- >L;T=DM-UF#OE9F^MW>@V>4J-S=G4I#+T6#/K(V
ML4;+W9"SS;S3E9F1^DY1EG\16S,C-G )-%P<F.6;[\$/DG\G]V >P?>IY)X)
M[0^E_P#@OZ^?)_@/'@/VBL[!F /5Q]-__P#$ZT>H<<?\C.>L7[_U_2/D1\>1
M^0_?E^%$:K;?%?Q1X?>UOZ>.^K_&,MQ8!6/*JNY=N(VHRY$V6HW)4>':RN_5
M\? @(CY^X?Y>?'/I%2G'P'Q\"(?(?/@0 ? ?OX\AY\?;R'G[ASIY*029I.7C
M@R:#%LW5<.'*IRE(D@W3,JY6./N "IMT2G54.82E*4AA$P>.0\4#UI>N\NRM
M-CON=;10*-#61[7JAH[#/[#H%!O,<E)O8UG*-;'58I1"$D'YXT[G\IEBF S1
M=JLVDW8F5*GR=5ZIT/0RQPZOJ,>"64E\-RRVD]E;D>0#GEH?%Z\CJO4.AZ)Q
MQZOJ<73RS;C$99D=^PW38W_#$'<M L2[E&YI..6)L._>?2L2A/0N*]KIJ 6:
MA(%F6/7FYD:?EP_K%^FB]!H_>-P2_P"H K!FZ750_6@BJ)BE-53(^X773<'+
MB+SO381_96)OIR5)G"O*=?(M8 *!T7]*M[:#LB"B9SE2.!8Y0@*C["G,8! +
M8O5/3\LHPAU>%G,N$63!R?7'O(_$/9AN'BM:8^JZ?(QC#+!9EX[=OQ#CG&RH
MR!9;!D%EI>KF..=866;&$I0!3R8/=X$"@(!Y$HB/DWQX, E#S_,/CV^0$.;Q
MWR1!('M4-[S>W])2_I'QY\F QRCX_;]/N'R ^0#G:SB?Q'^_CQWODXJ]="(T
MC?MY_3Z>?;S6N;QS:,J0I1,;R  'D?/CSX /(_'GR/C]P !'X^ 'XYQE9!NE
MX]WN'R B7P!0\^/ ^/U'+X$?/P!O'GP/^'F;*O\ O].^@+V%^Q>N=QS82<$5
M3(H!3%*<//@WL\E 1$ ]P%.8 'X_81^/'-0JE 0\ )O/P(E]O@/Z>?)@'Y_P
M >-Q5J!QR\=ZJ[[79P^^E*UYUN\<XYG)"B4!*H/N'P(@4/!?O_-\@(>/'[ /
M/OXE+^H_]A_^W%GN:4^S^C].WOW-;_.,X6.G[0)[1$?O[A\"4OGQ[@#_ ,7R
M/CQ\?/[\W05((>0$1_P !\_[?X?Y<Z&:E8^-;N)%^JFV9L6+AV\=N%$4&S=J
MA_>+'6674310(F4IE#KJJ%233(8YSE*41Y3)(C!=Q'B[L.#EI>#B[E_"6^+U
M#1^+@.7Q0<KS7CWX]^-=7:KC#5.L3UHL,S%0D#78][*SDW+.$F47$Q<<DHY?
M/Y!RN<B+=JU:I**KK*'*D0"&\F#QYY'?"P=F[W2K"ZZ*TFJWT^C'H.*!EK]N
MXAI#L@9 _P!=CH.I1Z@D=MLJ!PFTDZ!15!24M1 3G[00T6O',1^Q#68[[6UK
M*R;!W"],J?84Y&KPC@ZK5?M)8X1P<[2S6-DH5%TRQ:MS3)4\'7G;=4NF2#9.
M9DDR5A-DE(26(1IFK<$4"M@*W2!!BD!/I(-T2(@BDF!$R 4H$* % $B)ID3
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M=89#TX*D>-SVQ4;^"/3HR0V;U^WHV"1I<PK8-0_.[99I-U(U%_  TKRD8DR
M&ED.D_442,DGR;'EEO6[T]>FW46R2EMZX==,NQN?FF#F,E).A0KV)=/6+PS
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M$[]D^^M?'''-M6TXXXXTTXXXXTTXXXXTTXXXXTU\$Q2^/<8"^1  \B >1'[
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M5 B+,B1")IWC1] ]2>T("I8>D]<?O" 8ZQMO]1NRO6"IA$3>TT%D6>1L>LD
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MSYN3R K)B:/B0_U']M?U=2X<H*P0C>[MQ7>^?'GZ\=]27\"( 'D1  #[B/P
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MC0V"ZF.95[JYU8GN\>DUI&KP]A0[$14%O.?X^?%;4\E_<ZKU1&NS]GL!I.N
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MZ2+[Z" NB+"BF)>T<Q[%X04W;5!PF8BB1B+)E4(9-8OL53.0X"4Z:A/TJ)F
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M$"QK\>F<PJ$<2&3-()06Z0!]4]8.J!#G*JL?+_;*&4(D/U!,!@!0#B'M$Q1
M? "7]@'R ^/O]A$?/GF+1Z=GH357%.Z.Y['=ZWK] K>$;'69KI;9FNDU9R6X
MTU2*G6D\M;V<4R?/Y%B8#,V"K&3;UQ5=@[.B1-?P=1#*7;M#-TD$B*A[40(
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MDW13=I$5!QQ1['Z?G_7G[\]]-TO]3SWY>>*_IQ]M>GEL6QZ>ILYG<WE.;3%
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MXXXTT!N@ F$$DRB<  XE(!1,!?Y0,)0#W>W]O/GQ^W MT! Q113\'+[#@!0
M#E'S^DW@ \E^1^!^/D0XXXTU\%JW$I2B@D)2@<I2^P/:4J@^3@4OCP4#_P#B
M   !YN?3)_\ *'W\_/D? ^!#R'D?@? CY$/O^_''&FM/T$0$# D0# (F P%
M# 8PB)A 0\" F$1$P@(>1$?/GSSX5N@4QSE23*90Y5#F H 8YRE]A3F$ \B<
MI0\%,/Z@_80XXXTUK!,A1$0* >1\CX^ $1^XB'V$P_N(AY'^O-7@/Z!_V#CC
*D4>Q^G]^QIK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g841036.jpg
<DESCRIPTION>G841036.JPG
<TEXT>
begin 644 g841036.jpg
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M0]0MA"*)Q2#-S,^JXRUO#@XGN*HPC*59+JS@[C=]L.6R3S]HQ\%A!",9 P'
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M[70TC4$]LU< 2@V-,9HV5N '!ASQ*',PIHB;&G*^IBAYDBYL;B@!P,7[\8\
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MJ?8QLIV9Z^R_7Z963M(];&M)ZDO7*UTSW&2ZU5PR8'Q6*XC[M8ZM=*&!ZHD
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MN[?MW<[-C"P.^[J;&M7MH-M6H3BU)B5KHWAJR[\KVU&H",2=8X(\5OE2B2*
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M/M)G25DYM\FGS'8<PC8&<1>#CYPV2&%HUK@<;@E6PLB=:J<TI" T2X)S_>V
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M-#JVG564317MBFDI9)813JZN+^YR,Y*0Z8ZAKK3L6V[WKL!UV$T+OG7"J(5
M=A]?M<:T(U_'5%*+ZHLV1LK]<UM6W<<3>VE2Z61L(YM@ONY V1(A;HQ'<+CW
M%R>Y+)W18FV$KPO2H-:ZMEMUWI.F*LZL@R5*ME4SD8SRFII(6N"5J0X,PE3J
ME:E0N<UJ-O0HT:90K5K%)"9.28:8$/,H)%B1>E3+DH_C)E:8A6F-^&8'UIU)
M0#R1X"8$(P>LHP _1D(1AP+'K"'.,^#.V1CP^Y!89P&P-]^V"ZB'+$/L78.
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MKHV0I_L=PL2>P^9U\0A@4;0'.KK+E#',F!GD@6+#22)S0+RV@9;N@$4H:_G
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M[:=0V!_66N4Q!*44&C?#G>F(J2[ML?D:Y_DK8P$J%;6WNQ2DR.M3.4$1!JQ
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g728775.jpg
<DESCRIPTION>G728775.JPG
<TEXT>
begin 644 g728775.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?3$E67T-!3E\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MK[(1];*N?>FY2QWOP90]'2^!^)J\:_J))2MY5LRID3M3"QBL]M4K%/,*Y8E
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MRG4RK8_<"5*MKE<;MFA[@"6BDJ9:E,)1P44F7(-G@+=4R$WV#7B^?_++X_\
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MZ&'?OU[UZ_Z01!^FOOO7Q:U[UK]=Z]ZU]/K]=8!]8SYT,._?UWKU]_B"(/\
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M?8'9 E:Y;94E:8PRA.4!6*C3%KGI*%E:'=Q0@3&QD'&GR.\@.E<6?:!UDO\
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MD(XPF-P!H2,=%5N]6VHF[Q6S3#4CHK_&22=QQMD+K*(M$'$UO+8IB[1%+%9
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MH:1)UZF)W-&8O-8JA>IO7TP+;5((PYQ)*[KG-4-"@"VEKG1L3K/S5WYEN"[
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M[7O6.%IRZZKBAN:>.SWE (!R.87!!)5<5X6.F$J3CVF4**N9;D@D-7_+V>)
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MP-<;BK$[R.0N9A*E0!N8F)O4NKNO&0B)4+#@HVY(I4;*2D'J#?E_+(*,-$$
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M4&V[GY%27YZ=226>>C-/(-*"K2[*_$IAF%B !01^()4D;/3B%HU/^(3J"@&
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M^[ )!8QC (Z3W_*.Y^U]?K#+[]_7?_W>L/X_W?N_3)%Y'2??Y1_/W^AE]_\
M[>L,D7@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#
M&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#/,3.5(X1%GV6KVR2O*)@;
MCW)2UPZ,/DSDZXHCX?B3L<6C2)Q?GUP'\7^);FI"J6'>A?**%\._7I\^1_\
M,%_^$7^[> 1=H_KNL.@I&_1F 1ZZ"%,762!HD+I-:)M>OHVT2*+*V]$_11=)
M9C%FAE)EC>>Y)M&QL2S3L(L*@T"81:4\0)29!CAS_P WZO\ _?AZ4_\ CS)D
MY\ B!Y!T2=RX+[8;E;%,).D7\D]'(U4:KU6%!/9 F4T[,B3V6%+!D*@)I6YE
MC$D8#1(UN@.9J?>T*W7M*=KS^)'DN?,$IXQN)W\<'A@A+>&"1=_4=*<Y6BXN
M-_)B'6K5*=/+8?&2J[7-2B5/VEA*&5$D60Y)0@<I$I(?%P0  9?5WTS]=O\
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M@A"'6@A#K6M:#K6M?36 ?6,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC
M&,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QG'O^O^[?\
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MBQKD9\?)%TUWJZ2&&N\#<S)YSN49'7QSC3NX$EE\VPT0%0ET2>G]E&0H,,-
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M?+*H*SX'%!70_M'39B,GG0^NFF(SN1QB5K+76.;<RM[4.3MB^-R$Q2URPII
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M&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC&
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M7#7R"?1]Q&4J5V 1*)G)'B.MA1J<(T8(2B$:'4L2J!@<7QQ+2LAB0,<$M/>
M)[L1!UMOC;.',@PNNX^L*<:V:5 #"A2MS+!_B;*>49X [TWI]B%_-PW'%Z^
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M&GY"98CK*BJ.;S1+B%S#);8>9O,""Q&[*2J@N\1K=WCGSM$?XPU&D&0(D_\
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MAW%68[GP61[:BXWJ@B]AR4P!\SG!4=0;W\0HI6@1H # ('PF(W:=O! Y*Y!
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MJZ2.*YW)A56PYBA$:_.'396W)W-:8^B1)5+LX_(3A6N:D!R]6%.G+/4&%IR
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M^M>\_5G$DMZ26WMZ26V_;>O;\+R_/@XDEO22V]O2UM_5_5^%Y^Q'']L>I_\
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MR"&-4%GA+I&YI6M)L$M;F98"5-B<913JVJEVDCD@=4&VX\ %?5<Z<VS_ )7
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M['9H8#6,I2WQ^0]'D.*@;_)F6+(])A."#\+K1*Q\3JU.SC2]!2)U 2MFGB*
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MFB2MI2UA>BBO@VH;7)85[#HS>?T$ :%H.M"T'6_7UT'?L.O_ &=;^$/O0?\
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MH_!GF% &:D_$$?XD_P#"F"$1\\K_ !9WR_F@_HCUK/UXP#Y'[^$7K6Q?3?\
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M9-'']2Q1P;,H4NXE"&0I_A"JZ4Q*UGNUND^@[*ZWM'H2J.H@=KG_ ,V40N*
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M8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8
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'& ,8Q@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g767377.jpg
<DESCRIPTION>G767377.JPG
<TEXT>
begin 644 g767377.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?5$-%3$Q?1E!/7S1#7TQ)3D4N15!3_]L
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MJ^F5P*=6)5/7<5FD'O(2&TK>0DN\/LF1+I?9$;@Z--.@(J=9[%E[DOEL^0U
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MHL0A "9LOU]O18AA$ (_9]@0];#H6Q:WK-.EU\6G=QO$W,53M](N#BH@%O\
MD"<F:JG6S:?BTDJ=[Z&F!#IQUTY*&:&S(BB8D]\V&!>G]=7O/[LZ-M>$OR='
M5$;7* +D1-E[SQETVX>4RR+YCU>F19D>R+7<D76NY[& %/=6S#CFKJ:K3G#[
MC4+\?8A ZXZ.C$HNOX)=$TT!2!4ZEC4_*9>^+FX %\P3BCBQB*& P.O> V(
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ML+'D">53>'1T35(I$D='=[3NR[;FX*]*RG5^*(>%NA)U1 -FKR@'Z$ 0/38
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MP&.7#,TTJM&-G12%6I&R&RSV,$4%,TP(\J=3FC:Y*F:@.0-[?A-_\+0_&O\
M[.W@W]QIS'_,O#,D3;E-UE>\.45_;<103:'*G!N=%#$Y&N)"4U>TG[4MRD1C
M8L0JM#2G_P"< '2C0!;^1@!A^61R\:@]F>.K@P>RS"M[XSYD_P V9K03 ^E,
M0W7H+6MBUK?R]?KW]>LCMY!N6^R;[G4&?.:+GU64>9(2YLLA;M69-X-](/ZE
M[.6HU_P47;U:99[E ,"?XQ2,*@O>O<EAV6'0M@3HKRH*<Y6KN5-]/P)OA<53
M;?)RZ,+,K<#0+W1&R@$K4Z->7!>,I2J1-*5+K>S@)P:)+%LO7H,6X<\9>4"
M=F6>XU?%JRF$.<&Z#N,X&YR!\BSDC,2-SFR-AB(*=D5'J@J3#'LDP)HP:(T
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M<!7G$I^:-\9MR7\L*8A'$+6K97.T6&EX'"B:NMU+:;O,9%&[6:*G4S'=J'P
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M2!.U&&!0,#E,^AD[M"NG*;B5XTD^Z'7-6II*D?W2(2XINF4=!$5S?$9$UK2
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M;.AZXV-)[%2..^2TM>0*HDW,7/A%4U7+$,\K*LR::KLN UY-VMP4.S;,81$
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M_/7UZ^SU^K&^W_ ,8UO6]>NM^NM_/6]?5O7VXP!C&, 8QC &,8P!C&, 8QC
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MM_:]NP8QC/<LC&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC&
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MG>&:C\T0EE2RO$2%TFT022ISC2*%NLOC3*YH9 YQ5ID:Z0$QI27) MHV+VG
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M\Y204-(9G8.P^FM:WK[/36];_P"'X<;KY^WX \L8UO6_JWZ_DQ@#&,8 QC&
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MR%,V-B!(F+"20F2(D99*<@@DH "RR@ T$  A!K7LAUK /JDF"-+ 8,H9 A
M,1)FR]F%"$'0ME&;)&:5LPO>_8'[HTP&QAW[ QA]D6Z!O*OY7[1Y5,=:NI:I
MY<1(W!,(EBOAXC+F.&,,MC;D6NE,:.BDQ@Q+1-6XR,EZ5 D$:E1J8I&O.7E&
MDB:C=G7_ &?'>8^R2%/I(^M#6\I=>^UI,[-R-S3ZTH3FI#]:(7$GE:T<E/.3
M':T#T-3G&D&:$48, L_4L;-RJ%5A9WP,VWVEBI[6<ZW"4>B$NTK=,NIJ7:QZ
MI+IVCTM]2RM9P]0S\*>-INIO2;K'M+*CC1R;56TU*%75;5V,Y;\71WLAMO6X
M3VFM1B/>>MT6<4S9@G5I6(W]N.BAX70R9PNC8"FKF*FDN"<V+L"HIP>#D#NR
MK$#:<EE#NI93'A.ID@]-2$\MH*/UE[Q8^33N>Z)\D;>B0.LLI94K4J3[23<^
MS-W>')X4*$4=:(%%W&L8^BB3:B3NHE+K(Y ]I5NVDA*L*/.+$:24FNI3>,/A
M8BRY=:IO.-;+Y'-$&T+H@<8\A5Q=,)4"1E/CBUQD96FM ZR@J3KRY$M 2,:[
M29L&2%(:WD&:G RL#-'&Y,T1]K;F1I1Z,TE:VA$G;6Y/HXP9QON42,LE,5LT
MXPPXT190=FG&&&F;$8,0MX%.C:_*RFW(UF-3QHPA7&M9.1&^-=BEOE0ED8ZG
M*Q=75+J<VG%-]U1.2P?T[^KEE8>3G_JB,8X%4<>%&-5F759]==C:MU&%V95&
MR^V.[G.'?W:CUN$5$^L#_NZU\OEO>M^FO37KK>];^7^/7Z_QYY8QG7GZ$,8Q
M@#&,8!#CO/IF0\E\U2:VX9$&B=3U5.*5J.NHU)'A='HFLL7H&YX%1L&63)]:
MT+FZ-,-9I-8+:]2E6U-RUVVR-ZTAJ3&N)R8&ZU>E_*US4G\83Q+>I+%@7/EK
M],<V]7P:+UXL=) ^()):-;-D\IV=M$#=2H_\6Z1\<_1E%QI<^)6AP5L[TS&+
M4I"P:HDFZJW*BK2^*XE51W!"H_8=;S9 4W2>'R=%I>S.R=,M2N:(9Q.AEFDK
M&UT0('9I<4AR9Q:79 A=&U4D7HTR@KSK^IJVJRNHO4M?0F.12MH7'R(K&(8T
M-:<IA:(^G)$G V)T1P3@C(-*&;M8-2(\]><>H4+SE*A0<:8!0KP?YO\ Q25M
MQ#QU7DW[:J*.S2!\M4##9?'UX9EI:Q2>,57%65^9UFB8F:5\4VN:-2D4>[,&
M7[TH7NQC![(Q2N^_Z>'S]GE2_P":;?V/RVY,SM2-.0D1MJ!*E2DE)TR9,B2D
M)TZ<@L)1)!!)1("BB2B@!+**+"$!8 A  .@AUK7[_ (OUJF_BY']7CCV_P >
M?OQCO?->C^_G[?%17W_3P^?L\J7_ #3;^Q^/O^GA\_9Y4O\ FFW]C\MU^ 1?
MK5-_%R/ZO.N2B0P>$-(W^9O<7B3$4M:VTQZD[BS,#26XOCFD965 -R=CD:,*
MUX>%Z%J:D@C]'N+DL2H499RI042.>/KZ_CS]KF.]^WT?W\_;XJH#Y^O#N(XQ
M.'O6EMG$@*&8#09OZ@"=[>R][W]Q_L^HM%BWZ:WZZU[.Q:UH8/:_7[_IX?/V
M>5+_ )IM_8_)_13G"M8ET';_ $FT >!V)=4!J.MYD2K6IE$;*C]*K9^LB F9
MJTWEFMSF:;8SX!\/.7JBUQ:5IT0E1B2&F*L[_ (OUJF_BY']7D<>W^//WXSW
MOIZ/Z?7S_P#"HK[_ *>'S]GE2_YIM_8_'W_3P^?L\J7_ #3;^Q^6Z_ (OUJF
M_BY']7CX!%^M4W\7(_J\GCZ^OX\_:YCO?M]']_/V^*BOO^GA\_9Y4O\ FFW]
MC\??]/#Y^SRI?\TV_L?ENOP"+]:IOXN1_5X^ 1?K5-_%R/ZO''U]?QY^UR[W
M[?1_?S]OBHK[_IX?/V>5+_FFW]C\??\ 3P^?L\J7_--O['Y;K\ B_6J;^+D?
MU>/@$7ZU3?Q<C^KQQ]?7\>?M<N]^WT?W\_;XJ*^_Y^'S]GE2_P#!FW]C\??]
M/#YK_P"_G2VM?DFVM:__ &?Z:RW7X!%^M4W\7(_J\Z%9]A5?2\!E5HVM)XM
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M!JEQ3Q>=-,5(HZ_L/G JQRE/"EX<ZJV"#7G6M:2&/&-'D/>>AJG@L<FIPW%
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MS2D8].\4?)HE>Q"8X!6'X]N_P4/&J@:.=UCE+(MQ]XVX2QO5:2/CEKC<G?\
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B,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g506507.jpg
<DESCRIPTION>G506507.JPG
<TEXT>
begin 644 g506507.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!!1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?4T]&5%]#5$Q!7S1#7TQ)3D4N15!3_]L
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M]?,;0>:XJIUA9TH0/<C55(RO*F:%-2EK"!H)<2CVY$OQX*\A-1>12K5]STA
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M.MVEK0.J^_\ G"%2AJG4/<I>L:X)9,Q3(9TE+C$7=0KU,P;V+XI.W$M*EU,
M\%;)1)70T9 #*K>J>1K'ZF\W?#;0,3RI3L-#5%:'E2! :QL./<UR1_Y;F>KD
MY<;FB9S5L5-TB52VWI"O;FZ&)I<ZR=N@,;)*EQJOX%<07<CY9.&+'\@?+;-1
MM56=%ZBFS)>](7$V3B61QPE30W&5/,02DS6F!O-(&Y+#3 %FHT:H].@5'$_"
MKE*8@\2@I$P+OST\>-,4N60V%7'5]-O?/EF41 KHK2Z:*-JZT*YC724CU%JH
MNR1Q*6RIO-*I=V>#D*1TDZ96H?6,UU9"W**$G/K.4NL(IKL2JKWZ$ZHYQK]O
MFJN5<?/=:1:V9:O8D2.NE$OL^'CG+=$H;(@O)ZV1O\9C^TILV3;94">/*G%O
M1B5*SE'H"BF[?'=8[;1WENZR\HMI5K85B=8<LQKG1 P\=TI<#C#X'"ZZ XI:
ME?([7SLHL&S)?9\@M9[A4D5H2QKF:)N36/9;Z..B5+V6=W@FYHM[GSQ_0N3=
M*Z?3.JNII7)NJ.D5<J0:;97J?VB!L2,+/(D B$Q[2]1>KHY V!U8S4R3;,](
MW1$)(0< _0D2('E#\Q]W<==U575=31&!2'EF@F"C++\EE@R!G<'%]JJN^EKT
M8J8K<J+N2=Z;DS*_MR54IFCB0I:GC3BT.;8( DQ:50$[*?6O5OD8EGE?8O'U
MQ'/^4ZZC>N &_L!YF'0%23BS3%SC^79[J=<SM*B%3^+#3I5*(^/.*'1J5027
MM*Y"$I/$M3%DX0LS]CJ,74,@\B-M]3]'VJXW5VC9$S<8M^1FRK$KVHXK5$<C
M:!BYD@EHUQM6-LM\ZI5+8B=%FG].8T#,+]PPID9@CE9WZR?Q;^4*O+]YDZNI
M;J_DTJ_:J\:L"\?]LO5P5):\^C]@"AEH/,Y4V,SH&.1Q!8WNCZB2PH"PQR4&
M"T[I9(<)N-2N23W")CM)YN.MI%3<5YT::AH9G\H,E\D5A^,-;]J.<Q,Y<:I?
M5K*U2V9=+HF?2W=@KZX!#G]F.::_V_G2$;TK$<H7J$@$K XS/Y-Z<[PAG0MZ
M\S7]:?$G<QT&I*765"9'RY.:QI6^T%Q0Q8E1O?.EJ<X2>W)"Z1\QQ-7(R&.S
M/AVN-1<\UO36"N2J7O1+)@ _P+SIAYLK]; ^KTY/D<@/<LR\CIW6\EJXA5"9
MMT98P$[?/HB_58D>QJ6ZGI)%FUBB_P!E(7I8M;!,P'M&WZ3."V-;R/QMXK>H
M:^\AW[9#TW-.*&RSY72-P5+9%8\:<\/E20MZ>YU*X!*FVU7N<RIT=)_:MC2-
M<Q2,V?R.PSM*4Y(XTU1@.D"5PV)$S%P3Y#>N>H(-Y%GZSN0T<1N#DGHR1T]6
M_*T1L:!JY\]A9:C@$W;X7+;A7S173+E.WM[DRP&I6TN;! &U$K;V\P:G[,5/
MKA$9F\W=[QSQ?=V=PW30M=U]<_.O;MI<>P.CU,I&.+Q.3-MD5O5D-;KFL9!(
MW!ED&X-()PX+[2FT+<(]&I"U1I69$4K,6L2*\MAXRX_DW,=K=[6"_P N89,A
MZZZX<>C(RWLZ)R2*HDQ+JNKR!ZCSZ8N#HE8[ 7PY8N$I;MC1"2K$P="T<$TL
M$"I'X9I!-N'_ ""\HR"X(NADO5_?]T=V55.4</6OC)7<AE-QPBYJSC4UBCTH
M*3R]"VNT))8)TE)%MN=F5V7;;"_B"R=;1,W>(OMRT^RXI>@[)O3B;HLFK9O'
MV*.67QUJUX:8H(>VQR5NS+:=(W(F-EM?K6MU;CPP.8(']\BML10>WMF^$-:5
MIR^X3*D/'QPST+371G8_;?8$[I.0])]BE4=&I##N:8]-F&D83#: B*^+1<YI
M4V0J53F12R4[=%#E)5[S[I(W"3IF]HT8G$<(%M^(C&,8B,8QB(QC&(C&,8B,
M8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C.!!T+7IOU
M_3K>P[U^C8=ZWK]6\YQB)QK6M:]->OZ][WO?Z=[WO>]_S[WO><XQB)QH.M;W
MOY^N_KZ[WO\ J]=[UK7\VO37\V<XQB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(Q
MC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(G'LZ]?:^?KZ>GUW
MO6OT:]?36_S[UK6]_CG.,8B<;UK>MZWZ^F_S;V'?ZMAWK>OU;SG6M:UZ:^FL
M8Q$8QC$1C&,1&,8Q$8QC$1C&,1&,8Q$8QC$1C&=1B]D A>GK[(1"]/S^FM[]
M/UXB=L90I5/D?MN>>62RN8YIN2P6EV&\["Y7IR+L\ J1Z:;!G]:\HPGIN4R>
MQI8NM770<16JV:2/3Q#'=CI<FCED8;8['7":+IU(3@H?:Z6[^\AW*G9',=:6
M;SWRFHY8ZR[<C/+%86#%K=LYVNA-')8%S=&J52N#K(BU1)H>=1YI5J%2-%('
M=$0ZZ*0Z+,3&:7:1+X<9P'?KK6_SZUO^O6<XB,8QB(QC&(C&,8B,8QB(QC&(
MC&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8SQF'%%>GO# %^OKZ>V, /7T]/
M7T]L0?7T]=>OI]/77K]<1/)C(F2GN/E^&7$31,CM% WV&)X98TM3?8\B4QQD
ME$D 2;'8O(ILE:CHA'Y$]E'@&WM+L])51GKH!H23!!!N5X#2QB$  P"$'UT(
M(1@$(.P[]G>A!"+>];UOY;]=:]-_+?SQ$\F,BEW-T@MY X^Z2Z@;HHEG*ZAJ
M=G%I)8>M=SV%))#XBT&N9;.H>4R!T4-A*X17N1K26Y:81K?MA3F[U[.X@OWF
MJX<BED='5U)Y)8K23RHFLDBXK#!5TG=*U99=422)FSNO4S\S <'<4T3N$VCC
M!$&UVCK,AM&1N(&"K769NI1R8M$MKQE(+]YN:XU9?/%50WF7II?/+1Z6<.<K
MFK.>5RYUU<7.CF90KQ?T*>9'7Z@M])EAUDPQ&AD$+;F22$('*&IYJ_#?B'N#
M+XDMR*[>;7B9%%:ZEK(HN&?(K1BO*,AB#=6]2ODWD#@[]H"L\-#UWIA95AKG
MNS'\=13,#O#$Z=2OCPDB3;B8$*P.RT2WG&4NOWGIX CL>ALC7O=P;3.L>E,O
MM9L*IN4ADG+T4A%Q*>?Y>^]-1A4),_5D7'+@;W6&N;4G0220E::'64ELQL);
MU,D#F?K/LV^8KT53O'G&E25/;-]V;2MF=,O#W>5GR:L:CB=+59*8+"SMDO$'
M@U@R.2S"P);/6B/1A,WM9+0P)MJ)4^GK6X@MN4HEG>,HG=?-TT5!8]K5_P!:
M<CWQS^=2W/G'UHV -F3I+V=&^T^L+"75>@IIC0U6G<VZ; :)F6C:HE,X<\O)
MEAGI)@E)BD=<XF)O=9_<9=>J>M5?3FS:W?:S24-T V4XU-<M*<FN;.3>Z\[4
M)>H%\XB3JWH5D$ES<HNA1%7N'&F.!C4ICNS%"WXI4>D2(DVL8QB(QC&_EB(Q
ME6.O,'R&Z0"[["@^K<LE%2G2D Y$#'H75[L.8VKT'9C=#ED1@%3QV3*XPK=C
M7);-$#)I]EXH1' ."!T7 =CHV6WOKE\HG\V/&:[=#*FU'>3C'KLC-?RQ^ER6
MHG0$8YV9[3O1]YB@)W2+@K<TQU=[DW0L6D]2(=M:26D%R"/.SRK/3PM+]Z#$
M2WG&5V\Z^3WF7I>W+%J&%[L6,KX1&[)G4;F]D0H4-K&YJWIJT%=+VY9-.352
MZJT4EA5<6>E!$Y.Y/A$75EC7-CZVM[C%W%*]CFY!K+KNSF]6[5Q/(9/FMO6:
M;USC"I4P2Q C7B3$K0HE:R/N+BF3*]HU*=5I,<: _:8\D_1?NC2QB1/ML8QB
M(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC./77KZ?/\-?3?I\
M_I\_3T_Z_F_/B)SC&?*,<[A4F>YE&HY+8V_R*NGENCL_865Z;W1XA+^[QQHE
M[4RRQM1*#UD?=7**/[')4+>ZDI52IA>6MV(*&A7I3S43ZO&==C#K?I\_T^R+
M>OG]-;WK7IK>_77H'>_7?KKTUOUUGS$.G$,L..-\P@$LC<XB3OI7MIE$/?&R
M3QUT^ 7JFI=]G/;(J7-B[X)T0K6Y7I*J.VF7I%2,_P!A0G.+ B?4XSK[8?G]
M=>GX["+6OE^;>]:UO]7X?/Z9X5*M*C3*%BM02D2)"35*I2J, F(3)R"Q&GGJ
M#CQ%EDDDE &::::(!9981&#$$ =BTB>QC(J5QW3Q=<$7G\WJWK'G*P8;53N@
M8K*ED1NBO'R-0-S=G +4RII:^(9 :V,(7UR$% P*7%20C?E>_AV=2N-]0YFV
M?6I6=5-[4[6=8$,KMK?7L$;9'&<25HBJ%WD)C2[OP&)L5O:M$0N>!LD??7@+
M:F&:KVV,SHNT3\,@5&E(GWV,8Q$Q4EHFDT5N.=_(Z@J])>CU&TT->+F30&*$
M6LZQ!'LD22+.5AE-(9<MCJ;:=/LAF4NYC>5[@@($^@$$A+I9\V?\/'@]_P";
M_17_ &)8&7]Y0)YL_P"'CP>_\W^BO^Q+ Q$OY!^\#_1#_AK.V=0?O _T0_X:
MSMB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(
MS EW\P41T?\ =O\ +57K?.]Q#[6^[FUSG(&[;7]NZ;].NROL)W:O??&::T'M
M_%>_]CX8/NO=^T9[>>\8B5-.WBNCNU<IKZ)6\ZP_E&>V+$+.FG/"2$L[FK6O
MD5*:M":V2UG%S,E#'''A0R-QJY&-(XN!)7QA")R)TH 8":5+\@\Y<\2!VE--
M5@UP=_?6?3 ZN*%VDR\Q6SZ7D.>D(B7M\<TQ9>ER8@_0R2"CO4O0/>^[V( I
M)>OX?/\ JW_CZ>F<XB80Z4H&#=44';W.5F'/R>O[K@$CK>8'Q=P3-,B*CTH0
M#;G(;,Y*V]U2H7$*<P6TJE0VK2BC/00TQH?4.ZQ;,\$/&ET7?<UW6W)+VL%?
M<<;M:/&11]G$7 VP'\L),?U(ET*G37 &^[5:6-.,78WZJ(98%JSNMJ<?485]
M:PN.!T405=1O>M?7\^M?KWO6M?\ 7?ZOKOY9 8/E"X..YYF_5B+HF-.U UU;
M9U$S"PF*.SY_3-5M$R9GAX826P,D17RQT<U<AD#&C:SV9@<&UW(=VUT:ERQI
M6)UQB)AJ$^(BCXG(H?9SY<O2MI= Q7J&&=8.71-D3B"+;5L&<5[4;S1,3A$Y
M''ZN8(.;5#?4L@>X3J)QF$QM<6C>79Y3/I$C<%+H9 2,>"Z=-5 PV#-=B0NH
M[->/+1&O(=8KU5$FF2U'5E91%WFQ,'I;GF73*#J',]16,9?6P<'#-H0WP_[>
M7RLAQ9]Q]<%$LM(+\K_ !](+NA4O0S4MKIOM=#1!J5'"+146>?=CHCTYL]1M
M]%@@WY;W.R7IHWM]9(8WUXH?7>.A,D;>D/8BCG$OZ9K\F?";K1C-T<#I*!MM
M3OUB!I] Z2,+_%94&W-29MB"JJE]8R1E:K0:K+:W]X;DKY W*&I90PI%(7EY
M;$+& QS B0N/\"O) 5,'>V>R^DX_.&=DE##;%CHYO7;O/.E$TXN5_O\ F;E<
M;[+JFDNFV5R2TY7*'E7-Z62U%+T;'(72#-+RWPHQ,QI9F]6>/^N>HI=65GHK
M4OGFNZ*FC$UKV)71S!.&2O+ _)78X&;4WJQY%(8A-XL]PMY4QYB=VXI?&3'N
M&25G;I3!7J-OR?:XS,;YUWS+&;<DU#O]X5TTVW"*BE5]SF$K9$C*<H)3L*51
M]));!GA_M";81'V\<H9E #Y6N9SW!M/4N[6G6M+:YK4?CYFZ[YV[#B;]-N<[
M+06,P1>0$1B1#+9)7%G9E=UL>99<TEN4:G#!&)*E0R&)2-AE<6>36C3+*XN\
MM<BCC@Z,ZY.L&B0G</#)R.>LBFV9WNN*L$4K?DFLBHBS6(C<&-\:^*;T%T)2
M#[)%LMBTGE;M+$<Z6/Q$I?-R8C<G9).^E*TI3P<A>D$]:=Y[@='R?H&6PPZ0
M&NG2=U&WS887MR3KTA$W.K*M:G&5'"2&]$-K8ONO5<9,TWJ37(_3J8Z+/CMD
MJRDB7.F,1&,8Q$9U%KV@B#]/:#O7K^G7IG;&(E$G3/B#F-V1;LM$S6[7ZP_I
M/N^A>UT%;V=7C])*3F#91]7U1 S.>>A8ZSRML>)Y64Z<ZVU(G@Y@6-1J);J.
MF":78IF5(G*/L:\$-L0Z.U57['T[ 15[)*[YYJSJYI45++-+QP;F;M&8]HUG
M%>5E*BSG0NM8XV'39=SP@;+*U8(V6I6>-OR14HES:>2KV7<8B4?\9>)%_P"=
M[5>#;7M"OK=YUK^C.HN9>>ZG2UHZ-+P?377W1A'1EIH[^>GV5R%GG#XTFMC%
M5<?U%F>/L;M#FY<^2!O$^O9R9)]'XMZ9J?GOI3RVT]1U=Q"IZLAW8E(ABM?P
M)B0QJ)Q\+YP-RS(G<+2RMI1")%]I/CJY.RWW)0?B'!<J5#ULPX>]W."^F_T;
M_P ,JOX9_P!]WS)?\8O/G_CLY)Q$M1QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC
M&(C&,8B,8QB(QC&(GPUECLDN#R$=0IX4JL<*4G<63V*I?$<+,6_&I=*-/RF-
MIU3V4FTW[6")V@3F&;6:3!,UH@1HM4+V(X7(&\)8=.5LR(\B:>\J42<ZL->K
MK?-YI.I=4@C Y F3G&IR(T?5SDBU/C[D6RI*5*27I 1M 46,I*6?L0YQ\O7\
M?7UU_P#W>GK^'\V(F**<,N\Z(GBOY)5B.<Z>G$*<JH%\L<8H*/:+2_91ABB9
MHF]WT[C,VM^.+TGTD"5I+LD6QB."'6<\D'%OD!D4WZ]E] US=CHR6YW)%+;C
MB>E[+B[7N?PUC\;=*4/&U=A0YMZ4Y=G"^'M5]1AY1HW1JNZ)2:K9(P-UK_D\
ML^.IT*(.UWG7?L[W[.]>OK\_F'UU\OIZ[]/36_S>N_7?X8B:FH./_)^\=-4^
MZ3Z#=(GSU1/> US)T+'NTE#OSE0?)D)IBO8_WISK9D*/MF.R^U+*L6;M5C)@
MRE/5\E>[=>)M$++(MB'KX*8%)$NF>0^K^86[QF\$()'8],S3IHV_^?NHZA;^
MCE#Q)8A1=5=G)>P2>L*@U!['E^V!JFM*,\]YU=9F:"'KB'2U(^SO3>1)=MR%
M=N_>H?:UZZWZ_36_9W\O7\/:]/36M_I]-[SP:^$&I]O02!*RBO8]OV0;/+)-
M%L7L['Z>\ 28(&Q!UO>BS!!]0^UL/KI$TBJBISR==&M?1EA<8/?3<"GYDZ\R
ME=R:\;&ZO/=:3LEL.N>;5_S+1M*UA)K=DZNIK+K.7L[L8P6.&L*T:*]2-VG,
M$^?"Y*WE1>SGFSB+L*:^.OR6\ZR R]*14=,P&9P'FFN.D9JW2%95[M(:'#")
M:N:7IDZA[ F49K:P["$8H<FB0W*_*R5XI5.6**L[),$\;+V0"P$%!]"@%EA$
M(0O0L 0:&,P6S!"UH.M:&(8A"'L6O78Q;V+>]BWO>=];#KT#K6]?S: +TUZ_
M/Y[UKTUO\=^N];^?KOZXB:F/57&W5';7$'0-6,7BIC7,$\BO(O+](PH];<%+
MQ^Z[=G%)7E!IV_5!7KY3EA?< ?,,+CD=D;E7CC:LNAYDHF[RS+D4(C)#:)8B
M\EA^,CM*>Q2Y9DXQ.ZI384N\JM@V+7,+LGIG4RC<#X9;^>+<CM1?=6'/]NO]
M<P]T(G5@::9!IHT.R5ZM:HVZ+EL53 -#MEZUK7KZ:UKUWO>_37UWOZ[W^?>_
MQ_/CTU^;7Y_I^/Y\1.<8QB(R@3S9_P /'@]_YO\ 17_8E@9?WE GFS_AX\'O
M_-_HK_L2P,1+^0?O _T0_P"&L[9U!^\#_1#_ (:SMB(QC&(C&,8B,8QB(QC&
M(C&,8B,8QB(QC&(C&]ZUK>][]-:^>][^FM?GWF&>A9K8]<TK8L[J2&1BP; B
M4=/?F&(3.9BKV,/ 6T].I> .\R"T/OV"0C8 .KD6J$UJ2S5*,A&9L@M2)23'
MCQU=36;V9R_$NCK*JR)5.GLA0K=Z]88C8*FQ2W:!A3I"$;R]+%4<C9K'(3'T
ME_;%\8VF6B;RFU,>:N$<L,2IK1?&W-XVGO .?^W9-^?F/,MN,=([-:7:,ZQP
MD^MK :G/H,7KSDC_  .JV42SJH!]+*'23RBMWZQ^1VU=5G>2;SH:M+2+2*[S
M 0,<H;6;19?VKN@NC&[S9_M8\O;L_=)_[1E&_ECU(/NINJORJPC\HNI1\)M?
MJ.;AGVU]X?MW:'6UFFC[/^/VE_\ 7T1[K]WGZM]='4?R_"$]D7_9D7JJ#*G]
MLBR:32Q6<C:SY"\DKE#6TE&D)U1@UJTAM7FIR]%;T,"4W>Q:]GYZP-T]T<W4
M7^R"C%5L4A6]<PJ$UH*E);;\N)B#)M'/92B9[D0=*K5"E@*"6XI$WPM6(G<;
MP;*5,>7*5:=X#H08P=][YD_+5S7=_$5BTYQW<S5:\QG#JUQRPON_5EAR!E;Z
M>/2O?Y15;?.'6#%P9C<@I"$";;U]LA<$+&M<G!C.(6;2N*;U?/\ T@ZNGM?
M<B.1\A9R/E?*X'5Z'3]%,R84=AY@QO\ <<63=EQ)4@1T#6Y5O 3&G+KS13SY
MG]1\".7\MU/Z'(#?P.EU>=BQ4; ?M;SE+,5UDU/ROTM8PB47Z4Z7=@1 =U5U
M-EZF[GJWH.NH_;=+S=AL:MY5]J?=Z8QI28K97;[%=U[ ZZ1GFDD&#VA>&Q>W
M*-"*!["E*<#YZ#H6\GYKC\$^5270WC6C8E;7'/>UKW#$H00SREQI'C.5BARY
M(F>'%'!C4CLJ%$8ZM<7.!$1]S<W)F3_8S@X&*STYVE!XBMW \K]D5MU7$29
MRL4RJ>4&O,J:#:@N@N*12XT((BX?9CBZN,":95(G) UFJ F;3&JA%* EE#$L
M3)-^P$>(^4?".W\=V=>V<]U<O!U=>!.O]3GUTQ2GO'.ZF*#.QZ7)3; V5BS)
M</\ DI:?>EUI^#\LY/9S\X0V*_N.OGYM;,OTNSD!M4DFK]66P -;'"!(_4.8
MN[H;(_'O<M\8QF+FIC&,8B,B[TC".KIC]S_]F2\ZSIG3?]N_?/5ATTIMK<B^
M*TU?8'V1M/-(C]@;:]D.WQVQ_:'VEI>E]GX7X+>SI18SFY0N62R)@B7CR26L
M0RO!45>K4F#!\W7B_4J]A\C?FKNKXO0.A1I,G )^ODD/=F;7J5%7HY!K:'FZ
MJB]3KV&[&_(W=7K"V5R'YPW/K]!,&7HH]UKXN;UNN-G$;G9D!J IK;$<> \.
M"CF =D*%"UD:C$RLN2Q'3GH4\.2N*H!Y'VX'W=W/.U?=GQ&5/J[I/HFI;AB*
MJ/Z2,##7]#*JI=&N1Z<TQVWA<]*)_+0N2 34!4BTU!1)A!4GEJ_B]Z)]R.8.
M,K,?&SXG-<O3T6DUQ/L7[]+5"1>WD?K]Z%@5[7X^^FGYJKL[NO,I^?\ 'LO.
MT/T*V=9QOT'IL-73U-2)'[>0^KW$&KKV_;^IIY_BKL[*O,CEUZR7O)N7[\B_
M,*F-M_04JJF:1:H'F7O2N/1R.3R3,JEA8I4ZNR%K>E:9/%%#CN2  0UK352A
MJ(1A)]5'M@UJV7PA]O\ -546U1],V11O04 ?W?QBW97Z>0IEG,"5'<W!]MPQ
MOE[ \,4;;K>0%ZM>A:X@9LBN+9CE(Y/8;#\8^1(LT9R]PVX=[UKY[WZ:_/O&
M6\OIK2.WCH[O.O\ 6>3PR%\]*>M"^P6.^ <;M%U2<%2+*<C7&$FXS210CHAR
MJ1L&?>YS/)%-AHYFXU*W0TMR3-L96>[0)"%*/E;XP.V[6\?=[T=?DAK>P[_E
M7=%%=(T1([$L%NLR0UA4\5LCEJ;2^)22[T%'5HXR2RF]AKBT(LKF3=7[1N9E
M*VIJ$J2QI824CV6?76_IO7]?\WK_ (?/]'SSG$2CGN/Q@S[J'I;H&Q(,JK>O
MXST!XE.LN'9!--[.13(^Y[EL:KGVN9)*&]H81JI+#62+0I:SOK@I>#G=*T[!
M'VMO,3JM&$YE\4G-G4G.T)NHCHM0HBK'-9Y!W"I*,5=*67UT;4K-$:@A4!G;
M@7>ELH4$M7H;<L://]F-<#**$PU^VO"1N;@HEBUT:T%L.,1&,>NO76O77KOZ
M:_'?I]?3]&,1&,8Q$8WOT^N,ZBUO81:UOTWO6]:W]/3?I\M^NOGKTW\_77SU
MB)!8'DOX<5PNX;$8^@8Q,H31-Q0[G^Q)'731+[.;R;FGP(AJ)US$=5U'94JL
MJ3NBZ=1IDVWUPFE0T,D5K8TX[2/K*]($'Y[YY/.*(Q*:4A4HMAZB\HO](PN%
M?L\IIR\HPJ1-LLL134<.<[0U(*U; T:VS:T$A\ @Z^[-U^EF4M"%FC9KDI&#
M0H#V?XQ+54M'>A[367.5R--_=_T3UY6-,RRWKUHED<X95-14M#GAD=[)I)H:
MWJL;/%+8!('^(+=,=K5VH,$T&31@<0NBPICB&P>&SO=MCE>P>66S4MFH;CJ7
ME"HNG)S-[8M:232B8QR9WS.NPX2T4PND]?O3MT&WI*IF27G5C6V,_P!8/:)V
MB#%8:Y:<V."V.(42^VC>]>4.D[8LNCZ8M=/,++JD$@/E#$*)3R.HW%MB4X<J
MQES_ %_)95%V2+6Q%XC9#2XP"62FKGF7QV-S--N./#FD=#4Z<V.'#._7MWS)
M?7_?&Y]U\];U]/';R3K\?3Y?+Y;^F]?/7KK>MY$?B+Q6WM3MI*V"^GFMUG/]
M0\S=I<GU$_5I8,\';EPPOM#JU-T4\SF?!-A\/,IB2P"(,[%7Y"&)32>+'F7F
MODZ:9+'T86MLUDSQ'4!7W+E\>6"B*KW+=P&"=B4P!@W.IS++*E?LR'@_EZ4.
M'VK-IR[/DK>]_:CRM^#V[.JO;>@^&:T6R6]$E3E(EWN,8Q$8QC$1C&,1&,8Q
M$8QC$1C&,1&,8Q$X$((=;$(6@A#K>Q"%O6M:UK6][WO>_36M:UK>][W\M:UO
M>\QG";KINRW):S5S;-9S]W;D>W%P:H3/(K*W) WZ4@1[7+4+"[+U25'I6:6E
MVI/*+(^(, 1[?O1A#O[21.3:T,3PYO#BWM#6WM:]8XNCLL3MS8W(B$IHU"UP
M7JS"DB)$F+T(U0J4FE$$%!$8:8$(=[S2G\1_Y<N8>E;T>*3H _LER?*_W6B.
M04-,&<BCFJ1F3U#(%(I-?TF:&:$E-S>E:32E(X[J3'*%0RRV\M25[:HJEZ?6
M+G[.9G^BVJW'H%S IC&HI0 06"$K8QMLLBKP(_CUO^;N9CM_(#X_2XF/]+;\
M_39K#2Y=.:_-6=2S5:LN=3G:"<1&/J(^:]/QY\_C<_L.?1>K(/*[&FRU4VQ*
M$L+C)9&O0L[S(%B1G:DXE2Y0F9(\@='QU.+) (1:%J;EJ]2+6BTR8TS>@[Q!
MS?UM0O6K%))+0DR731DB;R3'WQP5PN<0\I.['I1+-)4NIK'8^-S]T4$8%1S6
M%8G1*RS4*LTE:48G!6#T\R^86Q><KED*R0T'1):2MI.M;J@YU9+.M^^)4<6V
MZ-*C#':IKE$T\:ECB;L:%K=8-&E[B@5^P>V'FG>Z4 QC^QWD5O):%OD=E%6.
M!B/N$G[C"FYLD&T#^':ER>>[B87PXQ&#0)^!\!+OLD(-&3#3L8[^\>!*S-\?
M[N\^QBP#D>K-IS:7$W1G(#NTUY&PNG^5!Y\"8O0+/8@JJ\'5U'_ZBUL^2<SD
MAS]*,.W'LT&_7D);2+.-D!+NM7LA?GP# U9 =[D T-4RBK8=QC&:":^8XMTR
MVBJYE)E%)J]66P%$GW#$UJJY$@K\U?MP1Z5!DJN))EDB)2::MKQ)Q-B8TX3@
M%( P.DXCA!U*+SF'E^3^2AI;1JK&2*-VM2!(8_5;GTN=Q&,1[=#-EIW)RVT%
M;#7ZW0PBM0SX36R%QLGU[L?L?NMQ[./9UZ^OS_M"]/ZO7T_Z?/\ '*?J\F^G
M2*K=JR?2Y;?""J@/Z_L\T0_MOR7OXLO:Q\#56%_S,[W^ 7<'+0]3?S_TVE&C
MQD.J!OT_;Y$A_;?L?V55G9D-4 U:BF$J#/Z+.@R@SI]#3+?9 9 ZA3D44XS9
MTA6XL$I%MG--43U W/FGT9^W'3@2!/\   )"BVF&(8C]!UE?(C,NX%'E";.R
MZCYKZ)FO/OC0EO.]:?>&$.9*2.32-6\H/<>Z%C13*S9%B7H:=5UKUQ%8P]5S
M'Y&R1*55*^K%1BH:9<2CVV,X]G7S^OS^O[K>M_JWK?KK7\VO37U_/O+58?6
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MU<KVSWSEL[?=&*^Q[K[ML'NOXO[%:_=__1/NU^\^$]G_ /IW_P"1?3_Z-_\
M*O\ Z?\ _#9W!%8R4(L1<>8RQ$C9S"=@9VT&RAQ\ RF(9>PI=; -F+&,#2(.
M]";0"$!#L@(A:VB:B[7^R%^B9ISA$)E7Z+E)\O4GC6C[=N.'DM4W=FBI+_M?
MR54MQBK@,TC[7:&I#%4C77T_D\E'!7IV*G"&1(&9V7KPL2HAM=,R+_,?VK4"
MJXE-Y#Y(<(W7*#RRUZA?HI5%YL!2>T?',I@)D+LZ0MR>V['>%5?6J38:)IE%
M5L" <@B*EG^V4-IN2%U6%Q[9O25Q7Z#;GM#!X>CV\KU#J[[2Q=A3[='-6XI'
MA4XN6R6\&UZ]2ZH$3FH6*_?*3G!&E6F&B5)R3@>^LAL2<"5B==&(\L3N 'PI
M>0K8VI22M*DQ.D\C+5E'(Q@4EOR<(2'H!X3 NQ.M%..E)>M!Q$TN!>9/LZV+
MHYD&Z=%\F<SKJ\Z3[JI6:V!/UX$/(-A,D6X;IJ\:^7W#$:QZULB*.4BCLOF3
MW'8N&-]/R!F02$Q,X "=)$#A#G+:]X5Z EW5?'',O2$]K]15TRNVDZ^LJ204
M\*D)3"[2N/I')66V:7#&X?8*\9OVM'-N0OM,4?<&S;D$"[:@.LTAI^IP,9<9
M!65>@CA20M 4P!A,7"REH2421M)1EM.FG3>!*4WH42$M.%/HD"-&E2A!HA.2
M6#(@  + $LL(0  $(  #K00A"'6@A"$.M:T$(0ZUH.M:UK6M:UK6M:UK$3MC
M&,1&,8Q$8R.<PZ\Y=KZ,7'-)ST#4$0B7/DB;(A=LDD<_C;0R5=+'MI8'QFB\
MU<EJ\I(QR-W:Y5&E36QJC=.CA]O-)"1(:J7$$#^>,[JXQ*=*'9!]4\^_:_4*
M1*OYV;@VW"!J[K0KCP)$"VM"0/(A2Y*X.!A;4WJ&GWY2YY, RI!'.PPHMHDK
M!?3?Z-_X95?PS_ON^9+_ (Q>?/\ QV<DY-2L^J.;+HL*TZEJ2^*DLJSJ2<_L
M6W8#!Y_&I-+JX==*U+<8@F+"TN*IP8E*=T1K6A6!80#X-X1+6A7LAS2*$A<*
M^&?]]WS)?\8O/G_3QV\DZW_UQ$M1QC&(C&,8B,8QB(QC&(C&,8B,8QB(S!/1
MO1U5<L5:]6W;KZ-HCK::F;&IL;DIKK*9G*G00B(]!X/'4OJODLQDJW043,S(
M0;&8/9BM68D;DJQ8GRE,IA&:^B<EG4T>D,;B$.8G632>0.9NR6YE86-">Y.S
MHM-T$0@ID*%.<H-]@(S!!![!8!F"  6L'R1WZP=]^62-&6#6;T[Q*+-%@E\G
M,C_( (8]3A48CKB\/%KO]?*&%5N0W78*%(F1HWP]W;-5FPJ_L5H)<5I)CH;4
M]/J*Q'DR4Q8[.B\<^6C$C$+(J&W, /W6 65"(^1IC2 +-86QJ\_V^XCF,Y^
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M#N8RENH(^RC(8D'PL>:VI$;I0>F,5'W@;^F_T;_PRJ_AG_?=\R7_ !B\^?\
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M.8Z*7-<EE#.Y;*(.,1)[2L,Z!UPG-'LHI:A7R%+[8@@.#JRLLL!18"RP!+
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M->OY_37K_7]<H%\V?\/'@]_YO]%?]B6!B)?R#]X'^B'_  UG;.H/W@?Z(?\
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M >\.,+*!K>M;&:,!8-;W\M:V(8@A]=[^6M>OKO?TS4;[I_9 MTU]TM4[+RK
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M\^M?7>OY\J0\Q%D2" \[L94)ZM?.9K!<7R8/$&8XI.JNIF4=!2*#U=,I4W5
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MR'_R&'8?]X3D#_4K+NO=E_Q8/[(?\L>[+_BP?V0_Y8B4B_MF'D/_ )##L/\
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M_P#D,.P_[PG('^I67=>[+_BP?V0_Y8]V7_%@_LA_RQ$I%_;,/(?_ "&'8?\
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MWK6]>F]:WG%?]0/G*M2MH?+_ ))6E'V_0=]G>0H^Y+$,I*2?:4T27,55*6%
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MH$)0 Z^')] A(%L9(0Z]CY!*%O8BM:]-%B_= T'?SS(2]FDO77D>XVMR<PB
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MNH^ZRAE>ES2E1HCR4Q4V#TZ=26(I002>6/6M#+.*+- /6M^NM" 8$01:UO\
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M$H"A<K1I"1*4J0L]6H(3E;5KE!21&G :<, -J%:DXE,F)"+WJ@\TL@D(S3
M%[6Q@U]1!U]?J+7_ -OS%^/_ -NOGO\ -^.(G;&>J-<C+*(.,5I@$J1EEIS1
MJ"0EGF&ZV(H!)@AZ :,S0=[ $O8A#UK>PZWK6\]K$1E>GE$994^\=SI- .04
MO<ECM\HK*2UKSX]NB!LA3W840L!AE<.EUA@<I5$$;[!:X?65'.7Z'GNFRIOI
MD31$XHI.\G.+?87G&]:%KT%K6]?FWK6]?U;Q$K@\3]+JZ#XEKFO':!VU74E#
M*[=F4TCER1*JJ\D>IW9-JRVPINYQ^M:2L2TZQK2M'63R5S5U97\8F[V&*0$3
M"U.JHY[)<E!]D&<:UH.O36M:U^;6M:U_5K.<1&,8Q$8QC$1C&,1&,8Q$8QC$
M1C&,1&,8Q$8QC$1C&,1&,8Q$8QC$1D)K?ZU7U?VYQWR45"T+JV=15IU?/W"<
M'OJA$LAIO-K?3ZY&VI&(#:H3O14K_*>I K5*')O$SA9BADDKMK#-)YLY CKW
MQ]P/KZQJ.M]QNKH^A;1Y\9;:CE>SOG&?1F"R MANQ/"DL_:G8Z30&>)ER5R(
M@,> 1HA,B-3;)/%HPP1I8B43XN7>5WDZ$=(N'.,A662CVPVG'J"EU[_DX>=\
MS0GH>6PY-/XU0LKN81H&9LLIUB*Y ZC3EHE499%#@W1^229FD[BA9CXUO7G%
MH26U3.I%0E>7,_649"**E-$1JY*GFM,Q:ZT/5M[LG-W-T\B;_(4?V@_53.['
MD2)V-DC&VG+BH2W.Z\",AU+);M_>J?"YS@XV4DGTBL_H>=1P^>PJ\I]1D_G4
M8?Z*NKIZ 54AJ1CZ7N**(8(R2:1V4Y,+2S.TO:8]-(E6LJES0V2Q=!"WM"E4
M%5STIX-.G(M%K2*FUXU\WR*+T9RK6O(S0W67=%P1.N9+QWT^+J2GP'NMC1.,
M2VN:7;GUBB-=-]8,JBT90R0LV0.3C:,QD1+0>%$L>7>4H39Y/&_@0ZIRUU=_
M=]'7KOTFED_P[,E[(<JB>>C&KG,N*'(3P@-=:#85,S2/1L@-6:>EK=%OL\U:
MH*&?$>G_ -D!1"W>,C^@R:+G4,N.'<WI.R9M4,MBT\:8=.>;(!:[5#>EI3SM
M;3RPLC5:ZVHHLK5.FST[:0WJ9 -E1'ECC[J-^1S(5^%GB%UL=;?CA#9"DZ9<
M^LDO9!W1Z%]:%%W,]AIYFBF!-<LEA*XD!071;>A1E5RCKLQH+3'5R#;6H4Z=
M3S7?4>G;P2U9!^?9G2E&W+<[@.3\Z+.)(2OOBP44L9N>N3+@M".RCJ-BIMKB
M5?1M2;-K*BJ!>C;ELR7/!9+BWQ..$/$<@#:L8E2),'J3OIQH+ICCFG62(1*0
M5OT)575M]619[W)9*@6P.I>6(;6\S?%L,BK!$WXR:222MMB$&MC6Y+8^E)*;
M#];6&*3R$X_RI)Y@>+F)B/<6N16//)$>Q<B/46KFOZCG$CLBPCNXXS,)ISM'
MZ_B>F]&IDLEE<0KZ:R9X9B3TY\,9XVY*I4-LV H!ORW;_!5K7YT!R=9M/O57
M,,)I'G3NCG*81Z<NLM;W8#%U;5=>0:)/\+^QHM*D;N?!W2OD1SRSR-6S%NC0
MM.TD= KBP:W"0'@B4UUS/ V^L+/>IEUZR X$6N-G6==4\BS5 7;B2$S6"Q_7
M-]@02N'"4UD!OC-I6)$8P?/J\N%C=X2[:8YW"G98J-=DB)(VP_-[0$?BM#7)
M%([.W:BIDUW#,KI='BNYNW6S6,1KOH%DXOBC813Y:'[RBG=B=?3!FKYECKX%
M&O#'8I8COIL,<6<E&#M,/.9SB&K^A7VO(!=^[2IGGOM&V66"7+44YIY@E-D\
M.1M<^791"N:N3:YHFR?PSUCZF3D(D[HA1,LA2*FQP=79.M94OR_*OA"KJ#\@
MRBC>EK!F%B69;\AKJ4VS,8=-7!:C9]5%U].^RZ]@M>R:=1=1+EL;36I.G5UL
M&12]*?)+2?W%^DZ\J-GN#:WL<FIIXA^4YX7893ZOMC9=FJN_U<E DF301KV_
M)'&F>*]"@;_;B9VTI21K9$>Z["9M1N,*1'FN0I$$82RT3Z>YNW)I6E7\%VNS
MUY%7IFZRO;E:GITSN,I>$#I!$?3Z)O+;G^*J4C$L2R-3%'==H*MN>P,9+JV@
M]Z0M2J]Z(W9 '?KK6_SZUO\ KUE)4E\5MFQ1KY?@57=/W!<5=57UYR=>\M+[
M!M8F8N=>UORFM>G1FAG/[17E,1M!IYFACDWM$BU-'E(W@;H^S+"%XEB<XE3=
MJ'7H'6M_AK6OZM8B<XQC$1C&,1&,8Q$8QC$1C&,1&,8Q$8QC$1C&,1&,8Q$8
MQC$1C&,1&,8Q$8QC$1C&,1&,8Q$933YA-RUB4>-*U&"M+DLZ,T=Y,*LM:U&^
MCJGL*Z)A'JW;*!Z2C;G)SH-6+!)98O:$3Y)X\@4FHVA2$"ER1E[#LPTL(KEL
M>GK_ /SO7^&(FJOV=V%W[/+F)FW,R;O&KF-TK3G!;P%43'QU-&B!W[=;E?4H
MA75L;[E2V?22^4T['HG7S:T+F8NP)-4#,WUDM57# UDGD &H*^'5P=P^0W[S
M=*0Y7=?226V)/SYYQ5[G315<P5+SE#77G1D()Y64\=7!&ZW8Y3:#K%:S>DS[
M)CB;$G;D191I2.6((Q+"/NJNW:_9UZZWZ?/7S^N_GZ?3U^?[KT_#U]?3\,C_
M  ODWEVN+,E]T5]SG1L&MZP /94YM&(U1!8Y8,P+DSB0\24$FE[0Q)'YZ!(G
M=,F=G\*]>?IZ<TY*]TTK5E@.TB:I/7\(ZP=>E.<.DN+^4+6L/E_Q*T?QRHYN
M=87(%; CL5EG[=$9[TONGJO1QYZ<NG4DVY471.E"-0-V*!%YF0_;3N4@?4ZQ
MG2>S03#T3%+TZ9JF?AZP9N4;J[+\RLSZ\JJYN<E,-Y:CW"<V8+/E]=]#PZ[Y
M35#&J66-,IZ?'D;&PDVW(-.[2M?2S(3"HNRZERK<+A\.B=?1:/P>"1IAAL,B
M;.@CT7BD7:D+%'(XPM2<"5K96)E;"$S<TM+:E++3(&Y"G(2(TY99"<HLH  :
M3"&Q.P8M(8/.XTQ3*&2UG7Q^4Q.4-2)]CDC875.-(YLKZRN9*EN=FIQ2F&)5
M[>N3GI%:8PQ.H*,)&(&T36,M/4RM?AO]C-_[3K7J73><=F\)+[6;+$;DSJHD
MS\+C6_GY.MFS.[ 4)UC^J=$++(G-.Y)]GDR@L*LU,G<4X0%1?;O)1Y5+-H"9
MS>LC;B6(8;Q[U<=,[37\]Q6*PP^Z8SY/(/5,6D]+V!)X&R5K9EJQ'C$^Q3:T
MKU@?W%DEL[9"FF31UYL9 I:@;<MFT?35TM<69+?JBN;19H/+V"P88U6#"X]+
MV^)3N*Z/U&9G&D;\WKD['*8_I4ITROS:6F<VP*@X*)23HT>A>NIH2CEM6/%&
MK*=J]72T@3OZ1^J17 HNJK1Z2RI\7R>3)W6#*&LR,N!,@D;HY/[T6K;#0N3T
MO6.BO1JU0:>)$U%VRW^U>L:U[+@D&E'75X%<&VOVATK1=CWA0""-74YV51?&
M5-E\"T8^U^P5!"61XMM-TE;<TZ#30-^KQIGR@NLZ^<I3$$"N1-[7N2\#-\L3
M%:T8;9I;O9%K5L7?/*L"D<<GM(UH1&I1472? <JL#IAVDSM"Z(B+UI!4'23<
MRQ:*OK.^,J*K7-<;!9/M\=W+9@MEJH:0IOG^(!K^BZIKFFX*!T<GO4/JZ%QV
M!QG[:>30'O#P)DC#>V-YCLZG%EG.3D8G&M7&%@&I/-V 'LY0]/T_U[_#]?\
M_/XXB:<2BU&=[\ ]1<Q3V@>EJWN;EZJ?'E]Y#N@>2KOJ"+1J>Q+J?G:"K@0.
MR+4@,=BCU,$/VTO2I0PUX5O V%8[*4PMMOVCH.XT5^]W_P#Y#O\ _J/,=6?3
M=2W8R-4:N.LH%:L=8I2PS=E8K$B3',V=IF464&*XU*FYMD*%P1HI%'U1IBEF
M>4Y('!L4#$<C/),%L69)UK6OIK6OGO?R^7SWOUWO].][WO?Y][]<1&,8Q$8Q
6C$1C&,1&,8Q$8QC$1C&,1&,8Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g721330.jpg
<DESCRIPTION>G721330.JPG
<TEXT>
begin 644 g721330.jpg
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M55EWD[;4UO$:*$5&1Y*5LF-T>(*$U^'_Q  = 0$  P$! 0$! 0
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MJ<W3]0XL&D3$G40^QH"V&8ZSI+4:'%_-%ZC$=GI<]G3)9;BMHSW3D\GO^O\
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MFQ3;BH0<F_FH6JK2CQ2O1$Q*)E1DY6,ASK"P8R,BB0B3UXV03<.DR%(LH<H
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M+2,>I"N[C&]IFW\NBQ=K-2"W7<-"/2HK*-Q%%0Z9C)>2B'-\7Z)F/W:-1_\
M\=+^YSQ]"R_<VO\ 9TO[G-V.+F8Z@M&F.*<Y%-E;FH+<4I*G/%5<KCF_O;6
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MTO[G,T<41D-2&3ICSB)#/LZR]J;SR@QRJ2&D+<94I"0%KMRD$J/,22!;J>_
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MMOEEV*%J<]5HZ=AJ;%I0DR*#V0;J5BNLH1=95S'%.S.1VJU,NB"9A,1(Y05
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M(:-/&C*Q<9>I?6F\=MNB6O"-)JV!9I4^PUJSS95)[/IA/=O\6.YM\_U"-IU
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M!6QWZK<CDR &**Q4#*&2 Q1.!0,'G]MG),)!%%RQ=(.V[E$KANX;J%6070.
M"15%9,3)*)G 0$IB', @("'MS,.M*66TN-EQ-BI 6DK2#:Q4D'F -Q8D#<=Q
M4<R>=2.8<Z0"I%QSI"@% J3N 4D*!(R"",&OMXYQ?.3 ? F^WD?/PF\>WW]_
M'C_3SV*JF?P!3 /D/(>/S /(>0_S#R]QW'S%2,WMFV]NGK7OQQQR:4XXXXI3
MCCCBE....*4XXXXI3CG@1  $1$  /<1$?  '[1$?MSYQ7,<?#<GS/'W.;]5(
M/_[O'DPA^PG^?]D$@>O;K2UZ^@3  ")A H![B)A   /V^?L ?T_U\^85CJ")
M4""8//NJ?R5,/M_-^QC_ +?U0\#^WQ]_(-_B$#KG%4P#Y OV2+^P 3#V'Q^T
MWQ#YY]/V^W&3Y?4]/AW[]_*GP_N\ZXTR&(40,<RAA,)A$? >//@/A* ?8H>/
M8/<?(B(CY'G)QQR:5 ;O7<*%8Z YZDSM(SW7],[6T/78/*,'UN4L]4S+9#9I
M6XVW7JK7:_5>OV-Q2H1K7G;>0<22L>HZ<&3!".0<*D5(6OKTG_3LNG4GL-OV
MS3/5'J-TSJFDY%DV91.3=6]:T';&]AL=*NE_M4UHECL=WI5&+6!=QEJ@ZVE7
MXB,=DDE85.7D'1544S*36[O>FUA_J Z-UEG^Q,6A=<TZ[S&PS;G(Y-C*EAM"
ME=.HT=48A[)6"$L$#,P2E)7CQF61&AG:4NLO]&X*W11*L;)W53TZ.E_2.9MU
MAZL8/6\<F+[%14+;WD#,7"4/.1D*\=R$6T=$M%DG4DBLGC]VLF=H1NL851(J
MHHD4A"T&1;)-TDW\BDXZ8WMO<>E3BW6]K6Z#I>]^H&=[WJ:*X"+90 ,)/)1#
MXP#R8@"/@QRE]Q,) $3%*'N<0 H!Y'E+4;D/=7;+KW%D.R6!4=^QNN5;7C?6
MNM3&\IJ=?V.3SDI%,HZDW.LYXS0U)&_;Y'1+28U_8UEU'%0B(Z%H](KD='1<
MC^E%UGPA\/P^_C^GW^_G[\ 4 _;_ )Q]_P#-RQ%[9/7;K>V_E0&VUK]S?'ID
M?6_I6OYF_3'M3EL8MJV68)G.8-*5VUR#=<TZ.&WE:W5MG6*?U[T' ]8<P>MR
M5<7J5'O&FN]#3OC%@QACP+A:@1R]BD8VTW>:=Q>&N_\ U;T#/?2.<.-1M]LI
MFDUWLG7-[O><Y=H3E]E$Q:NS/J/9YJLOGEK.[KC!QI54S56]!%UI^HUKX*3,
M6M-)-2M7B+9*[#MWM&KY1"9+6L,J])LNM;QL]=QFF.=)D)IE0*>=[5+Q?[->
MK:VK@I6&>C*Y4,^FQ9UB#?1#^>G7\.Q&:B69W;U&A7U:NY6A:?Z7&:R=@BZ+
M1)?0>Q%MQOL=%PE\CCQ$+,]<==M.;VEM0WEN<U:>M%5G-KI55%F_0B7$E"14
ME$+3*;8@.)9OR3))AQ7I*6EOJ90%!AJW.XHJ2D)3[O\ $2;#!QL,BN+4YJM/
MT^7.3&=EJC,K=;C1DK6_(6D (:;2D+-UJ(',$FPNH@\MJVE1?,FJ2RKARBW2
M146%95=0J**7A57W455$J28?JF\"8Q0'X1\#^J/C&MBW#'ZZ5XC+:?1F;QE\
ML7+ MFBG<JB*WGY(&B6#EW)B98?!4B S$53&*0@&,8 '5?R['K?KF/YG=M.]
M37$LSTQY BYLE!NV^4N2M%:?F7<LU(>?=J:!/L7#IR@S06=I)J+L2D>*$0(7
M]8H978T",J+9)%_W?Q*X'^:F4S7/^Q?3=XP.1-8BA%306RQC*,:J (?-,V8'
M^1\?GP)C*"8OS@UW7GE-I:X:?90XE*@^])0XA(58@J;;0E8 2;FYO<6*1B_B
M-:UJS[3#O[.S&4/M-N^^_'6I"74I6$K;"VW$+2E5EA20I*[@I%JL:V[U@>O6
M.=@,8Q!1M:)K^4UW,-K+85X-]32T/YB*;.B+.F5[9UL[QA=;+\^*_%G*T=%Q
MD>@>=^N<L1 P2I5[?0B[4J\7$551N0A3*+6#><,ASG#Y@%^8DE7[G=A43)Y\
MJ%*8JZ0@8HI"H D#3T[QGS)[WUZX_#O=-<1T@GF"<I;SVCKV5S6WT-:?JFKQ
M,>NQ9')H1V]=&!C"34]'R,FXDD$Y*W$)!-BD+?@^F\!4?+.W/J9]KXUHX467
M^@A^P?6"#C"%54.!B-&U1^@6*T(?PF@#8AF[=1(X$. F4 WF,:QK;DF8V&U/
M*:>90E ;91X1L\% >(ZVNQ*057)( N0";5P:7K^KRIVOQ76$%N!J34>,$,L)
M6AI3!NA?-*2E5E)YUJ2I9)*B"!9">A^H/ZMNG=>M$Z[5W-:YGT\PF] C[)>C
MTK0V5Y"QTR".>+F,J=24A4:_&UF>L:TVQF49R/<RJ,:WA6H.54"R945[9:KV
M[JDA'(OI^OSC0OT;!Z]=TM[7-@81XNTDS_3O6692L[=62Q/FD^>VDJ-'N4%!
M52^4H5 ZXZ<OJZ)9V^U;"WM%[03&VQ;ZN3T&-@WC8XZ\2U:D5[%%N5D2/*[-
M2S:#I:*16;N240:1CU21=)B07J3951E<E&6_K)"MJ\62]47*3OV-88LU:SN\
MU2;4SC)$T6U(_/\ C5[4NS5F1DL06[55HHV<MFY .=VMY#QA"U;5D3M0\0K>
M;;+:%QEO15EA/BE!4CQGX[9)38*(=R<JR!;GT76=6?X@XG9DESV6"K32S'<\
M )C>*R>="5EQ*>19 7S)<(YCFQP=A^IZ50[LD)ZM;Z_/'#P)VT?)-U9!#X@$
M0(ZC#&3DFBA0 0,FY9HJ$$IRF #$. =K"5C17.U!\T%TFB5RHV^H2^I(W,<Z
M15SM_B^<5$RB:B953$!,RA#D PF*8 UA91/)-(BQ-G'>_I-KB\,555VYS'L/
MC<'8&XQYRN%(ENV86RDMX-H@L9,SYXE+LUER'33=@)"E *G\][8=DZ=ZC%N;
MU_L;!U>0<@^Q=>TV72J1H-%)G%4B O5?@"3TK*Z)2GZ@3:BZJ#V(?V"89R4Q
M*)-%CG(X2)ZC_%,Z&IOVK17TLK4 'VG/&\4 "Z6$I0&77C?W&D2EE1!R.GJ:
MGQ*O27(").ER7$SYS,%M<=:%D./WY+ I\-Q1Q[J'B-[J!%JWXC.FY"_&=9,A
M? #\1C@4/ AY#W'P'N'O_1[_ &X(Y;J?#\"R9_C\_#\)@'XO'W\>/OX_:'-9
M9UZJ.TY],R#>P]D>D-XC_J(J.B6DIIG7^NO@=NP(FK]4A8=EPQ_)/2JF*)V$
M*B10P!Y2 @&^43&=Z]=+5LV[/4"LST/D=ARR&J+U+1FM56>03>PV6X(@]ITM
M#6=M/ZZR8P]:)$?"1[#RD_'2J-G='DFS)2*0,'7^UD-(2IV+J#/,I*2V[$(=
M2#8J4I+;KIY4@] 5*V2%$@'IF<3:9IR6EZ@F;$#S[,9'B1%JN\^M*6T@-%PK
MW)(0E1P+ W%]KD%$Q#X@.00_;\0> \??S[^WV'GCYJ0@ @H00'["!RB ^?X@
M/^GE"-7_ ,(.Z.IM&O\ +/*+XJLN=L1)P^M%'T".5([1%5-P@A5)Q.WF0,M\
M38#.*:@L*WL=-(I3"67E:]7GTT+-]$T:=W>N#61=MFCE&/GK_'U9X(.OUD$%
M$;">-(BZ$1 BK8QQ504^(BI2" B/HQ]?TB4DK9U&(4 V45N!I22+7"DO%LA0
M)L4[I.#WKT&M7TMX*\/4(I6A00M#CR&5I6>BFW2EQ)Z%*D@@D!5CBK,@62$/
M(*$$ \^?UB_E]_S_ "_/]G/)5$S!Y*<I@$/("4P" A^WR'MRN'/_ %2NANA6
M?0:VR[/8A7G&>VEM532ETTVF4V&NH/(&'FU)W.Y.RS\8UMM?:.91:ON9.,,X
M0+.Q<DU 0(F@HK(HG;?JP+0SM#LIU\,P%+YP.R[7F!VH(B<B0J?4!:Q2%+YQ
MR)BH)OA^8<I $3&#SWLRFY+?BQ7&Y#:E%"%M*YDE8-E74"04C>Z2;BQ!(()Z
MV)$:2E+D>0RZRLJ"7&W4+22A9;79224W2I*@=]A8F^9*?,)_PR^_O]P_/_K]
MOOSV 0'[#R',/WMZ?2%CL]5)V=P,):IMJX]F!7U:CM(U%K:D9%:#.SG7DZW@
MI95RE$/SKMH:1D'4;\E )1)F9XV*IV\.YG4,G\[M+US*(@'\_=,J#S_1_P!E
MO\?_ %<V0OG 4DI4FY!*3>RDGE4D]BE8*3?8BQL=]0I"P2A06D*4GF3D<R%%
M*AZI4"DC<$6-27$Q0^X@']/L'^?[< 8IOL(#_0/[!\?;^GVY%UYW,ZBJ$*1/
MM)UO.8YO@^#^7;*0.H8PE*0I/^R\HB8QA H>X>X_D/CG7J=WRZ;VV"C['%=H
M, 3AY#\119+2VM46NOE1BI=["//F1-BL$9+MRED8QXFDHX9$2<II$<M5%VJZ
M*QX+B0ZEKF2%J2I:4F_,4(*4K4!U *DB_F.XJ"I(4$%20I04I*2H!:@@I"U!
M-^8I25("E $ J2#:XO,3CD:/\<_J#_XT_7#_ -.N5?\ W6\?XY_4'_QI^N'_
M *=<J_\ NMYK5JDOQS$=!W_"]5E74'F.S9/HLTQ8GDWL31-'I=PDVD<FNBU.
M_=1]<G)-XW9$<N6[<SM9$C<JRZ*1E 453*;+G%*<<<<4K\B;?HQD:^?NU"-V
M#)FZ>OG:G_<VS-H@=PY7. !\0E10356-\(B<"IC\)3F$I1UA>T&$[?VE[*TO
M;.HG7ON1)5S0-CZJ:[5^WT+ZD4A1^HUGQAA.9A:KU+(=66VJ-YPE4L&9Q]@K
MAZVSSB*D[!/N$Y](54)%=9[LUVZ*<3]<L,"V72:J3,#,Q*3E5$RY&Z\G&.F*
M2YT2'(99- [@JJB13D,H0AB%,4Q@,%&/6+T .KN(TW"D;!JG;6R:-D<)G*DK
M*PG;KL/7LVFK;22Q3QXK%9<%T/6X>DRLQ''71HIFBD6UAG'X*9,[4!$U%"YV
MVVP"#M:]R #<D8S5DD 'O??KFW3K:U[&P^=7VI>X*"'OY.8P#^T#"(E^_P!O
M80\@/V^WY<IN]0U/6+WI=7P)IU,WK0^MNA5V!ENRFNX+6<FE[EH4%"VUTXK/
M6IA+W'7,UGJ;65)-O^FFG77Z6Q*?H<^<T6@QK*>N$Y9X"Y8I0+Y\ (>1$1\C
MY]Q,)O\ G_+V#[?ESP9,AQ 3%*(A^8E*(_YQ 1Y:VW6PMVO>V;YMM4 V^_OZ
MXJAVV]9>P5DWKMQ6<RSOL)G%1V3.^X"6B6G3>PL=>NL.TS^U975:CAS[)\T_
M221E<PND+8HQX>U*AG-17IE;8S->E[7HD=8JP>+[]G]>[)VRM]I-F+"F]-V:
MLN2=7,HJ]AVNLX[ICJL+8 UT=[IEPEJ=7-,"B/*/*%T N:9_,S=_BWR\?'+V
MDL"P9E@V;ZUW8-"C<?RK2M8EF+F1BLSH-RT&58,A1(]?QU*K<G97C%H=<2HE
M=O$(P[5H=<WR4UUB'4#Y93 -)_:;8^P_8[H!W[QG9.O<)0]VKN$9??(K/\EM
MTMM43::#M:ZLW6V;)R]IE2E7=WJ\A2+E3[Q!M8-]$+24$C-5V1?PLPU^7S27
M2PP^\ %+;9<<2G-R6VU+";@8"BD#;KM7/-D+C09<I#1>5&BOO(923SNJ9;+@
M;%@2><I"?=0I0O>QMF3/HD6>N._2HZ%PS.P0SV5JO5W(8"SQ[238N7U?G&-6
M;$=Q,ZS;+K*P\J@;P9Q&/P0>-_B JB)>6FR,W#Q+%62E)6.C(]$@G4D)%XW8
ML4B@43?&H[=J(MR% H";XCJ 'P@(^?'OS2?](OJ%W!V3%+Q;<3[6WCIIFUEO
M$3-1\E#5Z:8EU9N^K46NC?ZP@J^B86QP*L:5M HV!-RZ!9=BJB5[X3*!+D6G
MI-ZG-2RE@T;U/^SUFL .2.B/XY&D&114#X1\-6.E2NJ1\>D!DRF*E"LXA$IP
M(J5$%2@H'@Q=;U66PVXUH;I6X5 %R5'99LGJ"M1>R-@IE)O>_**^=TK7M4U.
M'&DCAN>P7T%3A>D0F6T64L#PT//IE. E(%UL,D%5R+;_ *OJ>^KX3I0?+&N,
MU2@[H_NK?0',^9Y:9J.AX(:@TKSA@UCYR!@YB(EGL@:86,]9MY$SR.1;M5%D
M2)OVQSS%HW>ROVVEYE,&RK:YBY7Z@UZ[$J6?9Z%S.!I6ILK*X,D[93J241 K
M&<G:P<];E*['2:BC-L5S]8N5$U+WJ+>CUV=V!IDJN1=EKUV9>5<;D,PS[2:O
M28IE4@D4*^,0&>LJ[38^/:MYA6.<$M;1;R"Q&$0= Y"D.09L8AZ2M/HV74>M
M/>V7;:D6M*G5<EYC,B[+V.HTY"V)1#4L\6!C6$@#-.&3DP=MHT#M5?ACTT$T
MR)IB!2\"97$RM0>M!>;87X/,TM<=UEL^&T"([KKS"%E2LDM*<Y5J5SINDI3Y
MD6;Q:>(=7"M-?.F!F$8+;[D1AMI9:C^.&7P5H?*U>.I:0\HMFW, 0&Q3O_A
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M$89UI^HF[ 7(L5'5RVN:UEMPEDJ?,22RM?MES6T5Y&09HX%GS!S-.[&\.Y;
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M4_1B;E7V;V"8!:WPX^"Q:\@>D?IW>AMV+QZ.<9-@O6OMD3.V=<J-OVZZX?\
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MD6ESG5?I-&095QMH71E'H&G7Z[8''S7S:-JV/-6TG#'58J+*VE!-9T Q7F-
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M$I$N"R"UFA(OXDF3,\<QQCK;_P#B#O?X^@-[6-1R&P-Q8[6N=\#I_?;8&MO
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M!+OL4;2&;0,U#RC-5FNQM](IDM%4>W-DBJ_61@VFM2;B)DT4):(6923<C@M
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M]\'>YZ;CH, W] 3TH2,D#%_]$ =-C>_3;>V22;FKMTOYH_\ &*_ZT_.3G$B
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MQ]_YI0_CY\<?(,H(&<&^+P/D$B"()A^?@WYJ>/\ RO ?P]^?0        'L
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MFX2X4H45A#8/.@)7R)!*>?EN2":J%ZN>F%LE,[_]B^T?8769"_XM:C,;9@.
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M2@Z9J-KL<13G4G$,+):%HC-%*[764L]+$M7D\>7>MWY(L&2VMKZU&U93N7I
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M()42E:EN%<0],C0Y6I2VU/*=U1]J1(2ZYXC:7&6D,)2P@BS22A">8>]>W8)
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MQ6<@S2AY;6W,H8AY)Q 9[4X>H0SA^HF )G>.(Z&;+.SI@"8N%%?@\E\&'*G
M!X^W' OU-_\  7^MZBND:+7GELI%PJ[%6%1=V2IV2 :*62O$MM=3=S,*_C6Z
MD_5EG\8A98--9T0\Q7UI!DG-QP.8PSMJ#KYZ=:W1/H]HW7S8M8V?0('JQF#F
M\XOA>)Q^5=-J#8<XR1ZWQJ6T":4U2R0L\UC"DN]D4O*=>BX%C&/DZ138&.KR
MMRMIB$=H6O\ @/\ .'C^KGS+E_F%*/PF,80*/CXOA,("'Q#^SX?/GV$HC[E
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1IQQQR]13CCCBE....*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g103210.jpg
<DESCRIPTION>G103210.JPG
<TEXT>
begin 644 g103210.jpg
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MAY*3E*:RL[;&TM/5UD1%1E1I=H.%AI66HJ/%_\0 %0$! 0
M      '_Q  C$0$  0(%! ,              2'P$3%A@:%!47'1D<'A_]H
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MY&L-*N),KH9ORT=U$WNQ0SZNQ;?,%0@)1Q(/6$@R0HC28.1P Y;U;!F8,Q^
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M?;5/4\E'A< XPHV3IW(LW9XXD+(1MOBHB452=IG;MDX@(@LN0@.U')DUQ14
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M0QSCP4H"(CP)N../4"@(^X#P >FL(-S._P"VL;5;G4:+G+)*=,N-K@92TU6
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M,G^@?F'/;^2'M^OT[B'[CJL0Y#CD>_8?3N'O[>X?\6M"B(\B/V=N.WI[#QW
M?8=5:"D"@ ]N   XXX#U^?/K^'.J>COSR'//(]@#WY]OW$>XZW--!08G4///
M?T#MZ![_ (C\_7CMK:% W/(*FYX'CN;U'T'D3"/ =NWOWYY[<?1IH-L$P#GJ
M^MU#R/(<>P!W .P\^_/M\^_.HD ?4I?E_P!;[!^OC[/EJO304"3GW$.W'MZ<
M@(!]W(!SZ\ZH\H.>>W/SX^T1_K ?L[_,.-[304@7L(<^OKP !S\^?7GGGO\
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M?6'7KH<IBJ@HD  ;S"B00$PD#@>P\F+W ./EWUQP,EBF*!'!D4RE$"D*<XB
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M,4IA 1&'ZN^-#DBR/< ,H[8UDM8^Z^LO9G;L!,ATQ1>Z2$6*(29)=(WDEKT
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M2^9JQF&U8UCV[2/QM($IK=^$%08"#DI"8=5JIJR;TLK, G(.EGZ[5!,44R$
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MD@ "NTS")@"]F&<AM\L8QIN1VE;M%0:W&$93J%9ND:,/:(5-^B18L?-1HJK
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M3AQ$MXI"V33M*(A6L3()JNEY))^1!1F1144CJ&*B,@5D\*[:E/PV%(DM?O\
M5%L"T!_B^CS--O\ *P-@/CV1767D:A/RS)-=>6B)7S%"NT@3;'%-94GG=!^
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M-- UIP'R#]6M=-!IP'R#OZ]O76NFF@:TX#Y!^K6NF@TX#Y!\O0/3Y:" #Z@
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MO4(B'/Z0]^YC&$>X\ 'UZ:::!IIIH&G(!ZCQIKY7HB#5;@!$W0/2 #T\B(<
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MSFM2@!Q]PCSH)K&8<)G^U98?_P#93_)KZ]</&&,*SLHF$2E$O "(\ (J+\B
M"(\<\!S]P:YC0---- TTTT#3330-4*D%1,Y .9,3!QUE'@Q>?42C[#QZ:J$1
M .0#G[/?6R#E(PG INLR8\'*0IS"0?8# 4HB7GN(<@ ?;QWT'$R->CI9JJRD
M6S9\S7(4CAL^;MWJ+D"&(=+XA-TBJFL**B95$S*IJ#Y@%/P!B%$-\D4F0@$*
M<Q>#B<!(!2])OK]PX* =0=7U3&*(E$I3!WYUR0*E$.1 X?\ X:GSX_F:"J0
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MW(=P_P G;4VVH2/%9'C._A1_]4#I_/;G_P"C,K^_;0311RJAU'*9Q#I3.(E
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M4 C57^04F"9;0\K;<R9T89S(CU&.Q(HDF;RRD*/*9!ZAXX"[I" 0H%+SP
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MUFE<TVN#5,VQH_S?D M_+B6K-G)#QU<H;.<DG+&,*P4(FD2:,W4E_A6Z/2N
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M 0;<?A_;/ZOLUH,DB B/QC(._;S3\&#@..P(G4)Q\@ZNKCV#0<YIKA"R;<0
M/BDQ-\^&_ C]G4X W'RY[\<:U&21X'^VTRAP// -> [>O^N=!S7'?G[./W'3
M7!A)I  B#N.'Y]9S ;L'N"9E$P'C^:;C[ UK]*%./":[!0P (B4K@"" !_*Y
M4.0. ]^XZ#F^0^>FN#-(IE,/G.6R0B "!4U&Z@" ]N1$RX<=^_80^8\ZU"32
M'T=QW(?]$.!OQ$#<<_/@PASZ"(=]!S0@ ^H!_FUIT!SR' #R ]@^7]?VC[
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M7DYSF$3"81'M   !P'8 UKIH&FFF@::::!IIIH&FFM!'@!'Y (_OZ?M#0!$
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MF*<H8<L(2,*JDC( :G9<J%)MI&1552D:RAX4L;(F*J$>Z<@@J)+O]0?;V]A
M0'OZ=A#D>?;@._ _(=!5IKH&2LH4?$-55NN0ID8"M(2]=@U9$8^3D.F4M<ZP
MK4"V^%BV;UX;XZ:DV++S2MQ0;^?Y[I1%N114G,4NXUW(5-J=_J,A]+52[UF"
MN%8E :O&?TE7K+%-)J%D 9/D&S]K\;&/FKGX5XV0=H>;Y3A!)8ATRAV?35(F
M  Y[CZ]@*8?V /K[#[^W.K*.-P6-$,ZL=N";^>D,K.J(7)+Z*B*9<): K5/<
MOI6,AY.Y7B/@W%+I[BS2$#.M*G$6&>83%E5A908ABZ3:** %[=-4@8!#GO\
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M;'.!6?AH89_L?&L6]SACVJ+YL?6S) YC>HI8X(PG3;I(* 3QH3%=6?%6L[>
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g154314.jpg
<DESCRIPTION>G154314.JPG
<TEXT>
begin 644 g154314.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!"1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?3$5725-?3%5.1U\T0U],24Y%+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( /H"*P,!(@ "$0$#$0'_Q  ?  $  @(# 0$! 0          " D'
M"@$%!@($ PO_Q !6$   !@,  @ #!0,&" H'!0D" P0%!@<  0@)$1(A,1,4
M%19!%U%A"B)Q@9&A&!DR5UB6U? C)2@X.5*8L='7)#1"66*7U#8W1%1X<G1W
M@I*TML'Q_\0 ' $! 0 " P$!              $$!0(#!@<(_\0 0Q$  0,"
M P0(!0,"!0(%!0   0 " P01!2$Q!A)!41-A<8&1H;'P!Q0BP=$5,N$C\18D
M,T)B%U,()41255=F<I+5_]H # ,!  (1 Q$ /P#?XQC&$3&,81,8QA$QC&$3
M&,81,8QA%C*ZI<ZP"G[4G+&%(-ZAM;SR5M %Y(U"$;G&XF\/3>%8G+.3F'I!
M+$).E)(#R1FD[,+":6(6AAK0H_R>Q2)^)WF+R#=@K2FQYMFH:=>':-U-#'AY
M>IU;EK;3M<;KRI:[1K'1Y>9'+7]06AC[ !Q- 0'[RM<7)$TH%J]-9M<$-7V+
M5%FP!K5)$+E-Z]FT0;UJ_1VT21=)XN[,214LTG",_:5.H<"SE&B0"-V2 >BP
MB'\.MZMJWPR>3>Y?'1 O'KT7:' P(1RPCY^EG*KQ6[+T2I<I98=%/KB6*,]'
MKW9U9-G0"9P9]>F%P>JN;XY)6AY.;WM CV2D4(U</OQ'O6_(%4#CE8$7S /<
M"0?#16R0+S1\I3-56;$]PWHBI)Y/^NXUP_(ZPN2JTL#L*D[_ )["%-@UBQW*
MQJ96L)86&U8\01NN9/&%\P:Y0XK2F]*(LY$\?AGU&/-7QA-H^^/42,M1]4M'
MD+:/&6ECR""HE,BD'2#ZN$G1+(ZV!E "W.M"FI,\RQ9*QK4BXF+QM_6[8?O2
M,M$?6V/PDWF^\!]"U;%*_P"*N/\ KB47QS_T504@YTFG1T^B,?L;FQV:G: /
M=M6M>6I3-7UT+&=,FQI'$H&U-D287I$B"BD*LA8N/_%R=_)_;5YQ[5XWN-5=
M$1>N<Z?K6N+BZ!K,A<^B?[,\CD*J>P:M<[V;2#8J0VN3$_;LAWE"A_>'=JE!
MRU&G1+FE7H859"^F1^_5E[MQ3+G?0C+7J-CDI%<W>:N ,?-?*RRQ%707<=[=
M$I>E9JTI^5>0A,TNU4U$WY+ZGDMD2*FT%D/>H]$(:X-2:+E',DCDDLF>V_;R
MV1,Q2K.3!E5Y>^X+8XFYJI2X*.1Q!:^V)UQS-33F58,;=G)"&"VW(UB*1FIV
MHMTCS@W2#3>G) @4+![$V'C.TH;S#P_ 737*_ EV"IX8XVY.8S>,EMGT JZ%
M5-G51LVZ1KZ\^8YC;G4,UN!CLSGR85JB93+";"*_DJ%MD5.3]OBK&=8+:0^$
MR=:DT68GM_\ +)P#??;_ !C55%4K9E?);BJF\^>KE2S>[B9&GB\M<:4-6*5Y
M\@(A2%T=B5LD<3BW12F0E *,$-8C N1;-*6E-,M;6U!T^^7'GK8);3K-N ^^
M7?8=?*9TZ[/J.N^I*ZY$D*68BM.SZ5MF^HZL;V-&JAY,(IQV9FB4)W5W&\D.
M"9_4'/B8UF0)V58D5DIE8E;BWF_="5==CQ_*!.)F^M^;K%:('U?/#^L:5LF]
M*/KJM*#6V%9TJC%3S0R&S1G.C,6DCDG9W]M"B?)4:>YNI$21P^.N[N[2IN/T
MWM[A'VT>$O,K:=W\T]>.=I^.6/=-5U$.D^;[#0QZ&=$+Z50<]7L;$'-FGD.9
M'R0F3&07##75J?QJ(R\2)BB+T5J-EC= %[?-'?KX.\.O0?*\[\84AF=@U&_-
M/$W''6G.MD;C3C+A+Y)++PM R80MWAR5QBR,A2P)696<"2&.ZUH7-KDG F;4
M+RF4??$SWF/[>^]6UKWMV!P.>7+O([,[\9,SCSR<21NHZ#M^#L/1M_-O0=)S
MKI!BB%"4FY3F>P2AJM=C(Y9]KVHQK'I@1PV(U_*DZV+2!3^+N:PUZ0+BV1([
MHDPEPO<]-^5N'U%XK5ODPKJJK D+?,81!G>CJJLIC.KN6RV2W#,VF 5(1)V[
M:IR,8X[('60-$G-<4JY1M="%!+HTJ1"<$8]:>_7G"MC\4(^!^4^B98QL3=0O
MCXZ=C+I9B>KNT9WSQ?LWM_K*7V69S9%97QV\U1=CI))3!G)$Q3R+V>XH:\3L
MB\T;/'G)V?TSUFV-+>3Y+Y2/"S7?/MIUVJX3LBS:'IA[8($SM2XXKG&Q*N<(
MY*ZP0)XHO4H'A-&F-?$8_P#>80ZJT<F:(TN-C;BL22- :J+ GC^?/(7''R.1
M4(MRO?J/ 'OU[,N-UZJK[8\D'*\"G]Y>1MVH:Y:Y)KR,.[;6O#G/=VO-]1R[
M91,H_'4%1Q2(%R"<@N*.KMR'34CEH!1=>WO"'3F^%I8J8XO+;YU3YX^+&"DI
MI=-CQ7IFH3JMZ1KOENX*;LFC7-KOJI;(M1K.?8,IF%:L[V^JUD9?V%.:\MKE
M#'"5N+DE#]V:V5<Z>D&X]VAR5YVNG^2KQHZ]>H^-JRF9[#7K+6#SS&GZ"@3I
M;VXE-6AXG0;KM0+HEEM9LEOPQO71)^;ZA8_O3>>\+%83_P &$I9%D.ZH\!74
M\0C=A$*'WF&"'6!Y&O'GV:B@<%L"_II%8)7_ "TF="[&@".;VVSR2Q9A*1A=
M-!BS](' ".6KDZM:K!7S:L0L;2'?GGGV#P_-T\.%LQU:Y^^JQM:\P^<WBQSY
MLN?H^0,?1=<"HF[&+G*:4#8U&R"-].*+OF(&XROJUCU/A7+ESM)["(<R5,80
M;=4@RDY+@9)-Q_36O^P_?*/-+SW%H%5+\;S]W"[6W;:NWBVODMHYE?1=415I
MH@U&3:TMG=;N;\V,\>A44$Z,H2Y8&8+F:4*'=(WPY2_N9+BB00JZ*\-/3%F2
M?M&VJXM:G(M;<G\E'+WD;XZ')BI6^PX$MYQIM)7.H5?3>F9$2QL:9*<YRI+L
MR(GR82--^#O&CRU(CF]'XOK[Q*=V=C23F?K&]F_@RY>I*YAEPU+;'/CJ^]/U
M=S Y57/9:DEE>AK^SH$\'VZEL*N5A*XE]?I RJH[.4CV8G!'&@UD2*UZ_/ER
M/VOZE+"X[>)&F79WZ=6:G!)//9PPW2#F6-01NZ&O5SZXIV.WE2Y-&4D]3XYV
M@SS9:ZK7PY]0 <VUWB[E73ZS2-QL=&\-Q!,79HR]"$L6.Y2-G6QJ\]7ECZQ\
M:4YXL9^8:VJ^RT5M(^F;(N%AG[')'1\65IS%&:_GTP109<PR1C+8744%=IJ[
M'.R]$]EI]M")3]T"E3+"E.4>.?%/:G./8O)'0BA!S%7M<T;XY[,Y2E54<^%V
MJV15GM6?]&*+K,7UFUV6JET@60':)U<BG-]E\[%*'"2:4KP,:5O="4C1(+NC
MQW2GKWN3QR] FN<!.I7EEH[6B]YP>4FO'YAG,6ZDHE-42-KB:-&SKV=:$H6W
M#4@"^.30 AO/+-1?B!WQIM,R.1MI^?NF0(Y97X]O4>/-5[>03S>6Q6W4O#-1
M\5,55SRK;9)Y"LOH>=S]C?WY4W5GVI<<9KVD(I!],$H9$K#.I!$MS">*%#P6
M\EDM((\K2HSB#%!2J=SQYP>-62_U=)*6'HI1#FSH0GD][ZR04=(57'S#TJ<Y
M;8M4HZW2%:'14O)D6R8\L6IHVJBB-U/!I1(BT(3EQ52_.7\G9Z!H?FYN@+E>
M%=V/=*/R1\8WSN<25YF>VTKC'AU^&V4U4Z53^5352>:-$+<Y(YIH\D:$<32/
MCU^  D)B1(&0FYH%X:^W ;DG%*>W>9]>,Z3]Y[[F6S ]GLT_L4I"*Y6Z]=T$
M2VB.#68TGYT:TC9^U<QYV[C9/MU8XY]N;IH+7(/5?\>6M[_A,LK=_6>/7R R
MMKGQ/]?(7YZH]'YI#J+XP4W BG$9\CW/W)UFWFZ\_'OO-<N/,L #%T#1L-M=
M\1NT=-L>/-ZA*2Z &@8W#[CI8X09Y<@@TXEV-K/,SR8BZ7_P<#(_T -M!TJ1
MQLJZ9)IAY'RDAZR4*B4)?.:RW-KPG%65^*J"& T(8P9%T[V:% ?)"A!&:"IQ
M[\)/D%0*'SGF WCRD3Q/&O*##?)%68I)'+.'T0[JEEOMLXEM3R]W1Z40=F:(
M0R#?%,<?$#4^.]@2 MJ0.2N%LBM4)M[NO/ S9%4=U2>SR*KX6O.A9AW&O[&0
MVS=LCZF*Z.JIJDED)['?:SC%3Q"3HJ)FTBC#FG&76=DRY6 MO4K%+G,8U*DV
MBV("_;K;C^-#K?V+86&8XZ:YVMRY]UCR5K7A[Z<NCK'EJ;65>TF32R9LW6/6
MU8(')-'F&,@3PNL+ODT2A+.)NCK>V(3!LD>0HVS:\Y.-S< I@*756N<!GK#K
M5\K>\7'']D\3<[3&IK3?X?(Y+(NF>GKE2N$)7/#@TAC-S7%(YY%DJI0]LK"L
MT^IV-S1A?TQ:(U$C=!*$B%P=$Q(%ZBR'*N*8QC")C&,(F,8PB8QC")C&,(F,
M8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8
MQC")C&1RL+KKF>JKNJ/FVP;J@49ON]S5Y=35&L>0'SR8E-J%R<5;@DCR M6N
M;V;2=G=2TSZ]EMC*N7-ZML0+U+D28D"2Q.@NI&XR$#!Y(N()1TY)^.F/HN"+
M>AX?^9R'V"BV])$93S!V8J1SJ)-TY6M*:O7R=P..G ?YW 6.5.,RAC&$]VDK
M(V(4BLXCPM;^6[QQVS"KSL6#]:5>OA/-[,5)[?D;J>^11NCL05K#FUIG#2.6
M,K(;-X)(G8G;-%)M RI+%Y8^&I66..CFZ+4211+CF/[:^"MCR/AST\58SC*V
M!>7OQSAYU)ZH_P )R+"IP^QE5/E+BXS81L]W;"%%MU7UF*F"XB*Y"YZ@8@BD
MZ^*&0,+RBB.OS:J2E1OTYY.2J+9K:]*WAEOU!-8[8M96&P(I/"YK$W$IV89"
MQN =B3K4*PC_ *HP&IE24\!*U N(5-Z],F7)5*<JWOZ^*GOWXK(>,8PB8QC"
M)C&,(F,8PB8QC")C&,(OG8-"^>_BU^G\T0@_V_#O7O\ AO?SU^F?6M>OE_O_
M +_QQC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8
MQC")C&,(F,8]Z]^O>O?KWZ_7U^_U^[YZPB8Q[U[]>_G]?7Z^M^_6_P"OUO\
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M;]ZUO^W7RWZWKY;U\OE[UOWK?K]=9SGP#_)_3YB'O7KZ;T(8MZW_ %ZWK?\
M3O/O.2B8QC")C&,(F,8PB8QC")C&,(F,8PB8QC"+Y'_DB^N_E]->];WZ_36]
M;UO6]_36];]ZW\]?/6:>5<UMT%77D'Z'_."/SQQ-MG'D;GMAL(./JUJ^-^.B
M6U])IS%1QV3RQ!,2]RY,SNC:E-2WG)F4Q65."T3Q.T"Q4Z/BH[>X:+_)W_1^
MORU_7OUOT'_K;]>]:][U],TRJ0JJ=W-W_P!+V?(N!.B>MB81Y-[3BS!UM+/)
MXNYQ!648@]AQ<QKBFN.MVO'27:&TN48:;#FXF%[(MB"EL;@2W&$OP46H=1SL
M?(C^.'\T?@]F8[/76RW-M?3]?J+_ "OK_E;_ +O^K_\ #Z]_/.<XU\M?3U\Q
M?+W[^HM[]_U_7U^GOU\O7K.<JB8QC")D8NS+LJ_G?EZZK<N24 AE=QJ#.Z-\
MD1C0_OH$*B5$[B+"6)KC#4]O2C[_ "%]:F[0DC:H"GVKTI5[(1DJ%!4G<QO<
M7_W3V;__  ]F_P#_ (L[X15I^!;>M^'CQZ^O]&^):_KTM>-;_OUENF5%^!;_
M *'CQZ__ *;XC_\ WKQENF1N@[!Z*NU/:?5,8QE43&,81,8QA$QC&$3&,XWO
M6M>][UK7\?[M?T[_ $UA%SGR(6@ZWO\ 7Y^M?J+?Z:U]=[WO^&M[_AE;W7_E
M.Y<Y$D"*J%2^77[U%(R] @W(7-,;.M_HN5*3=!T0<KA3"=M- (_KXPGJI;93
MI$X^0E+.&G5+E02D9T2">>/*%Y#1%NO8-KF^.3F)W*, =QSR9-$TFZ7G+&IV
M0+;;?G8"=&0B@X5A8%*1UAW/30GV<SN)J!=. K@'"+(H7V1Y@>R;7Z<[[@G(
M\ZXGAR3QW+[H,-YFO&)6[)[BZ1BO-K:R&WG/)';46D,>K7G"'*7!S4L%(J7H
M+FXRE_;7-9(4^XVV.2U+L?\ -EVLO2O/5&=#QQI=&!@O2H:XMYF8GLLTIW96
MRQHBTRU&TN834R,0ES:2ZA1*3@)BB5!A&U"<.B#2\JM/_D\WC%2*=(H/6-JU
M-7CXT1YAMREZGZ-O*$4]T4TQ128KCZ7H6%(9N<"U34*D]2>H<'IP*<WHU6J,
M?UKH8>8/=U3*RM$<9VJ/Q]K;V1B8VU SLK,THT[<U-+2UI"4+:V-C>D+*2H6
M] B3D)$2-,44G2IB2B"2P%EA#J"^?YOP_/9IHB[/&,K9[2\I_,G"\WA]<VN7
M8$BF$M9@2<QGKJ/-K\9&HN<XG-:1[D1SH^L1!('%4C<=-K:WF.#LK*;%A_W,
MHG[J-3CU=92T,)J*N>.GA:YK3)([=;O/-FCF23P .5SH"1B5M=1X=3NJJZIB
MI:=CF-=-,\,8'/<&L;<ZESB  +G4Z D639QO>M?7?U^G\?Z/W_U9621Y&EER
M&$(.)>:+CZ> I 4/=FO#<;05 ( ')]FB&;9UHMR-QD)R,0BA'I(5#Y#]Y!]J
M!$L./+V7GZ/\&SMZ]#OO/276H*>ARLKTJIGBUG40PT91X/\ A$3WT+.276R7
M'8-:  :N%LE>&#^(_18@ &6+6+^IQS94$$^($FPD@:&4@_Y?.3F.GD:+_5\L
MZHD'_;)R6*,6BGRPZ"?$KY"6G:UE'GH[YZ=T5-*P7^KY5]3(!>T1.1D_>?7?
M-G-@$I=TW##(2[N.RP,T34N.W2=/YYX!#3)H] V(ISF#XI5[#]DD);F4_:@\
M19)>]F&!UNA[RE=#=T=)57#E/(G/O9=94HR2(U?-9P3&'&OY]91K@D(+B.V6
M QQW-NQM@3284Y+'58[,C$6X.3@R!<FP*=&48*[.J^3>0>2$[Q.H;74"@CML
MH2N56]-' 3[.EOL ?O:V26S8+D[2@850P_>%83W\A(8?L1NDX=_#H.LCYGNT
MVR?]$4\?SM9DZ51!NJ:1MBR61B73NM:Z?)"&;?&!<S2- <T%3E.V)=*4)KJP
M%.;<(XP21(XGF%'%E>JV3^'6T'Q,Q!V BO."4L\%2^:MHJ26LBIC3POJ615%
M9,^E83.8MP1,;2O?=S0][=X'S>U4U6S!:HXC6MH8IS#"VEPDO?5GI9XHP75L
MS-^2(%P=,R"AISN;T;IRQQ*MOXN@OES?^8*P2V)>%55*]DMJXE,7<E(2VU;Y
M"PA=%06(RQ'0ZU8LQ">]-H2ONR=4TF/A+7]P!)E:E[^^B#*@KFKNYT3#)E?D
M?6M^C?D,-9<ITU$C2][U]"5DO<+"4!UK6]_#OX?B]ZUO>]^O65'^%Y?VQ:U%
MW"I@%^5BS,J*[U* ]XLB,6+>4G 9J%QPX!+"X/5A1Y(F8@$G%F)R%9*DXQ:-
M6>,0"S A'<6#E_JQ^_X2=>0.T0;-%\1J"J:@IJNF\H'O7LA*>[,$W>0!UKWH
M)IKF:=\_>Q>\R<:^&]!LOBE7@%=M?%/+A3HJ6222JVF9/-NP1.WG4]#334D3
MK. ,9J;7&;LRLG!H(:K"J"9L>/3-=2Q,#Y<8J(RX1@1[[VQXA3-+G[F\7" ?
MNT&BI:\QU#2&M* B4>M;MKJJZI//9J!? (;,HI5JJKE[S"4Y:]T%(6VM(1#W
MUJ7D-3P8IC+L$U];T"\@[:YJ%LPE8FPCXGX5XU&ZJ)^9UZ[P:263!)VT2,UH
MN[[VUUY'"90UF)FAF@\#?9"<@GK^;J/*W.8/Q\#T?HU<U-!0UB%$0:.PWR#>
M(*T.C&VK!U;>LYGS[%GR2N$H,Z>NN<NC,)&ZM*! D#%F>'QT#:SJC#BU)B_:
M%$W%FD%IDX]GE[]%^\\5WBTD7%\BNB3W6PT1*'F:G0$V!.D/2.DG<XKJ.II(
M2_Z+=9O'T[HU&.@G1N&(QL6#^^_=M_>=%[(*V+?LV$^#46R?^(:G$J_$]L8H
M3$W#OFG-;,1B[(6D4V(LK=QS<-<^1DL@D :TSB$2AL:TIP"I=M;%5_H\#Z)L
M(IS4UU145[!'\J^42F.9[P^=M7NQ-WI;,:;M&_:026B/6=-,+0H8N-N3;:LU
MH$,'W4ZF*.04_5:@T1>_NA^YG-D]>1U4A-WO8 KV=(]?9E!-,T4(&@:,]@0[
M^1FS1*-I8?SER^PJO@*+.E+Y)>@;'0!^S"+:DIKC/Y'@0C=C]E_8*GE2$GUO
M>PGZUH6Y^: #6M!T'7K6M:T'U_-UK6O6M!#_ )(=:U\O0=:U_#/K/-LQ+#J1
MNYAV T,6[;HYL0DFQ*H9:Q_TKTN%O%QH_"W"V6E[^^;2O :UU0]K&BPBIF,I
MH@.3=T/F:.ILP]+4M]G^,6]^JZ5<84^=EV!-9NKE$1?4S?,4[37]((RV1S^_
M.0@P"K8Z6\K%FR@A+8A.\B<A-INQG;5;.WH[,1>.WQ)7AQWTHQW+.K+I^215
MAKJ<0=&PP=#.D[S]K*SF100L-/DI)J<TI.:U&Z/T)5H[>C]"!LS?\T.P#C-]
M#\1MJH,!K-FHZND9A%<*D3TT>&8?" *N*."?H>@IXFP;T<;6CHFLW27$9N).
M"_9_#),0BQ-T,AK8A$ULQJ)W$M@D=+$UX=([?#7O+K.N";7T%F-[]?O_ +-[
M_P"[.!;WH(MAU\0M:WO0?>M?%O6OEKWOY:][^7O?RU]<UB_,SU%V1#(%1"@F
M$S?EC\0LV7MHWJ!=*L U4P0D0PY62A<5$72MND:=,<42N)+<OO ='C^R)^ X
M>Q[UNR.R]5M?C5)@M)54=))5/>SIJNH@CW=VGJ*B\=/)-'457TT[FN%,R0Q;
MS72[C7 G(Q7$HL)HI:V6*:5D0:2R&*21QWI8XLRQCPP R W?8$!Q%[&VSK[]
M_O\ Z];U_P!^,U-/#OU5V7*+"Z#1E,UB]6DM</K120TSWI]E&GAQS@YRK[RL
M;5\G(<D)IKP-.4F4%(RBE"<M&3M0,11A( [6[(K<E[*T+GEJTQ/"QL;U3JR:
M7D.FF=R4)"3ES5IS2@+3..FY4,U'I<G+ 0L^Q^\$@"68$.N[;/9&KV,QF;!Z
MNLHJUT3*=XGI*BG>7"HI8*L"2E;/)54]FSM:'3QL9*6N=$Y[<UPP?%H<8HV5
MD,,\+7NF863Q2QD&&>2!UG/C8UX+HR1NDG=() NNT]_[_P"_^_\ ;C-<CS#]
M]2^@+\KB.UW;<R@!?)=5)NW++@L*;I(]%=+;.LIOA$=YJEFHLS.06^//-/1K
MHR=+$<@7M"8V6H*G>OM2D+8J7)\YWEY-;PB$QO6:5!!Z-G7+_."OA=[DLB=9
M/-@63;$#[)5QQ$:IK<30G-A;&NA37*6F9LSV_#?FR;)S110QIC@_4OSR-^?L
M6UZO?-;6WGDKP_>M_P ?6_7[_6__ /6<^_7_ /S>_P#NS7;WU'UPTRVXM7=+
M8K,8.Q^;?F'E&IT-7O%DU))8M$YFZT6M4MTE<F)]&GFM?IF*>(5SE ) 6X(I
MA)'"8-TI=%L+$PLR'U/D#ZV>)E*^#6N#POOIHA4L['M*K[5JFJX?<7,U[6ZT
M,7&U_P \8"8,*1O=+O$GAS'-F&.3)8]-<Q1QD6HP?M<I6EIQ-RM^./WY*VTZ
MS;T_*OZ^(/KW[UO7KW[UOWKU]??OZ>OX^_6<_+ZZ_7Y^_P!_\<UTJ+@?6%EW
MAS)S9V!>W2\'FZ#QR7':$D#7=]*X;-F*P/\ "VB,7K:46 ]U K25I8]K0>FG
MUEC$L5O+/,JY=I23(W +0\(EIBI1+WQU]I36[>9><6:SCK1L2WK&C=K-";H^
M'<_3!;2,T05G:=LUC#K=DD[C3&94L+<[.CE;M-ACBR]Y8TQRN3H"FQN1M3\R
M%&K]HOIW<[:>B$:9]O5>Q'JK:0$)PG'*2R20J% 2BSU "P:.. GV9]B6::$.
MAF (V<=]D 8A!*V:;\&@[&/W_;XM:^N_7S]>]_+7O?Z:WOY;_=\OU^7URM;Q
MQ*[(2A[;@-DW+9EY+JJ[BGD#CTYM5Q:%TG_+QM&\[S7;6G31QCC,786%'(YI
M(E+'&XS'F=C94BW[DB2;^ U0= V<&6_)_'KY7>BH7T):M1V@DZ(\ALXU+:].
MCA$Q31?CW]H%#5+5#&\OC _&06+%ME*Q)_>%L32-TN/5+)$-MD32JD[DY"O<
M@%S;KMY]RV$ER1$X)%*!Q3)EJ%:G/2K$:PDI2E5I#RQ%*$ZI,> PD],<4,19
MY)P!DF%BV P(@BWK?Y65D9XXUH62/M3<R,S:0%*W-+.A2MC6@3 WO8$Z)N0E
M)T:0@.][V$I.066'>][T'6Q;]T;7Y)+$N_HZ44H\]"VW2D/J#Q0,/5D7<JIL
M-VK%]/O2=3>Q(J9;4P>&96B,FC14K?5[0H;H%,=NE8K5TS>E$YBLD+4-8&_$
ML.\HG;BNE4MK-]7<_2]@J.!^- -M%S.3SV&V!9DV[IJFCU3R*-"C$==H=7A$
M!G]OM[ZJ6*V26)I!'0N4>0QZ.N#<F>G& WSZO7V+\$MUCW;CWY\K+8WWKWK>
MM_3?RWGF6>(Q"+HP(6"-1R/H NI[P6C:&9J:$87MP^,I2Z 3H4J8C3HM^W,+
M/7!!]\4_:C 8:9]H((J$[2\L70]3M2RLY=$J"9;MB_5%_P#/$MLXIINJ6TN8
MBIGFNO.E8\]LU61 ;A< 7&R$UM0>IR"SY(M8XS-A'KC'-]52"'PQVRT58=L]
M:V!XT:JOF (()9D9J-)Y-^HZX9T[\U-U<2>)L_Y3YSJAX1/[HK?"EZ>YYZ[R
MP]&[:-4GR7G!U,T%&20<C*7Y"Y_ME?O\DL;<@<_6V6O85=QK?OY_]^MZ_NW\
M\>_T_?\ [_[Z_I_=O-63B3RH6FU>.V&29.AA24NH#^0>1S)->;S/I-9RJV;+
M1L[A/>A+-@$>6;GSA1:2(O[6]U2"/&.TSN=O;Y+8*Y\@5=-:E[32HK7I2_IM
M:7BWZ MID88W)>C+T[*Y:5,];1ZQXQ&IC08ZTLNTJOLM3#K55F2QN(?7_F.)
MV*S.3RWM[HUQ2<!1(!;:W=:<\S>TYFQ\2!]_(J[IOWV[3P\?!7YXSC6_>M;^
MGO6M^M_77O.<Y+BF,8PB8QC")C&,(F,8PB8QC")C&,(L27O^W'513L?-8:M-
MO,IEV=6Z:Z_S4"K%S^0L2'?ALT4P@7YJ;VES0 7-^G9E)6JVA8I2NFVQU(1G
M-JO5FD/CXZ'G'2SCT)(_ )QN9TVYV7JWEO5#MY1++65LIM!$YIW]KEX8*V1!
M/. _8R! WK-,(8,F;$Z1/]W))V4$*06WF+>]!WO7[OKZ]^OW[]?/WZU\_7Z_
M3]<U+9!Y2^VXEY [WYL?+#DA]DS"?K8-SIQNV<>R/\,@J"']?4_&X?,]WX&&
M.B:T(OT#QXMM*XY=8KM*6"#U:%M6LS84VRME0)%L(OS/5EP/7SROGG94"_?8
M=ESK_/7UK9ZHLF[R*C@A?2*ZKW&\]L@#;,4TLVREIJO4E/4J3STT'1S9Q=)7
MMC0IC$R$E:^JPKW,U,<YF(VT*P#:DRQOWZWZU[WZWZU[]>]_IKW^GO\ ?G =
M[WKWO7K?Q"UK_P#9T+>@[_K#K6_Z\YW[WK>M;];];];^OK?[_6_EOUE45)4K
M\I-L5!VMWK25[4=#X71/(? 3]W5#)1'9LKE]EVA!XM*Y:P+%[RF3I4,<A0)$
M7"G[;'#@)GAY:RBFMS>I ,YW4,;-74/SI=LTW'G2&=!T7S;(>A.AN:N0.G^'
MV*JY#8+- TZ+M*[FNBXA4E^KI0>Y.B^056]/:.22V:0DQK:I8UI%+:UMC.>K
M)7H[,)EXE)'9?;ET]965V19,P@U_4;+>4K+YQ54]1Z&%O/*<D1S(]#214U11
MP$W1)X[*YLZ2Y'/DJ@FP'-46G9GQ^<&#[1O''1F_D^$-=*NL&)W5V/?-SV:*
MEN=N>><;N<(K64-EO,-3\G6*1;%$M<3:XPT%M<YDK1.D2!PFLOFQBETG")+]
MR-TSG'G+Q<;'K-^9[+C(ZZVX#UH]BVNEOYY\\UB6.>6?R#32Q"?'9':[Y-)\
MDR3J"]*->K3<OVICY$*KFC:+K[H)5;1$%*=BK4 [2]BLF/09!!=2U6!F>P.$
MF/>UZ(HIC%)..^;#FJ2^-+GKJ'J!2\47*.OJRO)A8(-$ZYN:ZT0;%J);):XL
MAL2.56U[,3V=C)DJ *QD7S #. YI<2=;6JQMSFI)_D1X.ES2A8K=B_<=UQ[O
M]MZ$MGHUV[=3UO4*ISD$HN^M(O3-B1-31)S."K4M>**RA<9:(U&R?C%&7ML!
M(4RQ0(P;=K]/:_+U)\&^"NP.7X],&-HJ2E:NBD;*G%\3&](\@=75VMEE?'62
MS>3\K::;;(?IG.I"O<BDD)(3,*N1O*)FDR(4 .?$PZ+C7/+[<\L[WO?JTS0\
M+6OQX=^0.5N'.]@%G7P+;UOP\>/7U_HWQ+7]>EKQK?\ ?K+=,J*\"O\ T._C
MU_\ TX1/Z>__ ,\\_O\ [_T]_3Y>LMUPW0=@]$=J>T^J8QC*HF,8PB8QC")G
MYEBQ*WI%*Y<H(1HT9!RI6K5'%ITR5,F*&>H4J#S1!*)(3DEF''&F"" LH QB
MWZ#O,;W+=M1<\US)[=O&QX;5-9PU$)?)9O.W]OCD=:2/6]$E'.#B<26<O6F_
M E;&I)I2ZNRXTA UHEBU00092XZ=2=S^4M$Y1#@"%N'(7&TG0&M[AY$.CJ]-
M46%:D8<23DSD/D3EF6::G54U/3>H)TSW-=A3%'#6Y8O4L$45N:1(=A%'6=?R
MG2FJL?JWF-C<D7:R<KWNZR=MYVN)LL&E'ZZ+L;6)Q=8\SV'%N.29<BNA'4$\
ME+.>Q06R'8],V/HUS(J E* ZE$@E-N(>5_R+F&?M$D*WQ.\@OI)8PP.LGIDF
MOD6L>/*A*0#1R^SRR72L>5].S<-"O$AKY--K-CJO[PT+7Y H"I^"OGG+^3GT
M_25E$\]![BK^PZ&;K)KZXI_1+I1=4[[)M",U:[1V5UO3EL]# G+A+P\]Q:51
MJ/R(N*0^L8:@=R=FMAP$I9I#@7M*V)<524\U;>[7LZOZS9]?:"TYSV8QZ(HC
M!Z ,X19)S\XH0G&B"$8@$$[,.'\.]  +?K6^LRQ!KI'2QM8PD/>7L#6$6W@]
MQ-FD'(@G+MTZW30M8Z0R1M8RXD>7M#&.;^X.<39I'$$BVA'/ G('!'*7"L.7
M1'FJI&.$'OYVU\ZG:TY=*K6LY[-,VH5O]G6G)E#G.)PZ*EIAZST]O)[:WFJ3
MB69M;$7V:4N8GT^F5SC\HO,$C-V@HPFXNI7O2C:83;SC2MA6 A(-V'>R1K)H
MJ9F&O$"4X0=A"M5RT"8&M;-,&$K6QYUY-^^1*SC]$UEQ'"J49CM_9$RSJF]F
M?\4)^/0MZ7;K&CVV>+E)*?7P;&B631E4GCWLK1A ="-U@G%J%QM!*^L)R'R,
M,U8V_)TM-')"SK,DC #D2"M><9P]V5/*^N)R'Z?!/7L!Y/FI8Y8(M=998P.)
M"L*<)3&FET:V-TD#(W/+V(8&9H7NS>C='<9>]!,"UMZE24L<! WO6AA1DG;#
MO>@[UK>_61FO[N+FSG!P31B>3\MVLUTT ,=I:N6QPLFZ),>;O6DY+/6D0)<Y
M&$M2+?P%N3LF:F8 _D>Y$^]>]<+MSQ.^3+H?K-FM=Y?:RL19,T\0+569!7Q7
M7$0I/3&2F;SFQDB<MD;Q.6QN8"TPGQL<(LI>G"2NJI4N5%-CLI-"'9FY\Y/H
M;F5@)::FKF,QYV/3E_F6:@;M+9Y-741!!;@^2Z:NQSG+) XNB@G:I0-V?%N@
M",T27Z*+ '6OI<1Q?$)ZV!N&_I<5/*&1U=<))72L=?==%31B*.1^Z-YQ;5F.
M(O8TF4[P6KH\4QS$JG$:=N$_H\-).(X:W$>DF-3&[>L^"EB$,<AW6[SG-KG1
MQ%[&GI7![1%H<X\B729Q0:UK^(<.52O^TUJ>7BE16ITBO;C=B^[.$?I>/..J
M[K]<:0,)A95B2V2.#>H (MQB_L/V(HQW?X2N<+S>F:4VWTGT=*K7)/3 GEA2
MRQHF[O\ ,FG0=&A8B65?'"X_ VI"(U0*,H8>TMR%D3KE!?W-Q$(HX%ST\G\(
MK"*.\VL.5,$*B+$F&J=Y%)'-(T-* K6M[UHU6K,++$><+T6F2E?:*E9X@$)B
M3CC  %HD>36PPWCW9=<[KU@EPX!)$M9?EF:R2$60WIW- W0!E;CW>-1HEM2K
M5:%S,3_>VQP=R6\M<BVE7 (&F/+]_3=@?A/%\1JZLHL3KJF.EIJ*2K=B572N
MJJ45$511Q"D@IXJG#Z:*=T=2Z;^B753H8GM<V5KB1KMIFX;04<;\5@EV@EJ*
MF.)M/5U)C8PF.602Q04\0IJ9K3%T73=!&3T@9-4N!(=N\I'.C^7Z7C"!7*(E
M6M/5C%&6),3I))&A0,K8Q1MN):&M#^,.2H.EZW[LB 3\(#5#@O5Z'_P9J@S8
M=QCWU9=%_$C1\:TNJ61U08,@'0_0B-[KJI0D;-$4!SA,-V0595I%C+T::G&E
M;HNQ#&4 ![T'1H-"B-XAN/JC7\><[7)9L??+.LTQDDIC4=;JUSDK77P$TWE*
M I%!((_>X[#1"+)VK/7$LPY">K5*C#W<91I915X("P%A" L(0  '00A#K6@A
M"'6M!"'6O6@A#K6M!#K6@ZUK6M:UK67$Z3 ]F,2Q#"::)V.5.%5]5A[:JLB-
M%A;30U$E-O18=3U$D]2+Q!T;YZV*"UXY:&9F;O24+YZVBHYRQM!#-2T\K::(
MMDFC;)$Q[8C,6B-@8';A;%&XY LE;HH',O"[%-7ILG/6M@R3J:9MQX'!NCDN
M))C]#Q1Q",HPHR(4@TF"C@A) EZ3EN,S4RUU4  !0I4?>M:,#,E5!(2N+0DK
M8A%U936D @;2E4>9U);>A+W\1:-" Y$8%&D!OY@3)M%$!W\PEZW[WGJ\9HZO
M%<0K71FHJI"V .;3P1!M/2TK'?N92TE.V*FI6..;F011M<?J<"22L^."&('<
M8+NL7O==\CR-#)(\N>\C@7N)'!=.S1YACI)R=A96ED(4&Z//):&Q"V%''Z+"
M5HXTM"G3@,-T4 !>C!A$/18 @T+X0ZUKN,8S <YSB7.<7..KG$DGM)N2NX #
M("PY!,8QD1,8QA$QC&$3,=6'4-56VE;$5IUK ['1LJE0L:$DZB;'*TS6K5D!
M3*E3>0^(EI2-0H3A"0<<0$!AA.M%C%L&M:SVSJZM;$V.+V]N2!G9F= L='9V
M=5B=O;&ML;TYJQ>XN*]684E1($*0DY4L5J32TZ9.48><8 L A:J"[B\TW+?)
ML0C*ZN'V']2SR8JEI;3$ZEL^(N3(S-K:60-:]S:8,9DH(CB4PQ4G3,Z #6O=
MGM1L\25(6A0K5I&'68W1X#&:^KQ!N'"!ID$PE>R< D1DPMBO.]Q,@9NPM<X[
M^[;->CV9V-VEVWQ&#!=FL#K,;K:N40,A@B:8&OZ-\W^:JIS'14D;8HI)72U<
M\,361N>YX#259O7=%TM42ES6554M;5LJ>B$R9X4P2$1R)GNB=&::>D(<36-O
M1#6$I3E!YJ<M1LP))AQHR]!$,6]Y5RK#C?R[<D]5525.)+8D YXFR%Y,CLFK
M"W[.A4>=T;F$E.H2KHRY/#@R E\9="5)?X<\HD"4\*HM4VN3>@<$PR!VG:WH
M6M;#O6];UK>MZWK>MZWKWK>MZ^6];UO6];_77SSG38S3XXQM?3X@,1$T<<G3
MF=TTI8YN['TO2$S1N 86!DH:]A86%H+2!T8_LKCVQ^(3X-M!@U9@E;23STSZ
M:II^BC,L!;TORTS+TU5$.DC>)Z66:"1DL<L<CF2,<[&393%7-$FM.8(86S@D
M=V_E\-K.2@"A<*;D1:)@@[ C>4RY0I1";FV*A$T%-B9,F;S"E"T]0F.6+UJD
M_"#/P7R2PUN_U$U4RRIZZE$8HZ&/T8&^3%4E<8OS:0SI:.9C%:R2*',I)726
M/LJ1DTG7$F&)6U*F<S%Y!?V>\<7[W_%J'Z[YNY67UO*Y.GNS:(F?VTU*B4T0
MH-;8;L^P[G))-TYR(TQQ'T'9<0F=?Q'[FN1FM[Q'1GJ"5A*TH (^V5Y1;%K:
MQ.LERGCYZD_*G%%IQ^MN@+_B=U1A9/(HW+ZHK&W)59B;GYTB+4M?*]KF-6>W
MN$P-9;'62W3*ROCLQ15X,2?APL@D:'K&G>?6Y6DL?*_@;>N0\E-1SX;Y9>+&
MEMKN-4I%,VG-HU#=DH6?FJ>$LCC;M$*FU75UDEPTB5%0MMF<?-9F8M=(&J/(
M7"5I&=H03$Z0(6M F3YIF-05O8$OJF>3"*H7R6TA+'R<U6]*#W E1#I7)(+)
MZS>WE 2D6)DBI0O@TSDT>-+=$Z],!,[''D$%+BDRHBO6P?(9;"^T+)B?*?*"
M3I2N:-ES;7%M6R[=*5A1C6OM)1&F:9O=644U31L=DULS6)1>2QM5(5,BD%70
M0EZ>2HNBFBQW:Y$!ES6[]I+6?N2J.,UU#6*TH;5J*U;-:+OD3I%FN%K'.JDE
M5N+W"8NPH7)YDDF6-Z.U&HJ32100P1MF=R-,K*LE:K\5&S,AIEIPRST[4L3U
MV'.]A]M5ZKH?@SE/JN6QR<WO5HIM)XM$WB!MK@1.[,AY*R#2%X;7Y]A<F:X)
M-(NTS2(N[LT-ZQRC4Q0OK,L$1LH]$-.<H*-DJRPB(QF'-5?1>.,\6A##'$D0
M8(M%D),:8X]&&]M"SMK#'F]B"WD,+6V-99:%K2- 493:F*)+0Z3Z)*V"#\4[
M_9%EH]QPRS:?G]+0KB:KH7<[Q8,W6Q]:JLBL9&GNLYVG$>@T66/;S'X\W?L-
MDYT?)DJQ-*Y6W'I',R+,"=0WA7_JX3[.EW9+//)4[5=6=<QEB-C(HPEAO4%=
M7_.T^I"D<' V,7?$Z]94S;25FLC<2T*W6$ZE4\2EB>#494C,5M"\&V5^LWX9
MY&Q\TS\+'72_+RT61N;^%^9>2GN>2.A8/(H@\V:8F4SM8[VY<]BZD;BET2$M
MZ6I;/L*9H@2 PA,C1K)"E3)WMP;V]M;EZ]2@;4*9/BI3XW:/E\.Z0J&X3'ZT
M:*O[I"6=*$UD;*+ @6HE(K)C+:DLV(J)'74YC#C+8+*YP.9ST4:="TS0!7/'
MAJ=F]\*1MZTOSJ'LKI*PXI>$MYTY/;+N#!NLK,YRKQO>[G9Z48WR+T>W C%H
M6I+YO)8_*1I$&[P8YU6D/9(3"Y8>YB9VQV=E;4UGO+DS]E!/*9R4]491MS6;
M/4-(++NHQ)?R&NIN8I=9;'8$F7(&69R-Q_*"!\1+83 'U>4FE-BHA?DQJ934
MDM<W1MC2PMQ"%M ,NS(^5BESK<W.77P[UZ65^,'AV=0NL(!,:3W)8U3[!*H?
M" /-EW$N>P02</*=_E];RV6G6$*7635TE=4B)2]UA9#[+8 X@0H$BB."1H4J
M<K.+QR=SN_$6.D<ZM8#$EM/U02:P4B8]X;DDA>J$,B1M0*Q)&US1IVPN"B@L
M3"THF4IM;S"F5,2X)5I(U)9_C6OO3CU[CMA2MGZ#KET8*P7P-OE;@@=5"H.S
MK74#15*?&4Y*(:R>MUN.)2AHJ5W@*>3M-GO:-<R0-=('5 L1D8;N;O\ AZ_D
MR87;R(^12W)Z[6<U\TTRTR-GF+4PO72\HGS-6"&&2!E<D<0E"HJ#R1V6N5B-
M* UM7-;;$I6A4N32N:7$QO9<+<_M?PR3/K\^H_@^"\3UIXQH?><UAMEUC^R&
M)REHLFU[4G,=N2KIG<-;69.K>K.LZ@>)T],T7N6H92S3.,P.K(VTQ@YEEI45
M$1I;MTBQ[R8W2%IS!Q5PLU<AMC^<[VY8%]3N25U2=3.%AV9M,9(-5Y1<0<V2
M)18H\L]>X*6\$BEM@RK[=W=G5VT.5E-:US<]LI#FLZBEO(-5<N<+CCMN26"U
M7)ZLMWJR(DMRV1'BTXU-RC(&V/S:\) -6C*30N'$FN27;NY/2TJ.M#DM1L"9
M_='4X!1G1SOR44^0QQR95 O26/$(ST[SS0?1RIT:YG7[I3+/THM(B<"ERQ!.
MHW&C3S"YE,JI<%Z$XK9>X!*CI*68$!K,)<%M1QS]CPOUVZE?JZ^'B;6SX<.Q
M>7Z(\5-$V+7,%C%*QNO:ED%:DT8PL9<IB,HLFN9A6W/+])9-6=2VE#TMC0E_
ME$2C3W*W=TCCT@FK1-XVL4J4B.0*XJ\RB*R#M^<?'6=3,BH*33*XEL]W0[[U
M!/XU#6F./4:K^.6%TJK9VP">MFF13ZP7Z%U74U<_G>"U_7CC)92> 5A/S^KD
M9?W=L94<_P"?V1#*N8D$DG;R!B9G.7P*!(U@D;@O"=++-FK#7<):=$MB18H
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M<WU]7&*!+6U$B5Q0:O)T7JJ^TK&FG-%LP![Y,N6"TJR5.^/T"5V7;\GN&,U
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MW0!F; G2DC//,^ L(S![ 46,7P@"(8O7PA"(6]:WW"FQ&<CIZUL#76_H8?"
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MU 5_ 9M?IR =L DHM& +];D]9<K\YTY_PM:TM745<-ZT$U]21EN62A9H)@C
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MS8O0,9#-)B&%C#A'!B?Z$650K8WTT&+'#9!B71U%#1UWZ7:KC&MZW\]?[_\
MAO7ZZ^NMXSWB_.Z8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC
M")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&
M,(F,8PB^1>OAW[_=_1Z_=OW\_7K?S^+]/7O],TX6RK)[?/=]U%4;RSW6_<51
M[R(2(FZJM.\C7-]-<MR:^(!9L>?;-M!UY6ET5(Z#W"E<Z^[7&;6+3,TL9M=Q
M+:I8A;! ?BT@MQX6O81?3Z;^OT_HW_\ #OZ;_A[^>LT?4W-W/45\IET2"T*P
M\6W0UKR#R'OEB1JW;>\M!T,ZW@36ZV)%E,6AJWG!B--:U4RJY0GT@@5>*D#4
MM,;T\8A#VG6N!"A^=)G<=A]1_*HXY&^6F=AQ^W+MY[P8=>M?3U_.%OU[]_46
M][W_ /S;W\7K]/?K.<^0_3]/\H7TW[_]K?O^OW]=?IOWK],^LJBX$$(P["(.
MA!%K81!%K0@B#O6];UO6_>MZWK>];UOY;UO>M_+/$I:TKM"G=$B."0U(E>VX
M]G>4R:*L"=.[-*GWI2V.9)+<64X-RC6]Z/0K G)3M;W]H2+/;XPBQPHIZIE<
M&1UBJK&O5-;M_P!T^X5^HA,8/A"'2!1I6ATCB1K4./I=(U6M*4OV#<7]W4:^
MW)^ W^=D!_,6PP)U\:?3+#/73GB-0H<5BI*I;T^]3^+T8C&CG<5.9$LG<ZID
M<0FR18>ZIV]#"$K$^(R5<V-C;>Y)U[*>N;55G^1-[HC5FR[DR\6"GWVJHW8"
MR$.!K0\W7!UMBULE1H!%N$A _1%O?8VJ<5"J.)79(P* NQ131(CVIY4IG),@
M-;E4\LO#^R>>>BAYX%?^AW\>OT_YN$3^GO\ _///[_U_?^GOWZ^66ZY45X%O
M^AX\>OO_ $<(E]/_ -]>-Z_N^O\ '+=<-T'8/15VI[3ZIC&,JB8QC")C&,(F
M,8PB9AV^J%J[I:KY)4%P1A-*87)B"M'IAF#2.32Z(S-*6>2QMX3_  KX]*8\
MO 4YQ]_;#2'!K7DEG$F;!LTHW,6,ZY8HIXI(9HV2PRL='+%(T/CDC>"U['M<
M"US7-)#FD$$&Q6125=5055/74-1/25E)/%4TM532OAJ*:HA>)(9X)HRV2*6*
M1K7QR,<'-< 000JJ:*OFU.4[2C'&O9\G72]!*SCV[E/KYZ)(;VJZ4*4.QI*A
MMU47\#?'.AV!  )*18>:2W6VA* YM.@2+[TC66K:WK?SU_O_ .&]?KKZZWF'
M[YH>K>E:LE-.7%%TLL@LM2 (7H#AF)EJ!:E-"J:G]A=$P@+F*2L+@40YL+\V
MFDN#4XIR5*<WY# 9 :CKXM+DNT8IQOV?*3Y:T3)>)@Y&ZS<B-)4-Q(TA7_H%
M/W.M#HMOC_1#.A 64W+Q;*:K:;R?Q-N,!) K$2O2Q2R8-)'25<CY<,E>R*AK
MI7%\E)(\AL=!7R.)<YKG%L=%72.)E);2U3OF>AFK/=55'2[;4M1BV#TT%'M3
M20S56/[/TD3(*?%Z>",RU.T.SM+$&QQ2Q1MDJ,>P"G8UE(QLF+X/%^D_.T.!
M6LXQK>M_/7^__AO7ZZ^NMXS?+YZF,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB
M8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC"
M)C&,(F,8PB8QC"+%EY7!#.>Z7MN^;&/<$M?TM6DYM><*6IN.>'1/$J^C3E*Y
M$<W-*<0#W-<6TM2L:1O)&$U8>$"<L01F!WFO;:?#/1?8%^Q:UV1T\1-7T3(^
MBZDZ:@]O0+FV8(O(0&(QV8QNTXO^*V"Y2LJ*J[.FK203&)VO4MHT*YO>G, $
MX]#^YF7R=847KI_E[HSFW<H'"-7]1MK4Q^<BV@,@,B>[-@[W#=20#$-Q: O(
MV/;QIR"U"=6T+AM-I+M>DT;L\%>--^ [Q24TIJ^3,O&]1J+,K#<(=VRQ0)9>
MC=E$WA(&E4DF84(IBL0I7%0_M1;_ *3C K((5F?9CVH #8C)[MWC/N17'!UZ
MUZ]^_F+?[O\ *%L7K^KWZ_CZ]YSG&M:U]/W[W_7O>][_ +=[WO.<J)C&,(F0
M4\EYO*I'#O0@^U=PO7.'Y03@G/[00.0XGMT,?&L%>!<0- 1.(CA62*)::])=
M;'^+;0['Z+T/>3KS$][!:ATQ:@7L+<-LW7LS^\A==)1(-^HTZ;*^WTMUM-O6
MCM%[!]KKU]IH&]?SO6$[57%X%O7^)X\>OK_1PB7]OWYX]_W^\MURESP9))Z;
MX?>!Q1M^B+>09S-$]-!;W$GEW.1*_P +EZ<)CD<@FC(!S3:E9K"[;)2IV@W<
M?1.\?T?^(N:.3--L T-K[4?$"4UZ%+][,%]D*!202C[CM_C!Y1&U&K'"7][#
M%T\R;#%7W?1(WYXC3X%&6WQQTC\H@T;V#T5=J>TK(>,QP%!;FOL_CE==;WH"
M?1WPU_)@Z&8$V9[5"+]V4+[,!I*NO@$ %LS9!C!,3##% 9<R%POE2@ML28 4
M<KKLI7I"< TU37\E4)Q.6VB.%)U)9!5E)C (0/Q$M7'(A*3%!S0[1UJ+7DK8
M^Y/,DO=Z?E19&QG@-(K1^]_%N3P+:'\4+,V3J#2'2O\ !M39P5F(_O6[!V3^
M)BKD;7'@.7W3[J":)5\Q$UC8EZ>#M_7E-US:2EA.F%9#6Z;=%F'%5O*BTHG?
M\I'I1*P)AVF::6V[G.TKWIO$J,5:BA1\7VY[=SRY>G(LGXSP*A%:(EFQI9-
MBF_[\I&%.?!I">LTV"D\>4(TPE9=A)R1+B8:1*VA2MTC"G429TC\C*;TS4PN
M,7D7\Q(;6^Q(T&45]I0'X/O)@H'(Q$F[T7*]&?8%:L8(R/B,4P<0/M#E'P@9
M94#?QBE#0.(D60L9C0;?</V9V@2ZMM&[2JPIQCKJ4"++6B;HB6B..+#9X!')
MB79+.U2I,6:2:J;GR)H"5253%GARE_[ HK1^_ &.30(39IT^T,3!@TA"N$R_
MFQZ4[1EK=V$).!S_ ",;'F33D)O,2_FMO>91^%;:'A#$60B]_C,9J&^XA)CP
MI9=6I2L3:,M*<?74H/3E/&X>-*6K4)R[03F'MH9]LM]&W%J4ZH<1".*!<P/(
MPS('[3D5I;6"&GD\!+;]N"H8$YT%D1JS36*4Q]0B3#5@L,DD2\F%$2EF5+M(
M@)E,G<V&2E-Z5I8W&*R B]_F([SHVL>C:OE506]&$DKA$M0"2N" \0TRQ$J+
M]FMSXPNA&P+F&2L:S13DP2!L.3N30XD$JTAX!!%H?;IT%M!*%I7*J[-/^ZEA
M"-/ )*05]]TW2@LTX19EDJ1[3#=U$+5@3!-T:6W,\G;Q*C%,D:G**_)J"V][
M5?92NN@A$2L"D";7\F,V4>-#$0(!J=@LHK[P20Y)9VI5DE:3#5HGR)HB3D9\
M6>%\OZY8XYXY(9HVRQ2L=')'(UKV/8\;KF/:ZX<UP)#@001<<KY%)5U5#54]
M;15$U)64D\532U5/(^&HIJB%[9(9X98RV2*6*1K7QR,<'-<T.:00%J#V'YK^
MPN)[>E?*:7=?] Q/F:R975AMA6JR2)%;5JQ>*.H4+85*) QR4AG0REM;BQL6
MY>GCR\R0GI$\C=VXU0I4$';0O.O<O+_34.ATCK:ZZL<GZ4QMJ?%M=DV)$U$]
MBJY:@3J7./2&,!<RGI&Z,*PTYL</M&XLH9Z89Q&Q)S"ABB!T#X;N7>D[W.OR
MQHG'MR9W>$+G-&Z.:GD88[!"A?G3>C9BU-%@DH%SRJA1<6C[H[H"&P;T[M3N
M\NZ98@>$;"S9ML3QY4=;#$G;K!H?CJ1N+>S!1-3D=S8:@&WKTT 0M#>80J9[
M%;I 6T(YZF.>@-A3^4JU!=HX42Z$/J4R=*O$8+AFV6&5>)?,8A05^'NE:W#*
M6JGJG/CIV.?T8^9$+Y*<LA,<3P]M:97MWW/W@9)?OVWFU?P.VKP?9,87LSM%
MLUM-'1/?M;C&$T.$MIZK%)H8/FG_ *4[$8*7$635[:JK@?32X"VE@F$#(3&Z
M.FHK"=& WKW[_F^O>A;]Z#O6_GK>A;_F[UO6_>MZWO6]?/6]ZSK'-_8V7[I^
M,/#6U_?U 4B'\2<4:#[XK'Z^!*DVK/)TI4B]Z^$@G8S=_$'T#YZ]U8:\5K#%
M7%:IH;H:_N8D1BD86YIIBV;5-86]I*DS8H1-Q<+M&?V/ -;+B!+HTJ1IHLD2
M&R12W2!*A1M#>IB[EK(>7'DSON.]$QIKM>2WKV+%28BR(:CMI)6BY<C,3G&&
MF/$9.C%<-CDQQB9M[T(1;B<(HAXE:(3.\B4J0?"E;<G']I<5P##S62[/OJG"
M:**]'7-FIF](3]4DAIF5<8^DM:XT1C,CHV.D:7@'5_#?X5;)?$?:2/ Z/XE4
MV"QNHJJL(QW9^6AQ67Y9L=XJ6F;BM1@T[[R=(^,;0MJ6TT4\\=-*V&3=WU-;
MUOYZ_P!__#>OUU]=;QE%')]3>9UBYNIAH=[UYHBRU! F4@,:NRH;'GEL1]!\
M!@VAEG\L9K!;&]XDK6T#0H7 P"(M4E$0!O<3ESDD5KU,A/V>>8K_ $DN%O\
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MS1M^8-4(RY[-N'&56?L\\Q7^DEPM_P!G.V__ #0Q^SSS%?Z27"W_ &<[;_\
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MCQ7OL9X#5JUEOWZL*#;];];]3"-[];_=O_C3Y;_AO.?VJ5G_ )P8/_K?&_\
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MK]1]0:M:>@6.U)T^SJ<BBHT8&Y$0]0%SB+(%_(?3EZX38) >W$$)MJ5<R/\
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M&_\ %@)U6LP_%(<1?6MBM_DZIT%Q;ZV!HW91;_:]XD:WF&7XK7*?O"9TX\<
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7,8PB8QC")C&,(F,8PB8QC")C&,(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g252679.jpg
<DESCRIPTION>G252679.JPG
<TEXT>
begin 644 g252679.jpg
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M>/=Z" 0"0)CSDDHUC21S&+@$6WQ?8&))',1),6 .70D;UI)F[[]1"F['[^H
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M:\83$-*FIN%4MB;5^ <JL_Q"4%@U5I)$RB_4 H@2KC'NCO4C*&(B840$(BO
M_@)Y@^X;C-ZO4\C-L2S9<%&HN0\DZ.P.B%AM-B:L+P-XKJF/DHFO6&V,:R*D
M JRMB\8WKY"S#N,C#J/TGB@R&>7+%5"R!I+F:V73 [S8^4PC6I?+V/L8,K#E
M*OJ2EO@(U5I^.5)AZ=@+Q/-86'?R4R[K<2Z4<S;9@JR9I)NU$G!([_\ @_CC
M%#A_MS'X284C(&/XE[A($-I,>4;87%57RC/2]9L<M/8Q#'6>\F926:R^&%U4
M6<E9*=8$HZ75LA6<]&L9Z.73YR=^J+Y$?.\WO)/<"+';JVS"1> 9M$$NIQ!D
M$B#%AF1@2?']P?.-F3'.Y^:,#XB;UFHXYQO@^[5RM2^3\<WX9VP9YBLT8,QY
M-YE?GDX>N0!,'8VA<HS:E>(TL(L+])U>:DYV5@XA2O)2'3AY:-S8BREK:N4,
M/6Y#6_)2E/NDFQQU$-W&^L:\W_1T^21Q<5E: ;4"?A:>X&P.OV(0F6+G)9$F
MBHMJH!T%,G>XX:QAD&1-+WC'E(N,FK2K-CE=Y::Y&SRZ]"N;F+>6RF*GDFS@
MJM8LCF$AUYR'5(=G)K1<>=VDJ9F@)?.V.G^L487$"<=KYA./1P JLXPDFSQC
M44 Q(X<K"Y=+XY]$4 U-=RZ$72RT2+<XN^WO8O3&<\V'>[!/]V>]B#(,D28F
M)BYR@<P"[)/ICN;>IC?M>'K2+RA9HM(Y>L&??S7/M:::]:U;10-;U>P7/W/)
MF*G.PN5LK8W<Z\NZ)CMY:Y^^.Z*G0(R=5LKIHRLQ6"]DD;!&LXY@V*%Y_AML
MC>Y:)56WM(Z?AVEJSIN%8FL/;(20K-JB6\SMOFJ01C++7)8I).!GV)' -I>'
M?IINXY\FNU733.D) OMQC@G#^%EKDYQ/BW'>-7&1+,I<;VO0Z?!U1:XVMT?_
M "JQ652&9,S3$PN!U!.]=^M3U++"  954REFOB=$1U ]Q$P_X2V[78C[?_SB
MYP]O[ Z#^/7?\>4 0;]# )GI-XO?O P+8DF6F! YFSYPZ+7C!QZJ2CCCCE*$
MXXXX1....$3CCCA$XXXX1;3F A#&,(   /N/Q_#Y_4?;D 7EOAT=@MQ_%%IV
M8BKV)N&>[9GS(+%)/U@2GX3AXZ33<+E5 43LU%SRS)VDH _436$O0D,?N?M;
MKZ9NP ?CH!]@$?4'I ?CY-T'O[?KR(Q\G#V?RT9-RY/"S3J&FVA4' NY)98@
MIQ5MSE?;1?K.LK]3TE9K1^-,?L%3JD PJQ\\?UG(!?W_ ++P+K#POC&OXTT.
M=5X+X>X]J]*&?K;Q+7<.J\#X2^GN:C.*<5T;V!L'F ,B"1Z3C^G_ #FCT^B(
MEFKXEPYE>?T_E=+JZ7$-6#8V=IM'689M#]S 4N""I3ID'L"B8H&] F#U%]8B
M(%Z]OY '0>W0 'QRORPKQM9TN&RNFV%\[7R96G;1DYI:;(]=&JA*<DU;+7FQ
M-8F'9Q)5#E=1E?AVS"%CK&013M31D2P)%*1^ !?I[^KY#T]?'W[[^?Y=<^6X
MCH=3PGB.NX5JVL.IX;K=3P_4^R+BQM?25G4*H!J!CRT5&.Y2YK7%L$M!LO;4
M*]+5:>AJJ!YJ.IH4=11<?[U*O3;5INM:[' V)'0D7.O'''/&75....$3CCCA
M$XXXX1....$5)<WI2,;L ](D,)A Q@* '*(F$I1 P@4 $1 !#OKKL ]^0B:P
MZC^1&H[<3>:[GL:7$6K*UIO:AM0'60K-MI(WJ+D9J=6KDVOE+)=>K+[!;4X/
M&EC94/'CRS04$DX"MD$$FXN.3=K=@3V^?6EU[^GL?JDZ 3 !A IAZ W11_=$
M?;F)GHYLYME ;GXRH=@V1S?8-'<P;6;4XTP=)9%J&LUJ6R7<*I9,OV":Q@]3
MB<A6'9W%M*KLI7+(VH=JNL2Y]<+48V,E&=<CY^&0&'"[3$Q(^)%L'S[ $R(5
ML!(<!&),@&S9)-YQY3@;WRS$/^23]^^B@'?77Q[?'VZ^  /8 ^/;E7G5?FD>
MT!DW=OFC=P]5!LS27<)HJ/'(D,L#=H1<Y3NEQ2 5/H( HJ"8"84RE#VT/.PR
M:+]PI*,$V\4?Z<FNH[;D0C5/I)+_ $Y!8Z@)L5 0716%-V9$Y4ED5!*!%4S&
MJ0-Q:QO_ )J!)_RNNVY&=B'_ )U?=+_LC:1?_?C:7DD02L<+@C7\:V_%*MSN
MTFOUD_Q*K5-1-)1TDW WUE6R:JJ29W"9#(D.HF4QP$Y>XW,0&*/E6W1Z,7WU
M&TBZ#L/5U^W&T8@/I'WZ'U% !ZZ['KY]N:J&'_\ 3_[FJ3+CCCA2G'''")QQ
MQPB<<<<(G-IQZ(<>^NBF'OKOKH!]^NA[Z_3H>_CF[E-7KZ9P$WI 2B F^/2
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M'3?(!R(W[8M(,$$$ K1(@IID((]B4.NQ]^^OO\!_<   ? >W*G'*:IC$)V4
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MHY6K367_ !#V2>15=6=I(.5H&#4D/R6'65;MA5CX]NH5LW3,1(EXW*!) /4
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MO]_T^>OUZ_VB ?(APBJ<<IBJF'R< ^!_O^/]_P"?Z#S4%4Q$0 Y1$OL8.P[
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M_P#FB/0"(] /8?YP?UA#L Z$.;_JEZ$>AZ !$1Z'[=]@ ="(F_='VZ['VZ[
M0'E]C?TZ1Z??9<T%),>OW ]O;V#[#]OCW >O</T^?@.1L9!  \LFKH   '^
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M%L<HN(2<"(?/#1$RAV'UHF1!L^1_SVX=\L*\3O\ Y( ?I_A+;M^G].O\,7.
M^W\.^_CFJQ_LW=>=GG'+4_R^2DIXXXX4)QQQPB<<<<(G'''")QQQPB<<<<(G
M'''")QQQPB<<<<(G'''")QQQPB<<<<(N.Z,)&ZI@ PB!?W0*7UB)A$ *'I^_
MJ,( ("(!T/[QBE[,&(7=;GFS83R%4-M9]>LOXUQ_([3XTR)"Q\IXH<-Q.<HF
M%QK<XM1K9G^S\CLU)6X*TJ_A#N)O+++$\@LUHT@YCTHP%C*"GEZ.^OPZW?8@
M)>A O]8?4(!T'\1[Z#[]_'OUS$1R5B+"SKS+2#C(.><2X?N=LVVQGE"H6#8[
M67,E-VSL4Q08*M,X_"6F6V[RQL\(63!=R,BG$&J[%FO93LIRX1#JLOEG",DE
MS>)M.0;0#N)S,6W[%=:8_4>@G )C'> "02<6]1*=YMM.-H]W-0[)AK7:P4E2
M/?PE[E;]B:SN+)!.,V3;2MG3Q%5XVXUV8BF\#&5R\G3M\G'V7\57+2[B8",G
M>HEN\ \<>0O&EN?>,FY8E5\%8Y0F4Z3GFQ6;,4;=:8P9;;1&8:MK*WJNJ:D>
M]<N[I QE,5P[::DYD\FD&E12:-;=0KJ1C9^8%GE=HI%%(HG( "8/WB  @0OO
M_4*4?<I"]  %$ ^ [ /CF@MD_28  0]7W*'0AT'M]^C![?!N_?H?ZP /*+9%
M^^"1GEG!&S0+R(O8FTAY:( 'F1?K];^<=!&(:W\5^Y4G>Z!:&N J=1*]D/-)
M+Y0:H2]8V,?QN5Z.\@L!MC+(QB<&X/'R[R_8IA7=64CL,'<,65MD34^274IJ
MZTB$H5/HVRU2\R],E\Y9^I>7Z)<-2]N)3!E*J^%$,62>'JA_3EKNN:N6>T(W
MBUGRE)*LG<0V-8'$96!37C73A..#\>8"S8@U1#W$GP !\]!T'\ 'KY$>_P!>
M^A[#KD;V0  /+)J^ ? :.;<_ZLR:N_\ B/\ \. "(\R?4Y_G!-\ FYD7%P/4
M#-Y(EHO?IL+3<SE25<<<<I0G'''")QQQPB<<<<(G'''")QQQPB<<<V'.)?8
M[]NP_OZ]_P"_A%OXYQ@6-ZA WI$/J%('I*;O]XW0]CWU[>W0@'7W[ZYR>$^_
MOS%_)....$3CCCA$XXXX1....$4?7DDR9=<>:T6]ACO#N3LQ6_(HFHD-'XZU
MWA]I(^JNWS-=^2V9&PO.WC'L=;J$T(Q59RC-6R-0,\=,1$2>@3ECJ\(%<N4K
M:]MLQ7VI6^HV#))L*P*J0:48VTQQ3(M,:,KQ'(+5*'Q[F#,Z=\O$<K-/8V]3
M$I8(U2!13K\&E&G(W%?DG'D;JR5XT?VHIZLKE"$1L>'[)#.)3"M,ELC9.8HO
MTD$EEZS0H-['35Q$4A,G,UN'?LI*4KYI9JR=HNE4C#&/X%:-AF!B=E[=B_-^
MLMIF;7-XTA+OK[J9B')6N.-<%/J!7Y>!92EJP#F.=ELCTG+V22.'#N]R$RRA
MFTT6#BS,4I$$%91S$>]CH=NN>L9\\8"Z _V;K'83!(L6Y-HFT9'NX$E6L;O>
M+7R$YCW.S1GMD^Q5EZK9&P#D>A1#9*=GJFHTQ36\YZ\Y#QUJ2>%N<V^IL86_
M5^B9#_:*[,XE&!LDW99T;RNT:N((6WG1_%QN5)6R"L$?K/3*8QR]DP]QQBP"
M^XQ.[\8[,GD$1VL>RK%*.<.&LI)36-&R<>I&X/5DF1[>=.G/TW54,I)ER_U4
M4U! 3AV!>A /</<H^PB(>YNN^@*(]#V/???ML!JB  7KV*4"=#V/[GP =B(C
M[>X /8B #[C\]BT&.WZ;FT 1OYSN<$Q98*CA AN.G<'R^G3%EC>Z*: [UX=8
M9U-3!QOI!D-U@;6C ,%D22K5)V&@LPY-PWEO*UQR;LY,XXJMNJ!9,F2J;>XV
MJP+V]6B)R*DY,X<V1HH6"C!<7_>&IC:(G0VFQ-WL,?;[K&9OV^C;?;8F!"JQ
M=HLS+;7-#>;L,=6"O)$E>92\@1=\VA"2#XD8DL5F1XY*D"QY1P1(3L2@/N<@
M_(]>QRB'MW[B ^_?_@'(W/$^'_S02!^FRV[0!_#K<C-X?[_W_/*%K9M:=@ !
M$_8^"'WFN=CWJ8@3'Z7WN3>WSV$!25<<<<U0G'''")QQQPB<<<<(G'''")QQ
MQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPBH.A$&ZHA\@7XZ]7?N'8=!\^H/
M;^WX'XY!A3LU^%>-WVS0REI_"\-OTPS['XVL1<X.GTEE)UDZ0K];-7D\,(WE
M[/L8> E(Z7C&,$?'"%?1&1"49'01>)NOJ3GNA$&ZH@(@/IZ#H?2/8B   "/L
M B(@'8^WO[]!S%$S4SSI$^7MD23RS4HMS);+8EE<>/AV^U+I6(*UKV[C8 UJ
MQ3D?3BS0H;!WW-=M?MYP\-88R2-*3M@EZM8*S.PD?!.HQ[#B1B#8YQL>E[@6
M,2=P5T8)YKD6$P8)$@_4#8Y65\D'290'[>H/CXZ,(=#[CV(? CW^\("/WY4Y
M9#NOMU8=/,7ER5$8"NN;8:':6VQ7Z0@[A0*!5\94*AU=Y;K):[Q=,@3$9$L%
MG;)F:%ID$W1<O;?;%VL*DM&IK"_)9@Z\UF,&LM9%5<!Y?:T-WCVXSV%KK*/*
M=$JYER=CVM8IL%PPHC57TLG-4&V,'&8ZG"1LI;A3B)E^PMBS?Z3."36?[S-:
M() @;VL(Z^?\LJ TF($STCK$=0?Y7PIK>1J9#_YV75W_ +#VW7_MBU>#EM3?
MS=8W;SE,JMCU]RC!6F*O/]'NU,,6RT"3'5.?=[&Q>JD&O8G3>72)D:$F\O34
M:9K)TM,/H4%8UU=-TT2?EI_8IG(] NWEWP+"U"\TZUS5*TOVYAKC$5>SP=@D
MZG+&S1K2D$9:8^)?NWE=?F,Q<E3:RZ#5915NY1!,%&ZA2X;EI!P;YZB?K?LM
M+3!D$6!'6SFG&8_E?"E>XXXY:E....$3CCCA$XXXX1....$3CCCA%0,Y0(3Z
MAE *3L ]0@8 [$?2 =]?<?\ Q^ Y9/L9L?98NV--?=<XJ/OFR4]!IS9VTD1<
M]!P[4WRQFK?(^79%MT=LP4."AZ;2F:A+)D&2;BTC"H1B+Z1;^>[?;297IMSJ
MNM>LN.ZS>]A<A8^MN0R2][L85_&.'*%7'[:#5R%D=5!NXD9&/7FGP,(*&8'2
M4DW[=472@1S9X8L*V)K3N?FR6LNHF ;SC2 0RU)/[OL-N71/VXMN3IN.<+O8
M.XWR.M]H_)(Q6&5<,EJ'BAW"UZ+@GJC%W'8U!&NUY[//OA..^*V4=71X1H6:
MFIJJU8T*M334C4<*P:US=%IWEO)[>H'!U34%E2CIJ(>][34Y6#YGC''&::HS
M0T6:VI5KU!IS4T>G%1[M0[DC2Z9[WBFVLX/:ZIJG%U+1#E]I-2HQK<K"(!TE
M&Q2,HY3?2J<>R2D'J34&*;M^F@F1VZ3:%.J5JFY<E46(U*JH5N10$/6;T>H>
MZY\K5(A2 KE<@/QKV2_)(2&B#2C]0#/I'\LCFS$7STP]E5>/0;_B'1B#T*ZJ
MH@(_(_5<^WI3[-A/ZBQO-[P<0X !P+FP"01!@"XG=?2@^Z)!:1D$DD&!(G!C
M!()D@W3CCCG1:G'''")QQQPB<<<<(K-M]K3K]2-1=A+7M4G8UM=8+'KU]F%"
MI.K"RL"E'_&QR,O^7.JG*0EC2$P*H@]"&EF<@M'_ (I% RHG,BIYAX],E>-N
MV4Z>I_CGLVN\K4Z6A NKG$X)4C%GD<>RI/75?>WETD@2?D9:22:R!DWMG=R$
MH*B+E%=<#I]#ZIOA%Y.EM0MDH[#5IIM*R@YQ39STNV9"=UR.IT#+-VA'0OIJ
M7N,=+5*!(1F@Z(PL5GC)"OUR648S4HS<-62J1HL?!B^NAVFS#J3O#"7H!I/%
MY:-C^T[6:Z[BYLIDR6&L'](L_=,MZZQ<;"Q]'O,]^#?T2IV4\C*LW3"PR,<,
M1#/F4&RCF@X$6!.X()&($VB;VG??H 33<9=9V/[M^6)_E8[P<QD)<<AZV(\N
M41J]ENYXYRWJ]F6$A4H+(3C"EI).XY5D\^6/'4GCJ >-JU01L1;-4J%9K-D^
MMUNF94N7Y?6)F82EFKI&,,C&A*^?AYNJ$QDZS"6;7/*5>EJM:%:CMVBM:: ]
M;ZF21MBT-6F#R>=-Y(@9.A7^47";\DC24DS-\="-R<MB&*:'#>9O4;?/[^[K
M.1QP)M-B#:)V/V;94X9_8 _ZQ/\ 6<H<C7\3WOJ"'7VV6W;#_P"V/F\?]G.E
MU6\H^*]CGF1$KC3937*(JE'QIFJHVG+=UH+:KY P)E^VV^E8XR2E-L9K\!47
M\Y9J-,QKRCV9PA.Q1W4%ZU72DNDDESO$5)1LSI?'S,-(L)B(E]B=T).*EXIV
MWD(N4C7VWV;7+*1C9!HJLU?,'C=1-PT=MEE4'""A%4E#D,!AT$''W:?H5L$,
M<#_OL[C]-0Y%L$$7N+A2;<<<<U<TXXXX1....$3CCCA$XXXX1:&,4H>HP]![
M>_\ ,>OMS8*J8!ZO4 A[^X?'[O7?]W8=\T7,4B9C&[Z[*'L F'LQ@+[  "(_
M/VYY+F#*-7POC:YY/N;@&U<ID"\G7XD14,X6(V('T(U@EZBF>2DN\.WCXYBF
M/UG+YT@DF4P^KJ*E2G28ZI4<&,8.9SC  :,DDD8^'4A>3HM'J^(ZS2</T&FK
M:S6Z[4T-'I-+IV.JZC4:G4U6T=/0HTF@NJ5:U5[:=-C;O>YK1<KUGZZ7O^^'
M0?(]#T'\_;V^0]_CL0#YYO*H0P^DINQZ]770_'M[^X=?</[^^1JZ[[&YIBK]
M6\-[95V&K]WRO%*7W#]EKJ#EE59MNLR5G9_#DH9<%TF>2\9QXD,+0[DBEFAB
M+R;=,7;5RWY(ZT4%554PD*4/27TF*;U^L/8>_8.B]? AWWW\@ @//&TFLIZR
MBRM394I\QY7T*S.2O2J0UQ959S'E+6.#I$MJ-<Q]-SFN!/NO%'A?B/A/B7\.
MXA5T.J;5H4]7H>)\+U;-=PGBNBJ/J41K.&:VF S4T!J:&ITE6S*FGU>FU&FU
M%.EJ*-2D.PXXXYYB^<3CCCA$XXXX1....$3CCCA%0<^S=;_J"'P)N^_;H  !
M[$>^@#H??Y 0YAMO(J&KOF&SN>S3J54D[3OE0IJN0D!J%X^<KQ]DB5:=B^.2
MFGV;\LY%<[34*<=RK%PSG5:M"LWD"HT),T2"06=*'#,A>J@@T<K"!C B@JL)
M2=>HP)$,J)2]B =F @@'J$"]C^\/I[YB#MLKZ:[I[8XHR@WVC\1>-9.Y[)8H
MR9"TD^OE<<^1-A<Z=9X5=#&TQE@V158Q3)TQ/P:U-EIL:L]3_)7 M6L<NZ31
M<$YO)%@1<'(S<6G )V)QGI'6G_>F8(BU[R(MO D@=8@S"R!]Y-%Z_O16\;5"
MVY>ROC.O8XR&EDH8''HTJ0J]_L,2V%*KM\H5#(=2MU:O5?J,KZ;)$5R<BG4(
MK8R-9.18/%F33Z'B,[XC,$V^YY!NMVR3G6TO+Q5KVSCH5S9JO'5S'63,KQ^.
M6V3\]XWBXBH,2065[I*8LJ-D75=*2%2KTP69_9BL13";E&;N6)(#&( FZ 1.
M81#OOT]G-ZB]@ ? ^W7\/?W[$:W0^WO_ #]OGW]O[OM_?S>4$7'SFUK=-H[@
M";J YPB#$&1$3-M\[!0[L_##K066Q]8Y*YYRGK# W):_9<EIBW0(O-GK4GG9
MGLO#/\\&8U1FA(HUK-D<RM\&SI3>GH-VJ!:TL1>MB:,-R$\%84Q)Y@,.6O%N
M(L:8XM.5]-]NK+E&Q4>D5RJSF0[$;-NMCTTY=9.$CF3RS2_XR3D7'YC,JO'?
MUGSH_P!8!74 TP/(U,A>WEEU>_CH]MW_ *\QZO#_ +.(#8'=L3VB?I<[[[(7
M.(,GIY7<T&WE;L+!25\<<<M2G'''")QQQPB<<<<(G'''"+:;OLH]]  ^_P#$
M/C[_ ,>O[1#G$=ND&J2RR[DC=)!!5=954Q02021(8ZRZAS!V!$B%,<XB)2@4
MHB(@ "/*ZPB %Z 1 3>_0=^W8#WT'S[_ -WN/(H?,-M4&KVGMT-"2/X3(V8C
M.<24 A%2D=-5K,S<M[+9$.B&.8E6KBCR45*4.C+JM"&.43]E];Q77T^':'5:
MRK,::FY[!):*CP&BDPFW^TJO;3$[F%X7$-;0X9H=7Q#4NY:&EHU*SS-SR-D,
M;)'O/=RL:+ N<.ZQT<D;0V':[;O9ZW4&4RC-I7-J2$QI0J'396\Q&0Z#BZPQ
M\=%UC,4)&D/-#@)LQ&PWV^Q4&F+JSR4XVBOPTBLN@V&8#1W:NK8*@9^EV:K0
M>7K!+2ZMBOV8\!G5D;M**D(#:-;7'6"WM:;G2A0]&AR-:U4J=1J?;*I6*TS;
M-H1JV ) Q]W@DTF5PCA]ULO>FSQOD/.<!&L*DQE$A*ZJN'6:X2< DJHL(*E?
M79WZ+3* ":!R)?DS50!%$3#,;EG6S!.<OHCEK$U#OKIIZ#,9>P5YBM8(TR9B
MF36A[.W21L48HD)0.BJPDVZB9_83B'MS\R\/>&.,OY/$M'B@IZW75ZU=E#54
M?:TG4-0XN?4:YX>ZDZLWG+.1I_LG-#7M:[E7PGAC@O&G:.GQNOK&T>*:]]?7
M?E-0U[Z--FJJ%[ 34J5A3>ZD\D^ST[7MIN]BUU.:A=[1&/D9"/C7[?ZPH/VS
M-XB+E([9<$W2:2R8*MU"D706$BA?J(*D(=$_K25(0Y3E+W?.LCX]!BS8,VR8
M(-V#9LU;D QS&(@U2*B@D"BHF5.4J1"$,*@B<_0F,8QA$P]GS]<9/(V2"Z!S
M%L\LD GE!VW'6< ROT<3 YHYH'- @<T7BYM,QA....6M3CCCA$XXXX1....$
M4:_EWAI*P^-G<^#B8V,EY"6PA8&36/EVU<>,5E5WL843&97"?K%3>N6Z8&=,
M6EIG8ZN/'R+1K,JJQRCINK8?X+G-;>,MB4*Y:Y.UIH#C$K\)/4W1O5]1HN#6
MQB4AS:86FR-[TNIT<%G5Z*S/&F(<]?%9!^X-R]3RG[-XHU^PA!5#,$AANK5[
M9.VR.$8R^;*5F-N>M=+L!Z58+Y&R6<:I(S< -CITL-24K[.&9/T73FQ2,2!%
M4T_J'+:5X6:G@!"^[9Y-PWL=H-F*:R"WPK%W*B^/G$<1B7%^/D:/'71M!3EF
MC$[7;IB0MUU+./B.72CJ.BS,Z^T,W8'=?7<GY&2\ Q8B;'SB3 /D!V,E=1 I
M.D&2;';+?V/3*]VO/B#Q7D[,6R^8<@9PV!M3S9^(8P=CKTR]QPY1QTPJDM V
M;%;'#MM4Q^K?,>0N)KG78V\5.J0]C1J$M:RN)2YPUE67,;G%0\+VMP/:E+R.
M0M@IR73LJMNS>^EKE7!_PKY<<ZALHW+L&W;4YJA)1[+,)$9UG&T8*6@E!)?L
M:=-2M",=R8WCE<C;2,1U&!'7^N\WF.=T@R9%ABWW_11C8+\4NJN(8_)D#:(*
M6V(JV1*QC?&J=0V/:U#)U-I^',16VRW7%^(:M67=6:1"E/HUKM\[-PR]D:3M
MB.[58F>3+DD6P!"CX?8"!J>D<+5JM#15<K-;V!W+@J]7H*/;Q,+!PL5MWFME
M&1$3%LR)-(^.CV:*39FR:I)MVR"9$D4R$(4H2>''H _B<@?WG+R-GQ.>^H'?
MZ[+[M_\ OBYOY0:!B?4D_6_Q)C:%N6.<3<.8.UVOVZ^Z/YJ2GCCCFJ$XYL]9
M/< ,41 >A #%[ ?CKKOY[#KKY[YN$Q0$ $0#U?'Z#_O_ +_;A)!P96O'-HG(
M7OU&*7KY[$ ^W?-/643>D!['[_H']H_]W,D#/W]RBW\<T 0'OK[?[_SX]0=]
M?QZ^0_\ 'O\ U=\ @B09!W"+7CF@F*7^L(!_,0_W_P#@/*1G"1?<3AT ]"/8
M=![=]?/8C\=% .Q[[ .N)'4?$(MCL?2W4$>@#H $1,!0#L?GU"'[O\PZ$/D!
M >N1TY(C7&S^R]?Q,4/Q^&-;Y&'R'F%(2MY"*M&9!(D_Q7C>10<+B#II58A;
M^D6?:"V523E#5M)P8SI,B:5Q>T.?H[ >*9FT(-$9Z]2RK&K8MHPN4D9&^9$L
MSM*'J=?8MSG!=PU5EG;=Q,.&Z:I6,0W>NE1(5/U<ZG5G";G!^)D(&9DV\[DJ
MUS,ID/+]O3;)-U;/DZXJEE+-(&!,QSILXY51. @&RRBAFD#%,&Y3 FF4A?3:
MT?GM71X>R'4*8;JN(N!LYC7SI-&\W'+J*],U*M.'!]"B^G4:&UV\WZ+X<8[P
MQX?U_C6LTLXCKCJ_#O@QKV$..NK4&,\0<?HN):0.!<,U=/1Z6JSE>SC'&M#J
MZ%4GA>IIGZC.V#*YG/'TG2YUU)0D@5RWL-3NL$JHRM5!O,:8'5=N]7E$3IN6
M$U!ODTE@405(D_:_7BWJ:\>[<(*>3ZJ9KO,](V/!^>F;2%V!QA&,EIX[4$V\
M+DVHK.E6,+END$3,9):"L (IEGHWU%?U>R'<1;Y$$5F*RUXY'!#E,!2JJ !0
M+ZB?XP/7V/?H]/N8"C\CUT/?\^O. @<?O\AQ$XZ85%3(E=K\Y'03PYHX]OBJ
MW,OFBL\U9H J23;0TDY:QZDA_B3-U':385! Y4R\\HZ<_F:>KH/--Y#:.H8X
MN+-10!YA+3^FO2>XNIO+2[E<^D;.YF>FT''FO\.\1\.<4T=3B.C8]_$^":JG
M/YSP_P 6/LFZBI0JGW'<*XKIZ;=/Q70U/==5IZ+B&FY=5I7-U'JH*!]Q#W^.
MOCOK]0[^?Y#[_P!W*O.,D0 *4# /MV!0[[$/<>^Q#Y']1 ?D![[Z$1Y//8+Y
M/K\O+NG'''")QQQPB<<<<(G'''"*DNBFX1505 1363.DH ")1$BA1(8 , @(
M")3"'8" AWV @/ORWW&>J&NV(:S3JK1,08_BX^B,V3.M/'%2K\G/LOP"YW39
MXI8Y"-7G'4F5VH=V>4</SOU'9C.5%S+F,H-P_',@=!B/3IY+9,0"0.Q(^BT*
M7T@ =B/7?N/N/N/?^KX#OL>OD1'WYKQQS5BT$0 >A$ $?@!'W_3_ &^W(U\A
M@'_&R:NC]PT?VZ_]L6KO+$?*!M;LSAW=S &/L59.M5%B758UTG,7XO@X2'D(
M;:/(>1MQJQB?.^/K/^/@9*2E6&-]>';J[E:P$K O*>616O#]=TR8 1#Z[-6>
MM@8GRJ8?-4]*<IW.6JFK&V-=JS,V6=?Z\AD.G+9EP"5QD:$>/\AN!AX5FO&Q
MC;\DM;6&M+DTW'J)1OH:R'7&J]K/><*A# 712HU:[C !_118]U\8SB3(!YY&
M.>0XM !/*Q[SEI@-8QSG$X'*#!(Q93T\<C"L6W^[$#!S5@<^+K-$@WA(J3F%
MHZO["ZVS,\_1CF:SM1E!PK*YBZF9AV5'Z$9$M@%>0?*-VJ79S]ASHO;;=B2B
M8R21\7N7VR$E&,9)-K)['ZTQDHU3D&B3PK63C7%T*XCI)L5<$)!@N +,GB:S
M57]](P\\1O%-.[_RM>W-G<-UX, Q,?EY@G!P1%[KQ?SE(F!3U>W_ ,CK-_.A
M.]Q$A27\<BCC]W]SG=]F<?M_%3L023@ZS$6A>P/\V:\LZ ^9S3QRQ1B(:^*W
M T%,6IB9H#J7K31<\A%,54'SD/I.$Q'LKAN;NW4JS.6=WXK,XS+:"CE9):'J
M>P6N=GLTFFW$ %G 5^)MJ\A+R:PG*"3%H3\0L =I^Q%.:>):>)]GK3&8X=KS
M'F1IC$;DP!O"?FZ7_#U9_P#L=9VZ4"-]B?I,I7'(R7>U^_1FI%(SQ<WA4QVY
M%"_F>UFNK,0^HF4X =-M-NUO44#='3.FDH4P"0P%, @'EL;NKY,)6?MD''>)
MFR-CU5W%-7+^P[1XFAHF8-,1*,PFM5)=5JI'V=E'IK$CI=U&+&+%S*;B+=E!
MPB80#B5$D 4.(7W/#=>T8FQ=IP#M;,'%BN3^(T6&#1UY/5O#.(.'Q&FCOY84
MQ''(1\I^1+?S#,;5);)'C!7A6EXR7CS$=:6:;;8@DR/+UDZ?2K-,BE$VK<7#
M1O)33A%HXE5$?PD:50%G8@F8@\]-7VR\HG?1/%4U @'+V(;C8:44]('#U%*)
M6I $1#L"F$?1W[B E'KC^(TC,4-<2,C^'ZT?_HCX2I_B=&W_ ';B=YC_ .%<
M1VC?\M&_7YJ6OCD+5,WG\GMY;6A6,\25K@#U>XV&E. O.Q^-*B$L_KYVX*SE
M80ETVJMGI,@5TG^0W*+4&'GQ1>"Q-Z6A^O@<B[@^9N/5@HNJ>,ZHLI"XSH5F
M*D5,T5&]LZQ(+Q;Z13FKF>&ML,SAJT@6/7;'FGJZ;$S]Y$QIE".7I1"'\48!
M+-%Q.L8,-IZ"NUQ(P :S:3).!+P <D"ZEW%*;?TZ/BM1T$\K.%ZXDP 8]ZBU
MH)D9(&22 "5.N\4%-(3 !A$ .80* B(@4HF$! H"8.^@'L.OCH?GH<5?9"LS
M7E%\M;'!R2SE_K1J(TCDLAO6*APA3*HF9/,@,4G()_A335OL!XFDM/0JHLG#
M0,P[**:(F./Q.9\6^?[/KM(F3Z59(^GK.O0_QQBC-N(<05M^Q-]05$'DE 7.
M3L3@OK,F4R[J542,V(<RC(5  !VZ':B[@T;%LI%Y#U6VRKN/[[;Y^=M.+L9Y
M0P5BRR7ALVE)&O,8C+&0;;EZ.RC*UQI'LE58V(AD:BWFH>4+)/',B64/]?X7
MCVNXKQ?4:/0_ZM\49H&ZMFHU-2KR 5@RF[V=%_LG5'4Z0=/MO[.L"YU%U-YJ
ML%,_%\5U7$_$>IT7"SX=XMI>$-UE/4ZVMK*;:/YQNG!?1TKVL=5]EIWZ@--<
MRZH6,'(PD\JR'9W<S5*@SZE(<Y2KA)* 3392T938FQ7:%IA4BIHM(RU25!@[
M% 4MP"7I2:Q\X]CE_H$+Z4"IE$P>AU#:76Z^*)(4W/.';$^5$"%B8S(E4/+D
M.!@[27AW4JA+-E.O5TDLR24*'OZ>NP"PUEG/87#==8XLUN\1^4ZTY&OR\K!0
MR&1M8*-BI(D,O'1YFUEN%?O<XBA8)-6227CV;YB\G9QFVF9$YQ*P<G-'WG.F
M[<9;J-TR'N=HU?J;1*U5;!:[?5M;4M#VLPTJ]9B9.>L)ELT7W+4]DR37+%1Z
MIR*U*#J$FX6233CTF[A4J@>_?KN.AU-FFTU'6.<Z/9T]%KM#IJ+&D #\YJ-4
MXGE9:VC'.^P:,+ZUVJXN'-;1H4-2\EK33_+ZG2TJ%V<S7:K45PZLT-D,]GI&
MF8E@$QD]H*@LF10G0D,!3%.!@,4Y#!V!BB7L! 0Z$O7[H@(" ]" \K\BSPON
MOFK(&'L8W_&7CIV>E\=77'M.M-%D7N6M0FLA(4^9K\>\KCMRT?Y^1>MW3F'4
M:++(/4TW955!!<I51-U]DWW%V:&QGK ^,C:\CLD"2?\ S13).HG[-&;&E%8H
M(].Q#L 2.4GRJD!V>$*L+U.*41D3)@W4 W/J:1=R-+P&.($LDF# D F";VN!
MC%U[L-=:>4$Y >V =Q)-H/6.ZD:XY'!;=R=FZI RUC=>,3;69:PS$[YQ'5/(
MVH]EL+TA%D$?PT+ 1>?W$E+OS?7%0C-FD904$5U/@@]_1'VIVA,EZB^-?90P
M&*40*&8=."J=& !#LIMA>RF !#UE$.RCV40]AYUG[_?HMY#GW?\ &S_^K^05
M_O'(Y(7<C9F6E;1#(^,;;-BM59"/8.GLQD34B+AY@\G#M)E)W5I9WG])G9&#
M9-V#"4>QAUD(Z90=Q;DY7;=0@=3=MW-E*+'LY>2\7>XDZWD+-7*PDUH]UU/N
MDHB[L\HUAV<J]BX+/;IXPK$8X<%=V>PN02BJW%(+RTHLDR244#)&9$==OBG*
M>WD'-)^ ,QWP5)CQRP!?:C:40,0?&MLC^X8P"),QZ;"!N@,0WI.78)0#!\BF
M;]TA_P!T1.4H^_J>IVSK39RK9-E5,9WG$-EQ#FN[8*O=&R!(TF9F8NY4=C7)
M*04;2V/+-;:Q(Q+MC9XM=BZ9S*IQ,9=-9),4RB??O_/Z#U"%I FQ S#@8VO!
M*NLXXXX4KP[+FNN(<Z3>*YS*E08W%UAB\N\CT)I+A^+B(ZVO:C8*.I)/85P5
M:*FBD@+-+(-FLJU<HM'BR,DV(F^:MUB?=U+'-"H9GHTFEU.H#(@B$A^R]8@:
MX#\K8#E:@\&%CV(NP;%4."'XD5?H@<X)^CU" _;<<R.GWC;R'HDGJG''*#H5
M ;K"B0%%03.*29C@F550"B*:1CB ^@JJGI3,;KL"G$0Z'H0U%O4$! O0@/\
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M&H87 C2N#2LB^];F:P8_<IL+%G;&B<NY+ZVT!#SZ%ML3M,A@(H=K7JD$],N
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M3CCCA$XXXX1?-SR#,#-Y1Q'D?N8<CE['BFV;KR**X-U2J%C%%P R#EXE_D@
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=@&1!M8$2<#J1BPO;==YQQQRU*<<<<(G'''"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g432762.jpg
<DESCRIPTION>G432762.JPG
<TEXT>
begin 644 g432762.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0T%25$].7S1#7T9,3U<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ G (' P$B  (1 0,1 ?_$ !X  0 " 04! 0             ("0<!! 4&
M"@(#_\0 3A   00! P," P,'!@P% @<  @$#! 4&  <1"!(A$S$4%2)!49$)
M%A@C,F%Q)4)6E='6%R0F,U57@92QT]7P-4-24Y(TX39$A:&BU/'_Q  < 0$
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M6&!B67/=SRWDN2!QX],D>'IG(UR ,+J6I%@T2ENTG(8%8S*\:=S@,65%=U8
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MA))GT9CX<=5'&=H!Z\], &C7) XU#4"V6P%N;DJ,1N5R6MT.TR"%<@;L.V5
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MT5O/.V^XMY@P@DD/O2H\:NT;N<M(I1E=R7W*2V=1>:9VSM+"RH[<NK9VEOQ
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MEZ:(#EE E20$&Y( .^T#7[J]:.UU. 07$\336DR*R17<29W[5;(#H 6)1BC
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M;I^I:?$,7P_(ZS\W7<9$(]-/R?#2CNS<HIX3"##KH$^_A+\+$KP"$Y'A#/:
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MT<8)P"Y0[5)/ W'"Y/ SD\5&O(FFM;B)/?DAD5?5BIP/F>/G5-O13N[C=?\
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M;F,G--<=4V]7?5L.XI;"':U5@P,F#8U\EJ7#EL%R@NL2&"-IP.4454251(2
MD$Q(4Y'63KTKI 00"""" 00<@@\@@C@@CD$=:::::56FFFFE*::::4IIKJF7
M9QB.!5J6V89!68_ (_3:>L9"-E(=Y'EJ)'!')4QT4)"-J*P\X +WF(A]6L5_
MI2;"?ZQZK_<+[_I&K2R@X+*#Y$@'\S6"2ZMH6V2W$$3X!VR31HV#T.UF!P?
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ML)'48SDC Y/6K&E#;E^SQ!' !52@9.Y*I$;FW9E7,B,N_M''8H&=SW@R/;C
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M)P$DI^A9M7_IS/?ZVH$_'_)CS_MT_0LVJ_TWGJ?PM:!/^&,)JXAF!&U #MP
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-FE*::::4IIIII2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g177295.jpg
<DESCRIPTION>G177295.JPG
<TEXT>
begin 644 g177295.jpg
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M6E>R@%@A4/'.BI([@',Y'+(KIR8"6]FWN-?#A0?'$KC12:WP7UY_G>^UM?\
MV6\/?_CS)D [&^GX_P"P4<C=D&1K2-=P_J" 01RM=TT?71WZ*T_VP?T@_P!;
M7]^/;!_2#_6U_?E5_P#(+Z\_SOG:W_-;P]_W9,B=V%S3ZEM-0&OGZ@?4>[8N
M:62+H"B*\E4?#2W(+UN/53/K!;8Y:%B?"QGG1L6)_N#%%2R1_:2U0:S-WPGO
MWA&L1>\+TWKJ=?B?E\OF?PZZWTGRVGH)6$_ "0?F6 ?'U^'QZ; /M@_I!_K:
M_OQ[8/Z0?ZVO[\JPWP7UWL0MA]7OM?0?:%H.MU;P]O?LZ%O0=^?Y,0//D/C>
M]^R'6]_/00ZWXUQ_(*Z\_P [YVM_S6</?]V3)Z_H_P"WU_1Z.1G_ %H_],O_
M ,?U_1Z6H>V#^D'^MK^_'M!_I!_CK^_*K]\&=>:"+>O5Z[6%O6M[UK]%O#WS
MWK6_&OES)^._&1FH+EWU&K"GG4K!9OJ6]L5_&JJO?4!I1^W3?'J$-J5?^C6
MR@,^"H>><EB-WW]\9#*8L)RCZ=L:/,<^&TCVO)6F[C?4 ZZ[]?AKY?,_@GEM
M[^:P@=R&R=-D#KM@/J>P/;TVKZ?;!_2#_6U_?CVP?T@_UM?WY5?_ ""NO/\
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ML."R=']G26%SF.,\MB<A;_?%*/@7R.2!$X,SLC^(((/^%<$2@CWQ!)ON_>%
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M7G7G6MZ\ZW\L(JD^*/5 ,ZXNQFKQ71IE<0>WJ=N6_.:I_P#I&)ESO8-9T5T
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M!U-&R'BTX;):R;P]-TOS,;6T/BD^KEI?Y'<S&ZW,US5Y:'LAFB2YD2L[='9
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M2K -.$:410]VZK4"-Q2F(5Z5,M1G ]V>E5D%*4QY?RW[!R<\!A)H/.M"T$P
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MO=$FH-+E D;DB2N"7:E-'W,PDW:=62<0(T@_6C2C/=[V P.A WKZ[[/,\+#
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M^R9O&..ZFW\.0LV@?;P$L9)A+#TQ^C Z0P"JD\]FRE08G/3E&LB0M1HL)X3
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M^-?+/O9A8+"5<)2C@@B:VQ)#6-^8.>XV[<-=D+[,G.]P\QX9HN:![H8SJUC
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MC]PY%L8YKQ=;6E"%/JOUW"T-_P!$D/[%'N7H^_U<KMJMXQ.H^_KK>FDE2HK
MIAUKF16!TN=*V)T8UE51F'3UF6T ]GI[2>8^P-,G0RYQH>.Q^&_S'T/\OAZJ
M["1S$'U'36QUV-=1]=_=T[+8:+WY+!OVO:\AUOVOEY%YUY]K?C6M>1?7?C6M
M?/Y:UKY:^8L861Q<FMX7M#6M=F02D3,YJVY&I<&D2PKW"L38N.(,5H!*B?\
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M)5I>1#Z&Z!M2G9E6L:AU%([-;[0?DT,8'PZV6F#"+G"AJD;]MC5-BZ,/1Y:
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M:V'6_.M8\&0H69[%6M=J6+--S6VZ\%F&6>JYQ<&ML0QO=) YQ8\-$K6DEK@
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M7NIFA?#A5SF8IBYDXM9OE7J+PW1II(4;P0:9.K6M:^FM?/Y[WK7CSO?UWO\
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MEB#@',\QI:YPC)RGV.7Z[ME1PEI@3I5/(G)DNBEH7A7$[?V5]EU[W9M4Y.]
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M2(23S#S"F<B0<\G@:A+A&! YC2^SM>20F)4>T @O6M/8;XA?:V*-:;A[[(;
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ME^&]?A^'UU\\IBI'U*NS^BJU9+=J/TI[-D4!D3C+6IH=UO7'*S"H4KH-,G^
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MN2-P92E\A$X/,E.?4YC&_7Z_ )U_K^OY^GPZJT/QK\M?PUG@/W>M>R(/G0O
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M,VS-)D&BS#%V]0WO$@6'JSY8K;F^I0KP2^^^,CK&(JTCIBF#Y2IH<?39(RK
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MVW-2]8\*DI:<64N./H3W3*I=:Q$SM;EM\K1RF7?UGUT!SHRPUMH3.5=KJ%R
MJ*=-3QCL>%.-@5]$6<Q(\+M0I=#I.Z3-,S.B5R++B#&8;^]@]!*S;7AU3U?U
MEUW,4M55FP]6NJ*.<HNC]6<I^_'5[ZWQN4QMYL:Q&N=R>R:T9*-3R""G.=BB
M<[.F3M/Y6LD<D$U:2I32#L-]_57IH>Q><5G0DJY9-M:)--Z11#7SB. R)U1Q
MQVDZ>S&21R*, KX#TH1?I$5;98H].+RDAH7E1'TQ!!CP6D"L3;,DY]?IFM+"
MO1CZG!:M0RBSN@>>9@R,R/TZ$]NSDNG9L9T"Z*O3D?Y*_P +=*IL%5)DC=!5
MMQ_$1UFM43DVNP-(OO(K8])U#E[A3LLZUXU^_>_X[WO^'S^7ZL(/G\_X]/R7
M.,8PBCY;/5_,U%*U[9</05+UD]-K *4K(_.;,AT<DVH]HI::6[)HPYO*:1+T
MJG3<O @$@;%0W%0D/2H *5(-E9!_E?ULO3JZS(G)L0ON/UH; W%(D6HN@5C%
M22Q^;G#XO;?(XF&:2!,G?V11M$> _2=06\- ]IP/S0UB6H]'SWLCFWG^X3UZ
MNU:5JJQ5[FR&1M<Z3.OHG(WDYA,+6%?9(7QT:5+P0A+ X+=)B4RXG20:H\Y+
MLDXP1FX9<O>CQZ>G)":<)ZRYYBK^9/G1.O=EMNE%7"O;T2':G[,CL=56 G>Q
M,,>;_C%&P(T 0*EY@BSGI<YGIDQA/98T\ C!Y$99G%+N(C[#]F&B_&#%C4SO
MM#VCSFF< PZ$&@X\^MZ&R=':'$1R%;V-^)&-_P 1[2+$=HVB.1OLXC\M_EDA
M^_,)+!R]@3I62M+TTR!H:G^/N;<^L3X@1.S.],ZU,YM+JT.2<M8@=&QQ0FGH
MW!O7)#BE2-:D..3*DYI9Q!HRS "%436_J4]'/G85V<WV]P>&DJMYTA(K<N3H
MUSZPJB8,T0I>1-UM+JJL4RNV2-))$X%SX=/R0IQCZ%U.=8$2(I=)/*;W6U-O
M34TMK&W(&=F;T32T-2)*V-;4V)$Z!M;6Y"2!,B0-Z%(62E1HD:8HM.E2IBBD
MZ<@L!1)0"P!#J$]V>GU25\+.JUTM?+/:%'8]+U-0%R"A\N1L0CZRJ-YG[HW,
ML;.$P+5#(9+$5FR^,SA4,Y>-VC;CI$W!9E9>UX^/=R\SN3FY.8\G-KFY=GEY
MM=.;6MZZ;WKHMV-Z&];T-Z[;]=;V=;^_7JH54QZW-56WPYT?U\II^50F8\[R
M%EBBWG)[F$<4S>7R"VVF$/W+"%HDB9(6RH@=&M-GU[]@J%:$X$3=G9[:'H*H
MR+KSSLPM7K#<HI*#YFO:RASZODO4+$X(8/&T<!EUCG_IQCCZ3#);S,F?(&R.
M;8\7BWSPE]BT;A9 4CI/!1A_=8RE4(6IQ^$ZB]>A%Z;R^4A71^E$M=5<[+:U
M=;*YEK<##%.9KM>Z?<)RZ5P^7%5)$=4)Y@YQI;8#R8$P#LV)W@M(QD/Z9U(9
MTQ>^%OH?<;_9#5$(L^7S6M:0>V)M?M)U+5UFI8)6_.][S(<14)[;I5@98J4H
MCLH@JZ+KW&N6U]<I1#8BLGMC"118PF6JB2:5*^XR>IM94NNJ:,<&X4NZ9<J0
MJR[@H]QZ]:)Q67V"GMFBB)(DLG;S4)KIJQ&*H&.811[@&K:4?$A5RM$).DB:
MA$>A6+<-<V^K_=EX1-L6RST[Y_6L]MSE4'7G),-0=&4M/6;HJL4[M7S1("CY
MN2"+IJB?(B&TX1))$W3=D,4%0]:Y.382YOC2;&CY(_\ BD^:]7^\7R1..E4*
M9[FTMMI50[7?LQ:N:"KRGS(YL<WO%-3#=I*Q L&6 >G=T?4QJDZ!KG]S<'TR
M%?:*U4:=CBC_ $4.<*,A[_%VN]NVIPZ&T['Z#K&P+"Z;D3C/N=*IC4DBTP;8
MCSRZQQEBS56K:9)H-"W%Y((8W,F2HHNU161$ND,"JCJHB["W>JHR+O30G_J+
MIZ+E\A;Z^.G[4JK&OI2SS9-*'& 6TKJ%?*X;9);4T(%]*J'%*9-CK4?(E'AL
MM8)G.8/D10_9IK<9@Q;ZW;(T<"E=FK^=#'R8N]V;HN"4?5O2-#W.UVO)$#:;
M,)(]UE>59/4AA#O'8_6;--9NJ+D+1%I1K[FKF5;&FXYS9ERR=,?]/.GXUS-8
MO,[3/N@&Y/:]@2RX)]=[#<+Y"^B'RYII+4LV>[8)LN!)(J4PRDU^0-XBVV-Q
MYHA&VE$7'%$24QX]:UJHJPKT'.!F0MC)LU@L;IY.BL.S+AER#J&9(;>9K8N*
MS8O#(,KM6T6!;&FIBD,RB$*A22,0$Y"W,S1&T3U)5_V0N?7<3L018LZ ]<R-
M5MUASIS/4-.5W;+9TE2O.][0.SY_UW4W-J"11#H^?KH7$&^OHO93$M76;*R4
MB,N0_=B,.VWA<0L2H"DA!QI2@WZW"?K4@[9Z0GU)DTE4U:1: :NX]XE"GMNE
M9E:S2V4W8"ZO=O,QYJ;V-ELN#M,C=$B=5IP?CRTC&B=FA0K.5IG%*I-E]S!Z
M7',?)D]9[#KC<_>W:+TE'>>(4WV'(6>7,T&JB&7-8-VPB-Q0DV,(7!MU"W^Q
MG2-QE88YJ53="&>,,>S#E+,!T/PQ3GHL<WT_();H=Q]66K3DZ36\@E7*US6M
M&ISS ^-=UOSU*9<T.=7ZKEH,7M:62/R]]8$BQ_4 ;7729<;M8H("9LGK\NO\
MM?S7VFSUB^7&NW.B:IN$R3T\30]LV'6*&S'B*3F1U#80JTH&)=&2 ;39[##1
MP9KG!E=ODB?&NIQ/[M,W9EACD[-I2O:Q*@#U^ZO69H>#\8)NPJ=@-EWB5(K1
M9ZDKNIE,?>*7F]B2=4Q&V"^#C9EF,B-$L:6.G6R1VD2]-X'-G>FMC&RI7!.]
M'F$(^U,'HX<H12PW.:15_O.)Q<Z:R6SXK2<-LT$*I:L+3D%%H><$5DU=%8C'
M65XALLA]1I%$;A2A')SFUB.=%KS]F*W<EK6-O2(CZ$G K03'6ZPHE)[^C+%8
M%BVNK@%WGP:15;*+-L2'0NOC9Y(JJBU?PJN]R2*0N$I&6**V*-,91:I[E,LD
M1$DF[^KDVB+M<M]8WEN$7!7<,?QR0RG;3Y7I3JN*=&QB.2^<5V@AEZ6L[U5$
MC+"%#XH]):PBQ3HF83E]B39^:XVE62,AH4@3F-R]8"V@ MB]KSKQXWO6OW;W
MK>OVZWKQO\-_77G6]92ZU>A+QTR-T3B[7-NE4=<1>#IJC4U21;B$J RZCV[H
M64=,,M)3!&"&:?'2N&&Q96M1,R)&_-C^B@R9/!]2(QA5OA#Q=&$.@^UXWO?M
M"V+?G?GQO?U\?J_C^7TUK"+RQC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,8
#1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g819917.jpg
<DESCRIPTION>G819917.JPG
<TEXT>
begin 644 g819917.jpg
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MLD5QY*H4HD87NPU@W!-3C@: @)@*40,80 0*4>HP@8>"B!2\F'J'[G@!ZO\
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MF$?/$O!:RK>,D%8F168JF-PLFRE$%X]R/!12=I*(F#K*(:Q(G( @ G( CQP
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MY[0>6?WV]N#^7RU3Q\%";Z=!^KLOZY:/@HC^[VZFXYYX]GA>.K@0ZN/7+CJ
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M-SV=.%#'L_F.?9\OM/RZ1PVS/G(\8<HXASV'VU+AR'S\>R@>/WN==QM>>/"
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M=<KO4ZF_LCCS2O,K+8(N#=SKKTG!POF\.WDG39626&8LU=BP39D6,,C/0[(
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M,ZZ1A$2%$X"0,5J<=*@G( ]8]12@?@O5TE[H6K.IS"#C$5*1* I<"GF1=<1
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M,XG\@QBVXNY%ZTCVI5$DS.7KE!HW*=90J:9#+.%$TP,H<P$(7JZCF$"D 3"
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MV-8)<%3)KI(IF9(D,V,0WAF,&49765Q4K\8E#MEK?@72/"XL]3R<$Y/ADYZ
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MD1(3PJ[IJ:613%T4%6R:@<F43 3%,8@&Q$RRR)$M2ORDD5%Y-: !<A1G%G(
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M>QBHQFVCHV-9MF$>P9HIMVC%BR03;,V;5!(I$D&S5LDDW023*4B:29"%*!0
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M_CS#-(;E;UK'E8CZZQ/X1459!=N05I6;>)D,8GI&?EUW\W)'*/!WT@X,'80
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M^P5NJTV1[2VJY0(NWV[XB15("B2H%43I,00Y0504514 # ( =)51,WO(<Q1
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ME'\TI=8?0=7E5:\>6<.XAA0W<]/S4JHI(NK&^ ^;WCS_  ]O_P"!_#W]^N>
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M4[0L,+IY,3&-WM]]O[S)N18&XW^<F%966I<!ARFMQJ%IJ>5:)<:J_@J_C!C
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MKDUBWK1HT:CU5T:-&C336IWU&+7H]Q1G)((>&5JMB2EI8P$,6+C%8=ZD_D#
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ME/,Q9.IAG,J+F3]J?C"\!PR21(<%@;@V,H!FYEQ*N78Q@<S@ B.3*%P'<?\
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M<2\&X-V*/4 =/8!Y!ZZ1>Y-)5;#%R213.JH8M?Z4TRB<YNFVU\QNDI0$1X*
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MF^Y, @8HB @.N W498.!NG M-,!""<XEW58:'I(42@)S" #TE*(E 3"(  B
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M0ZBB)3 !@Y 1*( /8=<!DO'*@\%OM,.)2G.(%MD /!"%$ZAC 62[D(0!,<3
M)2E 3#P ".G=R?-O[K?5IZ1!\]%[Z^7GYC5-UD\HMO&I-TN-.6VAR\LWK45F
M:QGG[+)2#('K2OY,S%78]6F,ZS64):]UC%<11*P\M#.KU2Q6JX5"SI6:%G/.
MFU?/D6QO9+><KY)VZ5BYYL<I/L@2UUS:FYD&E8EJ=&257B<Z9*A<<R<#7IZ,
MAYYE6)+'$=4GU76G67IN3KSB,E9=W)2+YS).WF.3<;<\C?Z5SW ?[;H /?\
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MQ3C.U2=LJM1E49*Q9?IKK'N.*VZ7$DJ^.-@JF69;&C)I8VL<DYB+W,5Q CB
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MF_@YB@' <?-VUA?62O\ [>0_XT8?G&N1L4 'OFX@.0 0YDV(=A#D![N/<("
M@/RAW#3@_P""WNGZM.\C^<3WE^O69T:PP6.OCSQ-PX\ (CQ*,.P!QR(_LCL
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MRRU6E4TD4DR+B=1550Q2)D* F.<Q2E 3" :E@1N^A]5OV6/V'\,:K7)$-2T
0Z$FM/@<E.3W3=,9Z_1K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g270592.jpg
<DESCRIPTION>G270592.JPG
<TEXT>
begin 644 g270592.jpg
M_]C_X  02D9)1@ ! 0$!60%9  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?0UE.7TU/3E\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MM%UJ_P H2+T:"7/T=FFF!M,)4/+4A>79,B/4_&\N?9Z[[HV<TG2\JKKBV?\
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M!<C]F+^%[4(10MB-D)]SMLXA< 5KHHW'S-.E>8,!ZG;,>%^5N+4Y&-Q2\\#
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M4LCT]">'KIFK^?\ P759()C2JJ1>-*]; LV^E31)IHH9Y(PRPNQQ(4M5J5<
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MU;[4C?X*;:DZ9%H%:5,[1UQ0ONUD4C\K2$(5.B1'B<R%3>GJ5L3P_>5D5?\
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MO>U)%8OC.*[4NBNJ;I:PN@IN_@(JJL:UDUMRJ3,J91)"RH'$HTKESP]M:1C
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MT*E()01=K*'Z;_K#_P XLW9M#]-_UA_YQ9NPBJ!\SSR>IYPKRK&X8MNUPWO
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M)X:V%G2C3 4NKRXHVIM3C6JR$*,!Z]><G2$B5+529&F"8<'9ZI00G*T,XXL
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MKGCOWF+HBE:VN=FM>NH@EL2(L<I,ADOLZMTLQAJAZ;R7 <8E[>BE*HALDC4
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MU0Z,O\J<D[<62<O/;XXT+'E:2B*4')B#%9J5":6F+.4$%#/$6$PXH&Q&!_0
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MI,S,[MV3,I4>57S.Q'Q@R^GX<Z4>ZW8OM:/3*0&_D&R6*&GQ0J)ND>;227)
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M21AY/1I#-C*= %N 0@#[CQ4?:,(6AA4WC7D^Z#DAMCNMB%*J]FNJ91$Q!N@
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MN^6[EJKNS>O.<*F6 @]-TLZ\-JWA-*ZV:KT1W4@K1#*Y0QUA5SE;%C)YQ'X
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$C"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g595141.jpg
<DESCRIPTION>G595141.JPG
<TEXT>
begin 644 g595141.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?04)37TQ935\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 3,!C ,!(@ "$0$#$0'_Q  ?  $  @(# 0$! 0          " D'"@$%
M!@,"! O_Q !4$   !@(" 0$% @@, P0$#P " P0%!@<!"  )$2$2$Q05,191
M"A=!87&!D? 8&2(X4WB3F;&YTM@R<J$DDK+1&B,W6"4G*#E78G>6F+:WP=76
M\?_$ !P! 0 #  ,! 0             $!08" P<!"/_$ #(1  (# 0 " @$#
M @0%!0$   (#  $$!081$A,A!Q0Q%2((%C)!(R1189$7)C-"4G'_V@ , P$
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M PZ[]+^T:W1VY=;2)I1P)U8'<<Z=@C(XBD\W#%DM*K+JC=@%1YQ7!KS+F39
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M2.QL$1+69O.D3<N$T)"C&E0:9S?Q$24,&2Q@"(&?J 6,"#G'W""+S@0<>,>
MBQD./&/&,>SCP$26/& C!@8<9P+P/^5C(@BP(.<X%Y]K(18P(.<^<A%C @YP
M+&,X1-=KIXU8V='TPZGULAO*Z-'YPIE]N6TS9BE<TX^3M@I^Q;BMF95[6SU%
M+XKFRHPQM;G%Y;&Y=DA$P(9 R9^6,J1P1MX%Z)3-KKIF6P/XV^PJA;XV'F.R
M_P#!GV5K. U[8D_A510B69B4XU*H:Z%S4Z(*7@-<Q)7A'++$?L(UN8^%PRAR
MF(4*3?=8\6FYQC <XQ]/&?S_ +<Y]<YS^7.?7.?7/KRK#1G^>[W)?UQ=?/\
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M96UO9V= B:FEI1)6UK:VU(G0-S:W(2 )D2! A2%DI4:)(F*+3I4J8HI.G(+
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MB3?K^9#\R]65U\K_ )OS[SKR;_.OFWF'F/\ 3U<G_-GE'?\ )/Z6AOWHYO\
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MP59$&FC&W)8I8E12==B#2N(ART$H6=00A<4EGC,VG($23#@I)<WG#<VI'9Z
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M'G7F?D?F/&5E+Q[Q4NJ;=;%.NZ9MH4"/M;:5A<#5?87^[OQZOX^J*O<_5_\
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M9I1MEO7 F:XE]7:=R-V9+)B*N,15OL][:R$D<=(M-(9'E$UPTKX=8[))4;W
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EQQQ$<<<<1''''$1QQQQ$<<<<1''''$1QQQQ$<<<<1''''$3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g239698.jpg
<DESCRIPTION>G239698.JPG
<TEXT>
begin 644 g239698.jpg
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M3H](A^W_ -+?A@Y$OV#UZKTWZ[:[[8LYT:K'_7,Z7^U7<@[@']_5;ZB/8/\
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MN(#R!L(!U ?(0W\M9F-+,H&G0#;PT'[\/J;#[D,'GR*E'R8S"7BV8[L5VXQ
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MIY$FS9DB# Z *+V\=;^6W[L/E#I8AI+$;EC^ZV_SPV8\,W#Z/\QO'/[E8O\
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M:=TE4ME0.";A0 ;"UCN3UWP2AE-LSE2!ZQ-B>H\#CUZ-&C5G$6#1HT:,&#7
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M1ZY;(CZDS4<^S3^K).G9T$%G )J"@D=14I#&(4AC,1>XM8$FX&PM<^OY_?@
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M %>LL@:PT%XSBI5^^0]L0YD3I1#@KAP!7<NT,0I2M'B)#"Y<,T@]7D1 XH^
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M#+-!=1L@BV;+';MFZ94&[=!046Z")  I$444A*DDF0H;$(0A2E .@=]?,"@
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M3VW'<.4@;B/TA\/L[:\#J_RS5D%5401\"IC'%/+$C/72YV6-R@+9:;*&(6Y
MT%[7-KFN9R"1EV)Z^'N]OT-;0_E=4_V3U[^K4;_9.CY75,.]GKP?^6HW^R=5
MJP5<E+&\490[$KI5%NL[7.8$TF[=L@F9515=PH )IEY2&*F4?OBRFR:1#G$0
MUE8VDR$JRBWB#FO(#-J.4H=G(2S=@_D%6BQ6JB;9%=$$Q,9<2I)@JX2*HH8I
M><-PU)#^5OCE0$:#LM'(CY\CK4U)5^4\$4@C;T8*[+)4T\9523S)XH[9G4,"
M9C8\LV/G;J!X>)]UQUWL4^5]3_917?ZMQO\ 9.JS_2S*$N/")+0U0,%KF#Y$
MQPY)$UD!GY0S9M-JJ.7!8Z(!X\,@W3^>NL5$4T2?.4,4O77I85QZ_>/V94F3
M$\4BX7E5Y9P@P9QJ318&ZYWCA4# F)7)B-RID(HJHL<I$R'WWUUD()_#NTVI
MB(+JK-$'[5:'<$DF[IDZ*8R;ELX8@<QT#E*;G*<B2B1@$BR9! "ZB?\ *]QD
MP&4]F8A"7,7-]*J+![E;?X-H<X9-1;."E\RG#EJ&0AQ'>Q%A?<Z=+7&M[WM\
MM=7$V*LI"/\ E:9#'X_(>T]>@?\ >GS[@'EJT'T1M5M%,XKGDQ<:U8JE$&Q%
M>6996SP4M7XTSQ>9IAT&@/Y=FS:"Z7(@N=%OXWC*D06.F0Q4CB6SL!=F*=0G
MK1TR;%,<H+F3*80YMC*%W*40*!C" F 0* F$.4!'70X.##R*IKF #@F)%"+"
M'BFVY2<IP'[Z(;\A-@.("(@ AJFGY8^( J_Y@I;:'_#)[$$7T_F_AMK\L3/Q
M!G4J8E ( ]8WZ7Z;^&XQ9]\KZG^RBN_U;C?[)US\KJI^R>O?U:C?[)U6 #-8
M3G1*R5%4@@!DBM%3+)B)3& IT@2%0AM@WY3% 1* CL.W3YE2-R&4\ ?#*<"&
M5\$?"*<0WY#* 3D(H(?@D$0.(#T 0U.?RT<2%S_)ZFL+W_GLX]6P;_R^F7KK
MW=SL<5N>?LCX^R_3ZN/?:%\KZG^RBN_U;C?[)US\KJI^R>O?U:C?[)U5^+8Q
M (91N9,JI0.B*B I@J3MSIB8A04)N(?.3$Q0W !'<0U\^5/;;PTP .P;$[#W
M\NFW?;2?^-5?>QX!2@BQ(-;-< BX_P#+C<:^%C\3GG[(^/\ #V_0UM58RT7)
M@<T;),)$J8@"AF+QN[*F([[ <6ZB@$$=A .80W$-@UD-0 P0\,PO?C)HNER$
M@)I11HP3\5P[!(K<Q$B-R&(5P<#&YDB', @;<0$!'?4R_ED;K_&K<^GG[![_
M /\ -]=_@'V:]-[*=LH>T/"1Q"JIUX?**J:F,*O)4*W*6)A(KB%;!A+E*FY!
M0D$A@,3(^8 D6))%M[VMM\?H:X6FHO\ $[_C-5/+^_I]U]W]]HZ>-W>O5&CI
MT:J7$Q6S=9P(&A/#*((IG4$#*"Z-X91 @[G$AN0/G"4>PPHR!E27R&U8MI.-
MC6:,>^6>LQ8&<F4Y%VXMQ17.NJ<JPE*('!9(B &-O][ HAM@_E)[2\(C[.5O
M"C.[5O$X5%)&L$V5O1ZJEED+R,@1+*>[<]YM-!KALK@*5W+#333IUVV-\2MP
M%_E:10>02$WM]'M5U]OTZ>?3,8"';&<4 B'^+YL [=0]JNMMMN_Y=/'XR/B>
M#XJ?B\@J>%SE\0$P,!!4%/?GY ./*)^7E WS1$!Z:[+LC_\ I;L[_P"R\-__
M !(L/3U%_JK]PQ]-&DE=;G"T2LRMKG'3=O&123<RIUWL>P(HX>O6T9'M?795
MXQC6QWLD]:,D5'CQN@"S@@'4+N&\9<C\9E%Q,]H;2^0TI")WRVH51JY66Y B
MA/"3$^M,2+1TQ:/ABR,H1VFW5;ME3/'*C<B7(B99PAOLZJ;,;'V$_<#B159O
M5%_AB8^C7 & P;@("'?<! >@]0'IY"'4!\P$!T;A[PZ!N/4.@>_Z-/PW'.C2
M0O=[JF-:A8+Y=IIM 5.K1RTM/S+HCE9&/8-^4%%? 9(N7CI<QCD3;,63=P^>
MN%$FS1NLX533-$GA3](1PX<6]:FYJAWB%B)JL/I)"T4RQR2<59*U'!D":H%5
MEIQK)(QPQR=S>1;1W$Q[DJ4FV/,QL7(-D9!=%-="P!L38_7UYV-MCAP5B"P!
M*@@$VTN>GUXCQ&)RZ-<<Q?\ 3!TZ#U#N ["'U#T^G1N ]A ?KTN&XYT:XW#?
M;<-_=N&_V:!$ [B ?2.C!CG4;., IU>&K,+=-7P3.*5+HBJ'=,#-SG _D/S#
M)E/N @(<NX#TU)+F+[P^T/=O^3K]&H5>D5R?5\-<$_$?E&Y/U(ZM4G&4U,R+
MM!@YE%B"84(]@DBP:$56=J.I-\R:D1*F)#"ONL)4"J&!C@E6 U)%@!J=?+#D
M]=?ZR_>,:>'$;:*9G_TF7%+5K?99.66Q#>X"DXQJTPEDV_UR/CL?5*&BW%3K
M&+JS3;<Q53L3N(>FGDV[N#KI&D@I)VTKX&YVR;Z&R(XH=M?$K4#<V$?7:]0J
MS)+9'L\C9DERY5R-CRKH^S)>43R2AA&P5-BZ<1C!JO&/FK!Y+*1:]7<RC\ZT
M53%P0YHROE_+&0Y.N7.:I+N\6M]F#)F0H0K.P9.<TVP7J>C;<H_]K1SEP]L\
MR7+#&+=QL/)@V90C)I,(PLFLV;G:6(<4O#_D'[@7$UD+'C;(]&JG#GA&1SY&
M,\JN(6$NN3B4"\1(1>0%X*LF=2#9Z[<IR<)1H^ZSJ[NG0D8/M"N(2+^/"(KR
MJ!($8C]4%;W%^Z;VM;Q\38WTTOH74*#F&@MO<=VP(!\;[:$ ZBV^'9O7&U/U
MC%%,RQ<.'&=:8=M-FJU;?W^IY:(=S+UBSK>H*W*CQ<K3J]*O"L%G+9XF$Y&M
M(AP=%./?G2;3+-^$@@OF.(>D.F]6XI\59BFGM=92V'V=?NUGA))W(606#:J&
MNM,2=MJDM;X@\LT8(1[F->(R\DFJ6./(,R(0)=>T<YR;#(E;@F0!EG'>$QQ8
MTI-4L:<C*T6&M\746KZ<=)1$E/V552(1EDDI-LV>.5F3R<BFJKPWL)^I#:OE
MX3<;7#,L=[:QK<<#U.RTJV5N1E#I46B \,^68QMCIJ5M@9V3=X@:5]D=+V]2
MH:"(9V45/:XJQQR,&2*-&BQ@A;,#<E;Y2I*@*P(8WL021:_JV-KX+D$&X"D;
M&^^][ZV%Q[[W-[6QEN.CB-M6&\96S'<-1)K'L\K#5=I.-F";>F0]F5RU8AKE
M2CJC5IN2AYF(@+7&L+JM<VL[ZVC)0C.&">B8D]UBYEM*?@DM_!_&UGAHRI0*
M7:ZC>N(#AGGJ,\?6&9G[_$5C(C!I7+;6V2M_>R4A7V0V)_CVT4VM+@9A+SCA
M6,KZ3)LW?%1>4I>EFK>8;U-8APWFK)$/>>(2-SI;[3D.\,DY5".F<5X\PPOD
M'#-BDY2!BU8CUJ<>.I^A1$?7S3"HV:ELGY8TZ)W?JLHR6:A7'A!EIR'P;3(N
M[1.$*!**7VCPLI9HC&%)Q<XC64)*S*5?K[VHUZ6G\J5N9R119>7,1]9Z!:7D
M2V&/BU(URY,F6-2"W?8B_>V-LI(-EU[S"XN-[:WPVRO8?LB]K>L<MQJ;D:@^
M&QVWW5<1K XQ[7U0$P@;VL4HG'F.)$YR3(GS#VYN0I1$/(>GEIR-4G\+_I<^
M'@F.</5W/J5JP-=KU)SL(R<6ZGRB&.'#]FS>6I=^;(4:[GZC!,5HM0C@S:8G
MTG+-9PW;""B2[=RK<Y"S,98HB,GX1^TE86;CV,O$2D>NFZ8R47)M$7T?(,W*
M1C)KM'K1=%RV63,)%454U"B)3!JQ&0447!(50?:  ?GUQ2=64G,I%R;>'CO[
M/.^,IHT:-289@T:-&C!@U"/.] O]CXNN!B\5N"EY"CXZD^(M7(TPR=)HQ< E
M:L7-8:JGF6YWB*CHDC-)G;, 1:OO"<@910&I!\09N:BIE[.%EQ[Q(\)>'(J)
M@GM>S^_S8UM,G($?FF88F-L?MK;$&@#-W23(IW[Y8S:3]H-G91:%*#4J*WWS
M37 (UO:Z[7^T.@/QWL+VUPY;WT )LPL?-3?Y:^W$J$QW(3^A#OTZ@&P]/+7?
M74@;%*'?8 [_ $:[:=AN#7P<N4FJ2BZYP(DF7<QA 1]P 4  =S&,(@!2E 1,
M(@ =AU]])"W',#=HEN %474$P"(@)Q(EN78 $.;E 3"(;CML [; .S68*+GQ
M ]Y-A\20 -R2 -3@&XOMUPSF8<X0N.(3VM,*.S$>N2Q\+7XPS;VU.NQ 3&(B
M5=9(J39N3960>&4!JQ1,F"OBK+((K1UC.(ZZ/V02WW&7IXE(P'>*L;21=VDU
MWW,HBBM!-VZJQ2;& BCA%(QOFBN7\+7@XL\?6BRL*?;ZW'N)LM,5F$I>'9)*
M.9'V=+^SC>U&#1(AU')61V DD$D0.Y*W4272(<B"@ P]8SE,,H=:JP\2]>OW
M:9F?L]I'O7+\YC@"?A"R20.OS@<P%$IB%V-T'8-M\^65Q(06LH L<H)8BVMB
M/&X[OAM>QQ:1$* @9B2;W)%@"+Z CH+ZCV8L4J-LAKK7HZRU]91>.D2* !5T
MQ1=M7#90R#M@^;B8PMWS)P0[=RCS&(4Q .F=1(Y%#*40';IU'H'T_ ?@/7?J
M'X],S@>H3-)QZU96%(6LU,RTK97\:)BF-$J2YF_A1JIB"8GK"#9LB=V5,QDR
M.EEDRF-R"(O*;H.XFV,(;"/+U$ [?9^/4R%C8D6+ $]=;#X6U^-K=<1,+,;=
M#H=6O;QM<^(/C?;2XZJH(N"@1=%%<A3@H4JR2:Q2J% 0!0A52'*50 $0!0"@
M< $0 VPB @F'J @ @'3J&^_NW^G7<H>?D/G[Q'N/;IOTZ?#7'F/Z;]>P"'41
M\OA^" "(Z4$:@DFP!L=-@-=?X:WOA 1?76UB/?E'Q&GSO@$0$GD(]![]?C]?
MY Z=@T$$.@=A^(AU[]O@'?IV^W>&.9N*8]5L$A2,<QC";L$:?U69L,D91S!Q
M+TZ8"=C'M&JJ9I>18G,!7IUUT8UNN7U8H/%"."HL3'9(XBYPZCA+(DX!ECF4
M%)E%5]NT1 P_X4V0]CF!-(O4")@<P$[ (] ")IE6ZZDW%K6T-A8:VVUM?6^V
MNHE$3E1KE!L023IMY;:[FWLOBT8P_-$=_+;?O\/[GPUT*)N40#MU_N^?N$>_
M]S5><'Q"Y=Q^X11R$R+=X(3!ZRY,P0B;2V;@(^(LS=,R-XR34* @8&S]JD=7
ME\(KU#<I@GG79Z(M$)%6.">)OXB99I/H]VF _?4%0$#%.01 R2Z"A5$'*"@
MJ@X351.7F)U=&ZN#8W-\UB"#TU_COKL;V+2A0:V-S=2 2#H/?>WO&O@<9O<0
M =Q 1W[;[>X//[?QZY* ;>_J(_1]'N#\^_GKIL B'*.P=/R^_P#TWP$-<[B
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M(E>R[5T4HB.VR[=!0! 1%, V,9T\?YYQ=DIP2/K5D!*<4*00KLZU5@9Q43D
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M=2=[=Z]O'0#;]^,F#Z__ +&J?M[PN\R/T_Z /T[Z/7[_ .5:I_E_HXF>X_\
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M][>VAQL<,JY)HI#,SR%7 !$;,1=03?EH1:^U]=^F'6U7SZ0'_(ICC_=5+_\
M(*FI0RESRJWC9!PTQ()W2#)VLV3"[P+D5'"3=11 GJZ*!%5^=4I"^"D<BBN_
MAIF*8P"%.F1LMY0R0@@RR!*N'Z$7+N'S5HM#-(LL7(KM3-'#-+U=DU62(1 #
MD]1=J+JIB0R@[' YA=VGXK3IP^2D,=29*M;1L8)(D7E20NV8S"-C<:#(KV.K
M918E>)U,:T[PY9,TJG*2C(!D96-RX4G_ '0?.VE[1^#+_*$K7_A>V?\ .-_J
M5.HK<&7^4)6O_"]M_P"<;_4J=;G!O\4\-_V&E_\ A3%VC_P2F_U$7_8N#1HT
M:TL6<>&2:'?L'K)-TX8G=M'34KUH?PW;0SENH@5TU/L/(X;BH"R!NQ52%'8=
MND&F<+,U27FJVHJ5:.C8"!C6[2::R\BSJQEWJ!K59F5;6F*_#6)@_D7[M^K,
MP(J6"+;3AUTWNT3['5GGI.V2O(6)B1FHX79F2<$<I.6P)&43,4BB9R<BQ#D%
M-9)51-3D\-8@F(L@LDNDDH5CKFL1H1<^W;0_#[O#$;IFU&X!%CL=B+]; @'2
MS::$&QPP#AK7HF(FIQ]#M)!RV0DP0R5&."6"9G91B[.0E:E$FPM9V52=E(G#
MM8X%W<4\:B#/PX\QTDS8:C'R8C)WR9:"QJ%;LV0(R[1;*8CXJ0)%U>1J$0V?
ML),S2UNU6<M8Y1):?(Y;E20AQ;(D4CG(2)VBN >2[R"=6N&G'*R\$KEEI%6)
MQ'QSQ[+P]419JS:=G0.DH5=\\DIA6)CY-W')O'E8C5IV13:KMV'/%+-F9)K*
M7;&R\/-2-%LHM'<&_8.&D3+0[B<(_2?,4$YM\PGWS=J]BFSN%G4FSYLC)+>Q
M4G*B;5%HCG93/6YB2HI(@8%RJ"\\J3B4NX5GY*Q",)E:-3,)%<RR)$J6XXVA
MHR(U0F?,U2P:Y6*G>F$"Y!E!D:4RER<\H@,>7(C2,Z>N4\YE5;BBPD(B9/CE
MC 1$;AVZ WA*M<)*;CF4RVF[#+S4,@Z>/G[1PXC*G'^.> :/6KQP^A7\R,>>
M*3%D@ZR[QX6BW)2N-8IU514B<78YKKB_V2@6)%HZBT&E&-#P;.1@J]4)!F#N
MKRYXV.5C9M639)R3:%9LFY')B:Q89=C::^REHZ[Q=AD(I>2LMD>,W#CV8PBH
M9-@R=H1SDLS&SK->/4%1FZA1;>N+JRQ'35RNLS30MBQ50Z7/2+ME9<2X.M5Z
MADX>0LT:Y>?*::F6[:18U!ZE"3DW&5^7EHA1^\<-)2;CIQ[,+(,XLC,$V:!R
M15T%3(<JI .9$J3>D(#&H*@:QI):5GL%*RS1I;](8W90C95)%4U9,2H59Y:E
M9/28:F3*AEE(*QK&S3)R^4%$9:$)8*SB.Y9[A(R1D&WTN0Q))>#3\IEE7*)\
MD# &4D;13J.:NP<Q8YV+DYQS)L,BC%N(2NK04Z1@>LJ2["80;2D:V:GD[-F+
M-O'M$&31%-NU:I$0;() ()HH)% B:9=^H\I0 !,.YC#N8PB81$8.<+E"EJK-
M/74$0\7 JJNR7IO.5V=<!(3:4:R8PWW.+7//&LJM 2@ME+;:A=QAV8S+M%FS
M0C'/KR*<[=6>&1214<"3/)*Z)D$DF3.R"V4DQK&C&U@6R*YL Y9E+&]Z,U(J
M0-*TS(@[TBJLJBY 29%50DJ@ ,HO;2[NUV)I.VA9RWBE%6LW&5]0%V9!DI9N
MFY9E3.[1(JT!)60C">LR"9C,FB@NP%%RLFJ5%R)00.HM8:>;"ZC'"9(UA+*E
M*19!C)F*FS5704(JB=54[-^"1D#E\=%4&JIB+)DY *80.6^U[&W[Q]VOPPHW
M'M'A^_3XZ>.,92#[4VK"(\V]?B1W* <H_P 1);[;"8/=T 1^GMIE<D\5^)<<
M/B0I'[W(-G]HRT4ZI^,S0ELM<=(0;07LG'/H0DVR=)S2*)3D;UI$%K-(N2BU
MCH=TOL07'8.8L,<0L?*2BT2G*4U%H*[!PHA*)(N(Q)HNZC#H)*N2/&OK9%$'
M"2!Q;KF25$GS=M0%HGHZ\;_*AM<\EYALV1;K&6*SV&OR-27AL6)MH.[!&,BD
M>)U%+VVK8W[.,C6K^Z-I]K9)$WKK5A(,H:57AD\2IXM!',E!3U?#S6@1<V"6
MNIDG@610T9:G+F>\J+(T8Y1#!";@:XZ7L_2]G9?3*GM%75=/%3I_-:.CI99I
MZ^9TER@2C+!%%%*L(GYM1!)EE#0\TJZB?F,\QXVS#$^W,=6EI8XTWB*HJIMW
MT>LY8E<';-Y=HRE6K%ZZ@I%1-3V3.MVZD1+D344CGCDJ:@D35FRA4&EOFL6V
M"KS#YT]A&DBP:J03:5B+LG*N$V+^*CF_,L1PLP.X;!,GED&L>BV6476=F09N
MC(MA"D98\B*I)\/#6=R-CF'<S]"DJ;"WI*1K%/9QL>H:*<1[:1B+#9UDX&PQ
M[&M%AZXX66C(NPNI0\=(1D45%*/F;\]<15'?9-R,ZKUA@<:8YQQ1K/ P]6I,
M4]LCR8R8NXK:L;>)_)D3%P#>/QY,HIVF[IT*PNG"4 @T2EB08J'55Z.+@''^
M*)2P\/KZ#AE;Z1"934*LJRWG%&:+D-,D\%1)//#)3.Q7*RQ/*#3M*IRWK>S]
M)65K/0UU?PQX9EHDEJA35<#76>*HGFAIG@F"QQ/%4Q+#RW2600R),L,H]3C%
M>/:[9)!E$XP@<-%EK/;9"TRU/\>]UK)<<]:27K%,RTA%,HETA44I-1.=;,%)
M+U"KNHQ>&B2IM'$N*B@D(+'&/KM4[%7I2BI+'C6JU@9XKKYH@Y(QY'.'K$[!
M6"2?RJ9)%=*6DB/I"TM&C>->NY1]'R9C-/6VKX;;?=,R3>8;'DK.F;5*; 6*
M%Q54'=KI]*KN-YY]7Y!I.3>285&#Q7'THL:ZNE5LU-K5C-D[($!:H1XQ9OF[
M4L]5HZ5LRKU>I+N'BP9-JU8DXYTS5++(1]=<$5GH-JC&!*B$.T2BFDNV!J5(
M/9[=H6-$I6K-!F@BD@GA=I^S/;.GDFHJGMM5\1G,U/*T]0W%X.5&8XJA:.:.
MCJ.&T5<C(_HTRS44;B$/!.LL@YB;/">/]DXS'.O8ZEHXA3S0&FH_S?/'+*0\
M7I<51Q*CXC7TLJ-:>(QUTA2H5)86@C')9@,,9*FGDS)52.B++88R4N=AFV=G
MMUIA?&BH.0%A-/(]6/1 \HR%@YDW<97*UZH=T"46_47=)QS0[P).UCI",0Z[
M\J_?W>MN-OK#SUB#8[I9K<WO1JY&C;&IESMIT4U1>MU'46G".5$?OO@)J+Q*
M2<>JH1$#G;$*F8P[;ZR]9_QE9?T*_P#][<:I=F^&\3X3224?$ZY:[EU,_H4B
M90J4%H3#&4]&ADB97,H,4L]>Z((QZ;+LL':?BG"N+UT-9PN@/#Q)1PFOC8.6
MDXB"XGD$AJIXY59!$>;#3\-C>0R6X?" "^>T:-&NCQS>#1HT:,&&(S_DKY T
MY1O&N2IV2Q>-'1(%/LLT;B3ED)8I0 1_B-)0J3<PB  ]<(&#F%,Q0J_,(F$1
M$1,(B(B8PB)C"(B(F,(]3&$1$3&'<1$1$1W'5CV0N'=7(MG>V23O;]L"Q4T&
M,:2%;KMHMB@0I$VC8YY$@B!C@=PLIX:8K+JG4,4/F@#"6GA6N["YXWBZHNTL
M5*G)*Q(9-M,BY9PLI1(UE!JNZX_@:_XCGY6KS<\5*'>M1=,?93,YY,3KB3P#
M?,'Y2>QWY1NV?:"2JAX,HX30AJ3A,3<4X6MX<PYE6T;5H*2UL@$C!U61(5@A
MD%X2<5W21VT70:"[*-.NYMK;WZ#'/#)DL*U8E*;+.2)0EE5YV"KA3D286 $R
MII!S#\TB4JDF5J<!$ %VFS'F 5#<UB8=OT_N?D#Z-0O+P>L0Y3!?Y I@Y3 )
M:^T*<I@V,42F+)_-.4P 8IBB E, &*(" "$O(1D\CHB-82$B>7>LF;=JYE%$
M"ME7ZJ"94Q=JH%56*FLOR@=4"JF**@F,&P&Y0])_)5P[MCP+A,O NU'#N134
M3&3A-6*ZBJCRIG+2T+I35,TBB&2\L#LN7)+)$641Q*7Q!P"K"P&QN/AH?A\.
MF,IHT:->K8EP:1M^J+:[5>2@7&Q55DA7CUQ_[5DVY3'9./Z %/O2Y?Y=NJL3
M<.;<%EHU6K*2GKZ6HHJJ,2TU5#)!/&VSQ2J4=?(E2;,-5-F&H&$(!%CJ#BIH
M2JHN7D>[3,UDXQTLPDV*NQ5F3YHH**Z:B8_.Y0.4124#<BJ8D,!AWUY7RIFS
M%ZX3'[XBU753Z&'91-(PD-TWZ@;8P@/;SV !THN+NN3&.LCL<@QP'4KM[#U=
MTDF($486>.;%%QRG#F*))1@F18J:@"FJJW6[&*)A9Z&R%$2Z M7@_.62.BIR
ME B@@H42&$[=0=C"("/ST#JE$=AY V$-?'7:;LOQ#LWQ"LI)HI)J.&0^CUT:
M%E> ]Z%Z@)<PR%"F>ZB+-<(YL57*:9$E>%S9U( !TS@@%2O2Y!U ZZ8R5(<!
MSNVQS<QCE(Z 3#N83@82JF$?,Q@,4QM^NX;CTTZI4$EFRR1@ >=(Y=M^X\HB
M40^DX '?J.W7;IICXA0(F9:[*E6;J*&0(N3<"K(J[IE$P"',4X&,F)TU"\Q3
M .P"  (NXF[Y0+U[>X1$1V[]0'ZA_N=:'#W22ER:'*60G0]QP#?33]8VZ:&W
MABSZVHU!MJ ;';WD6\#J1[,8QB=N"RZ).4@JHE4VZ<PF1'8>@;#V.._GT]VE
MG JF.T52$ $K=<2)F_V!PYQ+W[%,([>77;Z&:!PX;V8C9N4ZQC.A(4I $PF1
M=AN!S!U I2 J F,?YA>01$=@$-/I'M/4FI$!$#*B)CK&+V,H?81 !V^<0@ !
M2CY[";IOJ3AY/+>-MX9'0C<C4$?/-;S!/7#;6%K:DBP\NAM[[#H?"XOCV@/3
MOMY!W[=]AZ=N_P!??IMKD0Z\N^X#L4=P#MVV#OT]_OW'N&NHJ>&4QAW$I"F.
M(% !$0*43#L'<1V#MOOY!UUXFD@5V8H 0$Q,F*A/OH*"!2B'0X 4.0?G!R]3
M .XEWZ;ZT+ZZVV/WCV6]FM_=@Z?O/NT&NH'LN-.APVED<&8Q<@<HF*IMZJF8
MHB&QEU01 W3L($,80-N( ;;H/7E:!( Z;=0#?J._T  ?1ML'P^.G?O20@PD^
M4!'D=-EAV$ V3%=,PF$/, %3H'7<1 0W -P:!(?(O;;KTZ[_ *#[A#KKDIAE
M=D  "N5(.FQM??K:WGI?"KUUUM;YKKH-_8/9Y9- @;E !WWY=]P[;]_=V#W#
MU\]*!HF F(7;8!Z#MML(!UV'Z0'Z?ITGD3<NWGT 0Z^8?EVZ]-9QNMV$.NW7
M[.W<.X>X0_.#=OKYX&Z#PO\ #H=];[[#X6PK4$RB&WP#MT'8.H#[^_;N/3Z=
M>M9-'P]MMQ\^N_0.X[=0'IWZ=]8-)Z4 #<>O3WB'GN'8=P#MU]X]=?55^4 '
M^6Z=.X?IT =]@'?WZ>"!Y:7WW.GGKMJ--"1I;5IZ:CPM:UM@/+\?+&"E4B 8
M=@VVZ@ ".VW7<.H]Q_ZOBFVK@S%^U<E^:*+@AA$>FY!,!%"C_L13$Q1]X#U\
M]9MZX\0P[[[CN'8/FE$.NVP!OY;![NVDVH05E")$#YZBA4R;=>JA@3#;N/<V
M_P!/7KJ,W\KW&^O7SWP]= ;@V-]O9K]:[7MIA[>@[#W =N780V,'\J(>>PAM
MU$=^O;2=EZXVDSF=)*BT>& .=0"^(FML&P"JGN40.'X/B$,!C@'S@-L Z492
M"0I"]Q(4I!$.G4H 7<>_-U#?R\] @8.W8 ^'E[P\_>'NWZ:G.H -MQ>^A]FG
MZUC[-_(88.A!VV.GUKAM#569*80(+10FX['!P) 'J'4"'(!PWVWY>^P=!$=A
MUF&-1*0Y59)P*_*.XMT ,1(P[]"J*&V44*/;E(! '?J;;NIWCU&/1(JL4YA4
M5(BD1/E ZAU $0 #&$"E*4H"8PF$ #8 [B&OHV=$<D5^:=,R:@I*$.)3B4Y0
M*;8#IF.F<O*8H[E'<!$2F !+IN50?'8V.O4; > N;>^V%N3??S^6_EK8=.F/
MN.Q (4@ 4"E "E -@*4 V* !V  #H ;= UT,8B8 *IDTRF'8!54*F CUZ 8Y
MB@(^8AU$ #RUW .H ;S$ #W?'MU^SS[Z:]9;VE+.3O3;@1PHB5$1$Q$$D3F2
M(FF0PF OS2B8^WX1S',([&#2DV  U)TN?QT\=+;>["?=:_W;>)_##GD.F<.9
M(Y%  =A%,Y5 *.W81*<0 1#J&X[_ &AH$! >O;</=V#H'81'MOI!*BWC7K%6
M,.8#J+I(KI%'8BY%%"E,0Q0#8P 41,4=A$A@ 0$.HZ5K^8CF(F]8<D$P"(@D
MG]\5,(;[[E)U+])A H  B(Z02 #O$ >).G0>WQ.M_;X!T%R0!XDVZ _"QW\/
MED-Q'YH=MQV#X;[^>OO&Q[Z?G(NK0B)G4Y+K@DBD00$K5 NYW#UT([E2102*
M8XG/L4  3&W   6<FLH,$!618F %4_F;(F!=SSF 1 !$-T$!$NV_,<YR (B)
M0Z#J6O!#69"<4M.5I9(4FJYU*K643"8XJ)(G3<34B90X\RIU5@:LP5  (8$%
M"D* %Z]AV3[(UW:7B=+3M%+2<-=A+55CKD9J9+-(M,CV9WF%HXYBIB1I%<YR
M C11RK+,L*&Y]9R-<BKJ;G4:Z)XAB-#N)V56O,ZK7HF 8@'@1C--OXFVQEUM
MN9RY/_LW+@RJQA'J GY>P:4.C1KZ^IX(J6"&F@18H:>*."&-!98XHD"1HHZ*
MJJ%'D,:NV#1HT:FP8J*XSJ?:W.95YEI6IY[%2%9KZ#2181+^09KN&)'J;Q %
MV2#@A%VQC$\5%02* 4Y% *)#E-J)7R4M7[%;1^YN<_@_6Q3RA\0\N@B'Y!#W
M=^^C8/C]H_GUQM;V/BK*NHJO37C](E:4Q\A6R%VN5#<Q;C>UU%A8:G7&//P=
M)II)><R\QRY7(" 2;D7S#3?I?]^NO\E+7^Q6T_N:G/X/U]F];N#1PV=H5>S$
M7;+HN4#GJ\NN0JR"A54C'07C%D%B@<A1,BNDJBJ "15-1,QB#L1;!\?M'\^C
M8/C]H_GU6'8B*^;\XR W!!%.-"+?Z;R-OH"+\R+>_I+7TUY8W%M1W]-1\#;%
M%Y+ID5!XQ<,\:1T<T:NIM^\AHS'-A8P\[)6&'7K\K(33=NH5PJLK$.EVK9O'
MNHZ.CB+*C'LFXJ' R,M\E:)&'81[RF)4VL1CAPX0C8>K3<#$&E)))%JO(O'4
MP=ZY>R:[9N@S0.\D%01:HE;LD4B"J!]@/8/C]H_GU$+C=#;!CW;?K:ZGW$1_
MSP/Y"(A_=V'N :CXCV:DIJ&KJ&XG+*(89)C&8%4.45&R9A)=4/*2X&EU5BI8
M @J>'&.":0U+,$0N5R!<V4*;7#$J#D%P-- ;7%\50/KI.OK<A=_%;L[ U=PK
MYLX9-RIHMW< SCV4<LFW6,N4PE2C&IEB*&.FLIXG,4"*<@+QEEB\.55V=3KT
M#$ JSG#J1=+JSPH ]FEXA>2L0-T74DZ"33-#1B#583>RXYNGZNWCTDUS 9F-
M3$X'=_NV+=]AHUDWV';_ +>@-OT]^P]P#7)<.-15UL-**AX?2YU5Y5NS*7(S
M. 2+DD#-WAF(6YT%LBF:26=(N8R<YP"PN2"2-=QN0"==3:^&PE+KDN3:.6*>
M/4(=J\);/74H/']BCP>.KLU8M;#(.!$7 F?.@CFRJ)B\C9DIXA&S4C82($R\
M!=[R69E5+53;$X@K)/3MBL32+HDB[,]>SM;6KCED=A*@W;N8%5JH47,<5_'O
M_$(1PRF6CA%(VKN]@^/VC^?1L'Q^T?SZ[M>RLP</^=I204-C3C*<@"@$"8#+
MENMM-#;2^F]^;&N#Z4YL00.6+7  %P'L186(ZC3%#>474W>[2G+Q5 M,-%,(
M"O5N-8C6)1$Q65>CRL$5S-6C-9JR%QL90C%!PZ3:)"F@+MTH51PHW7R5M7[%
MK1^YN<_@_6Q3L'Q^T?SZ-@^/VC^?4$O8M9I'EDXBQ>1B[$4R@78@FP$P &]@
M+6'RB?@JR.SM4-F8EC:, 7.]AGT&]ATT\-:),+TRWKY:QL8E4LP)M;M6W[I9
M6 EFZ#9DPEFKMX[<.'+-)!%NW;HJ*JJ**%*!2[ (F$I1O<[ZXY0'OO\ :/Y]
M<]M;W!>#IP:&:)9VGYTBR%F01A<J!; !GO?4DDCH+"VMZBHUHT=5<R9V#$D!
M;6%K  G[\ @ ]!U7OQ_D(G5,=^&0I/$MDN=3E*!14/[ ,'.<0 .8VQ2AS&W-
ML4 WV -6$:A1QI4B;N]=HS:%<5YNK'V.2<KC8;/!UE$R2L,9$H-EIMVT2=K
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MQ'=99N6HO&H@:1,)8Y;=-0 TUNFMM1KK]H:>_;Z.'+OMFT.GN/W;^[#]%'<
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M4!PNZ:J)%!-VV*4VXB)@ Q!3$=NFQB"7<ON, ;CTTR2J"S-<[=8!*<AN7L(
M8!VY5"CL "0Y=A 0$>^W<!V;RY6FRLG,>JWFGI"G;+)<HG*<-TE2F#H<@[_-
M4'OOMMI&+WBUN"@!I4#JD 03479ME@V$=Q(8H)D$Q!'81 #%$.I@'???FZKL
M;Q1II7CFH65F+*&EG4]X@ZCT<@;DGO>\[X4<1B4V*2#:]LOD3LP-MQMA_4U
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M\1GBX16S0..)\/JN&5B0"KGIH))J6K2%SSFIJA%EBC:%W@FRLHR@I+1UE+%
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MWCGKUF[?243!1;4)^A_CT3_P4KV[?XL3^WZ?/5JE[,TG"JRIXS)04,7&N+I
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M^RJ,2*6I*#3*LZYE!L"!S$L=-1;(3YG7%.#C3^CJ\\0<J-7C)4]RP/<;,";
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M+K/9Z*G!<*J0[=O'PSUTK.QQFR1QM&%.>$HE\:'Z@)=_57N^PAUZ^N;[_O\
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M[MTT;P\V\>-T8M=JY*]21565.V(HB=#T]H^\?7SWMA5M?O;6/QL;?.V) $_
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M8B-D")<FV1KL6)-R.]T%ZH$(HH"(4A:5EEIP"99Y*=6J8)I:B8HJZU$02*-
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M/( HI+C-),LQB8(L@D?31ILKCF''=!MV/Z):YY6+M64I)Y$42,)!6.2+.2+
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MF\EIR+MK!=>0:K4Z7%Q'"VT'C;Q?Q(\7LUC/@9X=^)/''$)DBF7>LWO*?$G
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MIM?K9X@[=PZ;_@]0$1[=PVVZCOOU#8=@ZAI'WEJ9U6WWSA$S4Z#HG0 Z(JE
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M00,9J047<PLCSA\Y,%BQ\4"A!V!5@_*)MQ.&K:]=;PVGY%,N8?I)#S7)&H+
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M8.6*(OBM5$C@26[?T15*9+%<L<ZY*8."D.F5PQB*VR<%34#90A7#3P5BD4
M!0@' B@  '*8  -></1 8_ 1'[M-_$1W$1&O5,1$1ZB(B*?<P[B8>YA$1'J(
M[Z/H=?RP! @;N@VF&3*I6R@9]"P-F))S* IV&62TMO5%]+]X6TR]/=8^-O9B
MAQ/F!-,#[\X)D ^^V_.!  V^W3?FWWVZ"/;7;5\7ZT!C_P#;HOW[G:E_6M'Z
MT!C_ /;HOW[GJE_6M4?S/7_YI?\ FQCP\6\QB+DOX#XCZ_N/E>KG@NV_578#
MWVW^Z"TVW]_L>9[?5U^K?RULLEX?**8I1&;R]N( /3/.:P !'J.P!?0  W[
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MK8$,-!<;@G6Q!!.%V \VQBFW*.PE';H8H]0$!]PE$.NN3% Y3$'L<IB#Y]#
M)1_$(ZPM<>>OP,4Z$=SJ,D2*]>H*H%]75 WN-SI&$0#MOK-]NH=^X?E#X?2/
MGJ&^NPZ>7M\OW>0Z2?OU^OX:8B>Z2%!PN@(;&0761-[]TE#$VZ]>G+T^P.VO
M/K/VE#U:Q3"/8 ?KJ%#;L5<07+Y=>B@#O\?+;6 TA_#[O=]>.^*YW.,]'[ F
M3M[QVW#<>H#^G7O\-+B-,F42<VP!L'< Z=O=[]@]^P^[3=,W()?,.;H.PE$=
M^@]=RCT'IOU 1_(.E"B^$@ )!W#;R$1#H(]0$-@V#?80\]_/4)%F-QH3Y]?
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M$2ID)ODF#KM-1O62)FZ.KA5YNM9 9'KE?IKAI7IA=O\ '/%MD/%?#;:JF;B
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M\AZ[C[$<:2AMO&D8]/W@0CA40^&XD3#?8=^@_$/+=YQZA]("'7IMW]_7;?\
M+KYF[B4/?V /@'Z;?7IIXO5'80K:VJHUQ;:UW(VTV^>Z-736 "QK?316O>PM
M;,Q]^F^FF&Q0QF@ AZS+JFWZB#=HF3L(;<IU551#W[\O4!UEAI%>8)<QD%G:
MIC% IG:YCE ?PC""28))]@_E@/WV$.7II= &Q?</7KV'OTWW^KOK$R!^90A
M';D#<=N@@)A#?J.P]"]@W[".F+7UDK@&=@-2<@5+>]0&U-AOAHJ9I",TA N+
MY0$MM<=VQWTU/6W77SQJ")3%!-,B*2(>)X:*12D#E 0*($3 I1-T$0#;<1
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M6M0<2I>)Q--2.S(CF-PZ,C*X"M:S#4%6!N"1K;>X%J"HBJ4+Q$E0Q4W!4@@
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M@';80V$"[;:<PP;"(;[B B'V=-*_C(H;:E91M\:P3!)LVF4)V,2 HD(E&6=
MK\B:77JW;/E5&I3@/)S(B4 *)1T@HQX$A',7@=G#5(X_ X%Y% W\_OA3Z\=D
MB>FJ*BGD%GCD8,+6U4Y6('@2-#U%CX7YC*4DDC(L0QOX7V;PZ_C?7"0R&EXD
M8R7#F$4'W()M^Q%T#EZ@'ES)E -NNX@/PTT([  <W78/=OU^D>V_QVT^5R1\
M:NOA  $4#-G ?#PUR%$?(>A3CV[]O<&F/V 1#<=@$0 1^ B =>O[P]>OOU4F
M]?V@?A^[$,AL_M OH38;#;J3>V."%,;\$IC=  >4IA[;]1V#M\?+SVT& 0'E
M'<#>X0$.P>8#L.WT!MT[Z<&&0:% @*@'*  (].X^8CY_'KV]V^O'9F[$"&.U
M "\HEY1#;FYAZ&W'OL(".P>0^X=0!K^SH==>GAX]+WZXA!U\";6WMN-_;OK\
MS8X1(=2].FX>[I]GTZRT:UC5P7%^X41,4!%/PQ*'8GS3?.'<P<VP"  'NZAK
M$B(  [=.GEY"("(?]8:Y#8P=N@^7U_GTX_A]_P"_#R+BV89AKIT^!\>O2^PT
MP&V#FZ\Q0$VP] W*4P["(= #H "(>74-)[E,Y<[%'_#5!W -N@;B(]?@0.X:
MR[P_AH']YQY [!^%T-]/S>81Z>>_4>NE)BVC2.1KY5*/%%4]>ML_'022B:9U
M1:MW:Y/:<D)";F\**C"NI%<_4")-SG.(  CJW20O,ZQQ#-+-(D,:[=YV %ST
M )!/@ 2=,3T\;.X11=W=8U\"6*@%NNER2>@!UMM=EZ.;$2%1Q.YR5(,_#G\D
MNSG9+J!LJC3(9=1K"HI@(CRI23XC^8,< +XZ+AD(\Q4R"-BNL17X..K4'#UV
M';E:14%&,(>-;$VY4&$:U29M$B[  ?-01( [!U-N(]1$=9?7LM+3I24T--&+
M)#&D8Z7R@ L?-S=B=R2;XZI$6-%C6^5%5%OO918$^9M<^)).#1HT:L8=@T:-
M&C!@T:-&C!@T:-&C!@UP;L/T#^37.N!Z@/T#HP8UO.,P-N)[+_O&>B>O_!*N
M[?8'348M@#L !]6I\<8F!\R2/$%?;-"XWM]C@+0[C)2'EJU!OY]FLW2@8F.6
M27-%HN3,G:+IBL51LZ(DH)!363!1(X&",'W!<Y_M-92_<)9?X.UXYQ*DJCQ"
MN(IJ@AJRI92(9""K3.RL"%L0RD$$:$$$8Y:>.3GRVB?660WRL-V)!O;9M-;V
M(\1AI"[[CN/;IMN/PZ[>[XZY,(%*8=^4 *;YW+S<NQ1^=R@ [\O?;8=]MM.S
M]P3.7[3.4OI^0EE ?M".WT#@/.@AL&&\I![_ .,6RAT^GV=]'Y=4O1*K_P!-
M4?\ )D_LXKF"0:Y)#M^J3<?\.MC;0^'3I(20K*,[39:LLJI!4E["8WKLN^@[
M;B1F ))$:0BK[(%0SQ7'1UY-Y+>MJ3K=I;':,8_2?JUEHW=ND$"IX)QA3'J-
MUF()Q"9DB(2GM\K-YN2ERPB"-M?8X@D9=J^JDFI"MD(XLT(*G=1*[";0C8E[
M%22,Z\65.STVRV+^*!:!3JZ]"SNM64N3PJVM!7M6O)^&H*R?A0JB1HL@)JB9
M4@%:@!51%0@%,/-K"VNL9^@(YM.7N$R[#Q$8T"MM)6V(7!HPCH^4*+8(!J\E
MQ!!HQD2)> ,4@HFW>$3!(Z"A";!HR/=0\G#Y[(L9+R1,%R(Q8J<R944*0"8^
M6A MRD4E399NK4\F@3O,IL #<@Z646WME!M;*HP]+O F,38\A["VN$A%V:S5
M."N\6V>N)F79,&5CL*,<V@9)-GCII "WBV+D6\A;U+XP#VXT60<UZ.35*@DJ
M+1PX8D@+;&02%JM<BE'3-[B+2Q9A(EEW:-0H4[;4I-D]G<<UF"@Y!P]AB-5X
M%!Y;4?9K]O(MY8Z1#J*0L^5-D+!C5?E'8 K K>L&K83<H%>%P*@*^.,(#L(L
M5O%^^BJ+3G\7[[OS_.TJ8=SEC(4@QB(%WD:[RL/%OR1<7&O[-8W\7#*($921
M(YFDX>+,8U1LNFT?$:D2:J-UB-W(&14 @QK54CV5.'HTA%.HRAB6,;EI0%#$
M%I 0,P3O 92@!)PT20FRB!22$T%S<J;L  ;DL-C;4"Q7$F:]@['\R>$*F[M[
M&HW5IB2U^J*?)J1M4,PM-/RK-R,:WL!X)N5VNT>TY,&JJ"$4PDD'()RL>JLT
M:N&V,A\'8VFX2"N[!CE22@;0EC5BQIL,]@Y*UP[Z]VRX59[/2$PC7#-'\%%C
M415:M$X)@+I_+H1[F5:IM2N'+4HXIXEVY&Y$<=9P0*U1:-VQ$JY>$BMF\>@\
M;,$&Y2( 5%%BA(2*#-)(")-47[U)N5--XY*JX.-8CB7Q@Z<.XW!-ZG5S,&T?
M&GL-&R&9: 29O5I%NG#.X5Y"NT(XSY=5T^KKA9U6I=8P*2L.\,&^IXU1GC63
MADZ(!(7?D.Y#, 4*KR_40Y_T?J$N"1W1:1;:9J=E'>)(1C9CJMERG0$FZVL;
MZZ*+1OND2VKERMU>9J+K,X"U6.#9K.#$.X5:0\T^C6ZK@R9$B&741;$.L8B2
M9#*"82)D*(%!-?.#SW^G8-ORB.^GCD\)\0$O(/Y60Q#E1W(2CYY)2#H]!L*9
MG+Z0<J.WC@Q$XPJ93+N5E53%3*5,@GY4R$(!2AXRX$SIUYL-93VV[#1+*/\
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M#PO28F)BF#F#B9!]$&=F;30L"IR.SY^@_?E!=RL]61)**-6X2R"*Q6CTI3(
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MN2+>WNG6+JS2;<^>H&7A[._BW;AS)/7#23E)*445D')BNEDW_K/WH40/(NG
M+ 5T34R-G=2X L8R-&S+E)%RUBI.8=X'-:U@"<5^)0=H*B%:.FFCIFDE60<0
MC=F>$0S"95D$:07$UDA*+$4Y E,A9G$18ZH\04>UIN89^:EFS*62E7Y:J+-&
M!/8)-5CBN%F4GRA.8T9,/47H&11='049  QK%=,R(=<-@#-L=7ZK,J6!P]58
M'MST45';LR1@4L%JEWSM1I'D0/'-E/6IM(7:"3QMZZY JK8BAE1(B\61N'2"
MOC5^U;,V]=!LM(*,W34?7)"3(\K 1!DT%W"Y6<0DHH=,B@OF$PN#B-:NP5!H
MHLR56[3"--8PD+%QT:G'*1TU4; \6(L[4/)R56E(Z716?@F[12=+BX8"FW45
M*=!F58Y4FIFQC-C6&FHN65R27E:/, !:,1J +$7-FU)WL20=L8L7#.UBUD4@
MJ:8KPZ*M6":02,*TULKRN&B>V4QR!$#-R[QQQNC,#JB\R9@3;4!4](DI!M:)
M=I$R4,1NW(673CRRD)(.'18MP11RNRDX0THDW?MFSEJJFW?+(+'2:JKI-S-\
M2S]KC>D2T,@:9F[-3H9XO%M'!49M.;=PZ\JX3+*.TRM"H$3122]?1AY!-9PK
MX:21@,H+9\V>&H!S<I*[R(S1I)5[) V17>LVZ0(N3S28J)'A ;G%BJVFE2,T
M'0%DD2) $DX=F5.37DE\$UJP+5=O*1T4,%4Y!'PHA9FWD2SD.UAI&,;LGR@M
MF*<<Q%62!T:O,6YX-%RP2=MT"+.3@BQ'HU"*R,V4F1FZDE?Z/2Q900MB"NI8
MDC4XMU=)VJJ)*BHAJ8J=ITCHX($+94ACJ(W%:P:\<,\B25)D4K*2B1):1@BA
M#366!^[&:KI6:72BT)RK1J0QTA7QBE'DI+T5%.'%%*(DW2Z,A[9=)/%7CAI)
MD!9TV9N6;46KM&60=0 ?> :9*,P_7RSA+&6%""=*23.9$6KU 9-!W%/XA="-
M=+H-W"$O%R1X5"0?.G[MQ+I;H1;1RWCT"(-GN#H ![M5YFB(C$8ME0!SIWFL
M+G0G<WZG7;3&[P>'B,35\G$)1(*BJ::F4&0\F%BQ$7Z4*P"@J "JD#0A2,BF
MH:\3V7;YC;)W!S6ZC,MXR(RWQ%?("]-5HR-?GF*K]SFYV 8]NN^156C5O:L.
MP<>NQQT7GAI&0\3PE%"FF5ID,M96H6-K%AB&N<0_DI7*F46>.J"X8P["3)$6
MY[ 3DTE(OG#QP@K#L@BX>004DV!7#PJBJ;<$136.8M9]M[:C7P[PM\?EUQN)
MZVV;1M/<=?=O[L/:01$A!$=Q$I1$?>(@'7781 .HZZD_ +MOMRAMOW -N@?4
M'37"@&$A@+^%L.WT^7?3L-QR!RB/* ]0[AL/3Z>G3Z]1\S]Q"\.^#8V'99\O
M53K+2['>,X: GVCJ=>V1"+%JK*KMJM&1DW)R$1#&>,#S4L:*/#PQGK 9-XT.
MZ:^(A<*8VXL*MQ$\45US+GFLY&P%?YJBN>&G%$324(&:PU$1,$JTN+*>L23=
MNI.J3DH9NLB55U,^.=!25%S$G<C#HQ?XWIV)Q[Q#8RR*\R!F#ACF P[;ZC7N
M)^GX[:YKQ/+B_O%;F93 ^6\<.:)< B)&17BH.[8_L[:2I\I- QMU=BK$W<MC
MLW]J&%&G2,OS 4#W@+ EC$).6"T3/F1CD?)#(<RMD5ELV,^IJI4I'F$7(82F
M*U6(BH03F+FL%J$B*2H,\0DJ8 0Z"1D8E,635F2QY?Z/!RE0=5:X8ZM$"R=5
M][ #&SM/FZT^0(HP5C#,2N89Y#.6_(* (E.S,0O*!=R"!5($7#AX8!&LMDF!
MHI$08);)QA_# \:D((\I&!P22 S%,0:F!,@"B($+MKE2,G#V0N$9_B]H'$5B
MZ"3P,[G^&"J\)](SKA\DIQ$%XALE+S]MB,4T-THUJ.;,IT0F&,B4W&.8',Q$
M0+*VW^.E5'"9+4J16<3F*\OA7?2 9NQH;+2>07?%=C#%<X^;2F:9TU8X.GE9
MX:IS.3;&..*#9X:4<-G)%+))W">P^K%Y)<1+>VM*?;V4BS21+8]!4R+&9BF=
MB S(#'F,\<0"R!P'RA[RL%7*ZE K7!Q1_.[<EY5I%D,:*S1)*1,%%+)4'/$8
M3RLS1V@1I&#QNLK.@NN-@7V-! ZCI#V1'>NQ+91E$N@C4/78QFJF5%9I'*@W
M]98M542$25;M3(HJ)%*0Y#$* !V)%PJ9DE$XQD4[8SXR)R1R0'0-*'!22%(Q
M&_,B9^?8[_PQ(9V;Y[KQ3#S:U=I>NY-1X2:96H_(P2W"*XXO+"TLT\KC+CJC
ML65[' 8,1>52-:K%SDZXL;/P^+Y^%ZX>W U]AJ%"7EXWK:C&7H$< %4*&";3
ME7&[_P"Z):N(.XM,5>CNXC[YA&6A9'BDP<*-NK6?+X]P),(P<YDN7R7:[#2J
MI%0C;&#W*]@GKE9Z:XBY^?KQG,J0!>W#D4!FJCEYC1_T#YE7O6#!G4++F_I(
M2P*JRL&<-B->-R,Q6/AZEN4DMS5)E9CRBS(4AD9X"K?H:E4M*\3HR1$7QL>P
M[K'EI"Y5J,CHJ01K<JUIEPB5*VHDQ3?-(2*EF<4X;O8I!C+M&L-+1AVZC,)"
M+;E5!FDN1PW7;(*AS"P+P8T7</'.S0RY',09Q%MW(Q+E%,J2:T<95NI[.722
M B::C44%")E A!*4NP:]U;Q38>)KB,BJ/G8N:Y'&ELXF,KSENAHRXYBQQ!S,
M8MZ.CA(DV4:[F*;.5=Y'TXN2I"Q2S*%C9:/@U+PQ?D!):4;2S92*=REG1L*U
MNQ<0TYQ0ML[5[A_X0H;A,F8F=X@(YBM6V^54ZCFI6Y*P#EI1Y:T.95@W1SC)
MYD*ZL+G'SJGOX]4@R3!9PB\/#%%$[%BL3%4CSVYUU7+^D4ME*EI>ZO+B&8&0
M@C _&C&LCM1HJ*]0J/),8@PI0DKYQR)!&6$J+3@,_/J#D/)#*QVUB[<H<O;;
MIY=/KZ]?Q]]<ZZ$[#_1J=_\ YPWZ!\-=]9?U];XZ+!H[Z-&C!BI;TKV-I4F)
MV&>J>CS3N.'+.+M;?PO$;R=%FGQ4%!?$( ',G$S"S-9-4IRG:@Y%<IR@AMJH
M3%/$'096(2BYV0"KRJ*ZA"(RX&*P4*L8%"%;R:8&; !3F.'*Z]6.0NPCSAN.
MMJ_)%%A\FT&YX]GTP4AKK6)JKR/S0.9-M-,%V)ETRF^;XS4RQ7*!A#YBR)#!
MVUHO6JHS6/;K;J%8D%6LY4+!+5R5252.D;UR$?+,%5@34 H@BZ!,CM 1Z';K
MIJ%$Q#E,+T[,<)X_',*E7@K(2&CJJ9@DIB?*,DJLK1RHK@D9ESKGLKJ#CS+M
MI7\0X#Q&CXA2".2EKH6AJ()E+1&HIV6T@*E7CDDADC2ZG*PANZMETMS>KLIJ
M"DACG32006CW)B+,'*#U(X%2%4HE4;J+$$-R@.P#O\-, ._3R["(#T$-]A#8
M1V#ZQZ?DU7\U?OH\_BQ[UXP4'H)V+IPT/U#J F;*I"8! W81$!W$!#7J:9%O
M$:82-K-*"4AA+RN5BO2B4!$  0>$7$ #X"&L&K_);4L;TG%X'MLM12R1&Q(W
M>.6:YZ7""^]AC"B[=TK!?2Z&>(VU-.\<X-K:A9#3V%[_ *S>()MK8(E(N4"\
MI!(8-@$.83"(!MMT'F#<._T?#7R<NUW(@*IQ';L4 $"[[#L/GS" ^?EYZ@XG
MF;(9-@&6:G+V'Q(F/$3= #YQBHD$1 .W4 ]X#KN;,^1% 'DE6A![;IQ# 1V\
M]A,D<0WZ!MY (^_67_X7<=N;5?"K>/.J@>@U'H9W]IV&+?\ ++@UBUJZ_3]!
M%>]@#_YJP\=]-K;6FN %$ Z;B(![_+I^GOU\UUT&A#*NET6B) W,JZ53;I@'
M7J)UC$*  /Q'OJ"$ADN^2("5S9)!(H[[D9^%'AL/< %FD@< ^'/L ]0V'2.=
M/7CXW.^>.GIA$1$SMRNY$1-WZKJ*;=O+;6A2_DJJVL:SBU/$!8LM-323FW4!
MI7IP#KN4(ZV.*$_;BD2_HU'4S&U@9WC@4>&B&<D7Z7&GAB9%KRQ4(HPHMWX3
M3I$IN5K$[.""L(B $4?=&B8=@,)5%C@ B'(81 H6L>B!Q[+W>3O?$5:6)$6,
M4J>@8]0(F8&K=RLD1W:G[8QPYUG*+9=I&+/3'YCB[<(D(F1,2!KQ1\>^EG["
M)BVRCN2E'K2-C6B93'.ZD)%RFR8MDR% 1$SAVLBB % 3"8_0!$=;RG#?AN)P
M'A+'6*(I-+>I5Q@TEG:90#VI8UT2.K'+'$"E$YI"95>+E$VXD1\%,!Y4RZZ,
M]E>$]G((A3B2IK)F-ZNH97=$2S.(45$CB#LRBX#2%,R&0J;8W>Q?$N(<?XG4
M5=05AH^'0'ET\*D(U159HXVE=BS2E(4J+:A Q5PBL 0^&C1HU'CU'!HT:-&#
M!HT:-&#!HT:-&#!HT:-&#!HT:-&#''* =@VWVWV$0[=/+1L'Q^T?SZYT:,&.
M-@^/VC^?7.WT_:.C1HP8XV#X_:/Y]00](OTX;I 0$0_CUH_F(]I54>W7\7T^
M0:GAJ"'I&-OU-TAOV^6M'\]O\]%?/RUF<:_Q3Q'_ &2;_L.*U9_@M1_JG^[%
M!@  ]1#J/QW[?1TU/?T;_P#)$N0ZAOC>V;AY /M2L;  A\ '?RZ!Y@&T!1$W
M\KOR^6P?;Y>_4^O1O;CQ$.>8.OW-[7MOT_SSK'E\-_Q_1KR[@G^-^'_[5']_
M[M\<[1W]*@T_RBBX&A%Q?IOX=/WWU;!\?M'\^C8/C]H_GUSHU[)CJ\<;!\?M
M'\^C8/C]H_GUSHT8,<<H#MN&^P[AON/7Z_T#7/;1HT8,&JY^/K!.4\TFQ8;&
ME8"QA7/EC[9_OWA(KU/VH%;]1_QXD& K^/Z@[_Q."OA^%]]Y.<G-8QJ _&[Q
MTQO!>?&I9'&TID+[HPVL$?9MFCZ[[)^2P0 J"MZ[%2?K?KGMXGA^%X/@>K'Y
MP4\0.2"IX:.+POP\B0BHRBT3(C_HW6?NM(K(-8A>XU%P+,010XI44=+0SS\0
MF-/2)R^=*%9BF>6-$T1)&.:1D71#8&YL 2).8$K,W3,+XOJ=E9>SI^NT>O0\
MPP]8;.O5)!BP20=-_66:R[5?PU"B7Q6ZRJ)]MR*&+L.E=8$[$=XR&+A:[*-0
M7;>.K+.%4G+9#F4%T=L4&JY!7*7PS-MC 4QA4!42 4HBWO#=FEOQ$81H&9VM
M><U1O?(Q[))5]Y(H2SF,*SFI.'%%61;-F:#HRAHT7 '3;(@4JQ4Q*)B"8SX:
MD%/Z.BTW>7T<+#J5+#E#)8D#*2,NI L3J-+8LTTD4U/!- W,@EABDA<AAGB=
M%:-[$*PS(0UBJD7L0#IAL69K(V>1!7T/66$H=S8_5HZ,?/B,UXT4XP2/5'18
M@R97Q=MG2*Q$B* !!;J*B!BDSRTQ8FKADU7B8<JTBNJ@U+[:?&*=5)NL[4()
MR01B)B5N@H<HK&3*H(<A#"<2E,KQ ![_ )1UP82AMS" ;] W';?X?'K[_/Z=
M 0B]G(N1T&P"C73>PM?;K;?$]QX?,_C]:^5D9(3\Y%^J^O142D#MPDT0,67D
MU@.X6$I")F%O7E2I[J&*0%%A3)MN?F#80UVD)Z=BDD5GT7$(IKN46B9_:\BL
M!G#@X$1*;U:OK"D0YA$OBJ 5,G3G.4!WTKQ,F.PB8/=^%MWV#KL(=!';OT[:
M;FXY?QA0)>*@+I=J_7)J<;+.X:,E'O@/9-LW4.DX69( 0QW":*A!35,F @F<
M2%/L*B?,Y(I'.6/.[6-E5<Y[NK: $Z6-R!H+^Z.26*%<\SQQ(" 7D<(EV(51
MF8@ L38:W)-@+VQDI:QS4$V*]DXV';MCKI-@4"7D7!A76-RID*DV@%5! P 8
MW,!! O+N<0+N8O,M8IN$8J24G&0[=FF=$AE"2\BX,)EE 33Y$6T JX,)A,4.
M4B1C!OU#8!'2?B<YX:G5XEG$9.H\@\FW)V<4Q;6...^>O$_$*+1)EXX.O6A,
MFH0C91(BRARF33(<X<NG4$4Q#83%Z?[(/+Z_TZZ'BE0V?.EQ=0Z%3<'>Q N+
MBQM;J-R3@BGAF&:*2*501<Q2*X%P"!=2P!(U%]P;VVPBGU@FXV-6FG<7#)QR
M+<CI1P68DE3 DIR F<$$:^JN;F Y-P(D8X;B(I]!#7=2P3B44::-&1 1Q6?K
MXK^UY 3 T\,JP* @6OBYYO"$3&2\+Q@$.0"<X[ LMR#L4# /D <V_;Z]_P!\
M=<@4O+R]P^G?S]_OW^P>VVFA6&F8@6\%W\=M1\]]=19X(]OO]GU[\((\K-K-
M6MD]69)1C9@Z?FY)V13;K-%D"J'7=L1KIG2QFR"0K-D2ID735.H3PCG, !Z6
M5AFY"+3F&L9#G8*H'<$7-+R28BBD"GBG,@K7TW!>04Q  ,D"AP^<!/P2F6H%
M  $ W#?SW'?Z=Q$1W^O7&P%*.W3H(]Q'R]XCOI;-I=S8"UK+O>Y-[=?,7U.N
M !1F(478@G4[@!?'P &_3QUPBHBQS,ZP2DXN,B5V2HK%*J>5DVQA.@8R:A?
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M1RQ2&Y"2(YM:]E8$VN0+V'4C%:LA:HI*JG0JKSTT\*EKY0TL3(I:P)R@L";
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M[;8DG*MOQ]7Z<E6C-Z[)1%B81Z+NL14XTM<0I(3D7*()D4AY2-!=#7?,G%A
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MRNJ*?<H@'$:L,P69L4S5U7#Q86:*84A+U66<I.+!('AQ5)!%V/1]&?P-#_\
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M;#2QMJ+U:NA%/&DHGCDSD#*HRD=T&X[QN/AXX=4.X;A]&Y0#M\=?374/?O\
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M<PVXU/8VQY),85\>OV::9JN(ENBZ>E>+UV&ERQB::3A'PUY$&R*ZAP20.HH
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%T8,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g315135.jpg
<DESCRIPTION>G315135.JPG
<TEXT>
begin 644 g315135.jpg
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M5U3)$\;S4Y#*]"L2-PJKGCWZ/MUC0U@89.B(F<C2N[YE?5\)+$95367,!)(
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M*"ZUIU%DO'B-GW:DH2^Z$@F[<Q>TK5T6ISA5RN5?HHF,9W-7-=6@&5(
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M2G\!#+[C#;">>H9_JP(-[9 ]QAMA//3L_P!6!!W;( )F@$,ON,-L)YZ=G^K
M@[MD#W&&V$\].S_5@0=VR "9H!&5#^F/:2L_,Y+Y:VH#:F+$I84.QNX2F@^*
MHTJVLI'(M7+6;)D19,5ZKE%S&=1L=F,U:6HDU1+[R]V>JKGI@ "34
M
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MY+\M*?-3)?2E/X4I2@_H.*4I2FZE-U-]:\W7=6MU:_QK6M:_+4<@
M
M                         XI6E=]*>+FKS5I_+?T_/3?3?OITT"O17YJB
M/;2HYG$L:P=I\B*K@6E5%:6H+3\F-9(45<^?3&RGJ6B?3^OJ2<WT\T9S%$0D
M?7%)06CI--PE2YI64#JGGQ9#IPQGR@2%
M
M        ZN B3+&#AHN4+8#*AEQ9SYC"7PXLYW-@+XBF'*;RX[+<AG+B*X<)
M?'DSW9+\>#%CPV76XL=EEO:
M
M'%>:E?FJ,+M/$QOY_P"IG7Y&SH5"QUI01,\,L^-".%*3R.='0'CI4AJ45XJ;
M/E<&,XLY3+S>"^H8S:GE,9RI<UA32]^,D4+XK,TND6^:L5L%DN^3GZUVX52'
M;,C@0'3):U@,*&7.ZU]KLM CM!4CF$T<,%"N9.9C70$''C3"Y$OD+IN+.8PY
M3N0P9S 7!           "H#BO^M/\JT &*;>URZ077,9K3XWM1L1JDU$W*XF
M9EC7 \DRQUY'>TJFZ.=J$T\QDP44'*@T3U&]40D_*:5"F--4LF4I2Q/.78.O
M#6N[1_J&>ET>0CJ'BZ47I1.6%>C?9CCQK1S(F-\UA)+)_#>7P<ESE$XUGQ8#
M&? 8R8Z9+Z6V77\]:8KPCH;=CDI8KSK)$L$VPR->6H75!'\"XB\0$&-8J6ZE
M95?4/.HZY45@FI244@V1<2=(N%",R3@X]3/%$U;+6(Q4RV+NGH0TI:IX0T7Q
M2U<FHN0&Q+Y.#6HTR493FQ8@DR'H4<9=5**"@63VW$J'#<CNFY(2<1QKI5%V
M?5K'A*&\1]0.+)PICOO DGOEJ+,<B?JBR24P,<K=P+G7^K.]Y-NV0:M>R[@7
MN2C*N4Z.:J!9?2MERSW+[FVW4K2IFE:5%NT+5SI3=#5>KZ;6IG3ZXF3&U$RZ
M1'@A31&JNUF%:LF,Y1(N>CA3W,82&K:JFBQ@LFU73A"AXQ@S82G'9<5]EL4Z
M[IMU!4G5S(U\'K;I=QC7&NZM<>J),-QTU6:XHC-:1%",L$=$5Y4=R_(S4=M7
M&9_48C,U3:JZDHS6Y \3RPL-W$H&LUFHVT[ZEF45@^I*#-3CTTPZ8WMI)=5L
M":@S.EE=G(^Y&+&.H"+7[6/3\9GFRVWLQ(5HZX(?:*2<RF7O<;U9[J6XEP9K
M<94HK 3VJ4[0DCF8Z)J\P1:EG)@L+7Q,44I"9Y$S)]AW&3S$[X[P&EG%E>UI
MO"HI^8M<V;52TQB/$\F&M]IK!7)U#.H: R2O(3?.S=$)-=B-#,.:544U);*+
MJT9MLIBQ9S+@D%-RKEAUEHA?#FPYLZJY<"80PXLN/)E,66Y+*W>;IQZ&M7&8
ME?A)0S)K6P.R+40I%<:,0SI]4H^P*"MM#9JU4X84U<+#B5%-PQVQXB:#KB[D
M"CIG<;8-9D2V1&XEO5UN%#8[?%\'WIE<DXFYWPNS2/J-8"&C9M2"1$D;0JG1
M$QU]Q-R9=1#<=LTRNXY^E-[OA+DF89O3$&Z2VK&:^WFU&C>1E,VP#Q]0>F-$
M=+8 FYP:K-+YJ/:RV5U'0,9BNCDHS:R67F&.LT?T=];+,E&K5Z8W)<VZ.2MF
M7%=1"[I]U*VY++J%.#=2M:Y,R[%)-^(,6&Y,CXK)KI1<KD;,=F7HV<#Z<3>P
M6&,F=>0FAE5+'"L(N#&4-7YE1.33)''86,77&*6X,M;(!7AIXUD.Q9CU_N=(
MU5*T4LAZZPT&/$4D@:.U;5F6:DN19!9..'5)A-QIN>*\Z>KOQI3PPK,UJ(:D
M,E%,@L9,E%0*HIU_WE?HP=I;UG,.=&>MOB.3&9TN&<M)<E.,NW&5IINT@LV*
MV3I=C*,Y02TZ_(3.S W9,AMTM60&W!Y=DGT=,1:.5J966F7,!7D?)<!Z+0'Y
MLINLLINW;K;:;N;FW4IS<W-_+F'Z                       %-O)XM:/&
MBZ7\^%]):C+9+=6G:[G0O'<*<B-QLMU.,*ZZNK"@8NMP$4M)3"AD^?.9KK<1
M8K@RYLE:6V5J,:&)KXT92:UGV]&'J7AQT-N,BJ(>?R@E/5,S7-,DYSEJ:US:
MT0R7850H6<ZI?1(;>?D-^)?6-Z0D7G%.E2@^AKK8+PE71/J\C&/D8PXGY(FF
M6=6.RT GF)%S:TZW7&;E0V\E%<ZD8*)V$PH*IXJ5PY3YHN3QY,MMQK/BPTOO
MI@;JBV;AF46!>ZWL[Y3U0RV=4='K *)SWK%K-36G$\?:Q(3F62K$9.BAF125
M,G*)K:67 LJJXI+:O1/;A9-;%"F?,9PJX$NS3>;7?*-8X6@MD'$B9%-?1K51
M)S5.$NZK6<"HU7&G79\=O!L.(CC159%4\%VZ\HHIYLMEI2_#<*EX=O/SUYNJ
MVZN_H_=YOVJ4W\];=]*>.M!YV<&FM]K<_P"F+!,^E[4 9(P_+LU2RISNQW#D
M6S;BJL:VIQ>&GJ'E*PC+27A1XL;+0<2/,$MJ*BV5E17FYD8$8)UAE*N?"*3M
M1'^C3: N@HX&S,JG+66YX.^#T[4,H-)148QODM1P:]8L>SS?S=E%-U3/EP+&
M9MZ>4E_EDQUQQ'L!%R,,+R7%U6YA<:&F-!K@>G_^^K^H#Y2&BIK;14AO(Q;D
M:0A)A!&2BG'&#/)4U+*82! OR@WESFL_$%"^'%QQG/F,9>!P\^7+ENOON^J
M                               _-U=U-_76VWYN%=2W?_#?OW>/H$>&
ME': )6J1YMEGD8R4V;E<D7S#)EAXZZ22U84P1%JH>.F$RD7ERR*GW9LRX>:.
M1X83EN6S$0)GL:+DP&S&"]1R 2(@             !_?\^D*4I3FI3=3JH
M#C=3?PMU-^[=OW4W[NK?T[OD#@V[JTX-NZO33=3=7YZ>,<@ ..#;S?LTYNCF
MIS?-U?P'%++*5K6EMM*UW[ZTMIOKOZ=]=W/O\?6/T  XX-N[@\&FZG13=3=_
M+H#=3?OW4W[MV_=S[NK?T[AR                           !T](?W_+H
M  !^:V65KOK;;6O76VF_IW].[KY_G'/!MIOW4I3?7?7FISUIT5KUUIUCD
M                               !^;J;Z;J>*MMWT;J7;OX[MPCPTH[/
M]*TMO-LO A)RF\LK<B^88SL(G6J21+#>"7=5#QU/FEB\P66E"[#F1#SNR,_"
M2MQ9,9\H1QK60P5,9[T['(B
M
M.*UI3I_OY?DI\O13QAPJ?+_"E:[_ )MU.?\ AO\ 'U5&!>T(S*!:.H$,I]Y[
M%0MKFT-&E/*1N-6<2A%M34>YUW,=N*UI=:EX4K&;RJ5<]>24)V9:FM^'AT$*
M>M[#*9A/DMWJ19Y$7'*>CMCRX?3"IE<,YD$Y(6TLA!7;;3LHG&3)+ >9<4V-
MMH&\2;0M3.60U)3.%<>125<F8#U0@/YXOW:_]YF_\V\?T
M
M                  <5I2N[?XOEK3^E:?R'' MZJT^:ZZG]*T^;YN;H'Z
M*4I3FH
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M)-<U5@SR[D%V&A^F(ERFE_(B_  "2@
M                                                     !@7M!B:
MD;CF!LB8243O<O7'H<752B:3.G<A) 0]3,>JJ^J&\9'#FRXDU+22AL\HF<EM
M"Q8I@RY3%]F*VMPA5UM,&6%9.DIUJ#.=YAUROH]9,F+Q--25M8RICAD':60B
M\4UCUS)I7.7R*+ B\JWFOE*E;,1BB*T<RP>*V4O43=_J=K2E>OQ=%:TKS?+2
MM*[ODZ K;2O7_"ZZGCW^*M.??TUZ:]%>8 ?C%^[7_O,W_FWC^@
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M)&2]#C3E7)-)\Z6D%X7)RJTE/*L);E)%P)<0
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M<E9%C9GI<B*QA;MI:N&5!XDD? OFC*W;;9:M&LAZIA7MQX[5+*:ICMI2^
M                                 .*4I3GI2E*]'-2G1OW[OY\_SA6Z
ME.FO\.FOS[J<^[KKT4\8XX5*]?T;O\N;G_AU5ZJ[@/T 4K2O/0
M'6Y85^$8/3X?;#EA7X1@]/A]L =D!UN6%?A&#T^'VPY85^$8/3X?; '9 =;E
MA7X1@]/A]L.6%?A&#T^'VP!V0'6Y85^$8/3X?;#EA7X1@]/A]L =D!UN6%?A
M&#T^'VPY85^$8/3X?; '9 =;EA7X1@]/A]L.6%?A&#T^'VP!V0'6Y85^$8/3
MX?;#EA7X1@]/A]L =D!UN6%?A&#T^'VPY85^$8/3X?; '9 =;EA7X1@]/A]L
M.6%?A&#T^'VP!V0'6Y85^$8/3X?;#EA7X1@]/A]L =D!UN6%?A&#T^'VPY85
M^$8/3X?; '9 =;EA7X1@]/A]L.6%?A&#T^'VP!V0'6Y85^$8/3X?;#EA7X1@
M]/A]L =D!UN6%?A&#T^'VPY85^$8/3X?; '9 =;EA7X1@]/A]L.6%?A&#T^'
MVP!V0'6Y85^$8/3X?;#EA7X1@]/A]L =D!UN6%?A&#T^'VPY85^$8/3X?; '
M9 =;EA7X1@]/A]L.6%?A&#T^'VP!V0'6Y85^$8/3X?;#EA7X1@]/A]L =D!U
MN6%?A&#T^'VPY85^$8/3X?; '9 =;EA7X1@]/A]L.6%?A&#T^'VP!V0'6Y85
M^$8/3X?;#EA7X1@]/A]L =D!UN6%?A&#T^'VPY85^$8/3X?; &"6T)SGBL<0
M,;(Y#N&PIKDT-FU3.3N,V<0@E-3,>F%XP>O*_M6)6!)QG,RG=GW%*$K,U35:
M8.&(5=;Y>4\R;)#M4R[P)N64='+&EU23B9I=-Y$)0D7:70BMH#2QU(9\Y3$<
M8\6_HXR\^-.L*\>00#RD<*8\B@JY,WJ6J;*5Z3&#T^*G],@XY23^$8:?,8QT
M_IDZ?EZ=V^G14 ?WQ?NU_P"\S?\ FWC^@ZW+"OPC!Z;#[8<L*_",'I\/M@#L
M@.MRPK\(P>GP^V'+"OPC!Z?#[8 [(#^%IDO?OX.?#=NW;]V7'=NW[]V_@W5W
M;]U=V_IW5Z@ $/QW8!;'A1.FU [H.APP</&<YPV8R&7_ ,/.9,9+LN;-?P7M
M;;PLF2ZZ^[@VVV[ZUW4I3F'5\'UV-_D$0S]9D#\[B9( !#;X/KL;_((AGZS(
M'YW#P?78W^01#/UF0/SN,^]7>I1*TF0*\II/LUS26J(F5 0F9%K(H7O>\H2
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M'UV-_D$0S]9D#\[B9( !#;X/KL;_ ""(9^LR!^=P\'UV-_D$0S]9D#\[B9(
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MZS('YW#P?78W^01#/UF0/SN)D@ $-O@^NQO\@B&?K,@?G</!]=C?Y!$,_69
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M9;+7;Q1'1V6DMPX?7E51QI]SG7'*=6CYZW+(8
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M+6VVN4J?(&BYHODX-M;\.:RZMM*UK2@'VP
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M>Y/<BDNO8\\/T;X'=%1Y=W!Y9W/[J\,KW2XOE-$\CPN(MOZ
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MM$_(C\-XS[S>IMOI)5,,.9SG<5MM#:TL92]QT]GONRYLF;+6XP9-Y^--9KE
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M2,QT%!*)T)1\R\37:#-0$4@T4K,62RQ-9.F5K)FA2F[^=:_SK6M?Z@#D
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=5ZX:)#(3J9*GJ(J73+7/3+6VA/'Q? WY.& '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g934962.jpg
<DESCRIPTION>G934962.JPG
<TEXT>
begin 644 g934962.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@ _1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?059)0U1?2U]#2$E?5%A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_   L(  X E $!$0#_Q  9   # 0$!
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M%RRMOE-\3T\% 1 *GQ81&A$C3 >O.O$@KL[#('_#%;!@,]F^,7'MT^S)YJ&
MA_/O,1]'WY*W7!VX,WQIQ2 2TE<L'] W8$/6V.=QGFX,BH,TY8I [VF]QD;^
:A_ 29:V,DQ'SATZ]/0*8+[3?D4AUEP(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g140919.jpg
<DESCRIPTION>G140919.JPG
<TEXT>
begin 644 g140919.jpg
M_]C_X  02D9)1@ ! 0$!K0&M  #__@! 1$E32S$P,SI;,C!:1%,Q+C(P6D13
M,3<V,#$N3U544%5473(Y.#<V7S%?34]$15-47TM?0TA)7U185"Y%4%/_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +"  . %@! 1$ _\0 &  ! 0$! 0
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M*!^DE!5GZK/S_H>G'O1V7*MT[E8C]E<9$7ZO$&QJNO0-JMO-9EG/J_\ :V^
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MJ/O"NHWI:[4B4I%8-J+3\2 "..D<?:?04;NLE0*=QZ221GD(,PXO*!V8Y_\
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
